

**UROLOGICAL CANCERS****PROSTATE CANCER****Review question:**

What is the risk of prostate cancer in patients presenting in primary care with symptom(s)?

**Results****Literature search**


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	All-2012	858	103	27/11/2012
<i>Premedline</i>	All-2012	33	3	27/11/2012
<i>Embase</i>	All-2012	2023	82	28/11/2012
<i>Cochrane Library</i>	All-2012	134	0	28/11/2012
<i>Psychinfo</i>	All-2012	33	4	27/11/2012
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	All-2012	540	66	28/11/2012
<i>Biomed Central</i>	All-2012	29	4	28/11/2012

Total References retrieved (after de-duplication): 215

**Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	11/2012-26/08/2014	115	11	26/08/2014
<i>Premedline</i>	11/2012-26/08/2014	57	1	26/08/2014
<i>Embase</i>	11/2012-26/08/2014	289	10	26/08/2014
<i>Cochrane Library</i>	11/2012-26/08/2014	77	0	26/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	11/2012-26/08/2014	160	5	26/08/2014

Total References retrieved (after de-duplication): 24



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15

**Risk of bias in the included studies**

The risk of bias and applicability concerns are summarised per study in the figure below. The main issue to note is that 4/5 studies employed samples of patients that are not directly representative of an unselected symptomatic population of patients presenting to the UK-based GP and the 5th study employed a case-control design which has been shown to inflate the test accuracy characteristics. However, the statistical analyses employed by the authors may have gone some way in counteracting this influence. Three of the studies also employed reference standards that are subject to an unclear risk of bias; all of which must be born in mind when evaluating the evidence contributed by these studies.

	<u>Risk of Bias</u>				<u>Applicability Concerns</u>		
	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard
Bouwman (2007)	?	+	?	?	?	+	+
Deyo (1988)	?	+	?	+	-	+	+
Friedlander (2014)	+	+	?	+	?	+	+
Hallissey (1990)	+	+	+	+	?	+	+
Hamilton (2006)	-	+	+	+	+	+	+

<b>- High</b>	<b>? Unclear</b>	<b>+ Low</b>
---------------	------------------	--------------

16

## Study results

Table 1: Prostate cancer: Single symptoms

Study	Symptom(s)	Patient group	Positive predictive value (95% CI)%
Bouwman (2007)	Urinary symptoms	Males aged $\geq$ 50 years	7.37 (5-10.7) 26/353
Deyo (1988)	Back pain	Male patients	0.13 (0.007-0.9) 1/750
Friedlander (2014)	Haematuria	All included patients	0.61 (0.36-1.03) 15/2455
Hamilton (2006)	Haematuria	All included patients	1 (0.57-1.8)
Hamilton (2006)	Haematuria (reported twice)	All included patients	1.6 (0.8-3.2)
Hamilton (2006)	Loss of weight	All included patients	0.75 (0.38-1.4)
Hamilton (2006)	Loss of weight (reported twice)	All included patients	2.1 (NR)
Hamilton (2006)	Nocturia	All included patients	2.2 (1.2-3.6)
		Patients 40-69 years	1.1 (NR)
		Patients $\geq$ 70 years	5.9 (NR)
Hamilton (2006)	Nocturia (reported twice)	All included patients	3.3 (NR)
Hamilton (2006)	Hesitancy	All included patients	3 (1.5-5.5)
Hamilton (2006)	Hesitancy (reported twice)	All included patients	2 (NR)
Hamilton (2006)	Rectal exam: Benign	All included patients	2.8 (1.6-4.6)
		Patients 40-69 years	0.85 (NR)
		Patients $\geq$ 70 years	8.7 (NR)
Hamilton (2006)	Rectal exam: Malignant	All included patients	12 (5-37)
Hamilton (2006)	Frequency/urgency	All included patients	2.2 (1.1-3.5)
Hamilton (2006)	Frequency/urgency (reported twice)	All included patients	3.1 (1.9-5.5)
Hamilton (2006)	Frequency	Patients 40-69 years	0.61 (NR)
		Patients $\geq$ 70 years	7.4 (NR)
Hamilton (2006)	Retention	All included patients	3.1 (1.5-6)
		* excluding 39 patients with unsuspected cancer	1.6 (NR)
Hamilton (2006)	Impotence	All included patients	3 (1.7-4.9)
		Patients 40-69 years	1.1 (NR)
		Patients $\geq$ 70 years	8.4 (NR)
Hamilton (2006)	When PSA was added to a small multivariate analysis (N = 208; N = 137 patients and N = 71 controls) with the following otherwise significant variables: urinary retention, second presentation with loss of weight, impotence, frequency, hesitancy, nocturia, haematuria, and rectal examination, these variables ceased to be significant predictors of prostate cancer while PSA > 4 ng/ml was significant (OR = 29, 95% CI 3.9-220; p = .001).		

Hallissey (1990)	Dyspepsia	All patients	0.08 (0.01-0.3) 2/2585
------------------	-----------	--------------	---------------------------

1 CI = Confidence interval. \*The authors report that a sub-analysis excluding the 39 patients who had  
2 previously unsuspected cancer identified at prostatectomy, showed that the PPVs of symptoms were  
3 little changed, other than for retention.

4  
5 Table 2: Prostate cancer: Symptom combinations

Study	Symptom(s)	Patient group	Positive predictive value (95% CI)%
Hamilton (2006)	Haematuria + nocturia	All included patients	1.9 (NR)
Hamilton (2006)	Haematuria + benign rectal exam	All included patients	3.3 (NR)
Hamilton (2006)	Haematuria + malignant rectal exam	All included patients	3.9 (NR)
Hamilton (2006)	Haematuria + frequency/urgency	All included patients	1.8 (0.9-3.9)
Hamilton (2006)	Loss of weight + nocturia	All included patients	12 (NR)
Hamilton (2006)	Loss of weight + benign rectal exam	All included patients	9.4 (NR)
Hamilton (2006)	Loss of weight + frequency/urgency	All included patients	1.8 (NR)
Hamilton (2006)	Nocturia + hesitancy	All included patients	2.8 (NR)
Hamilton (2006)	Nocturia + benign rectal exam	All included patients	3.9 (2.1-7.8)
Hamilton (2006)	Nocturia + malignant rectal exam	All included patients	15 (NR)
Hamilton (2006)	Nocturia + frequency/urgency	All included patients	3.2 (1.9-6)
Hamilton (2006)	Hesitancy + benign rectal exam	All included patients	3.3 (NR)
Hamilton (2006)	Hesitancy + malignant rectal exam	All included patients	10 (NR)
Hamilton (2006)	Hesitancy + frequency/urgency	All included patients	4.7 (NR)
Hamilton (2006)	Benign rectal exam + frequency/urgency	All included patients	4 (2.3-7.4)
Hamilton (2006)	Malignant rectal exam + frequency/urgency	All included patients	13 (NR)

6 CI = Confidence interval.

7

8 **Evidence statement(s):**

9 The positive predictive values for prostate cancer of single symptoms presenting in a primary care  
10 setting ranged from 0.08% (for dyspepsia) to 12% (for malignant rectal exam; 5 studies, N = 7440).  
11 The studies were associated with 1-4 bias or applicability concerns (see also Table 1).

12

13 The positive predictive values for prostate cancer of symptom pairs presenting in a primary care  
14 setting ranged from 1.8% (for haematuria + frequency/urgency) to 15% (for nocturia + malignant  
15 rectal exam; 1 study, N = 1297). This study was a case-control study (i.e, high risk of bias for patient  
16 selection; see also Table 2).

17

1  
2  
3**Evidence tables****Bouwman (2007)**

<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Database study using data from the Registration Network Groningen (RNG) from 2003 and 2004, which is a database registering continuous automatic recorded data from, on average, 17 GPs working in practices in Groningen, Hoogeveen and Hoogezand-Sappemeer (population of approximately 30000 people) in the Netherlands.
Was a consecutive or random sample of patients enrolled?	<b>Unclear</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Yes (probably)</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	In the whole sample there were 4422 men aged $\geq 50$ years in the period 2003 to 2004. Of these 353 men consulted the GP for urinary symptoms. <i>No further details reported.</i>  <u>Inclusion criteria:</u> Male patients aged $\geq 50$ years in the period 2003 to 2004 who visited participating practices because of urinary symptoms (see "Index test" for further details) for the first time. <u>Exclusion criteria:</u> None listed <u>Clinical setting:</u> Primary care in the Netherlands.
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	The following ICPC codes were used: U01 (painful urination), U02 (increased urinary frequency / urgency), U04 (urinary incontinence), other micturition U05) and Y06 (symptoms / complaints prostate) and some minor codes: U07 (other symptoms / complaints urine) and U13 (other symptoms / complaints bladder). The code Y85 for BPH / LUTS was not included in this selection because the RNG agreements apply to the use of the different parts of the ICPC. This agreement is that a health problem is initially registered as a symptom or complaint until by advancing knowledge and further research a diagnosis code may be added to the records.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	The reference standard consisted checking the database to see if a BHP diagnosis (ICPC code Y85) or prostate carcinoma diagnosis (ICPC code Y77)

	had been registered by 2005.	
Is the reference standard likely to correctly classify the target condition?		<b>Unclear</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?		<b>No (but all patients had a positive index test)</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>		<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		<b>Low concern</b>
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	There is very little information about the included patients and the patient pool from which they were drawn. It is therefore not possible to ascertain whether all patients are accounted for.	
Was there an appropriate interval between index test and reference standard?		<b>Yes (probably)</b>
Did all patients receive the same reference standard?		<b>Yes</b>
Were all patients included in the analysis?		<b>Unclear</b>
<b>Could the patient flow have introduced bias?</b>		<b>Unclear risk</b>
<b>NOTES</b>	Original paper is published in Dutch	
1		
2	<b>Deyo (1988)</b>	
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Prospective consecutive? patient series	
Was a consecutive or random sample of patients enrolled?		<b>Unclear</b>
Was a case-control design avoided?		<b>Yes</b>
Did the study avoid inappropriate exclusions?		<b>Yes (probably)</b>
<b>Could the selection of patients have introduced bias?</b>		<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>		
Patient characteristics and setting	<p>N = 1975, mean (SD; range) age = 39.5 (15.4; 15-86) years, 62% females. 54% of the patients were seeking medical care for back pain for the first time and 76% of the patients had had back pain for &lt; 3 months. 3% had a history of back pain surgery. Maximal back pain in the low back (84%) or in the upper back (16%).</p> <p><u>Inclusion criteria:</u> Patients who sought treatment between March 1982 and September 1984 in the walk-in clinic of a public hospital where virtually all patients are self-referred. In each case back pain was part of the chief complaint.</p> <p><u>Exclusion criteria:</u> Neck pain.</p> <p><u>Clinical setting:</u> Walk-in clinic of a public hospital; this clinic is a source of primary care for indigent persons in a county in the USA with a population of approximately 1 million.</p>	
<b>Are there concerns that the included patients and setting do not match the review question?</b>		<b>High concern</b>

<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	Back pain; not further specified.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
<b>Reference standard(s)</b>	The reference standard consisted of a search on each patient name in the institutional tumour registry $\geq 6$ months after the index visit. The registry included every patient with a histological diagnosis of cancer made in the authors' hospital system regardless of site of care. The authors point out that "while this method might fail to identify cancer patients who sought care elsewhere, it is likely that most patients sought follow-up for a particular illness at the same facility.
Is the reference standard likely to correctly classify the target condition?	<b>Unclear</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No (but all patients had a positive index test)</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
<b>Flow and timing</b>	All the patients are accounted for in the results.
Was there an appropriate interval between index test and reference standard?	<b>Yes (probably)</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	It is a concern that some patients with cancer might have been missed due to the choice of reference standard because this would result in an underestimation of the positive predictive value. 38/1975 patients were found in the tumour registry. Of those 38, 13 patients had tumours that were probable causes of back pain, and 4 of these 13 patients already had a diagnosis of cancer at presentation. The 9/1975 patients who had undiagnosed cancer that the back pain could be attributed to had: Lymphoma (NOS; 2), cancer of unknown primary (1), prostate cancer (1), retroperitoneal liposarcoma (1), lung cancer (1), renal cell (1), multiple myeloma (1), mucinous adenocarcinoma (of gallbladder?; 1)

1

**Friedlander (2014)**

<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Retrospective cohort study, using claims data and laboratory values from the Vanderbilt University Medical Centre's (VUMC) Research Derivative, which is a "data repository that contains administrative and clinical information, including a complete record of visits and admissions, laboratory data, and diagnosis and procedure codes, on every patient treated in the Vanderbilt health system" (p 634) located in Tennessee in the USA.
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Yes (probably)</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>N = 2455 patients, 724 males / 1731 females, median (inter-quartile range) age = 58 (49-68) years; smoking history: current smoker (N = 406), former smoker (N = 473), non-smoker (N = 1514).</p> <p><u>Inclusion criteria:</u> "Patients aged <math>\geq</math> 40 years with a first diagnosis of hematuria" "between 2004 and 2012 by urinalysis (&gt;3 red blood counts per high power field) or International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes for hematuria (599.7, 599.70, 599.71 or 599.72) at one of the VUMC's 19 primary care clinics. To be included in the study, patients must have had records for 1 year before the date of hematuria diagnosis."</p> <p><u>Exclusion criteria:</u> "Patients were excluded if they had a urinary tract infection (defined as a urinalysis positive for both leukocyte esterase and urine nitrites, or a positive urine culture) within 4 weeks before or 1 week after the index hematuria episode (n = 590, 9.0%) or had a prior explanatory diagnoses and procedures that would preclude the need for a hematuria evaluation (according to a convened panel of content experts; prostate/renal/bladder/other cancer, benign prostate/renal/bladder/other mass, prostate dysplasia, cystitis, urethritis, epididymitis/orchitis, prostatitis, pyelonephritis, urolithiasis, prostatic enlargement, trauma, medical renal disease, haematologic/thrombotic disease?, anatomic abnormality, prostatectomy, prostate biopsy, transurethral incision of prostate, resection of prostate, cystoscopy, cystectomy, ureteroscopy, nephrectomy, pyeloplasty, ureteral reimplantation)." We then used Physicians Current Procedural Terminology Coding System, 4th Edition and ICD-9 codes to exclude patients with an explanatory diagnosis or procedure within 180 days preceding their hematuria diagnosis (n = 3540, 53.8%)."</p> <p><u>Clinical setting:</u> Primary care, USA.</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	First diagnosis of hematuria" "by urinalysis (>3 red blood counts per high power field) or International Classification of Diseases, Ninth Revision (ICD-9)



	diagnosis codes for hematuria (599.7, 599.70, 599.71 or 599.72)".
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	Low risk
<b>B. Concerns regarding applicability</b>	
Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Low
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	The reference standard consisted checking the database for diagnoses of genitourinary neoplasms within 180 days after haematuria diagnosis, as determined by ICD-9 codes.
Is the reference standard likely to correctly classify the target condition?	Unclear (is 180 days enough time to get a diagnosis of all cancers?)
Were the reference standard results interpreted without knowledge of the results of the index tests?	Unclear (but all patients had a positive index test)
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	Unclear risk
<b>B. Concerns regarding applicability</b>	
Are there concerns that the target condition as defined by the reference standard does not match the question?	Low concern
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients appear to be accounted for.
Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	Yes
<b>Could the patient flow have introduced bias?</b>	Low risk
<b>NOTES</b>	There were 66 patients with cancer: Bladder (N = 33), renal cell (N = 16), prostate (N = 15). The types of cancer for the remaining two cases were not reported.
1	
2	<b>Hallissey (1990)</b>
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Propective consecutive patient series from a group of 10 general practices in England.
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
<b>Could the selection of patients have introduced bias?</b>	Low risk
<b>B. Concerns regarding applicability</b>	
Patient characteristics and	N = 2585 aged > 40 years. No other information reported. The patient group was equally divided between new patients with dyspepsia, old patients with

setting	uninvestigated dyspepsia, and and old patients with investigated dyspepsia.  <u>Inclusion criteria:</u> All patients over 40 years making their first attendance during the study period (4 years and 9 months) with any degree of dyspepsia <u>Exclusion criteria:</u> None listed. <u>Clinical setting:</u> Primary care, England.
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	Dyspepsia of any degree
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
<b>Reference standard(s)</b>	Upper gastrointestinal endoscopy within 4 weeks and follow up.
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
<b>Flow and timing</b>	2659 patients were seen and 2585 attended for investigation
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	Malignancy was detected in 115 patients: Gastric adenocarcinoma (57), gastric lymphoma (1; added to the gastric adenocarcinoma data in the PPV), oesophageal cancer (15), colorectal (14), pancreatic (6), bronchial (8), prostatic (2), duodenal (1, also added to the gastric carcinoma data in the PPV), liver (1), gall bladder (1), carcinoid (1), uterine (1), leukaemia (1), circinomatosis of unknown primary (7).

1

2

Hamilton (2006)

<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Population-based case-control study, involving all 21 general practices in Exeter, Devon, UK.
Was a consecutive or random sample of patients enrolled?	<b>No</b>
Was a case-control design avoided?	<b>No</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>High risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p><u>Cases:</u> 217 male patients; age at diagnosis: &lt; 60 years: N = 15 (7%); 60-69 years: N = 51 (24%); 70-79 years: N = 100 (46%); ≥ 80 years: N = 51 (24%); median number of consultations in the 2 years preceding diagnosis = 14 (IQR = 10-21).</p> <p><u>Controls:</u> 1080 male patients; age at diagnosis: &lt; 60 years: N = 79 (7%); 60-69 years: N = 253 (23%); 70-79 years: N = 494 (46%); ≥ 80 years: N = 254 (24%); median number of consultations in the 2 years preceding diagnosis = 14 (IQR = 10-21).</p> <p><u>Inclusion criteria:</u> Cases: All patients aged 40 years or over with prostate cancer, diagnosed from 1998 to 2002 inclusive, were identified from the cancer registry at the Royal Devon and Exeter Hospital (the only hospital offering urological services to Exeter patients). Computerised searches at every practice identified any cases missing from the register. Cases without positive histology were included if the records contained a consultant urologist diagnosis of cancer based on strong clinical evidence. Controls: Five male controls were matched to each case on general practice and on age (to 1-year bands if possible, increased in 1-year multiples to a maximum of 5 years). Controls were eligible if they were alive at the time of diagnosis of their case.</p> <p><u>Exclusion criteria:</u> Unobtainable records; no consultations in the 2 years before diagnosis; previous prostate cancer; or residence outside Exeter at the time of diagnosis.</p> <p><u>Clinical setting:</u> Primary care, UK</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	All entries into the primary care records for 2 years before diagnosis were coded, blinded to case/control status, using the International Classification of Primary Care-2. Only variables occurring in >2.5% of cases or

	controls were analysed.	
Were the index test results interpreted without knowledge of the results of the reference standard?		Yes
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?		Yes
<b>Could the conduct or interpretation of the index test have introduced bias?</b>		Low risk
<b><u>B. Concerns regarding applicability</u></b>		
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>		Low concern
<b>REFERENCE STANDARD</b>		
<b><u>A. risk of bias</u></b>		
Reference standard(s)	Prostate cancer code, from 1998 to 2002 inclusive, in the cancer registry at the Royal Devon and Exeter Hospital or the general practice records	
Is the reference standard likely to correctly classify the target condition?		Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?		Unclear
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>		Low risk
<b><u>B. Concerns regarding applicability</u></b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		Low concern
<b>FLOW AND TIMING</b>		
<b><u>A. risk of bias</u></b>		
Flow and timing	All patients appear to be accounted for	
Was there an appropriate interval between index test and reference standard?		Yes
Did all patients receive the same reference standard?		Yes
Were all patients included in the analysis?		Yes
<b>Could the patient flow have introduced bias?</b>		Low risk
<b>NOTES</b>		

1

2 **References**3 **Included studies**

- 4 Bouwman, I., Van Der Heide, W. K., Van Der Veen, W. J., and Van Der Meer, K. GPs and patients still  
5 think that lower urinary tract symptoms are an indication of prostate cancer. [Dutch]. *Huisarts*  
6 *en Wetenschap* 50[7], 321-325. 2007.
- 7 Deyo, R. A. and Diehl, A. K. Cancer as a cause of back pain: Frequency, clinical presentation, and  
8 diagnostic strategies. *Journal of General Internal Medicine* 3, 230-238. 1-11-1988.
- 9 Friedlander, D.F., Resnick, M.J., You, C., Bassett, J., Yarlagadda V., Penson, D.F., Barocas D.A.  
10 Variation in the intensity of hematuria evaluation: A target for primary care quality  
11 improvement. *American Journal of Medicine*, 127, 633-640. 2014.
- 12 Hallissey, M.T., Allum, W.H., Jewkes, A.J., Ellis, A.J., Fielding, J.W.L. Early detection of gastric cancer.  
13 *British Medical Journal* 301, 513-515. 1990.

1 Hamilton, W., Sharp, D. J., Peters, T. J., and Round, A. P. Clinical features of prostate cancer before  
 2 diagnosis: a population-based, case-control study. *British Journal of General Practice* 56[531],  
 3 756-762. 2006.

4  
 5 **Excluded studies (with excl reason)**

6 Acheson, H. W. & Henley, M. H. (1984) Clinical knowledge and education for general practice.  
 7 *Journal of the Royal College of General Practitioners - Occasional Paper.(27):1-28, 1984 Oct., 1-28.*  
 8 Not in PICO

9 Afifi, A. H. A. A., Etaby, A. N., Ahmad, M. A. Y. & Farghaly, Y. T. (2013) Value of diffusion weighted  
 10 magnetic resonance imaging in the prediction of cancer prostate. *Alexandria Journal of Medicine*,  
 11 49: 57-66.

12 Not in PICO

13 Ahaghotu, C., Baffoe-Bonnie, A., Kittles, R., Pettaway, C., Powell, I., Royal, C., Wang, H., Vijayakumar,  
 14 S., Bennett, J., Hoke, G., Mason, T., Bailey-Wilson, J., Boykin, W., Berg, K., Carpten, J., Weinrich, S.,  
 15 Trent, J., Dunston, G. & Collins, F. (2004) Clinical characteristics of African-American men with  
 16 hereditary prostate cancer: the AAHPC study. *Prostate Cancer and Prostatic Diseases*, 7: 165-169.

17 Not in PICO

18 Ahmad, S., Cao, R., Varghese, T., Bidaut, L. & Nabi, G. (2013) Transrectal quantitative shear wave  
 19 elastography in the detection and characterisation of prostate cancer. *Surgical Endoscopy and*  
 20 *Other Interventional Techniques*, 27: 3280-3287.

21 Not in PICO

22 Allen, D., Popert, R. & O'Brien, T. (2004) The two-week-wait cancer initiative in urology: useful  
 23 modernization? *Journal of the Royal Society of Medicine*, 97: 279-281.

24 Not in PICO

25 Allgar, V. L. & Neal, R. D. (2005) General practitioners' management of cancer in England: secondary  
 26 analysis of data from the National Survey of NHS Patients - Cancer. *European Journal of Cancer*  
 27 *Care*, 14: 409-416.

28 Not in PICO

29 Allgar, V. L., Neal, R. D., Ali, N., Leese, B., Heywood, P., Proctor, G. & Evans, J. (2006) Urgent GP  
 30 referrals for suspected lung, colorectal, prostate and ovarian cancer. *British Journal of General*  
 31 *Practice*, 56: 355-362.

32 Not in PICO

33 Anast, J. W., Andriole, G. L. & Grubb, R. L. (2007) Managing the local complications of locally  
 34 advanced prostate cancer. [Review] [24 refs]. *Current Urology Reports*, 8: 211-216.

35 Narrative review

36 Antunes, A. A., Srougi, M., Dall'oglio, M. F., Vicentini, F., Paranhos, M. & Freire, G. C. (2008) The role  
 37 of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who  
 38 undergo prostate cancer screening. *Journal of Sexual Medicine*, 5: 1702-1707.

39 Not in PICO

40 Arumainayagam, N., Ahmed, H. U., Moore, C. M., Freeman, A., Allen, C., Sohaib, S. A., Kirkham, A.,  
 41 van der Meulen, J. & Emberton, M. (2013) Multiparametric MR imaging for detection of clinically  
 42 significant prostate cancer: a validation cohort study with transperineal template prostate  
 43 mapping as the reference standard. *Radiology*, 268: 761-769.

44 Not in PICO

45 Babaian, R. J., Miyashita, H., Evans, R. B., Voneschenbach, A. C. & Ramirez, E. I. (1991) Early  
 46 Detection Program for Prostate-Cancer - Results and Identification of High-Risk Patient  
 47 Population. *Urology*, 37: 193-197.

48 Not in PICO

49 Bagi, C. M. (2003) Skeletal implications of prostate cancer. *Journal of Musculoskeletal Neuronal*  
 50 *Interactions*, 3: 112-117.

51 Narrative review

- 1 Bailey, C. & Broadbent, A. Cutaneous metastases of prostate cancer. [References]. *Journal of*  
2 *Palliative Medicine* 10[4], 980-982. 2007.  
3 Not in PICO
- 4 Bajramovic, S. & Junuzovic, D. (2013) Detection of prostate cancer at low volume prostate and low  
5 PSA range. *European Urology, Supplements*, 12: e1286.  
6 Not in PICO
- 7 Barkin, J. (2008) Management of benign prostatic hyperplasia by the primary care physician in the  
8 21st century: the new paradigm. *The Canadian journal of urology*, 15: 21-30.  
9 Narrative review
- 10 Barkin, J., Rosenberg, M. T. & Miner, M. (2014) A guide to the management of urologic dilemmas for  
11 the primary care physician (PCP). *Canadian Journal of Urology*, 21: 55-63.  
12 Narrative review
- 13 Barrett, J. & Hamilton, W. (2005) Pathways to the diagnosis of prostate cancer in a British city. A  
14 population-based study. *Scandinavian Journal of Urology and Nephrology*, 39: 267-270.  
15 Not in PICO
- 16 Basha, R., Baker, C. H. & Abdelrahim, M. (2009) Biomarkers clinical relevance in cancer: Emphasis on  
17 breast cancer and prostate cancer. *Current Trends in Biotechnology and Pharmacy*, 3: 1-7.  
18 Narrative review
- 19 Bastide, C., Beuzeboc, P., Cormier, L., Fromont, G., Hennequin, C., Mongiat-Artus, P., Peyromaure,  
20 M., Ploussard, G., Renard-Penna, R., Rozet, F., Richaud, P., Soulie, M., Salomon, L., Azria, D.,  
21 Coloby, P., Molinie, V., Ravery, V., Rebillard, X., Villers, A. & Les membres du, C. C. A. F. (2013)  
22 [CCAFU Recommendations 2013: Prostate cancer]. [French]. *Progres En Urologie*, 23: Suppl-S101.  
23 Guideline
- 24 Baughan, P., O'Neill, B. & Fletcher, E. (2009) Auditing the diagnosis of cancer in primary care: the  
25 experience in Scotland. *British Journal of Cancer*, 101: Suppl-91.  
26 Not in PICO
- 27 Baughan, P., Keatings, J. & O'Neill, B. (2011) Urgent suspected cancer referrals from general practice:  
28 Audit of compliance with guidelines and referral outcomes. *British Journal of General Practice*, 61:  
29 e700-e706.  
30 Not in PICO
- 31 Berney, D. M. (2012) Early prostate cancer. *Journal of Pathology*, 226: S3.  
32 Narrative review
- 33 Bhojani, N., Perrotte, P., Hutterer, G., Suardi, N., Jeldres, C., Shariat, S. F., Capitanio, U., Arjane, P.,  
34 Widmer, H., Benard, F., Peloquin, F., Montorsi, F. & Karakiewicz, P. (2008) Body mass index and  
35 its association with genitourinary disorders in men undergoing prostate cancer screening. *Journal*  
36 *of Sexual Medicine*, 5: 2141-2151.  
37 Not in PICO
- 38 Bianco, F. J., Jr., McHone, B. R., Wagner, K., King, A., Burgess, J., Patierno, S. & Jarrett, T. W. (2009)  
39 Prevalence of erectile dysfunction in men screened for prostate cancer. *Urology*, 74: 89-93.  
40 Not in PICO
- 41 Billington, A. (1998) Prostate cancer and its effect on sexuality. *Community Nurse*, 4: 33-34.  
42 Not in PICO
- 43 Bjurlin, M. A., Carter, H. B., Schellhammer, P., Cookson, M. S., Gomella, L. G., Troyer, D., Wheeler, T.  
44 M., Schlossberg, S., Penson, D. F. & Taneja, S. S. (2013) Optimization of initial prostate biopsy in  
45 clinical practice: sampling, labeling and specimen processing. [Review]. *Journal of Urology*, 189:  
46 2039-2046.  
47 Not in PICO
- 48 Bjurlin, M. A. & Taneja, S. S. (2014) Standards for prostate biopsy. *Current Opinion in Urology*, 24:  
49 155-161.  
50 Narrative review

- 1 Blanker, M. H., Bernsen, R. M., Bosch, J. L., Thomas, S., Groeneveld, F. P., Prins, A. & Bohnen, A. M.  
2 (2002) Relation between nocturnal voiding frequency and nocturnal urine production in older  
3 men: a population-based study. [Erratum appears in *Urology*. 2003 Jan;61(1):259.]. *Urology*, 60:  
4 612-616.  
5 Not in PICO
- 6 Blanker, M. H., Bernsen, R. M., Ruud Bosch, J. L., Thomas, S., Groeneveld, F. P., Prins, A. & Bohnen, A.  
7 M. (2002) Normal values and determinants of circadian urine production in older men: a  
8 population based study. *Journal of Urology*, 168: t-7.  
9 Not in PICO
- 10 Blanker, M. H., Driessen, L. F. C., Ruud Bosch, J. L. H., Bohnen, A. M., Thomas, S., Prins, A., Bernsen,  
11 R. M. D. & Groeneveld, F. P. M. J. (2002) Health status and its correlates among Dutch  
12 community-dwelling older men with and without lower urogenital tract dysfunction. *European*  
13 *Urology*, 41: 602-607.  
14 Not in PICO
- 15 Blanker, M. H., Bernsen, R. M. D., Bosch, J. L. H. R., Thomas, S., Groeneveld, F. P. M. J., Prins, A. &  
16 Bohnen, A. M. (2002) Relation between nocturnal voiding frequency and nocturnal urine  
17 production in older men: A population-based study. *Urology*, 60: 612-616.  
18 Not in PICO
- 19 Blanker, M. H., Klomp, M. A., van den Donk, M., van der Heide, W. K., Opstelten, W. & Burgers, J. S.  
20 (2013) [Summary of the NHG practice guideline 'Lower urinary tract symptoms in men']. [Review]  
21 [Dutch]. *Nederlands Tijdschrift Voor Geneeskunde*, 157: A6178.  
22 Narrative review/guideline
- 23 Bodelle, B., Naguib, N. N., Schulz, B., Eichler, K., Muller, C., Hansmann, M. L., Hammerstingl, R.,  
24 Hubner, F., Vogl, T. J. & Zangos, S. (2013) 1.5-T magnetic resonance-guided transgluteal biopsies  
25 of the prostate in patients with clinically suspected prostate cancer: technique and feasibility.  
26 *Investigative Radiology*, 48: 458-463.  
27 Not in PICO
- 28 Booth, C. M., Chaudry, A. A., Smith, K. & Griffiths, K. (1996) The benefits of a shared-care prostate  
29 clinic. *British Journal of Urology*, 77: 830-835.  
30 Not in PICO
- 31 Borneman, T., Koczywas, M., Sun, V., Piper, B. F., Smith-Idell, C., Laroya, B., Uman, G. & Ferrell, B.  
32 (2011) Effectiveness of a clinical intervention to eliminate barriers to pain and fatigue  
33 management in oncology. *Journal of Palliative Medicine*, 14: 197-205.  
34 Not in PICO
- 35 Borneman, T., Piper, B. F., Koczywas, M., Munevar, C. M., Sun, V., Uman, G. C. & Ferrell, B. R. (2012)  
36 A qualitative analysis of cancer-related fatigue in ambulatory oncology. *Clinical Journal of*  
37 *Oncology Nursing*, 16: E26-E32.  
38 Not in PICO
- 39 Bos, E. (2008) "It is not going to happen to me". Andros male clinic: A diagnostic center for typical  
40 male problems. [Dutch]. *Pharmaceutisch Weekblad*, 143: 30-34.  
41 Narrative review
- 42 Braun, K. P., May, M., Grassmell, Y., Fuhrer, S., Hoschke, B. & Braun, V. (2008) The General  
43 Practitioner's part in the initiation of diagnostic procedures in prostate cancer. *Aktuelle Urologie*,  
44 39: 141-146.  
45 Not in PICO (referred population)
- 46 Brawer, M. K. (1993) The diagnosis of prostatic carcinoma. *Problems in Urology*, 7: 129-136.  
47 Narrative review
- 48 Bundred, N. J., Walls, J. & Ratcliffe, W. A. (1996) Parathyroid hormone-related protein, bone  
49 metastases and hypercalcaemia of malignancy. *Annals of the Royal College of Surgeons of*  
50 *England*, 78: 354-358.  
51 Not in PICO

- 1 Bunting, P. S., Goel, V., Williams, J. I. & Iscoe, N. A. (1999) Prostate-specific antigen testing in  
2 Ontario: reasons for testing patients without diagnosed prostate cancer. *Canadian Medical*  
3 *Association Journal*, 160: 70-75.  
4 Not in PICO
- 5 Buntinx, F. & Wauters, H. (1997) The diagnostic value of macroscopic haematuria in diagnosing  
6 urological cancers: A meta-analysis. *Family Practice*, 14: 63-68.  
7 SR, but no studies conducted in primary care included
- 8 Burnett, A. L. & Wein, A. J. (2006) Benign prostatic hyperplasia in primary care: What you need to  
9 know. *Journal of Urology*, 175: S19-S24.  
10 Narrative review
- 11 Cahill, D. (2005) The GP's role in lower urinary tract obstruction. *Practitioner*, 249: 38-42.  
12 Narrative review
- 13 Calhoun, E. A., Clemens, J. Q., Litwin, M. S., Walker-Corkery, E., Markossian, T., Kusek, J. W. &  
14 McNaughton-Collins, M. (2009) Primary care physician practices in the diagnosis, treatment and  
15 management of men with chronic prostatitis/chronic pelvic pain syndrome. *Prostate Cancer and*  
16 *Prostatic Diseases*, 12: 288-295.  
17 Not in PICO
- 18 Carey, M., Bryant, J., Yoong, S. L., Russell, G., Barker, D. & Sanson-Fisher, R. (2013) Prostate specific  
19 antigen testing in family practice: a cross sectional survey of self-reported rates of and reasons  
20 for testing participation and risk disclosure. *BMC Family Practice*, 14: 186.  
21 Not in PICO
- 22 Carlsson, L., Hakansson, A. & Nordenskjold, B. (2001) Common cancer-related symptoms among GP  
23 patients - Opportunistic screening in primary health care. *Scandinavian Journal of Primary Health*  
24 *Care*, 19: 199-203.  
25 Not in PICO
- 26 Cescon, D. W., Canil, C., Le, L. W. & Tannock, I. F. (2009) Use of the Prostate Cancer-specific Quality  
27 of Life Instrument (PROSQOLI) in clinical practice. *Journal of Clinical Oncology*, 27: e20569.  
28 Not in PICO
- 29 Chang, V. T., Hwang, S. S., Kasimis, B. & Thaler, H. T. (2004) Shorter symptom assessment  
30 instruments: The condensed Memorial Symptom Assessment Scale (CMSAS). *Cancer*  
31 *Investigation*, 22: 526-536.  
32 Not in PICO
- 33 Chisholm, G. D., Carne, S. J., Fitzpatrick, J. M., George, N. J. R., Gingell, J. C., Keen, J. W., Kirby, R. S.,  
34 Kirk, D., Odonoghue, E. P. N., Peeling, W. B., Shearer, R. J. & Williams, G. B. (1995) Prostate  
35 Disease - Management Options for the Primary Health-Care Team - Report of A Working Party of  
36 the British Prostate Group. *Postgraduate Medical Journal*, 71: 136-142.  
37 Narrative review
- 38 Clements, A., Watson, E., Rai, T., Bukach, C., Shine, B. & Austoker, J. (2007) The PSA testing dilemma:  
39 GPs' reports of consultations with asymptomatic men: a qualitative study. *BMC Family Practice*,  
40 8: 35.  
41 Not in PICO
- 42 Coeurdacier, P., Staerman, F., Thoquenne, G., Cipolla, B., Guille, F. & Lobel, B. (1996) [General  
43 practitioners' approach to urination disorders in men over the age of 50. A survey of 250  
44 physicians in Brittany]. [French]. *Progres En Urologie*, 6: 52-59.  
45 Not in PICO
- 46 Collins, M. (1997) Increasing prostate cancer awareness in African American men. *Oncology Nursing*  
47 *Forum*, 24: 91-95.  
48 Not in PICO
- 49 Collins, M. M., Barry, M., Roberts, R. G., Oesterling, J. E. & Fowler, F. J. (1997) Diagnosis and  
50 treatment of benign prostatic hyperplasia - Practice patterns of primary care physicians. *Journal*



- 1 of *General Internal Medicine*, 12: 224-229.  
 2 Not in PICO
- 3 Collins, M. M., O'Leary, M. P. & Barry, M. J. (1998) Prevalence of bothersome genitourinary  
 4 symptoms and diagnoses in younger men on routine primary care visits. *Urology*, 52: 422-427.  
 5 Not in PICO
- 6 Couzi, L., Cluzeau, J., Skopinski, S., Constans, J. & Conri, C. (2002) Henoch-Schonlein purpura and  
 7 prostatic carcinoma. [French]. *Revue de Medecine Interne*, 23: 717-719.  
 8 Not in PICO
- 9 Cunningham, R. S. (2006) Clinical practice guideline use by oncology advanced practice nurses.  
 10 *Applied Nursing Research*, 19: 126-133.  
 11 Not in PICO
- 12 D'Ambrosio, G. G., Campo, S., Cancian, M., Pecchioli, S. & Mazzaglia, G. (2010) Opportunistic  
 13 prostate-specific antigen screening in Italy: 6 years of monitoring from the Italian general practice  
 14 database. *European Journal of Cancer Prevention*, 19: 413-416.  
 15 Not in PICO
- 16 Dalla, P. L., Ricci, C. & Magnaldi, S. (1995) Referral criteria for selection of patients and diagnostic  
 17 procedures. *Radiation Protection Dosimetry*, 57: 3-8.  
 18 Narrative review
- 19 Davalli, P., Rizzi, F., Caporali, A., Pellacani, D., Davoli, S., Bettuzzi, S., Brausi, M. & D'Arca, D. (2012)  
 20 Anticancer activity of green tea polyphenols in prostate gland. [Review]. *Oxidative medicine &  
 21 cellular longevity*, 2012: 984219.  
 22 Narrative review
- 23 Delgado-Guay, M. O., Yennurajalingam, S. & Bruera, E. (2008) Delirium with severe symptom  
 24 expression related to hypercalcemia in a patient with advanced cancer: an interdisciplinary  
 25 approach to treatment. *Journal of Pain and Symptom Management*, 36: 442-449.  
 26 Not in PICO
- 27 Delongchamps, N. B., Peyromaure, M., Schull, A., Beuvon, F., Bouazza, N., Flam, T., Zerbib, M.,  
 28 Muradyan, N., Legman, P. & Cornud, F. (2013) Prebiopsy magnetic resonance imaging and  
 29 prostate cancer detection: comparison of random and targeted biopsies. *Journal of Urology*, 189:  
 30 493-499.  
 31 Not in PICO
- 32 Drummond, F., Carsin, A. E., Sharp, L. & Comber, H. (2009) Factors prompting PSA-testing of  
 33 asymptomatic men in a country with no guidelines: a national survey of general practitioners.  
 34 *BMC Family Practice*, 10: 3.  
 35 Not in PICO
- 36 Durmus, T., Goldmann, U., Baur, A. D., Huppertz, A., Schwenke, C., Hamm, B. & Franiel, T. (2013)  
 37 MR-guided biopsy of the prostate: comparison of diagnostic specimen quality with 18 G and 16 G  
 38 biopsy needles. *European Journal of Radiology*, 82: e749-e754.  
 39 Not in PICO
- 40 Ebrahimi, M., Assadi, M. & Rezaei, M. M. (2012) New bone pain palliation radiopharmaceuticals in  
 41 Iran. *Iranian Journal of Nuclear Medicine*, 20: 135.  
 42 Narrative review
- 43 Edwards, J. L. (2008) Diagnosis and management of benign prostatic hyperplasia. *American Family  
 44 Physician*, 77: 1403-1410+1413.  
 45 Narrative review
- 46 Emery, J. D., Walter, F. M., Gray, V., Sinclair, C., Howting, D., Bulsara, M., Bulsara, C., Webster, A.,  
 47 Auret, K., Saunders, C., Nowak, A. & Holman, C. D. (2013) Diagnosing cancer in the bush: a mixed-  
 48 methods study of symptom appraisal and help-seeking behaviour in people with cancer from  
 49 rural Western Australia. *Family Practice*, 30: 294-301.  
 50 Not in PICO

- 1 Fawzy, A., Fontenot, C., Guthrie, R. & Baudier, M. M. (1997) Practice patterns among primary care  
2 physicians in benign prostatic hyperplasia and prostate cancer. *Family Medicine*, 29: 321-325.  
3 Not in PICO
- 4 Fernandez, J. C., Olmo, J. M. C., Fernandez-Pro, A., Martin, J. A., Bermudez, F. J. B., Pulido, E. N.,  
5 Molero, J. M. & Morales, D. P. (2010) Referral criteria for benign prostatic hyperplasia in primary  
6 care. *Actas Urologicas Espanolas*, 34: 24-34.  
7 Narrative review
- 8 Fiset, P. O., Aprikian, A. & Brimo, F. (2013) Length of prostate biopsy cores: does it impact cancer  
9 detection? *Canadian Journal of Urology*, 20: 6848-6853.  
10 Not in PICO
- 11 Fitzpatrick, P., Corcoran, N. & Fitzpatrick, J. M. (1998) Prostate cancer: how aware is the public?  
12 *British Journal of Urology*, 82: 43-48.  
13 Not in PICO
- 14 Fletcher, S. G., Clark, S. J., Overstreet, D. L. & Steers, W. D. (1126) An improved approach to followup  
15 care for the urological patient: drop-in group medical appointments. *Journal of Urology*, 176:  
16 1122-1126.  
17 Not in PICO
- 18 Forbes, L. J. L., Warburton, F., Richards, M. A. & Ramirez, A. J. (2014) Risk factors for delay in  
19 symptomatic presentation: A survey of cancer patients. *British Journal of Cancer*, 111: 581-588.  
20 Not in PICO
- 21 Franc, B. L., Cho, S. Y., Rosenthal, S. A., Cui, Y., Tsui, B., Vandewalker, K. M., Holz, A. L., Poonamallee,  
22 U., Pomper, M. G. & James, R. B. (2013) Detection and localization of carcinoma within the  
23 prostate using high resolution transrectal gamma imaging (TRGI) of monoclonal antibody directed  
24 at prostate specific membrane antigen (PSMA)--proof of concept and initial imaging results.  
25 *European Journal of Radiology*, 82: 1877-1884.  
26 Not in PICO
- 27 Franiel, T., Vargas, H. A., Mazaheri, Y., Bohmer, S., Hricak, H., Akin, O. & Beyersdorff, D. (2013) Role  
28 of endorectal prostate MRI in patients with initial suspicion of prostate cancer.[Erratum appears  
29 in Rofo. 2013 Sep;184(10):E5 Note: Vargas, A H [corrected to Vargas, H A]]. *Rofo: Fortschritte auf  
30 dem Gebiete der Rontgenstrahlen und der Nuklearmedizin*, 184: 967-974.  
31 Not in PICO
- 32 Fransson, P. (2008) Quality of life for members of Swedish Prostate Cancer Patient Associations.  
33 *Cancer Nursing*, 31: 23-31.  
34 Not in PICO
- 35 Frydenberg, M. & Wijesinha, S. (2007) Diagnosing prostate cancer - What GPs need to know.  
36 *Australian Family Physician*, 36: 345-347.  
37 Narrative review
- 38 Fukagai, T., Maruyama, K., Nagata, M., Morita, M., Naoe, M. & Yoshida, H. (2007) Practice patterns  
39 regarding prostate cancer and benign prostatic hyperplasia in Japanese primary care  
40 practitioners. *International Journal of Urology*, 14: 412-415.  
41 Not in PICO
- 42 Gades, N. M., Jacobson, D. J., Girman, C. J., Roberts, R. O., Lieber, M. M. & Jacobsen, S. J. (2005)  
43 Prevalence of conditions potentially associated with lower urinary tract symptoms in men. *BJU  
44 International*, 95: 549-553.  
45 Not in PICO
- 46 Ganie, F. A., Wani, M. S., Shaheen, F., Wani, M. L., Ganie, S. A., Mir, M. F., Wani, S. N. & Masaratul, G.  
47 (2013) Endorectal coil MRI and MR-spectroscopic imaging in patients with elevated serum  
48 prostate specific antigen with negative trus transrectal ultrasound guided biopsy. *Urology annals*,  
49 5: 172-178.  
50 Not in PICO

- 1 Gao, X., Porter, A. T., Grignon, D. J., Pontes, J. E. & Honn, K. V. (1997) Diagnostic and prognostic  
2 markers for human prostate cancer. [Review] [185 refs]. *Prostate*, 31: 264-281.  
3 Narrative review
- 4 Gentile, M., Carini, M., Morgia, G., Selvaggi, F. P., Randone, D. & Rosati, A. (2001) Management of  
5 patients with LUTS suggestive of BPH. *European Urology*, 40: 5-8.  
6 Narrative review
- 7 Giordana, M. T., Cordera, S. & Boghi, A. (2000) Cerebral metastases as first symptom of cancer: a  
8 clinico-pathologic study. *Journal of Neuro-Oncology*, 50: 265-273.  
9 Narrative review
- 10 Gittens, P. R., Lallas, C. D., Pe, M. L., Perkel, R., Folia, C. & Gomella, L. G. (2008) Uro pharmacology for  
11 the primary care physician. [Review] [86 refs]. *Canadian Journal of Urology*, 15: Suppl-91.  
12 Narrative review
- 13 Gjengsto, P., Eide, J., Frugard, J., Bakke, A. & Hoisaeter, P. A. (2004) The potentially curable prostate  
14 cancer patient and the pathways leading to diagnosis and treatment. *Scandinavian Journal of  
15 Urology and Nephrology*, 38: 15-18.  
16 Not in PICO
- 17 Godley, P. A. & Carpenter, W. R. (2007) Case-control prostate cancer screening studies should not  
18 exclude subjects with lower urinary tract symptoms. *Journal of Clinical Epidemiology*, 60: 176-  
19 180.  
20 Narrative review
- 21 Goedendorp, M. M., Gielissen, M. F., Verhagen, C. A., Peters, M. E. & Bleijenberg, G. (2008) Severe  
22 fatigue and related factors in cancer patients before the initiation of treatment. *British Journal of  
23 Cancer*, 99: 1408-1414.  
24 Not in PICO
- 25 Gonsalves, L., Cartmel, B. & Mueller, L. (2012) The burden of cancer in Connecticut. *Connecticut  
26 Medicine*, 76: 335-351.  
27 Not in PICO
- 28 Gottesman, J. & Baum, N. (1997) Common urologic disorders: When to treat and when to refer.  
29 *Postgraduate Medicine*, 102: 235-246.  
30 Narrative review
- 31 Gourova, L. W., van de Beek, C., Spigt, M. G., Nieman, F. H. & van Kerrebroeck, P. E. (2006) Predictive  
32 factors for nocturia in elderly men: a cross-sectional study in 21 general practices. *BJU  
33 International*, 97: 528-532.  
34 Not in PICO
- 35 Gratzke, C., Schlenker, B., Weidlich, P., Seitz, M., Reich, O. & Stief, C. G. (2007) Benign prostatic  
36 hyperplasia: Background and diagnosis. [German]. *MMW-Fortschritte der Medizin*, 149: 25-28.  
37 Narrative review
- 38 Gray, M. A., Crampton, P., Weinstein, P. & Nacey, J. N. (2004) Differences in prostate disease  
39 symptoms and visits to the general practitioner among three ethnic groups in New Zealand. *BJU  
40 International*, 94: 96-100.  
41 Not in PICO
- 42 Greenwald, H. P., Bonica, J. J. & Bergner, M. (1987) The prevalence of pain in four cancers. *Cancer*,  
43 60: 2563-2569.  
44 Not in PICO
- 45 Gui, Q., Xu, C., Zhao, X., Wang, X., Yang, L., Duan, X., Li, H., Yang, Z. & Hu, W. (2013) Diagnostic value  
46 of transrectal real-time elastography in prostatic benign and malignant lesions. *Chinese Journal of  
47 Andrology*, 27: 14-17+21.  
48 Not in PICO
- 49 Gutierrez, C., Hernansanz, S., Rubiales, A. S., Del Valle, M. L., Cuadrillero, R. F., Flores, L. A. & Garcia,  
50 C. (2006) Clinical manifestations and care in tumors with pelvic involvement: Is there a pelvic

- 1 syndrome in Palliative Care?. [Spanish]. *Medicina Paliativa*, 13: 32-36.  
2 Not in PICO
- 3 Hamilton, W. & Sharp, D. (2004) Symptomatic diagnosis of prostate cancer in primary care: a  
4 structured review. *British Journal of General Practice*, 54: 617-621.  
5 Narrative review
- 6 Hamilton, W. (2009) The CAPER studies: five case-control studies aimed at identifying and  
7 quantifying the risk of cancer in symptomatic primary care patients. *British Journal of Cancer*,  
8 101: Suppl-6.  
9 Narrative review
- 10 Hamilton, W. (2009) Five misconceptions in cancer diagnosis. *British Journal of General Practice*, 59:  
11 441-447.  
12 Narrative review
- 13 Hamilton, W. (2010) Cancer diagnosis in primary care. *British Journal of General Practice*, 60: 121-  
14 128.  
15 Narrative review
- 16 Hansen, R., Vedsted, P., Sokolowski, I., Sondergaard, J. & Olesen, F. (2011) Time intervals from first  
17 symptom to treatment of cancer: a cohort study of 2,212 newly diagnosed cancer patients. *BMC*  
18 *Health Services Research*, 11: 284.  
19 Not in PICO
- 20 Hawary, A. M., Warburton, H. E., Brough, R. J., Collins, G. N., Brown, S. C., O'Reilly, P. H. & Adeyoju,  
21 A. A. (2008) The '2-week wait' rule for referrals for suspected urological cancers--urgent need for  
22 refinement of criteria. *Annals of the Royal College of Surgeons of England*, 90: 517-522.  
23 Not in PICO
- 24 Heedman, P. A. & Strang, P. (2003) Pain and pain alleviation in hospital-based home care:  
25 demographic, biological and treatment factors. *Supportive Care in Cancer*, 11: 35-40.  
26 Not in PICO
- 27 Heins, M. J., Korevaar, J. C., Rijken, P. M. & Schellevis, F. G. (2013) For which health problems do  
28 cancer survivors visit their General Practitioner? *European Journal of Cancer*, 49: 211-218.  
29 Not in PICO
- 30 Heinzer, H. & Steuber, T. (2009) Prostate cancer in the elderly. *Urologic Oncology*, 27: 668-672.  
31 Narrative review
- 32 Helmy, H., Rasheed, M. & Al-Abd, S. (2009) Vardenafil improves erectile function and urinary  
33 symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with  
34 benign prostatic hyperplasia: A randomized, double-blind, placebo controlled trial. *European*  
35 *Urology, Supplements*, 8: 238.  
36 Not in PICO
- 37 Herman, C. J., Hoffman, R. M. & Altobelli, K. K. (1999) Variation in recommendations for cancer  
38 screening among primary care physicians in New Mexico. *Journal of Community Health*, 24: 253-  
39 267.  
40 Not in PICO
- 41 Hicks, R. J. & Cook, J. B. (1995) Managing patients with benign prostatic hyperplasia. *American*  
42 *Family Physician*, 52: 135-142.  
43 Narrative review
- 44 Higano, C. S. (2014) - To treat or not to treat, that is the question: the role of bone-targeted therapy  
45 in metastatic prostate cancer. - *Journal of Clinical Oncology*, 32: 1107-1111.  
46 Not in PICO
- 47 Hodgson, F., Obertova, Z., Brown, C. & Lawrenson, R. (2012) PSA testing in general practice. *Journal*  
48 *of Primary Health Care*, 4: 199-204.  
49 Not in PICO

- 1 Hofstetter, A. (2004) The 10-minute consultation. With weak discharge often past the target...  
 2 [German]. *MMW Fortschritte der Medizin*, 146: 67-68.  
 3 Narrative review
- 4 Holden, J. & Emery, C. B. (2004) Prostate cancer. Primary care providers play critical role. *Advance  
 5 for Nurse Practitioners*, 12: 28-35.  
 6 Narrative review
- 7 Horchani, A., Binous, M. Y., Ben, H. A., Sallami, S., El, A. H. & Naji, A. (2007) [Prevalence of benign  
 8 prostatic hyperplasia in general practice and practical approach of the Tunisian general  
 9 practitioner (Prevapt study)]. [French]. *Tunisie Medicale*, 85: 619-624.  
 10 Not in PICO
- 11 Huang, S., Lin, J., Guo, N., Zhang, M., Yun, X., Liu, S., Zhou, J., He, E. & Skog, S. (2011) Elevated serum  
 12 thymidine kinase 1 predicts risk of pre/early cancerous progression. *Asian Pacific Journal of  
 13 Cancer Prevention: Apjcp*, 12: 497-505.  
 14 Not in PICO
- 15 Hughes, A. M., Sladden, M. J., Hirst, G. H. & Ward, J. E. (2000) Community study of uncomplicated  
 16 lower urinary tract symptoms among male Italian immigrants in Sydney, Australia. *European  
 17 Urology*, 37: 191-198.  
 18 Not in PICO
- 19 Ikoma, F., Mori, Y., Arima, M., Shimada, K., Shima, H., Terakawa, T., Kanokogi, M., Yabumoto, H.,  
 20 Fujisue, K. & Tsujimoto, S. (1988) Clinical statistics on outpatients, inpatients and operations in  
 21 1986. [Japanese]. *Hinyokika kiyo, Acta*: 2047-2052.  
 22 Not in PICO
- 23 Jarvis, S. (2003) The CHARM study: Implications for general practice a commentary from primary  
 24 care. *British Journal of Cardiology*, 10: 337-338.  
 25 Not in PICO
- 26 Jichlinski, P. (2014) Urology. [French]. *Revue Medicale Suisse*, 10: 127-129.  
 27 Duplicate
- 28 Jichlinski, P. (2014) - [Urology]. [Review] [French]. - *Revue Medicale Suisse*, 10: 127-129.  
 29 Narrative review
- 30 Jolly, S., Howson, J., Catto, J., Haynes, M., Cutinha, P., Yates, D. & Rosario, D. (2013) Clinical  
 31 microsystems in designing trus-biopsy services - A closed-loop audit of a specialist nurse-led  
 32 triage clinic for men with suspected prostate cancer. *International Journal of Surgery*, 11: 727.  
 33 Not in PICO
- 34 Jordan, K. P., Hayward, R. A., Blagojevic-Bucknall, M. & Croft, P. (2013) Incidence of prostate, breast,  
 35 lung and colorectal cancer following new consultation for musculoskeletal pain: A cohort study  
 36 among UK primary care patients. *International Journal of Cancer*, 133: 713-720.  
 37 Duplicate
- 38 Jordan, K. P., Hayward, R. A., Blagojevic-Bucknall, M. & Croft, P. (2013) Incidence of prostate, breast,  
 39 lung and colorectal cancer following new consultation for musculoskeletal pain: a cohort study  
 40 among UK primary care patients. *International Journal of Cancer*, 133: 713-720.  
 41 Cannot extract outcome in PICO (PPVs) as cancer data only reported in total for 10-year follow up
- 42 Kamalov, A. A., Maksimov, V. A., Takhirzade, T. B., Gevorkian, A. R., Okhobotov, D. A., Avakian, A. I. &  
 43 Vasil'eva, E. G. (2012) [Detection of prostate cancer based on monitoring of prostate-specific  
 44 antigen in outpatient clinic]. [Russian]. *Urologiia (Moscow, Russia)*.(6):58-60, 2012 Sep-Oct., 58-  
 45 60.  
 46 Not in PICO
- 47 Kaplan, S. & Naslund, M. (2006) Public, patient, and professional attitudes towards the diagnosis and  
 48 treatment of enlarged prostate: A landmark national US survey. *International Journal of Clinical  
 49 Practice*, 60: 1157-1165.  
 50 Not in PICO

- 1 Kapoor, A. (2012) Benign prostatic hyperplasia (BPH) management in the primary care setting.  
2 *Canadian Journal of Urology*, 19: Suppl-7.  
3 Narrative review
- 4 Karakiewicz, P. I., Aprikian, A. G., Bazinet, M. & Elhilali, M. M. (1997) Patient attitudes regarding  
5 treatment-related erectile dysfunction at time of early detection of prostate cancer. *Urology*, 50:  
6 704-709.  
7 Not in PICO
- 8 Katz, B., Srougi, M., Dall'Oglio, M., Nesrallah, A. J., Sant'anna, A. C., Pontes, J., Jr., Reis, S. T., Sanudo,  
9 A., Camara-Lopes, L. H. & Leite, K. R. (2012) Are we able to correctly identify prostate cancer  
10 patients who could be adequately treated by focal therapy? *Urologic Oncology*, 30: 794-797.  
11 Not in PICO
- 12 Khan, M. A., Shaw, G. & Paris, A. M. (2002) Is microscopic haematuria a urological emergency? *BJU*  
13 *International*, 90: 355-357.  
14 Not in PICO
- 15 Khoury, S., Cockett, A., Aso, Y., Chatelain, C., Andersson, L., Abrams, P., Griffiths, K. & Denis, L. (2000)  
16 International Consultation on Urological Diseases: a decade of progress. *Prostate*, 45: 194-199.  
17 Narrative review
- 18 Kim, Y. M., Kim, J., Park, S., Lee, J. H., Ryu, D. S., Choi, S. H. & Cheon, S. H. (2013) Role of prostate  
19 volume in the early detection of prostate cancer in a cohort with slowly increasing prostate  
20 specific antigen. *Yonsei Medical Journal*, 54: 1202-1206.  
21 Not in PICO
- 22 Kimura, T., Ikemoto, I. & Ohishi, Y. (2000) [Clinical profiles of prostate cancer in our hospital:  
23 association between primary symptoms and clinical stage]. [Japanese]. *Hinyokika Kiyo - Acta*  
24 *Urologica Japonica*, 46: 83-86.  
25 Not in PICO
- 26 Kirkham, A. P., Haslam, P., Keanie, J. Y., McCafferty, I., Padhani, A. R., Punwani, S., Richenberg, J.,  
27 Rottenberg, G., Sohaib, A., Thompson, P., Turnbull, L. W., Kurban, L., Sahdev, A., Clements, R.,  
28 Carey, B. M. & Allen, C. (2013) Prostate MRI: who, when, and how? Report from a UK consensus  
29 meeting. *Clinical Radiology*, 68: 1016-1023.  
30 Narrative review
- 31 Kiyota, H., Onodera, S., Ohishi, Y., Tsukamoto, T. & Matsumoto, T. (2003) Questionnaire survey of  
32 Japanese urologists concerning the diagnosis and treatment of chronic prostatitis and chronic  
33 pelvic pain syndrome. *International Journal of Urology*, 10: 636-642.  
34 Not in PICO
- 35 Koo, J. H., Kim, C. K., Choi, D., Park, B. K., Kwon, G. Y. & Kim, B. (2013) Diffusion-weighted magnetic  
36 resonance imaging for the evaluation of prostate cancer: optimal B value at 3T. *Korean Journal of*  
37 *Radiology*, 14: 61-69.  
38 Not in PICO
- 39 Krause, B. J., Souvatzoglou, M. & Treiber, U. (2013) Imaging of prostate cancer with PET/CT and  
40 radioactively labeled choline derivatives. [Review]. *Urologic Oncology*, 31: 427-435.  
41 Narrative review
- 42 Kumar, P., Kapoor, S. & Nargund, V. (2006) Haemospermia - a systematic review. [Review] [15  
43 refs]. *Annals of the Royal College of Surgeons of England*, 88: 339-342.  
44 Narrative review
- 45 Lamy, P. J., Montels, F., Tosi, D., Leizour, B., Bascoul-Mollevis, C., Castan, F., Roques, S., Nielloud, F. &  
46 Rebillard, X. (2013) [Evaluation of (-2)proPSA in combination with total PSA and free PSA for the  
47 early detection of prostate cancer]. [French]. *Annales de Biologie Clinique*, 71: 537-544.  
48 Not in PICO
- 49 Lane, J. A., Hamdy, F. C., Martin, R. M., Turner, E. L., Neal, D. E. & Donovan, J. L. (2010) Latest results  
50 from the UK trials evaluating prostate cancer screening and treatment: The CAP and ProtecT

- 1 studies. *European Journal of Cancer*, 46: 3095-3101.
- 2 Not in PICO
- 3 Leader, A., Daskalakis, C., Braddock, C. H., III, Kunkel, E. J., Cocroft, J. R., Berekenyei, S., Riggio, J. M.,  
4 Capkin, M. & Myers, R. E. (2012) Measuring informed decision making about prostate cancer  
5 screening in primary care. *Medical Decision Making*, 32: 327-336.
- 6 Not in PICO
- 7 Lee, S. J., Hwang, I., Hwang, E. C., Jung, S. I., Kang, T. W., Kwon, D. D. & Park, K. (2013) Are more low-  
8 risk prostate cancers detected by repeated biopsy? A retrospective pilot study. *Korean Journal of*  
9 *Urology*, 54: 364-368.
- 10 Not in PICO
- 11 Lenk, V. S. (2005) [Diagnosis of the "aging male"--what is recommended?]. [Review] [27 refs]  
12 [German]. *Urologe (Ausg.A)*, 44: 1167-1172.
- 13 Narrative review
- 14 Li, L., Wang, L., Feng, Z., Hu, Z., Wang, G., Yuan, X., Wang, H. & Hu, D. (2013) Prostate cancer  
15 magnetic resonance imaging (MRI): multidisciplinary standpoint. *Quantitative Imaging in*  
16 *Medicine & Surgery*, 3: 100-112.
- 17 Narrative review
- 18 Lippi, G., Plebani, M., Franchini, M., Guidi, G. C. & Favaloro, E. J. (2009) Prostate-specific antigen,  
19 prostate cancer, and disorders of hemostasis. [Review] [111 refs]. *Seminars in Thrombosis &*  
20 *Hemostasis*, 35: 654-664.
- 21 Narrative review
- 22 Litwin, M. S., Lubeck, D. P., Henning, J. M. & Carroll, P. R. (1998) Differences in urologist and patient  
23 assessments of health related quality of life in men with prostate cancer: results of the CaPSURE  
24 database. *Journal of Urology*, 159: 1988-1992.
- 25 Not in PICO
- 26 Liu, J., Yue, Q.-X., Zhou, Y., Yu, G.-H. & Li, S. (2013) Application of transrectal real-time elastography  
27 in prostate biopsy. [Chinese]. *Chinese Journal of Interventional Imaging and Therapy*, 10: 101-  
28 103.
- 29 Not in PICO
- 30 Mannini, D., Ferri, C., Maver, P., Corrado, G., Stasi, G., Querze, R., Bacchini, P. & Galanti, G. (1992)  
31 Nonspecific granulomatous prostatitis (PGA): Diagnosis and follow-up. [Italian]. *Acta Urologica*  
32 *Italica*, 6: 479-480.
- 33 Not in PICO
- 34 Mansson, J. & Bengtsson, C. (1994) Prostate cancer. From the general practitioner's point of view.  
35 *Neoplasma*, 41: 237-240.
- 36 Not in PICO
- 37 Mansson, J., Bjorkelund, C. & Hultborn, R. (1999) Symptom pattern and diagnostic work-up of  
38 malignancy at first symptom presentation as related to level of care. A retrospective study from  
39 the primary health care centre area of Kungsbacka, Sweden. *Neoplasma*, 46: 93-99.
- 40 Not in PICO
- 41 Mansson, J., Marklun, B. & Hultborn, R. (2001) The diagnosis of cancer in the "roar" of potential  
42 cancer symptoms of patients in primary health care. Research by means of the computerised  
43 journal. *Scandinavian Journal of Primary Health Care*, 19: 83-89.
- 44 Symptoms not linked with cancers; analysis based on number of codes, not patients.
- 45 Mansson, J., Marklund, B. & Carlsson, P. (2006) Costs in primary care of investigating symptoms  
46 suspicious of cancer in a defined population. *Scandinavian Journal of Primary Health Care*, 24:  
47 243-250.
- 48 Symptoms not linked with cancers; analysis based on number of codes, not patients
- 49 Martin, R. M., Vatten, L., Gunnell, D., Romundstad, P. & Nilsen, T. I. (2008) Lower urinary tract  
50 symptoms and risk of prostate cancer: the HUNT 2 Cohort, Norway. *International Journal of*

- 1 *Cancer*, 123: 1924-1928.  
2 Not in PICO
- 3 Mason, M. D., Bosnyak, Z., Malmberg, A. & Neijber, A. (2014) Lower urinary tract symptoms (LUTS)  
4 in prostate cancer (PC) patients treated with GnRH antagonist compared to agonist: Results of a  
5 pooled analysis. *Journal of Clinical Oncology*, 32.  
6 Not in PICO
- 7 Matthew, A. G., Currie, K. L., Irvine, J., Ritvo, P., Santa, M. D., Jamnicky, L., Nam, R. & Trachtenberg, J.  
8 (2007) Serial personal digital assistant data capture of health-related quality of life: a randomized  
9 controlled trial in a prostate cancer clinic. *Health & Quality of Life Outcomes*, 5: 38.  
10 Not in PICO
- 11 Mazzola, C. R., Ghoneim, T. & Shariat, S. F. (2011) [Emerging biomarkers for the diagnosis, staging  
12 and prognosis of prostate cancer]. [Review] [French]. *Progres En Urologie*, 21: 1-10.  
13 Narrative review
- 14 McCombie, S., Logan, C., Hawks, C., Ling, O. W. & Hayne, D. (2014) The 'one stop' prostate clinic: A  
15 report on Fremantle Hospital's first 200 patients. *BJU International*, 113: 37.  
16 Not in PICO
- 17 McNaughton-Collins, M. & Barry, M. J. (2005) Managing patients with lower urinary tract symptoms  
18 suggestive of benign prostatic hyperplasia. *American Journal of Medicine*, 118: 1331-1339.  
19 Narrative review
- 20 McVary, K. T., Monnig, W., Camps, J., Young, J. M., Tseng, L.-J. & van den Ende, G. (2007) Sildenafil  
21 Citrate Improves Erectile Function and Urinary Symptoms in Men With Erectile Dysfunction and  
22 Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Randomized,  
23 Double-Blind Trial. *Journal of Urology*, 177: 1071-1077.  
24 Not in PICO
- 25 Melia, J., Moss, S. & Johns, L. (2004) Rates of prostate-specific antigen testing in general practice in  
26 England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. *BJU  
27 International*, 94: 51-56.  
28 Not in PICO
- 29 Melia, J., Coulson, P., Coleman, D. & Moss, S. (2008) Urological referral of asymptomatic men in  
30 general practice in England. *British Journal of Cancer*, 98: 1176-1181.  
31 Not in PICO
- 32 Melia, J., Coulson, P., Moss, S. & Coleman, D. (2010) Effects of a prostate awareness pilot on GP  
33 consultations and PSA requests. *Family Practice*, 27: 69-76.  
34 Not in PICO
- 35 Mengus, C., Le, M. C., Trella, E., Yousef, K., Bubendorf, L., Provenzano, M., Bachmann, A., Heberer,  
36 M., Spagnoli, G. C. & Wyler, S. (2011) Elevated levels of circulating IL-7 and IL-15 in patients with  
37 early stage prostate cancer. *Journal of Translational Medicine*, 9: 162.  
38 Not in PICO
- 39 Merino, M., Gonzales, E. L. M., Rodriguez, L. & Roehrborn, C. G. (2009) The Health Improvement  
40 Network (THIN) database: Focused safety study of acute urinary retention (AUR) in men. *Journal  
41 of Urology*, 181: 593.  
42 Not in PICO
- 43 Mischi, M., Saidov, T., Kompatsiari, K., Engelbrecht, M. R., Breeuwer, M. & Wijkstra, H. (2013)  
44 Prostate cancer localization by novel magnetic resonance dispersion imaging. *Conference  
45 Proceedings: ...Annual International Conference of the IEEE Engineering in Medicine & Biology  
46 Society*, 2013: 2603-2606.  
47 Narrative review
- 48 Miser, W. F. (2007) Cancer screening in the primary care setting - The role of the primary care  
49 physician in screening for breast, cervical, colorectal, lung, ovarian, and prostate cancers. *Primary  
50 Care*, 34: 137-+.  
51 Narrative review



- 1 Mishina, T. (1992) [Clinical statistics on outpatients at Mishina urological office between July, 1984  
2 and December, 1990]. [Japanese]. *Hinyokika Kiyō - Acta Urologica Japonica*, 38: 367-372.  
3 Not in PICO
- 4 Mohamed, Z. K., Dominguez-Escrig, J., Vasdev, N., Bharathan, B. & Greene, D. (2013) The prognostic  
5 value of transrectal ultrasound guided biopsy in patients over 70 years old with a prostate  
6 specific Antigen (PSA) level <15 ng/ml and normal digital rectal examination: A 10-year  
7 prospective follow-up study of 427 consecutive patients. *Urologic Oncology: Seminars and  
8 Original Investigations*, 31: 1489-1496.  
9 Not in PICO
- 10 Mold, J. W., Holtgrave, D. R., Bissoni, R. S., Marley, D. S., Wright, R. A. & Spann, S. J. (1992) The  
11 Evaluation and Treatment of Men with Asymptomatic Prostate Nodules in Primary Care - A  
12 Decision-Analysis. *Journal of Family Practice*, 34: 561-568.  
13 Not in PICO
- 14 Molero, J. M., Morales, D. P., Bermudez, F. J. B., Pulido, E. N., Fernandez-Pro, A., Martin, J. A.,  
15 Fernandez, J. C. & Olmo, J. M. C. (2010) Referral criteria for benign prostatic hyperplasia in  
16 primary care. *Atencion Primaria*, 42: 36-46.  
17 Narrative review
- 18 Molina, R., Bosch, X., Auge, J. M., Filella, X., Escudero, J. M., Molina, V., Sole, M. & Lopez-Soto, A.  
19 (2012) Utility of serum tumor markers as an aid in the differential diagnosis of patients with  
20 clinical suspicion of cancer and in patients with cancer of unknown primary site. *Tumor Biology*,  
21 33: 463-474.  
22 Not in PICO
- 23 Monreal, M., Fernandez-Llamazares, J., Perandreu, J., Urrutia, A., Sahuquillo, J. C. & Contel, E. (1997)  
24 Occult cancer in patients with venous thromboembolism: which patients, which cancers.  
25 *Thrombosis & Haemostasis*, 78: 1316-1318.  
26 Not in PICO
- 27 Monreal, M. & Prandoni, P. (1999) Venous thromboembolism as first manifestation of cancer.  
28 [Review] [31 refs]. *Seminars in Thrombosis & Hemostasis*, 25: 131-136.  
29 Narrative review
- 30 Morris, L., Gorayski, P. & Turner, S. (2014) - Back pain in a cancer patient: a case study. - *Australian  
31 Family Physician*, 43: 529-530.  
32 Not in PICO
- 33 Mouraviev, V., Verma, S., Kalyanaraman, B., Zhai, Q. J., Gaitonde, K., Pugnale, M. & Donovan, J. F.  
34 (2013) The feasibility of multiparametric magnetic resonance imaging for targeted biopsy using  
35 novel navigation systems to detect early stage prostate cancer: the preliminary experience.  
36 *Journal of Endourology*, 27: 820-825.  
37 Not in PICO
- 38 Mouton, W. G., Kienle, Y., Muggli, B., Naef, M. & Wagner, H. E. (2009) Tumors associated with  
39 superficial thrombophlebitis. *Vasa - Journal of Vascular Diseases*, 38: 167-170.  
40 Not in PICO
- 41 Mowatt, G., Scotland, G., Boachie, C., Cruickshank, M., Ford, J. A., Fraser, C., Kurban, L., Lam, T. B.,  
42 Padhani, A. R., Royle, J., Scheenen, T. W. & Tassie, E. (2001) The diagnostic accuracy and cost-  
43 effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging  
44 techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and  
45 economic evaluation. *Health technology assessment (Winchester, England)*, 17: vii-281.  
46 Not in PICO
- 47 Naslund, M. J., Gilsenan, A. W., Midkiff, K. D., Bown, A., Wolford, E. T. & Wang, J. (2007) Prevalence  
48 of lower urinary tract symptoms and prostate enlargement in the primary care setting.  
49 *International Journal of Clinical Practice*, 61: 1437-1445.  
50 Not in PICO

- 1 Neal, R. D., Allgar, V. L., Ali, N., Leese, B., Heywood, P., Proctor, G. & Evans, J. (2007) Stage, survival  
2 and delays in lung, colorectal, prostate and ovarian cancer: Comparison between diagnostic  
3 routes. *British Journal of General Practice*, 57: 212-219.  
4 Not in PICO
- 5 Neal, R. D., Pasterfield, D., Wilkinson, C., Hood, K., Makin, M. & Lawrence, H. (2008) Determining  
6 patient and primary care delay in the diagnosis of cancer - lessons from a pilot study of patients  
7 referred for suspected cancer. *BMC Family Practice*, 9.  
8 Not in PICO
- 9 Neheman, A., Shotland, Y., Metz, Y. & Stein, A. (1988) [Screening for early detection of prostate  
10 cancer (first experience in Israel)]. [Hebrew]. *Harefuah*, 140: 4-10.  
11 Not in PICO
- 12 Neppl-Huber, C., Zappa, M., Coebergh, J. W., Rapiti, E., Rachtan, J., Holleczeck, B., Rosso, S., Aareleid,  
13 T., Brenner, H., Gondos, A. & EUNICE Survival Working Group (2012) Changes in incidence,  
14 survival and mortality of prostate cancer in Europe and the United States in the PSA era:  
15 additional diagnoses and avoided deaths. *Annals of Oncology*, 23: 1325-1334.  
16 Not in PICO
- 17 Ng, Y. H., Seeley, J. P. & Smith, G. (2013) Haemospermia as a presenting symptom: Outcomes of  
18 investigation in 300 men. *Surgeon-Journal of the Royal Colleges of Surgeons of Edinburgh and  
19 Ireland*, 11: 35-38.  
20 Not in PICO
- 21 Ng, Y. H., Seeley, J. P. & Smith, G. (2013) Haemospermia as a presenting symptom: outcomes of  
22 investigation in 300 men. *Surgeon Journal of the Royal Colleges of Surgeons of Edinburgh &  
23 Ireland*, 11: 35-38.  
24 Not in PICO
- 25 Ngo, T. C., Turnbull, B. B., Lavori, P. W. & Presti, J. C. (2011) The Prostate Cancer Risk Calculator From  
26 the Prostate Cancer Prevention Trial Underestimates the Risk of High Grade Cancer in  
27 Contemporary Referral Patients. *Journal of Urology*, 185: 483-487.  
28 Not in PICO
- 29 Nielsen, T. N., Hansen, R. P. & Vedsted, P. (2010) [Symptom presentation in cancer patients in  
30 general practice]. [Danish]. *Ugeskrift for Laeger*, 172: 2827-2831.  
31 Not in PICO
- 32 Numao, N., Yoshida, S., Komai, Y., Ishii, C., Kagawa, M., Kijima, T., Yokoyama, M., Ishioka, J.,  
33 Matsuoka, Y., Koga, F., Saito, K., Masuda, H., Fujii, Y., Kawakami, S. & Kihara, K. (2013) Usefulness  
34 of pre-biopsy multiparametric magnetic resonance imaging and clinical variables to reduce initial  
35 prostate biopsy in men with suspected clinically localized prostate cancer. *Journal of Urology*,  
36 190: 502-508.  
37 Not in PICO
- 38 Nunes, J., Naymark, M., Sauer, L., Muhammad, A., Keun, H., Sturge, J., Stebbing, J., Waxman, J. &  
39 Pchejetski, D. (2012) Circulating sphingosine-1-phosphate and erythrocyte sphingosine kinase-1  
40 activity as novel biomarkers for early prostate cancer detection. *British Journal of Cancer*, 106:  
41 909-915.  
42 Not in PICO
- 43 Nunez, C., Angulo, J., Sanchez-Chapado, M., Alonso, S., Portillo, J. A. & Villavicencio, H. (2012)  
44 [Variability of the urological clinical practice in prostate cancer in Spain]. [Spanish]. *Actas  
45 Urologicas Espanolas*, 36: 333-339.  
46 Not in PICO
- 47 O'Leary, M. P., Gee, W. F., Holtgrewe, H. L., Blute, M. L., Cooper, T. P., Miles, B. J., Nellans, R. E.,  
48 Thomas, R., Painter, M. R., Meyer, J. J., Naslund, M. J., Gormley, E. A., Blizzard, R. & Fenninger, R.  
49 B. (2000) 1999 American Urological Association Gallup Survey: changes in physician practice  
50 patterns, treatment of incontinence and bladder cancer, and impact of managed care. *Journal of*

- 1 *Urology*, 164: 1311-1316.
- 2 Not in PICO
- 3 O'Rourke, M. E. (2000) Urinary incontinence as a factor in prostate cancer treatment selection.
- 4 *Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy*
- 5 *and Continence Nurses Society / WOCN*, 27: 146-154.
- 6 Narrative review
- 7 Obertova, Z., Brown, C., Hodgson, F. & Lawrenson, R. (2013) What do men say about diagnostic
- 8 pathways? From prostate-specific antigen (PSA) test to prostate cancer. *BJU International*, 112:
- 9 14.
- 10 Not in PICO
- 11 Oh, J. H., Lotan, Y., Gurnani, P., Rosenblatt, K. P. & Gao, J. (2009) Prostate cancer biomarker
- 12 discovery using high performance mass spectral serum profiling. *Computer Methods & Programs*
- 13 *in Biomedicine*, 96: 33-41.
- 14 Not in PICO
- 15 Ok, J. H., Meyers, F. J. & Evans, C. P. (2005) Medical and surgical palliative care of patients with
- 16 urological malignancies. [Review] [48 refs]. *Journal of Urology*, 174: t-82.
- 17 Narrative review
- 18 Onur, M. R., Turgut, A. T. & Dogra, V. (2014) Ultrasound-guided biopsy of the prostate: New updates.
- 19 *Ultrasound Clinics*, 9: 81-94.
- 20 Narrative review
- 21 Opalinska, E., Stoma, F., Michalak, A., Latalski, M. & Goniewicz, M. (2002) Benign prostatic
- 22 hyperplasia, prostate cancer and other prostate diseases diagnosed as a result of screening
- 23 procedure among 1,004 men in the Lublin district. *Annales Universitatis Mariae Curie-Sklodowska*
- 24 *- Sectio d - Medicina*, 57: 493-501.
- 25 Not in PICO
- 26 Oranusi, C. K., Mbieri, U. T., Oranusi, I. O. & Nwofor, A. M. E. (2012) Prostate cancer awareness and
- 27 screening among male public servants in Anambra state, Nigeria. *African Journal of Urology*, 18:
- 28 72-74.
- 29 Not in PICO
- 30 Orom, H., Underwood, W., Homish, D. L., Homish, G. G., Brasel, A. & Nelson, C. J. (2012) Treatment
- 31 decision-making self-efficacy predicts better quality of life in prostate cancer patients managed
- 32 with active surveillance. *Psycho-Oncology*, 21: 19.
- 33 Not in PICO
- 34 Paneesha, S., McManus, A., Arya, R., Scriven, N., Farren, T., Nokes, T., Bacon, S., Nieland, A., Cooper,
- 35 D., Smith, H., O'Shaughnessy, D. & Rose, P. (2010) Frequency, demographics and risk (according
- 36 to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT
- 37 clinics. *Thrombosis and Haemostasis*, 103: 338-343.
- 38 Not in PICO (referred patients)
- 39 Paparella, S. & Rocco, F. (2010) Degarelix: A new GnRH antagonist in the treatment of prostate
- 40 cancer. [Italian]. *Geriatric and Medical Intelligence*, 19: 119-124.
- 41 Not in PICO
- 42 Paranhos, M., Antunes, A., Andrade, E., Freire, G. & Srougi, M. (2009) The prevalence of erectile
- 43 dysfunction among Brazilian men screened for prostate cancer. *BJU International*, 104: 1130-
- 44 1133.
- 45 Not in PICO
- 46 Parsons, B. A., Evans, S. & Wright, M. P. (2009) Prostate cancer and urinary incontinence. [Review]
- 47 [70 refs]. *Maturitas*, 63: 323-328.
- 48 Narrative review
- 49 Payne, H. & Cornford, P. (2011) Prostate-specific antigen: an evolving role in diagnosis, monitoring,
- 50 and treatment evaluation in prostate cancer. [Review]. *Urologic Oncology*, 29: 593-601.
- 51 Narrative review

- 1 Perez, C. E., Simonet Aineto, P. J., Vargas, B. C., Castells, E. M. & Parellada, E. N. (2000) [The  
2 diagnostic situation with prostatic cancer in primary care]. [Spanish]. *Atencion Primaria*, 25: 137-  
3 141.  
4 Not in PICO
- 5 Pieczyrak, R., Kotulska, A. & Kucharz, E. (2010) Neoplasia in patients with symptoms of inflammatory  
6 connective tissue diseases. *Internal Medicine Journal*, 40: 150.  
7 Not in PICO
- 8 Pinedo, H. M. (2003) Thrombosis, prevalence and new evidence on current perceptions of risk.  
9 *Cancer Treatment Reviews*, 29: 3-5.  
10 Not in PICO
- 11 Plawker, M. W., Fleisher, J. M., Nitti, V. W. & Macchia, R. J. (1996) Primary care practitioners: An  
12 analysis of their perceptions of voiding dysfunction and prostate cancer. *Journal of Urology*, 155:  
13 601-604.  
14 Not in PICO
- 15 Potvin, K. & Winqvist, E. (2008) Hormone-refractory prostate cancer: a primer for the primary care  
16 physician. *Canadian Journal of Urology*, 15: 14-20.  
17 Narrative review
- 18 Prystajecy, M., Lang, E., Wang, D., Lonergan, K., Simon, J., Sinnarajah, A., Martin, T. L. W., Murray,  
19 A., Hagen, N., Waller, A., Bultz, B., Carlson, L., Groff, S., McRae, A. & Thomas, B. (2012) Emergency  
20 department utilization by adult cancer patients: A prospective cohort study. *Canadian Journal of*  
21 *Emergency Medicine*, 14: S7-S8.  
22 Not in PICO
- 23 Quinlan, M. R., O'Daly, B. J., O'Brien, M. F., Gardner, S., Lennon, G., Mulvin, D. W. & Quinlan, D. M.  
24 (2009) The value of appropriate assessment prior to specialist referral in men with prostatic  
25 symptoms. *Irish Journal of Medical Science*, 178: 281-285.  
26 Not in PICO
- 27 Ramachandran, S., Foster, M. C., Thomas, D. R., Roalfe, A. K. & Hall, R. A. (1998) An audit of prostate-  
28 specific antigen and clinical symptoms in general practice. *Postgraduate Medical Journal*, 74: 28-  
29 32.  
30 Not in PICO (no symptoms per patient reported; population?)
- 31 Rana, A., Chisholm, G. D., Rashwan, H. M., Salim, A., Merrick, M. V. & Elton, R. A. (1994)  
32 Symptomatology of metastatic prostate cancer: prognostic significance. *British Journal of*  
33 *Urology*, 73: 683-686.  
34 Not in PICO
- 35 Rao, G. & Card, A. (2014) An unusual case of acute back pain. *Journal of General Internal Medicine*,  
36 29: S312-S313.  
37 Not in PICO
- 38 Rees, J., Waldron, D., O'Boyle, C., Ewings, P. & MacDonagh, R. (2003) Prospective vs retrospective  
39 assessment of lower urinary tract symptoms in patients with advanced prostate cancer: the  
40 effect of 'response shift'. *BJU International*, 92: 703-706.  
41 Not in PICO
- 42 Reggio, E., de, B. J., Jr., Junqueira, R. G., Timm, O., Jr., Sette, M. J., Sansana, V. & Gomes, C. M. (2007)  
43 Correlation between lower urinary tract symptoms and erectile dysfunction in men presenting for  
44 prostate cancer screening. *International Journal of Impotence Research*, 19: 492-495.  
45 Not in PICO
- 46 Rodriguez, L. A. G., Merino, M. E. M., Gonzales, E. L. M. & Roehrborn, C. G. (2009) The health  
47 improvement network (THIN) database: Focused safety study of acute urinary retention (AUR) in  
48 men. *European Urology, Supplements*, 8: 236.  
49 Not in PICO

- 1 Roehrborn, C. G. (2011) Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia  
2 (BPH). [Review]. *Medical Clinics of North America*, 95: 87-100.  
3 Narrative review
- 4 Rohayem, J. & Kliesch, S. (565) [Androgen deprivation therapy in prostate cancer. Indication and  
5 systemic consequences]. [German]. *Urologe (Auszg.A)*, 51: 557-564.  
6 Narrative review
- 7 Rosenberg, M. T., Miner, M. M., Riley, P. A. & Staskin, D. R. (2010) STEP: simplified treatment of the  
8 enlarged prostate. [Review]. *International Journal of Clinical Practice*, 64: 488-496.  
9 Narrative review
- 10 Roth, A. J., Nelson, C., Rosenfeld, B., Scher, H., Slovin, S., Morris, M., O'Shea, N., Arauz, G. &  
11 Breitbart, W. (2010) Methylphenidate for fatigue in ambulatory men with prostate cancer.  
12 *Cancer*, 116: 5102-5110.  
13 Not in PICO
- 14 Rothke, M., Blondin, D., Schlemmer, H. P. & Franiel, T. (2013) [PI-RADS classification: structured  
15 reporting for MRI of the prostate]. [German]. *Rofo: Fortschritte auf dem Gebiete der*  
16 *Rontgenstrahlen und der Nuklearmedizin*, 185: 253-261.  
17 Not in PICO
- 18 Ruiz-Torreon, A., Ramos-Monserrat, M. & Llobera-Canaves, J. (2006) [Family practice and diagnosis  
19 of cancer]. [Spanish]. *Atencion Primaria*, 37: 16-21.  
20 Not in PICO
- 21 Sanchez-Martinez, L. C., Paredes-Solis, C. A., Hernandez-Ordenez, O. F. & Sanchez-Ruvalcaba, I. R.  
22 (2013) [Prostate-specific antigen. The role in the prostate cancer diagnosis]. [Spanish]. *Revista*  
23 *Medica del Instituto Mexicano del Seguro Social*, 51: 124-126.  
24 Narrative review
- 25 Sausville, J. & Naslund, M. (2010) Benign prostatic hyperplasia and prostate cancer: an overview for  
26 primary care physicians. [Review]. *International Journal of Clinical Practice*, 64: 1740-1745.  
27 Narrative review
- 28 Saw, S. & Aw, T. C. (2000) Age-related reference intervals for free and total prostate-specific antigen  
29 in a Singaporean population. *Pathology*, 32: 245-249.  
30 Narrative review
- 31 Schiff, G. D. (2014) Diagnosis and diagnostic errors: Time for a new paradigm. *BMJ Quality and*  
32 *Safety*, 23: 1-3.  
33 Not in PICO
- 34 Schmid, M., Hansen, J., Rink, M., Fisch, M. & Chun, F. (2013) The development of nomograms for  
35 stratification of men at risk of prostate cancer prior to prostate biopsy. *Biomarkers in Medicine*, 7:  
36 843-850.  
37 Narrative review
- 38 Seamonds, B., Whitaker, B. & Yang, N. (1986) Evaluation of prostate-specific antigen and prostatic  
39 acid phosphatase as prostate cancer markers. *Urology*, 28: 472-479.  
40 Not in PICO
- 41 Seftel, A. (2005) Correlation between LUTS (AUA-SS) and erectile dysfunction (SHIM) in an age-  
42 matched racially diverse male population: data from the prostate cancer awareness week  
43 (PCAW). *Journal of Urology*, 174: 1940.  
44 Not in PICO
- 45 Shahab, A. A., Soebadi, D. M., Djatisoesanto, W., Hardjowijoto, S., Soetojo, S. & Hakim, L. (2013)  
46 Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian  
47 population suspected for prostate cancer. *Prostate International*, 1: 23-30.  
48 Not in PICO
- 49 Shapley, M., Mansell, G., Jordan, J. L. & Jordan, K. P. (2010) Positive predictive values of  $\geq 5\%$  in  
50 primary care for cancer: systematic review. [Review]. *British Journal of General Practice*, 60:

- 1 e366-e377.
- 2 Systematic review. Relevant included studies are already included in our review.
- 3 Shariat, S. F., Scherr, D. S., Gupta, A., Bianco, F. J., Jr., Karakiewicz, P. I., Zeltser, I. S., Samadi, D. B. &  
4 Akhavan, A. (2011) Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis.  
5 [Review]. *Archivos Espanoles de Urologia*, 64: 681-694.
- 6 Narrative review
- 7 Sharp, V. J., Takacs, E. B. & Powell, C. R. (2010) Prostatitis: Diagnosis and treatment. *American Family*  
8 *Physician*, 82: 397-406.
- 9 Narrative review
- 10 Shinotoh, K. & Takigawa, H. (1999) [Voiding condition in elderly males examined prostate cancer  
11 screening in total health check and the effect of subjective urinary symptoms on quality of life].  
12 [Japanese]. *Nippon Hinyokika Gakkai Zasshi - Japanese Journal of Urology*, 90: 32-40.
- 13 Not in PICO
- 14 Siguel, E. Balancing the harms and benefits of early detection of prostate cancer. [References].  
15 *Cancer* 117[15], 3533-3534. 2011.
- 16 Comment
- 17 Sing, R. I. & Singal, R. K. (2012) What is significant hematuria for the primary care physician?  
18 *Canadian Journal of Urology*, 19: Suppl-41.
- 19 Narrative review
- 20 Skillinge, D., Langan, R., Krafczyk, M. & McGarey, M. (2011) Benign prostate hyperplasia: A clinical  
21 review. *Osteopathic Family Physician*, 3: 182-186.
- 22 Narrative review
- 23 Sladden, M. J., Hughes, A. M., Hirst, G. H. & Ward, J. E. (2000) A community study of lower urinary  
24 tract symptoms in older men in Sydney, Australia. *Australian & New Zealand Journal of Surgery*,  
25 70: 322-328.
- 26 Not in PICO
- 27 Smith, S. D. & Birtwhistle, R. (2012) Exploring patient perceptions of PSA screening for prostate  
28 cancer: Risks, effectiveness, and importance. *Canadian Family Physician*, 58: e502-e507.
- 29 Not in PICO
- 30 Sohn, M. W., Zhang, H., Taylor, B., Fischer, M., Yano, E., Saigal, C., Wilt, T. & the Urologic Diseases in  
31 America Project (2006) Prevalence and trends of selected urologic conditions for VA healthcare  
32 users. *BMC Urology*, 6: 30.
- 33 Not in PICO
- 34 Song, J. M., Kim, C. B., Chung, H. C. & Kane, R. L. (2005) Prostate-specific antigen, digital rectal  
35 examination and transrectal ultrasonography: A meta-analysis for this diagnostic triad of prostate  
36 cancer in symptomatic Korean men. *Yonsei Medical Journal*, 46: 414-424.
- 37 Not in PICO
- 38 Sorensen, F. B. & Marcussen, N. (1989) Non-specific granulomatous prostatitis. [Danish]. *Ugeskrift*  
39 *for Laeger*, 151: 287-290.
- 40 Narrative review
- 41 Sorum, P. C., Shim, J., Chasseigne, G., Bonnin-Scaon, S., Cogneau, J. & Mullet, E. (2003) Why do  
42 primary care physicians in the United States and France order prostate-specific antigen tests for  
43 asymptomatic patients? *Medical Decision Making*, 23: 301-313.
- 44 Not in PICO
- 45 Sothilingam, S., Sundram, M., Malek, R. & Sahabuddin, R. M. (2010) Prostate cancer screening  
46 perspective, Malaysia. *Urologic Oncology*, 28: 670-672.
- 47 Not in PICO
- 48 Spain, P., Carpenter, W. R., Talcott, J. A., Clark, J. A., Do, Y. K., Hamilton, R. J., Galanko, J. A., Jackman,  
49 A. & Godley, P. A. (2008) Perceived family history risk and symptomatic diagnosis of prostate  
50 cancer: the North Carolina Prostate Cancer Outcomes study. *Cancer*, 113: 2180-2187.
- 51 Not in PICO

- 1 Starreveld, J. S., Wolters, R. J., Romeijnders, A. C., Pijnenborg, L. & Goudswaard, A. N. (2005)  
2 [Summary of the practice guideline 'Lower urinary-tract symptoms in middle-aged and elderly  
3 men' (second revision) from the Dutch College of General Practitioners]. [Dutch]. *Nederlands*  
4 *Tijdschrift Voor Geneeskunde*, 149: 1568-1572.  
5 Narrative review
- 6 Stefanovic, K. B., Gregg, P. C. & Soung, M. (2009) Evaluation and treatment of hematospermia.  
7 *American Family Physician*, 80: 1421-1427.  
8 Narrative review
- 9 Sturgeon, C. M., Duffy, M. J., Stenman, U. H., Lilja, H., Brunner, N., Chan, D. W., Babaian, R., Bast, R.  
10 C., Jr., Dowell, B., Esteva, F. J., Haglund, C., Harbeck, N., Hayes, D. F., Holten-Andersen, M., Klee,  
11 G. G., Lamerz, R., Looijenga, L. H., Molina, R., Nielsen, H. J., Rittenhouse, H., Semjonow, A., Shih,  
12 I., Sibley, P., Soletormos, G., Stephan, C., Sokoll, L., Hoffman, B. R., Diamandis, E. P. & National  
13 Academy of Clinical Biochemistry (2008) National Academy of Clinical Biochemistry laboratory  
14 medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast,  
15 and ovarian cancers. *Clinical Chemistry*, 54: e11-e79.  
16 Narrative review
- 17 Tanguay, S., Awde, M., Brock, G., Casey, R., Kozak, J., Lee, J., Nickel, J. C. & Saad, F. (2009) Diagnosis  
18 and management of benign prostatic hyperplasia in primary care. *Cuaj-Canadian Urological*  
19 *Association Journal*, 3: S92-S100.  
20 Narrative review
- 21 Tasian, G. E., Cooperberg, M. R., Cowan, J. E., Keyashian, K., Greene, K. L., Daniels, N. A., Carroll, P. R.  
22 & Chan, J. M. (2012) Prostate specific antigen screening for prostate cancer: knowledge of,  
23 attitudes towards, and utilization among primary care physicians. *Urologic Oncology*, 30: 155-  
24 160.  
25 Not in PICO
- 26 Thiruchelvam, N. (2014) Benign prostatic hyperplasia. *Surgery (United Kingdom)*, 32: 314-322.  
27 Narrative review
- 28 Tohfe, M., Baki, S. A., Saliba, W., Ghandour, F., Ashou, R., Ghazal, G., Bahous, J. & Chamseddine, N.  
29 (2008) Metastatic prostate adenocarcinoma presenting with pulmonary symptoms: a case report  
30 and review of the literature. *Cases journal*, 1: 316.  
31 Not in PICO
- 32 Tsang, K. K. & Garraway, W. M. (1993) Impact of benign prostatic hyperplasia on general well-being  
33 of men. *Prostate*, 23: 1-7.  
34 Not in PICO
- 35 Tscholl, R. (1989) [Check-ups from the urologic viewpoint]. [German]. *Therapeutische Umschau*, 46:  
36 378-383.  
37 Narrative review
- 38 Turner, J. A., Ciol, M. A., Von Korff, M. & Berger, R. (2005) Health concerns of patients with  
39 nonbacterial prostatitis/pelvic pain. *Archives of Internal Medicine*, 165: 1054-1059.  
40 Not in PICO
- 41 Umehara, T., Kumamoto, Y., Mikuma, N., Yamaguchi, Y., Tsukamoto, T., Miura, T., Watanabe, H. &  
42 Ooe, H. (1990) [Mass screening of prostate in Shiribeshi area in Hokkaido--incidence and clinical  
43 symptoms of benign prostatic hypertrophy and prostatic carcinoma]. [Japanese]. *Hinyokika Kyo -*  
44 *Acta Urologica Japonica*, 36: 415-423.  
45 Not in PICO
- 46 Van der Meer, S., Kollen, B. J., Hirdes, W. H., Steffens, M. G., Hoekstra-Weebers, J. E., Nijman, R. M.  
47 & Blanker, M. H. (2013) Impact of the European Randomized Study of Screening for Prostate  
48 Cancer (ERSPC) on prostate-specific antigen (PSA) testing by Dutch general practitioners. *BJU*  
49 *International*, 112: 26-31.  
50 Not in PICO

- 1 Van Gils, M. P. M. Q. & Mulders, P. F. A. (2005) The standard of the Dutch College of General  
2 Practitioners on micturation disorder in elderly men. [Dutch]. *Nederlands Tijdschrift voor Urologie*,  
3 13: 207-214.  
4 Guideline
- 5 Vasdev, N. & Thorpe, A. C. (2011) Has the introduction of the '2 week rule' in the UK led to an earlier  
6 diagnosis of urological malignancy? *ecancermedicalscience*, 5.  
7 Not in PICO
- 8 Vickers, A. J. (2013) Counterpoint: Prostate-specific antigen velocity is not of value for early  
9 detection of cancer. *Journal of the National Comprehensive Cancer Network*, 11: 286-290.  
10 Narrative review
- 11 Voskanyan, G. A., Glybochko, P. V., Vinarov, A. Z., Korobkin, A. S., Ternovoy, S. K. & Shariya, M. A.  
12 (2013) Anticipating metabolic changes: Magnetic resonance spectroscopy as a diagnostic tool for  
13 early detection of prostate cancer. *European Urology, Supplements*, 12: 149-150.  
14 Not in PICO
- 15 Wagg, A., Harari, D., Lowe, D. & Potter, J. (2011) Use of the dre in male continence/luts assessment;  
16 a dying art? Data from a national audit. *Neurourology and Urodynamics*, 30: 993-994.  
17 Not in PICO
- 18 Walker, N. A. & Challacombe, B. (2013) Managing epididymo-orchitis in general practice.  
19 *Practitioner*, 257: 21-25.  
20 Narrative review
- 21 Walz, J., Suardi, N., Hutterer, G. C., Perrotte, P., Gallina, A., Benard, F., Valiquette, L., McCormack,  
22 M., Graefen, M., Montorsi, F. & Karakiewicz, P. I. (2008) Lower urinary tract symptoms affect one-  
23 third of men in a prostate cancer screening population. *Journal of Endourology*, 22: 369-376.  
24 Not in PICO
- 25 Warshaw, G. (2009) Providing quality primary care to older adults. *Journal of the American Board of*  
26 *Family Medicine: JABFM*, 22: 239-241.  
27 Comment
- 28 Wayte, N., Da, S. L., Chenevix-Trench, G. & Lakhani, S. R. (2008) What's in a cancer syndrome?  
29 Genes, phenotype and pathology. *Pathology*, 40: 247-259.  
30 Narrative review
- 31 Webb, V. & Holmes, A. (2000) Urological cancers: do early detection strategies exist? *BJU*  
32 *International*, 86: 996-1000.  
33 Not in PICO
- 34 Wei, J. T., Dunn, R. L., Litwin, M. S., Sandler, H. M. & Sanda, M. G. (2000) Development and validation  
35 of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of  
36 health-related quality of life in men with prostate cancer. *Urology*, 56: 899-905.  
37 Not in PICO
- 38 Wei, J. T., Calhoun, E. & Jacobsen, S. J. (2005) Urologic diseases in America project: Benign prostatic  
39 hyperplasia. *Journal of Urology*, 173: 1256-1261.  
40 Not in PICO
- 41 Weight, C. J., Kim, S. P., Jacobson, D. J., McGree, M. E., Boorjian, S. A., Thompson, R. H., Leibovich, B.  
42 C., Karnes, R. J. & St, S. J. (2013) The effect of benign lower urinary tract symptoms on  
43 subsequent prostate cancer testing and diagnosis. *European Urology*, 63: 1021-1027.  
44 Not in PICO
- 45 Whelan, T. J., Mohide, E. A., Willan, A. R., Arnold, A., Tew, M., Sellick, S., Gafni, A. & Levine, M. N.  
46 (1997) The supportive care needs of newly diagnosed cancer patients attending a regional cancer  
47 center. *Cancer*, 80: 1518-1524.  
48 Not in PICO
- 49 Williams, R. M. & Naz, R. K. (2010) Novel biomarkers and therapeutic targets for prostate cancer.  
50 [Review] [43 refs]. *Frontiers in Bioscience*, 2: 677-684.  
51 Narrative review



- 1 Wirth, M. P., Froschermaier, S. E. & Pilarsky, C. P. (1995) Early detection of prostate cancer.  
2 [German]. *Onkologie*, 18: 56-60.  
3 Narrative review
- 4 Wolters, R., Wensing, M., Klomp, M., Van Weel, C. & Grol, R. (2004) Shared care and the  
5 management of lower urinary tract symptoms. *BJU International*, 94: 1287-1290.  
6 Not in PICO
- 7 Wolters, R., Wensing, M., Klomp, M., Lagro-Jansen, T., Weel, C. & Grol, R. (2005) Effects of distance  
8 learning on clinical management of LUTS in primary care: a randomised trial. *Patient Education &  
9 Counseling*, 59: 212-218.  
10 Not in PICO
- 11 Wong, J. G. & Feussner, J. R. (1993) Screening for prostate cancer. Does it make a difference? *North  
12 Carolina Medical Journal*, 54: 568-571.  
13 Not in PICO
- 14 Wong, M. Y. C. (2011) Update of LUTS & BPH. Guidelines for the family physician in the management  
15 of benign prostatic hyperplasia (BPH). *Journal of Men's Health*, 8: S110-S111.  
16 Narrative review
- 17 Yafi, F. A., Aprikian, A. G., Tanguay, S. & Kassouf, W. (2010) Practice and referral patterns among  
18 primary care physicians with regards to the use of 5-alpha reductase inhibitors and BPH. *Journal  
19 of Urology*, 183: e690.  
20 Not in PICO
- 21 Yakimovapolyzou, V., Georgiou, S., Soukouli, P., Bandis, E. & Babaliaris, K. (2011) Clinical findings and  
22 grade of malignancy at the time of diagnosis of prostate cancer. *International Journal of Cancer*,  
23 128: 47.  
24 Not in PICO
- 25 Yatani, R., Yabana, T. & Soga, T. (1985) Atypical hyperplasia and latent carcinoma of the prostate as  
26 an early stage of carcinoma. [Japanese]. *Gan to Kagaku Ryoho*, Cancer: 714-719.  
27 Not in PICO
- 28 Yazici, C. M. & Dogan, C. (2014) Can Non-Urological Doctors Play a Role in Early Prostate Cancer  
29 Detection? *Urology Journal*, 11: 1429-1434.  
30 Not in PICO
- 31 You, J., Cozzi, P., Walsh, B., Willcox, M., Kearsley, J., Russell, P. & Li, Y. (2010) Innovative biomarkers  
32 for prostate cancer early diagnosis and progression. [Review] [127 refs]. *Critical Reviews in  
33 Oncology-Hematology*, 73: 10-22.  
34 Narrative review
- 35 Zaenker, P. & Ziman, M. R. (2013) Serologic autoantibodies as diagnostic cancer biomarkers--a  
36 review. *Cancer Epidemiology, Biomarkers & Prevention*, 22: 2161-2181.  
37 Narrative review
- 38 Zeng, L. A., Zhang, L. Y., Culleton, S., Jon, F., Holden, L., Kwong, J., Khan, L., Tsao, M., Danjoux, C.,  
39 Sahgal, A., Barnes, E. & Chow, E. (2011) Edmonton Symptom Assessment Scale as a  
40 Prognosticative Indicator in Patients with Advanced Cancer. *Journal of Palliative Medicine*, 14:  
41 337-342.  
42 Not in PICO
- 43 Zucca, A. C., Boyes, A. W., Linden, W. & Girgis, A. (2012) All's well that ends well? Quality of life and  
44 physical symptom clusters in long-term cancer survivors across cancer types. *Journal of Pain and  
45 Symptom Management*, 43: 720-731.  
46 Not in PICO  
47
- 48 **Review question:**  
49 Which investigations of symptoms of suspected prostate cancer should be done with clinical  
50 responsibility retained by primary care?

**Results**

**Literature search**


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1980-2013	3732	59	04/02/2013
<i>Premedline</i>	1980-2013	179	22	04/02/2013
<i>Embase</i>	1980-2013	1695	122	04/02/2013
<i>Cochrane Library</i>	1980-2013	139	15	31/01/2013
<i>Psychinfo</i>	1980-2013	73	3	04/02/2013
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	1980-2013	491	99	31/01/2013
<i>Biomed Central</i>	1980-2013	695	2	31/01/2013

Total References retrieved (after de-duplication): 317

**Update Search**


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	2013-26/08/2014	189	21	26/08/2014
<i>Premedline</i>	2013-26/08/2014	196	43	26/08/2014
<i>Embase</i>	2013-26/08/2014	179	42	26/08/2014
<i>Cochrane Library</i>	2013-26/08/2014	38	0	26/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	2013-26/08/2014	76	14	26/08/2014

Total References retrieved (after de-duplication): 84



**Risk of bias in the included studies**

1 The risk of bias and applicability concerns are summarised for the included study in the figure below.  
 2 The main risk of bias in this study pertains to the ca 20% of missing data in this study. It is not  
 3 possible to ascertain whether these data are missing in a systematic manner and whether they are  
 4 likely to substantially influence the test accuracy estimates provided by this study. The only  
 5 applicability concern identified for this study concerns the underspecification of the patients, that is,  
 6 it is not clear from the study whether all the patients were symptomatic patients presenting to  
 7 primary care, and to the extent they are not from this patient group, the applicability to the current  
 8 guideline is limited.  
 9



10  
11  
12  
13  
14

**Study results**

Table 1: Prostate cancer: PSA

Study	Test	Prevalence	Sensitivity (95% CI)	Specificity (95% CI)	Other results
Ramachandran (1998)	PSA 4 ng/ml	54/582	88.9% (NR)	70% (NR)	False negativity rate = 11.1%
	PSA 5 ng/ml		88.9% (NR)	78% (NR)	False negativity rate = 11.1%
	PSA 6 ng/ml		87% (NR)	82.6% (NR)	False negativity rate = 13%
	PSA 7 ng/ml		83.3% (NR)	86% (NR)	False negativity rate = 16.7%
	PSA 8 ng/ml		83.3% (NR)	88.3% (NR)	False negativity rate = 16.7%
	PSA 9 ng/ml		83.3% (NR)	89% (NR)	False negativity rate = 16.7%
	PSA 10 ng/ml		77.8% (NR)	90.2% (NR)	False negativity rate = 22.2%

15  
16  
17  
18

No evidence was found for MRI.

**Evidence statement(s):**

PSA testing (1 study, N = 582) conducted in patients presenting in a primary/hospital care setting is associated with sensitivities that ranged from 77.8-88.9%, specificities that ranged from 70-90.2% and false negativity rates that ranged from 11.1-22.2% for prostate cancer. The study was associated with one bias and one applicability concern (see also Table 1).

## Evidence tables

### Ramachandran (1998)

PATIENT SELECTION	
<b>A. risk of bias</b>	
Patient sampling	Audit of laboratory database, England.
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	N = 582. <i>No further detail reported.</i>  <u>Inclusion criteria:</u> All patients who had a prediagnostic PSA estimation between August 1991 and December 1992 in the laboratory "Telepath" database. <i>Unclear if they are all symptomatic and if they are all from primary care.</i>  <u>Exclusion criteria:</u> None listed.  <u>Clinical setting:</u> Primary/hospital (?) care, England.
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	PSA
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Follow up for min 18 months using GP, Family Services Health Authority, hospice and hospital records
Is the reference standard likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	No
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>

<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	A total of 721 patients met the inclusion criteria. However, complete data were only available for 582 patients.
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Unclear</b>
Were all patients included in the analysis?	<b>No</b>
<b>Could the patient flow have introduced bias?</b>	<b>High risk</b>
<b>NOTES</b>	2-by-2 tables cannot be extracted

1

2

3

**References**

4

**Included studies**

5

Ramachandran, S., Foster, M. C., Thomas, D. R., Roalfe, A. K., and Hall, R. A. An audit of prostate-specific antigen and clinical symptoms in general practice. *Postgraduate Medical Journal* 74[867], 28-32. 1998.

6

7

8

9

(2001) American cancer society guidelines for the early detection of cancer. *Ca-A Cancer Journal for Clinicians*, 51: 87-88.

10

11

12

Not in PICO  
(2005) Prostate specific antigen (PSA) near patient testing for diagnosis and management of prostate cancer (Structured abstract). *Health Technology Assessment Database.*, 49.

13

14

15

16

Not in PICO  
Aarnink, R. G., De La Rosette, J. J. M. C., Witjes, J. A., Debruyne, F. M. J. & Wijkstra, H. (1997)

17

18

19

Diagnosis of prostate cancer in patients with prostate related problems in urological clinic:

20

21

Current status and future developments. [Dutch]. *Tijdschrift Voor Gerontologie En Geriatrie*, 28:

22

23

24

264-271.

25

26

27

Not in PICO  
Aarnink, R. G., de la Rosette, J. J., Witjes, J. A., Debruyne, F. M. & Wijkstra, H. (1997) [Diagnosis of

28

29

prostate cancer in urination disorders in urological practice: current status and future

30

31

developments]. [Dutch]. *Tijdschrift Voor Gerontologie En Geriatrie*, 28: 264-271.

32

33

34

Not in PICO  
Abul, F. T., Arun, N., Abu-Assi, M. A. & Asbeutah, A. M. (2007) Transrectal ultrasound guided biopsy

35

for detecting prostate cancer: can random biopsies be reduced using the 4-dimensional

technique? *International Urology & Nephrology*, 39: 517-524.

Not in PICO  
Acino, S. & Resnick, M. I. (1988) Office urologic ultrasound. [Review] [34 refs]. *Urologic Clinics of*

*North America*, 15: 577-588.

Narrative review

Afifi, A. H. A. A., Etaby, A. N., Ahmad, M. A. Y. & Farghaly, Y. T. (2013) Value of diffusion weighted magnetic resonance imaging in the prediction of cancer prostate. *Alexandria Journal of Medicine*, 49: 57-66.

- 1 Ahmad, S., Cao, R., Varghese, T., Bidaut, L. & Nabi, G. (2013) Transrectal quantitative shear wave  
2 elastography in the detection and characterisation of prostate cancer. *Surgical Endoscopy and*  
3 *Other Interventional Techniques*, 27: 3280-3287.  
4 Not in PICO
- 5 Ahmed, M. (2011) Prostate cancer diagnosis in a resource-poor setting: the changing role of digital  
6 rectal examination. *Tropical Doctor*, 41: 141-143.  
7 Not in PICO
- 8 Akbayir, S., Muslu, N., Erden, S. & Bozlu, M. (2014) Detection of micrnas' diagnostic value in  
9 prostate cancer patients with 2-10 ng/ml prostate specific antigen (PSA) levels. *Clinical Chemistry*  
10 *and Laboratory Medicine*, 52: S359.  
11 Not in PICO
- 12 Ali, M. & Rashwan, H. (2010) Impact of lower urinary tract symptoms on sexual function in patients  
13 with symptomatic prostatic disorders. *Urology*, 76: S53.  
14 Not in PICO
- 15 Alioune, S., Yaya, S., Ibou, T., Boubacar, F., Babacar, D., Ahmed, F. P., Mamadou, B., Meissa, T. &  
16 Assane, D. B. (2011) Early detection of prostate cancer in Senegalese men 40-50years old.  
17 [French]. *Progres En Urologie*, 21: 260-263.  
18 Not in PICO
- 19 Allard, C. B., Dason, S., Lusic, J. & Kapoor, A. (2012) Prostate cancer screening: Attitudes and  
20 practices of family physicians in Ontario. *Canadian Urological Association Journal*, 6: 188-193.  
21 Not in PICO
- 22 Allepuz Losa, C. A., Gil Sanz, M. J., Gonzalvo, I. A., Blas, M. M., Sanz Velez, J. I. & Rioja Sanz, L. A.  
23 (1997) The early diagnosis of prostate cancer in a selected population. The usefulness of PSAD,  
24 PSAD ad. and age-adjusted PSA in patients with a PSA between 4-10 ngr./ml. [Spanish]. *Actas*  
25 *Urologicas Espanolas*, 21: 344-353.  
26 Not in PICO
- 27 Allhoff, E. P., Liedke, S. G., Gonnermann, O., Stief, C. G., Jonas, U. & Schneider, B. (1993) Efficient  
28 pathway for early detection of prostate cancer concluded from a 5-year prospective study. *World*  
29 *Journal of Urology*, 11: 201-205.  
30 Not in PICO
- 31 Andruss, C. M., Dinella, T. J., Macpherson, D. S., Pietropaoli, A. P., Tsao, L., Wachman, J., Whittle, J.,  
32 Cameron, M. L., Hines, J. M., Mcneil, M., Conigliaro, J., Good, C. B., Labkoff, S. E., Cohen, M. G.,  
33 Deswal, A., Gulinson, M. D., Hankin, L. M., Heinle, M. S., Higham, C. J., Hoffmann, E. L., Hunn, R.  
34 H., Hunter, T. M., Kam, L. W., Leon, R. J., Lilie, S., Lipinski, J. L., Marr, L. A., Mccullum, K. J.,  
35 Michelson, G. C., Nace, D. A., Orourke, D. J., Osborn, J. L., Pendergast, W. J., Provencano, M. A.,  
36 Ramsey, L. C., Reardon, L. C., Sandberg, M. L., Szawaluk, J. J., Vancleeff, S., Young, M. A., Yee, E. L.,  
37 Zeldin, R. K., Bushman, K. E., Richards, S. A., Balderston, V., Caldwell, K. E., Collins, M. E., Dianesi,  
38 E. G., Dale, C. G., Dippl, J. M., Finikiotis, M. W., Finkel, R. G., Friedland, D. M., Gorby, R. S.,  
39 Guilinger, R. A., Hally, R. J., Hammerman, S. I., Harris, J. V., Keyes, J. V., Leuzzi, R. A., Lubick, C. J.,  
40 Mcguinness, M. A., Needleman, D. C., Pritchard, R. J., Rodman, M. T., Rohn, S. G., Santora, D. M.,  
41 Schloss, E. J., Selvaggi, T. A., Shuster, T. D., Stein, A. R., Sweet, L. J., Tee, S. T., Thomas, A., Hogan,  
42 R. C., Kosar, E. M. & Murtaugh, T. I. (1995) Effect of Digital Rectal Examination on Serum Prostate-  
43 Specific Antigen in A Primary-Care Setting. *Archives of Internal Medicine*, 155: 389-392.  
44 Not in PICO
- 45 Applewhite, J. C., Matlaga, B. R., McCullough, D. L. & Hall, M. C. (2001) Transrectal ultrasound and  
46 biopsy in the early diagnosis of prostate cancer. [Review] [56 refs]. *Cancer Control*, 8: 141-150.  
47 Not in PICO
- 48 Arumainayagam, N., Ahmed, H. U., Moore, C. M., Freeman, A., Allen, C., Sohaib, S. A., Kirkham, A.,  
49 van der Meulen, J. & Emberton, M. (2013) Multiparametric MR imaging for detection of clinically  
50 significant prostate cancer: a validation cohort study with transperineal template prostate

- 1 mapping as the reference standard. *Radiology*, 268: 761-769.
- 2 Not in PICO
- 3 Audenet, F., Roupret, M., Perrin, P. & de La, T. A. (2011) [How to select the best candidates for  
4 prostate biopsies? The role of traditional tools and contribution of new biomarkers in prostate  
5 cancer]. [French]. *Progres En Urologie*, 21: Suppl-92.
- 6 Narrative review
- 7 Avery, K. N., Metcalfe, C., Blazeby, J. M., Lane, J. A., Neal, D. E., Hamdy, F. C. & Donovan, J. L. (2008)  
8 Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract  
9 symptoms and health-related quality of life associated with the decision to undergo these  
10 investigations? *Bju International*, 102: 1629-1633.
- 11 Not in PICO
- 12 Avery, K. N. L., Blazeby, J. M., Lane, J. A., Neal, D. E., Hamdy, F. C. & Donovan, J. L. (2008) Decision-  
13 making about PSA testing and prostate biopsies: A qualitative study embedded in a primary care  
14 randomised trial. *European Urology*, 53: 1186-1193.
- 15 Not in PICO
- 16 Babaian, R. J., Miyashita, H., Evans, R. B., Voneschenbach, A. C. & Ramirez, E. I. (1991) Early  
17 Detection Program for Prostate-Cancer - Results and Identification of High-Risk Patient  
18 Population. *Urology*, 37: 193-197.
- 19 Not in PICO (screening)
- 20 Babaian, R. J., Dinney, C. P., Ramirez, E. I. & Evans, R. B. (1993) Diagnostic testing for prostate cancer  
21 detection: less is best. *Urology*, 41: 421-425.
- 22 Not in PICO
- 23 Bajramovic, S. & Junuzovic, D. (2013) Detection of prostate cancer at low volume prostate and low  
24 PSA range. *European Urology, Supplements*, 12: e1286.
- 25 Not in PICO
- 26 Barak, M., Cohen, M., Mecz, Y., Stein, A., Rashkovitzki, R., Laver, B. & Lurie, A. (1997) The additional  
27 value of free prostate specific antigen to the battery of age-dependent prostate-specific antigen,  
28 prostate-specific antigen density and velocity. *European Journal of Clinical Chemistry and Clinical  
29 Biochemistry*, 35: 475-481.
- 30 Not in PICO (147/3470 received reference test)
- 31 Barakzai, M. A., Mubarak, M. & Kazi, J. I. (2011) Histopathological lesions in transrectal ultrasound  
32 guided biopsies of prostate in patients with raised serum prostate specific antigen: A preliminary  
33 report. *Nephro-Urology Monthly*, 3: 186-190.
- 34 Not in PICO
- 35 Bardon, Y., De la Taille, A., Chartier-Kastler, E., Moreau, J. L., Davin, J. L., Mignard, J. P. & Coulange, C.  
36 (2007) The prostate : how to treat this symbol of male vulnerability ? An Association Francaise  
37 d'Urologie (AFU)-IPSOS qualitative survey. *Progres En Urologie*, 17: 199-202.
- 38 Not in PICO
- 39 Barkin, J. (2008) Management of benign prostatic hyperplasia by the primary care physician in the  
40 21(st) century: the new paradigm. *Canadian Journal of Urology*, 15: 21-30.
- 41 Not in PICO
- 42 Barkin, J., Rosenberg, M. T. & Miner, M. (2014) A guide to the management of urologic dilemmas for  
43 the primary care physician (PCP). *Canadian Journal of Urology*, 21: 55-63.
- 44 Narrative review
- 45 Barrett, J. & Hamilton, W. (2005) Pathways to the diagnosis of prostate cancer in a British city. A  
46 population-based study. *Scandinavian Journal of Urology and Nephrology*, 39: 267-270.
- 47 Not in PICO
- 48 Basky, G., Belon, R., Boutin, B., McGowan, V., Nisbet, B. & Tonita, J. (1995) Prostate specific antigen  
49 (PSA) testing (Structured abstract). *Health Technology Assessment Database*.
- 50 Not available. Unlikely to be relevant (mass screening).

- 1 Bastide, C., Beuzeboc, P., Cormier, L., Fromont, G., Hennequin, C., Mongiat-Artus, P., Peyromaure,  
2 M., Ploussard, G., Renard-Penna, R., Rozet, F., Richaud, P., Soulie, M., Salomon, L., Azria, D.,  
3 Coloby, P., Molinie, V., Ravery, V., Rebillard, X., Villers, A. & Les membres du, C. C. A. F. (2013)  
4 [CCAFU Recommendations 2013: Prostate cancer]. [French]. *Progres En Urologie*, 23: Suppl-S101.  
5 Guideline
- 6 Beemsterboer, P. M., Koning, H. J., Kranse, R., Trienekens, P. H., Maas, P. J. & Schröder, F. H. (2000)  
7 Prostate specific antigen testing and digital rectal examination before and during a randomized  
8 trial of screening for prostate cancer: European randomized study of screening for prostate  
9 cancer, Rotterdam. *The Journal of urology*, 164: 1216-1220.  
10 Not in PICO
- 11 Belas, O., Klap, J., Cornud, F., Beuvon, F., Peyromaure, M., Zerbib, M. & Delongchamps, N. B. (2012)  
12 Prebiopsy multiparametric MRI of the prostate: The end of randomized biopsies?. [French].  
13 *Progres En Urologie*, 22: 583-589.  
14 Not in PICO (38/71 patients had cancer)
- 15 Billia, M., Burtnyk, M., Kuru, T., Pahernik, S., Roethke, M., Schlemmer, H. P., Romagnoli, C. & Chin, J.  
16 (2014) MRI-guided transurethral ultrasound ablation of prostate cancer: Preliminary outcomes of  
17 a phase I clinical trial. *European Urology, Supplements*, 13: e1133.  
18 Not in PICO
- 19 Bjurlin, M. A., Carter, H. B., Schellhammer, P., Cookson, M. S., Gomella, L. G., Troyer, D., Wheeler, T.  
20 M., Schlossberg, S., Penson, D. F. & Taneja, S. S. (2013) Optimization of initial prostate biopsy in  
21 clinical practice: sampling, labeling and specimen processing. [Review]. *Journal of Urology*, 189:  
22 2039-2046.  
23 Not in PICO
- 24 Bjurlin, M. A. & Taneja, S. S. (2014) - Standards for prostate biopsy. - *Current Opinion in Urology*, 24:  
25 155-161.  
26 Narrative review
- 27 Bjurlin, M. A. & Taneja, S. S. (2014) Standards for prostate biopsy. *Current Opinion in Urology*, 24:  
28 155-161.  
29 Narrative review
- 30 Blanker, M. H., Klomp, M. A., van den Donk, M., van der Heide, W. K., Opstelten, W. & Burgers, J. S.  
31 (2013) [Summary of the NHG practice guideline 'Lower urinary tract symptoms in men']. [Review]  
32 [Dutch]. *Nederlands Tijdschrift Voor Geneeskunde*, 157: A6178.  
33 Narrative review/guideline
- 34 Bodelle, B., Naguib, N. N., Schulz, B., Eichler, K., Muller, C., Hansmann, M. L., Hammerstingl, R.,  
35 Hubner, F., Vogl, T. J. & Zangos, S. (2013) 1.5-T magnetic resonance-guided transgluteal biopsies  
36 of the prostate in patients with clinically suspected prostate cancer: technique and feasibility.  
37 *Investigative Radiology*, 48: 458-463.  
38 Not in PICO
- 39 Boman, H. & Hedelin, H. (2005) Each fifth man above the age of 50 years who is referred to a  
40 urologist has cancer. PSA is important to get the priorities right. [Swedish]. *Lakartidningen*, 102:  
41 1519-1521.  
42 Not in PICO
- 43 Boman, H. & Hedelin, H. (2005) [One man of five aged 50 years and over referred to a urologist is  
44 diagnosed with cancer. PSA analysis is important for correct prioritization of the referrals].  
45 [Swedish]. *Lakartidningen*, 102: 1519-1521.  
46 Duplicate
- 47 Booth, C. M., Chaudry, A. A., Smith, K. & Griffiths, K. (1996) The benefits of a shared-care prostate  
48 clinic. *British Journal of Urology*, 77: 830-855.  
49 Not in PICO
- 50 Bories, P.-N., Younes, P., Zerbib, M., Denjean, L., Popovici, T., Cynober, L. & Delongchamps, N. B.  
51 (2013) TMPRSS2-ERG fusion transcripts in matched urine and needle rinse material after biopsy



- 1 for the detection of prostate cancer. *Clinical Chemistry*, 59: 245-251.  
2 Not in PICO
- 3 Bosch, J. L. H. R., Bohnen, A. M. & Groeneveld, F. P. M. J. (2004) Validity of digital rectal examination  
4 and serum prostate specific antigen in the estimation of prostate volume in community-based  
5 men aged 50 to 78 years: The Krimpen study. *European Urology*, 46: 753-759.  
6 Not in PICO
- 7 Bouwman, I., van der Heide, W. K., Van Der Veen, W. J. & Van der Meer, K. (2007) GPs and patients  
8 still think that lower urinary tract symptoms are an indication of prostate cancer. [Dutch].  
9 *Huisarts en Wetenschap*, 50: 321-325.  
10 Not in PICO
- 11 Brackett, C., Kearing, S., Cochran, N., Tosteson, A. N. A. & Brooks, W. B. (2010) Strategies for  
12 distributing cancer screening decision aids in primary care. *Patient Education and Counseling*, 78:  
13 166-168.  
14 Not in PICO
- 15 Braun, K.-P., May, M., Grassmel, Y., Fuhrer, S., Hoschke, B. & Braun, V. (2008) The general  
16 practitioner's part in the initiation of diagnostic procedures in prostate cancer. [German].  
17 *Aktuelle Urologie*, 39: 141-146.  
18 Not in PICO
- 19 Braun, K. P., Brookman-Amisshah, S., May, M., Grassmel, Y., Hoschke, B. & Braun, V. (2009) The  
20 Assessment of Pathological PSA Values by the General Practitioner - Observation or Intervention?  
21 *Aktuelle Urologie*, 40: 171-174.  
22 Not in PICO
- 23 Brett, J., Watson, E., Hewitson, P., Bukach, C., Edwards, A., Elwyn, G. & Austoker, J. (2005) PSA  
24 testing for prostate cancer: an online survey of the views and reported practice of General  
25 Practitioners in the UK. *Bmc Family Practice*, 6: 24.  
26 Not in PICO
- 27 Brett, T. (2005) Low prostate specific antigen levels and normal digital rectal examination--a report  
28 on a follow up cohort in general practice. *Australian Family Physician*, 34: 301-302.  
29 Not in PICO
- 30 Brett, T. (2011) Prostate specific antigen. [Review][Summary for patients in Aust Fam Physician. 2011  
31 Jul;40(7):501; PMID: 21743855]. *Australian Family Physician*, 40: 497-500.  
32 Narrative review
- 33 Brett, T. D. (1998) An analysis of digital rectal examination and serum-prostate-specific antigen in  
34 the early detection of prostate cancer in general practice. *Family Practice*, 15: 529-533.  
35 Not in PICO
- 36 Brewster, S., Tuerkeri, L., Brausi, M., Ravery, V. & Djavan, B. (2010) A prospective survey of current  
37 prostate biopsy practices among oncological urologists. *Canadian Journal of Urology*, 17: 5071-  
38 5076.  
39 Not in PICO
- 40 Bunting, P. S., Goel, V., Williams, J. I. & Iscoe, N. A. (1999) Prostate-specific antigen testing in  
41 Ontario: reasons for testing patients without diagnosed prostate cancer. *Canadian Medical*  
42 *Association Journal*, 160: 70-75.  
43 Not in PICO
- 44 Burin, B., Bouchot, O. & Rigaud, J. (2006) Practices of general practitioners in the Loire-Atlantique  
45 region and their patients' knowledge about prostate cancer screening. *Progres En Urologie*, 16:  
46 559-563.  
47 Not in PICO
- 48 Burnett, A. L. & Wein, A. J. (2006) Benign prostatic hyperplasia in primary care: What you need to  
49 know. *Journal of Urology*, 175: S19-S24.  
50 Not in PICO

- 1 Calvo, N., Henriquez, L., I, Pujol, F., Milia, L., Pont, A., Grino, J., Elias, J., Monllau, V., Pont, M. &  
2 Parada, J. (2010) Utility of magnetic resonance spectroscopy and guided biopsies in patients with  
3 previous negative biopsies and suspicious of prostate cancer. *Radiotherapy and Oncology*, 96:  
4 S419.  
5 Not in PICO
- 6 Cam, K., Ozveri, H., Turkeri, L. & Akdas, A. (2001) The significance of hypoechoic lesion directed and  
7 transition zone biopsies in improving the diagnostic ability in prostate cancer. *Brazilian Journal of*  
8 *Urology*, 27: 222-226.  
9 Not in PICO
- 10 Candas, B., Cusan, L., Gomez, J. L., Diamond, P., Suburu, R. E., Lévesque, J., Brousseau, G., Bélanger,  
11 A. & Labrie, F. (2000) Evaluation of prostatic specific antigen and digital rectal examination as  
12 screening tests for prostate cancer. *The Prostate*, 45: 19-35.  
13 Not in PICO
- 14 Carducci, M. A. & Carroll, P. R. (2005) Multidisciplinary management of advanced prostate cancer:  
15 changing perspectives on referring patients and enhancing collaboration between oncologists  
16 and urologists in clinical trials. *Urology*, 65: Suppl-22.  
17 Not in PICO
- 18 Carey, M., Bryant, J., Yoong, S. L., Russell, G., Barker, D. & Sanson-Fisher, R. (2013) Prostate specific  
19 antigen testing in family practice: a cross sectional survey of self-reported rates of and reasons  
20 for testing participation and risk disclosure. *Bmc Family Practice*, 14.  
21 Duplicate
- 22 Carey, M., Bryant, J., Yoong, S. L., Russell, G., Barker, D. & Sanson-Fisher, R. (2013) Prostate specific  
23 antigen testing in family practice: a cross sectional survey of self-reported rates of and reasons  
24 for testing participation and risk disclosure. *Bmc Family Practice*, 14: 186.  
25 Not in PICO
- 26 Carter, H. B. & Pearson, J. D. (1999) Prostate-specific antigen testing for early diagnosis of prostate  
27 cancer: Formulation of guidelines. *Urology*, 54: 780-786.  
28 Narrative review
- 29 Carter, H. B. (2011) Management of low (favourable)-risk prostate cancer. [Review]. *Bju*  
30 *International*, 108: 1684-1695.  
31 Not in PICO
- 32 Castelli, T., Cimino, S., Magno, C. & Morgia, G. (2010) Molecular markers for prostatic cancer.  
33 [Review] [139 refs]. *Frontiers in Bioscience*, 2: 641-656.  
34 Narrative review
- 35 Cevik, I., Turkeri, L. N., Ozveri, H., Ilker, Y. & Akdas, A. (1996) Short-term effect of digital rectal  
36 examination on serum prostate-specific antigen levels. A prospective study. *European Urology*,  
37 29: 403-406.  
38 Not in PICO
- 39 Chadwick, D. J., Kemple, T., Astley, J. P., MacIver, A. G., Gillatt, D. A., Abrams, P. & Gingell, J. C.  
40 (1991) Pilot study of screening for prostate cancer in general practice. *Lancet.*, 338: 613-616.  
41 Not in PICO
- 42 Chan, A. Y. T., Yiu, M. K. & Yiu, T. F. (1999) Diagnosis of benign prostatic hyperplasia and when to  
43 refer. *Hong Kong Practitioner*, 21: 116-124.  
44 Not in PICO
- 45 Chan, E. C. Y., Barry, M. J., Vernon, S. W. & Ahn, C. (2006) Brief report: Physicians and their personal  
46 prostate cancer-screening practices with prostate-specific antigen. *Journal of General Internal*  
47 *Medicine*, 21: 257-259.  
48 Not in PICO
- 49 Chappell, B. & McLoughlin, J. (2005) Technical considerations when obtaining and interpreting  
50 prostatic biopsies from men with suspicion of early prostate cancer: part 2. [Review] [58 refs]. *Bju*

- 1 *International*, 95: 1141-1145.
- 2 Not in PICO
- 3 Chappell, B. & McLoughlin, J. (2005) Technical considerations when obtaining and interpreting  
4 prostatic biopsies from men with suspicion of early prostate cancer: part I. [Review] [83 refs]. *Bju*  
5 *International*, 95: 1135-1140.
- 6 Not in PICO
- 7 Chapple, A., Ziebland, S., Hewitson, P. & McPherson, A. (2008) Why men in the United Kingdom still  
8 want the prostate specific antigen test. *Qualitative Health Research*, 18: 56-64.
- 9 Not in PICO
- 10 Chepurov, A. K., Vladimirov, V. G., Zarinskaia, S. A., Meshkov, V. V., Kobaladze, K. M. & Iremashvili, V.  
11 V. (2010) [On extended biopsy of the prostatic gland]. [Russian]. *Urologiia (Moscow,*  
12 *Russia).(1):52-5, 2010 Jan-Feb., 52-55.*
- 13 Not in PICO
- 14 Chesa, P. N. & Orengo Valverde, J. C. (2002) [Knowledge about PSA among primary care physicians].  
15 [Spanish]. *Archivos Espanoles de Urologia*, 55: 113-116.
- 16 Not in PICO
- 17 Chisholm, G. D., Carne, S. J., Fitzpatrick, J. M., George, N. J., Gingell, J. C., Keen, J. W., Kirby, R. S.,  
18 Kirk, D., O'Donoghue, E. P. & Peeling, W. B. (1995) Prostate disease: management options for the  
19 primary healthcare team. Report of a working party of the British Prostate Group. *Postgraduate*  
20 *Medical Journal*, 71: 136-142.
- 21 Narrative review
- 22 Cho, S., Matsuno, D., Isshiki, S., Kojima, S., Sato, N. & Furuya, Y. (2006) Trends in systematic prostatic  
23 biopsy in Teikyo University Chiba Medical Center, 1996 to 2005. [Japanese]. *Teikyo Medical*  
24 *Journal*, 29: 353-358.
- 25 Not in PICO
- 26 Chung, M. S., Lee, S. H., Lee, D. H., Kim, S. J., Kim, C. S., Lee, K. S., Jung, I. J., Kim, S. W., Lee, Y. S. &  
27 Chung, B. H. (2012) Practice Patterns of Korean Urologists for Screening and Managing Prostate  
28 Cancer according to PSA Level. *Yonsei Medical Journal*, 53: 1136-1141.
- 29 Not in PICO
- 30 Ciatto, S., Houssami, N., Martinelli, F., Giusti, F. & Zappa, M. (2008) PSA use and incidence of  
31 prostate biopsy in the Tuscany region: is opportunistic screening discounting biopsy in subjects  
32 with PSA elevation? *Tumori*, 94: 518-522.
- 33 Not in PICO
- 34 Coley, C. M., Barry, M. J., Fleming, C. & Mulley, A. G. (1997) Early detection of prostate cancer. Part I:  
35 Prior probability and effectiveness of tests. *Annals of Internal Medicine*, 126: 394-406.
- 36 Unclear if systematic review; no data synthesis; any relevant individual studies will be included  
37 separately.
- 38 Collin, S. M., Metcalfe, C., Donovan, J. L., Athene, L. J., Davis, M., Neal, D. E., Hamdy, F. C. & Martin,  
39 R. M. (2009) Associations of sexual dysfunction symptoms with PSA-detected localised and  
40 advanced prostate cancer: a case-control study nested within the UK population-based ProtecT  
41 (Prostate testing for cancer and Treatment) study. *European journal of cancer (Oxford, England :*  
42 *1990)*, 45: 3254-3261.
- 43 Not in PICO
- 44 Collins, M. M., Fowler, J., Roberts, R. G., Oesterling, J. E., Annas, G. J. & Barry, M. J. (2009) Medical  
45 malpractice implications of PSA testing for early detection of prostate cancer. *The Journal of law,*  
46 *medicine & ethics : a journal of the American Society of Law, Medicine & Ethics*, 25: 234-242, 230.
- 47 Not in PICO
- 48 Collins, M. M., Barry, M., Roberts, R. G., Oesterling, J. E. & Fowler, F. J. (1997) Diagnosis and  
49 treatment of benign prostatic hyperplasia - Practice patterns of primary care physicians. *Journal*  
50 *of General Internal Medicine*, 12: 224-229.
- 51 Not in PICO

- 1 Concato, J. & Wells, C. K. (2006) Prostate-specific antigen 'velocity' as a diagnostic test for prostate  
2 cancer. *Journal of Investigative Medicine*, 54: 361-364.  
3 Not in PICO
- 4 Cooper, C. P., Merritt, T. L., Ross, L. E., John, L. V. & Jorgensen, C. M. (2004) To screen or not to  
5 screen, when clinical guidelines disagree: primary care physicians' use of the PSA test. *Preventive*  
6 *Medicine*, 38: 182-191.  
7 Not in PICO
- 8 Corcoran, A. T., Smaldone, M. C., Egleston, B. L., Simhan, J., Ginzburg, S., Morgan, T. M., Walton, J.,  
9 Chen, D. Y. T., Viterbo, R., Greenberg, R. E., Uzzo, R. G. & Kutikov, A. (2013) Comparison of  
10 prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer  
11 care. *Bju International*, 112: 161-168.  
12 Not in PICO
- 13 Costa, D. N., Pedrosa, I., Roehrborn, C. & Rofsky, N. M. (2014) - Multiparametric magnetic resonance  
14 imaging of the prostate: technical aspects and role in clinical management. - *Topics in Magnetic*  
15 *Resonance Imaging*, 23: 243-257.  
16 Narrative review
- 17 Cramer, R. & Dahm, F. J. (2005) [The follow-up of PSA tests for the early detection of prostate  
18 cancer. The responsibility of the physician to explain treatment methods which are not covered  
19 by public health insurance plans]. [German]. *Urologe (Ausg.A)*, 44: 798-800.  
20 Narrative review
- 21 Curran, V., Solberg, S., Mathews, M., Church, J., Buehler, S., Wells, J. & Lopez, T. (2005) Prostate  
22 cancer screening attitudes and continuing education needs of primary care physicians. *Journal of*  
23 *Cancer Education*, 20: 162-166.  
24 Not in PICO
- 25 D'Ambrosio, G. G., Campo, S., Cancian, M., Pecchioli, S. & Mazzaglia, G. (2010) Opportunistic  
26 prostate-specific antigen screening in Italy: 6 years of monitoring from the Italian general practice  
27 database. *European Journal of Cancer Prevention*, 19: 413-416.  
28 Not in PICO
- 29 Da, P. L., Scattoni, V., Mazzoccoli, B., Rigatti, P., Manferrari, F., Martorana, G., Pietropaolo, F.,  
30 Belgrano, E., Prezioso, D., Lotti, T., Villari, D. & Nicita, G. (2007) Tissue-resonance interaction  
31 method for the noninvasive diagnosis of prostate cancer: analysis of a multicentre clinical  
32 evaluation. *Bju International*, 100: 1055-1059.  
33 Not in PICO
- 34 Dalla, P. L., Ricci, C. & Magnaldi, S. (1995) Referral criteria for selection of patients and diagnostic  
35 procedures. *Radiation Protection Dosimetry*, 57: 3-8.  
36 Narrative review
- 37 Dason, S., Allard, C. B., Barrett, K., Wright, I. & Shayegan, B. (2014) Transurethral (TURP) biopsy of  
38 suspected anterior prostate cancers identified by MRI: Pilot study of a novel technique. *Journal of*  
39 *Clinical Oncology*, 32.  
40 Not in PICO
- 41 Davis, K., Haisfield, L., Dorfman, C., Krist, A. & Taylor, K. L. (2011) Physicians' Attitudes About Shared  
42 Decision Making for Prostate Cancer Screening. *Family Medicine*, 43: 260-266.  
43 Not in PICO
- 44 De, V. P., Oosterlinck, W., De, M. G. & Villeirs, G. (2010) Clinical and imaging tools in the early  
45 diagnosis of prostate cancer, a review. *JBR-BTR*, 93: 62-70.  
46 Narrative review
- 47 Delongchamps, N. B., Peyromaure, M., Schull, A., Beuvon, F., Bouazza, N., Flam, T., Zerbib, M.,  
48 Muradyan, N., Legman, P. & Cornud, F. (2013) Prebiopsy magnetic resonance imaging and  
49 prostate cancer detection: comparison of random and targeted biopsies. *Journal of Urology*, 189:  
50 493-499.  
51 Not in PICO

- 1 Diefenbach, M. A. (2012) - To screen or not to screen: A comment on Lepore et al. [References]. -  
2 *Annals of Behavioral Medicine*, Vol.44: 299-300.  
3 Not in PICO
- 4 Dijkstra, S., van der Heijden, A. G., Schaafsma, H. E. & Mulders, P. F. (2012) Synchronous penile  
5 metastasis from a high-grade adenocarcinoma of the prostate. *Case Reports Urology*, 2012:  
6 193787.  
7 Not in PICO
- 8 Dijkstra, S., Mulders, P. F. & Schalken, J. A. (2014) - Clinical use of novel urine and blood based  
9 prostate cancer biomarkers: a review. - *Clinical Biochemistry*, 47: 889-896.  
10 Narrative review
- 11 Djavan, B., Zlotta, A. R., Byttebier, G., Shariat, S., Omar, M., Schulman, C. C. & Marberger, M. (1998)  
12 Prostate specific antigen density of the transition zone for early detection of prostate cancer.  
13 *Journal of Urology*, 160: 411-419.  
14 Not in PICO
- 15 Djavan, B., Zlotta, A. R., Remzi, M., Ghawidel, K., Bursa, B., Hruby, S., Wolfram, R., Schulman, C. C. &  
16 Marberger, M. (1999) Total and transition zone prostate volume and age: How do they affect the  
17 utility of PSA-based diagnostic parameters for early prostate cancer detection? *Urology*, 54: 846-  
18 852.  
19 Not in PICO
- 20 Djavan, B., Zlotta, A., Kratzik, C., Remzi, M., Seitz, C., Schulman, C. C. & Marberger, M. (1999) PSA,  
21 PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early  
22 detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. *Urology*, 54: 517-522.  
23 Not in PICO
- 24 Djavan, B., Zlotta, A. R., Remzi, M., Ghawidel, K., Bursa, B., Hruby, S., Wolfram, R., Schulman, C. C. &  
25 Marberger, M. (1999) Total and transition zone prostate volume and age: how do they affect the  
26 utility of PSA-based diagnostic parameters for early prostate cancer detection? *Urology*, 54: 846-  
27 852.  
28 Duplicate
- 29 Donovan, J., Hamdy, F., Neal, D., Peters, T., Oliver, S., Brindle, L., Jewell, D., Powell, P., Gillatt, D.,  
30 Dedman, D., Mills, N., Smith, M., Noble, S. & Lane, A. (2003) Prostate Testing for Cancer and  
31 Treatment ( ProtecT) feasibility study. *Health technology assessment (Winchester, England)*, 7: 1-  
32 88.  
33 Not in PICO
- 34 Dubey, D. (2009) The routine use of prostate-specific antigen for early detection of cancer prostate  
35 in India: Is it justified? *Indian Journal of Urology*, 25: 177-184.  
36 Not in PICO
- 37 Durmus, T., Goldmann, U., Baur, A. D., Huppertz, A., Schwenke, C., Hamm, B. & Franiel, T. (2013)  
38 MR-guided biopsy of the prostate: comparison of diagnostic specimen quality with 18 G and 16 G  
39 biopsy needles. *European Journal of Radiology*, 82: e749-e754.  
40 Not in PICO
- 41 Durmus, T., Baur, A. & Hamm, B. (2014) - Multiparametric magnetic resonance imaging in the  
42 detection of prostate cancer. - *Aktuelle Urologie*, 45: 119-126.  
43 Narrative review
- 44 Durmus, T., Baur, A. & Hamm, B. (2014) - Multiparametric magnetic resonance imaging in the  
45 detection of prostate cancer. [Review]. - *Rofo: Fortschritte auf dem Gebiete der Rontgenstrahlen  
46 und der Nuklearmedizin*, 186: 238-246.  
47 Narrative review
- 48 Dwivedi, D. K., Kumar, V., Javali, T., Dinda, A. K., Thulkar, S., Jagannathan, N. R. & Kumar, R. (2012) A  
49 positive magnetic resonance spectroscopic imaging with negative initial biopsy may predict  
50 future detection of prostate cancer. *Indian Journal of Urology*, 28: 243-245.  
51 Not in PICO

- 1 Emokpae, M. A., Das, S. C., Orok, T., Mohammed, A. Z. & Hassan, S. A. (2004) Early detection of  
2 prostate cancer: evaluating the diagnostic performance of prostate specific antigen by comparing  
3 with histological technique among africans. *Indian Journal of Clinical Biochemistry*, 19: 62-66.  
4 Not in PICO
- 5 Engehausen, D. G., Engelhard, K., Schwab, S. A., Uder, M., Wach, S., Wullich, B. & Krause, F. S. (2012)  
6 Magnetic resonance image-guided biopsies with a high detection rate of prostate cancer.  
7 *TheScientificWorldJournal*, 2012: 975971.  
8 Not in PICO
- 9 Evans, R., Elwyn, G., Edwards, A., Newcombe, R., Kinnersley, P., Wright, P., Griffiths, J., Austoker, J. &  
10 Grol, R. (2007) A randomised controlled trial of the effects of a web-based PSA decision aid,  
11 Prosdex. Protocol. *Bmc Family Practice*, 8: 58.  
12 Not in PICO
- 13 Evans, R., Edwards, A. G. K., Elwyn, G., Watson, E., Grol, R., Brett, J. & Austoker, J. (2007) 'It's a  
14 maybe test': men's experiences of prostate specific antigen testing in primary care. *British Journal  
15 of General Practice*, 57: 303-310.  
16 Not in PICO
- 17 Falsaperla, M., Morgia, G., Giammusso, B., Condorelli, S. V., Saita, A., Marchese, F., Spampinato, A. &  
18 Motta, M. (2003) Role of Ca 15-3 in patients with biochemically suspected prostate cancer and  
19 multiple negative ultrasound-guided prostate biopsies. *Prostate Cancer and Prostatic Diseases*, 6:  
20 45-49.  
21 Not in PICO
- 22 Fernandez, J. C., Olmo, J. M. C., Fernandez-Pro, A., Martin, J. A., Bermudez, F. J. B., Pulido, E. N.,  
23 Molero, J. M. & Morales, D. P. (2010) Referral criteria for benign prostatic hyperplasia in primary  
24 care. *Actas Urologicas Espanolas*, 34: 24-34.  
25 Not in PICO
- 26 Fischer, K., Loertzer, H. & Fornara, P. (2005) The use of complexed PSA for the early detection of  
27 prostate cancer. *Anticancer Research*, 25: 1591-1596.  
28 Not in PICO
- 29 Fiset, P. O., Aprikian, A. & Brimo, F. (2013) Length of prostate biopsy cores: does it impact cancer  
30 detection? *Canadian Journal of Urology*, 20: 6848-6853.  
31 Not in PICO
- 32 Fowke, J. H., Motley, S. S., Cookson, M. S., Concepcion, R., Chang, S. S., Wills, M. L. & Smith, J. (2007)  
33 The association between body size, prostate volume and prostate-specific antigen. *Prostate  
34 Cancer and Prostatic Diseases*, 10: 137-142.  
35 Not in PICO
- 36 Franc, B. L., Cho, S. Y., Rosenthal, S. A., Cui, Y., Tsui, B., Vandewalker, K. M., Holz, A. L., Poonamallee,  
37 U., Pomper, M. G. & James, R. B. (2013) Detection and localization of carcinoma within the  
38 prostate using high resolution transrectal gamma imaging (TRGI) of monoclonal antibody directed  
39 at prostate specific membrane antigen (PSMA)--proof of concept and initial imaging results.  
40 *European Journal of Radiology*, 82: 1877-1884.  
41 Not in PICO
- 42 Franiel, T., Vargas, H. A., Mazaheri, Y., Bohmer, S., Hricak, H., Akin, O. & Beyersdorff, D. (2013) Role  
43 of endorectal prostate MRI in patients with initial suspicion of prostate cancer.[Erratum appears  
44 in Rofo. 2013 Sep;184(10):E5 Note: Vargas, A H [corrected to Vargas, H A]]. *Rofo: Fortschritte auf  
45 dem Gebiete der Rontgenstrahlen und der Nuklearmedizin*, 184: 967-974.  
46 Not in PICO
- 47 Franiel, T., Eckardt, N., Waginger, M. & Horstmann, M. (2014) - [Prostate cancer]. [German]. -  
48 *Radiologe*, 54: 491-506.  
49 Narrative review

- 1 Frydenberg, M. & Wijesinha, S. (2007) Diagnosing prostate cancer - What GPs need to know.  
2 *Australian Family Physician*, 36: 345-347.  
3 Narrative review
- 4 Fukagai, T., Maruyama, K., Nagata, M., Morita, M., Naoe, M. & Yoshida, H. (2007) Practice patterns  
5 regarding prostate cancer and benign prostatic hyperplasia in Japanese primary care  
6 practitioners. *International Journal of Urology*, 14: 412-415.  
7 Not in PICO
- 8 Gambert, S. R. (2001) Prostate cancer - When to offer screening in the primary care setting.  
9 *Geriatrics*, 56: 22-+.  
10 Not in PICO
- 11 Ganie, F. A., Wani, M. S., Shaheen, F., Wani, M. L., Ganie, S. A., Mir, M. F., Wani, S. N. & Masaratul, G.  
12 (2013) Endorectal coil MRI and MR-spectroscopic imaging in patients with elevated serum  
13 prostate specific antigen with negative trus transrectal ultrasound guided biopsy. *Urology annals*,  
14 5: 172-178.  
15 Not in PICO
- 16 Ganie, F. A., Wanie, M. S., Ganie, S. A., Lone, H., Gani, M., Mir, M. F. & Khan, N. A. (2014) -  
17 Correlation of transrectal ultrasonographic findings with histo pathology in prostatic cancer. -  
18 *Journal of Education & Health Promotion*, 3: 38.  
19 Not in PICO
- 20 Gann P.H., Hennekens, C. H. & Stampfer, M. J. (1995) A prospective evaluation of plasma prostate-  
21 specific antigen for detection of prostatic cancer. *Journal of the American Medical Association*,  
22 273: 289-294.  
23 Not in PICO (not symptomatic population)
- 24 Gattellari, M., Young, J. M. & Ward, J. E. (2003) GP and patient predictors of PSA screening in  
25 Australian general practice. *Family Practice*, 20: 294-303.  
26 Not in PICO
- 27 Gattellari, M., Donnelly, N., Taylor, N., Meerkin, M., Hirst, G. & Ward, J. E. (2005) Does 'peer  
28 coaching' increase GP capacity to promote informed decision making about PSA screening? A  
29 cluster randomised trial. *Family Practice*, 22: 253-265.  
30 Not in PICO
- 31 Gentile, M., Carini, M., Morgia, G., Selvaggi, F. P., Randone, D. & Rosati, A. (2001) Management of  
32 patients with LUTS suggestive of BPH. *European Urology*, 40: 5-8.  
33 Not in PICO
- 34 Getzenberg, R. (2008) What is the future of prostate-specific antigen for the early detection of  
35 prostate cancer? *Bju International*, 102: 157-158.  
36 Commentary
- 37 Giguere, A., Legare, F., Grad, R., Pluye, P., Haynes, R. B., Cauchon, M., Rousseau, F., Argote, J. A. &  
38 Labrecque, M. (2012) Decision boxes for clinicians to support evidence-based practice and shared  
39 decision making: the user experience. *Implementation Science*, 7: 72.  
40 Not in PICO
- 41 Gjengsto, P., Eide, J., Frugard, J., Bakke, A. & Hoisaeter, P. A. (2004) The potentially curable prostate  
42 cancer patient and the pathways leading to diagnosis and treatment. *Scandinavian Journal of*  
43 *Urology and Nephrology*, 38: 15-18.  
44 Not in PICO
- 45 Gonzalez, H. M., West, B. & Underwood, W. (2005) PSA testing in office-based clinics: Are we testing  
46 as much as we think? *Journal of the American College of Surgeons*, 201: 906-912.  
47 Not in PICO
- 48 Gormley, G. J., Catney, D., McCall, J. R., Reilly, P. M. & Gavin, A. T. (2006) Prostate-specific antigen  
49 testing: uncovering primary care influences. *Bju International*, 98: 996-1000.  
50 Not in PICO

- 1 Gottesman, J. & Baum, N. (1997) Common urologic disorders: When to treat and when to refer.  
2 *Postgraduate Medicine*, 102: 235-246.  
3 Narrative review
- 4 Grasso-Leanza, F., Pepe, P., Panella, P. & Pennisi, M. (1995) PSA and prostatic adenocarcinoma.  
5 Experience with 805 patients. [Italian]. *Minerva urologica e nefrologica = The Italian journal of*  
6 *urology and nephrology*, 47: 161-165.  
7 Not in PICO
- 8 Gravalos, G. J. D., Fernandez, G. P., Gorriz, I. C., Garcia, M. A., Araujo, S. A. & Dacosta, M. G. (2007)  
9 Survival of patients diagnosed with prostate cancer and monitored in primary care. *Atencion*  
10 *Primaria*, 39: 603-608.  
11 Not in PICO
- 12 Greene, K. L., Albertsen, P. C., Babaian, R. J., Carter, H. B., Gann, P. H., Han, M., Kuban, D. A., Sartor,  
13 A. O., Stanford, J. L., Zietman, A. & Carroll, P. (2009) Prostate Specific Antigen Best Practice  
14 Statement: 2009 Update. *Journal of Urology*, 182: 2232-2241.  
15 Narrative review
- 16 Greene, K. L., Albertsen, P. C., Babaian, R. J., Carter, H. B., Gann, P. H., Han, M., Kuban, D. A., Sartor,  
17 A. O., Stanford, J. L., Zietman, A. & Carroll, P. (2013) Prostate Specific Antigen Best Practice  
18 Statement: 2009 Update. *Journal of Urology*, 189: S2-S11.  
19 Narrative review
- 20 Guerra, C. E., Gimotty, P. A., Shea, J. A., Pagan, J. A., Schwartz, J. S. & Armstrong, K. (2008) Effect of  
21 guidelines on primary care physician use of PSA screening: Results from the community tracking  
22 study physician survey. *Medical Decision Making*, 28: 681-689.  
23 Not in PICO
- 24 Gueye, S. M., Zeigler-Johnson, C. M., Friebel, T., Spangler, E., Jalloh, M., MacBride, S., Malkowicz, S.  
25 B. & Rebbeck, T. R. (2003) Clinical characteristics of prostate cancer in African Americans,  
26 American whites, and Senegalese men. *Urology*, 61: 987-992.  
27 Not in PICO
- 28 Gui, Q., Xu, C., Zhao, X., Wang, X., Yang, L., Duan, X., Li, H., Yang, Z. & Hu, W. (2013) Diagnostic value  
29 of transrectal real-time elastography in prostatic benign and malignant lesions. *Chinese Journal of*  
30 *Andrology*, 27: 14-17+21.  
31 Not in PICO
- 32 Guichard, G., Larre, S., Gallina, A., Lazar, A., Faucon, H., Chemama, S., Allory, Y., Patard, J. J., Vordos,  
33 D., Hoznek, A., Yiou, R., Salomon, L., Abbou, C. C. & De la Taille, A. (2007) Extended 21-sample  
34 needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. *European*  
35 *Urology*, 52: 430-435.  
36 Not in PICO
- 37 Gustafsson, O., Carlsson, P., Norming, U., Nyman, C. R. & Svensson, H. (1995) Cost-effectiveness  
38 analysis in early detection of prostate cancer: an evaluation of six screening strategies in a  
39 randomly selected population of 2,400 men (Structured abstract). *Prostate*, 26: 299-309.  
40 Not in PICO
- 41 Haider, M. A., Krieger, A., Elliott, C., Da Rosa, M. R. & Milot, L. (2014) - Prostate imaging: evaluation  
42 of a reusable two-channel endorectal receiver coil for MR imaging at 1.5 T. - *Radiology*, 270: 556-  
43 565.  
44 Not in PICO
- 45 Hall, I. J., Taylor, Y. J., Ross, L. E., Richardson, L. C., Richards, T. B. & Rim, S. H. (2011) Discussions  
46 About Prostate Cancer Screening Between US Primary Care Physicians and Their Patients. *Journal*  
47 *of General Internal Medicine*, 26: 1098-1104.  
48 Not in PICO
- 49 Hamoen, E. H. J., Reukers, D. F. M., Numans, M. E., Barentsz, J. O., Witjes, J. A. & Rovers, M. M.  
50 (2013) Discrepancies between guidelines and clinical practice regarding prostate-specific antigen



- 1 testing. *Family Practice*, 30: 648-654.  
 2 Not in PICO
- 3 Hansen, M. V. & Gronberg, A. (1995) Attitudes of European urologists to early prostatic carcinoma. I.  
 4 Diagnostic work-up on suspected prostatic cancer cases. *European Urology*, 28: 189-195.  
 5 Not in PICO
- 6 Harvey, P., Basuita, A., Endersby, D., Curtis, B., Iacovidou, A. & Walker, M. (2009) A systematic  
 7 review of the diagnostic accuracy of prostate specific antigen (Structured abstract). *BMC Urology*,  
 8 9.  
 9 Not in PICO
- 10 He, H., Fan, S., Li, Y., Ke, M., Li, Y., Chen, B. & Yu, H. (2014) - [Value of magnetic resonance imaging  
 11 for early diagnosis of prostatic carcinoma in central zone]. [Chinese]. - *Chung-Hua i Hsueh Tsa  
 12 Chih [Chinese Medical Journal]*, 94: 1051-1054.  
 13 Not in PICO
- 14 He, H., Fan, S., Ke, M., Li, Y., Chen, B. & Yu, H. (2014) Value of magnetic resonance imaging for early  
 15 diagnosis of prostatic carcinoma in central zone. [Chinese]. *National Medical Journal of China*, 94:  
 16 1051-1054.  
 17 Not in PICO
- 18 Heins, M. J., Korevaar, J. C., Rijken, P. M. & Schellevis, F. G. (2013) For which health problems do  
 19 cancer survivors visit their General Practitioner? *European Journal of Cancer*, 49: 211-218.  
 20 Not in PICO
- 21 Helmy, H., Rasheed, M. & Al-Abd, S. (2009) Vardenafil improves erectile function and urinary  
 22 symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with  
 23 benign prostatic hyperplasia: A randomized, double-blind, placebo controlled trial. *European  
 24 Urology, Supplements*, 8: 238.  
 25 Not in PICO
- 26 Helpap, B. & Oehler, U. (2012) [Importance of second opinions on histology of prostate biopsy  
 27 specimens]. [German]. *Pathologe*, 33: 103-112.  
 28 Not in PICO
- 29 Herranz, A. F., Verdu, T. F., Diez Cordero, J. M., Sanchez, C. F., Lledo, G. E., Bueno, C. G. & Leal, H. F.  
 30 (1997) Yield of transrectal ultrasonography in the diagnosis of prostatic cancer in symptomatic  
 31 patients with normal rectal digital test. [Spanish]. *Actas Urologicas Espanolas*, 21: 565-571.  
 32 Not in PICO
- 33 Herranz, A. F., Verdu, T. F., Diez Cordero, J. M., Saiz, C. A., Lledo, G. E., Rodriguez, F. E. & Bueno, C. G.  
 34 (1997) [Yield of ultrasound-guided transrectal biopsy in the diagnosis of prostatic cancer in  
 35 symptomatic patients]. [Spanish]. *Archivos Espanoles de Urologia*, 50: 283-288.  
 36 Not in PICO
- 37 Herranz, A. F., Verdu, T. F., Diez Cordero, J. M., Bueno, C. G., Leal, H. F., Bielsa, C. A. & Garcia, B. J.  
 38 (1999) Incidence of prostatic cancer in symptomatic patients with non-suspicious rectal palpation  
 39 and PSA levels greater than 10 ng/ml. [Spanish]. *Actas Urologicas Espanolas*, 23: 316-322.  
 40 Not in PICO
- 41 Herranz, A. F., Verdu, T. F., Diez Cordero, J. M., Leal, H. F., Bielsa, C. A., Garcia, B. J. & Subira, R. D.  
 42 (2000) Usefulness of free PSA/total PSA ratio in the diagnosis of prostatic cancer in symptomatic  
 43 patients with PSA levels ranging from 2.5 to 20 ng/ml. [Spanish]. *Actas Urologicas Espanolas*, 24:  
 44 24-30.  
 45 Not in PICO I believe (very little patient detail given but authors from "Servicio de Urologia" and  
 46 cancer prevalence 25%).
- 47 Heyns, C., Fisher, M., Lecuona, A. & Van Der Merwe, A. (2010) Evidence that initial PSA testing  
 48 should be extended to men aged <45 years to detect those at risk of presenting with aggressive  
 49 Prostate cancer at the age of <50 years. *Journal of Urology*, 183: e666-e667.  
 50 Not in PICO

- 1 Heyns, C. F., Mathee, S., Isaacs, A., Kharwa, A., De Beer, P. M. & Pretorius, M. A. (2003) Problems  
2 with prostate specific antigen screening for prostate cancer in the primary healthcare setting in  
3 South Africa. *Bju International*, 91: 785-788.  
4 Not in PICO
- 5 Hillig, T., Sole-Tormos, G., Hansen, S. I. & Meyhoff, H. H. (2011) Diagnostic ability of tpsa and cpsa in  
6 a patient cohort referred to a Danish Urological Department. *European Journal of Cancer*, 47:  
7 S179.  
8 Not in PICO
- 9 Hocaoglu, Y., Seitz, M., Stief, C. G. & Bastian, P. J. (2012) [Early diagnosis of prostate cancer].  
10 [German]. *MMW Fortschritte der Medizin*, 154: 43-46.  
11 Not in PICO
- 12 Hodgson, F., Obertova, Z., Brown, C. & Lawrenson, R. (2012) PSA testing in general practice. *Journal*  
13 *of Primary Health Care*, 4: 199-204.  
14 Not in PICO
- 15 Hodgson, F., Obertova, Z., Brown, C. & Lawrenson, R. (2012) PSA testing in general practice. *Journal*  
16 *of Primary Health Care*, 4: 199-204.  
17 Not in PICO
- 18 Hoffman, R. M., Clanon, D. L., Littenberg, B., Frank, J. J. & Peirce, J. C. (2000) Using the free-to-total  
19 prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of  
20 prostate-specific antigen levels (Structured abstract). *Journal of General Internal Medicine*, 15:  
21 739-748.  
22 Not in PICO
- 23 Hoffman, R. M., Barry, M. J., Roberts, R. G. & Sox, H. C. (2012) Reconciling primary care and specialist  
24 perspectives on prostate cancer screening. *Annals of Family Medicine*, 10: 568-571.  
25 Not in PICO
- 26 Holmes, J. A., Wang, A. Z., Hoffman, K. E., Hendrix, L. H., Rosenman, J. G., Carpenter, W. R., Godley,  
27 P. A. & Chen, R. C. (2012) Is Primary Prostate Cancer Treatment Influenced by Likelihood of  
28 Extraprostatic Disease? A Surveillance, Epidemiology and End Results Patterns of Care Study.  
29 *International Journal of Radiation Oncology Biology Physics*, 84: 88-94.  
30 Not in PICO
- 31 Hong, C. W., Walton-Diaz, A., Rais-Bahrami, S., Hoang, A. N., Turkbey, B., Stamatakis, L., Xu, S.,  
32 Amalou, H., Siddiqui, M. M., Nix, J. W., Vourganti, S., Merino, M. J., Choyke, P. L., Wood, B. J. &  
33 Pinto, P. A. (2014) - Imaging and pathology findings after an initial negative MRI-US fusion-guided  
34 and 12-core extended sextant prostate biopsy session. - *Diagnostic & Interventional Radiology*,  
35 20: 234-238.  
36 Not in PICO
- 37 Hoogendam, A., Buntinx, F. & Vet, H. C. (1999) The diagnostic value of digital rectal examination in  
38 primary care screening for prostate cancer: a meta-analysis (Structured abstract). *Family Practice*,  
39 16: 621-626.  
40 Not in PICO
- 41 Hori, S., Fuge, O., Trabucchi, K., Donaldson, P. & McLoughlin, J. (2013) Can a trained non-physician  
42 provider perform transrectal ultrasound-guided prostatic biopsies as effectively as an  
43 experienced urologist? *Bju International*, 111: 739-744.  
44 Not in PICO
- 45 Houlgatte, A., Vincendeau, S., Desfemmes, F., Ramirez, J., Benoist, N., Bensalah, K. & Durand, X.  
46 (2012) [Use of [-2] pro PSA and phi index for early detection of prostate cancer: a prospective of  
47 452 patients]. [French]. *Progres En Urologie*, 22: 279-283.  
48 Not in PICO
- 49 Huber, J., Ihrig, A., Huber, C. G., Hadaschik, B., Pahernik, S. & Hohenfellner, M. (2011) [Patient  
50 centeredness and decision-making in localised prostate cancer: possible fields of health services

- 1 research in urology]. [German]. *Urologe (Auszg.A)*, 50: 691-696.  
2 Not in PICO
- 3 Huber, S., Stenzl, A. & Schilling, D. (2009) Exploring new avenues to an early identification of a  
4 prostate carcinoma - Tumor-specific markers and imaging. [German]. *Klinikerarzt*, 38: 376-381.  
5 Narrative review
- 6 Hudson, S. V., Ohman-Strickland, P., Ferrante, J. M., Lu-Yao, G., Orzano, A. J. & Crabtree, B. F. (2009)  
7 Prostate-Specific Antigen Testing among the Elderly in Community-Based Family Medicine  
8 Practices. *Journal of the American Board of Family Medicine*, 22: 257-265.  
9 Not in PICO
- 10 Hultin, S., Hotston, M., Day, A., Taylor, A., Goodall, R., Thomas, P., Bahl, A., Persad, R. & Gjini, A.  
11 (2014) Audit of PSA requesting practices in primary care compared to guidelines established by  
12 the Prostate Cancer Risk Management programme in the Avon region of the South West of  
13 England. *Journal of Clinical Urology*, 7: 45-54.  
14 Not in PICO
- 15 Hwang, J. W., Bang, W. J., Oh, C. Y., Yoo, C. & Cho, J. S. (2014) - Factors influencing the acceptance of  
16 transrectal ultrasound-guided prostate biopsies. - *Korean Journal of Urology*, 55: 460-464.  
17 Not in PICO
- 18 Iqbal, N. & Chughtai, N. (2005) Evaluation of the diagnostic use of free prostate specific  
19 antigen/total prostate specific antigen ratio in detecting prostate cancer. *Journal of the Pakistan  
20 Medical Association*, 55: 318-320.  
21 Not in PICO
- 22 Issa, M. M., Zasada, W., Ward, K., Hall, J. A., Petros, J. A., Ritenour, C. W., Goodman, M., Kleinbaum,  
23 D., Mandel, J. & Marshall, F. F. (2006) The value of digital rectal examination as a predictor of  
24 prostate cancer diagnosis among United States Veterans referred for prostate biopsy. *Cancer  
25 Detection & Prevention*, 30: 269-275.  
26 Not in PICO
- 27 Iwamoto, H., Yumioka, T., Yamaguchi, N., Inoue, S., Masago, T., Morizane, S., Yao, A., Honda, M.,  
28 Sejima, T. & Takenaka, A. (2014) - The Efficacy of Target Biopsy of Suspected Cancer Lesions  
29 Detected by Magnetic Resonance Imaging and/or Transrectal Ultrasonography during Initial  
30 Prostate Biopsies: Comparison of Outcomes between Two Physicians. - *Yonago Acta Medica*, 57:  
31 53-58.  
32 Not in PICO
- 33 Iwamoto, H., Yumioka, T., Yamaguchi, N., Inoue, S., Masago, T., Morizane, S., Yao, A., Honda, M.,  
34 Sejima, T. & Takenaka, A. (2014) The efficacy of target biopsy of suspected cancer lesions  
35 detected by magnetic resonance imaging and/or transrectal ultrasonography during initial  
36 prostate biopsies: Comparison of outcomes between two physicians. *Yonago Acta Medica*, 57:  
37 53-58.  
38 Duplicate
- 39 Jamaspishvili, T., Kral, M., Khomeriki, I., Student, V., Kolar, Z. & Bouchal, J. (2010) Urine markers in  
40 monitoring for prostate cancer. [Review] [106 refs]. *Prostate Cancer & Prostatic Diseases*, 13: 12-  
41 19.  
42 Narrative review
- 43 Jimbo, H., Totsuka, Y., Mashimo, T., Umeyama, T., Uehara, H. & Sinozaki, T. (1994) [Investigation of  
44 ultrasound guided systematic biopsy of the prostate]. [Japanese]. *Nippon Hinyokika Gakkai Zasshi*  
45 - *Japanese Journal of Urology*, 85: 964-967.  
46 Not in PICO
- 47 Jolly, S., Howson, J., Catto, J., Haynes, M., Cutinha, P., Yates, D. & Rosario, D. (2013) Clinical  
48 microsystems in designing trus-biopsy services - A closed-loop audit of a specialist nurse-led  
49 triage clinic for men with suspected prostate cancer. *International Journal of Surgery*, 11: 727.  
50 Not in PICO

- 1 Jonler, M., Eddy, B. & Poulsen, J. (2005) Prostate-specific antigen testing in general practice: A survey  
2 among 325 general practitioners in Denmark. *Scandinavian Journal of Urology and Nephrology*,  
3 39: 214-218.  
4 Not in PICO
- 5 Jordan, K. P., Hayward, R. A., Blagojevic-Bucknall, M. & Croft, P. (2013) Incidence of prostate, breast,  
6 lung and colorectal cancer following new consultation for musculoskeletal pain: a cohort study  
7 among UK primary care patients. *International Journal of Cancer*, 133: 713-720.  
8 Cannot extract outcome in PICO (PPVs) as cancer data only reported in total for 10-year follow up
- 9 Jung, A. J., Westphalen, A. C., Kurhanewicz, J., Wang, Z. J., Carroll, P. R., Simko, J. P. & Coakley, F. V.  
10 (2014) - Clinical utility of endorectal MRI-guided prostate biopsy: Preliminary experience. -  
11 *Journal of Magnetic Resonance Imaging*, 40: 314-323.  
12 Not in PICO
- 13 Jung, A. J., Westphalen, A. C., Kurhanewicz, J., Wang, Z. J., Carroll, P. R., Simko, J. P. & Coakley, F. V.  
14 (2014) Clinical utility of endorectal MRI-guided prostate biopsy: Preliminary experience. *Journal*  
15 *of Magnetic Resonance Imaging*, 40: 314-323.  
16 Duplicate
- 17 Kamalov, A. A., Maksimov, V. A., Takhirzade, T. B., Gevorkian, A. R., Okhobotov, D. A., Avakian, A. I. &  
18 Vasil'eva, E. G. (2012) [Detection of prostate cancer based on monitoring of prostate-specific  
19 antigen in outpatient clinic]. [Russian]. *Urologiia (Moscow, Russia).(6):58-60, 2012 Sep-Oct., 58-*  
20 *60.*  
21 Not in PICO
- 22 Kaplan, S. & Naslund, M. (2006) Public, patient, and professional attitudes towards the diagnosis and  
23 treatment of enlarged prostate: A landmark national US survey. *International Journal of Clinical*  
24 *Practice*, 60: 1157-1165.  
25 Not in PICO
- 26 Kapoor, A. (2012) Benign prostatic hyperplasia (BPH) management in the primary care setting.  
27 *Canadian Journal of Urology*, 19: 10-17.  
28 Not in PICO
- 29 Kapoor, N., Surange, S., Gupta, K. N., Husainy, M. A. & Faizi, M. (2004) Diagnosis of malignancy of  
30 prostate. *Indian Journal of Pathology and Microbiology*, 47: 186-188.  
31 Not in PICO
- 32 Katz, A., Katz, A. & Burchill, C. (2007) Androgen therapy: testing before prescribing and monitoring  
33 during therapy. *Canadian Family Physician*, 53: 1936-1942.  
34 Not in PICO
- 35 Katz, B., Srougi, M., Dall'Oglio, M., Nesrallah, A. J., Sant'anna, A. C., Pontes, J., Jr., Reis, S. T., Sanudo,  
36 A., Camara-Lopes, L. H. & Leite, K. R. (2012) Are we able to correctly identify prostate cancer  
37 patients who could be adequately treated by focal therapy? *Urologic Oncology*, 30: 794-797.  
38 Not in PICO
- 39 Katz, B., Srougi, M., Dall'Oglio, M., Nesrallah, A. J., Sant'anna, A. C., Pontes, J., Jr., Reis, S. T., Sanudo,  
40 A., Camara-Lopes, L. H. & Leite, K. R. (2012) Are we able to correctly identify prostate cancer  
41 patients who could be adequately treated by focal therapy? *Urologic Oncology*, 30: 794-797.  
42 Not in PICO
- 43 Kell, J. S. (2010) Prostate-specific antigen tests and prostate cancer screening: an update for primary  
44 care physicians. *Canadian Journal of Urology*, 17: 18-25.  
45 Narrative review
- 46 Kiknavelidze, K., Tsintsadze, O., Gogvadze, M., Pertia, A. & Managadze, L. (2006) Prostate cancer  
47 detection rate in patients with obstructive voiding symptoms by sextant biopsy: preliminary  
48 results. *Georgian Medical News.(133):9-14, 2006 Apr., 9-14.*  
49 Not in PICO
- 50 Kiknavelidze, K. G., Chanturaia, Z. M., Silagava, D. D., Nikoleishvili, D. O., Tsintsadze, O. V. &  
51 Managadze, L. G. (2006) Is sextant biopsy a valid method in diagnosis of prostatic cancer?.

- 1 [Russian]. *Urologiia*, 32-35.  
2 Not in PICO
- 3 Kim, D. K., Kim, S. J., Moon, H. S., Park, S. Y., Kim, Y. T., Choi, H. Y., Lee, T. Y. & Park, H. Y. (2010) The  
4 Role of TURP in the Detection of Prostate Cancer in BPH Patients with Previously Negative  
5 Prostate Biopsy. *Korean Journal of Urology*, 51: 313-317.  
6 Not in PICO
- 7 Kim, J. Y., Kim, S. H., Kim, Y. H., Lee, H. J., Kim, M. J. & Choi, M. S. (2014) - Low-risk prostate cancer:  
8 the accuracy of multiparametric MR imaging for detection. - *Radiology*, 271: 435-444.  
9 Not in PICO
- 10 Kim, Y. M., Kim, J., Park, S., Lee, J. H., Ryu, D. S., Choi, S. H. & Cheon, S. H. (2013) Role of prostate  
11 volume in the early detection of prostate cancer in a cohort with slowly increasing prostate  
12 specific antigen. *Yonsei Medical Journal*, 54: 1202-1206.  
13 Not in PICO
- 14 Kimura, G., Nishimura, T., Kimata, R., Saito, Y. & Yoshida, K. (2005) Random systematic sextant  
15 biopsy versus power doppler ultrasound-guided target biopsy in the diagnosis of prostate cancer:  
16 positive rate and clinicopathological features. *Journal of Nippon Medical School = Nihon Ika*  
17 *Daigaku Zasshi*, 72: 262-269.  
18 Not in PICO
- 19 Kimura, T., Ikemoto, I. & Ohishi, Y. (2000) Clinical profiles of prostate cancer in our hospital:  
20 association between primary symptoms and clinical stage. [Japanese]. *Hinyokika kiyo, Acta*: 83-  
21 86.  
22 Not in PICO
- 23 Kirby, R. & Fitzpatrick, J. (2004) Prostate-specific antigen testing for the early detection of prostate  
24 cancer. *Bju International*, 94: 966-967.  
25 Narrative review
- 26 Kirkham, A. P., Haslam, P., Keanie, J. Y., McCafferty, I., Padhani, A. R., Punwani, S., Richenberg, J.,  
27 Rottenberg, G., Sohaib, A., Thompson, P., Turnbull, L. W., Kurban, L., Sahdev, A., Clements, R.,  
28 Carey, B. M. & Allen, C. (2013) Prostate MRI: who, when, and how? Report from a UK consensus  
29 meeting. *Clinical Radiology*, 68: 1016-1023.  
30 Narrative review
- 31 Klein, T., Palisaar, R. J., Holz, A., Brock, M., Noldus, J. & Hinkel, A. (2010) The impact of prostate  
32 biopsy and periprostatic nerve block on erectile and voiding function: A prospective study.  
33 *Journal of Urology*, 184: 1447-1452.  
34 Not in PICO
- 35 Kok, E. T., Groeneveld, F. P. M. J., Gouweloos, J., Jonkheijm, R., Bosch, J. L. H. R., Thomas, S. &  
36 Bohnen, A. M. (2006) Determinants of Seeking of Primary Care for Lower Urinary Tract  
37 Symptoms: The Krimpen Study in Community-Dwelling Men. *European Urology*, 50: 811-817.  
38 Not in PICO
- 39 Konety, B. R., Sharp, V. J., Verma, M. & Williams, R. D. (2006) Practice patterns in screening and  
40 management of prostate cancer in elderly men. *Urology*, 68: 1051-1056.  
41 Not in PICO
- 42 Kong, J. P. L., Bultitude, M. F., Longano, A., Grummet, J. & Corcoran, N. M. (2010) Metastatic  
43 prostate cancer presenting as a syndrome of inappropriate antidiuretic hormone secretion. *Bju*  
44 *International*, 105: 28.  
45 Not in PICO
- 46 Koo, J. H., Kim, C. K., Choi, D., Park, B. K., Kwon, G. Y. & Kim, B. (2013) Diffusion-weighted magnetic  
47 resonance imaging for the evaluation of prostate cancer: optimal B value at 3T. *Korean Journal of*  
48 *Radiology*, 14: 61-69.  
49 Not in PICO
- 50 Koo, V., McMahan, J., O'Brien, A., Young, M. & Marley, J. (2008) Outcome audit of nurse-led lower  
51 urinary tract symptoms clinic: lessons and challenges for practice. *International Journal of*

- 1 *Urological Nursing*, 2: 72-77.  
2 Not in PICO
- 3 Korde, L. A. & Gadalla, S. M. (2009) Cancer Risk Assessment for the Primary Care Physician. *Primary*  
4 *Care - Clinics in Office Practice*, 36: 471-488.  
5 Narrative review
- 6 Kotsis, S. V., Spencer, S. L., Peyser, P. A., Montie, J. E. & Cooney, K. A. (2002) Early onset prostate  
7 cancer: Predictors of clinical grade. *Journal of Urology*, 167: 1659-1663.  
8 Not in PICO
- 9 Krause, B. J., Souvatzoglou, M. & Treiber, U. (2013) Imaging of prostate cancer with PET/CT and  
10 radioactively labeled choline derivates. [Review]. *Urologic Oncology*, 31: 427-435.  
11 Narrative review
- 12 Kronz, J. D., Milord, R., Wilentz, R., Weir, E. G., Schreiner, S. R. & Epstein, J. I. (2003) Lesions missed  
13 on prostate biopsies in cases sent in for consultation. *Prostate*, 54: 310-314.  
14 Not in PICO
- 15 Kuo, N. W., Lin, H. C. & Lee, H. C. (2008) Physician Clinical Experience and Inappropriate Prostate  
16 Specific Antigen Screening: Evidence From an Asian Country. *Journal of Urology*, 180: 1954-1958.  
17 Not in PICO
- 18 Laguna Pes, M. P., Guinda, S. C., Zazo, R. A., Dominguez, J., Garcia, L. A., Borrego, H. J. & Gimeno, C.  
19 A. (2000) Clinical usefulness of free PSA/total PSA ratio in the early diagnosis of prostatic cancer.  
20 [Spanish]. *Archivos Espanoles de Urologia*, 53: 333-341.  
21 Not in PICO (referred population)
- 22 Lai, T. C. T., Tsu, J. H., Ng, C. M., Wong, E. M., Ho, K. L. & Yiu, M. K. (2014) Optimizing prostate cancer  
23 diagnosis: 10-core versus 12-core prostate biopsy protocol. *Bju International*, 113: 6.  
24 Not in PICO
- 25 Lamy, P. J., Montels, F., Tosi, D., Leizour, B., Bascoul-Mollevi, C., Castan, F., Roques, S., Nielloud, F. &  
26 Rebillard, X. (2013) [Evaluation of (-2)proPSA in combination with total PSA and free PSA for the  
27 early detection of prostate cancer]. [French]. *Annales de Biologie Clinique*, 71: 537-544.  
28 Not in PICO
- 29 Laufer, M., Keller, T., Gershman, V., Ferman, Z., Sarid, M. & Leibovitch, I. (2014) - [InoPro trial:  
30 collaboration between urologists and primary care physicians in the treatment of osteoporosis in  
31 prostate cancer patients]. [Hebrew]. - *Harefuah*, 153: 151-154.  
32 Not in PICO
- 33 Lawrence, E. M., Tang, S. Y., Barrett, T., Koo, B., Goldman, D. A., Warren, A. Y., Axell, R. G., Doble, A.,  
34 Gallagher, F. A., Gnanapragasam, V. J., Kastner, C. & Sala, E. (2014) - Prostate cancer:  
35 performance characteristics of combined T2W and DW-MRI scoring in the setting of template  
36 transperineal re-biopsy using MR-TRUS fusion. - *European Radiology*, 24: 1497-1505.  
37 Not in PICO
- 38 Lawrentschuk, N., Daljeet, N., Ma, C. M., Hersey, K., Zlotta, A. & Fleshner, N. (2011) Prostate-specific  
39 antigen test result interpretation when combined with risk factors for recommendation of biopsy:  
40 a survey of urologist's practice patterns. *International Urology and Nephrology*, 43: 31-37.  
41 Not in PICO
- 42 Lebentrau, S., May, M., Maurer, O., Schostak, M., Lehnau, M., Ecke, T., Al-Dumaini, S., Hallmann, S.,  
43 Ahmed, A. M., Braun, V., Haferkamp, A., Bauer, R. M., Stief, C. G., Baumunk, D., Hoschke, B.,  
44 Braun, H. P., Schafer, C., Hipp, M., Maurer, J., Braun, K. P., Wolff, I., Brookman-May, S. & Gilfrich,  
45 C. (2014) Rates of prostate-specific antigen testing for early detection of prostate cancer. A first  
46 comparison of German results with current international data. *Urologe*, 53: 715-724.  
47 Not in PICO
- 48 Lee, J., Yamaguchi, T., Abe, A., Shizukuishi, K., Uemura, H., Miyagi, E., Sakata, K. & Inoue, T. (2004)  
49 Clinical evaluation of choline measurement by proton MR spectroscopy in patients with  
50 malignant tumors. *Radiation Medicine*, 22: 148-154.  
51 Not in PICO

- 1 Lee, S. J., Hwang, I., Hwang, E. C., Jung, S. I., Kang, T. W., Kwon, D. D. & Park, K. (2013) Are more low-  
2 risk prostate cancers detected by repeated biopsy? A retrospective pilot study. *Korean Journal of*  
3 *Urology*, 54: 364-368.  
4 Not in PICO
- 5 Lee, T. H. (2001) By the way, doctor... I can't understand why there are reservations about the  
6 prostate-specific antigen (PSA) test. The "score" goes up when you have prostate cancer. So isn't  
7 getting a PSA test a good way of catching prostate cancer early? But my doctor seems reluctant  
8 to order it. What's the problem? *Harvard Health Letter*, 26: 8.  
9 Not in PICO
- 10 Lent, V., Baumbusch, F. & Weber, B. (2012) Criteria for errors in prostate-specific antigen  
11 diagnostics. [German]. *Urologe - Ausgabe A*, 51: 1558-1561.  
12 Not in PICO
- 13 Lentini, M., Marzano, D., Perrone, M., Annunziata, S. & Cianetti, A. (1997) Comparison of free/total  
14 PSA (F/T PSA) ratio and PSA density (PSAD) in the early diagnosis of cancer of the prostate.  
15 [Italian]. *Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di*  
16 *ecografia urologica e nefrologica / Associazione ricerche in urologia*, 69: 101-104.  
17 Narrative review
- 18 Li, L., Wang, L., Feng, Z., Hu, Z., Wang, G., Yuan, X., Wang, H. & Hu, D. (2013) Prostate cancer  
19 magnetic resonance imaging (MRI): multidisciplinary standpoint. *Quantitative Imaging in*  
20 *Medicine & Surgery*, 3: 100-112.  
21 Narrative review
- 22 Li, Y.-H., Elshafei, A., Li, J., Gong, M., Susan, L., Fareed, K. & Jones, J. S. (2014) Transrectal saturation  
23 technique may improve cancer detection as an initial prostate biopsy strategy in men with  
24 prostate-specific antigen <10 ng/ml. *European Urology*, 65: 1178-1183.  
25 Not in PICO
- 26 Little, B., Ho, K. J., Gormley, G. & Young, M. (2003) PSA testing in general practice. *Prostate Cancer*  
27 *and Prostatic Diseases*, 6: 154-158.  
28 Not in PICO
- 29 Liu, J., Yue, Q.-X., Zhou, Y., Yu, G.-H. & Li, S. (2013) Application of transrectal real-time elastography  
30 in prostate biopsy. [Chinese]. *Chinese Journal of Interventional Imaging and Therapy*, 10: 101-  
31 103.  
32 Not in PICO
- 33 Loeb, S. & Cooperberg, M. R. (2014) - Early detection of prostate cancer. - *Urologic Clinics of North*  
34 *America*, 41: xiii.  
35 Narrative review
- 36 Lokuhetty, M. D., Wijesinghe, H. D., Abeyesuriya, D. T., Samarasinghe, U. C. & Perera, N. D. (2009)  
37 Trans rectal ultra sound guided prostate biopsies: a single centre experience in Sri Lanka. *The*  
38 *Ceylon medical journal*, 54: 6-9.  
39 Not in PICO
- 40 Lopez-Saez, J.-B., Otero, M., Senra-Varela, A., Ojea, A., Saez Martin, J. L., Duran, M. B. & Vieito, F. J.  
41 (2004) Prospective observational study to assess value of prostate cancer diagnostic methods.  
42 *Journal of Diagnostic Medical Sonography*, 20: 383-393.  
43 Not in PICO (same data as other Lopez-Saez)
- 44 Lopez-Saez, J.-B., Otero, M., Villar, M. D., Penueles, A. L., Navarro, P. R., Moreira, P. G. & Senra-  
45 Varela, A. (2007) Diagnostic methods in the detectiion of prostate cancer: Prospective  
46 observational study. *Current Medical Imaging Reviews*, 3: 27-35.  
47 Not in PICO (same data as other Lopez-Saez)
- 48 Luboldt, H.-J., Swoboda, A., Borgermann, C., Fornara, P. & Rubben, H. (2001) Clinical usefulness of  
49 free PSA in early detection of prostate cancer. *Onkologie*, 24: 33-37.  
50 Not in PICO

- 1 Luboldt, H. J., Husing, J., Altwein, J. E., Bichler, K. H., Czaja, D., Fornara, P., Jockel, K. H., Schalkhauser,  
2 K., Weissbach, L., Wirth, M. & Rubben, H. (2000) [Early detection of prostatic carcinoma in  
3 urologic practice with digital rectal examination and prostate-specific antigen. Early Detection  
4 Project Group]. [German]. *Urologe (Auszg.A)*, 39: 330-333.  
5 Narrative review
- 6 Lumbreras, B., Lopez-Garrigos, M. & Salinas, M. (2012) Variation in Prostate Specific Antigen (PSA)  
7 Test Ordering in Primary Care Centers: Tendencies 2002-2009. *Clinical Laboratory*, 58: 573-577.  
8 Not in PICO
- 9 Luo, Y., Gou, X., Huang, P. & Mou, C. (2014) The PCA3 test for guiding repeat biopsy of prostate  
10 cancer and its cut-off score: A systematic review and meta-analysis. *Asian Journal of Andrology*,  
11 16: 487-492.  
12 Not in PICO
- 13 Malli, G. (2013) [Early Detection of Prostate Cancer by PSA Testing: The Results of a Qualitative Study  
14 on Barriers Caused by Physicians in Austria Implementing Informed Decision Making]. [German].  
15 *Gesundheitswesen*, 75: 22-28.  
16 Not in PICO
- 17 Manolovic, D., Pejicic, T. & Milovic, N. (1994) Prostatic specific antigen: role and significance in  
18 urologic practice. [Croatian]. *Srpski Arhiv Za Celokupno Lekarstvo*, 122: 171-173.  
19 Narrative review
- 20 Mantelli, M., Iacono, R., Quattropanetti, S., Quattropanetti, R. & Begani, P. R. (1993) Validity of  
21 transrectal ultrasonography and echo-guided biopsy in the early diagnosis of prostatic neoplasms.  
22 Our experience on 100 cases. [Italian]. *Archivio italiano di urologia, andrologia : organo ufficiale*  
23 *[di] Societa italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia*, 65:  
24 413-415.  
25 Not in PICO
- 26 McNaughton, C. M., Stafford, R. S. & Barry, M. J. (2000) Age-specific patterns of prostate-specific  
27 antigen testing among primary care physician visits. *The Journal of family practice*, 49: 169-172.  
28 Not in PICO
- 29 Melia, J. & Moss, S. (2001) Survey of the rate of PSA testing in general practice. *British Journal of*  
30 *Cancer*, 85: 656-657.  
31 Not in PICO
- 32 Melia, J., Moss, S. & Johns, L. (2004) Rates of prostate-specific antigen testing in general practice in  
33 England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. *Bju*  
34 *International*, 94: 51-56.  
35 Not in PICO
- 36 Melia, J., Coulson, P., Coleman, D. & Moss, S. (2008) Urological referral of asymptomatic men in  
37 general practice in England. *British Journal of Cancer*, 98: 1176-1181.  
38 Not in PICO
- 39 Melia, J., Coulson, P., Moss, S. & Coleman, D. (2010) Effects of a prostate awareness pilot on GP  
40 consultations and PSA requests. *Family Practice*, 27: 69-76.  
41 Not in PICO
- 42 Metcalfe, C., Evans, S., Ibrahim, F., Patel, B., Anson, K., Chinegwundoh, F., Corbishley, C., Gillatt, D.,  
43 Kirby, R., Muir, G., Nargund, V., Popert, R., Persad, R. & Ben-Shlomo, Y. (2008) Pathways to  
44 diagnosis for Black men and White men found to have prostate cancer: The PROCESS cohort  
45 study. *British Journal of Cancer*, 99: 1040-1045.  
46 Not in PICO
- 47 Miao, H., Fukatsu, H. & Ishigaki, T. (2007) Prostate cancer detection with 3-T MRI: comparison of  
48 diffusion-weighted and T2-weighted imaging. *European Journal of Radiology*, 61: 297-302.  
49 Not in PICO
- 50 Minguez, M. R., Fernandez, B. A., Gomez, S. F., Ruiz, Z. C., Teba del, P. F., Romero Tejada, J. C.,  
51 Arellano, G. R. & Pereira, S., I (1999) Early diagnosis of prostate cancer in patients with prostate



- 1 symptoms by DRE, PSA, TRU and DPSA. [Spanish]. *Actas Urologicas Espanolas*, 23: 688-693.  
 2 Not in PICO
- 3 Mischi, M., Saidov, T., Kompatsiari, K., Engelbrecht, M. R., Breeuwer, M. & Wijkstra, H. (2013)  
 4 Prostate cancer localization by novel magnetic resonance dispersion imaging. *Conference*  
 5 *Proceedings: ...Annual International Conference of the IEEE Engineering in Medicine & Biology*  
 6 *Society*, 2013: 2603-2606.  
 7 Narrative review
- 8 Mitchell, J. M. (2012) Urologists' self-referral for pathology of biopsy specimens linked to increased  
 9 use and lower prostate cancer detection. *Health Affairs*, 31: 741-749.  
 10 Not in PICO
- 11 Mohamed, Z. K., Dominguez-Escrig, J., Vasdev, N., Bharathan, B. & Greene, D. (2013) The prognostic  
 12 value of transrectal ultrasound guided biopsy in patients over 70 years old with a prostate  
 13 specific Antigen (PSA) level <15 ng/ml and normal digital rectal examination: A 10-year  
 14 prospective follow-up study of 427 consecutive patients. *Urologic Oncology: Seminars and*  
 15 *Original Investigations*, 31: 1489-1496.  
 16 Not in PICO
- 17 Molero, J. M., Morales, D. P., Bermudez, F. J. B., Pulido, E. N., Fernandez-Pro, A., Martin, J. A.,  
 18 Fernandez, J. C. & Olmo, J. M. C. (2010) Referral criteria for benign prostatic hyperplasia in  
 19 primary care. *Atencion Primaria*, 42: 36-46.  
 20 Narrative review
- 21 Monda, J. M., Barry, M. J. & Oesterling, J. E. (1994) Prostate specific antigen cannot distinguish stage  
 22 T1a (A1) prostate cancer from benign prostatic hyperplasia. *Journal of Urology*, 151: 1291-1295.  
 23 Not in PICO
- 24 Morote, J., Raventos, C. X., Lorente, J. A., Lopez-Pacios, M. A., Encabo, G., de, T., I & Andreu, J. (1997)  
 25 Comparison of percent free prostate specific antigen and prostate specific antigen density as  
 26 methods to enhance prostate specific antigen specificity in early prostate cancer detection in  
 27 men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.  
 28 *Journal of Urology*, 158: 502-504.  
 29 Not in PICO
- 30 Morris, S. B., Hampson, S. J., Shearer, R. J. & Corbishley, C. M. (1994) Rapid processing in the  
 31 management of prostatic cancer. *British Journal of Urology*, 73: 681-682.  
 32 Not in PICO
- 33 Mosca, P. & Roy, J. B. (1980) Outpatient needle-biopsy of the prostate: a retrospective study. *Journal*  
 34 *- Oklahoma State Medical Association*, 73: 3-6.  
 35 Not in PICO
- 36 Mosli, H. A. (1997) Prostate cancer: Experience at King Abdulaziz University Hospital, Jeddah. *Annals*  
 37 *of Saudi Medicine*, 17: 590-594.  
 38 Not in PICO
- 39 Mosquera, M. J., Pinto, S., I, Enguix, A. A. & Sahagun Arguello, J. L. (2001) Usefulness of free/total  
 40 PSA ratio and PSA density in distinguishing benign prostatic hypertrophy from prostatic cancer.  
 41 [Spanish]. *Actas Urologicas Espanolas*, 25: 651-655.  
 42 Not in PICO
- 43 Mouraviev, V., Verma, S., Kalyanaraman, B., Zhai, Q. J., Gaitonde, K., Pugnale, M. & Donovan, J. F.  
 44 (2013) The feasibility of multiparametric magnetic resonance imaging for targeted biopsy using  
 45 novel navigation systems to detect early stage prostate cancer: the preliminary experience.  
 46 *Journal of Endourology*, 27: 820-825.  
 47 Not in PICO
- 48 Mowatt, G., Scotland, G., Boachie, C., Cruickshank, M., Ford, J. A., Fraser, C., Kurban, L., Lam, T. B.,  
 49 Padhani, A. R., Royle, J., Scheenen, T. W. & Tassie, E. (2001) The diagnostic accuracy and cost-  
 50 effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging  
 51 techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and

- 1 economic evaluation. *Health technology assessment (Winchester, England)*, 17: vii-281.  
 2 Not in PICO
- 3 Murphy, D. G., Ahlering, T., Catalona, W. J., Crowe, H., Crowe, J., Clarke, N., Cooperberg, M., Gillatt,  
 4 D., Gleave, M., Loeb, S., Roobol, M., Sartor, O., Pickles, T., Wootten, A., Walsh, P. C. & Costello, A.  
 5 J. (2014) - The Melbourne Consensus Statement on the early detection of prostate cancer.  
 6 [Review]. - *BJU International*, 113: 186-188.  
 7 Narrative review
- 8 Myers, R. E., Daskalakis, C., Cocroft, J., Kunkel, E. J. S., Delmoor, E., Liberatore, M., Nydick, R. L.,  
 9 Brown, E. R., Gay, R. N., Powell, T. & Powell, R. L. (2005) Preparing African-American men in  
 10 community primary care practices to decide whether or not to have prostate cancer screening.  
 11 *Journal of the National Medical Association*, 97: 1143-1154.  
 12 Not in PICO
- 13 Naslund, M. J., Gilsenan, A. W., Midkiff, K. D., Bown, A., Wolford, E. T. & Wang, J. (2007) Prevalence  
 14 of lower urinary tract symptoms and prostate enlargement in the primary care setting.  
 15 *International Journal of Clinical Practice*, 61: 1437-1445.  
 16 Not in PICO
- 17 Nepple, K. G., Joudi, F. N., Hillis, S. L. & Wahls, T. L. (2008) Prevalence of delayed clinician response  
 18 to elevated prostate-specific antigen values. *Mayo Clinic Proceedings*, 83: 439-445.  
 19 Not in PICO
- 20 Ng, Y. H., Seeley, J. P. & Smith, G. (2013) Haemospermia as a presenting symptom: Outcomes of  
 21 investigation in 300 men. *Surgeon-Journal of the Royal Colleges of Surgeons of Edinburgh and  
 22 Ireland*, 11: 35-38.  
 23 Not in PICO
- 24 Ng, Y. H., Seeley, J. P. & Smith, G. (2013) Haemospermia as a presenting symptom: outcomes of  
 25 investigation in 300 men. *Surgeon Journal of the Royal Colleges of Surgeons of Edinburgh &  
 26 Ireland*, 11: 35-38.  
 27 Not in PICO
- 28 Ng, Y. H., Seeley, J. P. & Smith, G. (2013) Haemospermia as a presenting symptom: Outcomes  
 29 of investigation in 300 men. *Surgeon Journal of the Royal Colleges of Surgeons of Edinburgh &  
 30 Ireland*, 11: 35-38.  
 31 Not in PICO
- 32 Ngo, T. C., Turnbull, B. B., Lavori, P. W. & Presti, J. C. (2011) The Prostate Cancer Risk Calculator From  
 33 the Prostate Cancer Prevention Trial Underestimates the Risk of High Grade Cancer in  
 34 Contemporary Referral Patients. *Journal of Urology*, 185: 483-487.  
 35 Not in PICO
- 36 Niang, L., Ndoye, M., Ouattara, A., Jalloh, M., Labou, M., Thiam, I., Kouka, S. C., Diaw, J. J. & Gueye, S.  
 37 M. (2013) [Management of prostate cancer in Senegal: What is being done?]. [French]. *Progres  
 38 En Urologie*, 23: 36-41.  
 39 Not in PICO
- 40 Nortje, C. J. (2002) General practitioner's Radiology Case 3. *SADJ*, 57: 287-288.  
 41 Not in PICO
- 42 Numao, N., Yoshida, S., Komai, Y., Ishii, C., Kagawa, M., Kijima, T., Yokoyama, M., Ishioka, J.,  
 43 Matsuoka, Y., Koga, F., Saito, K., Masuda, H., Fujii, Y., Kawakami, S. & Kihara, K. (2013) Usefulness  
 44 of pre-biopsy multiparametric magnetic resonance imaging and clinical variables to reduce initial  
 45 prostate biopsy in men with suspected clinically localized prostate cancer. *Journal of Urology*,  
 46 190: 502-508.  
 47 Not in PICO
- 48 Numao, N., Matsuoka, Y., Ito, M., Yoshida, S., Ishikawa, Y., Uchida, Y., Toide, M., Higuchi, S.,  
 49 Nakayama, T., Inoue, M., Takeshita, H., Kijima, T., Nakanishi, Y., Ishioka, J., Saito, K., Yasuhisa, F. &  
 50 Kazunori, K. (2014) Direct comparison of the ability to detect significant prostate cancer and  
 51 assess cancer characteristics between magnetic resonance imaging targeted biopsy and

- 1 systematic 14-core biopsy, including anterior samplings. *European Urology, Supplements*, 13:  
2 e949.
- 3 Not in PICO
- 4 Nygard, Y., Haukaas, S. A., Halvorsen, O. J., Gravdal, K., Frugard, J., Akslen, L. A. & Beisland, C. (2014)  
5 - A positive real-time elastography is an independent marker for detection of high-risk prostate  
6 cancers in the primary biopsy setting. - *BJU International*, 113: E90-E97.
- 7 Not in PICO
- 8 Nygard, Y., Haukaas, S. A., Halvorsen, O. J., Gravdal, K., Frugard, J., Akslen, L. A. & Beisland, C. (2014)  
9 A positive real-time elastography is an independent marker for detection of high-risk prostate  
10 cancers in the primary biopsy setting. *Bju International*, 113: E90-E97.
- 11 Duplicate
- 12 Obertova, Z., Brown, C., Hodgson, F. & Lawrenson, R. (2013) What do men say about diagnostic  
13 pathways? From prostate-specific antigen (PSA) test to prostate cancer. *Bju International*, 112:  
14 14.
- 15 Not in PICO
- 16 Oesterling, J. E. (1994) PSA and early prostate cancer detection: the importance of age-specific  
17 reference ranges. *The Canadian journal of oncology*, 4: 52-56.
- 18 Not available. WWS not conducted as unlikely to be relevant.
- 19 Oesterling, J. E. (1995) Prostate-Specific Antigen - Its Role in the Diagnosis and Staging of Prostate-  
20 Cancer. *Cancer*, 75: 1795-1804.
- 21 Narrative review
- 22 Ojewola, R. W., Tijani, K. H., Jeje, E. A., Anunobi, C. C., Ogunjimi, M. A., Ezenwa, E. V. & Ogundiniyi, O.  
23 S. (2012) Is extended biopsy protocol justified in all patients with suspected prostate cancer?  
24 *Nigerian Journal of Clinical Practice*, 15: 315-319.
- 25 Not in PICO
- 26 Okada, K. & Suzuki, Y. (2000) [Diagnosis of prostate cancer in general practice]. [Review] [13 refs]  
27 [Japanese]. *Nippon Rinsho - Japanese Journal of Clinical Medicine*, 58: Suppl-93.
- 28 Narrative review (asked Lily)
- 29 Onishi, T., Akazawa, Y., Sakamaki, K., Shintani, T., Sugiyama, H., Senzaki, T., Numata, K., Sakaki, M.,  
30 Fukawa, T., Yamamoto, Y., Izaki, H., Oka, N., Kanda, M., Takahashi, M., Naroda, T., Fukumori, T.,  
31 Nishitani, M., Yamanaka, M., Kurokawa, Y., Miyamoto, T., Kanayama, H.-O. & Kagawa, S. (2002)  
32 Clinical statistics on outpatients in the Urology Clinic of Tokushima University Hospital between  
33 1991 and 2000. [Japanese]. *Nishinohon Journal of Urology*, 64: 176-178.
- 34 Not in PICO
- 35 Onur, M. R., Turgut, A. T. & Dogra, V. (2014) Ultrasound-guided biopsy of the prostate: New updates.  
36 *Ultrasound Clinics*, 9: 81-94.
- 37 Narrative review
- 38 Onur, M. R., Turgut, A. T. & Dogra, V. (2014) Ultrasound-guided biopsy of the prostate: New updates.  
39 *Ultrasound Clinics*, 9: 81-94.
- 40 Narrative review
- 41 Oranusi, C. K., Mbieri, U. T., Oranusi, I. O. & Nwofor, A. M. E. (2012) Prostate cancer awareness and  
42 screening among male public servants in Anambra state, Nigeria. *African Journal of Urology*, 18:  
43 72-74.
- 44 Not in PICO
- 45 Oremek, G. M., Sapoutzis, N., Eden, F. & Jonas, D. (2003) Complexed PSA in routine diagnosis.  
46 *Anticancer Research*, 23: 975-977.
- 47 Not in PICO
- 48 Ornstein, D. K., Rao, G. S., Smith, D. S. & Andriole, G. L. (1997) The impact of systematic prostate  
49 biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia  
50 undergoing transurethral resection of the prostate. *Journal of Urology*, 157: 880-884.
- 51 Not in PICO

- 1 Ouzzane, A., Coloby, P., Mignard, J. P., Allegre, J. P., Soulie, M., Rebillard, X., Salomon, L., Villers, A.,  
 2 Committee of Infectious Diseases of the French Association of Urology (CIAFU) & Committee of  
 3 Cancerology of the French Association of Urology (CCAFU) (2011) [Recommendations for best  
 4 practice for prostate biopsy]. [Review] [French]. *Progres En Urologie*, 21: 18-28.  
 5 Not in PICO
- 6 Overduin, C. G., Futterer, J. J. & Barentsz, J. O. (2013) MRI-Guided Biopsy for Prostate Cancer  
 7 Detection: A Systematic Review of Current Clinical Results. *Current Urology Reports*, 14: 209-213.  
 8 Not in PICO
- 9 Ozen, H., Aygun, C., Ergen, A., Sozen, S., Aki, F. T. & Uygur, M. C. (2001) Combined use of prostate-  
 10 specific antigen derivatives decreases the number of unnecessary biopsies to detect prostate  
 11 cancer. *American Journal of Clinical Oncology: Cancer Clinical Trials*, 24: 610-613.  
 12 Not in PICO
- 13 Pan, D. & McCahy, P. (2012) Patient knowledge about prostate-specific antigen (PSA) and prostate  
 14 cancer in Australia. *Bju International*, 109: Suppl-6.  
 15 Not in PICO
- 16 Pascual, D. T., Gonzalez, R. J., Sanchez, S. E., Ruiz De La Roja, J. C., Berenguer, S. A. & Miravalles, G. E.  
 17 (1996) Prostate specific antigen in the early detection of prostate cancer. [Spanish]. *Revista de la*  
 18 *Sociedad Espanola de Quimica Clinica*, 15: 29-33.  
 19 Not in PICO
- 20 Patel, N. S., Blick, C., Kumar, P. V. S. & Malone, P. R. (2009) The diagnostic value of abdominal  
 21 ultrasound, urine cytology and prostate-specific antigen testing in the lower urinary tract  
 22 symptoms clinic. *International Journal of Clinical Practice*, 63: 1734-1738.  
 23 Not in PICO
- 24 Payne, H., Clarke, N., Huddart, R., Parker, C., Troup, J. & Graham, J. (2013) Nasty or Nice? Findings  
 25 from a UK Survey to Evaluate the Impact of the National Institute for Health and Clinical  
 26 Excellence (NICE) Clinical Guidelines on the Management of Prostate Cancer. *Clinical Oncology*,  
 27 25: 178-189.  
 28 Not in PICO
- 29 Pelechano, G. P., Casanova Ramon-Borja, J. & Collado, S. A. (2014) - An update on imaging  
 30 techniques to optimize active surveillance in prostate cancer. - *Archivos Espanoles de Urologia*,  
 31 67: 473-485.  
 32 Narrative review
- 33 Perachino, M., Puppo, P., Scannapieco, G., Vitali, A. & Di, C. L. (1993) The diagnostic value of PSA  
 34 compared to rectal monitoring and transrectal echography in the diagnosis of prostatic  
 35 carcinoma in patients with obstructive diseases: Results of 202 cases. [Italian]. *Acta Urologica*  
 36 *Italica*, 7: 7-8.  
 37 Not in PICO (referred patients; cancer rate 33.7%)
- 38 Perachino, M., Di, C. L., Barbetti, V., Ardoino, S., Vitali, A., Introini, C., Vigliercio, G. & Puppo, P.  
 39 (1997) Results of rebiopsy for suspected prostate cancer in symptomatic men with elevated PSA  
 40 levels. *European Urology*, 32: 155-159.  
 41 Not in PICO
- 42 Perez, C. E., Simonet Aineto, P. J., Vargas, B. C., Castells, E. M. & Parellada, E. N. (2000) [The  
 43 diagnostic situation with prostatic cancer in primary care]. [Spanish]. *Atencion Primaria*, 25: 137-  
 44 141.  
 45 Not in PICO
- 46 Perez, C. E., Simonet Aineto, P. J., Vargas, B. C., Castells, E. M. & Parellada, E. N. (2000) The  
 47 diagnostic situation with prostatic cancer in primary care. [Spanish]. *Atencion primaria / Sociedad*  
 48 *Espanola de Medicina de Familia y Comunitaria*, 25: 137-141.  
 49 Not in PICO
- 50 Perrin, P., Maquet, J. H., Bringeon, G. & Devonec, M. (1991) Screening for prostate cancer.  
 51 Comparison of transrectal ultrasound, prostate specific antigen and rectal examination. *British*

- 1 *Journal of Urology*, 68: 263-265.  
2 Not in PICO
- 3 Pinnock, C. B., Weller, D. P. & Marshall, V. R. (1998) Self-reported prevalence of prostate-specific  
4 antigen testing in South Australia: A community study. *Medical Journal of Australia*, 169: 25-28.  
5 Not in PICO
- 6 Pinnock, C. B. (2004) PSA testing in general practice: can we do more now? *Medical Journal of*  
7 *Australia*, 180: 379-381.  
8 Narrative review
- 9 Plawker, M. W., Fleisher, J. M., Nitti, V. W. & Macchia, R. J. (1996) Primary care practitioners: An  
10 analysis of their perceptions of voiding dysfunction and prostate cancer. *Journal of Urology*, 155:  
11 601-604.  
12 Not in PICO
- 13 Plekhanov, A. I., Zhivov, A. V., Petrov, S. B., Veliev, E. I., Galanin, S. V., Urbanskii, A. I. & Lysenko, I. S.  
14 (2007) [Estimation of predictive prostate cancer probability with logistic regression equation].  
15 [Russian]. *Urologiia (Moscow, Russia).(4):81-5, 2007 Jul-Aug.*, 81-85.  
16 Not in PICO
- 17 Pokorny, M. R., de, R. M., Duncan, E., Schroder, F. H., Parkinson, R., Barentsz, J. O. & Thompson, L. C.  
18 (2014) - Prospective study of diagnostic accuracy comparing prostate cancer detection by  
19 transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent  
20 MR-guided biopsy in men without previous prostate biopsies. - *European Urology*, 66: 22-29.  
21 Not in PICO
- 22 Pollack, C. E., Platz, E. A., Bhavsar, N. A., Noronha, G., Green, G. E., Chen, S. & Carter, H. B. (2012)  
23 Primary Care Providers' Perspectives on Discontinuing Prostate Cancer Screening. *Cancer*, 118:  
24 5518-5524.  
25 Not in PICO
- 26 Pourmand, G., Ramezani, R., Sabahgoulian, B., Nadali, F., Mehrsai, A., Nikoobakht, M., Allameh, F.,  
27 Hossieni, S., Seraji, A., Rezai, M., Haidari, F., Dehghani, S., Razmandeh, R. & Pourmand, B. (2012)  
28 Preventing Unnecessary Invasive Cancer-Diagnostic Tests: Changing the Cut-off Points. *Iranian*  
29 *Journal of Public Health*, 41: 47-52.  
30 Not in PICO
- 31 Powles, L. A. R., Rolls, A. E., Lamb, B. W., Taylor, E. & Green, J. S. A. (2012) Can redesigning a  
32 laboratory request form reduce the number of inappropriate PSA requests without compromising  
33 clinical outcome. *British Journal of Medical and Surgical Urology*, 5: 67-73.  
34 Not in PICO
- 35 Presti, J. (2004) What is the most efficient biopsy regimen for detecting early prostate cancer?  
36 *Nature Clinical Practice Urology*, 1: 76-77.  
37 Not in PICO
- 38 Puppo, P., Perachino, M., Ricciotti, G., Vitali, A., Arduino, S. & Di, C. L. (1992) Comparison between  
39 digital rectal examination, prostate-specific antigen and transrectal ultrasound in symptomatic  
40 patients. Results on 141 cases. *European Urology*, 21: 87-91.  
41 Not in PICO
- 42 Puzone, R., Paleari, L., Montefiore, F., Ruggiero, L., Puntoni, M., Maffezzini, M., Bobbio, B., Marroni,  
43 P., Libener, R. & Betta, P. G. (2010) Osteopontin plasma level does not detect prostate cancer in  
44 patients referred for diagnostic prostate biopsy. *International Journal of Biological Markers*, 25:  
45 200-206.  
46 Not in PICO
- 47 Qu, M., Ren, S. C. & Sun, Y. H. (2014) - Current early diagnostic biomarkers of prostate cancer. - *Asian*  
48 *Journal of Andrology*, 16: 549-554.  
49 Narrative review
- 50 Quentin, M., Pentang, G., Schimmoller, L., Kott, O., Muller-Lutz, A., Blondin, D., Arsov, C., Hiester, A.,  
51 Rabenalt, R. & Wittsack, H. J. (2014) - Feasibility of diffusional kurtosis tensor imaging in prostate

- 1 MRI for the assessment of prostate cancer: Preliminary results. - *Magnetic Resonance Imaging*,  
2 32: 880-885.  
3 Not in PICO
- 4 Quinlan, M. R., Teahan, S., Mulvin, D. & Quinlan, D. M. (2007) Is digital rectal examination still  
5 necessary in the early detection of prostate cancer? *Irish Journal of Medical Science*, 176: 161-  
6 163.  
7 Not in PICO
- 8 Quinlan, M. R., O'Daly, B. J., O'Brien, M. F., Gardner, S., Lennon, G., Mulvin, D. W. & Quinlan, D. M.  
9 (2009) The value of appropriate assessment prior to specialist referral in men with prostatic  
10 symptoms. *Irish Journal of Medical Science*, 178: 281-285.  
11 Not in PICO
- 12 Radavoi, G. D., Petrescu, A., Berdan, M. G., Manea, N. F., Tanase, F. & Jinga, V. (2014) The use of  
13 multiplex biopsies as a cost-effective method in the diagnostic of prostate cancer. *European*  
14 *Urology, Supplements*, 13: e745.  
15 Not in PICO
- 16 Randrup, E. & Baum, N. (2011) Prostate-specific antigen testing for prostate cancer. Practical  
17 interpretation of values. [Review] [14 refs]. *Postgraduate Medicine*, 99: 227-228.  
18 Narrative review
- 19 Ravery, V., Schmid, H. P., Billebaud, T., Toublanc, M., Boccon-Gibod, L., Hermieu, J. F., Delmas, V. &  
20 Boccon-Gibod, L. (1996) Detection of prostate cancer in symptomatic patients with prostate  
21 specific antigen between 4 and 10 ng/ml. [French]. *Presse Medicale*, 25: 272-276.  
22 Not in PICO
- 23 Recker, F. (1996) Prostate specific antigen in the diagnosis of organ confined curable prostate  
24 cancer. [German]. *Schweizerische Medizinische Wochenschrift*, 126: 1881-1890.  
25 Narrative review
- 26 Rehsia, S. & Shayegan, B. (2012) PSA implications and medical management of prostate cancer for  
27 the primary care physician. *Canadian Journal of Urology*, 19: 28-35.  
28 Not in PICO
- 29 Reljic, A., Tomaskovic, I., Simundic, A.-M. & Kruslin, B. (2004) Diagnostic value of age specific  
30 prostate specific antigen in prostate cancer patients. *Acta Clinica Croatica*, 43: 379-383.  
31 Not in PICO
- 32 Richter, F., Dudley, A. W., Irwin, R. J. & Sadeghi-Nejad, H. (2001) Are we ordering too many PSA  
33 tests? Prostate cancer diagnosis and PSA screening patterns for a single Veterans Affairs Medical  
34 Center. *Journal of Cancer Education*, 16: 38-41.  
35 Not in PICO
- 36 Riedinger, C. B., Womble, P. R., Linsell, S. M., Ye, Z., Montie, J. E., Miller, D. C., Lane, B. R. & -  
37 Michigan Urological Surgery Improvement Collaborative (2014) - Variation in prostate cancer  
38 detection rates in a statewide quality improvement collaborative. - *Journal of Urology*, 192: 373-  
39 378.  
40 Not in PICO
- 41 Rinaldi, D., Fiocchi, F., Ligabue, G., Bianchi, G. & Torricelli, P. (2012) Role of diffusion-weighted  
42 magnetic resonance imaging in prostate cancer evaluation. *Radiologia Medica*, 117: 1429-1440.  
43 Not in PICO
- 44 Rinnab, L., Gottfried, H. W., Schnoller, T., Hautmann, R. E. & Kuefer, R. (2007) Clinical value of  
45 transrectal ultrasound in the diagnosis of suspected neoplasia in the small pelvis. *Ultraschall in*  
46 *der Medizin*, 28: 195-200.  
47 Not in PICO
- 48 Rochester, M. A., Donaldson, P. J. & McLoughlin, J. (2008) Perception of abnormal serum prostate-  
49 specific antigen (PSA) test results amongst family practitioners. *Annals of the Royal College of*  
50 *Surgeons of England*, 90: 398-402.  
51 Not in PICO

- 1 Roddam, A. W., Hamdy, F. C., Allen, N. E., Price, C. P. & UK Prostate Cancer Risk Management  
2 Program (2007) The impact of reducing the prostate-specific antigen threshold and including  
3 isoform reflex tests on the performance characteristics of a prostate-cancer detection  
4 programme. [Review] [19 refs]. *Bju International*, 100: 514-517.  
5 Not in PICO
- 6 Rodriguez-Cantalejo, F., Lopez-Garrigos, M., Benitez-Benitez, D., Sanchez-Fernandez, E., Moreno-  
7 Noguero, E., Rodriguez-Borja, E., Roldan-Fontana, E., Martin-Oncina, F. J., Gascon, F., Velasco-  
8 Pena, F., Miralles, F., Marcaida, G., Barrionuevo, M., Dominguez-Pascual, I., Herrera-Contreras, I.,  
9 Ferrero, J. A. & Salinas, M. (2014) Differences in prostatic specific antigen requesting patterns in  
10 primary care setting: A pilot study in Spain. *Clinical Chemistry and Laboratory Medicine*, 52: S459.  
11 Not in PICO
- 12 Rodriguez, D. C., Aguillon, J. & Rodriguez, H. (1991) Occult cancer in patients with symptomatic  
13 benign prostatic hyperplasia. [Spanish]. *Archivos Espanoles de Urologia*, 44: 411-414.  
14 Not in PICO
- 15 Roehrborn, C. G., Pickens, G. J. & Carmody, T., III (1996) Variability of repeated serum prostate-  
16 specific antigen (PSA) measurements within less than 90 days in a well-defined patient  
17 population. *Urology*, 47: 59-66.  
18 Not in PICO
- 19 Roehrborn, C. G. (2011) Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia  
20 (BPH). [Review]. *Medical Clinics of North America*, 95: 87-100.  
21 Narrative review
- 22 Romagnoli, A., Giglio, M., Timossi, L., Bertolotto, F., Germinale, F. & Carmignani, G. (2002)  
23 [Ultrasonography-guided transperineal prostatic biopsy: optimization of sampling protocol after  
24 1,352 biopsies]. [Italian]. *Archivio Italiano di Urologia, Andrologia*, 74: 285-289.  
25 Not in PICO
- 26 Roobol, M. J., Schröder, F. H., Kranse, R., ERSPC & Rotterdam (2006) A comparison of first and repeat  
27 (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged  
28 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam). *The Prostate*, 66:  
29 604-612.  
30 Not in PICO
- 31 Roobol, M. J., van Vugt, H. A., Loeb, S., Zhu, X. Y., Bul, M., Bangma, C. H., van Leenders, A. G. L. J.,  
32 Steyerberg, E. W. & Schroder, F. H. (2012) Prediction of Prostate Cancer Risk: The Role of Prostate  
33 Volume and Digital Rectal Examination in the ERSPC Risk Calculators. *European Urology*, 61: 577-  
34 583.  
35 Not in PICO
- 36 Rosario, D. J., Lane, J. A., Metcalfe, C., Donovan, J. L., Doble, A., Goodwin, L., Davis, M., Catto, J. W.,  
37 Avery, K., Neal, D. E. & Hamdy, F. C. (2012) Short term outcomes of prostate biopsy in men tested  
38 for cancer by prostate specific antigen: prospective evaluation within ProtecT study. *BMJ*, 344:  
39 d7894.  
40 Not in PICO
- 41 Rosenberg, M. T., Miner, M. M., Riley, P. A. & Staskin, D. R. (2010) STEP: Simplified Treatment of the  
42 Enlarged Prostate. *International Journal of Clinical Practice*, 64: 488-496.  
43 Narrative review
- 44 Roshanai, A., Nordin, K. & Berglund, G. (2012) Factors influencing primary care physicians' decision  
45 to order prostate-specific antigen (PSA) test for healthy men. *Asia-Pacific Journal of Clinical  
46 Oncology*, 8: 249.  
47 Not in PICO
- 48 Roshanai, A. H., Nordin, K. & Berglund, G. (2013) Factors influencing primary care physicians'  
49 decision to order prostate-specific antigen (PSA) test for men without prostate cancer. *Acta  
50 Oncologica*, 52: 1602-1608.  
51 Not in PICO

- 1 Ross, L. E., Berkowitz, Z. & Ekwueme, D. U. (2008) Use of the prostate-specific antigen test among US  
2 men: Findings from the 2005 national health interview survey. *Cancer Epidemiology Biomarkers &*  
3 *Prevention*, 17: 636-644.  
4 Not in PICO
- 5 Ross, L. E., Taylor, Y. J., Richardson, L. C. & Howard, D. L. (2009) Patterns in Prostate-Specific Antigen  
6 Test Use and Digital Rectal Examinations in the Behavioral Risk Factor Surveillance System, 2002-  
7 2006. *Journal of the National Medical Association*, 101: 316-324.  
8 Not in PICO
- 9 Ross, L. E., Taylor, Y. J. & Howard, D. L. (2011) Trends in Prostate-Specific Antigen Test Use, 2000-  
10 2005. *Public Health Reports*, 126: 228-239.  
11 Not in PICO
- 12 Rothke, M., Blondin, D., Schlemmer, H. P. & Franiel, T. (2013) [PI-RADS classification: structured  
13 reporting for MRI of the prostate]. [German]. *Rofo: Fortschritte auf dem Gebiete der*  
14 *Rontgenstrahlen und der Nuklearmedizin*, 185: 253-261.  
15 Not in PICO
- 16 Ruckle, H. C., Klee, G. G. & Oesterling, J. E. (1994) Prostate-specific antigen: critical issues for the  
17 practicing physician. [Review] [41 refs]. *Mayo Clinic Proceedings*, 69: 59-68.  
18 Narrative review
- 19 Ruckle, H. C., Klee, G. G. & Oesterling, J. E. (1994) Prostate-specific antigen: Critical issues for the  
20 practicing physician. *Mayo Clinic Proceedings*, 69: 59-68.  
21 Narrative review
- 22 Rud, E., Baco, E. & Eggesbo, H. B. (2012) MRI and ultrasound-guided prostate biopsy using soft image  
23 fusion. *Anticancer Research*, 32: 3383-3389.  
24 Not in PICO
- 25 Sadchenko, A. V., Govorov, A. V., Pushkar', D. I., Sidorenkov, A. V., Vasil'ev, A. O., Kovylyna, M. V. &  
26 Prilepskaia, E. A. (2014) [Perineal saturation biopsy of the prostate]. [Russian]. *Urologii{combining*  
27 *double inverted breve}a (Moscow, Russia : 1999)*, 33-36.  
28 Not in PICO
- 29 Salinas, M., Lopez-Garrigos, M., Miralles, F., Chinchilla, V., Ortuno, M., Aguado, C., Marcaida, G.,  
30 Guaita, M., Carratala, A., Diaz, J., Yago, M., Esteban, A., Laiz, B., Rodriguez-Borja, E., Lorente, M.  
31 A. & Uris, J. (2011) Evaluation of psa testing by general practitioners: Regional study in the  
32 autonomic community of valencia. *Archivos Espanoles de Urologia*, 64: 435-440.  
33 Not in PICO
- 34 Sanchez-Martinez, L. C., Paredes-Solis, C. A., Hernandez-Ordonez, O. F. & Sanchez-Ruvalcaba, I. R.  
35 (2013) [Prostate-specific antigen. The role in the prostate cancer diagnosis]. [Spanish]. *Revista*  
36 *Medica del Instituto Mexicano del Seguro Social*, 51: 124-126.  
37 Narrative review
- 38 Sanz Velez, J. I., Allepuz, L. C., Gil Sanz, M. J., Plaza, L., Castrillo, J., Cuesta Presedo, J. M. & Rioja Sanz,  
39 L. A. (1997) Early diagnosis of cancer of the prostate. 5-year analysis. [Spanish]. *Actas Urologicas*  
40 *Espanolas*, 21: 827-834.  
41 Not in PICO
- 42 Sarle, R., Zvara, P., Bunnell, M. L. & Plante, M. K. (2001) Statewide prostate cancer screening  
43 practices among primary care physicians. *American Journal of Managed Care*, 137-143.  
44 Not in PICO
- 45 Sato, C., Naganawa, S., Nakamura, T., Kumada, H., Miura, S., Takizawa, O. & Ishigaki, T. (2005)  
46 Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values  
47 in transition and peripheral zones of the prostate. *Journal of Magnetic Resonance Imaging*, 21:  
48 258-262.  
49 Not in PICO
- 50 Scales, C. D., Jr., Curtis, L. H., Norris, R. D., Schulman, K. A., Albala, D. M. & Moul, J. W. (2006)  
51 Prostate specific antigen testing in men older than 75 years in the United States. *Journal of*



- 1 *Urology*, 176: 511-514.  
 2 Not in PICO
- 3 Scheidler, J., Weores, I., Brinkschmidt, C., Zeitler, H., Panzer, S., Scharf, M., Heuck, A. & Siebels, M.  
 4 (2012) Diagnosis of prostate cancer in patients with persistently elevated PSA and tumor-negative  
 5 biopsy in ambulatory care: performance of MR imaging in a multi-reader environment. *Rofo:*  
 6 *Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin*, 184: 130-135.  
 7 Not in PICO
- 8 Schenk, J. M., Kristal, A. R., Arnold, K. B., Tangen, C. M., Neuhouser, M. L., Lin, D. W., White, E. &  
 9 Thompson, I. M. (2011) Association of symptomatic benign prostatic hyperplasia and prostate  
 10 cancer: results from the prostate cancer prevention trial. *American Journal of Epidemiology*, 173:  
 11 1419-1428.  
 12 Not in PICO
- 13 Schiff, G. D. (2014) Diagnosis and diagnostic errors: Time for a new paradigm. *BMJ Quality and*  
 14 *Safety*, 23: 1-3.  
 15 Not in PICO
- 16 Schmid, M., Hansen, J., Rink, M., Fisch, M. & Chun, F. (2013) The development of nomograms for  
 17 stratification of men at risk of prostate cancer prior to prostate biopsy. *Biomarkers in Medicine*, 7:  
 18 843-850.  
 19 Narrative review
- 20 Shahab, A. A., Soebadi, D. M., Djatisoesanto, W., Hardjowijoto, S., Soetojo, S. & Hakim, L. (2013)  
 21 Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian  
 22 population suspected for prostate cancer. *Prostate International*, 1: 23-30.  
 23 Not in PICO
- 24 Shariat, S. F. & Roehrborn, C. G. (2008) Using biopsy to detect prostate cancer. *Reviews in Urology*,  
 25 10: 262-280.  
 26 Narrative review
- 27 Shatov, A. V. & Ognerubov, N. A. (2004) [Magnetic resonance imaging in diagnosis of localized  
 28 prostatic cancer]. [Russian]. *Urologiia (Moscow, Russia)*.(3):25-9, 2004 May-Jun., 25-29.  
 29 Not in PICO
- 30 Sheikh, M., Al-Saeed, O., Kehinde, E. O., Sinan, T., Anim, J. T. & Ali, Y. (2005) Utility of volume  
 31 adjusted prostate specific antigen density in the diagnosis of prostate cancer in Arab men.  
 32 *International Urology & Nephrology*, 37: 721-726.  
 33 Not in PICO
- 34 Shen, J., Lu, Y., Yang, Y., Zhao, W., Jiang, Z., Zhang, C., Ma, Q., Zhang, Y. & Shan, Y. (2014) Application  
 35 evaluation of MR diffusion weighted imaging in the diagnosis and differential diagnosis of early  
 36 prostate cancer. [Chinese]. *Chinese Journal of Radiology (China)*, 48: 114-118.  
 37 Not in PICO
- 38 Shenker, B. S. & Stern, J. (2012) The effect of lowering the prostate-specific antigen normal cutoff on  
 39 referral rates to urology. *Journal of the American Board of Family Medicine*, 25: 927-929.  
 40 Not in PICO
- 41 Siddiqui, E., Mumtaz, F. H. & Gelister, J. (2004) Understanding prostate cancer. [Review] [8 refs].  
 42 *Journal of the Royal Society for the Promotion of Health*, 124: 219-221.  
 43 Narrative review
- 44 Sing, R. I. & Singal, R. K. (2012) What is significant hematuria for the primary care physician?  
 45 *Canadian Journal of Urology*, 19: Suppl-41.  
 46 Narrative review
- 47 Smith, R. A., Cokkinides, V. & Eyre, H. J. (2006) American Cancer Society guidelines for the early  
 48 detection of cancer, 2006. *Ca-A Cancer Journal for Clinicians*, 56: 11-25.  
 49 Guideline

- 1 Smith, S. D. & Birtwhistle, R. (2012) Exploring patient perceptions of PSA screening for prostate  
2 cancer: Risks, effectiveness, and importance. *Canadian Family Physician*, 58: e502-e507.  
3 Not in PICO
- 4 Smith, S. D. & Birtwhistle, R. (2012) Exploring patient perceptions of PSA screening for prostate  
5 cancer: Risks, effectiveness, and importance. *Canadian Family Physician*, 58: e502-e507.  
6 Not in PICO
- 7 Snow, D. C. & Klein, E. A. (2010) Use of nomograms for early detection in prostate cancer. *JNCCN  
8 Journal of the National Comprehensive Cancer Network*, 8: 271-276.  
9 Narrative review
- 10 Song, J. M., Kim, C. B., Chung, H. C. & Kane, R. L. (2005) Prostate-specific antigen, digital rectal  
11 examination and transrectal ultrasonography: A meta-analysis for this diagnostic triad of prostate  
12 cancer in symptomatic Korean men. *Yonsei Medical Journal*, 46: 414-424.  
13 Not in PICO (cancer prevalence rate = 25.4%)
- 14 Sonn, G. A., Chang, E., Natarajan, S., Margolis, D. J., Macairan, M., Lieu, P., Huang, J., Dorey, F. J.,  
15 Reiter, R. E. & Marks, L. S. (2014) - Value of targeted prostate biopsy using magnetic resonance-  
16 ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. -  
17 *European Urology*, 65: 809-815.  
18 Not in PICO
- 19 Sorum, P. C., Shim, J., Chasseigne, G., Bonnin-Scaon, S., Cogneau, J. & Mullet, E. (2003) Why do  
20 primary care physicians in the United States and France order prostate-specific antigen tests for  
21 asymptomatic patients? *Medical Decision Making*, 23: 301-313.  
22 Not in PICO
- 23 Sorum, P. C., Mullet, E., Shim, J., Bonnin-Scaon, S., Chasseigne, G. & Cogneau, J. (2004) Avoidance of  
24 anticipated regret: the ordering of prostate-specific antigen tests. *Medical Decision Making*, 24:  
25 149-159.  
26 Not in PICO
- 27 Spencer, B. A., Babey, S. H., Etzioni, D. A., Ponce, N. A., Brown, E. R., Yu, H. J., Chawla, N. & Litwin, M.  
28 S. (2006) A population-based survey of prostate-specific antigen testing among California men at  
29 higher risk for prostate carcinoma. *Cancer*, 106: 765-774.  
30 Not in PICO
- 31 Sperandeo, G., Sperandeo, M., Morcaldi, M., Caturelli, E., Dimitri, L. & Camagna, A. (2003)  
32 Transrectal ultrasonography for the early diagnosis of adenocarcinoma of the prostate: a new  
33 maneuver designed to improve the differentiation of malignant and benign lesions. *Journal of  
34 Urology*, 169: 607-610.  
35 Not in PICO
- 36 Stamatiou, K., Alevizos, A., Karanasiou, V., Mariolis, A., Mihas, C., Papathanasiou, M., Bovis, K. &  
37 Sofras, F. (2007) Impact of additional sampling in the TRUS-guided biopsy for the diagnosis of  
38 prostate cancer. *Urologia Internationalis*, 78: 313-317.  
39 Not in PICO
- 40 Stapleton, A. M., Johns, R. L., Kopsaftis, T., Tamblyn, D. J. & Pinnock, C. B. (2008) Abnormal PSA tests-  
41 -delays in referral. *Australian Family Physician*, 37: 84-88.  
42 Not in PICO
- 43 Stephan, C., Miller, K. & Jung, K. (2011) Is there an optimal prostate-specific antigen threshold for  
44 prostate biopsy? *Expert Review of Anticancer Therapy*, 11: 1215-1221.  
45 Narrative review
- 46 Stephenson, S. K., Chang, E. K. & Marks, L. S. (2014) - Screening and detection advances in magnetic  
47 resonance image-guided prostate biopsy. [Review]. - *Urologic Clinics of North America*, 41: 315-  
48 326.  
49 Narrative review
- 50 Stone, C. A., May, F. W., Pinnock, C. B., Elwood, M. & Rowett, D. S. (2005) Prostate cancer, the PSA  
51 test and academic detailing in Australian general practice: an economic evaluation. *Australian*

- 1 *and New Zealand Journal of Public Health*, 29: 349-357.
- 2 Not in PICO
- 3 Szabo, J., Vegh, A., Gasman, D., Hoznek, A., Chopin, D. K. & Abbou, C. C. (1998) Biopsy-based  
4 diagnosis of prostate cancer in 1290 patients referred for prostate examination: results according  
5 to the PSA level, digital rectal examination and ultrasonography. *Acta Chirurgica Hungarica*, 37:  
6 95-100.
- 7 Not in PICO
- 8 Takahashi, C. & Miyagawa, I. (1997) [Serum prostate-specific antigen in a urological outpatient clinic.  
9 Efficacy of age-specific and prostate volume-specific reference range in detection of prostate  
10 cancer]. [Japanese]. *Nippon Hinyokika Gakkai Zasshi - Japanese Journal of Urology*, 88: 612-617.
- 11 Not in PICO
- 12 Taneja, S. S. (2003) Optimizing prostate biopsy strategies for the diagnosis of prostate cancer.  
13 *Reviews in Urology*, 5: 149-155.
- 14 Narrative review
- 15 Taneja, S. S. (2014) - Early detection of prostate cancer. - *Urologic Clinics of North America*, 41: xi-xii.
- 16 Narrative review
- 17 Tasian, G. E., Cooperberg, M. R., Potter, M. B., Cowan, J. E., Greene, K. L., Carroll, P. R. & Chan, J. M.  
18 (2012) PSA screening: determinants of primary-care physician practice patterns. *Prostate Cancer  
19 and Prostatic Diseases*, 15: 189-194.
- 20 Not in PICO
- 21 Tasian, G. E., Cooperberg, M. R., Cowan, J. E., Keyashian, K., Greene, K. L., Daniels, N. A., Carroll, P. R.  
22 & Chan, J. M. (2012) Prostate specific antigen screening for prostate cancer: Knowledge of,  
23 attitudes towards, and utilization among primary care physicians. *Urologic Oncology-Seminars  
24 and Original Investigations*, 30: 155-160.
- 25 Not in PICO
- 26 Thanigasalam, R., Mancuso, P., Tsao, K. & Rashid, P. (2009) Prostate-specific antigen velocity (PSAV):  
27 a practical role for PSA?. [Review] [31 refs]. *ANZ Journal of Surgery*, 79: 703-706.
- 28 Narrative review
- 29 Tilburt, J. C., Kelley, S., DeCourtney, C. A., Humeniuk, K. M., Latini, J. & Kim, S. P. (2014) - Caring for  
30 Alaska Native prostate cancer survivors in primary care: a survey of Alaska Tribal Health System  
31 providers. - *International Journal of Circumpolar Health*, 73: 23637.
- 32 Not in PICO
- 33 Tohfe, M., Baki, S. A., Saliba, W., Ghandour, F., Ashou, R., Ghazal, G., Bahous, J. & Chamseddine, N.  
34 (2008) Metastatic prostate adenocarcinoma presenting with pulmonary symptoms: a case report  
35 and review of the literature. *Cases journal*, 1: 316.
- 36 Not in PICO
- 37 Tong, Y.-J., Wang, X.-Y., Li, F.-Y. & Jiang, X.-X. (2006) Value of MR in differential diagnosis of prostate  
38 carcinoma. [Chinese]. *Chinese Journal of Medical Imaging Technology*, 22: 1061-1063.
- 39 Not in PICO
- 40 Tsugawa, M., Sasaki, K., Senoo, T., Arata, R., Nasu, Y. & Kumon, H. (2000) Efficacy of ultrasound  
41 contrast agent in the diagnosis and treatment of prostate diseases. [Japanese]. *Nishinohon Journal  
42 of Urology*, 62: 176-181.
- 43 Not in PICO
- 44 Tudiver, F., Guibert, R., Haggerty, J., Ciampi, A., Medved, W., Brown, J. B., Herbert, C., Katz, A., Ritvo,  
45 P., Grant, B., Goel, V., Smith, P., O'Beirne, M., Williams, J. I. & Moliner, P. (2002) What influences  
46 family physicians' cancer screening decisions when practice guidelines are unclear or conflicting?  
47 *Journal of Family Practice*, 51: 760-7U8.
- 48 Not in PICO
- 49 Tuppin, P., Samson, S., Fagot-Campagna, A., Lukacs, B., Alla, F., Allemand, H., Paccaud, F., Thalabard,  
50 J. C., Vicaut, E., Vidaud, M. & Millat, B. (2014) - [PSA testing, biopsy and cancer and benign

- 1 prostate hyperplasia in France]. [French]. - *Progres en Urologie*, 24: 572-580.  
 2 Not in PICO
- 3 Umbehre, M., Bachmann, L. M., Held, U., Kessler, T. M., Sulser, T., Weishaupt, D., Kurhanewicz, J. &  
 4 Steurer, J. (2009) Combined magnetic resonance imaging and magnetic resonance spectroscopy  
 5 imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. [Review] [54  
 6 refs]. *European Urology*, 55: 575-590.  
 7 Not in PICO (referred population)
- 8 van Bokhoven, M., Koch, H., van der Weijden, T., Weekers-Muyres, A., Bindels, P., Grol, R. & Dinant,  
 9 G. J. (2012) The effect of watchful waiting compared to immediate test ordering instructions on  
 10 general practitioners' blood test ordering behaviour for patients with unexplained complaints; a  
 11 randomized clinical trial (ISRCTN55755886). *Implementation Science*, 7: 29.  
 12 Not in PICO
- 13 Van der Meer, S., Lowik, S. A. M., Hirdes, W. H., Nijman, R. M., Van der Meer, K., Hoekstra-Weebers,  
 14 J. E. H. M. & Blanker, M. H. (2012) Prostate specific antigen testing policy worldwide varies  
 15 greatly and seems not to be in accordance with guidelines: a systematic review. *Bmc Family  
 16 Practice*, 13.  
 17 Not in PICO
- 18 Van der Meer, S., Kollen, B. J., Hirdes, W. H., Steffens, M. G., Hoekstra-Weebers, J. E., Nijman, R. M.  
 19 & Blanker, M. H. (2013) Impact of the European Randomized Study of Screening for Prostate  
 20 Cancer (ERSPC) on prostate-specific antigen (PSA) testing by Dutch general practitioners. *Bju  
 21 International*, 112: 26-31.  
 22 Not in PICO
- 23 van Renterghem, K., Van Koeveringe, G. & Van Kerrebroeck, P. (2007) Rising PSA in patients with  
 24 minor LUTS without evidence of prostatic carcinoma: a missing link? *International Urology and  
 25 Nephrology*, 39: 1107-1113.  
 26 Not in PICO
- 27 Vedel, I., Puts, M. T. E., Monette, M., Monette, J. & Bergman, H. (2011) The decision-making process  
 28 in prostate cancer screening in primary care with a prostate-specific antigen: A systematic review.  
 29 *Journal of Geriatric Oncology*, 2: 161-176.  
 30 Not in PICO
- 31 Venderbos, L. D. F. & Roobol, M. J. (2011) PSA-based prostate cancer screening: the role of active  
 32 surveillance and informed and shared decision making. *Asian Journal of Andrology*, 13: 219-224.  
 33 Narrative review
- 34 Verma, A., St, O. J., Dhillon, K. & Chorneyko, A. (2014) - PSA density improves prediction of prostate  
 35 cancer. - *Canadian Journal of Urology*, 21: 7312-7321.  
 36 Not in PICO
- 37 Vickers, A. J., Savage, C., O'Brien, M. F. & Lilja, H. (2009) Systematic review of pretreatment prostate-  
 38 specific antigen velocity and doubling time as predictors for prostate cancer. [Review] [27 refs].  
 39 *Journal of Clinical Oncology*, 27: 398-403.  
 40 Not in PICO
- 41 Vickers, A. J., Till, C., Tangen, C. M., Lilja, H. & Thompson, I. M. (2011) An Empirical Evaluation of  
 42 Guidelines on Prostate-specific Antigen Velocity in Prostate Cancer Detection. *Journal of the  
 43 National Cancer Institute*, 103: 462-469.  
 44 Not in PICO
- 45 Vickers, A. J. (2013) Counterpoint: Prostate-specific antigen velocity is not of value for early  
 46 detection of cancer. *Journal of the National Comprehensive Cancer Network*, 11: 286-290.  
 47 Narrative review
- 48 Vincendeau, S., Moussa, M. A., Manunta, A., Patard, J. J., Guille, F. & Lobel, B. (2003) PSA: the  
 49 difficult position of general practitioners between patients and urologists. *Progres En Urologie*,  
 50 13: 252-255.  
 51 Not in PICO

- 1 von, E. A., Ho, R., Murphy, G. P., Cunningham, M. & Lins, N. (1997) American Cancer Society  
2 guidelines for the early detection of prostate cancer: update, June 10, 1997. *Cancer*, 80: 1805-  
3 1807.  
4 Guideline
- 5 Voskanyan, G. A., Glybochko, P. V., Vinarov, A. Z., Korobkin, A. S., Ternovoy, S. K. & Shariya, M. A.  
6 (2013) Anticipating metabolic changes: Magnetic resonance spectroscopy as a diagnostic tool for  
7 early detection of prostate cancer. *European Urology, Supplements*, 12: 149-150.  
8 Not in PICO
- 9 Wadhwa, K., Serrao, E., Frey, J., Gallagher, F., Koo, B. & Kastner, C. (2014) Diagnostic MRI prostate  
10 prebiopsy is associated with a significant false negative rate. *Bju International*, 113: 46-47.  
11 Not in PICO
- 12 Walker, N. A. & Challacombe, B. (2013) Managing epididymo-orchitis in general practice.  
13 *Practitioner*, 257: 21-25.  
14 Narrative review
- 15 Walker, P. L. C. & Crook, M. (2011) Tumour marker requesting in primary care and the role of the  
16 laboratory. *Journal of Clinical Pathology*, 64: 443-446.  
17 Not in PICO
- 18 Wallner, L. P., Frencher, S. K., Hsu, J. W. Y., Chao, C. R., Nichol, M. B., Loo, R. K. & Jacobsen, S. J.  
19 (2013) Changes in serum prostate-specific antigen levels and the identification of prostate cancer  
20 in a large managed care population. *Bju International*, 111: 1245-1252.  
21 Not in PICO (screening)
- 22 Walsh, P. C. (2012) Re: Urologists' self-referral for pathology of biopsy specimens linked to increased  
23 use and lower prostate cancer detection. *Journal of Urology*, 188: 1767.  
24 Not in PICO
- 25 Ward, J., Young, J. & Sladden, M. (1998) Australian general practitioners' views and use of tests to  
26 detect early prostate cancer. *Australian and New Zealand Journal of Public Health*, 22: 374-380.  
27 Not in PICO
- 28 Warshaw, G. (2009) Providing quality primary care to older adults. *Journal of the American Board of*  
29 *Family Medicine: JABFM*, 22: 239-241.  
30 Not in PICO
- 31 Watanabe, Y., Terai, A., Araki, T., Nagayama, M., Okumura, A., Amoh, Y., Ishimori, T., Ishibashi, M.,  
32 Nakashita, S. & Dodo, Y. (2012) Detection and localization of prostate cancer with the targeted  
33 biopsy strategy based on ADC map: a prospective large-scale cohort study. *Journal of Magnetic*  
34 *Resonance Imaging*, 35: 1414-1421.  
35 Not in PICO
- 36 Weight, C. J., Kim, S. P., Jacobson, D. J., McGree, M. E., Boorjian, S. A., Thompson, R. H., Leibovich, B.  
37 C., Karnes, R. J. & St, S. J. (2013) The effect of benign lower urinary tract symptoms on  
38 subsequent prostate cancer testing and diagnosis. *European Urology*, 63: 1021-1027.  
39 Not in PICO
- 40 Weller, D., May, F., Rowett, D., Esterman, A., Pinnock, C., Nicholson, S., Doust, J. & Silagy, C. (2003)  
41 Promoting better use of the PSA test in general practice: randomized controlled trial of  
42 educational strategies based on outreach visits and mailout. *Family Practice*, 20: 655-661.  
43 Not in PICO
- 44 Williams, N., Hughes, L. J., Turner, E. L., Donovan, J. L., Hamdy, F. C., Neal, D. E., Martin, R. M. &  
45 Metcalfe, C. (2011) Prostate-specific antigen testing rates remain low in UK general practice: a  
46 cross-sectional study in six English cities. *Bju International*, 108: 1402-1408.  
47 Not in PICO
- 48 Willis, S. R., Ahmed, H. U., Moore, C. M., Donaldson, I., Emberton, M., Miners, A. H. & van der  
49 Meulen, J. (2014) - Multiparametric MRI followed by targeted prostate biopsy for men with  
50 suspected prostate cancer: a clinical decision analysis. - *BMJ Open*, 4: e004895.  
51 Not in PICO

- 1 Willis, S. R., Ahmed, H. U., Moore, C. M., Donaldson, I., Emberton, M., Miners, A. H. & van der  
2 Meulen, J. (2014) Multiparametric MRI followed by targeted prostate biopsy for men with  
3 suspected prostate cancer: A clinical decision analysis. *BMJ Open*, 4.  
4 Duplicate
- 5 Wilson, C., Boyd, K., Mohammed, A. & Little, B. (2010) A single episode of haemospermia can be  
6 safely managed in the community. *International Journal of Clinical Practice*, 64: 1436-1439.  
7 Not in PICO
- 8 Wu, J. D., Lin, D. W., Page, S. T., Lundgren, A. D., True, L. D. & Plymate, S. R. (2009) Oxidative DNA  
9 damage in the prostate may predispose men to a higher risk of prostate cancer. *Clinical &  
10 translational oncology*, 2: 39-45.  
11 Not in PICO
- 12 Xoxakos, I., Sotiropoulou, G., Rompolis, D., Chatzinicolaou, V., Kalyvas, C., Louka, G. & Stokidis, D.  
13 (2009) Incidental prostate cancer. A malignancy while treating a benign disease. *Journal of  
14 Endourology*, 23: A15.  
15 Not in PICO
- 16 Xu, Y. M. (254) [Transperineal prostatic biopsy guided by ultrasound]. [Chinese]. *Chung-Hua Wai Ko  
17 Tsa Chih [Chinese Journal of Surgery]*, 27: 231-232.  
18 Not in PICO
- 19 Yafi, F. A., Aprikian, A. G., Tanguay, S. & Kassouf, W. (2011) Are men on 5 alpha-reductase inhibitors  
20 appropriately referred to urology? A survey of primary care physicians. *Bju International*, 108:  
21 1269-1273.  
22 Not in PICO
- 23 Yamaguchi, S., Baba, Y. & Naito, K. (1997) [Systematic ultrasound guided transrectal core prostate  
24 biopsy based on serum level of prostate-specific antigen]. [Japanese]. *Hinyokika Kyo - Acta  
25 Urologica Japonica*, 43: 641-645.  
26 Not in PICO
- 27 Yamamoto, M., Hibi, H. & Miyake, K. (1994) Role of prostate-specific antigen and digital rectal  
28 examination in the detection of prostate cancer. *International journal of urology : official journal  
29 of the Japanese Urological Association*, 1: 74-77.  
30 Not in PICO (44/260 received reference standard)
- 31 Yamazaki, H., Yoshigoe, F., Kobari, T., Takeuchi, H., Katoh, N. & Ohishi, Y. (1999) [Digital rectal  
32 examination, transrectal ultrasonography and prostate specific antigen for diagnosis of prostate  
33 cancer in clinical urological practice-detection of impalpable cancer]. [Japanese]. *Nippon  
34 Hinyokika Gakkai Zasshi - Japanese Journal of Urology*, 90: 595-601.  
35 Not in PICO
- 36 Yazici, C. M. & Dogan, C. (2014) Can Non-Urological Doctors Play a Role in Early Prostate Cancer  
37 Detection? *Urology Journal*, 11: 1429-1434.  
38 Not in PICO
- 39 Yazici, C. M. & Dogan, C. (2014) - Can non-urological doctors play a role in early prostate cancer  
40 detection? - *Urology Journal*, 11: 1429-1434.  
41 Duplicate
- 42 Yerram, N., Volkin, D., Nix, J., Vourganti, S., Hoang, A., Ahmed, F., Gupta, G., Kruecker, J., Kadoury, S.,  
43 Locklin, J., Gates, S., Xu, S., Merino, M., Linehan, W. M., Turkbey, I. B., Choyke, P. L., Wood, B. J. &  
44 Pinto, P. A. (2012) Multiparametric magnetic resonance imaging and ultrasound fusion biopsy  
45 detects prostate cancer in patients with prior negative trus biopsies. *Journal of Urology*, 187:  
46 e828.  
47 Not in PICO
- 48 Yoneyama, T., Tobisawa, Y., Hatakeyama, S., Narita, S., Habuchi, T., Mori, K., Koie, T. & Ohyama, C.  
49 (2014) Measurement of prostate cancer-associated aberrant glycosylation of prostate specific  
50 antigen can improve diagnostic accuracy. *European Urology, Supplements*, 13: e112-e112a.  
51 Not in PICO

1 Yoo, D. S., Woo, S. H., Cho, S., Kang, S. H., Kim, S. J., Park, S. Y., Lee, S. H., Jeon, S. H. & Park, J. (2014)  
2 Practice Patterns of Urologists in Managing Korean Men Aged 40 Years or Younger With High  
3 Serum Prostate-specific Antigen Levels. *Urology*, 83: 1339-1343.  
4 Not in PICO

5 Zaenker, P. & Ziman, M. R. (2013) Serologic autoantibodies as diagnostic cancer biomarkers--a  
6 review. *Cancer Epidemiology, Biomarkers & Prevention*, 22: 2161-2181.  
7 Narrative review

8 Zangos, S., Eichler, K., Engelmann, K., Ahmed, M., Dettmer, S., Herzog, C., Pegios, W., Wetter, A.,  
9 Lehnert, T., Mack, M. G. & Vogl, T. J. (2005) MR-guided transgluteal biopsies with an open low-  
10 field system in patients with clinically suspected prostate cancer: technique and preliminary  
11 results. *European Radiology*, 15: 174-182.  
12 Not in PICO

13 Zhang, B., Ma, X., Zhan, W., Zhu, F., Li, M., Huang, J., Li, Y., Xue, L., Liu, L. & Wei, Y. (2014) - Real-time  
14 elastography in the diagnosis of patients suspected of having prostate cancer: a meta-analysis. -  
15 *Ultrasound in Medicine & Biology*, 40: 1400-1407.  
16 Not in PICO

17 Zhang, V. Y., Westphalen, A., Delos, S. L., Tabatabai, Z. L., Shinohara, K., Vigneron, D. B. &  
18 Kurhanewicz, J. (2014) - The role of metabolic imaging in radiation therapy of prostate cancer. -  
19 *NMR in Biomedicine*, 27: 100-111.  
20 Not in PICO

21 Zlotta, A. R. & Schulman, C. C. (1998) Use of transrectal ultrasonography in prostate pathology:  
22 determination and clinical usefulness of the prostate transition zone. [French]. *Revue Medicale de*  
23 *Bruxelles*, 19: 119-123.  
24 Narrative review  
25  
26

**BLADDER CANCER****Review question:**

What is the risk of bladder cancer in patients presenting in primary care with symptom(s)?

**Results****Literature search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	All - 2012	1070	189	03/09/2012
<i>Premedline</i>	All - 2012	17	5	03/09/2012
<i>Embase</i>	All - 2012	2103	111	30/08/2012
<i>Cochrane Library</i>	All - 2012	126	1	03/09/2012
<i>Psychinfo</i>	All - 2012	2	0	03/09/2012
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	All - 2012	163	28	03/09/2012
<i>Biomed Central</i>	All - 2012	158	3	12/09/2012


Total References retrieved (after de-duplication): 263

**Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	2013-11/08/2014	64	7	11/08/2014
<i>Premedline</i>	2013-11/08/2014	48	11	11/08/2014
<i>Embase</i>	2013-11/08/2014	283	18	11/08/2014
<i>Cochrane Library</i>	2013-11/08/2014	65	0	11/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	2013-11/08/2014	68	3	11/08/2014

Total References retrieved (after de-duplication): 26








1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17

**Risk of bias in the included studies**

The risk of bias and applicability concerns are summarised per study in the figure below. The main bias and validity issues to note are that one study was conducted in a Belgian primary care population (Bruyninckx, 2003) and another in US primary care setting (Friedlander, 2014) and these studies are therefore only applicable to the extent that the populations are comparable to a UK GP population, another study (Hippisley-Cox 2012) only presented data for 967681 out of 1240722 eligible patients and it is unclear why, a third study (Jones, 2007) report the results for both 6 months and 3 years after first symptom presentation and it is unclear whether 3 years is too long an interval to be confident that the symptom is a result of underlying cancer, similarly, Friedlander (2014) only followed up the included patients for 180 days, which may be too short a time period. The final study (Shephard, 2012) employed a case-control design which has been shown to be associated with inflated test accuracy parameters compared to designs that incorporate random or consecutive patient selection.

	Risk of Bias				Applicability Concerns		
	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard
Bruyninckx (2003)	+	+	+	+	?	+	+
Collins (2013)	+	+	+	+	+	+	+
Friedlander (2014)	+	+	?	+	?	+	+
Hippisley-Cox (2012)	+	+	+	-	+	+	+
Jones (2007)	+	+	+	+	+	+	+
Shephard/Price (2012/14)	-	+	+	+	+	+	+

 High	 Unclear	 Low
--	---	---

1  
2  
3  
4  
5  
6

**Study results**

Table 1: Bladder cancer: Meta-analyses

Studies included	Symptom(s)	Patient group	Positive predictive value, % (95% CI)
Bruyninckx (2003), Collins (2013), Friedlander (2014), Hippisley-Cox (2012), Jones (2007, at 6 months)	Haematuria	All patients (N = 70330)	4.43 (2.48-7.79)
Bruyninckx (2003), Collins (2013), Friedlander (2014), Hippisley-Cox (2012), Jones (2007, at 3 years)	Haematuria	All patients (N = 70330)	4.72 (2.63-8.32)

Please note that the data from Shephard (2012) are not included in these meta-analyses due to the case-control design of the study. These data are instead reported in the table below.

7  
8  
9

Table 2: Bladder cancer: Individual positive predictive values from the meta-analyses

Studies included	Symptom(s)	Patient group	Positive predictive value, % (95% CI)
Bruyninckx (2003)	Haematuria	All patients (N = 409)	10.27 (7.6-13.7)
Collins (2013)	Haematuria	All patients (N = 37810)	4.35 (4.1-4.6)
Friedlander (2014)	Haematuria	All included patients (N = 2455)	1.34 (0.94-1.91) 33/2455
Hippisley-Cox (2012)	Haematuria	All patients (N = 18548)	6.48 (6.1-6.8)
Jones (2007, at 6 months),	Haematuria	All patients (N = 11108)	4.2 (3.8-4.6)

10

Jones (2007, at 3 years),	Haematuria	All patients (N = 11108)	5.7 (5.3-6.2)
---------------------------	------------	--------------------------	---------------

1  
2  
3

Table 3: Bladder cancer: Additional results reported by the individual papers

Study	Symptom(s)	Patient group	Positive predictive value, % (95% CI)
Bruyningx (2003)	Macroscopic haematuria	Men (all ages)	14.2 (10.1-19.5)
Collins (2013)	Haematuria	Men (all ages)	5.5 (5.2-5.8)
Jones (2007)	Haematuria	Men (all ages) at 6 months	5.47 (4.9-6.1)
Bruyningx (2003)	Macroscopic haematuria	Men < 40 years	0 (0-12)
Jones (2007)	Haematuria	Men < 45 years at 3 years	0.99 (0.53-1.69)
Bruyningx (2003)	Macroscopic haematuria	Men 40-59 years	3.6 (.6-13.4)
Jones (2007)	Haematuria	Men 45-54 years at 3 years	4.35 (3.11-5.9)
Jones (2007)	Haematuria	Men 55-64 years at 3 years	8.51 (6.94-10.32)
Bruyningx (2003)	Macroscopic haematuria	Men > 59 years	22.1 (15.8-30.1)
Jones (2007)	Haematuria	Men 65-74 years at 3 years	11.21 (9.66-12.9)
Jones (2007)	Haematuria	Men 75-84 years at 3 years	10.27 (8.61-12.13)
Jones (2007)	Haematuria	Men ≥ 85 years at 3 years	9.22 (6.43-12.7)
Bruyningx (2003)	Macroscopic haematuria	Women (all ages)	5.1 (2.5-9.8)
Collins (2013)	Haematuria	Women (all ages)	2.6 (2.3-2.8)
Jones (2007)	Haematuria	Women (all ages) at 6 months	2.48 (2.1-3)
Bruyningx (2003)	Macroscopic haematuria	Women < 40 years	0 (NR)
Jones (2007)	Haematuria	Women < 45 years at 3 years	0.22 (0.05-0.64)
Bruyningx (2003)	Macroscopic haematuria	Women 40-59 years	6.4 (1.7-18.6)
Jones (2007)	Haematuria	Women 45-54 years at 3 years	1.34 (0.65-2.45)
Jones (2007)	Haematuria	Women 55-64 years at 3 years	3.42 (2.26-4.93)
Bruyningx (2003)	Macroscopic haematuria	Women > 59 years	8.3 (3.4-17.9)
Jones (2007)	Haematuria	Women 65-74 years at 3 years	5.91 (4.42-7.72)
Jones (2007)	Haematuria	Women 75-84 years at 3 years	6.83 (5.06-8.98)
Jones (2007)	Haematuria	Women ≥ 85 years at 3 years	8.53 (5.6-12.3)
Bruyningx (2003)	Macroscopic haematuria	All patients < 60 years	2.6 (.9-6.2)
Shephard (2012)	Visible haematuria (coded data only)	All patients 40-59 years	3.1 (1-9.8)
Price (2014)	Visible haematuria (coded and uncoded)	All patients 40-59 years	1.2 (0.64-2.3)

	data)		
Shephard (2012)	Visible haematuria (coded data only)	All patients ≥ 60 years	3.9 (3.5-4.6)
Price (2014)	Visible haematuria (coded and uncoded data)	All patients ≥ 60 years	2.8 (2.5-3.1)
<i>Shephard (2012)</i>	<i>Visible haematuria</i>	<i>All patients</i>	<i>Cases: 2595/4915 Controls: 196/21718</i>
Shephard (2012)	Visible haematuria (second attendance)	All patients ≥ 60 years	6.1 (5.1-8.2)
Price (2014)	Non-visible haematuria (coded and uncoded data)	Patients 40-59 years	0.79 (0.11-5.6)
Price (2014)	Non-visible haematuria (coded and uncoded data)	All patients ≥ 60 years	1.6 (1.2-2.1)
Bruyninckx (2003)	Macroscopic haematuria + pain	All patients	5.3 (2.7-9.8)
Bruyninckx (2003)	Macroscopic haematuria + pain	Men > 60 years	17.8 (8.5-32.6)
Shephard (2012)	Visible haematuria + abdominal pain (coded data only)	All patients ≥ 60 years	3.2 (1.9-5.8)
Price (2014)	Visible haematuria + abdominal pain (coded and uncoded data)	All patients ≥ 60 years	2.3 (1.5-3.5)
Price (2014)	Non-visible haematuria + abdominal pain (coded and uncoded data)	All patients ≥ 60 years	1.7 (0.6-4.2)
Bruyninckx (2003)	Macroscopic haematuria without pain	All patients	10.9 (7.3-16)
Bruyninckx (2003)	Macroscopic haematuria without pain	Men > 60 years	18.9 (11.9-28.6)
Bruyninckx (2003)	Macroscopic haematuria + increased frequency of micturition	All patients	7.2 (3.8-12.8)
Bruyninckx (2003)	Macroscopic haematuria + increased frequency of micturition	Men > 60 years	22.6 (10.3-41.5)
Bruyninckx (2003)	Macroscopic haematuria without increased frequency of micturition	All patients	13.4 (9.4-18.7)
Bruyninckx (2003)	Macroscopic haematuria without increased frequency of micturition	Men > 60 years	22 (14.9-31.2)
Bruyninckx (2003)	Macroscopic haematuria + dysuria	All patients	5.6 (2.6-11)
Bruyninckx (2003)	Macroscopic haematuria + dysuria	Men > 60 years	24.1 (11-43.9)
Shephard (2012)	Visible haematuria + dysuria (coded data)	All patients ≥ 60 years	6.4 (NR as N < 10)

	only)		
Price (2014)	Visible haematuria + dysuria (coded and uncoded data)	All patients ≥ 60 years	4.1 (2.6-6.3)
Price (2014)	Non-visible haematuria + dysuria (coded and uncoded data)	All patients ≥ 60 years	4.5 (NR)
Bruyninckx (2003)	Macroscopic haematuria without dysuria	All patients	23.6 (17.1-31.5)
Bruyninckx (2003)	Macroscopic haematuria without dysuria	Men > 60 years	21.6 (14.6-30.6)
Bruyninckx (2003)	Macroscopic haematuria + nocturia	All patients	6.3 (2.4-14.8)
Bruyninckx (2003)	Macroscopic haematuria + nocturia	Men > 60 years	12.5 (3.3-33.5)
Bruyninckx (2003)	Macroscopic haematuria without nocturia	All patients	11.2 (8.1-15.2)
Bruyninckx (2003)	Macroscopic haematuria without nocturia	Men > 60 years	23.3 (16.3-32.1)
Bruyninckx (2003)	Macroscopic haematuria + weight loss	All patients	10 (.5-45.9)
Bruyninckx (2003)	Macroscopic haematuria + weight loss	Men > 60 years	33.3 (1.8-87.5)
Bruyninckx (2003)	Macroscopic haematuria without weight loss	All patients	8.3 (5.8-11.5)
Bruyninckx (2003)	Macroscopic haematuria without weight loss	Men > 60 years	18.2 (12.4-26)
Bruyninckx (2003)	Macroscopic haematuria + fatigue	All patients	20.8 (11-35.4)
Bruyninckx (2003)	Macroscopic haematuria + fatigue	Men > 60 years	30 (12.8-54.3)
Bruyninckx (2003)	Macroscopic haematuria without fatigue	All patients	8.9 (6.2-12.4)
Bruyninckx (2003)	Macroscopic haematuria without fatigue	Men > 60 years	20.8 (14.2-29.4)
Bruyninckx (2003)	Macroscopic haematuria with other symptoms	All patients	6.4 (4.3-9.3)
Bruyninckx (2003)	Macroscopic haematuria without other symptoms	All patients	3.9 (2.3-6.4)
Shephard (2012)	Visible haematuria + constipation (coded data only)	All patients ≥ 60 years	2.7 (1.6-4.5)
Price (2014)	Visible haematuria + constipation (coded and uncoded data)	All patients ≥ 60 years	2.2 (1.5-3.4)
Price (2014)	Non-visible haematuria + constipation (coded and uncoded data)	All patients ≥ 60 years	2 (NR)
Shephard (2012)	Visible haematuria + urinary tract infection (coded data only)	All patients ≥ 60 years	4.1 (3-6.2)

Price (2014)	Visible haematuria + urinary tract infection (coded and uncoded data)	All patients ≥ 60 years	2.2 (1.8-2.8)
Price (2014)	Non-visible haematuria + urinary tract infection (coded and uncoded data)	All patients ≥ 60 years	1.4 (0.8-2.4)
Shephard (2012)	Visible haematuria + raised inflammatory markers (coded data only)	All patients ≥ 60 years	5.6 (NR as N < 10)
Price (2014)	Visible haematuria + raised inflammatory markers (coded and uncoded data)	All patients ≥ 60 years	3.3 (2-5.4)
Price (2014)	Non-visible haematuria + raised inflammatory markers (coded and uncoded data)	All patients ≥ 60 years	1.25 (NR)
Shephard (2012)	Visible haematuria + raised creatinine (coded data only)	All patients ≥ 60 years	5.1 (3.4-8.4)
Price (2014)	Visible haematuria + raised creatinine (coded and uncoded data)	All patients ≥ 60 years	2.9 (2.1-3.9)
Price (2014)	Non-visible haematuria + raised creatinine (coded and uncoded data)	All patients ≥ 60 years	1.1 (0.6-2.2)
Shephard (2012)	Visible haematuria + raised white blood cell count (coded data only)	All patients ≥ 60 years	8.8 (NR as N < 10)
Price (2014)	Visible haematuria + raised white blood cell count (coded and uncoded data)	All patients ≥ 60 years	3.7 (2.1-6.3)
Price (2014)	Non-visible haematuria + raised white blood cell count (coded and uncoded data)	All patients ≥ 60 years	3.9 (NR)
Collins (2013)	Abdominal pain	All patients	0.11 (0.1-0.13)
		Men	0.2 (0.2-0.21)
		Women	0.1 (0.1-0.1)
Hippisley-Cox (2012)	Abdominal pain	All patients	0.2 (0.2-0.2)
Shephard (2012)	Abdominal pain	All patients ≥ 60	0.2 (0.1-0.2)
<i>Shephard (2012)</i>	<i>Abdominal pain</i>	<i>All patients</i>	<i>Cases: 358/4915 Controls: 787/21718</i>
Shephard (2012)	Abdominal pain (second attendance)	All patients ≥ 60	0.2 (0.1-0.2)
Shephard (2012)	Abdominal pain +	All patients ≥ 60	0.4 (0.3-0.7)

	dysuria		
Shephard (2012)	Abdominal pain + constipation	All patients ≥ 60	0.2 (0.1-0.3)
Shephard (2012)	Abdominal pain + urinary tract infection	All patients ≥ 60	0.4 (0.3-0.6)
Shephard (2012)	Abdominal pain + raised inflammatory markers	All patients ≥ 60	0.2 (0.1-0.3)
Shephard (2012)	Abdominal pain + raised creatinine	All patients ≥ 60	0.3 (0.2-0.4)
Shephard (2012)	Abdominal pain + raised white blood cell count	All patients ≥ 60	0.2 (0.1-0.3)
Shephard (2012)	Dysuria	All patients ≥ 60	0.7 (0.6-0.8)
<i>Shephard (2012)</i>	<i>Dysuria</i>	<i>All patients</i>	<i>Cases: 444/4915 Controls: 209/21718</i>
Shephard (2012)	Dysuria (second attendance)	All patients ≥ 60	1 (0.7-1.5)
Shephard (2012)	Dysuria + constipation	All patients ≥ 60	0.5 (0.3-0.9)
Shephard (2012)	Dysuria + urinary tract infection	All patients ≥ 60	0.7 (0.4-1.1)
Shephard (2012)	Dysuria + raised inflammatory markers	All patients ≥ 60	0.9 (0.5-1.7)
Shephard (2012)	Dysuria + raised creatinine	All patients ≥ 60	0.6 (0.4-1)
Shephard (2012)	Dysuria + raised white blood cell count	All patients ≥ 60	0.9 (0.5-1.9)
Shephard (2012)	Constipation	All patients ≥ 60	0.1 (0.1-0.2)
<i>Shephard (2012)</i>	<i>Constipation</i>	<i>All patients</i>	<i>Cases: 286/4915 Controls: 708/21718</i>
Shephard (2012)	Constipation (second attendance)	All patients ≥ 60	0.1 (0.1-0.2)
Shephard (2012)	Constipation + urinary tract infection	All patients ≥ 60	0.5 (0.3-0.7)
Shephard (2012)	Constipation + raised inflammatory markers	All patients ≥ 60	0.2 (0.1-0.2)
Shephard (2012)	Constipation + raised creatinine	All patients ≥ 60	0.2 (0.2-0.3)
Shephard (2012)	Constipation + raised white blood cell count	All patients ≥ 60	0.3 (0.2-0.5)
Shephard (2012)	Urinary tract infection	All patients ≥ 60	0.4 (0.3-0.4)
<i>Shephard (2012)</i>	<i>Urinary tract infection</i>	<i>All patients</i>	<i>Cases: 835/4915 Controls: 705/21718</i>
Shephard (2012)	Urinary tract infection (second attendance)	All patients ≥ 60	0.5 (0.4-1.6)
Shephard (2012)	Urinary tract infection + raised inflammatory markers	All patients ≥ 60	0.4 (0.3-0.7)
Shephard (2012)	Urinary tract infection + raised creatinine	All patients ≥ 60	0.5 (0.3-0.6)
Shephard (2012)	Urinary tract infection + raised white blood cell	All patients ≥ 60	0.6 (0.4-0.9)

	count		
Shephard (2012)	Raised inflammatory markers	All patients ≥ 60	0.1 (0.1-0.2)
<i>Shephard (2012)</i>	<i>Raised inflammatory markers</i>	<i>All patients</i>	<i>Cases: 293/4915 Controls: 717/21718</i>
Shephard (2012)	Raised inflammatory markers + raised creatinine	All patients ≥ 60	0.3 (0.2-0.3)
Shephard (2012)	Raised inflammatory markers + raised white blood cell count	All patients ≥ 60	0.2 (0.1-0.3)
Shephard (2012)	Raised creatinine	All patients ≥ 60	0.1 (0.12-0.14) As reported, but PPV or CI not reported correctly
<i>Shephard (2012)</i>	<i>Raised creatinine</i>	<i>All patients</i>	<i>Cases: 660/4915 Controls: 1668/21718</i>
Shephard (2012)	Raised creatinine + raised white blood cell count	All patients ≥ 60	0.3 (0.2-0.4)
Shephard (2012)	Raised white blood cell count	All patients ≥ 60	0.2 (0.17-0.23)
<i>Shephard (2012)</i>	<i>Raised white blood cell count</i>	<i>All patients</i>	<i>Cases: 250/4915 Controls: 401/21718</i>
Collins (2013)	Appetite loss	Women	0.1 (0.04-0.3)
Hippisley-Cox (2012)	Appetite loss	All patients	0.18 (0.07-0.4)
Collins (2013)	Weight loss	Women	0.1 (0.1-0.2)
Hippisley-Cox (2012)	Weight loss	All patients	0.41 (0.3-0.6)
Collins (2013)	Anaemia	All patients	0.6 (0.5-0.7)
		Men	1.4 (1.1-1.9)
		Women	0.3 (0.3-0.5)
Hippisley-Cox (2012)	Anaemia	All patients	0.69 (0.5-0.9)

1 NR = Not reported. Please note the calculations of the positive predictive values differ between the  
2 studies with Bruyninckx (2003), Hippisley-Cox (2012) and Jones (2007) using (TP)/(TP+FP) and  
3 Shephard (2012) using Bayesian statistics due to the case-control design of this study.  
4

##### 5 **Evidence statement(s):**

6 Haematuria (6 studies, N = 89345) presenting in a primary care setting is associated with overall  
7 positive predictive values ranging from 1.34%-10.27% for bladder cancer, which tended to be higher  
8 in men (5.47%-14.2%) than in women (2.48%-5.1%; 3 studies, total N = 49327) and to increase with  
9 age in men (up 22.1%; 2 studies, total N = 11517) and much less so in women (up to 8.53%; 2  
10 studies, total N = 11517). All the studies were associated with 0-2 bias or applicability concern (see  
11 also Tables 1-3).

12  
13 Haematuria in combination with other symptoms presenting in a primary care setting was  
14 associated with positive predictive values ranging from 1.1% (non-visible with raised creatinine in  
15 patients ≥ 60 years; 1 study, total N = 26633) to 33.3% (with weight loss in men > 60 years old; 1  
16 study, total N = 409) for bladder cancer. Both studies were associated with 1 bias or applicability  
17 concern (see also Table 3).



Other symptoms (than haematuria) presenting alone or in combination with each other (but not haematuria) in a primary care setting were all associated with positive predictive values  $\leq 1.5\%$  for bladder cancer (3 studies, total N = 1284137). All the studies were associated with 0-1 bias or applicability concern (see also Table 3).

## Evidence tables

### Bruyninckx (2003)

PATIENT SELECTION	
<b>A. risk of bias</b>	
Patient sampling	Prospective consecutive patient series using a register populated by GPs in Belgium. This register is based on the voluntary and constant registration of epidemiological data by GPs and is spread equally over the country. At the time of the study data (1993-1994) this GP network covered ca 1% of the Belgian population. GP participation rate was ca 90% (N = 83).
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>A total of 83890 patient-years were registered.</p> <p><u>Patients with macroscopic haematuria:</u> N = 409 (232 males/176 females/ 1 of unknown sex); mean (SD) age of patients with macroscopic haematuria but not cancer = 57 (20) years.</p> <p><u>Inclusion criteria:</u> All patients complaining to their GP of macroscopic haematuria in 1993-1994 were included. Patients complaining repeatedly of haematuria were included only once.</p> <p><u>Exclusion criteria:</u> None reported.</p> <p><u>Clinical setting:</u> Primary care, Belgium.</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	<p>Haematuria was registered if a patient complained to the GP of any blood of urological origin that had not necessarily been checked by the GP during the study period, irrespective of the duration of the complaint and irrespective of the existence or absence of other signs or symptoms.</p> <p>Registered associated signs and symptoms were fatigue, weight loss, pain, nocturia, dysuria or frequency of micturition.</p>
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>

REFERENCE STANDARD	
<b>A. risk of bias</b>	
Reference standard(s)	Diagnosis of urological cancer during a clinical follow-up of $\geq 18$ months was registered as the reference standard. Urological cancer was defined as any malignancy of the urological tract that was confirmed histologically or by cystoscopy, intravenous pyelogram, or ultrasound scan. Recall letters were sent to the practices every six months, to check the included cases again upon the emergence of a diagnosis of any urological cancer. To ensure that all cases of urological cancer diagnosed within the follow-up period were identified, at the end of the period each of the GPs was sent a list of all their patients with macroscopic haematuria who were included in the study, in order to check for any 'hidden' urological cancer diagnosis.
Is the reference standard likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	No (but all patients had a positive index test)
Could the reference standard, its conduct, or its interpretation have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Are there concerns that the target condition as defined by the reference standard does not match the question?	Low concern
FLOW AND TIMING	
<b>A. risk of bias</b>	
Flow and timing	All patients are accounted for in the results but the number of true negatives and false negatives could not be ascertained from the reported results.
Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	Yes
Could the patient flow have introduced bias?	Low risk
NOTES	Type of urological cancer found in the 409 haematuria patients: Bladder: N = 34, other urological cancer: N = 8. All these cancers were included in the meta-analysis.
1	
2	<b>Collins (2013)</b>
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Retrospective patient series using the THIN database.
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
Could the selection of patients have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	A total of 2145133 patients (1063355 men, 1081778 women) were identified from 364 practices. <u>Symptoms:</u>

	<p>Haemoglobin &lt; 11 g/dl recorded in the last year (N = 16961; 3969 men, 12992 women), abdominal pain (N = 253344; 105247 men, 148097 women), appetite loss (N = 6097; 2616 men, 3481 women), weight loss (N = 29369; 13332 men, 16037 women), haematuria (N = 37810; 22810 men, 15000 women), previous diagnosis of cancer apart from renal tract cancer at study entry (N = 49303; 18130 men, 31173 women).</p> <p><u>Incident cases of renal tract cancer during the 2-year follow up period:</u> N = 2283 (1685 men, 598 women).</p> <p><u>Inclusion criteria:</u> Patients aged 30–84 years and registered with practices between 1 January 2000 and 30 June 2008. Entry to the cohort was defined as the latest of the study start date; the date the patient registered with the practice; and for those patients with red flag symptoms (e.g., haematuria, abdominal pain, weight loss, appetite loss, and anaemia), the date of the first recorded onset within the study period.</p> <p><u>Exclusion criteria:</u> Patients with a prior diagnosis of renal tract cancer, registered less than 12 months with the general practice, had invalid dates, &lt; 30 years old or ≥ 85 years old.</p> <p><u>Clinical setting:</u> Primary care, UK</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	'Red-flag' symptoms were defined as symptoms that might alarm the patient and also indicate the presence of renal tract cancer; that is, symptoms of haematuria, loss of appetite, weight loss, or abdominal pain.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
<b>Reference standard(s)</b>	Renal tract cancer, which was defined as incident diagnosis of cancer of the bladder, kidney, ureter, or urethra during the 2 years after study entry, recorded either on the patient's GP record using the relevant UK diagnostic Read Codes. Patients without the outcome were censored at the earliest of the date of death, date of leaving the practice study of 2 years of follow up.
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>

<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients seem to be accounted for
Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	Yes
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	It is unclear why no data has been presented for men for the symptoms of appetite loss and weight loss.

1

2

**Friedlander (2014)**

<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Retrospective cohort study, using claims data and laboratory values from the Vanderbilt University Medical Centre's (VUMC) Research Derivative, which is a "data repository that contains administrative and clinical information, including a complete record of visits and admissions, laboratory data, and diagnosis and procedure codes, on every patient treated in the Vanderbilt health system" (p 634) located in Tennessee in the USA.
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes (probably)
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>N = 2455 patients, 724 males / 1731 females, median (inter-quartile range) age = 58 (49-68) years; smoking history: current smoker (N = 406), former smoker (N = 473), non-smoker (N = 1514).</p> <p><u>Inclusion criteria</u>: "Patients aged <math>\geq</math> 40 years with a first diagnosis of hematuria" "between 2004 and 2012 by urinalysis (<math>&gt;</math>3 red blood counts per high power field) or International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes for hematuria (599.7, 599.70, 599.71 or 599.72) at one of the VUMC's 19 primary care clinics. To be included in the study, patients must have had records for 1 year before the date of hematuria diagnosis."</p> <p><u>Exclusion criteria</u>: "Patients were excluded if they had a urinary tract infection (defined as a urinalysis positive for both leukocyte esterase and urine nitrites, or a positive urine culture) within 4 weeks before or 1 week after the index hematuria episode (n = 590, 9.0%) or had a prior explanatory diagnoses and procedures that would preclude the need for a hematuria evaluation (according to a convened panel of content experts; prostate/renal/bladder/other cancer, benign prostate/renal/bladder/other mass, prostate dysplasia, cystitis, urethritis, epididymitis/orchitis, prostatitis, pyelonephritis, urolithiasis, prostatic enlargement, trauma, medical renal disease, haematologic/thrombotic disease?, anatomic abnormality, prostatectomy, prostate biopsy, transurethral incision of prostate, resection of prostate, cystoscopy, cystectomy, ureteroscopy, nephrectomy,</p>

	pyeloplasty, ureteral reimplantation).” We then used Physicians Current Procedural Terminology Coding System, 4th Edition and ICD-9 codes to exclude patients with an explanatory diagnosis or procedure within 180 days preceding their hematuria diagnosis (n = 3540, 53.8%).” Clinical setting: Primary care, USA.
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	First diagnosis of hematuria” “by urinalysis (>3 red blood counts per high power field) or International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes for hematuria (599.7, 599.70, 599.71 or 599.72)”.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
<b>Reference standard(s)</b>	The reference standard consisted checking the database for diagnoses of genitourinary neoplasms within 180 days after haematuria diagnosis, as determined by ICD-9 codes.
Is the reference standard likely to correctly classify the target condition?	<b>Unclear (is 180 days enough time to get a diagnosis of all cancers?)</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear (but all patients had a positive index test)</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
<b>Flow and timing</b>	All patients appear to be accounted for.
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	There were 66 patients with cancer: Bladder (N = 33), renal cell (N = 16), prostate (N = 15). The types of cancer for the remaining two cases were not reported.
<b>Hippisley-Cox (2012)</b>	
<b>PATIENT SELECTION</b>	

1  
2

<b>A. risk of bias</b>	
Patient sampling	Prospective patient series using patients in the QResearch database (version 30).
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>A total of 1240722 patients were identified from 189 practices (622166 males, 618556 females), mean (SD) age = 50.1 (14.9) years, mean (SD) Townsend score = -0.2 (3.6).</p> <p><u>Current symptoms and symptoms in the preceding year:</u>            Current haematuria (N = 25553), current abdominal pain (N = 128721), current appetite loss (N = 5531), current weight loss (N = 14464), constipation in the last year (N = 8472), diarrhoea in the last year (N = 12171), tiredness in the last year (N = 12669), haemoglobin recoded in the last year (N = 216201), haemoglobin &lt; 11 g/dl in the last year (N = 16169).</p> <p><u>Incident cases of renal tract cancer during the 2-year follow up period:</u>            N = 1622; mean age at diagnosis = 70 years, 1187 males/ 435 females; <b>Type of cancer: Bladder: N = 1292; Kidney: N = 307; Ureter: N = 21; Urethra: N = 2.</b></p> <p><u>Inclusion criteria:</u>            All practices in England and Wales that had been using their Egton Medical Information Systems (EMIS) computer system for ≥ a year were included. Two-thirds of practices were randomly allocated to the derivation dataset and the remaining practices were allocated to the validation dataset. An open cohort of patients aged 30–84 years was identified, drawn from patients registered with practices between 1 January 2000 and 30 September 2010. Entry to the cohort was defined as the latest of the study start date (1 January 2000) and 12 months after the patient registered with the practice, ensuring that all patients had ≥ 12 months' registration prior to study entry. For patients with incident haematuria, appetite loss, weight loss, or abdominal pain, the entry date was the date of the first consultation with the symptom within the study period. <i>The relevant data for the present purposes is only available for the validation cohort, therefore only information pertaining to these patients will be reported.</i></p> <p><u>Exclusion criteria:</u> Patients without a postcode-related Townsend score, patients with a history of renal tract cancer at baseline, and patients with a recorded 'red-flag' (see "Definition of symptom" below) symptom in the 12 months prior to the study entry date.</p> <p><u>Clinical setting:</u> Primary care</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	'Red-flag' symptoms were defined as symptoms that might alarm the patient and also indicate the presence of renal tract cancer; that is, symptoms of haematuria, loss of appetite, weight loss, or abdominal pain.
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes

<b>Could the conduct or interpretation of the index test have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>		<b>Low concern</b>
<b>REFERENCE STANDARD</b>		
<b>A. risk of bias</b>		
Reference standard(s)	Renal tract cancer, which was defined as incident diagnosis of cancer of the bladder, kidney, ureter, or urethra during the 2 years after study entry, recorded either on the patient's GP record using the relevant UK diagnostic Read Codes, or their linked Office for National Statistics cause-of-death record, using the relevant ICD-9 codes (188 or 189) or ICD-10 diagnostic codes (C64–67).	
Is the reference standard likely to correctly classify the target condition?		<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?		<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		<b>Low concern</b>
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	A total of 1342329 patients were initially identified of whom 101607 patients were excluded for the following reasons: No recorded Townsend score (N = 70847), history of renal tract cancer (N = 1506), and $\geq$ one 'red flag' symptom recorded in the 12 months prior to study entry (N = 29254), leaving 1240722 patients. However, data is presented for 967681 / 1240722 patients. The missing data does not appear to include any of the cancer cases, but it is unclear whether some of the missing data includes symptomatic patients, i.e., false positives.	
Was there an appropriate interval between index test and reference standard?		<b>Yes</b>
Did all patients receive the same reference standard?		<b>Yes</b>
Were all patients included in the analysis?		<b>No</b>
<b>Could the patient flow have introduced bias?</b>		<b>High risk</b>
<b>NOTES</b>	Please note, the included cancer cases were for renal tract cancer, not just bladder cancer.	
1		
2 <b>Jones (2007)</b>		
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Retrospective consecutive patient series using patients in the UK's General Practice Research Database.	
Was a consecutive or random sample of patients enrolled?		<b>Yes</b>
Was a case-control design avoided?		<b>Yes</b>

Did the study avoid inappropriate exclusions?	Yes
Could the selection of patients have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>A total of 923605 patients were identified, of whom 762325 were aged <math>\geq 15</math> years.</p> <p>Number of first occurrences in patients with no previous diagnosis of cancer:</p> <p><u>Haematuria</u>: N = 11138, mean (SD) age at first symptom = 58.5 (18.9) years. Patients excluded due to incomplete dates for their first symptom: N = 30. Sex (of final sample): 6385 males, 4723 females.</p> <p><u>Haemoptysis</u>: N = 4822, mean (SD) age at first symptom = 61.6 (18) years. Patients excluded due to incomplete dates for their first symptom: N = 10. Sex (of final sample): 2930 males, 1882 females.</p> <p><u>Dysphagia</u>: N = 6003, mean (SD) age at first symptom = 54.5 (19.4) years. Patients excluded due to incomplete dates for their first symptom: N = 4. Sex (of final sample): 2628 males, 3371 females.</p> <p><u>Rectal bleeding</u>: N = 15314, mean (SD) age at first symptom = 52.5 (18.8) years. Patients excluded due to incomplete dates for their first symptom: N = 25. Sex (of final sample): 7523 males, 7766 females.</p> <p><u>Inclusion criteria</u>: All patients from 128 general practices that provided data of a sufficient standard from 1 January 1994 to 31 December 2000 and which provided exclusively Read coded data, who were aged between 15 and 100 years, whose first ever recorded occurrence of each alarm symptom (haematuria, haemoptysis, dysphagia, or rectal bleeding) was after 31 December 1994 and who had not previously been diagnosed as having any cancer.</p> <p><u>Exclusion criteria</u>: Patients whose date of first symptom or first relevant diagnosis of cancer was before 1 January 1995 and patients with a diagnosis of any other cancer than the ones of interest before the date of the first recorded symptom or before the index cancer diagnosis date if the related symptom was not recorded.</p> <p><u>Clinical setting</u>: Primary care</p>
Are there concerns that the included patients and setting do not match the review question?	Low concern
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	Identification of all patients who ever had symptoms recorded for haematuria, haemoptysis, dysphagia, or rectal bleeding.
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
Could the conduct or interpretation of the index test have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Low concern
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Cancer code in the UK's General Practice Research Database: <u>Haematuria</u> : Urinary tract neoplasms, including neoplasms of the urethra, bladder, ureter, and kidney but excluding neoplasms of the prostate and



	<p>other reproductive organs.  <u>Haemoptysis</u>: Respiratory tract neoplasms.  <u>Dysphagia</u>: Oesophageal neoplasms.  <u>Rectal bleeding</u>: Colorectal neoplasms.</p>
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear (but all patients had a positive index test)</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients are accounted for in the results
Was there an appropriate interval between index test and reference standard?	<b>Unclear</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	<p>Diagnoses of cancer were most often made in the first three months after the onset of alarm symptoms; very few diagnoses of cancer were made later than three years after symptom onset. In the 4th and 5th years of study, the small number of observed occurrences of cancer was similar to the number expected from background incidence rates.</p> <p>Secondary analyses evaluating whether the incidence of neoplasms other than those prespecified was increased after the occurrence of alarm symptoms showed for:</p> <p><u>Haematuria</u>: Inclusion of cancers of the reproductive organs yielded 21 additional cancers in women and 158 cancers in men, mostly cancers of the prostate. Inclusion of these cancers in the analysis would give a positive predictive value of 3.9% in women and 9.9% in men.</p> <p><u>Dysphagia</u>: Inclusion of gastric cancers yielded 17 additional cancer diagnoses in women and 30 in men. Inclusion of these cancers gave positive predictive values of 5.2% in women and 6.9% in men.</p> <p><i>Estimates based on the pre-specified cancers may be thus conservative for these symptoms.</i></p> <p><u>Haemoptysis</u>: Extension of the diagnostic criteria yielded 6 additional cancers.</p> <p><u>Rectal bleeding</u>: Extension of the diagnostic criteria yielded 2 additional cancers.</p>
1	
2	<b>Shephard (2012)/Price (2014)</b>
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Matched case-control study using patients in the UK's General Practice Research Database.

Was a consecutive or random sample of patients enrolled?	No
Was a case-control design avoided?	No
Did the study avoid inappropriate exclusions?	Yes
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?	Yes
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?	Yes
<b>Could the selection of patients have introduced bias?</b>	<b>High risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p><u>Cases:</u> Males: 3563 patients, median age at diagnosis = 73 (IQR = 65-80) years, median number of consultations = 14 (IQR = 9-22), UK. Females: 1352 patients, median age at diagnosis = 75 (IQR = 67-82) years, median number of consultations = 15 (IQR = 10-23), UK.</p> <p><u>Controls:</u> Males: 15452 patients, median age at diagnosis = 73 (IQR = 66-79) years, median number of consultations = 8 (IQR = 4-15), UK. Females: 6266 patients, median age at diagnosis = 75 (IQR = 67-82) years, median number of consultations = 9 (IQR = 4-15), UK.</p> <p><u>Inclusion criteria:</u> Cases: Patients with a first record of bladder cancer between January 2000 and December 2009 inclusive, aged ≥ 40 years, with min. 1 year of data before diagnosis. The first instance of a bladder cancer code was assigned the data of diagnosis/index date. Controls: Up to 5 controls were matched on sex, general practice, and to 1 year of age of the case. The index date was the index date of the matched case.</p> <p><u>Exclusion criteria:</u> Metastatic cancer of the bladder from a non-bladder primary, diagnosis before 2000, or no consultations in the year before diagnosis.</p> <p><u>Clinical setting:</u> Primary care</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	A list of symptoms, signs and investigations (features) potentially associated with bladder cancer was compiled from the authors' literature search, augmented by viewing material from bladder cancer support organisations and online chat rooms. Internet search terms included 'bladder cancer', 'bladder symptoms', and 'early signs/indications'. Visible and non-visible haematuria were studied separately. Only codes specifying the word 'microscopic' were assigned to the latter group, so generic codes such as the single word 'haematuria' were assumed to be visible haematuria. For each feature a list of relevant medical codes from the GPRD's master list of over 100,000 codes was assembled. Occurrences of these in the year before the index date were identified. Repeated consultations for the same complaint were also identified along with all codes for fractures as a test for any

	recording bias between cases and controls (making the assumption that the fracture rate would be approximately equal). Variables were retained only if they occurred in at least 5% of either cases or controls (this was always cases). Investigation results were deemed to be abnormal if they fell outside their local laboratory's normal range: for analysis, patients with a normal laboratory result were grouped with those who had not been tested.
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?	Yes
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	Low risk
<b><u>B. Concerns regarding applicability</u></b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	Low concern
<b>REFERENCE STANDARD</b>	
<b><u>A. risk of bias</u></b>	
Reference standard(s)	Bladder cancer code in the UK's General Practice Research Database.
Is the reference standard likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	Unclear
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	Low risk
<b><u>B. Concerns regarding applicability</u></b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	Low concern
<b>FLOW AND TIMING</b>	
<b><u>A. risk of bias</u></b>	
Flow and timing	A total of 29033 patients were identified, 24098 controls and 4935 cases. Of the controls the following exclusions were applied: bladder cancer post-2000 (N = 134), bladder control [?] pre-2000 (N = 125), metastatic cancer (N = 35), and no data in year pre-index date (N = 2086). Of the cases the following exclusions were applied: No controls (N = 13), metastatic cancer (N = 7).
Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	Yes
<b>Could the patient flow have introduced bias?</b>	Low risk
<b>NOTES</b>	43 symptoms and 104 abnormal test results were considered initially. 6 symptoms and 7 abnormal test variables were present in $\geq 5\%$ of cases. The proportion of patients with a recorded fracture did not differ between cases (1.45%) and controls (1.46%).  The authors have published extra analyses of the same data in an additional paper (Price, 2014) wherein the data analysis is extended to the uncoded

	data in the CPRD, namely ‘free text’ notes added by GPs to augment a coded entry in a patient’s record. In particular, the authors “sought to identify whether there were sufficient additional non-visible haematuria entries to allow reliable estimates of its association with bladder cancer.”
--	---

1

2 **References**3 **Included studies**

4 Bruyninckx, R., Buntinx, F., Aertgeerts, B., and Van, Casteren, V. The diagnostic value of macroscopic  
5 haematuria for the diagnosis of urological cancer in general practice. *British Journal of General  
6 Practice* 53[486], 31-35. 1-1-2003.

7 Collins, G.S., and Altman, D.G. Identifying patients with undetected renal tract cancer in primary  
8 care: An independent and external validation of QCancer (renal) prediction model. *Cancer  
9 Epidemiology*, 37, 115-120. 2013.

10 Friedlander, D.F., Resnick, M.J., You, C., Bassett, J., Yarlagadda V., Penson, D.F., Barocas D.A.  
11 Variation in the intensity of hematuria evaluation: A target for primary care quality  
12 improvement. *American Journal of Medicine*, 127, 633-640. 2014.

13 Hippisley-Cox, J. and Coupland, C. Identifying patients with suspected renal tract cancer in primary  
14 care: derivation and validation of an algorithm. *British Journal of General Practice* 62[597], e251-  
15 e260. 2012.

16 Jones, R., Latinovic, R., Charlton, J., and Gulliford, M. C. Alarm symptoms in early diagnosis of cancer  
17 in primary care: cohort study using General Practice Research Database. *BMJ* 334[7602], 1040.  
18 19-5-2007.

19 Shephard, E. A., Stapley, S., Neal, R. D., Rose, P., Walter, F. M., and Hamilton, W. T. Clinical features  
20 of bladder cancer in primary care. *British Journal of General Practice* 62[602], 598-604. 2012.

21 Price, S.J., Shephard, E. A., Stapley, S.A., Barraclough, K., and Hamilton, W. T. The risk of bladder  
22 cancer with non-visible haematuria: A primary care study using electronic records. *British  
23 Journal of General Practice* 64, e584-e589. 2014.

24

25

26 **Excluded studies (with excl reason)**

27 Bladder cancer. Early detection is critical. *Mayo Clinic health letter* (English ed 16[3], 6. 1998.  
28 Excl reason: Narrative review

29 Abbaszadeh, S., Taheri, S., and Nourbala, M. H. Bladder tumor in women with microscopic  
30 hematuria: an Iranian experience and a review of the literature. *Advances in Urology*:231861,  
31 2009. 231861. 2009.

32 Excl reason: Not in PICO (secondary care)

33 Adeniyi, A. American Urological Association--94th annual meeting. 1-6 May 1999, Dallas, USA. *Idrugs*  
34 2[7], 656-658. 1999.

35 Excl reason: Narrative review/meeting summary

36 Akan, S., Yuksel, O., Ozbay, N., Uruc, F. & Verit, A. (2014) - A rare entity of benign bladder neoplasm:  
37 female lipoma. - *Georgian Medical News*, 17-20.

38 Not in PICO

39 Ali-El-Dein, B., El-Sobky, E., El-Baz, M., and Shaaban, A. A. Abdominal and pelvic extra-adrenal  
40 paraganglioma: A review of literature and a report on 7 cases. *In Vivo* 16[4], 249-254. 2002.

41 Excl reason: Not in PICO

42 Allen, D., Popert, R., and O'Brien, T. The two-week-wait cancer initiative in urology: useful  
43 modernization? *Journal of the Royal Society of Medicine* 97[6], 279-281. 2004.

44 Excl reason: Not in PICO

- 1 Altwein, J. E. [Dysuria. Typical symptoms for proper diagnosis]. [German]. *MMW Fortschritte der*  
2 *Medizin* 143, Suppl-30. 2001.  
3 Excl reason: Narrative review
- 4 Amin, M. F. & Abd El Hamid, A. M. (2013) The diagnostic accuracy of multidetector computed  
5 tomography with multiplanar reformatted imaging and virtual cystoscopy in the early detection  
6 and evaluation of bladder carcinoma: comparison with conventional cystoscopy. *Abdominal*  
7 *Imaging*, 38: 184-192.  
8 Not in PICO
- 9 Amling, C. L. Diagnosis and management of superficial bladder cancer. *Current Problems in Cancer*  
10 25[4], 219-278. 2001.  
11 Excl reason: Narrative review
- 12 Andreyev, H. J., Vlavianos, P., Blake, P., Dearnaley, D., Norman, A. R., and Tait, D. Gastrointestinal  
13 symptoms after pelvic radiotherapy: role for the gastroenterologist? *International Journal of*  
14 *Radiation Oncology, Biology, Physics* 62[5], 1464-1471. 1-8-2005.  
15 Excl reason: Not in PICO
- 16 Arzimanoglou, I. I., Gilbert, F., and Barber, H. R. Microsatellite instability in human solid tumors.  
17 [Review] [132 refs]. *Cancer* 82[10], 1808-1820. 15-5-1998.  
18 Excl reason: Not in PICO
- 19 Attallah, A. M., el-Didi, M., Seif, F., el-Mohamady, H., and Dalbagni, G. Comparative study between  
20 cytology and dot-ELISA for early detection of bladder cancer. *American Journal of Clinical*  
21 *Pathology* 105[1], 109-114. 1996.  
22 Excl reason: Not in PICO
- 23 Banek, S., Schwentner, C., Tager, D., Pesch, B., Nasterlack, M., Leng, G., Gawrych, K., Bonberg, N.,  
24 Johnen, G., Kluckert, M., Gakis, G., Todenhofer, T., Hennenlotter, J., Bruning, T. & Stenzl, A.  
25 (2013) Prospective evaluation of fluorescence-in situ-hybridization to detect bladder cancer:  
26 Results from the UroScreen-Study. *Urologic Oncology: Seminars and Original Investigations*, 31:  
27 1656-1662.  
28 Not in PICO
- 29 Baniel, J. and Vishna, T. Primary transitional cell carcinoma in vesical diverticula. *Urology* 50[5], 697-  
30 699. 1997.  
31 Excl reason: Not in PICO
- 32 Basak, M., Ozkurt, H., Tanriverdi, O., Cay, E., Aydin, M., and Miroglu, C. Sixteen-slice multidetector  
33 computed tomographic virtual cystoscopy in the evaluation of a patient with suspected bladder  
34 tumor and history of bladder carcinoma operation. *Journal of Computer Assisted Tomography*  
35 33[6], 867-871. 2009.  
36 Excl reason: Not in PICO
- 37 Bassett, J. C., Gore, J. L., McCarthy, W. J., Morrison, C., Kwan, L., Bennett, C. J., Cookson, M. S.,  
38 Penson, D. F. & Saigal, C. (2013) Introduction of a tobacco-screening initiative for those at risk for  
39 bladder cancer in a high volume urology clinic. *Journal of Clinical Oncology*, 31.  
40 Not in PICO
- 41 Bassett, J., Alvarez, J. A., You, C., Koyama, T., Ni, S., Penson, D. & Barocas, D. (2014) Gender, race,  
42 and variation in the workup of hematuria. *Journal of Urology*, 191: e62-e63.  
43 Published as abstract only. Not enough information can be extracted to ascertain the relevance  
44 of the study.
- 45 Batool, A., Ramachandran, R., Dubrovskaya, V. & Lee, D. (2013) Recurrent urothelial cancer  
46 masquerading as a large colonic mass and massive gastrointestinal hemorrhage. *American*  
47 *Journal of Gastroenterology*, 108: S458-S459.  
48 Not in PICO
- 49 Baughan, P., O'Neill, B., and Fletcher, E. Auditing the diagnosis of cancer in primary care: the  
50 experience in Scotland. *British Journal of Cancer* 101, Suppl-91. 3-12-2009.  
51 Excl reason: Not in PICO

- 1 Begara, Morillas F., Silmi, Moyano A., Espinosa, Fernandez B., Prieto, Chiparro L., Rapariz, Gonzalez  
2 M., Gonzalez Morales, M. L., Martin, Rodilla C., Bravo de Rueda, Accinelli C., and Resel, Estevez L.  
3 [Bladder amyloidosis in a female patient with suspected bladder carcinoma]. [Spanish]. Archivos  
4 Espanoles de Urologia 47[2], 176-179. 1994.  
5 Excl reason: Not in PICO
- 6 Bevers, R. F., Battermann, J. J., Gietema, J. A., Hulsbergen-Van de Kaa CA, de Reijke, T. M., Feller, N.,  
7 Witjes, J. A., De Nederlandse Vereniging voor Urologie, and Vereniging van Integrale  
8 Kankercentra (VIKC). [Guideline on urothelial carcinoma of the bladder]. [Dutch]. Nederlands  
9 Tijdschrift Voor Geneeskunde 153, A956. 2009.  
10 Excl reason: Guideline/narrative review
- 11 Bhatia, S. and Landier, W. Evaluating survivors of pediatric cancer. Cancer Journal 11[4], 340-354.  
12 2005.  
13 Excl reason: Not in PICO
- 14 Blanker, M. H., Bohnen, A. M., Groeneveld, F. P. M. J., Bernsen, R. M. D., Prins, A., Thomas, S., and  
15 Bosch, J. L. H. R. Erectile dysfunction amongst men aged 50 years and over: Prevalence, risk  
16 factors and inconvenience. [Dutch]. Nederlands Tijdschrift Voor Geneeskunde 145[29], 1404-  
17 1409. 21-7-2001.  
18 Excl reason: Not in PICO
- 19 Blanker, M. H. [Diagnosis of urothelial carcinoma by the general practitioner--significance of  
20 haematuria]. [Dutch]. Nederlands Tijdschrift Voor Geneeskunde 153, A1198. 2009.  
21 Excl reason: Narrative review
- 22 Blick, C., Bailey, D., Haldar, N., Bdesha, A., Kelleher, J., and Muneer, A. The impact of the two-week  
23 wait rule on the diagnosis and management of bladder cancer in a single UK institution. Annals  
24 of the Royal College of Surgeons of England 92[1], 46-50. 2010.  
25 Excl reason: Not in PICO
- 26 Blochlinger, A. M., Gasser, T. C., Stoffel, F., Laschke, S., and Buhring, C. Hematuria. [German].  
27 Therapeutische Umschau Revue[9], 672-675. 1996.  
28 Excl reason: Narrative review
- 29 Bock-Oruma, A. A., Dienye, P. O. & Oghu, I. S. (2013) Prevalence of lower urinary tract symptoms  
30 suggestive of benign prostatic hyperplasia in primary care, Port Harcourt, Nigeria. *South African*  
31 *Family Practice*, 55: 467-472.  
32 Not in PICO
- 33 Boman, H., Hedelin, H., and Holmang, S. The results of routine evaluation of adult patients with  
34 haematuria analysed according to referral form information with 2-year follow-up. Scandinavian  
35 Journal of Urology and Nephrology 35[6], 497-501. 2001.  
36 Excl reason: Not in PICO
- 37 Borchini, R., Bonzini, M., Veronesi, G., Fava, C., Carezzi, M. C., Mombelli, S., Marconi, A., Bono, A. V.,  
38 and Ferrario, M. M. [Validation of a screening method for occupational bladder cancer]. [Italian].  
39 Medicina del Lavoro 100[6], 438-447. 2009.  
40 Excl reason: Not in PICO
- 41 Botteman, M. F., Pashos, C. L., Redaelli, A., Laskin, B., and Hauser, R. The Health Economics of  
42 Bladder Cancer: A Comprehensive Review of the Published Literature. Pharmacoeconomics  
43 21[18], 1315-1330. 2003.  
44 Excl reason: Not in PICO
- 45 Bowden, E. A. and Foley, S. J. Haematuria; a late complication of TURP? Prostate Cancer and  
46 Prostatic Diseases 4[3], 178-179. 2001.  
47 Excl reason: Not in PICO
- 48 Bremnor, J. D. and Sadovsky, R. Evaluation of dysuria in adults. American Family Physician 65[8],  
49 1589-1597. 15-4-2002.  
50 Excl reason: Narrative review

- 1 Britton, J. P., Dowell, A. C., and Whelan, P. Dipstick haematuria and bladder cancer in men over 60:  
2 results of a community study. *BMJ* 299[6706], 1010-1012. 21-10-1989.  
3 Excl reason: Not in PICO
- 4 Britton, J. P., Dowell, A. C., Whelan, P., and Harris, C. M. A community study of bladder cancer  
5 screening by the detection of occult urinary bleeding. *Journal of Urology* 148[3 I], 788-790. 1992.  
6 Excl reason: Not in PICO
- 7 Britton, J. P. Effectiveness of haematuria clinics. [Review] [37 refs]. *British Journal of Urology* 71[3],  
8 247-252. 1993.  
9 Excl reason: Narrative review
- 10 Britton, J. P., Dowell, A. C. & Whelan, P. (1989) Dipstick haematuria and bladder cancer in men over  
11 60: results of a community study. *BMJ*, 299: 1010-1012.  
12 Not in PICO
- 13 Brock, M., Martin, W., Sommerer, F., and Noldus, J. [Ductal Adenocarcinoma of the prostate with  
14 infiltration of the bladder. Can radical cystectomy and antiandrogen therapy cure the disease?].  
15 [German]. *Urologe (Aussg.A)* 48[7], 770-773. 2009.  
16 Excl reason: Not in PICO
- 17 Buntinx, F. and Wauters, H. The diagnostic value of macroscopic haematuria in diagnosing urological  
18 cancers: A meta-analysis. *Family Practice* 14[1], 63-68. 1997.  
19 Excl reason: SR, but no studies conducted in primary care included
- 20 Burger, M., Grossman, H. B., Droller, M., Schmidbauer, J., Hermann, G., Dragoescu, O., Ray, E.,  
21 Fradet, Y., Karl, A., Burgues, J. P., Witjes, J. A., Stenzl, A., Jichlinski, P. & Jocham, D. (2013)  
22 Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinic  
23 cystoscopy: A meta-analysis of detection and recurrence based on raw data. *European Urology*,  
24 64: 846-854.  
25 Not in PICO
- 26 Buteau, A., Seideman, C. A., Svatek, R. S., Youssef, R. F., Chakrabarti, G., Reed, G., Bhat, D. & Lotan, Y.  
27 (2014) What is evaluation of hematuria by primary care physicians? Use of electronic medical  
28 records to assess practice patterns with intermediate follow-up. *Urologic Oncology*, 32: 128-134.  
29 Not in PICO
- 30 Caballero Alcantara, J. E., Castro Pita, M. A., Carrero, Lopez, V, Rodriguez, Antolin A., Pamplona,  
31 Casamayor M., and Leiva, Galvis O. [Leukemoid reaction as a paraneoplastic manifestation of  
32 bladder carcinoma]. [Spanish]. *Actas Urológicas Españolas* 15[5], 496-499. 1991.  
33 Excl reason: Not in PICO
- 34 Cai, T. and Bartoletti, R. Long-term outcome of hematuria home screening for bladder cancer in  
35 men. *Cancer* 109[9], 1923-1924. 2007.  
36 Excl reason: Not in PICO
- 37 Chakarov, S. Hematuria. *General Medicine* 4[1], 14-19. 2002.  
38 Excl reason: Narrative review
- 39 Chan, E. S., Ng, C. F., Hou, S. M., and Yip, S. K. Using urine microscopy and cytology for early  
40 detection of bladder cancer in male patients with lower urinary tract symptoms. *International*  
41 *Urology & Nephrology* 43[2], 289-294. 2011.  
42 Excl reason: Not in PICO
- 43 Chen, K. S., Lai, M. K., Huang, C. C., Chu, S. H., and Leu, M. L. Urologic cancers in uremic patients.  
44 *American Journal of Kidney Diseases* 25[5], 694-700. 1995.  
45 Excl reason: Not in PICO
- 46 Chiong, E., Gaston, K. E., and Grossman, H. B. Urinary markers in screening patients with hematuria.  
47 [Review] [44 refs]. *World Journal of Urology* 26[1], 25-30. 2008.  
48 Excl reason: Narrative review
- 49 Chou, R. and Dana, T. Screening adults for bladder cancer: update of the 2004 evidence review for  
50 the U.S. Preventive Services Task Force (DARE structured abstract). Agency for Healthcare

- 1 Research and Quality , 1. 2010.  
2 Excl reason: Not in PICO
- 3 Crocetti, E., Arniani, S., and Buiatti, E. Synchronous and metachronous diagnosis of multiple primary  
4 cancers. *Tumori* 84[1], 9-13. 1998.  
5 Excl reason: Not in PICO
- 6 Datta, S. N., Allen, G. M., Evans, R., Vaughton, K. C., and Lucas, M. G. Urinary tract ultrasonography in  
7 the evaluation of haematuria - A report of over 1000 cases. *Annals of the Royal College of*  
8 *Surgeons of England* 84[3], 203-205. 2002.  
9 Excl reason: Not in PICO
- 10 De, Ridder D., Van, Poppel H., Demonty, L., D'Hooghe, B., Gonsette, R., Carton, H., and Baert, L.  
11 Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. *Journal of*  
12 *Urology* 159[6], 1881-1884. 1998.  
13 Excl reason: Not in PICO
- 14 DeSouza, K., Chowdhury, S. & Hughes, S. (2003) - Prompt diagnosis key in bladder cancer. [Review]. -  
15 *Practitioner*, 258: 23-27.  
16 Narrative review
- 17 Dondalski, M., White, E. M., Ghahremani, G. G., and Patel, S. K. Carcinoma arising in urinary bladder  
18 diverticula: Imaging findings in six patients. *American Journal of Roentgenology* 161[4], 817-820.  
19 1993.  
20 Excl reason: Not in PICO
- 21 Donohue, J. F. and Barber, N. J. How do we investigate haematuria and what role has finasteride?  
22 *BJU International* 93[1], 3-4. 2004.  
23 Excl reason: Narrative review
- 24 Dregan, A., Moller, H., Charlton, J. & Gulliford, M. C. (2013) Are alarm symptoms predictive of cancer  
25 survival? Population-based cohort study. *British Journal of General Practice*, 63: E807-E812.  
26 Not in PICO
- 27 Droller, M. J. Primary care update on kidney and bladder cancer - A urologic perspective. *Medical*  
28 *Clinics of North America* 88[2], 309+. 2004.  
29 Excl reason: Narrative review
- 30 Eissa, S., Badr, S., Elhamid, S. A., Helmy, A. S., Nour, M. & Esmat, M. (2013) The value of combined  
31 use of survivin mRNA and matrix metalloproteinase 2 and 9 for bladder cancer detection in  
32 voided urine. *Disease Markers*, 34: 57-62.  
33 Not in PICO
- 34 Eissa, S., Matboli, M., Mansour, A., Mohamed, S., Awad, N. & Kotb, Y. M. (2014) Evaluation of urinary  
35 HURP mRNA as a marker for detection of bladder cancer: relation to bilharziasis. *Medical*  
36 *Oncology*, 31: 804.  
37 Not in PICO
- 38 Elias, K., Svatek, R. S., Gupta, S., Ho, R., and Lotan, Y. High-risk patients with hematuria are not  
39 evaluated according to guideline recommendations. *Cancer* 116[12], 2954-2959. 15-6-2010.  
40 Excl reason: Not in PICO
- 41 Erbersdobler, A., Friedrich, M. G., Schwaibold, H., Henke, R. P., and Hulan, H. Microsatellite  
42 alterations at chromosomes 9p, 13q, and 17p in nonmuscle-invasive transitional cell carcinomas  
43 of the urinary bladder. *Oncology Research* 10[8], 415-420. 1998.  
44 Excl reason: Not in PICO
- 45 Feifer, A. H., Steinberg, J., Tanguay, S., Aprikian, A. G., Brimo, F., and Kassouf, W. Utility of urine  
46 cytology in the workup of asymptomatic microscopic hematuria in low-risk patients. *Urology*  
47 75[6], 1278-1282. 2010.  
48 Excl reason: Not in PICO
- 49 Feil, G. and Stenzl, A. [Tumor marker tests in bladder cancer]. [Review] [60 refs] [Spanish]. *Actas*  
50 *Urologicas Espanolas* 30[1], 38-45. 2006.  
51 Excl reason: Not in PICO



- 1 Ferre, A., Cordonnier, C., Demailly, M., Hakami, F., Sevestre, H. & Saint, F. (2013) [Bladder tumor  
2 targeting by Hexvix() fluorescence: 4 years results after prospective monocentric evaluation].  
3 [French]. *Progres En Urologie*, 23: 195-202.  
4 Not in PICO
- 5 Fiore, D. C. & Fox, C. L. (2014) Urology and nephrology update: bladder and kidney cancer. *Fp*  
6 *Essentials*, 416: 26-29.  
7 Narrative review
- 8 Fiore, D. C. & Fox, C. L. (2014) - Section three: bladder and kidney cancer. - *Fp Essentials*, 416: 26-29.  
9 Narrative review
- 10 Flores-Carreras, O., Martinez-Espinoza, C. J., Gonzalez-Ruiz, M. I., and Montes-Casillas, Y. E.  
11 [Contribution of bladder biopsy to the study of urogynaecological patient]. [Spanish].  
12 *Ginecologia y Obstetricia de Mexico* 78[3], 187-190. 2010.  
13 Excl reason: Not in PICO
- 14 Foo, K. T. (2013) The role of transabdominal ultrasound in office urology. *Proceedings of Singapore*  
15 *Healthcare*, 22: 125-130.  
16 Narrative review
- 17 Foresman, W. H. and Messing, E. M. Bladder cancer: Natural history, tumor markers, and early  
18 detection strategies. *Seminars in Surgical Oncology* 13[5], 299-306. 1997.  
19 Excl reason: Not in PICO
- 20 Forrest, J. B. Epidemiology and quality of life. [Review] [40 refs]. *Journal of Reproductive Medicine*  
21 51[3:Suppl], Suppl-33. 2006.  
22 Excl reason: Narrative review
- 23 Fossa, S. D., Ous, S., Espetveit, S., and Langmark, F. Patterns of Primary Care and Survival in 336  
24 Consecutive Unselected Norwegian Patients with Bladder-Cancer. *Scandinavian Journal of*  
25 *Urology and Nephrology* 26[2], 131-138. 1992.  
26 Excl reason: Not in PICO
- 27 Friedman, G. D., Hiatt, R. A., Quesenberry, C. P., Jr., Selby, J. V., and Weiss, N. S. Problems in  
28 assessing screening experience in observational studies of screening efficacy: example of  
29 urinalysis screening for bladder cancer. *Journal of Medical Screening* 2[4], 219-223. 1995.  
30 Excl reason: Not in PICO
- 31 Friedman, G. D., Carroll, P. R., Cattolica, E. V., and Hiatt, R. A. Can hematuria be a predictor as well as  
32 a symptom or sign of bladder cancer? *Cancer Epidemiology, Biomarkers & Prevention* 5[12], 993-  
33 996. 1996.  
34 Excl reason: Not in PICO (screening population w/o symptoms, risk based analyses, setting?)
- 35 Gervino, G., Autino, E., Kolomoets, E., Leucci, G., and Balma, M. Diagnosis of bladder cancer at 465  
36 MHz. *Electromagnetic Biology & Medicine* 26[2], 119-134. 2007.  
37 Excl reason: Not in PICO
- 38 Gittens, P. R., Lallas, C. D., Pe, M. L., Perkel, R., Folia, C., and Gomella, L. G. Uro pharmacology for the  
39 primary care physician. *Canadian Journal of Urology* 15, 78-91. 2008.  
40 Excl reason: Not in PICO
- 41 Gittes, R. F. and Nakamura, R. M. Female urethral syndrome. A female prostatitis? *Western Journal*  
42 *of Medicine* 164[5], 435-438. 1996.  
43 Excl reason: Not in PICO
- 44 Goepel, M., Hoffmann, J. A., Piro, M., Rubben, H., and Michel, M. C. Prevalence and physician  
45 awareness of symptoms of urinary bladder dysfunction. *European Urology* 41[3], 234-239. 1-3-  
46 2002.  
47 Excl reason: Not in PICO
- 48 Golijanin, D., Shapiro, A., and Pode, D. Immunostaining of cytokeratin 20 in cells from voided urine  
49 for detection of bladder cancer. *Journal of Urology* 164[6], 1922-1925. 2000.  
50 Excl reason: Not in PICO

- 1 Gomella, L. G., Lallas, C. D., Perkel, R., Folia, C., Hirsch, I., Das, A., and Shenot, P. Uro pharmacology in  
2 primary care: 2010 update. *Canadian Journal of Urology* 17, 35-51. 2010.  
3 Excl reason: Not in PICO
- 4 Gomella, L., Grossman, H. B., Droller, M., Schmidbauer, J., Hermann, G., Dragoescu, O., Ray, E.,  
5 Witjes, A., Karl, A., Stenzl, A., Fradet, Y., Burgues, J. & Jocham, D. (2013) A meta-analysis of blue  
6 light cystoscopy with hexaminolevulinate in patients with non-muscle invasive bladder cancer.  
7 *Journal of Urology*, 189: e528.  
8 Not in PICO
- 9 Gomes, C. A., de Figueiredo, A. A., Soares, Junior C., Bastos Netto, J. M., and Tassi, F. R. [Acute  
10 abdomen: spontaneous bladder rupture as an important differential diagnosis]. [Portuguese].  
11 *Revista do Colegio Brasileiro de Cirurgioes* 36[4], 364-365. 2009.  
12 Excl reason: Not in PICO
- 13 Gontero, P., Oderda, M., Altieri, V., Bartoletti, R., Cai, T., Colombo, R., Curotto, A., Di Stasi, S.,  
14 Maffezzini, M., Tamagno, S., Serretta, V., Sogni, F., Terrone, C., Tizzani, A., Morgia, G., Mirone,  
15 V., and Carmignani, G. Are Referral Centers for Non-Muscle-Invasive Bladder Cancer Compliant  
16 to EAU Guidelines? A Report from the Vesical Antitlastic Therapy Italian Study. *Urologia*  
17 *Internationalis* 86[1], 19-24. 2011.  
18 Excl reason: Not in PICO
- 19 Goodison, S., Rosser, C. J. & Urquidi, V. (2013) Bladder cancer detection and monitoring: assessment  
20 of urine- and blood-based marker tests. [Review]. *Molecular Diagnosis & Therapy*, 17: 71-84.  
21 Narrative review
- 22 Goonewardena, S. A. S., De Silva, W. A. S., and De Silva, M. V. C. Bladder cancer in Sri Lanka:  
23 Experience from a tertiary referral center. *International Journal of Urology* 11[11], 969-972.  
24 2004.  
25 Excl reason: Not in PICO
- 26 Gorich, J., Hasan, I., Kunze, V., Sittek, H., Brensing, K. A., Reiser, M., Layer, G., Rilinger, N., Sokiranski,  
27 R., and Steudel, A. [Intra-arterial treatment of therapy-resistant residual tumors of the pelvis].  
28 [German]. *Strahlentherapie und Onkologie* 171[12], 671-678. 1995.  
29 Excl reason: Not in PICO
- 30 Gorich, J., Hasan, I., Kunze, V., Sittek, H., Brensing, K.-A., Reiser, M., Layer, G., Rilinger, N., Sokiranski,  
31 R., and Steudel, A. Evaluation of intraarterial cancer treatment in recurrent pelvic tumors.  
32 [German]. *Strahlentherapie und Onkologie* 171[12], 671-678. 1995.  
33 Excl reason: Not in PICO
- 34 Gourova, L. W., van de Beek, C., Spigt, M. G., Nieman, F. H., and van Kerrebroeck, P. E. Predictive  
35 factors for nocturia in elderly men: a cross-sectional study in 21 general practices. *BJU*  
36 *International* 97[3], 528-532. 2006.  
37 Excl reason: Not in PICO
- 38 Granberg, S., Wikland, M., and Norstrom, A. Endovaginal ultrasound scanning to identify bladder  
39 tumors as the source of vaginal bleeding in postmenopausal women. *Ultrasound in Obstetrics &*  
40 *Gynecology* 1[1], 63-65. 1-1-1991.  
41 Excl reason: Not in PICO
- 42 Griffiths, T. R. & Action on Bladder Cancer (2013) Current perspectives in bladder cancer  
43 management. [Review]. *International Journal of Clinical Practice*, 67: 435-448.  
44 Narrative review
- 45 Grossfeld, G. D., Wolf, J. S., Litwin, M. S., Hricak, H., Shuler, C. L., Agerter, D. C., and Carroll, P. R.  
46 Asymptomatic microscopic hematuria in adults: Summary of the AUA Best Practice Policy  
47 recommendations. *American Family Physician* 63[6], 1145-1154. 2001.  
48 Excl reason: Guideline
- 49 Hall, C. L. The patient with haematuria. *The Practitioner* 243[1600], 564-571. 5-7-0568.  
50 Excl reason: Narrative review

- 1 Hamid, A. A. (2013) The diagnostic accuracy of multidetector computed tomography with  
2 multiplanar reformatted imaging and virtual cystoscopy in the early detection and evaluation of  
3 bladder carcinoma: Comparison with conventional cystoscopy. *Journal of Endourology*, 27: A165.  
4 Not in PICO
- 5 Hansen, Rikke, Vedsted, Peter, Sokolowski, Ineta, Sondergaard, Jens, and Olesen, Frede. Time  
6 intervals from first symptom to treatment of cancer: a cohort study of 2,212 newly diagnosed  
7 cancer patients. *BMC Health Services Research* 11[1], 284. 2011.  
8 Excl reason: Not in PICO
- 9 Hargunani, R., Al-Dujaily, S., Abdulla, A. K. S., and Osborne, D. R. Haematuria as a presentation of  
10 metastatic oesophageal carcinoma. *International Seminars in Surgical Oncology* 2[1], 4. 2005.  
11 Excl reason: Not in PICO
- 12 Harima, M., Narita, K., Kobayakawa, H., Tsujino, T., Yamamoto, S., Fukushima, S., and Kishimoto, T.  
13 [A case of synchronous triple primary cancers of prostate, kidney and bladder]. [Review] [20  
14 refs] [Japanese]. *Hinyokika Kiyo - Acta Urologica Japonica* 44[9], 675-678. 1998.  
15 Excl reason: Not in PICO
- 16 Harzmann, R. [Early diagnosis of urogenital tumors]. [German]. *Zeitschrift fur Hautkrankheiten* 62[9],  
17 665-676. 681.  
18 Excl reason: Narrative review
- 19 Hasan, S. T., German, K., and Derry, C. D. Same day diagnostic service for new cases of haematuria -  
20 A District General Hospital experience. *British Journal of Urology* 73[2], 152-154. 1994.  
21 Excl reason: Not in PICO
- 22 Hattori, R., Matsuura, O., Takeuchi, N., Hashimoto, J., Ohshima, S., Ono, Y., Kinukawa, T., and  
23 Miyake, K. Clinical importance of microhematuria as an initial sign of bladder tumor. *Japanese*  
24 *Journal of Urology* 81[3], 414-419. 1990.  
25 Excl reason: Not in PICO
- 26 Hautmann, S., Lokeshwar, V. B., and Juenemann, K. P. [Urine-based diagnostics: an update on the  
27 Kiel Tumor Bank]. [Review] [21 refs] [German]. *Urologe (Ausg.A)* 48[6], 619-624. 2009.  
28 Excl reason: Narrative review
- 29 Hawary, A. M., Warburton, H. E., Brough, R. J., Collins, G. N., Brown, S. C., O'Reilly, P. H., and  
30 Adeyoju, A. A. The '2-week wait' rule for referrals for suspected urological cancers--urgent need  
31 for refinement of criteria. *Annals of the Royal College of Surgeons of England* 90[6], 517-522.  
32 2008.  
33 Excl reason: Not in PICO
- 34 Hedelin, H., Boman, H., and Holmang, S. [When is it meaningful to investigate hematuria?  
35 Macroscopic hematuria--investigate always. Microscopic hematuria--symptoms and age decide].  
36 [Swedish]. *Lakartidningen* 98[48], 5498-5500. 20-11-1103.  
37 Excl reason: Not in PICO
- 38 Hedelin, H., Boman, H., and Holmang, S. When is it meaningful to investigate hematuria?  
39 Macroscopic hematuria--investigate always. Microscopic hematuria--symptoms and age decide.  
40 [Swedish]. *Lakartidningen* 98[48], 5498-5500, 5503. 28-3-1955.  
41 Excl reason: Not in PICO
- 42 Hedelin, H., Jonsson, K., Salomonsson, K., and Boman, H. Screening for bladder tumours in men aged  
43 60-70 years with a bladder tumour marker (UBC) and dipstick-detected haematuria using both  
44 white-light and fluorescence cystoscopy. *Scandinavian Journal of Urology & Nephrology* 40[1],  
45 26-30. 2006.  
46 Excl reason: Not in PICO
- 47 Hee, T. G., Shah, S. A., Ann, H. S., Hemdan, S. N., Shen, L. C., Al-Fahmi Abdul, G. N., Singam, P., Ho, C.  
48 C., Hong, G. E., Bahadzor, B. & Zainuddin, Z. M. (2013) Stratifying patients with haematuria into  
49 high or low risk groups for bladder cancer: a novel clinical scoring system. *Asian Pacific Journal of*  
50 *Cancer Prevention: Apjcp*, 14: 6327-6330.  
51 Not in PICO

- 1 Heins, M. J., Korevaar, J. C., Rijken, P. M. & Schellevis, F. G. (2013) For which health problems do  
2 cancer survivors visit their General Practitioner? *European Journal of Cancer*, 49: 211-218.  
3 Not in PICO
- 4 Henning, A., Wehrberger, M., Madersbacher, S., Pycha, A., Martini, T., Comploj, E., Jeschke, K.,  
5 Tripolt, C. & Rauchenwald, M. (2013) Do differences in clinical symptoms and referral patterns  
6 contribute to the gender gap in bladder cancer? *BJU International*, 112: 68-73.  
7 Not in PICO
- 8 Henningsohn, L., Wijkstrom, H., Steven, K., Pedersen, J., Ahlstrand, C., Aus, G., Kallestrup, E. B.,  
9 Bergmark, K., Onelov, E., and Steineck, G. Relative importance of sources of symptom-induced  
10 distress in urinary bladder cancer survivors. *European Urology* 43[6], 651-662. 2003.  
11 Excl reason: Not in PICO
- 12 Herranz, Amo F., Diez Cordero, J. M., Verdu, Tartajo F., Bueno, Chomon G., Leal, Hernandez F., and  
13 Bielsa, Carrillo A. Abdominal pain in patients undergoing radical cystectomy for bladder cancer.  
14 [Spanish]. *Archivos Espanoles de Urologia* 51[4], 342-346. 1998.  
15 Excl reason: Not in PICO
- 16 Herrera, Puerto J., Laguna, Alvarez E., Sevilla, Zabaleta M., Caballero, Gomez M., Soler, Fernandez J.,  
17 Castano Casaseca, J. L., and Asuar, Aydillo S. [Bladder metastasis of a renal cell carcinoma].  
18 [Spanish]. *Archivos Espanoles de Urologia* 43[6], 615-617. 1990.  
19 Excl reason: Not in PICO
- 20 Hirshberg, A. J., Holliman, C. J., Wuerz, R. C., and Chapman, D. M. Case management by physician  
21 assistants and primary care physicians vs emergency physicians. *Academic Emergency Medicine*  
22 4[11], 1046-1052. 1997.  
23 Excl reason: Not in PICO
- 24 Ho, E. T., Johnston, S. R., and Keane, P. F. The haematuria clinic--referral patterns in Northern  
25 Ireland. *The Ulster medical journal* 67[1], 25-28. 1998.  
26 Excl reason: Not in PICO
- 27 Hochreiter, W. Painful micturition (dysuria, algiuria). [German]. *Therapeutische Umschau Revue*[9],  
28 668-671. 1996.  
29 Excl reason: Narrative review
- 30 Hollingsworth, J. M., Zhang, Y. S., Miller, D. C., Skolarus, T. A., Wood, D. P., Lee, C. T., Montie, J. E.,  
31 and Hollenbeck, B. K. Identifying better practices for early-stage bladder cancer. *Medical Care*  
32 49[12], 1112-1117. 2011.  
33 Excl reason: Not in PICO
- 34 Holmang, S. and Johansson, S. L. Impact of diagnostic and treatment delay on survival in patients  
35 with renal pelvic and ureteral cancer. *Scandinavian Journal of Urology & Nephrology* 40[6], 479-  
36 484. 2006.  
37 Excl reason: Not in PICO
- 38 Hooda, M. N., Siddique, F. H., Nabi, S., Islam, M. W., Ara, K. & Bhuiyan, Z. I. (2014) - Clinicopathologic  
39 features and treatment outcome of urinary bladder neoplasm. - *Mymensingh Medical Journal:*  
40 *MMJ*, 23: 341-344.  
41 Not in PICO
- 42 House, A. A. and Cattran, D. C. Nephrology: 2. Evaluation of asymptomatic hematuria and  
43 proteinuria in adult primary care. *Canadian Medical Association Journal* 166[3], 348-353. 2002.  
44 Excl reason: Narrative review
- 45 Huang, C. Y., Shun, C. T., Huang, K. H., Chen, J., and Pu, Y. S. Primary amyloidosis of the urinary  
46 bladder. *Journal of the Formosan Medical Association* 105[2], 164-167. 2006.  
47 Excl reason: Not in PICO
- 48 Hussain, S. A., Stocken, D. D., Peake, D. R., Glaholm, J. G., Zarkar, A., Wallace, D. M., and James, N. D.  
49 Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle  
50 invasive bladder cancer. *British Journal of Cancer* 90[11], 2106-2111. 1-6-2004.  
51 Excl reason: Not in PICO

- 1 Iavarone, C., Forte, F., Bronzetti, E., Minocchi, L., Mezzetti, G., Greco, L., D'Orazi, V., Urciuoli, P., and  
 2 Custureri, F. [Pseudosarcoma of the urinary bladder. Report of a case]. [Review] [8 refs] [Italian].  
 3 *Minerva Urologica e Nefrologica* 52[1], 45-48. 2000.  
 4 Excl reason: Not in PICO
- 5 Ibragimova, M. I., Chushnikov, V. N., Moiseev, V. N., Petukhov, V. I., Zheglov, E. P. & Cherepnev, G. V.  
 6 (2013) [Electron paramagnetic resonance study of blood of anemic patients with urological  
 7 cancer]. [Russian]. *Biofizika*, 58: 289-294.  
 8 Not in PICO
- 9 Jain, M., Kumari, N., Chhabra, P., and Gupta, R. K. Localized amyloidosis of urinary bladder: a  
 10 diagnostic dilemma. *Indian Journal of Pathology & Microbiology* 51[2], 247-249. 2008.  
 11 Excl reason: Not in PICO
- 12 Jiang, X. Z., Xu, C., Zhang, N. Z., and Xu, Z. S. Influence of clinical characteristics and tumor size on  
 13 symptoms of bladder leiomyoma: a pooled analysis of 61 cases. *Chinese Medical Journal*  
 14 125[14], 2436-2439. 2012.  
 15 Excl reason: Not in PICO
- 16 Jichlinski, P. (2014) - [Urology]. [Review] [French]. - *Revue Medicale Suisse*, 10: 127-129.  
 17 Narrative review
- 18 Jimbo, M. Evaluation and management of hematuria. [Review]. *Primary Care; Clinics in Office*  
 19 *Practice* 37[3], 461-472. 20-11-2010.  
 20 Excl reason: Narrative review
- 21 Johnson, E. K., Daignault, S., Zhang, Y., and Lee, C. T. Patterns of hematuria referral to urologists:  
 22 does a gender disparity exist? *Urology* 72[3], 498-502. 502.  
 23 Excl reason: Not in PICO
- 24 Jones, M. W., Cox, R., Davies, K. I., and Rose, M. B. The value of the pre-clinic intravenous urogram in  
 25 the earlier diagnosis of the cause of haematuria. *British Journal of Urology* 62[1], 11-12. 1988.  
 26 Excl reason: Not in PICO
- 27 Kajita, Y., Megumi, Y., and Okabe, T. [Renal carcinoid tumor presenting as bladder tamponade: a  
 28 case report and review of the Japanese cases]. [Review] [10 refs] [Japanese]. *Hinyokika Kyo* -  
 29 *Acta Urologica Japonica* 51[7], 459-462. 2005.  
 30 Excl reason: Not in PICO
- 31 Kamat, A. M., Hegarty, P. K., Gee, J. R., Clark, P. E., Svatek, R. S., Hegarty, N., Shariat, S. F., Xylinas, E.,  
 32 Schmitz-Drager, B. J., Lotan, Y., Jenkins, L. C., Droller, M., van Rhijn, B. W., Karakiewicz, P. I. &  
 33 International Consultation on Urologic Disease-European Association of Urology Consultation on  
 34 Bladder Cancer (2013) ICUD-EAU International Consultation on Bladder Cancer 2012: Screening,  
 35 diagnosis, and molecular markers. [Review]. *European Urology*, 63: 4-15.  
 36 Narrative review
- 37 Kaplan, J. and Loftus, L. Bladder cancer after pelvic irradiation for cervical cancer. *Southern Medical*  
 38 *Journal* 78[9], 1068-1070. 1985.  
 39 Excl reason: Not in PICO
- 40 Karam, J. A., Kabbani, W., and Sagalowsky, A. I. Pseudosarcomatous fibromyxoid tumor of the  
 41 bladder. *Urologic Oncology* 26[3], 291-294. 2008.  
 42 Excl reason: Not in PICO
- 43 Karl, A., Stief, C. & Zaak, D. (2013) [Photodynamic diagnostics of the bladder: current study results].  
 44 [Review] [German]. *Urologe (Auszg.A)*, 52: 504-508.  
 45 Narrative review
- 46 Kazi, J. I., Mubarak, M., Hashmi, A., Hussain, M., Naqvi, S. A., and Rizvi, S. A. H. Spectrum of  
 47 pathological lesions in cystoscopic bladder biopsies - A clinicopathologic study. *Journal of the*  
 48 *College of Physicians and Surgeons Pakistan* 12[12], 744-747. 1-12-2002.  
 49 Excl reason: Not in PICO
- 50 Keeble, S., Abel, G. A., Saunders, C. L., McPhail, S., Walter, F. M., Neal, R. D., Rubin, G. P. &  
 51 Lyratzopoulos, G. (2014) - Variation in promptness of presentation among 10,297 patients

- 1 subsequently diagnosed with one of 18 cancers: evidence from a National Audit of Cancer  
 2 Diagnosis in Primary Care. - *International Journal of Cancer*, 135: 1220-1228.  
 3 Not in PICO
- 4 Kelly, J. D., Fawcett, D. P., and Goldberg, L. C. Assessment and management of non-visible  
 5 haematuria in primary care. *British Medical Journal* 338. 2009.  
 6 Excl reason: Narrative review
- 7 Kelly, J. D., Dudderidge, T. J., Wollenschlaeger, A., Okoturo, O., Burling, K., Tulloch, F., Halsall, I.,  
 8 Prevost, T., Prevost, A. T., Vasconcelos, J. C., Robson, W., Leung, H. Y., Vasdev, N., Pickard, R. S.,  
 9 Williams, G. H., and Stoeber, K. Bladder Cancer Diagnosis and Identification of Clinically  
 10 Significant Disease by Combined Urinary Detection of Mcm5 and Nuclear Matrix Protein 22. *Plos*  
 11 *One* 7[7]. 2012.  
 12 Excl reason: Not in PICO
- 13 Khan, M. A., Shaw, G., and Paris, A. M. I. Is microscopic haematuria a urological emergency? *BJU*  
 14 *International* 90[4], 355-357. 2002.  
 15 Excl reason: Not in PICO
- 16 Khandelwal, C. & Kistler, C. (2013) Diagnosis of urinary incontinence. *American Family Physician*, 87:  
 17 543-551.  
 18 Narrative review
- 19 Kikuchi, T., Yamada, Y., Satoh, T., Honda, N., Katoh, O., Fukatsu, H., and Segawa, A. [A case of  
 20 paraganglioma of the urinary bladder]. [Japanese]. *Hinyokika Kyo - Acta Urologica Japonica*  
 21 29[3], 333-337. 1983.  
 22 Excl reason: Not in PICO
- 23 King, K. & Steggall, M. (2014) - Haematuria: from identification to treatment. - *British Journal of*  
 24 *Nursing*, 23: S28-S32.  
 25 Narrative review
- 26 Kjaer, S. K., Knudsen, J. B., Sorensen, B. L., and Moller, Jensen O. The Copenhagen case-control study  
 27 of bladder cancer. V. Review of the role of urinary-tract infection. [Review] [33 refs]. *Acta*  
 28 *Oncologica* 28[5], 631-636. 1989.  
 29 Excl reason: Not in PICO (risk, not symptoms)
- 30 Klein, F. A. and White, F. K. H. Flow cytometry deoxyribonucleic acid determinations and cytology of  
 31 bladder washings: Practical experience. *Journal of Urology* 139[2], 275-278. 1988.  
 32 Excl reason: Not in PICO
- 33 Kohler, C. and Varenhorst, E. Microscopic hematuria in adults--a diagnostic dilemma. Scientific  
 34 guidelines for management are not available according to a review of the literature. [Swedish].  
 35 *Lakartidningen* 96[45], 4911-4916. 10-11-1999.  
 36 Excl reason: Not in PICO (mixed population that cannot be disentangled)
- 37 Konety, B. R., Lavelle, J. P., Pirtskalaishvili, G., Dhir, R., Meyers, S. A., Nguyen, T. S., Hershberger, P.,  
 38 Shurin, M. R., Johnson, C. S., Trump, D. L., Zeidel, M. L., and Getzenberg, R. H. Effects of vitamin  
 39 D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. *Journal of Urology*  
 40 165[1], 253-258. 2001.  
 41 Excl reason: Not in PICO
- 42 Konety, B. R., Joyce, G. F., and Wise, M. Bladder and upper tract urothelial cancer. *Journal of Urology*  
 43 177[5], 1636-1645. 2007.  
 44 Excl reason: Not in PICO
- 45 Kruck, S., Scharpf, M., Stenzl, A. & Bedke, J. (2013) A rare case of synchronous renal cell carcinoma of  
 46 the bladder presenting with gross hematuria. *Rare Tumors*, 5: 72-74.  
 47 Not in PICO
- 48 Krupski, T. and Theodorescu, D. Orthotopic neobladder following cystectomy: indications,  
 49 management, and outcomes. [Review] [27 refs]. *Journal of Wound, Ostomy, & Continence*  
 50 *Nursing* 28[1], 37-46. 2001.  
 51 Excl reason: Not in PICO

- 1 Kuyumcuoglu, U. and Kale, A. Unusual presentation of a dermoid cyst that derived from the bladder  
2 dome presenting as subserosal leiomyoma uteri. *Clinical & Experimental Obstetrics &*  
3 *Gynecology* 35[4], 309-310. 2008.  
4 Excl reason: Not in PICO
- 5 La, Vecchia C., Negri, E., D'Avanzo, B., Savoldelli, R., and Franceschi, S. Genital and urinary tract  
6 diseases and bladder cancer. *Cancer Research* 51[2], 629-631. 15-1-1991.  
7 Excl reason: Not in PICO
- 8 Lafuente, A., Rodriguez, A., Gibanel, R., Lafuente, M. J., Alonso, M., Molina, R., Ballesta, A., and  
9 Carretero, P. Limitations in the use of glutathione S-transferase P1 in urine as a marker for  
10 bladder cancer. *Anticancer Research* 18[5B], 3771-3772. 1998.  
11 Excl reason: Not in PICO
- 12 Larsson, G. Multiple leiomyomata of the urinary bladder in a hysterectomized woman. *Acta*  
13 *Obstetrica et Gynecologica Scandinavica* 73[1], 78-80. 1994.  
14 Excl reason: Not in PICO
- 15 Lazaro, Santander R., Castillo Gimeno, J. M., Garcia Prats, M. D., Andre, Gozalbo C., and Vera Roman,  
16 J. M. [Intravesical hemangiopericytoma]. [Review] [12 refs] [Spanish]. *Archivos Espanoles de*  
17 *Urologia* 52[7], 797-799. 1999.  
18 Excl reason: Not in PICO
- 19 Lee, M. Y., Tsou, M. H., Cheng, M. H., Chang, D. S., Yang, A. L., and Ko, J. S. Clinical application of  
20 NMP22 and urinary cytology in patients with hematuria or a history of urothelial carcinoma.  
21 *World Journal of Urology* 18[6], 401-405. 2000.  
22 Excl reason: Not in PICO
- 23 Lodde, M., Pycha, A., Palermo, S., Comploj, E., and Hohenfellner, R. Uretero-ureterocutaneostomy  
24 (wrapped by omentum). *BJU International* 95[3], 371-373. 2005.  
25 Excl reason: Not in PICO
- 26 Lokeshwar, V. B. and Soloway, M. S. Current bladder tumor tests: does their projected utility fulfill  
27 clinical necessity?. [Review] [90 refs]. *Journal of Urology* 165[4], 1067-1077. 2001.  
28 Excl reason: Not in PICO
- 29 Lokeshwar, V. B., Habuchi, T., Grossman, H. B., Murphy, W. M., Hautmann, S. H., Hemstreet III, G. P.,  
30 Bono, A. V., Getzenberg, R. H., Goebell, P., Schmitz-Drager, B. J., Schalken, J. A., Fradet, Y.,  
31 Marberger, M., Messing, E., and Droller, M. J. Bladder tumor markers beyond cytology:  
32 International Consensus Panel on bladder tumor markers. *Urology* 66[6 SUPPL. 1], 35-63. 2005.  
33 Excl reason: Not in PICO
- 34 Lopes, R. I., Nogueira, L., Albertotti, C. J., Takahashi, D. Y., and Lopes, R. N. Comparison of virtual  
35 cystoscopy and transabdominal ultrasonography with conventional cystoscopy for bladder  
36 tumor detection. *Journal of Endourology* 22[8], 1725-1729. 2008.  
37 Excl reason: Not in PICO
- 38 Lotan, Y., Elias, K., Svatek, R. S., Bagrodia, A., Nuss, G., Moran, B., and Sagalowsky, A. I. Bladder  
39 cancer screening in a high risk asymptomatic population using a point of care urine based  
40 protein tumor marker. *Journal of Urology* 182[1], 52-57. 20-11-1958.  
41 Excl reason: Not in PICO
- 42 Ludecke, G., Pilatz, A., Hauptmann, A., Bschiepfer, T., and Weidner, W. Comparative analysis of  
43 sensitivity to blood in the urine for urine-based point-of-care assays (UBC rapid, NMP22  
44 BladderChek and BTA-stat) in primary diagnosis of bladder carcinoma. Interference of blood on  
45 the results of urine-based POC tests. *Anticancer Research* 32[5], 2015-2018. 2012.  
46 Excl reason: Not in PICO
- 47 Lynch, T. H., Waymont, B., Dunn, J. A., Hughes, M. A., and Wallace, D. M. Rapid diagnostic service for  
48 patients with haematuria. *British Journal of Urology* 73[2], 147-151. 1994.  
49 Excl reason: Same as Lynch 1994

- 1 Lynch, T. H., Waymont, B., Dunn, J. A., Hughes, M. A., and Wallace, D. M. Repeat testing for  
2 haematuria and underlying urological pathology. *British Journal of Urology* 74[6], 730-732. 1994.  
3 Excl reason: Not in PICO (selected referred population). Same as Lynch 1994
- 4 Lyratzopoulos, G., Abel, G. A., McPhail, S., Neal, R. D. & Rubin, G. P. (2013) Gender inequalities in the  
5 promptness of diagnosis of bladder and renal cancer after symptomatic presentation: Evidence  
6 from secondary analysis of an English primary care audit survey. *BMJ Open*, 3.  
7 Not in PICO
- 8 Mack, D. and Jakse, G. [Bladder cancer as an incidental finding]. [German]. *Wiener Klinische*  
9 *Wochenschrift* 98[6], 175-178. 21-3-1986.  
10 Excl reason: Not in PICO
- 11 Maguire, A., Porta, M., Malats, N., Gallen, M., Pinol, J. L., Fernandez, E., Planas, J., Gomez, G.,  
12 Digiacomio, S., Guallar, E., Calle, M. L., Grifol, E., and Saez, M. Cancer Survival and the Duration of  
13 Symptoms - An Analysis of Possible Forms of the Risk-Function. *European Journal of Cancer*  
14 30A[6], 785-792. 1994.  
15 Excl reason: Not in PICO
- 16 Manassero, A., Chierchia, S. & Carone, R. (2013) Neurogenic lower urinary tract dysfunctions and  
17 bladder cancer: Our experience and proposal of evaluation algorithm. *Neurourology and*  
18 *Urodynamics*, 32: S15-S16.  
19 Not in PICO
- 20 Mansson, A., Anderson, H., and Colleen, S. Time lag to diagnosis of bladder cancer-influence of  
21 psychosocial parameters and level of health-care provision. *Scandinavian Journal of Urology and*  
22 *Nephrology* 27[3], 363-369. 1993.  
23 Excl reason: Not in PICO
- 24 Mantadakis, E., Panagiotidis, C., Delakas, D., and Samonis, G. Symptomatic relief of patients with  
25 advanced bladder carcinoma after regional intra-arterial chemotherapy. *Anticancer Research*  
26 23[6D], 5143-5147. 2003.  
27 Excl reason: Not in PICO
- 28 Mao, L. Genetic alterations as clonal markers for bladder cancer detection in urine. [Review] [39  
29 refs]. *Journal of Cellular Biochemistry - Supplement* 25, 191-196. 1996.  
30 Excl reason: Not in PICO
- 31 Mariani, A., Cha, S. S., Bergstralh, E. J., Boardman, L. A., Dowdy, S. C., Keeney, G. L., Podratz, K. C.,  
32 and Melton, L. J., III. Referral and ascertainment bias in patients with synchronous and  
33 metachronous endometrial malignancy. *European Journal of Gynaecological Oncology* 31[1], 5-  
34 9. 2010.  
35 Excl reason: Not in PICO
- 36 Marlin, E. S., Hyams, E. S., Dulabon, L., and Shah, O. Metastatic esophageal adenocarcinoma to the  
37 prostate presenting with bilateral ureteral obstruction. *Canadian Journal of Urology* 17[1], 5035-  
38 5037. 2010.  
39 Excl reason: Not in PICO
- 40 Mason, T. J. and Vogler, W. J. Bladder cancer screening at the Dupont Chambers Works: a new  
41 initiative. *Journal of Occupational Medicine* 32[9], 874-877. 1990.  
42 Excl reason: Not in PICO
- 43 Mason, T. J., Walsh, W. P., Lee, K., and Vogler, W. New opportunities for screening and early  
44 detection of bladder cancer. *Journal of Cellular Biochemistry Supplement.*, 13-22. 1992.  
45 Excl reason: Not in PICO
- 46 Matsumoto, K., Irie, A., Satoh, T., Kuruma, H., Arakawa, T., and Baba, S. Occupational bladder cancer:  
47 From cohort study to biologic molecular marker. *Medical Science Monitor* 11[10], RA311-RA315.  
48 2005.  
49 Excl reason: Not in PICO
- 50 Matsuo, H., Kato, T., Hirai, T., Kodera, Y., Kito, T., and Nakamura, H. A case of cancerous familial  
51 adenomatous polyposis in urinary bladder due to migration of colonic mucosa through



- 1 rectovesical fistula. *American Journal of Gastroenterology* 95[5], 1352-1354. 2000.  
 2 Excl reason: Not in PICO
- 3 Matzkin, H. and Merimsky, E. [Paraneoplastic syndromes in cancer of the bladder. Review of the  
 4 literature]. [French]. *Journal d Urologie* 93[2], 77-79. 1987.  
 5 Excl reason: Not in PICO
- 6 Mayfield, M. P. and Whelan, P. Bladder tumours detected on screening: results at 7 years. *British*  
 7 *Journal of Urology* 82[6], 825-828. 1998.  
 8 Excl reason: Not in PICO
- 9 Mayr, R. & Burger, M. (2013) Value of fluorescence cystoscopy in high risk non-muscle invasive  
 10 bladder cancer. *Current Urology Reports*, 14: 90-93.  
 11 Narrative review
- 12 Mebel, M. and Vogler, H. Special problems of early detection of malignant tumors of the genito-  
 13 urinary system (author's transl). [German]. *Archiv fur Geschwulstforschung* 51[8], 679-684.  
 14 1981.  
 15 Excl reason: Not in PICO
- 16 Meeks, J. J., Herr, H. W., Bernstein, M., Al-Ahmadie, H. A. & Dalbagni, G. (2013) Preoperative  
 17 accuracy of diagnostic evaluation of the urachal mass. *Journal of Urology*, 189: 1260-1262.  
 18 Not in PICO
- 19 Messing, E. M., Young, T. B., Hunt, V. B., Gilchrist, K. W., Newton, M. A., Bram, L. L., Hisgen, W. J.,  
 20 Greenberg, E. B., Kuglitsch, M. E., and Wegenke, J. D. Comparison of bladder cancer outcome in  
 21 men undergoing hematuria home screening versus those with standard clinical presentations.  
 22 *Urology* 45[3], 387-396. 396.  
 23 Excl reason: Not in PICO
- 24 Messing, E. M. and Vaillancourt, A. Hematuria screening for bladder cancer. *Journal of Occupational*  
 25 *Medicine* 32[9], 838-845. 1990.  
 26 Excl reason: Not in PICO
- 27 Messing, E. M., Young, T. B., Hunt, V. B., Roecker, E. B., Vaillancourt, A. M., Hisgen, W. J., Greenberg,  
 28 E. B., Kuglitsch, M. E., and Wegenke, J. D. Home screening for hematuria: results of a multiclinic  
 29 study. *Journal of Urology* 148[2:Pt 1], t-92. 1992.  
 30 Excl reason: Not in PICO
- 31 Messing, E. M., Madeb, R., Young, T., Gilchrist, K. W., Bram, L., Greenberg, E. B., Wegenke, J. D.,  
 32 Stephenson, L., Gee, J., and Feng, C. Long-term outcome of hematuria home screening for  
 33 bladder cancer in men. *Cancer* 107[9], 2173-2179. 1-11-2006.  
 34 Excl reason: Not in PICO
- 35 Michaud, D. S., Spiegelman, D., Clinton, S. K., Rimm, E. B., Curhan, G. C., Willett, W. C., and  
 36 Giovannucci, E. L. Fluid intake and the risk of bladder cancer in men. *New England Journal of*  
 37 *Medicine* 340[18], 1390-1397. 6-5-1999.  
 38 Excl reason: Not in PICO
- 39 Mishail, A., Shahsavari, M., Kim, J., Welliver, R. C., Vemulapalli, P., and Adler, H. L. Deficits in  
 40 Urological Knowledge Among Medical Students and Primary Care Providers: Potential for Impact  
 41 on Urological Care. *Journal of Urology* 180[5], 2140-2147. 2008.  
 42 Excl reason: Not in PICO
- 43 Mishriki, S. F., Nabi, G. & Cohen, N. P. (2008) Diagnosis of urologic malignancies in patients with  
 44 asymptomatic dipstick hematuria: prospective study with 13 years' follow-up. *Urology*, 71: 13-16.  
 45 Not in PICO (secondary care)
- 46 Misra, V., Mukherjee, J., Gupta, S. C., Tandon, S., and Gupta, A. K. AgNORs in benign, borderline and  
 47 transitional cell neoplasms of the urinary bladder. *APMIS* 106[10], 987-992. 1998.  
 48 Excl reason: Not in PICO
- 49 Mitterberger, M., Pinggera, G. M., Neuwirt, H., Maier, E., Akkad, T., Strasser, H., Gradl, J., Pallwein,  
 50 L., Bartsch, G., and Frauscher, F. Three-dimensional ultrasonography of the urinary bladder:  
 51 preliminary experience of assessment in patients with haematuria. *BJU International* 99[1], 111-

- 1 116. 2007.  
2 Excl reason: Not in PICO  
3 Miyanaga, N., Akaza, H., Tsukamoto, T., Ishikawa, S., Noguchi, R., Ohtani, M., Kawabe, K., Kubota, Y.,  
4 Fujita, K., Obata, K., Hirao, Y., Kotake, T., Ohmori, H., Kumazawa, J., and Koiso, K. Urinary nuclear  
5 matrix protein 22 as a new marker for the screening of urothelial cancer in patients with  
6 microscopic hematuria. *International Journal of Urology* 6[4], 173-177. 1999.  
7 Excl reason: Not in PICO  
8 Miyoshi, Y., Asakura, T., Matsuzaki, J., Fukuda, M., Satomi, Y., and Akabane, H. [A case of CEA and  
9 CA19-9 producing recurrent transitional cell carcinoma in an Indiana pouch after total  
10 cystectomy]. [Japanese]. *Hinyokika Kiyō - Acta Urologica Japonica* 42[12], 961-964. 1996.  
11 Excl reason: Not in PICO  
12 Mizusawa, H., Oguchi, T., Domen, T., Koizumi, K., Mimura, Y., Saito, T. & Kato, H. (2014) - [Two cases  
13 of lower abdominal tumors difficult to differentiate from urachal tumors]. [Japanese]. - *Nippon*  
14 *Hinyokika Gakkai Zasshi - Japanese Journal of Urology*, 105: 17-21.  
15 Not in PICO  
16 Mkrtchian, L. N. and Ambartsumian, A. M. [The experience of the Armenian Republic Endoscopic  
17 Center in the active detection of tumors of the urinary system]. [Russian]. *Voprosy Onkologii*  
18 35[6], 709-711. 1989.  
19 Excl reason: Not in PICO  
20 Mobley, D. F. and Baum, N. Interstitial cystitis. When urgency and frequency mean more than  
21 routine inflammation. [Review] [16 refs]. *Postgraduate Medicine* 99[5], 201-204. 207.  
22 Excl reason: Narrative review  
23 Mohammed, A., Khan, Z., Zamora, I., and Bhatti, A. Biological markers in the diagnosis of recurrent  
24 bladder cancer: an overview. [Review] [65 refs]. *Expert Review of Molecular Diagnostics* 8[1], 63-  
25 72. 2008.  
26 Excl reason: Not in PICO  
27 Mommsen, S., Aagaard, J., and Sell, A. Presenting symptoms, treatment delay and survival in bladder  
28 cancer. *Scandinavian Journal of Urology and Nephrology* 17[2], 163-167. 1983.  
29 Excl reason: Not in PICO  
30 Morant, S., Bloomfield, G., Vats, V., and Chapple, C. Increased sexual dysfunction in men with  
31 storage and voiding lower urinary tract symptoms. *Journal of Sexual Medicine* 6[4], 1103-1110.  
32 2009.  
33 Excl reason: Not in PICO  
34 Morsi, M. I., Youssef, A. I., Hassouna, M. E., El-Sedafi, A. S., Ghazal, A. A., and Zaher, E. R. Telomerase  
35 activity, cytokeratin 20 and cytokeratin 19 in urine cells of bladder cancer patients. *Journal of*  
36 *Egyptian National Cancer Institute* 18[1], 82-92. 2006.  
37 Excl reason: Not in PICO  
38 Mostafid, H., Persad, R., Kockelbergh, R., and Fawcett, D. Is it time to re-design the haematuria  
39 clinic? *BJU International* 105[5], 585-588. 2010.  
40 Excl reason: Narrative review  
41 Mottola, A., Di, Cello, V., Saltutti, C., and Natali, A. [Paraneoplastic syndromes associated with  
42 bladder carcinoma. Apropos of 2 cases of hypercalcemia]. [Review] [22 refs] [Italian]. *Minerva*  
43 *Urologica e Nefrologica* 42[2], 99-101. 1990.  
44 Excl reason: Not in PICO  
45 Murakami, N., Tanabe, K., Murasugi, K., Kadoya, S., Matsumoto, Y., Yoshii, I., Fujikawa, Y., and  
46 Ohura, F. [A case report of a patient treatable by home palliative care, administered zoledronic  
47 acid used for bladder cancer with hypercalcemia]. [Japanese]. *Gan to Kagaku Ryōho [Japanese*  
48 *Journal of Cancer & Chemotherapy]* 37[5], 939-942. 2010.  
49 Excl reason: Not in PICO  
50 Murakami, T., Hoshino, K., Hasumi, H., Makiyama, K., Miyoshi, Y., Yoshida, M., Nakaigawa, N.,  
51 Ogawa, T., Uemura, H., Yao, M., and Kubota, Y. [Only metastasis to uterine corpus from

- 1 superficial bladder cancer that of no original recurrence]. [Japanese]. *Hinyokika Kiyo - Acta*  
2 *Urologica Japonica* 53[1], 75-77. 2007.
- 3 Excl reason: Not in PICO
- 4 Murata, I., Makiyama, K., Funatsu, S., Kubo, K., Mizuta, Y., Nishihata, S., Imanishi, T., Hara, K.,  
5 Nakamura, N., and Murase, K. A study involving early carcinomas of the gall bladder. [Japanese].  
6 *Gan no rinsho Japan*[7], 867-874. 1988.
- 7 Excl reason: Not in PICO
- 8 Nakopoulou, L., Vourlakou, C., Zervas, A., Tzonou, A., Gakiopoulou, H., and Dimopoulos, M. A. The  
9 prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and  
10 their clinicopathologic correlates. *Human Pathology* 29[2], 146-154. 1998.
- 11 Excl reason: Not in PICO
- 12 Naslund, M. J., Gilseman, A. W., Midkiff, K. D., Bown, A., Wolford, E. T., and Wang, J. Prevalence of  
13 lower urinary tract symptoms and prostate enlargement in the primary care setting.  
14 *International Journal of Clinical Practice* 61[9], 1437-1445. 2007.
- 15 Excl reason: Not in PICO
- 16 Nasterlack, M., Feil, G., Leng, G., Pesch, B., Huber, S., Sievert, K. D., Johnen, G., Taeger, D., Mayer, T.,  
17 Kluckert, M., Bruning, T., and Stenzl, A. [Bladder cancer screening with urine-based tumour  
18 markers - occupational medical experience]. [German]. *Aktuelle Urologie* 42[2], 128-134. 2011.
- 19 Excl reason: Not in PICO
- 20 Nasuti, J. F., Gomella, L. G., Ismial, M., and Bibbo, M. Utility of the BTA stat test kit for bladder cancer  
21 screening. *Diagnostic Cytopathology* 21[1], 27-29. 1999.
- 22 Excl reason: Not in PICO
- 23 Navon, J. D., Soliman, H., Khonsari, F., and Ahlering, T. Screening cystoscopy and survival of spinal  
24 cord injured patients with squamous cell cancer of the bladder. *Journal of Urology* 157[6], 2109-  
25 2111. 1997.
- 26 Excl reason: Not in PICO
- 27 Neal, R. D., Din, N. U., Hamilton, W., GBRoumunne, O. C., Carter, B., Stapley, S. & Rubin, G. (2014)  
28 Comparison of cancer diagnostic intervals before and after implementation of NICE guidelines:  
29 Analysis of data from the GBR General Practice Research Database. *British Journal of Cancer*, 110:  
30 584-592.
- 31 Not in PICO
- 32 Nieder, A. M., Lotan, Y., Nuss, G. R., Langston, J. P., Vyas, S., Manoharan, M., and Soloway, M. S. Are  
33 patients with hematuria appropriately referred to Urology? A multi-institutional questionnaire  
34 based survey. *Urologic Oncology* 28[5], 500-503. 2010.
- 35 Excl reason: Not in PICO
- 36 Nisman, B., Barak, V., Shapiro, A., Golijanin, D., Peretz, T., and Pode, D. Evaluation of urine CYFRA 21-  
37 1 for the detection of primary and recurrent bladder carcinoma. *Cancer* 94[11], 2914-2922. 1-6-  
38 2002.
- 39 Excl reason: Not in PICO
- 40 Nitti, V. and Taneja, S. Overactive bladder: achieving a differential diagnosis from other lower urinary  
41 tract conditions. [Review] [43 refs]. *International Journal of Clinical Practice* 59[7], 825-830.  
42 2005.
- 43 Excl reason: Narrative review
- 44 Nozais, J. P., Danis, M., and Gentilini, M. Symptoms and development of *Schistosoma haematobium*  
45 infestation seen in a metropolis. [French]. *La Revue du praticien* 43[4], 428-431. 15-2-1993.
- 46 Excl reason: Narrative review
- 47 O'Brien, T. S., Perkins, J. M. T., and Cranston, D. Efficiency in the outpatient department: The lessons  
48 from urology. *Annals of the Royal College of Surgeons of England* 77[4], 287-289. 1995.
- 49 Excl reason: Not in PICO
- 50 Obroniecka, I., Rojewska, J., and Wankowicz, Z. The value of urine sediment cytomorphology in the  
51 ambulatory differential diagnosis of hematuria. [Polish]. *Polski merkuriusz lekarski : organ*

- 1       Polskiego Towarzystwa Lekarskiego 5[29], 285-287. 1998.  
2       Excl reason: Not in PICO
- 3       Ojo, P., Abenthroth, A., Fiedler, P., and Yavorek, G. Migrating mesh mimicking colonic malignancy.  
4       American Surgeon 72[12], 1210-1211. 2006.  
5       Excl reason: Not in PICO
- 6       Okuno, H., Kihara, Y., and Arai, Y. [Primary paraganglioma of the urinary bladder: a report of two  
7       cases]. [Japanese]. Hinyokika Kiyo - Acta Urologica Japonica 36[6], 691-696. 1990.  
8       Excl reason: Not in PICO
- 9       Okuno, T., Masuda, M., Yamazaki, A., Hirokawa, M., Matsushita, K., and Asakura, S. [Malignant  
10       fibrous histiocytoma of the urinary bladder: a case report]. [Review] [13 refs] [Japanese]. Nippon  
11       Hinyokika Gakkai Zasshi - Japanese Journal of Urology 82[2], 312-315. 1991.  
12       Excl reason: Not in PICO
- 13       Ollesch, J., Drees, S. L., Heise, H. M., Behrens, T., Bruning, T. & Gerwert, K. (2013) FTIR spectroscopy  
14       of biofluids revisited: an automated approach to spectral biomarker identification. *Analyst*, 138:  
15       4092-4102.  
16       Not in PICO
- 17       Ooi, W. L., Lee, F., Wallace, D. M., and Hayne, D. 'One stop' haematuria clinic in Fremantle Hospital,  
18       Western Australia: a report of the first 500 patients. *BJU International* 108, Suppl-6. 2011.  
19       Excl reason: Not in PICO
- 20       Owens, J. L., DiPiero, J. M., Elson, P. & Hansel, D. E. (2013) Urine biobanking: Methods, validation,  
21       and research results. *Laboratory Investigation*, 93: 499A.  
22       Not in PICO
- 23       Oya, M., Schmidt, B., Schmitz-Drager, B. J., and Schulz, W. A. Expression of G1-->S transition  
24       regulatory molecules in human urothelial cancer. *Japanese Journal of Cancer Research* 89[7],  
25       719-726. 1998.  
26       Excl reason: Not in PICO
- 27       Palmer, S., Sokolovski, S. G., Rafailov, E. & Nabi, G. (2013) Technologic developments in the field of  
28       photonics for the detection of urinary bladder cancer. *Clinical Genitourinary Cancer*, 11: 390-396.  
29       Narrative review
- 30       Park, J. W., Jeong, B. C., Seo, S. I., Jeon, S. S., Kwon, G. Y., and Lee, H. M. Leiomyoma of the urinary  
31       bladder: a series of nine cases and review of the literature. [Review]. *Urology* 76[6], 1425-1429.  
32       2010.  
33       Excl reason: Not in PICO
- 34       Parkin, D. E., Davis, J. A., and Symonds, R. P. Long-term bladder symptomatology following  
35       radiotherapy for cervical carcinoma. *Radiotherapy & Oncology* 9[3], 195-199. 1987.  
36       Excl reason: Not in PICO
- 37       Parsons, B. A., Evans, S., and Wright, M. P. Prostate cancer and urinary incontinence. [Review] [70  
38       refs]. *Maturitas* 63[4], 323-328. 20-8-2009.  
39       Excl reason: Not in PICO
- 40       Pascual, Samaniego M., Torrecilla Garcia-Ripoll, J. R., Calleja, Escudero J., Egea, Camacho J., Rivera,  
41       Ferro J., and Fernandez del, Busto E. [Hypercalcemia, leukemoid reaction, and thrombocytosis as  
42       paraneoplastic presentation of transitional cell carcinoma of the kidney]. [Spanish]. *Actas*  
43       *Urologicas Espanolas* 25[5], 400-403. 2001.  
44       Excl reason: Not in PICO
- 45       Paul, A. B., Collie, D. A., Wild, S. R., and Chisholm, G. D. An integrated haematuria clinic. *British*  
46       *Journal of Clinical Practice* 47[3], 128-130. 1993.  
47       Excl reason: Not in PICO
- 48       Pedalino, M., Vercesi, E., Manini, C., Piras, D., Di Primio, O. G., Vella, R., and Marino, G. [A case of  
49       chronic schistosomiasis four years after infestation]. [Italian]. *Urologia (Treviso)* 77, Suppl-41.  
50       2010.  
51       Excl reason: Not in PICO

- 1 Plail, R. Detecting bladder cancer. *BMJ* 301[6752], 567-568. 22-9-1990.  
 2 Excl reason: Narrative review
- 3 Pode, D., Shapiro, A., Wald, M., Nativ, O., Laufer, M., and Kaver, I. Noninvasive detection of bladder  
 4 cancer with the BTA stat test. *The Journal of urology* 161[2], 443-446. 1999.  
 5 Excl reason: Not in PICO
- 6 Pode, D., Golijanin, D., Sherman, Y., Lebensart, P., and Shapiro, A. Immunostaining of Lewis X in cells  
 7 from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors.  
 8 *Journal of Urology* 159[2], 389-392. 19-12-7777.  
 9 Excl reason: Not in PICO
- 10 Pomara, G. & Francesca, F. (2013) [Endoscopic resection. Aspects of technique and optimization of  
 11 outcomes. Current indications to PDD-guided resection]. [Italian]. *Urologia*, 80: 16-19.  
 12 Narrative review
- 13 Ponsky, L. E., Sharma, S., Pandrangi, L., Kedia, S., Nelson, D., Agarwal, A., and Zippe, C. D. Screening  
 14 and monitoring for bladder cancer: Refining the use of NMP22. *Journal of Urology* 166[1], 75-78.  
 15 2001.  
 16 Excl reason: Not in PICO
- 17 Porru, S., Assennato, G., Bergamaschi, E., Carta, P., Foa, V., Forni, A., Gabbani, G., Mastrangelo, G.,  
 18 and Sartorelli, P. [The toxicology and prevention of the risks of occupational exposure to  
 19 aromatic polycyclic hydrocarbons. III. The effects: epidemiological evidence, early effects.  
 20 Individual hypersusceptibility. Health surveillance]. [Review] [60 refs] [Italian]. *Giornale Italiano*  
 21 *di Medicina del Lavoro ed Ergonomia* 19[4], 152-163. 1997.  
 22 Excl reason: Not in PICO
- 23 Poulakis, V., Witzsch, U., De, Vries R., Altmannsberger, H.-M., Manyak, M. J., and Becht, E. A  
 24 comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided  
 25 urinary cytology in detecting and following bladder cancer: The prognostic value of false-positive  
 26 results. *BJU International* 88[7], 692-701. 2001.  
 27 Excl reason: Not in PICO
- 28 Quek, P., Chin, C. M., and Lim, P. H. The role of BTA stat in clinical practice. *Annals of the Academy of*  
 29 *Medicine, Singapore* 31[2], 212-216. 2002.  
 30 Excl reason: Not in PICO
- 31 Rafique, M. Clinico-pathological features of bladder carcinoma in women in Pakistan and smokeless  
 32 tobacco as a possible risk factor. *World Journal of Surgical Oncology* 3. 5-8-2005.  
 33 Excl reason: Not in PICO
- 34 Rath, G. D. Bladder cancer, 1992. [Review] [23 refs]. *Postgraduate Medicine* 92[1], 105-112. 115.  
 35 Excl reason: Narrative review
- 36 Restrepo, N. C. and Carey, P. O. Evaluating hematuria in adults. *American Family Physician* 40[2],  
 37 149-156. 1989.  
 38 Excl reason: Narrative review
- 39 Rinsho, K., Ishikawa, S., Uchida, K., and Koiso, K. The value of ultrasonography in early detection of  
 40 renal cell carcinoma. *Japanese Journal of Clinical Oncology* 14[3], 329-334. 1984.  
 41 Excl reason: Not in PICO
- 42 Ripley, T. L., Havrda, D. E., Blevins, S., and Culkin, D. Early evaluation of hematuria in a patient  
 43 receiving anticoagulant therapy and detection of malignancy. *Pharmacotherapy: The Journal of*  
 44 *Human Pharmacology & Drug Therapy* 24[11], 1638-1640. 2004.  
 45 Excl reason: Not in PICO
- 46 Ritchie, C. D., Bevan, E. A., and Collier, S. J. Importance of occult haematuria found at screening.  
 47 *British Medical Journal Clinical Research Ed.* 292[6521], 681-683. 8-3-1986.  
 48 Excl reason: Not in PICO
- 49 Rodgers, M. A., Hempel, S., Aho, T., Kelly, J. D., Kleijnen, J. & Westwood, M. (2006) Diagnostic tests  
 50 used in the investigation of adult haematuria: a systematic review. *BMJ Int*, 98: 1154-1160.  
 51 Systematic review, checked for relevant studies

- 1 Roobol, M. J., Bangma, C. H., el, Bouazzaoui S., Franken-Raab, C. G., and Zwarthoff, E. C. Feasibility  
2 study of screening for bladder cancer with urinary molecular markers (the BLU-P project).  
3 Urologic Oncology 28[6], 686-690. 2010.  
4 Excl reason: Not in PICO
- 5 Rosenberg, M. T., Hazzard, M. A., and Kuritzky, L. Chronic pelvic pain: When to suspect interstitial  
6 cystitis. Consultant 45[12], 1371-1381. 2005.  
7 Excl reason: Not in PICO
- 8 Rosenberg, M. T., Staskin, D. R., Kaplan, S. A., MacDiarmid, S. A., Newman, D. K., and Ohl, D. A. A  
9 practical guide to the evaluation and treatment of male lower urinary tract symptoms in the  
10 primary care setting. [Review] [53 refs]. International Journal of Clinical Practice 61[9], 1535-  
11 1546. 2007.  
12 Excl reason: Not in PICO
- 13 Rosser, C. J., Urquidi, V. & Goodison, S. (2013) Urinary biomarkers of bladder cancer: an update and  
14 future perspectives. *Biomarkers in Medicine*, 7: 779-790.  
15 Narrative review
- 16 Rous, S. N. Evaluation of gross and microscopic hematuria. Primary Care; Clinics in Office Practice  
17 12[4], 647-659. 1985.  
18 Excl reason: Narrative review
- 19 Rozanski, T. A. and Grossman, H. B. Recent developments in the pathophysiology of bladder cancer.  
20 [Review] [30 refs]. AJR.American Journal of Roentgenology 163[4], 789-792. 1994.  
21 Excl reason: Narrative review
- 22 Sakamoto, W., Sugita, O., Nishijima, T., Kishimoto, T., and Maekawa, M. [Case report of primary  
23 carcinoma in situ in upper urinary tract and review of the Japanese literature]. [Review] [13 refs]  
24 [Japanese]. Nippon Hinyokika Gakkai Zasshi - Japanese Journal of Urology 80[4], 602-606. 1989.  
25 Excl reason: Not in PICO
- 26 Sakamoto, Y., Tanaka, H., and Kawabata, G. [Inflammatory pseudotumor of the urinary bladder  
27 diagnosed using 3D-CT cystoscopy]. [Review] [9 refs] [Japanese]. Hinyokika Kiyo - Acta Urologica  
28 Japonica 49[10], 587-590. 2003.  
29 Excl reason: Not in PICO
- 30 Sallami, S., Ben, Rhouma S., Hafsia, G., Nouira, Y., and Horchani, A. [Intradiverticular tumors of the  
31 bladder: diagnostic and therapeutic problems: report of 32 cases]. [French]. Tunisie Medicale  
32 89[8-9], 663-667. 2011.  
33 Excl reason: Not in PICO
- 34 Sanchez-Carbayo, M., Urrutia, M., Silva, J. M., Romani, R., Gonzalez De Buitrago, J. M., and Navajo, J.  
35 A. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1  
36 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. Journal of Urology  
37 165[5 I], 1462-1466. 2001.  
38 Excl reason: Not in PICO
- 39 Sanchini, M. A., Gunelli, R., Nanni, O., Bravaccini, S., Fabbri, C., Sermasi, A., Bercovich, E., Ravaioli, A.,  
40 Amadori, D., and Calistri, D. Relevance of urine telomerase in the diagnosis of bladder cancer.  
41 JAMA : the journal of the American Medical Association 294[16], 2052-2056. 26-10-2005.  
42 Excl reason: Not in PICO
- 43 Sandhu, K. S., LaCombe, J. A., Fleischmann, N., Greston, W. M., Lazarou, G., and Mikhail, M. S. Gross  
44 and Microscopic Hematuria Guidelines for Obstetricians and Gynecologists. Obstetrical &  
45 Gynecological Survey 64[1], 39-49. 2009.  
46 Excl reason: Not in PICO
- 47 Sawczuk, I. S., Volfson, I. A., Bagiella, E., Sawczuk, A., and Ghafar, M. A. Detection of bladder cancer  
48 in patients with asymptomatic hematuria by urinary matrix protein 22, voided cytology and  
49 cystoscopy. International Journal of Cancer Prevention 2[1], 55-61. 2005.  
50 Excl reason: Not in PICO

- 1 See, W. A. and Williams, R. D. Tumors of the kidney, ureter, and bladder. [Review] [117 refs].  
2 Western Journal of Medicine 156[5], 523-534. 1992.  
3 Excl reason: Narrative review
- 4 Sharfi, A. R. and Hassan, O. Evaluation of haematuria in Khartoum. East African Medical Journal  
5 71[1], 29-31. 1994.  
6 Excl reason: Not in PICO
- 7 Sharp, V. J., Barnes, K. T. & Erickson, B. A. (2013) Assessment of asymptomatic microscopic  
8 hematuria in adults. *American Family Physician*, 88: 747-754.  
9 Narrative review
- 10 Sheldon, C. A., Clayman, R. V., Gonzalez, R., Williams, R. D., and Fraley, E. E. Malignant urachal  
11 lesions. [Review] [97 refs]. *Journal of Urology* 131[1], 1-8. 1984.  
12 Excl reason: Not in PICO
- 13 Shinagare, A. B., Silverman, S. G., Gershanik, E. F., Chang, S. L. & Khorasani, R. (2014) Evaluating  
14 hematuria: Impact of guideline adherence on urologic cancer diagnosis. *American Journal of  
15 Medicine*, 127: 625-632.  
16 Not in PICO (setting)
- 17 Shirodkar, S. P. and Lokeshwar, V. B. Potential new urinary markers in the early detection of bladder  
18 cancer. [Review] [47 refs]. *Current Opinion in Urology* 19[5], 488-493. 2009.  
19 Excl reason: Not in PICO
- 20 Siddiqui, I., Bhally, H. S., Niaz, Q., and Burney, I. A. Tumor-induced hypercalcemia: predictors of early  
21 mortality. *JPMA - Journal of the Pakistan Medical Association* 52[8], 361-364. 2002.  
22 Excl reason: Not in PICO
- 23 Siegel, M. J. Pelvic tumors in childhood. *Radiologic Clinics of North America* 35[6], 1455-1475. 1997.  
24 Excl reason: Not in PICO
- 25 Simon, J., Bartsch, G., Jr., Rinnab, L., Hautmann, R. E., and Volkmer, B. G. Transrectal ultrasound as  
26 diagnostic tool for the detection of local recurrence following cystectomy and urinary diversion.  
27 *Urologia Internationalis* 82[1], 12-16. 2009.  
28 Excl reason: Not in PICO
- 29 Smellie, W. S., Forth, J. O., McNulty, C. A. M., Hirschowitz, L., Lilib, D., Gosling, R., Bareford, D., Logan,  
30 E., Kerr, K. G., Spickett, G. P., Hoffman, J., Galloway, A., and Bloxham, C. A. Best practice in  
31 primary care pathology: review 2. *Journal of Clinical Pathology* 59[2], 113-120. 2006.  
32 Excl reason: Not in PICO
- 33 Soga, N., Komeda, Y., Suzuki, R., and Kawamura, J. [Two cases of squamous cell carcinoma of the  
34 ureter]. [Japanese]. *Hinyokika Kiyo - Acta Urologica Japonica* 41[11], 879-882. 1995.  
35 Excl reason: Not in PICO
- 36 Sommariva, M. L., Sandri, S. D., and Ceriani, V. Efficacy of sodium hyaluronate in the management of  
37 chemical and radiation cystitis. *Minerva Urologica e Nefrologica* 62[2], 145-150. 2010.  
38 Excl reason: Not in PICO
- 39 Srivastava, A. K., Singh, P. K., Srivastava, K., Singh, D., Dalela, D., Rath, S. K., Goel, M. M. & Brahma  
40 Bhatt, M. L. (2013) Diagnostic role of survivin in urinary bladder cancer. *Asian Pacific Journal of  
41 Cancer Prevention: Apjcp*, 14: 81-85.  
42 Not in PICO
- 43 Stower, M. J. Delays in diagnosing and treating bladder cancer. *British Medical Journal Clinical  
44 Research Ed.* 296[6631], 1228-1229. 30-4-1988.  
45 Excl reason: Not in PICO
- 46 Sturgeon, S. R., Hartge, P., Silverman, D. T., Kantor, A. F., Linehan, W. M., Lynch, C., and Hoover, R. N.  
47 Associations between bladder cancer risk factors and tumor stage and grade at diagnosis.  
48 *Epidemiology* 5[2], 218-225. 1994.  
49 Excl reason: Not in PICO
- 50 Sugiono, M. and Hammonds, J. C. Do patients with frank haematuria referred under the two-week  
51 rule have a higher incidence of bladder cancer? *Annals of the Royal College of Surgeons of*

- 1 England 88[1], 26. 2006.  
2 Excl reason: Not in PICO
- 3 Sultana, S. R., Goodman, C. M., Byrne, D. J., and Baxby, K. Microscopic haematuria: Urological  
4 investigation using a standard protocol. *British Journal of Urology* 78[5], 691-698. 1996.  
5 Excl reason: Not in PICO
- 6 Summerton, N., Mann, S., Rigby, A. S., Ashley, J., Palmer, S., and Hetherington, J. W. Patients with  
7 new onset haematuria: assessing the discriminant value of clinical information in relation to  
8 urological malignancies. [Review] [28 refs]. *British Journal of General Practice* 52[477], 284-289.  
9 2002.  
10 Excl reason: Not in PICO - secondary care
- 11 Svatek, R. S., Lotan, Y., Karakiewicz, P. I., and Shariat, S. F. Screening for bladder cancer using urine-  
12 based tumor markers. [Review] [26 refs]. *Minerva Urologica e Nefrologica* 60[4], 247-253. 2008.  
13 Excl reason: Not in PICO
- 14 Svatek, R. S., Hollenbeck, B. K., Holmang, S., Lee, R., Kim, S. P., Stenzl, A. & Lotan, Y. (2014) The  
15 economics of bladder cancer: Costs and considerations of caring for this disease. *European*  
16 *Urology*, 66: 253-262.  
17 Not in PICO
- 18 Tabata, T., Suzuki, H., Nakamura, Y., Morito, T., Yabuki, Y., Shibuya, A., and Ando, M. [Adult male  
19 with chronic renal failure due to reflux nephropathy that was possibly induced by neurogenic  
20 bladder since childhood]. [Japanese]. *Nippon Jinzo Gakkai Shi. Japanese Journal of Nephrology*  
21 51[8], 1086-1090. 2009.  
22 Excl reason: Not in PICO
- 23 Takai, K., Kakizoe, T., Tobisu, K., Tanaka, Y., Teshima, S., and Kishi, K. [A case of proliferative chronic  
24 cystitis, progressing to obstructive nephropathy, treated by total cystectomy and  
25 enterocystoplasty]. [Japanese]. *Nippon Hinyokika Gakkai Zasshi - Japanese Journal of Urology*  
26 80[7], 1059-1062. 1989.  
27 Excl reason: Not in PICO
- 28 Tan, P. K., Chang, H. C., and Sitoh, Y. Y. Haematuria clinic--a preliminary audit and considerations for  
29 a one-stop assessment centre. *Singapore Medical Journal* 39[11], 501-503. 1998.  
30 Excl reason: Not in PICO
- 31 Taniguchi, H., Sakagami, J., Suzuki, N., Hasegawa, H., Shinoda, M., Tosa, M., Baba, T., Yasuda, H.,  
32 Kataoka, K., and Yoshikawa, T. Adenoendocrine cell carcinoma of the gallbladder clinically  
33 mimicking squamous cell carcinoma. *International Journal of Clinical Oncology* 14[2], 167-170.  
34 2009.  
35 Excl reason: Not in PICO
- 36 Tawfik, H. N. Carcinoma of the urinary bladder associated with schistosomiasis in Egypt: the possible  
37 causal relationship. *Princess Takamatsu Symposia* 18, 197-209. 1987.  
38 Excl reason: Not in PICO
- 39 Teichman, J. M. H., Weiss, B. D., and Solomon, D. Urological needs assessment for primary care  
40 practice: Implications for undergraduate medical education. *Journal of Urology* 161[4], 1282-  
41 1285. 1999.  
42 Excl reason: Not in PICO
- 43 Thiruchelvam, N. and Mostafid, H. Do patients with frank haematuria referred under the two-week  
44 rule have a higher incidence of bladder cancer? *Annals of the Royal College of Surgeons of*  
45 *England* 87[5], 345-347. 2005.  
46 Excl reason: Not in PICO
- 47 Tissot, W. D., Diokno, A. C., and Peters, K. M. A referral center's experience with transitional cell  
48 carcinoma misdiagnosed as interstitial cystitis. *Journal of Urology* 172[2], 478-480. 2004.  
49 Excl reason: Not in PICO
- 50 Tsukagoshi, S. [ImmuCyst intravesical (freeze-dried preparation made from the connaught strain of  
51 *Bacillus Calmette Guerin*) for the treatment of superficial bladder cancer and carcinoma in situ of



- 1 urinary bladder]. [Review] [30 refs] [Japanese]. *Gan to Kagaku Ryoho [Japanese Journal of*  
2 *Cancer & Chemotherapy]* 30[7], 1027-1038. 2003.  
3 Excl reason: Not in PICO
- 4 Turner, C. & Grady, M. (2013) 12-Year-old boy with back spasms. *Clinical Journal of Sport Medicine,*  
5 23: e13.  
6 Not in PICO
- 7 Ueda, T., Miura, N., Suzuki, K., Suzuki, F., Inomiya, H., Kotake, T., Nishikawa, Y., Yamaguchi, K., and  
8 Ito, H. [Metastatic bladder tumor from gastric carcinoma: a case report]. [Japanese]. *Hinyokika*  
9 *Kiyo - Acta Urologica Japonica* 38[10], 1175-1177. 1992.  
10 Excl reason: Not in PICO
- 11 Vaidyanathan, S., Mansour, P., Ueno, M., Yamazaki, K., Wadhwa, M., Soni, B. M., Singh, G., Hughes,  
12 P. L., Watson, I. D., and Sett, P. Problems in early diagnosis of bladder cancer in a spinal cord  
13 injury patient: report of a case of simultaneous production of granulocyte colony stimulating  
14 factor and parathyroid hormone-related protein by squamous cell carcinoma of urinary bladder.  
15 *BMC Urology* 2[1], 8. 30-8-2002.  
16 Excl reason: Not in PICO
- 17 Vaish, M., Mandhani, A., Mittal, R. D., and Mittal, B. Microsatellite instability as prognostic marker in  
18 bladder tumors: a clinical significance. *BMC Urology* 5, 2. 2005.  
19 Excl reason: Not in PICO
- 20 Villalbi, J. R., Gelabert-Mas, A., Comin, E., and Coronado-Garcia, J. Cancer of the urothelium:  
21 background and characteristics of the care process related to the prognosis in a series of clinical  
22 cases. [Spanish]. *Actas Urologicas Espanolas* 14[2], 89-91. 1990.  
23 Excl reason: Not in PICO
- 24 Viswanath, S., Zelhof, B., Ho, E., Sethia, K., and Mills, R. Is routine urine cytology useful in the  
25 haematuria clinic? *Annals of the Royal College of Surgeons of England* 90[2], 153-155. 2008.  
26 Excl reason: Not in PICO
- 27 Volkmer, B. G., Kuefer, R., Bartsch, G. C., Jr., Gust, K., and Hautmann, R. E. Oncological followup after  
28 radical cystectomy for bladder cancer-is there any benefit? *Journal of Urology* 181[4], 1587-  
29 1593. 20-11-1593.  
30 Excl reason: Not in PICO
- 31 Volpe, A., Racioppi, M., D'Agostino, D., Cappa, E., Gardi, M., Totaro, A., Pinto, F., Sacco, E., Marangi,  
32 F., Palermo, G., and Bassi, P. F. Bladder tumor markers: a review of the literature. [Review] [145  
33 refs]. *International Journal of Biological Markers* 23[4], 249-261. 2008.  
34 Excl reason: Not in PICO
- 35 Wadhwa, N., Jatawa, S. K. & Tiwari, A. (2013) Non-invasive urine based tests for the detection of  
36 bladder cancer. *Postgraduate Medical Journal*, 89: 352-357.  
37 Narrative review
- 38 Wadhwa, N., Jatawa, S. K. & Tiwari, A. (2013) Republished: non-invasive urine based tests for the  
39 detection of bladder cancer.[Reprint of *J Clin Pathol.* 2012 Nov;65(11):970-5; PMID: 22685259].  
40 *Postgraduate Medical Journal*, 89: 352-357.  
41 Narrative review
- 42 Wakui, M. and Shiigai, T. Urinary tract cancer screening through analysis of urinary red blood cell  
43 volume distribution. *International Journal of Urology* 7[7], 248-253. 2000.  
44 Excl reason: Not in PICO
- 45 Wallace, D. M., Bryan, R. T., Dunn, J. A., Begum, G., Bathers, S., and West Midlands Urological  
46 Research Group. Delay and survival in bladder cancer. *BJU International* 89[9], 868-878. 2002.  
47 Excl reason: Not in PICO
- 48 Wang, J. and Wang, F. W. Clinical Characteristics and Outcomes of Patients with Primary Signet-Ring  
49 Cell Carcinoma of the Urinary Bladder. *Urologia Internationalis* 86[4], 453-460. 2011.  
50 Excl reason: Not in PICO

- 1 Ward, E., Halperin, W., Thun, M., Grossman, H. B., Fink, B., Koss, L., Osorio, A. M., and Schulte, P.  
2 Screening workers exposed to 4,4'-methylenebis(2-chloroaniline) for bladder cancer by  
3 cystoscopy. *Journal of Occupational Medicine* 32[9], 865-868. 1990.  
4 Excl reason: Not in PICO
- 5 Wawroschek, F. and Roth, S. Hematuria in cases of bladder cancer. [German]. *Urologe - Ausgabe A*  
6 42[7], 902-907. 1-7-2003.  
7 Excl reason: Not in PICO/narrative review
- 8 Wax, J. R., Pinette, M. G., Blackstone, J., Cartin, A., and McCrann, D. J. Nonbilharzial bladder  
9 carcinoma complicating pregnancy: review of the literature. [Review] [25 refs]. *Obstetrical &*  
10 *Gynecological Survey* 57[4], 236-244. 2002.  
11 Excl reason: Not in PICO
- 12 Webb, V. and Holmes, A. Urological cancers: Do early detection strategies exist? *BJU International*  
13 86[9], 996-1000. 2000.  
14 Excl reason: Not in PICO
- 15 Wise, G. J. and Shteynshlyuger, A. An update on lower urinary tract tuberculosis. [Review] [50 refs].  
16 *Current Urology Reports* 9[4], 305-313. 2008.  
17 Excl reason: Not in PICO
- 18 Wu, C. F., Chang, P. L., Chen, C. S., Chuang, C. K., Weng, H. H., and Pang, S. T. The outcome of  
19 patients on dialysis with upper urinary tract transitional cell carcinoma. *Journal of Urology*  
20 176[2], 477-481. 2006.  
21 Excl reason: Not in PICO
- 22 Wu, X., Amos, C. I., Zhu, Y., Zhao, H., Grossman, B. H., Shay, J. W., Luo, S., Hong, W. K., and Spitz, M.  
23 R. Telomere dysfunction: A potential cancer predisposition factor. *Journal of the National Cancer*  
24 *Institute* 95[16], 1211-1218. 20-8-2003.  
25 Excl reason: Not in PICO
- 26 Wu, Z., Zhang, Y., and Liu, D. [Relationship between the abnormal expression of CD44 gene and  
27 bladder cancer]. [Chinese]. *Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery]* 34[11], 645-  
28 647. 1996.  
29 Excl reason: Not in PICO
- 30 Yafi, F. A., Aprikian, A. G., Tanguay, S., and Kassouf, W. Patients with microscopic and gross  
31 hematuria: practice and referral patterns among primary care physicians in a universal health  
32 care system. *Canadian Urological Association Journal* 5[2], 97-101. 2011.  
33 Excl reason: Not in PICO
- 34 Yakasai, A., Allam, M., and Thompson, A. J. Incidence of bladder cancer in a one-stop clinic. *Annals of*  
35 *African Medicine* 10[2], 112-114. 2011.  
36 Excl reason: Not in PICO
- 37 Yang, C. C. and Clowers, D. E. Screening cystoscopy in chronically catheterized spinal cord injury  
38 patients. *Spinal Cord* 37[3], 204-207. 1999.  
39 Excl reason: Not in PICO
- 40 Yeaton-Massey, A., Brookfield, K. F., Aziz, N., Mrazek-Pugh, B. & Chueh, J. (2013) Maternal bladder  
41 cancer diagnosed at routine first-trimester obstetric ultrasound examination. *Obstetrics &*  
42 *Gynecology*, 122: t-7.  
43 Not in PICO
- 44 Yegin, Z., Gunes, S. & Buyukalpelli, R. (2013) Hypermethylation of TWIST1 and NID2 in tumor tissues  
45 and voided urine in urinary bladder cancer patients. *DNA & Cell Biology*, 32: 386-392.  
46 Not in PICO
- 47 Yi, S. K., Yoder, M., Zaner, K., and Hirsch, A. E. Palliative radiation therapy of symptomatic recurrent  
48 bladder cancer. *Pain Physician* 10[2], 285-290. 2007.  
49 Excl reason: Not in PICO
- 50 Yilmaz, Y., Aydin, S., Bayrakli, H., Ugras, S., Ozman, E., and Berktaş, M. Using of NMP 22 only or  
51 together with the cytology in the diagnosis and follow-up of bladder tumors. [Turkish]. *Turk*

1 Uroloji Dergisi 29[2], 138-145. 2003.

2 Excl reason: Not in PICO (secondary care)

3 Yip, S. K., Peh, W. C., Tam, P. C., Li, J. H., and Lam, C. H. Day case hematuria diagnostic service: use of  
4 ultrasonography and flexible cystoscopy. *Urology* 52[5], 762-766. 1998.

5 Excl reason: Not in PICO

6 Yip, S. K., Peh, W. C., Tam, P. C., Li, J. H., and Lam, C. H. Role of ultrasonography in screening for  
7 urological malignancies in patients presenting with painless haematuria. *Annals of the Academy  
8 of Medicine, Singapore* 28[2], 174-177. 1999.

9 Excl reason: Not in PICO

10 Yokoyama, S., Hirakawa, H., Ueno, S., Yabe, H., and Hiraoka, N. Neuroblastoma of the urinary  
11 bladder, preclinically detected by mass screening. *Pediatrics* 103[5], e67. 1999.

12 Excl reason: Not in PICO

13 Yun, E. J., Meng, M. V., and Carroll, P. R. Evaluation of the patient with hematuria. *Medical Clinics of  
14 North America* 88[2], 329-+. 2004.

15 Excl reason: Narrative review

16 Zhu, J., Zeng, Y. & Yang, B. (2013) Research progress of bladder cancer-related factors. [Chinese].  
17 *Chinese Journal of Clinical Oncology*, 40: 741-744.

18 Narrative review

19 Zippe, C., Pandrangi, L., and Agarwal, A. NMP22 is a sensitive, cost-effective test in patients at risk  
20 for bladder cancer. *Journal of Urology* 161[1], 62-65. 1999.

21 Excl reason: Not in PICO

### 23 Review question:

24 Which investigations of symptoms of suspected bladder cancer should be done with clinical  
25 responsibility retained by primary care?

### 27 Results

#### 28 Literature search

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1980-2013	796	91	16/01/2013
<i>Premedline</i>	1980-2013	30	5	16/01/2013
<i>Embase</i>	1980-2013	358	40	17/01/2013
<i>Cochrane Library</i>	1980-2013	40	1	17/01/2013
<i>Psychinfo</i>	1980-2013	1	0	16/01/2013
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	1980-2013	46	9	17/01/2013
<i>Biomed Central</i>	1980-2013	114	2	17/01/2013


29 Total number of references retrieved after de-duplication: 104

#### 31 Update Search

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	2013- 11/08/2014	37	14	11/08/2014
<i>Premedline</i>	2013- 11/08/2014	52	10	11/08/2014
<i>Embase</i>	2013- 11/08/2014	53	19	11/08/2014
<i>Cochrane Library</i>	2013-	25	0	11/08/2014

	11/08/2014			
<b>Web of Science (SCI &amp; SSCI) and ISI Proceedings</b>	2013-11/08/2014	10	1	11/08/2014

1 Total References retrieved (after de-duplication): 34



3 # of studies included in quantitative synthesis (meta-analysis): N = 0

4  
5 **Study results**

6 No evidence was identified pertaining to the diagnostic accuracy of urine cytology, ultrasound,  
7 cystoscopy, blood HCG, urine marker NMP22, and urine marker MCM5 in patients with suspected  
8 bladder cancer where the clinical responsibility was retained by primary care.

9  
10 **References**

11 **Included studies**

12 None

13  
14 **Excluded studies**

15 (2002) Can blood tests detect cancer early? *Health News*, 8: 4.

16 Narrative review

17 (2002) [Suspected bladder carcinoma. New rapid test with high sensitivity]. [German]. *MMW Fortschritte der Medizin*, 144: 65.

18 Not in PICO

19  
20 Abbaszadeh, S., Taheri, S. & Nourbala, M. H. (2009) Bladder tumor in women with microscopic  
21 hematuria: an Iranian experience and a review of the literature. *Advances in Urology*:231861,  
22 2009., 231861.

23 Not in PICO

24 Alameddine, M. & Nassir, A. (2012) The influence of urine cytology on our practice. *Urology annals*,  
25 4: 80-83.

26 Not in PICO

- 1 Allen, D., Popert, R. & O'Brien, T. (2004) The two-week-wait cancer initiative in urology: useful  
2 modernization? *Journal of the Royal Society of Medicine*, 97: 279-281.  
3 Not in PICO
- 4 Amin, M. F. & Abd El Hamid, A. M. (2013) The diagnostic accuracy of multidetector computed  
5 tomography with multiplanar reformatted imaging and virtual cystoscopy in the early detection  
6 and evaluation of bladder carcinoma: comparison with conventional cystoscopy. *Abdominal  
7 Imaging*, 38: 184-192.  
8 Not in PICO
- 9 Arora, V. K., Sarungbam, J., Bhatia, A., Singh, N., Agrawal, V. & Aggarwal, S. (2010) Usefulness of  
10 NMP22 as an adjunct to a typical urine cytology and low-grade urothelial carcinoma. *Diagnostic  
11 Cytopathology*, 38: 788-790.  
12 Not in PICO
- 13 Banek, S., Schwentner, C., Tager, D., Pesch, B., Nasterlack, M., Leng, G., Gawrych, K., Bonberg, N.,  
14 Johnen, G., Kluckert, M., Gakis, G., Todenhofer, T., Hennenlotter, J., Bruning, T. & Stenzl, A.  
15 (2013) Prospective evaluation of fluorescence-in situ-hybridization to detect bladder cancer:  
16 Results from the UroScreen-Study. *Urologic Oncology: Seminars and Original Investigations*, 31:  
17 1656-1662.  
18 Not in PICO
- 19 Barlandas-Rendon, E., Muller, M. M., Garcia-Latorre, E. & Heinschink, A. (2002) Comparison of urine  
20 cell characteristics by flow cytometry and cytology in patients suspected of having bladder  
21 cancer. *Clinical Chemistry & Laboratory Medicine*, 40: 817-823.  
22 Not in PICO
- 23 Basak, M., Ozkurt, H., Tanriverdi, O., Cay, E., Aydin, M. & Miroglu, C. (2009) Sixteen-slice  
24 multidetector computed tomographic virtual cystoscopy in the evaluation of a patient with  
25 suspected bladder tumor and history of bladder carcinoma operation. *Journal of Computer  
26 Assisted Tomography*, 33: 867-871.  
27 Not in PICO
- 28 Bassett, J. C., Gore, J. L., McCarthy, W. J., Morrison, C., Kwan, L., Bennett, C. J., Cookson, M. S.,  
29 Penson, D. F. & Saigal, C. (2013) Introduction of a tobacco-screening initiative for those at risk for  
30 bladder cancer in a high volume urology clinic. *Journal of Clinical Oncology*, 31.  
31 Not in PICO
- 32 Batool, A., Ramachandran, R., Dubrovskaya, V. & Lee, D. (2013) Recurrent urothelial cancer  
33 masquerading as a large colonic mass and massive gastrointestinal hemorrhage. *American  
34 Journal of Gastroenterology*, 108: S458-S459.  
35 Not in PICO
- 36 Bhuiyan, J., Akhter, J. & O'Kane, D. J. (2003) Performance characteristics of multiple urinary tumor  
37 markers and sample collection techniques in the detection of transitional cell carcinoma of the  
38 bladder. *Clinica Chimica Acta*, 331: 69-77.  
39 Not in PICO
- 40 Blanker, M. H. (2009) [Diagnosis of urothelial carcinoma by the general practitioner--significance of  
41 haematuria]. [Dutch]. *Nederlands Tijdschrift Voor Geneeskunde*, 153: A1198.  
42 Narrative review
- 43 Blochlinger, A. M., Gasser, T. C., Stoffel, F., Laschke, S. & Buhring, C. (1996) [Hematuria]. [German].  
44 *Therapeutische Umschau*, 53: 672-675.  
45 Narrative review
- 46 Bock-Oruma, A. A., Dienye, P. O. & Oghu, I. S. (2013) Prevalence of lower urinary tract symptoms  
47 suggestive of benign prostatic hyperplasia in primary care, Port Harcourt, Nigeria. *South African  
48 Family Practice*, 55: 467-472.  
49 Not in PICO
- 50 Bonner, R. B., Hemstreet, G. P., III, Fradet, Y., Rao, J. Y., Min, K. W. & Hurst, R. E. (1993) Bladder  
51 cancer risk assessment with quantitative fluorescence image analysis of tumor markers in

- 1 exfoliated bladder cells. *Cancer*, 72: 2461-2469.  
2 Not in PICO
- 3 Britton, J. P., Dowell, A. C. & Whelan, P. (1989) Dipstick haematuria and bladder cancer in men over  
4 60: results of a community study. *BMJ*, 299: 1010-1012.  
5 Not in PICO
- 6 Browne, R. F., Murphy, S. M., Grainger, R. & Hamilton, S. (2005) CT cystography and virtual  
7 cystoscopy in the assessment of new and recurrent bladder neoplasms. *European Journal of*  
8 *Radiology*, 53: 147-153.  
9 Not in PICO
- 10 Budman, L. I., Kassouf, W. & Steinberg, J. R. (2008) Biomarkers for detection and surveillance of  
11 bladder cancer. *Canadian Urological Association Journal*, 2: 212-221.  
12 Narrative review
- 13 Burger, M., Grossman, H. B., Droller, M., Schmidbauer, J., Hermann, G., Dragoescu, O., Ray, E.,  
14 Fradet, Y., Karl, A., Burgues, J. P., Witjes, J. A., Stenzl, A., Jichlinski, P. & Jocham, D. (2013)  
15 Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate  
16 cystoscopy: A meta-analysis of detection and recurrence based on raw data. *European Urology*,  
17 64: 846-854.  
18 Not in PICO
- 19 Buteau, A., Seideman, C. A., Svatek, R. S., Youssef, R. F., Chakrabarti, G., Reed, G., Bhat, D. & Lotan, Y.  
20 (2014) What is evaluation of hematuria by primary care physicians? Use of electronic medical  
21 records to assess practice patterns with intermediate follow-up. *Urologic Oncology*, 32: 128-134.  
22 Not in PICO
- 23 Cauberg, E. C., Kloen, S., Visser, M., de la Rosette, J. J., Babjuk, M., Soukup, V., Pesl, M., Duskova, J. &  
24 de Reijke, T. M. (2010) Narrow band imaging cystoscopy improves the detection of non-muscle-  
25 invasive bladder cancer. *Urology*, 76: 658-663.  
26 Not in PICO
- 27 Chan, E. S., Ng, C. F., Hou, S. M. & Yip, S. K. (2011) Using urine microscopy and cytology for early  
28 detection of bladder cancer in male patients with lower urinary tract symptoms. *International*  
29 *Urology & Nephrology*, 43: 289-294.  
30 Not in PICO
- 31 Cohan, R. H., Caoili, E. M., Cowan, N. C., Weizer, A. Z. & Ellis, J. H. (2009) MDCT Urography: Exploring  
32 a new paradigm for imaging of bladder cancer. [Review] [47 refs]. *AJR.American Journal of*  
33 *Roentgenology*, 192: 1501-1508.  
34 Narrative review
- 35 Daniely, M., Rona, R., Kaplan, T., Olsfanger, S., Elboim, L., Zilberstien, Y., Friberger, A., Kidron, D.,  
36 Kaplan, E., Lew, S. & Leibovitch, I. (2005) Combined analysis of morphology and fluorescence in  
37 situ hybridization significantly increases accuracy of bladder cancer detection in voided urine  
38 samples. *Urology*, 66: 1354-1359.  
39 Not in PICO
- 40 Datta, S. N., Allen, G. M., Evans, R., Vaughton, K. C. & Lucas, M. G. (2002) Urinary tract  
41 ultrasonography in the evaluation of haematuria--a report of over 1,000 cases. *Annals of the*  
42 *Royal College of Surgeons of England*, 84: 203-205.  
43 Not in PICO
- 44 Datta, S. N., Allen, G. M., Evans, R., Vaughton, K. C. & Lucas, M. G. (2002) Urinary tract  
45 ultrasonography in the evaluation of haematuria—a report of over 1,000 cases. *Ann R Coll Surg*  
46 *Engl*, 84: 200-205.  
47 Duplicate
- 48 De, G. N., D'Hallewin, M. A. & Baert, L. (1997) Contemporary non-imaging methods in diagnosis of  
49 bladder cancer: a review. [Review] [22 refs]. *Acta Urologica Belgica*, 65: 55-58.  
50 Narrative review

- 1 DeSouza, K., Chowdhury, S. & Hughes, S. (2003) - Prompt diagnosis key in bladder cancer. [Review]. -  
2 *Practitioner*, 258: 23-27.  
3 Narrative review
- 4 Dobrowolska-Glazar, B., Glazar, W., Dobrowolski, Z. & Lipczynski, W. (2010) [Bladder cancer  
5 biomarkers]. [Review] [Polish]. *Przegląd Lekarski*, 67: 479-483.  
6 Narrative review
- 7 Dobry, E. & Danuser, H. (2009) [Imaging of the kidney and the urinary tract]. [Review] [22 refs]  
8 [German]. *Therapeutische Umschau*, 66: 39-42.  
9 Narrative review
- 10 Doehn, C., Krockenberger, K., Zumbe, J., Rassler, J., Sommerauer, M., Feller, A. C., Gebhardt, M.,  
11 Hemmelmann, C., Grozinger, K., Nolte, S., Breitling, C., Jocham, D. & Ziegler, A. (2014)  
12 Comparison of white-light, photodynamic diagnosis and narrow-band imaging for the detection  
13 of non-muscle invasive bladder cancer: Results from a randomized multicenter diagnostic phase-  
14 III study. *European Urology, Supplements*, 13: e23.  
15 Not in PICO
- 16 Dregan, A., Moller, H., Charlton, J. & Gulliford, M. C. (2013) Are alarm symptoms predictive of cancer  
17 survival? Population-based cohort study. *British Journal of General Practice*, 63: E807-E812.  
18 Not in PICO
- 19 Eissa, S., Shabayek, M. I., Ismail, M. F., El-Allawy, R. M. & Hamdy, M. A. (2010) Diagnostic evaluation  
20 of apoptosis inhibitory gene and tissue inhibitor matrix metalloproteinase-2 in patients with  
21 bladder cancer. *IUBMB Life*, 62: 394-399.  
22 Not in PICO
- 23 Eissa, S., Swellam, M., El-Khouly, I. M., Kassim, S. K., Shehata, H., Mansour, A., Esmat, M., Nossier, A.  
24 I., Hamdy, M. A., Awad, N. M. & El-Ahmady, O. (2011) Aberrant methylation of RARbeta2 and APC  
25 genes in voided urine as molecular markers for early detection of bilharzial and nonbilharzial  
26 bladder cancer. *Cancer Epidemiology, Biomarkers & Prevention*, 20: 1657-1664.  
27 Not in PICO
- 28 Eissa, S., Badr, S., Elhamid, S. A., Helmy, A. S., Nour, M. & Esmat, M. (2013) The value of combined  
29 use of survivin mRNA and matrix metalloproteinase 2 and 9 for bladder cancer detection in  
30 voided urine. *Disease Markers*, 34: 57-62.  
31 Not in PICO
- 32 Eissa, S., Matboli, M., Mansour, A., Mohamed, S., Awad, N. & Kotb, Y. M. (2014) Evaluation of urinary  
33 HURP mRNA as a marker for detection of bladder cancer: relation to bilharziasis. *Medical  
34 Oncology*, 31: 804.  
35 Not in PICO
- 36 Feil, G. & Stenzl, A. (2006) [Tumor marker tests in bladder cancer]. [Review] [60 refs] [Spanish]. *Actas  
37 Urologicas Espanolas*, 30: 38-45.  
38 Narrative review
- 39 Ferre, A., Cordonnier, C., Demailly, M., Hakami, F., Sevestre, H. & Saint, F. (2013) [Bladder tumor  
40 targeting by Hexvix() fluorescence: 4 years results after prospective monocentric evaluation].  
41 [French]. *Progres En Urologie*, 23: 195-202.  
42 Not in PICO
- 43 Fiore, D. C. & Fox, C. L. (2014) Urology and nephrology update: bladder and kidney cancer. *Fp  
44 Essentials*, 416: 26-29.  
45 Narrative review
- 46 Flores-Carreras, O., Martinez-Espinoza, C. J., Gonzalez-Ruiz, M. I. & Montes-Casillas, Y. E. (2010)  
47 [Contribution of bladder biopsy to the study of urogynaecological patient]. [Spanish]. *Ginecologia  
48 y Obstetricia de Mexico*, 78: 187-190.  
49 Not in PICO

- 1 Foo, K. T. (2013) The role of transabdominal ultrasound in office urology. *Proceedings of Singapore*  
2 *Healthcare*, 22: 125-130.  
3 Narrative review
- 4 Friedlander, D. F., Resnick, M. J., You, C., Bassett, J., Yarlagadda, V., Penson, D. F. & Barocas, D. A.  
5 (2014) - Variation in the intensity of hematuria evaluation: a target for primary care quality  
6 improvement. - *American Journal of Medicine*, 127: 633-640.  
7 Not in PICO
- 8 Gervino, G., Autino, E., Kolomoets, E., Leucci, G. & Balma, M. (2007) Diagnosis of bladder cancer at  
9 465 MHz. *Electromagnetic Biology & Medicine*, 26: 119-134.  
10 Not in PICO
- 11 Gomella, L., Grossman, H. B., Droller, M., Schmidbauer, J., Hermann, G., Dragoescu, O., Ray, E.,  
12 Witjes, A., Karl, A., Stenzl, A., Fradet, Y., Burgues, J. & Jocham, D. (2013) A meta-analysis of blue  
13 light cystoscopy with hexaminolevulinate in patients with non-muscle invasive bladder cancer.  
14 *Journal of Urology*, 189: e528.  
15 Not in PICO
- 16 Goodison, S., Rosser, C. J. & Urquidi, V. (2013) Bladder cancer detection and monitoring: assessment  
17 of urine- and blood-based marker tests. [Review]. *Molecular Diagnosis & Therapy*, 17: 71-84.  
18 Narrative review
- 19 Griffiths, T. R. & Action on Bladder Cancer (2013) Current perspectives in bladder cancer  
20 management. [Review]. *International Journal of Clinical Practice*, 67: 435-448.  
21 Narrative review
- 22 Gutierrez Banos, J. L., Rebollo Rodrigo, M. H., Antolin, J. F., Martin, G. B., Hernandez, R. R., Portillo  
23 Martin, J. A., Correas Gomez, M. A., del Valle Schaan, J. I., Roca, E. A., de Diego, R. E. & Rado  
24 Velazquez, M. A. (2000) [Comparative study of BTA stat test, NMP-22, and cytology in the  
25 diagnosis of bladder cancer]. [Spanish]. *Archivos Espanoles de Urologia*, 53: 21-27.  
26 Not in PICO
- 27 Hamid, A. A. (2013) The diagnostic accuracy of multidetector computed tomography with  
28 multiplanar reformatted imaging and virtual cystoscopy in the early detection and evaluation of  
29 bladder carcinoma: Comparison with conventional cystoscopy. *Journal of Endourology*, 27: A165.  
30 Not in PICO
- 31 Harzmann, R. (681) [Early diagnosis of urogenital tumors]. [German]. *Zeitschrift fur Hautkrankheiten*,  
32 62: 665-676.  
33 Narrative review
- 34 Hasan, S. T., German, K. & Derry, C. D. (1994) Same day diagnostic service for new cases of  
35 haematuria--a district general hospital experience. *British Journal of Urology*, 73: 152-154.  
36 Not in PICO
- 37 Hawary, A. M., Warburton, H. E., Brough, R. J., Collins, G. N., Brown, S. C., O'Reilly, P. H. & Adeyoju,  
38 A. A. (2008) The '2-week wait' rule for referrals for suspected urological cancers--urgent need for  
39 refinement of criteria. *Annals of the Royal College of Surgeons of England*, 90: 517-522.  
40 Not in PICO
- 41 Hee, T. G., Shah, S. A., Ann, H. S., Hemdan, S. N., Shen, L. C., Al-Fahmi Abdul, G. N., Singam, P., Ho, C.  
42 C., Hong, G. E., Bahadzor, B. & Zainuddin, Z. M. (2013) Stratifying patients with haematuria into  
43 high or low risk groups for bladder cancer: a novel clinical scoring system. *Asian Pacific Journal of*  
44 *Cancer Prevention: Apjcp*, 14: 6327-6330.  
45 Not in PICO
- 46 Heins, M. J., Korevaar, J. C., Rijken, P. M. & Schellevis, F. G. (2013) For which health problems do  
47 cancer survivors visit their General Practitioner? *European Journal of Cancer*, 49: 211-218.  
48 Not in PICO
- 49 Henning, A., Wehrberger, M., Madersbacher, S., Pycha, A., Martini, T., Comploj, E., Jeschke, K.,  
50 Tripolt, C. & Rauchenwald, M. (2013) Do differences in clinical symptoms and referral patterns



- 1 contribute to the gender gap in bladder cancer? *BJU International*, 112: 68-73.
- 2 Not in PICO
- 3 Hermann, G. G., Mogensen, K., Carlsson, S., Marcussen, N. & Duun, S. (2011) Fluorescence-guided  
4 transurethral resection of bladder tumours reduces bladder tumour recurrence due to less  
5 residual tumour tissue in Ta/T1 patients: a randomized two-centre study. *BJU International*, 108:  
6 t-303.
- 7 Not in PICO
- 8 Herr, H. W. (2010) Narrow-band imaging cystoscopy to evaluate the response to bacille Calmette-  
9 Guerin therapy: preliminary results. *BJU International*, 105: 314-316.
- 10 Not in PICO
- 11 Hollingsworth, J. M., Zhang, Y. S., Miller, D. C., Skolarus, T. A., Wood, D. P., Lee, C. T., Montie, J. E. &  
12 Hollenbeck, B. K. (2011) Identifying better practices for early-stage bladder cancer. *Medical Care*,  
13 49: 1112-1117.
- 14 Not in PICO
- 15 Ibragimova, M. I., Chushnikov, V. N., Moiseev, V. N., Petukhov, V. I., Zheglov, E. P. & Cherepnev, G. V.  
16 (2013) [Electron paramagnetic resonance study of blood of anemic patients with urological  
17 cancer]. [Russian]. *Biofizika*, 58: 289-294.
- 18 Not in PICO
- 19 Jeon, S. S., Kang, I., Hong, J. H., Choi, H. Y. & Chai, S. E. (2001) Diagnostic efficacy of fluorescence  
20 cystoscopy for detection of urothelial neoplasms. *Journal of Endourology*, 15: 753-759.
- 21 Not in PICO
- 22 Jichlinski, P. & Lovisa, B. (2011) High magnification cystoscopy in the primary diagnosis of bladder  
23 tumors. [Review]. *Current Opinion in Urology*, 21: 398-402.
- 24 Narrative review
- 25 Jochem, D., Witjes, F., Wagner, S., Zeylemaker, B., van, M. J., Grimm, M. O., Muschter, R., Popken,  
26 G., Konig, F., Knuchel, R. & Kurth, K. H. (2005) Improved detection and treatment of bladder  
27 cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. *Journal of*  
28 *Urology*, 174: 862-866.
- 29 Not in PICO
- 30 Jones, M. W., Cox, R., Davies, K. I. & Rose, M. B. (1988) The value of the pre-clinic intravenous  
31 urogram in the earlier diagnosis of the cause of haematuria. *British Journal of Urology*, 62: 11-12.
- 32 Not in PICO
- 33 Kamat, A. M., Hegarty, P. K., Gee, J. R., Clark, P. E., Svatek, R. S., Hegarty, N., Shariat, S. F., Xylinas, E.,  
34 Schmitz-Drager, B. J., Lotan, Y., Jenkins, L. C., Droller, M., van Rhijn, B. W., Karakiewicz, P. I. &  
35 International Consultation on Urologic Disease-European Association of Urology Consultation on  
36 Bladder Cancer (2013) ICUD-EAU International Consultation on Bladder Cancer 2012: Screening,  
37 diagnosis, and molecular markers. [Review]. *European Urology*, 63: 4-15.
- 38 Narrative review
- 39 Karl, A., Stief, C. & Zaak, D. (2013) [Photodynamic diagnostics of the bladder: current study results].  
40 [Review] [German]. *Urologe (Auszg.A)*, 52: 504-508.
- 41 Narrative review
- 42 Khan, M. A., Shaw, G. & Paris, A. M. (2002) Is microscopic haematuria a urological emergency? *BJU*  
43 *International*, 90: 355-357.
- 44 Not in PICO
- 45 Khandelwal, C. & Kistler, C. (2013) Diagnosis of urinary incontinence. *American Family Physician*, 87:  
46 543-551.
- 47 Narrative review
- 48 Kim, J. Y. & Kim, H. J. (2014) - A Comparison Between ThinPrep Monolayer and Cytospin Cytology for  
49 the Detection of Bladder Cancer. - *Korean Journal of Urology*, 55: 390-394.
- 50 Not in PICO

- 1 King, K. & Steggall, M. (2014) - Haematuria: from identification to treatment. - *British Journal of*  
2 *Nursing*, 23: S28-S32.  
3 Narrative review
- 4 Kitahara, S., Iwatsubo, E., Yasuda, K., Ushiyama, T., Nakai, H., Suzuki, T., Yamashita, T., Sato, R.,  
5 Kihara, T., Yamanishi, T. & Nohara, Y. (2006) Practice patterns of Japanese physicians in urologic  
6 surveillance and management of spinal cord injury patients. *Spinal Cord*, 44: 362-368.  
7 Not in PICO
- 8 Kivrak, A. S., Kiresi, D., Emlik, D., Odev, K. & Kilinc, M. (2009) Comparison of CT virtual cystoscopy of  
9 the contrast material-filled bladder with conventional cystoscopy in the diagnosis of bladder  
10 tumours. *Clinical Radiology*, 64: 30-37.  
11 Not in PICO
- 12 Kohler, C. & Varenhorst, E. (1999) [Microscopic hematuria in adults--a diagnostic dilemma. Scientific  
13 guidelines for management are not available according to a review of the literature]. [Review]  
14 [199 refs] [Swedish]. *Lakartidningen*, 96: 4911-4916.  
15 Not in PICO
- 16 Koiso, K., Kano, K., Nemoto, R., Ishikawa, H., Ohtani, M., Sato, T. & Iwasaki, A. (1989) [Detection and  
17 diagnosis of bladder cancer in the early stage]. [Japanese]. *Nippon Rinsho - Japanese Journal of*  
18 *Clinical Medicine*, 47: 1172-1177.  
19 In Japanese. No translation available.
- 20 Kruck, S., Scharpf, M., Stenzl, A. & Bedke, J. (2013) A rare case of synchronous renal cell carcinoma of  
21 the bladder presenting with gross hematuria. *Rare Tumors*, 5: 72-74.  
22 Not in PICO
- 23 Kundal, V. K., Pandith, A. A., Hamid, A., Shah, A., Kundal, R. & Wani, S. M. (2010) Role of NMP22  
24 Bladder Check Test in early detection of bladder cancer with recurrence. *Asian Pacific Journal of*  
25 *Cancer Prevention: Apjcp*, 11: 1279-1282.  
26 Not in PICO
- 27 Lahme, S., Bichler, K. H., Feil, G. & Krause, S. (2001) Comparison of cytology and nuclear matrix  
28 protein 22 for the detection and follow-up of bladder cancer. *Urologia Internationalis*, 66: 72-77.  
29 Not in PICO
- 30 Lokeshwar, V. B. & Soloway, M. S. (2001) Current bladder tumor tests: does their projected utility  
31 fulfill clinical necessity?. [Review] [90 refs]. *Journal of Urology*, 165: 1067-1077.  
32 Narrative review
- 33 Lopes, R. I., Nogueira, L., Albertotti, C. J., Takahashi, D. Y. & Lopes, R. N. (2008) Comparison of virtual  
34 cystoscopy and transabdominal ultrasonography with conventional cystoscopy for bladder tumor  
35 detection. *Journal of Endourology*, 22: 1725-1729.  
36 Not in PICO
- 37 Ludecke, G., Pilatz, A., Hauptmann, A., Bschiepfer, T. & Weidner, W. (2012) Comparative analysis of  
38 sensitivity to blood in the urine for urine-based point-of-care assays (UBC rapid, NMP22  
39 BladderChek and BTA-stat) in primary diagnosis of bladder carcinoma. Interference of blood on  
40 the results of urine-based POC tests. *Anticancer Research*, 32: 2015-2018.  
41 Not in PICO
- 42 Lynch, T. H., Waymont, B., Dunn, J. A., Hughes, M. A. & Wallace, D. M. (1994) Rapid diagnostic  
43 service for patients with haematuria. *British Journal of Urology*, 73: 147-151.  
44 Not in PICO
- 45 Lyratzopoulos, G., Neal, R. D., Barbiere, J. M., Rubin, G. P. & Abel, G. A. (2012) Variation in number of  
46 general practitioner consultations before hospital referral for cancer: findings from the 2010  
47 National Cancer Patient Experience Survey in England. *Lancet Oncology*, 13: 353-365.  
48 Not in PICO
- 49 Lyratzopoulos, G., Abel, G. A., McPhail, S., Neal, R. D. & Rubin, G. P. (2013) Gender inequalities in the  
50 promptness of diagnosis of bladder and renal cancer after symptomatic presentation: Evidence

- 1 from secondary analysis of an English primary care audit survey. *BMJ Open*, 3.  
 2 Not in PICO
- 3 MacArthur, C., Pendleton, L. L. & Smith, A. (1985) Treatment delay in patients with bladder tumours.  
 4 *Journal of Epidemiology & Community Health*, 39: 63-66.  
 5 Not in PICO
- 6 Mack, D. & Jakse, G. (1986) [Bladder cancer as an incidental finding]. [German]. *Wiener Klinische*  
 7 *Wochenschrift*, 98: 175-178.  
 8 Not in PICO
- 9 Mady, H. H. E., Omar, A. M. A., Elgammal, M. A. A. & Ibrahim, G. H. M. (2014) Utility of urine cytology  
 10 in evaluating hematuria with sonographically suspected bladder lesion in patients older than 50  
 11 years. *Urology annals*, 6: 212-217.  
 12 Not in PICO
- 13 Mahnert, B. (2003) Measurements of complement factor H-related protein (BTA-TRAK (TM) assay)  
 14 and nuclear matrix protein (NMP22 assay) - Useful diagnostic tools in the diagnosis of urinary  
 15 bladder cancer? *Clinical Chemistry and Laboratory Medicine*, 41: 104-110.  
 16 Not in PICO
- 17 Manassero, A., Chierchia, S. & Carone, R. (2013) Neurogenic lower urinary tract dysfunctions and  
 18 bladder cancer: Our experience and proposal of evaluation algorithm. *Neurourology and*  
 19 *Urodynamics*, 32: S15-S16.  
 20 Not in PICO
- 21 Martingano, P., Stacul, F., Cavallaro, M., Casagrande, F., Cernic, S., Belgrano, M. & Cova, M. (2010)  
 22 64-Slice CT urography: 30 months of clinical experience. *Radiologia Medica*, 115: 920-935.  
 23 Not in PICO
- 24 Mayr, R. & Burger, M. (2013) Value of fluorescence cystoscopy in high risk non-muscle invasive  
 25 bladder cancer. *Current Urology Reports*, 14: 90-93.  
 26 Narrative review
- 27 Meeks, J. J., Herr, H. W., Bernstein, M., Al-Ahmadie, H. A. & Dalbagni, G. (2013) Preoperative  
 28 accuracy of diagnostic evaluation of the urachal mass. *Journal of Urology*, 189: 1260-1262.  
 29 Not in PICO
- 30 Mian, C., Lodde, M., Comploj, E., Palermo, S., Mian, M., Maier, K. & Pycha, A. (2005) The value of the  
 31 ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder.  
 32 *Anticancer Research*, 25: 3641-3644.  
 33 Not in PICO
- 34 Mishriki, S. F., Nabi, G. & Cohen, N. P. (2008) Diagnosis of urologic malignancies in patients with  
 35 asymptomatic dipstick hematuria: prospective study with 13 years' follow-up. *Urology*, 71: 13-16.  
 36 Not in PICO (secondary care)
- 37 Mitra, A. P., Jorda, M. & Cote, R. J. (2012) Pathological possibilities and pitfalls in detecting  
 38 aggressive bladder cancer. [Review]. *Current Opinion in Urology*, 22: 397-404.  
 39 Narrative review
- 40 Mitterberger, M., Pinggera, G. M., Neuwirt, H., Maier, E., Akkad, T., Strasser, H., Gradl, J., Pallwein,  
 41 L., Bartsch, G. & Frauscher, F. (2007) Three-dimensional ultrasonography of the urinary bladder:  
 42 preliminary experience of assessment in patients with haematuria. *BJU International*, 99: 111-  
 43 116.  
 44 Not in PICO
- 45 Mohammed, A., Shergill, I. S., Vandal, M. T. & Gujral, S. S. (2010) Incidental urinary tract pathologies  
 46 in the one-stop prostate cancer clinic.[Erratum appears in Arch Ital Urol Androl. 2010 Jun;82(2):III  
 47 Note: Aza, Mohammed [corrected to Mohammed, Aza]; Iqbal, S Shergill [corrected to Shergill,  
 48 Iqbal S]; Muhammad, M Vandal [corrected to Vandal, Muhammad T]; Sandeep, S Gujrai  
 49 [corrected to Gujral, Sandeep S]]. *Archivio Italiano di Urologia, Andrologia*, 82: 15-17.  
 50 Not in PICO

- 1 Monreal, M., Lafoz, E., Casals, A., Inaraja, L., Montserrat, E., Callejas, J. M. & Martorell, A. (1991)  
2 Occult cancer in patients with deep venous thrombosis. A systematic approach. *Cancer*, 67: 541-  
3 545.  
4 Not in PICO
- 5 Nakamura, K. (2009) Utility of serial urinary cytology in the initial evaluation of the patient with  
6 microscopic hematuria. *BMC Urology*, 9.  
7 Not in PICO
- 8 Naslund, I. (1988) Reliability and accuracy of Urotel test, a device for urinary cytology. *European*  
9 *Urology*, 15: 54-58.  
10 Not in PICO
- 11 Neal, R. D., Din, N. U., Hamilton, W., GBroumune, O. C., Carter, B., Stapley, S. & Rubin, G. (2014)  
12 Comparison of cancer diagnostic intervals before and after implementation of NICE guidelines:  
13 Analysis of data from the GBR General Practice Research Database. *British Journal of Cancer*,  
14 110: 584-592.  
15 Not in PICO
- 16 Nemoto, S., Ishikawa, S., Takeshima, H., Iizumi, T., Uchida, K., Yazaki, T., Nemoto, R., Rinsho, K. &  
17 Kano, S. (1983) [Clinical study of urinary cytology: with special reference to bladder cancer].  
18 [Japanese]. *Hinyokika Kiyo - Acta Urologica Japonica*, 29: 1611-1615.  
19 Not in PICO
- 20 Ng, K. L., Htun, T. H., Dublin, N., Ong, T. A. & Razack, A. H. (2012) Assessment and clinical significance  
21 of haematuria in Malaysian patients - relevance to early cancer diagnosis. *Asian Pacific Journal of*  
22 *Cancer Prevention: Apjcp*, 13: 2515-2518.  
23 Not in PICO
- 24 Nicolau, C., Bunesch, L., Peri, L., Salvador, R., Corral, J. M., Mallofre, C. & Sebastia, C. (2011) Accuracy  
25 of contrast-enhanced ultrasound in the detection of bladder cancer. *British Journal of Radiology*,  
26 84: 1091-1099.  
27 Not in PICO
- 28 Nitti, V. & Taneja, S. (2005) Overactive bladder: achieving a differential diagnosis from other lower  
29 urinary tract conditions. [Review] [43 refs]. *International Journal of Clinical Practice*, 59: 825-830.  
30 Narrative review
- 31 O'Donoghue, J. M., Horgan, P. G., Corcoran, M., Bredin, H., McGuire, M. & Given, H. F. (1991) Urinary  
32 cytology in the detection of bladder carcinoma. *Irish Journal of Medical Science*, 160: 352-353.  
33 Not in PICO
- 34 Ollesch, J., Drees, S. L., Heise, H. M., Behrens, T., Bruning, T. & Gerwert, K. (2013) FTIR spectroscopy  
35 of biofluids revisited: an automated approach to spectral biomarker identification. *Analyst*, 138:  
36 4092-4102.  
37 Not in PICO
- 38 Owens, J. L., DiPiero, J. M., Elson, P. & Hansel, D. E. (2013) Urine biobanking: Methods, validation,  
39 and research results. *Laboratory Investigation*, 93: 499A.  
40 Not in PICO
- 41 Palmer, S., Sokolovski, S. G., Rafailov, E. & Nabi, G. (2013) Technologic developments in the field of  
42 photonics for the detection of urinary bladder cancer. *Clinical Genitourinary Cancer*, 11: 390-396.  
43 Narrative review
- 44 Park, J. W., Jeong, B. C., Seo, S. I., Jeon, S. S., Kwon, G. Y. & Lee, H. M. (2010) Leiomyoma of the  
45 urinary bladder: a series of nine cases and review of the literature. [Review]. *Urology*, 76: 1425-  
46 1429.  
47 Not in PICO
- 48 Patel, N. (2009) The diagnostic value of abdominal ultrasound, urine cytology and prostate-specific  
49 antigen testing in the lower urinary tract symptoms clinic. *International Journal of Clinical*  
50 *Practice*, 63: 1734-1738.  
51 Not in PICO

- 1 Paul, A. B., Collie, D. A., Wild, S. R. & Chisholm, G. D. (1993) An integrated haematuria clinic. *British*  
2 *Journal of Clinical Practice*, 47: 128-130.  
3 Not in PICO
- 4 Pode, D., Golijanin, D., Sherman, Y., Lebensart, P. & Shapiro, A. (1993) Immunostaining of Lewis X in  
5 cells from voided urine, cytopathology and ultrasound for noninvasive detection of bladder  
6 tumors. *Journal of Urology*, 159: 389-392.  
7 Not in PICO
- 8 Pomara, G. & Francesca, F. (2013) [Endoscopic resection. Aspects of technique and optimization of  
9 outcomes. Current indications to PDD-guided resection]. [Italian]. *Urologia*, 80: 16-19.  
10 Narrative review
- 11 Poulakis, V., Witzsch, U., De, V. R., Altmannsberger, H. M., Manyak, M. J. & Becht, E. (2001) A  
12 comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided  
13 urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive  
14 results. *BJU International*, 88: 692-701.  
15 Not in PICO
- 16 Purysko, A. S., Leao Filho, H. M. & Herts, B. R. (2012) Radiologic imaging of patients with bladder  
17 cancer. [Review]. *Seminars in Oncology*, 39: 543-558.  
18 Narrative review
- 19 Ren, H., Waltzer, W. C., Bhalla, R., Liu, J., Yuan, Z., Lee, C. S., Darras, F., Schulsinger, D., Adler, H. L.,  
20 Kim, J., Mishail, A. & Pan, Y. (2009) Diagnosis of bladder cancer with microelectromechanical  
21 systems-based cystoscopic optical coherence tomography. *Urology*, 74: 1351-1357.  
22 Not in PICO
- 23 Restrepo, N. C. & Carey, P. O. (1989) Evaluating hematuria in adults. [Review] [27 refs]. *American*  
24 *Family Physician*, 40: 149-156.  
25 Narrative review
- 26 Rodgers, M. A., Hempel, S., Aho, T., Kelly, J. D., Kleijnen, J. & Westwood, M. (2006) Diagnostic tests  
27 used in the investigation of adult haematuria: a systematic review. *BMJ Int*, 98: 1154-1160.  
28 Systematic review, checked for relevant studies
- 29 Rosser, C. J., Urquidi, V. & Goodison, S. (2013) Urinary biomarkers of bladder cancer: an update and  
30 future perspectives. *Biomarkers in Medicine*, 7: 779-790.  
31 Narrative review
- 32 Sanchez-Carbayo, M., Urrutia, M., Silva, J. M., Romani, R., De Buitrago, J. M. & Navajo, J. A. (2001)  
33 Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1  
34 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. *Journal of Urology*,  
35 165: 1462-1467.  
36 Not in PICO
- 37 Schamhart, D. H., de Reijke, T. M., van der Poel, H. G., Witjes, J. A., de Boer, E. C., Kurth, K. &  
38 Schalken, J. A. (1998) The Bard BTA test: its mode of action, sensitivity and specificity, compared  
39 to cytology of voided urine, in the diagnosis of superficial bladder cancer. *European Urology*, 34:  
40 99-106.  
41 Not in PICO
- 42 Schulze, S., Holm-Nielsen, A. & Mogensen, P. (1991) Transurethral ultrasound scanning in the  
43 evaluation of invasive bladder cancer. *Scandinavian Journal of Urology & Nephrology*, 25: 215-  
44 217.  
45 Not in PICO
- 46 Sharp, V. J., Barnes, K. T. & Erickson, B. A. (2013) Assessment of asymptomatic microscopic  
47 hematuria in adults. *American Family Physician*, 88: 747-754.  
48 Narrative review
- 49 Siemens, D. R., Morales, A., Johnston, B. & Emerson, L. (2003) A comparative analysis of rapid urine  
50 tests for the diagnosis of upper urinary tract malignancy. *Canadian Journal of Urology*, 10: 1754-

- 1 1758.  
2 Not in PICO
- 3 Simon, J., Bartsch, G., Jr., Rinnab, L., Hautmann, R. E. & Volkmer, B. G. (2009) Transrectal ultrasound  
4 as diagnostic tool for the detection of local recurrence following cystectomy and urinary  
5 diversion. *Urologia Internationalis*, 82: 12-16.  
6 Not in PICO
- 7 Singh, R., Saleemi, A., Walsh, K., Popert, R. & O'Brien, T. (2003) Near misses in bladder cancer - an  
8 airline safety approach to urology. *Annals of the Royal College of Surgeons of England*, 85: 378-  
9 381.  
10 Not in PICO
- 11 Siracusano, S., Niccolini, B., Knez, R., Tiberio, A., Benedetti, E., Bonin, S., Ciciliato, S., Pappagallo, G.  
12 L., Belgrano, E. & Stanta, G. (2005) The simultaneous use of telomerase, cytokeratin 20 and CD4  
13 for bladder cancer detection in urine. *European Urology*, 47: 327-333.  
14 Not in PICO
- 15 Spencer, J., Lindsell, D. & Mastorakou, I. (1990) Ultrasonography compared with intravenous  
16 urography in the investigation of adults with haematuria. *BMJ*, 301: 1074-1076.  
17 Not in PICO
- 18 Srivastava, A. K., Singh, P. K., Srivastava, K., Singh, D., Dalela, D., Rath, S. K., Goel, M. M. & Brahma  
19 Bhatt, M. L. (2013) Diagnostic role of survivin in urinary bladder cancer. *Asian Pacific Journal of*  
20 *Cancer Prevention: Apjcp*, 14: 81-85.  
21 Not in PICO
- 22 Subramonian, K. R., Puranik, S. & Mufti, G. R. (2003) How will the two-weeks-wait rule affect delays  
23 in management of urological cancers? *Journal of the Royal Society of Medicine*, 96: 398-399.  
24 Not in PICO
- 25 Talbot, R. W., Bannister, J. J. & Hills, N. H. (1984) A haematuria diagnostic service in a district general  
26 hospital. *Annals of the Royal College of Surgeons of England*, 66: 348-350.  
27 Not in PICO
- 28 Tan, P. K., Chang, H. C. & Sitoh, Y. Y. (1998) Haematuria clinic--a preliminary audit and considerations  
29 for a one-stop assessment centre. *Singapore Medical Journal*, 39: 501-503.  
30 Not in PICO
- 31 Tanaka, M. (2011) Diagnosis and Management of Urothelial Carcinoma of the Bladder. *Postgraduate*  
32 *Medicine*, 123: 43-55.  
33 Narrative review
- 34 Tauber, S., Liedl, B., Schneede, P., Liessmann, F., Waidelich, R. & Hofstetter, A. (2001) [Fluorescence  
35 cytology of the urinary bladder]. [German]. *Urologe (Ausg.A)*, 40: 217-221.  
36 Not in PICO (at least 17/27 had cancer)
- 37 Thiruchelvam, N. & Mostafid, H. (2005) Do patients with frank haematuria referred under the two-  
38 week rule have a higher incidence of bladder cancer? *Annals of the Royal College of Surgeons of*  
39 *England*, 87: 345-347.  
40 Not in PICO
- 41 Tissot, W. D., Diokno, A. C. & Peters, K. M. (2004) A referral center's experience with transitional cell  
42 carcinoma misdiagnosed as interstitial cystitis. *Journal of Urology*, 172: 478-480.  
43 Not in PICO
- 44 Tomera, K. (2004) NMP22 (R) BladderChek (R) Test: point-of-care technology with life. and money-  
45 saving potential. *Expert Review of molecular diagnostics*, 4: 783-794.  
46 Narrative review
- 47 Trivedi, D. (2009) Commentary: the role of cytologic analysis of voided urine in the work-up of  
48 asymptomatic microhematuria. *BMC Urology*, 9.  
49 Narrative review

- 1 Turner, C. & Grady, M. (2013) 12-Year-old boy with back spasms. *Clinical Journal of Sport Medicine*,  
2 23: e13.  
3 Not in PICO
- 4 Vaish, M., Mandhani, A., Mittal, R. D. & Mittal, B. (2005) Microsatellite instability as prognostic  
5 marker in bladder tumors: a clinical significance. *BMC Urology*, 5: 2.  
6 Not in PICO
- 7 Volpe, A., Racioppi, M., D'Agostino, D., Cappa, E., Gardi, M., Totaro, A., Pinto, F., Sacco, E., Marangi,  
8 F., Palermo, G. & Bassi, P. F. (2008) Bladder tumor markers: a review of the literature. [Review]  
9 [145 refs]. *International Journal of Biological Markers*, 23: 249-261.  
10 Narrative review
- 11 Wadhwa, N., Jatawa, S. K. & Tiwari, A. (2012) Non-invasive urine based tests for the detection of  
12 bladder cancer. *Journal of Clinical Pathology*, 65: 970-975.  
13 Narrative review
- 14 Wadhwa, N., Jatawa, S. K. & Tiwari, A. (2013) Non-invasive urine based tests for the detection of  
15 bladder cancer. *Postgraduate Medical Journal*, 89: 352-357.  
16 Narrative review
- 17 Wadhwa, N., Jatawa, S. K. & Tiwari, A. (2013) Republished: non-invasive urine based tests for the  
18 detection of bladder cancer.[Reprint of J Clin Pathol. 2012 Nov;65(11):970-5; PMID: 22685259].  
19 *Postgraduate Medical Journal*, 89: 352-357.  
20 Narrative review
- 21 Wawroschek, F. & Roth, S. (2003) [Hematuria in cases of bladder cancer]. [Review] [28 refs]  
22 [German]. *Urologe (Ausg.A)*, 42: 902-907.  
23 Narrative review
- 24 Wilson, C., Boyd, K., Mohammed, A. & Little, B. (2010) A single episode of haemospermia can be  
25 safely managed in the community. *International Journal of Clinical Practice*, 64: 1436-1439.  
26 Not in PICO
- 27 Yafi, F. (2011) Patients with microscopic and gross hematuria: practice and referral patterns among  
28 primary care physicians in a universal health care system. *Canadian Urological Association*  
29 *Journal*, 5: 97-101.  
30 Not in PICO
- 31 Yakasai, A., Allam, M. & Thompson, A. J. (2011) Incidence of bladder cancer in a one-stop clinic.  
32 *Annals of African Medicine*, 10: 112-114.  
33 Not in PICO
- 34 Yeaton-Massey, A., Brookfield, K. F., Aziz, N., Mrazek-Pugh, B. & Chueh, J. (2013) Maternal bladder  
35 cancer diagnosed at routine first-trimester obstetric ultrasound examination. *Obstetrics &*  
36 *Gynecology*, 122: t-7.  
37 Not in PICO
- 38 Yegin, Z., Gunes, S. & Buyukalpelli, R. (2013) Hypermethylation of TWIST1 and NID2 in tumor tissues  
39 and voided urine in urinary bladder cancer patients. *DNA & Cell Biology*, 32: 386-392.  
40 Not in PICO
- 41 Yip, S. K., Peh, W. C., Tam, P. C., Li, J. H. & Lam, C. H. (1998) Day case hematuria diagnostic service:  
42 use of ultrasonography and flexible cystoscopy. *Urology*, 52: 762-766.  
43 Not in PICO
- 44 Yoo, J. H., Suh, B., Park, T. S., Shin, M. G., Choi, Y. D., Lee, C. H. & Choi, J. R. (2010) Analysis of  
45 fluorescence in situ hybridization, mtDNA quantification, and mtDNA sequence for the detection  
46 of early bladder cancer. *Cancer Genetics & Cytogenetics*, 198: 107-117.  
47 Not in PICO
- 48 Young, M. J. & Soloway, M. S. (1998) Office evaluation and management of bladder neoplasms.  
49 [Review] [43 refs]. *Urologic Clinics of North America*, 25: 603-611.  
50 Narrative review

1 Yun, E. (2004) Evaluation of the patient with hematuria. *Medical Clinics of North America*, 88: 329.  
2 Narrative review

3 Zhu, J., Zeng, Y. & Yang, B. (2013) Research progress of bladder cancer-related factors. [Chinese].  
4 *Chinese Journal of Clinical Oncology*, 40: 741-744.  
5 Narrative review

6 Zippe, C., Pandrangi, L., Potts, J. M., Kursh, E., Novick, A. & Agarwal, A. (1999) NMP22: a sensitive,  
7 cost-effective test in patients at risk for bladder cancer. *Anticancer Research*, 19: 2621-2623.  
8 Not in PICO

9 Zippe, C., Pandrangi, L. & Agarwal, A. (1999) NMP22 is a sensitive, cost-effective test in patients at  
10 risk for bladder cancer. *Journal of Urology*, 161: 62-65.  
11 Not in PICO  
12

13



**RENAL CANCER****Review question:**

What is the risk of renal cancer in patients presenting in primary care with symptom(s)?

**Results****Literature search**


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	All-2012	718	72	10/12/2012
<i>Premedline</i>	All-2012	29	2	10/12/2012
<i>Embase</i>	All-2012	662	57	10/12/2012
<i>Cochrane Library</i>	All-2012	289	0	11/12/2012
<i>Psychinfo</i>	All-2012	1	0	10/12/2012
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	All-2012	283	5	11/12/2012
<i>Biomed Central</i>	All-2012	18	0	11/12/2012

Total References retrieved (after de-duplication): 94

**Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	2013-18/08/2014	49	8	18/08/2014
<i>Premedline</i>	2013-18/08/2014	67	7	18/08/2014
<i>Embase</i>	2013-18/08/2014	140	8	18/08/2014
<i>Cochrane Library</i>	2013-18/08/2014	207	0	18/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	2013-18/08/2014	67	5	18/08/2014

Total References retrieved (after de-duplication): 22



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12

**Risk of bias in the included studies**

The risk of bias and applicability concerns are summarised per study in the figure below. The main issue to note is that patient selection is associated with a number of bias or applicability concerns in most of the included studies, with some studies employing non-consecutive or non-random selection of patients and with some studies being employed in settings that are not clearly directly representative of UK-based primary care. Other areas of concern include missing data, compromised reference standards and underspecified presenting symptoms. These issues should all be born in mind when evaluating the evidence along with the fact that a large number of the included cancers were not renal cancers.

	Risk of Bias				Applicability Concerns		
	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard
Collins (2013)	+	+	+	+	+	+	+
Deyo (1988)	?	+	?	+	-	+	+
Dommett (2012, 2013)	-	+	+	+	+	+	+
Friedlander (2014)	+	+	?	+	?	+	+
Hippisley-Cox (2012)	+	+	+	-	+	+	+
Jones (2007)	+	+	+	+	+	+	+
Muris (1995)	-	+	+	+	-	-	+
Oudega (2006)	+	+	+	+	?	+	+
Shephard (2013)	-	+	+	+	+	+	+

High	Unclear	Low
------	---------	-----

1  
2  
3  
4  
5  
6

**Study results**

Table 1: Renal cancer: Meta-analyses

Studies included	Symptom(s)	Patient group	Positive predictive value, % (95% CI)
Collins (2013), Friedlander (2014), Hippisley-Cox (2012), Jones (2007, at 6 months)	Haematuria	All patients (N = 69921)	3.05 (1.3-7.01)
Collins (2013), Friedlander (2014), Hippisley-Cox (2012), Jones (2007, at 3 years)	Haematuria	All patients (N = 69921)	3.3 (1.35-7.84)

Please note that the data from Shephard (2012) are not included in these meta-analyses due to the case-control design of the study. These data are instead reported in the table below.

7  
8  
9

Table 2: Renal cancer: Individual positive predictive values from the meta-analyses

Studies included	Symptom(s)	Patient group	Positive predictive value, % (95% CI)
Collins (2013)	Haematuria	All patients (N = 37810)	4.35 (4.1-4.6)
Friedlander (2014)	Haematuria	All included patients (N = 2455)	0.65 (0.39-1.83) 16/2455
Hippisley-Cox (2012)	Haematuria	All patients (N = 18548)	6.48 (6.1-6.8)
Jones (2007, at 6 months)	Haematuria	All patients (N = 11108)	4.2 (3.8-4.6)

months),			
Jones (2007, at 3 years),	Haematuria	All patients (N = 11108)	5.7 (5.3-6.2)

1  
2

Table 3: Renal cancer: Patients aged &gt; 14 years: Single symptoms

Study	Symptom(s)	Patient group	Positive predictive value % (95% CI)
Collins (2013)	Abdominal pain	All patients	0.11 (0.1-0.13)
		Men	0.2 (0.2-0.21)
		Women	0.1 (0.1-0.1)
Hippisley-Cox (2012)	Abdominal pain	All patients	0.2 (0.2-0.2)
Muris (1995)	Non-acute abdominal complaints	All patients	0.11 (0.01-0.7) 1/933
Shephard (2013)	Abdominal pain	Patients ≥ 60 years	0.1 (0.1-0.2) Cases: 350/3149 Controls: 514/14091
Shephard (2013)	Abdominal pain: 2 presentations	Patients ≥ 60 years	0.2 (0.1-0.2)
Shephard (2013)	Constipation	Patients ≥ 60 years	0.1 (0.08-0.11) Cases: 194/3149 Controls: 420/14091
Shephard (2013)	Constipation: 2 presentations	Patients ≥ 60 years	0.1 (0.06-0.12)
Shephard (2013)	Lower urinary tract infection	Patients ≥ 60 years	0.1 (0.09-0.12) Cases: 339/3149 Controls: 608/14091
Shephard (2013)	Lower urinary tract infection: 2 presentations	Patients ≥ 60 years	0.1 (0.1-0.2)
Shephard (2013)	Fatigue	Patients ≥ 60 years	0.1 (0.09-0.13) Cases: 210/3149 Controls: 405/14091
Shephard (2013)	Fatigue: 2 presentations	Patients ≥ 60 years	0.1 (0.1-0.2)
Shephard (2013)	Nausea	Patients ≥ 60 years	0.1 (0.1-0.2) Cases: 171/3149 Controls: 263/14091
Shephard (2013)	Nausea: 2 presentations	Patients ≥ 60 years	0.2 (0.1-0.2)
Shephard (2013)	Raised inflammatory markers	Patients ≥ 60 years	0.2 (0.1-0.2) Cases: 738/3149 Controls: 993/14091
Shephard (2013)	Thrombocytosis	Patients ≥ 60 years	0.3 (0.2-0.3) Cases: 348/3149 Controls: 251/14091
Shephard (2013)	Microcytosis	Patients ≥ 60 years	0.3 (0.2-0.4) Cases: 233/3149 Controls: 158/14091
Deyo (1988)	Back pain	All included patients	0.05 (0.002-0.3) TP = 1, FP = 1974 N = 8 had other

			types of cancer
Shephard (2013)	Back pain	Patients ≥ 60 years	0.1 (0.07-0.12) Cases: 341/3149 Controls: 901/14091
Shephard (2013)	Back pain: 2 presentations	Patients ≥ 60 years	0.1 (0.07-0.12)
Collins (2013)	Anaemia	All patients	0.6 (0.5-0.7)
		Men	1.4 (1.1-1.9)
		Women	0.3 (0.3-0.5)
Hippisley-Cox (2012)	Anaemia	All patients	.69 (0.5-0.9)
Collins (2013)	Appetite loss	Women	0.1 (0.04-0.3)
Hippisley-Cox (2012)	Appetite loss	All patients	0.18 (0.07-0.4)
Oudega (2006)	Deep vein thrombosis	All patients	1.16 (0.4-2.9) 5/430
Collins (2013)	Weight loss	Women	0.1 (0.1-0.2)
Hippisley-Cox (2012)	Weight loss	All patients	0.41 (0.3-0.6)
Collins (2013)	Haematuria	Men	5.5 (5.2-5.8)
		Women	2.6 (2.3-2.8)
Shephard (2013)	Visible haematuria	Patients 40-59 years	0.7 (0.4-1.3)
Shephard (2013)	Visible haematuria	Patients ≥ 60 years	1 (0.08-1.3) Cases: 558/3149 Controls: 97/14091
Shephard (2013)	Visible haematuria: 2 presentations	Patients ≥ 60 years	1.2 (0.9-1.8)
Jones (2007)	Haematuria	Men (all ages) at 6 months	5.47 (4.9-6.1)
Jones (2007)	Haematuria	Men < 45 years at 3 years	0.99 (0.53-1.69)
Jones (2007)	Haematuria	Men 45-54 years at 3 years	4.35 (3.11-5.9)
Jones (2007)	Haematuria	Men 55-64 years at 3 years	8.51 (6.94-10.32)
Jones (2007)	Haematuria	Men 65-74 years at 3 years	11.21 (9.66-12.9)
Jones (2007)	Haematuria	Men 75-84 years at 3 years	10.27 (8.61-12.13)
Jones (2007)	Haematuria	Men ≥ 85 years at 3 years	9.22 (6.43-12.7)
Jones (2007)	Haematuria	Women (all ages) at 6 months	2.48 (2.1-3)
Jones (2007)	Haematuria	Women < 45 years at 3 years	0.22 (0.05-0.64)
Jones (2007)	Haematuria	Women 45-54 years at 3 years	1.34 (0.65-2.45)
Jones (2007)	Haematuria	Women 55-64 years at 3 years	3.42 (2.26-4.93)
Jones (2007)	Haematuria	Women 65-74 years at 3 years	5.91 (4.42-7.72)
Jones (2007)	Haematuria	Women 75-84 years at 3 years	6.83 (5.06-8.98)

Jones (2007)	Haematuria	Women ≥ 85 years at 3 years	8.53 (5.6-12.3)
--------------	------------	-----------------------------	-----------------

1 TP = True positives, FP = False positives. Shephard (2013) calculated the positive predictive values  
 2 using Bayesian statistics.

3  
 4 Table 4: Renal cancer: Patients aged ≥ 60 years: Symptom combinations

Study	Symptom(s)	Patient group	Positive predictive value % (95% CI)
Shephard (2013)	Abdominal pain and back pain	Patients ≥ 60 years	0.2 (0.1-0.3)
Shephard (2013)	Abdominal pain and constipation	Patients ≥ 60 years	0.1 (0.1-0.2)
Shephard (2013)	Abdominal pain and lower urinary tract infections	Patients ≥ 60 years	0.3 (0.2-0.4)
Shephard (2013)	Abdominal pain and fatigue	Patients ≥ 60 years	0.2 (0.1-0.3)
Shephard (2013)	Abdominal pain and nausea	Patients ≥ 60 years	0.2 (0.1-0.2)
Shephard (2013)	Abdominal pain and raised inflammatory markers	Patients ≥ 60 years	0.2 (0.2-0.3)
Shephard (2013)	Abdominal pain and thrombocytosis	Patients ≥ 60 years	0.5 (0.3-1)
Shephard (2013)	Abdominal pain and microcytosis	Patients ≥ 60 years	> 5 (NR)
Shephard (2013)	Abdominal pain and visible haematuria	Patients ≥ 60 years	2.8 (NR)
Shephard (2013)	Visible haematuria and back pain	Patients ≥ 60 years	0.7 (0.4-1.3)
Shephard (2013)	Visible haematuria and constipation	Patients ≥ 60 years	1 (NR)
Shephard (2013)	Visible haematuria and lower urinary tract infections	Patients ≥ 60 years	0.6 (0.4-1)
Shephard (2013)	Visible haematuria and fatigue	Patients ≥ 60 years	0.9 (NR)
Shephard (2013)	Visible haematuria and nausea	Patients ≥ 60 years	1.1 (NR)
Shephard (2013)	Visible haematuria and raised inflammatory markers	Patients ≥ 60 years	1.3 (0.7-2.2)
Shephard (2013)	Visible haematuria and thrombocytosis	Patients ≥ 60 years	2.1 (NR)
Shephard (2013)	Visible haematuria and microcytosis	Patients ≥ 60 years	1.5 (NR)
Shephard (2013)	Constipation and back pain	Patients ≥ 60 years	0.2 (0.1-0.2)
Shephard (2013)	Constipation and lower urinary tract infections	Patients ≥ 60 years	0.1 (0.1-0.2)
Shephard (2013)	Constipation and fatigue	Patients ≥ 60 years	0.2 (0.1-0.3)

Shephard (2013)	Constipation and nausea	Patients $\geq$ 60 years	0.2 (0.1-0.2)
Shephard (2013)	Constipation and raised inflammatory markers	Patients $\geq$ 60 years	0.3 (0.2-0.4)
Shephard (2013)	Constipation and thrombocytosis	Patients $\geq$ 60 years	0.3 (0.2-0.5)
Shephard (2013)	Constipation and microcytosis	Patients $\geq$ 60 years	0.6 (NR)
Shephard (2013)	Back pain and lower urinary tract infections	Patients $\geq$ 60 years	0.2 (0.1-0.3)
Shephard (2013)	Back pain and fatigue	Patients $\geq$ 60 years	0.2 (0.1-0.3)
Shephard (2013)	Back pain and nausea	Patients $\geq$ 60 years	0.2 (0.1-0.3)
Shephard (2013)	Back pain and raised inflammatory markers	Patients $\geq$ 60 years	0.2 (0.1-0.2)
Shephard (2013)	Back pain and thrombocytosis	Patients $\geq$ 60 years	0.3 (0.2-0.4)
Shephard (2013)	Back pain and microcytosis	Patients $\geq$ 60 years	0.3 (0.1-0.6)
Shephard (2013)	Lower urinary tract infections and fatigue	Patients $\geq$ 60 years	0.2 (0.1-0.3)
Shephard (2013)	Lower urinary tract infections and nausea	Patients $\geq$ 60 years	0.2 (0.1-0.4)
Shephard (2013)	Lower urinary tract infections and raised inflammatory markers	Patients $\geq$ 60 years	0.2 (0.1-0.3)
Shephard (2013)	Lower urinary tract infections and thrombocytosis	Patients $\geq$ 60 years	0.3 (0.2-0.4)
Shephard (2013)	Lower urinary tract infections and microcytosis	Patients $\geq$ 60 years	0.4 (0.2-0.8)
Shephard (2013)	Fatigue and nausea	Patients $\geq$ 60 years	0.2 (0.1-0.3)
Shephard (2013)	Fatigue and raised inflammatory markers	Patients $\geq$ 60 years	0.2 (0.2-0.3)
Shephard (2013)	Fatigue and thrombocytosis	Patients $\geq$ 60 years	0.5 (0.3-0.9)
Shephard (2013)	Fatigue and microcytosis	Patients $\geq$ 60 years	0.4 (0.2-0.8)
Shephard (2013)	Nausea and raised inflammatory markers	Patients $\geq$ 60 years	0.2 (0.2-0.3)
Shephard (2013)	Nausea and thrombocytosis	Patients $\geq$ 60 years	0.4 (0.2-0.6)
Shephard (2013)	Nausea and microcytosis	Patients $\geq$ 60 years	0.5 (NR)
Shephard (2013)	Raised inflammatory markers and thrombocytosis	Patients $\geq$ 60 years	0.4 (0.3-0.5)
Shephard (2013)	Raised inflammatory markers and microcytosis	Patients $\geq$ 60 years	0.7 (0.5-1)
Shephard (2013)	Thrombocytosis and microcytosis	Patients $\geq$ 60 years	0.6 (0.4-1)

1 NR = Not reported. TP = True positives, FP = False positives. Shephard (2013) calculated the positive  
2 predictive values using Bayesian statistics.

1  
2

Table 5: Renal cancer: Positive predictive values for any childhood cancer: All patients

Study	Symptom(s)	Patient group	Positive predictive value (95% CI) Frequency
Dommett (2012)	Any NICE alert symptom 0-3 months before diagnosis	All included patients	0.055 (0.047-0.065) Cases: 342/1267 Control: 211/15318
Dommett (2012)	Any NICE alert symptom 0-12 months before diagnosis	All included patients	0.07 (0.064-0.078) Cases: 427/1267 Control: 829/15318
Dommett (2012)	Neurological symptoms 0-12 months before diagnosis	All included patients	0.083 (0.067-0.105) Cases: 108/1267 Control: 207/15318
Dommett (2012)	Headache 0-12 months before diagnosis	All included patients	0.064 (0.051-0.082) Cases: 90/1267 Control: 224/15318
Dommett (2013)	Headache 0-3 months before diagnosis	All included patients	0.06 (0.04-0.08) Cases: 73/1267 Control: 55/15318
Dommett (2013)	Headache 0-3 months before diagnosis and $\geq 3$ consultations	All included patients	0.13 (0.08-0.22)
Dommett (2012)	Lymphadenopathy 0-12 months before diagnosis	All included patients	0.096 (0.074-0.126) Cases: 82/1267 Control: 136/15318
Dommett (2013)	Lymphadenopathy 0-3 months before diagnosis	All included patients	0.09 (0.06-0.13) Cases: 69/1267 Control: 33/15318
Dommett (2013)	Lymphadenopathy 0-3 months before diagnosis and $\leq 3$ consultations	All included patients	0.2 (0.1-0.39)
Dommett (2012)	Lump/mass/swelling 0-12 months before diagnosis	All included patients	0.172 (0.119-0.25) Cases: 56/1267 Control: 52/15318
Dommett (2013)	Lump/mass/swelling below neck excluding abdomen 0-3 months before diagnosis	All included patients	0.11 (0.06-0.2) Cases: 42/1267 Control: 16/15318
Dommett (2013)	Lump/mass/swelling below neck excluding abdomen 0-3 months before diagnosis and $\geq 3$ consultations	All included patients	0.3 (0.09-0.99)
Dommett (2012)	Fatigue 0-12 months before diagnosis	All included patients	0.085 (0.06-0.121) Cases: 47/1267 Control: 88/15318
Dommett (2013)	Fatigue 0-12 months before diagnosis	All included patients	0.07 (0.04-0.12) Cases: 42/1267 Control: 24/15318
Dommett (2013)	Fatigue 0-12 months	All included patients	0.12 (0.06-0.23)



	before diagnosis and $\geq 3$ consultations		
Dommett (2012)	Back pain 0-12 months before diagnosis	All included patients	0.088 (0.06-0.128) Cases: 40/1267 Control: 73/15318
Dommett (2012)	Bruising 0-12 months before diagnosis	All included patients	0.08 (0.054-0.118) Cases: 38/1267 Control: 76/15318
Dommett (2013)	Bruising 0-3 months before diagnosis	All included patients	0.08 (0.05-0.13) Cases: 33/1267 Control: 18/15318
Dommett (2013)	Bruising 0-3 months before diagnosis and $\geq 3$ consultations	All included patients	0.38 (0.09-1.64)
Dommett (2013)	Pallor 0-3 months before diagnosis	All included patients	0.41 (0.12-1.34) Cases: 33/1267 Control: 18/15318
Dommett (2013)	Pallor 0-3 months before diagnosis and $\geq 3$ consultations	All included patients	0.76 (0.1-5.7)
Dommett (2013)	Lump mass swelling head and neck 0-3 months before diagnosis	All included patients	0.3 (0.1-0.84) Cases: 28/1267 Control: 4/15318
Dommett (2013)	Lump mass swelling head and neck 0-3 months before diagnosis and $\leq 3$ consultations	All included patients	0.76 (0.1-5.7)
Dommett (2013)	Abnormal movement 0-3 months before diagnosis	All included patients	0.08 (0.04-0.14) Cases: 49/1267 Control: 26/15318
Dommett (2013)	Abnormal movement 0-3 months before diagnosis and $\geq 3$ consultations	All included patients	0.15 (0.07-0.32)
Dommett (2013)	Bleeding 0-3 months before diagnosis	All included patients	0.06 (0.03-0.1) Cases: 28/1267 Control: 21/15318
Dommett (2013)	Bleeding 0-3 months before diagnosis and $\geq 3$ consultations	All included patients	0.11 (0.04-0.31)
Dommett (2013)	Visual symptoms 0-3 months before diagnosis	All included patients	0.06 (0.03-0.10) Cases: 28/1267 Control: 21/15318
Dommett (2013)	Visual symptoms 0-3 months before diagnosis and $\leq 3$ consultations	All included patients	0.23 (0.07-0.77)
Dommett (2013)	Pain 0-3 months before diagnosis	All included patients	0.04 (0.03-0.06) Cases: 42/1267 Control: 41/15318
Dommett (2013)	Pain 0-3 months before diagnosis and $\geq 3$	All included patients	0.14 (0.07-0.31)

	consultations		
Dommett (2013)	Musculoskeletal symptoms 0-3 months before diagnosis	All included patients	0.04 (0.03-0.07) Cases: 107/1267 Control: 102/15318
Dommett (2013)	Musculoskeletal symptoms 0-3 months before diagnosis and $\geq 3$ consultations	All included patients	0.13 (0.08-0.19)
Dommett (2012)	Urinary symptoms 0-12 months before diagnosis	All included patients	0.266 (0.117-0.609) Cases: 15/1267 Control: 9/15318
Dommett (2013)	$\geq 3$ consultations	All included patients	0.02
Dommett (2013)	Childhood infection 0-3 months before diagnosis	All included patients	Cases: 54/1267 Control: 236/15318
Dommett (2013)	Upper respiratory tract infection 0-3 months before diagnosis	All included patients	Cases: 143/1267 Control: 942/15318
Dommett (2013)	Vomiting 0-3 months before diagnosis	All included patients	Cases: 86/1267 Control: 105/15318
Dommett (2013)	Cough 0-3 months before diagnosis	All included patients	Cases: 77/1267 Control: 654/15318
Dommett (2013)	Rash 0-3 months before diagnosis	All included patients	Cases: 63/1267 Control: 555/15318
Dommett (2013)	Abdominal pain 0-3 months before diagnosis	All included patients	Cases: 60/1267 Control: 137/15318
Dommett (2013)	Abdominal mass 0-3 months before diagnosis	All included patients	Cases: 48/1267 Control: 0/15318
Dommett (2013)	Fever 0-3 months before diagnosis	All included patients	Cases: 49/1267 Control: 166/15318
Dommett (2013)	Eye swelling 0-3 months before diagnosis	All included patients	Cases: 39/1267 Control: 238/15318
Dommett (2013)	Shortness of breath 0-3 months before diagnosis	All included patients	Cases: 35/1267 Control: 221/15318
Dommett (2013)	Constipation 0-3 months before diagnosis	All included patients	Cases: 26/1267 Control: 61/15318
Dommett (2012)	Hepatosplenomegaly 0-12 months before diagnosis	All included patients	2.19 (0.295-17.034) Cases: 14/1267 Control: 1/15318

1 The positive predictive values are calculated using Bayesian statistics.

2

3 Table 6: Renal cancer: Positive predictive values for any childhood cancer: Patients aged 0-4 years

Study	Symptom(s)	Patient group	Positive predictive value (95% CI) Frequency
Dommett (2012)	Any NICE alert symptom 0-3 months before diagnosis	Patients aged 0-4 years	0.081 (0.059-0.112) Cases: 96/436 Control: 55/4802
Dommett (2012)	Any NICE alert symptom 0-12 months before diagnosis	Patients aged 0-4 years	0.093 (0.077-0.113) Cases: 124/436 Control: 248/4802
Dommett (2012)	Neurological symptoms	Patients aged 0-4 years	0.076 (0.054-0.107)

	0-12 months before diagnosis		Cases: 43/436 Control: 105/4802
Dommett (2012)	Headache 0-12 months before diagnosis	Patients aged 0-4 years	0.135 (0.055-0.335) Cases: 8/436 Control: 11/4802
Dommett (2012)	Lymphadenopathy 0-12 months before diagnosis	Patients aged 0-4 years	0.061 (0.037-0.1) Cases: 20/436 Control: 61/4802
Dommett (2012)	Lump/mass/swelling 0-12 months before diagnosis	Patients aged 0-4 years	0.198 (0.099-0.399) Cases: 16/436 Control: 15/4802
Dommett (2012)	Fatigue 0-12 months before diagnosis	Patients aged 0-4 years	0.087 (0.048-0.16) Cases: 15/436 Control: 32/4802
Dommett (2012)	Back pain 0-12 months before diagnosis	Patients aged 0-4 years	0.186 (0.047-0.742) Cases: 4/436 Control: 4/4802
Dommett (2012)	Bruising 0-12 months before diagnosis	Patients aged 0-4 years	0.155 (0.086-0.279) Cases: 20/436 Control: 24/4802
Dommett (2012)	Urinary symptoms 0-12 months before diagnosis	Patients aged 0-4 years	0.739 (0.159-3.496) Cases: 8/436 Control: 2/4802
Dommett (2012)	Hepatosplenomegaly 0-12 months before diagnosis	Patients aged 0-4 years	1.286 (0.161-10.569) Cases: 7/436 Control: 1/4802

1 The positive predictive values are calculated using Bayesian statistics.

2  
3 Table 7: Renal cancer: Positive predictive values for any childhood cancer: Patients aged 5-14 years

Study	Symptom(s)	Patient group	Positive predictive value (95% CI) Frequency
Dommett (2012)	Any NICE alert symptom 0-3 months before diagnosis	Patients aged 5-14 years	0.056 (0.047-0.068) Cases: 246/831 Control: 156/10516
Dommett (2012)	Any NICE alert symptom 0-12 months before diagnosis	Patients aged 5-14 years	0.075 (0.066-0.084) Cases: 303/831 Control: 581/10561
Dommett (2012)	Neurological symptoms 0-12 months before diagnosis	Patients aged 5-14 years	0.091 (0.067-0.123) Cases: 65/831 Control: 102/10516
Dommett (2012)	Headache 0-12 months before diagnosis	Patients aged 5-14 years	0.055 (0.043-0.07) Cases: 82/831 Control: 213/10516
Dommett (2012)	Lymphadenopathy 0-12 months before diagnosis	Patients aged 5-14 years	0.118 (0.085-0.164) Cases: 62/831 Control: 75/10516
Dommett (2012)	Lump/mass/swelling 0-12 months before diagnosis	Patients aged 5-14 years	0.154 (0.099-0.24) Cases: 40/831 Control: 37/10516
Dommett (2012)	Fatigue 0-12 months	Patients aged 5-14 years	0.082 (0.053-0.125)

	before diagnosis	years	Cases: 32/831 Control: 56/10516
Dommett (2012)	Back pain 0-12 months before diagnosis	Patients aged 5-14 years	0.075 (0.05-0.111) Cases: 36/831 Control: 69/10516
Dommett (2012)	Bruising 0-12 months before diagnosis	Patients aged 5-14 years	0.049 (0.029-0.084) Cases: 18/831 Control: 52/10516
Dommett (2012)	Urinary symptoms 0-12 months before diagnosis	Patients aged 5-14 years	0.143 (0.05-0.407) Cases: 7/831 Control: 7/10516
Dommett (2012)	Hepatosplenomegaly 0-12 months before diagnosis	Patients aged 5-14 years	Cases: 7/831 Control: 0/10516

The positive predictive values are calculated using Bayesian statistics.

### Evidence statement(s):

#### Patients aged > 14 years

Haematuria (5 studies, N = 87161) presenting in a primary care setting is associated with overall positive predictive values of 0.65-6.48% for renal cancer, which tended to be higher in men (5.47-5.5%) than in women (2.48-2.6%; 2 studies, N = 48918) and to increase with age in men (up to 11.21%; 1 study, N = 11108) and less so in women (up to 8.53%; 1 study, N = 11108). The evidence was, however, compromised by a large number of the included cancers being non-renal cancers. Each of the studies was associated with 0-2 bias concern (see also Tables 1-3).

For renal cancer the positive predictive values of single symptoms (excluding haematuria; 6 studies, N = 344897) presenting in primary care ranged from 0.05% (for back pain) to 1.4% (for anaemia in men). The evidence was, however, compromised by a large number of the included cancers being non-renal cancers and ≤ 3 bias or applicability concerns associated with 4 of the 6 included studies (see also Table 3).

For renal cancer the positive predictive values of symptom combinations (1 study, N = 17240) presenting in primary care ranged from 0.1% (for constipation in combination with either abdominal pain, nausea or lower urinary tract infection) to > 5% (for abdominal pain combined with microcytosis). The included study was associated with 1 bias concern (see also Table 4).

#### Patients aged < 15 years

The positive predictive values of having any childhood cancer ranged from 0.04% (for pain and musculoskeletal symptoms) to 2.19% (for hepatosplenomegaly) in all included patients, and from 0.061% (for lymphadenopathy) to 1.286% (for hepatosplenomegaly) for patients aged 0-4 years old, and from 0.049% (for bruising) to 0.154% (for 'lump/mass/swelling' [the PPV for hepatosplenomegaly could not be calculated as none of the controls experienced this symptom]) for patients aged 5-14 years old (all from 1 study, N = 16585). The evidence quality is somewhat compromised by the case-control design of the study (see also Tables 5-7).

### Evidence tables

#### Collins (2013)

#### PATIENT SELECTION

##### A. risk of bias

Patient sampling	Retrospective patient series using the THIN database.	
Was a consecutive or random sample of patients enrolled?	Yes	
Was a case-control design avoided?	Yes	
Did the study avoid inappropriate exclusions?	Yes	
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>	
<b>B. Concerns regarding applicability</b>		
Patient characteristics and setting	<p>A total of 2145133 patients (1063355 men, 1081778 women) were identified from 364 practices.</p> <p><u>Symptoms:</u>  Haemoglobin &lt; 11 g/dl recorded in the last year (N = 16961; 3969 men, 12992 women), abdominal pain (N = 253344; 105247 men, 148097 women), appetite loss (N = 6097; 2616 men, 3481 women), weight loss (N = 29369; 13332 men, 16037 women), haematuria (N = 37810; 22810 men, 15000 women), previous diagnosis of cancer apart from renal tract cancer at study entry (N = 49303; 18130 men, 31173 women).</p> <p><u>Incident cases of renal tract cancer during the 2-year follow up period:</u>  N = 2283 (1685 men, 598 women).</p> <p><u>Inclusion criteria:</u>  Patients aged 30–84 years and registered with practices between 1 January 2000 and 30 June 2008. Entry to the cohort was defined as the latest of the study start date; the date the patient registered with the practice; and for those patients with red flag symptoms (e.g., haematuria, abdominal pain, weight loss, appetite loss, and anaemia), the date of the first recorded onset within the study period.</p> <p><u>Exclusion criteria:</u> Patients with a prior diagnosis of renal tract cancer, registered less than 12 months with the general practice, had invalid dates, &lt; 30 years old or ≥ 85 years old.</p> <p><u>Clinical setting:</u> Primary care, UK</p>	
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>	
<b>INDEX TEST</b>		
<b>A. Risk of bias</b>		
Index test	'Red-flag' symptoms were defined as symptoms that might alarm the patient and also indicate the presence of renal tract cancer; that is, symptoms of haematuria, loss of appetite, weight loss, or abdominal pain.	
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes	
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>	
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>	
<b>REFERENCE STANDARD</b>		
<b>A. risk of bias</b>		
Reference standard(s)	Renal tract cancer, which was defined as incident diagnosis of cancer of the bladder, kidney, ureter, or urethra during the 2 years after study entry, recorded either on the patient's GP record using the relevant UK diagnostic Read Codes. Patients without the outcome were censored at the earliest of the date of death, date of leaving the practice study of 2 years of follow up.	

Is the reference standard likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	Unclear
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	Low risk
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	Low concern
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients seem to be accounted for
Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	Yes
<b>Could the patient flow have introduced bias?</b>	Low risk
<b>NOTES</b>	It is unclear why no data has been presented for men for the symptoms of appetite loss and weight loss.
1	
2 <b>Deyo (1988)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective consecutive? patient series
Was a consecutive or random sample of patients enrolled?	Unclear
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes (probably)
<b>Could the selection of patients have introduced bias?</b>	Unclear risk
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	N = 1975, mean (SD; range) age = 39.5 (15.4; 15-86) years, 62% females. 54% of the patients were seeking medical care for back pain for the first time and 76% of the patients had had back pain for < 3 months. 3% had a history of back pain surgery. Maximal back pain in the low back (84%) or in the upper back (16%).  <u>Inclusion criteria:</u> Patients who sought treatment between March 1982 and September 1984 in the walk-in clinic of a public hospital where virtually all patients are self-referred. In each case back pain was part of the chief complaint. <u>Exclusion criteria:</u> Neck pain. <u>Clinical setting:</u> Walk-in clinic of a public hospital; this clinic is a source of primary care for indigent persons in a county in the USA with a population of approximately 1 million.
<b>Are there concerns that the included patients and setting do not match the review question?</b>	High concern
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	

<b>Index test</b>	Back pain; not further specified.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	The reference standard consisted of a search on each patient name in the institutional tumour registry $\geq 6$ months after the index visit. The registry included every patient with a histological diagnosis of cancer made in the authors' hospital system regardless of site of care. The authors point out that "while this method might fail to identify cancer patients who sought care elsewhere, it is likely that most patients sought follow-up for a particular illness at the same facility.
Is the reference standard likely to correctly classify the target condition?	<b>Unclear</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No (but all patients had a positive index test)</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All the patients are accounted for in the results.
Was there an appropriate interval between index test and reference standard?	<b>Yes (probably)</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	It is a concern that some patients with cancer might have been missed due to the choice of reference standard because this would result in an underestimation of the positive predictive value. 38/1975 patients were found in the tumour registry. Of those 38, 13 patients had tumours that were probable causes of back pain, and 4 of these 13 patients already had a diagnosis of cancer at presentation. The 9/1975 patients who had undiagnosed cancer that the back pain could be attributed to had: Lymphoma (NOS; 2), cancer of unknown primary (1), prostate cancer (1), retroperitoneal liposarcoma (1), lung cancer (1), renal cell (1), multiple myeloma (1), mucinous adenocarcinoma (of gallbladder?; 1)
<b>Dommett (2012, 2013)</b>	
<b>PATIENT SELECTION</b>	

1  
2

<b>A. risk of bias</b>	
Patient sampling	Population-based nested case-control study using data from the General Practice Research Database (GPRD)
Was a consecutive or random sample of patients enrolled?	No
Was a case-control design avoided?	No
Did the study avoid inappropriate exclusions?	Yes
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?	Yes
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?	Yes
<b>Could the selection of patients have introduced bias?</b>	<b>High risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p><u>Cases:</u> 1267 children; aged 0-4 years: N = 436; aged 5-14years: N = 831; 703 males/564 females. Cancer type: Leukemia: N = 368; brain: N = 270; lymphoma: N = 142; bone: N = 107; soft tissue sarcoma: N = 91; renal: N = 82; neuroblastoma: N = 75; other ICD codes: N = 132.</p> <p><u>Controls:</u> 15318 children; aged 0-4 years: N = 4802; aged 5-14years: N = 10516; 8461 males/6857 females.</p> <p><u>Inclusion criteria:</u> The sample comprised all children aged 0–14 years, inclusive, drawn from all general practices contributing research-standard data to the GPRD between 1 January 1988 and 31 December 2010. To be included, the practices had to have been contributing research-standard data for a minimum of 1 year before each child's date of cancer diagnosis or the index date (see below) for matched controls. Cases: Patients diagnosed with the following cancers: leukaemia, lymphoma, neuroblastoma, soft tissue sarcoma, hepatic, renal, bone and central nervous system tumours, using pre-defined medical codes used in the GPRD. The date of diagnosis for cases was defined as the date of pathological diagnosis, but if this was unavailable, the date of the first cancer code entered in the GPRD was used. Controls: Up to 13 controls (children with no diagnosis of cancer at any time) were selected per case, using a computer-generated random sequence, matched on age (within 1 year), sex and practice, and had to be currently registered on the date of diagnosis of their matched case (the index date).</p> <p><u>Exclusion criteria:</u> None listed <u>Clinical setting:</u> Primary care, UK.</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	The GPRD uses just over 100 000 medical codes to encompass all primary care events, including both symptoms and diagnoses. From this list, libraries of codes were assembled representing individual alert symptoms derived



	from the NICE referral guidelines for suspected cancer in children. <i>No more information reported.</i>	
Were the index test results interpreted without knowledge of the results of the reference standard?		Yes
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?		Yes
<b>Could the conduct or interpretation of the index test have introduced bias?</b>		Low risk
<b><u>B. Concerns regarding applicability</u></b>		
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>		Low concern
<b>REFERENCE STANDARD</b>		
<b><u>A. risk of bias</u></b>		
Reference standard(s)	Cancer diagnosis in the UK's General Practice Research Database.	
Is the reference standard likely to correctly classify the target condition?		Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?		Unclear
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>		Low risk
<b><u>B. Concerns regarding applicability</u></b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		Low concern
<b>FLOW AND TIMING</b>		
<b><u>A. risk of bias</u></b>		
Flow and timing	All patients appear to be accounted for.	
Was there an appropriate interval between index test and reference standard?		Yes
Did all patients receive the same reference standard?		Yes
Were all patients included in the analysis?		Yes
<b>Could the patient flow have introduced bias?</b>		Low risk
<b>NOTES</b>	This study is published in two papers.	
1		
2	<b>Friedlander (2014)</b>	
<b>PATIENT SELECTION</b>		
<b><u>A. risk of bias</u></b>		
Patient sampling	Retrospective cohort study, using claims data and laboratory values from the Vanderbilt University Medical Centre's (VUMC) Research Derivative, which is a "data repository that contains administrative and clinical information, including a complete record of visits and admissions, laboratory data, and diagnosis and procedure codes, on every patient treated in the Vanderbilt health system" (p 634) located in Tennessee in the USA.	
Was a consecutive or random sample of patients enrolled?		Yes
Was a case-control design avoided?		Yes

Did the study avoid inappropriate exclusions?	<b>Yes (probably)</b>
Could the selection of patients have introduced bias?	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>N = 2455 patients, 724 males / 1731 females, median (inter-quartile range) age = 58 (49-68) years; smoking history: current smoker (N = 406), former smoker (N = 473), non-smoker (N = 1514).</p> <p><u>Inclusion criteria:</u> "Patients aged <math>\geq</math> 40 years with a first diagnosis of hematuria" "between 2004 and 2012 by urinalysis (<math>&gt;3</math> red blood counts per high power field) or International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes for hematuria (599.7, 599.70, 599.71 or 599.72) at one of the VUMC's 19 primary care clinics. To be included in the study, patients must have had records for 1 year before the date of hematuria diagnosis."</p> <p><u>Exclusion criteria:</u> "Patients were excluded if they had a urinary tract infection (defined as a urinalysis positive for both leukocyte esterase and urine nitrites, or a positive urine culture) within 4 weeks before or 1 week after the index hematuria episode (n = 590, 9.0%) or had a prior explanatory diagnoses and procedures that would preclude the need for a hematuria evaluation (according to a convened panel of content experts; prostate/renal/bladder/other cancer, benign prostate/renal/bladder/other mass, prostate dysplasia, cystitis, urethritis, epididymitis/orchitis, prostatitis, pyelonephritis, urolithiasis, prostatic enlargement, trauma, medical renal disease, haematologic/thrombotic disease?, anatomic abnormality, prostatectomy, prostate biopsy, transurethral incision of prostate, resection of prostate, cystoscopy, cystectomy, ureteroscopy, nephrectomy, pyeloplasty, ureteral reimplantation)." We then used Physicians Current Procedural Terminology Coding System, 4th Edition and ICD-9 codes to exclude patients with an explanatory diagnosis or procedure within 180 days preceding their hematuria diagnosis (n = 3540, 53.8%)."</p> <p>Clinical setting: Primary care, USA.</p>
Are there concerns that the included patients and setting do not match the review question?	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	First diagnosis of hematuria" "by urinalysis ( $>3$ red blood counts per high power field) or International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes for hematuria (599.7, 599.70, 599.71 or 599.72)".
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
Could the conduct or interpretation of the index test have introduced bias?	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Are there concerns that the index test, its conduct, or interpretation differ from the review question?	<b>Low</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	The reference standard consisted checking the database for diagnoses of genitourinary neoplasms within 180 days after haematuria diagnosis, as determined by ICD-9 codes.

Is the reference standard likely to correctly classify the target condition?	<b>Unclear (is 180 days enough time to get a diagnosis of all cancers?)</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear (but all patients had a positive index test)</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients appear to be accounted for.
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	There were 66 patients with cancer: Bladder (N = 33), renal cell (N = 16), prostate (N = 15). The types of cancer for the remaining two cases were not reported.
1	
2	<b>Hippisley-Cox (2012)</b>
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective patient series using patients in the QResearch database (version 30).
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	A total of 1240722 patients were identified from 189 practices (622166 males, 618556 females), mean (SD) age = 50.1 (14.9) years, mean (SD) Townsend score = -0.2 (3.6). <u>Current symptoms and symptoms in the preceding year:</u> Current haematuria (N = 25553), current abdominal pain (N = 128721), current appetite loss (N = 5531), current weight loss (N = 14464), constipation in the last year (N = 8472), diarrhoea in the last year (N = 12171), tiredness in the last year (N = 12669), haemoglobin recoded in the last year (N = 216201), haemoglobin < 11 g/dl in the last year (N = 16169). <u>Incident cases of renal tract cancer during the 2-year follow up period:</u> N = 1622; mean age at diagnosis = 70 years, 1187 males/ 435 females; <b>Type of cancer: Bladder: N = 1292; Kidney: N = 307; Ureter: N = 21; Urethra: N = 2.</b> <u>Inclusion criteria:</u> All practices in England and Wales that had been using their Egton Medical Information Systems (EMIS) computer system for ≥ a year were included.

	<p>Two-thirds of practices were randomly allocated to the derivation dataset and the remaining practices were allocated to the validation dataset. An open cohort of patients aged 30–84 years was identified, drawn from patients registered with practices between 1 January 2000 and 30 September 2010. Entry to the cohort was defined as the latest of the study start date (1 January 2000) and 12 months after the patient registered with the practice, ensuring that all patients had <math>\geq 12</math> months' registration prior to study entry. For patients with incident haematuria, appetite loss, weight loss, or abdominal pain, the entry date was the date of the first consultation with the symptom within the study period. <i>The relevant data for the present purposes is only available for the validation cohort, therefore only information pertaining to these patients will be reported.</i></p> <p><u>Exclusion criteria:</u> Patients without a postcode-related Townsend score, patients with a history of renal tract cancer at baseline, and patients with a recorded 'red-flag' (see "Definition of symptom" below) symptom in the 12 months prior to the study entry date.</p> <p><u>Clinical setting:</u> Primary care</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	'Red-flag' symptoms were defined as symptoms that might alarm the patient and also indicate the presence of renal tract cancer; that is, symptoms of haematuria, loss of appetite, weight loss, or abdominal pain.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
<b>Reference standard(s)</b>	Renal tract cancer, which was defined as incident diagnosis of cancer of the bladder, kidney, ureter, or urethra during the 2 years after study entry, recorded either on the patient's GP record using the relevant UK diagnostic Read Codes, or their linked Office for National Statistics cause-of-death record, using the relevant ICD-9 codes (188 or 189) or ICD-10 diagnostic codes (C64–67).
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>

<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	A total of 1342329 patients were initially identified of whom 101607 patients were excluded for the following reasons: No recorded Townsend score (N = 70847), history of renal tract cancer (N = 1506), and $\geq$ one 'red flag' symptom recorded in the 12 months prior to study entry (N = 29254), leaving 1240722 patients. However, data is presented for 967681 / 1240722 patients. The missing data does not appear to include any of the cancer cases, but it is unclear whether some of the missing data includes symptomatic patients, i.e., false positives.
Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	No
<b>Could the patient flow have introduced bias?</b>	<b>High risk</b>
<b>NOTES</b>	
1	
2 <b>Jones (2007)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Retrospective consecutive patient series using patients in the UK's General Practice Research Database.
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>A total of 923605 patients were identified, of whom 762325 were aged <math>\geq</math> 15 years.</p> <p><u>Number of first occurrences in patients with no previous diagnosis of cancer:</u></p> <p><u>Haematuria:</u> N = 11108, mean (SD) age at first symptom = 58.5 (18.9) years. Patients excluded due to incomplete dates for their first symptom: N = 30. Sex (of final sample): 6385 males, 4723 females.</p> <p><u>Haemoptysis:</u> N = 4822, mean (SD) age at first symptom = 61.6 (18) years. Patients excluded due to incomplete dates for their first symptom: N = 10. Sex (of final sample): 2930 males, 1882 females.</p> <p><u>Dysphagia:</u> N = 6003, mean (SD) age at first symptom = 54.5 (19.4) years. Patients excluded due to incomplete dates for their first symptom: N = 4. Sex (of final sample): 2628 males, 3371 females.</p> <p><u>Rectal bleeding:</u> N = 15314, mean (SD) age at first symptom = 52.5 (18.8) years. Patients excluded due to incomplete dates for their first symptom: N = 25. Sex (of final sample): 7523 males, 7766 females.</p> <p><u>Inclusion criteria:</u></p> <p>All patients from 128 general practices that provided data of a sufficient standard from 1 January 1994 to 31 December 2000 and which provided exclusively Read coded data, who were aged between 15 and 100 years, whose first ever recorded occurrence of each alarm symptom (haematuria, haemoptysis, dysphagia, or rectal bleeding) was after 31 December 1994 and</p>

	<p>who had not previously been diagnosed as having any cancer.</p> <p><u>Exclusion criteria:</u> Patients whose date of first symptom or first relevant diagnosis of cancer was before 1 January 1995 and patients with a diagnosis of any other cancer than the ones of interest before the date of the first recorded symptom or before the index cancer diagnosis date if the related symptom was not recorded.</p> <p><u>Clinical setting:</u> Primary care</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	Identification of all patients who ever had symptoms recorded for haematuria, haemoptysis, dysphagia, or rectal bleeding.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
<b>Reference standard(s)</b>	<p>Cancer code in the UK's General Practice Research Database (the authors report cancer diagnosis at two time points, namely in the first 6 months and 3 years after the first alarm symptom):</p> <p><u>Haematuria:</u> Urinary tract neoplasms, including neoplasms of the urethra, bladder, ureter, and kidney but excluding neoplasms of the prostate and other reproductive organs.</p> <p><u>Haemoptysis:</u> Respiratory tract neoplasms.</p> <p><u>Dysphagia:</u> Oesophageal neoplasms.</p> <p><u>Rectal bleeding:</u> Colorectal neoplasms.</p>
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear (but all patients had a positive index test)</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
<b>Flow and timing</b>	All patients are accounted for in the results
Was there an appropriate interval between index test and reference standard?	<b>Unclear</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>

<b>Could the patient flow have introduced bias?</b>		<b>Low risk</b>
<b>NOTES</b>	<p>Diagnoses of cancer were most often made in the first three months after the onset of alarm symptoms; very few diagnoses of cancer were made later than three years after symptom onset. In the 4th and 5th years of study, the small number of observed occurrences of cancer was similar to the number expected from background incidence rates.</p> <p>Secondary analyses evaluating whether the incidence of neoplasms other than those prespecified was increased after the occurrence of alarm symptoms showed for:</p> <p><u>Haematuria</u>: Inclusion of cancers of the reproductive organs yielded 21 additional cancers in women and 158 cancers in men, mostly cancers of the prostate. Inclusion of these cancers in the analysis would give a positive predictive value of 3.9% in women and 9.9% in men.</p> <p><u>Dysphagia</u>: Inclusion of gastric cancers yielded 17 additional cancer diagnoses in women and 30 in men. Inclusion of these cancers gave positive predictive values of 5.2% in women and 6.9% in men.</p> <p><i>Estimates based on the pre-specified cancers may be thus conservative for these symptoms.</i></p> <p><u>Haemoptysis</u>: Extension of the diagnostic criteria yielded 6 additional cancers.</p> <p><u>Rectal bleeding</u>: Extension of the diagnostic criteria yielded 2 additional cancers.</p>	
1		
2	<b>Muris (1995)</b>	
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Prospective patient series from 80/460 general practitioners in Limburg (Holland)	
Was a consecutive or random sample of patients enrolled?	<b>No</b>	
Was a case-control design avoided?	<b>Yes</b>	
Did the study avoid inappropriate exclusions?	<b>Unclear</b>	
<b>Could the selection of patients have introduced bias?</b>	<b>High risk</b>	
<b>B. Concerns regarding applicability</b>		
Patient characteristics and setting	<p>N = 933; 335 males, 598 females; age range = 18-75, aged &gt; 30 years: N = 712, aged &gt; 40 years: N = 517, aged &gt; 60 years: N = 171.</p> <p><u>Inclusion criteria</u>: Patients who in 1989 consulted one of the participating GPs for new abdominal complaints lasting <math>\geq</math> 2 weeks and with whom the GPs had a diagnostic problem.</p> <p><u>Exclusion criteria</u>: None listed.</p> <p><u>Clinical setting</u>: GPs in Holland</p>	
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>High concern</b>	
<b>INDEX TEST</b>		
<b>A. Risk of bias</b>		
Index test	New abdominal complaints lasting $\geq$ 2 weeks. Not further specified.	
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>	
<b>Could the conduct or interpretation of the index test</b>	<b>Low risk</b>	

<b>have introduced bias?</b>		
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>		<b>High concern</b>
<b>REFERENCE STANDARD</b>		
<b>A. risk of bias</b>		
Reference standard(s)	Follow up for $\geq 12$ months (mean = 18 months).	
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>	
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No</b>	
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>	
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		<b>Low concern</b>
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	All patients appear to be accounted for	
Was there an appropriate interval between index test and reference standard?	<b>Unclear</b>	
Did all patients receive the same reference standard?	<b>Yes</b>	
Were all patients included in the analysis?	<b>Yes</b>	
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>	
<b>NOTES</b>	Other cancers diagnosed in these patients were: Stomach (2/933), pancreas (2/933), trachea/bronchus/lung (2/933), colorectal (4/933), cervix (1/933), other cancer of the female genital system (2/933), and other and unspecified sites (2/933).	
1		
2	<b>Oudega (2006)</b>	
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Prospective study of all primary care physicians (N = 50) within a catchment area (ca 130000 inhabitants) of a non-teaching hospital in Holland.	
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>	
Was a case-control design avoided?	<b>Yes</b>	
Did the study avoid inappropriate exclusions?	<b>Yes</b>	
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>	
<b>B. Concerns regarding applicability</b>		
Patient characteristics and setting	N = 430; 162 males, 268 females; mean age (SD) = 60.7 (18.2) years.  <u>Inclusion criteria:</u> Consecutive patients who consulted their GP between January 1996 and July 2002 and who, after investigation (not referral) was confirmed to have deep vein thrombosis. <u>Exclusion criteria:</u> Patients with a known malignancy or a malignancy	



	detected within 2 weeks of deep vein thrombosis diagnosis. Clinical setting: Primary care, Holland.
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	Deep vein thrombosis (suspicion based on painful swollen leg ≤ 30 days). Patients were classified as having secondary deep vein thrombosis if ≥ 1 of the following risk factors for deep vein thrombosis were present: Recent surgery, prolonged immobilisation, use of oral contraceptives or hormonal replacement therapy. If no risk factors were present patients were classified as having idiopathic deep vein thrombosis.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	2 years follow up.
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients appear to be accounted for
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	In total N = 19 had cancer: 3 colorectal, 5 urogenital (not further subgrouped), 4 breast, 3 lung and 4 other. The urogenital data is added to the renal cancer evidence review.
<b>1 Shephard (2013)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Matched case-control study using patients in the UK's General Practice

1  
2

	Research Database (GPRD).
Was a consecutive or random sample of patients enrolled?	No
Was a case-control design avoided?	No
Did the study avoid inappropriate exclusions?	Yes
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?	Yes
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?	Yes
<b>Could the selection of patients have introduced bias?</b>	<b>High risk</b>
<b><u>B. Concerns regarding applicability</u></b>	
Patient characteristics and setting	<p><u>Cases:</u> N = 3149, median age at diagnosis = 69 (IQR = 61-77) years, 1930 males / 1219 females; median number of consultations = 16 (IQR = 10-25), UK.</p> <p><u>Controls:</u> N = 14091, median age at diagnosis = 70 (IQR = 61-77) years, 8429 males / 5662 females; median number of consultations = 8 (IQR = 4-15), UK.</p> <p><u>Inclusion criteria:</u> Cases: Patients with a record of one of 22 GPRD kidney cancer codes between January 2000 and December 2009 inclusive, aged ≥ 40 years, with min. 1 year of data before diagnosis. The first instance of a kidney cancer code was assigned the data of diagnosis/index date. Controls: Up to 5 controls were matched to cases on sex, general practice, and to 1 year of age of the case. The index date was the index date of the matched case.</p> <p><u>Exclusion criteria:</u> Metastatic cancer to the kidney from a non-kidney primary, diagnosis before 2000, or no consultations in the year before diagnosis.</p> <p><u>Clinical setting:</u> Primary care</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b><u>A. Risk of bias</u></b>	
<b>Index test</b>	<p>A list of symptoms, signs and investigations (features) potentially associated with kidney cancer was compiled from the authors' literature search, augmented by viewing material from kidney cancer support organisations and online chat rooms. Internet search terms included 'kidney cancer', 'kidney cancer symptoms', and 'early signs/indications kidney cancer'. Visible and non-visible haematuria were studied separately. Only codes specifying the word 'microscopic' were assigned to the latter group, so generic codes such as the single word 'haematuria' were assumed to be visible haematuria. Over 1800 GPRD codes were compiled for the putative features of kidney cancer from the GPRD's master list of over 100,000 codes. Occurrences of these features in the year before the index date were identified. Repeated consultations for the same complaint were also identified along with all codes for fractures as a test for any recording bias between cases and controls (making the assumption that the fracture rate would be approximately equal). Variables were retained only if they</p>

	<p>occurred in at least 5% of either cases or controls. Investigation results were deemed to be abnormal if they fell outside their local laboratory's normal range: for analysis, patients with a normal laboratory result were grouped with those who had not been tested.</p> <p>The raised inflammatory markers variable was a composite of any of abnormal erythrocyte sedimentation rate, plasma viscosity, or C-reactive protein; similarly abnormal liver function tests reflected a raised value of any of the hepatic enzymes reported by each laboratory.</p>
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Kidney cancer code in the UK's General Practice Research Database.
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	A total of 18890 patients were identified, 15707 controls and 3183 cases. Of the controls the following exclusions were applied: bladder cancer (N = 29), metastatic cancer (N = 104), and no data in year pre-index date (N = 1483). Of the cases the following exclusions were applied: No controls (N = 2), metastatic cancer (N = 24), and bladder cancer (N = 8).
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	24 symptoms and 22 abnormal test results were considered initially. 10 symptoms and 11 abnormal test variables were present in $\geq 5\%$ of cases.

1

2 **References**

**Included studies**

- Collins, G.S., and Altman, D.G. Identifying patients with undetected renal tract cancer in primary care: An independent and external validation of Qcancer (renal) prediction model. *Cancer Epidemiology*, 37, 115-120. 2013.
- Deyo, R. A. and Diehl, A. K. Cancer as a cause of back pain: Frequency, clinical presentation, and diagnostic strategies. *Journal of General Internal Medicine* 3, 230-238. 1988.
- Dommett, R. M., Redaniel, M. T., Stevens, M. C. G., Hamilton, W., and Martin, R. M. Features of childhood cancer in primary care: A population-based nested case-control study. *British Journal of Cancer* 106[5], 982-987. 28-2-2012.
- Dommett, R. M., Redaniel, T., Stevens, M. C. G., Martin, R. M., and Hamilton, W. Risk of childhood cancer with symptoms in primary care: A population-based case-control study. *British Journal of General Practice*; DOI:10.3399/bjgp13X660742. 2013.
- Friedlander, D.F., Resnick, M.J., You, C., Bassett, J., Yarlagadda V., Penson, D.F., Barocas D.A. Variation in the intensity of hematuria evaluation: A target for primary care quality improvement. *American Journal of Medicine*, 127, 633-640. 2014.
- Hippisley-Cox, J. and Coupland, C. Identifying patients with suspected renal tract cancer in primary care: derivation and validation of an algorithm. *British Journal of General Practice* 62[597], e251-e260. 2012.
- Jones, R., Latinovic, R., Charlton, J., and Gulliford, M. C. Alarm symptoms in early diagnosis of cancer in primary care: cohort study using General Practice Research Database. *BMJ* 334[7602], 1040. 19-5-2007.
- Muris, J. W., Starmans, R., Fijten, G. H., Crebolder, H. F., Schouten, H. J., and Knottnerus, J. A. Non-acute abdominal complaints in general practice: diagnostic value of signs and symptoms. *British Journal of General Practice* 45[395], 313-316. 1995.
- Oudega, R., Moons, K. G. M., Nieuwenhuis, H. K., van Nierop, F. L., and Hoes, A. W. Deep vein thrombosis in primary care: Possible malignancy? *British Journal of General Practice* 56[530], 693-696. 2006.
- Shephard, E., Neal, R., Rose, P., Walter, F., and Hamilton, W. Clinical features of kidney cancer in primary care: A case-control study using primary care records. *British Journal of General Practice* DOI: 10.3399/bjgp13X665215. 2013

**Excluded studies (with excl reason)**

- Abouassaly, R., Finelli, A., Tomlinson, G. A., Urbach, D. R. & Alibhai, S. M. H. (2011) How often are patients with diabetes or hypertension being treated with partial nephrectomy for renal cell carcinoma? A population-based analysis. *BJU International*, 108: 1806-1812.  
Not in PICO
- Ares, V. Y. (2009) [Correlation between symptoms and survival in patients with renal cell carcinoma]. [Spanish]. *Archivos Espanoles de Urologia*, 62: 201-206.  
Not in PICO
- Ayllon, J., Verkarre, V., Scotte, F., Fournier, L., Correas, J. M., Mejean, A., Teghom, C. & Oudard, S. (2012) Renal malacoplakia: Case report of a differential diagnosis for renal cell carcinoma. *The American Journal of Case Reports*, 13: 38-40.  
Not in PICO
- Barkin, J., Rosenberg, M. T. & Miner, M. (2014) A guide to the management of urologic dilemmas for the primary care physician (PCP). *Canadian Journal of Urology*, 21: 55-63.  
Narrative review
- Barroca, H. & Bom-Successo, M. (2014) Fine needle biopsy with cytology in paediatrics: The importance of a multidisciplinary approach and the role of ancillary techniques. *Cytopathology*, 25: 6-20.  
Narrative review

- 1 Belani, J. S., Farooki, A., Prasad, S., Yan, Y., Heiken, J. P. & Kibel, A. S. (2005) Parenchymal imaging  
2 adds diagnostic utility in evaluating haematuria. *BJU International, Supplement*, 95: 64-67.  
3 Not in PICO
- 4 Bliznakova, D. (2003) Differential diagnosis of some kidney diseases in childhood. [Bulgarian].  
5 *Bulgarian Medicine*, 11: 7-10.  
6 Narrative review
- 7 Buteau, A., Seideman, C. A., Svatek, R. S., Youssef, R. F., Chakrabarti, G., Reed, G., Bhat, D. & Lotan, Y.  
8 (2014) What is evaluation of hematuria by primary care physicians? Use of electronic medical  
9 records to assess practice patterns with intermediate follow-up. *Urologic Oncology*, 32: 128-134.  
10 Not in PICO
- 11 Carrafiello, G., Fontana, F., Mangini, M., Ierardi, A. M., Cotta, E., Piacentino, F., De, C. M., Floridi, C.,  
12 Di, M. A., Marconi, A. M. & Fugazzola, C. (2012) Upper urinary tract biopsy: an old device for a  
13 new approach. *Radiologia Medica*, 117: 1152-1160.  
14 Not in PICO
- 15 Cave, D. G. (1994) Analyzing the content of physicians' medical practices. *Journal of Ambulatory Care  
16 Management*, 17: 15-36.  
17 Not in PICO
- 18 Chan, K. & Kamangar, N. (2012) Tuberos sclerosi complex manifesting with massive  
19 angiomyolipomas in multiple organs. *Chest*, 142.  
20 Not in PICO
- 21 Chen, D. Y. T. & Uzzo, R. G. (2011) Evaluation and Management of the Renal Mass. *Medical Clinics of  
22 North America*, 95: 179-+.  
23 Narrative review
- 24 Chow, W.-H., Dong, L. M. & Devesa, S. S. (2010) Epidemiology and risk factors for kidney cancer.  
25 *Nature Reviews Urology*, 7: 245-257.  
26 Narrative review
- 27 Coxon, J. P., Harris, H. J. & Watkin, N. A. (2003) A prospective audit of the implementation of the 2-  
28 week rule for assessment of suspected urological cancers. *Annals of the Royal College of Surgeons  
29 of England*, 85: 347-350.  
30 Not in PICO
- 31 Crispin, P. L., Soljic, A., Stewart, G., Kutikov, A., Davenport, D. & Uzzo, R. G. (2012) Enhancing renal  
32 tumors in patients with prior normal abdominal imaging: further insight into the natural history  
33 of renal cell carcinoma. *Journal of Urology*, 188: 1089-1093.  
34 Not in PICO
- 35 Cukier, J., Pascal, B. & Mangin, P. (1981) [Symptomatology manifesting cancer of the kidney in  
36 adults. Review of 184 observations]. [French]. *Acta Urologica Belgica*, 49: 259-262.  
37 Not in PICO
- 38 Dall'Oglio, M. F., Srougi, M., Goncalves, P. D., Leite, K., Nesrallah, L. & Hering, F. (2002) Incidental  
39 and symptomatic renal tumors: impact on patient survival. *Sao Paulo Medical Journal = Revista  
40 Paulista de Medicina*, 120: 165-169.  
41 Not in PICO
- 42 Debre, B., Peyromaure, M., Saighi, D. & Zerbib, M. (2004) [Advances in diagnosis and treatment of  
43 renal cell carcinoma]. [Review] [29 refs] [French]. *Bulletin de l'Academie Nationale de Medecine*,  
44 188: 15-24.  
45 Narrative review
- 46 DeSouza, K., Chowdhury, S. & Hughes, S. (2003) - Prompt diagnosis key in bladder cancer. [Review]. -  
47 *Practitioner*, 258: 23-27.  
48 Narrative review
- 49 Dragoescu, E. A. & Liu, L. (2013) Indications for renal fine needle aspiration biopsy in the era of  
50 modern imaging modalities. *CytoJournal*, 10.  
51 Not in PICO

- 1 Duque, J. L., Loughlin, K. R., O'Leary, M. P., Kumar, S. & Richie, J. P. (1998) Partial nephrectomy:  
2 alternative treatment for selected patients with renal cell carcinoma. [Review] [26 refs]. *Urology*,  
3 52: 584-590.  
4 Not in PICO
- 5 Edwards, T. J., Dickinson, A. J., Gosling, J., McInerney, P. D., Natale, S. & McGrath, J. S. (2011)  
6 Patient-specific risk of undetected malignant disease after investigation for haematuria, based on  
7 a 4-year follow-up. *BJU International*, 107: 247-252.  
8 Not in PICO
- 9 Eisenberger, C. F., Schoenberg, M., Enger, C., Hortopan, S., Shah, S., Chow, N. H., Marshall, F. F. &  
10 Sidransky, D. (1999) Diagnosis of renal cancer by molecular urinalysis. *Journal of the National  
11 Cancer Institute*, 91: 2028-2032.  
12 Not in PICO
- 13 Fall, B., Diao, B., Sow, Y., Sarr, A., Thiam, A., Fall, P. A., Ndoeye, A. K., Sylla, C., Ba, M., Mendes, V. &  
14 Diagne, B. A. (2011) [Adult renal cancer in Senegal: Current epidemiological, clinical features,  
15 profile's evolution over the two past decades]. [French]. *Progres En Urologie*, 21: 521-526.  
16 Not in PICO
- 17 Feldstein, M. S., Rhodes, D. J., Parker, A. S., Orford, R. R. & Castle, E. P. (2009) The haphazard  
18 approach to the early detection of asymptomatic renal cancer: results from a contemporary  
19 executive health programme. *BJU International*, 104: 53-56.  
20 Not in PICO
- 21 Ferda, J., Ferdova, E., Hora, M., Hes, O., Finek, J., Topolcan, O. & Kreuzberg, B. (2013) 18F-FDG-  
22 PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis  
23 estimation. *Anticancer Research*, 33: 2665-2672.  
24 Not in PICO
- 25 Fernandez, R. E., Suarez, P. G., Blanco, D. A., Barbagelata, L. A., Ponce Diaz-Reixa, J. L., Novas, C. S.,  
26 Ruibal, M. M., Gomez, V. F., Chantada, A., V & Gonzalez, M. M. (2005) [Clinical-pathological study  
27 of incidental renal cell carcinoma]. [Spanish]. *Archivos Espanoles de Urologia*, 58: 635-640.  
28 Not in PICO
- 29 Ferzli, P. G., Millett, C. R., Newman, M. D. & Heymann, W. R. (2008) The dermatologist's guide to  
30 hereditary syndromes with renal tumors. *Cutis*, 81: 41-48.  
31 Narrative review
- 32 Flamm, J. & Wober, L. (1981) [The malignant kidney tumour - a report on 117 cases (1969-1977)  
33 (author's transl)]. [German]. *Wiener Medizinische Wochenschrift*, 131: 579-585.  
34 Not in PICO
- 35 Ghalayini, I. F. & Bani-Hani, I. H. (2003) Detection, staging and clinical implications of renal cell  
36 carcinoma. *Saudi Medical Journal*, 24: 79-83.  
37 Not in PICO
- 38 Glick, R. D., Hicks, M. J., Nuchtern, J. G., Wesson, D. E., Olutoye, O. O. & Cass, D. L. (2004) Renal  
39 tumors in infants less than 6 months of age. [Review] [21 refs]. *Journal of Pediatric Surgery*, 39:  
40 522-525.  
41 Not in PICO
- 42 Gourova, L. W., van de Beek, C., Spigt, M. G., Nieman, F. H. & van Kerrebroeck, P. E. (2006) Predictive  
43 factors for nocturia in elderly men: a cross-sectional study in 21 general practices. *BJU  
44 International*, 97: 528-532.  
45 Not in PICO
- 46 Gu, F. L. (1990) Imaging techniques for the diagnosis of renal tumors. *Proceedings of the Chinese  
47 Academy of Medical Sciences & the Peking Union Medical College*, 5: 75-78.  
48 Not in PICO
- 49 Gupta, N. P., Ishwar, R., Kumar, A., Dogra, P. N. & Seth, A. (2010) Renal tumors presentation:  
50 changing trends over two decades. *Indian Journal of Cancer*, 47: 287-291.  
51 Not in PICO

- 1 Guy, L., Alfidja, A. T., Chabrot, P., Ravel, A., Boiteux, J. P. & Boyer, L. (2007) Palliative transarterial  
2 embolization of renal tumors in 20 patients. *International Urology & Nephrology*, 39: 47-50.  
3 Not in PICO
- 4 Haliloglu, A. H., Gulpinar, O., Ozden, E. & Beduk, Y. (2011) Urinary ultrasonography in screening  
5 incidental renal cell carcinoma: is it obligatory? *International Urology & Nephrology*, 43: 687-690.  
6 Not in PICO
- 7 Hellsten, S., Berge, T. & Wehlin, L. (1981) Unrecognized renal cell carcinoma. Clinical and diagnostic  
8 aspects. *Scandinavian Journal of Urology & Nephrology*, 15: 269-272.  
9 Not in PICO
- 10 Henning, A., Wehrberger, M., Madersbacher, S., Pycha, A., Martini, T., Comploj, E., Jeschke, K.,  
11 Tripolt, C. & Rauchenwald, M. (2013) Do differences in clinical symptoms and referral patterns  
12 contribute to the gender gap in bladder cancer? *BJU International*, 112: 68-73.  
13 Not in PICO
- 14 Henrique, R., Costa, V. L. & Jeronimo, C. (2007) Methylation-based biomarkers for early detection of  
15 urological cancer. [Review] [73 refs]. *Critical Reviews in Oncogenesis*, 13: 265-282.  
16 Narrative review
- 17 Higgins, J. C. & Arnold, M. J. (2013) When to worry about incidental renal and adrenal masses.  
18 *Journal of Family Practice*, 62: 476-483.  
19 Narrative review
- 20 Hofstetter, A., Rothenberger, K. H. & Kori-Lindner, C. (1981) [Urologic emergencies in general  
21 practice. 6. Diagnosis in hematuria]. [German]. *Fortschritte der Medizin*, 99: 1556-1561.  
22 Narrative review
- 23 Holley, J. L. (1998) Nephrologists as primary care providers: A review of the issues. *American Journal  
24 of Kidney Diseases*, 31: 574-583.  
25 Narrative review
- 26 Holmang, S., Lele, S. M. & Johansson, S. L. (2007) Squamous cell carcinoma of the renal pelvis and  
27 ureter: incidence, symptoms, treatment and outcome. *Journal of Urology*, 178: 51-56.  
28 Not in PICO
- 29 Hornak, M., Skablova, D., Bardos, A. & Ondrus, D. (1998) [Incidental renal carcinoma]. [Slovak].  
30 *Bratislavske Lekarske Listy*, 99: 322-326.  
31 Not in PICO
- 32 Hruby, W., Stellamor, K., Zinner, G. & Marberger, M. (1983) [The renal pelvic tumor in the  
33 sonogram]. [German]. *Rofo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der  
34 Nuklearmedizin*, 138: 469-472.  
35 Not in PICO
- 36 Ibragimova, M. I., Chushnikov, A. I., Moiseev, V. N., Petukhov, V. I. & Zheglov, E. P. (2011) [The  
37 abilities of the electron paramagnetic resonance technique to diagnose urological cancers].  
38 [Russian]. *Klinicheskaia Laboratornaia Diagnostika*.(3):29-33, 2011 Mar., 29-33.  
39 Not in PICO
- 40 Iczkowski, K. A., Sweat, S. D. & Bostwick, D. G. (1999) Subepithelial pelvic hematoma of the kidney  
41 clinically mimicking cancer: Report of six cases and review of the literature. *Urology*, 53: 276-279.  
42 Not in PICO
- 43 Ikemoto, I., Oishi, Y., Onodera, S., Kishimoto, K., Kiyota, H., Furuta, N., Suzuki, Y., Asano, K. &  
44 Hasegawa, N. (2003) [Retrospective analysis of chief complaints of patients with urogenital  
45 malignancies over the past decade at the Jikei University Hospital]. [Japanese]. *Hinyokika Kiyo -  
46 Acta Urologica Japonica*, 49: 65-68.  
47 Not in PICO
- 48 Ishikawa, M., Takeda, M., Okabe, H., Kuwabara, S., Tsuyuguchi, M., Hirano, M., Kawamura, K.,  
49 Mishima, M., Fujimoto, N., Saito, H., Sakurada, K., Shimamura, S., Sakai, S., Minase, T., Miyake, M.  
50 & Andou, M. (2000) Studies on incidental renal cell carcinoma detected by abdominal

- 1 ultrasonography during health check-up. [Japanese]. *Nishinihon Journal of Urology*, 62: 563-567.  
2 Not in PICO
- 3 Izkison, L., English, J. C., III & Zirwas, M. J. (2006) The flushing patient: differential diagnosis, workup,  
4 and treatment. [Review] [101 refs]. *Journal of the American Academy of Dermatology*, 55: 193-  
5 208.  
6 Narrative review
- 7 Jayson, M. & Sanders, H. (1998) Increased incidence of serendipitously discovered renal cell  
8 carcinoma. [Review] [9 refs]. *Urology*, 51: 203-205.  
9 Not in PICO
- 10 Junuzovic, D., Kerleta, A. & Masic, I. (2013) The frequency of renal cell carcinoma in population of  
11 patients with kidney tumors. *Medicinski Arhiv*, 67: 27-30.  
12 Not in PICO
- 13 Kam, M. H., Barben, C. P., Eu, K. W. & Seow-Choen, F. (2004) Small bowel malignancies: A review of  
14 29 patients at a single centre. *Colorectal Disease*, 6: 195-197.  
15 Not in PICO
- 16 Kawaciuk, I., Hyrsi, L., Dusek, P., Jarolim, L., Schmidt, M., Kaliska, V., Chocholaty, M. & Vesely, S.  
17 (2008) Influence of tumour-associated symptoms on the prognosis of patients with renal cell  
18 carcinoma. *Scandinavian Journal of Urology and Nephrology*, 42: 406-411.  
19 Not in PICO
- 20 Kawamura, T., Ohta, T., Ohno, Y., Wakai, K., Aoki, R., Tamakoshi, A., Maeda, K. & Mizuno, Y. (1995)  
21 Significance of urinalysis for subsequent kidney and urinary tract disorders in mass screening of  
22 adults. *Internal Medicine*, 34: 475-480.  
23 Not in PICO
- 24 Kim, S. W., Yoon, B. I., Ha, U. S., Sohn, D. W. & Cho, Y. H. (2013) Xanthogranulomatous  
25 pyelonephritis: clinical experience with 21 cases. *Journal of Infection & Chemotherapy*, 19: 1221-  
26 1224.  
27 Not in PICO
- 28 Krol, E., Rutkowski, B., Czekalski, S., Sulowicz, W., Wiecek, A., Lizakowski, S., Czarniak, P., Szubert, R.,  
29 Karczewska-Maksymienko, L., Orlikowska, M., Kraszewska, E. & Magdon, R. (2005) [Early  
30 diagnosis of renal diseases--preliminary results from the pilot study PolNef]. [Polish]. *Przegląd  
31 Lekarski*, 62: 690-693.  
32 Not in PICO
- 33 Kurien, A., Mathew, A., Mishra, S., Ganpule, A., Sabnis, R. & Desai, M. (2009) Widening the plane of  
34 dissection in laparoscopic simple nephrectomy for symptomatic non-functioning kidneys keeping  
35 in mind the hidden upper track urothelial malignancy. *Journal of Endourology*, 23: A278.  
36 Not in PICO
- 37 Leslie, J. A. & Cain, M. P. (2006) Pediatric urologic emergencies and urgencies. [Review] [6 refs].  
38 *Pediatric Clinics of North America*, 53: 513-527.  
39 Narrative review
- 40 Lin, M. S., Hung, Y. S., Wu, H. H., Kuo, M. C., Shiu, T. F., Chuang, C. K., Shih, L. Y. & Chu, P. H. (2009)  
41 Polycythemia vera as a presentation of renal angiomyolipoma: a case report. *Journal of Medical  
42 Case Reports [Electronic Resource]*, 3: 90.  
43 Not in PICO
- 44 Lyratzopoulos, G., Abel, G. A., McPhail, S., Neal, R. D. & Rubin, G. P. (2013) Gender inequalities in the  
45 promptness of diagnosis of bladder and renal cancer after symptomatic presentation: evidence  
46 from secondary analysis of an English primary care audit survey. *BMJ Open*, 3: 2013.  
47 Not in PICO
- 48 Lyratzopoulos, G., Abel, G. A., McPhail, S., Neal, R. D. & Rubin, G. P. (2013) Gender inequalities in the  
49 promptness of diagnosis of bladder and renal cancer after symptomatic presentation: evidence  
50 from secondary analysis of an English primary care audit survey. *BMJ Open*, 3.  
51 Not in PICO



- 1 Macis, G., Di, G. S., Di, F. D. & Bonomo, L. (2013) [Future perspectives for diagnostic imaging in  
2 urology: from anatomic and functional to molecular imaging]. [Italian]. *Urologia (Treviso)*, 80: 29-  
3 41.  
4 Not in PICO/Narrative review
- 5 Masood, J., Lane, T., Koye, B., Vandal, M. T., Barua, J. M. & Hill, J. T. (2001) Renal cell carcinoma:  
6 incidental detection during routine ultrasonography in men presenting with lower urinary tract  
7 symptoms. *BJU International*, 88: 671-674.  
8 Not in PICO
- 9 Masuda, F., Suzuki, H., Kondo, I. & Furuta, N. (1991) [Clinical and pathological studies on incidental  
10 renal cell carcinoma]. [Japanese]. *Hinyokika Kyo - Acta Urologica Japonica*, 37: 1223-1227.  
11 Not in PICO
- 12 Matz, M., Fabricius, P. G. & Adler, F. (1981) [Considerations on possibilities of early diagnosis of  
13 tumors of the kidney parenchyma]. [German]. *Zeitschrift fur Arztliche Fortbildung (Jena)*, 75: 810-  
14 812.  
15 Not in PICO
- 16 Mayordomo, J. I., Guerra, J. M., Guijarro, C., Garciaprats, M. D., Gomez, A., Lopezbrea, M., Gonzalez,  
17 R., Hergueta, P., Lopezpino, M. A., Martineztello, F. & Cortesfunes, H. (1993) Neoplasms of  
18 Unknown Primary Site - A Clinicopathological Study of Autopsied Patients. *Tumori*, 79: 321-324.  
19 Not in PICO
- 20 McBride, D. (2010) Identification of proteins may lead to urinary test for kidney cancer. *ONS*  
21 *Connect*, 25: 17.  
22 Not in PICO
- 23 McCauley, L. R., Beckham, C. J., Hunter, T. B. & Nguyen, M. M. (2010) Gender and Renal Cancer: Do  
24 Variations in Clinical Presentation and Imaging Patterns Explain Observed Differences Between  
25 Males and Females? *Urology*, 76: 536-540.  
26 Not in PICO
- 27 McDonald, M. M., Swagerty, D. & Wetzel, L. (2006) Assessment of microscopic hematuria in adults.  
28 *American Family Physician*, 73: 1748-1754.  
29 Narrative review
- 30 McLernon, D. J., Dillon, J. F., Sullivan, F. M., Roderick, P., Rosenberg, W. M., Ryder, S. D. & Donnan, P.  
31 T. (2012) The utility of liver function tests for mortality prediction within one year in primary care  
32 using the algorithm for liver function investigations (ALFI). *PLoS ONE [Electronic Resource]*, 7:  
33 e50965.  
34 Not in PICO
- 35 Mevorach, R. A., Segal, A. J., Tersegno, M. E. & Frank, I. N. (1992) Renal cell carcinoma: Incidental  
36 diagnosis and natural history: Review of 235 cases. *Urology*, 39: 519-522.  
37 Not in PICO
- 38 Morbidelli, A., Zaniboni, N. & Bortolani, E. (1989) [Tumors of the upper excretory tract. Cases  
39 contribution and review of the literature]. [Review] [20 refs] [Italian]. *Minerva Chirurgica*, 44:  
40 883-894.  
41 Not in PICO
- 42 Murphy, E., Bassett, J. H. & Williams, G. R. (2008) Disorders of calcium metabolism. [Review] [3 refs].  
43 *Practitioner*, 250: 4-6.  
44 Narrative review
- 45 Narshimhaswamy, P., Jayaprakasha, G., Goyal, S., Soni, M. K., Ravishankar, T. H. S., Shivshankarappa,  
46 M. & Imdad, A. N. (2014) Renal cell carcinoma in an ENT clinic. *Indian Journal of Urology*, 30:  
47 S138.  
48 Not in PICO
- 49 Nelson, C. P. & Sanda, M. G. (2002) Contemporary diagnosis and management of renal  
50 angiomyolipoma. *Journal of Urology*, 168: 1315-1325.  
51 Not in PICO

- 1 Ng, Y. H., Seeley, J. P. & Smith, G. (2013) Haematospermia as a presenting symptom: Outcomes of  
2 investigation in 300 men. *Surgeon-Journal of the Royal Colleges of Surgeons of Edinburgh and*  
3 *Ireland*, 11: 35-38.  
4 Not in PICO
- 5 Oldbring, J., Glifberg, I., Mikulowski, P. & Hellsten, S. (1989) Carcinoma of the renal pelvis and ureter  
6 following bladder carcinoma: frequency, risk factors and clinicopathological findings. *Journal of*  
7 *Urology*, 141: 1311-1313.  
8 Not in PICO
- 9 Parekh, D. J., Cookson, M. S., Chapman, W., Harrell, F., Jr., Wells, N., Chang, S. S. & Smith, J. A., Jr.  
10 (2005) Renal cell carcinoma with renal vein and inferior vena caval involvement:  
11 clinicopathological features, surgical techniques and outcomes. *Journal of Urology*, 173: 1897-  
12 1902.  
13 Not in PICO
- 14 Patard, J. J. (1996) [Hematuria: current strategies]. [French]. *Annales d Urologie*, 30: 274-275.  
15 Narrative review
- 16 Patard, J. J., Bensalah, K., Vincendeau, S., Rioux-Leclercq, N., Guille, F. & Lobel, B. (2003) [Correlation  
17 between the mode of presentation of renal tumors and patient survival]. [French]. *Progres En*  
18 *Urologie*, 13: 23-28.  
19 Not in PICO
- 20 Patel, J. V., Chambers, C. V. & Gomella, L. G. (2008) Hematuria: etiology and evaluation for the  
21 primary care physician. [Review] [19 refs]. *Canadian Journal of Urology*, 15: Suppl-61.  
22 Narrative review
- 23 Pfister, D., Thuer, D. & Heidenreich, A. (2010) Pitfalls and outcome of nephrectomy for patients with  
24 polycystic kidney disease: Peri- and postoperative results. [German]. *Urologe - Ausgabe A*, 49:  
25 1156-1162.  
26 Not in PICO
- 27 Pozzi-Mucelli, F., Medeot, A., Cernic, S., Calgaro, A., Braini, M. & Cova, M. (2011) Multimodal  
28 approach to the endovascular treatment of embolisation or exclusion of the renal arteries and  
29 their distal and/or polar branches: personal experience. *Radiologia Medica*, 116: 945-959.  
30 Not in PICO
- 31 Protzel, C., Woenckhaus, C., Zimmermann, U. & Klebingat, K.-J. (2001) Renal leiomyoma. An aspect  
32 of differential diagnosis of renal cell carcinoma with increasing clinical significance. [German].  
33 *Urologe - Ausgabe A*, 40: 384-387.  
34 Narrative review
- 35 Puthenparambil, J., Lechner, K. & Kornek, G. (2010) Autoimmune hemolytic anemia as a  
36 paraneoplastic phenomenon in solid tumors: A critical analysis of 52 cases reported in the  
37 literature. [Review] [68 refs]. *Wiener Klinische Wochenschrift*, 122: 229-236.  
38 Not in PICO
- 39 Rais-Bahrami, S., Guzzo, T. J., Jarrett, T. W., Kavoussi, L. R. & Allaf, M. E. (2009) Incidentally  
40 discovered renal masses: Oncological and perioperative outcomes in patients with delayed  
41 surgical intervention. *BJU International*, 103: 1355-1358.  
42 Not in PICO
- 43 Schachter, L. R., Cookson, M. S., Chang, S. S., Smith, J. A., Jr., Dietrich, M. S., Jayaram, G. & Herrell, S.  
44 D. (2007) Second prize: frequency of benign renal cortical tumors and histologic subtypes based  
45 on size in a contemporary series: what to tell our patients. *Journal of Endourology*, 21: 819-823.  
46 Not in PICO
- 47 Schlomer, B., Figenshau, R. S., Yan, Y., Venkatesh, R. & Bhayani, S. B. (2006) Pathological features of  
48 renal neoplasms classified by size and symptomatology. *Journal of Urology*, 176: t-20.  
49 Not in PICO
- 50 Schwentner, C., Hennenlotter, J., Kuehs, U., Sleiman, H., Colleselli, D., Huber, S., Schilling, D., Sievert,  
51 K.-D. & Stenzl, A. (2010) Early detection of transitional cell carcinoma - Predictive power of urine-

- 1 based tumor markers with regard to tumor grade and stage. *Journal of Urology*, 183: e454-e455.  
2 Not in PICO
- 3 Schwentner, C., Hennenlotter, J., Kuehs, U., Tews, V., Colleselli, D., Huber, S., Schilling, D., Sievert, K.-  
4 D. & Stenzl, A. (2010) Hematuria: Helpful or misleading for the early detection of transitional cell  
5 carcinoma-results from a cohort of 2008 patients. *Journal of Urology*, 183: e454.  
6 Not in PICO
- 7 Sells, H. & Cox, R. (2001) Undiagnosed macroscopic haematuria revisited: a follow-up of 146  
8 patients. *BJU International*, 88: 6-8.  
9 Not in PICO
- 10 Shi, G. H., Chen, Y., Yao, X. D., Zhang, S. L., Dai, B., Feng, L. Q., Zhang, H. L., Shen, Y. J., Zhu, Y., Zhu, Y.  
11 P., Xiao, W. J., Ma, C. G., Wen, L. G., Qin, X. J., Yang, L. F. & Ye, D. W. (2013) Individualized renal  
12 mass biopsy strategy for Chinese patients with different subtypes and necrosis area. *Urologic  
13 Oncology*, 31: 920-923.  
14 Not in PICO
- 15 Shvarts, O., Han, K. R., Lam, J. S. & Belldegrun, A. S. (2004) Primary leiomyosarcoma of the inferior  
16 vena cava presenting as a renal mass. *Reviews in Urology*, 6: 39-42.  
17 Not in PICO
- 18 Siemer, S., Hack, M., Lehmann, J., Becker, F. & Stockle, M. (1243) Outcome of renal tumors in young  
19 adults. *Journal of Urology*, 175: 1240-1243.  
20 Not in PICO
- 21 Sigalow, D. A., Waldbaum, R. S. & Lowe, F. C. (1991) Identification of asymptomatic renal cell  
22 carcinomas utilizing modern radiographic techniques. *New York State Journal of Medicine*, 91:  
23 200-202.  
24 Not in PICO
- 25 Slywotzky, C. M. & Bosniak, M. A. (2001) Localized cystic disease of the kidney. *AJR.American Journal  
26 of Roentgenology*, 176: 843-849.  
27 Not in PICO
- 28 Song, J., Tanagho, Y., Bhayani, S. & Figenshau, R. (2013) Factors predictive of symptomatic  
29 presentation in renal cell carcinoma. *Journal of Endourology*, 27: A383.  
30 Not in PICO
- 31 Stefanovic, K. B., Gregg, P. C. & Soung, M. (2009) Evaluation and treatment of hematospermia.  
32 *American Family Physician*, 80: 1421-1427.  
33 Narrative review
- 34 Steiner, M. S., Goldman, S. M., Fishman, E. K. & Marshall, F. F. (1993) The natural history of renal  
35 angiomyolipoma. *Journal of Urology*, 150: 1782-1786.  
36 Not in PICO
- 37 Szecei, A. & Szokoly, V. (1999) Retrospective clinical examination of incidentally detected kidney  
38 tumors. [Hungarian]. *Magyar Urologia*, 11: 349-356.  
39 Not in PICO
- 40 Taguchi, Y., Hori, S., Tomita, M., Matsuoka, Y., Suzuki, H., Odera, H. & Ishitani, H. (1994) Study of  
41 urine occult blood test with reagent strips - With special reference to results of workers' health  
42 check and ultrasonographic examination. [Japanese]. *Journal of Transportation Medicine*, 48:  
43 276-280.  
44 Not in PICO
- 45 Takashi, M., Takagi, Y., Sakata, T., Shimoji, T. & Miyake, K. (1994) Clinicopathological characteristics  
46 of small renal cell carcinomas. *International Urology and Nephrology*, 26: 621-629.  
47 Not in PICO
- 48 Thaller, T. R. & Wang, L. P. (1154) Evaluation of asymptomatic microscopic hematuria in adults.  
49 [Review] [28 refs]. *American Family Physician*, 60: 1143-1152.  
50 Narrative review

- 1 Thariat, J., Vendrely, B., Roca, S., Ravaud, A., Bay, J. O., Lacout, A., Marcy, P. Y., Thyss, A. &  
 2 Besancenot, J. F. (2012) [Renal involvement in cancer and renal paraneoplastic syndromes].  
 3 [Review] [French]. *Bulletin du Cancer*, 99: 263-275.  
 4 Narrative review
- 5 Tijani, K. H., Anunobi, C. C., Ezenwa, E. V., Lawal, A., Habeebu, M. Y. M., Jeje, E. A., Ogunjimi, M. A. &  
 6 Afolayan, M. O. (2012) Adult renal cell carcinoma in Lagos: Experience and challenges at the  
 7 Lagos University Teaching Hospital. *African Journal of Urology*, 18: 20-23.  
 8 Not in PICO
- 9 Tong, Y. C., Chieng, P. U., Tsai, T. C. & Lin, S. N. (1990) Renal angiomyolipoma: report of 24 cases.  
 10 *British Journal of Urology*, 66: 585-589.  
 11 Not in PICO
- 12 Tosaka, A., Ohya, K., Yamada, K., Ohashi, H., Kitahara, S., Sekine, H., Takehara, Y. & Oka, K. (1990)  
 13 Incidence and properties of renal masses and asymptomatic renal cell carcinoma detected by  
 14 abdominal ultrasonography. *Journal of Urology*, 144: 1097-1099.  
 15 Not in PICO
- 16 Tsivian, M., Mouraviev, V., Kimura, M., Mayes, J., Albala, D., Robertson, C., Walther, P. & Polascik, T.  
 17 (2009) Rationale for a less aggressive therapy for small renal tumors. *Urology*, 74: S19.  
 18 Not in PICO
- 19 Valero-Aguilera, B., Bermudez-Tamayo, C., Garcia-Gutierrez, J. F., Jimenez-Pernett, J., Cozar-Olmo, J.  
 20 M., Guerrero-Tejada, R. & Alba-Ruiz, R. (2014) - Information needs and Internet use in urological  
 21 and breast cancer patients. - *Supportive Care in Cancer*, 22: 545-552.  
 22 Not in PICO
- 23 Venables, Z., Ramaiya, A., Holden, S. & Millington, G. W. M. (2013) Three generations of hereditary  
 24 leiomyomatosis associated with renal cell cancer. *British Journal of Dermatology*, 169: 21.  
 25 Not in PICO
- 26 Vogelzang, N. J. & Stadler, W. M. (1998) Kidney cancer. *Lancet*, 352: 1691-1696.  
 27 Narrative review
- 28 Wang, G. Y. (700) [Asymptomatic renal cell carcinoma and small renal cell carcinoma]. [Chinese].  
 29 *Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery]*, 27: 656-657.  
 30 Not in PICO
- 31 Wayte, N., Da, S. L., Chenevix-Trench, G. & Lakhani, S. R. (2008) What's in a cancer syndrome?  
 32 Genes, phenotype and pathology. *Pathology*, 40: 247-259.  
 33 Narrative review
- 34 Yamaguchi, K., Tominaga, T. & Nishimura, Y. (1995) Clinical study on incidental renal cell carcinoma.  
 35 [Japanese]. *Hinyokika kiyo, Acta*: 93-99.  
 36 Not in PICO
- 37 Yap, N. Y., Ng, K. L., Ong, T. A., Pailoor, J., Gobe, G. C., Ooi, C. C., Razack, A. H., Dublin, N., Morais, C.  
 38 & Rajandram, R. (2013) Clinical prognostic factors and survival outcome in renal cell carcinoma  
 39 patients - a malaysian single centre perspective. *Asian Pacific Journal of Cancer Prevention: Apjcp*,  
 40 14: 7497-7500.  
 41 Not in PICO
- 42 Yazaki, T., Iiyama, T., Sato, S., Hata, R., Amemiya, H., Tomomasa, H., Muramatsu, H., Iizumi, T.,  
 43 Toyoshima, A. & Umeda, T. (1991) [Clinical study of renal cell carcinoma as incidental finding].  
 44 [Japanese]. *Nippon Jinzo Gakkai Shi. Japanese Journal of Nephrology*, 33: 409-415.  
 45 Not in PICO
- 46 Yeoh, M., Lai, N. K., Anderson, D. & Appadurai, V. (2013) Macroscopic haematuria--a urological  
 47 approach. *Australian Family Physician*, 42: 123-126.  
 48 Narrative review
- 49 Yokom, D. W., Ihaddadene, R., Le, G. G., Moretto, P. & Carrier, M. (2013) Incidental venous  
 50 thromboembolism in kidney cancer patients: A case-control study. *Journal of Thrombosis and*

1 *Haemostasis*, 11: 330.

2 Not in PICO

3 Zielinski, H. (2005) Early detection of renal cancer. [Polish]. *Wspolczesna Onkologia*, 9: 98-100.

4 Narrative review

5 Zollner, S., Dirksen, U., Jurgens, H. & Ranft, A. (2013) Renal Ewing tumors. *Annals of Oncology*, 24:  
6 2455-2461.

7 Not in PICO

8  
9 **Review question:**

10 Which investigations of symptoms of suspected renal cancer should be done with clinical  
11 responsibility retained by primary care?

12  
13 **Results**

14 **Literature search**


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1980-2013	377	127	20/02/2013
<i>Premedline</i>	1980-2013	11	3	20/02/2013
<i>Embase</i>	1980-2013	457	94	21/03/2013
<i>Cochrane Library</i>	1980-2013	128	1	20/02/2013
<i>Psychinfo</i>	1980-2013	1	0	21/03/2013
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	1980-2013	45	8	21/03/2013
<i>Biomed Central</i>	1980-2013	814	0	21/03/2013

15 Total References retrieved (after de-duplication): 189

16 **Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	2/2013- 18/08/2014	10	1	18/08/2014
<i>Premedline</i>	2/2013- 18/08/2014	15	3	18/08/2014
<i>Embase</i>	2/2013- 18/08/2014	74	7	18/08/2014
<i>Cochrane Library</i>	2/2013- 18/08/2014	70	0	18/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	2/2013- 18/08/2014	11	2	18/08/2014

17 Total References retrieved (after de-duplication): 11



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

### Study results

No evidence was identified pertaining to the diagnostic accuracy of abdominal ultrasound, urine cytology, x-ray, intravenous pyelogram, or CT scan of the abdomen and pelvis in patients with suspected renal cancer where the clinical responsibility was retained by primary care.

### References

#### Included studies

None

#### Excluded studies (with excl reason)

Acino, S. & Resnick, M. I. (1988) Office urologic ultrasound. [Review] [34 refs]. *Urologic Clinics of North America*, 15: 577-588.  
Narrative review

Aharony, S., Baniel, J., Tikva, P., Yossepowitch, O. & Hasharon, R. (2010) Clinically Unconfirmed positive Urine cytology - Oncological implications over long term follow-up. *Journal of Urology*, 183: e522.  
Not in PICO

Ajit, D., Dighe, S. & Desai, S. (2010) Has urine cytology a role to play in the era of fluorescence in situ hybridization? *Acta Cytologica*, 54: 1118-1122.  
Not in PICO

Ak, I. & Can, C. (2005) F-18 FDG PET in detecting renal cell carcinoma. *Acta Radiologica*, 46: 895-899.  
Not in PICO

Akbari, A., Mayhew, A., Al-Alawi, M. A., Grimshaw, J., Winkens, R., Glidewell, E., Pritchard, C., Thomas, R. & Fraser, C. (2008) Interventions to improve outpatient referrals from primary care to secondary care. *Cochrane Database of Systematic Reviews*.  
Not in PICO

Amendola, M. A. (1989) Comparison of MR imaging and CT in the evaluation of renal masses. [Review] [45 refs]. *Critical Reviews in Diagnostic Imaging*, 29: 117-150.  
Narrative review

Andresen, R. & Wegner, H. E. (1997) Intravenous urography revisited in the age of ultrasound and computerized tomography: diagnostic yield in cases of renal colic, suspected pelvic and

- 1 abdominal malignancies, suspected renal mass, and acute pyelonephritis. *Urologia*  
2 *Internationalis*, 58: 221-226.  
3 Not in PICO
- 4 Arora, V. K., Sarungbam, J., Bhatia, A., Singh, N., Agrawal, V. & Aggarwal, S. (2010) Usefulness of  
5 NMP22 as an adjunct to a typical urine cytology and low-grade urothelial carcinoma. *Diagnostic*  
6 *Cytopathology*, 38: 788-790.  
7 Not in PICO
- 8 Aslaksen, A. & Gothlin, J. H. (1991) Imaging of solid renal masses. [Review] [37 refs]. *Current Opinion*  
9 *in Radiology*, 3: 654-662.  
10 Narrative review
- 11 Ayllon, J., Verkarre, V., Scotte, F., Fournier, L., Correas, J. M., Mejean, A., Teghom, C. & Oudard, S.  
12 (2012) Renal malacoplakia: Case report of a differential diagnosis for renal cell carcinoma. *The*  
13 *American Journal of Case Reports*, 13: 38-40.  
14 Not in PICO
- 15 Barroca, H. & Bom-Successo, M. (2014) Fine needle biopsy with cytology in paediatrics: The  
16 importance of a multidisciplinary approach and the role of ancillary techniques. *Cytopathology*,  
17 25: 6-20.  
18 Narrative review
- 19 Battista, G., Sassi, C., Schiavina, R., Franceschelli, A., Baglivo, E., Martorana, G. & Canini, R. (2009)  
20 Computerized tomography virtual endoscopy in evaluation of upper urinary tract tumors: Initial  
21 experience. *Abdominal Imaging*, 34: 107-112.  
22 Not in PICO
- 23 Bayanati, H., Vakili, M. & Fasih, C. (2011) Syndromes in abdominal imaging-a case-based review of  
24 imaging findings. *American Journal of Roentgenology*, 196: A149.  
25 Narrative review
- 26 Beillard, C., Ardilouze, P. & Guillet, G. (2004) Dermatomyositis and kidney cancer: Interest of a  
27 thoraco-abdomino-pelvic scanner. [French]. *Nouvelles Dermatologiques*, 23: 543-545.  
28 Not in PICO
- 29 Beland, M. D., Mayo-Smith, W. W., Dupuy, D. E., Cronan, J. J. & DeLellis, R. A. (2007) Diagnostic yield  
30 of 58 consecutive imaging-guided biopsies of solid renal masses: should we biopsy all that are  
31 indeterminate? *AJR.American Journal of Roentgenology*, 188: 792-797.  
32 Not in PICO
- 33 Belville, J. S., Morgentaler, A., Loughlin, K. R. & Tumei, S. S. (1989) Spontaneous perinephric and  
34 subcapsular renal hemorrhage: evaluation with CT, US, and angiography. *Radiology*, 172: 733-  
35 738.  
36 Not in PICO
- 37 Bilal, M. M. & Brown, J. J. (1997) MR imaging of renal and adrenal masses in children. *Magnetic*  
38 *Resonance Imaging Clinics of North America*, 5: 179-197.  
39 Narrative review
- 40 Bloncourt, J., Dana, A., Galakhoff, C., Hospitel, S. & Michel, J. R. (1989) [Echography in pyelocaliceal  
41 tumors]. [French]. *Journal de Radiologie*, 70: 79-84.  
42 Not in PICO
- 43 Bonekamp, S., Corona-Villalobos, C. P. & Kamel, I. R. (2012) Oncologic applications of diffusion-  
44 weighted MRI in the body. *Journal of Magnetic Resonance Imaging*, 35: 257-279.  
45 Narrative review
- 46 Bos, S. D., Mellema, C. T. & Mensink, H. J. (2000) Increase in incidental renal cell carcinoma in the  
47 northern part of the Netherlands. *European Urology*, 37: 267-270.  
48 Not in PICO
- 49 Brown, F. M. (2000) Urine cytology. It is still the gold standard for screening?. [Review] [25 refs].  
50 *Urologic Clinics of North America*, 27: 25-37.  
51 Narrative review

- 1 Budoff, M. J. & Gopal, A. (2007) Incidental findings on cardiac computed tomography. Should we  
2 look? *Journal of cardiovascular computed tomography*, 1: 97-105.  
3 Narrative review
- 4 Buteau, A., Seideman, C. A., Svatek, R. S., Youssef, R. F., Chakrabarti, G., Reed, G., Bhat, D. & Lotan, Y.  
5 (2014) What is evaluation of hematuria by primary care physicians? Use of electronic medical  
6 records to assess practice patterns with intermediate follow-up. *Urologic Oncology*, 32: 128-134.  
7 Not in PICO
- 8 Carrafiello, G., Fontana, F., Mangini, M., Ierardi, A. M., Cotta, E., Piacentino, F., De, C. M., Floridi, C.,  
9 Di, M. A., Marconi, A. M. & Fugazzola, C. (2012) Upper urinary tract biopsy: an old device for a  
10 new approach. *Radiologia Medica*, 117: 1152-1160.  
11 Not in PICO
- 12 Cepulic, M., Cizmic, A., Petkovic, I., Fattorini, I., Nakic, M. & Stepan, G. J. (2003) Nephroblastomas -  
13 Wilms' tumor (WT). [Croatian]. *Paediatrica Croatica, Supplement*, 47: 75-80.  
14 Narrative review
- 15 Chahal, R., Taylor, K., Eardley, I., Lloyd, S. N. & Spencer, J. A. (2011) Patients at high risk for upper tract  
16 urothelial cancer: evaluation of hydronephrosis using high resolution magnetic resonance  
17 urography. *Journal of Urology*, 174: 478-482.  
18 Not in PICO
- 19 Chan, K. & Kamangar, N. (2012) Tuberos sclerosi complex manifesting with massive  
20 angiomyolipomas in multiple organs. *Chest*, 142.  
21 Not in PICO
- 22 Chen, D. Y. T. & Uzzo, R. G. (2011) Evaluation and management of the renal mass. *Medical Clinics of*  
23 *North America*, 95: 179-189.  
24 Narrative review
- 25 Chen, Y. F., Li, Y. W., Sheih, C. P. & Hsu, C. Y. (1999) Renal cell carcinoma: unusual pediatric renal  
26 tumors. *Journal of the Formosan Medical Association*, 98: 118-121.  
27 Not in PICO
- 28 Chisholm, R. A., Millet, B., Sherwood, T., Wraight, E. P. & Doyle, P. T. (1988) The investigation of  
29 painless haematuria - a comparison of intravenous urography and DMSA scintigraphy. *Clinical*  
30 *Radiology*, 39: 494-495.  
31 Not in PICO
- 32 Choyke, P. L. (2008) Radiologic evaluation of hematuria: Guidelines from the American College of  
33 Radiology's appropriateness criteria. *American Family Physician*, 78: 347-352.  
34 Narrative review
- 35 Collins, G. S. & Altman, D. G. (2013) Identifying patients with undetected renal tract cancer in  
36 primary care: An independent and external validation of Q Cancer (Renal) prediction model.  
37 *Cancer Epidemiology*, 37: 115-120.  
38 Already included
- 39 Craft, A. W., Parker, L., Stiller, C. & Cole, M. (1995) Screening for Wilms' tumour in patients with  
40 Aniridia, Beckwith syndrome, or hemihypertrophy. *Medical and Pediatric Oncology*, 24: 231-234.  
41 Not in PICO
- 42 Crispen, P. L., Soljic, A., Stewart, G., Kutikov, A., Davenport, D. & Uzzo, R. G. (2012) Enhancing renal  
43 tumors in patients with prior normal abdominal imaging: further insight into the natural history  
44 of renal cell carcinoma. *Journal of Urology*, 188: 1089-1093.  
45 Not in PICO
- 46 Croft, D. & Dickerson, M. (1994) Ultrasound differentiation of two pediatric abdominal masses.  
47 *Journal of Diagnostic Medical Sonography*, 10: 12-17.  
48 Narrative review
- 49 Czemberek, H. (1986) [Nephrology for general practice--roentgenologic diagnosis]. [German]. *Wiener*  
50 *Medizinische Wochenschrift*, 136: 17-19.  
51 Narrative review



- 1 Dalla, P. L., Pozzi-Mucelli, R., Magnaldi, S. & Pozzi-Mucelli, F. (1988) [Diagnostic imaging of renal  
2 tumors of small dimensions]. [Italian]. *Radiologia Medica*, 76: 590-596.  
3 Not in PICO
- 4 Dalla, P. L., Ricci, C. & Magnaldi, S. (1995) Referral criteria for selection of patients and diagnostic  
5 procedures. *Radiation Protection Dosimetry*, 57: 3-8.  
6 Narrative review
- 7 Damgaard-Pedersen, K. (1980) CT and IVU in the diagnosis of Wilms' tumour. A comparative study.  
8 *Pediatric Radiology*, 9: 207-211.  
9 Not in PICO
- 10 Datta, S. N., Allen, G. M., Evans, R., Vaughton, K. C. & Lucas, M. G. (2002) Urinary tract  
11 ultrasonography in the evaluation of haematuria--a report of over 1,000 cases. *Annals of the  
12 Royal College of Surgeons of England*, 84: 203-205.  
13 Not in PICO
- 14 Debre, B., Peyromaure, M., Saighi, D. & Zerbib, M. (2004) [Advances in diagnosis and treatment of  
15 renal cell carcinoma]. [Review] [29 refs] [French]. *Bulletin de l'Academie Nationale de Medecine*,  
16 188: 15-24.  
17 Narrative review
- 18 Deidda, G., Paoni, A., Pischedda, A., Foddis, G., Bottaru, M. & Bercovich, E. (1996) [Developments in  
19 the last 10 years in diagnostic imaging discovery of renal carcinoma]. [Italian]. *Archivio Italiano di  
20 Urologia, Andrologia*, 68: Suppl-51.  
21 Not in PICO
- 22 Delorme, S. & van, K. G. (1996) [Cui bono? Comments on cost-benefit analysis in ultrasound  
23 diagnosis]. [German]. *Radiologe*, 36: 285-291.  
24 Narrative review
- 25 Delorme, S. (2012) [Ultrasound in oncology: screening and staging]. [Review] [German]. *Internist*, 53:  
26 271-281.  
27 Narrative review
- 28 Demirer, Z., Zor, M., Kurt, B., Bozkurt, Y. & Yildirim, I. (2012) Bilateral renal metastasis of an inguinal  
29 malignant solitary fibrous tumor, 9 years after primary surgical treatment. *Medical Principles &  
30 Practice*, 21: 585-587.  
31 Not in PICO
- 32 Descotes, J.-L. & Doublet, J.-D. (2006) Renal imaging and biopsy for diagnosis of renal masses.  
33 [French]. *Annales d'Urologie*, 40: S86-S90.  
34 Narrative review
- 35 Di, N. A. & Signoretti, S. (2009) Tissue biomarkers in renal cell carcinoma: issues and solutions.  
36 [Review] [44 refs]. *Cancer*, 115: Suppl-7.  
37 Narrative review
- 38 Dikranian, A. H., Petitti, D. B., Shapiro, C. E. & Kosco, A. F. (2005) Intravenous urography in  
39 evaluation of asymptomatic microscopic hematuria. *Journal of Endourology*, 19: 595-597.  
40 Not in PICO
- 41 Dirim, A., Tutar, N., Peskircioglu, L., Celik, H., Tekin, M. I. & Ozkardes, H. (2010) Can dynamic  
42 multidetector computerized tomography detect renal cell carcinoma subtypes? *Turkish Journal of  
43 Medical Sciences*, 40: 31-38.  
44 Not in PICO
- 45 Dobry, E. & Danuser, H. (2009) [Imaging of the kidney and the urinary tract]. [Review] [22 refs]  
46 [German]. *Therapeutische Umschau*, 66: 39-42.  
47 Narrative review
- 48 Dragoescu, E. A. & Liu, L. (2013) Indications for renal fine needle aspiration biopsy in the era of  
49 modern imaging modalities. *CytoJournal*, 10.  
50 Not in PICO

- 1 Ell, C. & Schott, G. (1994) [Suspected kidney tumor--diagnostic-therapeutic procedure]. [German].  
 2 *Fortschritte der Medizin*, 112: 123-124.  
 3 Narrative review
- 4 Etemad, A., Brems-Dalgaard, E. & Thomsen, H. S. (2003) Outcome of intravenous urography in the  
 5 year 2000. *Abdominal Imaging*, 28: 226-229.  
 6 Not in PICO
- 7 Fekak, H., Bennani, S., Taha, A., Rabii, R., Joual, A., Sarf, S., Hafiani, M., el, M. M. & Benjelloun, S.  
 8 (2001) [Kidney cancer. Report of 170 cases]. [French]. *Annales d Urologie*, 35: 249-256.  
 9 Not in PICO
- 10 Fekak, H., Bennani, S., Taha, A., Rabii, R., Joual, A., Sarf, S., Hafiani, M., el, M. M. & Benjelloun, S.  
 11 (2001) The cancer of kidney. A report of 170 cases. [French]. *Annales d'Urologie*, 35: 249-256.  
 12 Not in PICO
- 13 Ferda, J., Hora, M., Hes, O., Ferdova, E. & Kreuzberg, B. (2007) Assessment of the kidney tumor  
 14 vascular supply by two-phase MDCT-angiography. *European Journal of Radiology*, 62: 295-301.  
 15 Not in PICO
- 16 Ferda, J., Ferdova, E., Hora, M., Hes, O., Finek, J., Topolcan, O. & Kreuzberg, B. (2013) 18F-FDG-  
 17 PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis  
 18 estimation. *Anticancer Research*, 33: 2665-2672.  
 19 Not in PICO
- 20 Ferrer, M. D., Marti-Bonmati, L., Belloch, V., Moreno, F., Galant, J., Martinez-Rodrigo, J. & Casillas, C.  
 21 (1993) Study of renal carcinoma in early stage by computerized tomography and magnetic  
 22 resonance. [Spanish]. *Neoplasia*, 10: 201-205.  
 23 Not in PICO
- 24 Fiegler, W., Felix, R., Schorner, W. & Kohler, D. (1985) [Diagnosis of kidney diseases with magnetic  
 25 resonance tomography including the use of nuclear magnetic resonance contrast media].  
 26 [German]. *Urologe (Auszg.A)*, 24: 264-269.  
 27 Narrative review
- 28 Flanigan, R. C. (2007) Renal tumors: The good, the bad, and the ugly. *International Journal of*  
 29 *Urology*, 14: 575-580.  
 30 Narrative review
- 31 Foley, W. D. (2003) Renal MDCT. [Review] [8 refs]. *European Journal of Radiology*, 45: Suppl-8.  
 32 Narrative review
- 33 Fornara, P. & Hoda, M. R. (2011) [Renal cell carcinoma]. [Review] [German]. *Urologe (Auszg.A)*, 50:  
 34 Suppl-22.  
 35 Narrative review
- 36 Furtwangler, R., Schenk, J.-P., Reinhard, H., Leuschner, I., Rube, C., Von, S. D. & Graf, N. (2005)  
 37 Nephroblastoma - Wilms' tumor. Genetics, radiological diagnostics and therapy concept - An  
 38 overview. [German]. *Onkologie*, 11: 1077-1089.  
 39 Narrative review
- 40 Ghani, K. R., Keeler, B. & Nargund, V. (2007) Haematuria 2: Imaging investigations, management and  
 41 follow up. *British Journal of Hospital Medicine*, 68: 489-493.  
 42 Narrative review
- 43 Gingu, C., Patrascoiu, S., Surcel, C., Chibelea, C., Harza, M., Zogas, V., Balsanu, C., Dick, A., Mirvald,  
 44 C., Lupu, F., Domnisor, L. & Sinescu, I. (2012) Primary carcinoma of the male urethra-diagnosis  
 45 and treatment. *European Urology, Supplements*, 11: e405-e405a.  
 46 Not in PICO
- 47 Golan, S., Lifshitz, D., Livne, P. M., Baniel, J. & Nadu, A. (2012) The yield of ureteroscopy for upper  
 48 tract urothelial carcinoma in the era of computerized tomography urography. *Journal of*  
 49 *Endourology*, 26: A94-A95.  
 50 Not in PICO

- 1 Grossfeld, G. D., Wolf, J. S., Litwin, M. S., Hricak, H., Shuler, C. L., Agerter, D. C. & Carroll, P. R. (2001)  
 2 Asymptomatic microscopic hematuria in adults: Summary of the AUA Best Practice Policy  
 3 recommendations. *American Family Physician*, 63: 1145-1154.  
 4 Narrative review
- 5 Gu, F. L. (1990) Imaging techniques for the diagnosis of renal tumors. *Proceedings of the Chinese  
 6 Academy of Medical Sciences & the Peking Union Medical College*, 5: 75-78.  
 7 Not in PICO
- 8 Guinan, P. & Rubenstein, M. (1987) Methods of early diagnosis in genitourinary cancer. [Review]  
 9 [163 refs]. *Cancer*, 60: Suppl-76.  
 10 Narrative review
- 11 Haendl, T., Strobel, D., Legal, W., Frieser, M., Hahn, E. G. & Bernatik, T. (2009) [Renal cell cancer does  
 12 not show a typical perfusion pattern in contrast-enhanced ultrasound]. [German]. *Ultraschall in  
 13 der Medizin*, 30: 58-63.  
 14 Not in PICO
- 15 Hafron, J. & Kaouk, J. H. (2007) Ablative techniques for the management of kidney cancer. *Nature  
 16 Clinical Practice Urology*, 4: 261-269.  
 17 Not in PICO
- 18 Heikkinen, M., Rasanen, H. & Farkkila, M. (2005) Clinical value of ultrasound in the evaluation of  
 19 dyspepsia in primary health care. *Scandinavian Journal of Gastroenterology*, 40: 980-984.  
 20 Not in PICO (Not diagnostic test accuracy study)
- 21 Heilbrun, M. E., Yu, J., Smith, K. J., Dechet, C. B., Zagoria, R. J. & Roberts, M. S. (2012) The cost-  
 22 effectiveness of immediate treatment, percutaneous biopsy and active surveillance for the  
 23 diagnosis of the small solid renal mass: evidence from a Markov model (Structured abstract).  
 24 *Journal of Urology*, 187: 39-43.  
 25 Not in PICO
- 26 Helenon, O., Eiss, D., Debrito, P., Merran, S. & Correas, J. M. (2012) How to characterise a solid renal  
 27 mass: a new classification proposal for a simplified approach. *Diagnostic and Interventional  
 28 Imaging*, 93: 232-245.  
 29 Narrative review
- 30 Henning, A., Wehrberger, M., Madersbacher, S., Pycha, A., Martini, T., Comploj, E., Jeschke, K.,  
 31 Tripolt, C. & Rauchenwald, M. (2013) Do differences in clinical symptoms and referral patterns  
 32 contribute to the gender gap in bladder cancer? *BJU International*, 112: 68-73.  
 33 Not in PICO
- 34 Hernandez, J. D., de la Torre, H. P., Alberola, B. J. & Amores, C. S. (2001) [Small renal mass.  
 35 Diagnostic management]. [Review] [20 refs] [Spanish]. *Archivos Espanoles de Urologia*, 54: 593-  
 36 601.  
 37 Narrative review
- 38 Heynemann, H. (2008) [Current aspects in the diagnosis of renal cell cancer]. [German]. *Praxis*, 97:  
 39 421-425.  
 40 Narrative review
- 41 Higgins, J. C. & Fitzgerald, J. M. (2009) Evaluation of incidental renal and adrenal masses. *American  
 42 Family Physician*, 63: 288-294.  
 43 Narrative review
- 44 Higgins, J. C. & Arnold, M. J. (2013) When to worry about incidental renal and adrenal masses.  
 45 *Journal of Family Practice*, 62: 476-483.  
 46 Narrative review
- 47 Ho, K. K. L. (2002) Nephrotic syndrome in adults - A common clinical syndrome of kidney diseases.  
 48 *Hong Kong Practitioner*, 24: 66-71.  
 49 Narrative review
- 50 Hoeffel, C., Pousset, M., Timsit, M. O., Elie, C., Mejean, A., Merran, S., Tranquart, F., Khairoune, A.,  
 51 Joly, D., Richard, S., Helenon, O. & Correas, J. M. (2010) Radiofrequency ablation of renal

- 1 tumours: diagnostic accuracy of contrast-enhanced ultrasound for early detection of residual  
2 tumour. *European Radiology*, 20: 1812-1821.
- 3 Not in PICO
- 4 Hricak, H. (1987) Urologic cancer. Methods of early detection and future developments. *Cancer*, 60:  
5 Suppl-85.
- 6 Narrative review
- 7 Iczkowski, K. A., Sweat, S. D. & Bostwick, D. G. (1999) Subepithelial pelvic hematoma of the kidney  
8 clinically mimicking cancer: report of six cases and review of the literature. [Review] [12 refs].  
9 *Urology*, 53: 276-279.
- 10 Not in PICO
- 11 Jimbo, M. (2010) Evaluation and Management of Hematuria. *Primary Care*, 37: 461-+.
- 12 Narrative review
- 13 Jinzaki, M., Matsumoto, K., Kikuchi, E., Sato, K., Horiguchi, Y., Nishiwaki, Y. & Silverman, S. G. (2011)  
14 Comparison of CT urography and excretory urography in the detection and localization of  
15 urothelial carcinoma of the upper urinary tract. *American Journal of Roentgenology*, 196: 1102-  
16 1109.
- 17 Not in PICO
- 18 Junuzovic, D., Kerleta, A. & Masic, I. (2013) The frequency of renal cell carcinoma in population of  
19 patients with kidney tumors. *Medicinski Arhiv*, 67: 27-30.
- 20 Not in PICO
- 21 Kang, N., Niu, Y., Zhang, J., Wang, J., Tian, X., Yan, Y., Yu, Z. & Xing, N. (2012) Intraoperative  
22 ultrasonography: a useful tool in retrolaparoscopic nephron-sparing surgery. *Urologia*  
23 *Internationalis*, 88: 338-342.
- 24 Not in PICO
- 25 Kawaciuk, I., Hyrsi, L., Dusek, P., Jarolim, L., Schmidt, M., Kaliska, V., Chocholaty, M. & Vesely, S.  
26 (2008) Influence of tumour-associated symptoms on the prognosis of patients with renal cell  
27 carcinoma. *Scandinavian Journal of Urology & Nephrology*, 42: 406-411.
- 28 Not in PICO
- 29 Kaya, K., Ayan, S., Gokce, G., Kilicarslan, H., Yildiz, E. & Gultekin, E. Y. (2005) Urinary nuclear matrix  
30 protein 22 for diagnosis of renal cell carcinoma. *Scandinavian Journal of Urology and Nephrology*,  
31 39: 25-29.
- 32 Not in PICO
- 33 Kim, J. (2006) Imaging findings of renal cell carcinoma. [Review] [43 refs]. *Expert Review of*  
34 *Anticancer Therapy*, 6: 895-904.
- 35 Narrative review
- 36 Kim, S. W., Yoon, B. I., Ha, U. S., Sohn, D. W. & Cho, Y. H. (2013) Xanthogranulomatous  
37 pyelonephritis: clinical experience with 21 cases. *Journal of Infection & Chemotherapy*, 19: 1221-  
38 1224.
- 39 Not in PICO
- 40 Knoflach, P., Judmaier, G., Reiner, A. & Mikuz, G. (1983) [Ultrasonically guided fine-needle biopsy].  
41 [German]. *Wiener Medizinische Wochenschrift*, 133: 514-519.
- 42 Not in PICO
- 43 Kreft, B. & Schild, H. H. (2003) [Cystic renal lesions]. [Review] [67 refs] [German]. *Rofo: Fortschritte*  
44 *auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin*, 175: 892-903.
- 45 Narrative review
- 46 Kumar, R., Chauhan, A., Lakhani, P., Xiu, Y., Zhuang, H. & Alavi, A. (2005) 2-Deoxy-2-[F-18]fluoro-D-  
47 glucose-positron emission tomography in characterization of solid renal masses. *Molecular*  
48 *Imaging & Biology*, 7: 431-439.
- 49 Not in PICO
- 50 Lee, K. S., Zeikus, E., DeWolf, W. C., Rofsky, N. M. & Pedrosa, I. (2010) MR urography versus  
51 retrograde pyelography/ureteroscopy for the exclusion of upper urinary tract malignancy. *Clinical*

- 1 *Radiology*, 65: 185-192.  
2 Not in PICO
- 3 Lee, S. Y., Landis, M. S., Ross, I. G., Goela, A. & Leung, A. E. (2012) Extraplural findings at lumbar  
4 spine CT examinations: prevalence and clinical importance. *Radiology*, 263: 502-509.  
5 Not in PICO
- 6 Lee, Y., Kim, N., Cho, K. S., Kang, S. H., Kim, D. Y., Jung, Y. Y. & Kim, J. K. (2009) Bayesian classifier for  
7 predicting malignant renal cysts on MDCT: early clinical experience. *AJR.American Journal of*  
8 *Roentgenology*, 193: W106-W111.  
9 Not in PICO
- 10 Leinonen, A., Paivansalo, M. & Kontturi, M. (1984) Ultrasonography, arteriography and CT in the  
11 diagnosis of renal carcinoma. *Annals of Clinical Research*, 16: Suppl-30.  
12 Not in PICO
- 13 Leveridge, M. J., Finelli, A., Kachura, J. R., Evans, A., Chung, H., Shiff, D. A., Fernandes, K. & Jewett, M.  
14 A. (2011) Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy,  
15 and the role of repeat biopsy. *European Urology*, 60: 578-584.  
16 Not in PICO
- 17 Liedl, B., Liedl, T. & Hofstetter, A. G. (1992) Renal cell carcinoma. Diagnosis, differential diagnosis and  
18 prognosis. [German]. *Fortschritte der Medizin*, 110: 27-32.  
19 Narrative review
- 20 Long, J. A., Descotes, J. L. & Rambeaud, J. J. (2007) [Kidney cancer diagnosis]. [Review] [10 refs]  
21 [French]. *Revue du Praticien*, 57: 603-612.  
22 Narrative review
- 23 Luk'ianenok, P. I. (1989) [Magnetic resonance tomography in kidney tumors concomitant with  
24 symptomatic hypertension]. [Russian]. *Meditinskaja Radiologija*, 34: 41-44.  
25 Not in PICO
- 26 Luscher, T. F., Wanner, C., Otto, R., Hauri, D. & Vetter, W. (1987) [An incidental finding of renal cysts:  
27 routine occurrence or a finding deserving clarification?]. [Review] [60 refs] [German].  
28 *Schweizerische Medizinische Wochenschrift.Journal Suisse de Medecine*, 117: 785-794.  
29 Narrative review
- 30 Lyratzopoulos, G., Abel, G. A., McPhail, S., Neal, R. D. & Rubin, G. P. (2013) Gender inequalities in the  
31 promptness of diagnosis of bladder and renal cancer after symptomatic presentation: evidence  
32 from secondary analysis of an English primary care audit survey. *BMJ Open*, 3: 2013.  
33 Not in PICO
- 34 Machida, T. & Ohnishi, T. (1983) [Diagnosis and treatment of renal cell carcinoma]. [Japanese]. *Gan*  
35 *to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*, 10: 2103-2110.  
36 Narrative review
- 37 Machida, T. & Ohnishi, T. (1994) [Diagnosis for renal cell carcinoma]. [Japanese]. *Gan to Kagaku*  
38 *Ryoho [Japanese Journal of Cancer & Chemotherapy]*, 21: 12-16.  
39 Narrative review
- 40 Macis, G., Di, G. S., Di, F. D. & Bonomo, L. (2013) [Future perspectives for diagnostic imaging in  
41 urology: from anatomic and functional to molecular imaging]. [Italian]. *Urologia (Treviso)*, 80: 29-  
42 41.  
43 Not in PICO/Narrative review
- 44 Manenti, G., Di, R. M., Mancino, S., Bartolucci, D. A., Palmieri, G., Mastrangeli, R., Miano, R.,  
45 Squillaci, E. & Simonetti, G. (2008) Malignant renal neoplasms: correlation between ADC values  
46 and cellularity in diffusion weighted magnetic resonance imaging at 3 T. *Radiologia Medica*, 113:  
47 199-213.  
48 Not in PICO
- 49 Marhuenda, C., Ezzedine, M., Maldonado, J., Piro, C., Fuentes, E., Perez, A., Jimenez, A. I., Sanchez  
50 de, T. J. & Boix-Ochoa, J. (1989) [Bolande's tumor: significance of its early diagnosis and

- 1 treatment]. [Spanish]. *Cirugia Pediatrica*, 2: 196-199.
- 2 Not in PICO
- 3 Masood, J., Lane, T., Koye, B., Vandal, M. T., Barua, J. M. & Hill, J. T. (2001) Renal cell carcinoma:  
4 Incidental detection during routine ultrasonography in men presenting with lower urinary tract  
5 symptoms. *BJU International*, 88: 671-674.
- 6 Not in PICO
- 7 Masuda, F., Suzuki, H., Kondo, I. & Furuta, N. (1991) [Clinical and pathological studies on incidental  
8 renal cell carcinoma]. [Japanese]. *Hinyokika Kyo - Acta Urologica Japonica*, 37: 1223-1227.
- 9 Not in PICO
- 10 McCauley, L. R., Beckham, C. J., Hunter, T. B. & Nguyen, M. M. (2010) Gender and renal cancer: do  
11 variations in clinical presentation and imaging patterns explain observed differences between  
12 males and females? *Urology*, 76: 536-540.
- 13 Not in PICO
- 14 McClennan, B. L. & Deyoe, L. A. (1994) The imaging evaluation of renal cell carcinoma: diagnosis and  
15 staging. *Radiologic Clinics of North America*, 32: 55-69.
- 16 Narrative review
- 17 McDonald, M. M., Swagerty, D. & Wetzel, L. (2006) Assessment of microscopic hematuria in adults.  
18 *American Family Physician*, 73: 1748-1754.
- 19 Narrative review
- 20 McHugh, K. (2007) Renal and adrenal tumours in children. [Review] [19 refs]. *Cancer Imaging*, 7: 41-  
21 51.
- 22 Narrative review
- 23 McLernon, D. J., Dillon, J. F., Sullivan, F. M., Roderick, P., Rosenberg, W. M., Ryder, S. D. & Donnan, P.  
24 T. (2012) The utility of liver function tests for mortality prediction within one year in primary care  
25 using the algorithm for liver function investigations (ALFI). *PLoS ONE [Electronic Resource]*, 7:  
26 e50965.
- 27 Not in PICO
- 28 Meyer, J. S., Harty, M. P. & Khademian, Z. (2002) Imaging of neuroblastoma and Wilms' tumor.  
29 [Review] [58 refs]. *Magnetic Resonance Imaging Clinics of North America*, 10: 275-302.
- 30 Narrative review
- 31 Mian, C., Mazzoleni, G., Vikoler, S., Martini, T., Knuchel-Clark, R., Zaak, D., Lazica, A., Roth, S., Mian,  
32 M. & Pycha, A. (2010) Fluorescence in situ hybridisation in the diagnosis of upper urinary tract  
33 tumours. *European Urology*, 58: 288-292.
- 34 Not in PICO
- 35 Milovanceva-Popovska, M. & Dzikova, S. (2008) Doppler ultrasonography: a tool for nephrologists--  
36 single centre experience. *Makedonska Akademija na Naukite i Umetnostite Oddelenie Za*  
37 *Biološki i Meditsinski Nauki Prilozi*, 29: 107-128.
- 38 Not in PICO
- 39 Minamimoto, R., Senda, M., Terauchi, T., Jinnouchi, S., Inoue, T., Inuma, T., Inoue, T., Ito, K., Iwata,  
40 H., Uno, K., Oku, S., Oguchi, K., Tsukamoto, E., Nakashima, R., Nishizawa, S., Fukuda, H., Murano,  
41 T. & Yoshida, T. (2011) Analysis of various malignant neoplasms detected by FDG-PET cancer  
42 screening program: based on a Japanese Nationwide Survey. *Annals of Nuclear Medicine*, 25: 45-  
43 54.
- 44 Not in PICO
- 45 Miyakita, H., Tokunaga, M., Onda, H., Usui, Y., Kinoshita, H., Kawamura, N. & Yasuda, S. (2002)  
46 Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of  
47 renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the  
48 cancer. *International Journal of Urology*, 9: 15-18.
- 49 Not in PICO

- 1 Morrissey, J. J., London, A. N., Luo, J. & Kharasch, E. D. (2010) Urinary biomarkers for the early  
2 diagnosis of kidney cancer. *Mayo Clinic Proceedings*, 85: 413-421.  
3 Not in PICO
- 4 Moslemi, M. K. & Mahfoozi, B. (2011) Urologist-operated ultrasound and its use in urological  
5 outpatient clinics. *Patient preference & adherence*, 5: 85-88.  
6 Not in PICO (outcomes not relevant, referred population[?])
- 7 Nakamura, L. & Ritchey, M. (2010) Current management of wilms' tumor. [Review] [58 refs]. *Current*  
8 *Urology Reports*, 11: 58-65.  
9 Narrative review
- 10 Ng, Y. H., Seeley, J. P. & Smith, G. (2013) Haemospermia as a presenting symptom: Outcomes of  
11 investigation in 300 men. *Surgeon-Journal of the Royal Colleges of Surgeons of Edinburgh and*  
12 *Ireland*, 11: 35-38.  
13 Not in PICO
- 14 Nicolai, N., Spreafico, C., Catanzaro, M., Torelli, T., Stagni, S., BIASONI, D., Piva, L., Necchi, A., Milani,  
15 A., Girotti, P., Marchiano, A. & Salvioni, R. (2010) Percutaneous cryoablation (PCA) for renal  
16 masses: Is something going to change? *Anticancer Research*, 30: 1398-1399.  
17 Not in PICO
- 18 O'Malley, M. E., Hahn, P. F., Yoder, I. C., Gazelle, G. S., McGovern, F. J. & Mueller, P. R. (2003)  
19 Comparison of excretory phase, helical computed tomography with intravenous urography in  
20 patients with painless haematuria. *Clinical Radiology*, 58: 294-300.  
21 Not in PICO
- 22 Olaniran, K., Cheng, W. & Pulinthanathu, R. (2014) - A 20-year-old female with hemoptysis and high  
23 blood pressure: An unusual case of papillary renal cell carcinoma. - *The American Journal of Case*  
24 *Reports*, 15: 254-257.  
25 Not in PICO
- 26 Oyama, N., Okazawa, H., Kusukawa, N., Kaneda, T., Miwa, Y., Akino, H., Fujibayashi, Y., Yonekura, Y.,  
27 Welch, M. J. & Yokoyama, O. (2009) 11C-Acetate PET imaging for renal cell carcinoma. *European*  
28 *Journal of Nuclear Medicine & Molecular Imaging*, 36: 422-427.  
29 Not in PICO
- 30 Ozulker, T., Ozulker, F., Ozbek, E. & Ozpacaci, T. (2011) A prospective diagnostic accuracy study of F-  
31 18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation  
32 of indeterminate renal masses. *Nuclear Medicine Communications*, 32: 265-272.  
33 Not in PICO
- 34 Pace, G., Bozzini, G., Marengi, C., Picozzi, S. & Carmignani, L. (2012) The pocket ultrasound: The  
35 phonendoscope of the urologist. *European Urology, Supplements*, 11: e801-e801a.  
36 Not in PICO
- 37 Palazzo, S., Martino, P., Ditunno, P., Battaglia, M., De, C. G., Garofalo, L., Annunziata, G. & Selvaggi, F.  
38 P. (2000) [Incidental kidney neoplasm: anatomopathologic characteristics and clinical behavior].  
39 [Review] [16 refs] [Italian]. *Archivio Italiano di Urologia, Andrologia*, 72: 216-220.  
40 Not in PICO
- 41 Palko, A., Kun, E., Greksa, E. & Khertelendi, A. (1991) [Computed tomography in the diagnosis of  
42 malignant renal neoplasms and their dissemination]. [Russian]. *Vestnik Rentgenologii i*  
43 *Radiologii.(2):37-40, 1991 Mar-Apr.*, 37-40.  
44 Not in PICO
- 45 Palko, A., Kun, E., Greksa, E. & Khertelendi, A. (1991) [The role of computerized tomography in the  
46 diagnosis and evaluation of the dissemination of malignant kidney tumors]. [Russian]. *Vestnik*  
47 *Rentgenologii i Radiologii.(2):37-40, 1991 Mar-Apr.*, 37-40.  
48 Not in PICO
- 49 Palmowski, M., Schifferdecker, I., Zwick, S., Macher-Goeppinger, S., Laue, H., Haferkamp, A.,  
50 Kauczor, H. U., Kiessling, F. & Hallscheidt, P. (2010) Tumor perfusion assessed by dynamic  
51 contrast-enhanced MRI correlates to the grading of renal cell carcinoma: initial results. *European*

- 1 *Journal of Radiology*, 74: e176-e180.  
2 Not in PICO
- 3 Palsdottir, H. B., Hardarson, S., Petursdottir, V., Jonsson, A., Jonsson, E., Sigurdsson, M. I., Einarsson,  
4 G. V. & Gudbjartsson, T. (2012) Incidental detection of renal cell carcinoma is an independent  
5 prognostic marker: results of a long-term, whole population study. *Journal of Urology*, 187: 48-  
6 53.  
7 Not in PICO
- 8 Park, S. H., Yoon, S. K., Cho, J. H., Oh, J. Y., Nam, K. J., Kwon, H. J., Kim, S. Y., Kang, M. J., Choi, S. &  
9 Sung, G. T. (2008) Radiofrequency ablation treatment for renal cell carcinoma: early clinical  
10 experience. *Korean Journal of Radiology*, 9: 340-347.  
11 Not in PICO
- 12 Patard, J. J. (1996) [Hematuria: current strategies]. [French]. *Annales d Urologie*, 30: 274-275.  
13 Narrative review
- 14 Patel, J. V., Chambers, C. V. & Gomella, L. G. (2008) Hematuria: etiology and evaluation for the  
15 primary care physician. *The Canadian journal of urology*, 15: 54-61.  
16 Narrative review
- 17 Patel, N. S., Blick, C., Kumar, P. V. S. & Malone, P. R. (2009) The diagnostic value of abdominal  
18 ultrasound, urine cytology and prostate-specific antigen testing in the lower urinary tract  
19 symptoms clinic. *International Journal of Clinical Practice*, 63: 1734-1738.  
20 Not in PICO
- 21 Patten, R. M., Byun, J. Y. & Freeny, P. C. (1993) CT of hypervascular hepatic tumors: are unenhanced  
22 scans necessary for diagnosis? *AJR.American Journal of Roentgenology*, 161: 979-984.  
23 Not in PICO
- 24 Paul, A. B., Collie, D. A., Wild, S. R. & Chisholm, G. D. (1993) An integrated haematuria clinic. *British  
25 Journal of Clinical Practice*, 47: 128-130.  
26 Not in PICO
- 27 Pieri, L., Tozzini, A., Orsitto, E., Bulleri, A. & Morelli, G. (1997) [Urotheliomas of the upper urinary  
28 tract. The role of computed tomography in integrated diagnostic imaging]. [Italian]. *Radiologia  
29 Medica*, 94: 202-207.  
30 Not in PICO
- 31 Pirasteh, A., Snyder, L., Boncher, N., Passalacqua, M., Rosenblum, D. & Prologo, J. D. (2011)  
32 Cryoablation vs. radiofrequency ablation for small renal masses. *Academic Radiology*, 18: 97-100.  
33 Not in PICO
- 34 Pisciolli, F., Pusioli, T., Scappini, P. & Luciani, L. (1985) Urine cytology in the detection of renal  
35 adenocarcinoma. *Cancer*, 56: 2251-2255.  
36 Not in PICO
- 37 Pluzarev, O. & Budimlija, Z. (1999) [Ultrasonography and computerized tomography in the  
38 evaluation of tumor invasion in renal adenocarcinoma]. [Croatian]. *Medicinski Pregled*, 52: 455-  
39 458.  
40 Not in PICO
- 41 Porena, M., Vespasiani, G., Rosi, P., Costantini, E., Virgili, G., Mearini, E. & Micali, F. (1992)  
42 Incidentally detected renal cell carcinoma: role of ultrasonography. *Journal of Clinical Ultrasound*,  
43 20: 395-400.  
44 Not in PICO
- 45 Prando, A., Prando, D. & Prando, P. (2006) Renal cell carcinoma: unusual imaging manifestations.  
46 *Radiographics*, 26: 233-244.  
47 Narrative review
- 48 Protzel, C., Woenckhaus, C., Zimmermann, U. & Klebingat, K.-J. (2001) Renal leiomyoma. An aspect  
49 of differential diagnosis of renal cell carcinoma with increasing clinical significance. [German].  
50 *Urologe - Ausgabe A*, 40: 384-387.  
51 Narrative review



- 1 Ramdave, S., Thomas, G. W., Berlangieri, S. U., Bolton, D. M., Davis, I., Danguy, H. T., Macgregor, D.  
2 & Scott, A. M. (2001) Clinical role of F-18 fluorodeoxyglucose positron emission tomography for  
3 detection and management of renal cell carcinoma. *Journal of Urology*, 166: 825-830.  
4 Not in PICO
- 5 Razavi, S. A., Sadigh, G., Kelly, A. M. & Cronin, P. (2012) Comparative effectiveness of imaging  
6 modalities for the diagnosis of upper and lower urinary tract malignancy: a critically appraised  
7 topic. *Academic Radiology*, 19: 1134-1140.  
8 Systematic review, have checked relevance of included papers
- 9 Razdan, S., Johannes, J., Cox, M. & Bagley, D. H. (2005) Current practice patterns in urologic  
10 management of upper-tract transitional-cell carcinoma. *Journal of Endourology*, 19: 366-371.  
11 Not in PICO
- 12 Reichelt, O., Wunderlich, H., Weirich, T., Schlichter, A. & Schubert, J. (2001) Computerized contrast  
13 angiosonography: a new diagnostic tool for the urologist? *BJU International*, 88: 9-14.  
14 Not in PICO
- 15 Reiman, T. A., Siegel, M. J. & Shackelford, G. D. (1986) Wilms tumor in children: abdominal CT and US  
16 evaluation. *Radiology*, 160: 501-505.  
17 Not in PICO
- 18 Rendon, R. A., Stanietzky, N., Panzarella, T., Robinette, M., Klotz, L. H., Thurston, W. & Jewett, M. A.  
19 S. (2000) The natural history of small renal masses. *Journal of Urology*, 164: 1143-1147.  
20 Not in PICO
- 21 Richenberg, J. (2008) Haematuria. *Imaging*, 20: 57-72.  
22 Narrative review
- 23 Rinnab, L., Gottfried, H. W., Schnoller, T., Hautmann, R. E. & Kuefer, R. (2007) Clinical value of  
24 transrectal ultrasound in the diagnosis of suspected neoplasia in the small pelvis. *Ultraschall in  
25 der Medizin*, 28: 195-200.  
26 Not in PICO
- 27 Rinsho, K., Ishikawa, S., Uchida, K. & Koiso, K. (1984) The value of ultrasonography in early detection  
28 of renal cell carcinoma. *Japanese Journal of Clinical Oncology*, 14: 329-334.  
29 Not in PICO
- 30 Ritchey, M., Daley, S., Shamberger, R. C., Ehrlich, P., Hamilton, T., Haase, G. & Sawin, R. (2008)  
31 Ureteral extension in Wilms' tumor: a report from the National Wilms' Tumor Study Group  
32 (NWTSG). *Journal of Pediatric Surgery*, 43: 1625-1629.  
33 Not in PICO
- 34 Rousseau, T., Chretien, Y. & Dufour, B. (1991) Accidental diagnosis of cancer of the renal  
35 parenchyma in adults. [French]. *Journal d'urologie*, 97: 141-144.  
36 Not in PICO
- 37 Rousseau, T., Peyret, C., Zerbib, M., Thiounn, N., Flam, T. & Debre, B. (1994) [Circumstances of the  
38 detection of kidney cancer. Current part of accidental discoveries]. [Review] [37 refs] [French].  
39 *Journal d Urologie*, 100: 189-195.  
40 Not in PICO
- 41 Saksena, M. & Gervais, D. (2009) Percutaneous renal tumor ablation. [Review] [40 refs]. *Abdominal  
42 Imaging*, 34: 582-587.  
43 Not in PICO
- 44 Schenk, J.-P., Engelmann, D., Rohrschneider, W., Zieger, B., Semler, O., Graf, N. & Troger, J. (2004)  
45 Rhabdoid tumors of the kidney in childhood - A retrospective radiomorphologic analysis of 22  
46 patients as part of the nephroblastoma study SIOP 93/01-GPOH registered cases. [German]. *RoFo  
47 Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren*, 176: 965-971.  
48 Not in PICO
- 49 Schlenker, B., Seitz, M., Bader, M. J., Ganzer, R., Tilki, D., Bayrle, F., Reich, O., Staehler, M.,  
50 Bachmann, A., Stief, C. G. & Gratzke, C. (2010) Comparison of Guideline Recommendations with  
51 Daily Practice in Patients with Renal Cell Carcinoma. *European Journal of Medical Research*, 15:

- 1 253-257.  
2 Not in PICO
- 3 Schoder, H. & Larson, S. M. (2004) Positron emission tomography for prostate, bladder, and renal  
4 cancer. [Review] [180 refs]. *Seminars in Nuclear Medicine*, 34: 274-292.  
5 Narrative review
- 6 Schwentner, C., Hennenlotter, J., Kuehs, U., Tews, V., Colleselli, D., Huber, S., Schilling, D., Sievert, K.  
7 D. & Stenzl, A. (2010) Impact of urinary sampling and urinary tract infection on the diagnostic  
8 value of urine tests (urovysionr, uCyt+R) and cytology for transitional cell carcinoma - Results  
9 from a cohort of 2077 patients. *European Urology, Supplements*, 9: 50.  
10 Abstract only so limited information, but I think it's not in PICO (referred patients because from  
11 Germany and authors from urology department)
- 12 Schwentner, C., Hennenlotter, J., Kuehs, U., Tews, V., Colleselli, D., Huber, S., Schilling, D., Sievert, K.-  
13 D. & Stenzl, A. (2010) Hematuria: Helpful or misleading for the early detection of transitional cell  
14 carcinoma-results from a cohort of 2008 patients. *Journal of Urology*, 183: e454.  
15 Abstract only so limited information, but I think it's not in PICO (referred patients because from  
16 Germany and authors from urology department)
- 17 Schwentner, C., Hennenlotter, J., Kuehs, U., Tews, V., Colleselli, D., Huber, S., Schilling, D., Sievert, K.-  
18 D. & Stenzl, A. (2010) Impact of instrumented urinary sampling on the diagnostic value of urine  
19 tests (urovysionr, uCyt+r) and cytology for transitional cell carcinoma - Results from a cohort of  
20 2077 patients. *Journal of Urology*, 183: e453-e454.  
21 Abstract only so limited information, but I think it's not in PICO (referred patients because from  
22 Germany and authors from urology department)
- 23 Sears, C. L. G., Ward, J. F., Sears, S. T., Puckett, M. F., Kane, C. J. & Amling, C. L. (2002) Prospective  
24 comparison pf computerized tomography and excretory urography in the initial evaluation of  
25 asymptomatic haematuria. *Journal of Urology*, 168: 2457-2460.  
26 Not in PICO
- 27 Shah, O. & Taneja, S. S. (2004) Renal imaging: what the urologist wants to know. [Review] [101 refs].  
28 *Magnetic Resonance Imaging Clinics of North America*, 12: 387-402.  
29 Narrative review
- 30 Shi, G. H., Chen, Y., Yao, X. D., Zhang, S. L., Dai, B., Feng, L. Q., Zhang, H. L., Shen, Y. J., Zhu, Y., Zhu, Y.  
31 P., Xiao, W. J., Ma, C. G., Wen, L. G., Qin, X. J., Yang, L. F. & Ye, D. W. (2013) Individualized renal  
32 mass biopsy strategy for Chinese patients with different subtypes and necrosis area. *Urologic  
33 Oncology*, 31: 920-923.  
34 Not in PICO
- 35 Shin, H. O., Kim, Y. S., Kim, K. D., Jang, I. H., Lee, S. Y., Kwon, Y. W. & Kim, T. H. (2008) Characteristics  
36 of incidentally detected renal cell carcinoma. [Korean]. *Korean Journal of Urology*, 49: 675-681.  
37 Not in PICO
- 38 Shinagare, A. B., Silverman, S. G., Gershanik, E. F., Chang, S. L. & Khorasani, R. (2014) Evaluating  
39 hematuria: Impact of guideline adherence on urologic cancer diagnosis. *American Journal of  
40 Medicine*, 127: 625-632.  
41 Not in PICO (setting; Willie agrees; also came up in bladder search)
- 42 Shvarts, O., Han, K. R., Seltzer, M., Pantuck, A. J. & Belldegrun, A. S. (2002) Positron emission  
43 tomography in urologic oncology. [Review] [52 refs]. *Cancer Control*, 9: 335-342.  
44 Not in PICO
- 45 Sigalow, D. A., Waldbaum, R. S. & Lowe, F. C. (1991) Identification of asymptomatic renal cell  
46 carcinomas utilizing modern radiographic techniques. *New York State Journal of Medicine*, 91:  
47 200-202.  
48 Not in PICO
- 49 Silver, D. A., Morash, C., Brenner, P., Campbell, S. & Russo, P. (1997) Pathologic findings at the time  
50 of nephrectomy for renal mass. *Annals of Surgical Oncology*, 4: 570-574.  
51 Not in PICO

- 1 Siow, W. Y., Yip, S. K. H., Ng, L. G., Tan, P. H., Cheng, W. S. & Foo, K. T. (2000) Renal cell carcinoma:  
 2 Incidental detection and pathological staging. *Journal of the Royal College of Surgeons of*  
 3 *Edinburgh*, 45: 291-295.  
 4 Not in PICO
- 5 Song, J., Tanagho, Y., Bhayani, S. & Figenshau, R. (2013) Factors predictive of symptomatic  
 6 presentation in renal cell carcinoma. *Journal of Endourology*, 27: A383.  
 7 Not in PICO
- 8 Speets, A. M., Kalmijn, S., Hoes, A. W., Van Der Graaf, Y. & Mali, W. P. T. (2006) Yield of abdominal  
 9 ultrasound in patients with abdominal pain referred by general practitioners. *European Journal of*  
 10 *General Practice*, 12: 135-137.  
 11 Not in PICO
- 12 Stepan, J., Cepulic, M., Petkovic, I., Cizmic, A. & Nakic, M. (2007) Nephroblastomas - Wilm's tumor  
 13 (WT). [Croatian]. *Paediatrica Croatica, Supplement*, 51: 92-97.  
 14 Narrative review
- 15 Stutte, H., Bauer, B. & Grossmann, E. (1987) [Early sonographic recognition of renal cell carcinoma].  
 16 [German]. *Deutsche Medizinische Wochenschrift*, 112: 879-883.  
 17 Not in PICO
- 18 Stutte, H., Bauer, B. & Grossmann, E. (1987) Early diagnosis of renal cell carcinoma by ultrasound.  
 19 [German]. *Deutsche Medizinische Wochenschrift*, 112: 879-883.  
 20 Not in PICO
- 21 Tada, S., Fukud, K., Aoyagi, Y. & Harada, J. (1980) CT of abdominal malignancies: dynamic approach.  
 22 *AJR. American Journal of Roentgenology*, 135: 455-461.  
 23 Not in PICO
- 24 Tada, S., Miura, S., Mizuma, K., Kurisu, Y. & Yasuda, M. (1988) Differential diagnosis of the early  
 25 cancer: imaging diagnosis "CT". [Japanese]. *Gan no rinsho*, Japan: 1223-1226.  
 26 Narrative review
- 27 Takahashi, N., Glockner, J. F., Hartman, R. P., King, B. F., Leibovich, B. C., Stanley, D. W., Fitz-Gibbon,  
 28 P. D. & Kawashima, A. (2010) Gadolinium enhanced magnetic resonance urography for upper  
 29 urinary tract malignancy. *Journal of Urology*, 183: 1330-1365.  
 30 Not in PICO
- 31 Takebayashi, S., Hosaka, M., Takase, K., Kubota, N., Kishida, T. & Matsubara, S. (1999) Computerized  
 32 tomography nephroscopic images of renal pelvic carcinoma. *Journal of Urology*, 162: 315-318.  
 33 Not in PICO
- 34 Tamai, H., Takiguchi, Y., Oka, M., Shingaki, N., Enomoto, S., Shiraki, T., Furuta, M., Inoue, I., Iguchi,  
 35 M., Yanaoka, K., Ariei, K., Shimizu, Y., Nakata, H., Shinka, T., Sanke, T. & Ichinose, M. (2005)  
 36 Contrast-enhanced ultrasonography in the diagnosis of solid renal tumors. *Journal of Ultrasound*  
 37 *in Medicine*, 24: 1635-1640.  
 38 Not in PICO
- 39 Tauber, S., Liedl, B., Schneede, P., Liessmann, F., Waidelich, R. & Hofstetter, A. (2001) [Fluorescence  
 40 cytology of the urinary bladder]. [German]. *Urologe (Ausg.A)*, 40: 217-221.  
 41 Not in PICO (at least 17/27 had cancer)
- 42 Taylor, P. M. (2002) Image-guided peritoneal access and management of complications in peritoneal  
 43 dialysis. [Review] [25 refs]. *Seminars in Dialysis*, 15: 250-258.  
 44 Narrative review
- 45 Teichman, J. M. H., Weiss, B. D. & Solomon, D. (1999) Urological needs assessment for primary care  
 46 practice: Implications for undergraduate medical education. *Journal of Urology*, 161: 1282-1285.  
 47 Not in PICO (at least 17/27 had cancer)
- 48 Telichko, F. F. & Iazykov, A. S. (1989) [Experimental and clinical rationale for the choice of optimal  
 49 methods of x-ray diagnosis of kidney diseases]. [Russian]. *Vestnik Rentgenologii i*  
 50 *Radiologii.(5):62-7, 1989 Sep-Oct.*, 62-67.  
 51 Narrative review

- 1 Teodorovich, O. V., Ternovoi, S. K., Vlasova, I. S., Zabrodina, N. B., Fominykh, E. V. & Kesov, I. (2006)  
 2 [Comparative analysis of modern combined methods in diagnosis of renal cell carcinoma].  
 3 [Russian]. *Urologiia (Moscow, Russia)*.(5):3-6, 11, 2006 Sep-Oct., 3-6.  
 4 Not in PICO
- 5 Terada, Y., Ueki, T. & Horiuchi, D. (1989) [A study on six cases of renal cell carcinoma detected by  
 6 renal ultrasound during health screening]. [Japanese]. *Nippon Jinzo Gakkai Shi.Japanese Journal  
 7 of Nephrology*, 31: 783-790.  
 8 Not in PICO
- 9 Thompson, R. H., Hartman, R. P., Lowe, V. J., Kawashima, A. & Leibovich, B. C. (2004) Applications of  
 10 positron emission tomography imaging, intraoperative ultrasonography, magnetic resonance  
 11 imaging, and angiography in the evaluation of renal masses. [Review] [25 refs]. *Current Urology  
 12 Reports*, 5: 30-34.  
 13 Narrative review
- 14 Tiang, K. W., Ng, K. L., Vega-Vega, A. & Wood, S. (2014) A management dilemma of a rapidly  
 15 enlarging chromophobe renal cell carcinoma during pregnancy. *BJU International*, 113: 70-71.  
 16 Not in PICO
- 17 Tong, Y. C., Chieng, P. U., Tsai, T. C. & Lin, S. N. (1990) Renal angiomyolipoma: report of 24 cases.  
 18 *British Journal of Urology*, 66: 585-589.  
 19 Not in PICO
- 20 Tsvivan, M., Rampersaud, E. N., Pes, M. D. L., Joniau, S., Leveillee, R. J., Shingleton, W. B., Aron, M.,  
 21 Kim, C. Y., DeMarzo, A. M., Desai, M. M., Meler, J. D., Donovan, J. F., Klingler, H. C., Sopko, D. R.,  
 22 Madden, J. F., Marberger, M., Ferrandino, M. N. & Polascik, T. J. (2014) Small renal mass biopsy -  
 23 how, what and when: report from an international consensus panel. *BJU International*, 113: 854-  
 24 863.  
 25 Not in PICO
- 26 Tsuboi, N., Horiuchi, K., Kimura, G., Kondoh, Y., Yoshida, K., Nishimura, T., Akimoto, M., Miyashita, T.  
 27 & Subosawa, T. (2000) Renal masses detected by general health checkup. *International Journal of  
 28 Urology*, 7: 404-408.  
 29 Not in PICO
- 30 Ueda, T., Yasumasu, T., Uozumi, J. & Naito, S. (1991) Comparison of clinical and pathological  
 31 characteristics in incidentally detected and suspected renal carcinoma. *British Journal of Urology*,  
 32 68: 470-472.  
 33 Not in PICO
- 34 Ulu, E. M., Tutar, N. U., Coskun, M., Tore, H. G., Guvenc, Z. & Haberal, M. (2007) Abdominal  
 35 computed tomography findings of malignant tumors in patients with solid organ transplants.  
 36 *Transplantation Proceedings*, 39: 1066-1070.  
 37 Not in PICO
- 38 van Weert, H. C. & Pinggen, F. (2009) Recurrent thrombophlebitis as a warning sign for cancer: a case  
 39 report. *Cases journal*, 2: 153.  
 40 Not in PICO
- 41 Van, C. R., Castillo, O., Aguirre, C., Azocar, G., Chamorro, A. & Medina, F. J. (1992) [Current diagnosis  
 42 of renal cancer: clinical experience with 71 cases]. [Spanish]. *Revista Medica de Chile*, 120: 1118-  
 43 1120.  
 44 Not in PICO
- 45 Vasdev, N. & Thorpe, A. C. (2011) Has the introduction of the '2 week rule' in the UK led to an earlier  
 46 diagnosis of urological malignancy? *ecancermedicalscience*, 5.  
 47 Not in PICO
- 48 Vegso, G., Toronyi, E., Hajdu, M., Piros, L., Gorog, D., Deak, P. A., Doros, A., Peter, A. & Langer, R. M.  
 49 (2011) Renal cell carcinoma of the native kidney: a frequent tumor after kidney transplantation  
 50 with favorable prognosis in case of early diagnosis. *Transplantation Proceedings*, 43: 1261-1263.  
 51 Not in PICO

- 1 Velkova, K. & Dimitrakov, D. (1992) Digital subtraction angiography in renal tumours. *Folia Medica*  
2 (*Plovdiv*), 34: 39-45.  
3 Not in PICO
- 4 Venables, Z., Ramaiya, A., Holden, S. & Millington, G. W. M. (2013) Three generations of hereditary  
5 leiomyomatosis associated with renal cell cancer. *British Journal of Dermatology*, 169: 21.  
6 Not in PICO
- 7 Wang, G. Y. (700) [Asymptomatic renal cell carcinoma and small renal cell carcinoma]. [Chinese].  
8 *Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery]*, 27: 656-657.  
9 Not in PICO
- 10 Wang, L.-J., Wong, Y.-C., Huang, C.-C., Wu, C.-H., Hung, S.-C. & Chen, H.-W. (2010) Multidetector  
11 computerized tomography urography is more accurate than excretory urography for diagnosing  
12 transitional cell carcinoma of the upper urinary tract in adults with hematuria. *Journal of Urology*,  
13 183: 48-55.  
14 Not in PICO
- 15 Wessely, K., Biassoni, L. & McHugh, K. (2011) Pitfalls in paediatric oncology imaging. *Cancer Imaging*,  
16 11: 144-154.  
17 Narrative review
- 18 Wiesbauer, P. (2008) [Nephrogenic tumors]. [German]. *Radiologe*, 48: 932-939.  
19 Narrative review
- 20 Wood, L. S. (2009) Renal cell carcinoma: screening, diagnosis, and prognosis. [Review] [29 refs].  
21 *Clinical Journal of Oncology Nursing*, 13: Suppl-7.  
22 Narrative review
- 23 Wu, K. R. & Chen, Y. H. (191) [Early diagnosis of renal cell carcinoma]. [Chinese]. *Chung-Hua Wai Ko*  
24 *Tsa Chih [Chinese Journal of Surgery]*, 26: 160-161.  
25 Not in PICO
- 26 Yap, N. Y., Ng, K. L., Ong, T. A., Pailoor, J., Gobe, G. C., Ooi, C. C., Razack, A. H., Dublin, N., Morais, C.  
27 & Rajandram, R. (2013) Clinical prognostic factors and survival outcome in renal cell carcinoma  
28 patients - a malaysian single centre perspective. *Asian Pacific Journal of Cancer Prevention: Apjcp*,  
29 14: 7497-7500.  
30 Not in PICO
- 31 Yashiro, N., Itai, Y., Ohtomo, K., Furui, S., Yoshikawa, K., Iio, M., Yoshida, H. & Asai, S. (1985) [Early  
32 renal carcinoma: clinical features, CT, and angiography]. [Japanese]. *Rinsho Hoshasen - Japanese*  
33 *Journal of Clinical Radiology*, 30: 875-881.  
34 Not in PICO
- 35 Yeoh, M., Lai, N. K., Anderson, D. & Appadurai, V. (2013) Macroscopic haematuria—a urological  
36 approach. *Australian Family Physician*, 42: 123-126.  
37 Narrative review
- 38 Yip, S. K., Peh, W. C., Tam, P. C., Li, J. H. & Lam, C. H. (1999) Role of ultrasonography in screening for  
39 urological malignancies in patients presenting with painless haematuria. *Annals of the Academy*  
40 *of Medicine, Singapore*, 28: 174-177.  
41 Not in PICO (referred population)
- 42 Yokom, D. W., Ihaddadene, R., Le, G. G. & Carrier, M. (2012) Incidental venous thromboembolism in  
43 kidney cancer patients: A retrospective case-control study. *Blood*, 120.  
44 Not in PICO
- 45 Yokom, D. W., Ihaddadene, R., Le, G. G., Moretto, P. & Carrier, M. (2013) Incidental venous  
46 thromboembolism in kidney cancer patients: A case-control study. *Journal of Thrombosis and*  
47 *Haemostasis*, 11: 330.  
48 Not in PICO
- 49 Yuan, X.-C., Wang, Y., Zhou, A.-Y., Chen, L., Den, L.-Y. & Liu, J. (2011) Comparison on contrast-  
50 enhanced ultrasonography and CT in diagnosing renal cell carcinoma. [Chinese]. *Chinese Journal*

1 *of Medical Imaging Technology*, 27: 2502-2505.  
2 Not in PICO  
3 Zeman, R. K., Zeiberg, A., Hayes, W. S., Silverman, P. M., Cooper, C. & Garra, B. S. (1996) Helical CT of  
4 renal masses: the value of delayed scans. *AJR.American Journal of Roentgenology*, 167: 771-776.  
5 Not in PICO  
6 Zieger, M., Buck, J. & Heuck, F. (1983) [Normal renal variations as a cause of sonographically suspect  
7 tumors]. [German]. *Radiologe*, 23: 256-259.  
8 Not in PICO  
9 Zieger, M., Buck, J. & Heuck, F. (1983) Physiological renal variations causing the sonographic  
10 tentative diagnosis of renal tumors. [German]. *Radiologe*, 23: 256-259.  
11 Not in PICO  
12 Zielinski, H. (2005) Early detection of renal cancer. [Polish]. *Wspolczesna Onkologia*, 9: 98-100.  
13 Narrative review  
14 Zollner, S., Dirksen, U., Jurgens, H. & Ranft, A. (2013) Renal Ewing tumors. *Annals of Oncology*, 24:  
15 2455-2461.  
16 Not in PICO  
17 Zubarev, A. V., Nasnikova, I. I., Kozlov, V. P., Grishin, M. A. & Sal'nikov, D. V. (2001) [Ultrasound  
18 angiography: new perspectives in diagnosis of renal mass lesions]. [Russian]. *Terapevticheskii*  
19 *Arkhiv*, 73: 46-50.  
20 Not in PICO  
21  
22

**TESTICULAR CANCER****Review question:**

What is the risk of testicular cancer in patients presenting in primary care with symptom(s)?

**Results****Literature search**


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	All-2012	901	159	13/09/2012
<i>Premedline</i>	All-2012	24	6	13/09/2012
<i>Embase</i>	All-2012	871	167	20/09/2012
<i>Cochrane Library</i>	All-2012	23	1	20/09/2012
<i>Psychinfo</i>	All-2012	9	6	13/09/2012
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	All-2012	106	23	20/09/2012
<i>Biomed Central</i>	All-2012	2	0	20/09/2012

Total References retrieved (after de-duplication): 258

**Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	9/2012-27/08/2014	30	1	27/08/2014
<i>Premedline</i>	9/2012-27/08/2014	52	0	27/08/2014
<i>Embase</i>	9/2012-27/08/2014	77	2	27/08/2014
<i>Cochrane Library</i>	9/2012-27/08/2014	13	0	27/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	9/2012-27/08/2014	18	0	27/08/2014

Total References retrieved (after de-duplication): 2



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

**Study results**

No evidence was identified.

**References**

**Included studies**

None

**Excluded studies (with excl reason)**

Information from your family doctor. Testicular cancer. American Family Physician 69[3], 613-614. 1-2-2004.

Excl reason: Patient information booklet

Information from your family doctor: Testicular cancer: what to look for. American Family Physician 74[9], 1571-1572. 1-11-2006.

Excl reason: Patient information booklet

Aigner, F., De, Zordo T., Pallwein-Prettner, L., Junker, D., Schafer, G., Pichler, R., Leonhartsberger, N., Pinggera, G., Dogra, V. S., and Frauscher, F. Real-time sonoelastography for the evaluation of testicular lesions. Radiology 263[2], 584-589. 2012.

Excl reason: Not in PICO

Albers, P., Albrecht, W., Algaba, F., Bokemeyer, C., Cohn-Cedermark, G., Fizazi, K., Horwich, A., Laguna, M. P., and European Association of Urology. [EAU guidelines on testicular cancer: 2011 update. European Association of Urology]. [Spanish]. Actas Urologicas Espanolas 36[3], 127-145. 2012.

Excl reason: Guideline

Allen, D., Popert, R., and O'Brien, T. The two-week-wait cancer initiative in urology: useful modernization? Journal of the Royal Society of Medicine 97[6], 279-281. 2004.

Excl reason: Not in PICO



- 1 Almstrup, K., Rajpert-De, Meyts E., Nielsen, J. E., Mogensen, H. O., Lippert, M. F., Foged, N. T.,  
2 Hansen, J. D., and Skakkebaek, N. E. Non-invasive screening for early stage testicular cancer by  
3 cytological slide scanning and image analysis of semen samples. *APMIS* 119, 52-53. 2011.  
4 Blackwell Munksgaard.  
5 Excl reason: Not in PICO
- 6 Anderson, E. E. Early diagnosis of testicular carcinoma: self-examination of the testicle. *North*  
7 *Carolina Medical Journal* 46[7], 407-409. 1985.  
8 Excl reason: Narrative review
- 9 Arce, Terroba Y., Algaba-Arrea, F., and Villavicencio, Maverich H. [Segmental infarct of testicle: an  
10 infrequent pseudotumor]. [Spanish]. *Actas Urologicas Espanolas* 34[2], 194-200. 2010.  
11 Excl reason: Not in PICO
- 12 Austoker, J. Screening for ovarian, prostatic, and testicular cancers. *British Medical Journal*  
13 309[6950], 315-320. 30-7-1994.  
14 Excl reason: Not in PICO
- 15 Austoker, J., Bankhead, C., Forbes, L. J. L., Atkins, L., Martin, F., Robb, K., Wardle, J., and Ramirez, A.  
16 J. Interventions to promote cancer awareness and early presentation: Systematic review. *British*  
17 *Journal of Cancer* 101, S31-S39. 2009.  
18 Excl reason: Not in PICO
- 19 Aviles-Salas, A., Turbiner-Miasnikova, J., Labardini-Mendez, J. R., and Sobrevilla-Calvo, P. D. J.  
20 Primary Testicular Lymphomas. Clinicopathologic Analysis of 10 Cases. Experience at the  
21 National Institute of Cancerology in Mexico City. [Spanish]. *Gaceta Medica de Mexico* 140[2],  
22 123-128. 2004.  
23 Excl reason: Not in PICO
- 24 Barnhouse, K., Powers, A., and Smith, P. C. Clinical inquiries. How should you further evaluate an  
25 adult with a testicular mass? *Journal of Family Practice* 56[10], 851-853. 2007.  
26 Excl reason: Narrative review
- 27 Barrass, B. J. R., Scurrill, S., Banerjee, G., and Parry, J. R. W. Anxious patients with benign scrotal  
28 symptoms achieve excellent reassurance from imaging in a one-stop clinic. *British Journal of*  
29 *Medical and Surgical Urology* 3[3], 111-115. 2010.  
30 Excl reason: Not in PICO
- 31 Bell, D., Morash, C., Dranitsaris, G., Izawa, J., Short, T., Klotz, L. H., Fleshner, N., and Canadian  
32 surgical wait times (SWAT) initiative. Does prolonging the time to testicular cancer surgery  
33 impact long-term cancer control: a systematic review of the literature. [Review] [24 refs].  
34 *Canadian Journal of Urology* 13, Suppl-6. 2006.  
35 Excl reason: Not in PICO
- 36 Bergholz, R. and Wenke, K. Polyorchidism: a meta-analysis. *Journal of Urology* 182[5], 2422-2427.  
37 2009.  
38 Excl reason: Not in PICO
- 39 Bleyer, A. CAUTION! Consider Cancer: Common Symptoms and Signs for Early Detection of Cancer in  
40 Young Adults. *Seminars in Oncology* 36[3], 207-212. 2009.  
41 Excl reason: Narrative review
- 42 Bosl, G. J., Vogelzang, N. J., Goldman, A., Fraley, E. E., Lange, P. H., Levitt, S. H., and Kennedy, B. J.  
43 Impact of delay in diagnosis on clinical stage of testicular cancer. *Lancet* 2[8253], 970-973. 31-  
44 10-1981.  
45 Excl reason: Not in PICO
- 46 Bower, M., Ma, R., Savage, P., Abel, P., and Waxman, J. British urological surgery practice: 2. Renal,  
47 bladder and testis cancer. *British Journal of Urology* 81[4], 513-517. 1998.  
48 Excl reason: Not in PICO
- 49 Brahams, D. Missed diagnosis of testicular cancer. *Lancet* 339[8795], 734-735. 21-3-1992.  
50 Excl reason: Not in PICO

- 1 Bridges, B. and Hussain, A. Testicular germ cell tumors. [Review] [45 refs]. *Current Opinion in*  
2 *Oncology* 18[3], 271-276. 2006.  
3 Excl reason: Not in PICO
- 4 Brock, D., Fox, S., Gosling, G., Haney, L., Kneebone, P., Nagy, C., and Qualitza, B. Testicular cancer.  
5 [Review] [57 refs]. *Seminars in Oncology Nursing* 9[4], 224-236. 1993.  
6 Excl reason: Narrative review
- 7 Buchler, T., Kubankova, P., Boublikova, L., Donatova, Z., Foldyna, M., Kanakova, J., Kordikova, D.,  
8 Kupec, M., Nepomucka, J., Vorsilkova, E., and Abrahamova, J. Detection of second malignancies  
9 during long-term follow-up of testicular cancer survivors. *Cancer* 117[18], 4212-4218. 15-9-2011.  
10 Excl reason: Not in PICO
- 11 Buckland, T. Hitting testicular cancer where it hurts: Through public awareness and post-treatment  
12 support. *Cancer Research* 71[8 SUPPL. 1]. 15-4-2011. American Association for Cancer Research  
13 Inc.  
14 Excl reason: Not in PICO
- 15 Carlsen, E., Giwercman, A., Keiding, N., and Skakkebaek, N. E. Declining Semen Quality and  
16 Increasing Incidence of Testicular Cancer - Is There A Common-Cause. *Environmental Health*  
17 *Perspectives* 103, 137-139. 1995.  
18 Excl reason: Narrative review
- 19 Carmignani, L., Colombo, R., Gadda, F., Galasso, G., Lania, A., Palou, J., Algaba, F., Villavicencio, H.,  
20 Colpi, G. M., Decobelli, O., Salvioni, R., Pizzocaro, G., Rigatti, P., and Rocco, F. Conservative  
21 Surgical Therapy for Leydig Cell Tumor. *Journal of Urology* 178[2], 507-511. 2007.  
22 Excl reason: Not in PICO
- 23 Casey, R. G., Grainger, R., Butler, M., McDermott, T. E., and Thornhill, J. A. Scrotal signs and  
24 symptoms in the general population, the value of testis self-examination and the pitfalls of a  
25 scrotal screening programme: is the two-week rule relevant? *World Journal of Urology* 29[3],  
26 387-391. 2011.  
27 Excl reason: Not in PICO
- 28 Cavanaugh, Jr. Genital self-examination in adolescent males. *American Family Physician* 28[3], 199-  
29 201. 1983.  
30 Excl reason: Not in PICO
- 31 Chapple, A., Ziebland, S., and McPherson, A. Qualitative study of men's perceptions of why  
32 treatment delays occur in the UK for those with testicular cancer. *British Journal of General*  
33 *Practice* 54[498], 25-32. 2004.  
34 Excl reason: Not in PICO
- 35 Chevalier, N., Vega, A., Bouskine, A., Siddeek, B., Michiels, J. F., Chevallier, D., and Fenichel, P.  
36 GPR30, the non-classical membrane G protein related estrogen receptor, is overexpressed in  
37 human seminoma and promotes seminoma cell proliferation. *PLoS ONE [Electronic Resource]*  
38 7[4], e34672. 2012.  
39 Excl reason: Not in PICO
- 40 Chierigo, P., Puccetti, O., Visona, A., Bassan, F., Rahmati, M., Lazzarotto, M., and Franzolin, N. [High  
41 alpha-fetoprotein persistence after orchiectomy. On a case of uncommon etiology]. [Italian].  
42 *Urologia (Treviso)* 77, Suppl-31. 2010.  
43 Excl reason: Not in PICO
- 44 Chilvers, C. E. D., Forman, D., Oliver, R. T. D., Pike, M. C., Davey, G., Coupland, C. A. C., Baker, K.,  
45 Dawson, S., Cartwright, R. A., Elwood, P. C., Birch, J., Tyrrell, C., Brett, R., Bush, T., Isbell, V.,  
46 Cornwell, A., Steer, R., Thistlethwaite, S., Gellman, H., Hughes, J., Llewellyn, M., Ardernjones, A.,  
47 Allen, A., Hilton, E., Lloyd, B., Mcveigh, S., Thorne, M., Trowbridge, P., and Reid, S. Social,  
48 Behavioral and Medical Factors in the Etiology of Testicular Cancer - Results from the Uk Study.  
49 *British Journal of Cancer* 70[3], 513-520. 1994.  
50 Excl reason: Not in PICO

- 1 Clarke, K., Howard, G. C., Elia, M. H., Hutcheon, A. W., Kaye, S. B., Windsor, P. M., and Yosef, H. M.  
2 Referral patterns within Scotland to specialist oncology centres for patients with testicular germ  
3 cell tumours. The Scottish Radiological Society and the Scottish Standing Committee of the Royal  
4 College of Radiologists. *British Journal of Cancer* 72[5], 1300-1302. 1995.  
5 Excl reason: Not in PICO
- 6 Congeni, J., Miller, S. F., and Bennett, C. L. Awareness of genital health in young male athletes.  
7 *Clinical Journal of Sport Medicine* 15[1], 22-26. 2005.  
8 Excl reason: Not in PICO
- 9 Connolly, J. G. Genitourinary malignancies. *Canadian Family Physician* 21[12], 38-43. 1975.  
10 Excl reason: Narrative review
- 11 Connolly, S. S., D'Arcy, F. T., Bredin, H. C., Callaghan, J., and Corcoran, M. O. Value of frozen section  
12 analysis with suspected testicular malignancy. *Urology* 67[1], 162-165. 2006.  
13 Excl reason: Not in PICO
- 14 Cook, N. Testicular cancer: testicular self-examination and screening. [Review] [52 refs]. *British*  
15 *Journal of Nursing* 9[6], 338-343. 23-3-2000.  
16 Excl reason: Not in PICO
- 17 Cummings, K. M., Lamponi, D., Mettlin, C., and Pontes, J. E. What young men know about testicular  
18 cancer. *Preventive Medicine* 12[2], 326-330. 1983.  
19 Excl reason: Not in PICO
- 20 Daneliia, E. V., Gotsadze, D. T., and Pirtskhalaishvili, G. G. The lack of knowledgeability of men about  
21 testicular tumors as a cause for the late diagnosis of this disease. [Russian]. *Voprosy Onkologii*  
22 38[10], 1254-1258. 1992.  
23 Excl reason: Not in PICO
- 24 Daneliya, E. V., Gotsadze, D. T., and Pirtskhalaishvili, G. G. Lack of knowledge about testicular cancer  
25 as a factor of untimely diagnosis. [Russian]. *Voprosy Onkologii* 38[10-12], 1254-1258. 1992.  
26 Excl reason: Not in PICO
- 27 Dawson, C. Testicular cancer: seek advice early. *Journal of Family Health Care* 12[1], 3. 2002.  
28 Excl reason: Not in PICO
- 29 De Backer A., Madern, G. C., Hakvoort-Cammel, F. G., Oosterhuis, J. W., and Hazebroek, F. W.  
30 Mediastinal germ cell tumors: clinical aspects and outcomes in 7 children. *European Journal of*  
31 *Pediatric Surgery* 16[5], 318-322. 2006.  
32 Excl reason: Not in PICO
- 33 De Padova S., Rosti, G., Scarpi, E., Salvioni, R., Amadori, D., De, Giorgi U., and Italian Germ Cell  
34 Cancer Group (. Expectations of survivors, caregivers and healthcare providers for testicular  
35 cancer survivorship and quality of life. *Tumori* 97[3], 367-373. 2011.  
36 Excl reason: Not in PICO
- 37 De, Nooijer J., Lechner, L., and De, Vries H. A qualitative study on detecting cancer symptoms and  
38 seeking medical help; an application of Andersen's model of total patient delay. *Patient*  
39 *Education and Counseling* 42[2], 145-157. 2001.  
40 Excl reason: Not in PICO
- 41 Descazeaud, A. and Mottet, N. [Cancers of the penis and testicle: news in 2008]. [French]. *Progres En*  
42 *Urologie* 18, Suppl-4. 2008.  
43 Excl reason: Not in PICO
- 44 Desgrandchamps, F. Undescended testes. Current state of knowledge. [French]. *Journal d'urologie*  
45 96[8], 407-414. 1990.  
46 Excl reason: Not in PICO
- 47 Dieckmann, K.-P., Kulejewski, M., Heinemann, V., and Loy, V. Testicular biopsy for early cancer  
48 detection - objectives, technique and controversies. *International Journal of Andrology* 34[4  
49 PART 2], e7-e13. 2011.  
50 Excl reason: Not in PICO

- 1 Dieckmann, K. P., Kulejewski, M., Pichlmeier, U., and Loy, V. Diagnosis of contralateral testicular  
2 intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site  
3 biopsies are more sensitive than a single random biopsy. *European Urology* 51[1], 175-183. 183.  
4 Excl reason: Not in PICO
- 5 Dieckmann, K. P., Becker, T., Dextl, A. M., and Bauer, H. W. [Early diagnosis in testicular tumors.  
6 Results of a survey]. [Review] [41 refs] [German]. *Medizinische Klinik* 82[18], 602-605. 4-9-1987.  
7 Excl reason: Not in PICO
- 8 Dieckmann, K. P., Kulejewski, M., Heinemann, V., and Loy, V. Testicular biopsy for early cancer  
9 detection--objectives, technique and controversies. [Review]. *International Journal of Andrology*  
10 34[4:Pt 2], t-13. 2011.  
11 Excl reason: Not in PICO
- 12 Diotallevi, M. Testicular self-examination: are primary care physicians teaching this preventive  
13 measure? *Canadian Family Physician* 35, 1037-1039. 1989.  
14 Excl reason: Not in PICO
- 15 Docimo, S. G., Silver, R. I., and Cromie, W. The undescended testicle: diagnosis and management.  
16 [Review] [34 refs]. *American Family Physician* 62[9], 2037-2044. 2047.  
17 Excl reason: Not in PICO
- 18 Doherty, A. P., Bower, M., and Christmas, T. J. The role of tumour markers in the diagnosis and  
19 treatment of testicular germ cell cancers. [Review] [41 refs]. *British Journal of Urology* 79[2],  
20 247-252. 1997.  
21 Excl reason: Not in PICO
- 22 Dube, C. E. and Fuller, B. K. A qualitative study of communication skills for male cancer screening  
23 discussions. *Journal of Cancer Education* 18[4], 182-187. 2003.  
24 Excl reason: Not in PICO
- 25 DuFour, J. L. Testicular cancer. Early action required. *Advance for Nurse Practitioners* 8[11], 77-78.  
26 2000.  
27 Excl reason: Narrative review
- 28 Edelman, M. J., Meyers, F. J., and Siegel, D. The utility of follow-up testing after curative cancer  
29 therapy. A critical review and economic analysis. [Review] [133 refs]. *Journal of General Internal*  
30 *Medicine* 12[5], 318-331. 1997.  
31 Excl reason: Not in PICO
- 32 Evans, R. E., Simon, A. E., and Wardle, J. Public perceptions of the harms and benefits of testicular  
33 cancer education: a qualitative study. *Cancer Epidemiology* 34[2], 212-219. 2010.  
34 Excl reason: Not in PICO
- 35 Farrer, F. Cancer screening in primary care. *SA Pharmaceutical Journal* 77[9], 41-45. 2010.  
36 Excl reason: Not in PICO
- 37 Favilla, V., Cimino, S., Madonia, M., and Morgia, G. New advances in clinical biomarkers in testis  
38 cancer. [Review] [246 refs]. *Frontiers in Bioscience* 2, 456-477. 2010.  
39 Excl reason: Not in PICO
- 40 Foo, K. T. (2013) The role of transabdominal ultrasound in office urology. *Proceedings of Singapore*  
41 *Healthcare*, 22: 125-130.  
42 Narrative review
- 43 Forman, D., Pike, M. C., Davey, G., Dawson, S., Baker, K., Chilvers, C. E. D., Oliver, R. T. D., and  
44 Coupland, C. A. C. Aetiology of testicular cancer: Association with congenital abnormalities, age  
45 at puberty, infertility, and exercise. *British Medical Journal* 308[6941], 1393-1399. 1994.  
46 Excl reason: Not in PICO
- 47 Fossa, S. D., Klepp, O., and Elgjo, R. F. The effects of patient's delay and doctor's delay in patients  
48 with malignant germ cell tumours. *International Journal of Andrology* 4[Suppl. 4], 134-145. 1981.  
49 Excl reason: Not in PICO
- 50 Foster, P. W., Ritchie, A. W., and Jones, D. J. Prospective analysis of scrotal pathology referrals - are  
51 referrals appropriate and accurate? *Annals of the Royal College of Surgeons of England* 88[4],

- 1 363-366. 2006.  
 2 Excl reason: Not in PICO  
 3 Fredslund, Breinholt M. and Moller, Hansen T. Testicular yolk sac tumour in an 82 years old man.  
 4 APMIS 119, 55. 2011. Blackwell Munksgaard.  
 5 Excl reason: Not in PICO  
 6 Friman, P. C., Finney, J. W., Glasscock, S. G., Weigel, J. W., and Christophersen, E. R. Testicular self-  
 7 examination: validation of a training strategy for early cancer detection. Journal of Applied  
 8 Behavior Analysis 19[1], 87-92. 1986.  
 9 Excl reason: Not in PICO  
 10 Garner, M. J., Turner, M. C., Ghadirian, P., and Krewski, D. Epidemiology of testicular cancer: an  
 11 overview. [Review] [173 refs]. International Journal of Cancer 116[3], 331-339. 1-9-2005.  
 12 Excl reason: Narrative review  
 13 Gascoigne, P., Mason, M. D., and Roberts, E. Factors affecting presentation and delay in patients  
 14 with testicular cancer: results of a qualitative study. Psycho-Oncology 8[2], 144-154. 1999.  
 15 Excl reason: Not in PICO  
 16 Gecki, L., Gomez, F., Horvath, Z., Bak, M., Kisbenedek, L., and Bodrogi, I. Three-year results of the  
 17 first educational and early detection program for testicular cancer in Hungary. Oncology 60[3],  
 18 228-234. 2001.  
 19 Excl reason: Not in PICO (respondents to an awareness campaign)  
 20 Gecki, L., Gomez, F., Bak, M., and Bodrogi, I. The incidence, prognosis, clinical and histological  
 21 characteristics, treatment, and outcome of patients with bilateral germ cell testicular cancer in  
 22 Hungary. Journal of Cancer Research & Clinical Oncology 129[5], 309-315. 2003.  
 23 Excl reason: Not in PICO  
 24 Geiss, K., Meyer, M., Eberle, A., Luttmann, S., Stabenow, R., Hentschel, S., Nennecke, A., Kieschke, J.,  
 25 Sirri, E., Holleczeck, B., Emrich, K., Kajuter, H., Mattauch, V., Katalinic, A., Kraywinkel, K., Brenner,  
 26 H., Gondos, A., and Hiripi, E. Survival from common and rare cancers in Germany in the early  
 27 21st century. Annals of Oncology 23[2], 472-479. 2012.  
 28 Excl reason: Not in PICO  
 29 Germa-Lluch, J. R., Garcia, del Muro, X, Maroto, P., Paz-Ares, L., Arranz, J. A., Guma, J., Alba, E.,  
 30 Sastre, J., Aparicio, J., Fernandez, A., Barnadas, A., Terrassa, J., Saenz, A., Almenar, D., Lopez-  
 31 Brea, M., Climent, M. A., Sanchez, M. A., Lasso, de la, V, Berenguer, G., Perez, X., and Spanish  
 32 Germ-Cell Cancer Group (. Clinical pattern and therapeutic results achieved in 1490 patients with  
 33 germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG).  
 34 European Urology 42[6], 553-562. 562.  
 35 Excl reason: Not in PICO  
 36 Giesinger, J. M., Oberguggenberger, A., Kemmler, G., Gamper, E., Steiner, H., Sztankay, M., and  
 37 Holzner, B. Electronic patient-reported outcome monitoring in testicular cancer patients. Value  
 38 in Health 14[7], A460. 2011. Elsevier Ltd.  
 39 Excl reason: Not in PICO  
 40 Giwercman, A. and Petersen, P. M. Cancer and male infertility. [Review] [79 refs]. Best Practice &  
 41 Research Clinical Endocrinology & Metabolism 14[3], 453-471. 2000.  
 42 Excl reason: Not in PICO  
 43 Goldenring, J. M. and Purtell, E. Knowledge of testicular cancer risk and need for self-examination in  
 44 college students: a call for equal time for men in teaching of early cancer detection techniques.  
 45 Pediatrics 74[6], 1093-1096. 1984.  
 46 Excl reason: Not in PICO  
 47 Golovsky, D. Scrotal swellings: An approach for GPs. Medicine Today 6[5], 45-48. 2005.  
 48 Excl reason: Narrative review  
 49 Gottesman, J. and Baum, N. Common urologic disorders: When to treat and when to refer.  
 50 Postgraduate Medicine 102[2], 235-246. 1997.  
 51 Excl reason: Narrative review

- 1 Grant, R. and Graus, F. Paraneoplastic movement disorders. [Review] [79 refs]. *Movement Disorders*  
2 24[12], 1715-1724. 15-9-2009.  
3 Excl reason: Not in PICO
- 4 Green, D. M. Testicular tumors in infants and children. [Review] [51 refs]. *Seminars in Surgical*  
5 *Oncology* 2[3], 156-162. 1986.  
6 Excl reason: Narrative review
- 7 Gruschwitz, T. and Grimm, M.-O. Studieearly recognition in urology. [German]. *Onkologie* 18[3], 243-  
8 247. 2012.  
9 Excl reason: Narrative review
- 10 Guinan, P. and Rubenstein, M. Methods of early diagnosis in genitourinary cancer. [Review] [163  
11 refs]. *Cancer* 60[3:Suppl], Suppl-76. 1-8-1987.  
12 Excl reason: Narrative review
- 13 Guthrie, J. A. and Fowler, R. C. Ultrasound diagnosis of testicular tumours presenting as epididymal  
14 disease. *Clinical Radiology* 46[6], 397-400. 1992.  
15 Excl reason: Not in PICO
- 16 Hagerty, J. A. and Yerkes, E. B. Pediatric Scrotal Masses. *Clinical Pediatric Emergency Medicine* 10[1],  
17 50-55. 2009.  
18 Excl reason: Narrative review
- 19 Haggerty, B. J. Prevention and differential of scrotal cancer. *Nurse Practitioner* 8[10], 45-Dec. 1983.  
20 Excl reason: Narrative review
- 21 Hanna, L. M., Taggart, L., and Cousins, W. Cancer prevention and health promotion for people with  
22 intellectual disabilities: an exploratory study of staff knowledge. *Journal of Intellectual Disability*  
23 *Research* 55[3], 281-291. 2011.  
24 Excl reason: Not in PICO
- 25 Harris, M. F. and McKenzie, S. Men's health: What's a GP to do? *Medical Journal of Australia* 185[8],  
26 440-444. 16-10-2006.  
27 Excl reason: Not in PICO
- 28 Harzmann, R. [Early diagnosis of urogenital tumors]. [German]. *Zeitschrift fur Hautkrankheiten* 62[9],  
29 665-676. 681.  
30 Excl reason: Narrative review
- 31 Hawary, A. M., Warburton, H. E., Brough, R. J., Collins, G. N., Brown, S. C., O'Reilly, P. H., and  
32 Adeyoju, A. A. The '2-week wait' rule for referrals for suspected urological cancers--urgent need  
33 for refinement of criteria. *Annals of the Royal College of Surgeons of England* 90[6], 517-522.  
34 2008.  
35 Excl reason: Not in PICO
- 36 Haynes, J. H. Inguinal and scrotal disorders. *Surgical Clinics of North America* 86[2], 371-+. 2006.  
37 Excl reason: Narrative review
- 38 Heidenreich, A., Krege, S., and Flashove, M. [Interdisciplinary cooperation in the treatment of  
39 complex patients with advanced testicular germ cell tumor]. [Review] [35 refs] [German].  
40 *Urologe (Auszg.)* 43[12], 1521-1530. 2004.  
41 Excl reason: Not in PICO
- 42 Heidenreich, A., Bokemeyer, C., and Souchon, R. [Stage-specific treatment for testicular germ cell  
43 tumours]. [Review] [55 refs] [German]. *Urologe (Auszg.)* 48[4], 377-385. 2009.  
44 Excl reason: Not in PICO
- 45 Hemminki, K., Sundquist, J., and Lorenzo, Bermejo J. Familial risks for cancer as the basis for  
46 evidence-based clinical referral and counseling. *The Oncologist* 13[3], 239-247. 2008.  
47 Excl reason: Not in PICO
- 48 Hernandez-Rodriguez, J., Tan, C. D., Koenig, C. L., Khasnis, A. A., Rodriguez, E. R., and Hoffman, G. S.  
49 Testicular vasculitis: Findings differentiating isolated from systemic disease in 75 patients.  
50 *Arthritis and Rheumatism* 60, 1832. 2009. John Wiley and Sons Inc.  
51 Excl reason: Not in PICO

- 1 Hernandez-Rodriguez, J., Tan, C. D., Koenig, C. L., Khasnis, A., Rodriguez, E. R., and Hoffman, G. S.  
2 Testicular vasculitis: findings differentiating isolated disease from systemic disease in 72  
3 patients. *Medicine* 91[2], 75-85. 2012.  
4 Excl reason: Not in PICO
- 5 Hernes, E. H., Harstad, K., and Fossa. Changing incidence and delay of testicular cancer in southern  
6 Norway (1981-1992). *European Urology* 30[3], 349-357. 1996.  
7 Excl reason: Not in PICO
- 8 Hisamatsu, E., Takagi, S., Nakagawa, Y., Sugita, Y., Yoshino, K., Ueoka, K., and Tanikaze, S.  
9 Prepubertal testicular tumors: a 20-year experience with 40 cases. *International Journal of*  
10 *Urology* 17[11], 956-959. 2010.  
11 Excl reason: Not in PICO
- 12 Horowitz, A. L., Reinert, S., and Caldamone, A. A. Teaching testicular self-examination in the pediatric  
13 outpatient setting: a survey of pediatricians and family doctors. *Medicine & Health, Rhode Island*  
14 *89*[11], 370-371. 375.  
15 Excl reason: Not in PICO
- 16 Houlgatte, A., Houdelette, P., Berlizot, P., Fournier, R., Bernard, O., and Schill, H. [Bilateral tumors of  
17 the testis: the role of the diagnosis of carcinoma in situ in early detection]. [French]. *Progres En*  
18 *Urologie* 5[4], 540-543. 1995.  
19 Excl reason: Not in PICO
- 20 Howard, G. C., Nairn, M., and Guideline Development Group. Management of adult testicular germ  
21 cell tumours: summary of updated SIGN guideline. *BMJ* 342, d2005. 2011.  
22 Excl reason: Not in PICO
- 23 Huddart, R. Learning lessons from the past: The path forward and new opportunities. *Radiotherapy*  
24 *and Oncology* 99, S224. 2011. Elsevier Ireland Ltd.  
25 Excl reason: Narrative review
- 26 Iammarino, N. K. and Scardino, P. T. Testicular cancer: the role of the primary care physician in  
27 prevention and early detection. [Review] [33 refs]. *Texas Medicine* 87[5], 66-71. 1991.  
28 Excl reason: Narrative review
- 29 Inatomi, H., Hamasaki, T., Ikuyama, T., Yamaguchi, R., Sato, H., Mineta, K., Takahashi, K., and  
30 Matsumoto, T. Testicular germ cell tumors in undescended testes: A report of five cases.  
31 [Japanese]. *Nishinihon Journal of Urology* 63[6], 395-398. 2001.  
32 Excl reason: Not in PICO
- 33 Isidori, A. M. Ultrasonography: Testis and accessory glands. *International Journal of Andrology* 33,  
34 25. 2010. Blackwell Publishing Ltd.  
35 Excl reason: Not in PICO
- 36 Ivaz, Stella. Testicular cancer awareness. [References]. *Family Practice* 19[6], 707. 2002.  
37 Excl reason: Not in PICO
- 38 Jeong, S. and Park, E. Neonatal scrotal disorder: Sonographic finding and anatomical consideration.  
39 *Pediatric Radiology* 41, S351. 2011. Springer Verlag.  
40 Excl reason: Not in PICO
- 41 Jones, R. H. and Vasey, P. A. Part I: testicular cancer--management of early disease. [Review] [53  
42 refs]. *Lancet Oncology* 4[12], 730-737. 2003.  
43 Excl reason: Not in PICO
- 44 Jones, T. D., MacLennan, G. T., Bonnin, J. M., Varsegi, M. F., Blair, J. E., and Cheng, L. Screening for  
45 intratubular germ cell neoplasia of the testis using OCT4 immunohistochemistry. *American*  
46 *Journal of Surgical Pathology* 30[11], 1427-1431. 2006.  
47 Excl reason: Not in PICO
- 48 Jones, W. and Appleyard, I. Early diagnosis of testicular cancer. *Practitioner* 233[1466], 509. 8-4-  
49 1989.  
50 Excl reason: Narrative review

- 1 Josephides, E., Gala, A., and Chowdhury, S. GPs have key role in managing men with testicular  
2 cancer. *Practitioner* 258, 19-23. 2014.  
3 Excl reason: Not in PICO
- 4 Junnila, J. and Lassen, P. Testicular masses. [Review] [21 refs]. *American Family Physician* 57[4], 685-  
5 692. 15-2-1998.  
6 Excl reason: Narrative review
- 7 Junuzovic, D., Mehmedbasic, S., Mehmedbasic, E., and Spahovic, A. Incidence of testicular  
8 carcinoma, therapy and quality assesment. *Medicinski Arhiv* 65[3], 164-167. 2011.  
9 Excl reason: Not in PICO
- 10 Karl, A., Seitz, M., Tritschler, S., Clevert, D., Gratzke, C., and Stief, C. [Scrotal masses]. [German].  
11 *MMW Fortschritte der Medizin* 149[17], 44-48. 20-11-1949.  
12 Excl reason: Narrative review
- 13 Kath, R., Schneider, C. P., and Hoffken, K. Measures for early detection in oncology: Secondary  
14 prevention. [German]. *Onkologe* 4[8], 731-739. 1998.  
15 Excl reason: Not in PICO/narrative review
- 16 Kawai, T., Yamauchi, T., Tachibana, Y., Yoshino, S., and Kokuho, M. [Early detection of urogenital  
17 cancers: kidney, bladder, prostatic and testicular cancers]. [Japanese]. *Gan No Rinsho - Japanese*  
18 *Journal of Cancer Clinics* 34[10], 1403-1407. 1988.  
19 Excl reason: Narrative review
- 20 Kaufman, M. & Levine, D. L. (2013) A case of advanced testicular cancer in a society of racial and  
21 socioeconomic health disparity. *Journal of General Internal Medicine*, 28: S264-S265.  
22 Not in PICO
- 23 Kay, R. Prepubertal testicular tumor registry. *Journal of Urology* 150[2 SUPPL.], 671-674. 1993.  
24 Excl reason: Not in PICO
- 25 Kedzierewicz, R., Chargari, C., Le, Moulec S., Jacques, Ferrandes N., Houlgatte, A., and Vedrine, L.  
26 Knowledge of testicular cancer and screening acceptance: Results from a prospective study.  
27 *Journal of Clinical Oncology* 29[7 SUPPL. 1]. 1-3-2011. American Society of Clinical Oncology.  
28 Excl reason: Not in PICO
- 29 Kelsberg, G., Bishop, R., and Morton, J. When should a child with an undescended testis be referred  
30 to a urologist? *Journal of Family Practice* 55[4], 336-337. 2006.  
31 Excl reason: Not in PICO
- 32 Kelsberg, G., Bishop, R., Morton, J., and Thomason, D. Clinical inquiries. When should a child with an  
33 undescended testis be referred to a urologist?. [Review] [9 refs]. *Journal of Family Practice* 55[4],  
34 336-337. 2006.  
35 Excl reason: Not in PICO
- 36 Khadra, A. and Oakeshott, P. Pilot study of testicular cancer awareness and testicular self-  
37 examination in men attending two South London general practices. *Family Practice* 19[3], 294-  
38 296. 2002.  
39 Excl reason: Not in PICO
- 40 Kiss, A., Csontai, A., Merksz, M., Szonyi, P., and Goracz, G. Intrascrotal and testicular solid masses in  
41 childhood. *International Urology & Nephrology* 28[6], 787-792. 1996.  
42 Excl reason: Not in PICO
- 43 Klein, J. F., Berry, C. C., and Felice, M. E. The development of a testicular self-examination  
44 instructional booklet for adolescents. *Journal of Adolescent Health Care* 11[3], 235-239. 1990.  
45 Excl reason: Not in PICO
- 46 Kliesch, S. [Diagnosis and primary treatment of testicular tumor]. [Review] [21 refs] [German].  
47 *Urologe (Auszg.A)* 43[12], 1494-1499. 2004.  
48 Excl reason: Narrative review
- 49 Knapp, R. H., Hurt, R. D., Payne, W. S., Farrow, G. M., Lewis, B. D., Hahn, R. G., Muhm, J. R., and  
50 Earle, J. D. Malignant germ cell tumors of the mediastinum. *Journal of Thoracic & Cardiovascular*



- 1 Surgery 89[1], 82-89. 1985.  
2 Excl reason: Not in PICO
- 3 Kobayashi, M. and Padival, S. Supraclavicular lymphadenopathy as initial presentation for testicular  
4 cancer: An important differential diagnosis for young men. *Journal of General Internal Medicine*  
5 26, S470-S471. 2011. Springer New York.  
6 Excl reason: Not in PICO
- 7 Kopp, H. G., Kuczyk, M., Classen, J., Stenzl, A., Kanz, L., Mayer, F., Bamberg, M., and Hartmann, J. T.  
8 Advances in the treatment of testicular cancer. [Review] [172 refs]. *Drugs* 66[5], 641-659. 2006.  
9 Excl reason: Not in PICO
- 10 Kosan, M., Gonulalan, U., Ugurlu, O., Oztekin, V., Akdemir, O., and Adsan, O. Testicular microlithiasis  
11 in patients with scrotal symptoms and its relationship to testicular tumors. *Urology* 70[6], 1184-  
12 1186. 2007.  
13 Excl reason: Not in PICO
- 14 Kumaraswamy, P., Cox, R., O'Rourke, J. S., and Willis, R. G. Audit of two-week rule referrals for  
15 suspected testicular cancer in Cornwall, 2003-2005. *Annals of the Royal College of Surgeons of*  
16 *England* 91[3], 239-244. 2009.  
17 Excl reason: Not in PICO
- 18 Laguna, M. P., Pizzocaro, G., Klepp, O., Algaba, F., Kisbenedek, L., Leiva, O., and EAU Working Group  
19 on Oncological Urology. EAU guidelines on testicular cancer. *European Urology* 40[2], 102-110.  
20 2001.  
21 Excl reason: Guideline
- 22 Lantz, J. M., Fullerton, J. T., Harshburger, R. J., and Sadler, G. R. Promoting screening and early  
23 detection of cancer in men. *Nursing and Health Sciences* 3[4], 189-196. 2001.  
24 Excl reason: Not in PICO
- 25 Leman, E. S. and Gonzalgo, M. L. Prognostic features and markers for testicular cancer management.  
26 *Indian Journal of Urology* 26[1], 76-81. 1-1-2010.  
27 Excl reason: Not in PICO
- 28 Leskinen, M., Ala-Lipasti, M., Marttila, T., Paaso, I., and Raitanen, M. [Scrotal masses in adulthood].  
29 [Finnish]. *Duodecim* 125[17], 1869-1876. 2009.  
30 Excl reason: Narrative review
- 31 Lesnik, G., Nickl, S., Kuschnig, P., Sinzig, M., Hausegger, K., and Jeschke, K. [Sonography of the  
32 scrotum]. [Review] [50 refs] [German]. *Rofo: Fortschritte auf dem Gebiete der Rontgenstrahlen*  
33 *und der Nuklearmedizin* 178[2], 165-179. 2006.  
34 Excl reason: Not in PICO
- 35 Leyh, H. Case history and palpation are the basis of early diagnosis of testicular tumors. [German].  
36 *Medizinische Klinik* 79[22], 612-615. 1984.  
37 Excl reason: Not in PICO
- 38 Li, M. & Jiang, T. (2013) MRI diagnosis of testicular neoplasm. [Chinese]. *Chinese Journal of Radiology*  
39 *(China)*, 47: 820-823.  
40 Not in PICO
- 41 Loy, V. and Linke, J. Endocrine tumours of the testis. [German]. *Pathologe* 24[4], 308-313. 2003.  
42 Excl reason: Narrative review
- 43 Lozano, J. M., Mestre, M. P., Lozano, M. A. M., Andres, P. M., and Lozano, C. M. Neoplasm of the  
44 testis in primary care: from the common to the very uncommon. *Swiss Medical Weekly* 139[33-  
45 34], 168S. 2009.  
46 Excl reason: Not in PICO
- 47 Lyratzopoulos, G., Neal, R. D., Barbiere, J. M., Rubin, G. P., and Abel, G. A. Variation in number of  
48 general practitioner consultations before hospital referral for cancer: findings from the 2010  
49 National Cancer Patient Experience Survey in England. *Lancet Oncology* 13[4], 353-365. 2012.  
50 Excl reason: Not in PICO

- 1 Lytras, A. and Tolis, G. Reproductive disturbances in multiple neuroendocrine tumor syndromes.  
2 Endocrine-Related Cancer 16[4], 1125-1138. 2009.  
3 Excl reason: Not in PICO
- 4 MacVicar, G. R. and Pienta, K. J. Testicular cancer. [Review] [16 refs]. Current Opinion in Oncology  
5 16[3], 253-256. 2004.  
6 Excl reason: Not in PICO
- 7 Maddineni, S. B. and Clarke, N. W. Testis cancer: The UK as a model. [German]. Urologe - Ausgabe A  
8 48[4], 386-392. 2009.  
9 Excl reason: Narrative review
- 10 Manuel, H. D. and Hussain, A. Update on testicular germ cell tumors. Current Opinion in Oncology  
11 22[3], 236-241. 2010.  
12 Excl reason: Not in PICO
- 13 Martin, B. and Tubiana, J. M. [Scrotal echography in the diagnosis of cancer of the testis: misleading  
14 images and echographic patterns]. [French]. Annales de Radiologie 32[2], 91-96. 1989.  
15 Excl reason: Not in PICO
- 16 Mathers, M. J., Sperling, H., Rubben, H., and Roth, S. The undescended testis: diagnosis, treatment  
17 and long-term consequences. [Review] [56 refs]. Deutsches Arzteblatt International 106[33],  
18 527-532. 2009.  
19 Excl reason: Not in PICO
- 20 Mathew, A. and Desai, K. M. An audit of urology two-week wait referrals in a large teaching hospital  
21 in England. Annals of the Royal College of Surgeons of England 91[4], 310-312. 2009.  
22 Excl reason: Not in PICO
- 23 McCullagh, J., Lewis, G., and Warlow, C. Promoting awareness and practice of testicular self-  
24 examination. Nursing Standard 19[51], 41-49. 31-8-2005.  
25 Excl reason: Not in PICO
- 26 Mebel, M. and Vogler, H. [Special problems of early detection of malignant tumors of the genito-  
27 urinary system (author's transl)]. [German]. Archiv fur Geschwulstforschung 51[8], 679-684.  
28 1981.  
29 Excl reason: Not in PICO
- 30 Meena, N. K. and Joshi, M. Small cell carcinoma presenting as limbic encephalopathy. American  
31 Journal of Respiratory and Critical Care Medicine 181[1 Meeting Abstracts]. 1-5-2010. American  
32 Thoracic Society.  
33 Excl reason: Not in PICO
- 34 Mevcha, A. and Gillatt, D. Suspicious testicular lumps warrant urgent referral. Practitioner  
35 253[1715], 23-24. 20-11-1926.  
36 Excl reason: Narrative review
- 37 Miller, F. N., Rosairo, S., Clarke, J. L., Sriprasad, S., Muir, G. H., and Sidhu, P. S. Testicular calcification  
38 and microlithiasis: association with primary intra-testicular malignancy in 3,477 patients.  
39 European Radiology 17[2], 363-369. 2007.  
40 Excl reason: Not in PICO
- 41 Minevich, E. Genitourinary emergencies in children. Minerva Pediatrica 61[1], 53-65. 2009.  
42 Excl reason: Narrative review
- 43 Misener, T. R. and Fuller, S. G. Testicular versus breast and colorectal cancer screening: early  
44 detection practices of primary care physicians. Cancer Practice 3[5], 310-316. 1995.  
45 Excl reason: Not in PICO
- 46 Moller, M. B. Association of testicular non-Hodgkin's lymphomas with elevated serum levels of  
47 human chorionic gonadotropin-like material. Oncology 53[2], 94-98. 1996.  
48 Excl reason: Not in PICO
- 49 Morita, A. and Kamei, S. [Limbic encephalitis with antibodies against intracellular antigens]. [Review]  
50 [50 refs] [Japanese]. Brain & Nerve / Shinkei Kenkyu no Shinpo 62[4], 347-355. 2010.  
51 Excl reason: Not in PICO

- 1 Motzer, R. J., Bolger, G. B., Boston, B., Carducci, M. A., Fishman, M., Hancock, S. L., Hauke, R. J.,  
2 Hudes, G. R., Jonasch, E., Kantoff, P., Kuzel, T. M., Lange, P. H., Levine, E. G., Logothetis, C.,  
3 Margolin, K. A., Pohar, K. S., Redman, B. G., Robertson, C. N., Samlowski, W. E., Sheinfeld, J., and  
4 National Comprehensive Cancer Network. Testicular cancer. Clinical practice guidelines in  
5 oncology. *Journal of the National Comprehensive Cancer Network* 4[10], 1038-1058. 2006.  
6 Excl reason: Guideline
- 7 Moul, J. W., Paulson, D. F., Dodge, R. K., and Walther, P. J. Delay in diagnosis and survival in  
8 testicular cancer: impact of effective therapy and changes during 18 years. *Journal of Urology*  
9 143[3], 520-523. 1990.  
10 Excl reason: Not in PICO
- 11 Moul, J. W. Timely diagnosis of testicular cancer. [Review] [77 refs]. *Urologic Clinics of North*  
12 *America* 34[2], 109-117. 2007.  
13 Excl reason: Not in PICO
- 14 Muller, T., Gozzi, C., Akkad, T., Pallwein, L., Bartsch, G., and Steiner, H. Management of incidental  
15 impalpable intratesticular masses of < or = 5 mm in diameter. *BJU International* 98[5], 1001-  
16 1004. 2006.  
17 Excl reason: Not in PICO
- 18 Mumperow, E., Lauke, H., Holstein, A. F., and Hartmann, M. Further practical experiences in the  
19 recognition and management of carcinoma in situ of the testis. *Urologia Internationalis* 48[2],  
20 162-166. 1992.  
21 Excl reason: Not in PICO
- 22 Muramori, K., Nagata, K., and Handa, N. Infantile epididymitis with calcification. *Journal of Indian*  
23 *Association of Pediatric Surgeons* 13[1], 25-27. 2008.  
24 Excl reason: Not in PICO
- 25 Murchie, P., Campbell, N. C., Delaney, E. K., Dinant, G., Hannaford, P. C., Johansson, L., Lee, A. J.,  
26 Rollano, P., and Spigt, M. Comparing diagnostic delay in cancer: A cross-sectional study in three  
27 european countries with primary care-led health care systems. *Family Practice* 29[1], 69-78.  
28 2012.  
29 Excl reason: Not in PICO
- 30 Napal, Lecumberri S., Pascual, Piedrola, I, Arrondo Arrondo, J. L., and Ipiens, Aznar A. [Unusual  
31 presentation form of testicular neoplasms. Report of 5 cases]. [Spanish]. *Archivos Espanoles de*  
32 *Urologia* 45[1], 11-13. 1992.  
33 Excl reason: Not in PICO
- 34 Nay, C., Luthi, F., Ketterer, N., Bauer, J., and Leyvraz, S. Overview on cancer in young adults. [French].  
35 *Revue Medicale Suisse* 3[112], 1305-1310. 23-5-2007.  
36 Excl reason: Narrative review
- 37 Nayyar, V., Bosman, D., and Laji, K. Bilateral testicular adrenal rests in congenital adrenal  
38 hyperplasia. *Endocrine Abstracts* 19, 30. 2009. BioScientifica.  
39 Excl reason: Not in PICO
- 40 Nichols, C. R. Testicular cancer. [Review] [294 refs]. *Current Problems in Cancer* 22[4], 187-274.  
41 1998.  
42 Excl reason: Not in PICO
- 43 Noonan, A. M., Carney, D. N., and McCaffrey, J. Study to assess satisfaction of general practitioners  
44 (GP) with oncology services, GP awareness of follow-up guidelines for patients with cancer, and  
45 GP access to oncology services. *Journal of Clinical Oncology* 29[15 SUPPL. 1]. 20-5-2011.  
46 American Society of Clinical Oncology.  
47 Excl reason: Not in PICO
- 48 Nordhaus, C., Stief, C. G., and Tullmann, E. M. [Inspection, palpation and ultrasound--the basics for  
49 clinical examination of the scrotum and testes]. [German]. *MMW Fortschritte der Medizin*  
50 151[23], 39-40. 4-6-2009.  
51 Excl reason: Narrative review

- 1 Nosov, A. K., Gafton, G. I., Meraboshvili, V. M., Mamizhev, E. M., Vorob'ev, A. V., and Petrov, S. B.  
2 [Testicular germ cell tumors, the state of diagnostics and staging in Saint-Petersburg]. [Russian].  
3 *Voprosy Onkologii* 58[2], 238-242. 2012.  
4 Excl reason: Narrative review
- 5 Nuver, J., Oosting, S. F., and Gietema, J. A. [Issues around testicular carcinoma]. [Review] [Dutch].  
6 *Nederlands Tijdschrift Voor Geneeskunde* 155[45], A4092. 2011.  
7 Excl reason: Narrative review
- 8 O'Brien, T. S., Perkins, J. M. T., and Cranston, D. Efficiency in the outpatient department: The lessons  
9 from urology. *Annals of the Royal College of Surgeons of England* 77[4], 287-289. 1995.  
10 Excl reason: Not in PICO
- 11 O'Callaghan, A. and Mead, G. M. Testicular carcinoma. [Review] [23 refs]. *Postgraduate Medical*  
12 *Journal* 73[862], 481-486. 1997.  
13 Excl reason: Not in PICO
- 14 Oliver, R. T. D., Ong, J., Blandy, J. P., and Altman, D. G. Testis conservation studies in germ cell cancer  
15 justified by improved primary chemotherapy response and reduced delay, 1978-1994. *British*  
16 *Journal of Urology* 78[1], 119-124. 1996.  
17 Excl reason: Not in PICO
- 18 Oosterlinck, W., Dekuyper, P., Christiaens, T., and De, Maeseneer J. Audit of non-profit referrals of  
19 general practitioners to an (academic) urological consultation. [Dutch]. *Tijdschrift voor*  
20 *Geneeskunde* 62[10], 782-787. 15-5-2006.  
21 Excl reason: Not in PICO
- 22 Opot, E. N. and Magoha, G. A. Testicular cancer at Kenyatta National Hospital, Nairobi. *East African*  
23 *Medical Journal* 77[2], 80-85. 2000.  
24 Excl reason: Not in PICO
- 25 Osswald, M., Harlan, L. C., Penson, D., Stevens, J. L., and Clegg, L. X. Treatment of a population based  
26 sample of men diagnosed with testicular cancer in the United States. *Urologic Oncology* 27[6],  
27 604-610. 2009.  
28 Excl reason: Not in PICO
- 29 Ostwald, S. K. and Rothenberger, J. Development of a testicular self-examination program for college  
30 men. *Journal of the American College Health Association* 33[6], 234-239. 1985.  
31 Excl reason: Not in PICO
- 32 Ott, J. J., Ullrich, A., and Miller, A. B. The importance of early symptom recognition in the context of  
33 early detection and cancer survival. *European Journal of Cancer* 45[16], 2743-2748. 2009.  
34 Excl reason: Narrative review
- 35 Pamenter, B., De Bono, J. S., Brown, I. L., Nandini, M., Kaye, S. B., Russell, J. M., Yates, A. J., and Kirk,  
36 D. Bilateral testicular cancer: a preventable problem? Experience from a large cancer centre. *BJU*  
37 *International* 92[1], 43-46. 2003.  
38 Excl reason: Not in PICO
- 39 Passman, C., Urban, D., Klemm, K., Lockhart, M., Kenney, P., and Kolettis, P. Testicular lesions other  
40 than germ cell tumours: feasibility of testis-sparing surgery. *BJU International* 103[4], 488-491.  
41 2009.  
42 Excl reason: Not in PICO
- 43 Pearse, I., Glick, R. D., Abramson, S. J., Gerald, W. R., Shamberger, R. C., and La Quaglia, M. P.  
44 Testicular-sparing surgery for benign testicular tumors. *Journal of Pediatric Surgery* 34[6], 1000-  
45 1003. 1999.  
46 Excl reason: Not in PICO
- 47 Perimenis, P., Speakman, M. J., and Higgins, S. Chronic scrotal pain. A study of its causes and  
48 management. *International Urology and Nephrology* 26[3], 345-347. 1994.  
49 Excl reason: Not in PICO/narrative review

- 1 Periyasamy, P., Subramaniam, S. R., and Rajalingham, S. An increasingly notorious mimicker of  
2 testicular tumours; crossing borders. *BMJ Case Reports* 2011, 2011. 2011.  
3 Excl reason: Not in PICO
- 4 Polak, V. and Hornak, M. The value of scrotal ultrasound in patients with suspected testicular  
5 tumour. *International Urology & Nephrology* 22[5], 467-473. 1990.  
6 Excl reason: Not in PICO
- 7 Raghavan, D. Towards the earlier diagnosis of testicular cancer. [Review] [20 refs]. *Australian Family*  
8 *Physician* 19[6], 865-875. 1990.  
9 Excl reason: Narrative review
- 10 Raghavan, D. and Skinner, E. Genitourinary Cancer in the Elderly. *Seminars in Oncology* 31[2], 249-  
11 263. 2004.  
12 Excl reason: Narrative review
- 13 Ravichandran, S., Smith, R., Cornford, P. A., and Fordham, M. V. Surveillance of testicular  
14 microlithiasis? Results of an UK based national questionnaire survey. *BMC Urology* 6, 8. 2006.  
15 Excl reason: Not in PICO
- 16 Ray-Coquard, I., Guastalla, J.-P., Treilleux, I., Weber, B., Guardiola, E., Lotz, J.-P., Meeus, P., Mignot,  
17 L., Raudrant, D., Tournigand, C., Duvillard, P., and Pujade-Lorraine, E. Sex cord-stromal tumours,  
18 rare events in oncology necessitating multidisciplinary approach and referral pathways.  
19 *European Journal of Cancer, Supplement* 5[5], 247-253. 2007.  
20 Excl reason: Not in PICO
- 21 Richie, J. P. and Sheinfeld, J. Introduction: International consultation on urologic diseases: testicular  
22 cancer: Societe Internationale d'Urologie/International Consultation on Urologic Diseases  
23 Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. *Urology* 78[4:Suppl], Suppl-6.  
24 2011.  
25 Excl reason: Narrative review
- 26 Riddick, A. Testicular lumps in general practice. [Review] [2 refs]. *Practitioner* 242[1590], 627-630.  
27 1998.  
28 Excl reason: Narrative review
- 29 Ringdahl, E., Claybrook, K., Teague, J. L., and Northrup, M. Testicular microlithiasis and its relation to  
30 testicular cancer on ultrasound findings of symptomatic men. *Journal of Urology* 172[5:Pt 1], t-6.  
31 2004.  
32 Excl reason: Not in PICO
- 33 Rochester, M., Scurrell, S., and Parry, J. R. Prospective evaluation of a novel one-stop testicular clinic.  
34 *Annals of the Royal College of Surgeons of England* 90[7], 565-570. 2008.  
35 Excl reason: Not in PICO
- 36 Rodriguez, J. G., Velez, M., Serrano, E., and Casado, M. P. Adolescent student's compliance with  
37 testicular self examination. *Boletin de la Asociacion Medica de Puerto Rico* 87[3-4], 49-53. 1995.  
38 Excl reason: Not in PICO
- 39 Rogers, M. and Todd, C. Information exchange in oncology outpatient clinics: Source, valence and  
40 uncertainty. *Psycho-Oncology* 11[4], 336-345. 2002.  
41 Excl reason: Not in PICO
- 42 Rosella, J. D. Testicular cancer health education: an integrative review. [Review] [38 refs]. *Journal of*  
43 *Advanced Nursing* 20[4], 666-671. 1994.  
44 Excl reason: Not in PICO
- 45 Rosenstein, D. and McAninch, J. W. Urologic emergencies. *Medical Clinics of North America* 88[2],  
46 495-518. 2004.  
47 Excl reason: Narrative review
- 48 Safah, H. and Weiner, R. S. The role of the primary physician in detecting cancer. [Review] [61 refs].  
49 *Comprehensive Therapy* 19[5], 203-208. 1993.  
50 Excl reason: Not in PICO

- 1 Sah, R. P., Anaparthi, R., and Sugumar, A. A Case of Malignant Abdominal Pain. *Onkologie* 32[11],  
2 666-668. 2009.  
3 Excl reason: Not in PICO
- 4 Saito, R., Ishizuka, E., Iwasaki, A., Chiba, K., Ambo, T., and Kobayashi, K. Malignant lymphoma of the  
5 testis: A case report. [Japanese]. *Nishinohon Journal of Urology* 57[9], 1016-1018. 1995.  
6 Excl reason: Not in PICO
- 7 Sanden, I., Larsson, U. S., and Eriksson, C. An interview study of men discovering testicular cancer.  
8 *Cancer Nursing* 23[4], 304-309. 2000.  
9 Excl reason: Not in PICO
- 10 Satie, A. P., Auger, J., Chevrier, C., Le, Bon C., Jouannet, P., Samson, M., and Jegou, B. Seminal  
11 expression of NY-ESO-1 and MAGE-A4 as markers for the testicular cancer. *International Journal*  
12 *of Andrology* 32[6], 713-719. 2009.  
13 Excl reason: Not in PICO
- 14 Saxon, P., Badler, R. L., Desser, T. S., Tublin, M. E., and Katz, D. S. Segmental testicular infarction:  
15 report of seven new cases and literature review. *Emergency Radiology* 19[3], 217-223. 2012.  
16 Excl reason: Not in PICO
- 17 Sayger, S. A., Fortenberry, J. D., and Beckman, R. J. Practice patterns of teaching testicular self-  
18 examination to adolescent patients. *Journal of Adolescent Health Care* 9[5], 441-442. 1988.  
19 Excl reason: Not in PICO
- 20 Schaffner, R. J. Knowledge of testicular self-exam. *Nurse Practitioner* 20[8], 10-12. 1995.  
21 Excl reason: Not in PICO
- 22 Schalamon, J., Ainoedhofer, H., Schleef, J., Singer, G., Haxhija, E. Q., and Hollwarth, M. E.  
23 Management of acute scrotum in children--the impact of Doppler ultrasound. *Journal of*  
24 *Pediatric Surgery* 41[8], 1377-1380. 2006.  
25 Excl reason: Not in PICO (referred population)
- 26 Scheiber, K. [Early diagnosis of testicular tumor]. [German]. *ZFA - Zeitschrift fur Allgemeinmedizin*  
27 59[28], 1541-1543. 10-10-1983.  
28 Excl reason: Narrative review
- 29 Scher, H., Bosl, G., Geller, N., Cirrincione, C., Whitmore, W., and Golbey, R. Impact of symptomatic  
30 interval on prognosis of patients with stage III testicular cancer. *Urology* 21[6], 559-561. 1983.  
31 Excl reason: Not in PICO
- 32 Schickedanz, H. and Kleinteich, B. [Epidemiology and symptomatology of malignant testicular tumors  
33 in children]. [German]. *Kinderarztliche Praxis* 52[8], 370-376. 1984.  
34 Excl reason: Not in PICO/narrative review
- 35 Schickedanz, H. and Kleinteich, B. Epidemiology and symptomatology of scrotal tumours. [German].  
36 *Zeitschrift fur Klinische Medizin* 40[7], 495-498. 1985.  
37 Excl reason: Not in PICO
- 38 Schumacher, H. Testicular involvement in internist-pediatric diseases. [German]. *Therapiewoche*  
39 30[3], 310-319. 1980.  
40 Excl reason: Narrative review
- 41 Segal, R., Lukka, H., Klotz, L. H., Eady, A., Bestic, N., Johnston, M., and Cancer Care Ontario Practice  
42 Guidelines Initiative Genitourinary Cancer Disease Site Group. Surveillance programs for early  
43 stage non-seminomatous testicular cancer: a practice guideline. [Review] [27 refs]. *Canadian*  
44 *Journal of Urology* 8[1], 1184-1192. 2001.  
45 Excl reason: Not in PICO
- 46 Shaw, J. Diagnosis and treatment of testicular cancer. [Review] [37 refs]. *American Family Physician*  
47 77[4], 469-474. 15-2-2008.  
48 Excl reason: Not in PICO
- 49 Sheth, K. R., Sharma, V., Zargaroff, S., Le, B., Dupree, J. M., and Brannigan, R. National incidence of  
50 testicular examination in men ages 15-45: Predictive factors and barriers. *Journal of Urology*

- 1 187[4 SUPPL. 1], e169-e170. 2012. Elsevier Inc.  
2 Excl reason: Not in PICO
- 3 Shindel, A. W., Akhavan, A., and Sharlip, I. D. Urologic aspects of HIV infection. *Medical Clinics of*  
4 *North America* 95[1], 129-151. 2011.  
5 Excl reason: Not in PICO
- 6 Shlebak, A. A. and Smith, D. B. Incidence of objectively diagnosed thromboembolic disease in cancer  
7 patients undergoing cytotoxic chemotherapy and/or hormonal therapy. *Cancer Chemotherapy &*  
8 *Pharmacology* 39[5], 462-466. 1997.  
9 Excl reason: Not in PICO
- 10 Shnorhavorian, M., Jacobs, M. A., Stearns, G., Mingin, G., and Koyle, M. A. Practice variation and  
11 clinical confusion regarding undescended testes and retractile testes among primary care  
12 respondents: A multi-regional survey study in the United States. *Pediatric Surgery International*  
13 28[6], 635-639. 2012.  
14 Excl reason: Not in PICO
- 15 Shokar, Gurjeet S., Carlson, Carol A., Davis, Brian, and Shokar, Navkiran K. Testicular Cancer  
16 Screening in a Primary Care Setting. [References]. *International Journal of Men's Health* 2[3],  
17 221-228. 2003.  
18 Excl reason: Not in PICO
- 19 Singer, A. J., Tichler, T., Orvieto, R., Finestone, A., and Moskovitz, M. Testicular carcinoma: a study of  
20 knowledge, awareness, and practice of testicular self-examination in male soldiers and military  
21 physicians. *Military Medicine* 158[10], 640-643. 1993.  
22 Excl reason: Not in PICO
- 23 Sladden, M. J. and Dickinson, J. A. General practitioners' attitudes to screening for prostate and  
24 testicular cancers. *Medical Journal of Australia* 162[8], 410-413. 17-4-1995.  
25 Excl reason: Not in PICO
- 26 Slaney, C., Livesey, E., and Carroll, D. Discontinuous spleno-gonadal fusion interpreted as a possible  
27 testicular malignancy-an important consideration in testicular imaging. *Pediatric Radiology* 41,  
28 S352. 2011. Springer Verlag.  
29 Excl reason: Not in PICO
- 30 Smart, C. R. The impact of the U.S. Preventive Services Task Force guidelines on cancer screening:  
31 perspective from the National Cancer Institute. *Journal of General Internal Medicine* 5[5:Suppl],  
32 Suppl-33. 1990.  
33 Excl reason: Not in PICO
- 34 Smith, F. C. T. and Gwynn, B. R. Direct access surgery. *Annals of the Royal College of Surgeons of*  
35 *England* 77[2], 94-96. 1995.  
36 Excl reason: Not in PICO
- 37 Snodgrass, W., Bush, N., Holzer, M., and Zhang, S. Current referral patterns and means to improve  
38 accuracy in diagnosis of undescended testis. *Pediatrics* 127[2], e382-e388. 2011.  
39 Excl reason: Not in PICO
- 40 Sokoloff, M. H., Joyce, G. F., and Wise, M. Testis cancer. *Journal of Urology* 177[6], 2030-2041. 2007.  
41 Excl reason: Narrative review
- 42 Sonpavde, G. and Einhorn, L. H. What to do when you discover testicular cancer: Helping patients  
43 overcome fear and choose treatment. *Postgraduate Medicine* 105[4], 229-236. 1999.  
44 Excl reason: Not in PICO
- 45 Spaan, J. A. and Van der Wouden, J. C. Delay in diagnosis of mammary, colorectal and testis tumors.  
46 Relationship with progression of the tumor and the part played by the general practitioner.  
47 [Dutch]. *Huisarts en Wetenschap* 32[4], 134-137. 1989.  
48 Excl reason: Not in PICO
- 49 Stotts, R. C. Cancers of the prostate, penis, and testicles: epidemiology, prevention, and treatment.  
50 [Review] [83 refs]. *Nursing Clinics of North America* 39[2], 327-340. 2004.  
51 Excl reason: Narrative review

- 1 Sturgeon, C. M., Duffy, M. J., Stenman, U. H., Lilja, H., Brunner, N., Chan, D. W., Babaian, R., Bast, R.  
2 C., Jr., Dowell, B., Esteva, F. J., Haglund, C., Harbeck, N., Hayes, D. F., Holten-Andersen, M., Klee,  
3 G. G., Lamerz, R., Looijenga, L. H., Molina, R., Nielsen, H. J., Rittenhouse, H., Semjonow, A., Shih,  
4 leM, Sibley, P., Soletormos, G., Stephan, C., Sokoll, L., Hoffman, B. R., Diamandis, E. P., and  
5 National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry laboratory  
6 medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast,  
7 and ovarian cancers. *Clinical Chemistry* 54[12], e11-e79. 2008.  
8 Excl reason: Not in PICO
- 9 Suardi, N., Strada, E., Colombo, R., Freschi, M., Salonia, A., Lania, C., Cestari, A., Carmignani, L.,  
10 Guazzoni, G., Rigatti, P., and Montorsi, F. Leydig cell tumour of the testis: presentation, therapy,  
11 long-term follow-up and the role of organ-sparing surgery in a single-institution experience. *BJU*  
12 *International* 103[2], 197-200. 2009.  
13 Excl reason: Not in PICO
- 14 Subramonian, K. R., Puranik, S., and Mufti, G. R. How will the two-weeks-wait rule affect delays in  
15 management of urological cancers? *Journal of the Royal Society of Medicine* 96[8], 398-399. 1-8-  
16 2003.  
17 Excl reason: Not in PICO
- 18 Swierz, J., Gomula, A., and Stawarz, B. [The role of clinical examination in early diagnosis of testicular  
19 malignancies]. [Polish]. *Wiadomosci Lekarskie* 45[23-24], 899-902. 1992.  
20 Excl reason: Not in PICO
- 21 Tal, R., Holland, R., Belenky, A., Konichezky, M., and Baniel, J. Incidental testicular tumors in infertile  
22 men. *Fertility & Sterility* 82[2], 469-471. 2004.  
23 Excl reason: Not in PICO
- 24 Tavolini, I. M., Zuliani, G., Norcen, M., Dal, Moro F., Abatangelo, G., and Oliva, G. [Prevention and  
25 early diagnosis of testicular neoplasms]. [Italian]. *Archivio Italiano di Urologia, Andrologia* 71[1],  
26 27-30. 1999.  
27 Excl reason: Not in PICO
- 28 Teichman, J. M., Weiss, B. D., and Solomon, D. Urological needs assessment for primary care  
29 practice: implications for undergraduate medical education. *Journal of Urology* 161[4], 1282-  
30 1285. 1999.  
31 Excl reason: Not in PICO
- 32 Thorup, J. and Cortes, D. Surgical treatment and follow up on undescended testis. [Review] [50 refs].  
33 *Pediatric Endocrinology Reviews* 7[1], 38-43. 2009.  
34 Excl reason: Narrative review
- 35 Tiemstra, J. D. and Kapoor, S. Evaluation of scrotal masses. *American Family Physician* 78[10], 1165-  
36 1170. 15-11-2008.  
37 Excl reason: Narrative review
- 38 Tilley, C. and Theaker, J. M. Pathology of tumours of the male genital tract. *Surgery* 28[12], 577-583.  
39 2010.  
40 Excl reason: Narrative review
- 41 Toklu, C., Ozen, H., Sahin, A., Rastadoskouee, M., and Erdem, E. Factors involved in diagnostic delay  
42 of testicular cancer. *International Urology & Nephrology* 31[3], 383-388. 1999.  
43 Excl reason: Narrative review
- 44 Toner, G. C., Neerhut, G. J., Schwarz, M. A., Thursfield, V. J., Sandeman, T. F., Giles, G. G., and Snow,  
45 R. M. The management of testicular cancer in Victoria, 1988-1993. Urology Study Committee of  
46 the Victorian Co-operative Oncology Group. *Medical Journal of Australia* 174[7], 328-331. 2-4-  
47 2001.  
48 Excl reason: Narrative review
- 49 Turner, D. Testicular cancer and the value of self-examination. *Nursing Times* 91[1], 30-31. 4-1-1995.  
50 Excl reason: Not in PICO



- 1 Ugboma, H. A. and Aburoma, H. L. Public awareness of testicular cancer and testicular self-  
2 examination in academic environments: a lost opportunity. *Clinics (Sao Paulo, Brazil)* 66[7],  
3 1125-1128. 2011.  
4 Excl reason: Not in PICO
- 5 Underhill, C., Packer, C., Myers, R., Mamouney, K., Clouston, D., Byrne, J., Simons, K., Szer, J.,  
6 McKendrick, J., Rosenthal, M., Mitchell, P., Gibbs, P., and Lewin, J. Urological cancer pathology  
7 project: Piloting a process for formalised second opinion pathology review for cancers of low  
8 incidence. *Asia-Pacific Journal of Clinical Oncology* 7, 194. 2011. Blackwell Publishing Ltd.  
9 Excl reason: Not in PICO
- 10 Vadaparampil, S. T., Moser, R. P., Loud, J., Peters, J. A., Greene, M. H., and Korde, L. Factors  
11 associated with testicular self-examination among unaffected men from multiple-case testicular  
12 cancer families. *Hereditary Cancer in Clinical Practice* 7. 2009.  
13 Excl reason: Not in PICO
- 14 Valentova, M. and Mladosevicova, B. Cardiovascular morbidity in patients after treatment for  
15 testicular cancer. [Slovak]. *Vnitřní Lekarství* 56[9], 915-919. 2010.  
16 Excl reason: Not in PICO
- 17 Varenhorst, E., Bjornlert, U., Herder, A., Nordenstam, G., and Alund, G. [Ultrasonic examination of  
18 the scrotum for the diagnosis of suspected testicular tumor]. [Swedish]. *Lakartidningen* 81[37],  
19 3242-3243. 12-9-1984.  
20 Excl reason: Not in PICO (patients with suspected testicular cancer)
- 21 Vasdev, N. and Thorpe, A. C. Has the introduction of the '2 week rule' in the UK led to an earlier  
22 diagnosis of urological malignancy? *ecancermedicalsecience* 5[1]. 31-8-2011.  
23 Excl reason: Not in PICO
- 24 Vasudev, N. S., Joffe, J. K., Cooke, C., Richards, F., and Jones, W. G. Delay in the diagnosis of testicular  
25 tumours - changes over the past 18 years. *British Journal of General Practice* 54[505], 595-597.  
26 2004.  
27 Excl reason: Not in PICO
- 28 Vogt, H. B. and McHale, M. S. Testicular cancer: Role of primary care physicians in screening and  
29 education. *Postgraduate Medicine* 92[1], 93-100. 1992.  
30 Excl reason: Narrative review
- 31 Walsh, T. J., Dall'Era, M. A., Croughan, M. S., Carroll, P. R., and Turek, P. J. Prepubertal orchiopexy for  
32 cryptorchidism may be associated with lower risk of testicular cancer. [Review] [21 refs]. *Journal*  
33 *of Urology* 178[4:Pt 1], t-6. 2007.  
34 Excl reason: Not in PICO
- 35 Wampler, S. M. and Llanes, M. Common scrotal and testicular problems. [Review]. *Primary Care;*  
36 *Clinics in Office Practice* 37[3], 613-626. 20-11-2010.  
37 Excl reason: Narrative review
- 38 Wani, A. M., Al Zayyani, N. R., and Jacob, S. Unusual presentation of mixed germ cell tumour from  
39 testis in a 45-year-old man. *BMJ Case Reports* 2011, 2011. 2011.  
40 Excl reason: Not in PICO
- 41 Ward, K. D., Vander Weg, M. W., Read, M. C., Sell, M. A., and Beech, B. M. Testicular cancer  
42 awareness and self-examination among adolescent males in a community-based youth  
43 organization. *Preventive Medicine* 41[2], 386-398. 2005.  
44 Excl reason: Not in PICO
- 45 Wardle, J., Steptoe, A., Burckhardt, R., Vogele, C., Vila, J., and Zarczynski, Z. Testicular self-  
46 examination: Attitudes and practices among young men in Europe. *Preventive Medicine* 23[2],  
47 206-210. 1994.  
48 Excl reason: Not in PICO
- 49 Webb, V. and Holmes, A. Urological cancers: do early detection strategies exist? *BJU International*  
50 86[9], 996-1000. 2000.  
51 Excl reason: Not in PICO

- 1 Weist, M. D. and Finney, J. W. Training in early cancer detection and anxiety in adolescent males: a  
2 preliminary report. *Journal of developmental and behavioral pediatrics* : JDBP 17[2], 98-99.  
3 1996.  
4 Excl reason: Not in PICO
- 5 Westlake, S. J. and Frank, J. W. Testicular self-examination: an argument against routine teaching.  
6 *Family Practice* 4[2], 143-148. 1987.  
7 Excl reason: Not in PICO
- 8 Wheater, M. J., Manners, J., Nolan, L., Simmonds, P. D., Hayes, M. C., and Mead, G. M. The clinical  
9 features and management of testicular germ cell tumours in patients aged 60 years and older.  
10 *BJU International* 108[11], 1794-1799. 2011.  
11 Excl reason: Not in PICO
- 12 Wiesenthal, J. D., Ettler, H., and Razvi, H. Testicular epidermoid cyst: a case report and review of the  
13 clinicopathologic features. [Review] [11 refs]. *Canadian Journal of Urology* 11[1], 2133-2135.  
14 2004.  
15 Excl reason: Not in PICO
- 16 Wijesinha, S. Male reproductive health--what is the GP's role?. [Review] [11 refs]. *Australian Family*  
17 *Physician* 32[6], 408-411. 2003.  
18 Excl reason: Not in PICO
- 19 Wijesinha, S. S. What do family physicians need to know about men's sexual health? *Hong Kong*  
20 *Practitioner* 25[10], 486-490. 2003.  
21 Excl reason: Not in PICO
- 22 Willson, P. C. and Judkins, A. F. Testicular and breast self-examinations: nurses' impact on early  
23 cancer detection. *Dimensions in Oncology Nursing* 4[3], 27-32. 1990.  
24 Excl reason: Not in PICO
- 25 Wilson, C., Boyd, K., Mohammed, A., and Little, B. A single episode of haemospermia can be safely  
26 managed in the community. *International Journal of Clinical Practice* 64[10], 1436-1439. 2010.  
27 Excl reason: Not in PICO
- 28 Winter, C. and Albers, P. Testicular germ cell tumors: pathogenesis, diagnosis and treatment.  
29 [Review]. *Nature Reviews Endocrinology* 7[1], 43-53. 2011.  
30 Excl reason: Narrative review
- 31 Wohl, R. E. and Kane, W. M. Teachers' beliefs concerning teaching about testicular cancer and  
32 testicular self-examination. *Journal of School Health* 67[3], 106-111. 1997.  
33 Excl reason: Not in PICO
- 34 Yeazel, M. W., Oeffinger, K. C., Gurney, J. G., Mertens, A. C., Hudson, M. M., Emmons, K. M., Chen, H.  
35 G., and Robison, L. L. The cancer screening practices of adult survivors of childhood cancer - A  
36 report from the childhood cancer survivor study. *Cancer* 100[3], 631-640. 2004.  
37 Excl reason: Not in PICO

**Review question:**

40 Which investigations of symptoms of suspected testicular cancer should be done with clinical  
41 responsibility retained by primary care?

**Results****Literature search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
Medline	1980-2013	266	54	22/03/2013
Premedline	1980-2013	14	6	22/03/2013
Embase	1980-2013	296	51	22/03/2013
Cochrane Library	1980-2013	0	0	22/03/2013


Psychinfo	1980-2013	0	0	22/03/2013
Web of Science (SCI & SSCI) and ISI Proceedings	1980-2013	51	2	22/03/2013

1 Total References retrieved (after de-duplication): 95

2  
3 **Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	3/2013-27/08/2014	6	0	27/08/2014
<i>Premedline</i>	3/2013-27/08/2014	17	0	27/08/2014
<i>Embase</i>	3/2013-27/08/2014	36	2	27/08/2014
<i>Cochrane Library</i>	3/2013-27/08/2014	6	0	27/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	3/2013-27/08/2014	6	0	27/08/2014

4 Total References retrieved (after de-duplication): 2



6  
7 **Study results**

8 No evidence was identified pertaining to the diagnostic accuracy of ultrasound in patients with  
9 suspected testicular cancer where the clinical responsibility was retained by primary care.

10  
11 **References**

12 **Included studies**

13 None

14  
15 **Excluded studies (with excl reason)**

- 1 Ahmad, I., Krishna, N. S., Clark, R., Nairn, R. & Al-Saffar, N. (2007) Testicular microlithiasis:  
2 prevalence and risk of concurrent and interval development of testicular tumor in a referred  
3 population. *International Urology & Nephrology*, 39: 1177-1181.  
4 Not in PICO
- 5 Aigner, A., Brachmann, P., Beyer, J., Jager, R., Raulais, D., Vigny, M., Neubauer, A., Heidenreich, A.,  
6 Weinknecht, S., Czubayko, F. & Zugmaier, G. (2003) Marked increase of the growth factors  
7 pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. *Annals of*  
8 *Oncology*, 14: 1525-1529.  
9 Not in PICO
- 10 Aigner, F., De, Z. T., Pallwein-Prettner, L., Junker, D., Schafer, G., Pichler, R., Leonhartsberger, N.,  
11 Pinggera, G., Dogra, V. S. & Frauscher, F. (2012) Real-time sonoelastography for the evaluation  
12 of testicular lesions. *Radiology*, 263: 584-589.  
13 Not in PICO
- 14 Albers, P., Goll, A., Bierhoff, E., Schoeneich, G. & Muller, S. C. (1999) Clinical course and  
15 histopathologic risk factor assessment in patients with bilateral testicular germ cell tumors.  
16 [Review] [20 refs]. *Urology*, 54: 714-718.  
17 Not in PICO
- 18 Albers, P., Albrecht, W., Algaba, F., Bokemeyer, C., Cohn-Cedermark, G., Fizazi, K., Horwich, A.,  
19 Laguna, M. P. & European Association of Urology (2012) [EAU guidelines on testicular cancer:  
20 2011 update. European Association of Urology]. [Spanish]. *Actas Urologicas Espanolas*, 36: 127-  
21 145.  
22 Guideline
- 23 Arce, T. Y., Algaba-Arrea, F. & Villavicencio, M. H. (2010) [Segmental infarct of testicle: an infrequent  
24 pseudotumor]. [Spanish]. *Actas Urologicas Espanolas*, 34: 194-200.  
25 Not in PICO
- 26 Badmos, K. B. (2012) Tuberculous epididymo-orchitis mimicking a testicular tumour: a case report.  
27 *African Health Sciences*, 12: 395-397.  
28 Not in PICO
- 29 Barnhouse, K., Powers, A. & Smith, P. C. (2007) Clinical inquiries. How should you further evaluate an  
30 adult with a testicular mass? *Journal of Family Practice*, 56: 851-853.  
31 Narrative review
- 32 Barrass, B. J. R., Scurrill, S., Banerjee, G. & Parry, J. R. W. (2010) Anxious patients with benign scrotal  
33 symptoms achieve excellent reassurance from imaging in a one-stop clinic. *British Journal of*  
34 *Medical and Surgical Urology*, 3: 111-115.  
35 Not in PICO
- 36 Bergholz, R. & Wenke, K. (2009) Polyorchidism: a meta-analysis. *Journal of Urology*, 182: 2422-2427.  
37 Not in PICO
- 38 Buchler, T., Simonova, K., Fencel, P. & Abrahamova, J. (2011) [Positron emission tomography in the  
39 diagnosis and monitoring of patients with nonseminomatous germ cell tumours]. [Czech].  
40 *Klinicka Onkologie*, 24: 413-417.  
41 Not in PICO
- 42 Carmignani, L., Colombo, R., Gadda, F., Galasso, G., Lania, A., Palou, J., Algaba, F., Villavicencio, H.,  
43 Colpi, G. M., Decobelli, O., Salvioni, R., Pizzocaro, G., Rigatti, P. & Rocco, F. (2007) Conservative  
44 Surgical Therapy for Leydig Cell Tumor. *Journal of Urology*, 178: 507-511.  
45 Not in PICO
- 46 Chapple, A., Ziebland, S. & McPherson, A. (2004) Qualitative study of men's perceptions of why  
47 treatment delays occur in the UK for those with testicular cancer. *British Journal of General*  
48 *Practice*, 54: 25-32.  
49 Not in PICO
- 50 Chierigo, P., Puccetti, O., Visona, A., Bassan, F., Rahmati, M., Lazzarotto, M. & Franzolin, N. (2010)  
51 [High alpha-fetoprotein persistence after orchiectomy. On a case of uncommon etiology].

- 1 [Italian]. *Urologia (Treviso)*, 77: Suppl-31.  
 2 Not in PICO
- 3 Church, D. N., Protheroe, A., Ian, S. D. R., Crane, G. L., Turner, G. D. & Verrill, C. (2012) Clinical  
 4 relevance of specialist pathologic testicular tumor review. *Journal of Clinical Oncology*, 30.  
 5 Not in PICO
- 6 Clarke, K., Howard, G. C. W., Elia, M. H., Hutcheon, A. W., Kaye, S. B., Windsor, P. M. & Yosef, H. M.  
 7 A. (1995) Referral patterns within Scotland to specialist oncology centres for patients with  
 8 testicular germ cell tumours. *British Journal of Cancer*, 72: 1300-1302.  
 9 Not in PICO
- 10 Cook, J. L. & Dewbury, K. (2000) The changes seen on high-resolution ultrasound in orchitis. [Review]  
 11 [22 refs]. *Clinical Radiology*, 55: 13-18.  
 12 Narrative review
- 13 Dieckmann, K.-P. & Loy, V. (1998) The value of the biopsy of the contralateral testis in patients with  
 14 testicular germ cell cancer: The recent German experience. *APMIS*, 106: 13-23.  
 15 Not in PICO
- 16 Dieckmann, K.-P., Kulejewski, M., Pichlmeier, U. & Loy, V. (2007) Diagnosis of Contralateral Testicular  
 17 Intraepithelial Neoplasia (TIN) in Patients with Testicular Germ Cell Cancer: Systematic Two-Site  
 18 Biopsies Are More Sensitive Than a Single Random Biopsy. *European Urology*, 51: 175-185.  
 19 Not in PICO
- 20 Dieckmann, K. P., Heinemann, V., Frey, U., Pichlmeier, U. & German Testicular Cancer Study Group  
 21 (2005) How harmful is contralateral testicular biopsy?--an analysis of serial imaging studies and  
 22 a prospective evaluation of surgical complications. *European Urology*, 48: 662-672.  
 23 Not in PICO
- 24 Dieckmann, K. P., Kulejewski, M., Heinemann, V. & Loy, V. (2011) Testicular biopsy for early cancer  
 25 detection--objectives, technique and controversies. [Review]. *International Journal of*  
 26 *Andrology*, 34: t-13.  
 27 Narrative review
- 28 Duffy, M. J. (2001) Clinical uses of tumor markers: a critical review. [Review] [129 refs]. *Critical*  
 29 *Reviews in Clinical Laboratory Sciences*, 38: 225-262.  
 30 Not in PICO
- 31 Fanti, S., Nanni, C., Ambrosini, V., Gross, M. D., Rubello, D. & Farsad, M. (2007) PET in genitourinary  
 32 tract cancers. [Review] [82 refs]. *The Quarterly Journal of Nuclear Medicine & Molecular*  
 33 *Imaging*, 51: 260-271.  
 34 Not in PICO
- 35 Favilla, V., Cimino, S., Madonia, M. & Morgia, G. (2010) New advances in clinical biomarkers in testis  
 36 cancer. [Review] [246 refs]. *Frontiers in Bioscience*, 2: 456-477.  
 37 Not in PICO
- 38 Foo, K. T. (2013) The role of transabdominal ultrasound in office urology. *Proceedings of Singapore*  
 39 *Healthcare*, 22: 125-130.  
 40 Narrative review
- 41 Gallardo, A. E., Pena, G. E., Lopez, R. G., Ortega, G. E., Calabria de, D. A., Portillo Martin, J. A. &  
 42 Martin, G. B. (1996) Testicular tumors. Echographic findings. [Spanish]. *Archivos Espanoles de*  
 43 *Urologia*, 49: 622-626.  
 44 Not in PICO
- 45 Geczi, L., Gomez, F., Horvath, Z., Bak, M., Kisbenedek, L. & Bodrogi, I. (2001) Three-year results of the  
 46 first educational and early detection program for testicular cancer in Hungary. *Oncology*, 60:  
 47 228-234.  
 48 Not in PICO
- 49 Gopalan, A., Dhall, D., Olgac, S., Fine, S. W., Korkola, J. E., Houldsworth, J., Chaganti, R. S., Bosl, G. J.,  
 50 Reuter, V. E. & Tickoo, S. K. (2009) Testicular mixed germ cell tumors: a morphological and  
 51 immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis

- 1 on morphologically difficult-to-classify areas. *Modern Pathology*, 22: 1066-1074.  
 2 Not in PICO
- 3 Guinan, P. & Rubenstein, M. (1987) Methods of early diagnosis in genitourinary cancer. *Cancer*, 60:  
 4 668-676.  
 5 Not in PICO
- 6 Guthrie, J. A. & Fowler, R. C. (1992) Ultrasound diagnosis of testicular tumours presenting as  
 7 epididymal disease. *Clinical Radiology*, 46: 397-400.  
 8 Not in PICO
- 9 Haas, R. J., Gobel, U., Harms, D., Schmidt, P. & Weissbach, L. (1988) Results of the cooperative  
 10 Malignant Testicular Tumors 82 Study of the German Society of Pediatric Oncology on the  
 11 therapy of malignant germ cell tumors in childhood. [German]. *Klinische Padiatrie*, 200: 230-  
 12 235.  
 13 Not in PICO
- 14 Haller, J., Gritzmann, N., Czembirek, H., Schmidbauer, C., Leitner, H., Sommer, G. & Tscholakoff, D.  
 15 (1987) Occult and clinically suspected testicular tumor. Assessment using real-time sonography.  
 16 [German]. *Der Radiologe*, 27: 113-117.  
 17 Not in PICO
- 18 Hemminki, K., Mousavi, S. M., Brandt, A., Ji, J. & Sundquist, J. (2010) Histology-specific risks in  
 19 testicular cancer in immigrants to Sweden. *Endocrine-Related Cancer*, 17: 329-334.  
 20 Not in PICO
- 21 Hisamatsu, E., Takagi, S., Nakagawa, Y., Sugita, Y., Yoshino, K., Ueoka, K. & Tanikaze, S. (2010)  
 22 Prepubertal testicular tumors: a 20-year experience with 40 cases. *International Journal of*  
 23 *Urology*, 17: 956-959.  
 24 Not in PICO
- 25 Holstein, A. F. & Lauke, H. (1996) Histologic diagnostics of early testicular germ-cell tumor.  
 26 *International Journal of Urology*, 3: 165-172.  
 27 Not in PICO
- 28 Isidori, A. M. (2010) Ultrasonography: Testis and accessory glands. *International Journal of*  
 29 *Andrology*, 33: 25.  
 30 Narrative review
- 31 Jones, W. & Appleyard, I. (1989) Early diagnosis of testicular cancer. *The Practitioner*, 233: 509.  
 32 Narrative review
- 33 Kaufman, M. & Levine, D. L. (2013) A case of advanced testicular cancer in a society of racial and  
 34 socioeconomic health disparity. *Journal of General Internal Medicine*, 28: S264-S265.  
 35 Not in PICO
- 36 Kennedy, P. T., Elliott, J. M., Rice, P. F. & Kelly, B. E. (1999) Ultrasonography of intratesticular lesions:  
 37 its role in clinical management. *Ulster Medical Journal*, 68: 54-58.  
 38 Not in PICO
- 39 Kinkade, S. (2549) Testicular cancer. [Review] [26 refs]. *American Family Physician*, 59: 2539-2544.  
 40 Narrative review
- 41 Kleinschmidt, K., Weissbach, L. & Holstein, A. F. (1989) Early diagnosis of the contralateral second  
 42 cancer in patients with germ cell tumors by screening for carcinoma in situ testis. [German].  
 43 *Urologe - Ausgabe A*, 28: 281-284.  
 44 Not in PICO
- 45 Kliesch, S. (2004) [Diagnosis and primary treatment of testicular tumor]. [Review] [21 refs] [German].  
 46 *Urologe (Auszg.A)*, 43: 1494-1499.  
 47 Narrative review
- 48 Kontos, S., Doumanis, G., Karagianni, M., Politis, V., Simaioforidis, V., Kachrilas, S. & Koritsiadis, S.  
 49 (2009) Burned-out testicular tumor with retroperitoneal lymph node metastasis: a case report.  
 50 *Journal of Medical Case Reports [Electronic Resource]*, 3: 8705.  
 51 Not in PICO

- 1 Krege, S. & Rubben, H. (2005) [Lymphadenectomy for testicular cancer. Diagnostic and prognostic  
2 significance as well as therapeutic benefit]. [Review] [28 refs] [German]. *Urologe (Ausg.A)*, 44:  
3 652-656.  
4 Narrative review
- 5 Krege, S., Beyer, J., Souchon, R., Albers, P., Albrecht, W., Algaba, F., Bamberg, M., Bodrogi, I.,  
6 Bokemeyer, C., Cavallin-Stahl, E., Classen, J., Clemm, C., Cohn-Cedermark, G., Culine, S.,  
7 Daugaard, G., De Mulder, P. H., De, S. M., de, W. M., de, W. R., Derigs, H. G., Dieckmann, K. P.,  
8 Dieing, A., Droz, J. P., Fenner, M., Fizazi, K., Flechon, A., Fossa, S. D., del Muro, X. G., Gauler, T.,  
9 Geczi, L., Gerl, A., Germa-Lluch, J. R., Gillessen, S., Hartmann, J. T., Hartmann, M., Heidenreich,  
10 A., Hoeltl, W., Horwich, A., Huddart, R., Jewett, M., Joffe, J., Jones, W. G., Kisbenedek, L., Klepp,  
11 O., Kliesch, S., Koehrmann, K. U., Kollmannsberger, C., Kuczyk, M., Laguna, P., Galvis, O. L., Loy,  
12 V., Mason, M. D., Mead, G. M., Mueller, R., Nichols, C., Nicolai, N., Oliver, T., Ondrus, D.,  
13 Oosterhof, G. O., Ares, L. P., Pizzocaro, G., Pont, J., Pottek, T., Powles, T., Rick, O., Rosti, G.,  
14 Salvioni, R., Scheiderbauer, J., Schmelz, H. U., Schmidberger, H., Schmoll, H. J., Schrader, M.,  
15 Sedlmayer, F., Skakkebaek, N. E., Sohaib, A., Tjulandin, S., Warde, P., Weinknecht, S.,  
16 Weissbach, L., Wittekind, C., Winter, E., Wood, L. & von der, M. H. (2008) European consensus  
17 conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of  
18 the European Germ Cell Cancer Consensus group (EGCCCG): part I. [Review] [164 refs].  
19 *European Urology*, 53: 478-496.  
20 Not in PICO
- 21 Kumaraswamy, P., Cox, R., O'Rourke, J. S. & Willis, R. G. (2009) Audit of two-week rule referrals for  
22 suspected testicular cancer in Cornwall, 2003-2005. *Annals of the Royal College of Surgeons of*  
23 *England*, 91: 239-244.  
24 Not in PICO
- 25 Lenz, S., Giwercman, A. & Skakkebaek, N. E. (1987) Ultrasound in detection of early neoplasia of the  
26 testis. *International Journal of Andrology*, 10: 187-190.  
27 Not in PICO
- 28 Lenz, S. (1991) Cancer of the testicle diagnosed by ultrasound and the ultrasonic appearance of the  
29 contralateral testicle. *Scandinavian Journal of Urology and Nephrology*, Supplementum.: 135-  
30 138.  
31 Not in PICO
- 32 Lenz, S. & Giwercman, A. (2008) Carcinoma-in-situ of the testis - Is ultrasound of the testes useful as  
33 a screening method? *Journal of Medical Ultrasound*, 16: 256-267.  
34 Narrative review
- 35 Leskinen, M., Ala-Lipasti, M., Marttila, T., Paaso, I. & Raitanen, M. (2009) [Scrotal masses in  
36 adulthood]. [Finnish]. *Duodecim*, 125: 1869-1876.  
37 Narrative review
- 38 Lesnik, G., Nickl, S., Kuschnig, P., Sinzig, M., Hausegger, K. & Jeschke, K. (2006) [Sonography of the  
39 scrotum]. [Review] [50 refs] [German]. *Rofo: Fortschritte auf dem Gebiete der Rontgenstrahlen*  
40 *und der Nuklearmedizin*, 178: 165-179.  
41 Narrative review
- 42 Li, M. & Jiang, T. (2013) MRI diagnosis of testicular neoplasm. [Chinese]. *Chinese Journal of Radiology*  
43 *(China)*, 47: 820-823.  
44 Not in PICO
- 45 Lifschitz-Mercer, B., Elliott, D. J., Schreiber-Bramante, L., Leider-Trejo, L., Eisenthal, A. & Bar-Shira,  
46 M. B. (2001) Intratubular germ cell neoplasia: associated infertility and review of the diagnostic  
47 modalities. [Review] [41 refs]. *International Journal of Surgical Pathology*, 9: 93-98.  
48 Not in PICO
- 49 Lomena, F., Simo, M., Setoain, X. & Perez, G. (2001) [Positron emission tomography (PET):  
50 application in urogenital system oncologic diseases]. [Review] [39 refs] [Spanish]. *Archivos*

- 1 *Espanoles de Urologia*, 54: 649-660.  
 2 Not in PICO
- 3 Mahmood, T., Farooq, K., Asghar, J. & Rashid, A. (2011) Evaluation of scrotal pathology on  
 4 ultrasonography. *Pakistan Journal of Medical and Health Sciences*, 5: 341-343.  
 5 Narrative review
- 6 Martin, B. & Conte, J. (1987) Ultrasonography of the acute scrotum. *Journal of Clinical Ultrasound*,  
 7 15: 37-44.  
 8 Not in PICO
- 9 Martin, B. & Tubiana, J. M. (1989) Scrotal echography in the diagnosis of cancer of the testis:  
 10 misleading images and echographic patterns. [French]. *Annales de Radiologie*, 32: 91-96.  
 11 Not in PICO
- 12 Mathew, A. & Desai, K. M. (2009) An audit of urology two-week wait referrals in a large teaching  
 13 hospital in England. *Annals of the Royal College of Surgeons of England*, 91: 310-312.  
 14 Not in PICO
- 15 Miller, F. N., Rosairo, S., Clarke, J. L., Sriprasad, S., Muir, G. H. & Sidhu, P. S. (2007) Testicular  
 16 calcification and microlithiasis: association with primary intra-testicular malignancy in 3,477  
 17 patients. *European Radiology*, 17: 363-369.  
 18 Not in PICO
- 19 Milovanceva-Popovska, M. & Dzikova, S. (2008) Doppler ultrasonography: a tool for nephrologists--  
 20 single centre experience. *Makedonska Akademija na Naukite i Umetnostite Oddelenie Za*  
 21 *Biološki i Meditsinski Nauki Prilozi*, 29: 107-128.  
 22 Not in PICO
- 23 Muller, T., Gozzi, C., Akkad, T., Pallwein, L., Bartsch, G. & Steiner, H. (2006) Management of  
 24 incidental impalpable intratesticular masses of < or = 5 mm in diameter. *BJU International*, 98:  
 25 1001-1004.  
 26 Not in PICO
- 27 Muramori, K., Nagata, K. & Handa, N. (2008) Infantile epididymitis with calcification. *Journal of*  
 28 *Indian Association of Pediatric Surgeons*, 13: 25-27.  
 29 Not in PICO
- 30 Napal, L. S., Pascual, P., I, Arrondo Arrondo, J. L. & Ipiens, A. A. (1992) Unusual presentation form of  
 31 testicular neoplasms. Report of 5 cases. [Spanish]. *Archivos Espanoles de Urologia*, 45: 11-13.  
 32 Not in PICO
- 33 Nguyen, M. M. & Ellison, L. M. (2005) Testicular cancer patterns in Asian-American males: an  
 34 opportunity for public health education to impact outcomes. *Urology*, 66: 606-609.  
 35 Not in PICO
- 36 Nordhaus, C., Stief, C. G. & Tullmann, E. M. (2009) [Inspection, palpation and ultrasound--the basics  
 37 for clinical examination of the scrotum and testes]. [German]. *MMW Fortschritte der Medizin*,  
 38 151: 39-40.  
 39 Narrative review
- 40 O'Brien, T. S., Perkins, J. M. T. & Cranston, D. (1995) Efficiency in the outpatient department: The  
 41 lessons from urology. *Annals of the Royal College of Surgeons of England*, 77: 287-289.  
 42 Not in PICO
- 43 Opot, E. N. & Magoha, G. A. (2000) Testicular cancer at Kenyatta National Hospital, Nairobi. *East*  
 44 *African Medical Journal*, 77: 80-85.  
 45 Not in PICO
- 46 Oszukowska, E., Slowikowska-Hilczer, J., Wolski, J. K., Kula, P., Sosnowski, M. & Kula, K. (2006)  
 47 Surgery in andrology. [Polish, English]. *Chirurgia Polska*, 8: 207-222.  
 48 Not in PICO
- 49 Parkinson, R. J., Walton, T. J. & Lemberger, R. J. (2009) Use and misuse of testicular ultrasound in  
 50 routine clinical practice in a UK teaching hospital. *British Journal of Medical and Surgical*



- 1 *Urology*, 2: 105-110.  
2 Not in PICO
- 3 Perimenis, P., Speakman, M. J. & Higgins, S. (1994) Chronic scrotal pain. A study of its causes and  
4 management. *International Urology and Nephrology*, 26: 345-347.  
5 Not in PICO
- 6 Phillips, N. & Jequier, A. M. (2007) Early testicular cancer: A problem in an infertility clinic.  
7 *Reproductive BioMedicine Online*, 15: 520-525.  
8 Not in PICO
- 9 Polak, V. & Hornak, M. (1990) The value of scrotal ultrasound in patients with suspected testicular  
10 tumour. *International Urology and Nephrology*, 22: 467-473.  
11 Not in PICO
- 12 Pompino, H. J. (1980) Testicular biopsy in children - indications and risks. [German]. *Therapiewoche*,  
13 30: 282-285.  
14 Not in PICO
- 15 Richenberg, J. & Brejt, N. (2012) Testicular microlithiasis: is there a need for surveillance in the  
16 absence of other risk factors? *European Radiology*, 22: 2540-2546.  
17 Not in PICO
- 18 Ringdahl, E., Claybrook, K., Teague, J. L. & Northrup, M. (2004) Testicular microlithiasis and its  
19 relation to testicular cancer on ultrasound findings of symptomatic men. *Journal of Urology*,  
20 172: t-6.  
21 Not in PICO
- 22 Rochester, M., Scurrill, S. & Parry, J. R. (2008) Prospective evaluation of a novel one-stop testicular  
23 clinic. *Annals of the Royal College of Surgeons of England*, 90: 565-570.  
24 Not in PICO
- 25 Roy, C. & Tuchmann, C. (2003) Scrotal ultrasound. Part II: Cysts, tumors and rare non tumoral  
26 processes. [French]. *Journal de Radiologie*, 84: 667-680.  
27 Narrative review
- 28 Saxon, P., Badler, R. L., Desser, T. S., Tublin, M. E. & Katz, D. S. (2012) Segmental testicular infarction:  
29 Report of seven new cases and literature review. *Emergency Radiology*, 19: 217-223.  
30 Not in PICO
- 31 Schalamon, J., Ainoedhofer, H., Schleef, J., Singer, G., Haxhija, E. Q. & Hollwarth, M. E. (2006)  
32 Management of acute scrotum in children--the impact of Doppler ultrasound. *Journal of*  
33 *Pediatric Surgery*, 41: 1377-1380.  
34 Not in PICO
- 35 Shvarts, O., Han, K. R., Seltzer, M., Pantuck, A. J. & Belldegrin, A. S. (2002) Positron emission  
36 tomography in urologic oncology. [Review] [52 refs]. *Cancer Control*, 9: 335-342.  
37 Not in PICO
- 38 Soh, E., Berman, L. H., Grant, J. W., Bullock, N. & Williams, M. V. (2008) Ultrasound-guided core-  
39 needle biopsy of the testis for focal indeterminate intratesticular lesions. *European Radiology*,  
40 18: 2990-2996.  
41 Not in PICO
- 42 Souchon, R. & Classen, J. (2007) Malignant testicular germ cell tumors: Early stages. [German].  
43 *Onkologe*, 13: 1029-1044.  
44 Narrative review
- 45 Stoop, H., Honecker, F., van de Geijn, G. J., Gillis, A. J., Cools, M. C., de, B. M., Bokemeyer, C.,  
46 Wolffenbittel, K. P., Drop, S. L., de Krijger, R. R., Dennis, N., Summersgill, B., McIntyre, A.,  
47 Shipley, J., Oosterhuis, J. W. & Looijenga, L. H. (2008) Stem cell factor as a novel diagnostic  
48 marker for early malignant germ cells. *Journal of Pathology*, 216: 43-54.  
49 Not in PICO
- 50 Sturgeon, C. M., Duffy, M. J., Stenman, U. H., Lilja, H., Brunner, N., Chan, D. W., Babaian, R., Bast, R.  
51 C., Jr., Dowell, B., Esteva, F. J., Haglund, C., Harbeck, N., Hayes, D. F., Holten-Andersen, M., Klee,

- 1 G. G., Lamerz, R., Looijenga, L. H., Molina, R., Nielsen, H. J., Rittenhouse, H., Semjonow, A., Shih,  
2 I., Sibley, P., Soletormos, G., Stephan, C., Sokoll, L., Hoffman, B. R., Diamandis, E. P. & National  
3 Academy of Clinical Biochemistry (2008) National Academy of Clinical Biochemistry laboratory  
4 medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast,  
5 and ovarian cancers. *Clinical Chemistry*, 54: e11-e79.  
6 Not in PICO
- 7 Teichman, J. M., Weiss, B. D. & Solomon, D. (1999) Urological needs assessment for primary care  
8 practice: implications for undergraduate medical education. *Journal of Urology*, 161: 1282-  
9 1285.  
10 Not in PICO
- 11 Torabi-Pour, N., Nouri, A. M., Perrett, D. & Oliver, R. T. (2000) The combined use of high  
12 performance liquid chromatography and immuno-biochemical techniques for protein isolation:  
13 a new approach for identification of an individual protein from a pool of proteins. *Biomedical*  
14 *Chromatography*, 14: 483-488.  
15 Not in PICO
- 16 Tsili, A. C., Argyropoulou, M. I., Astrakas, L. G., Ntoulia, E. A., Giannakis, D., Sofikitis, N. &  
17 Tsampoulas, K. (2013) Dynamic contrast-enhanced subtraction MRI for characterizing  
18 intratesticular mass lesions. *AJR.American Journal of Roentgenology*, 200: 578-585.  
19 Not in PICO
- 20 van Casteren, N. J., Stoop, H., Dohle, G. R., de, W. R., Oosterhuis, J. W. & Looijenga, L. H. (2008)  
21 Noninvasive detection of testicular carcinoma in situ in semen using OCT3/4. *European Urology*,  
22 54: 153-158.  
23 Not in PICO
- 24 Vasdev, N. & Thorpe, A. C. (2011) Has the introduction of the '2 week rule' in the UK led to an earlier  
25 diagnosis of urological malignancy? *ecancermedicalscience*, 5.  
26 Not in PICO
- 27 Wakat, J. P., Zwicker, C. & Claussen, C. (1988) Scrotal changes in the 3.5 MHz ultrasound image.  
28 [German]. *Rontgen-Blatter; Zeitschrift fur Rontgen-Technik und medizinisch-wissenschaftliche*  
29 *Photographie*, 41: 304-309.  
30 Not available, and doesn't appear to be relevant.
- 31 Wheeler, M. J., Manners, J., Nolan, L., Simmonds, P. D., Hayes, M. C. & Mead, G. M. (2011) The  
32 clinical features and management of testicular germ cell tumours in patients aged 60 years and  
33 older. *BJU International*, 108: 1794-1799.  
34 Not in PICO
- 35 Wiesenthal, J. D., Ettler, H. & Razvi, H. (2004) Testicular epidermoid cyst: a case report and review of  
36 the clinicopathologic features. [Review] [11 refs]. *Canadian Journal of Urology*, 11: 2133-2135.  
37 Not in PICO
- 38 Wilson, C., Boyd, K., Mohammed, A. & Little, B. (2010) A single episode of haematospermia can be  
39 safely managed in the community. *International Journal of Clinical Practice*, 64: 1436-1439.  
40 Not in PICO
- 41 Winstanley, A. M., Mikuz, G., Debryne, F., Schulman, C. C. & Parkinson, M. C. (2004) Handling and  
42 reporting of biopsy and surgical specimens of testicular cancer. *European Urology*, 45: 564-573.  
43 Not in PICO
- 44 Yee, W. S., Kim, Y. S., Kim, S. J., Choi, J. B., Kim, S. I. & Ahn, H. S. (2011) Testicular microlithiasis:  
45 prevalence and clinical significance in a population referred for scrotal ultrasonography. *Korean*  
46 *Journal of Urology*, 52: 172-177.  
47 Not in PICO
- 48 Zengerling, F., Hartmann, M., Heidenreich, A., Kregge, S., Albers, P., Karl, A., Wagner, W., Bedke, J.,  
49 Schmelz, H. U., Retz, M., Kliesch, S., Winter, E., Kuczyk, M. & Schrader, M. (2012) Five years into  
50 the national second-opinion project of the German Testicular Cancer Group (GCTSG): Impact on  
51 guideline implementation and the quality of care for testicular cancer patients. *Journal of*

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11

*Clinical Oncology*, 30.  
Not in PICO  
Zynger, D. L., Dimov, N. D., Luan, C., Teh, B. T. & Yang, X. J. (2006) Glypican 3: a novel marker in testicular germ cell tumors. *American Journal of Surgical Pathology*, 30: 1570-1575.  
Not in PICO  
Zynger, D. L., Everton, M. J., Dimov, N. D., Chou, P. M. & Yang, X. J. (2008) Expression of glypican 3 in ovarian and extragonadal germ cell tumors. *American Journal of Clinical Pathology*, 130: 224-230.  
Not in PICO

**PENILE CANCER****Review question:**

What is the risk of penile cancer in patients presenting in primary care with symptom(s)?

**Results****Literature search**


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	All-2012	298	45	20/09/2012
<i>Premedline</i>	All-2012	3	1	20/09/2012
<i>Embase</i>	All-2012	400	44	20/09/2012
<i>Cochrane Library</i>	All-2012	32	0	21/09/2012
<i>Psychinfo</i>	All-2012	2	0	20/09/2012
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	All-2012	2	0	24/09/2012
<i>Biomed Central</i>	All-2012	52	2	24/09/2012

Total References retrieved (after de-duplication): 76

**Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	9/2012-26/08/2014	25	2	26/08/2014
<i>Premedline</i>	9/2012-26/08/2014	18	1	26/08/2014
<i>Embase</i>	9/2012-26/08/2014	57	2	26/08/2014
<i>Cochrane Library</i>	9/2012-26/08/2014	6	0	26/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	9/2012-26/08/2014	11	0	26/08/2014

Total References retrieved (after de-duplication): 4



1

2 **Study results**

3 No evidence was identified.

4 **References**

5 **Included studies**

6 None

7

8 **Excluded studies (with excl reason)**

9 Information from your family doctor. Penile cancer. American Family Physician 69[3], 617-618. 1-2-  
10 2004.

11 Excl reason: Information leaflet

12 Arya, M., Kalsi, J., Kelly, J. & Muneer, A. (2013) Malignant and premalignant lesions of the penis.  
13 [Review]. *BMJ*, 346: f1149.

14 Narrative review

15 Barbagli, G., Palminteri, E., Mirri, F., Guazzoni, G., Turini, D., and Lazzeri, M. Penile carcinoma in  
16 patients with genital lichen sclerosus: a multicenter survey. *Journal of Urology* 175[4], 1359-  
17 1363. 2006.

18 Excl reason: Not in PICO

19 Barocas, D. A. and Chang, S. S. Penile cancer: clinical presentation, diagnosis, and staging. *Urologic  
20 Clinics of North America* 37[3], 343-352. 2010.

21 Excl reason: Narrative review

22 Bastide, C. [Prevention and screening of penile cancer]. [Review] [44 refs] [French]. *Progres En  
23 Urologie* 13[5:Suppl 2], Suppl-42. 2003.

24 Excl reason: Not in PICO

25 Bigot, P. and Longvert, C. [Penile dermatological lesions: how to identify premalignant lesions?].  
26 [French]. *Progres En Urologie* 21, Suppl-2. 2011.

27 Excl reason: Narrative review

- 1 Bleeker, M. C., Heideman, D. A., Snijders, P. J., Horenblas, S., Dillner, J., and Meijer, C. J. Penile  
2 cancer: epidemiology, pathogenesis and prevention. [Review] [99 refs]. *World Journal of Urology*  
3 27[2], 141-150. 2009.  
4 Excl reason: Narrative review
- 5 Bouchot, O. and Rigaud, J. [Penis tumours: techniques and indications]. [Review] [30 refs] [French].  
6 *Annales d Urologie* 38[6], 285-297. 2004.  
7 Excl reason: Narrative review
- 8 Bradway, C. and Rodgers, J. Evaluation and management of genitourinary emergencies. [Review] [24  
9 refs]. *Nurse Practitioner* 34[5], 36-43. 1943.  
10 Excl reason: Narrative review
- 11 Brady, K. L., Mercurio, M. G. & Brown, M. D. (2013) Malignant tumors of the penis. [Review].  
12 *Dermatologic Surgery*, 39: 527-547.  
13 Narrative review
- 14 Bray, F., Klint, A., Gislum, M., Hakulinen, T., Engholm, G., Tryggvadottir, L., and Storm, H. H. Trends in  
15 survival of patients diagnosed with male genital cancers in the Nordic countries 1964-2003  
16 followed up until the end of 2006. *Acta Oncologica* 49[5], 644-654. 2010.  
17 Excl reason: Not in PICO
- 18 Buechner, S. A. Common skin disorders of the penis. *BJU International* 90[5], 498-506. 2002.  
19 Excl reason: Narrative review
- 20 Cathomas, R., Geldart, T. R., Iveson, T., Singh, N., and Rowen, D. An unusual differential diagnosis of  
21 penile warts: metastases from rectal carcinoma. *International Journal of STD & AIDS* 17[7], 491-  
22 492. 2006.  
23 Excl reason: Not in PICO
- 24 Cherian, Jacob, Rajan, Sreekumar, Thwaini, Ali, Elmasry, Yaser, Shah, Tariq, and Puri, Rajiv.  
25 Secondary penile tumours revisited. *International Seminars in Surgical Oncology* 3[1], 33. 2006.  
26 Excl reason: Not in PICO
- 27 Chiu, T.-Y., Huang, H.-S., Lai, M.-K., Chen, J., Hsieh, T.-S., and Chueh, S.-C. Penile cancer in Taiwan -  
28 20 years' experience at National Taiwan University Hospital. *Journal of the Formosan Medical*  
29 *Association* 97[10], 673-678. 1998.  
30 Excl reason: Not in PICO
- 31 Cottrell, A. M., Dickerson, D., and Oxley, J. D. Suspected penile cancer: a method to improve  
32 handling of pathology specimens. [Review] [3 refs]. *BJU International* 101[10], 1325-1328. 2008.  
33 Excl reason: Not in PICO
- 34 David, N. and Tang, A. Efficacy and safety of penile biopsy in a GUM clinic setting. *International*  
35 *Journal of STD & AIDS* 13[8], 573-576. 2002.  
36 Excl reason: Not in PICO
- 37 Dawson, C. and Whitfield, H. ABC of Urology. Urological emergencies in general practice. [Review] [0  
38 refs]. *BMJ* 312[7034], 838-840. 30-3-1996.  
39 Excl reason: Narrative review
- 40 De Freitas, Calmon M., Babeto, E., Mota, M. T. O., Candido, N. M., Girol, A. P., Oliani, S. M., Bonilha,  
41 J. L., Vassallo, J., and Rahal, P. Differential gene expression and HPV in penile carcinoma. *Cancer*  
42 *Research* 71[8 SUPPL. 1]. 15-4-2011. American Association for Cancer Research Inc.  
43 Excl reason: Not in PICO
- 44 Dechev, I. and Banchev, A. More about the clinical characteristics of penile cancer. [Bulgarian].  
45 *General Medicine* 8[4], 42-46. 2006.  
46 Excl reason: Narrative review
- 47 Demeter, L. M., Stoler, M. H., Bonnez, W., Corey, L., Pappas, P., Strussenberg, J., and Reichman, R. C.  
48 Penile intraepithelial neoplasia: Clinical presentation and an analysis of the physical state of  
49 human papillomavirus DNA. *Journal of Infectious Diseases* 168[1], 38-46. 1993.  
50 Excl reason: Not in PICO

- 1 Descazeaud, A. and Mottet, N. [Cancers of the penis and testicle: news in 2008]. [French]. Progres En  
2 Urologie 18, Suppl-4. 2008.  
3 Excl reason: Not in PICO
- 4 Ficarra, V., Martignoni, G., Maffei, N., Cerruto, M. A., Novara, G., Cavalleri, S., and Artibani, W.  
5 Predictive pathological factors of lymph nodes involvement in the squamous cell carcinoma of  
6 the penis. International Urology and Nephrology 34[2], 245-250. 2002.  
7 Excl reason: Not in PICO
- 8 Ficarra, V., Zattoni, F., Artibani, W., Fandella, A., Martignoni, G., Novara, G., Galetti, T. P., Zambolin,  
9 T., and Kattan, M. W. Nomogram Predictive of Pathological Inguinal Lymph Node Involvement in  
10 Patients With Squamous Cell Carcinoma of the Penis. Journal of Urology 175[5], 1700-1705.  
11 2006.  
12 Excl reason: Not in PICO
- 13 Fossa, S. D., Jones, W. G., Hamers, H. P., and van den Bogaert, W. Penile cancer. [Norwegian].  
14 Tidsskrift for Den Norske Laegeforening 110[11], 1354-1356. 30-4-1990.  
15 Excl reason: Narrative review
- 16 Fraley, E. E., Zhang, G., Sazama, R., and Lange, P. H. Cancer of the penis. Prognosis and treatment  
17 plans. Cancer 55[7], 1618-1624. 1985.  
18 Excl reason: Not in PICO
- 19 Giannakopoulos, X., Basioukas, K., Dimou, S., and Agnantis, N. Squamous cell carcinoma of the penis  
20 arising from balanitis xerotica obliterans. International Urology & Nephrology 28[2], 223-227.  
21 1996.  
22 Excl reason: Not in PICO
- 23 Gingu, C., Patrascioiu, S., Surcel, C., Chibeleian, C., Harza, M. C., Zogas, V., Balsanu, C., Dick, A.,  
24 Mirvald, C., Lupu, F., Domnisor, L., and Sinescu, I. Primary carcinoma of the male urethra -  
25 Diagnosis and treatment. European Urology, Supplements 10[9], 626. 2011. Elsevier.  
26 Excl reason: Not in PICO
- 27 Grossman, H. B. Premalignant and early carcinomas of the penis and scrotum. Urologic Clinics of  
28 North America 19[2], 221-226. 1992.  
29 Excl reason: Narrative review
- 30 Gulia, A. K., Mandhani, A., Muruganandham, K., Kapoor, R., Ansari, M. S., and Srivastava, A. Impact  
31 of delay in inguinal lymph node dissection in patients with carcinoma of penis. Indian Journal of  
32 Cancer 46[3], 214-218. 2009.  
33 Excl reason: Not in PICO
- 34 Gutierrez, C., Hernansanz, S., Rubiales, A. S., Del Valle, M. L., Cuadrillero, Rodriguez F., Flores, L. A.,  
35 and Garcia, C. Clinical manifestations and care in tumors with pelvic involvement: Is there a  
36 pelvic syndrome in Palliative Care?. [Spanish]. Medicina Paliativa 13[1], 32-36. 2006.  
37 Excl reason: Not in PICO
- 38 Harzmann, R. Early diagnosis of urogenital tumors. [German]. Zeitschrift fur Hautkrankheiten 62[9],  
39 665-682. 1-5-0681.  
40 Excl reason: Narrative review
- 41 Hawary, A. M., Warburton, H. E., Brough, R. J., Collins, G. N., Brown, S. C., O'Reilly, P. H., and  
42 Adeyoju, A. A. B. The '2-week wait' rule for referrals for suspected urological cancers - Urgent  
43 need for refinement of criteria. Annals of the Royal College of Surgeons of England 90[6], 517-  
44 522. 2008.  
45 Excl reason: Not in PICO
- 46 Horenblas, S., Jansen, L., Meinhardt, W., Hoefnagel, C. A., De Jong D., and Nieweg, O. E. Detection of  
47 occult metastasis in squamous cell carcinoma of the penis using a dynamic sentinel node  
48 procedure. Journal of Urology 163[1], 100-104. 2000.  
49 Excl reason: Not in PICO

- 1 Inoue, T., Satou, M., Morii, H., and Matsuda, T. [Schwannoma of the penis: a case report]. [Review]  
2 [17 refs] [Japanese]. *Hinyokika Kiyo - Acta Urologica Japonica* 54[8], 569-572. 2008.  
3 Excl reason: Not in PICO
- 4 Jones, W. G., Fossa, S. D., Hamers, H., and van den Bogaert, W. Penis cancer: A review by the joint  
5 radiotherapy committee of the European Organisation for Research and Treatment of Cancer  
6 (EORTC) Genitourinary and Radiotherapy Groups. *Journal of Surgical Oncology* 40[4], 227-231.  
7 1989.  
8 Excl reason: Narrative review
- 9 Kamat, A. M., Carpenter, S. M., Czerniak, B. A., and Pisters, L. L. Metastatic penile cancer in a young  
10 Caucasian male: impact of delayed diagnosis. *Urologic Oncology* 23[2], 130-131. 2005.  
11 Excl reason: Not in PICO
- 12 Karanikas, Christos, Ptohis, Nikolaos, Mainta, Evgenia, Baltas, Christos, Athanasiadis, Dimitris,  
13 Lechareas, Simos, Katirtzoglou, Nikolaos, and Xynogalos, Spyros. Pulmonary adenocarcinoma  
14 presenting with penile metastasis: a case report. *Journal of Medical Case Reports* 6[1], 252.  
15 2012.  
16 Excl reason: Not in PICO
- 17 Kattan, M. W., Ficarra, V., Artibani, W., Cunico, S. C., Fandella, A., Martignoni, G., Novara, G., Galetti,  
18 T. P., and Zattoni, F. Nomogram Predictive of Cancer Specific Survival in Patients Undergoing  
19 Partial or Total Amputation for Squamous Cell Carcinoma of the Penis. *Journal of Urology* 175[6],  
20 2103-2108. 2006.  
21 Excl reason: Not in PICO
- 22 Katz, A. The top 13: What family physicians should know about prostate cancer. *Canadian Family*  
23 *Physician* 54[2], 198-203. 2008.  
24 Excl reason: Not in PICO
- 25 Kohn, F. M. [Skin changes of the penis. Differentiation between local findings and systemic  
26 diseases!]. [German]. *MMW Fortschritte der Medizin* 144[12], 30-32. 1934.  
27 Excl reason: Narrative review
- 28 Kreuter, A., Brockmeyer, N. H., Weissenborn, S. J., Gambichler, T., Stucker, M., Altmeyer, P., Pfister,  
29 H., Wieland, U., and German Competence Network HIV/AIDS. Penile intraepithelial neoplasia is  
30 frequent in HIV-positive men with anal dysplasia. *Journal of Investigative Dermatology* 128[9],  
31 2316-2324. 2008.  
32 Excl reason: Not in PICO
- 33 Kumar, P., Singh, S., Goddard, J. C., Terry, T. R., and Summerton, D. J. The development of a  
34 supraregional network for the management of penile cancer. *Annals of the Royal College of*  
35 *Surgeons of England* 94[3], 204-209. 2012.  
36 Excl reason: Not in PICO
- 37 Leslie, J. A. and Cain, M. P. Pediatric Urologic Emergencies and Urgencies. *Pediatric Clinics of North*  
38 *America* 53[3], 513-527. 2006.  
39 Excl reason: Narrative review
- 40 Lont, A. P., Kroon, B. K., Horenblas, S., Gallee, M. P., Berkhof, J., Meijer, C. J., and Snijders, P. J.  
41 Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable  
42 outcome in survival. *International Journal of Cancer* 119[5], 1078-1081. 1-9-2006.  
43 Excl reason: Not in PICO
- 44 Lucky, M. A., Rogers, B., and Parr, N. J. Referrals into a dedicated British penile cancer centre and  
45 sources of possible delay. *Sexually Transmitted Infections* 85[7], 527-530. 2009.  
46 Excl reason: Not in PICO
- 47 Lutterbach, J., Pagenstecher, A., Weyerbrock, A., Schultze-Seemann, W., and Waller, C. F. Early-stage  
48 penile carcinoma metastasizing to brain: case report and literature review. [Review] [15 refs].  
49 *Urology* 66[2], 432. 2005.  
50 Excl reason: Not in PICO



- 1 Markos, A. R. The presentation of anogenital cancers as sexually transmissible infection: a case for  
2 vigilance. *Sexual Health* 4[1], 79-80. 2007.  
3 Excl reason: Narrative review
- 4 Mebel, M. and Vogler, H. Special problems of early detection of malignant tumors of the genito-  
5 urinary system. [German]. *Archiv fur Geschwulstforschung* 51[8], 679-684. 1981.  
6 Excl reason: Not in PICO
- 7 Minevich, E. Genitourinary emergencies in children. *Minerva Pediatrica* 61[1], 53-65. 2009.  
8 Excl reason: Narrative review
- 9 Misra, S., Chaturvedi, A., and Misra, N. C. Penile carcinoma: A challenge for the developing world.  
10 *Lancet Oncology* 5[4], 240-247. 1-4-2004.  
11 Excl reason: Narrative review
- 12 Miyamoto, T., Ikehara, A., Araki, M., Akaeda, T., and Mihara, M. Cutaneous metastatic carcinoma of  
13 the penis: suspected metastasis implantation from a bladder tumor. *Journal of Urology* 163[5],  
14 1519. 2000.  
15 Excl reason: Not in PICO
- 16 Moiyadi, A. V., Tongaonkar, H. B., and Bakshi, G. K. Symptomatic intracranial metastasis in penile  
17 carcinoma. *Indian Journal of Urology* 26[4], 585-586. 2010.  
18 Excl reason: Not in PICO
- 19 Mosconi, A. M., Roila, F., Gatta, G., and Theodore, C. Cancer of the penis. [Review] [98 refs]. *Critical*  
20 *Reviews in Oncology-Hematology* 53[2], 165-177. 2005.  
21 Excl reason: Narrative review
- 22 Naumann, C. M., Filippow, N., Seif, C., van der Horst, C., Roelver, L., Braun, P. M., Juenemann, K. P.,  
23 and Portillo, F. J. Penile carcinoma (pT1 G2): surveillance or inguinal lymph node dissection?  
24 *Onkologie* 28[3], 135-138. 2005.  
25 Excl reason: Not in PICO
- 26 Palamaras, I., Hamill, M., Sethi, G., Wilkinson, D., and Lamba, H. The usefulness of a diagnostic  
27 biopsy clinic in a genitourinary medicine setting: recent experience and a review of the  
28 literature. [Review] [21 refs]. *Journal of the European Academy of Dermatology & Venereology*  
29 20[8], 905-910. 2006.  
30 Excl reason: Not in PICO
- 31 Persaud, S., Sebro, K., Saroop, S. & Goetz, L. (2012) Urethral cancer: A difficult diagnosis? *West*  
32 *Indian Medical Journal*, 61: 52.  
33 Not in PICO
- 34 Piccinelli, A., Romano, C., Ranieri, A., Chinaglia, D., and Lembo, A. [Precancerous lesions of the  
35 penis]. [Italian]. *Archivio Italiano di Urologia, Andrologia* 68[3], 133-135. 1996.  
36 Excl reason: Narrative review
- 37 Ritchie, A. W., Foster, P. W., Fowler, S., and BAUS Section of Oncology. Penile cancer in the UK:  
38 clinical presentation and outcome in 1998/99. *BJU International* 94[9], 1248-1252. 2004.  
39 Excl reason: Not in PICO
- 40 Rotolo, J. E. and Lynch, J. H. Penile cancer: Curable with early detection. *Hospital Practice* 26[6], 131-  
41 138. 1991.  
42 Excl reason: Narrative review
- 43 Rubben, H., Hering, F. J., Durben, G., and Lutzeyer, W. Value of screening for early detection of  
44 urological tumors (author's transl). [German]. *Urologia Internationalis* 37[1], 1-18. 1982.  
45 Excl reason: Not in PICO
- 46 Schoeneich, G. and Bruhl, P. Penile carcinoma. [German]. *Tumor Diagnostik und Therapie* 15[5], 163-  
47 167. 1994.  
48 Excl reason: Narrative review
- 49 Shigehara, K.; Sasagawa, T.; Kawaguchi, S.; Nakashima, K.; Nakashima, T.; Shimamura, M.;  
50 Furubayashi, K.; Namiki, M. (2014). Cytological evaluation using liquid-based cytology in the male  
51 urogenital tract infected with human papillomavirus. *Diagnostic Cytopathology*, 42, 491-7.

- 1 Not in PICO
- 2 Shim, T. N., Muneer, A., and Bunker, C. B. Chronic erosive and verrucous herpes simplex of the penis  
3 in chronic lymphocytic leukaemia. *British Journal of Dermatology* 167, 115-116. 2012. Blackwell  
4 Publishing Ltd.
- 5 Excl reason: Not in PICO
- 6 Siow, W. Y. and Cheng, C. Penile cancer: current challenges. [Review] [83 refs]. *Canadian Journal of*  
7 *Urology* 12, Suppl-23. 2005.
- 8 Excl reason: Narrative review
- 9 Sonpavde, G., Pagliaro, L. C., Buonerba, C., Dorff, T. B., Lee, R. J. & Di, L. G. (2013) Penile cancer:  
10 current therapy and future directions. [Review]. *Annals of Oncology*, 24: 1179-1189.
- 11 Narrative review
- 12 Spiess, P. E. & National Comprehensive, C. N. (2013) New treatment guidelines for penile cancer.  
13 *Journal of the National Comprehensive Cancer Network*, 11: Suppl-62.
- 14 Not in PICO
- 15 Stehr, M., Rohrbach, H., Schuster, T., and Dietz, H. G. [Leiomyoma of the glans penis]. [German].  
16 *Urologe (Ausg.A)* 39[2], 171-173. 2000.
- 17 Excl reason: Not in PICO
- 18 Stotts, R. C. Cancers of the prostate, penis, and testicles: epidemiology, prevention, and treatment.  
19 [Review] [83 refs]. *Nursing Clinics of North America* 39[2], 327-340. 2004.
- 20 Excl reason: Narrative review
- 21 Teichman, J. M., Sea, J., Thompson, I. M., and Elston, D. M. Noninfectious penile lesions. [Review]  
22 [49 refs]. *American Family Physician* 81[2], 167-174. 15-1-2010.
- 23 Excl reason: Narrative review
- 24 Theiss, M., Tack, W., and Frohmuller, H. Screening examination for urological malignancies.  
25 [German]. *Medizinische Welt* 47[12], 493-497. 1996.
- 26 Excl reason: Not in PICO
- 27 Tsauro, I., Ochsendorf, F. R., Bug, R., and Jonas, D. [Primary syphilitic lesion mimicking penile cancer.  
28 Atypical manifestation with an unconventional diagnostic approach]. [German]. *Urologe*  
29 *(Ausg.A)* 48[10], 1210-1213. 2009.
- 30 Excl reason: Not in PICO
- 31 Tsen, H. F., Morgenstern, H., Mack, T., and Peters, R. K. Risk factors for penile cancer: results of a  
32 population-based case-control study in Los Angeles County (United States). *Cancer Causes &*  
33 *Control* 12[3], 267-277. 2001.
- 34 Excl reason: Not in PICO
- 35 Urrutia, Alonso J., Machuca, Santacruz J., Tallada, Bunuel M., Moreno, Jimenez J., Vicente, Prados J.,  
36 Cozar Olmo, J. M., and Camara, Ortega M. [Epidermoid carcinoma of the male urethra. Our  
37 experience in 5 cases]. [Review] [25 refs] [Spanish]. *Archivos Espanoles de Urologia* 48[4], 355-  
38 363. 1995.
- 39 Excl reason: Not in PICO
- 40 Vasdev, N. and Thorpe, A. C. Has the introduction of the '2 week rule' in the UK led to an earlier  
41 diagnosis of urological malignancy? *ecancermedicalscience* 5[1]. 31-8-2011.
- 42 Excl reason: Not in PICO
- 43 Vincent, M. V. and Mackinnon, E. The response of clinical balanitis xerotica obliterans to the  
44 application of topical steroid-based creams. *Journal of Pediatric Surgery* 40[4], 709-712. 2005.
- 45 Excl reason: Not in PICO
- 46 Vogt, H., Schmidt, M., Bares, R., Brenner, W., Grunwald, F., Kopp, J., Reiners, C., Schober, O.,  
47 Schumichen, C., Schicha, H., Sciuk, J., Sudbrock, F., and Wengenmair, H. [Procedure guideline for  
48 sentinel lymph node diagnosis]. [German]. *Nuclear-Medizin* 49[4], 167-172. 2010.
- 49 Excl reason: Not in PICO
- 50 Wessels, R., De Bruin, D. M., Faber, D. J., Horenblas, S., Van Rhijn, B. W. G., Vincent, A. D., Van  
51 Leeuwen, T. G. & Ruers, T. J. M. (2013) Optical coherence tomography (OCT) in neoplasia of the

1 penis. *European Journal of Cancer*, 49: S249.

2 Published as poster abstract only. Not enough information can be extracted to ascertain  
3 relevance, but I think it is not in PICO

4 Willson, P. Testicular, prostate and penile cancers in primary care settings: the importance of early  
5 detection. *The Nurse practitioner* 16[11], 18-26. 1991.

6 Excl reason: Narrative review

7 Wood, S. A guide to common conditions of the penis. [Review] [0 refs]. *Practitioner* 244[1614], 764-  
8 770. 2000.

9 Excl reason: Not in PICO

10 Wren, T. Penile and testicular disorders. [Review] [30 refs]. *Nursing Clinics of North America* 39[2],  
11 319-326. 2004.

12 Excl reason: Narrative review

13 Yao, H. J., Ying, J., Wang, Z., Yao, D. H., Ren, X. M., and Bao, Y. Y. [One case report of primary penile  
14 malignant lymphoma (with a review of 24 case reports)]. [Chinese]. *Zhong Hua Nan Ke Xue*  
15 12[6], 520-524. 20-11-0157.

16 Excl reason: Not in PICO

17 Zimet, G., Weiss, T., Rosenthal, S., Brennenman, S., and Klein, J. Physicians' sexual health discussions  
18 with adolescent males and attitudes about HPV vaccination. *Journal of Adolescent Health* 48[2  
19 SUPPL. 1], S27-S28. 2011. Elsevier USA.

20 Excl reason: Not in PICO

## 22 Review question:

23 Which investigations of symptoms of suspected penile cancer should be done with clinical  
24 responsibility retained by primary care?

## 26 Results

### 27 Literature search

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
Medline	1980-2013	85	31	14/05/2013
Premedline	1980-2013	14	2	14/05/2013
Embase	1980-2013	122	25	14/05/2013
Cochrane Library	1980-2013	32	0	14/05/2013
Psychinfo	1980-2013	0	0	14/05/2013
Web of Science (SCI & SSCI) and ISI Proceedings	1980-2013	23	0	14/05/2013

28 Total References retrieved (after de-duplication): 43


### 30 Update Search

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<b>Medline</b>	5/2013-26/08/2014	4	2	26/08/2014
<b>Premedline</b>	5/2013-26/08/2014	5	0	26/08/2014
<b>Embase</b>	5/2013-26/08/2014	25	2	26/08/2014
<b>Cochrane Library</b>	5/2013-26/08/2014	2	0	26/08/2014
<b>Web of Science (SCI &amp;</b>	5/2013-	1	0	26/08/2014

<b>SSCI) and ISI Proceedings</b>	26/08/2014			
----------------------------------	------------	--	--	--

1 Total References retrieved (after de-duplication): 3

2



3

#### 4 Study results

5 No evidence was identified pertaining to the diagnostic accuracy of tests used in patients with  
6 suspected penile cancer where the clinical responsibility was retained by primary care.

7

#### 8 References

##### 9 Included studies

10 None

11

##### 12 Excluded studies (with excl reason)

13 Arya, M., Kalsi, J., Kelly, J. & Muneer, A. (2013) Malignant and premalignant lesions of the penis.  
14 [Review]. *BMJ*, 346: f1149.

15 Narrative review

16 Azevedo Cavalcanti, R. F., Quirino, R., Monnerat, L. F., Ornellas, A. A. & Arcuri, R. (2004) Merkel cell  
17 carcinoma of penis. [French]. *Progres En Urologie*, 14: 558-560.

18 Not in PICO

19 Barbagli, G., Palminteri, E., Mirri, F., Guazzoni, G., Turini, D. & Lazzeri, M. (2006) Penile carcinoma in  
20 patients with genital lichen sclerosus: A multicenter survey. *Journal of Urology*, 175: 1359-1363.

21 Not in PICO

22 Barocas, D. A. & Chang, S. S. (2010) Penile Cancer: Clinical Presentation, Diagnosis, and Staging.  
23 *Urologic Clinics of North America*, 37: 343-352.

24 Narrative review

25 Bhagat, S. K., Gopalakrishnan, G., Kekre, N. S., Chacko, N. K., Kumar, S., Manipadam, M. T. & Samuel,  
26 P. (2010) Factors predicting inguinal node metastasis in squamous cell cancer of penis. *World  
27 Journal of Urology*, 28: 93-98.

28 Not in PICO

- 1 Bigot, P. & Longvert, C. (2011) [Penile dermatological lesions: how to identify premalignant lesions?].  
 2 [French]. *Progres en urologie : journal de l'Association francaise d'urologie et de la Societe*  
 3 *francaise d'urologie*, 21: S50-S52.  
 4 Not in PICO
- 5 Bleeker, M. C., Heideman, D. A., Snijders, P. J., Horenblas, S., Dillner, J. & Meijer, C. J. (2009) Penile  
 6 cancer: epidemiology, pathogenesis and prevention. [Review] [99 refs]. *World Journal of*  
 7 *Urology*, 27: 141-150.  
 8 Not in PICO
- 9 Bouchot, O. & Rigaud, J. (2004) [Penis tumours: techniques and indications]. [Review] [30 refs]  
 10 [French]. *Annales d Urologie*, 38: 285-297.  
 11 Narrative review
- 12 Brady, K. L., Mercurio, M. G. & Brown, M. D. (2013) Malignant tumors of the penis. [Review].  
 13 *Dermatologic Surgery*, 39: 527-547.  
 14 Narrative review
- 15 Buechner, S. A. (2002) Common skin disorders of the penis. [Review] [39 refs]. *BJU International*, 90:  
 16 498-506.  
 17 Not in PICO
- 18 Chiu, T.-Y., Huang, H.-S., Lai, M.-K., Chen, J., Hsieh, T.-S. & Chueh, S.-C. (1998) Penile cancer in  
 19 Taiwan - 20 years' experience at National Taiwan University Hospital. *Journal of the Formosan*  
 20 *Medical Association*, 97: 673-678.  
 21 Not in PICO
- 22 Cho, Y. S., Lee, J. A., Kim, S. B., Gong, S. J., Kim, J. H., Youn, S. M. & Kim, E. T. (2010) A case of  
 23 synchronous double primary cancer of the penis and urinary bladder. *Cancer Research &*  
 24 *Treatment*, 42: 53-56.  
 25 Not in PICO
- 26 Cottrell, A. M., Dickerson, D. & Oxley, J. D. (2008) Suspected penile cancer: A method to improve  
 27 handling of pathology specimens. *BJU International*, 101: 1325-1328.  
 28 Not in PICO
- 29 David, N. & Tang, A. (2002) Efficacy and safety of penile biopsy in a GUM clinic setting. *International*  
 30 *Journal of STD and AIDS*, 13: 573-576.  
 31 Not in PICO
- 32 Dechev, I. & Banchev, A. (2006) More about the clinical characteristics of penile cancer. [Bulgarian].  
 33 *General Medicine*, 8: 42-46.  
 34 Not in PICO
- 35 Descazeaud, A. & Mottet, N. (2008) Cancers of the penis and testicle: news in 2008. [French].  
 36 *Progres En Urologie*, 18: S130-S134.  
 37 Narrative review
- 38 Eliezri, Y. D. (1988) The toluidine blue test: an aid in the diagnosis and treatment of early squamous  
 39 cell carcinomas of mucous membranes. *Journal of the American Academy of Dermatology*, 18:  
 40 1339-1349.  
 41 Narrative review
- 42 Ficarra, V., Zattoni, F., Artibani, W., Fandella, A., Martignoni, G., Novara, G., Galetti, T. P., Zambolin,  
 43 T., Kattan, M. W. & Penile Cancer Project Members, U. O. N. E. (1704) Nomogram predictive of  
 44 pathological inguinal lymph node involvement in patients with squamous cell carcinoma of the  
 45 penis. *Journal of Urology*, 175: 1700-1704.  
 46 Not in PICO
- 47 Ficarra, V., Martignoni, G., Maffei, N., Cerruto, M. A., Novara, G., Cavalleri, S. & Artibani, W. (2002)  
 48 Predictive pathological factors of lymph nodes involvement in the squamous cell carcinoma of  
 49 the penis. *International Urology and Nephrology*, 34: 245-250.  
 50 Not in PICO

- 1 Gipponi, M. (2005) Clinical applications of sentinel lymph-node biopsy for the staging and treatment  
2 of solid neoplasms. [Review] [99 refs]. *Minerva Chirurgica*, 60: 217-233.  
3 Not in PICO
- 4 Hawary, A. M., Warburton, H. E., Brough, R. J., Collins, G. N., Brown, S. C., O'Reilly, P. H. & Adeyoku,  
5 A. A. B. (2008) The '2-week wait' rule for referrals for suspected urological cancers - Urgent  
6 need for refinement of criteria. *Annals of the Royal College of Surgeons of England*, 90: 517-522.  
7 Not in PICO
- 8 Horenblas, S., Jansen, L., Meinhardt, W., Hoefnagel, C. A., de, J. D. & Nieweg, O. E. (2000) Detection  
9 of occult metastasis in squamous cell carcinoma of the penis using a dynamic sentinel node  
10 procedure. *Journal of Urology*, 163: 100-104.  
11 Not in PICO
- 12 Jakobsen, J., Ording, O. K., Egbert Arnold, Z. K. & Bjerggaard, J. J. (2012) Sources of delay to a penile  
13 cancer referral centre in West Denmark. *Urology*, 80: S265-S266.  
14 Not in PICO
- 15 Kirrander, P., Andren, O. & Windahl, T. (2013) Dynamic sentinel node biopsy in penile cancer: initial  
16 experiences at a Swedish referral centre. *BJU International*, 111: t-53.  
17 Not in PICO
- 18 Kumar, P., Singh, S., Goddard, J. C., Terry, T. R. & Summerton, D. J. (2012) The development of a  
19 supraregional network for the management of penile cancer. *Annals of the Royal College of  
20 Surgeons of England*, 94: 204-209.  
21 Not in PICO
- 22 Luciani, L., Pisciolli, F., Scappini, P. & Pusioli, T. (1984) Value and role of percutaneous regional node  
23 aspiration cytology in the management of penile carcinoma. *European Urology*, 10: 294-302.  
24 Narrative review
- 25 Minevich, E. (2009) Genitourinary emergencies in children. *Minerva Pediatrica*, 61: 53-65.  
26 Narrative review
- 27 Mosconi, A. M., Roila, F., Gatta, G. & Theodore, C. (2005) Cancer of the penis. *Critical Reviews in  
28 Oncology/Hematology*, 53: 165-177.  
29 Narrative review
- 30 Nicolai, N. (2013) Has dynamic sentinel node biopsy achieved its top performance in penile cancer?  
31 What clinicians still need to manage lymph nodes in early stage penile cancer. *European  
32 Urology*, 63: 664-666.  
33 Not in PICO
- 34 Palamaras, I., Hamill, M., Sethi, G., Wilkinson, D. & Lamba, H. (2006) The usefulness of a diagnostic  
35 biopsy clinic in a genitourinary medicine setting: recent experience and a review of the  
36 literature. [Review] [21 refs]. *Journal of the European Academy of Dermatology & Venereology*,  
37 20: 905-910.  
38 Not in PICO
- 39 Persaud, S., Sebro, K., Saroop, S. & Goetz, L. (2012) Urethral cancer: A difficult diagnosis? *West  
40 Indian Medical Journal*, 61: 52.  
41 Not in PICO
- 42 Ritchie, A. W., Foster, P. W., Fowler, S. & BAUS Section of Oncology (2004) Penile cancer in the UK:  
43 clinical presentation and outcome in 1998/99. *BJU International*, 94: 1248-1252.  
44 Not in PICO
- 45 Rotolo, J. E. & Lynch, J. H. (1991) Penile cancer: curable with early detection. [Review] [10 refs].  
46 *Hospital Practice (Office Edition)*, 26: 131-138.  
47 Narrative review
- 48 Saisorn, I., Lawrentschuk, N., Leewansangtong, S. & Bolton, D. M. (2006) Fine-needle aspiration  
49 cytology predicts inguinal lymph node metastasis without antibiotic pretreatment in penile  
50 carcinoma. *BJU International*, 97: 1225-1228.  
51 Not in PICO

- 1 Scher, B., Seitz, M., Reiser, M., Hungerhuber, E., Hahn, K., Tiling, R., Herzog, P., Reiser, M., Schneede,  
2 P. & Dresel, S. (2005) 18F-FDG PET/CT for staging of penile cancer. *Journal of Nuclear Medicine*,  
3 46: 1460-1465.  
4 Not in PICO
- 5 Schoeneich, G. & Bruhl, P. (1994) Penile carcinoma. [German]. *Tumor Diagnostik und Therapie*, 15:  
6 163-167.  
7 Narrative review
- 8 Shim, T. N., Muneer, A. & Bunker, C. B. (2012) Chronic erosive and verrucous herpes simplex of the  
9 penis in chronic lymphocytic leukaemia. *British Journal of Dermatology*, 167: 115-116.  
10 Not in PICO
- 11 Siow, W. Y. & Cheng, C. (2005) Penile cancer: current challenges. *The Canadian journal of urology*,  
12 12: 18-23.  
13 Narrative review
- 14 Skeppner, E., Andersson, S.-O., Johansson, J.-E. & Windahl, T. (2012) Initial symptoms and delay in  
15 patients with penile carcinoma. *Scandinavian Journal of Urology and Nephrology*, 46: 319-325.  
16 Not in PICO
- 17 Sonpavde, G., Pagliaro, L. C., Buonerba, C., Dorff, T. B., Lee, R. J. & Di, L. G. (2013) Penile cancer:  
18 current therapy and future directions. [Review]. *Annals of Oncology*, 24: 1179-1189.  
19 Narrative review
- 20 Spiess, P. E. & National Comprehensive, C. N. (2013) New treatment guidelines for penile cancer.  
21 *Journal of the National Comprehensive Cancer Network*, 11: Suppl-62.  
22 Not in PICO
- 23 Teichman, J. M., Sea, J., Thompson, I. M. & Elston, D. M. (2010) Noninfectious penile lesions.  
24 [Review] [49 refs]. *American Family Physician*, 81: 167-174.  
25 Narrative review
- 26 Vasdev, N. & Thorpe, A. C. (2011) Has the introduction of the '2 week rule' in the UK led to an earlier  
27 diagnosis of urological malignancy? *ecancermedicalscience*, 5.  
28 Not in PICO
- 29 Vogt, H., Schmidt, M., Bares, R., Brenner, W., Grunwald, F., Kopp, J., Reiners, C., Schober, O.,  
30 Schumichen, C., Schicha, H., Sciuk, J., Sudbrock, F. & Wengenmair, H. (2010) [Procedure  
31 guideline for sentinel lymph node diagnosis]. [German]. *Nuclear-Medizin*, 49: 167-172.  
32 Narrative review
- 33 Wajzman, Z. & Klimberg, I. (1987) Needle aspiration and needle biopsy procedures. *Urologic Clinics*  
34 *of North America*, 14: 103-113.  
35 Narrative review
- 36 Wawroschek, F., Harzmann, R. & Weckermann, D. (2005) [Value of sentinel node biopsy for  
37 urological tumors]. [Review] [15 refs] [German]. *Urologe (Ausg.A)*, 44: 630-634.  
38 Narrative review
- 39 Wessels, R., De Bruin, D. M., Faber, D. J., Horenblas, S., Van Rhijn, B. W. G., Vincent, A. D., Van  
40 Leeuwen, T. G. & Ruers, T. J. M. (2013) Optical coherence tomography (OCT) in neoplasia of the  
41 penis. *European Journal of Cancer*, 49: S249.  
42 Published as poster abstract only. Not enough information can be extracted to ascertain  
43 relevance, but I think it is not in PICO
- 44 Willson, P. (1923) Testicular, prostate and penile cancers in primary care settings: the importance of  
45 early detection. *The Nurse practitioner*, 16: 18-26.  
46 Narrative review  
47  
48

**SKIN CANCERS****MALIGNANT MELANOMA****Review question:**

What is the risk of malignant melanoma in patients presenting in primary care with symptom(s)?

**Results****Literature search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1980-2013	1403	49	08/04/2013
<i>Premedline</i>	1980-2013	50	1	08/04/2013
<i>Embase</i>	1980-2013	2470	47	09/04/2013
<i>Cochrane Library</i>	1980-2013	199	7	09/04/2013
<i>Psychinfo</i>	1980-2013	10	0	08/04/2013
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	1980-2013	275	23	09/04/2013


Total References retrieved (after de-duplication): 101

**Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	4/2013-19/08/2014	39	7	19/08/2014
<i>Premedline</i>	4/2013-19/08/2014	70	6	19/08/2014
<i>Embase</i>	4/2013-19/08/2014	184	11	19/08/2014
<i>Cochrane Library</i>	4/2013-19/08/2014	224	0	19/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	4/2013	162	3	19/08/2014

Total References retrieved (after de-duplication): 19





1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11

**Risk of bias in the included studies**

The risk of bias and applicability concerns are summarised per study in the figure below. The main bias risks and applicability concerns that the studies are subject to relate to (1) the patient sampling method not clearly being consecutive or random, (2) the extent to which the study setting matches UK primary care, (3) the quality of the reference standard, which may not always reliably diagnose the symptoms, (4) the fact that the reference standard did not in all cases match that of the current question, namely histology, and 5) data missing .

	Risk of Bias				Applicability Concerns		
	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard
Emery (2010)	?	+	?	+	?	+	?
Walter (2012; 2013)	?	+	?	?	+	+	?

High	Unclear	Low
------	---------	-----

12  
13  
14  
15  
16  
17

**Study results**

Table 1: Melanoma: Study results.

Study	Symptom(s)	Patient group	Positive predictive value % (95% CI) Prevalence
Emery (2010)	Pigmented lesion	All included	1.4 (0.8-2.3)

Lesion-based analysis		patients	17/1211
		England sample	0.8 (0.3-2) 5/630
		Australia sample	1.9 (1-3.5) 11/581
Walter (2012) Lesion-based analysis	Suspicious pigmented lesions	All included patients	2.3 (1.6-3.2) 36/1573
Walter (2013) Lesion-based analysis	7PCL: Suspicious pigmented lesions: Change in size of lesion	All included patients	3.8 (2.5-5.5) 26/693
Walter (2013) Lesion-based analysis	7PCL: Suspicious pigmented lesions: Irregular pigmentation	All included patients	4.4 (3.1-6.3) 31/702
Walter (2013) Lesion-based analysis	7PCL: Suspicious pigmented lesions: Irregular border	All included patients	5.1 (3.4-7.5) 25/492
Walter (2013) Lesion-based analysis	7PCL: Suspicious pigmented lesions: Inflammation	All included patients	4.5 (1.9-10.1) 6/132
Walter (2013) Lesion-based analysis	7PCL: Suspicious pigmented lesions: Itch or altered sensation	All included patients	2.3 (1.1-4.4) 9/397
Walter (2013) Lesion-based analysis	7PCL: Suspicious pigmented lesions: Lesion larger than other (diameter > 7 mm)	All included patients	3.9 (2.6-5.7) 27/695
Walter (2013) Lesion-based analysis	7PCL: Suspicious pigmented lesions: Oozing/crusting of lesion	All included patients	4.9 (2.1-10.1) 7/144
Walter (2013) Lesion-based analysis	Original 7PCL: Score $\geq$ 1*	All included patients	2.7 (1.9-3.8) 36/1334
Walter (2013) Lesion-based analysis	Original 7PCL: Score $\geq$ 2*	All included patients	3.3 (2.4-4.7) 34/1016
Walter (2013) Lesion-based analysis	Original 7PCL: Score $\geq$ 3*	All included patients	5.1 (3.5-7.4) 29/565
Walter (2013) Lesion-based analysis	Original 7PCL: Score $\geq$ 4*	All included patients	8.2 (5.2-12.5) 20/245

Lesion-based analysis			
Walter (2013) Lesion-based analysis	Original 7PCL: Score $\geq$ 5*	All included patients	12.3 (6.1-22.6) 9/73
Walter (2013) Lesion-based analysis	Original 7PCL: Score $\geq$ 6*	All included patients	10.5 (1.8-34.5) 2/19
Walter (2013) Lesion-based analysis	Weighted 7PCL: Score $\geq$ 1**	All included patients	2.7 (1.9-3.8) 36/1334
Walter (2013) Lesion-based analysis	Weighted 7PCL: Score $\geq$ 2**	All included patients	2.9 (2.1-4.1) 36/1221
Walter (2013) Lesion-based analysis	Weighted 7PCL: Score $\geq$ 3**	All included patients	3.4 (2.4-4.8) 33/969
Walter (2013) Lesion-based analysis	Weighted 7PCL: Score $\geq$ 4**	All included patients	4.8 (3.4-6.8) 33/685
Walter (2013) Lesion-based analysis	Weighted 7PCL: Score $\geq$ 5**	All included patients	5.9 (4-8.5) 27/459
Walter (2013) Lesion-based analysis	Weighted 7PCL: Score $\geq$ 6**	All included patients	8.3 (5.4-12.6) 21/252
Walter (2013) Lesion-based analysis	Weighted 7PCL: Score $\geq$ 7**	All included patients	10.9 (6.7-17.1) 17/156
Walter (2013) Lesion-based analysis	Weighted 7PCL: Score $\geq$ 8**	All included patients	15.7 (7.5-29.1) 8/51
Walter (2013) Lesion-based analysis	Weighted 7PCL: Score $\geq$ 9**	All included patients	8.3 (0.4-40.2) 1/12

- 1 \* Original 7PCL consists of 7 items (change in shape, size and/or colour, inflammation,
- 2 crusting/bleeding, sensory change, diameter  $\geq$  7 mm) and each present feature score 1 point. \*\*
- 3 The Weighted 7PCL consists of the same 7 items, but these are divided into major (change in

1 **shape, size and/or colour) scoring 2 points each and minor (inflammation, crusting/bleeding,**  
 2 **sensory change, diameter  $\geq$  7 mm) scoring 1 point.**

4 **Evidence statement(s):**

5 Pigmented skin lesions presenting in a primary care setting are associated with positive predictive  
 6 values of 0.8-5.1% for malignant melanoma (2 studies, N = 2784 *lesions*), and the positive predictive  
 7 values increased proportionally to the number of different risk features the lesions displayed up to  
 8 15.7% (1 study, 1436 *lesions*). The studies were associated with 4 bias/applicability concerns (see  
 9 also Table 1).

11 **Evidence tables**

12 **Emery (2010)**

<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective series of pigmented lesions recruited from England (6 general practices covering urban, suburban and rural areas with a registered population of 52913) and Australia (3 primary care skin cancer clinics operated by GPs from a metropolitan area)
Was a consecutive or random sample of patients enrolled?	<b>Unclear</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>England: N = 389 patients, mean age = 44.9 years, 68.6% females with, interpretable images from N = 630 lesions. 0/630 lesions were squamous cell carcinoma, 0/630 lesions were basal cell carcinoma, 5/630 lesions were melanoma, and 0/630 lesions were lentigo maligna (melanoma).</p> <p>Australia: N = 469 patients, mean age = 50 years, 48% females, with interpretable images from N = 581 lesions. 0/581 lesions were squamous cell carcinoma, 22/581 lesions were basal cell carcinoma, 7/581 lesions were melanoma, and 4/581 lesions were lentigo maligna (melanoma).</p> <p><u>Inclusion criteria:</u>            England: Patients aged &gt; 18 years were recruited into the study by their GP if they presented with concerns about a pigmented skin lesion between January 2005 and January 2006.            Australia: Patients aged &gt; 18 years were recruited into the study by their GP if they presented with concerns about a pigmented skin lesion between April 2008 and January 2009. Additional lesions were also included when a pigmented skin lesion was identified as potentially suspicious during their clinical examination</p> <p><u>Exclusion criteria:</u> None reported.</p> <p><u>Clinical setting:</u> Primary care, UK, and primary care skin cancer practice, Queensland Australia.</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>

<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	Pigmented skin lesions that concerned patients, which were evaluated using macroscopic clinical photographs, dermoscopic images and SIAscan.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
Could the conduct or interpretation of the index test have introduced bias?	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Are there concerns that the index test, its conduct, or interpretation differ from the review question?	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Histopathology or in-person clinical review of the lesion by one expert, including the 7-point melanoma checklist and digital dermoscopy or clinical diagnosis made on the basis of the 7-point melanoma checklist, photographic and dermoscopy images
Is the reference standard likely to correctly classify the target condition?	<b>Unclear</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
Could the reference standard, its conduct, or its interpretation have introduced bias?	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
Are there concerns that the target condition as defined by the reference standard does not match the question?	<b>Unclear concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients are accounted for in the results
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
Could the patient flow have introduced bias?	<b>Low risk</b>
NOTES	Analysis was on a per-lesion basis rather than a per-patient basis

1 **Walter (2012; 2013)**

<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective series of suspicious pigmented lesions
Was a consecutive or random sample of patients enrolled?	<b>Unclear</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Unclear</b>
Could the selection of patients have introduced bias?	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	N = 1293 patients, mean age (SD) = 44.6 (16.8) years; 465 males / 828 females with N = 1573 lesions, of which 1 was squamous cell carcinoma, 10 basal cell carcinomas, and 36 melanomas.  <u>Inclusion criteria:</u> Patients aged ≥ 18 years presenting to one of the 15

	participating general practices with a suspicious (any lesion presented buy a patient, or opportunistically seen by a family doctor or practice nurse, that could not immediately be diagnosed as benign and about which the patient could not be reassured) pigmented lesion from March 2008 to May 2010. <u>Exclusion criteria:</u> Patients who were unable to give informed consent or were considere3d inappropriate to include by their family doctor. <u>Clinical setting:</u> UK primary care.
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	Suspicious (any lesion presented buy a patient, or opportunistically seen by a family doctor or practice nurse, that could not immediately be diagnosed as benign and about which the patient could not be reassured) pigmented lesion
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Expert opinion by a histologist or dermatologist or review by two other dermatology experts of the recorded clinical history and examination, a digital photograph, and MoleMate images where available with or without follow up 3-6 months later.
Is the reference standard likely to correctly classify the target condition?	<b>Unclear</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Unclear concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients are accounted for in the results
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes Tests: No signs &amp; symptoms (S&amp;S)</b>
<b>Could the patient flow have introduced bias?</b>	<b>Tests: Low risk; S&amp;S: Unclear risk</b>
<b>NOTES</b>	Data from this study published in 2 papers: Details above refer to the data from Walter (2012). Further publication-specific details for Walter (2013): Of the 1573 included lesions, 42 did not have a reference standard assessment and the 7PCL was not fully completed for a further 95 lesions. The analyses were therefore based on 1436 lesions from 1182 patients (mean age (SD) = 44.7 (16.6) years; 424 males / 758 females with 36 melanomas). Analysis was

	on a per-lesion basis rather than a per-patient basis for both papers.
--	--

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

## References

### Included Studies

- Emery, J.D., Hunter, J., Hall, P.N., Watson, A.J., Moncrieff, M., Walter, F.M. (2010). Accuracy of SIAscopy for pigmented skin lesions encountered in primary care: development and validation of a new diagnostic algorithm. *BMJ Dermatology*, 10:9.
- Walter, F.M., Morris, H.C., Humphrys, E., Hall, P.N., Prevost, A.T., Burrows, N., Bradshaw, L., Wilson, E.C., Norris, P., Walls, J., Johnson, M., Kinmonth, A.L., Emery, J.D. (2012). Effect of adding a diagnostic aid to best practice to manage suspicious pigmented lesions in primary care: randomised controlled trial. *BMJ*, 345: e4110.
- Walter, F.M., Prevost, A.T., Vasconcelos, J., Hall, P.N., Burrows, N., Morris, H.C., Kinmonth, A.L., Emery, J.D. (2013). Using the 7-point checklist as a diagnostic aid for pigmented skin lesions in general practice: A diagnostic validation study. *British Journal of General Practice*, DOI: 10.3399/bjgp13X667213.

### Excluded Studies

- Ackerman, A. B. & Ackerman, A. B. (1988) A "changing mole" is not the best clue to clinical detection of an "early" malignant melanoma. *Archives of Dermatological Research*, 280 Suppl: S13-S14.  
Narrative review
- Agarwal, S. (2001) Out patient waiting time for common skin conditions - Do general practitioners and dermatologists have the same priorities? A questionnaire-based survey. *Clinical and Experimental Dermatology*, 26: 13-15.  
Not in PICO
- Aitken, J. F., Janda, M., Elwood, M., Youl, P. H., Ring, I. T., Lowe, J. B., Aitken, J. F., Janda, M., Elwood, M., Youl, P. H., Ring, I. T. & Lowe, J. B. (2006) Clinical outcomes from skin screening clinics within a community-based melanoma screening program. *Journal of the American Academy of Dermatology*, 54: 105-114.  
Not in PICO
- Aldridge, R. B. Z. (2011) The 'ABCD' mnemonic does not function as a useful guide in assisting novices with the diagnosis of melanoma. *British Journal of Dermatology*, Conference: July.  
Not in PICO
- Allon, I., Allon, D. M., Gal, G., Anavi, Y., Chaushu, G. & Kaplan, I. (2013) Re-evaluation of common paradigms regarding the clinical appearance of oral mucosal malignancies. *Journal of Oral Pathology and Medicine*, 42: 670-675.  
Not in PICO
- Antonio, J. R., Soubhia, R. M., D'Avila, S. C., Caldas, A. C., Tridico, L. A. & Alves, F. T. (2013) Correlation between dermoscopic and histopathological diagnoses of atypical nevi in a dermatology outpatient clinic of the Medical School of Sao Jose do Rio Preto, SP, Brazil. *Anais Brasileiros de Dermatologia*, 88: 199-203.  
Not in PICO
- Askari, S. K., Schram, S. E., Wenner, R. A., Bowers, S., Liu, A., Bangerter, A. K. & Warshaw, E. M. (2007) Evaluation of prospectively collected presenting signs/symptoms of biopsy-proven melanoma, basal cell carcinoma, squamous cell carcinoma, and seborrheic keratosis in an elderly male population. *Journal of the American Academy of Dermatology*, 56: 739-747.  
Not in PICO
- Baade, P. D. B. (2005) Community perceptions of suspicious pigmented skin lesions: Are they accurate when compared to general practitioners? *Cancer Detection and Prevention*, 29: 267-275.  
Not in PICO
- Baade, P. D. D. (2005) Clinical diagnosis and management of suspicious pigmented skin lesions--a survey of GPs. *Australian Family Physician*, 34: 79-83.  
Not in PICO

- 1 Badertscher, N., Rosemann, T., Tandjung, R. & Braun, R. P. (2011) minSKIN does a multifaceted  
2 intervention improve the competence in the diagnosis of skin cancer by general practitioners?  
3 Study protocol for a randomised controlled trial. *Trials*, 12: 165.  
4 Not in PICO
- 5 Balois, T. & Amar, M. B. (2014) Morphology of melanocytic lesions in situ. *Science Reporter*, 4: 3622.  
6 Not in PICO
- 7 Barchuk, A. S., Anisimov, V. V., Vagner, R. I., Barchuk, A. S., Anisimov, V. V. & Vagner, R. I. (1996)  
8 [Clinical diagnosis of primary melanoma of the skin]. [Review] [18 refs] [Russian]. *Voprosy*  
9 *Onkologii*, 42: 96-100.  
10 In Russian. Not enough information can be extracted to definitely ascertain whether it is in PICO,  
11 but I don't think so.
- 12 Basra, M. (2012) An online survey of the awareness of malignant melanoma among general  
13 practitioners with special interest in dermatology. *British Journal of Dermatology*, Conference:  
14 July.  
15 Not in PICO
- 16 Bataille, V. & Bataille, V. (2003) Early detection of melanoma improves survival. *Practitioner*, 253: 29-  
17 32.  
18 Narrative review
- 19 Baughan, P., O'Neill, B., Fletcher, E., Baughan, P., O'Neill, B. & Fletcher, E. (2009) Auditing the  
20 diagnosis of cancer in primary care: the experience in Scotland. *British Journal of Cancer*, 101  
21 Suppl 2: S87-S91.  
22 Not in PICO
- 23 Baughan, P., Keatings, J., O'Neill, B., Baughan, P., Keatings, J. & O'Neill, B. (2011) Urgent suspected  
24 cancer referrals from general practice: audit of compliance with guidelines and referral  
25 outcomes. *British Journal of General Practice*, 61: e700-e706.  
26 Not in PICO
- 27 Betti, R., Vergani, R., Tolomio, E., Santambrogio, R. & Crosti, C. (2003) Factors of delay in the  
28 diagnosis of melanoma. *European Journal of Dermatology*, 13: 183-188.  
29 Not in PICO
- 30 Biernikiewicz, M. (1998) Pigmented nevus in children as a diagnostic and treatment problem. *Polski*  
31 *merkurusz lekarski : organ Polskiego Towarzystwa Lekarskiego*, 5: 72-73.  
32 Not in PICO
- 33 Bishop, J. N., Bataille, V., Gavin, A., Lens, M., Marsden, J., Mathews, T. & Wheelhouse, C. (2007) The  
34 prevention, diagnosis, referral and management of melanoma of the skin: concise guidelines.  
35 *Clinical Medicine*, 7: 283-290.  
36 Narrative review
- 37 Bogucki, P. (2013) Malignant melanoma, index and nonindex lesions. *Journal of the American*  
38 *Academy of Dermatology*, Conference: AB153.  
39 Not in PICO
- 40 Bonfa, R., Bonamigo, R. R., Bonfa, R., Duro, K. M., Furian, R. D. & Zelmanowicz, A. D. (2011) Early  
41 diagnosis of cutaneous melanoma: an observation in southern Brazil. *Anais Brasileiros de*  
42 *Dermatologia*, 86: 215-221.  
43 Not in PICO
- 44 Bourdeaud'hui, F., del, M., V, Bourdeaud'hui, F. & del Marmol, V. (2011) [Managing moles in general  
45 practice]. [French]. *Revue Medicale de Bruxelles*, 32: 205-209.  
46 Narrative review
- 47 Branstrom, R., Hedblad, M. A., Krakau, I., Ullen, H., Branstrom, R., Hedblad, M. A., Krakau, I. & Ullen,  
48 H. (2002) Laypersons' perceptual discrimination of pigmented skin lesions. *Journal of the*  
49 *American Academy of Dermatology*, 46: 667-673.  
50 Not in PICO



- 1 Brochez, L., Verhaeghe, E., Bleyen, L. & Naeyaert, J. M. (2001) Diagnostic ability of general  
2 practitioners and dermatologists in discriminating pigmented skin lesions. *Journal of the*  
3 *American Academy of Dermatology*, 44: 979-986.  
4 Not in PICO
- 5 Brodell, R. T., Helms, S. E., Brodell, R. T. & Helms, S. E. (1998) The changing mole. Additional warning  
6 signs of malignant melanoma. *Postgraduate Medicine*, 104: 145-148.  
7 Not in PICO
- 8 Bruce, A. J. & Brodland, D. G. (2000) Overview of skin cancer detection and prevention for the  
9 primary care physician. *Mayo Clinic Proceedings*, 75: 491-500.  
10 Narrative review
- 11 Brundel, K.-H. (1990) Skin cancer in general practice. *Dermatosen in Beruf und Umwelt*, 38: 54-57.  
12 Not in PICO
- 13 Buis, P. A. J. (2005) Value of histopathologic analysis of skin excisions by GPs. *British Journal of*  
14 *General Practice*, 55: 458-460.  
15 Not in PICO (no symptoms)
- 16 Burton, R. C. H. (1998) General practitioner screening for melanoma: Sensitivity, specificity, and  
17 effect of training. *Journal of Medical Screening*, 5: 156-161.  
18 Not in PICO
- 19 Carli, P., De, G., V, Nardini, P., Mannone, F., Palli, D., Giannotti, B., Carli, P., De Giorgi, V., Nardini, P.,  
20 Mannone, F., Palli, D. & Giannotti, B. (2002) Melanoma detection rate and concordance between  
21 self-skin examination and clinical evaluation in patients attending a pigmented lesion clinic in  
22 Italy. *British Journal of Dermatology*, 146: 261-266.  
23 Not in PICO
- 24 Carli, P., De, G., V, Betti, R., Vergani, R., Catricala, C., Mariani, G., Simonacci, M., Bettacchi, A.,  
25 Bottoni, U., Lo, S. G., Mulas, P., Giannotti, B., Carli, P., De Giorgi, V., Betti, R., Vergani, R.,  
26 Catricala, C., Mariani, G., Simonacci, M., Bettacchi, A., Bottoni, U., Lo Scocco, G., Mulas, P. &  
27 Giannotti, B. (2003) Relationship between cause of referral and diagnostic outcome in pigmented  
28 lesion clinics: a multicentre survey of the Italian Multidisciplinary Group on Melanoma (GIPMe).  
29 *Melanoma Research*, 13: 207-211.  
30 Not in PICO
- 31 Casey, S., Dvorkin, L., Alsanjari, N., Dezso, B., Casey, S., Dvorkin, L., Alsanjari, N. & Dezso, B. (2011)  
32 Symptomatic malignant melanoma presenting as multiple gastrointestinal polyps. *BMJ Case*  
33 *Reports*, 2011, 2011..  
34 Not in PICO
- 35 Chattopadhyay, M. & Ha, T. (2013) How to examine a patient with suspected skin cancer. *Medicine*  
36 *(United Kingdom)*, 41: 400-401.  
37 Narrative review
- 38 Chen, S. C., Bravata, D. M., Weil, E. & Olkin, I. (2001) A comparison of dermatologists' and primary  
39 care physicians' accuracy in diagnosing melanoma. *Archives of Dermatology*, 137: 1627-1634.  
40 Not in PICO
- 41 Cheng, H., Oakley, A. & Rademaker, M. (2013) Please see this child with ? melanoma. *Australasian*  
42 *Journal of Dermatology*, 54: 35.  
43 Not in PICO
- 44 Cheng, H., Oakley, A. & Rademaker, M. (2014) - Change in a child's naevus prompts referral to a  
45 dermatology service. - *Journal of Primary Health Care*, 6: 123-128.  
46 Not in PICO
- 47 Ciocan, D., Barbe, C., Aubin, F., Granel-Brocard, F., Lipsker, D., Velten, M., Dalac, S., Truchetet, F.,  
48 Michel, C., Mitschler, A., Arnoult, G., Buemi, A., Dalle, S., Bernard, P., Woronoff, A. S. & Grange, F.  
49 (2013) Distinctive features of melanoma and its management in elderly patients: a population-  
50 based study in France. *JAMA Dermatology*, 149: 1150-1157.  
51 Not in PICO

- 1 Corey, K. (2012) An analysis of terminology used by primary care physicians to describe concerning  
2 lesions referred to an urgent dermatology clinic. *Journal of Investigative Dermatology*,  
3 Conference: May.  
4 Not in PICO
- 5 Cox, N. H. (2004) Evaluation of the UK 2-week referral rule for skin cancer. *British Journal of*  
6 *Dermatology*, 150: 291-298.  
7 Not in PICO
- 8 Cox, N. H., Madan, V., Sanders, T., Cox, N. H., Madan, V. & Sanders, T. (2008) The U.K. skin cancer  
9 'two-week rule' proforma: assessment of potential modifications to improve referral accuracy.  
10 *British Journal of Dermatology*, 158: 1293-1298.  
11 Not in PICO
- 12 Dewan, P. (2010) Are NICE skin cancer guidelines being followed in primary care? A re-audit to  
13 review changes in practice in an inner city setting. *British Journal of Dermatology*, Conference:  
14 July.  
15 Not in PICO
- 16 Du Vivier, A. W., Williams, H. C., Brett, J. V., Higgins, E. M., Du Vivier, A. W., Williams, H. C., Brett, J.  
17 V. & Higgins, E. M. (1991) How do malignant melanomas present and does this correlate with the  
18 seven-point check-list? *Clinical & Experimental Dermatology*, 16: 344-347.  
19 Not in PICO
- 20 Durbec, F., Vitry, F., Granel-Brocard, F., Lipsker, D., Aubin, F., Hedelin, G., Dalac, S., Truchetet, F.,  
21 Michel, C., Batard, M. L., Domissy-Baury, B., Halna, J. M., Schmutz, J. L., Delvincourt, C., Reuter,  
22 G., Dalle, S., Bernard, P., Danzon, A. & Grange, F. (2010) The Role of Circumstances of Diagnosis  
23 and Access to Dermatological Care in Early Diagnosis of Cutaneous Melanoma A Population-  
24 Based Study in France. *Archives of Dermatology*, 146: 240-246.  
25 Not in PICO
- 26 El-Khalawany, M. (2014) - Acquired melanocytic nevi in Egyptian patients: a clinicopathological  
27 study. - *Acta Dermatovenerologica Alpina, Panonica et Adriatica*, 23: 5-11.  
28 S&S: Population not in PICO; tests: Not a DTA study
- 29 English, D. R., Burton, R. C., Mar, C. B., Donovan, R. J., Ireland, P. D. & Emery, G. (2003) Evaluation of  
30 aid to diagnosis of pigmented skin lesions in general practice: controlled trial randomised by  
31 practice. *BMJ (Clinical research ed.)*, 327: 375.  
32 Not in PICO (excised lesions only)
- 33 Foley, C. C., Corby, P. & Barnes, L. (1111) A dermatology outpatient waiting list initiative. *Irish*  
34 *Medical Journal*, 106: -August.  
35 Not in PICO
- 36 Friedman, R. J., Rigel, D. S., Kopf, A. W., Friedman, R. J., Rigel, D. S. & Kopf, A. W. (1985) Early  
37 detection of malignant melanoma: the role of physician examination and self-examination of the  
38 skin. *CA: A Cancer Journal for Clinicians*, 35: 130-151.  
39 Narrative review
- 40 Gallagher, R. P., Elwood, J. M., Rootman, J., Threlfall, W. J., Davis, J., Gallagher, R. P., Elwood, J. M.,  
41 Rootman, J., Threlfall, W. J. & Davis, J. (1988) Symptoms and time to presentation and treatment  
42 in ocular melanoma: the Western Canada Melanoma Study. *Canadian Journal of Ophthalmology*,  
43 23: 11-13.  
44 Not in PICO
- 45 Garmyn, M. (2007) How to recognize a malignant melanoma between the other pigmented spots.  
46 *Tijdschrift voor Geneeskunde*, 63: 1240-1243.  
47 Narrative review
- 48 Garmyn, M. (2009) How to recognize a malignant melanoma between the other pigmented spots.  
49 *Tijdschrift voor Geneeskunde*, 65: 9.  
50 Narrative review

- 1 Gazzani, P., Rothwell, J., Kasparis, C. & Gee, B. (2013) Progress towards integrating a melanoma  
2 diagnostic index into a U.K. dermatology department quality dashboard. *British Journal of*  
3 *Dermatology*, 169: 46-47.  
4 Not in PICO
- 5 Giacomel, J. & Zalaudek, I. (2013) Pink Lesions. *Dermatologic Clinics*, 31: 649-678.  
6 Narrative review
- 7 Giard, R. W. M. (2004) Diagnosis of pigmented skin lesions: How to recognize a malignant  
8 melanoma. *Nederlands Tijdschrift Voor Geneeskunde*, 148: 2261-2267.  
9 Narrative review
- 10 Gibbon, K. L. & Gibbon, K. L. (1998) Pigmented lesion clinics--are they a waste of resources? *Clinical*  
11 *& Experimental Dermatology*, 23: 3-8.  
12 Narrative review
- 13 Girardi, S., Gaudy, C., Gouvernet, J., Teston, J., Richard, M. A., Grob, J. J., Girardi, S., Gaudy, C.,  
14 Gouvernet, J., Teston, J., Richard, M. A. & Grob, J. J. (2006) Superiority of a cognitive education  
15 with photographs over ABCD criteria in the education of the general population to the early  
16 detection of melanoma: a randomized study. *International Journal of Cancer*, 118: 2276-2280.  
17 Not in PICO
- 18 Grange, F., Hedelin, G., Halna, J. M., Grall, J. C., Kirstetter, H., Guillaume, J. C. & Michel, C. (2005)  
19 Assessment of a general practitioner training campaign for early detection of cutaneous  
20 melanoma in the Haut-Rhin department of France. *Annales de Dermatologie et de Venereologie*,  
21 132: 956-961.  
22 Not in PICO
- 23 Grange, F., Barbe, C., Mas, L., Granel-Brocard, F., Lipsker, D., Aubin, F., Velten, M., Dalac, S.,  
24 Truchetet, F., Michel, C., Mitschler, A., Arnoult, G., Buemi, A., Dalle, S., Reuter, G., Bernard, P.,  
25 Woronoff, A. S. & Arnold, F. (2012) The role of general practitioners in diagnosis of cutaneous  
26 melanoma: a population-based study in France. *British Journal of Dermatology*, 167: 1351-1359.  
27 Not in PICO
- 28 Green, J., Murchie, P. & Lee, A. J. (2013) Does patients' place of residence affect the type of  
29 physician performing primary excision of cutaneous melanoma in northern Scotland? *Journal of*  
30 *Rural Health*, 29: Suppl-42.  
31 Not in PICO
- 32 Griffiths, W. A. & Griffiths, W. A. (2010) Improving melanoma diagnosis in primary care--a tele-  
33 dermatoscopy project. *Journal of Telemedicine & Telecare*, 16: 185-186.  
34 Not in PICO
- 35 Gupta, A., Stacey, S. & Amissah-Arthur, K. N. (2014) Eyelid lumps and lesions. *BMJ (Online)*, 348.  
36 Narrative review
- 37 Gupta, M., Aggarwal, A., Ahuja, R., Pachauri, A. & Kumar, P. (2013) Significance of early detection of  
38 oral malignant melanoma: Some reasonable facts. *Clinical Cancer Investigation Journal*, 2: 178-  
39 180.  
40 Narrative review
- 41 Halkud, R., Shenoy, A. M., Naik, S. M., Chavan, P., Sidappa, K. T. & Biswas, S. (2014) Xeroderma  
42 Pigmentosum: Clinicopathological Review of the Multiple Oculocutaneous Malignancies and  
43 Complications. *Indian Journal of Surgical Oncology*, 5: 120-124.  
44 Not in PICO
- 45 Halpern, A. C. & Lieb, J. A. (2007) Early melanoma diagnosis: a success story that leaves room for  
46 improvement. *Current Opinion in Oncology*, 19: 109-115.  
47 Narrative review
- 48 Hamidi, R., Peng, D., Cockburn, M., Hamidi, R., Peng, D. & Cockburn, M. (2010) Efficacy of skin self-  
49 examination for the early detection of melanoma. [Review] [45 refs]. *International Journal of*  
50 *Dermatology*, 49: 126-134.  
51 Narrative review

- 1 Hansen, C., Wilkinson, D., Hansen, M., Argenziano, G., Hansen, C., Wilkinson, D., Hansen, M. &  
2 Argenziano, G. (2009) How good are skin cancer clinics at melanoma detection? Number needed  
3 to treat variability across a national clinic group in Australia. *Journal of the American Academy of*  
4 *Dermatology*, 61: 599-604.  
5 Not in PICO (only excised lesions, not examined lesions; no information about symptoms/lesion  
6 features)
- 7 Harris, J. (1999) Using the Internet to teach melanoma management guidelines to primary care  
8 physicians. *Journal of Evaluation in Clinical Practice*, 5: 199-211.  
9 Not in PICO
- 10 Healsmith, M. F. B. (1994) An evaluation of the revised seven-point checklist for the early diagnosis  
11 of cutaneous malignant melanoma. *British Journal of Dermatology*, 130: 48-50.  
12 Not in PICO
- 13 Higgins, E. M., Hall, P., Todd, P., Murthi, R., Du Vivier, A. W., Higgins, E. M., Hall, P., Todd, P., Murthi,  
14 R. & Du Vivier, A. W. (1992) The application of the seven-point check-list in the assessment of  
15 benign pigmented lesions. *Clinical & Experimental Dermatology*, 17: 313-315.  
16 Not in PICO
- 17 Hillner, B. E., Kirkwood, J. M. & Agarwala, S. S. (2001) Burden of illness associated with metastatic  
18 melanoma - An audit of 100 consecutive referral center cases. *Cancer*, 91: 1814-1821.  
19 Not in PICO
- 20 Holme, S. A. (2003) GPs have role in early detection of melanoma. [Review]. *Practitioner*, 257: 27-30.  
21 Narrative review
- 22 Humzah, M. D. E. (2003) Diagnosing pigmented skin lesions in general practice [2] (multiple letters).  
23 *British Medical Journal*, 327: 1167-1168.  
24 Letter
- 25 Jackson, A. (1995) Prevention, Early Detection and Team Management of Skin-Cancer in Primary-  
26 Care - Contribution to the Health-Of-The-Nation Objectives. *British Journal of General Practice*,  
27 45: 97-101.  
28 Narrative review
- 29 Jackson, A. M., Morgan, D. R., Ellison, R., Jackson, A. M., Morgan, D. R. & Ellison, R. (2000) Diagnosis  
30 of malignant melanoma by general practitioners and hospital specialists. *Postgraduate Medical*  
31 *Journal*, 76: 295-298.  
32 Not in PICO
- 33 Jassim, O. W., Lind, A. C., Jassim, O. W. & Lind, A. C. (2010) Melanoma: from patient presentation to  
34 pathology report. [Review] [13 refs]. *Missouri Medicine*, 107: 101-106.  
35 Narrative review
- 36 Jemec, G. B. E. (1999) The diagnostic accuracy of Danish GPs in the diagnosis of pigmented skin  
37 lesions. *Family Practice*, 16: 619-620.  
38 Not in PICO
- 39 Kaminska-Winciorek, G. & Spiewak, R. (2013) [Dermoscopy on subungual melanoma]. [Polish].  
40 *Postepy Higieny i Medycyny do Swiadczalnej (Online)*, 67: 380-387.  
41 Narrative review
- 42 Kelly, J. W., Shen, S., Pan, Y., Dowling, J. & McLean, C. A. (2014) Postexcisional melanocytic regrowth  
43 extending beyond the initial scar: A novel clinical sign of melanoma. *British Journal of*  
44 *Dermatology*, 170: 961-964.  
45 Not in PICO
- 46 Koelink, C. J. L., Kollen, B. J., Groenhof, F., van der Meer, K. & van der Heide, W. K. (2014) Skin lesions  
47 suspected of malignancy: an increasing burden on general practice. *Bmc Family Practice*, 15.  
48 Results only reported in 'number of contacts' for true positives, so PPV cannot be calculated.
- 49 Kossard, S. (2001) An irregular, dappled, pigmented patch. *Medicine Today*, 2: 121.  
50 Not in PICO

- 1 Krige, J. E. J., Isaacs, S., Hudson, D. A., King, H. S., Strover, R. M. & Johnson, C. A. (1991) Delay in the  
2 Diagnosis of Cutaneous Malignant-Melanoma - A Prospective-Study in 250 Patients. *Cancer*, 68:  
3 2064-2068.  
4 Not in PICO
- 5 Kundu, R. V. & Patterson, S. (2013) Dermatologic conditions in skin of color: part I. Special  
6 considerations for common skin disorders.[Summary for patients in Am Fam Physician. 2013 Jun  
7 15;87(12):Online; PMID: 23939576]. *American Family Physician*, 87: 850-856.  
8 Narrative review
- 9 Kutcher, M. J. R. (1946) Fifteen inches from cancer: early recognition of facial lesions by the dentist.  
10 *Compendium of continuing education in dentistry (Jamesburg, N, J.: 939-942.*  
11 Narrative review
- 12 Lathlean, S. & Lathlean, S. (1999) Skin cancer in general practice in South Australia. A five year study.  
13 *Australian Family Physician*, 28 Suppl 1: S28-S31.  
14 Not in PICO (only excised lesions, not examined lesions; no information about symptoms/lesion  
15 features)
- 16 Lee, K. C., Jayarajan, R. & Daruwalla, M. (2013) Skin cancer diagnosis hit or miss? the leicester  
17 experience. *International Journal of Surgery*, 11: 683.  
18 Not in PICO
- 19 Lin, M. J. & Kelly, J. W. (2013) When is it melanoima? An update on diagnosis and management.  
20 *Medicine Today*, 14: 44-53.  
21 Narrative review
- 22 Lin, M. J., Mar, V., McLean, C., Wolfe, R. & Kelly, J. W. (2014) Diagnostic accuracy of malignant  
23 melanoma according to subtype. *Australasian Journal of Dermatology*, 55: 35-42.  
24 Not in PICO
- 25 Long, M. D. (2012) Cutaneous malignancies in patients with inflammatory bowel disease.  
26 *Gastroenterology and Hepatology*, 8: 467-471.  
27 Narrative review
- 28 Lyratzopoulos, G., Neal, R. D., Barbieri, J. M., Rubin, G. P. & Abel, G. A. (2012) Variation in number of  
29 general practitioner consultations before hospital referral for cancer: findings from the 2010  
30 National Cancer Patient Experience Survey in England. *Lancet Oncology*, 13: 353-365.  
31 Not in PICO
- 32 Maguire-Eisen, M., Frost, C., Maguire-Eisen, M. & Frost, C. (1994) Knowledge of malignant  
33 melanoma and how it relates to clinical practice among nurse practitioners and dermatology and  
34 oncology nurses. [Review] [26 refs]. *Cancer Nursing*, 17: 457-463.  
35 Not in PICO
- 36 Marghoob, A. A., Usatine, R. P. & Jaimes, N. (2013) Dermoscopy for the family physician. [Review].  
37 *American Family Physician*, 88: 441-450.  
38 Narrative review
- 39 Marks, R. (1997) Who removes pigmented skin lesions? *Journal of the American Academy of*  
40 *Dermatology*, 36: 721-726.  
41 Not in PICO
- 42 Martinez, J. C. & Otley, C. C. (2001) The management of melanoma and nonmelanoma skin cancer: A  
43 review for the primary care physician. *Mayo Clinic Proceedings*, 76: 1253-1265.  
44 Narrative review
- 45 McCourt, C., Dolan, O. & Gormley, G. (2014) Malignant melanoma: A pictorial review. *Ulster Medical*  
46 *Journal*, 83: 103-110.  
47 Not in PICO
- 48 McGovern, T. W., Litaker, M. S., McGovern, T. W. & Litaker, M. S. (1992) Clinical predictors of  
49 malignant pigmented lesions. A comparison of the Glasgow seven-point checklist and the  
50 American Cancer Society's ABCDs of pigmented lesions. *Journal of Dermatologic Surgery &*

- 1 *Oncology*, 18: 22-26.  
 2 Not in PICO
- 3 McWhirter, J. E. & Hoffman-Goetz, L. (2013) Visual images for patient skin self-examination and  
 4 melanoma detection: a systematic review of published studies. [Review]. *Journal of the American*  
 5 *Academy of Dermatology*, 69: 47-55.  
 6 Not in PICO
- 7 Menzies, S. W., Moloney, F. J., Byth, K., Avramidis, M., Argenziano, G., Zalaudek, I., Braun, R. P.,  
 8 Malvehy, J., Puig, S., Rabinovitz, H. S., Oliviero, M., Cabo, H., Bono, R., Pizzichetta, M. A., Claeson,  
 9 M., Gaffney, D. C., Soyer, H. P., Stanganelli, I., Scolyer, R. A., Guitera, P., Kelly, J., McCurdy, O.,  
 10 Llambrich, A., Marghoob, A. A., Zaballos, P., Kirchesch, H. M., Piccolo, D., Bowling, J., Thomas, L.,  
 11 Terstappen, K., Tanaka, M., Pellacani, G., Pagnanelli, G., Ghigliotti, G., Ortega, B. C., Crafter, G.,  
 12 Ortiz, A. M., Tromme, I., Karaarslan, I. K., Ozdemir, F., Tam, A., Landi, C., Norton, P., Kacar, N.,  
 13 Rudnicka, L., Slowinska, M., Simionescu, O., Di, S. A., Coates, E. & Kreusch, J. (2013) Dermoscopic  
 14 evaluation of nodular melanoma. *JAMA Dermatology*, 149: 699-709.  
 15 Not in PICO
- 16 Menzies, S. W. (2013) Evidence-Based Dermoscopy. *Dermatologic Clinics*, 31: 521-524.  
 17 Narrative review
- 18 Menzies, S. W., Moloney, F. J., Byth, K., Avramidis, M., Argenziano, G., Zalaudek, I., Braun, R. P.,  
 19 Malvehy, J., Puig, S., Rabinovitz, H. S., Oliviero, M., Cabo, H., Bono, R., Pizzichetta, M. A., Claeson,  
 20 M., Gaffney, D. C., Soyer, H. P., Stanganelli, I., Scolyer, R. A., Guitera, P., Kelly, J., McCurdy, O.,  
 21 Llambrich, A., Marghoob, A. A., Zaballos, P., Kirchesch, H. M., Piccolo, D., Bowling, J., Thomas, L.,  
 22 Terstappen, K., Tanaka, M., Pellacani, G., Pagnanelli, G., Ghigliotti, G., Ortega, B. C., Crafter, G.,  
 23 Perusquia Ortiz, A. M., Tromme, I., Karaarslan, I. K., Ozdemir, F., Tam, A., Landi, C., Norton, P.,  
 24 Kacar, N., Rudnicka, L., Slowinska, M., Simionescu, O., Di, S. A., Coates, E. & Kreusch, J. (2013)  
 25 Dermoscopic evaluation of nodular melanoma. *JAMA Dermatology*, 149: 699-709.  
 26 Not in PICO
- 27 Morrison, A., O'Loughlin, S. & Powell, F. C. (2001) Suspected skin malignancy: a comparison of  
 28 diagnoses of family practitioners and dermatologists in 493 patients. *International Journal of*  
 29 *Dermatology*, 40: 104-107.  
 30 Not in PICO
- 31 Murchie, P., Raja, E. A., Lee, A. J. & Campbell, N. C. (2013) Mortality and morbidity after initial  
 32 diagnostic excision biopsy of cutaneous melanoma in primary versus secondary care. *British*  
 33 *Journal of General Practice*, 63: e563-e572.  
 34 Not in PICO
- 35 Newell, E. L., Shaw, L. & Bragonier, R. (2014) Rising referrals for suspected paediatric melanoma via  
 36 the 2-week rule referral system. *British Journal of Dermatology*, 170: e15.  
 37 Not in PICO
- 38 Newell, E. L., Shaw, L. & Bragonier, R. (2014) Rising referrals for suspected paediatric melanoma via  
 39 the 2-week rule referral system. *British Journal of Dermatology*, 170: e15.  
 40 Not in PICO
- 41 Nielsen, T. N., Hansen, R. P., Vedsted, P., Nielsen, T. N., Hansen, R. P. & Vedsted, P. (2010) [Symptom  
 42 presentation in cancer patients in general practice]. [Danish]. *Ugeskrift for Laeger*, 172: 2827-  
 43 2831.  
 44 Not in PICO
- 45 Offidani, A., Simonetti, O., Bernardini, M. L., Alpagut, A., Cellini, A., Bossi, G., Offidani, A., Simonetti,  
 46 O., Bernardini, M. L., Alpagut, A., Cellini, A. & Bossi, G. (2002) General practitioners' accuracy in  
 47 diagnosing skin cancers. *Dermatology*, 205: 127-130.  
 48 Not in PICO
- 49 Osborne, J. E., Bourke, J. F., Holder, J., Colloby, P., Graham-Brown, R. A., Osborne, J. E., Bourke, J. F.,  
 50 Holder, J., Colloby, P. & Graham-Brown, R. A. (1998) The effect of the introduction of a  
 51 pigmented lesion clinic on the interval between referral by family practitioner and attendance at

- 1 hospital. *British Journal of Dermatology*, 138: 418-421.
- 2 Not in PICO
- 3 Patel, L. M., Lambert, P. J., Gagna, C. E., Maghari, A. & Lambert, W. C. (2011) Cutaneous signs of  
4 systemic disease. *Clinics in Dermatology*, 29: 511-522.
- 5 Narrative review
- 6 Paul, E. (1990) The slow growth of malignant melanomas - The great chance of their early detection.  
7 *Regional Cancer Treatment*, 3: 107-110.
- 8 Narrative review
- 9 Pereda, C., Traves, V., Requena, C., Serra-Guillen, C., Llombart, B., Sanmartin, O., Guillen, C. &  
10 Nagore, E. (2013) Clinical presentation of acral lentiginous melanoma: a descriptive study. *Actas*  
11 *Dermo-Sifiliograficas*, 104: 220-226.
- 12 Not in PICO
- 13 Pfister, R. & Pfister, R. (1983) [Early symptoms of malignant skin changes]. [German]. *Fortschritte der*  
14 *Medizin*, 101: 445-450.
- 15 Not in PICO
- 16 Pflugfelder, A., Kochs, C., Blum, A., Capellaro, M., Czeschik, C., Dettenborn, T., Dill, D., Dippel, E.,  
17 Eigentler, T., Feyer, P., Follmann, M., Frerich, B., Ganten, M.-K., Gartner, J., Gutzmer, R., Hassel, J.,  
18 Hauschild, A., Hohenberger, P., Hubner, J., Kaatz, M., Kleeberg, U. R., Kolbl, O., Kortmann, R.-D.,  
19 Krause-Bergmann, A., Kurschat, P., Leiter, U., Link, H., Loquai, C., Loser, C., MacKensen, A., Meier,  
20 F., Mohr, P., Mohrle, M., Nashan, D., Reske, S., Rose, C., Sander, C., Satzger, I., Schiller, M.,  
21 Schlemmer, H.-P., Strittmatter, G., Sunderkotter, C., Swoboda, L., Trefzer, U., Voltz, R.,  
22 Vordermark, D., Weichenthal, M., Werner, A., Wesselmann, S., Weyergraf, A. J., Wick, W., Garbe,  
23 C. & Schadendorf, D. (2013) S3-Guideline "diagnosis, therapy and follow-up of melanoma" - Short  
24 version. [German, English]. *JDDG - Journal of the German Society of Dermatology*, 11: 593-602.
- 25 Guideline
- 26 Porte, A. & Viguier, J. (2013) General practitioners and early detection of skin cancer Summary, Step  
27 2 of the barometric survey. *Oncologie*, 15: 535-542.
- 28 Not in PICO
- 29 Ramineni, M., Sonabend, M., Katta, R., Ramineni, M., Sonabend, M. & Katta, R. (2008) Tender  
30 growth on toe. *Journal of Family Practice*, 57: 473-475.
- 31 Not in PICO
- 32 Reusch, M., Schaefer, I., Siebert, J., Kornek, T. & Augustin, M. (2013) Histological and epidemiological  
33 characteristics of cutaneous malignant melanoma in routine ambulatory care in germany. *JDDG -*  
34 *Journal of the German Society of Dermatology*, 11: 38-39.
- 35 Not in PICO
- 36 Richard, M. A., Grob, J. J., Avril, M. F., Delaunay, M., Gouvernet, J., Wolkenstein, P., Souteyrand, P.,  
37 Dreno, B., Bonerandi, J. J., Dalac, S., Machet, L., Guillaume, J. C., Chevrant-Breton, J., Vilmer, C.,  
38 Aubin, F., Guillot, B., Beylot-Barry, M., Lok, C., Raison-Peyron, N. & Chemaly, P. (2000) Delays in  
39 diagnosis and melanoma prognosis (II): The role of doctors. *International Journal of Cancer*, 89:  
40 280-285.
- 41 Not in PICO
- 42 Robinson, J. K., Turrisi, R., Robinson, J. K. & Turrisi, R. (2006) Skills training to learn discrimination of  
43 ABCDE criteria by those at risk of developing melanoma. *Archives of Dermatology*, 142: 447-452.
- 44 Not in PICO
- 45 Rosendahl, C., Hishon, M., Cameron, A., Barksdale, S., Weedon, D. & Kittler, H. (2014) - Nodular  
46 melanoma: five consecutive cases in a general practice with polarized and non-polarized  
47 dermatoscopy and dermatopathology. - *Dermatology Practical & Conceptual*, 4: 69-75.
- 48 Not in PICO
- 49 Sahin, M. T., Ozturkcan, S., Ermertcan, A. T. & Gunes, A. T. (2004) A comparison of dermoscopic  
50 features among lentigo senilis/initial seborrheic keratosis, seborrheic keratosis, lentigo maligna

- 1 and lentigo maligna melanoma on the face. *Journal of Dermatology*, 31: 884-889.
- 2 Not in PICO
- 3 Schofield, J. (2011) The costs of diagnosing and treating skin cancer using the 2-week-wait referral  
4 process. *British Journal of Dermatology*, Conference: July.
- 5 Not in PICO
- 6 Shelton, R. M. (2001) Skin cancer: a review and atlas for the medical provider. *The Mount Sinai  
7 journal of medicine, New York*, 68: 243-252.
- 8 Narrative review
- 9 Steel, B. J. (2014) - Skin cancer - an overview for dentists. - *British Dental Journal*, 216: 575-581.
- 10 Narrative review
- 11 Stefano, Z., Cesare, B., Claudio, C., Fausto, C., Aldo, B., Natale, C., Stefano, Z., Cesare, B., Claudio, C.,  
12 Fausto, C., Aldo, B. & Natale, C. (1992) Melanocytic neoplasia of the sole: diagnosis and  
13 therapeutic approach. *Journal of Dermatology*, 19: 280-284.
- 14 Not in PICO
- 15 Stollery, N. & Stollery, N. (2007) Pigmented lesions. [Review] [12 refs]. *Practitioner*, 251: 36-38.
- 16 Narrative review
- 17 Tlougan, B. E., Orlow, S. J. & Schaffer, J. V. (2013) Spitz nevi: beliefs, behaviors, and experiences of  
18 pediatric dermatologists. *JAMA Dermatology*, 149: 283-291.
- 19 Not in PICO
- 20 Tolpinrud, W. L., Viola, K. V., Kirsner, R. S., Gross, C. P., Imaeda, S. & Federman, D. G. (2011)  
21 Nondermatologists' Use of Predictive Terms for a Potentially Malignant Lesion. *Southern Medical  
22 Journal*, 104: 477-481.
- 23 Not in PICO
- 24 Turner, T. & Turner, T. (1993) Pigmented lesions--a plan for management in general practice.  
25 *Medical Journal of Australia*, 159: 809-814.
- 26 Narrative review
- 27 Urbancek, S., Simekova, P. & Tomkova, J. (2013) Misdiagnosis of melanoma: A 5 years analysis. *JDDG  
28 - Journal of the German Society of Dermatology*, 11: 31.
- 29 Not in PICO
- 30 van der Rhee, J. I., Bergman, W., Kukutsch, N. A., van der Rhee, J. I., Bergman, W. & Kukutsch, N. A.  
31 (2010) The impact of dermoscopy on the management of pigmented lesions in everyday clinical  
32 practice of general dermatologists: a prospective study. *British Journal of Dermatology*, 162: 563-  
33 567.
- 34 Not in PICO
- 35 Van Rijsingen, M. C. J., Van, B. B., Van Der Wilt, G. J., Lagro-Janssen, A. L. M. & Gerritsen, M. J. P.  
36 (2014) The current and future role of general practitioners in skin cancer care: An assessment of  
37 268 general practitioners. *British Journal of Dermatology*, 170: 1366-1368.
- 38 Not in PICO
- 39 Van Rijsingen, M. C. J., Hanssen, S. C. A., Groenewoud, J. M. M., Van Der Wilt, G. J. & Gerritsen, M.-J.  
40 (2014) Referrals by general practitioners for suspicious skin lesions: The urgency of training. *Acta  
41 Dermato-Venereologica*, 94: 138-141.
- 42 Not in PICO
- 43 Walter, F. M., Humphrys, E., Tso, S., Johnson, M. & Cohn, S. (2010) Patient understanding of moles  
44 and skin cancer, and factors influencing presentation in primary care: a qualitative study. *Bmc  
45 Family Practice*, 11.
- 46 Narrative review
- 47 Walter, F. M., Morris, H. C., Humphrys, E., Hall, P. N., Kinmonth, A. L., Prevost, A. T., Wilson, E. C.,  
48 Burrows, N., Norris, P., Johnson, M. & Emery, J. (2010) Protocol for the MoleMate UK Trial: a  
49 randomised controlled trial of the MoleMate system in the management of pigmented skin  
50 lesions in primary care [ISRCTN 79932379]. *Bmc Family Practice*, 11: 36.
- 51 Protocol



- 1 Walter, F. M. P. (2012) The diagnostic accuracy of the 7-point checklist to assess pigmented skin  
 2 lesions in primary care. *Asia-Pacific Journal of Clinical Oncology*, Conference: November.  
 3 Same data as Walter 2012
- 4 Walton, R. G. (1994) Recognition and importance of precursor lesions in the diagnosis of early  
 5 cutaneous malignant melanoma. *International Journal of Dermatology*, 33: 302-307.  
 6 Narrative review
- 7 Ward, J. (1994) General practitioners' estimates of the ideal benign-to-malignant ratio for excised  
 8 pigmented lesions. *Australian Journal of Public Health*, 18: 454-455.  
 9 Not in PICO
- 10 Watkins, J. & Watkins, J. (2010) Dermatology and the community nurse: actinic (solar) keratosis.  
 11 [Review] [13 refs]. *British Journal of Community Nursing*, 15: 6-1.  
 12 Narrative review
- 13 Westbrook, R. H. G. (2006) Diagnostic accuracy for skin cancer: Comparison of general practitioner  
 14 with dermatologist and dermatopathologist [1]. *Journal of Dermatological Treatment*, 17: 57-58.  
 15 Not in PICO
- 16 Whited, J. D., Hall, R. P., Simel, D. L. & Horner, R. D. (1997) Primary care clinicians' performance for  
 17 detecting actinic keratoses and skin cancer. *Archives of Internal Medicine*, 157: 985-990.  
 18 Not in PICO
- 19 Wietfeldt, E. D., Thiele, J., Wietfeldt, E. D. & Thiele, J. (2009) Malignancies of the anal margin and  
 20 perianal skin. *Clinics in Colon & Rectal Surgery*, 22: 127-135.  
 21 Narrative review
- 22 Wilson, E. C., Emery, J. D., Kinmonth, A. L., Prevost, A. T., Morris, H. C., Humphrys, E., Hall, P. N.,  
 23 Burrows, N., Bradshaw, L., Walls, J., Norris, P., Johnson, M. & Walter, F. M. (2013) The cost-  
 24 effectiveness of a novel SIAscopic diagnostic aid for the management of pigmented skin lesions in  
 25 primary care: a decision-analytic model. *Value in Health*, 16: 356-366.  
 26 Same data as Walter (2012) already included.
- 27 Wood, A., Morris, H., Emery, J., Hall, P. N., Cotton, S., Prevost, A. T., Walter, F. M., Wood, A., Morris,  
 28 H., Emery, J., Hall, P. N., Cotton, S., Prevost, A. T. & Walter, F. M. (2008) Evaluation of the  
 29 MoleMate training program for assessment of suspicious pigmented lesions in primary care.  
 30 *Informatics in Primary Care*, 16: 41-50.  
 31 Not in PICO (for signs and symptoms or for tests)
- 32 Wray, E. V., Brant, B., Hussain, F. & Muller, F. M. (2013) A new model of teledermoscopy combining  
 33 service and education. *British Journal of Dermatology*, 169: 139.  
 34 Not in PICO
- 35 Youl, P. H., Raasch, B. A., Janda, M., Aitken, J. F., Youl, P. H., Raasch, B. A., Janda, M. & Aitken, J. F.  
 36 (2007) The effect of an educational programme to improve the skills of general practitioners in  
 37 diagnosing melanocytic/pigmented lesions. *Clinical & Experimental Dermatology*, 32: 365-370.  
 38 Not in PICO
- 39 Youl, P. H., Baade, P. D., Janda, M., del Mar, C. B., Whiteman, D. C. & Aitken, J. F. (2007) Diagnosing  
 40 skin cancer in primary care: how do mainstream general practitioners compare with primary care  
 41 skin cancer clinic doctors? *Medical Journal of Australia*, 187: 215-220.  
 42 Not in PICO: Data only reported for 3231[excised]/8790[examined] patients.
- 43 Zortea, M., Schopf, T. R., Thon, K., Geilhufe, M., Hindberg, K., Kirchesch, H., Mollersen, K., Schulz, J.,  
 44 Skrovseth, S. O. & Godtlielsen, F. (2014) Performance of a dermoscopy-based computer vision  
 45 system for the diagnosis of pigmented skin lesions compared with visual evaluation by  
 46 experienced dermatologists. *Artificial Intelligence in Medicine*, 60: 13-26.  
 47 Not in PICO
- 48
- 49 **Review question:**  
 50 Which investigations of symptoms of suspected malignant melanoma should be done with clinical  
 51 responsibility retained by primary care?

**Results**

**Literature search**


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1980-2013	875	206	03/05/2013
<i>Premedline</i>	1980-2013	69	29	03/05/2013
<i>Embase</i>	1980-2013	1413	130	03/05/2013
<i>Cochrane Library</i>	1980-2013	129	9	08/05/2013
<i>Psychinfo</i>	1980-2013	9	1	08/05/2013
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	1980-2013	431	98	08/05/2013

Total number of studies identified after de-duplication: 300

**Update Search**


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	2013-19/08/2014	34	2	19/08/2014
<i>Premedline</i>	2013-19/08/2014	105	17	19/08/2014
<i>Embase</i>	2013-19/08/2014	73	28	19/08/2014
<i>Cochrane Library</i>	2013-19/08/2014	52	0	19/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	2013-19/08/2014	70	20	19/08/2014

Total References retrieved (after de-duplication): 42



**Risk of bias in the included studies**

1 The risk of bias and applicability concerns are summarised per study in the figure below. The main  
 2 issues to note are that the study populations may not be directly representative of an unselected  
 3 symptomatic population of patients presenting to the UK-based GP, that the criteria for malignancy  
 4 of the index test are not specified in one case which may limit its external validity, and that the  
 5 results presented are based on a best case scenario, and are therefore likely to be inflated, and only  
 6 available for skin malignancy as a whole in some cases and not for malignant melanoma separately.  
 7 The reference standards employed were also subject to high or unclear risk of bias in the majority of  
 8 the studies.  
 9



10  
11  
12  
13

**Study results**

Table 1: Melanoma: SIAscan/MoleMate

Study	Intervention	Prevalence	Sensitivity % (95% CI)	Specificity % (95% CI)	Positive predictive value % (95% CI)	False negativity rate %
Emery (2010)	SIAscan/MoleMate: Moncrieff scoring system	England development set: 24 "suspicious" and 3 melanomas /422 lesions	54 (35-72)	77 (73-81)	12 (7.5-20)	46
Emery (2010)	SIAscan/MoleMate: Primary scare scoring algorithm	England validation set: 6 "suspicious" and 2 melanomas /208 lesions	50 (18-81)	84 (78-88)	9 (3-22)	50
Emery (2010)	SIAscan/MoleMate: Primary scare scoring algorithm	Australia dataset: 45 "suspicious" and 11 melanomas /581 lesions	44 (32-58)	95 (93-97)	52 (38-66)	56

Walter (2012)	SIAscan/MoleMate	18 melanomas/ 766 lesions	100 (78.1-100)	71.79 (68.4-75)	7.86 (4.9-12.3)	0
---------------	------------------	---------------------------	----------------	-----------------	-----------------	---

1  
2

Table 2: Melanoma: Dermoscopy/dermatoscopy

Study	Intervention	Prevalence	Sensitivity % (95% CI)	Specificity % (95% CI)	Positive predictive value % (95% CI)	False negativity rate %
Menzies (2009)	Dermoscopy	Unclear/331 lesions	53.1 (34.7-70.9)	89 (84.9-92.3)	34 (21.2-48.8)	46.9
Menzies (2009)	Dermoscopy ± sequential digital dermoscopy imaging	Unclear/331 lesions	71.9 (53.3-86.3)	86.6 (82.2-90.3)	36.4 (24.7-49.6)	28.1
Menzies (2009)	Sequential digital dermoscopy imaging	Unclear/149 lesions	72.7 (39-94)	92.8 (87.1-96.5)	44.4 (21.5-69.2)	27.3
Rosendahl (2011)	Clinical images and dermatoscopy	138 malignancies/463 lesions	82.6	80	Not reported	17.4

3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

There was no evidence relating to the diagnostic accuracy of biopsy or ophthalmoscopy for diagnosing malignant melanoma in a primary care setting.

**Evidence statement(s):**

SIAscan/MoleMate (2 studies, N = 1977 lesions) performed in symptomatic patients presenting in a primary care setting is associated with sensitivities ranging between 44-100%, specificities ranging between 71.79-95%, positive predictive values ranging between 7.86-52%, and false negativity rates ranging between 0-56% for skin cancer/malignant melanoma. The studies were each associated with 3-4 bias/applicability concerns (see also Table 1).

Dermoscopy/dermoscopy with and without clinical images or sequential digital dermoscopy imaging (2 studies, N = 794 lesions) performed in symptomatic patients presenting in a primary care setting is associated with sensitivities ranging between 53.1- 82.6%, specificities ranging between 80-92.8%, positive predictive values ranging between 34-44.4%, and false negativity rates ranging between 17.4-46.9% for skin cancer/malignant melanoma. The studies were each associated with 3 bias/applicability concerns (see also Table 2).

**Evidence tables**

**Emery (2010)**

PATIENT SELECTION	
A. risk of bias	
Patient sampling	Prospective series of pigmented lesions recruited from England (6 general practices covering urban, suburban and rural areas with a registered population of 52913) and Australia (3 primary care skin

	cancer clinics operated by GPs from a metropolitan area)
Was a consecutive or random sample of patients enrolled?	<b>Unclear</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>England: N = 389 patients, mean age = 44.9 years, 68.6% females with, interpretable images from N = 630 lesions. 0/630 lesions were squamous cell carcinoma, 0/630 lesions were basal cell carcinoma, 5/630 lesions were melanoma, and 0/630 lesions were lentigo maligna (melanoma). For the evaluation of SIAscopy this sample was further split into 2 samples: Development: N = 422 lesions of which 0 were squamous cell carcinoma, 0 were basal cell carcinoma, 3 were melanoma and 0 were lentigo maligna. Validation: N = 208 lesions of which 0 were squamous cell carcinoma, 0 were basal cell carcinoma, 2 were melanoma and 0 were lentigo maligna.</p> <p>Australia: N = 469 patients, mean age = 50 years, 48% females, with interpretable images from N = 581 lesions. 0/581 lesions were squamous cell carcinoma, 22/581 lesions were basal cell carcinoma, 7/581 lesions were melanoma, and 4/581 lesions were lentigo maligna (melanoma).</p> <p><u>Inclusion criteria:</u>  England: Patients aged &gt; 18 years were recruited into the study by their GP if they presented with concerns about a pigmented skin lesion between January 2005 and January 2006.  Australia: Patients aged &gt; 18 years were recruited into the study by their GP if they presented with concerns about a pigmented skin lesion between April 2008 and January 2009. Additional lesions were also included when a pigmented skin lesion was identified as potentially suspicious during their clinical examination</p> <p><u>Exclusion criteria:</u> None reported.</p> <p><u>Clinical setting:</u> Primary care, UK, and primary care skin cancer practice, Queensland Australia.</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	<p>Pigmented skin lesions that concerned patients, which were evaluated using macroscopic clinical photographs, dermoscopic images and SIAscan.</p> <p>SIAscan images and data (including the location of the lesion and the age group and sex of the patients) were assessed by a SIAscopy expert, who was blinded to the 7-item melanoma checklist results and clinical photographs. The SIAscopy expert scored the presence or absence of each specific SIAscopic feature including those previously associated with melanoma (Moncrieff et al. (2002) Br J Dermatol, 146: 448-57): Size of lesion, age of patient, dermal melanin, collagen holes and blood displacement with erythematous blush. Additional features that were also scored were blood vessels, white dots on the collagen view, blood lacunes and a cerebriform melanin pattern.</p> <p>From this information a primary care scoring algorithm was developed:</p>

	<p>All lesions -&gt; Any collagen white dots OR cerebriform pattern?                  Yes -&gt; Seborrheic keratosis STOP                  No -&gt; Any blood lacunes?                  Yes -&gt; Haemangioma STOP                  No -&gt;                  Dermal melanin within the lesion: 3 points                  Presence of any blood vessels: 2 points                  Blood displacement with erythematous blush: 1 point                  Maximum diameter &gt; 6 mm: 1 point                  For every COMPLETED 15 years of age: 1 point                  Score of 6 or more?                  Yes -&gt; Suspicious                  No-&gt; Not suspicious</p>
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Histopathology or in-person clinical review of the lesion by one expert, including the 7-point melanoma checklist and digital dermoscopy or clinical diagnosis made on the basis of the 7-point melanoma checklist, photographic and dermoscopy images
Is the reference standard likely to correctly classify the target condition?	<b>Unclear</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Yes</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Unclear concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients are accounted for in the results
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	Analysis was on a per-lesion basis rather than a per-patient basis. Please note the diagnostic accuracy results given above relates to the diagnosis of a "suspicious" lesion, and not just melanomas. The 2-by-2 tables could not be extracted.
<b>1</b>	
<b>2</b>	
<b>Menzies (2009)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	

Patient sampling	Prospective consecutive patient series
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>102 GPs were initially recruited, 74 of whom completed the educational intervention and online assessment of learning. 63 GPs from 19 practices assessed 374 lesions as requiring referral or excision (median number of lesions per GP = 6, mean = 5.9, SD = 3). No other information reported.</p> <p><u>Inclusion criteria:</u> Consecutive patients with pigmented lesions (some brown, grey, blue or black colour within some part of the lesion) which, after routine naked eye examination by the GP would have been biopsied or referred (that is, a suspicious pigmented lesion) presenting to GPs who worked in practices in metropolitan Perth with a minimum of 3 doctors. The GPs and practices had to meet the following criteria: A history of excision or referral of at least 10 pigmented skin lesions over the previous 12-month period for each doctor, and available space for a sequential digital dermoscopy imaging device. During the pretrial period all GPs underwent a training program in the use of dermoscopy and sequential digital dermoscopy imaging. This included reading a textbook in dermoscopic diagnosis and the use of sequential digital dermoscopy imaging, and a tutorial on a CD-rom showing examples of changed and unchanged monitored lesions. In addition, GPs attended a 2 hour workshop on the use of diagnostic devices and recruitment procedures. The training was assessed through an online pre- and post-education intervention test of 245 lesions not seen in the textbook or on the CD-rom. Answers were provided during the post-test as a component of the educational intervention. Before formal patient recruitment began, GPs assessed at least one pretrial lesion to determine the quality of imaging with the sequential digital dermoscopy imaging device and undertake completion of the trial paperwork. GPs were allowed to practise using the dermoscopy device during this pretrial phase. The pretrial phase of education and run-in period occurred from May 2005 to January 2006.</p> <p><u>Exclusion criteria:</u> GPs who already used dermoscopy or sequential digital dermoscopy imaging in their routine practice.</p> <p><u>Clinical setting:</u> Primary care, Australia.</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	<p>Dermoscopy examination performed using a hand-held oil immersion glass plate device (Delta 10 Dermatoscope: Heine Ltd, Herrsching, Germany). All lesions were then photographed with the dermoscopy imaging device (Sentry pilot; Polartechnics Ltd, Sydney, Australia). This incorporated a higher resolution megapixel camera which could be used for telemedicine diagnosis and for colour-calibrated sequential digital dermoscopy imaging. For melanocytic lesions that did not have dermoscopic evidence of melanoma, but were still considered to be suspicious, short term sequential digital dermoscopy imaging was performed over a period of 3 months.</p>

Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Hierarchical diagnosis order of (1) histopathology, (2) unchanged lesions after sequential digital dermoscopy imaging indicating a benign diagnosis, (3) specialist opinion following referral, and (4) dermoscopy telemedicine. All sequential digital dermoscopy imaging and dermoscopy telemedicine images of nonexcised lesions were reviewed by an expert in dermoscopy and sequential digital dermoscopy imaging and a diagnosis recorded.
Is the reference standard likely to correctly classify the target condition?	<b>Unclear</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>High risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	The results only appear to be reported for 348/374 lesions for dermoscopy and dermoscopy ± sequential digital dermoscopy imaging (for melanoma: of which 9 had an unknown diagnosis and 8 had a diagnosis of basal cell carcinoma or Bowen disease – these were all excluded from the analyses) and for 160/192 lesions that received sequential digital dermoscopy imaging (for melanoma: of which 9 had an unknown diagnosis and 2 had a diagnosis of basal cell carcinoma or Bowen disease – these were all excluded from the analyses).
Was there an appropriate interval between index test and reference standard?	<b>Unclear, but probably</b>
Did all patients receive the same reference standard?	<b>No</b>
Were all patients included in the analysis?	<b>No</b>
<b>Could the patient flow have introduced bias?</b>	<b>High risk</b>
<b>NOTES</b>	Analysis appears to be on a per-lesion basis rather than a per-patient basis. The 2-by-2 tables could not be extracted.
<b>1 Rosendahl (2011)</b>	
<b>2 PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Consecutive series of lesions submitted for histology from the primary care skin cancer clinic of one of the authors.
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Probably</b>



<b>Could the selection of patients have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
<b>Patient characteristics and setting</b>	<p>N = 463 pigmented lesions from 389 patients, mean (SD) age = 57 (17) years, 32.6% females. Lesion location: Trunk: N = 241; extremities: N = 128; head and face: N = 82; palms and soles: N = 10. Histopathologically, 246 pigmented lesions turned out to be melanocytic and 217 were of non-melanocytic origin.</p> <p>Final diagnoses:  Malignant lesions: Basal cell carcinoma: N = 72; squamous cell carcinoma: N = 37; melanoma: N = 29.  Benign lesions: Melanocytic nevi: N = 217; seborrheic keratosis: N = 43; solar lentigo: N = 37; lichen planus-like keratosis: N = 21, others: N = 7.</p> <p><u>Inclusion criteria:</u> All pigmented lesions biopsied or excised during a 30-month period. <i>Patients included are only those who received resection. This changes the spectrum of disease as it excludes patients with lesions that were not considered concerning enough to warrant resection.</i></p> <p><u>Exclusion criteria:</u> Poor image quality (N = 3).</p> <p><u>Clinical setting:</u> Primary care skin cancer practice in Queensland, Australia</p>	
<b>Are there concerns that the included patients and setting do not match the review question?</b>		<b>Unclear concern</b>
<b>INDEX TEST</b>		
<b>A. Risk of bias</b>		
<b>Index test</b>	<p>For each lesion: A triplet of high-resolution digital images consisting of two clinical images (overview and close-up) followed by one dermatoscopic image. The clinical images were taken with Canon EOS digital single lens reflex cameras. The close-up was taken using a macro lens (60-mm f2.8 macro, Canon) with diffuse illumination at a constant reproduction ratio determined by a custom-fabricated spacer. The degree of magnification of the close-up images was similar to that of the dermatoscopy images. Dermatoscopic images were nonpolarising, preferentially using the Dermlite Fluid device (3 Gen, San Juan, Capistrano, Ca); alternatively Dermlite Foto (custom nonpolarised; 3 Gen) and Heine Delta 20 devices (Heines, Optotechnic GmbH&lt; Herrsching, Germany) were used for large and inaccessible lesions, respectively. Dermatoscopic photographs were taken with Canon EOS single lens reflex cameras. Images were presented to the assessors as powerpoint slides. After inspection of the images, the assessor was required to give a diagnosis (criteria not reported, so presumably based on qualitative criteria). Dermatoscopic images were also screened for asymmetry of structure and colour (“chaos”) and for clues to malignancy. Asymmetry of colour and structure were defined according to the basic principles of pattern analysis as revised by Kittler (2007, Dermatopathology: Practical &amp; Conceptual, 13:1). Clues to malignancy included: Eccentric structureless zone (any colour except skin colour), gray or blue structures, peripheral black dots or clods, segmental radial lines or pseudopods, polymorphous vessels, white lines, thick reticular or branched lines, and parallel lines on ridges (acral lesions). <i>Not further information regarding the specific cut-off criteria for malignancy reported. The reporting of the results suggests that the test performance is based on best possible scenario.</i></p>	
<b>Were the index test results interpreted without knowledge of the results of the reference standard?</b>		<b>Yes</b>

<b>Could the conduct or interpretation of the index test have introduced bias?</b>		<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>		<b>Unclear concern</b>
<b>REFERENCE STANDARD</b>		
<b>A. risk of bias</b>		
Reference standard(s)	Histopathology	
Is the reference standard likely to correctly classify the target condition?		<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?		<b>Yes</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		<b>Low concern</b>
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing		
Was there an appropriate interval between index test and reference standard?		<b>Yes</b>
Did all patients receive the same reference standard?		<b>Yes</b>
Were all patients included in the analysis?		<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>		<b>Low concern</b>
<b>NOTES</b>	The results are presented for all malignancies combined. The 2-by-2 table could not be extracted and the results could not be separated into the different malignancies	

1 **Walter (2012)**

<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Prospective series of suspicious pigmented lesions	
Was a consecutive or random sample of patients enrolled?		<b>Unclear</b>
Was a case-control design avoided?		<b>Yes</b>
Did the study avoid inappropriate exclusions?		<b>Unclear</b>
<b>Could the selection of patients have introduced bias?</b>		<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>		
Patient characteristics and setting	<p>N = 643 patients, mean age (SD) = 44.5 (16.7) years; 230 males / 413 females with N = 788 lesions:</p> <p><u>Inclusion criteria:</u> Patients aged <math>\geq 18</math> years presenting to one of the 15 participating general practices with a suspicious (any lesion presented by a patient, or opportunistically seen by a family doctor or practice nurse, that could not immediately be diagnosed as benign and about which the patient could not be reassured) pigmented lesion from March 2008 to May 2010.</p> <p><u>Exclusion criteria:</u> Patients who were unable to give informed consent or were considered inappropriate to include by their family doctor.</p> <p><u>Clinical setting:</u> UK primary care.</p>	

<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	Clinical assessment (clinical history and naked eye examination) followed by SIAscopy/MoleMate system (assessing clinician had completed a 2-hour training CD-ROM to identify relevant SIAscopic features of various pigmented skin lesions) .
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
<b>Reference standard(s)</b>	Expert opinion by a histologist or dermatologist or review by two other dermatology experts of the recorded clinical history and examination, a digital photograph, and MoleMate images where available with or without follow up 3-6 months later.
Is the reference standard likely to correctly classify the target condition?	<b>Unclear</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Unclear concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
<b>Flow and timing</b>	Data are missing for 22/788 lesions
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes Tests: No</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	Analysis was on a per-lesion basis rather than a per-patient basis. TP = 18, FN = 0, FP = 211, TN = 537.

1

2 **Cost-effectiveness evidence**

3

4 **Information sources and eligibility criteria**

5 The following databases were searched for economic evidence relevant to the PICO: MEDLINE,  
6 EMBASE, COCHRANE, NHS EED and HEED. Studies conducted in OECD countries other than the UK  
7 were considered.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

Studies were selected for inclusion in the evidence review if the following criteria were met:

- Both cost and health consequences of interventions reported (i.e. true cost-effectiveness analyses)
- Conducted in an OECD country
- Incremental results are reported or enough information is presented to allow incremental results to be derived
- Studies that matched the population, interventions, comparators and outcomes specified in PICO
- Studies that meet the applicability and quality criteria set out by NICE, including relevance to the NICE reference case and UK NHS

Note that studies that measured effectiveness using quality of life based outcomes (e.g. QALYs) were desirable but, where this evidence was unavailable, studies using alternative effectiveness measures (e.g. life years) were considered.


***Selection of studies***

The literature search results were screened by checking the article’s title and abstract for relevance to the review question. The full articles of non-excluded studies were then attained for appraisal and compared against the inclusion criteria specified above.

***Results***

The diagram below summarises the search and sifting process for this topic.

1 **Figure:** Summary of evidence search and sifting process for this topic



2  
3 It can be seen that, in total, 473 possibly relevant papers were identified. Of these, 471 papers were  
4 excluded at the initial sifting stage based on the title and abstract while two full papers were  
5 obtained for appraisal. One of these papers was excluded based on the full text as they were not  
6 applicable to the PICO or did not include an incremental analysis of both costs and health effects.  
7 Therefore, only one paper was included in the systematic review of the economic evidence for this  
8 topic; Wilson et al. 2012. Mowatt et al. 2010 was a comprehensive report conducted as part of the  
9 NIHR HTA programme. The study included was a cost-effectiveness analysis comparing standard care  
10 (clinical history, naked eye examination and completion of a seven point checklist) with standard  
11 care plus the addition of the Molemate system (SIAscopy scanner integrated with a diagnostic  
12 algorithm) for the diagnosis of potentially suspicious lesions.

13  
14 **Quality and applicability of included study**

15 Wilson et al. 2012 was deemed to be directly applicable to the decision problem that we are  
16 evaluating since it considers relevant comparators in the UK primary care setting and takes a NHS  
17 and PSS perspective. Results were presented in terms of cost per QALY gained. No serious limitations  
18 were identified with the analysis, which was generally of a very high standard.

19 **Table:** Methodological quality and applicability of the included study

<b>Methodological quality</b>	<b>Applicability</b>	
	<b>Directly applicable</b>	<b>Partially applicable</b>
<b>Minor limitations</b>	Wilson et al. 2012	

<b><i>Methodological quality</i></b>	<b><i>Applicability</i></b>	
<b>Potentially serious limitations</b>		
<b>Very serious limitations</b>		

1

2 ***Modified GRADE table***

3 The primary results of the analysis by Wilson et al. 2012 are summarised in the modified GRADE  
4 table below.

5

6

7

**Modified GRADE table showing the included evidence (Wilson et al. 2012) on the cost-effectiveness of adding the molemate system to standard care in patients presenting in primary care with suspected melanoma.**

Study	Population	Comparators	Costs	Effects	Incr costs	Incr effects	ICER	Uncertainty	Applicability and limitations
Wilson et al. 2012  UK study considering NHS and PSS perspective.  Cost-utility analysis (CUA).	Patients presenting in primary care with at least one suspicious pigmented lesion.	Standard Care: Lesions assessed by lead clinician following NICE guidelines including clinical history, naked eye examination and completion of 7 point checklist.	£1115	15.098 QALYs	Reference			<p><b>Threshold Sensitivity Analysis</b></p> <p>The maximum cost per Molemate scan which would result in an ICER less than £30,000 was found to be £290 per consultation.</p> <p><b>Deterministic Sensitivity Analysis</b></p> <p>Use of East of England cancer registry data rather than trial data resulted in an ICER of £3,172 per QALY</p> <p><b>Probabilistic Sensitivity Analysis</b></p> <p>66.1% of iterations led to an ICER below £30,000 per QALY. The molemate system was dominant in 19.6% and dominated in 7.9% of iterations.</p>	<p><b>Directly Applicable</b></p> <p>Analysis conducted from a UK Health Service perspective.</p> <p>Results reported as incremental cost per QALY.</p> <p><b>Minor Limitations</b></p> <p>Further one-way sensitivity analysis could have been conducted.</p>
		Standard Care (as above) plus the addition of the Molemate system (SIAscopy scanner integrated with a diagnostic algorithm)	£1133	15.108 QALYs	£18	0.01 QALYs	£1896 per QALY		
<b>Comments:</b>									

**1 Evidence statement**

2 Wilson et al (2012) compared the cost-effectiveness of the Molemate system (SIAscopy scanner  
3 integrated with a diagnostic algorithm) in addition to usual care (clinical history, naked eye  
4 examination and completion of a seven point checklist) in comparison to usual care alone for the  
5 diagnosis of potentially suspicious lesions. The authors found that the addition of the Molemate  
6 system would increase lifetime costs by £18 and yield an additional 0.01 QALYs per patient. The  
7 resulting ICER of £1,896 per QALY falls well below the NICE threshold of £20,000 per QALY and so  
8 the base case results suggest that Molemate is a cost-effective addition to usual care.

9 The addition of the Molemate scan also appears to be cost-effective in an alternative analysis in  
10 which East of England cancer registry data were used rather than the trial data with an ICER of  
11 £3,172 per QALY. Furthermore, a threshold analysis showed that the cost of adding the Molemate  
12 scan would have to exceed £290 for it to no longer be considered cost-effective at a threshold of  
13 £30,000 per QALY. The true cost of adding the Molemate scan is unlikely to be as high as this and so  
14 this too appears to be a strong result.

15 The probabilistic sensitivity analysis showed that, at a threshold of £20,000 per QALY, the addition of  
16 the Molemate scan was cost-effective in 60.3% of iterations. This suggests that there is considerable  
17 uncertainty, which the authors attribute to uncertainty in the sensitivity and specificity of Molemate  
18 versus usual care and the risk of disease progression in undiagnosed melanoma.

19 While these results appear favourable, further consideration needs to be given to the key effects  
20 that are driving the result. The results were primarily driven by the differences in diagnostic accuracy  
21 between the two strategies, which were informed by RCT evidence showing that Molemate had  
22 higher sensitivity and lower specificity than usual care. However, only the lower specificity result was  
23 found to be statistically significant. Indeed, the conclusion drawn from the trial was that Molemate  
24 did not add to best application of NICE guidelines in terms of appropriateness of referral.

25 Furthermore, the implications of the diagnostic accuracy data used in the model is that both  
26 appropriate and inappropriate referrals would be increased by using the Molemate system (driven  
27 by better sensitivity and poorer specificity, respectively). Therefore, the results of the model  
28 essentially suggest that benefits of picking up more cancer through appropriate referral outweigh  
29 the costs of making more inappropriate referrals. In other words, a policy of 'over-referring' may be  
30 cost-effective.

31 This interpretation has implications for the cost-effectiveness of the Molemate system itself as it  
32 could be argued that the Molemate system is not actually required to achieve such a policy. Being  
33 less strict as primary care gatekeepers would very likely lead to similarly cost-effective outcomes  
34 without the need for the additional spending on the Molemate system. Indeed, it could be further  
35 argued that it would be counter-intuitive to spend money on a system that has only been proven to  
36 decrease specificity in comparison to current best practice.

37  
38  
39  
40  
41



## References

### Included Studies

- Emery, J. D., Hunter, J., Hall, P. N., Watson, A. J., Moncrieff, M. & Walter, F. M. (2010) Accuracy of SIAscopy for pigmented skin lesions encountered in primary care: development and validation of a new diagnostic algorithm. *BMC Dermatology*, 10: 9.
- Menzies, S. W., Emery, J., Staples, M., Davies, S., McAvoy, B., Fletcher, J., Shahid, K. R., Reid, G., Avramidis, M., Ward, A. M., Burton, R. C. & Elwood, J. M. (2009) Impact of dermoscopy and short-term sequential digital dermoscopy imaging for the management of pigmented lesions in primary care: a sequential intervention trial. *British Journal of Dermatology*, 161: 1270-1277.
- Rosendahl, C., Tschandl, P., Cameron, A. & Kittler, H. (2011) Diagnostic accuracy of dermatoscopy for melanocytic and nonmelanocytic pigmented lesions. *Journal of the American Academy of Dermatology*, 64: 1068-1073.
- Walter, F.M., Morris, H.C., Humphrys, E., Hall, P.N., Prevost, A.T., Burrows, N., Bradshaw, L., Wilson, E.C., Norris, P., Walls, J., Johnson, M., Kinmonth, A.L., Emery, J.D. (2012). Effect of adding a diagnostic aid to best practice to manage suspicious pigmented lesions in primary care: randomised controlled trial. *BMJ*, 345: e4110.

### Excluded Studies

- (2009) New tools aid in diagnosing and detecting skin cancer in earliest stages. *Dermatology Nursing*, 21: 222-223.  
Narrative review
- Aberg, P., Birgersson, U., Elsner, P., Mohr, P. & Ollmar, S. (2011) Electrical impedance spectroscopy and the diagnostic accuracy for malignant melanoma. *Experimental Dermatology*, 20: 648-652.  
Not in PICO
- Achar, S. (1996) Principles of skin biopsies for the family physician. [Review] [14 refs]. *American Family Physician*, 54: 2411-2418.  
Narrative review
- Ackerman, A. B. (1988) A "changing mole" is not the best clue to clinical detection of an "early" malignant melanoma. *Archives of Dermatological Research*, 280: Suppl-4.  
Not in PICO
- Aharon, O., Abdulhalim, I., Arnon, O., Rosenberg, L., Dyomin, V. & Silberstein, E. (2011) Differential optical spectropolarimetric imaging system assisted by liquid crystal devices for skin imaging. *Journal of Biomedical Optics*, 16: 086008.  
Narrative review
- Ahmed, M. M., Moore, B. A. & Schmalbach, C. E. (2014) Utility of Head and Neck Cutaneous Squamous Cell Carcinoma Sentinel Node Biopsy: A Systematic Review. *Otolaryngology-Head and Neck Surgery*, 150: 180-187.  
Not in PICO
- Alendar, F., Drljevic, I., Drljevic, K. & Alendar, T. (2009) Early detection of melanoma skin cancer. *Bosnian Journal of Basic Medical Sciences*, 9: 77-80.  
Not in PICO
- Alexandrescu, D. T., Kauffman, C. L., Jatcoe, T. A., Hartmann, D. P., Vener, T., Wang, H., Derecho, C., Rajpurohit, Y., Wang, Y. & Palma, J. F. (2010) Melanoma-specific marker expression in skin biopsy tissues as a tool to facilitate melanoma diagnosis. *Journal of Investigative Dermatology*, 130: 1887-1892.  
Not in PICO
- Allon, I., Allon, D. M., Gal, G., Anavi, Y., Chaushu, G. & Kaplan, I. (2013) Re-evaluation of common paradigms regarding the clinical appearance of oral mucosal malignancies. *Journal of Oral Pathology and Medicine*, 42: 670-675.  
Not in PICO

- 1 Amin, K., Edmonds, K., Fleming, A. & Powell, B. (2011) Subungual malignant melanoma--re-learning  
2 the lesson. *BMJ Case Reports*, 2011, 2011.  
3 Not in PICO
- 4 Andersen, W. K. & Silvers, D. N. (1991) 'Melanoma? It can't be melanoma!' A subset of melanomas  
5 that defies clinical recognition. *JAMA*, 266: 3463-3465.  
6 Not in PICO
- 7 Anderson, A., Love, R. & Chan, J. (2012) Is sentinel node biopsy the standard of care in melanoma  
8 management? The opinions and practices of Australian specialists. *Australasian Journal of*  
9 *Dermatology*, 53: 93-97.  
10 Not in PICO
- 11 Antonio, J. R., Soubhia, R. M., D'Avila, S. C., Caldas, A. C., Tridico, L. A. & Alves, F. T. (2013)  
12 Correlation between dermoscopic and histopathological diagnoses of atypical nevi in a  
13 dermatology outpatient clinic of the Medical School of Sao Jose do Rio Preto, SP, Brazil. *Anais*  
14 *Brasileiros de Dermatologia*, 88: 199-203.  
15 Not in PICO
- 16 Apalla, Z., Lallas, A., Argenziano, G., Ricci, C., Piana, S., Moscarella, E., Longo, C. & Zalaudek, I. (2013)  
17 The light and the dark of dermoscopy in the early diagnosis of melanoma: Facts and  
18 controversies. *Clinics in Dermatology*, 31: 671-676.  
19 Narrative review
- 20 Argenziano, G., Puig, S., Zalaudek, I., Sera, F., Corona, R., Alsina, M., Barbato, F., Carrera, C., Ferrara,  
21 G., Guilabert, A., Massi, D., Moreno-Romero, J. A., Munoz-Santos, C., Petrillo, G., Segura, S.,  
22 Soyer, H. P., Zanchini, R. & Malvehy, J. (2006) Dermoscopy improves accuracy of primary care  
23 physicians to triage lesions suggestive of skin cancer. *Journal of Clinical Oncology*, 24: 1877-1882.  
24 Not in PICO (reference standard is expert opinion, not follow up and histopathology)
- 25 Argenziano, G., Albertini, G., Castagnetti, F., De Pace, B., Di Lernia, V., Longo, C., Pellacani, G., Piana,  
26 S., Ricci, C. & Zalaudek, I. (2012) Early diagnosis of melanoma: what is the impact of dermoscopy?  
27 *Dermatologic Therapy*, 25: 403-409.  
28 Narrative review
- 29 Argenziano, G., Cerroni, L., Zalaudek, I., Staibano, S., Hofmann-Wellenhof, R., Arpaia, N., Bakos, R.  
30 M., Balme, B., Bandic, J., Bandelloni, R., Brunasso, A. M. G., Cabo, H., Calcara, D. A., Carlos-  
31 Ortega, B., Carvalho, A. C., Casas, G., Dong, H. T., Ferrara, G., Filotico, R., Gomez, G., Halpern, A.,  
32 Ilardi, G., Ishiko, A., Kandiloglu, G., Kawasaki, H., Kobayashi, K., Koga, H., Kovalyshyn, I., Langford,  
33 D., Liu, X., Marghoob, A. A., Mascolo, M., Massone, C., Mazzoni, L., Menzies, S., Minagawa, A.,  
34 Nugnes, L., Ozdemir, F., Pellacani, G., Seidenari, S., Siamas, K., Stanganelli, I., Stoecker, W. V.,  
35 Tanaka, M., Thomas, L., Tschandl, P. & Kittler, H. (2012) Accuracy in melanoma detection: A 10-  
36 year multicenter survey. *Journal of the American Academy of Dermatology*, 67: 54-U274.  
37 Not in PICO
- 38 Argenziano, G., Giacomel, J., Abramavicus, A., Pellacani, G., Longo, C., De Pace, B., Albertini, G.,  
39 Cristofolini, M. & Zalaudek, I. (2012) Improving triage and management of patients with skin  
40 cancer: challenges and considerations for the future. *Expert Review of Anticancer Therapy*, 12:  
41 609-621.  
42 Narrative review
- 43 Ascierto, P. A., Palmieri, G., Botti, G., Satriano, R. A., Stanganelli, I., Bono, R., Testori, A., Bosco, L.,  
44 Daponte, A., Caraco, C., Chiofalo, M. G., Melucci, M. T., Calignano, R., Tatangelo, F., Cochran, A. J.,  
45 Castello, G. & Melanoma Cooperative Group (2003) Early diagnosis of malignant melanoma:  
46 Proposal of a working formulation for the management of cutaneous pigmented lesions from the  
47 Melanoma Cooperative Group. *International Journal of Oncology*, 22: 1209-1215.  
48 Not in PICO
- 49 Augsburger, J. J. & Shields, J. A. (1984) Fine needle aspiration biopsy of solid intraocular tumors:  
50 indications, instrumentation and techniques. *Ophthalmic Surgery*, 15: 34-40.  
51 Not in PICO

- 1 Azimi, P., Mohmmadi, H. R. & Refieezadeh, M. (2012) Primary pineal melanoma presenting with  
2 leptomeningeal spreading in a 22-year-old woman: a case report. *Journal of Medical Case Reports*  
3 *[Electronic Resource]*, 6: 165.  
4 Not in PICO
- 5 Baade, P. D., Del Mar, C. B., Lowe, J. B., Stanton, W. R. & Balanda, K. P. (2005) Clinical diagnosis and  
6 management of suspicious pigmented skin lesions--a survey of GPs. *Australian Family Physician*,  
7 34: 79-83.  
8 Not in PICO
- 9 Baade, P. D., Youl, P. H., English, D. R., Mark, E. J. & Aitken, J. F. (2007) Clinical pathways to diagnose  
10 melanoma: a population-based study. *Melanoma Research*, 17: 243-249.  
11 Not in PICO
- 12 Baade, P. D., Youl, P. H., Janda, M., Whiteman, D. C., Del Mar, C. B. & Aitken, J. F. (2008) Factors  
13 associated with the number of lesions excised for each skin cancer: a study of primary care  
14 physicians in Queensland, Australia. *Archives of Dermatology*, 144: 1468-1476.  
15 Not in PICO
- 16 Bafounta, M. L., Beauchet, A., Aegerter, P. & Saiag, P. (2001) Is dermoscopy (epiluminescence  
17 microscopy) useful for the diagnosis of melanoma: results of a meta-analysis using techniques  
18 adapted to the evaluation of diagnostic tests (DARE structured abstract). *Archives of*  
19 *Dermatology*, 137: 1343-1350.  
20 Not in PICO (secondary care)
- 21 Baldwin, B. T., Cherpelis, B. S. & Fenske, N. A. (2010) Discussing Sentinel Lymph Node Biopsy With  
22 Your Melanoma Patients. *Journal of Drugs in Dermatology*, 9: 790-792.  
23 Not in PICO
- 24 Balois, T. & Amar, M. B. (2014) Morphology of melanocytic lesions in situ. *Science Reporter*, 4: 3622.  
25 Not in PICO
- 26 Bichakjian, C. K., Halpern, A. C., Johnson, T. M., Foote, H. A., Grichnik, J. M., Swetter, S. M., Tsao, H.,  
27 Barbosa, V. H., Chuang, T. Y., Duvic, M., Ho, V. C., Sober, A. J., Beutner, K. R., Bhushan, R., Smith,  
28 B. W. & American Academy of Dermatology (2011) Guidelines of care for the management of  
29 primary cutaneous melanoma. American Academy of Dermatology. *Journal of the American*  
30 *Academy of Dermatology*, 65: 1032-1047.  
31 Guideline
- 32 Bishop, J. N., Bataille, V., Gavin, A., Lens, M., Marsden, J., Mathews, T. & Wheelhouse, C. (2007) The  
33 prevention, diagnosis, referral and management of melanoma of the skin: concise guidelines.  
34 [Review] [9 refs]. *Clinical Medicine*, 7: 283-290.  
35 Guideline
- 36 Blum, A. (1994) [Diagnostic dermoscopic algorithms]. [Review] [30 refs] [German]. *Hautarzt*, 56: 81-  
37 93.  
38 Narrative review
- 39 Boiko, P. E. & Piepkorn, M. W. (1994) Reliability of skin biopsy pathology. *Journal of the American*  
40 *Board of Family Practice*, 7: 371-374.  
41 Not in PICO
- 42 Boiko, P. E., Koepsell, T. D., Larson, E. B. & Wagner, E. H. (1996) Skin cancer diagnosis in a primary  
43 care setting. *Journal of the American Academy of Dermatology*, 34: 608-611.  
44 Not in PICO
- 45 Bomm, L., Benez, M. D., Maceira, J. M., Succi, I. C. & Scotelaro, M. F. (2013) Biopsy guided by  
46 dermoscopy in cutaneous pigmented lesion - Case report. *Anais Brasileiros de Dermatologia*, 88:  
47 125-127.  
48 Not in PICO
- 49 Bonfa, R., Bonamigo, R. R., Bonfa, R., Duro, K. M., Furian, R. D. & Zelmanowicz, A. M. (2011) Early  
50 diagnosis of cutaneous melanoma: an observation in southern Brazil. *Anais Brasileiros de*

- 1 *Dermatologia*, 86: 215-221.  
2 Not in PICO
- 3 Bordeaux, J. S., Lu, K. Q. & Cooper, K. D. (2007) Melanoma: prevention and early detection. [Review]  
4 [73 refs]. *Seminars in Oncology*, 34: 460-466.  
5 Narrative review
- 6 Bourdeaud'hui, F. & del, M., V (2011) [Managing moles in general practice]. [French]. *Revue*  
7 *Medicale de Bruxelles*, 32: 205-209.  
8 Narrative review
- 9 Bowns, I. R., Collins, K., Walters, S. J. & McDonagh, A. J. (2006) Telemedicine in dermatology: a  
10 randomised controlled trial. *Health Technology Assessment (Winchester, England)*, 10: iii-iv.  
11 Not in PICO
- 12 Braun, R. P., Rabinovitz, H., Oliviero, M., Kopf, A. W., Saurat, J. H. & Thomas, L. (2002)  
13 [Dermatoscopy of pigmented lesions]. [Review] [112 refs] [French]. *Annales de Dermatologie et*  
14 *de Venereologie*, 129: 187-202.  
15 Narrative review
- 16 Braun, R. P., Gaide, O., Le Gal, F. A., Saurat, J. H. & Marghoob, A. A. (2007) [Follow-up of melanoma  
17 lesions]. [Review] [5 refs] [French]. *Revue Medicale Suisse*, 3: 1119-1123.  
18 Narrative review
- 19 Breitbart, E. W., Mohsenian, F., Roser, M., Schiers, C., Wiebecke, G. F., Reimitz, P. E. & Hohne, K. H.  
20 (1989) [Clinical recognition of early forms of malignant melanoma]. [German]. *Onkologie*, 12:  
21 264-268.  
22 Not in PICO
- 23 Brenner, S. & Tamir, E. (2002) Early detection of melanoma: the best strategy for a favorable  
24 prognosis. [Review] [74 refs]. *Clinics in Dermatology*, 20: 203-211.  
25 Narrative review
- 26 Bricknell, M. C. (1993) Skin biopsies of pigmented skin lesions performed by general practitioners  
27 and hospital specialists. *British Journal of General Practice*, 43: 199-201.  
28 Not in PICO
- 29 Bristow, I. R. & Bowling, J. (2009) Dermoscopy as a technique for the early identification of foot  
30 melanoma. *Journal of Foot and Ankle Research*, 2.  
31 Narrative review
- 32 Brochez, L., Verhaeghe, E., Grosshans, E., Haneke, E., Pierard, G., Ruiters, D. & Naeyaert, J. M. (2002)  
33 Inter-observer variation in the histopathological diagnosis of clinically suspicious pigmented skin  
34 lesions. *Journal of Pathology*, 196: 459-466.  
35 Not in PICO
- 36 Brown, M. D. (2010) Office management of melanoma patients. [Review]. *Seminars in Cutaneous*  
37 *Medicine & Surgery*, 29: 232-237.  
38 Narrative review
- 39 Brown, S. J. & Lawrence, C. M. (2006) The management of skin malignancy: to what extent should  
40 we rely on clinical diagnosis? *British Journal of Dermatology*, 155: 100-103.  
41 Not in PICO
- 42 Brundel, K. H. (1990) [Skin cancer in general practice]. [German]. *Dermatosen in Beruf und*  
43 *Umwelt.Occupational & Environmental Dermatoses*, 38: 54-57.  
44 Not in PICO
- 45 Buckley, D. & McMonagle, C. (2014) Melanoma in primary care. The role of the general practitioner.  
46 *Irish Journal of Medical Science*, 183: 363-368.  
47 Not in PICO
- 48 Buckley, D. & McMonagle, C. (2014) - Melanoma in primary care. The role of the general  
49 practitioner. - *Irish Journal of Medical Science*, 183: 363-368.  
50 Duplicate

- 1 Buis, P. A. J., Chorus, R. M. H. & van Diest, P. J. (2005) Value of histopathologic analysis of skin  
2 excisions by GPs. *British Journal of General Practice*, 55: 458-460.  
3 Not in PICO
- 4 Buljan, M., Situm, M., Bolanca, Z., Zivkovic, M. V. & Mihic, L. L. (2010) Multiple primary melanoma:  
5 epidemiological and prognostic implications; analysis of 36 cases. *Collegium Antropologicum*, 34:  
6 Suppl-4.  
7 Not in PICO
- 8 Burroni, M., Wollina, U., Torricelli, R., Gilardi, S., Dell'Eva, G., Helm, C., Bardey, W., Nami, N., Nobile,  
9 F., Ceccarini, M., Pomponi, A., Alessandro, B. & Rubegni, P. (2011) Impact of digital dermoscopy  
10 analysis on the decision to follow up or to excise a pigmented skin lesion: a multicentre study.  
11 *Skin Research & Technology*, 17: 451-460.  
12 Not in PICO (secondary care)
- 13 Carli, P., De, G., V, Nardini, P., Mannone, F., Palli, D. & Giannotti, B. (2002) Melanoma detection rate  
14 and concordance between self-skin examination and clinical evaluation in patients attending a  
15 pigmented lesion clinic in Italy. *British Journal of Dermatology*, 146: 261-266.  
16 Not in PICO
- 17 Carli, P., De Giorgi, V., Argenziano, G., Palli, D. & Giannotti, B. (2002) Pre-operative diagnosis of  
18 pigmented skin lesions: in vivo dermoscopy performs better than dermoscopy on photographic  
19 images. *Journal of the European Academy of Dermatology and Venereology*, 16: 339-346.  
20 Not in PICO
- 21 Carli, P., De, G., V, Betti, R., Vergani, R., Catricala, C., Mariani, G., Simonacci, M., Bettacchi, A.,  
22 Bottoni, U., Lo, S. G., Mulas, P. & Giannotti, B. (2003) Relationship between cause of referral and  
23 diagnostic outcome in pigmented lesion clinics: a multicentre survey of the Italian  
24 Multidisciplinary Group on Melanoma (GIPMe). *Melanoma Research*, 13: 207-211.  
25 Not in PICO
- 26 Carlson, J. A., Mu, X. C., Slominski, A., Weismann, K., Crowson, A. N., Malfetano, J., Prieto, V. G. &  
27 Mihm, M. C., Jr. (2002) Melanocytic proliferations associated with lichen sclerosus. *Archives of*  
28 *Dermatology*, 138: 77-87.  
29 Not in PICO
- 30 Carlson, J. A., Ross, J. S. & Slominski, A. J. (2009) New techniques in dermatopathology that help to  
31 diagnose and prognosticate melanoma. *Clinics in Dermatology*, 27: 75-102.  
32 Narrative review
- 33 Castelli, F. (1993) [Cutaneous melanoma at the Turin Melanoma Center. Correlations of anamnestic  
34 data, histopathologic aspects and clinical picture in 306 stage-I patients (1990-1991)]. [Italian].  
35 *Minerva Medica*, 84: 615-620.  
36 Not in PICO
- 37 Chamberlain, A. & Ng, J. (2009) Cutaneous melanoma--atypical variants and presentations. [Review]  
38 [25 refs]. *Australian Family Physician*, 38: 476-482.  
39 Narrative review
- 40 Chattopadhyay, M. & Ha, T. (2013) How to examine a patient with suspected skin cancer. *Medicine*  
41 *(United Kingdom)*, 41: 400-401.  
42 Narrative review
- 43 Chen, S. C., Bravata, D. M., Weil, E. & Olkin, I. (2001) A comparison of dermatologists' and primary  
44 care physicians' accuracy in diagnosing melanoma - A systematic review. *Archives of*  
45 *Dermatology*, 137: 1627-1634.  
46 Not in PICO
- 47 Chen, S. C., Pennie, M. L., Kolm, P., Warshaw, E. M., Weisberg, E. L., Brown, K. M., Ming, M. E. &  
48 Weintraub, W. S. (2006) Diagnosing and managing cutaneous pigmented lesions: Primary care  
49 physicians versus dermatologists. *Journal of General Internal Medicine*, 21: 678-682.  
50 Not in PICO

- 1 Cheng, H., Oakley, A. & Rademaker, M. (2013) Please see this child with ? melanoma. *Australasian*  
2 *Journal of Dermatology*, 54: 35.  
3 Not in PICO
- 4 Cheng, H., Oakley, A. & Rademaker, M. (2014) - Change in a child's naevus prompts referral to a  
5 dermatology service. - *Journal of Primary Health Care*, 6: 123-128.  
6 Not in PICO
- 7 Chiu, V., Won, E., Malik, M. & Weinstock, M. A. (2006) The use of mole-mapping diagrams to  
8 increase skin self-examination accuracy. *Journal of the American Academy of Dermatology*, 55:  
9 245-250.  
10 Not in PICO
- 11 Ciocan, D., Barbe, C., Aubin, F., Granel-Brocard, F., Lipsker, D., Velten, M., Dalac, S., Truchetet, F.,  
12 Michel, C., Mitschler, A., Arnoult, G., Buemi, A., Dalle, S., Bernard, P., Woronoff, A. S. & Grange, F.  
13 (2013) Distinctive features of melanoma and its management in elderly patients: a population-  
14 based study in France. *JAMA Dermatology*, 149: 1150-1157.  
15 Not in PICO
- 16 Ciocan, D., Barbe, C., Aubin, F., Granel-Brocard, F., Lipsker, D., Velten, M., Dalac, S., Truchetet, F.,  
17 Michel, C., Mitschler, A., Arnoult, G., Buemi, A., Dalle, S., Bernard, P., Woronoff, A. S. & Grange, F.  
18 (2013) Distinctive Features of Melanoma and Its Management in Elderly Patients A Population-  
19 Based Study in France. *JAMA Dermatology*, 149: 1150-1157.  
20 Not in PICO
- 21 Civantos, F., Zitsch, R. & Bared, A. (2007) Sentinel node biopsy in oral squamous cell carcinoma.  
22 [Review] [49 refs]. *Journal of Surgical Oncology*, 96: 330-336.  
23 Not in PICO
- 24 Cockerell, C. J., Howell, J. B. & Balch, C. M. (1993) Think melanoma. [Review] [28 refs][Erratum  
25 appears in South Med J 1994 Feb;87(2):168]. *Southern Medical Journal*, 86: 1325-1333.  
26 Narrative review
- 27 Cooke, K., McNoe, B. & Spears, G. (1993) General practice consultations involving pigmented naevi  
28 presented for assessment of malignancy. *New Zealand Medical Journal*, 106: 493-495.  
29 Not in PICO
- 30 Cooper, S. M. & Wojnarowska, F. (2002) The accuracy of clinical diagnosis of suspected premalignant  
31 and malignant skin lesions in renal transplant recipients. *Clinical & Experimental Dermatology*, 27:  
32 436-438.  
33 Not in PICO
- 34 Corbo, M. D., Vender, R. & Wismer, J. (2012) Comparison of Dermatologists' and Nondermatologists'  
35 Diagnostic Accuracy for Malignant Melanoma. *Journal of Cutaneous Medicine and Surgery*, 16:  
36 272-280.  
37 Not in PICO
- 38 Crocetti, E., Caldarella, A., Massi, D., Sacchettini, C., Amunni, G. & Borgognoni, L. (2013) Indicators of  
39 the standard of care for melanoma: Tuscany data. *Melanoma Research*, 23: 283-289.  
40 Not in PICO
- 41 Czerniak, B., Woyke, S., Domagala, W. & Krzysztolek, Z. (1983) Fine needle aspiration cytology of  
42 intraocular malignant melanoma. *Acta Cytologica*, 27: 157-165.  
43 Not in PICO
- 44 Dalal, A., Moss, R. H., Stanley, R. J., Stoecker, W. V., Gupta, K., Calcara, D. A., Xu, J., Shrestha, B.,  
45 Drugge, R., Malters, J. M. & Perry, L. A. (2011) Concentric decile segmentation of white and  
46 hypopigmented areas in dermoscopy images of skin lesions allows discrimination of malignant  
47 melanoma. *Computerized Medical Imaging & Graphics*, 35: 148-154.  
48 Narrative review
- 49 Damato, B. (2001) Detection of uveal melanoma by optometrists in the United Kingdom. *Ophthalmic*  
50 *& Physiological Optics*, 21: 268-271.  
51 Not in PICO

- 1 de Gannes, G. C., Ip, J. L., Martinka, M., Crawford, R. I. & Rivers, J. K. (2004) Early detection of skin  
2 cancer by family physicians: a pilot project. *Journal of Cutaneous Medicine & Surgery*, 8: 103-109.  
3 Not in PICO
- 4 De Giorgi, V., Grazzini, M., Rossari, S., Gori, A., Alfaioli, B., Papi, F., Savarese, I., Cervadoro, E. & Lotti,  
5 T. (2011) Adding dermatoscopy to naked eye examination of equivocal melanocytic skin lesions:  
6 effect on intention to excise by general dermatologists. *Clinical and Experimental Dermatology*,  
7 36: 255-259.  
8 Not in PICO
- 9 De Giorgi, V., Gori, A., Alfaioli, B., Rossari, S., Grazzini, M., Pata, M. A., Moretti, S. & Lotti, T. Early  
10 diagnosis for melanoma: Is open access to skin cancer clinics really significant? A prospective  
11 study. [References]. *Preventive Medicine: An International Journal Devoted to Practice and  
12 Theory* 51[3-4], 334-335. 2010.  
13 Not in PICO
- 14 de Queiroz Fuscaldi, L. A., Bucard, A. M., Alvarez, C. D. & Barcaui, C. B. (2011) Epidermolysis bullosa  
15 nevi: report of a case and review of the literature. *Case Reports Dermatology*, 3: 235-239.  
16 Not in PICO
- 17 De, G., V, Grazzini, M., Rossari, S., Gori, A., Papi, F., Scarfi, F., Savarese, I. & Gandini, S. (2012) Is skin  
18 self-examination for cutaneous melanoma detection still adequate? A retrospective study.  
19 *Dermatology*, 225: 31-36.  
20 Not in PICO
- 21 Debniak, T. (2007) Some molecular and clinical aspects of genetic predisposition to malignant  
22 melanoma and tumours of various site of origin. *Hereditary Cancer in Clinical Practice*, 5: 97-116.  
23 Not in PICO
- 24 Del Mar, C. B. & Lowe, J. B. (1997) The skin cancer workload in Australian general practice. *Australian  
25 Family Physician*, 26: Suppl-7.  
26 Not in PICO
- 27 Del Mar, C. B., Green, A. C. & Battistutta, D. (1997) Patterns of excision and referral from primary  
28 care of melanocytic lesions. *Melanoma Research*, 7: 496-499.  
29 Not in PICO
- 30 Demierre, M. F., Chung, C., Miller, D. R. & Geller, A. C. (2005) Early detection of thick melanomas in  
31 the United States: beware of the nodular subtype. *Archives of Dermatology*, 141: 745-750.  
32 Not in PICO
- 33 Dhawan, A. P. (1985) Early detection of cutaneous malignant melanoma by three-dimensional  
34 nevoscopy. *Computer Methods & Programs in Biomedicine*, 21: 59-68.  
35 Narrative review
- 36 Divito, S. J. & Ferris, L. K. (2010) Advances and short comings in the early diagnosis of melanoma.  
37 *Melanoma Research*, 20: 450-458.  
38 Narrative review
- 39 Dixon, A. J. & Hall, R. S. (2005) Managing skin cancer--23 golden rules. [Review] [0 refs]. *Australian  
40 Family Physician*, 34: 669-671.  
41 Narrative review
- 42 Dolianitis, C., Kelly, J., Wolfe, R. & Simpson, P. (2005) Comparative performance of 4 dermoscopic  
43 algorithms by nonexperts for the diagnosis of melanocytic lesions. *Archives of Dermatology*, 141:  
44 1008-1014.  
45 Not in PICO
- 46 Dove, S., Smith, M., Phillips, E. & Levell, N. (2010) Routine recording of dermoscopic images as an aid  
47 to diagnosis. *Journal of Visual Communication in Medicine*, 33: 150-152.  
48 Narrative review
- 49 Duff, C. G., Melsom, D., Rigby, H. S., Kenealy, J. M. & Townsend, P. L. (2001) A 6 year prospective  
50 analysis of the diagnosis of malignant melanoma in a pigmented-lesion clinic: even the experts

- 1 miss malignant melanomas, but not often. *British Journal of Plastic Surgery*, 54: 317-321.  
2 Not in PICO
- 3 Dummer, W., Doehnel, K. A. & Remy, W. (1993) [Videomicroscopy in differential diagnosis of skin  
4 tumors and secondary prevention of malignant melanoma]. [German]. *Hautarzt*, 44: 772-776.  
5 Not in PICO
- 6 Durbec, F., Vitry, F., Granel-Brocard, F., Lipsker, D., Aubin, F., Hedelin, G., Dalac, S., Truchetet, F.,  
7 Michel, C., Batard, M. L., Domissy-Baury, B., Halna, J. M., Schmutz, J. L., Delvincourt, C., Reuter,  
8 G., Dalle, S., Bernard, P., Danzon, A. & Grange, F. (2010) The role of circumstances of diagnosis  
9 and access to dermatological care in early diagnosis of cutaneous melanoma: a population-based  
10 study in France. *Archives of Dermatology*, 146: 240-246.  
11 Not in PICO
- 12 Durrani, A. J., Moir, G. C., Diaz-Cano, S. J. & Cerio, R. (2003) Malignant melanoma in an 8-year-old  
13 Caribbean girl: diagnostic criteria and utility of sentinel lymph node biopsy. *British Journal of*  
14 *Dermatology*, 148: 569-572.  
15 Not in PICO
- 16 Edlich, R. F., Becker, D. G., Long, W. B. & Masterson, T. M. (2004) Excisional biopsy of skin tumors.  
17 [Review] [25 refs]. *Journal of Long-Term Effects of Medical Implants*, 14: 201-214.  
18 Narrative review
- 19 Edman, R. L. & Wolfe, J. T. (2000) Prevention and early detection of malignant melanoma. *American*  
20 *Family Physician*, 62: 2277-2284.  
21 Narrative review
- 22 Eichhorn, R., Wessler, G., Scholz, M., Leupold, D., Stankovic, G., Buder, S., Stucker, M. & Hoffmann,  
23 K. (2009) Early diagnosis of melanotic melanoma based on laser-induced melanin fluorescence.  
24 *Journal of Biomedical Optics*, 14: 034033-034Jun.  
25 Narrative review
- 26 Elder, D. E. (2006) Pathology of melanoma. [Review] [48 refs]. *Clinical Cancer Research*, 12: t-2311s.  
27 Narrative review
- 28 Emery, J. (2011) Melanoma Improving diagnosis in general practice. *Australian Family Physician*, 40:  
29 991.  
30 Narrative review
- 31 Esdaile, B., Mahmud, I., Palmer, A. & Bowling, J. (2014) Diagnosing melanoma: how do we assess  
32 how good we are? *Clinical and Experimental Dermatology*, 39: 129-134.  
33 Not in PICO
- 34 Foley, C. C., Corby, P. & Barnes, L. (1111) A dermatology outpatient waiting list initiative. *Irish*  
35 *Medical Journal*, 106: -August.  
36 Not in PICO
- 37 Fox, G. N. (2008) Dermoscopy: An invaluable tool for evaluating skin lesions. *American Family*  
38 *Physician*, 78: 704-+.  
39 Narrative review
- 40 Friedman, T., Klein, D., Hadad, E., Westreich, M. & Shalom, A. (1111) [Diagnostic accuracy of skin  
41 lesions excised by a plastic surgeon]. [Hebrew]. *Harefuah*, 147: 305-308.  
42 Not in PICO
- 43 Gannes, G. C., Ip, J. L., Martinka, M., Crawford, R. I. & Rivers, J. K. (2004) Early detection of skin  
44 cancer by family physicians: a pilot project. *Journal of Cutaneous Medicine and Surgery*, 8: 103-  
45 109.  
46 Not in PICO
- 47 Garbe, C., Eigentler, T. K., Bauer, J., Blodorn-Schlicht, N., Fend, F., Hantschke, M., Kurschat, P.,  
48 Kutzner, H., Metze, D., Pressler, H., Reusch, M., Rocken, M., Stadler, R., Tronnier, M., Yazdi, A. &  
49 Metzler, G. (2011) Histopathological diagnostics of malignant melanoma in accordance with the  
50 recent AJCC classification 2009: Review of the literature and recommendations for general



- 1 practice. *Journal der Deutschen Dermatologischen Gesellschaft*, 9: 690-699.
- 2 Not in PICO
- 3 Gazzani, P., Rothwell, J., Kasparis, C. & Gee, B. (2013) Progress towards integrating a melanoma  
4 diagnostic index into a U.K. dermatology department quality dashboard. *British Journal of*  
5 *Dermatology*, 169: 46-47.
- 6 Not in PICO
- 7 Geisse, J. K. (1994) Biopsy techniques for pigmented lesions of the skin. [Review] [43 refs].  
8 *Pathology*, 2: 181-193.
- 9 Narrative review
- 10 Gerbert, B., Bronstone, A., Maurer, T., Hofmann, R. & Berger, T. (2000) Decision support software to  
11 help primary care physicians triage skin cancer - A pilot study. *Archives of Dermatology*, 136: 187-  
12 192.
- 13 Not in PICO
- 14 Giacomel, J. & Zalaudek, I. (2013) Pink Lesions. *Dermatologic Clinics*, 31: 649-678.
- 15 Narrative review
- 16 Giard, R. W. & Neumann, H. A. (2004) [Diagnosis of pigmented skin lesions: how to recognize a  
17 malignant melanoma]. [Review] [24 refs] [Dutch]. *Nederlands Tijdschrift Voor Geneeskunde*, 148:  
18 2261-2267.
- 19 Narrative review
- 20 Gilde, K. (2006) [Malignant tumors of the skin]. [Review] [25 refs] [Hungarian]. *Orvosi Hetilap*, 147:  
21 2321-2330.
- 22 Narrative review
- 23 Gonzalez, S., Swindells, K., Rajadhyaksha, M. & Torres, A. (2003) Changing paradigms in  
24 dermatology: Confocal microscopy in clinical and surgical dermatology. *Clinics in Dermatology*,  
25 21: 359-369.
- 26 Narrative review
- 27 Goodson, A. G. & Grossman, D. (2009) Strategies for early melanoma detection: Approaches to the  
28 patient with nevi. *Journal of the American Academy of Dermatology*, 60: 719-735.
- 29 Narrative review
- 30 Goppner, D. & Leverkus, M. (2011) Prognostic parameters for the primary care of melanoma  
31 patients: what is really risky in melanoma? *Journal of Skin Cancer*, 2011: 521947.
- 32 Narrative review
- 33 Grange, F., Maubec, E., Barbe, C., Kassouma, J., Vitry, F., Johanet, H., Granel-Brocard, F., Boitier, F.,  
34 Girod, A., Couturaud, B., Saez, P., Albert, S., Le, C. A., Descamps, V. & Avril, M. F. (2011) Sentinel  
35 lymph node biopsy or nodal observation in melanoma: a prospective study of patient choices.  
36 *Dermatologic Surgery*, 37: 199-206.
- 37 Not in PICO
- 38 Grange, F., Barbe, C., Mas, L., Granel-Brocard, F., Lipsker, D., Aubin, F., Velten, M., Dalac, S.,  
39 Truchetet, F., Michel, C., Mitschler, A., Arnoult, G., Buemi, A., Dalle, S., Reuter, G., Bernard, P.,  
40 Woronoff, A. S. & Arnold, F. (2012) The role of general practitioners in diagnosis of cutaneous  
41 melanoma: a population-based study in France. *British Journal of Dermatology*, 167: 1351-1359.
- 42 Not in PICO
- 43 Gray, R. J., Pockaj, B. A., Vega, M. L., Connolly, S. M., DiCaudo, D. J., Kile, T. A. & Buchel, E. W. (2006)  
44 Diagnosis and treatment of malignant melanoma of the foot. *Foot & Ankle International*, 27: 696-  
45 705.
- 46 Not in PICO
- 47 Green, J., Murchie, P. & Lee, A. J. (2013) Does patients' place of residence affect the type of  
48 physician performing primary excision of cutaneous melanoma in northern Scotland? *Journal of*  
49 *Rural Health*, 29: Suppl-42.
- 50 Not in PICO

- 1 Griffiths, W. A. (2010) Improving melanoma diagnosis in primary care--a tele-dermatoscopy project.  
2 *Journal of Telemedicine & Telecare*, 16: 185-186.  
3 Not in PICO
- 4 Grimaldi, L., Silvestri, A., Brandi, C., Nisi, G., Brafa, A., Calabro, M., Campa, A. & D'Aniello, C. (2009)  
5 Digital epiluminescence dermoscopy for pigmented cutaneous lesions, primary care physicians,  
6 and telediagnosis: a useful tool? *Journal of Plastic, Reconstructive & Aesthetic Surgery: JPRAS*, 62:  
7 1054-1058.  
8 Not in PICO
- 9 Guillod, J. (1999) [Clinical differential diagnosis of pigmented skin changes and contribution of  
10 epiluminescence microscopy]. [German]. *Therapeutische Umschau*, 56: 312-317.  
11 Narrative review
- 12 Guitera-Rovel, P. & Vestergaard, M. E. (2008) Diagnosis tools for cutaneous melanoma. *Annales de*  
13 *Dermatologie et de Venereologie*, 135: 828-834.  
14 Narrative review
- 15 Guitera, P., Haydu, L. E., Menzies, S. W., Scolyer, R. A., Hong, A., Fogarty, G. B., Gallardo, F. & Segura,  
16 S. (2014) - Surveillance for treatment failure of lentigo maligna with dermoscopy and in vivo  
17 confocal microscopy: new descriptors. - *British Journal of Dermatology*, 170: 1305-1312.  
18 Not in PICO
- 19 Gunther, V., Alkatout, I., Lez, C., Altarac, S., Fures, R., Cupic, H., Persec, Z., Hrgovic, Z. & Mundhenke,  
20 C. (2012) Malignant melanoma of the urethra: a rare histologic subdivision of vulvar cancer with a  
21 poor prognosis. *Case Reports in Obstetrics and Gynecology*, 2012: 385175.  
22 Not in PICO
- 23 Gupta, M., Aggarwal, A., Ahuja, R., Pachauri, A. & Kumar, P. (2013) Significance of early detection of  
24 oral malignant melanoma: Some reasonable facts. *Clinical Cancer Investigation Journal*, 2: 178-  
25 180.  
26 Narrative review
- 27 Hajar-Serviansky, T., Gutierrez-Mendoza, D., Galvan, I. L., Lammoglia-Ordiales, L., Mosqueda-Taylor,  
28 A., Hernandez-Cazares, M. L. & Toussaint-Caire, S. (2012) A case of oral mucosal melanoma.  
29 Clinical and dermoscopic correlation. *Journal of Dermatological Case Reports*, 6: 1-4.  
30 Not in PICO
- 31 Hald, M., Christensen, B., Lock-Andersen, J. & Jemec, G. B. (2004) [Referrals for malignant  
32 melanoma. Opportunities for quality assurance and development]. [Danish]. *Ugeskrift for Laeger*,  
33 166: 163-165.  
34 Not in PICO
- 35 Haliasos, E. C., Kerner, M., Jaimes, N., Zalaudek, I., Malvey, J., Lanschuetzer, C. M., Hinter, H.,  
36 Hofmann-Wellenhof, R., Braun, R. P. & Marghoob, A. A. (2013) Dermoscopy for the pediatric  
37 dermatologist, part ii: dermoscopy of genetic syndromes with cutaneous manifestations and  
38 pediatric vascular lesions. *Pediatric Dermatology*, 30: 172-181.  
39 Narrative review
- 40 Halpern, A. C. & Lieb, J. A. (2007) Early melanoma diagnosis: a success story that leaves room for  
41 improvement. *Current Opinion in Oncology*, 19: 109-115.  
42 Narrative review
- 43 Hamm, H. & Hoyer, P. H. (2011) Skin tumors in childhood. [Review]. *Deutsches Arzteblatt*  
44 *International*, 108: 347-353.  
45 Narrative review
- 46 Harbour, J. W. & Chao, D. L. (2014) A Molecular Revolution in Uveal Melanoma Implications for  
47 Patient Care and Targeted Therapy. *Ophthalmology*, 121: 1281-1288.  
48 Narrative review
- 49 Haw, W. Y., Fraser, S., Affleck, A. & Holme, A. (2014) Skin cancer excision performance in primary  
50 and secondary care in Scotland. *British Journal of Dermatology*, 171: 25.  
51 Not in PICO

- 1 Heal, C. F., Raasch, B. A., Buettner, P. G. & Weedon, D. (2008) Accuracy of clinical diagnosis of skin  
2 lesions. *British Journal of Dermatology*, 159: 661-668.  
3 Not in PICO
- 4 Hengge, U. R. & Meurer, M. (2005) [Pigmented lesions of the genital mucosa]. [Review] [83 refs]  
5 [German]. *Hautarzt*, 56: 540-549.  
6 Narrative review
- 7 Hennrikus, D., Girgis, A., Redman, S. & Sanson-Fisher, R. W. (1991) A community study of delay in  
8 presenting with signs of melanoma to medical practitioners. *Archives of Dermatology*, 127: 356-  
9 361.  
10 Not in PICO
- 11 Herd, R. M., Hunter, J. A., McLaren, K. M., Chetty, U., Watson, A. C. & Gollock, J. M. (1992) Excision  
12 biopsy of malignant melanoma by general practitioners in south east Scotland 1982-91. *BMJ*, 305:  
13 1476-1478.  
14 Not in PICO
- 15 Hermes, H. M., Sahu, J., Schwartz, L. R. & Lee, J. B. (2014) - Clinical and histologic characteristics of  
16 clinically unsuspected melanomas. - *Clinics in Dermatology*, 32: 324-330.  
17 Not in PICO
- 18 Herschorn, A. (2012) Dermoscopy for melanoma detection in family practice (Provisional abstract).  
19 *Database of Abstracts of Reviews of Effects.*, 740-745.  
20 Semi systematic review, no new studies
- 21 High, W. A. (2008) Malpractice in dermatopathology - Principles, risk mitigation, and opportunities  
22 for improved care for the histologic diagnosis of melanoma and pigmented lesions. *Clinics in*  
23 *Laboratory Medicine*, 28: 261-+.  
24 Narrative review
- 25 Holme, S. A. (2003) GPs have role in early detection of melanoma. [Review]. *Practitioner*, 257: 27-30.  
26 Narrative review
- 27 Hornung, R. L., Hansen, L. A., Sharp, L. K., Poorsattar, S. P. & Lipsky, M. S. (2007) Skin cancer  
28 prevention in the primary care setting: assessment using a standardized patient. *Pediatric*  
29 *Dermatology*, 24: 108-112.  
30 Not in PICO
- 31 Horsch, A., Stolz, W., Neiss, A., Abmayr, W., Pompl, R., Bernklau, A., Bunk, W., Dersch, D. R., Glassl,  
32 A., Schiffner, R. & Morfill, G. (1997) Improving early recognition of malignant melanomas by  
33 digital image analysis in dermatoscopy. *Studies in Health Technology & Informatics*, 43: t-5.  
34 Narrative review
- 35 Husemann, R., Tolg, S., Von Seelen, W., Altmeyer, P., Frosch, P. J., Stucker, M., Hoffmann, K. & el-  
36 Gammal, S. (1997) Computerised diagnosis of skin cancer using neural networks. *Skin Cancer and*  
37 *Uv Radiation*, 1052-1063.  
38 Not in PICO
- 39 Ishihara, Y., Saida, T., Miyazaki, A., Koga, H., Taniguchi, A., Tsuchida, T., Toyama, M. & Ohara, K.  
40 (2006) Early acral melanoma in situ: correlation between the parallel ridge pattern on  
41 dermoscopy and microscopic features. *American Journal of Dermatopathology*, 28: 21-27.  
42 Not in PICO
- 43 Jackson, A. M., Morgan, D. R. & Ellison, R. (2000) Diagnosis of malignant melanoma by general  
44 practitioners and hospital specialists. *Postgraduate Medical Journal*, 76: 295-298.  
45 Not in PICO
- 46 Jin, L., Arai, E., Anzai, S., Kimura, T., Tsuchida, T., Nagata, K. & Shimizu, M. (2010) Reassessment of  
47 histopathology and dermoscopy findings in 145 Japanese cases of melanocytic nevus of the sole:  
48 toward a pathological diagnosis of early-stage malignant melanoma in situ. *Pathology*  
49 *International*, 60: 65-70.  
50 Not in PICO

- 1 Jolliffe, V. M., Harris, D. W. & Whittaker, S. J. (2001) Can we safely diagnose pigmented lesions from  
2 stored video images? A diagnostic comparison between clinical examination and stored video  
3 images of pigmented lesions removed for histology. *Clinical & Experimental Dermatology*, 26: 84-  
4 87.  
5 Not in PICO (secondary care)
- 6 Jones, T. P., Boiko, P. E. & Piepkorn, M. W. (1996) Skin biopsy indications in primary care practice: a  
7 population-based study. *Journal of the American Board of Family Practice*, 9: 397-404.  
8 Not in PICO
- 9 Kahn, E., Sossong, S., Goh, A., Carpenter, D. & Goldstein, S. (2013) Evaluation of Skin Cancer in  
10 Northern California Kaiser Permanente's Store-and-Forward Teledermatology Referral Program.  
11 *Telemedicine and E-Health*, 19: 780-785.  
12 Not in PICO
- 13 Kaiser, S., Vassell, R., Pinckney, R. G., Holmes, T. E. & James, T. A. (2014) - Clinical impact of biopsy  
14 method on the quality of surgical management in melanoma. - *Journal of Surgical Oncology*, 109:  
15 775-779.  
16 Not in PICO
- 17 Kaminska-Winciorek, G. & Spiewak, R. (2011) [Basic dermoscopy of melanocytic lesions for  
18 beginners]. [Review] [Polish]. *Postepy Higieny i Medycyny do Swiadczalnej (Online)*, 65: 501-508.  
19 Not in PICO
- 20 Kaminska-Winciorek, G. & Spiewak, R. (2013) [Dermoscopy on subungual melanoma]. [Polish].  
21 *Postepy Higieny i Medycyny do Swiadczalnej (Online)*, 67: 380-387.  
22 Narrative review
- 23 Karakousis, C. P., Rizos, S. & Driscoll, D. L. (1994) Residual nodal disease after excisional biopsy of a  
24 palpable, positive node in melanoma. *American Journal of Surgery*, 168: 69-70.  
25 Not in PICO
- 26 Kester, B. S., Wayne, J. D., Ross, M. I., Bentrem, D. J., Merkow, R. P. & Bilimoria, K. Y. (2013) An  
27 Opportunity to Ensure High-Quality Melanoma Care Through the Use of a Preoperative  
28 Treatment Algorithm. *Annals of Surgical Oncology*, 20: 3976-3983.  
29 Not in PICO
- 30 Khorshid, S. M., Pinney, E. & Bishop, J. A. (1998) Melanoma excision by general practitioners in  
31 north-east Thames region, England. *British Journal of Dermatology*, 138: 412-417.  
32 Not in PICO
- 33 King, R., Hayzen, B. A., Page, R. N., Googe, P. B., Zeagler, D. & Mihm, M. C., Jr. (2009) Recurrent  
34 nevus phenomenon: a clinicopathologic study of 357 cases and histologic comparison with  
35 melanoma with regression. *Modern Pathology*, 22: 611-617.  
36 Not in PICO
- 37 Kirkwood, J. M., Jukic, D. M., Averbok, B. J. & Sender, L. S. (2009) Melanoma in pediatric,  
38 adolescent, and young adult patients. [Review] [111 refs]. *Seminars in Oncology*, 36: 419-431.  
39 Narrative review
- 40 Kitchener, S., McMaster, S. & Nasveld, P. (2009) Dermoscopy in primary care for detection of  
41 melanoma. *International Journal of Dermatology*, 48: 1397-1398.  
42 Letter
- 43 Klein, D., Westreich, M. & Shalom, A. (2012) Accuracy of malignant melanoma detection in the  
44 community. *Acta Dermatovenerologica Croatica*, 20: 165-169.  
45 Not in PICO
- 46 Kolm, I., Hofbauer, G. & Braun, R. P. (2010) [Early diagnosis of skin cancer]. [Review] [German].  
47 *Therapeutische Umschau*, 67: 439-446.  
48 Narrative review
- 49 Kretschmer, L. & Hilgers, R. (2006) Research supports the view that sentinel node biopsy is the  
50 standard of care in high-risk primary melanoma. *Journal of Clinical Oncology*, 24: 2965-2966.  
51 Not in PICO

- 1 Kundu, R. V. & Patterson, S. (2013) Dermatologic conditions in skin of color: part I. Special  
2 considerations for common skin disorders.[Summary for patients in Am Fam Physician. 2013 Jun  
3 15;87(12):Online; PMID: 23939576]. *American Family Physician*, 87: 850-856.  
4 Narrative review
- 5 Lallas, A., Zalaudek, I., Apalla, Z., Longo, C., Moscarella, E., Piana, S., Reggiani, C. & Argenziano, G.  
6 (2013) Management Rules to Detect Melanoma. *Dermatology*, 226: 52-60.  
7 Narrative review
- 8 Lathlean, S. (1999) Skin cancer in general practice in South Australia. A five year study. *Australian  
9 Family Physician*, 28: Suppl-31.  
10 Not in PICO
- 11 LeBoit, P. E. (2009) What sentinel node biopsy in patients with melanoma (or patients whose doctors  
12 worry that they could have melanoma) might and might not do. [Review] [12 refs]. *Clinics in  
13 Dermatology*, 27: 588-593.  
14 Narrative review
- 15 Lee, K. C., Jayarajan, R. & Daruwalla, M. (2013) Skin cancer diagnosis hit or miss? the leicester  
16 experience. *International Journal of Surgery*, 11: 683.  
17 Not in PICO
- 18 Lee, S., Lee, H. J., Oh, S. H., Im, M., Lee, J. H., Seo, Y. J. & Lee, Y. (2011) The Appearance of a  
19 Candidate Site for a Primary Melanoma: A 5 Year-gap with a Melanoma of an Unknown Site.  
20 *Annals of Dermatology*, 23: 2-8.  
21 Not in PICO
- 22 Li, Z. G. & Qin, X. J. (2014) - Primary anorectal melanoma on FDG PET/CT. - *Clinical Nuclear Medicine*,  
23 39: 762-764.  
24 Not in PICO
- 25 Liew, Y., De, B. D. & Sansom, J. (2014) Rapid clinical review of patients assessed by a teledermatology  
26 service: Analysis of pathways and outcomes. *British Journal of Dermatology*, 171: 138.  
27 Not in PICO
- 28 Lin, M. J. & Kelly, J. W. (2013) When is it melanoima? An update on diagnosis and management.  
29 *Medicine Today*, 14: 44-53.  
30 Narrative review
- 31 Lin, M. J., Mar, V., McLean, C., Wolfe, R. & Kelly, J. W. (2014) Diagnostic accuracy of malignant  
32 melanoma according to subtype. *Australasian Journal of Dermatology*, 55: 35-42.  
33 Not in PICO
- 34 Lin, M. J., Mar, V., McLean, C., Wolfe, R. & Kelly, J. W. (2014) - Diagnostic accuracy of malignant  
35 melanoma according to subtype. - *Australasian Journal of Dermatology*, 55: 35-42.  
36 Not in PICO
- 37 Lindelof, B., Hedblad, M. A. & Sigurgeirsson, B. (1998) Melanocytic naevus or malignant melanoma?  
38 A large-scale epidemiological study of diagnostic accuracy. *Acta Dermato-Venereologica*, 78: 284-  
39 288.  
40 Not in PICO
- 41 Liu, Z., Sun, J., Smith, L., Smith, M. & Warr, R. (2012) Distribution quantification on dermoscopy  
42 images for computer-assisted diagnosis of cutaneous melanomas. [Review]. *Medical & Biological  
43 Engineering & Computing*, 50: 503-513.  
44 Not in PICO
- 45 Lourari, S., Paul, C., Gouraud, P. A., Tavitian, S., Viraben, R., Leccia, M. T., Saiag, P., Lebbe, C. &  
46 Meyer, N. (2012) Sentinel lymph node biopsy for melanoma is becoming a consensus: a national  
47 survey of French centres involved in melanoma care in 2008. *Journal of the European Academy of  
48 Dermatology and Venereology*, 26: 1230-1235.  
49 Not in PICO
- 50 Lowy, A., Willis, D. & Abrams, K. (1997) Is histological examination of tissue removed by general  
51 practitioners always necessary? Before and after comparison of detection rates of serious skin

- 1 lesions. *BMJ*, 315: 406-408.
- 2 Not in PICO
- 3 Lukacs, L. & Peter, S. (1982) Early recognition of cutaneous malignant melanomas. *Acta Chirurgica*  
4 *Academiae Scientiarum Hungaricae*, 23: 183-191.
- 5 Narrative review
- 6 Luttrell, M. J., McClenahan, P., Hofmann-Wellenhof, R., Fink-Puches, R. & Soyer, H. P. (2012)  
7 Laypersons' sensitivity for melanoma identification is higher with dermoscopy images than  
8 clinical photographs. *British Journal of Dermatology*, 167: 1037-1041.
- 9 Not in PICO
- 10 MacDonald, A., Berty, C. & Holmes, S. (2006) An audit of the management of melanoma patients at  
11 Glasgow Royal Infirmary 1998-2003. *Scottish Medical Journal*, 51: 30-33.
- 12 Not in PICO
- 13 MacKie, R. M., Fleming, C., McMahon, A. D. & Jarrett, P. (2002) The use of the dermatoscope to  
14 identify early melanoma using the three-colour test. *British Journal of Dermatology*, 146: 481-  
15 484.
- 16 Not in PICO
- 17 MacNeill, K. N., Ghazarian, D., McCready, D. & Rotstein, L. (2005) Sentinel lymph node biopsy for  
18 cutaneous melanoma of the head and neck. *Annals of Surgical Oncology*, 12: 726-732.
- 19 Not in PICO
- 20 Macy-Roberts, E. & Ackerman, A. B. (1982) A critique of techniques for biopsy of clinically suspected  
21 malignant melanomas. *American Journal of Dermatopathology*, 4: 391-398.
- 22 Not in PICO
- 23 Magro, C. M., Crowson, A. N. & Mihm, M. C. (2006) Unusual variants of malignant melanoma.  
24 [Review] [204 refs]. *Modern Pathology*, 19: Suppl-70.
- 25 Narrative review
- 26 Malik, A., Bansil, S., Junglee, N., Sutton, J., Gasem, J. & Ahmed, W. (2011) Synchronous primary  
27 oesophageal malignant melanoma and sigmoid adenocarcinoma. *BMJ Case Reports*, 2011, 2011.
- 28 Not in PICO
- 29 Malvey, J. & Puig, S. (2004) Dermoscopic patterns of benign volar melanocytic lesions in patients  
30 with atypical mole syndrome. *Archives of Dermatology*, 140: 538-544.
- 31 Not in PICO
- 32 Manca, G., Romanini, A., Rubello, D., Mazzarri, S., Boni, G., Chiacchio, S., Tredici, M., Duce, V.,  
33 Tardelli, E., Volterrani, D. & Mariani, G. (2014) - A critical reappraisal of false negative sentinel  
34 lymph node biopsy in melanoma. - *The Quarterly Journal of Nuclear Medicine & Molecular*  
35 *Imaging*, 58: 105-113.
- 36 Not in PICO
- 37 Marghoob, A. A., Usatine, R. P. & Jaimes, N. (2013) Dermoscopy for the family physician. [Review].  
38 *American Family Physician*, 88: 441-450.
- 39 Narrative review
- 40 Marghoob, A. A., Usatine, R. P. & Jaimes, N. (2013) Dermoscopy for the Family Physician. *American*  
41 *Family Physician*, 88: 441-450.
- 42 Narrative review
- 43 Marsden, J. R., Newton-Bishop, J. A., Burrows, L., Cook, M., Corrie, P. G., Cox, N. H., Gore, M. E.,  
44 Lorigan, P., Mackie, R., Nathan, P., Peach, H., Powell, B., Walker, C. & British Association of  
45 Dermatologists (BAD) Clinical Standards Unit (2010) Revised UK guidelines for the management  
46 of cutaneous melanoma 2010. *Journal of Plastic, Reconstructive & Aesthetic Surgery: JPRAS*, 63:  
47 1401-1419.
- 48 Guideline
- 49 May, C., Giles, L. & Gupta, G. (2008) Prospective observational comparative study assessing the role  
50 of store and forward teledermatology triage in skin cancer. *Clinical & Experimental Dermatology*,

- 1 33: 736-739.  
2 Not in PICO
- 3 Mayer, J. (1997) Systematic review of the diagnostic accuracy of dermoscopy in detecting  
4 malignant melanoma. [Review] [25 refs]. *Medical Journal of Australia*, 167: 206-210.  
5 Not in PICO (secondary care)
- 6 McCannel, T. A. (2013) Fine-needle aspiration biopsy in the management of choroidal melanoma.  
7 *Current Opinion in Ophthalmology*, 24: 262-266.  
8 Narrative review
- 9 McCourt, C., Dolan, O. & Gormley, G. (2014) Malignant melanoma: A pictorial review. *Ulster Medical  
10 Journal*, 83: 103-110.  
11 Not in PICO
- 12 McWhirter, J. E. & Hoffman-Goetz, L. (2013) Visual images for patient skin self-examination and  
13 melanoma detection: a systematic review of published studies. [Review]. *Journal of the American  
14 Academy of Dermatology*, 69: 47-55.  
15 Not in PICO
- 16 Medalie, N. S. & Ackerman, A. B. (2003) Sentinel lymph node biopsy has no benefit for patients with  
17 primary cutaneous melanoma metastatic to a lymph node: An assertion based on  
18 comprehensive, critical analysis - Part II. *American Journal of Dermatopathology*, 25: 473-484.  
19 Not in PICO
- 20 Mehra, M., Stitson, R., Natkunarajah, J., George, S., Harland, C. C. & Abdul-Wahab, A. (2008) Skin  
21 cancer biopsies in primary care: neither BAD nor NICE. *British Journal of Dermatology*, 159: 56.  
22 Not in PICO
- 23 Menzies, S. W., Bischof, L., Talbot, H., Gutenev, A., Avramidis, M., Wong, L., Lo, S. K., Mackellar, G.,  
24 Skladnev, V., McCarthy, W., Kelly, J., Cranney, B., Lye, P., Rabinovitz, H., Oliviero, M., Blum, A.,  
25 Varol, A., De'Ambrosis, B., McCleod, R., Koga, H., Grin, C., Braun, R. & Johr, R. (2005) The  
26 performance of SolarScan: an automated dermoscopy image analysis instrument for the  
27 diagnosis of primary melanoma.[Erratum appears in Arch Dermatol. 2006 May;142(5):558 Note:  
28 Virol, Alexandra [corrected to Varol, Alexandra]]. *Archives of Dermatology*, 141: 1388-1396.  
29 Not in PICO (secondary care)
- 30 Menzies, S. W. (2006) Technologies for the diagnosis of primary melanoma of the skin. *Medical  
31 Journal of Australia*, 185: 533-534.  
32 Narrative review
- 33 Menzies, S. W. & Zalaudek, I. (2006) Why perform dermoscopy? The evidence for its role in the  
34 routine management of pigmented skin lesions. *Archives of Dermatology*, 142: 1211-1212.  
35 Narrative review
- 36 Menzies, S. W. (2007) Dermoscopy not yet shown to increase sensitivity of melanoma diagnosis in  
37 real practice - Reply. *Archives of Dermatology*, 143: 665-666.  
38 Letter
- 39 Menzies, S. W., Moloney, F. J., Byth, K., Avramidis, M., Argenziano, G., Zalaudek, I., Braun, R. P.,  
40 Malvey, J., Puig, S., Rabinovitz, H. S., Oliviero, M., Cabo, H., Bono, R., Pizzichetta, M. A., Claeson,  
41 M., Gaffney, D. C., Soyer, H. P., Stanganelli, I., Scolyer, R. A., Guitera, P., Kelly, J., McCurdy, O.,  
42 Llambrich, A., Marghoob, A. A., Zaballos, P., Kirchesch, H. M., Piccolo, D., Bowling, J., Thomas, L.,  
43 Terstappen, K., Tanaka, M., Pellacani, G., Pagnanelli, G., Ghigliotti, G., Ortega, B. C., Crafter, G.,  
44 Ortiz, A. M., Tromme, I., Karaarslan, I. K., Ozdemir, F., Tam, A., Landi, C., Norton, P., Kacar, N.,  
45 Rudnicka, L., Slowinska, M., Simionescu, O., Di, S. A., Coates, E. & Kreusch, J. (2013) Dermoscopic  
46 evaluation of nodular melanoma. *JAMA Dermatology*, 149: 699-709.  
47 Not in PICO
- 48 Menzies, S. W. (2013) Evidence-Based Dermoscopy. *Dermatologic Clinics*, 31: 521-524.  
49 Narrative review
- 50 Menzies, S. W., Moloney, F. J., Byth, K., Avramidis, M., Argenziano, G., Zalaudek, I., Braun, R. P.,  
51 Malvey, J., Puig, S., Rabinovitz, H. S., Oliviero, M., Cabo, H., Bono, R., Pizzichetta, M. A., Claeson,

- 1 M., Gaffney, D. C., Soyer, H. P., Stanganelli, I., Scolyer, R. A., Guitera, P., Kelly, J., McCurdy, O.,  
2 Llambrich, A., Marghoob, A. A., Zaballos, P., Kirchesch, H. M., Piccolo, D., Bowling, J., Thomas, L.,  
3 Terstappen, K., Tanaka, M., Pellacani, G., Pagnanelli, G., Ghigliotti, G., Ortega, B. C., Crafter, G.,  
4 Perusquia Ortiz, A. M., Tromme, I., Karaarslan, I. K., Ozdemir, F., Tam, A., Landi, C., Norton, P.,  
5 Kacar, N., Rudnicka, L., Slowinska, M., Simionescu, O., Di, S. A., Coates, E. & Kreusch, J. (2013)  
6 Dermoscopic evaluation of nodular melanoma. *JAMA Dermatology*, 149: 699-709.  
7 Not in PICO
- 8 Menzies, S. W. (2013) Evidence-Based Dermoscopy. *Dermatologic Clinics*, 31: 521-+.  
9 Narrative review
- 10 Messmer, E. M., Mackert, M. J., Zapp, D. M. & Kampik, A. (2006) In vivo confocal microscopy of  
11 pigmented conjunctival tumors. *Graefes Archive for Clinical & Experimental Ophthalmology*, 244:  
12 1437-1445.  
13 Not in PICO
- 14 Metzger, S., Ellwanger, U., Stroebel, W., Schiebel, U., Rassner, G. & Fierlbeck, G. (1998) Extent and  
15 consequences of physician delay in the diagnosis of acral melanoma. *Melanoma Research*, 8: 181-  
16 186.  
17 Not in PICO
- 18 Midena, E. & Parrozzani, R. (2012) Biopsies in uveal melanoma. [Review]. *Developments in*  
19 *Ophthalmology*, 49: 81-95.  
20 Narrative review
- 21 Mihic-Probst, D. & Beer, M. (2013) [Insights into melanoma from a pathologist's perspective].  
22 [Review] [German]. *Praxis*, 102: 219-224.  
23 Narrative review
- 24 Moffatt, C. R., Green, A. C. & Whiteman, D. C. (2006) Diagnostic accuracy in skin cancer clinics: the  
25 Australian experience. *International Journal of Dermatology*, 45: 656-660.  
26 Not in PICO
- 27 Mondragon, G. & Nygaard, F. (1981) Routine and special procedures for processing biopsy  
28 specimens of lesions suspected to be malignant melanomas. *American Journal of*  
29 *Dermatopathology*, 3: 265-272.  
30 Not in PICO
- 31 Monshizadeh, L., Hanikeri, M., Beer, T. W. & Heenan, P. J. (2012) A critical review of melanoma  
32 pathology reports for patients referred to the Western Australian Melanoma Advisory Service.  
33 *Pathology*, 44: 441-447.  
34 Not in PICO
- 35 Moore, P., Hundley, J., Hundley, J., Levine, E. A., Williford, P., Sanguenza, O., Mccoy, T. & Shen, P.  
36 (2009) Does Shave Biopsy Accurately Predict the Final Breslow Depth of Primary Cutaneous  
37 Melanoma? *American Surgeon*, 75: 369-373.  
38 Not in PICO
- 39 Moreno-Ramirez, D., Ferrandiz, L., Nieto-Garcia, A., Carrasco, R., Moreno-Alvarez, P., Galdeano, R.,  
40 Bidegain, E., Rios-Martin, J. J. & Camacho, F. M. (2007) Store-and-forward teledermatology in skin  
41 cancer triage: experience and evaluation of 2009 teleconsultations.[Erratum appears in Arch  
42 Dermatol. 2007 Jul;143(7):886]. *Archives of Dermatology*, 143: 479-484.  
43 Not in PICO
- 44 Moreno, G., Tran, H., Chia, A. L., Lim, A. & Shumack, S. (2007) Prospective study to assess general  
45 practitioners' dermatological diagnostic skills in a referral setting. *Australasian Journal of*  
46 *Dermatology*, 48: 77-82.  
47 Not in PICO
- 48 Morrison, A., O'Loughlin, S. & Powell, F. C. (2001) Suspected skin malignancy: a comparison of  
49 diagnoses of family practitioners and dermatologists in 493 patients. *International Journal of*  
50 *Dermatology*, 40: 104-107.  
51 Not in PICO



- 1 Morton, C. A., Downie, F., Auld, S., Smith, B., van der Pol, M., Baughan, P., Wells, J. & Wootton, R.  
2 (2011) Community photo-triage for skin cancer referrals: an aid to service delivery. *Clinical &*  
3 *Experimental Dermatology*, 36: 248-254.  
4 Not in PICO
- 5 Morton, D. L., Cochran, A. J., Thompson, J. F., Elashoff, R., Essner, R., Glass, E. C., Mozzillo, N.,  
6 Nieweg, O. E., Roses, D. F., Hoekstra, H. J., Karakousis, C. P., Reintgen, D. S., Coventry, B. J. &  
7 Wang, H. J. (2005) Sentinel node biopsy for early-stage melanoma - Accuracy and morbidity in  
8 MSLT-I, an international multicenter trial. *Annals of Surgery*, 242: 302-313.  
9 Not in PICO
- 10 Moulin, C., Poulalhon, N., Duru, G., Debarbieux, S., Dalle, S. & Thomas, L. (2013) Dermoscopy use by  
11 French private practice dermatologists: a nationwide survey. *British Journal of Dermatology*, 168:  
12 74-79.  
13 Not in PICO
- 14 Mowbray, M. & Yoo, J. (2014) - Diagnostic biopsy of melanoma: primary or secondary care? - *British*  
15 *Journal of General Practice*, 64: 14.  
16 Letter
- 17 Mowbray, M. & Yoo, J. (2014) Diagnostic biopsy of melanoma: primary or secondary care? *British*  
18 *Journal of General Practice*, 64: 14.  
19 Duplicate
- 20 Mozzillo, N., Pennacchioli, E., Gandini, S., Caraco, C., Crispo, A., Botti, G., Lastoria, S., Barberis, M.,  
21 Verrecchia, F. & Testori, A. (2013) Sentinel Node Biopsy in Thin and Thick Melanoma. *Annals of*  
22 *Surgical Oncology*, 20: 2780-2786.  
23 Not in PICO
- 24 Murchie, P., Sinclair, E. & Lee, A. J. (2011) Primary excision of cutaneous melanoma: does the  
25 location of excision matter. *British Journal of General Practice*, 61: 131-134.  
26 Not in PICO
- 27 Murchie, P., Raja, E. A., Lee, A. J. & Campbell, N. C. (2013) Mortality and morbidity after initial  
28 diagnostic excision biopsy of cutaneous melanoma in primary versus secondary care. *British*  
29 *Journal of General Practice*, 63: e563-e572.  
30 Not in PICO
- 31 Murchie, P., Raja, E. A., Lee, A. J. & Campbell, N. C. (2013) Mortality and morbidity after initial  
32 diagnostic excision biopsy of cutaneous melanoma in primary versus secondary care. *British*  
33 *Journal of General Practice*, 63: E563-E572.  
34 Not in PICO
- 35 Murchie, P., Raja, E. A., Lee, A. J. & Campbell, N. C. (2014) Diagnostic biopsy of melanoma: primary  
36 or secondary care? Response. *British Journal of General Practice*, 64: 14.  
37 Not in PICO
- 38 Nami, N., Rubegni, P., Massone, C., Fimiani, M. & Hofmann-Wellenhof, R. (2011) New trends in  
39 dermoscopy. *Giornale Italiano di Dermatologia e Venereologia*, 146: 333-339.  
40 Narrative review
- 41 Nathansohn, N., Orenstein, A., Trau, H., Liran, A. & Schachter, J. (2007) Pigmented lesions clinic for  
42 early detection of melanoma: preliminary results. *Israel Medical Association Journal: Imaj*, 9: 708-  
43 712.  
44 Not in PICO
- 45 Negrier, S., Fervers, B., Bailly, C., Beckendorf, V., Cupissolv, D., Dore, J. F., Dorval, T., Garbay, J. R. &  
46 Vilmer, C. (2000) Standards, Options and Recommendations (SOR): clinical practice guidelines for  
47 diagnosis, treatment and follow-up of cutaneous melanoma. *Bulletin du Cancer*, 87: 173-182.  
48 Guideline
- 49 Newell, E. L., Shaw, L. & Bragonier, R. (2014) Rising referrals for suspected paediatric melanoma via  
50 the 2-week rule referral system. *British Journal of Dermatology*, 170: e15.  
51 Not in PICO

- 1 Newell, E. L., Shaw, L. & Bragonier, R. (2014) Rising referrals for suspected paediatric melanoma via  
2 the 2-week rule referral system. *British Journal of Dermatology*, 170: e15.  
3 Not in PICO
- 4 Ng, J. C., Swain, S., Dowling, J. P., Wolfe, R., Simpson, P. & Kelly, J. W. (2010) The impact of partial  
5 biopsy on histopathologic diagnosis of cutaneous melanoma: experience of an Australian tertiary  
6 referral service. *Archives of Dermatology*, 146: 234-239.  
7 Not in PICO
- 8 Ng, P. C., Barzilai, D. A., Ismail, S. A., Averitte, R. L., Jr. & Gilliam, A. C. (2003) Evaluating invasive  
9 cutaneous melanoma: is the initial biopsy representative of the final depth? *Journal of the  
10 American Academy of Dermatology*, 48: 420-424.  
11 Not in PICO
- 12 Niebling, M. G., Haydu, L. E., Karim, R. Z., Thompson, J. F. & Scolyer, R. A. (2014) - Pathology review  
13 significantly affects diagnosis and treatment of melanoma patients: an analysis of 5011 patients  
14 treated at a melanoma treatment center. - *Annals of Surgical Oncology*, 21: 2245-2251.  
15 Not in PICO
- 16 Nielsen, P. S., Lindebjerg, J., Rasmussen, J., Starklint, H., Waldstrom, M. & Nielsen, B. (2010) Virtual  
17 microscopy: an evaluation of its validity and diagnostic performance in routine histologic  
18 diagnosis of skin tumors. *Human Pathology*, 41: 1770-1776.  
19 Not in PICO
- 20 Nurnberg, D. (2005) [Ultrasound of adrenal gland tumours and indications for fine needle biopsy  
21 (uFNB)]. [Review] [116 refs] [German]. *Ultraschall in der Medizin*, 26: 458-469.  
22 Narrative review
- 23 Osborne, J. E. & Hutchinson, P. E. (2001) Clinical correlates of Breslow thickness of malignant  
24 melanoma. *British Journal of Dermatology*, 144: 476-483.  
25 Not in PICO
- 26 Osborne, J. E., Chave, T. A. & Hutchinson, P. E. (2003) Comparison of diagnostic accuracy for  
27 cutaneous malignant melanoma between general dermatology, plastic surgery and pigmented  
28 lesion clinics. *British Journal of Dermatology*, 148: 252-258.  
29 Not in PICO
- 30 Parkinson, R. W. (11111) Shave biopsies--simple and useful. *Postgraduate Medicine*, 84: 161-163.  
31 Narrative review
- 32 Penel, N., Valentin, F., Giscard, S., Vanseymortier, L. & Beuscart, R. (2007) General practitioners  
33 assessment of a structured report on medical decision making by a regional multidisciplinary  
34 cancer committee. *Bulletin du Cancer*, 94: E23-E26.  
35 Not in PICO
- 36 Pereda, C., Traves, V., Requena, C., Serra-Guillen, C., Llombart, B., Sanmartin, O., Guillen, C. &  
37 Nagore, E. (2013) Clinical presentation of acral lentiginous melanoma: a descriptive study. *Actas  
38 Dermo-Sifiliograficas*, 104: 220-226.  
39 Not in PICO
- 40 Pereda, C., Traves, V., Requena, C., Serra-Guillen, C., Llombart, B., Sanmartin, O., Guillen, C. &  
41 Nagore, E. (2013) Clinical presentation of acral lentiginous melanoma: a descriptive study. *Actas  
42 Dermo-Sifiliograficas*, 104: 220-226.  
43 Not in PICO
- 44 Pereira, R. D., Martin, A. A., Tierra-Criollo, C. J. & Santos, I. D. A. O. (2004) Diagnosis of squamous cell  
45 carcinoma of human skin by Raman spectroscopy. *Optical Biopsy V*, 5326: 106-112.  
46 Not in PICO
- 47 Perkins, P. J. (1992) Malignant melanoma: mole watching and the adolescent. *Professional Nurse*, 7:  
48 678-680.  
49 Narrative review

- 1 Perniciaro, C. (1997) Dermatopathologic variants of malignant melanoma. [Review] [38 refs]. *Mayo*  
2 *Clinic Proceedings*, 72: 273-279.  
3 Narrative review
- 4 Perrinaud, A., Gaide, O., French, L. E., Saurat, J. H., Marghoob, A. A. & Braun, R. P. (2007) Can  
5 automated dermoscopy image analysis instruments provide added benefit for the dermatologist?  
6 A study comparing the results of three systems. *British Journal of Dermatology*, 157: 926-933.  
7 Not in PICO (secondary care)
- 8 Petousis, V., Finger, P. T. & Milman, T. (2011) Anterior segment tumor biopsy using an aspiration  
9 cutter technique: clinical experience. *American Journal of Ophthalmology*, 152: 771-775.  
10 Not in PICO
- 11 Pflugfelder, A., Weide, B., Eigentler, T. K., Forschner, A., Leiter, U., Held, L., Meier, F. & Garbe, C.  
12 (2010) Incisional biopsy and melanoma prognosis: Facts and controversies. *Clinics in*  
13 *Dermatology*, 28: 316-318.  
14 Narrative review
- 15 Pflugfelder, A., Kochs, C., Blum, A., Capellaro, M., Czeschik, C., Dettenborn, T., Dill, D., Dippel, E.,  
16 Eigentler, T., Feyer, P., Follmann, M., Frerich, B., Ganten, M.-K., Gartner, J., Gutzmer, R., Hassel, J.,  
17 Hauschild, A., Hohenberger, P., Hubner, J., Kaatz, M., Kleeberg, U. R., Kolbl, O., Kortmann, R.-D.,  
18 Krause-Bergmann, A., Kurschat, P., Leiter, U., Link, H., Loquai, C., Loser, C., MacKensen, A., Meier,  
19 F., Mohr, P., Mohrle, M., Nashan, D., Reske, S., Rose, C., Sander, C., Satzger, I., Schiller, M.,  
20 Schlemmer, H.-P., Strittmatter, G., Sunderkotter, C., Swoboda, L., Trefzer, U., Voltz, R.,  
21 Vordermark, D., Weichenthal, M., Werner, A., Wesselmann, S., Weyergraf, A. J., Wick, W., Garbe,  
22 C. & Schadendorf, D. (2013) S3-Guideline "diagnosis, therapy and follow-up of melanoma" - Short  
23 version. [German, English]. *JDDG - Journal of the German Society of Dermatology*, 11: 593-602.  
24 Guideline
- 25 Phillips, C., Newsome, A., Jennifer, D., Lindsey, F., Green, H. & McLean, T. (2014) Anatomy of a skin  
26 biopsy: A retrospective analysis of outpatient biopsy results from 2000 to 2010. *Journal of the*  
27 *American Academy of Dermatology*, 70: AB36.  
28 Not in PICO (setting)
- 29 Pickett, H. (2011) Shave and punch biopsy for skin lesions. *American Family Physician*, 84: 995-1002.  
30 Narrative review
- 31 Pluddemann, A., Heneghan, C., Thompson, M., Wolstenholme, J. & Price, C. P. (2011) Dermoscopy  
32 for the diagnosis of melanoma: primary care diagnostic technology update. *British Journal of*  
33 *General Practice*, 61: 416-417.  
34 Narrative review
- 35 Pockney, P., Primrose, J., George, S., Jayatilleke, N., Leppard, B., Smith, H., Little, P., Kneebone, R. &  
36 Lowy, A. (2009) Recognition of skin malignancy by general practitioners: observational study  
37 using data from a population-based randomised controlled trial. *British Journal of Cancer*, 100:  
38 24-27.  
39 Not in PICO (secondary care, clinical diagnosis v histology)
- 40 Poelmann, T. A., van der Heide, W. K. & Berendsen, A. J. (2012) [Skin tumours underexposed in  
41 general practice]. [Dutch]. *Nederlands Tijdschrift Voor Geneeskunde*, 156: A5279.  
42 Narrative review
- 43 Poulsen, A. G., Larsen, F. G., Weismann, K., Petersen, C. S., Ravnborg, L. R., Heidenheim, M.,  
44 Lauritzen, T. E., Held, E. & Osterlind, A. L. (1999) [Investigation of malignant melanoma in an  
45 "open house" setting]. [Danish]. *Ugeskrift for Laeger*, 161: 1758-1761.  
46 Not in PICO
- 47 Raasch, B. A. (1999) Suspicious skin lesions and their management. *Australian Family Physician*, 28:  
48 466-471.  
49 Not in PICO (no verification of cancer/non-cancer diagnosis)

- 1 Rademaker, M. & Thorburn, M. (2010) Pathology referrals for skin lesions--are we giving the  
2 pathologist sufficient clinical information? *New Zealand Medical Journal*, 123: 53-58.  
3 Not in PICO
- 4 Rajpara, S. M., Botello, A. P., Townend, J. & Ormerod, A. D. (2009) Systematic review of dermoscopy  
5 and digital dermoscopy/artificial intelligence for the diagnosis of melanoma (DARE structured  
6 abstract). *British Journal of Dermatology*, 161: 591-604.  
7 Not in PICO (secondary care)
- 8 Ramcharan, M., Evans, M. W., Jr., Ndetan, H. & Beddard, J. (2011) Knowledge, perceptions, and  
9 practices of chiropractic interns in the early detection of atypical moles. *Journal of Chiropractic*  
10 *Medicine*, 10: 77-85.  
11 Not in PICO
- 12 Rampen, F. H. & Rumke, P. (1987) [The changing pattern of referrals in relation to melanoma of the  
13 skin?]. [Dutch]. *Nederlands Tijdschrift Voor Geneeskunde*, 131: 997-999.  
14 Not in PICO
- 15 Reusch, M., Schaefer, I., Siebert, J., Kornek, T. & Augustin, M. (2013) Histological and epidemiological  
16 characteristics of cutaneous malignant melanoma in routine ambulatory care in germany. *JDDG -*  
17 *Journal of the German Society of Dermatology*, 11: 38-39.  
18 Not in PICO
- 19 Riker, A. I. (2001) Utility of fine-needle aspiration biopsy for prospective analysis of patients  
20 undergoing therapy for metastatic melanoma. *Methods in Molecular Medicine*, 61: 287-299.  
21 Not in PICO
- 22 Rivers, J. K. & Wulkan, S. (2010) The case for early detection of melanoma. [Review] [53 refs]. *Journal*  
23 *of Cutaneous Medicine & Surgery*, 14: 24-29.  
24 Narrative review
- 25 Roaten, J. B., Partrick, D. A., Pearlman, N., Gonzalez, R. J., Gonzalez, R. & McCarter, M. D. (2005)  
26 Sentinel lymph node biopsy for melanoma and other melanocytic tumors in adolescents. *Journal*  
27 *of Pediatric Surgery*, 40: 232-235.  
28 Not in PICO
- 29 Roberts, A. A. & Cochran, A. J. (2004) Pathologic analysis of sentinel lymph nodes in melanoma  
30 patients: Current and future trends. *Journal of Surgical Oncology*, 85: 152-161.  
31 Narrative review
- 32 Roberts, D. L., Anstey, A. V., Barlow, R. J., Cox, N. H., Newton Bishop, J. A., Corrie, P. G., Evans, J.,  
33 Gore, M. E., Hall, P. N., Kirkham, N., British Association of Dermatologists & Melanoma Study  
34 Group (2002) U.K. guidelines for the management of cutaneous melanoma. *British Journal of*  
35 *Dermatology*, 146: 7-17.  
36 Guideline
- 37 Robison, S., Kljakovic, M. & Barry, P. (2012) Choosing to biopsy or refer suspicious melanocytic  
38 lesions in general practice. *BMC Family Practice*, 13: 78.  
39 Not in PICO
- 40 Roldan-Marin, R., Puig, S. & Malveyh, J. (2012) Dermoscopic criteria and melanocytic lesions.  
41 [Review]. *Giornale Italiano di Dermatologia e Venereologia*, 147: 149-159.  
42 Narrative review
- 43 Rolfe, H. M. (2012) Accuracy in skin cancer diagnosis: A retrospective study of an Australian public  
44 hospital dermatology department. *Australasian Journal of Dermatology*, 53: 112-117.  
45 Not in PICO
- 46 Romani, A., Baldeschi, L., Genovesi-Ebert, F., Gremigni, E., Ragone, M. C., Rizzo, S. & Nardi, M. (1998)  
47 Sensitivity and specificity of ultrasonography, fluorescein videoangiography, indocyanine green  
48 videoangiography, magnetic resonance and radioimmunosintigraphy in the diagnosis of primary  
49 choroidal malignant melanoma. *Ophthalmologica*, 212: Suppl-6.  
50 Not in PICO

- 1 Ropcke, D. M., Lorenzen, J. A. & Jorgensen, P. H. (2012) [Leiomyosarcoma of the great saphenous  
2 vein]. [Danish]. *Ugeskrift for Laeger*, 174: 1384-1385.  
3 Not in PICO
- 4 Rosendahl, C., Hansen, C., Cameron, A., Bourne, P., Wilson, T., Cook, B., Baker, M., Keir, J., Dicker, T.,  
5 Reid, M., Williamson, R., Weedon, D., Soyer, H. P., Youl, P. H. & Wilkinson, D. (2011) Measuring  
6 performance in skin cancer practice: the SCARD initiative. *International Journal of Dermatology*,  
7 50: 44-51.  
8 Not in PICO
- 9 Rosendahl, C., Williams, G., Eley, D., Wilson, T., Canning, G., Keir, J., McColl, I. & Wilkinson, D. (2012)  
10 The impact of subspecialization and dermatoscopy use on accuracy of melanoma diagnosis  
11 among primary care doctors in Australia. *Journal of the American Academy of Dermatology*, 67:  
12 846-852.  
13 Not in PICO
- 14 Rosendahl, C., Cameron, A., McColl, I. & Wilkinson, D. (2012) Dermatoscopy in routine practice -  
15 'chaos and clues'. *Australian Family Physician*, 41: 482-487.  
16 Narrative review
- 17 Rosendahl, C., Hishon, M., Cameron, A., Barksdale, S., Weedon, D. & Kittler, H. (2014) - Nodular  
18 melanoma: five consecutive cases in a general practice with polarized and non-polarized  
19 dermatoscopy and dermatopathology. - *Dermatology Practical & Conceptual*, 4: 69-75.  
20 Not in PICO
- 21 Roses, D. F. (1982) Proper biopsy of a lesion suspect of being a malignant melanoma. *American*  
22 *Journal of Dermatopathology*, 4: 475-476.  
23 Narrative review
- 24 Ross, M. I. & Gershenwald, J. E. (2013) Sentinel lymph node biopsy for melanoma: A critical update  
25 for dermatologists after two decades of experience. *Clinics in Dermatology*, 31: 298-310.  
26 Narrative review
- 27 Ruggieri, M., Iannetti, P., Polizzi, A., La, M., I, Spalice, A., Giliberto, O., Platania, N., Gabriele, A. L.,  
28 Albanese, V. & Pavone, L. (2005) Earliest clinical manifestations and natural history of  
29 neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients. *Neuropediatrics*, 36: 21-34.  
30 Not in PICO
- 31 Sahin, M. T., Ozturkcan, S., Ermertcan, A. T. & Gunes, A. T. (2004) A comparison of dermoscopic  
32 features among lentigo senilis/initial seborrheic keratosis, seborrheic keratosis, lentigo maligna  
33 and lentigo maligna melanoma on the face. *Journal of Dermatology*, 31: 884-889.  
34 Not in PICO
- 35 Salerni, G., Lovatto, L., Carrera, C., Puig, S. & Malvehy, J. (2011) Melanomas detected in a follow-up  
36 program compared with melanomas referred to a melanoma unit. *Archives of Dermatology*, 147:  
37 549-555.  
38 Not in PICO
- 39 Salopek, T. G., Slade, J., Marghoob, A. A., Rigel, D. S., Kopf, A. W., Bart, R. S. & Friedman, R. J. (1995)  
40 Management of cutaneous malignant melanoma by dermatologists of the American Academy of  
41 Dermatology. I. Survey of biopsy practices of pigmented lesions suspected as melanoma. *Journal*  
42 *of the American Academy of Dermatology*, 33: 441-450.  
43 Not in PICO
- 44 Satzger, I., Klein, M., Loser, C., Reske, S., Kapp, A. & Gutzmer, R. (2010) Sentinel node biopsy in  
45 malignant melanoma. *Onkologe*, 16: 1140-+.  
46 Narrative review
- 47 Schade, A. T., Raymond, A. C. & Amirfeyz, R. (2013) If it is not healing, do worry about it! *BMJ Case*  
48 *Reports*, 2013, 2013.  
49 Not in PICO

- 1 Schmid-Wendtner, M. H., Baumert, J., Stange, J. & Volkenandt, M. (2002) Delay in the diagnosis of  
2 cutaneous melanoma: an analysis of 233 patients. *Melanoma Research*, 12: 389-394.  
3 Not in PICO
- 4 Schmoeckel, C., Wagner-Grosser, G. & Braun-Falco, O. (1985) [Clinical diagnosis of early malignant  
5 melanomas]. [German]. *Hautarzt*, 36: 558-562.  
6 Not in PICO
- 7 Schopf, T. & Funk, J. (2012) [Nevus or malignant melanoma?]. [Norwegian]. *Tidsskrift for Den Norske*  
8 *Laegeforening*, 132: 511.  
9 Narrative review
- 10 Sellheyer, K. & Bergfeld, W. F. (2005) A retrospective biopsy study of the clinical diagnostic accuracy  
11 of common skin diseases by different specialties compared with dermatology. *Journal of the*  
12 *American Academy of Dermatology*, 52: 823-830.  
13 Not in PICO
- 14 Sergieva, S. B. & Virtcheva-Genkova, A. (1997) Radioimmunosintigraphy in patients with ocular  
15 melanoma. *Clinical Nuclear Medicine*, 22: 25-29.  
16 Not in PICO
- 17 Setala, L., Kemppainen, T., Virolainen, S. & Narkio, M. (2012) [Punch biopsy in the diagnosis of skin  
18 tumors]. [Review] [Finnish]. *Duodecim*, 128: 81-87.  
19 Narrative review
- 20 Shapiro, M., James, W. D., Kessler, R., Lazarik, F. C., Katz, K. A., Tam, J., Nieves, D. S. & Miller, J. J.  
21 (2004) Comparison of skin biopsy triage decisions in 49 patients with pigmented lesions and skin  
22 neoplasms: store-and-forward teledermatology vs face-to-face dermatology. *Archives of*  
23 *Dermatology*, 140: 525-528.  
24 Not in PICO
- 25 Shariff, Z., Roshan, A., Williams, A. M. & Platt, A. J. (2010) 2-Week wait referrals in suspected skin  
26 cancer: does an instructional module for general practitioners improve diagnostic accuracy?  
27 *Surgeon Journal of the Royal Colleges of Surgeons of Edinburgh & Ireland*, 8: 247-251.  
28 Not in PICO
- 29 Shenenberger, D. W. (2012) Cutaneous malignant melanoma: a primary care perspective.  
30 [Review][Summary for patients in Am Fam Physician. 2012 Jan 15;85(2):169; PMID: 22335217].  
31 *American Family Physician*, 85: 161-168.  
32 Narrative review
- 33 Sheth, N., Sarker, S. J., Harries, M., Healy, C., Russell-Jones, R. & Acland, K. (2010) Predictors of  
34 patient satisfaction with initial diagnosis and management of malignant melanoma. *Clinical &*  
35 *Experimental Dermatology*, 35: 599-602.  
36 Not in PICO
- 37 Shields, J. A., Shields, C. L., Ehya, H., Eagle, R. C., Jr. & De, P. P. (1993) Fine-needle aspiration biopsy  
38 of suspected intraocular tumors. The 1992 Urwick Lecture. *Ophthalmology*, 100: 1677-1684.  
39 Not in PICO
- 40 Shoo, B. A., Sagebiel, R. W. & Kashani-Sabet, M. (2010) Discordance in the histopathologic diagnosis  
41 of melanoma at a melanoma referral center. *Journal of the American Academy of Dermatology*,  
42 62: 751-756.  
43 Not in PICO
- 44 Shorrock, K. (1993) Use of histopathology services by general practitioners: recent changes in  
45 referral practice. *Journal of Clinical Pathology*, 46: 989-992.  
46 Not in PICO
- 47 Shrestha, B., Bishop, J., Kam, K., Chen, X., Moss, R. H., Stoecker, W. V., Umbaugh, S., Stanley, R. J.,  
48 Celebi, M. E., Marghoob, A. A., Argenziano, G. & Soyer, H. P. (2010) Detection of atypical texture  
49 features in early malignant melanoma. *Skin Research & Technology*, 16: 60-65.  
50 Not in PICO

- 1 Simionescu, O., Costache, M. & Testori, A. (2006) Cutaneous melanoma: digital dermoscopy-  
2 essential tool for positive diagnosis. *Journal of Cellular & Molecular Medicine*, 10: 991-994.  
3 Narrative review
- 4 Soares, T. F., Laman, S. D., Yiannias, J. A., Connolly, S. M., Lim, K. K., Wu, Q. & Swanson, D. L. (2009)  
5 Factors leading to the biopsy of 1547 pigmented lesions at Mayo Clinic, Scottsdale, Arizona, in  
6 2005. *International Journal of Dermatology*, 48: 1053-1056.  
7 Not in PICO
- 8 Sober, A. J., Chuang, T. Y., Duvic, M., Farmer, E. R., Grichnik, J. M., Halpern, A. C., Ho, V., Holloway,  
9 V., Hood, A. F., Johnson, T. M., Lowery, B. J. & Guidelines/Outcomes Committee (2001) Guidelines  
10 of care for primary cutaneous melanoma. *Journal of the American Academy of Dermatology*, 45:  
11 579-586.  
12 Guideline
- 13 Stanganelli, I., Seidenari, S., Serafini, M., Pellacani, G. & Bucchi, L. (1999) Diagnosis of pigmented skin  
14 lesions by epiluminescence microscopy: determinants of accuracy improvement in a nationwide  
15 training programme for practical dermatologists. *Public Health*, 113: 237-242.  
16 Not in PICO
- 17 Stefano, Z., Cesare, B., Claudio, C., Fausto, C., Aldo, B. & Natale, C. (1992) Melanocytic neoplasia of  
18 the sole: diagnosis and therapeutic approach. *Journal of Dermatology*, 19: 280-284.  
19 Not in PICO
- 20 Stolz, W., Semmelmayr, U., Johow, K. & Burgdorf, W. H. (2003) Principles of dermatoscopy of  
21 pigmented skin lesions. [Review] [32 refs]. *Seminars in Cutaneous Medicine & Surgery*, 22: 9-20.  
22 Narrative review
- 23 Takata, M. & Saida, T. (2005) Early cancers of the skin: clinical, histopathological, and molecular  
24 characteristics. [Review] [44 refs]. *International Journal of Clinical Oncology*, 10: 391-397.  
25 Narrative review
- 26 Tan, E., Oakley, A., Soyer, H. P., Haskett, M., Marghoob, A., Jameson, M. & Rademaker, M. (2010)  
27 Interobserver variability of teledermoscopy: an international study. *British Journal of*  
28 *Dermatology*, 163: 1276-1281.  
29 Not in PICO
- 30 ten Koppel, P. G., Vuyk, H. D. & Neumann, H. A. (2005) [The feasibility of the razor-blade shave  
31 technique in the diagnosis and treatment of benign and malignant skin lesions on the face].  
32 [Review] [26 refs] [Dutch]. *Nederlands Tijdschrift Voor Geneeskunde*, 149: 1561-1567.  
33 Narrative review
- 34 Terushkin, V. & Halpern, A. C. (2009) Melanoma Early Detection. *Hematology-Oncology Clinics of*  
35 *North America*, 23: 481-+.  
36 Narrative review
- 37 Terushkin, V., Braga, J. C., Dusza, S. W., Scope, A., Busam, K., Marghoob, A. A., Gill, M. & Halpern, A.  
38 C. (2010) Agreement on the clinical diagnosis and management of cutaneous squamous  
39 neoplasms. *Dermatologic Surgery*, 36: 1514-1520.  
40 Not in PICO
- 41 Thomas, J. M. (2006) Research supports the view that sentinel node biopsy is the standard of care in  
42 high-risk primary melanoma - Reply. *Journal of Clinical Oncology*, 24: 2966-2967.  
43 Not in PICO
- 44 Thomas, S., Meng, Y. X., Patel, V. G. & Strayhorn, G. (2012) A rare form of melanoma masquerading  
45 as a diabetic foot ulcer: a case report. *Case Reports in Endocrinology Print*, 2012: 502806.  
46 Not in PICO
- 47 Thrasivoulou, C., Virich, G., Krenacs, T., Korom, I. & Becker, D. L. (2011) Optical delineation of human  
48 malignant melanoma using second harmonic imaging of collagen. *Biomedical Optics Express*, 2:  
49 1282-1295.  
50 Not in PICO

- 1 Tlougan, B. E., Orlow, S. J. & Schaffer, J. V. (2013) Spitz nevi: beliefs, behaviors, and experiences of  
2 pediatric dermatologists. *JAMA Dermatology*, 149: 283-291.  
3 Not in PICO
- 4 Topar, G. & Zelger, B. (2007) Assessment of value of the sentinel lymph node biopsy in melanoma in  
5 children and adolescents and applicability of subcutaneous infusion anesthesia. *Journal of*  
6 *Pediatric Surgery*, 42: 1716-1720.  
7 Not in PICO
- 8 Tran, K. T., Wright, N. A. & Cockerell, C. J. (2008) Biopsy of the pigmented lesion--when and how.  
9 [Review] [174 refs]. *Journal of the American Academy of Dermatology*, 59: 852-871.  
10 Narrative review
- 11 Tyler, I., Rivers, J. K., Shoveller, J. A. & Blum, A. (2005) Melanoma detection in British Columbia,  
12 Canada. *Journal of the American Academy of Dermatology*, 52: 48-54.  
13 Not in PICO
- 14 Ulrich, M., Lange-Asschenfeldt, S. & Gonzalez, S. (2012) In vivo reflectance confocal microscopy for  
15 early diagnosis of nonmelanoma skin cancer. *Actas Dermo-Sifiliograficas*, 103: 784-789.  
16 Narrative review
- 17 Urbancek, S., Simekova, P. & Tomkova, J. (2013) Misdiagnosis of melanoma: A 5 years analysis. *JDDG*  
18 *- Journal of the German Society of Dermatology*, 11: 31.  
19 Not in PICO
- 20 Uren, R. F. (2006) Sentinel lymph node biopsy in melanoma. [Review] [44 refs]. *Journal of Nuclear*  
21 *Medicine*, 47: 191-195.  
22 Not in PICO
- 23 van der Heijden, J. P., Thijssing, L., Witkamp, L., Spuls, P. I. & de Keizer, N. F. (2013) Accuracy and  
24 reliability of teledermatology with images taken by general practitioners during everyday  
25 practice. *Journal of Telemedicine and Telecare*, 19: 320-325.  
26 Not in PICO
- 27 van der Rhee, J. I., Bergman, W. & Kukutsch, N. A. (2010) The impact of dermoscopy on the  
28 management of pigmented lesions in everyday clinical practice of general dermatologists: a  
29 prospective study. *British Journal of Dermatology*, 162: 563-567.  
30 Not in PICO
- 31 van der Rhee, J. I., Bergman, W. & Kukutsch, N. A. (2011) Impact of Dermoscopy on the Management  
32 of High-risk Patients From Melanoma Families: A Prospective Study. *Acta Dermato-Venereologica*,  
33 91: 428-431.  
34 Not in PICO
- 35 Venkata, R. B. (2010) Desmoplastic melanoma presenting as pyogenic granuloma: report of a case  
36 with review of literature. *Indian Journal of Dermatology*, 55: 284-289.  
37 Not in PICO
- 38 Vestergaard, M. E., Macaskill, P., Holt, P. E. & Menzies, S. W. (2008) Dermoscopy compared with  
39 naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies  
40 performed in a clinical setting. *British Journal of Dermatology*, 159: 669-676.  
41 Systematic review, no new studies identified. Relevant studies will be include separately.
- 42 Vikey, A. K. & Vikey, D. (2012) Primary malignant melanoma, of head and neck: a comprehensive  
43 review of literature. [Review]. *Oral Oncology*, 48: 399-403.  
44 Narrative review
- 45 Viola, K. V., Tolpinrud, W. L., Gross, C. P., Kirsner, R. S., Imaeda, S. & Federman, D. G. (2011)  
46 Outcomes of referral to dermatology for suspicious lesions: implications for teledermatology.  
47 *Archives of Dermatology*, 147: 556-560.  
48 Not in PICO
- 49 Vogt, H., Schmidt, M., Bares, R., Brenner, W., Grunwald, F., Kopp, J., Reiners, C., Schober, O.,  
50 Schumichen, C., Schicha, H., Sciuk, J., Sudbrock, F. & Wengenmair, H. (2010) [Procedure guideline



- 1 for sentinel lymph node diagnosis]. [German]. *Nuclear-Medizin*, 49: 167-172.  
2 Not in PICO
- 3 Voigt, H. & Classen, R. (2002) Computer vision and digital imaging technology in melanoma  
4 detection. [Review] [234 refs]. *Seminars in Oncology*, 29: 308-327.  
5 Narrative review
- 6 Voit, C., Mayer, T., Proebstle, T. M., Weber, L., Kron, M., Krupienski, M., Zeelen, U., Sterry, W. &  
7 Schoengen, A. (2000) Ultrasound-guided fine-needle aspiration cytology in the early detection of  
8 melanoma metastases. *Cancer*, 90: 186-193.  
9 Not in PICO
- 10 Voit, C., Schoengen, A., Schwurzer-Voit, M., Weber, L., Ulrich, J., Sterry, W. & Proebstle, T. M. (2002)  
11 The role of ultrasound in detection and management of regional disease in melanoma patients.  
12 [Review] [58 refs]. *Seminars in Oncology*, 29: 353-360.  
13 Not in PICO
- 14 Voit, C. A., Gooskens, S. L., Siegel, P., Schaefer, G., Schoengen, A., Rowert, J., van Akkooi, A. C. &  
15 Eggermont, A. M. (2014) - Ultrasound-guided fine needle aspiration cytology as an addendum to  
16 sentinel lymph node biopsy can perfect the staging strategy in melanoma patients. - *European*  
17 *Journal of Cancer*, 50: 2280-2288.  
18 Not in PICO
- 19 Waller, J. M. & Zedek, D. C. (2010) How informative are dermatopathology requisition forms  
20 completed by dermatologists? A review of the clinical information provided for 100 consecutive  
21 melanocytic lesions. *Journal of the American Academy of Dermatology*, 62: 257-261.  
22 Not in PICO
- 23 Walter, F. M., Humphrys, E., Tso, S., Johnson, M. & Cohn, S. (2010) Patient understanding of moles  
24 and skin cancer, and factors influencing presentation in primary care: a qualitative study. *BMC*  
25 *Family Practice*, 11: 62.  
26 Not in PICO
- 27 Walter, F. M., Morris, H. C., Humphrys, E., Hall, P. N., Kinmonth, A. L., Prevost, A. T., Wilson, E. C.,  
28 Burrows, N., Norris, P., Johnson, M. & Emery, J. (2010) Protocol for the MoleMate UK Trial: a  
29 randomised controlled trial of the MoleMate system in the management of pigmented skin  
30 lesions in primary care [ISRCTN 79932379]. *BMC Family Practice*, 11: 36.  
31 Protocol
- 32 Walter, F. M., Prevost, A. T., Vasconcelos, J., Hall, P. N., Burrows, N. P., Morris, H. C., Kinmonth, A. L.  
33 & Emery, J. D. (2013) Using the 7-point checklist as a diagnostic aid for pigmented skin lesions in  
34 general practice: A diagnostic validation study. *British Journal of General Practice*, 63: e345-e353.  
35 Not in PICO
- 36 Wang, S. Q., Kopf, A. W., Koenig, K., Polsky, D., Nudel, K. & Bart, R. S. (2004) Detection of melanomas  
37 in patients followed up with total cutaneous examinations, total cutaneous photography, and  
38 dermoscopy. *Journal of the American Academy of Dermatology*, 50: 15-20.  
39 Not in PICO
- 40 Warsaw, E. M., Lederle, F. A., Grill, J. P., Gravely, A. A., Bangerter, A. K., Fortier, L. A., Bohjanen, K.  
41 A., Chen, K., Lee, P. K., Rabinovitz, H. S., Johr, R. H., Kaye, V. N., Bowers, S., Wenner, R., Askari, S.  
42 K., Kedrowski, D. A. & Nelson, D. B. (2009) Accuracy of teledermatology for pigmented  
43 neoplasms.[Erratum appears in J Am Acad Dermatol. 2010 Feb;62(2):319]. *Journal of the*  
44 *American Academy of Dermatology*, 61: 753-765.  
45 Not in PICO
- 46 Watson, T., Walter, F. M., Wood, A., Morris, H., Hall, P., Karner, S. & Emery, J. (2009) Learning a  
47 novel technique to identify possible melanomas: are Australian general practitioners better than  
48 their U.K. colleagues? *Asia Pacific Family Medicine*, 8: 3.  
49 Not in PICO
- 50 Webb, J. B. & Khanna, A. (2006) Can we rely on a general practitioner's referral letter to a skin lesion  
51 clinic to prioritize appointments and does it make a difference to the patient's prognosis? *Annals*

- 1 of the Royal College of Surgeons of England, 88: 40-45.  
2 Not in PICO
- 3 Weidner, F. (1980) [Malignant melanomas of the skin. Early diagnosis and differential diagnosis.--  
4 conclusion]. [German]. *Fortschritte der Medizin*, 98: 1449-1452.  
5 Narrative review
- 6 Welch, H. G., Woloshin, S. & Schwartz, L. M. (2005) Skin biopsy rates and incidence of melanoma:  
7 population based ecological study. *BMJ*, 331: 481.  
8 Not in PICO
- 9 Wells, K. E., Rapaport, D. P., Cruse, C. W., Payne, W., Albertini, J., Berman, C., Lyman, G. H. &  
10 Reintgen, D. S. (1997) Sentinel lymph node biopsy in melanoma of the head and neck. *Plastic and  
11 Reconstructive Surgery*, 100: 591-594.  
12 Not in PICO
- 13 Westerhoff, K., McCarthy, W. H. & Menzies, S. W. (2000) Increase in the sensitivity for melanoma  
14 diagnosis by primary care physicians using skin surface microscopy. *British Journal of  
15 Dermatology*, 143: 1016-1020.  
16 Not in PICO
- 17 Wharton, J. M., Carlson, J. A. & Mihm, M. C., Jr. (1999) Desmoplastic malignant melanoma: diagnosis  
18 of early clinical lesions. *Human Pathology*, 30: 537-542.  
19 Not in PICO
- 20 Whitaker, D. (1991) Skin cancer: diagnosis and management. *Iowa Medicine*, 81: 211-214.  
21 Narrative review
- 22 Whitaker, D. K. (2004) Guideline on the management of melanoma. *Samj South African Medical  
23 Journal*, 94: 699-708.  
24 Guideline
- 25 White, J. W., Jr. (1985) Evaluating cancer metastatic to the skin. *Geriatrics*, 40: 67-73.  
26 Narrative review
- 27 Whited, J. D. & Grichnik, J. M. (1998) Does this patient have a mole or a melanoma? *Jama-Journal of  
28 the American Medical Association*, 279: 696-701.  
29 Not in PICO
- 30 Wilkes, D. (2010) The use of dermoscopy in medical photography for the early detection of skin  
31 cancer. *Journal of Visual Communication in Medicine*, 33: 169-173.  
32 Narrative review
- 33 Wilkinson, D., Askew, D. A. & Dixon, A. (2006) Skin cancer clinics in Australia: workload profile and  
34 performance indicators from an analysis of billing data. *Medical Journal of Australia*, 184: 162-  
35 164.  
36 Not in PICO
- 37 Wilson, E. C., Emery, J. D., Kinmonth, A. L., Prevost, A. T., Morris, H. C., Humphrys, E., Hall, P. N.,  
38 Burrows, N., Bradshaw, L., Walls, J., Norris, P., Johnson, M. & Walter, F. M. (2013) The cost-  
39 effectiveness of a novel SIAscopic diagnostic aid for the management of pigmented skin lesions in  
40 primary care: a decision-analytic model. *Value in Health*, 16: 356-366.  
41 Same data as Walter (2012) already included.
- 42 Wilson, E. C., Emery, J. D., Louise, K. A., Toby, P. A., Morris, H. C., Humphrys, E., Hall, P. N., Burrows,  
43 N., Bradshaw, L., Walls, J., Norris, P., Johnson, M. & Walter, F. M. (2013) The Cost-Effectiveness of  
44 a Novel SIAscopic Diagnostic Aid for the Management of Pigmented Skin Lesions in Primary Care:  
45 A Decision-Analytic Model. *Value in Health*, 16: 356-366.  
46 Not in PICO
- 47 Wilson, E. C. F., Emery, J. D., Kinmonth, A. L., Prevost, A. T., Morris, H. C., Humphrys, E., Hall, P. N.,  
48 Burrows, N., Bradshaw, L., Walls, J., Norris, P., Johnson, M. & Walter, F. M. (2013) The Cost-  
49 Effectiveness of a Novel SIAscopic Diagnostic Aid for the Management of Pigmented Skin Lesions  
50 in Primary Care: A Decision-Analytic Model. *Value in Health*, 16: 356-366.  
51 Not in PICO

- 1 Wilson, M. A. & Nathanson, K. L. (2012) Molecular testing in melanoma. [Review]. *Cancer Journal*,  
2 18: 117-123.  
3 Not in PICO
- 4 Wilson, R. L., Yentzer, B. A., Isom, S. P., Feldman, S. R. & Fleischer, A. B. (2012) How good are US  
5 dermatologists at discriminating skin cancers? A number-needed-to-treat analysis. *Journal of*  
6 *Dermatological Treatment*, 23: 65-69.  
7 Not in PICO
- 8 Wolchok, J. D. & Saenger, Y. M. (2007) Current topics in melanoma. *Current Opinion in Oncology*, 19:  
9 116-120.  
10 Not in PICO
- 11 Wolf, O. & Shalom, A. (1111) [Dermoscopy--a glimpse into the skin]. [Review] [Hebrew]. *Harefuah*,  
12 149: 519-523.  
13 Narrative review
- 14 Wood, A., Morris, H., Emery, J., Hall, P. N., Cotton, S., Prevost, A. T. & Walter, F. M. (2008) Evaluation  
15 of the MoleMate training program for assessment of suspicious pigmented lesions in primary  
16 care. *Informatics in Primary Care*, 16: 41-50.  
17 Not in PICO
- 18 Woodman, S. E., Lazar, A. J., Aldape, K. D. & Davies, M. A. (2012) New strategies in melanoma:  
19 molecular testing in advanced disease. [Review]. *Clinical Cancer Research*, 18: 1195-1200.  
20 Narrative review
- 21 Wray, E. V., Brant, B., Hussain, F. & Muller, F. M. (2013) A new model of teledermoscopy combining  
22 service and education. *British Journal of Dermatology*, 169: 139.  
23 Not in PICO
- 24 Wright, B. E., Scheri, R. P., Ye, X., Faries, M. B., Turner, R. R., Essner, R. & Morton, D. L. (2008)  
25 Importance of sentinel lymph node biopsy in patients with thin melanoma. *Archives of Surgery*,  
26 143: 892-899.  
27 Not in PICO
- 28 Yang, J. C., Sherry, R. M. & Rosenberg, S. A. (2014) Why is sentinel lymph node biopsy 'standard of  
29 care' for melanoma? *Nature Reviews Clinical Oncology*, 11: 245-246.  
30 Not in PICO
- 31 Youl, P. H., Baade, P. D., Janda, M., Del Mar, C. B., Whiteman, D. C. & Aitken, J. F. (2007) Diagnosing  
32 skin cancer in primary care: how do mainstream general practitioners compare with primary care  
33 skin cancer clinic doctors? *Medical Journal of Australia*, 187: 215-220.  
34 Not in PICO
- 35 Youl, P. H., Janda, M., Aitken, J. F., Del Mar, C. B., Whiteman, D. C. & Baade, P. D. (2011) Body-site  
36 distribution of skin cancer, pre-malignant and common benign pigmented lesions excised in  
37 general practice. *British Journal of Dermatology*, 165: 35-43.  
38 Not in PICO
- 39 Zager, J. S., Hochwald, S. N., Marzban, S. S., Francois, R., Law, K. M., Davis, A. H., Messina, J. L.,  
40 Vincek, V., Mitchell, C., Church, A., Copeland, E. M., Sondak, V. K. & Grobmyer, S. R. (2011) Shave  
41 Biopsy Is a Safe and Accurate Method for the Initial Evaluation of Melanoma. *Journal of the*  
42 *American College of Surgeons*, 212: 454-460.  
43 Not in PICO
- 44 Zhang, J., Chang, C. I., Miller, S. J. & Kang, K. A. (2000) A feasibility study of multispectral image  
45 analysis of skin tumors. *Biomedical Instrumentation & Technology*, 34: 275-282.  
46 Not in PICO
- 47 Zortea, M., Schopf, T. R., Thon, K., Geilhufe, M., Hindberg, K., Kirchesch, H., Mollersen, K., Schulz, J.,  
48 Skrovseth, S. O. & Godtlielsen, F. (2014) Performance of a dermoscopy-based computer vision  
49 system for the diagnosis of pigmented skin lesions compared with visual evaluation by  
50 experienced dermatologists. *Artificial Intelligence in Medicine*, 60: 13-26.  
51 Not in PICO

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11

Zortea, M., Schopf, T. R., Thon, K., Geilhufe, M., Hindberg, K., Kirchesch, H., Mollersen, K., Schulz, J., Skrovseth, S. O. & Godtlielsen, F. (2014) Performance of a dermoscopy-based computer vision system for the diagnosis of pigmented skin lesions compared with visual evaluation by experienced dermatologists. *Artificial Intelligence in Medicine*, 60: 13-26.  
Not in PICO

Wilson ECF, Emery JD, Kinmonth AL et al 'The Cost-Effectiveness of a Novel SIAscopic Diagnostic Aid for the Management of Pigmented Skin Lesions in Primary Care: A Decision-Analytical Model' *Value in Health* 16.2 (2012): p356-366.

**SQUAMOUS CELL CARCINOMA****Review question:**

What is the risk of squamous cell carcinoma in patients presenting in primary care with symptom(s)?

**Results****Literature search**


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	All-2012	501	66	09/01/2013
<i>Premedline</i>	All-2012	66	5	09/01/2013
<i>Embase</i>	All-2012	2129	76	15/01/2013
<i>Cochrane Library</i>	All-2012	201	3	16/01/2013
<i>Psychinfo</i>	All-2012	4	1	09/01/2013
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	All-2012	569	36	16/01/2013
<i>Biomed Central</i>	All-2012	287	3	21/01/2013

Total References retrieved (after de-duplication): 151

**Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	2013-11/08/2014	78	4	11/08/2014
<i>Premedline</i>	2013-11/08/2014	13	3	11/08/2014
<i>Embase</i>	2013-11/08/2014	123	6	11/08/2014
<i>Cochrane Library</i>	2013-11/08/2014	48	0	11/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	2013-11/08/2014	89	7	11/08/2014

Total References retrieved (after de-duplication): 20



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11

**Risk of bias in the included studies**

The risk of bias and applicability concerns are summarised per study in the figure below. The main bias risks and applicability concerns that the studies are subject to relate to (1) the patient sampling method not clearly being consecutive or random, (2) the extent to which the study setting matches UK primary care, (3) the quality of the reference standard, which may not always reliably diagnose the symptoms, and (4) the fact that the reference standard did not in all cases match that of the current question, namely histology.

	Risk of Bias				Applicability Concerns		
	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard
Emery (2010)	?	+	?	+	?	+	?
Rosendahl (2012)	?	+	+	+	?	+	+
Walter (2012)	?	+	?	+	+	+	?

⊖ High	⊕ Unclear	⊕ Low
--------	-----------	-------

12  
13  
14  
15  
16  
17

**Study results**

Table 1: Squamous cell carcinoma of the skin: Study results.

Study	Symptom(s)	Patient group	Positive predictive value % (95% CI) Prevalence
Emery (2010)  Patient-based analysis	Pigmented lesion	All included patients	0 (0-0.6) 0/858
		England sample	0 (0-1.2) 0/389
		Australia sample	0 (0-1) 0/469
Walter (2012)  Lesion, not patient,-based analysis	Suspicious pigmented lesions	All included patients	0.06 (0.003-0.4) 1/1573
Rosendahl (2012)  Lesion, not patient,-based analysis	Non-pigmented raised skin lesions	All included patients	SCC total: 41.26 (34.5-48.3) 85/206
			SCC: 15.53 (11-21.4) 32/206
			Keratoacanthoma: 14.08 (9.8-19.8) 29/206
			Bowen disease: 11.65 (7.8-17) 24/206
		Females	SCC and KA: 31.81 (21.2-44.6) 21/66
		Males	SCC and KA: 28.57 (21.4-36.9) 40/140
	Non-pigmented raised skin lesions on head and neck	Patients with specific symptom	SCC and KA: 23.33 (15.3-33.7) 21/90
	Non-pigmented raised skin lesions on trunk	Patients with specific symptom	SCC and KA: 14.29 (6.4-27.9) 7/49
	Non-pigmented raised skin lesions on upper extremities	Patients with specific symptom	SCC and KA: 45.16 (27.8-63.7) 14/31
	Non-pigmented raised skin lesions on lower extremities	Patients with specific symptom	SCC and KA: 52.78 (35.7-69.2) 19/36
Non-pigmented raised skin lesions with monomorphic vascular pattern	Patients with specific symptom	SCC and KA: 26.47 (19.5-34.8) 36/136	
Non-pigmented raised skin lesions with polymorphic vascular	Patients with specific symptom	SCC and KA: 31.71 (18.6-48.2) 13/41	

pattern		
Non-pigmented raised skin lesions with vessels absent	Patients with specific symptom	SCC and KA: 39.29 (22.1-59.3) 11/28
Non-pigmented raised skin lesions with vessel morphologic findings: Dots	Patients with specific symptom	SCC and KA: 0 (0-95) 0/1
Non-pigmented raised skin lesions with vessel morphologic findings: Coils	Patients with specific symptom	SCC and KA: 40 (30.1-49.8) 44/110
Non-pigmented raised skin lesions with vessel morphologic findings: Serpentine	Patients with specific symptom	SCC and KA: 9.76 (4.6-18.8) 8/82
Non-pigmented raised skin lesions with vessel morphologic findings: Looped	Patients with specific symptom	SCC and KA: 41.67 (22.8-63.1) 10/24
Non-pigmented raised skin lesions with vessel arrangement: No arrangement	Patients with specific symptom	SCC and KA: 36.7 (27.8-46.5) 40/109
Non-pigmented raised skin lesions with vessel arrangement: Radial	Patients with specific symptom	SCC and KA: 41.18 (19.4-66.5) 7/17
Non-pigmented raised skin lesions with vessel arrangement: Centered	Patients with specific symptom	SCC and KA: 0 (0-30.1) 0/12
Non-pigmented raised skin lesions with vessel arrangement: Branched	Patients with specific symptom	SCC and KA: 0 (0-12.3) 0/35
Non-pigmented raised skin lesions with vessel arrangement: Branched and radial	Patients with specific symptom	SCC and KA: 2/2 (TP = 2, FP = 0)
Non-pigmented raised skin lesions with vessel arrangement: Others	Patients with specific symptom	SCC and KA: 100 (19.8-100) 0/2
Non-pigmented raised skin lesions and keratin	Patients with specific symptom	SCC and KA: 52.17 (41.6-62.6) 48/92
Non-pigmented raised skin lesions and ulceration	Patients with specific symptom	SCC and KA: 27.27 (13.9-45.8) 9/33
Non-pigmented raised skin lesions with white structures: White clods	Patients with specific symptom	SCC and KA: 20 (5.3-48.6) 3/15
Non-pigmented raised skin lesions with white	Patients with	SCC and KA: 47.06 (3.2-61.4)



	structures: White structureless zones	specific symptom	24/51
	Non-pigmented raised skin lesions with white structures: White circles	Patients with specific symptom	SCC and KA: 58.7 (43.3-72.7) 27/46
	Non-pigmented raised skin lesions with white structures: White lines	Patients with specific symptom	SCC and KA: 6.67 (0.3-34) 1/15
	Non-pigmented raised skin lesions with white structures: White dots (milia)	Patients with specific symptom	SCC and KA: 16.67 (0.9-63.5) 1/6
	Non-pigmented raised skin lesions with white structures: Blood spots	Patients with specific symptom	SCC and KA: 45.61 (32.6-59.2) 26/57
	Non-pigmented raised skin lesions with white structures: Scale	Patients with specific symptom	SCC and KA: 40 (28.7-52.4) 28/70

1 KA = keratoacanthoma; TP = true positives; FP = false positives

2 **Evidence statement(s):**

3 Pigmented skin lesions (2 studies, N = 2784 *lesions*) presenting in a primary care setting do not seem  
4 to confer a risk of squamous cell carcinoma (1 case observed in total). The studies were associated  
5 with 3-4 bias and applicability concerns (See also Table 1).

6  
7 Non-pigmented raised skin lesions (1 study, N = 206 *lesions*) presenting in a primary care setting are  
8 associated with a positive predictive value of 41.26% for squamous cell carcinoma. The study was  
9 associated with 2 bias and applicability concerns (See also Table 1).

10  
11 **Evidence tables**

12 **Emery (2010)**

PATIENT SELECTION	
A. risk of bias	
Patient sampling	Prospective series of pigmented lesions recruited from England (6 general practices covering urban, suburban and rural areas with a registered population of 52913) and Australia (3 primary care skin cancer clinics operated by GPs from a metropolitan area)
Was a consecutive or random sample of patients enrolled?	Unclear
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
<b>Could the selection of patients have introduced bias?</b>	<b>Unclear risk</b>
B. Concerns regarding applicability	
Patient characteristics and setting	England: N = 389 patients, mean age = 44.9 years, 68.6% females with, interpretable images from N = 630 lesions. 0/630 lesions were squamous cell carcinoma, 0/630 lesions were basal cell carcinoma, 5/630 lesions were melanoma, and 0/630 lesions were lentigo maligna (melanoma). Australia: N = 469 patients, mean age = 50 years, 48% females, with

	<p>interpretable images from N = 581 lesions. 0/581 lesions were squamous cell carcinoma, 22/581 lesions were basal cell carcinoma, 7/581 lesions were melanoma, and 4/581 lesions were lentigo maligna (melanoma).</p> <p><u>Inclusion criteria:</u>  England: Patients aged &gt; 18 years were recruited into the study by their GP if they presented with concerns about a pigmented skin lesion between January 2005 and January 2006.  Australia: Patients aged &gt; 18 years were recruited into the study by their GP if they presented with concerns about a pigmented skin lesion between April 2008 and January 2009. Additional lesions were also included when a pigmented skin lesion was identified as potentially suspicious during their clinical examination</p> <p><u>Exclusion criteria:</u> None reported.  <u>Clinical setting:</u> Primary care, UK, and primary care skin cancer practice, Queensland Australia.</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	Pigmented skin lesions that concerned patients, which were evaluated using macroscopic clinical photographs, dermoscopic images and SIAscan.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
<b>Reference standard(s)</b>	Histopathology or in-person clinical review of the lesion by one expert, including the 7-point melanoma checklist and digital dermoscopy or clinical diagnosis made on the basis of the 7-point melanoma checklist, photographic and dermoscopy images
Is the reference standard likely to correctly classify the target condition?	<b>Unclear</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Unclear concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
<b>Flow and timing</b>	All patients are accounted for in the results
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>

<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	

1

<b>Rosendahl (2012)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective unselected consecutive series of raised non-pigmented lesions
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Unclear</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	N = 186 patients, mean (SD) age = 65 (13) years, 32.8% females with N = 206 lesions. 32/206 lesions were squamous cell carcinoma (SCC), 29/206 lesions were keratoacanthoma (SCC), 24/206 lesions were Bowen disease (SCC), and 56/ 206 lesions were basal cell carcinoma.  <u>Inclusion criteria:</u> Patients presenting with non-pigmented raised lesions treated from March 1 through December 31 2011. All the lesions were excised or biopsied. It is unclear if there were any patients presenting with non-pigmented raised lesions not biopsied/excised who were not included. <u>Exclusion criteria:</u> None reported. <u>Clinical setting:</u> Private primary care skin cancer practice, Queensland Australia.
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	Non-pigmented raised skin lesions (not further defined, but see subgroup analyses) evaluated using dermoscopic images
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Histopathology
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined</b>	<b>Low concern</b>

<b>by the reference standard does not match the question?</b>		
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	All patients are accounted for in the results	
Was there an appropriate interval between index test and reference standard?	Yes	
Did all patients receive the same reference standard?	Yes	
Were all patients included in the analysis?	Yes	
<b>Could the patient flow have introduced bias?</b>		<b>Low risk</b>
<b>NOTES</b>	Analysis was on a per-lesion basis rather than a per-patient basis; some patients may have had more than one lesion diagnosed as skin cancer though it is not possible to ascertain the actual numbers from the data provided.	

1

<b>Walter (2012)</b>		
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Prospective series of suspicious pigmented lesions	
Was a consecutive or random sample of patients enrolled?	Unclear	
Was a case-control design avoided?	Yes	
Did the study avoid inappropriate exclusions?	Unclear	
<b>Could the selection of patients have introduced bias?</b>		<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>		
Patient characteristics and setting	<p>N = 1293 patients, mean age (SD) = 44.6 (16.8) years; 465 males / 828 females with N = 1573 lesions, of which 1 was squamous cell carcinoma, 10 basal cell carcinomas, and 36 melanomas.</p> <p><u>Inclusion criteria:</u> Patients aged ≥ 18 years presenting to one of the 15 participating general practices with a suspicious (any lesion presented by a patient, or opportunistically seen by a family doctor or practice nurse, that could not immediately be diagnosed as benign and about which the patient could not be reassured) pigmented lesion from March 2008 to May 2010.</p> <p><u>Exclusion criteria:</u> Patients who were unable to give informed consent or were considered inappropriate to include by their family doctor.</p> <p><u>Clinical setting:</u> UK primary care.</p>	
<b>Are there concerns that the included patients and setting do not match the review question?</b>		<b>Low concern</b>
<b>INDEX TEST</b>		
<b>A. Risk of bias</b>		
Index test	Suspicious (any lesion presented by a patient, or opportunistically seen by a family doctor or practice nurse, that could not immediately be diagnosed as benign and about which the patient could not be reassured) pigmented lesion	
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes	
<b>Could the conduct or interpretation of the index test have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>		<b>Low concern</b>
<b>REFERENCE STANDARD</b>		

<b>A. risk of bias</b>	
Reference standard(s)	Expert opinion by a histologist or dermatologist or review by two other dermatology experts of the recorded clinical history and examination, a digital photograph, and MoleMate images where available with or without follow up 3-6 months later.
Is the reference standard likely to correctly classify the target condition?	<b>Unclear</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Unclear concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients are accounted for in the results
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes Tests: No</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	Analysis was on a per-lesion basis rather than a per-patient basis.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

**References**

**Included Studies**

Emery, J.D., Hunter, J., Hall, P.N., Watson, A.J., Moncrieff, M., Walter, F.M. (2010). Accuracy of SIAscopy for pigmented skin lesions encountered in primary care: development and validation of a new diagnostic algorithm. *BMJ Dermatology*, 10:9.

Rosendahl, C. (2012) Dermoscopy of squamous cell carcinoma and keratoacanthoma. *Archives of Dermatology*, 148: 1386-1392.

Walter, F.M., Morris, H.C., Humphrys, E., Hall, P.N., Prevost, A.T., Burrows, N., Bradshaw, L., Wilson, E.C., Norris, P., Walls, J., Johnson, M., Kinmonth, A.L., Emery, J.D. (2012). Effect of adding a diagnostic aid to best practice to manage suspicious pigmented lesions in primary care: randomised controlled trial. *BMJ*, 345: e4110.

**Excluded Studies**

Abbas, A., Yang, G. & Fakih, M. (2010) Management of Anal Cancer in 2010 Part 1: Overview, Screening, and Diagnosis. *Oncology-New York*, 24: 364-369.  
Narrative review

ADAMS, W. M., HENDRIX, J. H., Jr., ADAMS, W. M. & HENDRIX, J. H. J. (1952) Facial lesions of interest to the general practitioner and the plastic surgeon. *Southern Medical Journal*, 45: 689-695.  
Narrative review

Aitken, J. F., Janda, M., Elwood, M., Youl, P. H., Ring, I. T., Lowe, J. B., Aitken, J. F., Janda, M., Elwood, M., Youl, P. H., Ring, I. T. & Lowe, J. B. (2006) Clinical outcomes from skin screening clinics within a community-based melanoma screening program. *Journal of the American Academy of Dermatology*, 54: 105-114.  
Not in PICO

- 1 Alam, M. & Ratner, D. (2001) Primary care: Cutaneous squamous-cell carcinoma. *New England*  
2 *Journal of Medicine*, 344: 975-983.  
3 Narrative review
- 4 Albert, M. R. W. (2003) Keratinocyte carcinoma. *Ca-A Cancer Journal for Clinicians*, 53: 292-302.  
5 Narrative review
- 6 Aldridge, R. B., Naysmith, L., Ooi, E. T., Murray, C. S. & Rees, J. L. (1111) The importance of a full  
7 clinical examination: Assessment of index lesions referred to a skin cancer clinic without a  
8 total body skin examination would miss one in three melanomas. *Acta Dermato-*  
9 *Venereologica*, 93: 2013.  
10 Not in PICO
- 11 Alho, O. P., Teppo, H., Mantyselka, P. & Kantola, S. (2006) Head and neck cancer in primary care:  
12 presenting symptoms and the effect of delayed diagnosis of cancer cases. *CMAJ.*, 174: 779-  
13 784.  
14 Not in PICO (cancer patients from one population, symptomatic patients from another  
15 population)
- 16 Allon, I., Allon, D. M., Anavi, Y. & Kaplan, I. (2013) The significance of surface ulceration as a sign of  
17 malignancy in exophytic oral mucosal lesions: myth or fact? *Head and neck pathology*, 7: 149-  
18 154.  
19 Not in PICO
- 20 Almeida, L. P. C. (2011) Spectrum of presentations of disseminated warts among immunodeficient  
21 patients in a specialized dermatology outpatient unit care. *Journal of Clinical Immunology*,  
22 Conference: September.  
23 Not in PICO
- 24 Askari, S. K., Schram, S. E., Wenner, R. A., Bowers, S., Liu, A., Bangerter, A. K. & Warshaw, E. M.  
25 (2007) Evaluation of prospectively collected presenting signs/symptoms of biopsy-proven  
26 melanoma, basal cell carcinoma, squamous cell carcinoma, and seborrheic keratosis in an  
27 elderly male population. *Journal of the American Academy of Dermatology*, 56: 739-747.  
28 Not in PICO
- 29 Awan, B. A., Alzanbagi, H., Samargandi, O. A. & Ammar, H. (2014) Scalp squamous cell carcinoma in  
30 xeroderma pigmentosum. *North American Journal of Medical Sciences*, 6: 105-106.  
31 Not in PICO
- 32 Badertscher, N. (2011) MinSKIN Does a multifaceted intervention improve the competence in the  
33 diagnosis of skin cancer by general practitioners? Study protocol for a randomised controlled  
34 trial. *Trials*, 12: 17-19.  
35 Protocol
- 36 Badoual, C., Righini, C., Barry, B., Bertolus, C., Naderi, S., Moriniere, S., de, R. D., Badoual, C., Righini,  
37 C., Barry, B., Bertolus, C., Naderi, S., Moriniere, S. & de Raucourt, D. (2012) Pre-therapeutic  
38 histological and cytological assessment in head and neck squamous cell carcinomas. French  
39 Society of Otorhinolaryngology Guidelines - 2012. *European annals of otorhinolaryngology*,  
40 *head & neck diseases*, 129: 319-326.  
41 Guidelines
- 42 Balkrishnan, R., Cayce, K. A., Kulkarni, A. S., Orsagh, T., Gallagher, J. R., Richmond, D., Feldman, S. R.,  
43 Balkrishnan, R., Cayce, K. A., Kulkarni, A. S., Orsagh, T., Gallagher, J. R., Richmond, D. &  
44 Feldman, S. R. (2006) Predictors of treatment choices and associated outcomes in actinic  
45 keratoses: results from a national physician survey study. *Journal of Dermatological*  
46 *Treatment*, 17: 162-166.  
47 Not in PICO
- 48 Balogh, K. (2012) Skin cancer 'filtered screening' by dermatologists: the 2-week wait system. *British*  
49 *Journal of Dermatology*, Conference: July.  
50 Not in PICO

- 1 Bataille, V. (2011) A teledermatology pilot study in Hertfordshire: Triage of 2-week-wait referrals.  
2 *British Journal of Dermatology*, Conference: July.  
3 Not in PICO
- 4 Benninger, M. S. & Benninger, M. S. (1992) Presentation and evaluation of patients with epidermoid  
5 head and neck cancers. [Review] [31 refs]. *Henry Ford Hospital Medical Journal*, 40: 144-148.  
6 Narrative review
- 7 Bentley, J. M., Barankin, B., Lauzon, G. J., Bentley, J. M., Barankin, B. & Lauzon, G. J. (2003) Paying  
8 more than lip service to lip lesions. [Review] [26 refs]. *Canadian Family Physician*, 49: 1111-  
9 1116.  
10 Narrative review
- 11 Behrens, A., May, A., Manner, H., Pohl, J. & Ell, C. (2013) Esophageal precancerous lesions: Early  
12 diagnosis, treatment, and preservation of quality of life. [German]. *Internist*, 54: 683-690.  
13 Narrative review
- 14 Bigot, P., Longvert, C., Bigot, P. & Longvert, C. (2011) [Penile dermatological lesions: how to identify  
15 premalignant lesions?]. [French]. *Progres En Urologie*, 21 Suppl 2: S50-S52.  
16 Narrative review
- 17 Bonsall, J. M., Hughes, R., Mosunjac, M., Harrison, D., Samady, H., Bonsall, J. M., Hughes, R.,  
18 Mosunjac, M., Harrison, D. & Samady, H. (2010) A rare case of squamous cell carcinoma of the  
19 bladder presenting as a metastatic right ventricular mass. *Case Reports in Medicine*, 2010:  
20 789609.  
21 Not in PICO
- 22 Bradley, P. J. & Bradley, P. T. (2010) Searching for metachronous tumours in patients with head and  
23 neck cancer: the ideal protocol! *Current Opinion in Otolaryngology & Head and Neck Surgery*,  
24 18: 124-133.  
25 Narrative review
- 26 Brocklehurst, P., Rafiq, R., Lowe, D. & Rogers, S. (2012) Analysis of the impact of deprivation on  
27 urgent suspected head and neck cancer referrals in the Mersey region between January 2004  
28 to December 2006. *British Journal of Oral & Maxillofacial Surgery*, 50: 215-220.  
29 Not in PICO
- 30 Bruce, A. J., Brodland, D. G., Bruce, A. J. & Brodland, D. G. (2000) Overview of skin cancer detection  
31 and prevention for the primary care physician. [Review] [34 refs]. *Mayo Clinic Proceedings*, 75:  
32 491-500.  
33 Narrative review
- 34 Brundel, K.-H. (1990) Skin cancer in general practice. *Dermatosen in Beruf und Umwelt*, 38: 54-57.  
35 Not in PICO
- 36 Buis, P. A. J. (2005) Value of histopathologic analysis of skin excisions by GPs. *British Journal of*  
37 *General Practice*, 55: 458-460.  
38 Not in PICO
- 39 Burghout, K., Sigurdsson, V. & Toonstra, J. (2013) Non-melanoma skin cancer. [Dutch]. *Huisarts en*  
40 *Wetenschap*, 56: 174-178.  
41 Narrative review
- 42 Butani, A. (2005) Premalignant and early squamous cell carcinoma. *Clinics in Plastic Surgery*, 32: 223-  
43 235.  
44 Narrative review
- 45 Carvalho, A. L., Pintos, J., Schlecht, N. F., Oliveira, B. V., Fava, A. S., Curado, M. P., Kowalski, L. P. &  
46 Franco, E. L. (2002) Predictive factors for diagnosis of advanced-stage squamous cell  
47 carcinoma of the head and neck. *Archives of Otolaryngology-Head & Neck Surgery*, 128: 313-  
48 318.  
49 Not in PICO
- 50 Cassarino, D. S., DeRienzo, D. P. & Barr, R. J. (2006) Cutaneous squamous cell carcinoma: a  
51 comprehensive clinicopathologic classification - Part two. *Journal of Cutaneous Pathology*, 33:

- 1 261-279.  
2 Narrative review
- 3 Chaidemenos, G. (2010) Inability of dermoscopy to differentiate early-stage squamous cell  
4 carcinoma from keratoacanthoma. *Melanoma Research*, Conference: June.  
5 Not in PICO
- 6 Chan, K. H. N. (2006) Warty growth of the penis - Genital wart? *Hong Kong Practitioner*, 28: 225-227.  
7 Not in PICO
- 8 Chattopadhyay, M. & Ha, T. (2013) How to examine a patient with suspected skin cancer. *Medicine*  
9 *(United Kingdom)*, 41: 400-401.  
10 Narrative review
- 11 Cohen, J. L. & Cohen, J. L. (2010) Actinic keratosis treatment as a key component of preventive  
12 strategies for nonmelanoma skin cancer. *The Journal of Clinical & Aesthetic Dermatology*, 3:  
13 39-44.  
14 Narrative review
- 15 Collins, S. L. (1995) Avoiding delay and misdiagnosis of head and neck cancer: rare tumors with  
16 common symptoms. *Comprehensive Therapy*, 21: 59-67.  
17 Narrative review
- 18 Corey, K. (2012) An analysis of terminology used by primary care physicians to describe concerning  
19 lesions referred to an urgent dermatology clinic. *Journal of Investigative Dermatology*,  
20 Conference: May.  
21 Not in PICO
- 22 Correa, G. T., Bandeira, G. A., Cavalcanti, B. G., Santos, F. B., Rodrigues Neto, J. F., Guimaraes, A. L.,  
23 Haikal, D. S. & De Paula, A. M. (2012) Analysis of ECOG performance status in head and neck  
24 squamous cell carcinoma patients: association with sociodemographical and clinical factors,  
25 and overall survival. *Supportive Care in Cancer*, 20: 2679-2685.  
26 Not in PICO
- 27 Cox, N. H. & Cox, N. H. (2004) Evaluation of the U.K. 2-week referral rule for skin cancer. *British*  
28 *Journal of Dermatology*, 150: 291-298.  
29 Not in PICO
- 30 Cox, N. H., Madan, V., Sanders, T., Cox, N. H., Madan, V. & Sanders, T. (2008) The U.K. skin cancer  
31 'two-week rule' proforma: assessment of potential modifications to improve referral accuracy.  
32 *British Journal of Dermatology*, 158: 1293-1298.  
33 Not in PICO
- 34 Das, S. (2005) Imaging of lumps and bumps in the nose: a review of sinonasal tumours. *Cancer*  
35 *imaging : the official publication of the International Cancer Imaging Society*, 5: 2005.  
36 Narrative review
- 37 de Leeuw, J., van der Beek, N., Neugebauer, W. D., Bjerring, P. & Neumann, H. A. M. (2009)  
38 Fluorescence Detection and Diagnosis of Non-Melanoma Skin Cancer at an Early Stage. *Lasers*  
39 *in Surgery and Medicine*, 41: 96-103.  
40 Not in PICO
- 41 Deal, A. M., Patel, M. R., Thorp, B. D., Cannon, T. Y., Shores, C. G. & Zanation, A. M. (2012) Liver  
42 function tests: inadequate screening modality for detection of liver metastasis in head and  
43 neck carcinoma. *Otolaryngology - Head and Neck Surgery*, 146: 88-91.  
44 Not in PICO
- 45 Delaney, E. K. D. (2012) Excising squamous cell carcinomas: Comparing the performance of GPs,  
46 hospital skin specialists and other hospital specialists. *Family Practice*, 29: 541-546.  
47 Not in PICO
- 48 Dewan, P. (2010) Are NICE skin cancer guidelines being followed in primary care? A re-audit to  
49 review changes in practice in an inner city setting. *British Journal of Dermatology*, Conference:  
50 July.  
51 Not in PICO



- 1 Dolan, R. W., Vaughan, C. W. & Fuleihan, N. (1998) Symptoms in early head and neck cancer: an  
2 inadequate indicator. *Otolaryngology - Head and Neck Surgery*, 119: 463-467.  
3 Not in PICO
- 4 Eekhof, J. A. (2013) [Actinic keratosis: the art of doing nothing]. [Dutch]. *Nederlands Tijdschrift Voor*  
5 *Geneeskunde*, 157: A5363.  
6 Narrative review
- 7 Eggesbo, H. B. & Eggesbo, H. B. (2012) Imaging of sinonasal tumours. [Review]. *Cancer Imaging*, 12:  
8 136-152.  
9 Narrative review
- 10 Eide, M. J., Weinstock, M. A., Dufresne, R. G., Neelagaru, S., Risica, P., Burkholder, G. J., Upegui, D.,  
11 Phillips, K. A., Armstrong, B. K. & Robinson-Bostom, L. (2005) Relationship of treatment delay  
12 with surgical defect size from keratinocyte carcinoma (basal cell carcinoma and squamous cell  
13 carcinoma of the skin). *Journal of Investigative Dermatology*, 124: 308-314.  
14 Not in PICO
- 15 Englert, C. (2012) A review of actinic keratosis for the nurse practitioner: Diagnosis, treatment, and  
16 clinical pearls. *Journal of the American Academy of Nurse Practitioners*, 24: 290-296.  
17 Narrative review
- 18 Epstein, J. B., Guneri, P., Boyacioglu, H. & Abt, E. (2013) The limitations of the clinical oral  
19 examination in detecting dysplastic oral lesions and oral squamous cell carcinoma.[Reprint of J  
20 Am Dent Assoc. 2012 Dec;143(12):1332-42; PMID: 23204089]. *Texas Dental Journal*, 130: 410-  
21 424.  
22 Not in PICO
- 23 Ferreira, P., Rodrigues, M., Ledo, S., Senra, R., Costa, S., V, Rocha, M. & Paiva, C. (2013) Back pain as  
24 the first manifestation of a cavum tumor. *European Journal of Internal Medicine*, 24: e149.  
25 Not in PICO
- 26 Firnhaber, J. M. (2012) Diagnosis and treatment of basal cell and squamous cell carcinoma. *American*  
27 *Family Physician*, 86: 161-168.  
28 Narrative review
- 29 Firooz, A. (2007) Pigmented Bowen's disease of the finger mimicking malignant melanoma. *Archives*  
30 *of Iranian Medicine*, 10: 255-257.  
31 Not in PICO
- 32 FitzGerald, K. L., Buttner, P. G., Donovan, S. A., FitzGerald, K. L., Buttner, P. G. & Donovan, S. A.  
33 (2006) Nonpigmented skin lesions - how many are nonmelanoma skin cancer? *Australian*  
34 *Family Physician*, 35: 555-557.  
35 Not in PICO (only excised lesions, not examined lesions)
- 36 Foley, C. (2012) A dermatology outpatient waiting list initiative. *British Journal of Dermatology*,  
37 Conference: e33-e34.  
38 Not in PICO
- 39 Fontes, K. B., Cunha, K. S., Rodrigues, F. R., Silva, L. E. & Dias, E. P. (2013) Concordance between  
40 cytopathology and incisional biopsy in the diagnosis of oral squamous cell carcinoma. *Brazilian*  
41 *oral research*, 27: 122-127.  
42 Not in PICO
- 43 Forsea, A. M., Carstea, E. M., Ghervase, L., Giurcaneanu, C., Pavelescu, G., Forsea, A. M., Carstea, E.  
44 M., Ghervase, L., Giurcaneanu, C. & Pavelescu, G. (2010) Clinical application of optical  
45 coherence tomography for the imaging of non-melanocytic cutaneous tumors: a pilot multi-  
46 modal study.[Erratum appears in J Med Life. 2011 Jan-Mar;4(1):7 p following 123]. *Journal of*  
47 *Medicine & Life*, 3: 381-389.  
48 Not in PICO
- 49 Forti, R. L., Medwell, S. J., Aboulafia, D. M., Surawicz, C. M., Spach, D. H., Forti, R. L., Medwell, S. J.,  
50 Aboulafia, D. M., Surawicz, C. M. & Spach, D. H. (1995) Clinical presentation of minimally  
51 invasive and in situ squamous cell carcinoma of the anus in homosexual men. *Clinical*

- 1 *Infectious Diseases*, 21: 603-607.  
2 Not in PICO
- 3 Friedrich, R. E. (2010) Delay in Diagnosis and Referral Patterns of 646 Patients with Oral and  
4 Maxillofacial Cancer: A Report from a Single Institution in Hamburg, Germany. *Anticancer*  
5 *Research*, 30: 1833-1836.  
6 Not in PICO
- 7 Garbe, C. (2008) Early detection and primary prevention of skin cancer. *Onkologie*, 14: 156-163.  
8 Narrative review
- 9 Genden, E. M., Rinaldo, A., Bradley, P. J., Lowry, J., Suarez, C., Shaha, A. R., Scully, C. & Ferlito, A.  
10 (2006) Referral guidelines for suspected cancer of the head and neck. *Auris Nasus Larynx*, 33:  
11 1-5.  
12 Narrative review
- 13 Giacomel, J. & Zalaudek, I. (2013) Pink Lesions. *Dermatologic Clinics*, 31: 649-678.  
14 Narrative review
- 15 Gilde, K. (2006) The importance of malignant skin tumors. *Orvosi Hetilap*, 147: 2321-2330.  
16 Narrative review
- 17 Gilde, K. & Gilde, K. (2006) [Malignant tumors of the skin]. [Review] [25 refs] [Hungarian]. *Orvosi*  
18 *Hetilap*, 147: 2321-2330.  
19 Narrative review
- 20 Golberg, O. (2011) Seasonal variation in 2-week-wait skin cancer referrals is not mirrored by changes  
21 in incidence of skin cancer: A message for service provision. *British Journal of Dermatology*,  
22 Conference: July.  
23 Not in PICO
- 24 Goy, J., Hall, S. F., Feldman-Stewart, D. & Groome, P. A. (2009) Diagnostic Delay and Disease Stage in  
25 Head Neck Cancer: A Systematic Review. *Laryngoscope*, 119: 889-898.  
26 Not in PICO
- 27 Graells, J., Espinola, A., Barrio, C., Munoz, M. D., Roman, A., Parellada, N., Graells, J., Espinola, A.,  
28 Barrio, C., Munoz, M. D., Roman, A. & Parellada, N. (2007) [Minor cutaneous ambulatory  
29 surgery and cryotherapy. Comparative study between a dermatologist and family physicians].  
30 [Spanish]. *Actas Dermo-Sifiliograficas*, 98: 171-177.  
31 Not in PICO
- 32 Graves, J. (2006) Derm Access: A new triage system to rapidly identify suspicious skin lesions.  
33 *Dermatologic Surgery*, 32: 1486-1490.  
34 Not in PICO
- 35 Gunson, T. (2009) Audit of histopathology request forms for cutaneous lesions comparing a large  
36 dermatology department with regional general practices. *British Journal of Dermatology*,  
37 Conference: July.  
38 Not in PICO
- 39 Haliasos, E. C., Kerner, M., Jaimes, N., Zalaudek, I., Malvey, J., Lanschuetzer, C. M., Hinter, H.,  
40 Hofmann-Wellenhof, R., Braun, R. P. & Marghoob, A. A. (2013) Dermoscopy for the pediatric  
41 dermatologist, part ii: dermoscopy of genetic syndromes with cutaneous manifestations and  
42 pediatric vascular lesions. [Review]. *Pediatric Dermatology*, 30: 172-181.  
43 Narrative review
- 44 Halpern, A. C., Hanson, L. J., Halpern, A. C. & Hanson, L. J. (2004) Awareness of, knowledge of and  
45 attitudes to nonmelanoma skin cancer (NMSC) and actinic keratosis (AK) among physicians.  
46 *International Journal of Dermatology*, 43: 638-642.  
47 Not in PICO
- 48 Hansen, C. (2009) Factors contributing to incomplete excision of nonmelanoma skin cancer by  
49 Australian general practitioners. *Archives of Dermatology*, 145: 1253-1260.  
50 Not in PICO

- 1 Haw, W. Y., Fraser, S., Affleck, A. & Holme, A. (2014) Skin cancer excision performance in primary  
2 and secondary care in Scotland. *British Journal of Dermatology*, 171: 25.  
3 Not in PICO
- 4 Haws, M. J. N. (1997) Management of nonmelanoma skin tumors of the hand. *Clinics in Plastic  
5 Surgery*, 24: 779-795.  
6 Narrative review
- 7 Heal, C., Buettner, P., Raasch, B., Browning, S., Heal, C., Buettner, P., Raasch, B. & Browning, S.  
8 (2006) Minor skin excisions in general practice in North Queensland. *Australian Family  
9 Physician*, 35: 825-828.  
10 Not in PICO (only excised lesions, not examined lesions; no information about symptoms/lesion  
11 features)
- 12 Helfand, M., Gorman, A. K., Mahon, S., Chan, B. K. & Swanson, N. (2001) Actinic keratoses  
13 (Structured abstract). *Health Technology Assessment Database*, 71.  
14 Narrative review
- 15 Hill, G. M., Sowden, J. M., Lister, R. K., Logan, R. A. & Finlay, A. Y. (2010) Dermatology outpatient  
16 case-mix survey for all Welsh Trusts, 2007. *British Journal of Dermatology*, 162: 152-158.  
17 Not in PICO
- 18 Ho, K.-Y. (2008) Early recognition of nasopharyngeal cancer in adults with only otitis media with  
19 effusion. *Journal of Otolaryngology - Head and Neck Surgery*, 37: 362-365.  
20 Not in PICO
- 21 Hobson, J. C. M. (2008) Outcomes for patients referred urgently with suspected head and neck  
22 cancer. *Journal of Laryngology and Otology*, 122: 1241-1244.  
23 Not in PICO
- 24 Hochman, M., Lang, P., Hochman, M. & Lang, P. (1999) Skin cancer of the head and neck. [Review]  
25 [75 refs]. *Medical Clinics of North America*, 83: 261-282.  
26 Narrative review
- 27 Holmang, S. (2007) Squamous Cell Carcinoma of the Renal Pelvis and Ureter: Incidence, Symptoms,  
28 Treatment and Outcome. *Journal of Urology*, 178: 51-56.  
29 Not in PICO
- 30 Jacobs, C. D., Goffinet, D. R. & Fee, W. E., Jr. (1990) Head and neck squamous cancers. *Current  
31 Problems in Cancer*, 14: 1-72.  
32 Narrative review
- 33 Jensen, A. O., Bautz, A., Olesen, A. B., Karagas, M. R., Sorensen, H. T. & Friis, S. (2008) Mortality in  
34 Danish patients with nonmelanoma skin cancer, 1978-2001. *British Journal of Dermatology*,  
35 159: 419-425.  
36 Not in PICO
- 37 Jerant, A. F. J. (2000) Early detection and treatment of skin cancer. *American Family Physician*, 62:  
38 357-376+381.  
39 Narrative review
- 40 Joly, P., Bastuji-Garin, S., Frances, C., Lebbe, C., Aubin, F., Penso-Assathiany, D., D'incan, M., Avril, M.  
41 F., Lair, G., Barete, S. & Euvrard, S. (2010) Squamous Cell Carcinomas Are Associated With  
42 Verrucokeratotic Cutaneous Lesions But Not With Common Warts in Organ-Transplant  
43 Patients. A Case-Control Study. *Transplantation*, 89: 1224-1230.  
44 Not in PICO
- 45 Kahn, E., Sossong, S., Goh, A., Carpenter, D. & Goldstein, S. (2013) Evaluation of Skin Cancer in  
46 Northern California Kaiser Permanente's Store-and-Forward Teledermatology Referral  
47 Program. *Telemedicine and E-Health*, 19: 780-785.  
48 Not in PICO
- 49 Kamyab-Hesari, K., Seirafi, H., Naraghi, Z. S., Shahshahani, M. M., Rahbar, Z., Damavandi, M. R.,  
50 Naraghi, M. M., Rezvani, M. & Aghazadeh, N. (2014) Diagnostic accuracy of punch biopsy in  
51 subtyping basal cell carcinoma. *Journal of the European Academy of Dermatology and*

- 1        *Venereology*, 28: 250-253.  
2        Not in PICO
- 3        Kennedy, A. M., Aziz, A., Khalid, S. & Hurman, D. (2012) Do GP referral guidelines really work? Audit  
4        of an electronic urgent referral system for suspected head and neck cancer. *European Archives*  
5        *of Oto-Rhino-Laryngology*, 269: 1509-1512.  
6        Not in PICO
- 7        Khorasgani, M. G. P. (2010) Dermatological surgery in the community: Are the guidelines being  
8        followed? *British Journal of Dermatology*, Conference: July.  
9        Not in PICO
- 10       Khorshid, S. M. R. (275) Recognising and treating. Premalignant skin conditions. *The Practitioner*,  
11       242: 270-275.  
12       Narrative review
- 13       Kleinpenning, M. M., Wolberink, E. W., Smits, T., Blokk, W. A., van De Kerkhof, P. C., van Erp, P. E.,  
14       Gerritsen, R. M., Kleinpenning, M. M., Wolberink, E. W., Smits, T., Blokk, W. A. M., van De  
15       Kerkhof, P. C. M., van Erp, P. E. J. & Gerritsen, R. M. J. P. (2010) Fluorescence diagnosis in  
16       actinic keratosis and squamous cell carcinoma. *Photodermatology, Photoimmunology &*  
17       *Photomedicine*, 26: 297-302.  
18       Not in PICO
- 19       Kok, L. P., V (2000) General practitioners use digital cameras and internet for telepathology of skin  
20       lesions. *Electronic Journal of Pathology and Histology*, 6: 7-19.  
21       Not in PICO
- 22       Kowal-Vern, A. (2005) Burn scar neoplasms: A literature review and statistical analysis. *Burns*, 31:  
23       403-413.  
24       Not in PICO
- 25       Kundu, R. V. & Patterson, S. (2013) Dermatologic conditions in skin of color: part I. Special  
26       considerations for common skin disorders.[Summary for patients in Am Fam Physician. 2013  
27       Jun 15;87(12):Online; PMID: 23939576]. *American Family Physician*, 87: 850-856.  
28       Narrative review
- 29       Kutcher, M. J., Rubenstein, D., Kutcher, M. J. & Rubenstein, D. (1995) Fifteen inches from cancer:  
30       early recognition of facial lesions by the dentist. [Review] [10 refs]. *Compendium of Continuing*  
31       *Education in Dentistry*, 25: 939-946.  
32       Narrative review
- 33       Lahiri, K. (1954) Skin diseases in general practice. *Indian Med, Forum* 5: 219-222.  
34       Narrative review
- 35       Lai, W.-Y. (1111) An elderly man with a painful scaly nodule. *Hong Kong Practitioner*, 35: September.  
36       Not in PICO
- 37       Lathlean, S. & Lathlean, S. (1999) Skin cancer in general practice in South Australia. A five year study.  
38       *Australian Family Physician*, 28 Suppl 1: S28-S31.  
39       Not in PICO (only excised lesions, not examined lesions; no information about symptoms/lesion  
40       features)
- 41       Laukkanen, A., Rummukainen, J., Kivinen, P., Lappalainen, K., Laukkanen, A., Rummukainen, J.,  
42       Kivinen, P. & Lappalainen, K. (2006) [Skin squamous cell carcinoma and its precancerous  
43       conditions]. [Review] [25 refs] [Finnish]. *Duodecim*, 122: 71-79.  
44       Narrative review
- 45       Leggett, P. (2004) A randomized controlled trial using instant photography to diagnose and manage  
46       dermatology referrals. *Family Practice*, 21: 54-56.  
47       Not in PICO
- 48       Leiter, U. (2012) Secondary prevention of skin cancer. *Onkologe*, 18: 237-242.  
49       Narrative review
- 50       Lin, Y.-C., Perng, C.-L., Chang, Y.-M., Li, Y.-F., Tsai, Y.-M., Wu, G.-J. & Lin, C.-K. (2013) Coexistent  
51       squamous cell carcinoma and adenoid basal carcinoma in the uterine cervix and infection with

- 1 human papillomavirus (HPV 31). *Taiwanese Journal of Obstetrics and Gynecology*, 52: 407-410.  
 2 Not in PICO
- 3 Lober, C. W., Fenske, N. A., Lober, C. W. & Fenske, N. A. (1991) Basal cell, squamous cell, and  
 4 sebaceous gland carcinomas of the periorbital region. [Review] [54 refs]. *Journal of the*  
 5 *American Academy of Dermatology*, 25: 685-690.  
 6 Narrative review
- 7 Long, M. D. (2012) Cutaneous malignancies in patients with inflammatory bowel disease.  
 8 *Gastroenterology and Hepatology*, 8: 467-471.  
 9 Narrative review
- 10 Loveland-Jones, C. E., Wang, F., Bankhead, R. R., Huang, Y., Reilly, K. J., Loveland-Jones, C. E., Wang,  
 11 F., Bankhead, R. R., Huang, Y. & Reilly, K. J. (2010) Squamous cell carcinoma of the nipple  
 12 following radiation therapy for ductal carcinoma in situ: a case report. *Journal of Medical Case*  
 13 *Reports [Electronic Resource]*, 4: 186.  
 14 Not in PICO
- 15 MacLean, A. B., Jones, R. W., Scurry, J. & Neill, S. (2009) Vulvar Cancer and the Need for Awareness  
 16 of Precursor Lesions. *Journal of Lower Genital Tract Disease*, 13: 115-117.  
 17 Narrative review
- 18 Marghoob, A. A. & Marghoob, A. A. (146) Basal and squamous cell carcinomas. What every primary  
 19 care physician should know. [Review] [20 refs]. *Postgraduate Medicine*, 102: 139-146.  
 20 Narrative review
- 21 Marghoob, A. A., Usatine, R. P. & Jaimes, N. (2013) Dermoscopy for the family physician. [Review].  
 22 *American Family Physician*, 88: 441-450.  
 23 Narrative review
- 24 Marks, R. & Marks, R. (2006) Who benefits from calling a solar keratosis a squamous cell carcinoma?  
 25 *British Journal of Dermatology*, 155: 23-26.  
 26 Not in PICO
- 27 Martinez, J. C. & Otley, C. C. (2001) The management of melanoma and nonmelanoma skin cancer: A  
 28 review for the primary care physician. *Mayo Clinic Proceedings*, 76: 1253-1265.  
 29 Narrative review
- 30 May, C., Giles, L., Gupta, G., May, C., Giles, L. & Gupta, G. (2008) Prospective observational  
 31 comparative study assessing the role of store and forward teledermatology triage in skin  
 32 cancer. *Clinical & Experimental Dermatology*, 33: 736-739.  
 33 Not in PICO
- 34 Maybury, C. M., Craythorne, E. & Martin, B. (2013) An ulcerated nodule on the nose. *BMJ Case*  
 35 *Reports*, 2013, 2013.  
 36 Not in PICO
- 37 McKie, C., Ahmad, U. A., Fellows, S., Meikle, D., Stafford, F. W., Thomson, P. J., Welch, A. R. & Paleri,  
 38 V. (2008) The 2-week rule for suspected head and neck cancer in the United Kingdom: referral  
 39 patterns, diagnostic efficacy of the guidelines and compliance. *Oral Oncology*, 44: 851-856.  
 40 Not in PICO
- 41 McNulty-Brown, E. (2012) An audit of all excisions undertaken by general practitioners in a rural  
 42 community between March 2009 and March 2010. *British Journal of Dermatology*,  
 43 Conference: July.  
 44 Not in PICO
- 45 Medeiros, F. (2005) Early vulvar squamous neoplasia: Advances in classification, diagnosis, and  
 46 differential diagnosis. *Advances in Anatomic Pathology*, 12: 20-26.  
 47 Narrative review
- 48 Mencia Gutierrez, E. (2001) Basal cell and squamous cell carcinomas of the eyelid in adults under 50  
 49 years of age: 13 cases. *Archivos de la Sociedad Espanola de Oftalmologia*, 76: 643-648.  
 50 Not in PICO

- 1 Malvey, J., Puig, S., Rabinovitz, H. S., Oliviero, M., Cabo, H., Bono, R., Pizzichetta, M. A., Claeson, M.,  
2 Gaffney, D. C., Soyer, H. P., Stanganelli, I., Scolyer, R. A., Guitera, P., Kelly, J., McCurdy, O.,  
3 Llambrich, A., Marghoob, A. A., Zaballos, P., Kirchesch, H. M., Piccolo, D., Bowling, J., Thomas,  
4 L., Terstappen, K., Tanaka, M., Pellacani, G., Pagnanelli, G., Ghigliotti, G., Ortega, B. C., Crafter,  
5 G., Ortiz, A. M., Tromme, I., Karaarslan, I. K., Ozdemir, F., Tam, A., Landi, C., Norton, P., Kacar,  
6 N., Rudnicka, L., Slowinska, M., Simionescu, O., Di, S. A., Coates, E. & Kreusch, J. (2013)  
7 Dermoscopic evaluation of nodular melanoma. *JAMA Dermatology*, 149: 699-709.  
8 Not in PICO
- 9 Moffatt, C. R., Green, A. C., Whiteman, D. C., Moffatt, C. R. M., Green, A. C. & Whiteman, D. C. (2006)  
10 Diagnostic accuracy in skin cancer clinics: the Australian experience. *International Journal of*  
11 *Dermatology*, 45: 656-660.  
12 Not in PICO
- 13 Molina, R. & Bosch, X. (2012) Utility of serum tumor markers as an aid in the differential diagnosis of  
14 patients with clinical suspicion of cancer and in patients with cancer of unknown primary site.  
15 *Tumor Biology*, 33: 463-474.  
16 Not in PICO
- 17 Montero Perez, F. J., Munoz, A. M., Calvo-Rubio, B. M., Fernandez Roldan, J. C., Montero Perez, F. J.,  
18 Munoz Alamo, M., Calvo-Rubio Burgos, M. & Fernandez Roldan, J. C. (1989) [Importance of  
19 skin cancer (non-melanoma): a study of 89 cases]. [Spanish]. *Atencion Primaria*, 6: 660-664.  
20 Not in PICO
- 21 Moran, B. & McDonald, I. (2010) Full skin examination is essential in the assessment of dermatology  
22 patients: An audit of 494 patients. *British Journal of Dermatology*, Conference: July.  
23 Not in PICO
- 24 Moran, B. & McDonald, I. (2011) Complete skin examination is essential in the assessment of  
25 dermatology patients: Findings from 483 patients. *British Journal of Dermatology*, 165: 1124-  
26 1126.  
27 Not in PICO
- 28 Morrison, A., O'Loughlin, S., Powell, F. C., Morrison, A., O'Loughlin, S. & Powell, F. C. (2001)  
29 Suspected skin malignancy: a comparison of diagnoses of family practitioners and  
30 dermatologists in 493 patients. *International Journal of Dermatology*, 40: 104-107.  
31 Not in PICO
- 32 Morteza, A. S., Salama, S. & Alowami, S. (2013) Lymphoepithelioma-like carcinoma of the skin: case  
33 report and approach to surgical pathology sign out. *Rare Tumors*, 5: e47.  
34 Not in PICO
- 35 Morton, C. A., Birnie, A. J. & Eedy, D. J. (2014) British Association of Dermatologists' guidelines for  
36 the management of squamous cell carcinoma in situ (Bowen's disease) 2014. *British Journal of*  
37 *Dermatology*, 170: 245-260.  
38 Guideline
- 39 Nordenvall, C., Nyren, O. & Ye, W. (2006) Elevated anal squamous cell carcinoma risk associated with  
40 benign inflammatory anal lesions. *Gut*, 55: 703-707.  
41 Not in PICO
- 42 Nthumba, P. M. & Nthumba, P. M. (2010) Marjolin's ulcers in sub-Saharan Africa. [Review]. *World*  
43 *Journal of Surgery*, 34: 2272-2277.  
44 Not in PICO
- 45 O'Hagan, A. (2010) Teledermatology triage for suspected skin cancers: An audit of service quality  
46 and effectiveness in a Northern Irish dermatology centre. *British Journal of Dermatology*,  
47 Conference: July.  
48 Not in PICO
- 49 Obata, H. (2005) Incidence of benign and malignant lesions of eyelid and conjunctival tumors.  
50 *Nippon Ganka Gakkai zasshi*, 109: 573-579.  
51 Not in PICO

- 1 Offidani, A., Simonetti, O., Bernardini, M. L., Alpagut, A., Cellini, A., Bossi, G., Offidani, A., Simonetti,  
2 O., Bernardini, M. L., Alpagut, A., Cellini, A. & Bossi, G. (2002) General practitioners' accuracy  
3 in diagnosing skin cancers. *Dermatology*, 205: 127-130.  
4 Not in PICO
- 5 Osthus, A. A., Aarstad, A. K., Olofsson, J. & Aarstad, H. J. (2013) Prediction of Survival by  
6 Pretreatment Health-Related Quality-of-Life Scores in a Prospective Cohort of Patients With  
7 Head and Neck Squamous Cell Carcinoma. *JAMA Otolaryngology - Head and Neck Surgery*,  
8 139: 14-20.  
9 Not in PICO
- 10 Pallagatti, S., Sheikh, S., Aggarwal, A., Gupta, D., Singh, R., Handa, R., Kaur, S. & Mago, J. (2013)  
11 Toluidine blue staining as an adjunctive tool for early diagnosis of dysplastic changes in the  
12 oral mucosa. *Journal of Clinical & Experimental Dentistry*, 5: e187-e191.  
13 Not in PICO
- 14 Palmer, V. M. & Wilson, P. R. (2013) Incompletely excised basal cell carcinoma: residual tumor rates  
15 at Mohs re-excision. *Dermatologic Surgery*, 39: 706-718.  
16 Not in PICO
- 17 Patel, L. M., Lambert, P. J., Gagna, C. E., Maghari, A. & Lambert, W. C. (2011) Cutaneous signs of  
18 systemic disease. *Clinics in Dermatology*, 29: 511-522.  
19 Narrative review
- 20 Peris, K., Neri, L., Pinton, P. C., Catricala, C., Pellacani, G., Pimpinelli, N. & Peserico, A. (2014)  
21 Physicians' opinions and clinical practice patterns for actinic keratosis management in Italy.  
22 *Giornale Italiano di Dermatologia e Venereologia*, 149: 185-192.  
23 Not in PICO
- 24 Peris, K., Neri, L., Fagnoli, M. C. & Pellacani, G. (2014) Physicians' concerns towards prescription  
25 adherence and treatment effectiveness in the clinical management of actinic keratosis.  
26 *Giornale Italiano di Dermatologia e Venereologia*, 149: 193-198.  
27 Not in PICO
- 28 Perrotto, J., Glick, B., Perrotto, J. & Glick, B. (2006) Lower extremity malignancies masquerading as  
29 ulcers. *Ostomy Wound Management*, 52: 46-52.  
30 Narrative review
- 31 Plate, A. M., Steiner, G., Posner, M. A., Plate, A. M., Steiner, G. & Posner, M. A. (2006) Malignant  
32 tumors of the hand and wrist. *Journal of the American Academy of Orthopaedic Surgeons*, 14:  
33 680-692.  
34 Narrative review
- 35 Qi Qi, C. & Ajit Singh, V. (2012) Palm oil thorn-induced squamous cell carcinoma with underlying  
36 burns scar. *BMJ Case Reports*, 2012.  
37 Not in PICO
- 38 Raasch, B. A. & Raasch, B. A. (1999) Suspicious skin lesions and their management. *Australian Family*  
39 *Physician*, 28: 466-471.  
40 Not in PICO (no verification of cancer/non-cancer diagnosis)
- 41 Raj, G. & Gupta, G. (1111) The need for full body skin examination on patients referred to  
42 dermatology with a lesion. *British Journal of Dermatology.Conference: 93rd Annual Meeting of*  
43 *the British Association of Dermatologists Liverpool United Kingdom.Conference Start:*  
44 *20130709 Conference End: 20130711.Conference Publication: (var.pagings)*, 169: July.  
45 Not in PICO
- 46 Ramani, C., Shah, N. & Nathan, R. S. (2014) - Verrucous carcinoma of the esophagus: A case report  
47 and literature review. - *World Journal of Clinical Cases*, 2: 284-288.  
48 Not in PICO
- 49 Renzi, C., Mastroeni, S., Mannooranparampil, T. J., Passarelli, F., Caggiati, A., Potenza, C. & Pasquini,  
50 P. (2010) Delay in diagnosis and treatment of squamous cell carcinoma of the skin. *Acta*

- 1 *Dermato-Venereologica*, 90: 595-601.  
2 Not in PICO
- 3 Renzi, C., Mastroeni, S., Passarelli, F., Mannooranparampil, T. J., Caggiati, A., Potenza, C. & Pasquini,  
4 P. (2010) Factors associated with large cutaneous squamous cell carcinomas. *Journal of the*  
5 *American Academy of Dermatology*, 63: 404-411.  
6 Not in PICO
- 7 Renzi, C., Mastroeni, S. & Mannooranparampil, T. J. (2011) Timely diagnosis of cutaneous squamous  
8 cell carcinoma: The GP's role. *Family Practice*, 28: 277-279.  
9 Not in PICO
- 10 Rice, S. A. S. (2012) Are we relying too heavily on dermoscopy? *British Journal of Dermatology*,  
11 Conference: July.  
12 Not in PICO
- 13 Richert, B., Lecerf, P., Caucanas, M. & Andre, J. (2013) Nail tumors. *Clinics in Dermatology*, 31: 602-  
14 617.  
15 Narrative review
- 16 Robinson, M. (2012) The pathology of virus-related carcinomas of the upper aerodigestive tract.  
17 *Journal of Pathology*, Conference: September.  
18 Narrative review
- 19 Roozeboom, M. H., Mosterd, K., Winnepeninckx, V. J., Nelemans, P. J. & Kelleners-Smeets, N. W.  
20 (2013) Agreement between histological subtype on punch biopsy and surgical excision in  
21 primary basal cell carcinoma. *Journal of the European Academy of Dermatology &*  
22 *Venereology*, 27: 894-898.  
23 Not in PICO
- 24 Rosendahl, C., Tschandl, P., Cameron, A., Kittler, H., Rosendahl, C., Tschandl, P., Cameron, A. &  
25 Kittler, H. (2011) Diagnostic accuracy of dermoscopy for melanocytic and nonmelanocytic  
26 pigmented lesions. *Journal of the American Academy of Dermatology*, 64: 1068-1073.  
27 Not in PICO (only excised lesions, not examined lesions)
- 28 Rousset, J., Abgral, R., Chinellato, S., Garetier, M., Barberot, C., Valette, G., Potard, G., Le, B. T. &  
29 Salaun, P. Y. (2013) Early recurrence or submucosal residual of laryngeal squamous cell  
30 carcinoma: diagnosis by CT-guided endolaryngeal core biopsy on a transcutaneous approach.  
31 *Head & Neck*, 35: E202-E204.  
32 Not in PICO
- 33 Rowert-Huber, J. (2007) Erratum: Actinic keratosis is an early in situ squamous cell carcinoma: A  
34 proposal for reclassification (*British Journal of Dermatology* (2007) 156, SUPPL., (S13-S17)).  
35 *British Journal of Dermatology*, 157: 431.  
36 Not in PICO
- 37 Rowert-Huber, J. (2007) Actinic keratosis is an early in situ squamous cell carcinoma: A proposal for  
38 reclassification. *British Journal of Dermatology*, 156: 8-12.  
39 Narrative review
- 40 Ruskiewicz, J. & Ruskiewicz, J. (1998) Skin cancer and actinic keratoses. *Journal of the American*  
41 *Optometric Association*, 69: 229-235.  
42 Not in PICO
- 43 Sanyal, S., Holme, A. & Kemmett, D. (2013) How are patients with actinic keratoses managed in  
44 primary care? *British Journal of Dermatology*, 169: 45.  
45 Not in PICO
- 46 Sharma, A., Alfa-Wali, M., Rodriguez-Justo, M. & Polychronis, A. (2013) Squamous cell carcinoma of  
47 pancreas: an unusual site of relapse from early-stage lung cancer: 12-month postsurgery. *BMJ*  
48 *Case Reports*, 2013, 2013.  
49 Not in PICO
- 50 Schofield, J. (2011) The costs of diagnosing and treating skin cancer using the 2-week-wait referral  
51 process. *British Journal of Dermatology*, Conference: July.  
52 Not in PICO



- 1 See, A. (2005) Operational teledermatology in Broken Hill, rural Australia. *Australasian Journal of*  
2 *Dermatology*, 46: 144-149.  
3 Not in PICO
- 4 Selim, M. A., Hoang, M. P., Selim, M. A. & Hoang, M. P. (2010) A histologic review of vulvar  
5 inflammatory dermatoses and intraepithelial neoplasm. [Review]. *Dermatologic Clinics*, 28:  
6 649-667.  
7 Narrative review
- 8 Shapiro, M., James, W. D., Kessler, R., Lazorik, F. C., Katz, K. A., Tam, J., Nieves, D. S., Miller, J. J.,  
9 Shapiro, M., James, W. D., Kessler, R., Lazorik, F. C., Katz, K. A., Tam, J., Nieves, D. S. & Miller, J.  
10 J. (2004) Comparison of skin biopsy triage decisions in 49 patients with pigmented lesions and  
11 skin neoplasms: store-and-forward teledermatology vs face-to-face dermatology. *Archives of*  
12 *Dermatology*, 140: 525-528.  
13 Not in PICO
- 14 Shariff, Z., Roshan, A., Williams, A. M., Platt, A. J., Shariff, Z., Roshan, A., Williams, A. M. & Platt, A. J.  
15 (2010) 2-Week wait referrals in suspected skin cancer: does an instructional module for  
16 general practitioners improve diagnostic accuracy? *Surgeon Journal of the Royal Colleges of*  
17 *Surgeons of Edinburgh & Ireland*, 8: 247-251.  
18 Not in PICO
- 19 Singh, T. & Schenberg, M. (2013) Delayed diagnosis of oral squamous cell carcinoma following dental  
20 treatment. *Annals of the Royal College of Surgeons of England*, 95: 369-373.  
21 Not in PICO
- 22 Socha, A. & Niedzielska, I. (2013) Exophytic tumours of skin of the head - Case study and review of  
23 the literature. *Dental and Medical Problems*, 50: 229-237.  
24 Not in PICO
- 25 Spencer, R. J., Young, R. H., Goodman, A., Spencer, R. J., Young, R. H. & Goodman, A. (2011) The risk  
26 of squamous cell carcinoma in persistent vulvar ulcers. *Menopause*, 18: 1067-1071.  
27 Not in PICO
- 28 Strayer, S. M. & Reynolds, P. (2003) Diagnosing skin malignancy: Assessment of predictive clinical  
29 criteria and risk factors. *Journal of Family Practice*, 52: 210-218.  
30 Narrative review
- 31 Stulberg, D. L., Crandell, B., Fawcett, R. S., Stulberg, D. L., Crandell, B. & Fawcett, R. S. (2004)  
32 Diagnosis and treatment of basal cell and squamous cell carcinomas. *American Family*  
33 *Physician*, 70: 1481-1488.  
34 Narrative review
- 35 Sukur, Y. E., Gozukucuk, M. & Berker, B. (2010) Hypercalcemia associated with early recurrence of  
36 vulvar cancer. *Archives of Gynecology and Obstetrics*, 281: 117-118.  
37 Not in PICO
- 38 Tangjaturonrasme, N., Rerknimitr, R., Pittayanon, R., Wisedopas, N. & Kullavanijaya, P. (2013) The  
39 difference in detection rates during surveillance endoscopy for early squamous cell neoplasia  
40 of the esophagus between patients with previous nasopharyngeal cancer and patients with  
41 other ent related squamous cell cancers pornphan thienchanachaiya1. *Gastrointestinal*  
42 *Endoscopy*, 77: AB339-AB340.  
43 Not in PICO
- 44 Tate, B. (2007) Checking pigmented skin lesions. *Medicine Today*, 8: 38-46.  
45 Narrative review
- 46 Teppo, H., Koivunen, P., Hyrynkangas, K., Alho, O. P., Teppo, H., Koivunen, P., Hyrynkangas, K. &  
47 Alho, O. P. (2003) Diagnostic delays in laryngeal carcinoma: professional diagnostic delay is a  
48 strong independent predictor of survival. *Head & Neck*, 25: 389-394.  
49 Not in PICO
- 50 Terrill, P. J., Fairbanks, S., Bailey, M., Terrill, P. J., Fairbanks, S. & Bailey, M. (2009) Is there just one  
51 lesion? The need for whole body skin examination in patients presenting with non-

- 1 melanocytic skin cancer. *ANZ Journal of Surgery*, 79: 707-712.  
2 Not in PICO
- 3 Terushkin, V. (2010) Agreement on the clinical diagnosis and management of cutaneous squamous  
4 neoplasms. *Dermatologic Surgery*, 36: 1514-1520.  
5 Not in PICO
- 6 Tochigi, T., Shuto, K., Staito, H., Kono, T. & Matsubara, H. (2013) Early esophageal squamous cell  
7 cancer by high-barium esophagography using flat panel X-ray detector in comparison with  
8 histological findings. *European Journal of Cancer*, 49: S252-S253.  
9 Not in PICO
- 10 Tolpinrud, W. L., Viola, K. V., Kirsner, R. S., Gross, C. P., Imaeda, S., Federman, D. G., Tolpinrud, W. L.,  
11 Viola, K. V., Kirsner, R. S., Gross, C. P., Imaeda, S. & Federman, D. G. (2011) Nondermatologists'  
12 use of predictive terms for a potentially malignant lesion. *Southern Medical Journal*, 104: 477-  
13 481.  
14 Not in PICO
- 15 Tromp, D. M., Brouha, X. D., Hordijk, G. J., Winnubst, J. A. & de Leeuw, J. R. (2005) Patient factors  
16 associated with delay in primary care among patients with head and neck carcinoma: a case-  
17 series analysis. *Family Practice*, 22: 554-559.  
18 Not in PICO
- 19 Tully, A. S. T. (2012) Evaluation of nail abnormalities. *American Family Physician*, 85: 779-787.  
20 Narrative review
- 21 Turan, E., Yurt, N., Yesilova, Y. & Turkcu, G. (2013) Early-onset basal cell carcinoma. *Turkish Journal*  
22 *of Pediatrics*, 55: 354-356.  
23 Not in PICO
- 24 van Rijnsingen, M. C. J., van Bon, B., van der Wilt, G. J., Lagro-Janssen, A. L. M. & Gerritsen, M. J. P.  
25 (2014) The current and future role of general practitioners in skin cancer care: an assessment  
26 of 268 general practitioners. *British Journal of Dermatology*, 170: 1366-1368.  
27 Not in PICO
- 28 Vargo, N. (2003) Basal cell and squamous cell carcinoma. *Seminars in Oncology Nursing*, 19: 12-21.  
29 Narrative review
- 30 Vermaak, P. V. & Manushakian, J. (2013) Rapidly enlarging skin lesion on the lip. *BMJ Case Reports*,  
31 2013, 2013.  
32 Not in PICO
- 33 Voisard, J.-J. & Lazareth, I. (2001) Leg ulcers and cancer. *Journal des Maladies Vasculaires*, 26: 85-91.  
34 Not in PICO
- 35 Vowles, R. H., Ghiacy, S., Jefferis, A. F., Vowles, R. H., Ghiacy, S. & Jefferis, A. F. (1998) A clinic for the  
36 rapid processing of patients with neck masses. *Journal of Laryngology & Otology*, 112: 1061-  
37 1064.  
38 Not in PICO
- 39 Waldmann, A., Nolte, S., Geller, A. C., Katalinic, A., Weinstock, M. A., Volkmer, B., Greinert, R.,  
40 Breitbart, E. W., Waldmann, A., Nolte, S., Geller, A. C., Katalinic, A., Weinstock, M. A., Volkmer,  
41 B., Greinert, R. & Breitbart, E. W. (2012) Frequency of excisions and yields of malignant skin  
42 tumors in a population-based screening intervention of 360,288 whole-body examinations.  
43 *Archives of Dermatology*, 148: 903-910.  
44 Not in PICO
- 45 Warshaw, E. M. G. (2010) Accuracy of teledermatology/teledermoscopy and clinic-based  
46 dermatology for specific categories of skin neoplasms. *Journal of the American Academy of*  
47 *Dermatology*, 63: 348-352.  
48 Not in PICO
- 49 Watkins, J. & Watkins, J. (2010) Dermatology and the community nurse: actinic (solar) keratosis.  
50 [Review] [13 refs]. *British Journal of Community Nursing*, 15: 6-1.  
51 Narrative review

1 White, G. M., Zhou, H. C. & Burchette, R. J. (2013) Biopsy followed by immediate curettage and  
 2 electrodesiccation of suspected basal cell carcinomas at the first visit. *JAMA Dermatology*,  
 3 149: 980-981.  
 4 Not in PICO

5 Wietfeldt, E. D., Thiele, J., Wietfeldt, E. D. & Thiele, J. (2009) Malignancies of the anal margin and  
 6 perianal skin. *Clinics in Colon & Rectal Surgery*, 22: 127-135.  
 7 Narrative review

8 Wolberink, E. A. W., Pasch, M. C., Zeiler, M., Van Erp, P. E. J. & Gerritsen, M. J. P. (2013) High  
 9 discordance between punch biopsy and excision in establishing basal cell carcinoma subtype:  
 10 Analysis of 500 cases. *Journal of the European Academy of Dermatology and Venereology*, 27:  
 11 985-989.  
 12 Not in PICO

13 Wolpoe, M. E. G. (2006) Squamous cell carcinoma of the sinonasal cavity arising as a second primary  
 14 in individuals with head and neck cancer. *Laryngoscope*, 116: 696-699.  
 15 Not in PICO

16 Woolley, S. D. & Hughes, C. (2013) A young military pilot presents with a periocular Basal Cell  
 17 Carcinoma: A case report. *Travel Medicine and Infectious Disease*, 11: 435-437.  
 18 Not in PICO

19 Wray, E. V., Brant, B., Hussain, F. & Muller, F. M. (2013) A new model of teledermoscopy combining  
 20 service and education. *British Journal of Dermatology*, 169: 139.  
 21 Not in PICO

22 Wustrow, J., Rudert, H., Diercks, M. & Beigel, A. (1989) Squamous cell carcinoma and  
 23 undifferentiated carcinoma of the inner nose and the paranasal sinuses. *Strahlentherapie und*  
 24 *Onkologie*, 165: 468-473.  
 25 Not in PICO

26 Yamamoto, E., Shibuya, H., Yoshimura, R. & Miura, M. (2002) Site specific dependency of second  
 27 primary cancer in early stage head and neck squamous cell carcinoma. *Cancer*, 94: 2007-2014.  
 28 Not in PICO

29 Youl, P. H., Janda, M., Aitken, J. F., Del Mar, C. B., Whiteman, D. C., Baade, P. D., Youl, P. H., Janda,  
 30 M., Aitken, J. F., Del Mar, C. B., Whiteman, D. C. & Baade, P. D. (2011) Body-site distribution of  
 31 skin cancer, pre-malignant and common benign pigmented lesions excised in general practice.  
 32 *British Journal of Dermatology*, 165: 35-43.  
 33 Not in PICO as results only reported for excised lesions (N = 11116, GPs and skin cancer clinic doctors),  
 34 not examined lesions (N = 28755, GPs and skin cancer clinic doctors).

35 Zalaudek, I., Kreusch, J., Giacomel, J., Ferrara, G., Catricala, C. & Argenziano, G. (2010) How to  
 36 diagnose nonpigmented skin tumors: A review of vascular structures seen with dermoscopy  
 37 Part II. Nonmelanocytic skin tumors. *Journal of the American Academy of Dermatology*, 63:  
 38 377-386.  
 39 Narrative review  
 40

41 **Review question:**

42 Which investigations of symptoms of suspected squamous cell carcinoma should be done with  
 43 clinical responsibility retained by primary care?  
 44

45 **Results**

46 **Literature search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1980-2013	2206	141	07/02/2013
<i>Premedline</i>	1980-2013	85	9	07/02/2013

<b>Embase</b>	1980-2013	2263	146	08/02/2013
<b>Cochrane Library</b>	1980-2013	37	1	07/02/2013
<b>Psychinfo</b>	1980-2013	3	0	07/02/2013
<b>Web of Science (SCI &amp; SSCI) and ISI Proceedings</b>	1980-2013	309	63	07/02/2013
<b>Biomed Central</b>	1980-2013	1026	4	07/02/2013

1 Total number of studies identified after de-duplication: 290

2


3 **Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<b>Medline</b>	2013-11/08/2014	87	7	11/08/2014
<b>Premedline</b>	2013-11/08/2014	123	6	11/08/2014
<b>Embase</b>	2013-11/08/2014	181	16	11/08/2014
<b>Cochrane Library</b>	2013-11/08/2014	55	0	11/08/2014
<b>Web of Science (SCI &amp; SSCI) and ISI Proceedings</b>	2013-11/08/2014	53	2	11/08/2014

4 Total References retrieved (after de-duplication): 23

5

6




7

8

9 **Risk of bias in the included studies**

10 The risk of bias and applicability concerns are summarised per study in the figure below. The main  
 11 issues to note are that the study population may not be directly representative of an unselected  
 12 symptomatic population of patients presenting to the UK-based GP, that the index test does not  
 13 specify the criteria for malignancy which may limit its external validity, and that the results

1 presented are based on a best case scenario, and are therefore likely to be inflated, and only  
 2 available for skin malignancy as a whole and not for squamous cell carcinoma separately.  
 3



4  
 5  
 6 **Study results**

7  
 8 Table 1: Squamous cell carcinoma of the skin: Study results.

Study	Intervention	Prevalence	Sensitivity (95% CI)	Specificity (95% CI)	Positive predictive value (95% CI)	False negativity rate
Rosendahl (2011)	Clinical images and dermatoscopy	138 malignancies/463 lesions	82.6% (NR)	80% (NR)	NR (NR)	17.4% (NR)

9 NR = Not reported

10  
 11 No evidence was identified pertaining to the diagnostic accuracy of excision biopsy of the lesion in  
 12 patients with suspected squamous cell cancer where the clinical responsibility was retained by  
 13 primary care.  
 14

15 **Evidence statement(s):**

16 Dermatoscopy and clinical images (1 study, N = 463 lesions/389 patients) performed in symptomatic  
 17 patients presenting in a primary care setting is associated with a best-case sensitivity of 82.6%,  
 18 specificity of 80%, and false negativity rate of 17.4% for skin malignancy. The study was associated  
 19 with 1 bias and 2 applicability concerns (See also Table 1)..  
 20

21 **Evidence tables**

22 **Rosendahl (2011)**

PATIENT SELECTION	
<b>A. risk of bias</b>	
Patient sampling	Consecutive series of lesions submitted for histology from the primary care skin cancer clinic of one of the authors.
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Probably
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>

<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>N = 463 pigmented lesions from 389 patients, mean (SD) age = 57 (17) years, 32.6% females. Lesion location: Trunk: N = 241; extremities: N = 128; head and face: N = 82; palms and soles: N = 10. Histopathologically, 246 pigmented lesions turned out to be melanocytic and 217 were of non-melanocytic origin.</p> <p>Final diagnoses:  Malignant lesions: Basal cell carcinoma: N = 72; squamous cell carcinoma: N = 37; melanoma: N = 29.  Benign lesions: Melanocytic nevi: N = 217; seborrheic keratosis: N = 43; solar lentigo: N = 37; lichen planus-like keratosis: N = 21, others: N = 7.</p> <p><u>Inclusion criteria:</u> All pigmented lesions biopsied or excised during a 30-month period. <i>Patients included are only those who received resection. This changes the spectrum of disease as it excludes patients with lesions that were not considered concerning enough to warrant resection.</i></p> <p><u>Exclusion criteria:</u> Poor image quality (N = 3).</p> <p><u>Clinical setting:</u> Primary care skin cancer practice in Queensland, Australia</p>
Are there concerns that the included patients and setting do not match the review question?	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	<p>For each lesion: A triplet of high-resolution digital images consisting of two clinical images (overview and close-up) followed by one dermatoscopic image. The clinical images were taken with Canon EOS digital single lens reflex cameras. The close-up was taken using a macro lens (60-mm f2.8 macro, Canon) with diffuse illumination at a constant reproduction ratio determined by a custom-fabricated spacer. The degree of magnification of the close-up images was similar to that of the dermatoscopy images. Dermatoscopic images were nonpolarising, preferentially using the Dermlite Fluid device (3 Gen, San Juan, Capistrano, Ca); alternatively Dermlite Foto (custom nonpolarised; 3 Gen) and Heine Delta 20 devices (Heines, Optotechnic GmbH&lt; Herrsching, Germany) were used for large and inaccessible lesions, respectively. Dermatoscopic photographs were taken with Canon EOS single lens reflex cameras. Images were presented to the assessors as powerpoint slides. After inspection of the images, the assessor was required to give a diagnosis (criteria not reported, so presumably based on qualitative criteria). Dermatoscopic images were also screened for asymmetry of structure and colour ("chaos") and for clues to malignancy. Asymmetry of colour and structure were defined according to the basic principles of pattern analysis as revised by Kittler (2007, Dermatopathology: Practical &amp; Conceptual, 13:1). Clues to malignancy included: Eccentric structureless zone (any colour except skin colour), gray or blue structures, peripheral black dots or clods, segmental radial lines or pseudopods, polymorphous vessels, white lines, thick reticular or branched lines, and parallel lines on ridges (acral lesions). <i>Not further information regarding the specific cut-off criteria for malignancy reported. The reporting of the results suggests that the test performance is based on best possible scenario.</i></p>
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
Could the conduct or interpretation of the index test	<b>Unclear risk</b>

<b>have introduced bias?</b>		
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>		<b>Unclear concern</b>
<b>REFERENCE STANDARD</b>		
<b>A. risk of bias</b>		
Reference standard(s)	Histopathology	
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>	
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Yes</b>	
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>	
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		<b>Low concern</b>
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing		
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>	
Did all patients receive the same reference standard?	<b>Yes</b>	
Were all patients included in the analysis?	<b>Yes</b>	
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>	
<b>NOTES</b>	The results are presented for all malignancies combined. The 2-by-2 table could not be extracted and the results could not be separated into the different malignancies	

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

**References**

**Included Studies**

Rosendahl C, Tschandl P, Med C, Cameron A, Kittler H. Diagnostic accuracy of dermatoscopy for melanocytic and nonmelanocytic pigmented lesions. *Journal of the American Academy of Dermatology* 2011;64(6):1068-73.

**Excluded Studies**

Abbas Q, Celebi ME, Garcia IF, Rashid M. Lesion border detection in dermoscopy images using dynamic programming. *Skin Research and Technology* 2011;17(1):91-100.  
Exclusion Reason: Not in PICO

Adinarayan M, Krishnamurthy SP. Clinicopathological evaluation of nonmelanoma skin cancer. *Indian Journal of Dermatology* 2011;56(6):670-2.  
Exclusion Reason: Narrative Review

Ahmed R, Soldin M. Incomplete excision rate of basal cell carcinoma: A 2-year retrospective clinical audit. *European Journal of Surgical Oncology* 2011;37(11):984.  
Exclusion Reason: Not in PICO

Ahmad K, Siah T, Langtry JAA. Recurrent and incompletely excised nonmelanoma skin cancers referred for Mohs micrographic surgery. *British Journal of Dermatology* 2012;167:56.  
Exclusion Reason: Not in PICO

- 1 Ahmed, M. M., Moore, B. A. & Schmalbach, C. E. (2014) Utility of Head and Neck Cutaneous  
2 Squamous Cell Carcinoma Sentinel Node Biopsy: A Systematic Review. *Otolaryngology-Head and*  
3 *Neck Surgery*, 150: 180-187.  
4 Exclusion Reason: Not in PICO
- 5 Aitken JF, Janda M, Elwood M, Youl PH, Ring IT, Lowe JB. Clinical outcomes from skin screening  
6 clinics within a community-based melanoma screening program. *Journal of the American*  
7 *Academy of Dermatology* 2006;54(1):105-14.  
8 Exclusion Reason: Not in PICO
- 9 Alendar F, Drljevic I, Drljevic K, Alendar T. Early detection of melanoma skin cancer. *Bosnian Journal*  
10 *of Basic Medical Sciences* 2009;9(1):77-80.  
11 Exclusion Reason: Not in PICO
- 12 Albert MR, Weinstock MA. Keratinocyte carcinoma. [Review] [74 refs]. *CA: A Cancer Journal for*  
13 *Clinicians* 2003;53(5):292-302.  
14 Exclusion Reason: Narrative Review
- 15 Aldridge, R. B., Naysmith, L., Ooi, E. T., Murray, C. S. & Rees, J. L. (1111) The importance of a full  
16 clinical examination: Assessment of index lesions referred to a skin cancer clinic without a total  
17 body skin examination would miss one in three melanomas. *Acta Dermato-Venereologica*, 93:  
18 2013.  
19 Exclusion Reason: Not in PICO
- 20 Allon, I., Allon, D. M., Anavi, Y. & Kaplan, I. (2013) The significance of surface ulceration as a sign of  
21 malignancy in exophytic oral mucosal lesions: myth or fact? *Head and neck pathology*, 7: 149-  
22 154.  
23 Exclusion Reason: Not in PICO
- 24 Alsharqi A, Wilson N, De Mozzi P. Basal cell carcinomas excision margins: Primary vs. secondary care.  
25 *British Journal of Dermatology* 2010;163:101.  
26 Exclusion Reason: Narrative Review
- 27 Alsharqi A, Wilson N. Will the introduction of new NICE guidelines change the management of basal  
28 cell carcinomas in the community? *British Journal of Dermatology* 2011;165:108.  
29 Exclusion Reason: Narrative Review
- 30 Altamura D, Menzies SW, Argenziano G, Zalaudek I, Soyer HP, Sera F, et al. Dermatoscopy of basal  
31 cell carcinoma: morphologic variability of global and local features and accuracy of diagnosis.  
32 *Journal of the American Academy of Dermatology* 2010;62(1):67-75.  
33 Exclusion Reason: Not in PICO
- 34 Angit C, Sharpe GR. Regional audit on squamous cell carcinoma excision margin. *Journal of the*  
35 *American Academy of Dermatology* 2011;64(2 SUPPL. 1):AB124.  
36 Exclusion Reason: Not in PICO
- 37 Anthony S, Vlachou C, Murdoch M, Tatnall F, Batta K, Brown V. Audit of 2-week-wait referrals: how  
38 does tertiary referral influence management? *British Journal of Dermatology* 2010;163:112-3.  
39 Exclusion Reason: Not in PICO
- 40 Anthony S, Ogden E, Blanshard M, Schofield JK. Basal cell carcinomas: Impact of national guidance  
41 on local specialist dermatology Department is likely to be manageable. *British Journal of*  
42 *Dermatology* 2009;161:64-5.  
43 Exclusion Reason: Not in PICO
- 44 Arits AHMM, Schlangen MHJ, Nelemans PJ, Kelleners-Smeets NWJ. Trends in the incidence of basal  
45 cell carcinoma by histopathological subtype. *Journal of the European Academy of Dermatology*  
46 *and Venereology* 2011;25(5):565-9.  
47 Exclusion Reason: Not in PICO
- 48 Arlt A, Luckhaupt H, Hildmann H. Diagnosis of recurrent squamous cell carcinomas with the tumor  
49 marker SCC-antigen. [German]. *Laryngo- Rhino- Otologie* 2000;79(4):207-12.  
50 Exclusion Reason: Not in PICO



- 1 Astner S, Dietterle S, Otberg N, Rowert-Huber HJ, Stockfleth E, Lademann J. Clinical applicability of in  
2 vivo fluorescence confocal microscopy for noninvasive diagnosis and therapeutic monitoring of  
3 nonmelanoma skin cancer. *Journal of Biomedical Optics* 2008;13(1):014003-Feb.  
4 Exclusion Reason: Not in PICO
- 5 Attili SK, Lesar A, McNeill A, Camacho-Lopez M, Moseley H, Ibbotson S, et al. An open pilot study of  
6 ambulatory photodynamic therapy using a wearable low-irradiance organic light-emitting diode  
7 light source in the treatment of nonmelanoma skin cancer. *British Journal of Dermatology*  
8 2009;161(1):170-3.  
9 Exclusion Reason: Not in PICO
- 10 Asuquo ME, Ebughe G. Major dermatological malignancies encountered in the University of Calabar  
11 Teaching Hospital, Calabar, southern Nigeria. *International Journal of Dermatology* 2012;51:32-6.  
12 Exclusion Reason: Not in PICO
- 13 Baade PD, Youl PH, Janda M, Whiteman DC, Del Mar CB, Aitken JF. Factors associated with the  
14 number of lesions excised for each skin cancer: a study of primary care physicians in Queensland,  
15 Australia. *Archives of Dermatology* 2008;144(11):1468-76.  
16 Exclusion Reason: Not in PICO
- 17 Bakis S, Irwig L, Wood G, Wong D. Exfoliative cytology as a diagnostic test for basal cell carcinoma: a  
18 meta-analysis. *British Journal of Dermatology* 2004;150(5):829-36.  
19 Exclusion Reason: Not in PICO
- 20 Balogh K, Trehan P, Bashir S, Higgins E, Morris-Jones R. Skin cancer 'filtered screening' by  
21 dermatologists: the 2-week wait system. *British Journal of Dermatology* 2012;167:63.  
22 Exclusion Reason: Not in PICO
- 23 Barry J, Oon SF, Watson R, Barnes L. The management of basal cell carcinomas. *Irish Medical Journal*  
24 2006;99(6):179-81.  
25 Exclusion Reason: Not in PICO
- 26 Bastiaens MT, Struyk L, Tjong AHung SP, Gruis N, ter Huurne J, Westendorp RG, et al. Cutaneous  
27 squamous cell carcinoma and p53 codon 72 polymorphism: a need for screening? *Molecular*  
28 *Carcinogenesis* 2001;30(1):56-61.  
29 Exclusion Reason: Not in PICO
- 30 Bataille V, Hargest E, Brown V, Blackwell V, Dawe S, Cooper A, et al. A teledermatology pilot study in  
31 Hertfordshire: Triage of 2-week-wait referrals. *British Journal of Dermatology* 2011;165:137-8.  
32 Exclusion Reason: Not in PICO
- 33 Beby F, Kodjikian L, Roche O, Bouvier R, Donate D, Guerillon F, et al. [Conjunctival tumors in children.  
34 A histopathologic study of 42 cases]. [French]. *Journal Francais d Ophthalmologie* 2005;28(8):817-  
35 23.  
36 Exclusion Reason: Not in PICO
- 37 Behrens, A., May, A., Manner, H., Pohl, J. & Ell, C. (2013) Esophageal precancerous lesions: Early  
38 diagnosis, treatment, and preservation of quality of life. [German]. *Internist*, 54: 683-690.  
39 Exclusion Reason: Narrative review
- 40 Bernard P, Derancourt C, Arnoult-Coudoux E, Picot R, Delvincourt C. Skin cancer diagnosis by  
41 dermatologists in the region of Champagne-Ardenne: A prospective study. *Annales de*  
42 *Dermatologie et de Venereologie* 2001;128(8-9):883-7.  
43 Exclusion Reason: Not in PICO
- 44 Bhatti AZ, Asif S, Alwan M. Factors affecting incomplete excision of nonmelanoma skin cancers in  
45 New Zealand. *Annals of Plastic Surgery* 2006;57(5):513-6.  
46 Exclusion Reason: Not in PICO
- 47 Bhatnagar A, Mohamad S, Sandramouli S. 'Fast-tracking' cancer referrals: application for periocular  
48 basal cell carcinoma. *Eye* 2006;20(4):428-30.  
49 Exclusion Reason: Not in PICO
- 50 Blakeslee D, Vaughan CW, Shapshay SM. Excisional biopsy in the selective management of T1 glottic  
51 cancer: A three-year follow-up study. *Laryngoscope* 1984;94(4):488-94.

- 1 Exclusion Reason: Not in PICO  
2 Blum A, Bauer J, Rassner G, Garbe C. Early detection of skin cancer. [German]. *Onkologie*  
3 2002;8(10):1064-71.  
4 Exclusion Reason: Narrative Review  
5 Boiko PE, Koepsell TD, Larson EB, Wagner EH. Skin cancer diagnosis in a primary care setting. *Journal*  
6 *of the American Academy of Dermatology* 1996;34(4):608-11.  
7 Exclusion Reason: Narrative Review  
8 Bolac C, Cordel N, Deschamps L, Renier M, Quist D, Derancourt C. Diagnosis of skin cancer by  
9 dermatologists in the French West Indies: A prospective study. *Annales de Dermatologie et de*  
10 *Venereologie* 2011;138(1):11-6.  
11 Exclusion Reason: Not in PICO  
12 Bollschweiler E, Ell C. Squamous cell carcinoma and adenocarcinoma of the esophagus. Differences  
13 in epidemiology, tumor biology, diagnostic procedures, and prevention. [German]. *Onkologie*  
14 2004;10(11):1168-78.  
15 Exclusion Reason: Narrative Review  
16 Borgulya M, Kurz CM, Knoll T, Velten T, Vieth M, Ell C, et al. Diagnosis of early barrett's neoplasia and  
17 esophageal squamous cell neoplasia by electrical bio-impedance spectroscopy in human tissue.  
18 *Gastrointestinal Endoscopy* 2012;75(4 SUPPL. 1):AB127.  
19 Exclusion Reason: Not in PICO  
20 Bostock-Ling N. Excising basal cell carcinoma in general practice. *Australian Family Physician*  
21 2006;35(7):558-60.  
22 Exclusion Reason: Narrative Review  
23 Bowns IR, Collins K, Walters SJ, McDonagh AJ. Telemedicine in dermatology: a randomised  
24 controlled trial. *Health Technology Assessment (Winchester, England)* 2006;10(43):iii-v.  
25 Exclusion Reason: Not in PICO  
26 Bower CP, Lear JT, de Berker DA. Basal cell carcinoma follow-up practices by dermatologists: a  
27 national survey. *British Journal of Dermatology* 2001;145(6):949-56.  
28 Exclusion Reason: Not in PICO  
29 Bradley N, Topham E. A service-evaluation of recurrence following curettage and cautery treatment  
30 of well-differentiated primary cutaneous squamous cell carcinoma. *British Journal of*  
31 *Dermatology* 2012;167:59.  
32 Exclusion Reason: Not in PICO  
33 Brewster DH, Bhatti LA, Inglis JH, Nairn ER, Doherty VR. Recent trends in incidence of nonmelanoma  
34 skin cancers in the East of Scotland, 1992-2003. *British Journal of Dermatology* 2007;156(6):1295-  
35 300.  
36 Exclusion Reason: Not in PICO  
37 Bristow Ivan, Bowling Jonathan. Dermoscopy as a technique for the early identification of foot  
38 melanoma. *Journal of Foot and Ankle Research* 2009;2(1):14.  
39 Exclusion Reason: Not in PICO  
40 Brown SJ, Lawrence CM. The management of skin malignancy: to what extent should we rely on  
41 clinical diagnosis? *British Journal of Dermatology* 2006;155(1):100-3.  
42 Exclusion Reason: Narrative Review  
43 Brundel K-H. Skin cancer in general practice. [German]. *Dermatosen in Beruf und Umwelt*  
44 1990;38(2):54-7.  
45 Exclusion Reason: Not in PICO  
46 Buis PAJ, Chorus RMH, van Diest PJ. Value of histopathologic analysis of skin excisions by GPs. *British*  
47 *Journal of General Practice* 2005;55(515):458-60.  
48 Exclusion Reason: Not in PICO  
49 Burghout, K., Sigurdsson, V. & Toonstra, J. (2013) Non-melanoma skin cancer. [Dutch]. *Huisarts en*  
50 *Wetenschap*, 56: 174-178.  
51 Exclusion Reason: Narrative review

- 1 Butani A, Arbesfeld DM, Schwartz RA. Premalignant and early squamous cell carcinoma. *Clinics in*  
2 *Plastic Surgery* 2005;32(2):223-+.  
3 Exclusion Reason: Not in PICO
- 4 Carducci M, Bozzetti M, Foscolo AM, Betti R. Margin detection using digital dermatoscopy improves  
5 the performance of traditional surgical excision of basal cell carcinomas of the head and neck.  
6 *Dermatologic Surgery* 2011;37(2):280-5.  
7 Exclusion Reason: Not in PICO
- 8 Carli P, Chiarugi A, De Giorgi V. Examination of lesions (including dermoscopy) without contact with  
9 the patient is associated with improper management in about 30% of equivocal melanomas.  
10 *Dermatologic Surgery* 2005;31(2):169-72.  
11 Exclusion Reason: Not in PICO
- 12 Carter EJ, Whittam LR, Buckley DA. Failure of adherence to NICE guidelines for skin cancer surgery in  
13 general practice. *British Journal of Dermatology* 2009;161:63.  
14 Exclusion Reason: Not in PICO
- 15 Carter J, Evans C, Ghebre R, Glubka B, Downs L. Superficially invasive squamous cell carcinoma of the  
16 vulva: Is radical excision necessary? *Gynecologic Oncology* 2012;125:S83.  
17 Exclusion Reason: Not in PICO
- 18 Chaidemenos G, Apalla Z, Trigoni A, Koussidou T, Karakatsanis G. Inability of dermoscopy to  
19 differentiate early-stage squamous cell carcinoma from keratoacanthoma. *Melanoma Research*  
20 2010;20:e66.  
21 Exclusion Reason: N=2
- 22 Chambers M, Esdaile B, De Vos S, Bowling J, Cassell O, Turner R, et al. The oxfordshire community  
23 dermatology service. *British Journal of Dermatology* 2012;167:97.  
24 Exclusion Reason: Not in PICO
- 25 Chan LS, Scholes NJ, Jones M. Skin excisions: not so simple for the regionally based general surgical  
26 trainee. *Australian Journal of Rural Health* 2011;19(4):205-10.  
27 Exclusion Reason: Not in PICO
- 28 Chattopadhyay, M. & Ha, T. (2013) How to examine a patient with suspected skin cancer. *Medicine*  
29 *(United Kingdom)*, 41: 400-401.  
30 Exclusion Reason: Narrative review
- 31 Cheah PL, Liam CK, Yap SF, Looi LM. Squamous cell carcinoma antigen as an adjunct tumour marker  
32 in primary carcinoma of the lung. *Journal of Clinical Pathology* 1994;47(6):535-7.  
33 Exclusion Reason: Not in PICO
- 34 Chen P, Patel DC. Evaluation of surgical excision of non-melanoma skin cancers - A retrospective  
35 study. *Australasian Journal of Dermatology* 2011;52(4):A9.  
36 Exclusion Reason: Not in PICO
- 37 Cheng B, Joe Stanley R, Stoecker WV, Osterwise CT, Stricklin SM,  
38 Hinton KA, et al. Automatic dirt trail analysis in dermoscopy images. *Skin Research & Technology*  
39 2013;19(1):e20-6.  
40 Exclusion Reason: Not in PICO
- 41 Cheng A, Bennett A, Pogrel MA, Schmidt BL. Should tumor depth measured from an incisional biopsy  
42 be used to guide the decision to perform an elective neck dissection? *Journal of Oral and*  
43 *Maxillofacial Surgery* 2012;70(9 SUPPL. 2):e-1.  
44 Exclusion Reason: Not in PICO
- 45 Chiesa F, Sala L, Costa L, Moglia D, Mauri M, Podrecca S, et al. Excision of oral leukoplakias by CO2  
46 laser on an out-patient basis: a useful procedure for prevention and early detection of oral  
47 carcinomas. *Tumori* 1986;72(3):307-12.  
48 Exclusion Reason: Not in PICO
- 49 Chong SLP, Ferguson L, Lateo S. Skin cancer surgery in primary care: Results of an audit and re-audit.  
50 *British Journal of Dermatology* 2012;167:39.  
51 Exclusion Reason: Not in PICO

- 1 Choy B, Bandla S, Xia Y, Tan D, Pennathur A, Luketich JD, et al. Clinicopathologic characteristics of  
2 high expression of Bmi-1 in esophageal adenocarcinoma and squamous cell carcinoma. *BMC*  
3 *Gastroenterology* 2012;12:146.  
4 Exclusion Reason: Not in PICO
- 5 Chren MM, Sahay AP, Sands LP, Maddock L, Lindquist K, Bertenthal D, et al. Variation in care for  
6 nonmelanoma skin cancer in a private practice and a veterans affairs clinic. *Medical Care*  
7 2004;42(10):1019-26.  
8 Exclusion Reason: Not in PICO
- 9 Civantos F Jr, Zitsch R, Bared A, Amin A. Sentinel node biopsy for squamous cell carcinoma of the  
10 head and neck. [Review] [64 refs]. *Journal of Surgical Oncology* 2008;97(8):683-90.  
11 Exclusion Reason: Narrative Review
- 12 Clarke P. Nonmelanoma skin cancers - treatment options. *Australian Family Physician*  
13 2012;41(7):476-80.  
14 Exclusion Reason: Narrative Review
- 15 Cleary RK, Schaldenbrand JD, Fowler JJ, Schuler JM, Lampman RM. Treatment options for perianal  
16 Bowen's disease: survey of American Society of Colon and Rectal Surgeons Members. *American*  
17 *Surgeon* 2000;66(7):686-8.  
18 Exclusion Reason: Not in PICO
- 19 Cooper SM, Wojnarowska F. The accuracy of clinical diagnosis of suspected premalignant and  
20 malignant skin lesions in renal transplant recipients. *Clinical & Experimental Dermatology*  
21 2002;27(6):436-8.  
22 Exclusion Reason: Not in PICO
- 23 Cortinas Saenz M, Saenz Guirado S, Gamez Moreno J, Iglesias Cerrillo JA, Pardo Martinez A, Martinez  
24 Gomez L. Analysis of results, quality indicators, and postsurgical complications in an outpatient  
25 dermatological surgery program. *Actas Dermo-Sifiliograficas* 2012;103(1):36-43.  
26 Exclusion Reason: Not in PICO
- 27 Corwin P, Munn E, Nicholls D. A study of general practitioners' skin surgery in Canterbury. *New*  
28 *Zealand Medical Journal* 1997;110(1047):253-5.  
29 Exclusion Reason: Not in PICO
- 30 Costa S, De Nuzzo M, Rubino A, Rambelli V, Marinelli M, Santini D, et al. Independent determinants  
31 of inaccuracy of colposcopically directed punch biopsy of the cervix. *Gynecologic Oncology*  
32 2003;90(1):57-63.  
33 Exclusion Reason: Not in PICO
- 34 Cox NH. Basal cell carcinoma in young adults. *British Journal of Dermatology* 1992;127(1):26-9.  
35 Exclusion Reason: Not in PICO
- 36 Cox NH, Wagstaff R, Popple AW. Using clinicopathological analysis of general practitioner skin  
37 surgery to determine educational requirements and guidelines. *BMJ* 1992;304(6819):93-6.  
38 Exclusion Reason: Not in PICO
- 39 Cuellar F, Vilalta A, Puig S, Palou J, Zaballos P, Malveyh J. Dermoscopy of early recurrent basal cell  
40 carcinoma. *Archives of Dermatology* 2008;144(9):1254.  
41 Exclusion Reason: N=3
- 42 de Hullu JA, Hollema H, Piers DA, Verheijen RH, van Diest PJ, Mourits MJ, et al. Sentinel lymph node  
43 procedure is highly accurate in squamous cell carcinoma of the vulva. *Journal of Clinical Oncology*  
44 2000;18(15):2811-6.  
45 Exclusion Reason: Not in PICO
- 46 De Berker DAR, Poirier V, Takwale A. Follow-up preferences for patients with basal cell carcinoma:  
47 The basis for modelling clinical practice and commissioning. *British Journal of Dermatology*  
48 2010;163:112.  
49 Exclusion Reason: Not in PICO
- 50 de Giorgi V, Alfaioli B, Papi F, Janowska A, Grazzini M, Lotti T, et al. Dermoscopy in Pigmented  
51 Squamous Cell Carcinoma. *Journal of Cutaneous Medicine and Surgery* 2009;13(6):326-9.

- 1 Exclusion Reason: N=1  
2 Delaney EK, Duckworth L, Thompson WD, Lee AJ, Murchie P. Excising squamous cell carcinomas:  
3 comparing the performance of GPs, hospital skin specialists and other hospital specialists. *Family*  
4 *Practice* 2012;29(5):541-6.  
5 Exclusion Reason: Not in PICO  
6 Demir H, Isken T, Kus E, Tan YZ, Isgoren S, Gorur GD, et al. Sentinel lymph node biopsy with a gamma  
7 probe in patients with high-risk cutaneous squamous cell carcinoma: follow-up results of sentinel  
8 lymph node-negative patients. *Nuclear Medicine Communications* 2011;32(12):1216-22.  
9 Exclusion Reason: Not in PICO  
10 Dewan P, Panagou E, Ajen S, Bewley AP, Sahota A, Gibbon K. Are NICE skin cancer guidelines being  
11 followed in primary care? A re-audit to review changes in practice in an inner city setting. *British*  
12 *Journal of Dermatology* 2010;163:65.  
13 Exclusion Reason: Not in PICO  
14 Dixon AJ, Hall RS. Managing skin cancer--23 golden rules. [Review] [0 refs]. *Australian Family*  
15 *Physician* 2005;34(8):669-71.  
16 Exclusion Reason: Narrative Review  
17 Dixon A. Rare skin cancers in general practice. *Australian Family Physician* 2007;36(3):141-3.  
18 Exclusion Reason: N=1  
19 Dua J, Clayton R. A comparison of skin cancer excision rates between general practitioners and  
20 dermatologists in West Berkshire, South East England. *British Journal of Dermatology*  
21 2012;167:60-1.  
22 Exclusion Reason: Not in PICO  
23 Durdu M, Baba M, Seckin D. Dermatoscopy versus Tzanck smear test: A comparison of the value of  
24 two tests in the diagnosis of pigmented skin lesions. *Journal of the American Academy of*  
25 *Dermatology* 2011;65(5):972-82.  
26 Exclusion Reason: Not in PICO  
27 Eekhof, J. A. (2013) [Actinic keratosis: the art of doing nothing]. [Dutch]. *Nederlands Tijdschrift Voor*  
28 *Geneeskunde*, 157: A5363.  
29 Exclusion Reason: Narrative review  
30 Ehrig T, Cockerell C, Piacquadio D, Dromgoole S. Actinic keratoses and the incidence of occult  
31 squamous cell carcinoma: a clinical-histopathologic correlation. *Dermatologic Surgery*  
32 2006;32(10):1261-5.  
33 Exclusion Reason: Not in PICO  
34 Emery JD, Hunter J, Hall PN, Watson AJ, Moncrieff M, Walter FM. Accuracy of SIAscopy for  
35 pigmented skin lesions encountered in primary care: Development and validation of a new  
36 diagnostic algorithm. *BMC Dermatology* 2010;10.  
37 Exclusion Reason: Not in PICO  
38 Epstein JB, Scully C. Assessing the patient at risk for oral squamous cell carcinoma. [Review] [87 refs].  
39 *Special Care in Dentistry* 1997;17(4):120-8.  
40 Exclusion Reason: Narrative review  
41 Epstein JB, Guneri P, Boyacioglu H, Abt E. The limitations of the clinical oral examination in detecting  
42 dysplastic oral lesions and oral squamous cell carcinoma. *Journal of the American Dental*  
43 *Association* 2012;143(12):1332-42.  
44 Exclusion Reason: Not in PICO  
45 Epstein JB, Silverman S, Epstein JD, Lonky SA, Bride MA. Analysis of oral lesion biopsies identified and  
46 evaluated by visual examination, chemiluminescence and toluidine blue. *Oral Oncology*  
47 2008;44(6):538-44.  
48 Exclusion Reason: Not in PICO  
49 Epstein JB, Gorsky M, Cabay RJ, Day T, Gonsalves W. Screening for and diagnosis of oral  
50 premalignant lesions and oropharyngeal squamous cell carcinoma - Role of primary care  
51 physicians. *Canadian Family Physician* 2008;54(6):870-5.

- 1 Exclusion Reason: Not in PICO  
2 Epstein, J. B., Guneri, P., Boyacioglu, H. & Abt, E. (2013) The limitations of the clinical oral  
3 examination in detecting dysplastic oral lesions and oral squamous cell carcinoma.[Reprint of J  
4 Am Dent Assoc. 2012 Dec;143(12):1332-42; PMID: 23204089]. *Texas Dental Journal*, 130: 410-  
5 424.  
6 Exclusion Reason: Not in PICO  
7 Felton J, Mellerio JE. Cutaneous squamous cell carcinomas in epidermolysis bullosa: A 20-year  
8 retrospective study. *British Journal of Dermatology* 2012;167:55-6.  
9 Exclusion Reason: Not in PICO  
10 Ferrandiz L, Ruiz-de-Casas A, Trakatelli M, de Vries E, Ulrich M, Aquilina S, et al. Assessing physicians'  
11 preferences on skin cancer treatment in Europe. *British Journal of Dermatology* 2012;167:Suppl-  
12 35.  
13 Exclusion Reason: Not in PICO  
14 Ferreira, P., Rodrigues, M., Ledo, S., Senra, R., Costa, S., V, Rocha, M. & Paiva, C. (2013) Back pain as  
15 the first manifestation of a cavum tumor. *European Journal of Internal Medicine*, 24: e149.  
16 Exclusion Reason: Not in PICO  
17 Firnhaber JM. Diagnosis and treatment of Basal cell and squamous cell carcinoma. [Review].  
18 *American Family Physician* 2012;86(2):161-8.  
19 Exclusion Reason: Narrative Review  
20 FitzGerald KL, Buttner PG, Donovan SA. Nonpigmented skin lesions - how many are nonmelanoma  
21 skin cancer? *Australian Family Physician* 2006;35(7):555-7.  
22 Exclusion Reason: Not in PICO  
23 Fleischer AB, Feldman SR, Barlow JO, Zheng BY, Hahn HB, Chuang TY, et al. The specialty of the  
24 treating physician affects the likelihood of tumor-free resection margins for basal cell carcinoma:  
25 Results from a multi-institutional retrospective study. *Journal of the American Academy of*  
26 *Dermatology* 2001;44(2):224-30.  
27 Exclusion Reason: Not in PICO  
28 Fontes, K. B., Cunha, K. S., Rodrigues, F. R., Silva, L. E. & Dias, E. P. (2013) Concordance between  
29 cytopathology and incisional biopsy in the diagnosis of oral squamous cell carcinoma. *Brazilian*  
30 *oral research*, 27: 122-127.  
31 Exclusion Reason: Not in PICO  
32 Freitag CP, Barros SG, Krueh CD, Putten AC, Dietz J, Gruber AC, et al. Esophageal dysplasias are  
33 detected by endoscopy with Lugol in patients at risk for squamous cell carcinoma in southern  
34 Brazil. *Diseases of the Esophagus* 1999;12(3):191-5.  
35 Exclusion Reason: Not in PICO  
36 French Society of Dermatology. Guideline for the diagnosis and treatment of cutaneous squamous  
37 cell carcinoma and precursor lesions. *Annales de Dermatologie et de Venereologie*  
38 2009;136:Suppl-86.  
39 Exclusion Reason: Guidelines  
40 Friedman T, Klein D, Hadad E, Westreich M, Shalom A. [Diagnostic accuracy of skin lesions excised by  
41 a plastic surgeon]. [Hebrew]. *Harefuah* 75;147(4):305-8.  
42 Exclusion Reason: Not in PICO  
43 Fujishiro M, Yahagi N, Kakushima N, Kodashima S, Muraki Y, Ono S, et al. Endoscopic submucosal  
44 dissection of esophageal squamous cell neoplasms. *Clinical Gastroenterology & Hepatology*  
45 2006;4(6):688-94.  
46 Exclusion Reason: Not in PICO  
47 Gait R, Milligan A, Burd RM, Fletcher A. A review of procedures carried out on basal cell carcinomas  
48 by Primary care physicians. *British Journal of Dermatology* 2009;161:64.  
49 Exclusion Reason: Not in PICO

- 1 Gao L, Lin WH, Gong ZJ, Liu Y, Liu YM, Zhu MH. [Fine needle aspiration cytology of eyelid sebaceous  
2 gland carcinoma and its differential diagnosis]. [Chinese]. *Chung-Hua Ping Li Hsueh Tsa Chih -*  
3 *Chinese Journal of Pathology* 2004;33(1):36-9.  
4 Exclusion Reason: Not in PICO
- 5 Garcia-Solano J, Lopez-Avila A, Acosta J, Montalbana S, Sanchez-Sanchez C, Benito A, et al. Non-  
6 melanoma skin cancer with positive surgical and histological margins. Comparative study among  
7 the departments involved in their surgical excision. [Spanish]. *Actas Dermo-Sifilograficas*  
8 2004;95(6):358-61.  
9 Exclusion Reason: Not in PICO
- 10 Garner KL, Rodney WM. Basal and squamous cell carcinoma. [Review] [21 refs]. *Primary Care; Clinics*  
11 *in Office Practice* 2000;27(2):447-58.  
12 Exclusion Reason: Narrative Review
- 13 Gerbert B, Bronstone A, Maurer T, Hofmann R, Berger T. Decision support software to help primary  
14 care physicians triage skin cancer - A pilot study. *Archives of Dermatology* 2000;136(2):187-92.  
15 Exclusion Reason: Not in PICO
- 16 Giacomel, J. & Zalaudek, I. (2013) Pink Lesions. *Dermatologic Clinics*, 31: 649-678.  
17 Exclusion Reason: Narrative review
- 18 Gilde K. [Malignant tumors of the skin]. [Review] [25 refs] [Hungarian]. *Orvosi Hetilap*  
19 2006;147(48):2321-30.  
20 Exclusion Reason: Narrative Review
- 21 Girardi F, Pickel H, Joura EA, Breitenecker G, Gitsch G, Graf AH, et al. [Guidelines for diagnosis and  
22 therapy of intraepithelial neoplasia and early invasive carcinoma of the female lower genital  
23 system (cervix uteri, vagina, vulva) established by the AGK (Colposcopy Work Group in the OGGG  
24 [Austrian Society of Gynecology and Obstetrics])]. [German]. *Gynakologisch-Geburtshilfliche*  
25 *Rundschau* 2001;41(3):197-200.  
26 Exclusion Reason: Guidelines
- 27 Golberg O, Alexandroff AB, Burd RM. Seasonal variation in 2-week-wait skin cancer referrals is not  
28 mirrored by changes in incidence of skin cancer: A message for service provision. *British Journal*  
29 *of Dermatology* 2011;165:20-1.  
30 Exclusion Reason: Not in PICO
- 31 Goldberg LH, Rubin HA. Management of basal cell carcinoma. Which option is best? *Postgraduate*  
32 *Medicine* 1961;85(1):57-8.  
33 Exclusion Reason: Narrative Review
- 34 Goldstone SE, Winkler B, Ufford LJ, Alt E, Palefsky JM. High prevalence of anal squamous  
35 intraepithelial lesions and squamous-cell carcinoma in men who have sex with men as seen in a  
36 surgical practice. *Diseases of the Colon & Rectum* 2001;44(5):690-8.  
37 Exclusion Reason: Not in PICO
- 38 Gonsalves WC, Chi AC, Neville BW. Common oral lesions: Part II. Masses and neoplasia. *American*  
39 *Family Physician* 2007;75(4):509-12.  
40 Exclusion Reason: Narrative Review
- 41 Goulding JMR, Levine S, Blizard RA, Deroide F, Swale VJ. Dermatological surgery: a comparison of  
42 activity and outcomes in primary and secondary care. *British Journal of Dermatology*  
43 2009;161(1):110-4.  
44 Exclusion Reason: Not in PICO
- 45 Graves J, Fleischman MH, Goldstein GD. Derm Access: A new triage system to rapidly identify  
46 suspicious skin lesions. *Dermatologic Surgery* 2006;32(12):1486-90.  
47 Exclusion Reason: Not in PICO
- 48 Griffiths RW, Suvarna SK, Stone J. Do basal cell carcinomas recur after complete conventional  
49 surgical excision? *British Journal of Plastic Surgery* 2005;58(6):795-805.  
50 Exclusion Reason: Not in PICO

- 1 Gross EA. Nonmelanoma skin cancer: Clues to early detection, keys to effective treatment.  
2 Consultant 1999;39(3):829-39.  
3 Exclusion Reason: Narrative Review
- 4 Gudi V, Ormerod AD, Dawn G, Green C, MacKie RM, Douglas WS, et al. Management of basal cell  
5 carcinoma by surveyed dermatologists in Scotland. *Clinical & Experimental Dermatology*  
6 2006;31(5):648-52.  
7 Exclusion Reason: Not in PICO
- 8 Gurudutt VV, Genden EM. Cutaneous squamous cell carcinoma of the head and neck. *Journal of Skin*  
9 *Cancer* 2011;2011:502723.  
10 Exclusion Reason: Not in PICO
- 11 Guther S, Ramrath K, Dyll-Smith D, Landthaler M, Stolz W. Development of a targeted risk-group  
12 model for skin cancer screening based on more than 100,000 total skin examinations. *Journal of*  
13 *the European Academy of Dermatology & Venereology* 2012;26(1):86-94.  
14 Exclusion Reason: Not in PICO
- 15 Haliasos, E. C., Kerner, M., Jaimes, N., Zalaudek, I., Malvey, J., Lanschuetzer, C. M., Hinter, H.,  
16 Hofmann-Wellenhof, R., Braun, R. P. & Marghoob, A. A. (2013) Dermoscopy for the pediatric  
17 dermatologist, part ii: dermoscopy of genetic syndromes with cutaneous manifestations and  
18 pediatric vascular lesions. [Review]. *Pediatric Dermatology*, 30: 172-181.  
19 Exclusion Reason: Narrative review
- 20 Halpern SM, Shall L. Establishment of a primary care-based teledermatology service in Kent. *British*  
21 *Journal of Dermatology* 2011;165:136-7.  
22 Exclusion Reason: Not in PICO
- 23 Hamm H, Hoger PH. Skin tumors in childhood. [Review]. *Deutsches Arzteblatt International*  
24 2011;108(20):347-53.  
25 Exclusion Reason: Narrative Review
- 26 Han MW, Lee B-J, Jang YJ, Chung Y-S. Clinical value of office-based endoscopic incisional biopsy in  
27 diagnosis of nasal cavity masses. *Otolaryngology - Head and Neck Surgery* 2010;143(3):341-7.  
28 Exclusion Reason: Not in PICO
- 29 Hansen C, Wilkinson D, Hansen M, Soyer HP. Factors contributing to incomplete excision of  
30 nonmelanoma skin cancer by Australian general practitioners. *Archives of Dermatology*  
31 2009;145(11):1253-60.  
32 Exclusion Reason: Not in PICO
- 33 Haw, W. Y., Fraser, S., Affleck, A. & Holme, A. (2014) Skin cancer excision performance in primary  
34 and secondary care in Scotland. *British Journal of Dermatology*, 171: 25.  
35 Exclusion Reason: Not in PICO
- 36 Hayashi T, Muto M, Hayashi R, Minashi K, Yano T, Kishimoto S, et al. Usefulness of narrow-band  
37 imaging for detecting the primary tumor site in patients with primary unknown cervical lymph  
38 node metastasis. *Japanese Journal of Clinical Oncology* 2010;40(6):537-41.  
39 Exclusion Reason: Not in PICO
- 40 Heal CF, Raasch BA, Buettner PG, Weedon D. Accuracy of clinical diagnosis of skin lesions. *British*  
41 *Journal of Dermatology* 2008;159(3):661-8.  
42 Exclusion Reason: Not in PICO
- 43 Heal C, Buettner P, Raasch B, Browning S. Minor skin excisions in general practice in North  
44 Queensland. *Australian Family Physician* 2006;35(10):825-8.  
45 Exclusion Reason: Not in PICO
- 46 Hermes, H. M., Sahu, J., Schwartz, L. R. & Lee, J. B. (2014) - Clinical and histologic characteristics of  
47 clinically unsuspected melanomas. - *Clinics in Dermatology*, 32: 324-330.  
48 Exclusion Reason: Not in PICO
- 49 Hernandez-Martin A, Arias-Palomo D, Barahona E, Hidalgo C, Munoz C, Garcia-Higuera I. [Analysis of  
50 surgical treatment for nonmelanoma skin cancer performed by dermatologists in a public  
51 hospital: clinical-pathological correlation, use of hospital resources, and waiting list time from



- 1 diagnosis]. [Spanish][Erratum appears in *Actas Dermosifiliogr.* 2008 Mar;99(2):170]. *Actas Dermo-*  
2 *Sifiliograficas* 2007;98(10):694-701.
- 3 Exclusion Reason: Not in PICO
- 4 Hjortdal O, Naess A, Berner A. Squamous cell carcinomas of the lower lip. *Journal of Cranio-Maxillo-*  
5 *Facial Surgery* 1995;23(1):34-7.
- 6 Exclusion Reason: Narrative Review
- 7 Holmkvist KA, Rogers GS, Dahl PR. Incidence of residual basal cell carcinoma in patients who appear  
8 tumor free after biopsy. *Journal of the American Academy of Dermatology* 1999;41(4):600-5.
- 9 Exclusion Reason: Not in PICO
- 10 Humphreys TR. Skin cancer: Recognition and management. *Clinical Cornerstone* 2001;4(1):23-9.
- 11 Exclusion Reason: Narrative Review
- 12 Ishihara R, Inoue T, Hanaoka N, Takeuchi Y, Tsujii Y, Kanzaki H, et al. Autofluorescence imaging  
13 endoscopy for screening of esophageal squamous mucosal high-grade neoplasia: a phase II study.  
14 *Journal of Gastroenterology & Hepatology* 2012;27(1):86-90.
- 15 Exclusion Reason: Not in PICO
- 16 Ismail N, D'Adhemar C, Kirby B, Collins P, Sheahan K, Lally A. An audit of basal cell carcinoma in St  
17 Vincent's University Hospital. *British Journal of Dermatology* 2012;167(6):e34-5.
- 18 Exclusion Reason: Not in PICO
- 19 Jaikittivong A, Swadison S, Thangpitsytotin M, Langlais RP. Oral squamous cell carcinoma: a  
20 clinicopathological study of 342 Thai cases. *Journal of Contemporary Dental Practice [Electronic*  
21 *Resource]* 2009;10(5):E033-40.
- 22 Exclusion Reason: Not in PICO
- 23 Janda, M., Youl, P., Neale, R., Aitken, J., Whiteman, D., Gordon, L. & Baade, P. (2014) - Clinical skin  
24 examination outcomes after a video-based behavioral intervention: analysis from a randomized  
25 clinical trial. - *JAMA Dermatology*, 150: 372-379.
- 26 Exclusion Reason: Population not in PICO
- 27 Jeong W-J, Paik JH, Cho S-W, Sung M-W, Kim KH, Ahn S-H. Excisional biopsy for management of  
28 lateral tongue leukoplakia. *Journal of Oral Pathology and Medicine* 2012;41(5):384-8.
- 29 Exclusion Reason: Not in PICO
- 30 Jerant AF, Johnson JT, Sheridan CD, Caffrey TJ. Early detection and treatment of skin cancer.  
31 [Review] [32 refs]. *American Family Physician* 375;62(2):357-68.
- 32 Exclusion Reason: Narrative Review
- 33 Johnson SJ, Wadehra V. How predictive is a cervical smear suggesting invasive squamous cell  
34 carcinoma? *Cytopathology* 2001;12(3):144-50.
- 35 Exclusion Reason: Not in PICO
- 36 Jung JE, Rah DK, Kim YO. Effects of preoperative biopsies on recurrence in head and neck skin  
37 cancer. *Archives of Plastic Surgery* 2012;39(5):518-21.
- 38 Exclusion Reason: Not in PICO
- 39 Kahn, E., Sossong, S., Goh, A., Carpenter, D. & Goldstein, S. (2013) Evaluation of Skin Cancer in  
40 Northern California Kaiser Permanente's Store-and-Forward Teledermatology Referral Program.  
41 *Telemedicine and E-Health*, 19: 780-785.
- 42 Exclusion Reason: Not in PICO
- 43 Kamyab-Hesari, K., Seirafi, H., Naraghi, Z. S., Shahshahani, M. M., Rahbar, Z., Damavandi, M. R.,  
44 Naraghi, M. M., Rezvani, M. & Aghazadeh, N. (2014) Diagnostic accuracy of punch biopsy in  
45 subtyping basal cell carcinoma. *Journal of the European Academy of Dermatology and*  
46 *Venereology*, 28: 250-253.
- 47 Exclusion Reason: Not in PICO
- 48 Karagozoglu KH, Castelijns J, Bloemena E, de Bree R, van der Waal L. [An enlarged lymph node in the  
49 neck; what to do?]. [Dutch]. *Nederlands Tijdschrift Voor Tandheelkunde* 2011;118(5):267-71.
- 50 Exclusion Reason: Narrative Review

- 1 Kersten RC, Ewing-Chow D, Kulwin DR, Gallon M. Accuracy of clinical diagnosis of cutaneous eyelid  
2 lesions. *Ophthalmology* 1997;104(3):479-84.  
3 Exclusion Reason: Not in PICO
- 4 Khalid S, Spicer A, Gee B, Carr R. The impact of Improved Outcome Guidance (IOG) for skin cancer: A  
5 comparative re-audit of excision rates of basal cell carcinomas by general practitioners in South  
6 Warwickshire. *British Journal of Dermatology* 2009;161:109.  
7 Exclusion Reason: Not in PICO
- 8 Khorasgani MG, Simpson R, Burd RM. How effective is the skin cancer referral pathway? *British*  
9 *Journal of Dermatology* 2011;165:109.  
10 Exclusion Reason: Not in PICO
- 11 Kibarian MA, Hruza GJ. Nonmelanoma skin cancer. Risks, treatment options, and tips on prevention.  
12 *Postgraduate Medicine* 1945;98(6):39-40.  
13 Exclusion Reason: Narrative Review
- 14 Koch FP, Kunkel M, Biesterfeld S, Wagner W. Diagnostic efficiency of differentiating small cancerous  
15 and precancerous lesions using mucosal brush smears of the oral cavity--a prospective and  
16 blinded study. *Clinical Oral Investigations* 2011;15(5):763-9.  
17 Exclusion Reason: Not in PICO
- 18 Koerner KR. Evaluation and treatment by general dentists of oral soft-tissue lesions. *Dentistry Today*  
19 2006;25(7):90-5.  
20 Exclusion Reason: Narrative Review
- 21 Kolm I, Hofbauer G, Braun RP. [Early diagnosis of skin cancer]. [Review] [German]. *Therapeutische*  
22 *Umschau* 2010;67(9):439-46.  
23 Exclusion Reason: Narrative Review
- 24 Kok LP, Van Drunen R, Boon ME, Beck S, Van Coevorden RS. General practitioners use digital  
25 cameras and internet for telepathology of skin lesions. *Electronic Journal of Pathology and*  
26 *Histology* 2000;6(3):7-19.  
27 Exclusion Reason: Narrative Review
- 28 Kopf AW, Salopek TG, Slade J, Marghoob AA, Bart RS. Techniques of cutaneous examination for the  
29 detection of skin cancer. *Cancer* 1995;75(2:Suppl):Suppl-90.  
30 Exclusion Reason: Narrative Review
- 31 Krol S, Keijser LMT, Van Der Rhee HJ, Welvaart K. Screening for skin cancer in The Netherlands. *Acta*  
32 *Dermato-Venereologica* 1991;71(4):317-21.  
33 Exclusion Reason: Not in PICO
- 34 Kundu, R. V. & Patterson, S. (2013) Dermatologic conditions in skin of color: part I. Special  
35 considerations for common skin disorders.[Summary for patients in *Am Fam Physician*. 2013 Jun  
36 15;87(12):Online; PMID: 23939576]. *American Family Physician*, 87: 850-856.  
37 Exclusion Reason: Narrative review
- 38 Kunte C, Konz B. Current recommendations in the treatment of basal cell carcinoma and squamous  
39 cell carcinoma of the skin. *Hautarzt* 2007;58(5):419-26.  
40 Exclusion Reason: Narrative Review
- 41 Kusakawa J, Kameyama T, Nakamura Y. Evaluation of excisional biopsy for stage I and II squamous  
42 cell carcinoma of the oral cavity. *International Journal of Clinical Oncology* 1998;3(5):317-22.  
43 Exclusion Reason: Not in PICO
- 44 Lacava V, Salesi N, Ferrone L, Veri A, Lembo R, Masi MC, et al. [Importance of dermatologic screening  
45 within the frame work of a general cancer prevention program]. [Italian]. *Minerva Medica*  
46 2001;92(2):85-8.  
47 Exclusion Reason: Not in PICO
- 48 Lai, W.-Y. (1111) An elderly man with a painful scaly nodule. *Hong Kong Practitioner*, 35: September.  
49 Exclusion Reason: Not in PICO
- 50 Lathlean S. Skin cancer in general practice in South Australia. A five year study. *Australian Family*  
51 *Physician* 1999;28:Suppl-31.

- 1 Exclusion Reason: Not in PICO  
2 Laukkanen A, Rummukainen J, Kivinen P, Lappalainen K. [Skin squamous cell carcinoma and its  
3 precancerous conditions]. [Review] [25 refs] [Finnish]. *Duodecim* 2006;122(1):71-9.  
4 Exclusion Reason: Narrative Review  
5 Lee C, Kang KH, Koh Y, Chang J, Chung HS, Park SK, et al. Characteristics of lung cancer in Korea,  
6 1997. *Lung Cancer* 2000;30(1):15-22.  
7 Exclusion Reason: Not in PICO  
8 Liebman TN, Wang SQ. Detection of early basal cell carcinoma with dermoscopy in a patient with  
9 psoriasis. *Dermatology Online Journal* 2011;17(2):12.  
10 Exclusion Reason: N=1  
11 Lim D, Oakley AMM, Rademaker M. Better, sooner, more convenient: A successful teledermoscopy  
12 service. *Australasian Journal of Dermatology* 2012;53(1):22-5.  
13 Exclusion Reason: Narrative Review  
14 Lin, Y.-C., Perng, C.-L., Chang, Y.-M., Li, Y.-F., Tsai, Y.-M., Wu, G.-J. & Lin, C.-K. (2013) Coexistent  
15 squamous cell carcinoma and adenoid basal carcinoma in the uterine cervix and infection with  
16 human papillomavirus (HPV 31). *Taiwanese Journal of Obstetrics and Gynecology*, 52: 407-410.  
17 Exclusion Reason: Not in PICO  
18 Lober CW, Fenske NA. Basal cell, squamous cell, and sebaceous gland carcinomas of the periorbital  
19 region. [Review] [54 refs]. *Journal of the American Academy of Dermatology* 1991;25(4):685-90.  
20 Exclusion Reason: Narrative Review  
21 Lohmann CM, Solomon AR. Clinicopathologic variants of cutaneous squamous cell carcinoma.  
22 [Review] [82 refs]. *Advances in Anatomic Pathology* 2001;8(1):27-36.  
23 Exclusion Reason: Narrative Review  
24 Lopes LL, Alchorne ADD, Pereira GC, Lopes LRS, de Carvalho TC. Histological and  
25 immunohistochemical evaluation of basal cell carcinoma following curettage and  
26 electrodesiccation. *International Journal of Dermatology* 2008;47(6):610-4.  
27 Exclusion Reason: Not in PICO  
28 Luckey L. Seeding of head and neck cancer during placement of percutaneous gastrostomy tube.  
29 *American Journal of Gastroenterology* 2012;107:S279.  
30 Exclusion Reason: Not in PICO  
31 Lyngset E, Hunskar S. [Skin neoplasms in general practice]. [Norwegian]. *Tidsskrift for Den Norske*  
32 *Laegeforening* 2001;121(19):2281-3.  
33 Exclusion Reason: Not in PICO  
34 Maguire-Eisen M. Risk assessment and early detection of skin cancers. [Review] [69 refs]. *Seminars*  
35 *in Oncology Nursing* 2003;19(1):43-51.  
36 Exclusion Reason: Narrative Review  
37 Malberger E, Tillinger R, Lichtig C. Diagnosis of basal-cell carcinoma with aspiration cytology. *Acta*  
38 *Cytologica* 1984;28(3):301-4.  
39 Exclusion Reason: Narrative Review  
40 Malvey J, Puig S, Marti-Laborda RM. Dermoscopy of skin lesions in two patients with xeroderma  
41 pigmentosum. *British Journal of Dermatology* 2005;152(2):271-8.  
42 Exclusion Reason: Not in PICO  
43 Marchonda PJ, Krause LK, Jensen JD, Dellavalle RP. A North American perspective on dermoscopy:  
44 benefits, limitations, and grey zones. *Giornale Italiano di Dermatologia e Venereologia*  
45 2010;145(1):89-97.  
46 Exclusion Reason: Narrative Review  
47 Marghoob AA. Basal and squamous cell carcinomas: What every primary care physician should  
48 know. *Postgraduate Medicine* 1997;102(2):139-59.  
49 Exclusion Reason: Narrative Review

- 1 Marghoob, A. A., Usatine, R. P. & Jaimes, N. (2013) Dermoscopy for the family physician. [Review].  
2 *American Family Physician*, 88: 441-450.  
3 Exclusion Reason: Narrative review
- 4 Martinez JC, Otley CC. The management of melanoma and nonmelanoma skin cancer: A review for  
5 the primary care physician. *Mayo Clinic Proceedings* 2001;76(12):1253-65.  
6 Exclusion Reason: Narrative Review
- 7 Maybury, C. M., Craythorne, E. & Martin, B. (2013) An ulcerated nodule on the nose. *BMJ Case*  
8 *Reports*, 2013, 2013.  
9 Exclusion Reason: Not in PICO
- 10 McGuire JF, Ge NN, Dyson S. Nonmelanoma skin cancer of the head and neck I: histopathology and  
11 clinical behavior. *American Journal of Otolaryngology* 2009;30(2):121-33.  
12 Exclusion Reason: Narrative Review
- 13 McNulty-Brown E, Veysey E. An audit of all excisions undertaken by general practitioners in a rural  
14 community between March 2009 and March 2010. *British Journal of Dermatology* 2012;167:91-2.  
15 Exclusion Reason: Not in PICO
- 16 Medeiros F, Nascimento AF, Crum CP. Early vulvar squamous neoplasia: advances in classification,  
17 diagnosis, and differential diagnosis. [Review] [32 refs]. *Advances in Anatomic Pathology*  
18 2005;12(1):20-6.  
19 Exclusion Reason: Narrative Review
- 20 Mehrotra R, Gupta DK. Exciting new advances in oral cancer diagnosis: avenues to early detection.  
21 [Review]. *Head & neck oncology* 2011;3:33.  
22 Exclusion Reason: Narrative Review
- 23 Mencia Gutierrez E, Herrero Lluch MJ, Gutierrez Diaz E, Galvez Ruiz A. [Basal cell and squamous cell  
24 carcinomas of the eyelid in adults under 50 years of age: 13 cases]. [Spanish]. *Archivos de la*  
25 *Sociedad Espanola de Oftalmologia* 2001;76(11):643-8.  
26 Exclusion Reason: Not in PICO
- 27 Menzies SW, Emery J, Staples M, Davies S, McAvoy B, Fletcher J, et al. Impact of dermoscopy and  
28 short-term sequential digital dermoscopy imaging for the management of pigmented lesions in  
29 primary care: a sequential intervention trial. *British Journal of Dermatology* 2009;161(6):1270-7.  
30 Exclusion Reason: Not in PICO
- 31 Menzies SW. Using dermoscopy to diagnose pigmented skin lesions. *Medicine Today* 2004;5(4):63-  
32 71.  
33 Exclusion Reason: Narrative Review
- 34 Menzies, S. W., Moloney, F. J., Byth, K., Avramidis, M., Argenziano, G., Zalaudek, I., Braun, R. P.,  
35 Malvey, J., Puig, S., Rabinovitz, H. S., Oliviero, M., Cabo, H., Bono, R., Pizzichetta, M. A., Claeson,  
36 M., Gaffney, D. C., Soyer, H. P., Stanganelli, I., Scolyer, R. A., Guitera, P., Kelly, J., McCurdy, O.,  
37 Llambrich, A., Marghoob, A. A., Zaballos, P., Kirchesch, H. M., Piccolo, D., Bowling, J., Thomas, L.,  
38 Terstappen, K., Tanaka, M., Pellacani, G., Pagnanelli, G., Ghigliotti, G., Ortega, B. C., Crafter, G.,  
39 Ortiz, A. M., Tromme, I., Karaarslan, I. K., Ozdemir, F., Tam, A., Landi, C., Norton, P., Kacar, N.,  
40 Rudnicka, L., Slowinska, M., Simionescu, O., Di, S. A., Coates, E. & Kreusch, J. (2013) Dermoscopic  
41 evaluation of nodular melanoma. *JAMA Dermatology*, 149: 699-709.  
42 Exclusion Reason: Not in PICO
- 43 Milicic-Juhas V, Peric M, Pajtler M, Prvulovic I, Curzik D. Pap test--with or without vaginal smear?  
44 *Collegium Antropologicum* 2010;34(1):69-74.  
45 Exclusion Reason: Not in PICO
- 46 Miller SJ. II. Biopsy techniques for suspected nonmelanoma skin cancers. *Dermatologic Surgery*  
47 2000;26(1):91.  
48 Exclusion Reason: Narrative Review
- 49 Moffatt CR, Green AC, Whiteman DC. Diagnostic accuracy in skin cancer clinics: the Australian  
50 experience. *International Journal of Dermatology* 2006;45(6):656-60.

- 1 Exclusion Reason: Not in PICO: Clinical versus histological diagnosis (not biopsy or dermatoscopy  
2 versus histology or follow up)
- 3 Mojsa I, Kaczmarzyk T, Zaleska M, Stypulkowska J, Zapala-Pospiech A, Sadecki D. Value of the ViziLite  
4 Plus System as a diagnostic aid in the early detection of oral cancer/premalignant epithelial  
5 lesions. *Journal of Craniofacial Surgery* 2012;23(2):e162-4.
- 6 Exclusion Reason: Not in PICO
- 7 Monnier P, Savary M. Epidermoid cancer of the upper respiratory and digestive tracts. [French].  
8 *Schweizerische medizinische Wochenschrift* 1986;116(51):1817-23.
- 9 Exclusion Reason: Narrative Review
- 10 Moreno G, Tran H, Chia ALK, Lim A, Shumack S. Prospective study to assess general practitioners'  
11 dermatological diagnostic skills in a referral setting. *Australasian Journal of Dermatology*  
12 2007;48(2):77-82.
- 13 Exclusion Reason: Not in PICO
- 14 Morrison A, O'Loughlin S, Powell FC. Suspected skin malignancy: a comparison of diagnoses of family  
15 practitioners and dermatologists in 493 patients. *International Journal of Dermatology*  
16 2001;40(2):104-7.
- 17 Exclusion Reason: Not in PICO
- 18 Morteza, A. S., Salama, S. & Alowami, S. (2013) Lymphoepithelioma-like carcinoma of the skin: case  
19 report and approach to surgical pathology sign out. *Rare Tumors*, 5: e47.
- 20 Exclusion Reason: Not in PICO
- 21 Morton CA, Downie F, Auld S, Smith B, Pol M, Baughan P, et al. Community photo-triage for skin  
22 cancer referrals: an aid to service delivery (Structured abstract). *Clinical and*  
23 *Experimental Dermatology* 2011;36:248-54.
- 24 Exclusion Reason: Not in PICO
- 25 Motley RJ, Gould DJ, Douglas WS, Simpson NB. Treatment of basal cell carcinoma by dermatologists  
26 in the United Kingdom. British Association of Dermatologists Audit Subcommittee and the British  
27 Society for Dermatological Surgery. *British Journal of Dermatology* 1995;132(3):437-40.
- 28 Exclusion Reason: Not in PICO
- 29 Muldoon TJ, Burgess SA, Chen BR, Ratner D, Hillman EMC. Analysis of skin lesions using laminar  
30 optical tomography. *Biomedical Optics Express* 2012;3(7):1701-12.
- 31 Exclusion Reason: Narrative Review
- 32 Mullen JT, Feng L, Xing Y, Mansfield PF, Gershenwald JE, Lee JE, et al. Invasive squamous cell  
33 carcinoma of the skin: Defining a high-risk group. *Annals of Surgical Oncology* 2006;13(7):902-9.
- 34 Exclusion Reason: Not in PICO
- 35 Murchie P, Delaney EK, Thompson WD, Lee AJ. Excising basal cell carcinomas: comparing the  
36 performance of general practitioners, hospital skin specialists and other hospital specialists.  
37 *Clinical & Experimental Dermatology* 2008;33(5):565-71.
- 38 Exclusion Reason: Not in PICO
- 39 Musiatowicz B, Dzieciol J, Sulkowska M, Polakow J, Baltaziak M. Fine needle aspiration biopsy  
40 cytology of pulmonary tumors. *Roczniki Akademii Medycznej W Bialymstoku* 1997;42:Suppl-13.
- 41 Exclusion Reason: Not in PICO
- 42 Myers M, Gurwood AS. Periocular malignancies and primary eye care. [Review] [22 refs]. *Optometry*  
43 (St.Louis, Mo.) 2001;72(11):705-12.
- 44 Exclusion Reason: Narrative Review
- 45 Nagami Y, Machida H, Tominaga K, Nakatani M, Kameda N, Sugimori S, et al. Accurate detection and  
46 diagnosis of esophageal squamous cancer by tandem conventional endoscopy with narrow-band  
47 imaging and iodine staining: A prospective study. *Gastrointestinal Endoscopy* 2010;71(5):AB252-  
48 3.
- 49 Exclusion Reason: Not in PICO
- 50 Navone R, Pentenero M, Gandolfo S. Liquid-based cytology in oral cavity squamous cell cancer.  
51 [Review]. *Current Opinion in Otolaryngology & Head & Neck Surgery* 2011;19(2):77-81.

- 1 Exclusion Reason: Narrative Review  
2 Nguyen TH, Ho DQ. Nonmelanoma skin cancer. Current treatment options in oncology  
3 2002;3(3):193-203.  
4 Exclusion Reason: Narrative Review  
5 Niederkorn A, Gabler G, Argenziano G, Muir J, Zalaudek I, Soyer HP, et al. The user-generated web-  
6 based dermoscopy image archive of the international dermoscopy society: A contribution to E-  
7 learning and exchange of knowledge. *Dermatology* 2011;222(2):131-7.  
8 Exclusion Reason: Not in PICO  
9 Ogden E, Schofield J. Two-week wait skin cancer referral outcomes: Differences in management  
10 between plastic surgery and dermatology. *British Journal of Dermatology* 2010;163:60-1.  
11 Exclusion Reason: Not in PICO  
12 Paderni C, Compilato D, Lo Muzio L, Campisi G. Direct visualization of oral-cavity tissue fluorescence  
13 and toluidine blue staining: New adjunctive aids for oral medicine practitioners in early oral  
14 cancer diagnosis and potentially malignant disorders follow-up? *Oral Diseases* 2010;16(6):535-6.  
15 Exclusion Reason: Not in PICO  
16 Palamaras I, Hamill M, Sethi G, Wilkinson D, Lamba H. The usefulness of a diagnostic biopsy clinic in a  
17 genitourinary medicine setting: recent experience and a review of the literature. *Journal of the*  
18 *European Academy of Dermatology and Venereology* 2006;20(8):905-10.  
19 Exclusion Reason: Not in PICO  
20 Palanivel JA, Macbeth AE, Dootson G, Graham R, Mahmood K, Garioch J. An audit of incomplete  
21 excision rates of basal cell carcinoma from four U.K. teaching hospitals. *British Journal of*  
22 *Dermatology* 2011;165:106.  
23 Exclusion Reason: Not in PICO  
24 Palka KT, Slebos RJ, Chung CH. Update on molecular diagnostic tests in head and neck cancer.  
25 [Review] [100 refs]. *Seminars in Oncology* 2008;35(3):198-210.  
26 Exclusion Reason: Narrative Review  
27 Pallagatti, S., Sheikh, S., Aggarwal, A., Gupta, D., Singh, R., Handa, R., Kaur, S. & Mago, J. (2013)  
28 Toluidine blue staining as an adjunctive tool for early diagnosis of dysplastic changes in the oral  
29 mucosa. *Journal of Clinical & Experimental Dentistry*, 5: e187-e191.  
30 Exclusion Reason: Not in PICO  
31 Palmer, V. M. & Wilson, P. R. (2013) Incompletely excised basal cell carcinoma: residual tumor rates  
32 at Mohs re-excision. *Dermatologic Surgery*, 39: 706-718.  
33 Exclusion Reason: Not in PICO  
34 Pariser DM, Phillips PK. Basal cell carcinoma: When to treat it yourself, and when to refer. *Geriatrics*  
35 1994;49(3):39-42+44.  
36 Exclusion Reason: Narrative Review  
37 Parkinson RW. Shave biopsies--simple and useful. *Postgraduate Medicine* 166;84(8):161-70.  
38 Exclusion Reason: Narrative Review  
39 Pech O, Rabenstein T, Manner H, Petrone MC, Pohl J, Vieth M, et al. Confocal laser endomicroscopy  
40 for in vivo diagnosis of early squamous cell carcinoma in the esophagus. *Clinical Gastroenterology*  
41 *& Hepatology* 2008;6(1):89-94.  
42 Exclusion Reason: Not in PICO  
43 Pereira RD, Martin AA, Tierra-Criollo CJ, Santos IDAO. Diagnosis of squamous cell carcinoma of  
44 human skin by Raman spectroscopy. *Optical Biopsy V* 2004;5326:106-12.  
45 Exclusion Reason: Not in PICO  
46 Phillips, C., Newsome, A., Jennifer, D., Lindsey, F., Green, H. & McLean, T. (2014) Anatomy of a skin  
47 biopsy: A retrospective analysis of outpatient biopsy results from 2000 to 2010. *Journal of the*  
48 *American Academy of Dermatology*, 70: AB36.  
49 Exclusion Reason: Not in PICO

- 1 Piccolo D, Smolle J, Argenziano G, Wolf IH, Braun R, Cerroni L, et al. Teledermoscopy--results of a  
2 multicentre study on 43 pigmented skin lesions. *Journal of Telemedicine & Telecare*  
3 2000;6(3):132-7.  
4 Exclusion Reason: Not in PICO
- 5 Pignatelli I, Poirier V, De Berker DAR, Verne J. Audit of completeness of cancer registration for basal  
6 cell carcinoma and its impact on use for quality assurance. *British Journal of Dermatology*  
7 2010;163:58.  
8 Exclusion Reason: Not in PICO
- 9 Pignatelli I, Poirier V, De Berker DAR, Verne J. Completeness of basal cell carcinoma excisions in an  
10 english region. *British Journal of Dermatology* 2010;163:69-70.  
11 Exclusion Reason: Not in PICO
- 12 Poirier V, Osinowo A, Takwale A, De Berker DAR, Verne J. Basal cell carcinoma follow-up in the South  
13 West, Hampshire and Isle of Wight. *British Journal of Dermatology* 2012;167:61.  
14 Exclusion Reason: Not in PICO
- 15 Pop Stefanija N, Blanken R, Vodegel RM. The positive predictive value of clinical diagnosis of basal  
16 cell carcinoma. [Dutch]. *Nederlands Tijdschrift voor Dermatologie en Venereologie*  
17 2006;16(6):237-40.  
18 Exclusion Reason: Not in PICO
- 19 Popadic, M. (2014) Statistical evaluation of dermoscopic features in basal cell carcinomas.  
20 *Dermatologic Surgery*, 40: 718-724.  
21 Exclusion Reason: Not in PICO
- 22 Poulsen AG, Larsen FG, Weismann K, Petersen CS, Ravnborg LR, Heidenheim M, et al. [Investigation  
23 of malignant melanoma in an "open house" setting]. [Danish]. *Ugeskrift for Laeger*  
24 1999;161(12):1758-61.  
25 Exclusion Reason: Not in PICO
- 26 Prout MN, Sidari JN, Witzburg RA, Grillone GA, Vaughan CW. Head and neck cancer screening among  
27 4611 tobacco users older than forty years. *Otolaryngology - Head & Neck Surgery*  
28 1997;116(2):201-8.  
29 Exclusion Reason: Not in PICO
- 30 Quereux G, Lequeux Y, Cary M, Jumbou O, Nguyen JM, Dreno B. Feasibility and effectiveness of a  
31 melanoma targeted screening strategy. *Melanoma Research* 2011;21:e1-2.  
32 Exclusion Reason: Not in PICO
- 33 Raasch B, Maclennan R, Wronski I, Robertson I. Body site specific incidence of basal and squamous  
34 cell carcinoma in an exposed population, Townsville, Australia. *Mutation Research*  
35 1998;422(1):101-6.  
36 Exclusion Reason: Not in PICO
- 37 Raasch BA. Suspicious skin lesions and their management. *Australian Family Physician*  
38 1999;28(5):466-71.  
39 Exclusion Reason: Not in PICO: Clinical versus histological diagnosis (not biopsy or dermatoscopy  
40 versus histology or follow up)
- 41 Rademaker M, Thorburn M. Pathology referrals for skin lesions - Are we giving the pathologist  
42 sufficient clinical information? *New Zealand Medical Journal* 2010;123(1325):53-8.  
43 Exclusion Reason: Not in PICO
- 44 Radziszewski J, Kowalewska M, Jedrzejczak T, Kozlowicz-Gudzinska I, Nasierowska-Guttmejer A,  
45 Bidzinski M, et al. The accuracy of the sentinel lymph node concept in early stage squamous cell  
46 vulvar carcinoma. *Gynecologic Oncology* 2010;116(3):473-7.  
47 Exclusion Reason: Not in PICO
- 48 Rahman F, Tippu SR, Khandelwal S, Girish KL, Manjunath BC, Bhargava A. A study to evaluate the  
49 efficacy of toluidine blue and cytology in detecting oral cancer and dysplastic lesions.  
50 *Quintessence International* 2012;43(1):51-9.  
51 Exclusion Reason: Not in PICO

- 1 Raj, G. & Gupta, G. (1111) The need for full body skin examination on patients referred to  
2 dermatology with a lesion. *British Journal of Dermatology. Conference: 93rd Annual Meeting of*  
3 *the British Association of Dermatologists Liverpool United Kingdom. Conference Start: 20130709*  
4 *Conference End: 20130711. Conference Publication: (var.pagings), 169: July.*  
5 Exclusion Reason: Not in PICO
- 6 Rajaram N, Tunnell J, Reichenberg J. Pilot clinical study for noninvasive diagnosis of nonmelanoma  
7 skin cancer. *Journal of the American Academy of Dermatology* 2011;64(2 SUPPL. 1):AB76.  
8 Exclusion Reason: Not in PICO
- 9 Reed SF, Britt RC, Novosel TJ, Collins JN, Weireter LJ, Britt LD. Screening human immunodeficiency  
10 virus-positive men for anal intraepithelial neoplasia. *American Surgeon* 2012;78(8):901-3.  
11 Exclusion Reason: Not in PICO
- 12 Reynolds PL, Strayer SM. Treatment of skin malignancies. [Review] [33 refs]. *Journal of Family*  
13 *Practice* 2003;52(6):456-64.  
14 Exclusion Reason: Narrative Review
- 15 Rezze GG, De Sa BCS, Neves RI. Dermoscopy: The pattern analysis. *Anais Brasileiros de Dermatologia*  
16 2006;81(3):261-8.  
17 Exclusion Reason: Narrative Review
- 18 Rice SA, Swale VJ, Cerio R. Are we relying too heavily on dermoscopy? *British Journal of Dermatology*  
19 2012;167:105.  
20 Exclusion Reason: Narrative review
- 21 Richert, B., Lecerf, P., Caucanas, M. & Andre, J. (2013) Nail tumors. *Clinics in Dermatology*, 31: 602-  
22 617.  
23 Exclusion Reason: Narrative review
- 24 Robison Sean, Kljakovic Marjan, Barry Peter. Choosing to biopsy or refer suspicious melanocytic  
25 lesions in general practice. *BMC Family Practice* 2012;13(1):78.  
26 Exclusion Reason: Not in PICO
- 27 Roozeboom, M. H., Mosterd, K., Winnepenninckx, V. J., Nelemans, P. J. & Kelleners-Smeets, N. W.  
28 (2013) Agreement between histological subtype on punch biopsy and surgical excision in primary  
29 basal cell carcinoma. *Journal of the European Academy of Dermatology & Venereology*, 27: 894-  
30 898.  
31 Exclusion Reason: Not in PICO
- 32 Rose LC. Recognizing neoplastic skin lesions: a photo guide. [Review] [18 refs]. *American Family*  
33 *Physician* 887;58(4):873-84.  
34 Exclusion Reason: Narrative Review
- 35 Rosen R. Managing nonmelanoma skin cancer. *Modern Medicine of Australia* 1999;42(2):74-85.  
36 Exclusion Reason: Narrative Review
- 37 Rosendahl C, Cameron A, Argenziano G, Zalaudek I, Tschandl P, Kittler H. Dermoscopy of Squamous  
38 Cell Carcinoma and Keratoacanthoma. *Archives of Dermatology* 2012;148(12):1386-92.  
39 Exclusion Reason: Not in PICO
- 40 Rosendahl C, Hansen C, Cameron A, Bourne P, Wilson T, Cook B, et al. Measuring performance in  
41 skin cancer practice: the SCARD initiative. *International Journal of Dermatology* 2011;50(1):44-51.  
42 Exclusion Reason: Not in PICO
- 43 Rosendahl C, Tschandl P, Cameron A, Kittler H. Diagnostic accuracy of dermoscopy for melanocytic  
44 and nonmelanocytic pigmented lesions. *Journal of the American Academy of Dermatology*  
45 2011;64(6):1068-73.  
46 Exclusion Reason: Duplicate
- 47 Rousset, J., Abgral, R., Chinellato, S., Garetier, M., Barberot, C., Valette, G., Potard, G., Le, B. T. &  
48 Salaun, P. Y. (2013) Early recurrence or submucosal residual of laryngeal squamous cell  
49 carcinoma: diagnosis by CT-guided endolaryngeal core biopsy on a transcutaneous approach.  
50 *Head & Neck*, 35: E202-E204.  
51 Exclusion Reason: Not in PICO



- 1 Rudkin AK, Dodd T, Muecke JS. The differential diagnosis of localised amelanotic limbal lesions: a  
2 review of 162 consecutive excisions. *British Journal of Ophthalmology* 2011;95(3):350-4.  
3 Exclusion Reason: Not in PICO
- 4 Russell EB, Carrington PR, Smoller BR. Basal cell carcinoma: a comparison of shave biopsy versus  
5 punch biopsy techniques in subtype diagnosis. *Journal of the American Academy of Dermatology*  
6 1999;41(1):69-71.  
7 Exclusion Reason: Not in PICO
- 8 Ryu IS, Choi SH, Kim do H, Han MW, Roh JL, Kim SY, et al. Detection of the primary lesion in patients  
9 with cervical metastases from unknown primary tumors with narrow band imaging endoscopy:  
10 preliminary report. *Head & Neck* 2013;35(1):10-4.  
11 Exclusion Reason: Not in PICO
- 12 Sabir F, Aziz M, Afroz N, Amin SS. Clinical and cyto-histopathological evaluation of skin lesions with  
13 special reference to bullous lesions. *Indian Journal of Pathology and Microbiology* 2010;53(1):41-  
14 6.  
15 Exclusion Reason: Narrative Review
- 16 Saldanha G, Fletcher A, Slater DN. Basal cell carcinoma: a dermatopathological and molecular  
17 biological update. *British Journal of Dermatology* 2003;148(2):195-202.  
18 Exclusion Reason: Narrative Review
- 19 Sandison A. Common head and neck cases in our consultation referrals: diagnostic dilemmas in  
20 inverted papilloma. [Review] [13 refs]. *Head and neck pathology* 2009;3(3):260-2  
21 Exclusion Reason: Narrative Review
- 22 Santi EG, Inoue H, Sato H, Maselli R, Ikeda H, Yoshida A, et al. Endoscopic treatment for esophageal  
23 achalasia with early squamous cell carcinoma: POEM plus ESD. *Journal of Gastroenterology and*  
24 *Hepatology* 2012;27:317-8.  
25 Exclusion Reason: Not in PICO
- 26 Sanyal, S., Holme, A. & Kemmett, D. (2013) How are patients with actinic keratoses managed in  
27 primary care? *British Journal of Dermatology*, 169: 45.  
28 Exclusion Reason: Not in PICO
- 29 Schlemper RJ, Dawsey SM, Itabashi M, Iwashita A, Kato Y, Koike M, et al. Differences in diagnostic  
30 criteria for esophageal squamous cell carcinoma between Japanese and Western pathologists.  
31 *Cancer* 2000;88(5):996-1006.  
32 Exclusion Reason: Not in PICO
- 33 Schofield J, Hepburn N, Scharrer K, Hussain K. The costs of diagnosing and treating skin cancer using  
34 the 2-week-wait referral process. *British Journal of Dermatology* 2011;165:22-3.  
35 Exclusion Reason: Not in PICO
- 36 Schroeder BM, American Cancer Society. ACS updates guideline for the early detection of cervical  
37 neoplasia and cancer. American Cancer Society. *American Family Physician* 2003;67(9):2011-6.  
38 Exclusion Reason: Not in PICO
- 39 Schwartzberg JB, Elgart GW, Romanelli P, Fangchao M, Federman DG, Kirsner RS. Accuracy and  
40 predictors of basal cell carcinoma diagnosis. *Dermatologic Surgery* 2005;31(5):534-7.  
41 Exclusion Reason: Not in PICO
- 42 Scully C, Newman L, Bagan JV. The role of the dental team in preventing and diagnosing cancer: 3.  
43 oral cancer diagnosis and screening. *Dental Update* 331;32(6):326-8.  
44 Exclusion Reason: Not in PICO
- 45 Sendagorta E, Herranz P, Guadalajara H, Zamora FX. [Early detection of anal intraepithelial neoplasia  
46 in high-risk patients]. [Review] [Spanish]. *Actas Dermo-Sifiliograficas* 2011;102(10):757-65.  
47 Exclusion Reason: Narrative Review
- 48 Senel E. Dermatoscopy of non-melanocytic skin tumors. *Indian Journal of Dermatology Venereology*  
49 *& Leprology* 2011;77(1):16-21.  
50 Exclusion Reason: Narrative Review

- 1 Shariff Z, Roshan A, Williams AM, Platt AJ. 2-Week wait referrals in suspected skin cancer: does an  
2 instructional module for general practitioners improve diagnostic accuracy? *Surgeon Journal of*  
3 *the Royal Colleges of Surgeons of Edinburgh & Ireland* 2010;8(5):247-51.  
4 Exclusion Reason: Not in PICO
- 5 Sharma, A., Alfa-Wali, M., Rodriguez-Justo, M. & Polychronis, A. (2013) Squamous cell carcinoma of  
6 pancreas: an unusual site of relapse from early-stage lung cancer: 12-month postsurgery. *BMJ*  
7 *Case Reports*, 2013, 2013.  
8 Exclusion Reason: Not in PICO
- 9 Shimizu Y, Omori T, Yokoyama A, Yoshida T, Hirota J, Ono Y, et al. Endoscopic diagnosis of early  
10 squamous neoplasia of the esophagus with iodine staining: high-grade intra-epithelial neoplasia  
11 turns pink within a few minutes. *Journal of Gastroenterology & Hepatology* 2008;23(4):546-50.  
12 Exclusion Reason: Not in PICO
- 13 Shitara, D., Ishioka, P., Alonso-Pinedo, Y., Palacios-Bejarano, L., Carrera, C., Malveyh, J. & Puig, S.  
14 (2014) Shiny White Streaks: A Sign of Malignancy at Dermoscopy of Pigmented Skin Lesions. *Acta*  
15 *Dermato-Venereologica*, 94: 132-137.  
16 Exclusion Reason: Setting not in PICO
- 17 Shum WY, Hsieh TC, Yeh JJ, Chen JH, Su CC, Liang JA, et al. Clinical usefulness of dual-time FDG PET-  
18 CT in assessment of esophageal squamous cell carcinoma. *European Journal of Radiology*  
19 2012;81(5):1024-8.  
20 Exclusion Reason: Not in PICO
- 21 Singh, T. & Schenberg, M. (2013) Delayed diagnosis of oral squamous cell carcinoma following dental  
22 treatment. *Annals of the Royal College of Surgeons of England*, 95: 369-373.  
23 Exclusion Reason: Not in PICO
- 24 Skiljevic D, Stojkovic-Filipovic J, Nikolic M, Medenica L. Early-onset basal cell carcinoma. *Melanoma*  
25 *Research* 2010;20:e68.  
26 Exclusion Reason: N=1
- 27 Smithers BM, Fahey PP, Corish T, Gotley DC, Falk GL, Smith GS, et al. Symptoms, investigations and  
28 management of patients with cancer of the oesophagus and gastro-oesophageal junction in  
29 Australia. *Medical Journal of Australia* 2010;193(10):572-7.  
30 Exclusion Reason: Not in PICO
- 31 Sober AJ. Diagnosis and management of skin cancer. *Cancer* 1983;51(12:Suppl):Suppl-52.  
32 Exclusion Reason: Not in PICO
- 33 Socha, A. & Niedzielska, I. (2013) Exophytic tumours of skin of the head - Case study and review of  
34 the literature. *Dental and Medical Problems*, 50: 229-237.  
35 Exclusion Reason: Not in PICO
- 36 Speel E-J, Leusink FKJ, Van Hooff SR, Kummer JA, van Diest PJ, Koole R, et al. Multi-center validation  
37 of a lymph node metastasis gene-expression signature for head and neck squamous cell  
38 carcinomas. *Cancer Research* 2011;71(8 SUPPL. 1).  
39 Exclusion Reason: Not in PICO
- 40 Spencer JM, Tannenbaum A, Sloan L, Amonette RA. Does inflammation contribute to the eradication  
41 of basal cell carcinoma following curettage and electrodesiccation? *Dermatologic Surgery*  
42 1997;23(8):625-30.  
43 Exclusion Reason: Not in PICO
- 44 Spencer RJ, Young RH, Goodman A. The risk of squamous cell carcinoma in persistent vulvar ulcers.  
45 *Menopause* 2011;18(10):1067-71.  
46 Exclusion Reason: Not in PICO
- 47 Stegman SJ. Basal cell carcinoma and squamous cell carcinoma. Recognition and treatment. [Review]  
48 [28 refs]. *Medical Clinics of North America* 1986;70(1):95-107.  
49 Exclusion Reason: Narrative Review
- 50 Stell PM, Wood GD, Scott MH. Early oral cancer: treatment by biopsy excision. *British Journal of Oral*  
51 *Surgery* 1982;20(4):234-8.

- 1 Exclusion Reason: Not in PICO  
2 Stockfleth E. Non melanoma skin cancer - Early excision is still the standard in therapy. [German].  
3 *Klinikaerzt* 2002;31(5):122-5.  
4 Exclusion Reason: Narrative Review  
5 Stoeckli SJ, Broglie MA. Sentinel node biopsy for early oral carcinoma. *Current Opinion in*  
6 *Otolaryngology & Head and Neck Surgery* 2012;20(2):103-8.  
7 Exclusion Reason: Narrative Review  
8 Stolte M. [The new "Vienna Classification" for epithelial neoplasia of the gastrointestinal tract. Pros  
9 or cons?]. [Review] [34 refs] [German]. *Pathologie* 2001;22(1):4-12.  
10 Exclusion Reason: Narrative Review  
11 Streeton CL, Gospodarevskaya E, Harris A. Treatment of basal cell carcinomas by general  
12 practitioners in Australia. *International Journal of Dermatology* 2006;45(4):345-51.  
13 Exclusion Reason: Not in PICO  
14 Stulberg DL, Crandell B, Fawcett RS. Diagnosis and treatment of basal cell and squamous cell  
15 carcinomas. *American Family Physician* 2004;70(8):1481-8.  
16 Exclusion Reason: Narrative Review  
17 Szalai K, Hatvani Z, Harsing J, Somlai B, Karpati S. High frequency ultrasonography in the diagnosis of  
18 cutaneous pigmented lesions and melanoma reduce the possibilities of diagnostic pitfalls.  
19 *Melanoma Research* 2011;21:e4-5.  
20 Exclusion Reason: Narrative Review  
21 Talbot S, Hitchcock B. Incomplete primary excision of cutaneous basal and squamous cell carcinomas  
22 in the Bay of Plenty. *New Zealand Medical Journal* 2004;117(1192):U848.  
23 Exclusion Reason: Not in PICO  
24 Tan E, Yung A, Jameson M, Oakley A, Rademaker M. Successful triage of patients referred to a skin  
25 lesion clinic using teledermoscopy (IMAGE IT trial). *British Journal of Dermatology*  
26 2010;162(4):803-11.  
27 Exclusion Reason: Not in PICO  
28 Tandon Y, Brodell RT. Local reactions to imiquimod in the treatment of basal cell carcinoma.  
29 *Dermatology Online Journal* 2012;18(9):1.  
30 Exclusion Reason: Not in PICO  
31 Tangjaturonrasme, N., Rerknimitr, R., Pittayanon, R., Wisedopas, N. & Kullavanijaya, P. (2013) The  
32 difference in detection rates during surveillance endoscopy for early squamous cell neoplasia of  
33 the esophagus between patients with previous nasopharyngeal cancer and patients with other  
34 ent related squamous cell cancers pornphan thienchanachaiya1. *Gastrointestinal Endoscopy*, 77:  
35 AB339-AB340.  
36 Exclusion Reason: Not in PICO  
37 Tannapfel A, Weber A. Tumor markers in squamous cell carcinoma of the head and neck: clinical  
38 effectiveness and prognostic value. *European Archives of Oto-Rhino-Laryngology* 2001;258(2):83-  
39 8.  
40 Exclusion Reason: Narrative Review  
41 Teoh YL, Halpern SM, Shall L. Factors associated with incomplete excision of basal cell carcinomas.  
42 *British Journal of Dermatology* 2010;163:55-6.  
43 Exclusion Reason: Not in PICO  
44 TerKonda SP, Perdakis G. Non-melanotic skin tumors of the upper extremity. [Review] [50 refs]. *Hand*  
45 *Clinics* 104;20(3):293-301.  
46 Exclusion Reason: Narrative Review  
47 Terrill PJ, Fairbanks S, Bailey M. Is there just one lesion? The need for whole body skin examination  
48 in patients presenting with non-melanocytic skin cancer. *ANZ Journal of Surgery* 2009;79(10):707-  
49 12.  
50 Exclusion Reason: Not in PICO

- 1 Terstappen K, Larko O, Wennberg AM. Pigmented basal cell carcinoma - Comparing the diagnostic  
2 methods of SIAscopy and dermoscopy. *Acta Dermato-Venereologica* 2007;87(3):238-42.  
3 Exclusion Reason: Narrative Review
- 4 Terushkin V, Braga JC, Dusza SW, Scope A, Busam K, Marghoob AA, et al. Agreement on the Clinical  
5 Diagnosis and Management of Cutaneous Squamous Neoplasms. *Dermatologic Surgery*  
6 2010;36(10):1514-20.  
7 Exclusion Reason: Not in PICO
- 8 Thienchanachaiya P, Rerknimitr R, Pittayanon R, Wisedopas N, Tangjaturonrasme N, Kullavanijaya P.  
9 Preliminary study of FICE for detection of early esophageal neoplasm in patients with history of  
10 ENT related squamous cell cancers. *Journal of Gastroenterology and Hepatology* 2012;27:319-20.  
11 Exclusion Reason: Not in PICO
- 12 Thissen MR, Neumann HA, Berretty PJ, Ideler AH. [The treatment of basal cell carcinoma patients by  
13 dermatologists in Netherland]. [Dutch]. *Nederlands Tijdschrift Voor Geneeskunde*  
14 1998;142(27):1563-7.  
15 Exclusion Reason: Not in PICO
- 16 Tochigi, T., Shuto, K., Staito, H., Kono, T. & Matsubara, H. (2013) Early esophageal squamous cell  
17 cancer by high-barium esophagography using flat panel X-ray detector in comparison with  
18 histological findings. *European Journal of Cancer*, 49: S252-S253.  
19 Exclusion Reason: Not in PICO
- 20 Tomas S. Difficult to diagnose skin cancer The 'aggressive' BCC. *Australian Family Physician*  
21 2009;38(7):492-7.  
22 Exclusion Reason: Narrative Review
- 23 Trotter MJ, Bruecks AK. Interpretation of Skin Biopsies by General Pathologists: Diagnostic  
24 Discrepancy Rate Measured by Blinded Review. *Archives of Pathology and Laboratory Medicine*  
25 2003;127(11):1489-92.  
26 Exclusion Reason: Not in PICO
- 27 Turan, E., Yurt, N., Yesilova, Y. & Turkcu, G. (2013) Early-onset basal cell carcinoma. *Turkish Journal*  
28 *of Pediatrics*, 55: 354-356.  
29 Exclusion Reason: Not in PICO
- 30 Ulrich M, Lange-Asschenfeldt S, Gonzalez S. In vivo reflectance confocal microscopy for early  
31 diagnosis of nonmelanoma skin cancer. *Actas Dermo-Sifiliograficas* 2012;103(9):784-9.  
32 Exclusion Reason: Narrative Review
- 33 Vacher-Lavenu MC. [Histology and cytology of cervical cancers]. [Review] [24 refs] [French]. *Revue*  
34 *du Praticien* 2001;51(13):1417-23.  
35 Exclusion Reason: Narrative Review
- 36 Vargo N. Basal cell and squamous cell carcinoma. [Review] [46 refs]. *Seminars in Oncology Nursing*  
37 2003;19(1):12-21.  
38 Exclusion Reason: Narrative Review
- 39 Vermaak, P. V. & Manushakian, J. (2013) Rapidly enlarging skin lesion on the lip. *BMJ Case Reports*,  
40 2013, 2013.  
41 Exclusion Reason: Not in PICO
- 42 Viglizzo G, Rongioletti F. Clinical, dermoscopic and pathologic correlation of pigmentary lesions  
43 observed in a dermoscopy service in the year 2003. [Italian, English]. *Giornale Italiano di*  
44 *Dermatologia e Venereologia* 2004;139(4):339-44.  
45 Exclusion Reason: Not in PICO
- 46 Viola KV, Tolpinrud WL, Gross CP, Kirsner RS, Imaeda S, Federman DG. Outcomes of referral to  
47 dermatology for suspicious lesions: implications for teledermatology. *Archives of Dermatology*  
48 2011;147(5):556-60.  
49 Exclusion Reason: Not in PICO

- 1 Wade S, Gonzalez ML, Basra M. An audit of the diagnostic accuracy and complete excision rate for  
2 skin cancers in primary and secondary care in the Cardiff area. *British Journal of Dermatology*  
3 2011;165:105.  
4 Exclusion Reason: Not in PICO
- 5 Wagoner J, Keehn C, Morgan MB. CD-10 immunostaining differentiates superficial basal cell  
6 carcinoma from cutaneous squamous cell carcinoma. *American Journal of Dermatopathology*  
7 2007;29(6):555-8.  
8 Exclusion Reason: Narrative Review
- 9 Wan A, Savage NW. Biopsy and diagnostic histopathology in dental practice in Brisbane: usage  
10 patterns and perceptions of usefulness. *Australian Dental Journal* 2010;55(2):162-9.  
11 Exclusion Reason: Not in PICO
- 12 Watson Tony, Walter Fiona, Wood Annabel, Morris Helen, Hall Per, Karner Simone, et al. Learning a  
13 novel technique to identify possible melanomas: are Australian general practitioners better than  
14 their U.K. colleagues? *Asia Pacific Family Medicine* 2009;8(1):3.  
15 Exclusion Reason: Narrative Review
- 16 Wetzig T, Woitek M, Eichhorn K, Simon JC, Paasch U. Surgical Excision of Basal Cell Carcinoma with  
17 Complete Margin Control: Outcome at 5-Year Follow-Up. *Dermatology* 2010;220(4):363-9.  
18 Exclusion Reason: Not in PICO
- 19 White, G. M., Zhou, H. C. & Burchette, R. J. (2013) Biopsy followed by immediate curettage and  
20 electrodesiccation of suspected basal cell carcinomas at the first visit. *JAMA Dermatology*, 149:  
21 980-981.  
22 Exclusion Reason: Not in PICO
- 23 Whitesides LM, Ferreira LR, Ord RA. Audit of clinical information and diagnoses supplied to the  
24 pathologist following biopsy of oral squamous cell carcinomas. *MSDA Journal* 1995;38(2):63-5.  
25 Exclusion Reason: Narrative Review
- 26 Wilkinson D, Askew DA, Dixon A. Skin cancer clinics in Australia: workload profile and performance  
27 indicators from an analysis of billing data. *Medical Journal of Australia* 2006;184(4):162-4.  
28 Exclusion Reason: Not in PICO
- 29 Williams RB, Burdge AH, Lewis Jones S. Skin biopsy in general practice. *British Medical Journal*  
30 1991;303(6811):1179-80.  
31 Exclusion Reason: Not in PICO
- 32 Wilson RL, Yentzer BA, Isom SP, Feldman SR, Fleischer AB Jr. How good are US dermatologists at  
33 discriminating skin cancers? A number-needed-to-treat analysis. *Journal of Dermatological*  
34 *Treatment* 2012;23(1):65-9.  
35 Exclusion Reason: Not in PICO
- 36 Winzenburg SM, Niehans GA, George E, Daly K, Adams GL. Basaloid squamous carcinoma: a clinical  
37 comparison of two histologic types with poorly differentiated squamous cell carcinoma.  
38 *Otolaryngology - Head & Neck Surgery* 1998;119(5):471-5.  
39 Exclusion Reason: Not in PICO
- 40 Wlodarczyk J. [Application of Lugol solution in the gastroesophageal reflux disease]. [Polish].  
41 *Przegląd Lekarski* 2007;64(9):549-51 Won S-S, Jung D-S, Kim H-S, Kwon K-S, Hee S-S.  
42 Clinicopathologic features of postlaser basal cell carcinoma: Does it differ from primary basal cell  
43 carcinoma? *Journal of the American Academy of Dermatology* 2010;62(3 SUPPL. 1):AB146.  
44 Exclusion Reason: Not in PICO
- 45 Wolberink, E. A. W., Pasch, M. C., Zeiler, M., Van Erp, P. E. J. & Gerritsen, M. J. P. (2013) High  
46 discordance between punch biopsy and excision in establishing basal cell carcinoma subtype:  
47 Analysis of 500 cases. *Journal of the European Academy of Dermatology and Venereology*, 27:  
48 985-989.  
49 Exclusion Reason: Not in PICO

- 1 Wong KY, Gilleard O, Price R. Non-melanoma skin cancer incomplete excision rates of different  
2 grades of plastic surgeons and the implications for service provision. *European Journal of Surgical*  
3 *Oncology* 2012;38(11):1121.  
4 Exclusion Reason: Not in PICO
- 5 Woolley, S. D. & Hughes, C. (2013) A young military pilot presents with a periocular Basal Cell  
6 Carcinoma: A case report. *Travel Medicine and Infectious Disease*, 11: 435-437.  
7 Exclusion Reason: Not in PICO
- 8 Wray, E. V., Brant, B., Hussain, F. & Muller, F. M. (2013) A new model of teledermoscopy combining  
9 service and education. *British Journal of Dermatology*, 169: 139.  
10 Exclusion Reason: Not in PICO
- 11 Wright VC. When to suspect squamous cancer at colposcopy. [Review] [22 refs]. *Nurse Practitioner*  
12 1959;26(9):50-6.  
13 Exclusion Reason: Narrative Review
- 14 Wustrow J, Rudert H, Diercks M, Beigel A. Squamous cell carcinoma and undifferentiated carcinoma  
15 of the inner nose and the paranasal sinuses. [German]. *Strahlentherapie und Onkologie*  
16 1989;165(6):468-73.  
17 Exclusion Reason: Not in PICO
- 18 Yamazaki N. [Squamous cell carcinoma]. [Review] [9 refs] [Japanese]. *Gan to Kagaku Ryoho*  
19 [Japanese Journal of Cancer & Chemotherapy] 2006;33(10):1392-7.  
20 Exclusion Reason: Narrative Review
- 21 Youl PH, Baade PD, Janda M, Del Mar CB, Whiteman DC, Aitken JF. Diagnosing skin cancer in primary  
22 care: how do mainstream general practitioners compare with primary care skin cancer clinic  
23 doctors? *Medical Journal of Australia* 2007;187(4):215-20.  
24 Exclusion Reason: Not in PICO: Clinical versus histological diagnosis (not biopsy or dermatoscopy  
25 versus histology or follow up)
- 26 Youl PH, Janda M, Aitken JF, Del Mar CB, Whiteman DC, Baade PD. Body-site distribution of skin  
27 cancer, pre-malignant and common benign pigmented lesions excised in general practice. *British*  
28 *Journal of Dermatology* 2011;165(1):35-43  
29 Exclusion Reason: Not in PICO
- 30 Zalaudek I, Argenziano G, Soyer HP, Corona R, Sera F, Blum A, et al. Three-point checklist of  
31 dermoscopy: an open internet study. *British Journal of Dermatology* 2006;154(3):431-7.  
32 Exclusion Reason: Not in PICO
- 33 Zedek DC, Smith ET Jr, Hitchcock MG, Feldman SR, Shelton BJ, White WL. Cutaneous lupus  
34 erythematosus simulating squamous neoplasia: the clinicopathologic conundrum and  
35 histopathologic pitfalls. *Journal of the American Academy of Dermatology* 2007;56(6):1013-20.  
36 Exclusion Reason: Not in PICO
- 37 Zheng W, Soo KC, Sivanandan R, Olivo M. Detection of squamous cell carcinomas and pre-cancerous  
38 lesions in the oral cavity by quantification of 5-aminolevulinic acid induced fluorescence  
39 endoscopic images. *Lasers in Surgery & Medicine* 2002;31(3):151-7.  
40 Exclusion Reason: Not in PICO
- 41 Zhou XH. Primary squamous cell carcinoma of the thyroid. *European Journal of Surgical Oncology*  
42 2002;28(1):42-5.  
43 Exclusion Reason: N=2  
44  
45  
46

**BASAL CELL CARCINOMA****Review question:**

What is the risk of basal cell carcinoma in patients presenting in primary care with symptom(s)?

**Results****Literature search**


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	All-2012	501	66	09/01/2013
<i>Premedline</i>	All-2012	66	5	09/01/2013
<i>Embase</i>	All-2012	2129	76	15/01/2013
<i>Cochrane Library</i>	All-2012	201	3	16/01/2013
<i>Psychinfo</i>	All-2012	4	1	09/01/2013
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	All-2012	569	36	16/01/2013
<i>Biomed Central</i>	All-2012	287	3	21/01/2013

Total References retrieved (after de-duplication): 127

**Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	2013-11/08/2014	17	2	11/08/2014
<i>Premedline</i>	2013-11/08/2014	26	2	11/08/2014
<i>Embase</i>	2013-11/08/2014	101	15	11/08/2014
<i>Cochrane Library</i>	2013-11/08/2014	63	0	11/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	2013-11/08/2014	114	0	11/08/2014

Total References retrieved (after de-duplication): 15



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11

**Risk of bias in the included studies**

The risk of bias and applicability concerns are summarised per study in the figure below. The main bias risks and applicability concerns that the studies are subject to relate to (1) the patient sampling method not clearly being consecutive or random, (2) the extent to which the study setting matches UK primary care, (3) the quality of the reference standard, which may not always reliably diagnose the symptoms, and (4) the fact that the reference standard did not in all cases match that of the current question, namely histology.

	Risk of Bias				Applicability Concerns		
	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard
Emery (2010)	?	+	?	+	?	+	?
Rosendahl (2012)	?	+	+	+	?	+	+
Walter (2012)	?	+	?	+	+	+	?

- High     
 ? Unclear     
 + Low

12  
13  
14  
15  
16  
17  
18

**Study results**

Table 1: Basal cell carcinoma: Study results

Study	Symptom(s)	Patient group	Positive predictive value % (95% CI) Prevalence



Emery (2010) Lesion, not patient,- based analysis	Pigmented lesion	All included patients	1.82 (1.2-2.8) 22/1211
		England sample	0/630 (0-0.8)
		Australia sample	3.79 (2.4-5.8) 22/581
Walter (2012) Lesion, not patient,- based analysis	Suspicious pigmented lesions	All included patients	0.64 (0.3-1.2) 10/1573
Rosendahl (2010) Lesion, not patient,- based analysis	Non-pigmented raised lesion	All included patients	27.18 (21.3-33.9) 56/206

1

2 **Evidence statement(s):**

3 Pigmented skin lesions (2 studies, N = 2784 *lesions*) presenting in a primary care setting are  
4 associated with positive predictive value of 0.64-1.82% for basal cell carcinoma. The studies were  
5 associated with 3-4 bias and applicability concerns (see also Table 1).

6

7 Non-pigmented skin lesions (1 study, N = 206 *lesions*) presenting in a primary care setting are  
8 associated with a positive predictive value of 27.18% for basal cell carcinoma. The study was  
9 associated with 2 bias and applicability concerns (see also Table 1).

10

11 **Evidence tables**12 **Emery (2010)**

PATIENT SELECTION	
A. risk of bias	
Patient sampling	Prospective series of pigmented lesions recruited from England (6 general practices covering urban, suburban and rural areas with a registered population of 52913) and Australia (3 primary care skin cancer clinics operated by GPs from a metropolitan area)
Was a consecutive or random sample of patients enrolled?	<b>Unclear</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Unclear risk</b>
B. Concerns regarding applicability	
Patient characteristics and setting	England: N = 389 patients, mean age = 44.9 years, 68.6% females with, interpretable images from N = 630 lesions. 0/630 lesions were squamous cell carcinoma, 0/630 lesions were basal cell carcinoma, 5/630 lesions were melanoma, and 0/630 lesions were lentigo maligna (melanoma). Australia: N = 469 patients, mean age = 50 years, 48% females, with interpretable images from N = 581 lesions. 0/581 lesions were squamous cell carcinoma, 22/581 lesions were basal cell carcinoma, 7/581 lesions were melanoma, and 4/581 lesions were lentigo maligna (melanoma).  <u>Inclusion criteria:</u>

	<p>England: Patients aged &gt; 18 years were recruited into the study by their GP if they presented with concerns about a pigmented skin lesion between January 2005 and January 2006.</p> <p>Australia: Patients aged &gt; 18 years were recruited into the study by their GP if they presented with concerns about a pigmented skin lesion between April 2008 and January 2009. Additional lesions were also included when a pigmented skin lesion was identified as potentially suspicious during their clinical examination</p> <p><u>Exclusion criteria:</u> None reported.</p> <p><u>Clinical setting:</u> Primary care, UK, and primary care skin cancer practice, Queensland Australia.</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	Pigmented skin lesions that concerned patients, which were evaluated using macroscopic clinical photographs, dermoscopic images and SIAscan.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
<b>Reference standard(s)</b>	Histopathology or in-person clinical review of the lesion by one expert, including the 7-point melanoma checklist and digital dermoscopy or clinical diagnosis made on the basis of the 7-point melanoma checklist, photographic and dermoscopy images
Is the reference standard likely to correctly classify the target condition?	<b>Unclear</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Unclear concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
<b>Flow and timing</b>	All patients are accounted for in the results
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	Analysis was on a per lesion basis rather than a per patient basis

1

Rosendahl (2012)

<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective unselected consecutive series of raised non-pigmented lesions
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Unclear</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>N = 186 patients, mean (SD) age = 65 (13) years, 32.8% females with N = 206 lesions. 32/206 lesions were squamous cell carcinoma (SCC), 29/206 lesions were keratoacanthoma (SCC), 24/206 lesions were Bowen disease (SCC), and 56/ 206 lesions were basal cell carcinoma.</p> <p><u>Inclusion criteria:</u> Patients presenting with non-pigmented raised lesions treated from March 1 through December 31 2011. All the lesions were excised or biopsied. It is unclear if there were any patients presenting with non-pigmented raised lesions not biopsied/excised who were not included.</p> <p><u>Exclusion criteria:</u> None reported.</p> <p><u>Clinical setting:</u> Private primary care skin cancer practice, Queensland Australia.</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	Non-pigmented raised skin lesions (not further defined, but see subgroup analyses) evaluated using dermoscopic images
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Histopathology
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients are accounted for in the results

Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	Yes
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	Analysis was on a per lesion basis rather than a per patient basis; some patients may have had more than one lesion diagnosed as skin cancer though it is not possible to ascertain the actual numbers from the data provided.

1 **Walter (2012)**

<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective series of suspicious pigmented lesions
Was a consecutive or random sample of patients enrolled?	Unclear
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Unclear
<b>Could the selection of patients have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	N = 1293 patients, mean age (SD) = 44.6 (16.8) years; 465 males / 828 females with N = 1573 lesions, of which 1 was squamous cell carcinoma, 10 basal cell carcinomas, and 36 melanomas.  <u>Inclusion criteria:</u> Patients aged ≥ 18 years presenting to one of the 15 participating general practices with a suspicious (any lesion presented buy a patient, or opportunistically seen by a family doctor or practice nurse, that could not immediately be diagnosed as benign and about which the patient could not be reassured) pigmented lesion from March 2008 to May 2010. <u>Exclusion criteria:</u> Patients who were unable to give informed consent or were considere3d inappropriate to include by their family doctor. <u>Clinical setting:</u> UK primary care.
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	Suspicious (any lesion presented buy a patient, or opportunistically seen by a family doctor or practice nurse, that could not immediately be diagnosed as benign and about which the patient could not be reassured) pigmented lesion
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Expert opinion by a histologist or dermatologist or review by two other dermatology experts of the recorded clinical history and examination, a digital photograph, and MoleMate images where available with or without

	follow up 3-6 months later.
Is the reference standard likely to correctly classify the target condition?	<b>Unclear</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Unclear concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients are accounted for in the results
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes Tests: No</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	Analysis was on a per lesion basis rather than a per patient basis.

1

2

**References**

3

4

**Included Studies**

5

Emery, J.D., Hunter, J., Hall, P.N., Watson, A.J., Moncrieff, M., Walter, F.M. (2010). Accuracy of SIAscopy for pigmented skin lesions encountered in primary care: development and validation of a new diagnostic algorithm. *BMJ Dermatology*, 10:9.

6

7

Rosendahl, C. (2012) Dermoscopy of squamous cell carcinoma and keratoacanthoma. *Archives of Dermatology*, 148: 1386-1392.

8

9

10

Walter, F.M., Morris, H.C., Humphrys, E., Hall, P.N., Prevost, A.T., Burrows, N., Bradshaw, L., Wilson, E.C., Norris, P., Walls, J., Johnson, M., Kinmonth, A.L., Emery, J.D. (2012). Effect of adding a diagnostic aid to best practice to manage suspicious pigmented lesions in primary care: randomised controlled trial. *BMJ*, 345: e4110.

11

12

13

14

15

**Excluded Studies**

16

Abuzahra, F., Parren, L. J., Frank, J., Abuzahra, F., Parren, L. J. M. T., and Frank, J. Multiple familial and pigmented basal cell carcinomas in early childhood - Bazex-Dupre-Christol syndrome. *Journal of the European Academy of Dermatology & Venereology* 26[1], 117-121. 2012.

17

18

19

Netherlands.

20

Reason Single Case

21

Agarwal S. Out patient waiting time for common skin conditions - Do general practitioners and dermatologists have the same priorities? A questionnaire-based survey. *Clinical and Experimental Dermatology* 26[1], 13-15. 2001. United Kingdom.

22

23

24

Reason Not relevant to PICO

Ahmad, I., Das Gupta, A. R., Ahmad, I., and Das Gupta, A. R. Epidemiology of basal cell carcinoma and squamous cell carcinoma of the pinna. *Journal of Laryngology & Otology* 115[2], 85-86. 2001.

25

26

27

England.

Reason Comparison not relevant to PICO

28

29

Alam, M., Goldberg, L. H., Silapun, S., Gardner, E. S., Strom, S. S., Rademaker, A. W., and Margolis, D. J. Delayed treatment and continued growth of nonmelanoma skin cancer. *Journal of the American Academy of Dermatology* 64[5], 839-848. 2011.

30

31

32

Reason Not relevant to PICO

- 1 Aldridge, R. B. F. Do laypersons have intrinsic pattern recognition abilities that could be harnessed to  
2 allow the accurate and early diagnosis of skin cancers? *British Journal of Dermatology*  
3 Conference[*var.pagings*], 949-950. 2010.  
4 Reason Not relevant to PICO
- 5 Aldridge, R. B., Naysmith, L., Ooi, E. T., Murray, C. S. & Rees, J. L. (1111) The importance of a full  
6 clinical examination: Assessment of index lesions referred to a skin cancer clinic without a  
7 total body skin examination would miss one in three melanomas. *Acta Dermato-*  
8 *Venereologica*, 93: 2013.  
9 Reason Not in PICO
- 10 Allon, I., Allon, D. M., Anavi, Y. & Kaplan, I. (2013) The significance of surface ulceration as a sign of  
11 malignancy in exophytic oral mucosal lesions: myth or fact? *Head and neck pathology*, 7: 149-  
12 154.  
13 Reason Not in PICO
- 14 Argenziano, G., Puig, S., Zalaudek, I., Sera, F., Corona, R., Alsina, M., Barbato, F., Carrera, C., Ferrara,  
15 G., Guilabert, A., Massi, D., Moreno-Romero, J. A., Munoz-Santos, C., Petrillo, G., Segura, S.,  
16 Soyer, H. P., Zanchini, R., and Malvehy, J. Dermoscopy improves accuracy of primary care  
17 physicians to triage lesions suggestive of skin cancer. *Journal of Clinical Oncology* 24[12],  
18 1877-1882. 20-4-2006.  
19 Reason Not relevant to PICO
- 20 Askari, S. K., Schram, S. E., Wenner, R. A., Bowers, S., Liu, A., Bangerter, A. K., and Warshaw, E. M.  
21 Evaluation of prospectively collected presenting signs/symptoms of biopsy-proven melanoma,  
22 basal cell carcinoma, squamous cell carcinoma, and seborrheic keratosis in an elderly male  
23 population. *Journal of the American Academy of Dermatology* 56[5], 739-747. 2007.  
24 Reason Not relevant to PICO
- 25 Baade, P. D., Youl, P. H., Janda, M., Whiteman, D. C., Del Mar, C. B., Aitken, J. F., Baade, Peter D.,  
26 Youl, Philippa H., Janda, Monika, Whiteman, David C., Del Mar, Christopher B., and Aitken,  
27 Joanne F. Factors associated with the number of lesions excised for each skin cancer: a study  
28 of primary care physicians in Queensland, Australia. *Archives of Dermatology* 144[11], 1468-  
29 1476. 2008. United States.  
30 Reason Not relevant to PICO
- 31 Bataille, V. A teledermatology pilot study in Hertfordshire: Triage of 2-week-wait referrals. *British*  
32 *Journal of Dermatology Conference*[*var.pagings*], July. 2011.  
33 Reason Not relevant to PICO
- 34 Behrens, A., May, A., Manner, H., Pohl, J. & Ell, C. (2013) Esophageal precancerous lesions: Early  
35 diagnosis, treatment, and preservation of quality of life. [German]. *Internist*, 54: 683-690.  
36 Reason Narrative review
- 37 Bekkenk, M. W. H. Basal cell carcinoma and squamous cell carcinoma arising from a sebaceous nevus  
38 in young patients. *Nederlands Tijdschrift voor Dermatologie en Venereologie* 17[9], 345-346.  
39 2007. Netherlands.  
40 Reason Narrative review
- 41 Berman, B. Basal cell carcinoma and actinic keratoses: Patients' perceptions of their disease and  
42 current treatments. *International Journal of Dermatology* 40[9], 573-576. 2001. United  
43 Kingdom.  
44 Reason Not relevant to PICO
- 45 Bernard, P. Skin cancer diagnosis by dermatologists in the region of Champagne-Ardenne: A  
46 prospective study. *Annales de Dermatologie et de Venereologie* 128[8-9], 883-887. 2001.  
47 France.  
48 Reason Not relevant to PICO
- 49 Bhatnagar, A., Mohamad, S., and Sandramouli, S. 'Fast-tracking' cancer referrals: application for  
50 periocular basal cell carcinoma. *Eye (London)* 20[4], 428-430. 2006.  
51 Reason Not relevant to PICO

- 1 Bitar, G. J., Herman, C. K., Dahman, M. I., and Hoard, M. A. Basal cell nevus syndrome: Guidelines for  
2 early detection. *American Family Physician* 65[12], 2501-2504. 2002.  
3 Reason Not relevant to PICO
- 4 Breglia, M. D., Oliva, P., Breglia, Michael D., and Oliva, Patricia. Basal cell carcinoma presenting as  
5 symptomatic iron deficiency anaemia. *BMJ Case Reports* 2011, 2011. 2011. England.  
6 Reason Case report
- 7 Bruce, A. J., Brodland, D. G., Bruce, A. J., and Brodland, D. G. Overview of skin cancer detection and  
8 prevention for the primary care physician. [Review] [34 refs]. *Mayo Clinic Proceedings* 75[5],  
9 491-500. 2000. UNITED STATES.  
10 Reason Narrative Review
- 11 Brundel, K. H. and Brundel, K. H. [Skin cancer in general practice]. [German]. *Dermatosen in Beruf  
12 und Umwelt Occupational & Environmental Dermatosen*. 38[2], 54-57. 1990. GERMANY,  
13 WEST.  
14 Reason Not relevant to PICO
- 15 Buis, P.A.J. et al (2005) Value of histopathologic analysis of skin lesions by GPs *British Journal of  
16 General Practice* 55;458-460  
17 Reason Not in PICO
- 18 Burghout, K., Sigurdsson, V. & Toonstra, J. (2013) Non-melanoma skin cancer. [Dutch]. *Huisarts en  
19 Wetenschap*, 56: 174-178.  
20 Reason Narrative review
- 21 Carli, P., Chiarugi, A., De, Giorgi, V, Carli, Paolo, Chiarugi, Alessandra, and De Giorgi, Vincenzo.  
22 Examination of lesions (including dermoscopy) without contact with the patient is associated  
23 with improper management in about 30% of equivocal melanomas. *Dermatologic Surgery*  
24 31[2], 169-172. 2005. United States.  
25 Reason Not relevant to PICO
- 26 Carlsson, L. Common cancer-related symptoms among GP patients: Opportunistic screening in  
27 primary health care. *Scandinavian Journal of Primary Health Care* 19[3], 199-203. 2001.  
28 Norway.  
29 Reason No relevant data
- 30 Carter, E. J. W. Failure of adherence to NICE guidelines for skin cancer surgery in general practice.  
31 *British Journal of Dermatology Conference*[var.pagings], July. 2009.  
32 Reason Not relevant to PICO
- 33 Castori, M., Morrone, A., Kanitakis, J., Grammatico, P., Castori, Marco, Morrone, Aldo, Kanitakis,  
34 Jean, and Grammatico, Paola. Genetic skin diseases predisposing to basal cell carcinoma.  
35 [Review]. *European Journal of Dermatology* 22[3], 299-309. 2012. France.  
36 Reason Narrative Review
- 37 Ceylan, C. A case of basal cell carcinoma arising in epidermal nevus. *International Journal of  
38 Dermatology* 41[12], 926-927. 2002. United Kingdom.  
39 Reason Narrative Review
- 40 Charman, C., Whitley, H. & Bogucki, P. (2014) Teledermatology using 'Choose and Book': A review of  
41 1000 patient referrals. *British Journal of Dermatology*, 171: 138.  
42 Reason Not in PICO
- 43 Chattopadhyay, M. & Ha, T. (2013) How to examine a patient with suspected skin cancer. *Medicine  
44 (United Kingdom)*, 41: 400-401.  
45 Reason Narrative review
- 46 Chiscop, I., Popescu, E., Mihai, C., Budacu, C., Chiscop, Iulia, Popescu, Eugenia, Mihai, Constantin,  
47 and Budacu, Cristian. [Cutaneous carcinoma of the face. Clinical and histopathological forms.  
48 Retrospective study of 308 cases]. [Romanian]. *Revista Medico-Chirurgicala a Societatii de  
49 Medici Si Naturalisti Din Iasi* 115[2], 560-566. 2011. Romania.  
50 Reason Not relevant to PICO

- 1 Coates, E. An observational study of skin disease in rural Australian general practice. *Australasian*  
2 *Journal of Dermatology Conference*[var.pagings], October. 2011.  
3 Reason Not relevant to PICO
- 4 Corey, K. An analysis of terminology used by primary care physicians to describe concerning lesions  
5 referred to an urgent dermatology clinic. *Journal of Investigative Dermatology*  
6 *Conference*[var.pagings], May. 2012.  
7 Reason Not relevant to PICO
- 8 Cox, N. H. and Cox, N. H. Basal cell carcinoma in young adults. *British Journal of Dermatology* 127[1],  
9 26-29. 1992. ENGLAND.  
10 Reason Narrative Review
- 11 de Antonio Garcia, M. P., Borbujo, Martinez J., Juez, Juez A., Olmos, Carrasco O., Castell Alcala, M. V.,  
12 Casado, Jimenez M., de Antonio Garcia, M. P., Borbujo Martinez, J., Juez Juez, A., Olmos  
13 Carrasco, O., Castell Alcala, M. V., and Casado Jimenez, M. [Pigmented basocellular  
14 epithelioma. Presentation of 7 cases]. [Spanish]. *Atencion Primaria* 9[8], 439-442. 15-5-1992.  
15 SPAIN.  
16 Reason Not relevant to PICO
- 17 De Stefano, A. Features of biopsy in diagnosis of metatypical basal cell carcinoma (Basosquamous  
18 Carcinoma) of head and neck. *Otolaryngologia Polska* 66[6], 419-423. 2012. Poland.  
19 Reason Narrative Review
- 20 Dewan, P. Are NICE skin cancer guidelines being followed in primary care? A re-audit to review  
21 changes in practice in an inner city setting. *British Journal of Dermatology*  
22 *Conference*[var.pagings], July. 2010.  
23 Reason Not relevant to PICO
- 24 Eekhof, J. A. (2013) [Actinic keratosis: the art of doing nothing]. [Dutch]. *Nederlands Tijdschrift Voor*  
25 *Geneeskunde*, 157: A5363.  
26 Reason Narrative review
- 27 Ehlers, G. Clinic data on basal cell epithelioma in connection with statistical investigations. *Zeitschrift*  
28 *fur Haut- und Geschlechtskrankheiten* 41[6], 226-238. 1966.  
29 Reason Narrative Review
- 30 Emery, J. D. H. Accuracy of SIAscopy for pigmented skin lesions encountered in primary care:  
31 Development and validation of a new diagnostic algorithm. *BMC Dermatology* 10 , 2010.  
32 Article Number, 9. 2009. United Kingdom.  
33 Reason Relevant for tests
- 34 Epstein, J. B., Guneri, P., Boyacioglu, H. & Abt, E. (2013) The limitations of the clinical oral  
35 examination in detecting dysplastic oral lesions and oral squamous cell carcinoma.[Reprint of J  
36 *Am Dent Assoc.* 2012 Dec;143(12):1332-42; PMID: 23204089]. *Texas Dental Journal*, 130: 410-  
37 424.  
38 Reason Not in PICO
- 39 Federman, D. G., Concato, J., Caralis, P. V., Hunkele, G. E., and Kirsner, R. S. Screening for skin cancer  
40 in primary care settings. *Archives of Dermatology* 133[11], 1423-1425. 1997.  
41 Reason Not relevant to PICO
- 42 Federman, D. G., Kravetz, J. D., Tobin, D. G., Ma, F., and Kirsner, R. S. Full-body skin examinations:  
43 the patient's perspective. *Archives of Dermatology* 140[5], 530-534. 2004.  
44 Reason Not relevant to PICO
- 45 Ferreira, P., Rodrigues, M., Ledo, S., Senra, R., Costa, S., V, Rocha, M. & Paiva, C. (2013) Back pain as  
46 the first manifestation of a cavum tumor. *European Journal of Internal Medicine*, 24: e149.  
47 Reason Not in PICO
- 48 Firnhaber, J. M. Diagnosis and treatment of basal cell and squamous cell carcinoma. *American Family*  
49 *Physician* 86[2], 161-168. 2012. United States.  
50 Reason Narrative Review



- 1 FitzGerald, K. L., Buttner, P. G., Donovan, S. A., FitzGerald, K. L., Buttner, P. G. & Donovan, S. A.  
2 (2006) Nonpigmented skin lesions - how many are nonmelanoma skin cancer? *Australian*  
3 *Family Physician*, 35: 555-557.  
4 Reason Not in PICO (only excised lesions, not examined lesions)
- 5 Fontes, K. B., Cunha, K. S., Rodrigues, F. R., Silva, L. E. & Dias, E. P. (2013) Concordance between  
6 cytopathology and incisional biopsy in the diagnosis of oral squamous cell carcinoma. *Brazilian*  
7 *oral research*, 27: 122-127.  
8 Reason Not in PICO
- 9 Gait, R. A review of procedures carried out on basal cell carcinomas by Primary care physicians.  
10 *British Journal of Dermatology Conference*[var.pagings], July. 2009.  
11 Reason Population not relevant to PICO
- 12 Gajdatsy, A. Common and clinically important eyelid lesions. *Medicine Today* 13[5], 71-74. 2012.  
13 Australia.  
14 Reason Narrative Review
- 15 Gallo, M. Relevance of early diagnosis of nevoid basal cell carcinoma syndrome (Gorlin's syndrome).  
16 *Rivista Italiana di Chirurgia Plastica* 28[3], 265-272. 1996. Italy.  
17 Reason Narrative Review
- 18 Garcia, L., Nagore, E., Llombart, B., Sanmartin, O., Botella-Estrada, R., Requena, C., Jorda, E., and  
19 Guillen, C. Basal cell carcinoma of the nasolabial fold: an apparently 'benign' tumour that  
20 often needs complex surgery. *Journal of the European Academy of Dermatology &*  
21 *Venereology* 20[8], 926-930. 2006.  
22 Reason Not relevant to PICO
- 23 Gerbert, B., Maurer, T., Berger, T., Pantilat, S., McPhee, S. J., Wolff, M., Bronstone, A., and Caspers,  
24 N. Primary care physicians as gatekeepers in managed care. Primary care physicians' and  
25 dermatologists' skills at secondary prevention of skin cancer. *Archives of Dermatology* 132[9],  
26 1030-1038. 1996.  
27 Not relevant to PICO
- 28 Giacomel, J. & Zalaudek, I. (2013) Pink Lesions. *Dermatologic Clinics*, 31: 649-678.  
29 Reason Narrative review
- 30 Gilde, K. The importance of malignant skin tumors. *Orvosi Hetilap* 147[48], 2321-2330. 2006.  
31 Hungary.  
32 Reason Narrative Review
- 33 Gordon, P. M., Cox, N. H., Paterson, W. D., Lawrence, C. M., Gordon, P. M., Cox, N. H., Paterson, W.  
34 D., and Lawrence, C. M. Basal cell carcinoma: are early appointments justifiable? *British*  
35 *Journal of Dermatology* 142[3], 446-448. 2000. ENGLAND.  
36 Reason Not relevant to PICO
- 37 Graves, J. Derm Access: A new triage system to rapidly identify suspicious skin lesions. *Dermatologic*  
38 *Surgery* 32[12], 1486-1490. 2006. United Kingdom.  
39 Reason Not relevant to PICO
- 40 Green, W. H., Wang, S. Q., and Cagnetta, A. B. Total-Body Cutaneous Examination, Total-Body  
41 Photography, and Dermoscopy in the Care of a Patient With Xeroderma Pigmentosum and  
42 Multiple Melanomas. *Archives of Dermatology* 145[8], 910-915. 2009.  
43 Reason Single Case
- 44 Grimaldi, L. Digital epiluminescence dermoscopy for pigmented cutaneous lesions, primary care  
45 physicians, and telediagnosis: a useful tool? *Journal of Plastic, Reconstructive and Aesthetic*  
46 *Surgery* 62[8], 1054-1058. 2009. United Kingdom.  
47 Reason Not relevant to PICO
- 48 Gupta, A., Stacey, S. & Amisshah-Arthur, K. N. (2014) Eyelid lumps and lesions. *BMJ (Online)*, 348.  
49 Reason Narrative review
- 50 Haliasos, E. C., Kerner, M., Jaimes, N., Zalaudek, I., Malveyh, J., Lanschuetzer, C. M., Hinter, H.,  
51 Hofmann-Wellenhof, R., Braun, R. P. & Marghoob, A. A. (2013) Dermoscopy for the pediatric

- 1 dermatologist, part ii: dermoscopy of genetic syndromes with cutaneous manifestations and  
 2 pediatric vascular lesions. [Review]. *Pediatric Dermatology*, 30: 172-181.  
 3 Reason Narrative review
- 4 Halpern, A. C., Hanson, L. J., Halpern, Allan C., and Hanson, Laura J. Awareness of, knowledge of and  
 5 attitudes to nonmelanoma skin cancer (NMSC) and actinic keratosis (AK) among physicians.  
 6 *International Journal of Dermatology* 43[9], 638-642. 2004. United States.  
 7 Reason Not relevant to PICO
- 8 Halpern, S. M. S. Establishment of a primary care-based teledermatology service in Kent. *British*  
 9 *Journal of Dermatology Conference*[var.pagings], July. 2011.  
 10 Reason Not relevant to PICO
- 11 Hansen, C., Wilkinson, D., Hansen, M., Soyer, H. P., Hansen, Craig, Wilkinson, David, Hansen, Mary,  
 12 and Soyer, H. Peter. Factors contributing to incomplete excision of nonmelanoma skin cancer  
 13 by Australian general practitioners. *Archives of Dermatology* 145[11], 1253-1260. 2009.  
 14 United States.  
 15 Reason Not relevant to PICO
- 16 Heal, C. and Raasch, B. Diagnosing skin cancer in primary care: how do main-stream general  
 17 practitioners compare with primary care skin cancer clinic doctors? *Medical Journal of*  
 18 *Australia* 188[2], 125. 21-1-2008.  
 19 Reason Narrative Review
- 20 Heal, C., Buettner, P., Raasch, B., Browning, S., Heal, C., Buettner, P., Raasch, B. & Browning, S.  
 21 (2006) Minor skin excisions in general practice in North Queensland. *Australian Family*  
 22 *Physician*, 35: 825-828.  
 23 Reason Not in PICO (only excised lesions, not examined lesions; no information about symptoms/lesion  
 24 features)
- 25 Hochman, M., Lang, P., Hochman, M., and Lang, P. Skin cancer of the head and neck. [Review] [75  
 26 refs]. *Medical Clinics of North America* 83[1], 261-282. 10-9-0010. UNITED STATES.  
 27 Reason Narrative Review
- 28 Jacobs, R. J., Phillips, G., Jacobs, Robert J., and Phillips, Geraint. Basal cell carcinoma mistaken for  
 29 actinic keratosis. *Clinical & Experimental Optometry* 89[3], 171-175. 2006. Australia.  
 30 Reason Single Case/Narrative Review
- 31 Jolliffe, V. M., Harris, D. W., Morris, R., Wallacet, P., Whittaker, S. J., Jolliffe, V. M., Harris, D. W.,  
 32 Morris, R., Wallacet, P., and Whittaker, S. J. Can we use video images to triage pigmented  
 33 lesions? *British Journal of Dermatology* 145[6], 904-910. 2001. England.  
 34 Reason Not relevant to PICO
- 35 Kahn, E., Sossong, S., Goh, A., Carpenter, D. & Goldstein, S. (2013) Evaluation of Skin Cancer in  
 36 Northern California Kaiser Permanente's Store-and-Forward Teledermatology Referral  
 37 Program. *Telemedicine and E-Health*, 19: 780-785.  
 38 Reason Not in PICO
- 39 Kamyab-Hesari, K., Seirafi, H., Naraghi, Z. S., Shahshahani, M. M., Rahbar, Z., Damavandi, M. R.,  
 40 Naraghi, M. M., Rezvani, M. & Aghazadeh, N. (2014) Diagnostic accuracy of punch biopsy in  
 41 subtyping basal cell carcinoma. *Journal of the European Academy of Dermatology and*  
 42 *Venereology*, 28: 250-253.  
 43 Reason Not in PICO
- 44 Keir, J. Re: Diagnosing skin cancer in primary care: how do main-stream general practitioners  
 45 compare with primary care skin cancer clinic doctors? *Medical Journal of Australia* 188[2],  
 46 125-126. 21-1-2008.  
 47 Reason Narrative Review
- 48 Khorasgani, M. G. P. Dermatological surgery in the community: Are the guidelines being followed?  
 49 *British Journal of Dermatology Conference*[var.pagings], July. 2010.  
 50 Reason Not relevant to PICO

- 1 Kiwilsza, M. and Sporniak-Tutak, K. Gorlin-Goltz syndrome--a medical condition requiring a  
2 multidisciplinary approach. *Medical Science Monitor* 18[9], RA145-RA153. 2012.  
3 Reason Narrative Review
- 4 Kok, L. P., V. General practitioners use digital cameras and internet for telepathology of skin lesions.  
5 *Electronic Journal of Pathology and Histology* 6[3], 7-19. 2000. Germany.  
6 Reason Narrative Review
- 7 Kundu, R. V. & Patterson, S. (2013) Dermatologic conditions in skin of color: part I. Special  
8 considerations for common skin disorders.[Summary for patients in *Am Fam Physician*. 2013  
9 Jun 15;87(12):Online; PMID: 23939576]. *American Family Physician*, 87: 850-856.  
10 Reason Narrative review
- 11 Kutcher, M. J. R. Fifteen inches from cancer: early recognition of facial lesions by the dentist.  
12 Compendium of continuing education in dentistry (Jamesburg, N J.[12], 939-942. 10-10-0106.  
13 United States.  
14 Reason Not relevant to PICO
- 15 Lai, W.-Y. (1111) An elderly man with a painful scaly nodule. *Hong Kong Practitioner*, 35: September.  
16 Reason Not in PICO
- 17 Lathlean, S. & Lathlean, S. (1999) Skin cancer in general practice in South Australia. A five year study.  
18 *Australian Family Physician*, 28 Suppl 1: S28-S31.  
19 Reason Not in PICO (only excised lesions, not examined lesions; no information about symptoms/lesion  
20 features)
- 21 Leber, K., Perron, V. D., and Sinni-McKeehen, B. Common skin cancers in the United States: A  
22 practical guide for diagnosis and treatment. *Nurse Practitioner Forum-Current Topics and  
23 Communications* 10[2], 106-116. 1999.  
24 Reason Narrative Review
- 25 Leggett, P. A randomized controlled trial using instant photography to diagnose and manage  
26 dermatology referrals. *Family Practice* 21[1], 54-56. 2004. United Kingdom.  
27 Reason Not relevant to PICO
- 28 Lester, J. & Weinstock, M. A. (2014) Telerriage for provision of dermatologic care: A pilot program in  
29 the Department of Veterans Affairs. *Journal of Cutaneous Medicine and Surgery*, 18: 170-173.  
30 Reason Not in PICO
- 31 Liebman, T. N., Wang, S. Q., Liebman, Tracey N., and Wang, Steven Q. Detection of early basal cell  
32 carcinoma with dermoscopy in a patient with psoriasis. *Dermatology Online Journal* 17[2], 12.  
33 2011. United States.  
34 Reason Single Case
- 35 Liew, Y., De, B. D. & Sansom, J. (2014) Rapid clinical review of patients assessed by a teledermatology  
36 service: Analysis of pathways and outcomes. *British Journal of Dermatology*, 171: 138.  
37 Reason Not in PICO
- 38 Lin, Y.-C., Perng, C.-L., Chang, Y.-M., Li, Y.-F., Tsai, Y.-M., Wu, G.-J. & Lin, C.-K. (2013) Coexistent  
39 squamous cell carcinoma and adenoid basal carcinoma in the uterine cervix and infection with  
40 human papillomavirus (HPV 31). *Taiwanese Journal of Obstetrics and Gynecology*, 52: 407-410.  
41 Reason Not in PICO
- 42 Ljubenovic, M., Ljubenovic, D., Binic, I., Jovanovic, D., Stanojevic, M., Ljubenovic, M., Ljubenovic, D.,  
43 Binic, I., Jovanovic, D., and Stanojevic, M. Gorlin-Goltz syndrome. *Acta Dermatovenerologica  
44 Alpina, Panonica et Adriatica* 16[4], 166-169. 2007. Slovenia.  
45 Reason Single Case
- 46 Lo, Muzio L., Nocini, P., Bucci, P., Pannone, G., Consolo, U., Procaccini, M., Lo Muzio, L., Nocini, P.,  
47 Bucci, P., Pannone, G., Consolo, U., and Procaccini, M. Early diagnosis of nevoid basal cell  
48 carcinoma syndrome. *Journal of the American Dental Association* 130[5], 669-674. 1999.  
49 UNITED STATES.  
50 Reason Not relevant to PICO
- 51 Lober, C. W., Fenske, N. A., Lober, C. W., and Fenske, N. A. Basal cell, squamous cell, and sebaceous  
52 gland carcinomas of the periorbital region. [Review] [54 refs]. *Journal of the American*

- 1 Academy of Dermatology 25[4], 685-690. 1991. UNITED STATES.  
2 Reason Narrative Review
- 3 Lyngset, E., Hunskar, S., Lyngset, E., and Hunskar, S. [Skin neoplasms in general practice].  
4 [Norwegian]. Tidsskrift for Den Norske Laegeforening 121[19], 2281-2283. 20-8-2001. Norway.  
5 Reason Population not relevant to PICO
- 6 Mantese, S. A. O. Basal cell Carcinoma - Analysis of 300 cases observed in Uberlandia - MG, Brazil.  
7 Anais Brasileiros de Dermatologia 81[2], 136-142. 2006. Brazil.  
8 Reason Not relevant to PICO
- 9 Marghoob, A. A. and Marghoob, A. A. Basal and squamous cell carcinomas. What every primary care  
10 physician should know. [Review] [20 refs]. Postgraduate Medicine 102[2], 139-142. 15-4-0146.  
11 UNITED STATES.  
12 Reason Narrative Review
- 13 Marghoob, A. A., Usatine, R. P. & Jaimes, N. (2013) Dermoscopy for the family physician. [Review].  
14 *American Family Physician*, 88: 441-450.  
15 Reason Narrative review
- 16 Martinez, J. C., Otley, C. C., Martinez, J. C., and Otley, C. C. The management of melanoma and  
17 nonmelanoma skin cancer: a review for the primary care physician. [Review] [54 refs]. Mayo  
18 Clinic Proceedings 76[12], 1253-1265. 2001. United States.  
19 Reason Narrative Review
- 20 Maybury, C. M., Craythorne, E. & Martin, B. (2013) An ulcerated nodule on the nose. *BMJ Case*  
21 *Reports*, 2013, 2013.  
22 Reason Not in PICO
- 23 McGregor, J. C. and McGregor, J. C. Skin cancer referrals--could prioritization be a reasonable  
24 approach in the new millennium? *Scottish Medical Journal* 45[3], 77-78. 2000. SCOTLAND.  
25 Reason Narrative Review
- 26 McLaughlin S.Tobin. The role of digital photography and electronic referral in the triage of patients  
27 with suspected skin cancer [6]. *British Journal of Dermatology* 154[1], 188-190. 2006. United  
28 Kingdom.  
29 Reason Not relevant to PICO
- 30 McNulty-Brown E.Veysey. An audit of all excisions undertaken by general practitioners in a rural  
31 community between March 2009 and March 2010. *British Journal of Dermatology*  
32 *Conference*[var.pagings], July. 2012.  
33 Reason Not relevant to PICO
- 34 Menzies, S. W. Using dermoscopy to diagnose pigmented skin lesions. *Medicine Today* 5[4], 63-71.  
35 2004. Australia.  
36 Reason Narrative Review
- 37 Menzies, S. W., Emery, J., Staples, M., Davies, S., McAvoy, B., Fletcher, J., Shahid, K. R., Reid, G.,  
38 Avramidis, M., Ward, A. M., Burton, R. C., Elwood, J. M., Menzies, S. W., Emery, J., Staples, M.,  
39 Davies, S., McAvoy, B., Fletcher, J., Shahid, K. R., Reid, G., Avramidis, M., Ward, A. M., Burton,  
40 R. C., and Elwood, J. M. Impact of dermoscopy and short-term sequential digital dermoscopy  
41 imaging for the management of pigmented lesions in primary care: a sequential intervention  
42 trial. *British Journal of Dermatology* 161[6], 1270-1277. 2009. England.  
43 Reason Not relevant to PICO
- 44 Menzies, S. W., Moloney, F. J., Byth, K., Avramidis, M., Argenziano, G., Zalaudek, I., Braun, R. P.,  
45 Malvehy, J., Puig, S., Rabinovitz, H. S., Oliviero, M., Cabo, H., Bono, R., Pizzichetta, M. A.,  
46 Claeson, M., Gaffney, D. C., Soyer, H. P., Stanganelli, I., Scolyer, R. A., Guitera, P., Kelly, J.,  
47 McCurdy, O., Llambrich, A., Marghoob, A. A., Zaballos, P., Kirchesch, H. M., Piccolo, D.,  
48 Bowling, J., Thomas, L., Terstappen, K., Tanaka, M., Pellacani, G., Pagnanelli, G., Ghigliotti, G.,  
49 Ortega, B. C., Crafter, G., Ortiz, A. M., Tromme, I., Karaarslan, I. K., Ozdemir, F., Tam, A., Landi,  
50 C., Norton, P., Kacar, N., Rudnicka, L., Slowinska, M., Simionescu, O., Di, S. A., Coates, E. &  
51 Kreuzsch, J. (2013) Dermoscopic evaluation of nodular melanoma. *JAMA Dermatology*, 149:

- 1 699-709.  
2 Reason Not in PICO
- 3 Mitchell, G. Farndon. Genetic predisposition to cancer: The consequences of a delayed diagnosis of  
4 Gorlin syndrome. *Clinical Oncology* 17[8], 650-654. 2005. United Kingdom.  
5 Reason Single Case
- 6 Moffatt, C. R. M. Diagnostic accuracy in skin cancer clinics: The Australian experience. *International*  
7 *Journal of Dermatology* 45[6], 656-660. 2006. United Kingdom.  
8 Reason Not relevant to PICO
- 9 Montero Perez, F. J. M. Importance of skin cancer (non-melanoma): a study of 89 cases. *Atencion*  
10 *primaria / Sociedad Espanola de Medicina de Familia y Comunitaria* 6[9], 660-664. 1989.  
11 Spain.  
12 Reason Outcomes not relevant to PICO
- 13 Moreno, G. Tran. Prospective study to assess general practitioners' dermatological diagnostic skills in  
14 a referral setting. *Australasian Journal of Dermatology* 48[2], 77-82. 2007. Australia.  
15 Reason Not relevant to PICO
- 16 Morteza, A. S., Salama, S. & Alowami, S. (2013) Lymphoepithelioma-like carcinoma of the skin: case  
17 report and approach to surgical pathology sign out. *Rare Tumors*, 5: e47.  
18 Reason Not in PICO
- 19 Naik, N. S., Brodell, R. T., and Fatteh, S. When to suspect superficial basal cell carcinoma.  
20 *Postgraduate Medicine* 104[5], 157-158. 1998.  
21 Reason Single Case
- 22 Nakjang, Y. and Kullavanijaya, P. Basal cell carcinoma: seven years' experience at the Institute of  
23 Dermatology in Bangkok. *Journal of Dermatology* 21[9], 660-663. 1994.  
24 Reason Population not relevant to PICO
- 25 Oakley, A. M. A. Diagnostic accuracy of teledermatology: results of a preliminary study in New  
26 Zealand. *The New Zealand medical journal* 110[1038], 51-53. 1997. New Zealand.  
27 Reason Not relevant to PICO
- 28 Obata, H. Aoki. Incidence of benign and malignant lesions of eyelid and conjunctival tumors. *Nippon*  
29 *Ganka Gakkai zasshi* 109[9], 573-579. 2005. Japan.  
30 Reason Not relevant to PICO
- 31 Offidani, A., Simonetti, O., Bernardini, M. L., Alpagut, A., Cellini, A., Bossi, G., Offidani, Annamaria,  
32 Simonetti, Oriana, Bernardini, Maria Luisa, Alpagut, Ayhan, Cellini, Andreina, and Bossi, Guido.  
33 General practitioners' accuracy in diagnosing skin cancers. *Dermatology* 205[2], 127-130.  
34 2002. Switzerland.  
35 Reason Not relevant to PICO
- 36 Ojeda, R. M. and Graells, J. [Effectiveness of primary care physicians and dermatologists in the  
37 diagnosis of skin cancer: a comparative study in the same geographic area][Spanish]. *Actas*  
38 *Dermosifiliograficas* 102[1], 48-52. 2011.  
39 Reason Not relevant to PICO
- 40 Pallagatti, S., Sheikh, S., Aggarwal, A., Gupta, D., Singh, R., Handa, R., Kaur, S. & Mago, J. (2013)  
41 Toluidine blue staining as an adjunctive tool for early diagnosis of dysplastic changes in the  
42 oral mucosa. *Journal of Clinical & Experimental Dentistry*, 5: e187-e191.  
43 Reason Not in PICO
- 44 Palmer, V. M. & Wilson, P. R. (2013) Incompletely excised basal cell carcinoma: residual tumor rates  
45 at Mohs re-excision. *Dermatologic Surgery*, 39: 706-718.  
46 Reason Not in PICO
- 47 Pan, Y. Chamberlain. Dermatoscopy aids in the diagnosis of the solitary red scaly patch or plaque-  
48 features distinguishing superficial basal cell carcinoma, intraepidermal carcinoma, and  
49 psoriasis. *Journal of the American Academy of Dermatology* 59[2], 268-274. 2008. United  
50 States.  
51 Reason Population not relevant to PICO

- 1 Pariser, D. M., Phillips, P. K., Pariser, D. M., and Phillips, P. K. Basal cell carcinoma: when to treat it  
2 yourself, and when to refer. [Review] [5 refs]. *Geriatrics* 49[3], 39-44. 1994. UNITED STATES.  
3 Reason Narrative Review
- 4 Piccolo, D. Smolle. Teledermoscopy--results of a multicentre study on 43 pigmented skin lesions.  
5 *Journal of Telemedicine and Telecare* 6[3], 132-137. 2000. United Kingdom.  
6 Reason Not relevant to PICO
- 7 Porta, N., San, Juan J., Grasa, M. P., Simal, E., Ara, M., Querol, M. A., Porta, N., San Juan, J., Grasa, M.  
8 P., Simal, E., Ara, M., and Querol, M. Ara. [Diagnostic agreement between primary care  
9 physicians and dermatologists in the health area of a referral hospital]. [Spanish]. *Actas*  
10 *Derma-Sifiliograficas* 99[3], 207-212. 2008. Spain.  
11 Reason Not relevant to PICO
- 12 Price, H. N., Zaenglein, A. L., Price, Harper N., and Zaenglein, Andrea L. Diagnosis and management of  
13 benign lumps and bumps in childhood. [Review] [34 refs]. *Current Opinion in Pediatrics* 19[4],  
14 420-424. 2007. United States.  
15 Reason Narrative Review
- 16 Raasch, B. A. and Raasch, B. A. Suspicious skin lesions and their management. *Australian Family*  
17 *Physician* 28[5], 466-471. 1999. AUSTRALIA.  
18 Reason Not relevant to PICO
- 19 Rademaker, M. Thorburn. Pathology referrals for skin lesions - Are we giving the pathologist  
20 sufficient clinical information? *New Zealand Medical Journal* 123[1325], 53-58. 2010. New  
21 Zealand.  
22 Reason Not relevant to PICO
- 23 Raj, G. & Gupta, G. (1111) The need for full body skin examination on patients referred to  
24 dermatology with a lesion. *British Journal of Dermatology.Conference: 93rd Annual Meeting of*  
25 *the British Association of Dermatologists Liverpool United Kingdom.Conference Start:*  
26 *20130709 Conference End: 20130711.Conference Publication: (var.pagings),* 169: July.  
27 Reason Not in PICO
- 28 Richert, B., Lecerf, P., Caucanas, M. & Andre, J. (2013) Nail tumors. *Clinics in Dermatology*, 31: 602-  
29 617.  
30 Reason Narrative review
- 31 Rodriguez, Caravaca G., Garcia-Cruces, Mendez J., Hobson, S., Rodriguez, Caravaca F., Villar Del,  
32 Campo M., Gonzalez, Mosquera M., Rodriguez Caravaca, G., Garcia-Cruces Mendez, J.,  
33 Hobson, S., Rodriguez Caravaca, F., Villar Del Campo, M., and Gonzalez Mosquera, M. [Validity  
34 of the clinical diagnosis of the basal cell carcinoma in primary health care]. [Spanish]. *Atencion*  
35 *Primaria* 28[6], 391-395. 15-10-2001. Spain.  
36 Reason Not relevant to PICO
- 37 Rodriguez, Caravaca G., Villar Del, Campo M., Gonzalez, Mosquera M., Garcia-Cruces, Mendez J.,  
38 Lopez, Bran E., Pombo, Liria N., Rodriguez Caravaca, G., Villar Del Campo, M., Gonzalez  
39 Mosquera, M., Garcia-Cruces Mendez, J., Lopez Bran, E., and Pombo Liria, N. [Diagnostic  
40 agreement between primary and hospital care in the assessment of basal cell carcinoma].  
41 [Spanish]. *Gaceta Sanitaria* 15[3], 255-258. 2001. Spain.  
42 Reason Setting not relevant to PICO
- 43 Roozeboom, M. H., Mosterd, K., Winnepeninckx, V. J., Nelemans, P. J. & Kelleners-Smeets, N. W.  
44 (2013) Agreement between histological subtype on punch biopsy and surgical excision in  
45 primary basal cell carcinoma. *Journal of the European Academy of Dermatology &*  
46 *Venereology*, 27: 894-898.  
47 Reason Not in PICO
- 48 Rosendahl, C., Tschandl, P., Cameron, A., Kittler, H., Rosendahl, C., Tschandl, P., Cameron, A. &  
49 Kittler, H. (2011) Diagnostic accuracy of dermatoscopy for melanocytic and nonmelanocytic  
50 pigmented lesions. *Journal of the American Academy of Dermatology*, 64: 1068-1073.  
51 Reason Not in PICO (only excised lesions, not examined lesions)

- 1 Rosendahl, C., Hansen, C., Cameron, A., Bourne, P., Wilson, T., Cook, B., Baker, M., Keir, J., Dicker, T.,  
2 Reid, M., Williamson, R., Weedon, D., Soyer, H. P., Youl, P. H., and Wilkinson, D. Measuring  
3 performance in skin cancer practice: the SCARD initiative. *International Journal of*  
4 *Dermatology* 50[1], 44-51. 2011.  
5 Reason Not relevant to PICO
- 6 Rousset, J., Abgral, R., Chinellato, S., Garetier, M., Barberot, C., Valette, G., Potard, G., Le, B. T. &  
7 Salaun, P. Y. (2013) Early recurrence or submucosal residual of laryngeal squamous cell  
8 carcinoma: diagnosis by CT-guided endolaryngeal core biopsy on a transcutaneous approach.  
9 *Head & Neck*, 35: E202-E204.  
10 Reason Not in PICO
- 11 Ruskiewicz, J. and Ruskiewicz, J. Skin cancer and actinic keratoses. *Journal of the American*  
12 *Optometric Association* 69[4], 229-235. 1998. UNITED STATES.  
13 Reason Narrative Review
- 14 Sambandan, P. G. G. Infiltrative basal cell carcinomas presenting as actinic keratosis: Implications for  
15 clinical practice. *Dermatologic Surgery* 34[1], 9-13. 2008. United Kingdom.  
16 Reason Narrative Review
- 17 Sanyal, S., Holme, A. & Kemmett, D. (2013) How are patients with actinic keratoses managed in  
18 primary care? *British Journal of Dermatology*, 169: 45.  
19 Reason Not in PICO
- 20 Schlien, H. P., Niemeyer, K., Habel, G., and Happle, R. [Keratocysts in adolescent patients--early  
21 symptoms in the diagnosis of basal cell nevus syndrome?][German]. *Deutsche Zahnärztliche*  
22 *Zeitschrift* 40[6], 521-524. 1985.  
23 Reason Awaiting arrival of paper
- 24 Schofield, J. Hepburn. The costs of diagnosing and treating skin cancer using the 2-week-wait referral  
25 process. *British Journal of Dermatology Conference*[var.pagings], July. 2011.  
26 Reason Health Economics
- 27 See, A. Lim. Operational teledermatology in Broken Hill, rural Australia. *Australasian Journal of*  
28 *Dermatology* 46[3], 144-149. 2005. Australia.  
29 Reason Narrative Review
- 30 Shapiro, M., James, W. D., Kessler, R., Lazorik, F. C., Katz, K. A., Tam, J., Nieves, D. S., Miller, J. J.,  
31 Shapiro, Michael, James, William D., Kessler, Rex, Lazorik, Francis C., Katz, Kenneth A., Tam,  
32 John, Nieves, David S., and Miller, Jeffrey J. Comparison of skin biopsy triage decisions in 49  
33 patients with pigmented lesions and skin neoplasms: store-and-forward teledermatology vs  
34 face-to-face dermatology. *Archives of Dermatology* 140[5], 525-528. 2004. United States.  
35 Reason Not relevant to PICO
- 36 Sharma, A., Alfa-Wali, M., Rodriguez-Justo, M. & Polychronis, A. (2013) Squamous cell carcinoma of  
37 pancreas: an unusual site of relapse from early-stage lung cancer: 12-month postsurgery. *BMJ*  
38 *Case Reports*, 2013, 2013.  
39 Reason Not in PICO
- 40 Shlyankevich, J., Kimball, A., Corey, K. & Kardos, M. (2014) Diagnostic accuracy of referring providers  
41 sending patients to dermatology urgent care clinic for suspected skin cancers. *Journal of the*  
42 *American Academy of Dermatology*, 70: AB81.  
43 Reason Not in PICO
- 44 Singh, T. & Schenberg, M. (2013) Delayed diagnosis of oral squamous cell carcinoma following dental  
45 treatment. *Annals of the Royal College of Surgeons of England*, 95: 369-373.  
46 Reason Not in PICO
- 47 Socha, A. & Niedzielska, I. (2013) Exophytic tumours of skin of the head - Case study and review of  
48 the literature. *Dental and Medical Problems*, 50: 229-237.  
49 Reason Not in PICO
- 50 Steel, B. J. (2014) - Skin cancer - an overview for dentists. - *British Dental Journal*, 216: 575-581.  
51 Reason Narrative review

- 1 Steiner, A. Pehamberger. In vivo epiluminescence microscopy of pigmented skin lesions. II. Diagnosis  
2 of small pigmented skin lesions and early detection of malignant melanoma. *Journal of the*  
3 *American Academy of Dermatology* 17[4], 584-591. 1987. United States.  
4 Reason Outcomes not relevant to PICO
- 5 Steinmann, A. Liebl. Prevention and Early Detection of Cancer of the Skin. *Gesundheitswesen,*  
6 *Supplement* 66[1], S37-S42. 2004. Germany.  
7 Reason Narrative Review
- 8 Streeton, C. L. G. Treatment of basal cell carcinomas by general practitioners in Australia.  
9 *International Journal of Dermatology* 45[4], 345-351. 2006. United Kingdom.  
10 Reason Narrative Review
- 11 Stulberg, D. L., Crandell, B., Fawcett, R. S., Stulberg, Daniel L., Crandell, Blain, and Fawcett, Robert S.  
12 Diagnosis and treatment of basal cell and squamous cell carcinomas. *American Family*  
13 *Physician* 70[8], 1481-1488. 15-10-2004. United States.  
14 Reason Narrative Review
- 15 Takahashi, H. and Takahashi, H. Non-ulcerative basal cell carcinoma arising on the genitalia. *Journal*  
16 *of Dermatology* 27[12], 798-801. 2000. Japan.  
17 Reason N=2
- 18 Tan, E., Yung, A., Jameson, M., Oakley, A., Rademaker, M., Tan, E., Yung, A., Jameson, M., Oakley, A.,  
19 and Rademaker, M. Successful triage of patients referred to a skin lesion clinic using  
20 teledermoscopy (IMAGE IT trial). *British Journal of Dermatology* 162[4], 803-811. 2010.  
21 England.  
22 Reason Not relevant to PICO
- 23 Tangjaturonrasme, N., Rerknimitr, R., Pittayanon, R., Wisedopas, N. & Kullavanijaya, P. (2013) The  
24 difference in detection rates during surveillance endoscopy for early squamous cell neoplasia  
25 of the esophagus between patients with previous nasopharyngeal cancer and patients with  
26 other ent related squamous cell cancers pornphan thienchanachaiya1. *Gastrointestinal*  
27 *Endoscopy*, 77: AB339-AB340.  
28 Reason Not in PICO
- 29 Tate, B. Checking pigmented skin lesions. *Medicine Today* 8[3], 38-46. 2007. Australia.  
30 Reason Narrative Review
- 31 Terrill, P. J. F. Is there just one lesion? the need for whole body skin examination in patients  
32 presenting with non-melanocytic skin cancer. *ANZ Journal of Surgery* 79[10], 707-712. 2009.  
33 Australia.  
34 Reason Population not relevant to PICO
- 35 Tochigi, T., Shuto, K., Staito, H., Kono, T. & Matsubara, H. (2013) Early esophageal squamous cell  
36 cancer by high-barium esophagography using flat panel X-ray detector in comparison with  
37 histological findings. *European Journal of Cancer*, 49: S252-S253.  
38 Reason Not in PICO
- 39 Tolpinrud, W. L., Viola, K. V., Kirsner, R. S., Gross, C. P., Imaeda, S., Federman, D. G., Tolpinrud,  
40 Whitney L., Viola, Kate V., Kirsner, Robert Scott, Gross, Cary P., Imaeda, Suguru, and  
41 Federman, Daniel G. Nondermatologists' use of predictive terms for a potentially malignant  
42 lesion. *Southern Medical Journal* 104[7], 477-481. 2011. United States.  
43 Reason Outcomes not relevant to PICO
- 44 Treiber, N., Huber, M. A., Scharffetter-Kochanek, K. & Schneider, L. A. (2014) - [Early detection of  
45 skin cancer]. [German]. - *MMW Fortschritte der Medizin*, 156: 37-40.  
46 Reason Narrative review
- 47 Turan, E., Yurt, N., Yesilova, Y. & Turkcu, G. (2013) Early-onset basal cell carcinoma. *Turkish Journal*  
48 *of Pediatrics*, 55: 354-356.  
49 Reason Not in PICO



- 1 Turner, T. Pigmented lesions - A plan for management in general practice. *Medical Journal of*  
2 *Australia* 159[11-12], 809-814. 1993. Australia.  
3 Reason Narrative Review
- 4 Twist, M. Rate of incomplete excision of basal cell carcinomas by General Practitioners with Special  
5 Interest. *British Journal of Dermatology* 161[1], 187. 2009.  
6 Reason Not relevant to PICO
- 7 Ubriani, R. Grossman. Facial Papules as a Marker of Internal Malignancy. *Medical Clinics of North*  
8 *America* 93[6], 1305-1331. 2009. United States.  
9 Reason Narrative Review
- 10 Uslu, M. Karaman. A case of nevoid basal cell carcinoma syndrome. *Turkderm Deri Hastaliklari ve*  
11 *Frenge Arsivi* 40[4], 136-138. 2006. Turkey.  
12 Reason Single Case
- 13 van Rijsingen, M. C., Van, B. B., Van Der Wilt, G. J., Lagro-Janssen, A. L. & Gerritsen, M. J. (2014) - The  
14 current and future role of general practitioners in skin cancer care: an assessment of 268  
15 general practitioners. - *British Journal of Dermatology*, 170: 1366-1368.  
16 Reason Not in PICO
- 17 Van Rijsingen, M. C. J., Hanssen, S. C. A., Groenewoud, J. M. M., Van Der Wilt, G. J. & Gerritsen, M.-J.  
18 (2014) Referrals by general practitioners for suspicious skin lesions: The urgency of training.  
19 *Acta Dermato-Venereologica*, 94: 138-141.  
20 Reason Not in PICO
- 21 Vermaak, P. V. & Manushakian, J. (2013) Rapidly enlarging skin lesion on the lip. *BMJ Case Reports*,  
22 2013, 2013.  
23 Reason Not in PICO
- 24 Viglizzo, G. Rongioletti. Clinical, dermoscopic and pathologic correlation of pigmentary lesions  
25 observed in a dermoscopy service in the year 2003. *Giornale Italiano di Dermatologia e*  
26 *Venereologia* 139[4], 339-344. 2004. Italy.  
27 Reason Setting not relevant to PICO
- 28 Walker, M. S. R. Treatment patterns and clinical characteristics of patients with advanced basal cell  
29 carcinoma (ABCC) in the community oncology setting. *Journal of the American Academy of*  
30 *Dermatology Conference*[var.pagings], AB159. 2012.  
31 Reason Not relevant to PICO
- 32 Warshaw, E. M., Lederle, F. A., Grill, J. P., Gravely, A. A., Bangerter, A. K., Fortier, L. A., Bohjanen, K.  
33 A., Chen, K., Lee, P. K., Rabinovitz, H. S., Johr, R. H., Kaye, V. N., Bowers, S., Wenner, R., Askari,  
34 S. K., Kedrowski, D. A., Nelson, D. B., Warshaw, Erin M., Lederle, Frank A., Grill, Joseph P.,  
35 Gravely, Amy A., Bangerter, Ann K., Fortier, Lawrence A., Bohjanen, Kimberly A., Chen, Karen,  
36 Lee, Peter K., Rabinovitz, Harold S., Johr, Robert H., Kaye, Valda N., Bowers, Sacharitha,  
37 Wenner, Rachel, Askari, Sharone K., Kedrowski, Deborah A., and Nelson, David B. Accuracy of  
38 teledermatology for pigmented neoplasms.[Erratum appears in *J Am Acad Dermatol*. 2010  
39 Feb;62(2):319]. *Journal of the American Academy of Dermatology* 61[5], 753-765. 2009.  
40 United States.  
41 Reason Not relevant to PICO
- 42 Watkins, J. and Watkins, Jean. *Dermatology and the community nurse: actinic (solar) keratosis.*  
43 [Review] [13 refs]. *British journal of community nursing* 15[1], 6-1. 2010. England.  
44 Reason Narrative Review
- 45 Westbrook, R. H. G. Diagnostic accuracy for skin cancer: Comparison of general practitioner with  
46 dermatologist and dermatopathologist [1]. *Journal of Dermatological Treatment* 17[1], 57-58.  
47 2006. United Kingdom.  
48 Reason Narrative Review
- 49 White, G. M., Zhou, H. C. & Burchette, R. J. (2013) Biopsy followed by immediate curettage and  
50 electrodesiccation of suspected basal cell carcinomas at the first visit. *JAMA Dermatology*,

- 1 149: 980-981.  
 2 Reason Not in PICO  
 3 Whited, J. D., Hall, R. P., Simel, D. L., and Horner, R. D. Primary care clinicians' performance for  
 4 detecting actinic keratoses and skin cancer. *Archives of Internal Medicine* 157[9], 985-990.  
 5 1997.  
 6 Reason Not relevant to PICO  
 7 Wietfeldt, E. D., Thiele, J., Wietfeldt, E Dawn, and Thiele, James. Malignancies of the anal margin and  
 8 perianal skin. *Clinics in Colon & Rectal Surgery* 22[2], 127-135. 2009. United States.  
 9 Reason Narrative Review  
 10 Winzenburg, S. M., Niehans, G. A., George, E., Daly, K., Adams, G. L., Winzenburg, S. M., Niehans, G.  
 11 A., George, E., Daly, K., and Adams, G. L. Basaloid squamous carcinoma: a clinical comparison  
 12 of two histologic types with poorly differentiated squamous cell carcinoma. *Otolaryngology -*  
 13 *Head & Neck Surgery* 119[5], 471-475. 1998. UNITED STATES.  
 14 Reason Not relevant to PICO  
 15 Wolberink, E. A. W., Pasch, M. C., Zeiler, M., Van Erp, P. E. J. & Gerritsen, M. J. P. (2013) High  
 16 discordance between punch biopsy and excision in establishing basal cell carcinoma subtype:  
 17 Analysis of 500 cases. *Journal of the European Academy of Dermatology and Venereology*, 27:  
 18 985-989.  
 19 Reason Not in PICO  
 20 Woolley, S. D. & Hughes, C. (2013) A young military pilot presents with a periocular Basal Cell  
 21 Carcinoma: A case report. *Travel Medicine and Infectious Disease*, 11: 435-437.  
 22 Reason Not in PICO  
 23 Wray, E. V., Brant, B., Hussain, F. & Muller, F. M. (2013) A new model of teledermoscopy combining  
 24 service and education. *British Journal of Dermatology*, 169: 139.  
 25 Reason Not in PICO  
 26 Youl, P. H., Janda, M., Aitken, J. F., Del Mar, C. B., Whiteman, D. C., Baade, P. D., Youl, P. H., Janda,  
 27 M., Aitken, J. F., Del Mar, C. B., Whiteman, D. C. & Baade, P. D. (2011) Body-site distribution of  
 28 skin cancer, pre-malignant and common benign pigmented lesions excised in general practice.  
 29 *British Journal of Dermatology*, 165: 35-43.  
 30 Reason Same data as Youl (20067), which is not in PICO as results only reported for excised lesions (N =  
 31 11116, GPs and skin cancer clinic doctors), not examined lesions (N = 28755, GPs and skin cancer clinic  
 32 doctors).  
 33 Youl, P.H. et. Al. (2007) Diagnosing skin cancer in primary care: how do mainstream general  
 34 practioners compare with primary care skin cancer clinic doctors? *Medical Journal of*  
 35 *Australia*187;215-220  
 36 Reason Not in PICO as results only reported for excised lesions (N = 11116, GPs and skin cancer clinic  
 37 doctors), not examined lesions (N = 28755, GPs and skin cancer clinic doctors).  
 38 Zalaudek, I., Kreusch, J., Giacomel, J., Ferrara, G., Catricala, C., and Argenziano, G. How to diagnose  
 39 nonpigmented skin tumors: A review of vascular structures seen with dermoscopy Part II.  
 40 Nonmelanocytic skin tumors. *Journal of the American Academy of Dermatology* 63[3], 377-  
 41 386. 2010.  
 42 Reason Narrative Review  
 43 Zucker, J. L. The eyelids: Some common disorders seen in everyday practice. *Geriatrics* 64[4], 14-  
 44 19+28. 2009. United States.  
 45 Reason Narrative Review

46

**47 Review question:**

48 Which investigations of symptoms of suspected basal cell carcinoma should be done with clinical  
 49 responsibility retained by primary care?  
 50

**51 Results**

1  
2  
3  
4  
5  
6  
7  
8  
9

**Literature search**


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1980-2013	2206	141	07/02/2013
<i>Premedline</i>	1980-2013	85	9	07/02/2013
<i>Embase</i>	1980-2013	2263	146	08/02/2013
<i>Cochrane Library</i>	1980-2013	37	1	07/02/2013
<i>Psychinfo</i>	1980-2013	3	0	07/02/2013
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	1980-2013	309	63	07/02/2013
<i>Biomed Central</i>	1980-2013	1026	4	07/02/2013

Total number of studies identified after de-duplication: 290

**Update Search**


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	2013-11/08/2014	87	7	11/08/2014
<i>Premedline</i>	2013-11/08/2014	123	6	11/08/2014
<i>Embase</i>	2013-11/08/2014	181	16	11/08/2014
<i>Cochrane Library</i>	2013-11/08/2014	55	0	11/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	2013-11/08/2014	53	2	11/08/2014

Total References retrieved (after de-duplication): 23



**Risk of bias in the included studies**

The risk of bias and applicability concerns are summarised per study in the figure below. The main issues to note are that the study population may not be directly representative of an unselected symptomatic population of patients presenting to the UK-based GP, that the index test does not specify the criteria for malignancy which may limit its external validity, and that the results presented are based on a best case scenario, and are therefore likely to be inflated, and only available for skin malignancy as a whole and not for basal cell carcinoma separately.



**Study results**

Table 1: Basal cell carcinoma: Study results

Study	Intervention	Prevalence	Sensitivity (95% CI)	Specificity (95% CI)	Positive predictive value (95% CI)	False negativity rate
Rosendahl (2011)	Clinical images and dermatoscopy	138 malignancies/463 lesions	82.6% (NR)	80% (NR)	NR (NR)	17.4% (NR)

NR = not reported

No evidence was identified pertaining to the diagnostic accuracy of excision biopsy of the lesion in patients with suspected basal cell cancer where the clinical responsibility was retained by primary care.

**Evidence statement(s):**

Dermatoscopy and clinical images (1 study, N = 463 lesions/389 patients) performed in symptomatic patients presenting in a primary care setting is associated with a best-case sensitivity of 82.6%, specificity of 80%, and false negativity rate of 17.4% for basal cell carcinoma. The study was associated with 1 bias and 2 applicability concerns (see also Table 1).

**Evidence tables**

**Rosendahl (2011)**

**PATIENT SELECTION**

<b>A. risk of bias</b>	
Patient sampling	Consecutive series of lesions submitted for histology from the primary care skin cancer clinic of one of the authors.
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Probably</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>N = 463 pigmented lesions from 389 patients, mean (SD) age = 57 (17) years, 32.6% females. Lesion location: Trunk: N = 241; extremities: N = 128; head and face: N = 82; palms and soles: N = 10. Histopathologically, 246 pigmented lesions turned out to be melanocytic and 217 were of non-melanocytic origin.</p> <p>Final diagnoses:  Malignant lesions: Basal cell carcinoma: N = 72; squamous cell carcinoma: N = 37; melanoma: N = 29.  Benign lesions: Melanocytic nevi: N = 217; seborrheic keratosis: N = 43; solar lentigo: N = 37; lichen planus-like keratosis: N = 21, others: N = 7.</p> <p><u>Inclusion criteria:</u> All pigmented lesions biopsied or excised during a 30-month period. <i>Patients included are only those who received resection. This changes the spectrum of disease as it excludes patients with lesions that were not considered concerning enough to warrant resection.</i></p> <p><u>Exclusion criteria:</u> Poor image quality (N = 3).</p> <p><u>Clinical setting:</u> Primary care skin cancer practice in Queensland, Australia</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	<p>For each lesion: A triplet of high-resolution digital images consisting of two clinical images (overview and close-up) followed by one dermatoscopic image. The clinical images were taken with Canon EOS digital single lens reflex cameras. The close-up was taken using a macro lens (60-mm f2.8 macro, Canon) with diffuse illumination at a constant reproduction ratio determined by a custom-fabricated spacer. The degree of magnification of the close-up images was similar to that of the dermatoscopy images.</p> <p>Dermatoscopic images were nonpolarising, preferentially using the DermLite Fluid device (3 Gen, San Juan, Capistrano, Ca); alternatively DermLite Foto (custom nonpolarised; 3 Gen) and Heine Delta 20 devices (Heines, Optotechnic GmbH&lt; Herrsching, Germany) were used for large and inaccessible lesions, respectively. Dermatoscopic photographs were taken with Canon EOS single lens reflex cameras. Images were presented to the assessors as powerpoint slides. After inspection of the images, the assessor was required to give a diagnosis (criteria not reported, so presumably based on qualitative criteria). Dermatoscopic images were also screened for asymmetry of structure and colour ("chaos") and for clues to malignancy. Asymmetry of colour and structure were defined according to the basic principles of pattern analysis as revised by Kittler (2007, Dermatopathology: Practical &amp; Conceptual, 13:1). Clues to malignancy included: Eccentric structureless zone (any colour except skin colour), gray or blue structures, peripheral black dots or clods, segmental radial lines or pseudopods,</p>

	polymorphous vessels, white lines, thick reticular or branched lines, and parallel lines on ridges (acral lesions). <i>Not further information regarding the specific cut-off criteria for malignancy reported. The reporting of the results suggests that the test performance is based on best possible scenario.</i>
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Unclear concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Histopathology
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Yes</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	The results are presented for all malignancies combined. The 2-by-2 table could not be extracted and the results could not be separated into the different malignancies

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15

**References**

**Included Studies**

Rosendahl C, Tschandl P, Med C, Cameron A, Kittler H. Diagnostic accuracy of dermatoscopy for melanocytic and nonmelanocytic pigmented lesions. *Journal of the American Academy of Dermatology* 2011;64(6):1068-73.

**Excluded Studies**

Abbas Q, Celebi ME, Garcia IF, Rashid M. Lesion border detection in dermoscopy images using dynamic programming. *Skin Research and Technology* 2011;17(1):91-100.  
Exclusion Reason: Not in PICO

Adinarayan M, Krishnamurthy SP. Clinicopathological evaluation of nonmelanoma skin cancer. *Indian Journal of Dermatology* 2011;56(6):670-2.  
Exclusion Reason: Narrative Review

- 1 Ahmed R, Soldin M. Incomplete excision rate of basal cell carcinoma: A 2-year retrospective clinical  
2 audit. *European Journal of Surgical Oncology* 2011;37(11):984.  
3 Exclusion Reason: Not in PICO
- 4 Ahmad K, Siah T, Langtry JAA. Recurrent and incompletely excised nonmelanoma skin cancers  
5 referred for Mohs micrographic surgery. *British Journal of Dermatology* 2012;167:56.  
6 Exclusion Reason: Not in PICO
- 7 Ahmed, M. M., Moore, B. A. & Schmalbach, C. E. (2014) Utility of Head and Neck Cutaneous  
8 Squamous Cell Carcinoma Sentinel Node Biopsy: A Systematic Review. *Otolaryngology-Head and*  
9 *Neck Surgery*, 150: 180-187.  
10 Exclusion Reason: Not in PICO
- 11 Aitken JF, Janda M, Elwood M, Youl PH, Ring IT, Lowe JB. Clinical outcomes from skin screening  
12 clinics within a community-based melanoma screening program. *Journal of the American*  
13 *Academy of Dermatology* 2006;54(1):105-14.  
14 Exclusion Reason: Not in PICO
- 15 Alendar F, Drljevic I, Drljevic K, Alendar T. Early detection of melanoma skin cancer. *Bosnian Journal*  
16 *of Basic Medical Sciences* 2009;9(1):77-80.  
17 Exclusion Reason: Not in PICO
- 18 Albert MR, Weinstock MA. Keratinocyte carcinoma. [Review] [74 refs]. *CA: A Cancer Journal for*  
19 *Clinicians* 2003;53(5):292-302.  
20 Exclusion Reason: Narrative Review
- 21 Aldridge, R. B., Naysmith, L., Ooi, E. T., Murray, C. S. & Rees, J. L. (1111) The importance of a full  
22 clinical examination: Assessment of index lesions referred to a skin cancer clinic without a total  
23 body skin examination would miss one in three melanomas. *Acta Dermato-Venereologica*, 93:  
24 2013.  
25 Exclusion Reason: Not in PICO
- 26 Allon, I., Allon, D. M., Anavi, Y. & Kaplan, I. (2013) The significance of surface ulceration as a sign of  
27 malignancy in exophytic oral mucosal lesions: myth or fact? *Head and neck pathology*, 7: 149-  
28 154.  
29 Exclusion Reason: Not in PICO
- 30 Alsharqi A, Wilson N, De Mozzi P. Basal cell carcinomas excision margins: Primary vs. secondary care.  
31 *British Journal of Dermatology* 2010;163:101.  
32 Exclusion Reason: Narrative Review
- 33 Alsharqi A, Wilson N. Will the introduction of new NICE guidelines change the management of basal  
34 cell carcinomas in the community? *British Journal of Dermatology* 2011;165:108.  
35 Exclusion Reason: Narrative Review
- 36 Altamura D, Menzies SW, Argenziano G, Zalaudek I, Soyer HP, Sera F, et al. Dermatoscopy of basal  
37 cell carcinoma: morphologic variability of global and local features and accuracy of diagnosis.  
38 *Journal of the American Academy of Dermatology* 2010;62(1):67-75.  
39 Exclusion Reason: Not in PICO
- 40 Angit C, Sharpe GR. Regional audit on squamous cell carcinoma excision margin. *Journal of the*  
41 *American Academy of Dermatology* 2011;64(2 SUPPL. 1):AB124.  
42 Exclusion Reason: Not in PICO
- 43 Anthony S, Vlachou C, Murdoch M, Tatnall F, Batta K, Brown V. Audit of 2-week-wait referrals: how  
44 does tertiary referral influence management? *British Journal of Dermatology* 2010;163:112-3.  
45 Exclusion Reason: Not in PICO
- 46 Anthony S, Ogden E, Blanshard M, Schofield JK. Basal cell carcinomas: Impact of national guidance  
47 on local specialist dermatology Department is likely to be manageable. *British Journal of*  
48 *Dermatology* 2009;161:64-5.  
49 Exclusion Reason: Not in PICO

- 1 Arits AHMM, Schlangen MHJ, Nelemans PJ, Kelleners-Smeets NWJ. Trends in the incidence of basal  
2 cell carcinoma by histopathological subtype. *Journal of the European Academy of Dermatology*  
3 *and Venereology* 2011;25(5):565-9.  
4 Exclusion Reason: Not in PICO
- 5 Arlt A, Luckhaupt H, Hildmann H. Diagnosis of recurrent squamous cell carcinomas with the tumor  
6 marker SCC-antigen. [German]. *Laryngo- Rhino- Otologie* 2000;79(4):207-12.  
7 Exclusion Reason: Not in PICO
- 8 Astner S, Dietterle S, Otberg N, Rowert-Huber HJ, Stockfleth E, Lademann J. Clinical applicability of in  
9 vivo fluorescence confocal microscopy for noninvasive diagnosis and therapeutic monitoring of  
10 nonmelanoma skin cancer. *Journal of Biomedical Optics* 2008;13(1):014003-Feb.  
11 Exclusion Reason: Not in PICO
- 12 Attili SK, Lesar A, McNeill A, Camacho-Lopez M, Moseley H, Ibbotson S, et al. An open pilot study of  
13 ambulatory photodynamic therapy using a wearable low-irradiance organic light-emitting diode  
14 light source in the treatment of nonmelanoma skin cancer. *British Journal of Dermatology*  
15 2009;161(1):170-3.  
16 Exclusion Reason: Not in PICO
- 17 Asuquo ME, Ebughe G. Major dermatological malignancies encountered in the University of Calabar  
18 Teaching Hospital, Calabar, southern Nigeria. *International Journal of Dermatology* 2012;51:32-6.  
19 Exclusion Reason: Not in PICO
- 20 Baade PD, Youl PH, Janda M, Whiteman DC, Del Mar CB, Aitken JF. Factors associated with the  
21 number of lesions excised for each skin cancer: a study of primary care physicians in Queensland,  
22 Australia. *Archives of Dermatology* 2008;144(11):1468-76.  
23 Exclusion Reason: Not in PICO
- 24 Bakis S, Irwig L, Wood G, Wong D. Exfoliative cytology as a diagnostic test for basal cell carcinoma: a  
25 meta-analysis. *British Journal of Dermatology* 2004;150(5):829-36.  
26 Exclusion Reason: Not in PICO
- 27 Balogh K, Trehan P, Bashir S, Higgins E, Morris-Jones R. Skin cancer 'filtered screening' by  
28 dermatologists: the 2-week wait system. *British Journal of Dermatology* 2012;167:63.  
29 Exclusion Reason: Not in PICO
- 30 Barry J, Oon SF, Watson R, Barnes L. The management of basal cell carcinomas. *Irish Medical Journal*  
31 2006;99(6):179-81.  
32 Exclusion Reason: Not in PICO
- 33 Bastiaens MT, Struyk L, Tjong AHung SP, Gruis N, ter Huurne J, Westendorp RG, et al. Cutaneous  
34 squamous cell carcinoma and p53 codon 72 polymorphism: a need for screening? *Molecular*  
35 *Carcinogenesis* 2001;30(1):56-61.  
36 Exclusion Reason: Not in PICO
- 37 Bataille V, Hargest E, Brown V, Blackwell V, Dawe S, Cooper A, et al. A teledermatology pilot study in  
38 Hertfordshire: Triage of 2-week-wait referrals. *British Journal of Dermatology* 2011;165:137-8.  
39 Exclusion Reason: Not in PICO
- 40 Beby F, Kodjikian L, Roche O, Bouvier R, Donate D, Guerillon F, et al. [Conjunctival tumors in children.  
41 A histopathologic study of 42 cases]. [French]. *Journal Francais d Ophthalmologie* 2005;28(8):817-  
42 23.  
43 Exclusion Reason: Not in PICO
- 44 Behrens, A., May, A., Manner, H., Pohl, J. & Ell, C. (2013) Esophageal precancerous lesions: Early  
45 diagnosis, treatment, and preservation of quality of life. [German]. *Internist*, 54: 683-690.  
46 Exclusion Reason: Narrative review
- 47 Bernard P, Derancourt C, Arnoult-Coudoux E, Picot R, Delvincourt C. Skin cancer diagnosis by  
48 dermatologists in the region of Champagne-Ardenne: A prospective study. *Annales de*  
49 *Dermatologie et de Venereologie* 2001;128(8-9):883-7.  
50 Exclusion Reason: Not in PICO



- 1 Bhatti AZ, Asif S, Alwan M. Factors affecting incomplete excision of nonmelanoma skin cancers in  
2 New Zealand. *Annals of Plastic Surgery* 2006;57(5):513-6.  
3 Exclusion Reason: Not in PICO
- 4 Bhatnagar A, Mohamad S, Sandramouli S. 'Fast-tracking' cancer referrals: application for periocular  
5 basal cell carcinoma. *Eye* 2006;20(4):428-30.  
6 Exclusion Reason: Not in PICO
- 7 Blakeslee D, Vaughan CW, Shapshay SM. Excisional biopsy in the selective management of T1 glottic  
8 cancer: A three-year follow-up study. *Laryngoscope* 1984;94(4):488-94.  
9 Exclusion Reason: Not in PICO
- 10 Blum A, Bauer J, Rassner G, Garbe C. Early detection of skin cancer. [German]. *Onkologie*  
11 2002;8(10):1064-71.  
12 Exclusion Reason: Narrative Review
- 13 Boiko PE, Koepsell TD, Larson EB, Wagner EH. Skin cancer diagnosis in a primary care setting. *Journal*  
14 *of the American Academy of Dermatology* 1996;34(4):608-11.  
15 Exclusion Reason: Narrative Review
- 16 Bolac C, Cordel N, Deschamps L, Renier M, Quist D, Derancourt C. Diagnosis of skin cancer by  
17 dermatologists in the French West Indies: A prospective study. *Annales de Dermatologie et de*  
18 *Venereologie* 2011;138(1):11-6.  
19 Exclusion Reason: Not in PICO
- 20 Bollschweiler E, Ell C. Squamous cell carcinoma and adenocarcinoma of the esophagus. Differences  
21 in epidemiology, tumor biology, diagnostic procedures, and prevention. [German]. *Onkologie*  
22 2004;10(11):1168-78.  
23 Exclusion Reason: Narrative Review
- 24 Borgulya M, Kurz CM, Knoll T, Velten T, Vieth M, Ell C, et al. Diagnosis of early barrett's neoplasia and  
25 esophageal squamous cell neoplasia by electrical bio-impedance spectroscopy in human tissue.  
26 *Gastrointestinal Endoscopy* 2012;75(4 SUPPL. 1):AB127.  
27 Exclusion Reason: Not in PICO
- 28 Bostock-Ling N. Excising basal cell carcinoma in general practice. *Australian Family Physician*  
29 2006;35(7):558-60.  
30 Exclusion Reason: Narrative Review
- 31 Bowns IR, Collins K, Walters SJ, McDonagh AJ. Telemedicine in dermatology: a randomised  
32 controlled trial. *Health Technology Assessment (Winchester, England)* 2006;10(43):iii-v.  
33 Exclusion Reason: Not in PICO
- 34 Bower CP, Lear JT, de Berker DA. Basal cell carcinoma follow-up practices by dermatologists: a  
35 national survey. *British Journal of Dermatology* 2001;145(6):949-56.  
36 Exclusion Reason: Not in PICO
- 37 Bradley N, Topham E. A service-evaluation of recurrence following curettage and cautery treatment  
38 of well-differentiated primary cutaneous squamous cell carcinoma. *British Journal of*  
39 *Dermatology* 2012;167:59.  
40 Exclusion Reason: Not in PICO
- 41 Brewster DH, Bhatti LA, Inglis JH, Nairn ER, Doherty VR. Recent trends in incidence of nonmelanoma  
42 skin cancers in the East of Scotland, 1992-2003. *British Journal of Dermatology* 2007;156(6):1295-  
43 300.  
44 Exclusion Reason: Not in PICO
- 45 Bristow Ivan, Bowling Jonathan. Dermoscopy as a technique for the early identification of foot  
46 melanoma. *Journal of Foot and Ankle Research* 2009;2(1):14.  
47 Exclusion Reason: Not in PICO
- 48 Brown SJ, Lawrence CM. The management of skin malignancy: to what extent should we rely on  
49 clinical diagnosis? *British Journal of Dermatology* 2006;155(1):100-3.  
50 Exclusion Reason: Narrative Review

- 1 Brundel K-H. Skin cancer in general practice. [German]. *Dermatosen in Beruf und Umwelt*  
2 1990;38(2):54-7.  
3 Exclusion Reason: Not in PICO
- 4 Buis PAJ, Chorus RMH, van Diest PJ. Value of histopathologic analysis of skin excisions by GPs. *British*  
5 *Journal of General Practice* 2005;55(515):458-60.  
6 Exclusion Reason: Not in PICO
- 7 Burghout, K., Sigurdsson, V. & Toonstra, J. (2013) Non-melanoma skin cancer. [Dutch]. *Huisarts en*  
8 *Wetenschap*, 56: 174-178.  
9 Exclusion Reason: Narrative review
- 10 Butani A, Arbesfeld DM, Schwartz RA. Premalignant and early squamous cell carcinoma. *Clinics in*  
11 *Plastic Surgery* 2005;32(2):223-+.  
12 Exclusion Reason: Not in PICO
- 13 Carducci M, Bozzetti M, Foscolo AM, Betti R. Margin detection using digital dermatoscopy improves  
14 the performance of traditional surgical excision of basal cell carcinomas of the head and neck.  
15 *Dermatologic Surgery* 2011;37(2):280-5.  
16 Exclusion Reason: Not in PICO
- 17 Carli P, Chiarugi A, De Giorgi V. Examination of lesions (including dermoscopy) without contact with  
18 the patient is associated with improper management in about 30% of equivocal melanomas.  
19 *Dermatologic Surgery* 2005;31(2):169-72.  
20 Exclusion Reason: Not in PICO
- 21 Carter EJ, Whittam LR, Buckley DA. Failure of adherence to NICE guidelines for skin cancer surgery in  
22 general practice. *British Journal of Dermatology* 2009;161:63.  
23 Exclusion Reason: Not in PICO
- 24 Carter J, Evans C, Ghebre R, Glubka B, Downs L. Superficially invasive squamous cell carcinoma of the  
25 vulva: Is radical excision necessary? *Gynecologic Oncology* 2012;125:S83.  
26 Exclusion Reason: Not in PICO
- 27 Chaidemenos G, Apalla Z, Trigoni A, Koussidou T, Karakatsanis G. Inability of dermoscopy to  
28 differentiate early-stage squamous cell carcinoma from keratoacanthoma. *Melanoma Research*  
29 2010;20:e66.  
30 Exclusion Reason: N=2
- 31 Chambers M, Esdaile B, De Vos S, Bowling J, Cassell O, Turner R, et al. The oxfordshire community  
32 dermatology service. *British Journal of Dermatology* 2012;167:97.  
33 Exclusion Reason: Not in PICO
- 34 Chan LS, Scholes NJ, Jones M. Skin excisions: not so simple for the regionally based general surgical  
35 trainee. *Australian Journal of Rural Health* 2011;19(4):205-10.  
36 Exclusion Reason: Not in PICO
- 37 Chattopadhyay, M. & Ha, T. (2013) How to examine a patient with suspected skin cancer. *Medicine*  
38 *(United Kingdom)*, 41: 400-401.  
39 Exclusion Reason: Narrative review
- 40 Cheah PL, Liam CK, Yap SF, Looi LM. Squamous cell carcinoma antigen as an adjunct tumour marker  
41 in primary carcinoma of the lung. *Journal of Clinical Pathology* 1994;47(6):535-7.  
42 Exclusion Reason: Not in PICO
- 43 Chen P, Patel DC. Evaluation of surgical excision of non-melanoma skin cancers - A retrospective  
44 study. *Australasian Journal of Dermatology* 2011;52(4):A9.  
45 Exclusion Reason: Not in PICO
- 46 Cheng B, Joe Stanley R, Stoecker WV, Osterwise CT, Stricklin SM,  
47 Hinton KA, et al. Automatic dirt trail analysis in dermoscopy images. *Skin Research & Technology*  
48 2013;19(1):e20-6.  
49 Exclusion Reason: Not in PICO
- 50 Cheng A, Bennett A, Pogrel MA, Schmidt BL. Should tumor depth measured from an incisional biopsy  
51 be used to guide the decision to perform an elective neck dissection? *Journal of Oral and*  
*Maxillofacial Surgery* 2012;70(9 SUPPL. 2):e-1.

- 1 Exclusion Reason: Not in PICO  
2 Chiesa F, Sala L, Costa L, Moglia D, Mauri M, Podrecca S, et al. Excision of oral leukoplakias by CO2  
3 laser on an out-patient basis: a useful procedure for prevention and early detection of oral  
4 carcinomas. *Tumori* 1986;72(3):307-12.  
5 Exclusion Reason: Not in PICO  
6 Chong SLP, Ferguson L, Lateo S. Skin cancer surgery in primary care: Results of an audit and re-audit.  
7 *British Journal of Dermatology* 2012;167:39.  
8 Exclusion Reason: Not in PICO  
9 Choy B, Bandla S, Xia Y, Tan D, Pennathur A, Luketich JD, et al. Clinicopathologic characteristics of  
10 high expression of Bmi-1 in esophageal adenocarcinoma and squamous cell carcinoma. *BMC*  
11 *Gastroenterology* 2012;12:146.  
12 Exclusion Reason: Not in PICO  
13 Chren MM, Sahay AP, Sands LP, Maddock L, Lindquist K, Bertenthal D, et al. Variation in care for  
14 nonmelanoma skin cancer in a private practice and a veterans affairs clinic. *Medical Care*  
15 2004;42(10):1019-26.  
16 Exclusion Reason: Not in PICO  
17 Civantos F Jr, Zitsch R, Bared A, Amin A. Sentinel node biopsy for squamous cell carcinoma of the  
18 head and neck. [Review] [64 refs]. *Journal of Surgical Oncology* 2008;97(8):683-90.  
19 Exclusion Reason: Narrative Review  
20 Clarke P. Nonmelanoma skin cancers - treatment options. *Australian Family Physician*  
21 2012;41(7):476-80.  
22 Exclusion Reason: Narrative Review  
23 Cleary RK, Schaldenbrand JD, Fowler JJ, Schuler JM, Lampman RM. Treatment options for perianal  
24 Bowen's disease: survey of American Society of Colon and Rectal Surgeons Members. *American*  
25 *Surgeon* 2000;66(7):686-8.  
26 Exclusion Reason: Not in PICO  
27 Cooper SM, Wojnarowska F. The accuracy of clinical diagnosis of suspected premalignant and  
28 malignant skin lesions in renal transplant recipients. *Clinical & Experimental Dermatology*  
29 2002;27(6):436-8.  
30 Exclusion Reason: Not in PICO  
31 Cortinas Saenz M, Saenz Guirado S, Gamez Moreno J, Iglesias Cerrillo JA, Pardo Martinez A, Martinez  
32 Gomez L. Analysis of results, quality indicators, and postsurgical complications in an outpatient  
33 dermatological surgery program. *Actas Dermo-Sifiliograficas* 2012;103(1):36-43.  
34 Exclusion Reason: Not in PICO  
35 Corwin P, Munn E, Nicholls D. A study of general practitioners' skin surgery in Canterbury. *New*  
36 *Zealand Medical Journal* 1997;110(1047):253-5.  
37 Exclusion Reason: Not in PICO  
38 Costa S, De Nuzzo M, Rubino A, Rambelli V, Marinelli M, Santini D, et al. Independent determinants  
39 of inaccuracy of colposcopically directed punch biopsy of the cervix. *Gynecologic Oncology*  
40 2003;90(1):57-63.  
41 Exclusion Reason: Not in PICO  
42 Cox NH. Basal cell carcinoma in young adults. *British Journal of Dermatology* 1992;127(1):26-9.  
43 Exclusion Reason: Not in PICO  
44 Cox NH, Wagstaff R, Popple AW. Using clinicopathological analysis of general practitioner skin  
45 surgery to determine educational requirements and guidelines. *BMJ* 1992;304(6819):93-6.  
46 Exclusion Reason: Not in PICO  
47 Cuellar F, Vilalta A, Puig S, Palou J, Zaballos P, Malveyh J. Dermoscopy of early recurrent basal cell  
48 carcinoma. *Archives of Dermatology* 2008;144(9):1254.  
49 Exclusion Reason: N=3

- 1 de Hullu JA, Hollema H, Piers DA, Verheijen RH, van Diest PJ, Mourits MJ, et al. Sentinel lymph node  
2 procedure is highly accurate in squamous cell carcinoma of the vulva. *Journal of Clinical Oncology*  
3 2000;18(15):2811-6.  
4 Exclusion Reason: Not in PICO
- 5 De Berker DAR, Poirier V, Takwale A. Follow-up preferences for patients with basal cell carcinoma:  
6 The basis for modelling clinical practice and commissioning. *British Journal of Dermatology*  
7 2010;163:112.  
8 Exclusion Reason: Not in PICO
- 9 de Giorgi V, Alfaioli B, Papi F, Janowska A, Grazzini M, Lotti T, et al. Dermoscopy in Pigmented  
10 Squamous Cell Carcinoma. *Journal of Cutaneous Medicine and Surgery* 2009;13(6):326-9.  
11 Exclusion Reason: N=1
- 12 Delaney EK, Duckworth L, Thompson WD, Lee AJ, Murchie P. Excising squamous cell carcinomas:  
13 comparing the performance of GPs, hospital skin specialists and other hospital specialists. *Family*  
14 *Practice* 2012;29(5):541-6.  
15 Exclusion Reason: Not in PICO
- 16 Demir H, Isken T, Kus E, Tan YZ, Isgoren S, Gorur GD, et al. Sentinel lymph node biopsy with a gamma  
17 probe in patients with high-risk cutaneous squamous cell carcinoma: follow-up results of sentinel  
18 lymph node-negative patients. *Nuclear Medicine Communications* 2011;32(12):1216-22.  
19 Exclusion Reason: Not in PICO
- 20 Dewan P, Panagou E, Ajen S, Bewley AP, Sahota A, Gibbon K. Are NICE skin cancer guidelines being  
21 followed in primary care? A re-audit to review changes in practice in an inner city setting. *British*  
22 *Journal of Dermatology* 2010;163:65.  
23 Exclusion Reason: Not in PICO
- 24 Dixon AJ, Hall RS. Managing skin cancer--23 golden rules. [Review] [0 refs]. *Australian Family*  
25 *Physician* 2005;34(8):669-71.  
26 Exclusion Reason: Narrative Review
- 27 Dixon A. Rare skin cancers in general practice. *Australian Family Physician* 2007;36(3):141-3.  
28 Exclusion Reason: N=1
- 29 Dua J, Clayton R. A comparison of skin cancer excision rates between general practitioners and  
30 dermatologists in West Berkshire, South East England. *British Journal of Dermatology*  
31 2012;167:60-1.  
32 Exclusion Reason: Not in PICO
- 33 Durdu M, Baba M, Seckin D. Dermatoscopy versus Tzanck smear test: A comparison of the value of  
34 two tests in the diagnosis of pigmented skin lesions. *Journal of the American Academy of*  
35 *Dermatology* 2011;65(5):972-82.  
36 Exclusion Reason: Not in PICO
- 37 Eekhof, J. A. (2013) [Actinic keratosis: the art of doing nothing]. [Dutch]. *Nederlands Tijdschrift Voor*  
38 *Geneeskunde*, 157: A5363.  
39 Exclusion Reason: Narrative review
- 40 Ehrig T, Cockerell C, Piacquadio D, Dromgoole S. Actinic keratoses and the incidence of occult  
41 squamous cell carcinoma: a clinical-histopathologic correlation. *Dermatologic Surgery*  
42 2006;32(10):1261-5.  
43 Exclusion Reason: Not in PICO
- 44 Emery JD, Hunter J, Hall PN, Watson AJ, Moncrieff M, Walter FM. Accuracy of SIAscopy for  
45 pigmented skin lesions encountered in primary care: Development and validation of a new  
46 diagnostic algorithm. *BMC Dermatology* 2010;10.  
47 Exclusion Reason: Not in PICO
- 48 Epstein JB, Scully C. Assessing the patient at risk for oral squamous cell carcinoma. [Review] [87 refs].  
49 *Special Care in Dentistry* 1997;17(4):120-8.  
50 Exclusion Reason: Narrative review

- 1 Epstein JB, Guneri P, Boyacioglu H, Abt E. The limitations of the clinical oral examination in detecting  
2 dysplastic oral lesions and oral squamous cell carcinoma. *Journal of the American Dental*  
3 *Association* 2012;143(12):1332-42.  
4 Exclusion Reason: Not in PICO
- 5 Epstein JB, Silverman S, Epstein JD, Lonky SA, Bride MA. Analysis of oral lesion biopsies identified and  
6 evaluated by visual examination, chemiluminescence and toluidine blue. *Oral Oncology*  
7 2008;44(6):538-44.  
8 Exclusion Reason: Not in PICO
- 9 Epstein JB, Gorsky M, Cabay RJ, Day T, Gonsalves W. Screening for and diagnosis of oral  
10 premalignant lesions and oropharyngeal squamous cell carcinoma - Role of primary care  
11 physicians. *Canadian Family Physician* 2008;54(6):870-5.  
12 Exclusion Reason: Not in PICO
- 13 Epstein, J. B., Guneri, P., Boyacioglu, H. & Abt, E. (2013) The limitations of the clinical oral  
14 examination in detecting dysplastic oral lesions and oral squamous cell carcinoma.[Reprint of J  
15 Am Dent Assoc. 2012 Dec;143(12):1332-42; PMID: 23204089]. *Texas Dental Journal*, 130: 410-  
16 424.  
17 Exclusion Reason: Not in PICO
- 18 Felton J, Mellerio JE. Cutaneous squamous cell carcinomas in epidermolysis bullosa: A 20-year  
19 retrospective study. *British Journal of Dermatology* 2012;167:55-6.  
20 Exclusion Reason: Not in PICO
- 21 Ferrandiz L, Ruiz-de-Casas A, Trakatelli M, de Vries E, Ulrich M, Aquilina S, et al. Assessing physicians'  
22 preferences on skin cancer treatment in Europe. *British Journal of Dermatology* 2012;167:Suppl-  
23 35.  
24 Exclusion Reason: Not in PICO
- 25 Ferreira, P., Rodrigues, M., Ledo, S., Senra, R., Costa, S., V, Rocha, M. & Paiva, C. (2013) Back pain as  
26 the first manifestation of a cavum tumor. *European Journal of Internal Medicine*, 24: e149.  
27 Exclusion Reason: Not in PICO
- 28 Firnhaber JM. Diagnosis and treatment of Basal cell and squamous cell carcinoma. [Review].  
29 *American Family Physician* 2012;86(2):161-8.  
30 Exclusion Reason: Narrative Review
- 31 FitzGerald KL, Buttner PG, Donovan SA. Nonpigmented skin lesions - how many are nonmelanoma  
32 skin cancer? *Australian Family Physician* 2006;35(7):555-7.  
33 Exclusion Reason: Not in PICO
- 34 Fleischer AB, Feldman SR, Barlow JO, Zheng BY, Hahn HB, Chuang TY, et al. The specialty of the  
35 treating physician affects the likelihood of tumor-free resection margins for basal cell carcinoma:  
36 Results from a multi-institutional retrospective study. *Journal of the American Academy of*  
37 *Dermatology* 2001;44(2):224-30.  
38 Exclusion Reason: Not in PICO
- 39 Fontes, K. B., Cunha, K. S., Rodrigues, F. R., Silva, L. E. & Dias, E. P. (2013) Concordance between  
40 cytopathology and incisional biopsy in the diagnosis of oral squamous cell carcinoma. *Brazilian*  
41 *oral research*, 27: 122-127.  
42 Exclusion Reason: Not in PICO
- 43 Freitag CP, Barros SG, Krueh CD, Putten AC, Dietz J, Gruber AC, et al. Esophageal dysplasias are  
44 detected by endoscopy with Lugol in patients at risk for squamous cell carcinoma in southern  
45 Brazil. *Diseases of the Esophagus* 1999;12(3):191-5.  
46 Exclusion Reason: Not in PICO
- 47 French Society of Dermatology. Guideline for the diagnosis and treatment of cutaneous squamous  
48 cell carcinoma and precursor lesions. *Annales de Dermatologie et de Venereologie*  
49 2009;136:Suppl-86.  
50 Exclusion Reason: Guidelines

- 1 Friedman T, Klein D, Hadad E, Westreich M, Shalom A. [Diagnostic accuracy of skin lesions excised by  
2 a plastic surgeon]. [Hebrew]. Harefuah 75;147(4):305-8.  
3 Exclusion Reason: Not in PICO
- 4 Fujishiro M, Yahagi N, Kakushima N, Kodashima S, Muraki Y, Ono S, et al. Endoscopic submucosal  
5 dissection of esophageal squamous cell neoplasms. Clinical Gastroenterology & Hepatology  
6 2006;4(6):688-94.  
7 Exclusion Reason: Not in PICO
- 8 Gait R, Milligan A, Burd RM, Fletcher A. A review of procedures carried out on basal cell carcinomas  
9 by Primary care physicians. British Journal of Dermatology 2009;161:64.  
10 Exclusion Reason: Not in PICO
- 11 Gao L, Lin WH, Gong ZJ, Liu Y, Liu YM, Zhu MH. [Fine needle aspiration cytology of eyelid sebaceous  
12 gland carcinoma and its differential diagnosis]. [Chinese]. Chung-Hua Ping Li Hsueh Tsa Chih -  
13 Chinese Journal of Pathology 2004;33(1):36-9.  
14 Exclusion Reason: Not in PICO
- 15 Garcia-Solano J, Lopez-Avila A, Acosta J, Montalbana S, Sanchez-Sanchez C, Benito A, et al. Non-  
16 melanoma skin cancer with positive surgical and histological margins. Comparative study among  
17 the departments involved in their surgical excision. [Spanish]. Actas Dermo-Sifiliograficas  
18 2004;95(6):358-61.  
19 Exclusion Reason: Not in PICO
- 20 Garner KL, Rodney WM. Basal and squamous cell carcinoma. [Review] [21 refs]. Primary Care; Clinics  
21 in Office Practice 2000;27(2):447-58.  
22 Exclusion Reason: Narrative Review
- 23 Gerbert B, Bronstone A, Maurer T, Hofmann R, Berger T. Decision support software to help primary  
24 care physicians triage skin cancer - A pilot study. Archives of Dermatology 2000;136(2):187-92.  
25 Exclusion Reason: Not in PICO
- 26 Giacomel, J. & Zalaudek, I. (2013) Pink Lesions. *Dermatologic Clinics*, 31: 649-678.  
27 Exclusion Reason: Narrative review
- 28 Gilde K. [Malignant tumors of the skin]. [Review] [25 refs] [Hungarian]. Orvosi Hetilap  
29 2006;147(48):2321-30.  
30 Exclusion Reason: Narrative Review
- 31 Girardi F, Pickel H, Joura EA, Breitenecker G, Gitsch G, Graf AH, et al. [Guidelines for diagnosis and  
32 therapy of intraepithelial neoplasia and early invasive carcinoma of the female lower genital  
33 system (cervix uteri, vagina, vulva) established by the AGK (Colposcopy Work Group in the OGGG  
34 [Austrian Society of Gynecology and Obstetrics])]. [German]. Gynakologisch-Geburtshilfliche  
35 Rundschau 2001;41(3):197-200.  
36 Exclusion Reason: Guidelines
- 37 Golberg O, Alexandroff AB, Burd RM. Seasonal variation in 2-week-wait skin cancer referrals is not  
38 mirrored by changes in incidence of skin cancer: A message for service provision. British Journal  
39 of Dermatology 2011;165:20-1.  
40 Exclusion Reason: Not in PICO
- 41 Goldberg LH, Rubin HA. Management of basal cell carcinoma. Which option is best? Postgraduate  
42 Medicine 1961;85(1):57-8.  
43 Exclusion Reason: Narrative Review
- 44 Goldstone SE, Winkler B, Ufford LJ, Alt E, Palefsky JM. High prevalence of anal squamous  
45 intraepithelial lesions and squamous-cell carcinoma in men who have sex with men as seen in a  
46 surgical practice. Diseases of the Colon & Rectum 2001;44(5):690-8.  
47 Exclusion Reason: Not in PICO
- 48 Gonsalves WC, Chi AC, Neville BW. Common oral lesions: Part II. Masses and neoplasia. American  
49 Family Physician 2007;75(4):509-12.  
50 Exclusion Reason: Narrative Review

- 1 Goulding JMR, Levine S, Blizard RA, Deroide F, Swale VJ. Dermatological surgery: a comparison of  
2 activity and outcomes in primary and secondary care. *British Journal of Dermatology*  
3 2009;161(1):110-4.  
4 Exclusion Reason: Not in PICO
- 5 Graves J, Fleischman MH, Goldstein GD. Derm Access: A new triage system to rapidly identify  
6 suspicious skin lesions. *Dermatologic Surgery* 2006;32(12):1486-90.  
7 Exclusion Reason: Not in PICO
- 8 Griffiths RW, Suvarna SK, Stone J. Do basal cell carcinomas recur after complete conventional  
9 surgical excision? *British Journal of Plastic Surgery* 2005;58(6):795-805.  
10 Exclusion Reason: Not in PICO
- 11 Gross EA. Nonmelanoma skin cancer: Clues to early detection, keys to effective treatment.  
12 *Consultant* 1999;39(3):829-39.  
13 Exclusion Reason: Narrative Review
- 14 Gudi V, Ormerod AD, Dawn G, Green C, MacKie RM, Douglas WS, et al. Management of basal cell  
15 carcinoma by surveyed dermatologists in Scotland. *Clinical & Experimental Dermatology*  
16 2006;31(5):648-52.  
17 Exclusion Reason: Not in PICO
- 18 Gurudutt VV, Genden EM. Cutaneous squamous cell carcinoma of the head and neck. *Journal of Skin*  
19 *Cancer* 2011;2011:502723.  
20 Exclusion Reason: Not in PICO
- 21 Guther S, Ramrath K, Dyll-Smith D, Landthaler M, Stolz W. Development of a targeted risk-group  
22 model for skin cancer screening based on more than 100,000 total skin examinations. *Journal of*  
23 *the European Academy of Dermatology & Venereology* 2012;26(1):86-94.  
24 Exclusion Reason: Not in PICO
- 25 Haliasos, E. C., Kerner, M., Jaimes, N., Zalaudek, I., Malvehy, J., Lanschuetzer, C. M., Hinter, H.,  
26 Hofmann-Wellenhof, R., Braun, R. P. & Marghoob, A. A. (2013) Dermoscopy for the pediatric  
27 dermatologist, part ii: dermoscopy of genetic syndromes with cutaneous manifestations and  
28 pediatric vascular lesions. [Review]. *Pediatric Dermatology*, 30: 172-181.  
29 Exclusion Reason: Narrative review
- 30 Halpern SM, Shall L. Establishment of a primary care-based teledermatology service in Kent. *British*  
31 *Journal of Dermatology* 2011;165:136-7.  
32 Exclusion Reason: Not in PICO
- 33 Hamm H, Hoger PH. Skin tumors in childhood. [Review]. *Deutsches Arzteblatt International*  
34 2011;108(20):347-53.  
35 Exclusion Reason: Narrative Review
- 36 Han MW, Lee B-J, Jang YJ, Chung Y-S. Clinical value of office-based endoscopic incisional biopsy in  
37 diagnosis of nasal cavity masses. *Otolaryngology - Head and Neck Surgery* 2010;143(3):341-7.  
38 Exclusion Reason: Not in PICO
- 39 Hansen C, Wilkinson D, Hansen M, Soyer HP. Factors contributing to incomplete excision of  
40 nonmelanoma skin cancer by Australian general practitioners. *Archives of Dermatology*  
41 2009;145(11):1253-60.  
42 Exclusion Reason: Not in PICO
- 43 Haw, W. Y., Fraser, S., Affleck, A. & Holme, A. (2014) Skin cancer excision performance in primary  
44 and secondary care in Scotland. *British Journal of Dermatology*, 171: 25.  
45 Exclusion Reason: Not in PICO
- 46 Hayashi T, Muto M, Hayashi R, Minashi K, Yano T, Kishimoto S, et al. Usefulness of narrow-band  
47 imaging for detecting the primary tumor site in patients with primary unknown cervical lymph  
48 node metastasis. *Japanese Journal of Clinical Oncology* 2010;40(6):537-41.  
49 Exclusion Reason: Not in PICO
- 50 Heal CF, Raasch BA, Buettner PG, Weedon D. Accuracy of clinical diagnosis of skin lesions. *British*  
51 *Journal of Dermatology* 2008;159(3):661-8.

- 1 Exclusion Reason: Not in PICO  
2 Heal C, Buettner P, Raasch B, Browning S. Minor skin excisions in general practice in North  
3 Queensland. *Australian Family Physician* 2006;35(10):825-8.  
4 Exclusion Reason: Not in PICO  
5 Hermes, H. M., Sahu, J., Schwartz, L. R. & Lee, J. B. (2014) - Clinical and histologic characteristics of  
6 clinically unsuspected melanomas. - *Clinics in Dermatology*, 32: 324-330.  
7 Exclusion Reason: Not in PICO  
8 Hernandez-Martin A, Arias-Palomo D, Barahona E, Hidalgo C, Munoz C, Garcia-Higuera I. [Analysis of  
9 surgical treatment for nonmelanoma skin cancer performed by dermatologists in a public  
10 hospital: clinical-pathological correlation, use of hospital resources, and waiting list time from  
11 diagnosis]. [Spanish][Erratum appears in *Actas Dermosifiliogr.* 2008 Mar;99(2):170]. *Actas Dermo-*  
12 *Sifiliograficas* 2007;98(10):694-701.  
13 Exclusion Reason: Not in PICO  
14 Hjortdal O, Naess A, Berner A. Squamous cell carcinomas of the lower lip. *Journal of Cranio-Maxillo-*  
15 *Facial Surgery* 1995;23(1):34-7.  
16 Exclusion Reason: Narrative Review  
17 Holmkvist KA, Rogers GS, Dahl PR. Incidence of residual basal cell carcinoma in patients who appear  
18 tumor free after biopsy. *Journal of the American Academy of Dermatology* 1999;41(4):600-5.  
19 Exclusion Reason: Not in PICO  
20 Humphreys TR. Skin cancer: Recognition and management. *Clinical Cornerstone* 2001;4(1):23-9.  
21 Exclusion Reason: Narrative Review  
22 Ishihara R, Inoue T, Hanaoka N, Takeuchi Y, Tsujii Y, Kanzaki H, et al. Autofluorescence imaging  
23 endoscopy for screening of esophageal squamous mucosal high-grade neoplasia: a phase II study.  
24 *Journal of Gastroenterology & Hepatology* 2012;27(1):86-90.  
25 Exclusion Reason: Not in PICO  
26 Ismail N, D'Adhemar C, Kirby B, Collins P, Sheahan K, Lally A. An audit of basal cell carcinoma in St  
27 Vincent's University Hospital. *British Journal of Dermatology* 2012;167(6):e34-5.  
28 Exclusion Reason: Not in PICO  
29 Jainkittivong A, Swasdison S, Thangpitsityotin M, Langlais RP. Oral squamous cell carcinoma: a  
30 clinicopathological study of 342 Thai cases. *Journal of Contemporary Dental Practice [Electronic*  
31 *Resource]* 2009;10(5):E033-40.  
32 Exclusion Reason: Not in PICO  
33 Janda, M., Youl, P., Neale, R., Aitken, J., Whiteman, D., Gordon, L. & Baade, P. (2014) - Clinical skin  
34 examination outcomes after a video-based behavioral intervention: analysis from a randomized  
35 clinical trial. - *JAMA Dermatology*, 150: 372-379.  
36 Exclusion Reason: Population not in PICO  
37 Jeong W-J, Paik JH, Cho S-W, Sung M-W, Kim KH, Ahn S-H. Excisional biopsy for management of  
38 lateral tongue leukoplakia. *Journal of Oral Pathology and Medicine* 2012;41(5):384-8.  
39 Exclusion Reason: Not in PICO  
40 Jerant AF, Johnson JT, Sheridan CD, Caffrey TJ. Early detection and treatment of skin cancer.  
41 [Review] [32 refs]. *American Family Physician* 375;62(2):357-68.  
42 Exclusion Reason: Narrative Review  
43 Johnson SJ, Wadehra V. How predictive is a cervical smear suggesting invasive squamous cell  
44 carcinoma? *Cytopathology* 2001;12(3):144-50.  
45 Exclusion Reason: Not in PICO  
46 Jung JE, Rah DK, Kim YO. Effects of preoperative biopsies on recurrence in head and neck skin  
47 cancer. *Archives of Plastic Surgery* 2012;39(5):518-21.  
48 Exclusion Reason: Not in PICO  
49 Kahn, E., Sossong, S., Goh, A., Carpenter, D. & Goldstein, S. (2013) Evaluation of Skin Cancer in  
50 Northern California Kaiser Permanente's Store-and-Forward Teledermatology Referral Program.



- 1 *Telemedicine and E-Health*, 19: 780-785.  
2 Exclusion Reason: Not in PICO
- 3 Kamyab-Hesari, K., Seirafi, H., Naraghi, Z. S., Shahshahani, M. M., Rahbar, Z., Damavandi, M. R.,  
4 Naraghi, M. M., Rezvani, M. & Aghazadeh, N. (2014) Diagnostic accuracy of punch biopsy in  
5 subtyping basal cell carcinoma. *Journal of the European Academy of Dermatology and*  
6 *Venereology*, 28: 250-253.  
7 Exclusion Reason: Not in PICO
- 8 Karagozoglu KH, Castelijns J, Bloemena E, de Bree R, van der Waal L. [An enlarged lymph node in the  
9 neck; what to do?]. [Dutch]. *Nederlands Tijdschrift Voor Tandheelkunde* 2011;118(5):267-71.  
10 Exclusion Reason: Narrative Review
- 11 Kersten RC, Ewing-Chow D, Kulwin DR, Gallon M. Accuracy of clinical diagnosis of cutaneous eyelid  
12 lesions. *Ophthalmology* 1997;104(3):479-84.  
13 Exclusion Reason: Not in PICO
- 14 Khalid S, Spicer A, Gee B, Carr R. The impact of Improved Outcome Guidance (IOG) for skin cancer: A  
15 comparative re-audit of excision rates of basal cell carcinomas by general practitioners in South  
16 Warwickshire. *British Journal of Dermatology* 2009;161:109.  
17 Exclusion Reason: Not in PICO
- 18 Khorasgani MG, Simpson R, Burd RM. How effective is the skin cancer referral pathway? *British*  
19 *Journal of Dermatology* 2011;165:109.  
20 Exclusion Reason: Not in PICO
- 21 Kibarian MA, Hruza GJ. Nonmelanoma skin cancer. Risks, treatment options, and tips on prevention.  
22 *Postgraduate Medicine* 1945;98(6):39-40.  
23 Exclusion Reason: Narrative Review
- 24 Koch FP, Kunkel M, Biesterfeld S, Wagner W. Diagnostic efficiency of differentiating small cancerous  
25 and precancerous lesions using mucosal brush smears of the oral cavity--a prospective and  
26 blinded study. *Clinical Oral Investigations* 2011;15(5):763-9.  
27 Exclusion Reason: Not in PICO
- 28 Koerner KR. Evaluation and treatment by general dentists of oral soft-tissue lesions. *Dentistry Today*  
29 2006;25(7):90-5.  
30 Exclusion Reason: Narrative Review
- 31 Kolm I, Hofbauer G, Braun RP. [Early diagnosis of skin cancer]. [Review] [German]. *Therapeutische*  
32 *Umschau* 2010;67(9):439-46.  
33 Exclusion Reason: Narrative Review
- 34 Kok LP, Van Drunen R, Boon ME, Beck S, Van Coevorden RS. General practitioners use digital  
35 cameras and internet for telepathology of skin lesions. *Electronic Journal of Pathology and*  
36 *Histology* 2000;6(3):7-19.  
37 Exclusion Reason: Narrative Review
- 38 Kopf AW, Salopek TG, Slade J, Marghoob AA, Bart RS. Techniques of cutaneous examination for the  
39 detection of skin cancer. *Cancer* 1995;75(2:Suppl):Suppl-90.  
40 Exclusion Reason: Narrative Review
- 41 Krol S, Keijser LMT, Van Der Rhee HJ, Welvaart K. Screening for skin cancer in The Netherlands. *Acta*  
42 *Dermato-Venereologica* 1991;71(4):317-21.  
43 Exclusion Reason: Not in PICO
- 44 Kundu, R. V. & Patterson, S. (2013) Dermatologic conditions in skin of color: part I. Special  
45 considerations for common skin disorders.[Summary for patients in *Am Fam Physician*. 2013 Jun  
46 15;87(12):Online; PMID: 23939576]. *American Family Physician*, 87: 850-856.  
47 Exclusion Reason: Narrative review
- 48 Kunte C, Konz B. Current recommendations in the treatment of basal cell carcinoma and squamous  
49 cell carcinoma of the skin. *Hautarzt* 2007;58(5):419-26.  
50 Exclusion Reason: Narrative Review

- 1 Kusukawa J, Kameyama T, Nakamura Y. Evaluation of excisional biopsy for stage I and II squamous  
2 cell carcinoma of the oral cavity. *International Journal of Clinical Oncology* 1998;3(5):317-22.  
3 Exclusion Reason: Not in PICO
- 4 Lacava V, Salesi N, Ferrone L, Veri A, Lembo R, Masi MC, et al. [Importance of dermatologic screening  
5 within the frame work of a general cancer prevention program]. [Italian]. *Minerva Medica*  
6 2001;92(2):85-8.  
7 Exclusion Reason: Not in PICO
- 8 Lai, W.-Y. (1111) An elderly man with a painful scaly nodule. *Hong Kong Practitioner*, 35: September.  
9 Exclusion Reason: Not in PICO
- 10 Lathlean S. Skin cancer in general practice in South Australia. A five year study. *Australian Family*  
11 *Physician* 1999;28:Suppl-31.  
12 Exclusion Reason: Not in PICO
- 13 Laukkanen A, Rummukainen J, Kivinen P, Lappalainen K. [Skin squamous cell carcinoma and its  
14 precancerous conditions]. [Review] [25 refs] [Finnish]. *Duodecim* 2006;122(1):71-9.  
15 Exclusion Reason: Narrative Review
- 16 Lee C, Kang KH, Koh Y, Chang J, Chung HS, Park SK, et al. Characteristics of lung cancer in Korea,  
17 1997. *Lung Cancer* 2000;30(1):15-22.  
18 Exclusion Reason: Not in PICO
- 19 Liebman TN, Wang SQ. Detection of early basal cell carcinoma with dermoscopy in a patient with  
20 psoriasis. *Dermatology Online Journal* 2011;17(2):12.  
21 Exclusion Reason: N=1
- 22 Lim D, Oakley AMM, Rademaker M. Better, sooner, more convenient: A successful teledermoscopy  
23 service. *Australasian Journal of Dermatology* 2012;53(1):22-5.  
24 Exclusion Reason: Narrative Review
- 25 Lin, Y.-C., Perng, C.-L., Chang, Y.-M., Li, Y.-F., Tsai, Y.-M., Wu, G.-J. & Lin, C.-K. (2013) Coexistent  
26 squamous cell carcinoma and adenoid basal carcinoma in the uterine cervix and infection with  
27 human papillomavirus (HPV 31). *Taiwanese Journal of Obstetrics and Gynecology*, 52: 407-410.  
28 Exclusion Reason: Not in PICO
- 29 Lober CW, Fenske NA. Basal cell, squamous cell, and sebaceous gland carcinomas of the periorbital  
30 region. [Review] [54 refs]. *Journal of the American Academy of Dermatology* 1991;25(4):685-90.  
31 Exclusion Reason: Narrative Review
- 32 Lohmann CM, Solomon AR. Clinicopathologic variants of cutaneous squamous cell carcinoma.  
33 [Review] [82 refs]. *Advances in Anatomic Pathology* 2001;8(1):27-36.  
34 Exclusion Reason: Narrative Review
- 35 Lopes LL, Alchorne ADD, Pereira GC, Lopes LRS, de Carvalho TC. Histological and  
36 immunohistochemical evaluation of basal cell carcinoma following curettage and  
37 electrodesiccation. *International Journal of Dermatology* 2008;47(6):610-4.  
38 Exclusion Reason: Not in PICO
- 39 Luckey L. Seeding of head and neck cancer during placement of percutaneous gastrostomy tube.  
40 *American Journal of Gastroenterology* 2012;107:S279.  
41 Exclusion Reason: Not in PICO
- 42 Lyngset E, Hunskar S. [Skin neoplasms in general practice]. [Norwegian]. *Tidsskrift for Den Norske*  
43 *Laegeforening* 2001;121(19):2281-3.  
44 Exclusion Reason: Not in PICO
- 45 Maguire-Eisen M. Risk assessment and early detection of skin cancers. [Review] [69 refs]. *Seminars*  
46 *in Oncology Nursing* 2003;19(1):43-51.  
47 Exclusion Reason: Narrative Review
- 48 Malberger E, Tillinger R, Lichtig C. Diagnosis of basal-cell carcinoma with aspiration cytology. *Acta*  
49 *Cytologica* 1984;28(3):301-4.  
50 Exclusion Reason: Narrative Review

- 1 Malvey J, Puig S, Marti-Laborda RM. Dermoscopy of skin lesions in two patients with xeroderma  
2 pigmentosum. *British Journal of Dermatology* 2005;152(2):271-8.  
3 Exclusion Reason: Not in PICO
- 4 Marchonda PJ, Krause LK, Jensen JD, Dellavalle RP. A North American perspective on dermoscopy:  
5 benefits, limitations, and grey zones. *Giornale Italiano di Dermatologia e Venereologia*  
6 2010;145(1):89-97.  
7 Exclusion Reason: Narrative Review
- 8 Marghoob AA. Basal and squamous cell carcinomas: What every primary care physician should  
9 know. *Postgraduate Medicine* 1997;102(2):139-59.  
10 Exclusion Reason: Narrative Review
- 11 Marghoob, A. A., Usatine, R. P. & Jaimes, N. (2013) Dermoscopy for the family physician. [Review].  
12 *American Family Physician*, 88: 441-450.  
13 Exclusion Reason: Narrative review
- 14 Martinez JC, Otley CC. The management of melanoma and nonmelanoma skin cancer: A review for  
15 the primary care physician. *Mayo Clinic Proceedings* 2001;76(12):1253-65.  
16 Exclusion Reason: Narrative Review
- 17 Maybury, C. M., Craythorne, E. & Martin, B. (2013) An ulcerated nodule on the nose. *BMJ Case*  
18 *Reports*, 2013, 2013.  
19 Exclusion Reason: Not in PICO
- 20 McGuire JF, Ge NN, Dyson S. Nonmelanoma skin cancer of the head and neck I: histopathology and  
21 clinical behavior. *American Journal of Otolaryngology* 2009;30(2):121-33.  
22 Exclusion Reason: Narrative Review
- 23 McNulty-Brown E, Veysey E. An audit of all excisions undertaken by general practitioners in a rural  
24 community between March 2009 and March 2010. *British Journal of Dermatology* 2012;167:91-2.  
25 Exclusion Reason: Not in PICO
- 26 Medeiros F, Nascimento AF, Crum CP. Early vulvar squamous neoplasia: advances in classification,  
27 diagnosis, and differential diagnosis. [Review] [32 refs]. *Advances in Anatomic Pathology*  
28 2005;12(1):20-6.  
29 Exclusion Reason: Narrative Review
- 30 Mehrotra R, Gupta DK. Exciting new advances in oral cancer diagnosis: avenues to early detection.  
31 [Review]. *Head & neck oncology* 2011;3:33.  
32 Exclusion Reason: Narrative Review
- 33 Mencia Gutierrez E, Herrero Lluch MJ, Gutierrez Diaz E, Galvez Ruiz A. [Basal cell and squamous cell  
34 carcinomas of the eyelid in adults under 50 years of age: 13 cases]. [Spanish]. *Archivos de la*  
35 *Sociedad Espanola de Oftalmologia* 2001;76(11):643-8.  
36 Exclusion Reason: Not in PICO
- 37 Menzies SW, Emery J, Staples M, Davies S, McAvoy B, Fletcher J, et al. Impact of dermoscopy and  
38 short-term sequential digital dermoscopy imaging for the management of pigmented lesions in  
39 primary care: a sequential intervention trial. *British Journal of Dermatology* 2009;161(6):1270-7.  
40 Exclusion Reason: Not in PICO
- 41 Menzies SW. Using dermoscopy to diagnose pigmented skin lesions. *Medicine Today* 2004;5(4):63-  
42 71.  
43 Exclusion Reason: Narrative Review
- 44 Menzies, S. W., Moloney, F. J., Byth, K., Avramidis, M., Argenziano, G., Zalaudek, I., Braun, R. P.,  
45 Malvey, J., Puig, S., Rabinovitz, H. S., Oliviero, M., Cabo, H., Bono, R., Pizzichetta, M. A., Claeson,  
46 M., Gaffney, D. C., Soyer, H. P., Stanganelli, I., Scolyer, R. A., Guitera, P., Kelly, J., McCurdy, O.,  
47 Llambrich, A., Marghoob, A. A., Zaballos, P., Kirchesch, H. M., Piccolo, D., Bowling, J., Thomas, L.,  
48 Terstappen, K., Tanaka, M., Pellacani, G., Pagnanelli, G., Ghigliotti, G., Ortega, B. C., Crafter, G.,  
49 Ortiz, A. M., Tromme, I., Karaarslan, I. K., Ozdemir, F., Tam, A., Landi, C., Norton, P., Kacar, N.,  
50 Rudnicka, L., Slowinska, M., Simionescu, O., Di, S. A., Coates, E. & Kreusch, J. (2013) Dermoscopic

- 1 evaluation of nodular melanoma. *JAMA Dermatology*, 149: 699-709.
- 2 Exclusion Reason: Not in PICO
- 3 Milicic-Juhas V, Peric M, Pajtler M, Prvulovic I, Curzik D. Pap test--with or without vaginal smear?
- 4 *Collegium Antropologicum* 2010;34(1):69-74.
- 5 Exclusion Reason: Not in PICO
- 6 Miller SJ. II. Biopsy techniques for suspected nonmelanoma skin cancers. *Dermatologic Surgery*
- 7 2000;26(1):91.
- 8 Exclusion Reason: Narrative Review
- 9 Moffatt CR, Green AC, Whiteman DC. Diagnostic accuracy in skin cancer clinics: the Australian
- 10 experience. *International Journal of Dermatology* 2006;45(6):656-60.
- 11 Exclusion Reason: Not in PICO: Clinical versus histological diagnosis (not biopsy or dermatoscopy
- 12 versus histology or follow up)
- 13 Mojsa I, Kaczmarzyk T, Zaleska M, Stypulkowska J, Zapala-Pospiech A, Sadecki D. Value of the ViziLite
- 14 Plus System as a diagnostic aid in the early detection of oral cancer/premalignant epithelial
- 15 lesions. *Journal of Craniofacial Surgery* 2012;23(2):e162-4.
- 16 Exclusion Reason: Not in PICO
- 17 Monnier P, Savary M. Epidermoid cancer of the upper respiratory and digestive tracts. [French].
- 18 *Schweizerische medizinische Wochenschrift* 1986;116(51):1817-23.
- 19 Exclusion Reason: Narrative Review
- 20 Moreno G, Tran H, Chia ALK, Lim A, Shumack S. Prospective study to assess general practitioners'
- 21 dermatological diagnostic skills in a referral setting. *Australasian Journal of Dermatology*
- 22 2007;48(2):77-82.
- 23 Exclusion Reason: Not in PICO
- 24 Morrison A, O'Loughlin S, Powell FC. Suspected skin malignancy: a comparison of diagnoses of family
- 25 practitioners and dermatologists in 493 patients. *International Journal of Dermatology*
- 26 2001;40(2):104-7.
- 27 Exclusion Reason: Not in PICO
- 28 Morteza, A. S., Salama, S. & Alowami, S. (2013) Lymphoepithelioma-like carcinoma of the skin: case
- 29 report and approach to surgical pathology sign out. *Rare Tumors*, 5: e47.
- 30 Exclusion Reason: Not in PICO
- 31 Morton CA, Downie F, Auld S, Smith B, Pol M, Baughan P, et al. Community photo-triage for skin
- 32 cancer referrals: an aid to service delivery (Structured abstract). *Clinical and*
- 33 *Experimental Dermatology* 2011;36:248-54.
- 34 Exclusion Reason: Not in PICO
- 35 Motley RJ, Gould DJ, Douglas WS, Simpson NB. Treatment of basal cell carcinoma by dermatologists
- 36 in the United Kingdom. British Association of Dermatologists Audit Subcommittee and the British
- 37 Society for Dermatological Surgery. *British Journal of Dermatology* 1995;132(3):437-40.
- 38 Exclusion Reason: Not in PICO
- 39 Muldoon TJ, Burgess SA, Chen BR, Ratner D, Hillman EMC. Analysis of skin lesions using laminar
- 40 optical tomography. *Biomedical Optics Express* 2012;3(7):1701-12.
- 41 Exclusion Reason: Narrative Review
- 42 Mullen JT, Feng L, Xing Y, Mansfield PF, Gershenwald JE, Lee JE, et al. Invasive squamous cell
- 43 carcinoma of the skin: Defining a high-risk group. *Annals of Surgical Oncology* 2006;13(7):902-9.
- 44 Exclusion Reason: Not in PICO
- 45 Murchie P, Delaney EK, Thompson WD, Lee AJ. Excising basal cell carcinomas: comparing the
- 46 performance of general practitioners, hospital skin specialists and other hospital specialists.
- 47 *Clinical & Experimental Dermatology* 2008;33(5):565-71.
- 48 Exclusion Reason: Not in PICO
- 49 Musiatowicz B, Dzieciol J, Sulkowska M, Polakow J, Baltaziak M. Fine needle aspiration biopsy
- 50 cytology of pulmonary tumors. *Roczniki Akademii Medycznej W Białymstoku* 1997;42:Suppl-13.
- 51 Exclusion Reason: Not in PICO

- 1 Myers M, Gurwood AS. Periocular malignancies and primary eye care. [Review] [22 refs]. *Optometry*  
2 (St.Louis, Mo.) 2001;72(11):705-12.  
3 Exclusion Reason: Narrative Review
- 4 Nagami Y, Machida H, Tominaga K, Nakatani M, Kameda N, Sugimori S, et al. Accurate detection and  
5 diagnosis of esophageal squamous cancer by tandem conventional endoscopy with narrow-band  
6 imaging and iodine staining: A prospective study. *Gastrointestinal Endoscopy* 2010;71(5):AB252-  
7 3.  
8 Exclusion Reason: Not in PICO
- 9 Navone R, Pentenero M, Gandolfo S. Liquid-based cytology in oral cavity squamous cell cancer.  
10 [Review]. *Current Opinion in Otolaryngology & Head & Neck Surgery* 2011;19(2):77-81.  
11 Exclusion Reason: Narrative Review
- 12 Nguyen TH, Ho DQ. Nonmelanoma skin cancer. Current treatment options in oncology  
13 2002;3(3):193-203.  
14 Exclusion Reason: Narrative Review
- 15 Niederkorn A, Gabler G, Argenziano G, Muir J, Zalaudek I, Soyer HP, et al. The user-generated web-  
16 based dermoscopy image archive of the international dermoscopy society: A contribution to E-  
17 learning and exchange of knowledge. *Dermatology* 2011;222(2):131-7.  
18 Exclusion Reason: Not in PICO
- 19 Ogden E, Schofield J. Two-week wait skin cancer referral outcomes: Differences in management  
20 between plastic surgery and dermatology. *British Journal of Dermatology* 2010;163:60-1.  
21 Exclusion Reason: Not in PICO
- 22 Paderni C, Compilato D, Lo Muzio L, Campisi G. Direct visualization of oral-cavity tissue fluorescence  
23 and toluidine blue staining: New adjunctive aids for oral medicine practitioners in early oral  
24 cancer diagnosis and potentially malignant disorders follow-up? *Oral Diseases* 2010;16(6):535-6.  
25 Exclusion Reason: Not in PICO
- 26 Palamaras I, Hamill M, Sethi G, Wilkinson D, Lamba H. The usefulness of a diagnostic biopsy clinic in a  
27 genitourinary medicine setting: recent experience and a review of the literature. *Journal of the*  
28 *European Academy of Dermatology and Venereology* 2006;20(8):905-10.  
29 Exclusion Reason: Not in PICO
- 30 Palanivel JA, Macbeth AE, Dootson G, Graham R, Mahmood K, Garioch J. An audit of incomplete  
31 excision rates of basal cell carcinoma from four U.K. teaching hospitals. *British Journal of*  
32 *Dermatology* 2011;165:106.  
33 Exclusion Reason: Not in PICO
- 34 Palka KT, Slebos RJ, Chung CH. Update on molecular diagnostic tests in head and neck cancer.  
35 [Review] [100 refs]. *Seminars in Oncology* 2008;35(3):198-210.  
36 Exclusion Reason: Narrative Review
- 37 Pallagatti, S., Sheikh, S., Aggarwal, A., Gupta, D., Singh, R., Handa, R., Kaur, S. & Mago, J. (2013)  
38 Toluidine blue staining as an adjunctive tool for early diagnosis of dysplastic changes in the oral  
39 mucosa. *Journal of Clinical & Experimental Dentistry*, 5: e187-e191.  
40 Exclusion Reason: Not in PICO
- 41 Palmer, V. M. & Wilson, P. R. (2013) Incompletely excised basal cell carcinoma: residual tumor rates  
42 at Mohs re-excision. *Dermatologic Surgery*, 39: 706-718.  
43 Exclusion Reason: Not in PICO
- 44 Pariser DM, Phillips PK. Basal cell carcinoma: When to treat it yourself, and when to refer. *Geriatrics*  
45 1994;49(3):39-42+44.  
46 Exclusion Reason: Narrative Review
- 47 Parkinson RW. Shave biopsies--simple and useful. *Postgraduate Medicine* 166;84(8):161-70.  
48 Exclusion Reason: Narrative Review
- 49 Pech O, Rabenstein T, Manner H, Petrone MC, Pohl J, Vieth M, et al. Confocal laser endomicroscopy  
50 for in vivo diagnosis of early squamous cell carcinoma in the esophagus. *Clinical Gastroenterology*  
51 *& Hepatology* 2008;6(1):89-94.

- 1 Exclusion Reason: Not in PICO  
2 Pereira RD, Martin AA, Tierra-Criollo CJ, Santos IDAO. Diagnosis of squamous cell carcinoma of  
3 human skin by Raman spectroscopy. *Optical Biopsy V* 2004;5326:106-12.  
4 Exclusion Reason: Not in PICO  
5 Phillips, C., Newsome, A., Jennifer, D., Lindsey, F., Green, H. & McLean, T. (2014) Anatomy of a skin  
6 biopsy: A retrospective analysis of outpatient biopsy results from 2000 to 2010. *Journal of the*  
7 *American Academy of Dermatology*, 70: AB36.  
8 Exclusion Reason: Not in PICO  
9 Piccolo D, Smolle J, Argenziano G, Wolf IH, Braun R, Cerroni L, et al. Teledermoscopy--results of a  
10 multicentre study on 43 pigmented skin lesions. *Journal of Telemedicine & Telecare*  
11 2000;6(3):132-7.  
12 Exclusion Reason: Not in PICO  
13 Pignatelli I, Poirier V, De Berker DAR, Verne J. Audit of completeness of cancer registration for basal  
14 cell carcinoma and its impact on use for quality assurance. *British Journal of Dermatology*  
15 2010;163:58.  
16 Exclusion Reason: Not in PICO  
17 Pignatelli I, Poirier V, De Berker DAR, Verne J. Completeness of basal cell carcinoma excisions in an  
18 english region. *British Journal of Dermatology* 2010;163:69-70.  
19 Exclusion Reason: Not in PICO  
20 Poirier V, Osinowo A, Takwale A, De Berker DAR, Verne J. Basal cell carcinoma follow-up in the South  
21 West, Hampshire and Isle of Wight. *British Journal of Dermatology* 2012;167:61.  
22 Exclusion Reason: Not in PICO  
23 Pop Stefaniija N, Blanken R, Vodegel RM. The positive predictive value of clinical diagnosis of basal  
24 cell carcinoma. [Dutch]. *Nederlands Tijdschrift voor Dermatologie en Venereologie*  
25 2006;16(6):237-40.  
26 Exclusion Reason: Not in PICO  
27 Popadic, M. (2014) Statistical evaluation of dermoscopic features in basal cell carcinomas.  
28 *Dermatologic Surgery*, 40: 718-724.  
29 Exclusion Reason: Not in PICO  
30 Poulsen AG, Larsen FG, Weismann K, Petersen CS, Ravnborg LR, Heidenheim M, et al. [Investigation  
31 of malignant melanoma in an "open house" setting]. [Danish]. *Ugeskrift for Laeger*  
32 1999;161(12):1758-61.  
33 Exclusion Reason: Not in PICO  
34 Prout MN, Sidari JN, Witzburg RA, Grillone GA, Vaughan CW. Head and neck cancer screening among  
35 4611 tobacco users older than forty years. *Otolaryngology - Head & Neck Surgery*  
36 1997;116(2):201-8.  
37 Exclusion Reason: Not in PICO  
38 Quereux G, Lequeux Y, Cary M, Jumbou O, Nguyen JM, Dreno B. Feasibility and effectiveness of a  
39 melanoma targeted screening strategy. *Melanoma Research* 2011;21:e1-2.  
40 Exclusion Reason: Not in PICO  
41 Raasch B, Maclennan R, Wronski I, Robertson I. Body site specific incidence of basal and squamous  
42 cell carcinoma in an exposed population, Townsville, Australia. *Mutation Research*  
43 1998;422(1):101-6.  
44 Exclusion Reason: Not in PICO  
45 Raasch BA. Suspicious skin lesions and their management. *Australian Family Physician*  
46 1999;28(5):466-71.  
47 Exclusion Reason: Not in PICO: Clinical versus histological diagnosis (not biopsy or dermatoscopy  
48 versus histology or follow up)  
49 Rademaker M, Thorburn M. Pathology referrals for skin lesions - Are we giving the pathologist  
50 sufficient clinical information? *New Zealand Medical Journal* 2010;123(1325):53-8.  
51 Exclusion Reason: Not in PICO

- 1 Radziszewski J, Kowalewska M, Jedrzejczak T, Kozlowicz-Gudzinska I, Nasierowska-Guttmejer A,  
2 Bidzinski M, et al. The accuracy of the sentinel lymph node concept in early stage squamous cell  
3 vulvar carcinoma. *Gynecologic Oncology* 2010;116(3):473-7.  
4 Exclusion Reason: Not in PICO
- 5 Rahman F, Tippu SR, Khandelwal S, Girish KL, Manjunath BC, Bhargava A. A study to evaluate the  
6 efficacy of toluidine blue and cytology in detecting oral cancer and dysplastic lesions.  
7 *Quintessence International* 2012;43(1):51-9.  
8 Exclusion Reason: Not in PICO
- 9 Raj, G. & Gupta, G. (1111) The need for full body skin examination on patients referred to  
10 dermatology with a lesion. *British Journal of Dermatology. Conference: 93rd Annual Meeting of  
11 the British Association of Dermatologists Liverpool United Kingdom. Conference Start: 20130709  
12 Conference End: 20130711. Conference Publication: (var.pagings), 169: July.*  
13 Exclusion Reason: Not in PICO
- 14 Rajaram N, Tunnell J, Reichenberg J. Pilot clinical study for noninvasive diagnosis of nonmelanoma  
15 skin cancer. *Journal of the American Academy of Dermatology* 2011;64(2 SUPPL. 1):AB76.  
16 Exclusion Reason: Not in PICO
- 17 Reed SF, Britt RC, Novosel TJ, Collins JN, Weireter LJ, Britt LD. Screening human immunodeficiency  
18 virus-positive men for anal intraepithelial neoplasia. *American Surgeon* 2012;78(8):901-3.  
19 Exclusion Reason: Not in PICO
- 20 Reynolds PL, Strayer SM. Treatment of skin malignancies. [Review] [33 refs]. *Journal of Family  
21 Practice* 2003;52(6):456-64.  
22 Exclusion Reason: Narrative Review
- 23 Rezze GG, De Sa BCS, Neves RI. Dermoscopy: The pattern analysis. *Anais Brasileiros de Dermatologia*  
24 2006;81(3):261-8.  
25 Exclusion Reason: Narrative Review
- 26 Rice SA, Swale VJ, Cerio R. Are we relying too heavily on dermoscopy? *British Journal of Dermatology*  
27 2012;167:105.  
28 Exclusion Reason: Narrative review
- 29 Richert, B., Lecerf, P., Caucanas, M. & Andre, J. (2013) Nail tumors. *Clinics in Dermatology*, 31: 602-  
30 617.  
31 Exclusion Reason: Narrative review
- 32 Robison Sean, Kljakovic Marjan, Barry Peter. Choosing to biopsy or refer suspicious melanocytic  
33 lesions in general practice. *BMC Family Practice* 2012;13(1):78.  
34 Exclusion Reason: Not in PICO
- 35 Roozeboom, M. H., Mosterd, K., Winnepeninckx, V. J., Nelemans, P. J. & Kelleners-Smeets, N. W.  
36 (2013) Agreement between histological subtype on punch biopsy and surgical excision in primary  
37 basal cell carcinoma. *Journal of the European Academy of Dermatology & Venereology*, 27: 894-  
38 898.  
39 Exclusion Reason: Not in PICO
- 40 Rose LC. Recognizing neoplastic skin lesions: a photo guide. [Review] [18 refs]. *American Family  
41 Physician* 887;58(4):873-84.  
42 Exclusion Reason: Narrative Review
- 43 Rosen R. Managing nonmelanoma skin cancer. *Modern Medicine of Australia* 1999;42(2):74-85.  
44 Exclusion Reason: Narrative Review
- 45 Rosendahl C, Cameron A, Argenziano G, Zalaudek I, Tschandl P, Kittler H. Dermoscopy of Squamous  
46 Cell Carcinoma and Keratoacanthoma. *Archives of Dermatology* 2012;148(12):1386-92.  
47 Exclusion Reason: Not in PICO
- 48 Rosendahl C, Hansen C, Cameron A, Bourne P, Wilson T, Cook B, et al. Measuring performance in  
49 skin cancer practice: the SCARD initiative. *International Journal of Dermatology* 2011;50(1):44-51.  
50 Exclusion Reason: Not in PICO

- 1 Rosendahl C, Tschandl P, Cameron A, Kittler H. Diagnostic accuracy of dermatoscopy for melanocytic  
2 and nonmelanocytic pigmented lesions. *Journal of the American Academy of Dermatology*  
3 2011;64(6):1068-73.  
4 Exclusion Reason: Duplicate
- 5 Rousset, J., Abgral, R., Chinellato, S., Garetier, M., Barberot, C., Valette, G., Potard, G., Le, B. T. &  
6 Salaun, P. Y. (2013) Early recurrence or submucosal residual of laryngeal squamous cell  
7 carcinoma: diagnosis by CT-guided endolaryngeal core biopsy on a transcutaneous approach.  
8 *Head & Neck*, 35: E202-E204.  
9 Exclusion Reason: Not in PICO
- 10 Rudkin AK, Dodd T, Muecke JS. The differential diagnosis of localised amelanotic limbal lesions: a  
11 review of 162 consecutive excisions. *British Journal of Ophthalmology* 2011;95(3):350-4.  
12 Exclusion Reason: Not in PICO
- 13 Russell EB, Carrington PR, Smoller BR. Basal cell carcinoma: a comparison of shave biopsy versus  
14 punch biopsy techniques in subtype diagnosis. *Journal of the American Academy of Dermatology*  
15 1999;41(1):69-71.  
16 Exclusion Reason: Not in PICO
- 17 Ryu IS, Choi SH, Kim do H, Han MW, Roh JL, Kim SY, et al. Detection of the primary lesion in patients  
18 with cervical metastases from unknown primary tumors with narrow band imaging endoscopy:  
19 preliminary report. *Head & Neck* 2013;35(1):10-4.  
20 Exclusion Reason: Not in PICO
- 21 Sabir F, Aziz M, Afroz N, Amin SS. Clinical and cyto-histopathological evaluation of skin lesions with  
22 special reference to bullous lesions. *Indian Journal of Pathology and Microbiology* 2010;53(1):41-  
23 6.  
24 Exclusion Reason: Narrative Review
- 25 Saldanha G, Fletcher A, Slater DN. Basal cell carcinoma: a dermatopathological and molecular  
26 biological update. *British Journal of Dermatology* 2003;148(2):195-202.  
27 Exclusion Reason: Narrative Review
- 28 Sandison A. Common head and neck cases in our consultation referrals: diagnostic dilemmas in  
29 inverted papilloma. [Review] [13 refs]. *Head and neck pathology* 2009;3(3):260-2  
30 Exclusion Reason: Narrative Review
- 31 Santi EG, Inoue H, Sato H, Maselli R, Ikeda H, Yoshida A, et al. Endoscopic treatment for esophageal  
32 achalasia with early squamous cell carcinoma: POEM plus ESD. *Journal of Gastroenterology and*  
33 *Hepatology* 2012;27:317-8.  
34 Exclusion Reason: Not in PICO
- 35 Sanyal, S., Holme, A. & Kemmett, D. (2013) How are patients with actinic keratoses managed in  
36 primary care? *British Journal of Dermatology*, 169: 45.  
37 Exclusion Reason: Not in PICO
- 38 Schlemper RJ, Dawsey SM, Itabashi M, Iwashita A, Kato Y, Koike M, et al. Differences in diagnostic  
39 criteria for esophageal squamous cell carcinoma between Japanese and Western pathologists.  
40 *Cancer* 2000;88(5):996-1006.  
41 Exclusion Reason: Not in PICO
- 42 Schofield J, Hepburn N, Scharrer K, Hussain K. The costs of diagnosing and treating skin cancer using  
43 the 2-week-wait referral process. *British Journal of Dermatology* 2011;165:22-3.  
44 Exclusion Reason: Not in PICO
- 45 Schroeder BM, American Cancer Society. ACS updates guideline for the early detection of cervical  
46 neoplasia and cancer. American Cancer Society. *American Family Physician* 2003;67(9):2011-6.  
47 Exclusion Reason: Not in PICO
- 48 Schwartzberg JB, Elgart GW, Romanelli P, Fangchao M, Federman DG, Kirsner RS. Accuracy and  
49 predictors of basal cell carcinoma diagnosis. *Dermatologic Surgery* 2005;31(5):534-7.  
50 Exclusion Reason: Not in PICO



- 1 Scully C, Newman L, Bagan JV. The role of the dental team in preventing and diagnosing cancer: 3.  
2 oral cancer diagnosis and screening. *Dental Update* 331;32(6):326-8.  
3 Exclusion Reason: Not in PICO
- 4 Sendagorta E, Herranz P, Guadalajara H, Zamora FX. [Early detection of anal intraepithelial neoplasia  
5 in high-risk patients]. [Review] [Spanish]. *Actas Dermo-Sifiliograficas* 2011;102(10):757-65.  
6 Exclusion Reason: Narrative Review
- 7 Senel E. Dermatoscopy of non-melanocytic skin tumors. *Indian Journal of Dermatology Venereology  
8 & Leprology* 2011;77(1):16-21.  
9 Exclusion Reason: Narrative Review
- 10 Shariff Z, Roshan A, Williams AM, Platt AJ. 2-Week wait referrals in suspected skin cancer: does an  
11 instructional module for general practitioners improve diagnostic accuracy? *Surgeon Journal of  
12 the Royal Colleges of Surgeons of Edinburgh & Ireland* 2010;8(5):247-51.  
13 Exclusion Reason: Not in PICO
- 14 Sharma, A., Alfa-Wali, M., Rodriguez-Justo, M. & Polychronis, A. (2013) Squamous cell carcinoma of  
15 pancreas: an unusual site of relapse from early-stage lung cancer: 12-month postsurgery. *BMJ  
16 Case Reports*, 2013, 2013.  
17 Exclusion Reason: Not in PICO
- 18 Shimizu Y, Omori T, Yokoyama A, Yoshida T, Hirota J, Ono Y, et al. Endoscopic diagnosis of early  
19 squamous neoplasia of the esophagus with iodine staining: high-grade intra-epithelial neoplasia  
20 turns pink within a few minutes. *Journal of Gastroenterology & Hepatology* 2008;23(4):546-50.  
21 Exclusion Reason: Not in PICO
- 22 Shitara, D., Ishioka, P., Alonso-Pinedo, Y., Palacios-Bejarano, L., Carrera, C., Malveyh, J. & Puig, S.  
23 (2014) Shiny White Streaks: A Sign of Malignancy at Dermoscopy of Pigmented Skin Lesions. *Acta  
24 Dermato-Venereologica*, 94: 132-137.  
25 Exclusion Reason: Setting not in PICO
- 26 Shum WY, Hsieh TC, Yeh JJ, Chen JH, Su CC, Liang JA, et al. Clinical usefulness of dual-time FDG PET-  
27 CT in assessment of esophageal squamous cell carcinoma. *European Journal of Radiology*  
28 2012;81(5):1024-8.  
29 Exclusion Reason: Not in PICO
- 30 Singh, T. & Schenberg, M. (2013) Delayed diagnosis of oral squamous cell carcinoma following dental  
31 treatment. *Annals of the Royal College of Surgeons of England*, 95: 369-373.  
32 Exclusion Reason: Not in PICO
- 33 Skiljevic D, Stojkovic-Filipovic J, Nikolic M, Medenica L. Early-onset basal cell carcinoma. *Melanoma  
34 Research* 2010;20:e68.  
35 Exclusion Reason: N=1
- 36 Smithers BM, Fahey PP, Corish T, Gotley DC, Falk GL, Smith GS, et al. Symptoms, investigations and  
37 management of patients with cancer of the oesophagus and gastro-oesophageal junction in  
38 Australia. *Medical Journal of Australia* 2010;193(10):572-7.  
39 Exclusion Reason: Not in PICO
- 40 Sober AJ. Diagnosis and management of skin cancer. *Cancer* 1983;51(12:Suppl):Suppl-52.  
41 Exclusion Reason: Not in PICO
- 42 Socha, A. & Niedzielska, I. (2013) Exophytic tumours of skin of the head - Case study and review of  
43 the literature. *Dental and Medical Problems*, 50: 229-237.  
44 Exclusion Reason: Not in PICO
- 45 Speel E-J, Leusink FKJ, Van Hooff SR, Kummer JA, van Diest PJ, Koole R, et al. Multi-center validation  
46 of a lymph node metastasis gene-expression signature for head and neck squamous cell  
47 carcinomas. *Cancer Research* 2011;71(8 SUPPL. 1).  
48 Exclusion Reason: Not in PICO
- 49 Spencer JM, Tannenbaum A, Sloan L, Amonette RA. Does inflammation contribute to the eradication  
50 of basal cell carcinoma following curettage and electrodesiccation? *Dermatologic Surgery*  
51 1997;23(8):625-30.

- 1 Exclusion Reason: Not in PICO  
2 Spencer RJ, Young RH, Goodman A. The risk of squamous cell carcinoma in persistent vulvar ulcers.  
3 Menopause 2011;18(10):1067-71.  
4 Exclusion Reason: Not in PICO  
5 Stegman SJ. Basal cell carcinoma and squamous cell carcinoma. Recognition and treatment. [Review]  
6 [28 refs]. Medical Clinics of North America 1986;70(1):95-107.  
7 Exclusion Reason: Narrative Review  
8 Stell PM, Wood GD, Scott MH. Early oral cancer: treatment by biopsy excision. British Journal of Oral  
9 Surgery 1982;20(4):234-8.  
10 Exclusion Reason: Not in PICO  
11 Stockfleth E. Non melanoma skin cancer - Early excision is still the standard in therapy. [German].  
12 Klinikerzt 2002;31(5):122-5.  
13 Exclusion Reason: Narrative Reivew  
14 Stoeckli SJ, Broglie MA. Sentinel node biopsy for early oral carcinoma. Current Opinion in  
15 Otolaryngology & Head and Neck Surgery 2012;20(2):103-8.  
16 Exclusion Reason: Narrative Review  
17 Stolte M. [The new "Vienna Classification" for epithelial neoplasia of the gastrointestinal tract. Pros  
18 or cons?]. [Review] [34 refs] [German]. Pathologe 2001;22(1):4-12.  
19 Exclusion Reason: Narrative Review  
20 Streeton CL, Gospodarevskaya E, Harris A. Treatment of basal cell carcinomas by general  
21 practitioners in Australia. International Journal of Dermatology 2006;45(4):345-51.  
22 Exclusion Reason: Not in PICO  
23 Stulberg DL, Crandell B, Fawcett RS. Diagnosis and treatment of basal cell and squamous cell  
24 carcinomas. American Family Physician 2004;70(8):1481-8.  
25 Exclusion Reason: Narrative Review  
26 Szalai K, Hatvani Z, Harsing J, Somlai B, Karpati S. High frequency ultrasonography in the diagnosis of  
27 cutaneous pigmented lesions and melanoma reduce the possibilities of diagnostic pitfalls.  
28 Melanoma Research 2011;21:e4-5.  
29 Exclusion Reason: Narrative Review  
30 Talbot S, Hitchcock B. Incomplete primary excision of cutaneous basal and squamous cell carcinomas  
31 in the Bay of Plenty. New Zealand Medical Journal 2004;117(1192):U848.  
32 Exclusion Reason: Not in PICO  
33 Tan E, Yung A, Jameson M, Oakley A, Rademaker M. Successful triage of patients referred to a skin  
34 lesion clinic using teledermoscopy (IMAGE IT trial). British Journal of Dermatology  
35 2010;162(4):803-11.  
36 Exclusion Reason: Not in PICO  
37 Tandon Y, Brodell RT. Local reactions to imiquimod in the treatment of basal cell carcinoma.  
38 Dermatology Online Journal 2012;18(9):1.  
39 Exclusion Reason: Not in PICO  
40 Tangjaturonrasme, N., Rerknimitr, R., Pittayanon, R., Wisedopas, N. & Kullavanijaya, P. (2013) The  
41 difference in detection rates during surveillance endoscopy for early squamous cell neoplasia of  
42 the esophagus between patients with previous nasopharyngeal cancer and patients with other  
43 ent related squamous cell cancers pornphan thienchanachaiya1. *Gastrointestinal Endoscopy*, 77:  
44 AB339-AB340.  
45 Exclusion Reason: Not in PICO  
46 Tannapfel A, Weber A. Tumor markers in squamous cell carcinoma of the head and neck: clinical  
47 effectiveness and prognostic value. European Archives of Oto-Rhino-Laryngology 2001;258(2):83-  
48 8.  
49 Exclusion Reason: Narrative Review  
50 Teoh YL, Halpern SM, Shall L. Factors associated with incomplete excision of basal cell carcinomas.  
51 British Journal of Dermatology 2010;163:55-6.

- 1 Exclusion Reason: Not in PICO  
2 TerKonda SP, Perdikis G. Non-melanotic skin tumors of the upper extremity. [Review] [50 refs]. *Hand*  
3 *Clinics* 104;20(3):293-301.  
4 Exclusion Reason: Narrative Review  
5 Terrill PJ, Fairbanks S, Bailey M. Is there just one lesion? The need for whole body skin examination  
6 in patients presenting with non-melanocytic skin cancer. *ANZ Journal of Surgery* 2009;79(10):707-  
7 12.  
8 Exclusion Reason: Not in PICO  
9 Terstappen K, Larko O, Wennberg AM. Pigmented basal cell carcinoma - Comparing the diagnostic  
10 methods of SIAscopy and dermoscopy. *Acta Dermato-Venereologica* 2007;87(3):238-42.  
11 Exclusion Reason: Narrative Review  
12 Terushkin V, Braga JC, Dusza SW, Scope A, Busam K, Marghoob AA, et al. Agreement on the Clinical  
13 Diagnosis and Management of Cutaneous Squamous Neoplasms. *Dermatologic Surgery*  
14 2010;36(10):1514-20.  
15 Exclusion Reason: Not in PICO  
16 Thienchanachaiya P, Rerknimitr R, Pittayanon R, Wisedopas N, Tangjaturonrasme N, Kullavanijaya P.  
17 Preliminary study of FICE for detection of early esophageal neoplasm in patients with history of  
18 ENT related squamous cell cancers. *Journal of Gastroenterology and Hepatology* 2012;27:319-20.  
19 Exclusion Reason: Not in PICO  
20 Thissen MR, Neumann HA, Berretty PJ, Ideler AH. [The treatment of basal cell carcinoma patients by  
21 dermatologists in Netherland]. [Dutch]. *Nederlands Tijdschrift Voor Geneeskunde*  
22 1998;142(27):1563-7.  
23 Exclusion Reason: Not in PICO  
24 Tochigi, T., Shuto, K., Staito, H., Kono, T. & Matsubara, H. (2013) Early esophageal squamous cell  
25 cancer by high-barium esophagography using flat panel X-ray detector in comparison with  
26 histological findings. *European Journal of Cancer*, 49: S252-S253.  
27 Exclusion Reason: Not in PICO  
28 Tomas S. Difficult to diagnose skin cancer The 'aggressive' BCC. *Australian Family Physician*  
29 2009;38(7):492-7.  
30 Exclusion Reason: Narrative Review  
31 Trotter MJ, Bruecks AK. Interpretation of Skin Biopsies by General Pathologists: Diagnostic  
32 Discrepancy Rate Measured by Blinded Review. *Archives of Pathology and Laboratory Medicine*  
33 2003;127(11):1489-92.  
34 Exclusion Reason: Not in PICO  
35 Turan, E., Yurt, N., Yesilova, Y. & Turkcu, G. (2013) Early-onset basal cell carcinoma. *Turkish Journal*  
36 *of Pediatrics*, 55: 354-356.  
37 Exclusion Reason: Not in PICO  
38 Ulrich M, Lange-Asschenfeldt S, Gonzalez S. In vivo reflectance confocal microscopy for early  
39 diagnosis of nonmelanoma skin cancer. *Actas Dermo-Sifiliograficas* 2012;103(9):784-9.  
40 Exclusion Reason: Narrative Review  
41 Vacher-Lavenu MC. [Histology and cytology of cervical cancers]. [Review] [24 refs] [French]. *Revue*  
42 *du Praticien* 2001;51(13):1417-23.  
43 Exclusion Reason: Narrative Review  
44 Vargo N. Basal cell and squamous cell carcinoma. [Review] [46 refs]. *Seminars in Oncology Nursing*  
45 2003;19(1):12-21.  
46 Exclusion Reason: Narrative Review  
47 Vermaak, P. V. & Manushakian, J. (2013) Rapidly enlarging skin lesion on the lip. *BMJ Case Reports*,  
48 2013, 2013.  
49 Exclusion Reason: Not in PICO

- 1 Viglizzo G, Rongioletti F. Clinical, dermoscopic and pathologic correlation of pigmentary lesions  
2 observed in a dermoscopy service in the year 2003. [Italian, English]. *Giornale Italiano di*  
3 *Dermatologia e Venereologia* 2004;139(4):339-44.  
4 Exclusion Reason: Not in PICO
- 5 Viola KV, Tolpinrud WL, Gross CP, Kirsner RS, Imaeda S, Federman DG. Outcomes of referral to  
6 dermatology for suspicious lesions: implications for teledermatology. *Archives of Dermatology*  
7 2011;147(5):556-60.  
8 Exclusion Reason: Not in PICO
- 9 Wade S, Gonzalez ML, Basra M. An audit of the diagnostic accuracy and complete excision rate for  
10 skin cancers in primary and secondary care in the Cardiff area. *British Journal of Dermatology*  
11 2011;165:105.  
12 Exclusion Reason: Not in PICO
- 13 Wagoner J, Keehn C, Morgan MB. CD-10 immunostaining differentiates superficial basal cell  
14 carcinoma from cutaneous squamous cell carcinoma. *American Journal of Dermatopathology*  
15 2007;29(6):555-8.  
16 Exclusion Reason: Narrative Review
- 17 Wan A, Savage NW. Biopsy and diagnostic histopathology in dental practice in Brisbane: usage  
18 patterns and perceptions of usefulness. *Australian Dental Journal* 2010;55(2):162-9.  
19 Exclusion Reason: Not in PICO
- 20 Watson Tony, Walter Fiona, Wood Annabel, Morris Helen, Hall Per, Karner Simone, et al. Learning a  
21 novel technique to identify possible melanomas: are Australian general practitioners better than  
22 their U.K. colleagues? *Asia Pacific Family Medicine* 2009;8(1):3.  
23 Exclusion Reason: Narrative Review
- 24 Wetzig T, Woitek M, Eichhorn K, Simon JC, Paasch U. Surgical Excision of Basal Cell Carcinoma with  
25 Complete Margin Control: Outcome at 5-Year Follow-Up. *Dermatology* 2010;220(4):363-9.  
26 Exclusion Reason: Not in PICO
- 27 White, G. M., Zhou, H. C. & Burchette, R. J. (2013) Biopsy followed by immediate curettage and  
28 electrodesiccation of suspected basal cell carcinomas at the first visit. *JAMA Dermatology*, 149:  
29 980-981.  
30 Exclusion Reason: Not in PICO
- 31 Whitesides LM, Ferreira LR, Ord RA. Audit of clinical information and diagnoses supplied to the  
32 pathologist following biopsy of oral squamous cell carcinomas. *MSDA Journal* 1995;38(2):63-5.  
33 Exclusion Reason: Narrative Review
- 34 Wilkinson D, Askew DA, Dixon A. Skin cancer clinics in Australia: workload profile and performance  
35 indicators from an analysis of billing data. *Medical Journal of Australia* 2006;184(4):162-4.  
36 Exclusion Reason: Not in PICO
- 37 Williams RB, Burdge AH, Lewis Jones S. Skin biopsy in general practice. *British Medical Journal*  
38 1991;303(6811):1179-80.  
39 Exclusion Reason: Not in PICO
- 40 Wilson RL, Yentzer BA, Isom SP, Feldman SR, Fleischer AB Jr. How good are US dermatologists at  
41 discriminating skin cancers? A number-needed-to-treat analysis. *Journal of Dermatological*  
42 *Treatment* 2012;23(1):65-9.  
43 Exclusion Reason: Not in PICO
- 44 Winzenburg SM, Niehans GA, George E, Daly K, Adams GL. Basaloid squamous carcinoma: a clinical  
45 comparison of two histologic types with poorly differentiated squamous cell carcinoma.  
46 *Otolaryngology - Head & Neck Surgery* 1998;119(5):471-5.  
47 Exclusion Reason: Not in PICO
- 48 Wlodarczyk J. [Application of Lugol solution in the gastroesophageal reflux disease]. [Polish].  
49 *Przegląd Lekarski* 2007;64(9):549-51  
50 Won S-S, Jung D-S, Kim H-S, Kwon K-S, Hee S-S. Clinicopathologic features of postlaser basal cell carcinoma: Does it differ from primary basal cell  
51 carcinoma? *Journal of the American Academy of Dermatology* 2010;62(3 SUPPL. 1):AB146.

- 1 Exclusion Reason: Not in PICO  
2 Wolberink, E. A. W., Pasch, M. C., Zeiler, M., Van Erp, P. E. J. & Gerritsen, M. J. P. (2013) High  
3 discordance between punch biopsy and excision in establishing basal cell carcinoma subtype:  
4 Analysis of 500 cases. *Journal of the European Academy of Dermatology and Venereology*, 27:  
5 985-989.  
6 Exclusion Reason: Not in PICO  
7 Wong KY, Gilleard O, Price R. Non-melanoma skin cancer incomplete excision rates of different  
8 grades of plastic surgeons and the implications for service provision. *European Journal of Surgical  
9 Oncology* 2012;38(11):1121.  
10 Exclusion Reason: Not in PICO  
11 Woolley, S. D. & Hughes, C. (2013) A young military pilot presents with a periocular Basal Cell  
12 Carcinoma: A case report. *Travel Medicine and Infectious Disease*, 11: 435-437.  
13 Exclusion Reason: Not in PICO  
14 Wray, E. V., Brant, B., Hussain, F. & Muller, F. M. (2013) A new model of teledermoscopy combining  
15 service and education. *British Journal of Dermatology*, 169: 139.  
16 Exclusion Reason: Not in PICO  
17 Wright VC. When to suspect squamous cancer at colposcopy. [Review] [22 refs]. *Nurse Practitioner*  
18 1959;26(9):50-6.  
19 Exclusion Reason: Narrative Review  
20 Wustrow J, Rudert H, Diercks M, Beigel A. Squamous cell carcinoma and undifferentiated carcinoma  
21 of the inner nose and the paranasal sinuses. [German]. *Strahlentherapie und Onkologie*  
22 1989;165(6):468-73.  
23 Exclusion Reason: Not in PICO  
24 Yamazaki N. [Squamous cell carcinoma]. [Review] [9 refs] [Japanese]. *Gan to Kagaku Ryoho*  
25 [Japanese Journal of Cancer & Chemotherapy] 2006;33(10):1392-7.  
26 Exclusion Reason: Narrative Review  
27 Youl PH, Baade PD, Janda M, Del Mar CB, Whiteman DC, Aitken JF. Diagnosing skin cancer in primary  
28 care: how do mainstream general practitioners compare with primary care skin cancer clinic  
29 doctors? *Medical Journal of Australia* 2007;187(4):215-20.  
30 Exclusion Reason: Not in PICO: Clinical versus histological diagnosis (not biopsy or dermatoscopy  
31 versus histology or follow up)  
32 Youl PH, Janda M, Aitken JF, Del Mar CB, Whiteman DC, Baade PD. Body-site distribution of skin  
33 cancer, pre-malignant and common benign pigmented lesions excised in general practice. *British  
34 Journal of Dermatology* 2011;165(1):35-43  
35 Exclusion Reason: Not in PICO  
36 Zalaudek I, Argenziano G, Soyer HP, Corona R, Sera F, Blum A, et al. Three-point checklist of  
37 dermoscopy: an open internet study. *British Journal of Dermatology* 2006;154(3):431-7.  
38 Exclusion Reason: Not in PICO  
39 Zedek DC, Smith ET Jr, Hitchcock MG, Feldman SR, Shelton BJ, White WL. Cutaneous lupus  
40 erythematosus simulating squamous neoplasia: the clinicopathologic conundrum and  
41 histopathologic pitfalls. *Journal of the American Academy of Dermatology* 2007;56(6):1013-20.  
42 Exclusion Reason: Not in PICO  
43 Zheng W, Soo KC, Sivanandan R, Olivo M. Detection of squamous cell carcinomas and pre-cancerous  
44 lesions in the oral cavity by quantification of 5-aminolevulinic acid induced fluorescence  
45 endoscopic images. *Lasers in Surgery & Medicine* 2002;31(3):151-7.  
46 Exclusion Reason: Not in PICO  
47 Zhou XH. Primary squamous cell carcinoma of the thyroid. *European Journal of Surgical Oncology*  
48 2002;28(1):42-5.  
49 Exclusion Reason: N=2  
50

**HEAD AND NECK CANCERS****LARYNGEAL CANCER****Review question:**

What is the risk of laryngeal cancer in patients presenting in primary care with symptom(s)?

**Results****Literature search**


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	All-2012	1085	97	08/10/2012
<i>Premedline</i>	All-2012	19	1	08/10/2012
<i>Embase</i>	All-2012	1352	75	08/10/2012
<i>Cochrane Library</i>	All-2012	89	0	10/10/2012
<i>Psychinfo</i>	All-2012	6	0	08/10/2012
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	All-2012	149	10	10/10/2012
<i>Biomed Central</i>	All-2012	200	3	08/10/2012

Total References retrieved (after de-duplication): 137

**Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	10/2012-26/08/2014	66	3	26/08/2014
<i>Premedline</i>	10/2012-26/08/2014	74	3	26/08/2014
<i>Embase</i>	10/2012-26/08/2014	262	5	26/08/2014
<i>Cochrane Library</i>	10/2012-26/08/2014	45	0	26/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	10/2012-26/08/2014	26	2	26/08/2014

Total References retrieved (after de-duplication): 7



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**Study results**

No evidence was identified.

**References**

**Included studies**

None

**Excluded studies (with excl reason)**

(1207) Society of Surgical Oncology Practice Guidelines. Laryngeal cancer surgical practice guidelines. *Oncology (Williston Park)*, 11: 1201-1203.  
Guideline

(1991) Early pharyngolaryngeal carcinomas with palpable nodes. French Head and Neck Study Group (GETTEC). *American Journal of Surgery*, 162: 377-380.  
Not in PICO

Ah-See, K. (2008) The evidence for different management strategies for laryngeal cancer: summaries of systematic reviews commissioned for an educational meeting. [Review] [13 refs]. *Clinical Otolaryngology*, 33: 90-93.  
Not in PICO

Alho, O.-P., Teppo, H., Mantyselka, P. & Kantola, S. (2006) Head and neck cancer in primary care: Presenting symptoms and the effect of delayed diagnosis of cancer cases. *CMAJ*, 174: 779-784.  
Study design not in PICO: Symptom prevalence study (with no case/no case verification) + cancer patient study

Ameille, J., Ruffie, P. & Bergeret, A. (2004) [Asbestos-related occupational cancers]. [French]. *Revue du Praticien*, 54: 1649-1659.  
Narrative review

Arens, C. (2004) [Early diagnosis of laryngeal cancer]. [German]. *Laryngo- Rhino- Otologie*, 83: 768-770.  
Narrative review

- 1 Arias, F., Villafranca, E., Duenas, M. T. & Vera, R. (2001) Prognostic factors in carcinomas of the head  
2 and neck. [Spanish]. *Anales del Sistema Sanitario de Navarra*, 24: 73-81.  
3 Narrative review
- 4 Assimakopoulos, D. & Patrikakos, G. (2002) The role of gastroesophageal reflux in the pathogenesis  
5 of laryngeal carcinoma. [Review] [77 refs]. *American Journal of Otolaryngology*, 23: 351-357.  
6 Narrative review
- 7 Babu, S., B, S., M, G. & Salih, S. (2011) A rare presentation of Pulmonary Lymphangitic  
8 Carcinomatosis in cancer of lip: case report. *World Journal of Surgical Oncology*, 9: 77.  
9 Not in PICO
- 10 Back, G. & Sood, S. (2005) The management of early laryngeal cancer: options for patients and  
11 therapists. [Review] [51 refs]. *Current Opinion in Otolaryngology & Head & Neck Surgery*, 13: 85-  
12 91.  
13 Narrative review
- 14 Bahar, G., Nageris, B. I., Spitzer, T., Popovtzer, A., Mharshak, G. & Feinmesser, R. (1929) [Subglottic  
15 carcinoma]. [Review] [33 refs] [Hebrew]. *Harefuah*, 141: 914-918.  
16 Narrative review
- 17 Bajaj, Y., Uppal, S., Sharma, R. K., Grace, A. R. H., Howard, D. M., Nicolaidis, A. R. & Coatesworth, A.  
18 P. (2011) Evaluation of voice and quality of life after transoral endoscopic laser resection of early  
19 glottic carcinoma. *Journal of Laryngology and Otology*, 125: 706-713.  
20 Not in PICO
- 21 Banfield, G., Tandon, P. & Solomons, N. (2000) Hoarse voice: an early symptom of many conditions.  
22 [Review] [3 refs]. *Practitioner*, 244: 267-271.  
23 Narrative review
- 24 Barnett, R. J., Ceasar, S. C. & Wisdom, G. S. (2001) Laryngoceles and saccular cyst. *The Journal of the*  
25 *Louisiana State Medical Society : official organ of the Louisiana State Medical Society*, 153: 170-  
26 173.  
27 Not in PICO
- 28 Barra, S., Mattotti, M., Bertos, G. & Barzan, L. (1992) [The program for early diagnosis of the upper  
29 respiratory tract and digestive system neoplasms offered to alcoholics in the region of Friuli-  
30 Venice Giulia]. [Italian]. *Acta Otorhinolaryngologica Italica*, 12: 337-344.  
31 Not in PICO
- 32 Baughan, P., Keatings, J. & O'Neill, B. (2011) Urgent suspected cancer referrals from general practice:  
33 audit of compliance with guidelines and referral outcomes. *British Journal of General Practice*, 61:  
34 e700-e706.  
35 Not in PICO
- 36 Betlejewski, S. & Betlejewski, A. (2008) Cancer or syphilis laryngis, politics or diagnostic failure -  
37 Problems of Emperor Frederick's III disease. [Polish]. *Otolaryngologia Polska*, 62: 803-809.  
38 Narrative review
- 39 Bibby, J. R., Cotton, S. M., Perry, A. & Corry, J. F. (2008) Voice outcomes after radiotherapy  
40 treatment for early glottic cancer: assessment using multidimensional tools. *Head & Neck*, 30:  
41 600-610.  
42 Not in PICO
- 43 Bjorck, G., Johansson, S., Milerad, J., Katz-Salamon, M., Hertegard, S. & Kuylensstierna, R. (2000)  
44 [Fiberoptic endoscopy confirms the cause of upper respiratory obstruction in small children. The  
45 most common causes to referrals are sleep apnea syndrome and inspiratory stridor]. [Swedish].  
46 *Lakartidningen*, 97: 2446-2450.  
47 Not in PICO
- 48 Blair, R. L. & McKerrow, W. S. (1994) The Scottish Otolaryngology Audit--laryngeal cancer audit.  
49 *Journal of Laryngology & Otology*, 108: 332-335.  
50 Narrative review



- 1 Bova, R. & McGuinness, J. (2007) Hoarseness: A guide to voice disorders. *Medicine Today*, 8: 38-45.  
2 Narrative review
- 3 Bradley, P. J. (1986) Dysphonia. *British Journal of Hospital Medicine*, 35: 331-334.  
4 Narrative review
- 5 Brenner, B., Marshak, G., Rakowsky, E., Shvero, J., Sulkes, A. & Gutman, H. (2001) Laryngeal  
6 carcinoma--epidemiological and clinical features: experience of the Rabin Medical Center in  
7 Israel. *Oncology Reports*, 8: 141-144.  
8 Not in PICO
- 9 Brouha, X. D., Tromp, D. M., de Leeuw, J. R., Hordijk, G. J. & Winnubst, J. A. (2005) Laryngeal cancer  
10 patients: analysis of patient delay at different tumor stages. *Head & Neck*, 27: 289-295.  
11 Not in PICO
- 12 Brouha, X. D., Tromp, D. M., Koole, R., Hordijk, G. J., Winnubst, J. A. & de Leeuw, J. R. (2007)  
13 Professional delay in head and neck cancer patients: analysis of the diagnostic pathway. *Oral  
14 Oncology*, 43: 551-556.  
15 Not in PICO
- 16 Brunton, S. & McGuigan, J. (2005) Diagnostic challenges: Differentiating nighttime GERD. *Journal of  
17 Family Practice*, 54: 1073-1078.  
18 Narrative review
- 19 Bulman, C. H. (1998) A ten year audit of the management of cancers of the larynx and pharynx.  
20 *Journal of Laryngology and Otology*, 112: 948-953.  
21 Not in PICO/narrative review
- 22 Cammarota, G., Galli, J., Agostino, S., De, C. E., Rigante, M., Cianci, R., Cesaro, P., Nista, E. C.,  
23 Candelli, M., Gasbarrini, A. & Gasbarrini, G. (2006) Accuracy of laryngeal examination during  
24 upper gastrointestinal endoscopy for premalignancy screening: prospective study in patients with  
25 and without reflux symptoms. *Endoscopy*, 38: 376-381.  
26 Not in PICO
- 27 Carvalho, A. L., Pintos, J., Schlecht, N. F., Oliveira, B. V., Fava, A. S., Curado, M. P., Kowalski, L. P. &  
28 Franco, E. L. (2002) Predictive factors for diagnosis of advanced-stage squamous cell carcinoma of  
29 the head and neck. *Archives of Otolaryngology - Head and Neck Surgery*, 128: 313-318.  
30 Not in PICO
- 31 Chan, T. V. (2010) The patient with sore throat. [Review] [44 refs]. *Medical Clinics of North America*,  
32 94: 923-943.  
33 Narrative review
- 34 Chen, A. Y., Frankowski, R., Bishop-Leone, J., Hebert, T., Leyk, S., Lewin, J. & Goepfert, H. (2001) The  
35 development and validation of a dysphagia-specific quality-of-life questionnaire for patients with  
36 head and neck cancer - The M. D. Anderson dysphagia inventory. *Archives of Otolaryngology-  
37 Head & Neck Surgery*, 127: 870-876.  
38 Not in PICO
- 39 Chen, J.-J. (2007) Laryngeal lesions in patients with chronic cough and normal chest radiographs and  
40 auscultation. *Tzu Chi Medical Journal*, 19: 145-151+182.  
41 Not in PICO
- 42 Chodynicky, S. & Pyd, M. (1985) [Use of questionnaires in the early diagnosis of precancerous  
43 conditions and cancer of the larynx]. [Polish]. *Polski Tygodnik Lekarski*, 40: 1089-1091.  
44 Not in PICO (screening)
- 45 Christopoulos, T. A., Papageorgakopoulou, N., Theocharis, D. A., Aletras, A. J., Tsiganos, C. P.,  
46 Papadas, T. A., Mastronikolis, N. S., Goumas, P. & Vynios, D. H. (2004) Diagnostic and  
47 classification value of metalloproteinases in squamous human laryngeal carcinoma. *International  
48 Journal of Oncology*, 25: 481-485.  
49 Not in PICO
- 50 Cnossen, I. C., de, B. R., Rinkel, R. N., Eerenstein, S. E., Rietveld, D. H., Doornaert, P., Buter, J.,  
51 Langendijk, J. A., Leemans, C. R. & Verdonck-de Leeuw, I. M. (2012) Computerized monitoring of

- 1 patient-reported speech and swallowing problems in head and neck cancer patients in clinical  
2 practice. *Supportive Care in Cancer*, 20: 2925-2931.
- 3 Not in PICO
- 4 Cohen, S. M., Kim, J., Roy, N., Asche, C. & Courey, M. (2012) Prevalence and causes of dysphonia in a  
5 large treatment-seeking population. *Laryngoscope*, 122: 343-348.
- 6 Not in PICO
- 7 Cohen, S. M., Kim, J., Roy, N. & Courey, M. (2014) Factors influencing referral of patients with voice  
8 disorders from primary care to otolaryngology. *Laryngoscope*, 124: 214-220.
- 9 Not in PICO
- 10 Cohen, S. M., Dinan, M. A., Roy, N., Kim, J. & Courey, M. (2014) Diagnosis Change in Voice-  
11 Disordered Patients Evaluated by Primary Care and/or Otolaryngology: A Longitudinal Study.  
12 *Otolaryngology - Head & Neck Surgery*, 150: 95-102.
- 13 Not in PICO
- 14 Corey, G. A., Hocutt, J. E., Jr. & Rodney, W. M. (1988) Preliminary study of rhinolaryngoscopy by  
15 family physicians. *Family Medicine*, 20: 262-265.
- 16 Not in PICO
- 17 Cotulbea, S., Marin, I., Golumba, R., Barbos, R., Valean, M. & Anghel, I. (1986) [Early diagnosis of  
18 laryngeal cancer in patients in the area of the Timisoara ENT Clinic]. [Romanian]. *Revista de*  
19 *Chirurgie Oncologie Radiologie ORL Oftalmologie Stomatologie - Oto-Rino-Laringologia*, 31: 137-  
20 141.
- 21 Not in PICO (referred patients; with cancer)
- 22 Crozier, E. & Sumer, B. D. (2010) Head and Neck Cancer. *Medical Clinics of North America*, 94: 1031-  
23 +.
- 24 Narrative review
- 25 Dammer, R., Bonkowski, V., Kutz, R., Friesenecker, J. & Schusselbauer, T. (1999) [Early detection of  
26 multiple tumors in primary diagnosis of oral carcinomas using panendoscopy]. [German]. *Mund-  
27 Kiefer- und Gesichtschirurgie*, 3: 61-66.
- 28 Not in PICO
- 29 de, B. R. (2011) [Early detection of laryngeal carcinoma: limited improvement possible]. [Dutch].  
30 *Nederlands Tijdschrift Voor Geneeskunde*, 155: A3045.
- 31 Narrative review
- 32 De, V. A. & Vicini, C. (2013) Narrow-band imaging in the early detection of laryngeal cancer: A  
33 prospective study. *European Archives of Oto-Rhino-Laryngology*, 270: 389.
- 34 Not in PICO
- 35 Dean, S. S. (2014) Otolaryngology head and neck surgery. A review of malignancies. *Australian*  
36 *Family Physician*, 23: 2130-2131.
- 37 Narrative review
- 38 Dechaphunkul, T. (2011) Epidemiology, risk factors, and overall survival rate of laryngeal cancer in  
39 Songklanagarind Hospital. *Journal of the Medical Association of Thailand*, 94: 355-360.
- 40 Not in PICO
- 41 DeSanto, L. W. & Olsen, K. D. (1994) Early glottic cancer. [Review] [32 refs]. *American Journal of*  
42 *Otolaryngology*, 15: 242-249.
- 43 Not in PICO/narrative review
- 44 Diouf, R., Diop, E. M., Ndiaye, I. C., Tall, A., Kasse, A. A. & Diop, L. S. (1990) Limitations on the  
45 practice of head-and-neck oncology in Africa. The example of laryngeal cancers. [French]. *Dakar*  
46 *Medical*, 35: 252-259.
- 47 Not in PICO
- 48 Djambazov, K., Djambazov, B., Traikova, N. & Semerdjieva, M. (2005) Factors delaying the diagnosis  
49 of Laryngeal carcinoma. [Bulgarian]. *General Medicine*, 7: 15-18.
- 50 Not in PICO

- 1 Dostalova, S., Smahel, Z. & Sonka, K. (1998) Craniofacial abnormalities in sleep apnoea syndrome.  
2 *Acta Chirurgiae Plasticae*, 40: 49-53.  
3 Not in PICO
- 4 Eckert, D., Bloom, H. J. & Ross, L. S. (1982) A review of oral cancer screening and detection in the  
5 metropolitan Detroit cancer control program. *Progress in Clinical & Biological Research*, 83: 195-  
6 206.  
7 Not in PICO
- 8 Eckley, C. A., Anelli, W. & Duprat, A. C. (2008) Auditory voice-perception analysis sensitivity and  
9 specificity in the screening of laryngeal disorders. *Revista Brasileira de Otorrinolaringologia*, 74:  
10 168-171.  
11 Not in PICO
- 12 Esser, D., Anke, S., Roessner, A. & Freigang, B. (2000) [Second carcinomas in cancers of the mouth  
13 cavity, pharynx and larynx. Clinical, histopathologic and cell kinetic findings]. [German]. *Laryngo-  
14 Rhino- Otologie*, 79: 478-482.  
15 Not in PICO
- 16 Fasunla, A. J. & Lasisi, O. A. (2009) Diagnostic challenges of laryngeal papillomatosis and its  
17 implications among children in developing country. *International Journal of Pediatric  
18 Otorhinolaryngology*, 73: 593-595.  
19 Not in PICO
- 20 Ferlito, A. (1995) The natural history of early vocal cord cancer. *Acta Oto-Laryngologica*, 115: 345-  
21 347.  
22 Narrative review
- 23 Ferlito, A., Carbone, A., Rinaldo, A., Ferlito, A., DeSanto, L. W., D'Angelo, L., Barnes, L. & Devaney, K.  
24 O. (1996) "Early" cancer of the larynx: the concept as defined by clinicians, pathologists, and  
25 biologists. [Review] [18 refs]. *Annals of Otology, Rhinology & Laryngology*, 105: 245-250.  
26 Narrative review
- 27 Fischinger, J. & Mlacak, B. (1997) The usefulness of screening in the early detection of laryngeal  
28 cancer. *Acta Oto-Laryngologica Supplement*, 527: 150-151.  
29 Not in PICO
- 30 Ford, S., Gollins, S., Hobson, P. & Vyas, S. (2009) Structural displacements during the swallow in  
31 patients with early laryngeal cancers and other early primary cancers of the head and neck.  
32 *Dysphagia*, 24: 127-136.  
33 Not in PICO
- 34 Garas, J. & McGuirt, W. F., Sr. (2006) Squamous cell carcinoma of the subglottis. *American Journal of  
35 Otolaryngology*, 27: 1-4.  
36 Not in PICO
- 37 Goon, P., Stanley, M., Ebmeyer, J., Steinstrasser, L., Upile, T., Jerjes, W., Bernal-Sprekelsen, M.,  
38 Gorner, M. & Sudhoff, H. (2009) HPV & head and neck cancer: a descriptive update. *Head & Neck  
39 Oncology*, 1: 36.  
40 Narrative review
- 41 Gorsky, M. & Dayan, D. (1995) Referral delay in diagnosis of oro/oropharyngeal cancer in Israel.  
42 *European Journal of Cancer.Part B, Oral Oncology*, 31B: 166-168.  
43 Not in PICO
- 44 Guo, T., Sun, J. W., Lv, Q. P. & Li, X. G. (2008) Allelic imbalance on chromosomes 3p, 9p and 17p in  
45 malignant progression of laryngeal mucosa. *Journal of Laryngology and Otology*, 122: 72-77.  
46 Not in PICO
- 47 Hagen, P., Lyons, G. D. & Nuss, D. W. (1996) Dysphonia in the elderly: diagnosis and management of  
48 age-related voice changes. *Southern Medical Journal*, 89: 204-207.  
49 Not in PICO

- 1 Hamzany, Y., Hadar, T., Feinmesser, R., Guttman, D. & Shvero, J. (2008) Laryngeal carcinoma in  
2 nonsmoking patients. *Annals of Otolaryngology, Rhinology & Laryngology*, 117: 564-568.  
3 Not in PICO
- 4 Hanson, J., Bruchmuller, W. & Nischwitz, A. S. (1989) [Precancerous diseases and the early  
5 recognition of pharyngeal and laryngeal carcinomas]. [German]. *Archiv fur Geschwulstforschung*,  
6 59: 99-105.  
7 Narrative review
- 8 Healy, G. B. (1984) Neoplasia of the pediatric larynx. *Otolaryngologic Clinics of North America*, 17:  
9 69-74.  
10 Narrative review
- 11 Herrera-Gomez, A., Villavicencio-Valencia, V., Rascon-Ortiz, M. & Luna-Ortiz, K. (2009) Demographic  
12 data of laryngeal cancer at the Instituto Nacional de Cancerologia in Mexico City. *Cirurgia y*  
13 *Cirujanos*, 77: 353-357.  
14 Not in PICO
- 15 Hoare, T. J., Thomson, H. G. & Proops, D. W. (1993) Detection of laryngeal cancer--the case for early  
16 specialist assessment. *Journal of the Royal Society of Medicine*, 86: 390-392.  
17 Not in PICO
- 18 Hordijk, G. J., Kaanders, J. H. & Nederlandse Werkgroep Hoofd-Halstumoren (NWHHT) (2001) [CBO  
19 guideline 'larynx carcinoma']. [Dutch]. *Nederlands Tijdschrift Voor Geneeskunde*, 145: 998-1002.  
20 Narrative review
- 21 Jaworowska, E., Serrano-Fernandez, P., Tarnowska, C., Brzosko, M., Flicinski, J., Masojc, B., Matyjasik,  
22 J., Scott, R. J., Narod, S. A. & Lubinski, J. (2008) Familial association of laryngeal, lung, stomach  
23 and early-onset breast cancer. *Breast Cancer Research and Treatment*, 112: 359-361.  
24 Not in PICO
- 25 Johnson, J. T., Newman, R. K. & Olson, J. E. (1980) Persistent hoarseness: an aggressive approach for  
26 early detection of laryngeal cancer. *Postgraduate Medicine*, 67: 122-126.  
27 Narrative review
- 28 Jovanovic, M. B. (2008) [Diagnosis of laryngeal carcinoma]. [Review] [52 refs] [Serbian]. *Medicinski*  
29 *Pregled*, 61: 591-595.  
30 Narrative review
- 31 Kaanders, J. H. A. M. & Hordijk, G. J. (2002) Carcinoma of the larynx: the Dutch national guideline for  
32 diagnostics, treatment, supportive care and rehabilitation. *Radiotherapy and Oncology*, 63: 299-  
33 307.  
34 Guideline
- 35 Kawakubo, J., Okikura, K. & Aika, Y. (1988) [Detection rate of laryngeal cancer in thorough medical  
36 check up performed by all Japan National Health Insurance Association of Engineering &  
37 Construction]. [Japanese]. *Nippon Jibiinkoka Gakkai Kaiho [Journal of the Oto-Rhino-*  
38 *Laryngological Society of Japan]*, 91: 553-560.  
39 Not in PICO (population)
- 40 Koscielny, S., Wagner, C. & Beleites, E. (1999) [Interval between initial symptoms and first treatment  
41 in patients with head-neck tumors]. [German]. *HNO*, 47: 551-555.  
42 Not in PICO
- 43 Koscielny, S., Wagner, C. & Beleites, E. (1999) Investigation of the time interval between the onset of  
44 symptoms and the beginning of therapy in patients with head and neck cancer. [German]. *HNO*,  
45 47: 551-555.  
46 Not in PICO
- 47 Koskinen, W. J., Brondbo, K., Mellin, D. H., Luostarinen, T., Hakulinen, T., Leivo, I., Molijn, A., Quint,  
48 W. G., Roysland, T., Munck-Wikland, E., Makitie, A. A., Pyykko, I., Dillner, J., Vaheri, A. & Aaltonen,  
49 L. M. (2007) Alcohol, smoking and human papillomavirus in laryngeal carcinoma: a Nordic  
50 prospective multicenter study. *Journal of Cancer Research & Clinical Oncology*, 133: 673-678.  
51 Not in PICO

- 1 Kosztyla-Hojna, B. & Rogowski, M. (2003) [Usefulness of video-laryngo-stroboscopy in the diagnosis  
2 of laryngeal pathology]. [Polish]. *Polski Merkurusz Lekarski*, 14: 413-416.  
3 Narrative review
- 4 Laccourreye, O., Weinstein, G., Chabardes, E., Housset, M., Laccourreye, H. & Brasnu, D. (1992) T1  
5 squamous cell carcinoma of the arytenoid. *Laryngoscope*, 102: 896-900.  
6 Not in PICO
- 7 Lai, Y.-H., Chen, M.-H. & Chang, S.-Y. (2009) Communication status, quality of life and their  
8 relationships in head and neck cancer patients with surgery in Taiwan. *Supportive Care in Cancer*,  
9 17: 1012-1013.  
10 Not in PICO
- 11 Leithauser, D. (1997) [Hoarseness often minimized by patients. Preventive examination of the larynx  
12 gets too little regard]. [German]. *Fortschritte der Medizin*, 115: 38-39.  
13 Narrative review
- 14 Lore, J. M., Jr. (1991) Controversies in the diagnosis and treatment of early carcinoma of the larynx.  
15 [Review] [9 refs]. *Seminars in Surgical Oncology*, 7: 31-37.  
16 Narrative review
- 17 Luft, A. & Pons, Y. (2011) [Signs of upper airways digestive tract cancers and the general  
18 practitioner. Study of the practices by a Script Test Concordance]. [French]. *Revue de*  
19 *Laryngologie Otologie Rhinologie*, 132: 131-136.  
20 Not in PICO
- 21 Lydiatt, D. D. (2002) Medical malpractice and cancer of the larynx. *Laryngoscope*, 112: 445-448.  
22 Not in PICO
- 23 Lyons, B. (1999) ENT malignancies. What the GP needs to know. [Review] [9 refs]. *Australian Family*  
24 *Physician*, 28: 209-215.  
25 Narrative review
- 26 Mau, T. (2010) Diagnostic evaluation and management of hoarseness. *Medical Clinics of North*  
27 *America*, 94: 945-960.  
28 Narrative review
- 29 McDonald, S., Haie, C., Rubin, P., Nelson, D. & Divers, L. D. (1989) Second malignant tumors in  
30 patients with laryngeal carcinoma: diagnosis, treatment, and prevention. [Review] [45 refs].  
31 *International Journal of Radiation Oncology, Biology, Physics*, 17: 457-465.  
32 Not in PICO
- 33 Meyer-Breiting, E. (1990) [Considerations and studies of the classification of glottis cancers].  
34 [German]. *Laryngo- Rhino- Otologie*, 69: 6-12.  
35 Narrative review
- 36 Michnay-Becker, A. (1993) [Recommendations for the physician's patient education consultation  
37 with laryngeal and pharyngeal cancer patients]. [German]. *HNO*, 41: A17.  
38 Not in PICO
- 39 Mikic, A., Petrovic, Z., Djukic, V., Dimitrijevic, M., Stankovic, P., Pendjer, I. & Dudvarski, Z. (2004)  
40 [Surgery treatment of laryngeal carcinoma T1]. [Serbian]. *Acta Chirurgica Iugoslavica*, 51: 21-25.  
41 Not in PICO
- 42 Minnis, N. L. (2002) A practical approach to managing hoarseness. *Medicine Today*, 3: 36-42.  
43 Narrative review
- 44 Mlacak, B. & Fischinger, J. (1997) The role of general practitioner in the detection of epithelial  
45 hyperplastic lesions and carcinoma of the larynx. *Acta Oto-Laryngologica Supplement*, 527: 152-  
46 154.  
47 Not in PICO - no method/result section detailing the population
- 48 Moore, P. L., Kim, D., Selby, G. & Proops, D. W. (2004) Detection of laryngeal carcinoma and  
49 epithelial hyperplastic laryngeal lesions via a rapid-access dysphonia clinic. *Journal of Laryngology*  
50 *& Otology*, 118: 633-636.  
51 Not in PICO

- 1 Morton, R. P. (1982) A profile of laryngeal cancer in Auckland 1965-1979. *New Zealand Medical*  
2 *Journal*, 95: 652-655.  
3 Narrative review
- 4 Muller, R. (1995) [Hoarseness]. [German]. *Therapeutische Umschau*, 52: 759-762.  
5 Narrative review
- 6 Myssiorek, D., Rinaldo, A., Barnes, L. & Ferlito, A. (2004) Laryngeal paraganglioma: an updated  
7 critical review. [Review] [57 refs]. *Acta Oto-Laryngologica*, 124: 995-999.  
8 Narrative review
- 9 Nedio, S. & Marcos, A. S. (2011) The world voice day as a public health program-rippling the idea.  
10 *European Archives of Oto-Rhino-Laryngology*, 268: 773.  
11 Narrative review
- 12 Ni, X. G., He, S., Xu, Z. G., Gao, L., Lu, N., Yuan, Z., Lai, S. Q., Zhang, Y. M., Yi, J. L., Wang, X. L., Zhang,  
13 L., Li, X. Y. & Wang, G. Q. (2011) Endoscopic diagnosis of laryngeal cancer and precancerous  
14 lesions by narrow band imaging. *Journal of Laryngology & Otology*, 125: 288-296.  
15 Not in PICO
- 16 Oburra, H. O. (1998) Late presentation of laryngeal and nasopharyngeal cancer in Kenyatta National  
17 Hospital. *East African Medical Journal*, 75: 223-226.  
18 Not in PICO
- 19 Okawa, T., Yamada, K. & Kita, M. (1988) Early cancer in the head and neck. [Japanese]. *Gan no*  
20 *rinsho*, Japan: 1295-1302.  
21 Narrative review
- 22 Omori, K. (2011) Diagnosis of voice disorders. *Japan Medical Association Journal*, 54: 248-253.  
23 Narrative review
- 24 Orvidas, L. J., Olsen, K. D., Lewis, J. E. & Suman, V. J. (1998) Verrucous carcinoma of the larynx: a  
25 review of 53 patients. *Head & Neck*, 20: 197-203.  
26 Not in PICO
- 27 Paleri, V., Mackenzie, K., Wight, R. G., Mehanna, H., Pracy, P., Bradley, P. J. & ENT-UK Head and Neck  
28 Group (2009) Management of laryngeal dysplasia in the United Kingdom: a web-based  
29 questionnaire survey of current practice. *Clinical Otolaryngology*, 34: 385-389.  
30 Not in PICO
- 31 Prout, M. N., Sidari, J. N., Witzburg, R. A., Grillone, G. A. & Vaughan, C. W. (1997) Head and neck  
32 cancer screening among 4611 tobacco users older than forty years. *Otolaryngology - Head &*  
33 *Neck Surgery*, 116: 201-208.  
34 Not in PICO
- 35 Rafferty, A., Greensmith, M., Robinson, S. & Jose, J. (2012) Laryngeal cancer social marketing project.  
36 *Clinical Otolaryngology*, 37: 46.  
37 Not in PICO
- 38 Reiter, R. & Brosch, S. (2009) [Chronic laryngitis--associated factors and voice assessment].  
39 [German]. *Laryngo- Rhino- Otologie*, 88: 181-185.  
40 Not in PICO
- 41 Resouly, A., Hope, A. & Thomas, S. (2001) A rapid access husky voice clinic: useful in diagnosing  
42 laryngeal pathology. *Journal of Laryngology & Otology*, 115: 978-980.  
43 Not in PICO
- 44 Reulbach, T. R., Belafsky, P. C., Blalock, P. D., Koufman, J. A. & Postma, G. N. (2001) Occult laryngeal  
45 pathology in a community-based cohort. *Otolaryngology - Head & Neck Surgery*, 124: 448-450.  
46 Not in PICO
- 47 Righini, C. A., Karkas, A., Morel, N., Soriano, E. & Reyt, E. (2008) [Risk factors for cancers of the oral  
48 cavity, pharynx (cavity excluded) and larynx]. [Review] [76 refs] [French]. *Presse Medicale*, 37:  
49 1229-1240.  
50 Not in PICO

- 1 Rodrigo, J. P., Garcia-Carracedo, D., Gonzalez, M. V., Mancebo, G., Fresno, M. F. & Garcia-Pedrero, J.  
2 (2010) Podoplanin expression in the development and progression of laryngeal squamous cell  
3 carcinomas. *Molecular Cancer*, 9: 48.  
4 Not in PICO
- 5 Rogachikova, T. A., Abakumova, L. I. & Denisova, I. I. (1990) [Determination of groups at risk for  
6 laryngeal tumors]. [Russian]. *Voprosy Onkologii*, 36: 1466-1469.  
7 Not in PICO
- 8 Rousset, J., Abgral, R., Chinellato, S., Garetier, M., Barberot, C., Valette, G., Potard, G., Le, B. T. &  
9 Salaun, P. Y. (2013) Early recurrence or submucosal residual of laryngeal squamous cell  
10 carcinoma: diagnosis by CT-guided endolaryngeal core biopsy on a transcutaneous approach.  
11 *Head & Neck*, 35: E202-E204.  
12 Not in PICO
- 13 Rua, S., Comino, A., Fruttero, A., Cera, G., Semeria, C., Lanzillotta, L. & Boffetta, P. (1991)  
14 Relationship between histologic features, DNA flow cytometry, and clinical behavior of squamous  
15 cell carcinomas of the larynx. *Cancer*, 67: 141-149.  
16 Not in PICO
- 17 Sahin, M., Kirazli, T., Ozturk, K. & Ogut, M. F. (2013) [A presentation of a practical algorithm which  
18 can be used in the management of vocal cord nodules, polyps and intraepithelial neoplasias].  
19 [Turkish]. *Kulak Burun Bogaz Ihtisas Dergisi/Journal of Ear, Nose & Throat: Kbb*, 23: 96-103.  
20 Not in PICO
- 21 Sato, T. (1987) [High-risk factors in the development of head and neck cancers]. [Japanese]. *Gan to*  
22 *Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*, 14: 2626-2631.  
23 Narrative review
- 24 Savic, D., Djeric, D., Jesic, S. & Bankovic, S. (1987) [Early diagnosis of malignant tumors of the glottis].  
25 [Serbian]. *Srpski Arhiv Za Celokupno Lekarstvo*, 115: 323-332.  
26 In Serbian without an English abstract. Looks like a narrative review
- 27 Seoane, J., Takkouche, B., Varela-Centelles, P., Tomas, I. & Seoane-Romero, J. M. (2012) Impact of  
28 delay in diagnosis on survival to head and neck carcinomas: a systematic review with meta-  
29 analysis. *Clinical Otolaryngology*, 37: 99-106.  
30 Not in PICO
- 31 Sereg-Bahar, M., Jerin, A. & Hocevar-Boltezar, I. (2013) The role of gastroesophageal reflux in  
32 pathogenesis of benign and malignant laryngeal lesions. *European Archives of Oto-Rhino-*  
33 *Laryngology*, 270: 398.  
34 Not in PICO
- 35 Sharma, S. J., Linke, J. J., Kroll, T., Klussmann, J.-P., Guntinas-Lichius, O. & Wittekindt, C. (2013)  
36 Current practice of tumour endoscopy in German ENT-clinics. [German]. *Laryngo- Rhino-*  
37 *Otologie*, 92: 166-169.  
38 Not in PICO
- 39 Shinozaki, N., Sakamoto, A., Kasai, N., Uchida, M. & Sakurai, K. (1983) Multiple primary malignancies  
40 associated with thyroid cancer. [Japanese]. *Gan no rinsho*, Japan: 1385-1391.  
41 Not in PICO
- 42 Singh, H. & Chauhan, A. (2011) Primary small cell carcinoma of the larynx: report of a rare tumor.  
43 *Case Reports in Oncological Medicine*, 2011: 978676.  
44 Not in PICO
- 45 Siupsinskiene, N., Vaitkus, S., Grebliauskaite, M., Engelmanaite, L. & Sumskiene, J. (2008) Quality of  
46 life and voice in patients treated for early laryngeal cancer. *Medicina (Kaunas, Lithuania)*, 44:  
47 288-295.  
48 Not in PICO
- 49 Smart, C. R. (1993) Screening for cancer of the aerodigestive tract. [Review] [6 refs]. *Cancer*, 72:  
50 Suppl-5.  
51 Narrative review

- 1 Smith, M. D., Fleming, J., Lew-Gor, S., Simcock, R., Weighill, J. & Harries, M. L. (2012) 4-Year  
2 demographic study of laryngeal carcinoma. *Otolaryngology - Head and Neck Surgery (United*  
3 *States)*, 147: 144.  
4 Not in PICO
- 5 Smulders, Y., De Bondt, B. J., Lacko, M., Hodge, J. & Kross, K. (2009) Laryngeal tuberculosis  
6 presenting as a supraglottic carcinoma: a case report and review of the literature. *Journal of*  
7 *Medical Case Reports*, 3: 9288.  
8 Not in PICO
- 9 Splete, H. (2009) Primary care physicians can expose laryngeal Ca. *Oncology Report*, 31.  
10 Letter
- 11 Steiner, W., Jaumann, M. P. & Pesch, H. J. (1980) [Early detection of laryngeal cancer (author's  
12 transl)]. [German]. *Therapeutische Umschau*, 37: 1087-1091.  
13 Narrative review
- 14 Steiner, W. (1982) Aspects of clinical differential diagnosis and therapy of early laryngeal cancer  
15 (microcarcinoma). *Clinics in Oncology*, 1: 489-493.  
16 Not in PICO
- 17 Steiner, W. (1982) Early detection of cancer in the upper aerodigestive tract and its prophylaxis.  
18 [German]. *Munchener Medizinische Wochenschrift*, 124: 22-30.  
19 Narrative review
- 20 Stephen, J. K., Chen, K. M., Shah, V., Havard, S., Lu, M., Schweitzer, V. P., Gardner, G. & Worsham, M.  
21 J. (2012) Human papillomavirus outcomes in an access-to-care laryngeal cancer cohort.  
22 *Otolaryngology - Head & Neck Surgery*, 146: 730-738.  
23 Not in PICO
- 24 Stiefelhagen, P. (2010) [Clinical assessment of a "voice disorder" with simple measures. In chronic  
25 hoarseness laryngoscopy is essential]. [German]. *MMW Fortschritte der Medizin*, 152: 25.  
26 Narrative review
- 27 Szlezak, L. & Przybora, L. A. (1983) Early cancer of the vocal cords: Clinical and pathological  
28 progression and results of treatment. [French]. *Annales d'Oto-Laryngologie et de Chirurgie*  
29 *Cervico-Faciale*, 100: 115-124.  
30 Not in PICO
- 31 Tan, I. B., Roodenburg, J. L., Copper, M. P., Coebergh, J. W. & van, d. W., I (2001) [Early diagnosis and  
32 prevention of malignant tumors in the head and neck region]. [Review] [8 refs] [Dutch].  
33 *Nederlands Tijdschrift Voor Geneeskunde*, 145: 567-572.  
34 Narrative review
- 35 Teppo, H., Koivunen, P., Hyrynkangas, K. & Alho, O. P. (2003) Diagnostic delays in laryngeal  
36 carcinoma: professional diagnostic delay is a strong independent predictor of survival. *Head &*  
37 *Neck*, 25: 389-394.  
38 Not in PICO
- 39 Teppo, H., Hyrynkangas, K., Koivunen, P., Jokinen, K. & Alho, O. P. (2005) Impact of patient and  
40 professional diagnostic delays on the risk of recurrence in laryngeal carcinoma. *Clinical*  
41 *Otolaryngology*, 30: 157-163.  
42 Not in PICO
- 43 Teppo, H. & Alho, O. P. (2009) Comorbidity and diagnostic delay in cancer of the larynx, tongue and  
44 pharynx. *Oral Oncology*, 45: 692-695.  
45 Not in PICO
- 46 Thirumaran, M., Sundar, R., Sutcliffe, I. M. & Currie, D. C. (2009) Is investigation of patients with  
47 haemoptysis and normal chest radiograph justified? *Thorax*, 64: 854-856.  
48 Not in PICO
- 49 Thompson, L. W. (1989) Head and neck cancer: early detection. [Review] [25 refs]. *Seminars in*  
50 *Surgical Oncology*, 5: 168-175.  
51 Narrative review



1 van, A. M., Heule-Dieleman, H. A., de Boer, M. F., Kaanders, J. H., Baatenburg de Jong, R. J., Kremer,  
2 B., Leemans, C. R., Marres, H. A., Manni, J. J., Langendijk, J. A., Levendag, P. C., Tjho-Heslinga, R.  
3 E., de Jong, J. M., Uyl-de Groot, C. A. & Knegt, P. P. (2005) Evaluating adherence to the Dutch  
4 guideline for diagnosis, treatment and follow-up of laryngeal carcinomas. *Radiotherapy &*  
5 *Oncology*, 74: 337-344.

6 Not in PICO

7 Vecerina, V. S., Kovac, D., Seiwert, S. & Manojlovic, S. (1997) Correlation between instability of  
8 fundamental voice frequency and malignant infiltration of vocal fold nerve endings. *Acta Oto-*  
9 *Laryngologica Supplement*, 527: 131-133.

10 Not in PICO

11 Vlachtsis, K., Naoum, V., Karasmanis, I. & Nikolaou, A. (2011) Inflammatory myofibroblastic tumor of  
12 the larynx. *European Archives of Oto-Rhino-Laryngology*, 268: 799.

13 Not in PICO

14 Vracko-Tusevljak, M. & Kambic, V. (1989) [The significance of psychological factors in the early  
15 diagnosis of laryngeal and hypopharyngeal tumors]. [German]. *Laryngo- Rhino- Otologie*, 68: 118-  
16 121.

17 Not in PICO

18 Wenig, B. M., Hyams, V. J. & Heffner, D. K. (1988) Moderately differentiated neuroendocrine  
19 carcinoma of the larynx. A clinicopathologic study of 54 cases. [Review] [103 refs]. *Cancer*, 62:  
20 2658-2676.

21 Not in PICO

22 Wilkins, T., Gillies, R. A., Getz, A., Zimmerman, D. & Kang, L. (2010) Nasolaryngoscopy in a family  
23 medicine clinic: indications, findings, and economics. *Journal of the American Board of Family*  
24 *Medicine: JABFM*, 23: 591-597.

25 Not in PICO

26 Wunsch, F., V (2004) The epidemiology of laryngeal cancer in Brazil. [Review] [89 refs]. *Sao Paulo*  
27 *Medical Journal = Revista Paulista de Medicina*, 122: 188-194.

28 Narrative review

29 Ya, S. (1985) Diagnosis of laryngeal cancer in tuberculous patients. [Russian]. *Problemy Tuberkuleza*,  
30 63: 10-13.

31 Not in PICO

32 Yoshino, K., Endo, M., Ishikawa, N. & Takahashi, Y. (1995) Diagnosis and treatment of metachronous  
33 cancers in the esophagus and the head and neck region. *Journal of Surgical Oncology*, 58: 246-  
34 251.

35 Not in PICO

### 37 Review question:

38 Which investigations of symptoms of suspected laryngeal cancer should be done with clinical  
39 responsibility retained by primary care?

### 41 Results

#### 42 Literature search

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1980-2013	210	47	10/04/2013
<i>Premedline</i>	1980-2013	10	2	10/04/2013
<i>Embase</i>	1980-2013	348	47	10/04/2013
<i>Cochrane Library</i>	1980-2013	2	0	10/04/2013
<i>Psychinfo</i>	1980-2013	0	0	10/04/2013


<b>Web of Science (SCI &amp; SSCI) and ISI Proceedings</b>	1980-2013	20	2	10/04/2013
--	-----------	----	---	------------

1 Total References retrieved (after de-duplication): 53

2  
3 **Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<b>Medline</b>	4/2013-26/08/2014	3	0	26/08/2014
<b>Premedline</b>	4/2013-26/08/2014	15	2	26/08/2014
<b>Embase</b>	4/2013-26/08/2014	28	3	26/08/2014
<b>Cochrane Library</b>	4/2013-26/08/2014	5	0	26/08/2014
<b>Web of Science (SCI &amp; SSCI) and ISI Proceedings</b>	4/2013-26/08/2014	3	0	26/08/2014

4 Total References retrieved (after de-duplication): 4



5  
6 **Study results**

7 No evidence was identified pertaining to the diagnostic accuracy of chest x-ray in patients with  
8 suspected laryngeal cancer where the clinical responsibility was retained by primary care.

9  
10 **References**

11 **Included studies**

12 None

13  
14 **Excluded studies (with excl reason)**

- 1 Arens, C., Glanz, H., Dreyer, T. & Malzahn, K. (2003) Compact endoscopy of the larynx. *Annals of*  
2 *Otology, Rhinology & Laryngology*, 112: 113-119.  
3 Not in PICO
- 4 Arens, C., Glanz, H., Wonckhaus, J., Hersemeyer, K. & Kraft, M. (2007) Histologic assessment of  
5 epithelial thickness in early laryngeal cancer or precursor lesions and its impact on endoscopic  
6 imaging. *European Archives of Oto-Rhino-Laryngology*, 264: 645-649.  
7 Not in PICO
- 8 Banko, B., Dukic, V., Milovanovic, J., Kovac, J. D., Artiko, V. & Maksimovic, R. (2011) Diagnostic  
9 significance of magnetic resonance imaging in preoperative evaluation of patients with  
10 laryngeal tumors. *European Archives of Oto-Rhino-Laryngology*, 268: 1617-1623.  
11 Not in PICO
- 12 Bongers, V., Hobbelink, M. G., van Rijk, P. P. & Hordijk, G. J. (2002) Cost-effectiveness of dual-head  
13 18F-fluorodeoxyglucose PET for the detection of recurrent laryngeal cancer. *Cancer*  
14 *Biotherapy & Radiopharmaceuticals*, 17: 303-306.  
15 Not in PICO
- 16 Brandt, R. H. & Weidner, I. (1984) [Early diagnosis of laryngeal cancer by endoscopy and histology in  
17 the risk group dispensary]. [German]. *Zeitschrift fur Arztliche Fortbildung (Jena)*, 78: 763-766.  
18 Not in PICO
- 19 Brouwer, J., Bodar, E. J., de Bree, R., Langendijk, J. A., Castelijns, J. A., Hoekstra, O. S. & Leemans, C.  
20 R. (2004) Detecting recurrent laryngeal carcinoma after radiotherapy: room for improvement.  
21 *European Archives of Oto-Rhino-Laryngology*, 261: 417-422.  
22 Not in PICO
- 23 Brouwera, J., de Bree, R., Comans, E. F. I., Akarriou, M., Langendijk, J. A., Castelijns, J. A., Hoekstra, O.  
24 S. & Leemans, C. R. (2008) Improved detection of recurrent laryngeal tumor after radiotherapy  
25 using (18)FDG-PET as initial method. *Radiotherapy and Oncology*, 87: 217-220.  
26 Not in PICO
- 27 Cetinkaya, E., Veyseller, B., Yildirim, Y. S., Aksoy, F., Ozgul, M. A., Gencoglu, A. & Altin, S. (2011)  
28 Value of autofluorescence bronchoscopy in patients with laryngeal cancer. *Journal of*  
29 *Laryngology & Otology*, 125: 181-187.  
30 Not in PICO
- 31 Chang, J., Fang, T. J., Yung, K., van, Z. A., Miller, T., Al-Jurf, S., Schneider, S. & Courey, M. (2012)  
32 Clinical and histologic predictors of voice and disease outcome in patients with early glottic  
33 cancer. *Laryngoscope*, 122: 2240-2247.  
34 Not in PICO
- 35 Cnossen, I. C., de, B. R., Rinkel, R. N., Eerenstein, S. E., Rietveld, D. H., Doornaert, P., Buter, J.,  
36 Langendijk, J. A., Leemans, C. R. & Verdonck-de Leeuw, I. M. (2012) Computerized monitoring  
37 of patient-reported speech and swallowing problems in head and neck cancer patients in  
38 clinical practice. *Supportive Care in Cancer*, 20: 2925-2931.  
39 Not in PICO
- 40 Cobben, D. C., van der Laan, B. F., Maas, B., Vaalburg, W., Suurmeijer, A. J., Hoekstra, H. J., Jager, P.  
41 L. & Elsinga, P. H. (2004) 18F-FLT PET for visualization of laryngeal cancer: comparison with  
42 18F-FDG PET. *Journal of Nuclear Medicine*, 45: 226-231.  
43 Not in PICO
- 44 Cohen, S. M., Kim, J., Roy, N. & Courey, M. (2014) Factors influencing referral of patients with voice  
45 disorders from primary care to otolaryngology. *Laryngoscope*, 124: 214-220.  
46 Not in PICO
- 47 Cohen, S. M., Dinan, M. A., Roy, N., Kim, J. & Courey, M. (2014) Diagnosis Change in Voice-  
48 Disordered Patients Evaluated by Primary Care and/or Otolaryngology: A Longitudinal Study.  
49 *Otolaryngology - Head & Neck Surgery*, 150: 95-102.  
50 Not in PICO

- 1 Conrad, R., Pauleit, D., Layer, G., Kandyba, J., Kohlbecher, R., Hortling, N., Baselides, P. & Schild, H.  
2 (1999) [Spiral CT of the head-neck area: the advantages of the early arterial phase in the  
3 detection of squamous-cell carcinomas]. [German]. *Rofo: Fortschritte auf dem Gebiete der*  
4 *Rontgenstrahlen und der Nuklearmedizin*, 171: 15-19.  
5 Not in PICO
- 6 Croce, A., de, V. M., Primerano, G., Gallo, A., Rendina, E. A. & Venuta, F. (1989) [Early diagnosis of  
7 pulmonary tumors in patients treated for laryngeal cancer]. [Review] [46 refs] [Italian]. *Acta*  
8 *Otorhinolaryngologica Italica*, 9: 139-147.  
9 Not in PICO
- 10 Dammer, R., Bonkowski, V., Kutz, R., Friesenecker, J. & Schusselbauer, T. (1999) [Early detection of  
11 multiple tumors in primary diagnosis of oral carcinomas using panendoscopy]. [German].  
12 *Mund-, Kiefer- und Gesichtschirurgie*, 3: 61-66.  
13 Not in PICO
- 14 De, V. A. & Vicini, C. (2013) Narrow-band imaging in the early detection of laryngeal cancer: A  
15 prospective study. *European Archives of Oto-Rhino-Laryngology*, 270: 389.  
16 Not in PICO
- 17 de Bree, R., van der Putten, L., Hoekstra, O. S., Kuik, D. J., Groot, C. A. U. D., van Tinteren, H.,  
18 Leemans, C. R. & Boers, M. (2007) A randomized trial of PET scanning to improve diagnostic  
19 yield of direct laryngoscopy in patients with suspicion of recurrent laryngeal carcinoma after  
20 radiotherapy. *Contemporary Clinical Trials*, 28: 705-712.  
21 Not in PICO
- 22 Dequanter, D., Lothaire, P., Zouaoui, K. & Brohee, D. (2012) Epidemiology and clinical characteristics  
23 of larynx and hypopharynx carcinoma: a comparative study in the Hainaut and review of the  
24 literature. *Acta Chirurgica Belgica*, 112: 423-425.  
25 Not in PICO
- 26 DeSanto, L. W. (1982) The options in early laryngeal carcinoma. [Review] [10 refs]. *New England*  
27 *Journal of Medicine*, 306: 910-912.  
28 Not in PICO
- 29 Dullerud, R., Johansen, J. G., Dahl, T. & Faye-Lund, H. (1992) Influence of CT on tumor classification  
30 of laryngeal carcinomas. *Acta Radiologica*, 33: 314-318.  
31 Not in PICO
- 32 Engelen, A. M., Stalpers, L. J., Manni, J. J., Ruijs, J. H. & van Daal, W. A. (1992) Yearly chest  
33 radiography in the early detection of lung cancer following laryngeal cancer. [Review] [30  
34 refs]. *European Archives of Oto-Rhino-Laryngology*, 249: 364-369.  
35 Not in PICO
- 36 Fasanla, A. J. & Lasisi, O. A. (2009) Diagnostic challenges of laryngeal papillomatosis and its  
37 implications among children in developing country. *International Journal of Pediatric*  
38 *Otorhinolaryngology*, 73: 593-595.  
39 Not in PICO
- 40 Gaafar, H., Hussein, M. & el-Assi, H. (1989) Cytopathology in cancer of larynx. *Orl; Journal of Oto-*  
41 *Rhino-Laryngology & its Related Specialties*, 51: 216-220.  
42 Not in PICO
- 43 Garcia Callejo, F. J., Dualde, B. D., Benlloch, R. E., Montoro Elena, M. J., Hernandorena, G. M. &  
44 Marco, A. J. (2008) [Use of imaging criteria to identify cervical metastases using CT scans in  
45 head and neck tumours]. [Spanish]. *Acta Otorrinolaringologica Espanola*, 59: 257-262.  
46 Not in PICO
- 47 Gugatschka, M., Kiesler, K., Beham, A., Rechenmacher, J. & Friedrich, G. (2008) Hyperplastic  
48 epithelial lesions of the vocal folds: combined use of exfoliative cytology and  
49 laryngostroboscopy in differential diagnosis. *European Archives of Oto-Rhino-Laryngology*,  
50 265: 797-801.  
51 Not in PICO

- 1 Hanson, J., Bruchmuller, W. & Nischwitz, A. S. (1989) [Precancerous diseases and the early  
2 recognition of pharyngeal and laryngeal carcinomas]. [German]. *Archiv fur*  
3 *Geschwulstforschung*, 59: 99-105.  
4 Narrative review
- 5 Hoare, T. J., Thomson, H. G. & Proops, D. W. (1993) Detection of Laryngeal-Cancer - the Case for  
6 Early Specialist Assessment. *Journal of the Royal Society of Medicine*, 86: 390-392.  
7 Not in PICO
- 8 Huang, Z., Xiao, W. & Li, G. (2002) [Evaluating the clinical applications of CTVL in laryngeal  
9 carcinomas]. [Chinese]. *Lin Chuang Erh Pi Yen Hou Ko Tsa Chih Journal of Clinical*  
10 *Otorhinolaryngology*, 16: 104-105.  
11 Not in PICO
- 12 Jarmuz, M., Szyfter, K., Grenman, R., Golusinski, W. & Szyfter, W. (2000) [Usefulness of chromosome  
13 alteration analysis in cell lines derived from laryngeal tumors for evaluation of laryngeal  
14 neoplasms]. [Polish]. *Otolaryngologia Polska*, 54: 567-572.  
15 Not in PICO
- 16 Kraft, M., Luerssen, K., Lubatschowski, H., Woenckhaus, J., Schoberlein, S., Glanz, H. & Arens, C.  
17 (2008) [Mucosal lesions in the larynx: predictive value of new imaging modalities for a  
18 histological diagnosis]. [German]. *HNO*, 56: 609-613.  
19 Not in PICO
- 20 Lell, M. M., Greess, H., Hothorn, T., Janka, R., Bautz, W. A. & Baum, U. (2004) Multiplanar functional  
21 imaging of the larynx and hypopharynx with multislice spiral CT. *European Radiology*, 14:  
22 2198-2205.  
23 Not in PICO
- 24 Lewin, J. S., Gillenwater, A. M., Garrett, J. D., Bishop-Leone, J. K., Nguyen, D. D., Callender, D. L.,  
25 Ayers, G. D. & Myers, J. N. (2003) Characterization of laryngopharyngeal reflux in patients with  
26 premalignant or early carcinomas of the larynx. *Cancer*, 97: 1010-1014.  
27 Not in PICO
- 28 Li, Y., Arens, C. & Glanz, H. (2005) [Autofluorescence endoscopy for diagnosing early laryngeal cancer  
29 and its precursor lesions]. [Chinese]. *Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = Chinese*  
30 *Journal of Otorhinolaryngology Head & Neck Surgery*, 40: 696-700.  
31 Not in PICO
- 32 Lim, S. (2014). Are we performing more laryngeal biopsies, and if so, why? A decade of results.  
33 *Journal of Laryngology and Otology*, 28, 3.  
34 Not in PICO
- 35 Lowe, V. J., Kim, H., Boyd, J. H., Eisenbeis, J. F., Dunphy, F. R. & Fletcher, J. W. (1999) Primary and  
36 recurrent early stage laryngeal cancer: preliminary results of 2-[fluorine 18]fluoro-2-deoxy-D-  
37 glucose PET imaging. *Radiology*, 212: 799-802.  
38 Not in PICO
- 39 Lydiatt, D. D. (2002) Medical malpractice and cancer of the larynx. *Laryngoscope*, 112: 445-448.  
40 Not in PICO
- 41 Mancuso, A. A., Tamakawa, Y. & Hanafee, W. N. (1980) CT of the fixed vocal cord. *AJR. American*  
42 *Journal of Roentgenology*, 135: 7529-7534.  
43 Not in PICO
- 44 Mashkova, T. A., Ovsiannikov, I. & Panchenko, I. G. (2010) [Potential of fibrolaryngoscopy for the  
45 improvement of diagnosis of laryngeal diseases]. [Russian]. *Vestnik Otorinolaringologii*.(5):28-  
46 9, 2010., 28-29.  
47 Not in PICO
- 48 Mehlmann, M., Betz, C. S., Stepp, H., Arbogast, S., Baumgartner, R., Grevers, G. & Leunig, A. (1999)  
49 Fluorescence staining of laryngeal neoplasms after topical application of 5-aminolevulinic acid:  
50 preliminary results. *Lasers in Surgery & Medicine*, 25: 414-420.  
51 Not in PICO

- 1 Naidu, H., Noordzij, J. P., Samim, A., Jalisi, S. & Grillone, G. A. (2012) Comparison of efficacy, safety,  
2 and cost-effectiveness of in-office cup forcep biopsies versus operating room biopsies for  
3 laryngopharyngeal tumors. *Journal of Voice*, 26: 604-606.  
4 Not in PICO
- 5 Ni, X. G., He, S., Xu, Z. G., Lu, N., Gao, L., Yuan, Z., Zhang, Y. M., Lai, S. Q., Yi, J. L., Wang, X. L., Zhang,  
6 L., Li, X. Y. & Wang, G. Q. (2010) [Application of narrow band imaging endoscopy in the  
7 diagnosis of laryngeal cancer]. [Chinese]. *Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi =*  
8 *Chinese Journal of Otorhinolaryngology Head & Neck Surgery*, 45: 143-147.  
9 Not in PICO
- 10 Ni, X. G., He, S., Xu, Z. G., Gao, L., Lu, N., Yuan, Z., Lai, S. Q., Zhang, Y. M., Yi, J. L., Wang, X. L., Zhang,  
11 L., Li, X. Y. & Wang, G. Q. (2011) Endoscopic diagnosis of laryngeal cancer and precancerous  
12 lesions by narrow band imaging. *Journal of Laryngology & Otology*, 125: 288-296.  
13 Not in PICO
- 14 Nix, P. A. & Salvage, D. (2004) Neoplastic invasion of laryngeal cartilage: the significance of cartilage  
15 sclerosis on computed tomography images. *Clinical Otolaryngology & Allied Sciences*, 29: 372-  
16 375.  
17 Not in PICO
- 18 Paczona, R., Temam, S., Janot, F., Marandas, P. & Luboinski, B. (2003) Autofluorescence  
19 videoendoscopy for photodiagnosis of head and neck squamous cell carcinoma. *European*  
20 *Archives of Oto-Rhino-Laryngology*, 260: 544-548.  
21 Not in PICO
- 22 Pan, C. T., Lee, L. A., Fang, T. J., Li, H. Y., Liao, C. T. & Chen, I. H. (2013) NBI flexible laryngoscopy  
23 targeted tissue sampling in head and neck cancer patients with difficult airways. *European*  
24 *Archives of Oto-Rhino-Laryngology*, 270: 263-269.  
25 Not in PICO
- 26 Rafferty, A., Greensmith, M., Robinson, S. & Jose, J. (2012) Laryngeal cancer social marketing project.  
27 *Clinical Otolaryngology*, 37: 46.  
28 Not in PICO
- 29 Ramirez-Anguiano, J., Lara-Sanchez, H., Martinez-Banos, D. & Martinez-Benitez, B. (2012)  
30 Extramedullary plasmacytoma of the larynx: a case report of subglottic localization. *Case*  
31 *Reports in Otolaryngology Print*, 2012: 437264.  
32 Not in PICO
- 33 Reiter, R. & Brosch, S. (2009) [Chronic laryngitis--associated factors and voice assessment].  
34 [German]. *Laryngo- Rhino- Otologie*, 88: 181-185.  
35 Not in PICO
- 36 Rodrigo, J. P., Garcia-Carracedo, D., Gonzalez, M. V., Mancebo, G., Fresno, M. F. & Garcia-Pedrero, J.  
37 (2010) Podoplanin expression in the development and progression of laryngeal squamous cell  
38 carcinomas. *Molecular Cancer*, 9: 48.  
39 Not in PICO
- 40 Rousset, J., Abgral, R., Chinellato, S., Garetier, M., Barberot, C., Valette, G., Potard, G., Le, B. T. &  
41 Salaun, P. Y. (2013) Early recurrence or submucosal residual of laryngeal squamous cell  
42 carcinoma: diagnosis by CT-guided endolaryngeal core biopsy on a transcutaneous approach.  
43 *Head & Neck*, 35: E202-E204.  
44 Not in PICO
- 45 Sahin, M., Kirazli, T., Ozturk, K. & Ogut, M. F. (2013) [A presentation of a practical algorithm which  
46 can be used in the management of vocal cord nodules, polyps and intraepithelial neoplasias].  
47 [Turkish]. *Kulak Burun Bogaz Ihtisas Dergisi/Journal of Ear, Nose & Throat: Kbb*, 23: 96-103.  
48 Not in PICO
- 49 Sereg-Bahar, M., Jerin, A. & Hocevar-Boltezar, I. (2013) The role of gastroesophageal reflux in  
50 pathogenesis of benign and malignant laryngeal lesions. *European Archives of Oto-Rhino-*

- 1 *Laryngology*, 270: 398.  
2 Not in PICO
- 3 Sharma, S. J., Linke, J. J., Kroll, T., Klussmann, J.-P., Guntinas-Lichius, O. & Wittekindt, C. (2013)  
4 Current practice of tumour endoscopy in German ENT-clinics. [German]. *Laryngo- Rhino-*  
5 *Otologie*, 92: 166-169.  
6 Not in PICO
- 7 Smith, M. D., Fleming, J., Lew-Gor, S., Simcock, R., Weighill, J. & Harries, M. L. (2012) 4-Year  
8 demographic study of laryngeal carcinoma. *Otolaryngology - Head and Neck Surgery (United*  
9 *States)*, 147: 144.  
10 Not in PICO
- 11 Stoeckli, S. J. & Broglie, M. A. (2012) Sentinel node biopsy for early oral carcinoma. *Current Opinion*  
12 *in Otolaryngology & Head and Neck Surgery*, 20: 103-108.  
13 Not in PICO
- 14 Stone, N., Stavroulaki, P., Kendall, C., Birchall, M. & Barr, H. (2000) Raman spectroscopy for early  
15 detection of laryngeal malignancy: preliminary results. *Laryngoscope*, 110: t-63.  
16 Not in PICO
- 17 Szmeja, Z., Wierzbicka, M. & Kordylewska, M. (1999) The value of ultrasound examination in  
18 preoperative neck assessment and in early diagnosis of nodal recurrences in the follow-up of  
19 patients operated for laryngeal cancer. *European Archives of Oto-Rhino-Laryngology*, 256:  
20 415-417.  
21 Not in PICO
- 22 Ustundag, E., Kaur, A. C., Boyaci, Z., Keskin, G. & Aydin, O. (2006) Combined use of histopathology  
23 with touch smear cytology in biopsies of the larynx. *European Archives of Oto-Rhino-*  
24 *Laryngology*, 263: 866-871.  
25 Not in PICO
- 26 van Agthoven, M., Heule-Dieleman, H. A. G., de Boer, M. F., Kaanders, J. H. A. M., de Jong, R. J. B.,  
27 Kremer, B., Leemans, C. R., Marres, H. A. M., Manni, J. J., Langendijk, J. A., Levendag, P. C.,  
28 Tjho-Heslinga, R. E., de Jong, J. M. A., Uyl-de Groot, C. A. & Knegt, P. P. (2005) Evaluating  
29 adherence to the Dutch guideline for diagnosis, treatment and follow-up of laryngeal  
30 carcinomas. *Radiotherapy and Oncology*, 74: 337-344.  
31 Not in PICO
- 32 Warnecke, A., Averbeck, T., Leinung, M., Soudah, B., Wenzel, G. I., Kreipe, H. H., Lenarz, T. & Stover,  
33 T. (2010) Contact endoscopy for the evaluation of the pharyngeal and laryngeal mucosa.  
34 *Laryngoscope*, 120: 253-258.  
35 Not in PICO
- 36 Zan, E., Yousem, D. M. & Aygun, N. (2011) Asymmetric mineralization of the arytenoid cartilages in  
37 patients without laryngeal cancer. *Ajnr: American Journal of Neuroradiology*, 32: 1113-1118.  
38 Not in PICO
- 39 Zargi, M., Smid, L., Fajdiga, I., Bubnic, B., Lenarcic, J. & Oblak, P. (1997) Detection and localization of  
40 early laryngeal cancer with laser-induced fluorescence: preliminary report. *European Archives*  
41 *of Oto-Rhino-Laryngology*, 254: Suppl-6.  
42 Not in PICO
- 43 Zargi, M., Fajdiga, I. & Smid, L. (2000) Autofluorescence imaging in the diagnosis of laryngeal cancer.  
44 *European Archives of Oto-Rhino-Laryngology*, 257: 17-23.  
45 Not in PICO  
46  
47

**ORAL CANCER****Review question:**

What is the risk of oral cancer in patients presenting in primary care with symptom(s)?

**Results****Literature search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1980-2013	766	43	15/04/2013
<i>Premedline</i>	1980-2013	31	9	15/04/2013
<i>Embase</i>	1980-2013	1551	118	16/04/2013
<i>Cochrane Library</i>	1980-2013	137	9	17/04/2013
<i>Psychinfo</i>	1980-2013	4	0	17/04/2013
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	1980-2013	594	70	17/04/2013


Total References retrieved (after de-duplication): 184

**Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	4/2013-20/08/2014	23	4	20/08/2014
<i>Premedline</i>	4/2013-20/08/2014	25	4	20/08/2014
<i>Embase</i>	4/2013-20/08/2014	85	2	20/08/2014
<i>Cochrane Library</i>	4/2013-20/08/2014	279	0	20/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	4/2013-20/08/2014	57	1	20/08/2014

Total References retrieved (after de-duplication): 10





1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

**Study results**

No evidence was identified.

**References**

**Included studies**

None

**Excluded studies (with excl reason)**

(1995) Early diagnosis and prevention of oral cancer and precancer: report of Symposium III. *Advances in Dental Research*, 9: 134-137.

Narrative review

Abdelghany, A., Nolan, A., Freeman, R., Abdelghany, A., Nolan, A. & Freeman, R. (2011) Treating patients with dry mouth: general dental practitioners' knowledge, attitudes and clinical management. *British Dental Journal*, 211: E21.

Not in PICO

Abdul-Hussein, N., Mekaeil, R. & Walker, D. M. (2001) Referral attendance pattern and risk factors for oral cancer. *Journal of Dental Research*, 80: 979.

Not in PICO

Alho, O.-P. (2006) Head and neck cancer in primary care: Presenting symptoms and the effect of delayed diagnosis of cancer cases. *CMAJ*, 174: 779-784.

Study design not in PICO: Symptom prevalence study (with no case/no case verification) + cancer patient study

Allison, P. (2003) Information on oral cancer encourages primary-care patients to accept oral cancer screening and reduces associated anxiety. *Evidence-Based Dentistry*, 4: 68-69.

Not in PICO

- 1 Allon, I., Allon, D. M., Gal, G., Anavi, Y., Chaushu, G. & Kaplan, I. (2013) Re-evaluation of common  
2 paradigms regarding the clinical appearance of oral mucosal malignancies. *Journal of Oral*  
3 *Pathology & Medicine*, 42: 670-675.  
4 Not in PICO
- 5 Alvi, A. (1996) Oral cancer: How to recognize the danger signs. *Postgraduate Medicine*, 99: 149-156.  
6 Narrative review
- 7 Applebaum, E. (2009) Oral cancer knowledge, attitudes and practices: a survey of dentists and  
8 primary care physicians in Massachusetts. *Journal of the American Dental Association (1939)*,  
9 140: 461-467.  
10 Not in PICO
- 11 Arishiya Thapasum, F. (2011) Primary care clinicians' knowledge of oral cancer: A study of oral and  
12 general physicians in Kuala Muda & Kota Setar Districts, Malaysia. *Oral Oncology*, Conference:  
13 July.  
14 Not in PICO
- 15 Awojobi, O., Scott, S. E. & Newton, T. (2012) Patients' perceptions of oral cancer screening in dental  
16 practice: a cross-sectional study. *Bmc Oral Health*, 12.  
17 Not in PICO
- 18 Barucchi, A. M. B. (1987) Aspects of various lesions in the early diagnosis of oral carcinoma. *Giornale*  
19 *di Stomatologia e di Ortognatodonzia*, 6: 29-35.  
20 Narrative review
- 21 Bassi, K. K., Srivastava, A., Seenu, V., Kumar, R., Parshad, R., Chumber, S., Gupta, S. D. & Bahadur, S.  
22 (2013) The first and second echelon sentinel lymph node evaluation in oral cancer. *Indian Journal*  
23 *of Surgery*, 75: 377-382.  
24 Not in PICO
- 25 Bateman, C. (2002) Oral cancer - An underestimated killer. *South African Medical Journal*, 92: 410-  
26 412.  
27 Narrative review
- 28 Beck-Mannagetta, J. (2009) Squamous cell carcinoma and potentially malignant disorders of the oral  
29 mucosa. *Hautarzt*, 60: 859-865.  
30 Narrative review
- 31 Beirne, P. (2007) Recall intervals for oral health in primary care patients. *Cochrane Database of*  
32 *Systematic Reviews*.  
33 Not in PICO
- 34 Bentley, J. M., Barankin, B., Lauzon, G. J., Bentley, J. M., Barankin, B. & Lauzon, G. J. (2003) Paying  
35 more than lip service to lip lesions. [Review] [26 refs]. *Canadian Family Physician*, 49: 1111-1116.  
36 Not in PICO
- 37 Blanchaert, J. (2002) Oral and oral pharyngeal cancer: an update on incidence and epidemiology,  
38 identification, advances in treatment, and outcomes. *Compendium of continuing education in*  
39 *dentistry (Jamesburg, N, J.: 25-29.*  
40 Narrative review
- 41 Bleyer, A. (2009) CAUTION! Consider Cancer: Common Symptoms and Signs for Early Detection of  
42 Cancer in Young Adults. *Seminars in Oncology*, 36: 207-212.  
43 Narrative review
- 44 Borhan-Mojabi, K., Moradi, A. & Yazdabadi, A. (2012) Evaluating the degree of knowledge on oral  
45 cancer among general practitioners and dentists in Qazvin. *Journal of Evaluation in Clinical*  
46 *Practice*, 18: 498-501.  
47 Not in PICO
- 48 Borowski, B., Margainaud, J. P., Borowski, B. & Margainaud, J. P. (1990) [Early diagnosis of cancers of  
49 the mouth]. [French]. *Revue d Odonto-Stomatologie*, 19: 291-297.  
50 Narrative review

- 1 Bradley, P. J. & McGurk, M. (2013) Incidence of salivary gland neoplasms in a defined UK population.  
2 *British Journal of Oral & Maxillofacial Surgery*, 51: 399-403.  
3 Not in PICO
- 4 Brocklehurst, P., Kujan, O., Glenny, A.-M., Oliver, R., Sloan, P., Ogden, G. & Shepherd, S. (2010)  
5 Screening programmes for the early detection and prevention of oral cancer. *Cochrane database*  
6 *of systematic reviews (Online)*, 11.  
7 Not in PICO
- 8 Brocklehurst, P. R., Baker, S. R. & Speight, P. M. (2010) Oral cancer screening: what have we learnt  
9 and what is there still to achieve? *Future Oncology*, 6: 299-304.  
10 Narrative review
- 11 Brocklehurst, P. R., Baker, S. R. & Speight, P. M. (2010) A qualitative study examining the experience  
12 of primary care dentists in the detection and management of potentially malignant lesions. 1.  
13 Factors influencing detection and the decision to refer. *British Dental Journal*, 208: 72-73.  
14 Not in PICO
- 15 Brocklehurst, P. R. B. (2009) Factors affecting the referral of potentially malignant lesions from  
16 primary dental care: a pilot study in South Yorkshire. *Primary dental care : journal of the Faculty*  
17 *of General Dental Practitioners (UK)*, 16: 13-18.  
18 Not in PICO
- 19 Brocklehurst, P. R. B. (2010) Factors which determine the referral of potentially malignant disorders  
20 by primary care dentists. *Journal of Dentistry*, 38: 569-578.  
21 Not in PICO
- 22 Brouha, X. D., Tromp, D. M., Hordijk, G. J., Winnubst, J. A., de Leeuw, J. R., Brouha, X. D. R., Tromp, D.  
23 M., Hordijk, G. J., Winnubst, J. A. M. & de Leeuw, J. R. (2005) Oral and pharyngeal cancer: analysis  
24 of patient delay at different tumor stages. *Head & Neck*, 27: 939-945.  
25 Not in PICO
- 26 Brouha, X. D. R. (2007) Professional delay in head and neck cancer patients: Analysis of the  
27 diagnostic pathway. *Oral Oncology*, 43: 551-556.  
28 Not in PICO
- 29 Brzak, B. L., Mravak-Stipetiv, M., Canjuga, I., Baricevic, M., Balicevic, D., Sikora, M. & Filipovic-Zore, I.  
30 (2012) The Frequency and Malignant Transformation Rate of Oral Lichen Planus and Leukoplakia -  
31 A Retrospective Study. *Collegium Antropologicum*, 36: 773-777.  
32 Not in PICO
- 33 Burgess, L., Hamburger, J., White, D. A. & Morris, A. J. (2003) Patients referred with suspected oral  
34 malignancy - General dental practitioners' approaches. *Journal of Dental Research*, 82: 587.  
35 Not in PICO
- 36 Campos, A. E. (1988) Early detection of oral cancer. *Factor Odontologico*, 15: 13-15.  
37 Nowhere available, but I think it is a narrative review
- 38 Casiglia, J., Woo, S. B., Casiglia, J. & Woo, S. B. (2001) A comprehensive review of oral cancer.  
39 [Review] [101 refs]. *General Dentistry*, 49: 72-82.  
40 Narrative review
- 41 Cianfriglia, F. M. (1991) Diagnostic delay in neoplasms of the oral cavity. *Minerva Stomatologica*, 40:  
42 717-728.  
43 Not in PICO
- 44 Cnossen, I. C., de B., Rinkel, R. N., Eerenstein, S. E., Rietveld, D. H., Doornaert, P., Buter, J.,  
45 Langendijk, J. A., Leemans, C. R., Verdonck-de Leeuw, I. M., Cnossen, I. C., de Bree, R., Rinkel, R.  
46 N. P. M., Eerenstein, S. E. J., Rietveld, D. H. F., Doornaert, P., Buter, J., Langendijk, J. A., Leemans,  
47 C. R. & Verdonck-de Leeuw, I. M. (2012) Computerized monitoring of patient-reported speech  
48 and swallowing problems in head and neck cancer patients in clinical practice. *Supportive Care in*  
49 *Cancer*, 20: 2925-2931.  
50 Not in PICO

- 1 Cowan, C. G. G. (1995) Prevention and detection of oral cancer: the views of primary care dentists in  
2 Northern Ireland. *British Dental Journal*, 179: 338-342.  
3 Not in PICO
- 4 Dave, B. (2013) Why do GPs fail to recognise oral cancer? The argument for an oral cancer  
5 checklist. *British Dental Journal*, 214: 223-225.  
6 Narrative review
- 7 Dave, B. (2013) Why do GPs fail to recognise oral cancer? The argument for an oral cancer  
8 checklist. *British Dental Journal*, 214: 223-225.  
9 Narrative review
- 10 Dedhia, R. C., Smith, K. J., Johnson, J. T. & Roberts, M. (2011) The Cost-Effectiveness of Community-  
11 Based Screening for Oral Cancer in High-Risk Males in the United States: A Markov Decision  
12 Analysis Approach. *Laryngoscope*, 121: 952-960.  
13 Not in PICO
- 14 Demko, C. A., Sawyer, D., Slivka, M., Smith, D., Wotman, S., Demko, C. A., Sawyer, D., Slivka, M.,  
15 Smith, D. & Wotman, S. (2009) Prevalence of oral lesions in the dental office. *General Dentistry*,  
16 57: 504-509.  
17 Not in PICO
- 18 Dequanter, D., Shahla, M., Paulus, P. & Lothaire, P. (2013) Long term results of sentinel lymph node  
19 biopsy in early oral squamous cell carcinoma. *Oncotargets and therapy*, 6: 799-802.  
20 Not in PICO
- 21 Desouky, A. F. (2012) Incidental finding of parotid neoplasia-a report of two cases. *Oral Diseases*,  
22 Conference: September.  
23 Not in PICO
- 24 Dimitroulis, G. R. (1992) Referral patterns of patients with oral squamous cell carcinoma, Australia.  
25 *European Journal of Cancer Part B: Oral Oncology*, 28: 23-27.  
26 Not in PICO
- 27 dos Santos, L. C. O., Batista, O. D. & Cangussu, M. C. T. (2010) Characterization of oral cancer  
28 diagnostic delay in the state of Alagoas. *Brazilian Journal of Otorhinolaryngology*, 76: 416-422.  
29 Not in PICO
- 30 Douglass, A. B. M. (2008) Promoting oral health: The family physician's role. *American Family*  
31 *Physician*, 78: 814-815.  
32 Editorial
- 33 Dreyer, W. P., de, W. J., Dreyer, W. P. & de Waal, J. (2010) Oral medicine case book 29. Early  
34 squamous cell carcinoma of the gingiva and erosive lichen planus of the buccal tissues. *SADJ*, 65:  
35 326-327.  
36 Not in PICO
- 37 Eisen, D., V (1991) Oral melanoma and other pigmented lesions of the oral cavity. *Journal of the*  
38 *American Academy of Dermatology*, 24: 527-537.  
39 Narrative review
- 40 Elango, K. J. A. (2011) Mouth self-examination to improve oral cancer awareness and early detection  
41 in a high-risk population. *Oral Oncology*, 47: 620-624.  
42 Not in PICO
- 43 Elkhoury, J. (2004) Undifferentiated malignant neoplasm involving the interdental gingiva: A case  
44 report. *Journal of Periodontology*, 75: 1295-1299.  
45 Not in PICO
- 46 Epstein, J. B. G. (2008) Screening for and diagnosis of oral premalignant lesions and oropharyngeal  
47 squamous cell carcinoma: Role of primary care physicians. *Canadian Family Physician*, 54: 870-  
48 875.  
49 Narrative review

- 1 Farah, C. S. & McCullough, M. J. (2008) Oral cancer awareness for the general practitioner: new  
2 approaches to patient care. *Australian Dental Journal*, 53: 2-10.  
3 Narrative review
- 4 Field, E. A. M. (1995) Oral mucosal screening as an integral part of routine dental care. *British Dental*  
5 *Journal*, 179: 262-266.  
6 Not in PICO
- 7 Foroughi, R., Seyedmajidi, M., Bijani, A. & Omid, D. M. (2013) Comparison of clinical diagnosis and  
8 histopathological report of referred biopsies to oral and maxillofacial pathology department of  
9 dental school of Babol, Iran (2003-2010). *Journal of Babol University of Medical Sciences*, 15: 71-  
10 77.  
11 Not in PICO
- 12 Fowler, G. G. R. (1980) Intraoral cancer in Victoria. *Medical Journal of Australia*, 2: 20-22.  
13 Not in PICO
- 14 Franklin, C. D. J. (2006) A survey of oral and maxillofacial pathology specimens submitted by general  
15 dental practitioners over a 30-year period. *British Dental Journal*, 200: 447-450.  
16 Not in PICO
- 17 Friedrich, R. E. & Friedrich, R. E. (2010) Delay in diagnosis and referral patterns of 646 patients with  
18 oral and maxillofacial cancer: a report from a single institution in Hamburg, Germany. *Anticancer*  
19 *Research*, 30: 1833-1836.  
20 Not in PICO
- 21 Garg, P. (2012) "Catch them before it becomes too late"-oral cancer detection. Report of two cases  
22 and review of diagnostic AIDS in cancer detection. *International Journal of Preventive Medicine*, 3:  
23 737-741.  
24 Not in PICO
- 25 Genden, E. M., Rinaldo, A., Bradley, P. J., Lowry, J., Suarez, C., Shaha, A. R., Scully, C. & Ferlito, A.  
26 (2006) Referral guidelines for suspected cancer of the head and neck. *Auris Nasus Larynx*, 33: 1-5.  
27 Narrative review
- 28 Gillenwater, A. M., Chambers, M. S., Gillenwater, A. M. & Chambers, M. S. (2006) Diagnosis of  
29 premalignant lesions and early cancers of the oral cavity. *Texas Dental Journal*, 123: 512-520.  
30 Narrative review
- 31 Gjurcheski, J. (2012) Understanding the role of general dentists in the process of screening and early  
32 diagnosis of oral premalignant and malignant lesions - brief literature review. *Macedonian*  
33 *Journal of Medical Sciences*, 5: 462-471.  
34 Narrative review
- 35 Gomez, I. (2010) Is early diagnosis of oral cancer a feasible objective? Who is to blame for diagnostic  
36 delay? *Oral Diseases*, 16: 333-342.  
37 Narrative review
- 38 Gonsalves, W. C. C. (2007) Common oral lesions: Part II. Masses and neoplasia. *American Family*  
39 *Physician*, 75: 509-512.  
40 Narrative review
- 41 Gorsky, M. (1995) Referral delay in diagnosis of oro/oropharyngeal cancer in Israel. *European Journal*  
42 *of Cancer Part B: Oral Oncology*, 31: 166-168.  
43 Not in PICO
- 44 Grant, E. (2010) The experiences of young oral cancer patients in Scotland: Symptom recognition and  
45 delays in seeking professional help. *British Dental Journal*, 208: 465-471.  
46 Not in PICO
- 47 Greenwood, M. & Lowry, R. J. (2001) Primary care clinicians' knowledge of oral cancer: a study of  
48 dentists and doctors in the North East of England. *British Dental Journal*, 191: 510-512.  
49 Not in PICO
- 50 Groome, P. A., Rohland, S. L., Hall, S. F., Irish, J., Mackillop, W. J., O'Sullivan, B., Groome, P. A.,  
51 Rohland, S. L., Hall, S. F., Irish, J., Mackillop, W. J. & O'Sullivan, B. (2011) A population-based study

- 1 of factors associated with early versus late stage oral cavity cancer diagnoses. *Oral Oncology*, 47:  
2 642-647.
- 3 Not in PICO
- 4 Hanken, H., Kraatz, J., Smeets, R., Heiland, M., Assaf, A. T., Blessmann, M., Eichhorn, W., Clauditz, T.  
5 S., Grobe, A., Kolk, A. & Rana, M. (2013) The detection of oral pre- malignant lesions with an  
6 autofluorescence based imaging system (VELscope) - a single blinded clinical evaluation.[Erratum  
7 appears in *Head Face Med.* 2013;9:26 Note: Assaf, Alexandre Thomas [added]]. *Head & Face*  
8 *Medicine*, 9: 23.
- 9 Not in PICO
- 10 Heiner, H. (1983) Early detection of tumors in the oral cavity. *Stomatologie der DDR*, 33: 438-445.  
11 Narrative review
- 12 Hirshberg, A., Calderon, S., Kaplan, I., Hirshberg, A., Calderon, S. & Kaplan, I. (1989) [Update review  
13 on prevention and early diagnosis in oral cancer]. [Review] [69 refs] [Hebrew]. *Refuat Hapeh*  
14 *Vehashinayim*, 19: 38-48.
- 15 Narrative review
- 16 Hodgson, T. A., Buchanan, J. A., Garg, A., Ilyas, S. E., Porter, S. R., Hodgson, T. A., Buchanan, J. A. G.,  
17 Garg, A., Ilyas, S. E. & Porter, S. R. (2006) An audit of the UK national cancer referral guidelines for  
18 suspected oral mucosal malignancy. *British Dental Journal*, 201: 643-647.
- 19 Not in PICO
- 20 Hollows, P. (2000) Delays in the referral and treatment of oral squamous cell carcinoma. *British*  
21 *Dental Journal*, 188: 262-265.
- 22 Not in PICO
- 23 Holmes, L., desVignes-Kendrick, M., Slomka, J., Mahabir, S., Beeravolu, S. & Emani, S. R. (2009) Is  
24 dental care utilization associated with oral cavity cancer in a large sample of community-based  
25 United States residents? *Community Dentistry and Oral Epidemiology*, 37: 134-142.
- 26 Not in PICO
- 27 Horowitz, A. M., Drury, T. F. & Canto, M. T. (2000) Practices of Maryland dentists: oral cancer  
28 prevention and early detection - baseline data from 1995. *Oral Diseases*, 6: 282-288.
- 29 Not in PICO
- 30 Horowitz, A. M., Drury, T. F., Goodman, H. S. & Yellowitz, J. A. (2000) Oral pharyngeal cancer  
31 prevention and early detection - Dentists' opinions and practices. *Journal of the American Dental*  
32 *Association*, 131: 453-462.
- 33 Not in PICO
- 34 Horowitz, A. M., Siriphant, P., Sheikh, A. & Child, W. L. (2001) Perspectives of Maryland dentists on  
35 oral cancer. *Journal of the American Dental Association*, 132: 65-72.
- 36 Not in PICO
- 37 Hsieh, R., Yen, M.-F., Chen, H.-H. & Zavras, A. (2013) Metabolic syndrome and development of oral  
38 neoplasms. *American Journal of Epidemiology*, 177: S60.
- 39 Not in PICO
- 40 Hueston, W. J. & Kaur, D. (2013) Upper respiratory conditions: oral cancers. *Fp Essentials*, 415: 22-  
41 26.
- 42 Narrative review
- 43 Huff, K. (2009) Sensitivity of direct tissue fluorescence visualization in screening for oral  
44 premalignant lesions in general practice. *General Dentistry*, 57: 34-38.
- 45 Not in PICO
- 46 Humphris, G. M., Ireland, R. S. & Field, E. A. (2001) Randomised trial of the psychological effect of  
47 information about oral cancer in primary care settings. *Oral Oncology*, 37: 548-552.
- 48 Not in PICO
- 49 Humphris, G. M. & Field, E. A. (2004) An oral cancer information leaflet for smokers in primary care:  
50 results from two randomised controlled trials. *Community Dentistry and Oral Epidemiology*, 32:

- 1 143-149.  
2 Not in PICO
- 3 Hyde, N., Hopper, C., Hyde, N. & Hopper, C. (760) Oral cancer: the importance of early referral.  
4 [Review] [5 refs]. *Practitioner*, 243: 753-758.  
5 Narrative review
- 6 Jainkittivong, A. (2009) Oral squamous cell carcinoma: a clinicopathological study of 342 Thai cases.  
7 *The journal of contemporary dental practice*, 10: E033-E040.  
8 Not in PICO
- 9 Jin, X., Zeng, X., Jin, X. & Zeng, X. (822) Images in emergency medicine. Woman with white patches  
10 on tongue. Malignant transformation of oral leukoplakia. *Annals of Emergency Medicine*, 60: 815.  
11 Not in PICO
- 12 Jones, D. L. & Rankin, K. V. (2013) Oral cancer: FAQ.[Reprint of Tex Dent J. 2013 May;130(5):438-43;  
13 PMID: 23923466]. *Journal of Michigan Dental Association*, 95: 32-35.  
14 Narrative review
- 15 Jovanovic, A. (1992) Delay in diagnosis of oral squamous cell carcinoma; a report from The  
16 Netherlands. *European Journal of Cancer Part B: Oral Oncology*, 28: 37-38.  
17 Not in PICO
- 18 Jurca, M. (1983) Observation of the oral mucosa for early diagnosis of malignant disease.  
19 *Zobozdravstveni Vestnik*, 38: 131-138.  
20 Narrative review
- 21 Kantola, S. (2001) Detection of tongue cancer in primary care. *British Journal of General Practice*, 51:  
22 106-111.  
23 Not in PICO
- 24 Kao, S.-Y. (2009) Detection and Screening of Oral Cancer and Pre-cancerous Lesions. *Journal of the  
25 Chinese Medical Association*, 72: 227-233.  
26 Narrative review
- 27 Koerner, K. R. (2006) Evaluation and treatment by general dentists of oral soft-tissue lesions.  
28 *Dentistry Today*, 25: 90-95.  
29 Narrative review
- 30 Kokalj, V. N., Cizmarevic, B., Zagorac, A., Zagradisnik, B. & Lanisnik, B. (2014) An evaluation of SOX2  
31 and hTERT gene amplifications as screening markers in oral and oropharyngeal squamous cell  
32 carcinomas. *Molecular Cytogenetics*, 7: 5.  
33 Not in PICO
- 34 Kominek, P., Vitek, P., Urban, O., Zelenik, K., Halamka, M., Feltl, D., Cvek, J. & Matousek, P. (2013)  
35 Chromoendoscopy to detect early synchronous second primary esophageal carcinoma in patients  
36 with squamous cell carcinomas of the head and neck? *Gastroenterology research & practice*,  
37 2013: 236264.  
38 Not in PICO
- 39 Kondori, I., Mottin, R. W., Laskin, D. M., Kondori, I., Mottin, R. W. & Laskin, D. M. (2011) Accuracy of  
40 dentists in the clinical diagnosis of oral lesions. *Quintessence International*, 42: 575-577.  
41 Not in PICO
- 42 Kowalski, I. S. G., Souza, C. P. & Kowalski, L. P. (2002) Factors delaying the diagnosis and lateness of  
43 referral as determinants of advanced stage oral cancer. *International Journal of Cancer*, 81.  
44 Not in PICO
- 45 Lam, D. K., Schmidt, B. L., Lam, D. K. & Schmidt, B. L. (2011) Orofacial pain onset predicts transition  
46 to head and neck cancer. *Pain*, 152: 1206-1209.  
47 Not in PICO
- 48 Langevin, S. M., Michaud, D. S., Eliot, M., Peters, E. S., McClean, M. D. & Kelsey, K. T. (2012) Regular  
49 dental visits are associated with earlier stage at diagnosis for oral and pharyngeal cancer. *Cancer  
50 Causes & Control*, 23: 1821-1829.  
51 Not in PICO

- 1 Laudenbach, J. M. (2013) Oral medicine update: oral cancer--screening, lesions and related  
2 infections. *Journal of the California Dental Association*, 41: 326-328.  
3 Narrative review
- 4 Lazarchik, D. A. F. (1996) Oral screening exam for the primary care physician. *Primary Care Update  
5 for Ob/Gyns*, 3: 108-113.  
6 Narrative review
- 7 Lee, K. H. P. (2009) Oral white lesions: Pitfalls of diagnosis. *Medical Journal of Australia*, 190: 274-  
8 277.  
9 Narrative review
- 10 Lehw, C., Epstein, J. B., Kaste, L. M. & Choi, Y. K. (2010) Assessing oral cancer early detection:  
11 clarifying dentists' practices. *Journal of Public Health Dentistry*, 70: 93-100.  
12 Not in PICO
- 13 Leocata, P. (2007) A screening program for the early detection and prevention of oral cancer. *Journal  
14 of Plastic Dermatology*, 3: 71-75.  
15 Not in PICO
- 16 Levi, J. (2005) Squamous cell carcinoma presenting as an endodontic-periodontic lesion. *Journal of  
17 Periodontology*, 76: 1798-1804.  
18 Not in PICO
- 19 Lim, K., Moles, D. R., Downer, M. C. & Speight, P. M. (2003) Opportunistic screening for oral cancer  
20 and precancer in general dental practice: results of a demonstration study. *British Dental Journal*,  
21 194: 497-502.  
22 Not in PICO
- 23 Liu, W. (2012) Oral cancer development in patients with leukoplakia - clinicopathological factors  
24 affecting outcome. *PLoS ONE*, 7.  
25 Not in PICO
- 26 Llewellyn, C. D., Johnson, N. W. & Warnakulasuriya, S. (2004) Factors associated with delay in  
27 presentation among younger patients with oral cancer. *Oral Surgery Oral Medicine Oral  
28 Pathology Oral Radiology and Endodontics*, 97: 707-713.  
29 Not in PICO
- 30 Lopez-Jornet, P. (2008) Influence of years of professional experience in relation to the diagnostic skill  
31 of general dental practitioners (GDPs) in identifying oral cancer and precancerous lesions.  
32 *International Dental Journal*, 58: 127-133.  
33 Not in PICO
- 34 Lopez-Jornet, P., Camacho-Alonso, F. & Molina-Minano, F. (2010) Knowledge and attitudes about  
35 oral cancer among dentists in Spain. *Journal of Evaluation in Clinical Practice*, 16: 129-133.  
36 Not in PICO
- 37 Lyons, B. (1999) ENT malignancies. What the GP needs to know. *Australian Family Physician*, 28: 209-  
38 215.  
39 Narrative review
- 40 M S, Shetty, P., Decruz, A. M. & Pai, P. (2013) The Self-Reported Knowledge, Attitude and the  
41 Practices Regarding the Early Detection of Oral Cancer and Precancerous Lesions among the  
42 Practising Dentists of Dakshina Kannada-A Pilot Study. *Journal of Clinical and Diagnostic Research  
43 JCDR*, 7: 1491-1494.  
44 Not in PICO
- 45 Mashberg, A. (1989) Appearance, site of occurrence, and physical and clinical characteristics of oral  
46 carcinoma in Torino, Italy. *Cancer*, 63: 2522-2527.  
47 Not in PICO
- 48 Mashberg, A. (2000) Diagnosis of early oral and oropharyngeal squamous carcinoma: Obstacles and  
49 their amelioration. *Oral Oncology*, 36: 253-255.  
50 Narrative review



- 1 Mccann, M. F., Macpherson, L. M. D., Binnie, V. I. & Stephen, K. W. (2000) A survey of Scottish  
2 primary care dental practitioners' oral cancer-related practices and training requirements.  
3 *Community Dental Health*, 17: 24-30.  
4 Not in PICO
- 5 McCullough, M. J., Prasad, G. & Farah, C. S. (2010) Oral mucosal malignancy and potentially  
6 malignant lesions: an update on the epidemiology, risk factors, diagnosis and management.  
7 *Australian Dental Journal*, 55: 61-65.  
8 Narrative review
- 9 McCunniff, M. D., Barker, G. J., Barker, B. E. & Williams, K. (2000) Health professionals' baseline  
10 knowledge of oral/pharyngeal cancers. *Journal of Cancer Education*, 15: 79-81.  
11 Not in PICO
- 12 McGurk, M. (2010) The reality of identifying early oral cancer in the general dental practice. *British*  
13 *Dental Journal*, 208: 347-351.  
14 Narrative review
- 15 McIntyre, G. T., Oliver, R. J., McIntyre, G. T. & Oliver, R. J. (1999) Update on precancerous lesions.  
16 *Dental Update*, 26: 382-386.  
17 Narrative review
- 18 McLeod, N. M. H. (2005) Oral cancer: Delays in referral and diagnosis persist. *British Dental Journal*,  
19 198: 681-684.  
20 Not in PICO
- 21 Mehanna, H. (2012) Salivary gland swellings. *BMJ (Online)*, 345.  
22 Narrative review
- 23 Messadi, D. V. (2013) Diagnostic aids for detection of oral precancerous conditions. [Review].  
24 *International Journal of Oral Science*, 5: 59-65.  
25 Narrative review
- 26 Mishra, R. & Mishra, R. (2012) Biomarkers of oral premalignant epithelial lesions for clinical  
27 application. [Review]. *Oral Oncology*, 48: 578-584.  
28 Narrative review
- 29 Morelato, R. A. H. (2007) Diagnostic delay of oral squamous cell carcinoma in two diagnosis centers  
30 in Cordoba Argentina. *Journal of Oral Pathology and Medicine*, 36: 405-408.  
31 Not in PICO
- 32 Morse, D. E., V (2011) Perspectives of San Juan healthcare practitioners on the detection deficit in  
33 oral premalignant and early cancers in Puerto Rico: a qualitative research study. *BMC public*  
34 *health*, 11: 2011.  
35 Not in PICO
- 36 Munde, A. D., Karle, R. R., Wankhede, P. K., Shaikh, S. S. & Kulkurni, M. (2013) Demographic and  
37 clinical profile of oral lichen planus: A retrospective study. *Contemporary Clinical Dentistry*, 4:  
38 181-185.  
39 Not in PICO
- 40 Nair, D. R., Pruthy, R., Pawar, U., Chaturvedi, P., Nair, D. R., Pruthy, R., Pawar, U. & Chaturvedi, P.  
41 (2012) Oral cancer: Premalignant conditions and screening--an update. [Review]. *Journal of*  
42 *Cancer Research & Therapeutics*, 8 Suppl 1: S57-S66.  
43 Narrative review
- 44 Ni Riordain, R. (2009) Oral cancer - Current knowledge, practices and implications for training among  
45 an Irish general medical practitioner cohort. *Oral Oncology*, 45: 958-962.  
46 Not in PICO
- 47 Nicotera, G., Di Stasio, S. M., Angelillo, I. F., Nicotera, G., Di Stasio, S. M. & Angelillo, I. F. (2004)  
48 Knowledge and behaviors of primary care physicians on oral cancer in Italy. *Oral Oncology*, 40:  
49 490-495.  
50 Not in PICO

- 1 Noorman van der Dussen, M. F. (1994) Oral cancer. The importance of early diagnosis and role of the  
2 dentist. *Revue Belge de Medecine Dentaire*, Belgisch tijdschrift voor tandheelkunde. 49: 35-49.  
3 Narrative review
- 4 Obradovic, R., Kesic, L., Mihailovic, D., Radicevic, G., Obradovic, R., Kesic, L., Mihailovic, D. &  
5 Radicevic, G. (2009) Malignant transformation of oral lichen planus. A case report. *West Indian  
6 Medical Journal*, 58: 490-492.  
7 Not in PICO
- 8 Ogden, G., Lewthwaite, R. & Shepherd, S. D. (2013) Early detection of oral cancer: how do I ensure I  
9 don't miss a tumour? *Dental Update*, 40: 462-465.  
10 Narrative review
- 11 Onizawa, K. (2003) Factors associated with diagnostic delay of oral squamous cell carcinoma. *Oral  
12 Oncology*, 39: 781-788.  
13 Not in PICO
- 14 Pakfetrat, A. (2010) Oral cancer knowledge among patients referred to Mashhad Dental School, Iran.  
15 *Archives of Iranian Medicine*, 13: 543-548.  
16 Not in PICO
- 17 Paleri, V. (2010) Evaluation of oral ulceration in primary care. *BMJ (Online)*, 340: 1234-1239.  
18 Narrative review
- 19 Patel, M. (196) Importance of quality in referral letters sent for potentially malignant oral, head and  
20 neck lesions. *Dental Update*, 38: 192-194.  
21 Not in PICO
- 22 Petti, S. & Scully, C. (2007) Oral cancer knowledge and awareness: Primary and secondary effects of  
23 an information leaflet. *Oral Oncology*, 43: 408-415.  
24 Not in PICO
- 25 Pitchers, M. (2006) Delay in referral of oropharyngeal squamous cell carcinoma to secondary care  
26 correlates with a more advanced stage at presentation, and is associated with poorer survival.  
27 *British Journal of Cancer*, 94: 955-958.  
28 Not in PICO
- 29 Poh, C. F., MacAulay, C. E., Laronde, D. M., Williams, P. M., Zhang, L., Rosin, M. P., Poh, C. F.,  
30 MacAulay, C. E., Laronde, D. M., Williams, P. M., Zhang, L. & Rosin, M. P. (2011) Squamous cell  
31 carcinoma and precursor lesions: diagnosis and screening in a technical era. [Review].  
32 *Periodontology 2000*, 57: 73-88.  
33 Narrative review
- 34 Raubenheimer, E. J. (1989) Clinical manifestations of oral precancer and cancer. *The Journal of the  
35 Dental Association of South Africa = Die Tydskrif van die Tandheelkundige Vereniging van Suid-  
36 Afrika*, Suppl 1: Mar.  
37 Narrative review
- 38 Reamy, B. V. D. (2010) Common tongue conditions in primary care. *American Family Physician*, 81:  
39 627-634.  
40 Narrative review
- 41 Reid, B. C. & Rozier, R. G. (2006) Continuity of care and early diagnosis of head and neck cancer. *Oral  
42 Oncology*, 42: 510-516.  
43 Not in PICO
- 44 Reychler, H., Weynand, B., Reychler, H. & Weynand, B. (2010) [Screening and diagnosis of  
45 precancerous oral mucosa lesions]. [Review] [French]. *Revue de Stomatologie et de Chirurgie  
46 Maxillo-Faciale*, 111: 203-207.  
47 Narrative review
- 48 Robinson, P. N. & Mickelson, A. R. (2006) Diagnosis of oral cavity cancers. *Otolaryngologic Clinics of  
49 North America*, 39: 295-+.  
50 Narrative review

- 1 Rodrigues, V. C., Moss, S. M., Tuomainen, H., Rodrigues, V. C., Moss, S. M. & Tuomainen, H. (1998)  
2 Oral cancer in the UK: to screen or not to screen. [Review] [142 refs]. *Oral Oncology*, 34: 454-465.  
3 Narrative review
- 4 Rogers, S. N., V (2011) Reasons for delayed presentation in oral and oropharyngeal cancer: The  
5 patients perspective. *British Journal of Oral and Maxillofacial Surgery*, 49: 349-353.  
6 Not in PICO
- 7 Rogers, S. N. G. (2008) A survey of general dental practitioners in Merseyside regarding urgent  
8 appointments and suspected cancer referrals. *Primary dental care : journal of the Faculty of*  
9 *General Dental Practitioners (UK)*, 15: 25-30.  
10 Not in PICO
- 11 Rosillo, G. M., Sanchez Lopez, J. D., Perez, A. A., Rosales Varo, A. P., Rosillo Galindo, M., Sanchez  
12 Lopez, J. D., Perez Abela, A. & Rosales Varo, A. P. (1999) [Premalignant lesions of the oral cavity in  
13 primary care]. [Spanish]. *Atencion Primaria*, 23: 445-446.  
14 Letter
- 15 Ryba, F., Rice, S. & Hutchison, I. L. (2010) Numb chin syndrome: an ominous clinical sign. *British*  
16 *Dental Journal*, 208: 283-285.  
17 Not in PICO
- 18 Sardella, A., Demarosi, F., Lodi, G., Canegallo, L., Rimondini, L., Carrassi, A., Sardella, A., Demarosi, F.,  
19 Lodi, G., Canegallo, L., Rimondini, L. & Carrassi, A. (2007) Accuracy of referrals to a specialist oral  
20 medicine unit by general medical and dental practitioners and the educational implications.  
21 *Journal of Dental Education*, 71: 487-491.  
22 Not in PICO
- 23 Sartori, L. C. & Frazao, P. (2012) Accuracy of Screening for Potentially Malignant Disorders of the Oral  
24 Mucosa by Dentists in Primary Care. *Oral Health & Preventive Dentistry*, 10: 53-58.  
25 Not in PICO
- 26 Schnetler, J. F. C. (1992) Oral cancer diagnosis and delays in referral. *British Journal of Oral and*  
27 *Maxillofacial Surgery*, 30: 210-213.  
28 Not in PICO
- 29 Scott S. (2008) Patient delay for potentially malignant oral symptoms. *European Journal of Oral*  
30 *Sciences*, 116: 141-147.  
31 Not in PICO
- 32 Scott, S. E., McGurk, M. & Grunfeld, E. A. (2007) The process of symptom appraisal: Cognitive and  
33 emotional responses to detecting potentially malignant oral symptoms. *Journal of Psychosomatic*  
34 *Research*, 62: 621-630.  
35 Not in PICO
- 36 Scott, S. E., Weinman, J. & Grunfeld, E. A. (2011) Developing ways to encourage early detection and  
37 presentation of oral cancer: What do high-risk individuals think? *Psychology & Health*, 26: 1392-  
38 1405.  
39 Not in PICO
- 40 Scott, S. E. G. (2006) Patient's delay in oral cancer: A systematic review. *Community Dentistry and*  
41 *Oral Epidemiology*, 34: 337-343.  
42 Not in PICO
- 43 Scott, S. E. G. (2009) Barriers and triggers to seeking help for potentially malignant oral symptoms:  
44 Implications for interventions. *Journal of Public Health Dentistry*, 69: 34-40.  
45 Not in PICO
- 46 Scott, S. E. K. (2012) A randomised controlled trial of a pilot intervention to encourage early  
47 presentation of oral cancer in high risk groups. *Patient Education and Counseling*, 88: 241-248.  
48 Not in PICO
- 49 Scully, C. (331) The role of the dental team in preventing and diagnosing cancer: 3. oral cancer  
50 diagnosis and screening. *Dental Update*, 32: 326-328.  
51 Narrative review

- 1 Scully, C. (1986) Sources and patterns of referrals of oral cancer: role of general practitioners. *British*  
2 *Medical Journal*, 293: 599-601.  
3 Not in PICO
- 4 Scully, C., Felix, D. H., Scully, C. & Felix, D. H. (2005) Oral Medicine--update for the dental  
5 practitioner: oral white patches. *British Dental Journal*, 199: 565-572.  
6 Narrative review
- 7 Scully, C. & Felix, D. H. (2006) Oral Medicine - Update for the dental practitioner - Oral cancer. *British*  
8 *Dental Journal*, 200: 13-17.  
9 Narrative review
- 10 Scully, C. (2008) Oral cancer: Current and future diagnostic techniques. *American Journal of*  
11 *Dentistry*, 21: 199-209.  
12 Narrative review
- 13 Scully, C. & Kirby, J. (2014) - Statement on mouth cancer diagnosis and prevention. - *British Dental*  
14 *Journal*, 216: 37-38.  
15 Narrative review
- 16 Scully, C. & Kirby, J. (2014) Statement on mouth cancer diagnosis and prevention. *British Dental*  
17 *Journal*, 216: 37-38.  
18 Narrative review
- 19 Seifert, G. (1981) Precursor and early stages of cancer of the oral cavity. *Deutsches Arzteblatt*, 78:  
20 327-332.  
21 Narrative review
- 22 Seoane-Romero, J. M., Vazquez-Mahia, I., Seoane, J., Varela-Centelles, P., Tomas, I., Lopez-Cedrun, J.  
23 L., Seoane-Romero, J. M., Vazquez-Mahia, I., Seoane, J., Varela-Centelles, P., Tomas, I. & Lopez-  
24 Cedrun, J. L. (2012) Factors related to late stage diagnosis of oral squamous cell carcinoma.  
25 *Medicina Oral, Patologia Oral y Cirugia Bucal*, 17: e35-e40.  
26 Not in PICO
- 27 Seoane, J., Warnakulasuriya, S., Varela-Centelles, P., Esparza, G. & Dios, P. D. (2006) Oral cancer:  
28 experiences and diagnostic abilities elicited by dentists in North-western Spain. *Oral Diseases*, 12:  
29 487-492.  
30 Not in PICO
- 31 Seoane, J., Varela-Centelles, P. I., Walsh, T. F., Lopez-Cedrun, J. L. & Vazquez, I. (2006) Gingival  
32 squamous cell carcinoma: Diagnostic delay or rapid invasion? *Journal of Periodontology*, 77:  
33 1229-1233.  
34 Not in PICO
- 35 Seoane, J., Corral-Lizana, C., Gonzalez-Mosquera, A., Cerero, R., Esparza, G., Sanz-Cuesta, T., Varela-  
36 Centelles, P., Seoane, J., Corral-Lizana, C., Gonzalez-Mosquera, A., Cerero, R., Esparza, G., Sanz-  
37 Cuesta, T. & Varela-Centelles, P. (2011) The use of clinical guidelines for referral of patients with  
38 lesions suspicious for oral cancer may ease early diagnosis and improve education of healthcare  
39 professionals. *Medicina Oral, Patologia Oral y Cirugia Bucal*, 16: e864-e869.  
40 Not in PICO
- 41 Seoane, J. (2012) Impact of delay in diagnosis on survival to head and neck carcinomas: A systematic  
42 review with meta-analysis. *Clinical Otolaryngology*, 37: 99-106.  
43 Not in PICO
- 44 Shetty, K. V. & Johnson, N. W. (1999) Knowledge, attitudes and beliefs of adult South Asians living in  
45 London regarding risk factors and signs for oral cancer. *Community Dental Health*, 16: 227-231.  
46 Not in PICO
- 47 Siar, C. H., Mah, M. C., Gill, P. P., Siar, C. H., Mah, M. C. & Gill, P. P. (2012) Prevalence of bilateral  
48 'mirror-image' lesions in patients with oral potentially malignant epithelial lesions. *European*  
49 *Archives of Oto-Rhino-Laryngology*, 269: 999-1004.  
50 Not in PICO

- 1 Silverman, J. (1988) Early diagnosis of oral cancer. *Cancer*, 62: 1796-1799.  
2 Narrative review
- 3 Silverman, S. (1994) Oral cancer. *Seminars in Dermatology*, 13: 132-137.  
4 Narrative review
- 5 Singh, P. & Warnakulasuriya, S. (2006) The two-week wait cancer initiative on oral cancer; the  
6 predictive value of urgent referrals to an oral medicine unit. *British Dental Journal*, 201: 717-720.  
7 Not in PICO
- 8 Singh, T. & Schenberg, M. (2013) Delayed diagnosis of oral squamous cell carcinoma following dental  
9 treatment. *Annals of the Royal College of Surgeons of England*, 95: 369-373.  
10 Not in PICO
- 11 Siriphant, P., Drury, T. F., Horowitz, A. M. & Harris, R. M. (2001) Oral cancer knowledge and opinions  
12 among Maryland nurse practitioners. *Journal of Public Health Dentistry*, 61: 138-144.  
13 Not in PICO
- 14 Siriphant, P., Horowitz, A. M. & Child, W. L. (2001) Perspectives of Maryland adult and family  
15 practice nurse practitioners on oral cancer. *Journal of Public Health Dentistry*, 61: 145-149.  
16 Not in PICO
- 17 Sousa, F. B., - de Freitas e Silva MR, Fernandes, C. P., Silva, P. G. & Alves, A. P. (2014) - Oral cancer  
18 from a health promotion perspective: experience of a diagnosis network in Ceara. - *Pesquisa*  
19 *Odontologica Brasileira = Brazilian Oral Research*, 28 Spec, 2014..  
20 Only 73/296 lesions were confirmed histologically. The others do not appear to have been  
21 followed up.
- 22 Souza, L. M. M. (2011) Scheduling delay in suspected cases of oral cancer. *Revista Brasileira de*  
23 *Epidemiologia*, 14: 642-650.  
24 Not in PICO
- 25 Speight, P. M. P. (2006) The cost-effectiveness of screening for oral cancer in primary care. *Health*  
26 *Technology Assessment*, 10: 1-65.  
27 Not in PICO
- 28 Spitzer, W. J. (1990) Cancers: concerns and early diagnosis by the dentist. *Zahnarztliche Praxis*, 41:  
29 365-367.  
30 Narrative review
- 31 St George, G., Welfare, R. D. & Lund, V. J. (2006) Referral speed. *British Dental Journal*, 200: 185-186.  
32 Comment
- 33 Steele, T. O., Meyers, A., Steele, T. O. & Meyers, A. (2011) Early detection of premalignant lesions  
34 and oral cancer. [Review]. *Otolaryngologic Clinics of North America*, 44: 221-229.  
35 Narrative review
- 36 Stoykova, M. (1999) Delayed diagnosis of cancer with emphasis on oral cavity cancers. *Folia Medica*,  
37 41: 132-135.  
38 Not in PICO
- 39 Szpirglas, H. (1995) Detection of oral cancers and current conception of precancerous conditions. *La*  
40 *Revue du praticien*, 45: 831-837.  
41 Narrative review
- 42 Teppo, H. (2009) Comorbidity and diagnostic delay in cancer of the larynx, tongue and pharynx. *Oral*  
43 *Oncology*, 45: 692-695.  
44 Not in PICO
- 45 Tripathi, P. (2010) Adenoid cystic carcinoma of the palate: A case report with review of literature.  
46 *Journal of Cancer Science and Therapy*, 2: 160-162.  
47 Not in PICO
- 48 van den Berg, A. D. & Palmer, N. O. (2012) An investigation of West Sussex general dental  
49 practitioners' awareness, attitudes and adherence to NICE dental recall guidelines. *Primary*  
50 *Dental Care*, 19: 11-22.  
51 Not in PICO

- 1 van der Meij, E. H., Bezemer, P. D., van, d. W., I, van der Meij, E. H., Bezemer, P. D. & van der Waal, I.  
 2 (2002) Cost-effectiveness of screening for the possible development of cancer in patients with  
 3 oral lichen planus. [Review] [57 refs]. *Community Dentistry & Oral Epidemiology*, 30: 342-351.  
 4 Not in PICO
- 5 van der Meij, E. H., Mast, H., van, d. W., I, van der Meij, E. H., Mast, H. & van der Waal, I. (2007) The  
 6 possible premalignant character of oral lichen planus and oral lichenoid lesions: a prospective  
 7 five-year follow-up study of 192 patients. [Review] [43 refs]. *Oral Oncology*, 43: 742-748.  
 8 Not in PICO
- 9 van der Meij, E. H. (2008) Epidemiology, aetiology, and clinical aspects of oral cancer and  
 10 premalignant lesions. *Nederlands Tijdschrift Voor Tandheelkunde*, 115: 186-191.  
 11 Narrative review
- 12 Van Der Meij, E. H. S. (2005) "Classical" oral lichen planus is not premalignant. *Nederlands Tijdschrift  
 13 voor Dermatologie en Venereologie*, 15: 334-338.  
 14 Narrative review
- 15 van der Waal, I. (1996) Mouth neoplasms: a review. *Nederlands Tijdschrift Voor Tandheelkunde*, 103:  
 16 345-347.  
 17 Narrative review
- 18 van der Waal, I. (2011) Early diagnosis in primary oral cancer: Is it possible? *Medicina Oral, Patologia  
 19 Oral y Cirugia Bucal*, 16: 300-305.  
 20 Narrative review
- 21 van Heerden, W. F. B. (2002) The role of the dentist in the prevention and early diagnosis of oral  
 22 cancer. *SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse  
 23 Tandheelkundige Vereniging*, 57: 22-24.  
 24 Narrative review
- 25 van, d. W., I (2014) - Oral potentially malignant disorders: is malignant transformation predictable  
 26 and preventable? - *Medicina Oral, Patologia Oral y Cirugia Bucal*, 19: e386-e390.  
 27 Narrative review
- 28 Venta, I., Oikarinen, V. J., Soderholm, A. L., Lindqvist, C., Venta, I., Oikarinen, V. J., Soderholm, A. L. &  
 29 Lindqvist, C. (1993) Third molars confusing the diagnosis of carcinoma. *Oral Surgery, Oral  
 30 Medicine, Oral Pathology*, 75: 551-555.  
 31 Not in PICO
- 32 von Arx, T., Koch, S. & Hardt, N. (2002) [Lesions of the mouth mucosa. An anamnestic and clinical  
 33 study of 100 consecutive patients with mucosal lesions]. [German]. *Schweizer Monatsschrift fur  
 34 Zahnmedizin*, 112: 326-329.  
 35 Not in PICO
- 36 Warnakulasuriya, K. A. A. S., Ekanayake, A. N. I., Sivayoham, S., Stjernsward, J., Pindborg, J. J., Sobin,  
 37 L. H. & Perera, K. S. G. P. (1984) Utilization of Primary Health-Care Workers for Early Detection of  
 38 Oral-Cancer and Precancer Cases in Sri-Lanka. *Bulletin of the World Health Organization*, 62: 243-  
 39 250.  
 40 Not in PICO (screening)
- 41 Warnakulasuriya, K. A. A. S. & Nanayakkara, B. G. (1991) Reproducibility of An Oral-Cancer and  
 42 Precancer Detection Program Using A Primary Health-Care Model in Sri-Lanka. *Cancer Detection  
 43 and Prevention*, 15: 331-334.  
 44 Not in PICO
- 45 Warnakulasuriya, S., Ekanayake, A., Stjernsward, J., Pindborg, J. J. & Sivayoham, S. (1988)  
 46 Compliance Following Referral in the Early Detection of Oral-Cancer and Precancer in Sri-Lanka.  
 47 *Community Dentistry and Oral Epidemiology*, 16: 326-329.  
 48 Not in PICO
- 49 Warnakulasuriya, S., Gould, A., Leuci, S., Mignogna, M., Seoane-Leston, J. M., Diz-Dios, P., McAlister,  
 50 C., McEvoy, P., Thermidou, I. & Rapidis, A. D. (2013) Leonardo da Vinci Partnership - A lifelong  
 51 learning programme to raise awareness of dental and medical professionals within Europe for the

1 early detection of oral cancer - Phase 2. *Oral Oncology*, 49: S59.  
 2 Not in PICO  
 3 Waskowska, J. (2012) Verrucous carcinoma of the tongue - A rare case study. *Central European*  
 4 *Journal of Medicine*, 7: 145-148.  
 5 Not in PICO  
 6 Williams, M. & Bethea, J. (2011) Patient awareness of oral cancer health advice in a dental access  
 7 centre: a mixed methods study. *British Dental Journal*, 210.  
 8 Not in PICO  
 9 Williams, R. G. (1981) The early diagnosis of carcinoma of the mouth. *Annals of the Royal College of*  
 10 *Surgeons of England*, 63: 423-425.  
 11 Not in PICO  
 12 Yeatts, D., Burns, J. C., Yeatts, D. & Burns, J. C. (1991) Common oral mucosal lesions in adults.  
 13 [Review] [5 refs]. *American Family Physician*, 44: 2043-2050.  
 14 Narrative review  
 15 Yellowitz, J., Horowitz, A. M., Goodman, H. S., Canto, M. T. & Farooq, N. S. (1998) Knowledge,  
 16 opinions and practices of general dentists regarding oral cancer: A pilot survey. *Journal of the*  
 17 *American Dental Association*, 129: 579-583.  
 18 Not in PICO  
 19 Yellowitz, J. A. & Goodman, H. S. (1995) Assessing Physicians and Dentists Oral-Cancer Knowledge,  
 20 Opinions and Practices. *Journal of the American Dental Association*, 126: 53-60.  
 21 Not in PICO  
 22 Yu, T. (2008) Delays in diagnosis of head and neck cancers. *Journal of the Canadian Dental*  
 23 *Association*, 74: 61-61c.  
 24 Not in PICO  
 25 Zohoori, F. V., Shah, K., Mason, J. & Shucksmith, J. (2012) Identifying Factors to Improve Oral Cancer  
 26 Screening Uptake: A Qualitative Study. *PLoS ONE*, 7.  
 27 Not in PICO  
 28

29 **Review question:**

30 Which investigations of symptoms of suspected oral cancer should be done with clinical  
 31 responsibility retained by primary care?  
 32

33 **Results**

34 **Literature search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1980-5/2013	499	116	09/05/2013
<i>Premedline</i>	1980-5/2013	47	20	09/05/2013
<i>Embase</i>	1980-5/2013	937	93	09/05/2013
<i>Cochrane Library</i>	1980-5/2013	194	3	09/05/2013
<i>Psychinfo</i>	1980-5/2013	2	0	09/05/2013
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	1980-5/2013	246	5	09/05/2013


35 Total References retrieved (after de-duplication): 190

36 **Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	5/2013-20/08/2014	23	0	20/08/2014

<b>Premedline</b>	5/2013-20/08/2014	75	20	20/08/2014
<b>Embase</b>	5/2013-20/08/2014	58	6	20/08/2014
<b>Cochrane Library</b>	5/2013-20/08/2014	98	0	20/08/2014
<b>Web of Science (SCI &amp; SSCI) and ISI Proceedings</b>	5/2013-20/08/2014	11	1	20/08/2014

1 Total References retrieved (after de-duplication): 24



2

3


4

5 **Risk of bias in the included studies**

6 The risk of bias and applicability concerns are summarised for the included study in the figure below.  
 7 The study was associated with a number of bias and validity issues. The following issues compromise  
 8 the validity and applicability of this study, (1) it is unclear (and probably unlikely) that the patient  
 9 population consists of consecutive or randomly recruited patients (and may therefore bias the  
 10 results), (2) the study is conducted in the USA in an unclear setting and it is therefore not clearly  
 11 transferable to UK-based primary care, and (3) the timespan between the index test and reference  
 12 standard is unclear in all but one patient and the results are therefore compromised to an unknown  
 13 extent.

14





**Study results**

Table 1: Oral cancer: Study results

Study	Test	Prevalence	Sensitivity (95% CI) %	Specificity (95% CI) %	Other results (95% CI)
Svirsky (2002)	Transepithelial oral brush biopsy with a computer-assisted method of analysis	15/298	93.3 (66-99.7)	19.1 (14.8-24.3)	<u>Malignancy:</u> TP = 14 FN = 1 TN = 54 FP = 229 Positive predictive value = 5.76 (3.3-9.7)% Negative predictive value = 98.18 (89-99.9)% False negativity rate = 6.7%
Svirsky (2002)	Transepithelial oral brush biopsy with a computer-assisted method of analysis	97/298	95.88 (89.2-98.7)%	25.37 (19.6-32.1)%	<u>Malignancy and dysplasia:</u> TP = 93 FN = 4 TN = 51 FP = 150 Positive predictive value = 38.27 (32.2-44.7) % Negative predictive value = 92.73 (81.6-97.6)% False negativity rate = 4.12%

TP = true positives, FP = false positives, TN = true negatives, FN = false negatives.

**Evidence statement(s):**

Transepithelial oral brush biopsy with a computer-assisted method of analysis (1 study, N = 298) is associated with a sensitivity of 93.3%, a specificity of 19.1%, a positive predictive value of 5.76%, and a false negativity rate of 6.7% for oral cancer. Transepithelial oral brush biopsy with a computer-assisted method of analysis (1 study, N = 298) is associated with a sensitivity of 95.88%, a specificity of 25.37%, a positive predictive value of 38.27%, and a false negativity rate of 4.12% for oral cancer/dysplasia. The study was associated with 4 bias or applicability concerns (see also Table 1).

**Evidence tables**

**Svirsky (2002)**

<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Retrospective patient series
Was a consecutive or random sample of patients enrolled?	Unclear
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Unclear
<b>Could the selection of patients have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>N = 298 (146 males/152 females), mean (range) age = 52 (18-89); location of surgical biopsy: Ventral/lateral tongue (N = 90), palate (N = 63), gingival (N = 65), buccal/alveolar mucosa (N = 43), floor of mouth (N = 8), unspecified/other (N = 29).</p> <p><u>Inclusion criteria</u>: "This study analyzed scalpel biopsies with test requisition forms that either were accompanied by an oral brush biopsy report or contained the findings of an oral brush biopsy report. Only oral pathology laboratories were included." "A total of 298 patients with scalpel biopsies that were accompanied by prior brush biopsy results were identified in the authors' laboratories".</p> <p><u>Exclusion criteria</u>: None reported.</p> <p><u>Clinical setting</u>: Unclear, USA</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	Transepithelial oral brush biopsy with a computer-assisted method of analysis (OralCDx, CDx Laboratories, NY).
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Unclear concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Scalpel biopsy
Is the reference standard likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	No
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>

<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	Data are available for all the included patients, but for least one of the patients the brush and scalpel biopsies were obtained 8 months apart.
Was there an appropriate interval between index test and reference standard?	<b>Unclear</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>High risk</b>
<b>NOTES</b>	

1

2 **References**3 **Included studies**

4 Svirsky, J. A., Burns, J. C., Carpenter, W. M. & et.al. (2002) Comparison of computer-assisted brush  
5 biopsy results with follow up scalpel biopsy and histology. *Gen Dent*, 50: 500-503.

6

7 **Excluded studies (with excl reason)**

8

Reference List

9

10 (2002) Study: one in 10 dental professionals had oral lesions that required additional testing.

11 *Dentistry Today*, 21: 40.

12 Narrative review

13 (2008) Guideline for the early detection of oral cancer in British Columbia 2008. *Journal (Canadian  
14 Dental Association)*, 74: 245.

15 Guideline

16 (2010) High-tech oral cancer detection. Less invasive, less painful microchip technology could  
17 identify mouth cancers in the very early stages. *Duke Medicine Health News*, 16: 4-5.

18 Not in PICO

19 Ahmed, S. M., Mubeen & Jigna, V. R. (2009) Molecular biology: an early detector of oral cancers.

20 *Annals of Diagnostic Pathology*, 13: 140-145.

21 Narrative review

22 Ahn, S.-H., Jeong, W.-J., Sung, M.-W. & Kim, K.-H. (2011) Management of lateral tongue leukoplakia  
23 proven as benign in incisional biopsy. *Oral Oncology*, 47: S93-S94.

24 Not in PICO

25 Ajayi, B. A., Pugh, N. D., Carolan, G. & Woodcock, J. P. (1992) Salivary gland tumours: Is colour  
26 Doppler imaging of added value in their preoperative assessment? *European Journal of Surgical  
27 Oncology*, 18: 463-468.

28 Not in PICO

29 Akrish, S., Buchner, A. & Dayan, D. (1993) Oral cancer: diagnostic options as an aid to histology in  
30 order to predict patients at high risk for malignant transformation. *Refuat Hapeh Vehashinayim*,  
31 21: 6-15.

32 Narrative review

33 Allegra, E., Lombardo, N., Puzzo, L. & Garozzo, A. (2009) The usefulness of toluidine staining as a  
34 diagnostic tool for precancerous and cancerous oropharyngeal and oral cavity lesions. [Italian].

35 *Acta Otorhinolaryngologica Italica*, 29: 187-190.

36 Not in PICO

37 Allon, I., Allon, D. M., Gal, G., Anavi, Y., Chaushu, G. & Kaplan, I. (2013) Re-evaluation of common  
38 paradigms regarding the clinical appearance of oral mucosal malignancies. *Journal of Oral*

- 1 *Pathology & Medicine*, 42: 670-675.  
 2 Not in PICO
- 3 Allon, I., Allon, D. M., Anavi, Y. & Kaplan, I. (2013) The significance of surface ulceration as a sign of  
 4 malignancy in exophytic oral mucosal lesions: myth or fact? *Head and neck pathology*, 7: 149-  
 5 154.  
 6 Not in PICO
- 7 Ardore, M., Tempia, V. G., Pentenero, M. & Gandolfo, S. (2012) Role of VELscope test in the  
 8 assessment of oral mucosal lesions suspected to be oncologically relevant. [Italian]. *Dental*  
 9 *Cadmos*, 80: 538-546.  
 10 Not in PICO (On the basis of the clinical diagnostic suspicion and state of dysplasia / carcinoma in  
 11 31/67 lesions, while the remaining 35/66 led to a clinical diagnosis of precancerous dysplasia  
 12 probably without)
- 13 Bahar, G., Dudkiewicz, M., Feinmesser, R., Joshua, B. Z., Braslavsky, D., Popovtzer, A., Galil, D. &  
 14 Shpitzer, T. (2006) Acute parotitis as a complication of fine-needle aspiration in Warthin's tumor.  
 15 A unique finding of a 3-year experience with parotid tumor aspiration. *Otolaryngology - Head &*  
 16 *Neck Surgery*, 134: 646-649.  
 17 Not in PICO
- 18 Bajaj, D. R., Khoso, N. A., Devrajani, B. R., Matlani, B. L. & Lohana, P. (2010) Oral lichen planus: A  
 19 clinical study. *Journal of the College of Physicians and Surgeons Pakistan*, 20: 154-157.  
 20 Not in PICO
- 21 Bakebua, B. P. (1987) Oral smear--early detection of oral malignant tumours. *Odonto-Stomatologie*  
 22 *Tropicale*, 10: 45-50.  
 23 Not in PICO
- 24 Balakrishnan, K., Castling, B., McMahon, J., Imrie, J., Feeley, K. M., Parker, A. J., Bull, P. D. &  
 25 Johnston, A. (2005) Fine needle aspiration cytology in the management of a parotid mass: a two  
 26 centre retrospective study. *Surgeon Journal of the Royal Colleges of Surgeons of Edinburgh &*  
 27 *Ireland*, 3: 67-72.  
 28 Not in PICO
- 29 Bassi, K. K., Srivastava, A., Seenu, V., Kumar, R., Parshad, R., Chumber, S., Gupta, S. D. & Bahadur, S.  
 30 (2013) The first and second echelon sentinel lymph node evaluation in oral cancer. *Indian Journal*  
 31 *of Surgery*, 75: 377-382.  
 32 Not in PICO
- 33 Bentley, R. H., Johnson, S. J. & Sloan, P. (2011) Audit of pre-operative fine needle aspiration cytology  
 34 (FNAC) for suspected salivary neoplasms. *Cytopathology*, 22: ii.  
 35 Published as abstract only. Not enough information available, but I think it is "Not in PICO".
- 36 Bhalla, R., Parker, D. C. & Tadros, T. S. (2006) Salivary duct carcinoma metastatic to inguinal lymph  
 37 node: a case report of salivary duct carcinoma with distant metastasis diagnosed by fine-needle  
 38 aspiration. *Diagnostic Cytopathology*, 34: 41-44.  
 39 Not in PICO
- 40 Bocking, A., Sproll, C., Stocklein, N., Naujoks, C., Depprich, R., Kubler, N. R. & Handschel, J. (2011)  
 41 Role of brush biopsy and DNA cytometry for prevention, diagnosis, therapy, and followup care of  
 42 oral cancer. *Journal of Oncology Print*, 2011: 875959.  
 43 Narrative review
- 44 Borgemeester, M. C., van den Brekel, M. W., van, T. H., Smeele, L. E., Pameijer, F. A., van Velthuysen,  
 45 M. L. & Balm, A. J. (2008) Ultrasound-guided aspiration cytology for the assessment of the  
 46 clinically NO neck: factors influencing its accuracy. *Head & Neck*, 30: 1505-1513.  
 47 Not in PICO
- 48 Bradley, P. J. & McGurk, M. (2013) Incidence of salivary gland neoplasms in a defined UK population.  
 49 *British Journal of Oral & Maxillofacial Surgery*, 51: 399-403.  
 50 Not in PICO

- 1 Brennan, P. A., Davies, B., Poller, D., Mead, Z., Bayne, D., Puxeddu, R. & Oeppen, R. S. (2010) Fine  
2 needle aspiration cytology (FNAC) of salivary gland tumours: repeat aspiration provides further  
3 information in cases with an unclear initial cytological diagnosis. *British Journal of Oral &*  
4 *Maxillofacial Surgery*, 48: 26-29.  
5 Not in PICO
- 6 British Columbia Oral Cancer Prevention Program, B. C. A. & College of Dental Surgeons of British  
7 Columbia (2008) Guideline for the early detection of oral cancer in British Columbia 2008. *Journal*  
8 *(Canadian Dental Association)*, 74: 245.  
9 Guideline
- 10 Broglie, M. A., Haerle, S. K., Huber, G. F., Haile, S. R. & Stoeckli, S. J. (2013) Occult metastases  
11 detected by sentinel node biopsy in patients with early oral and oropharyngeal squamous cell  
12 carcinomas: Impact on survival. *Head and Neck*, 35: 660-666.  
13 Not in PICO
- 14 Brown, J. S., Griffith, J. F., Phelps, P. D. & Browne, R. M. (1994) A comparison of different imaging  
15 modalities and direct inspection after periosteal stripping in predicting the invasion of the  
16 mandible by oral squamous cell carcinoma. *British Journal of Oral & Maxillofacial Surgery*, 32:  
17 347-359.  
18 Not in PICO
- 19 Canto, M. T., Horowitz, A. M., Drury, T. F. & Goodman, H. S. (2002) Maryland family physicians'  
20 knowledge, opinions and practices about oral cancer. *Oral Oncology*, 38: 416-424.  
21 Not in PICO
- 22 Carpenter, W. M. & Silverman S Jr (2001) Oral cancer: the role of the dentist in prevention and early  
23 detection. *Dentistry Today*, 20: 92-97.  
24 Narrative review
- 25 Casparis, S., Borm, J. M., Tomic, M. A., Burkhardt, A. & Locher, M. C. (2014) Transepithelial brush  
26 biopsy - Oral CDx - A noninvasive method for the early detection of precancerous and cancerous  
27 lesions. *Journal of Clinical and Diagnostic Research*, 8: 222-226.  
28 Not in PICO (secondary care)
- 29 Chaudhari, V. V., Dandekar, R., Mahajan, A. M. & Prakash, N. (2014) - Sediment cytology in  
30 diagnostic evaluation of oral neoplasms. - *Indian Journal of Dental Research*, 25: 147-149.  
31 Not in PICO
- 32 Chen, C. T., Wang, C. Y., Kuo, Y. S., Chiang, H. H., Chow, S. N., Hsiao, I. Y. & Chiang, C. P. (1996) Light-  
33 induced fluorescence spectroscopy: a potential diagnostic tool for oral neoplasia. *Proceedings of*  
34 *the National Science Council, Republic of China - Part B, Life Sciences*, 20: 123-130.  
35 Narrative review
- 36 Chiesa, F., Mauri, S., Grana, C., Tradati, N., Calabrese, L., Ansarin, M., Mazzarol, G. & Paganelli, G.  
37 (2000) Is there a role for sentinel node biopsy in early N0 tongue tumors? *Surgery*, 128: 16-21.  
38 Not in PICO
- 39 Civantos, F., Zitsch, R. & Bared, A. (2007) Sentinel node biopsy in oral squamous cell carcinoma.  
40 [Review] [49 refs]. *Journal of Surgical Oncology*, 96: 330-336.  
41 Not in PICO
- 42 Collins, B. M. (2002) The oral brush biopsy: an adjunct to early oral cancer detection. *Pennsylvania*  
43 *Dental Journal*, 69: 35-37.  
44 Narrative review
- 45 Cornfield, D., Liu, Z., Gorczyca, W. & Weisberger, J. (2003) The potential role of flow cytometry in the  
46 diagnosis of small cell carcinoma. *Archives of Pathology & Laboratory Medicine*, 127: 461-464.  
47 Not in PICO
- 48 Costa Fontes, K. B., Cunha, K. S., Rodrigues, F. R., Silva, L. E. & Dias, E. P. (2013) Concordance  
49 between cytopathology and incisional biopsy in the diagnosis of oral squamous cell carcinoma.  
50 *Pesquisa Odontologica Brasileira = Brazilian Oral Research*, 27: 122-127.  
51 Not in PICO

- 1 Cruz, I. B., Snijders, P. J., Meijer, C. J., Braakhuis, B. J., Snow, G. B., Walboomers, J. M. & van, d. W., I  
2 (1998) p53 expression above the basal cell layer in oral mucosa is an early event of malignant  
3 transformation and has predictive value for developing oral squamous cell carcinoma. *Journal of*  
4 *Pathology*, 184: 360-368.  
5 Not in PICO
- 6 Daneshbod, Y., Oryan, A., Davarmanesh, M., Shirian, S., Negahban, S., Aledavood, A., Davarpanah,  
7 M. A., Soleimanpoor, H. & Daneshbod, K. (2011) Clinical, histopathologic, and cytologic diagnosis  
8 of mucosal leishmaniasis and literature review. [Review]. *Archives of Pathology & Laboratory*  
9 *Medicine*, 135: 478-482.  
10 Not in PICO
- 11 Das, D. K. & Anim, J. T. (2005) Pleomorphic adenoma of salivary gland: to what extent does fine  
12 needle aspiration cytology reflect histopathological features? *Cytopathology*, 16: 65-70.  
13 Not in PICO
- 14 Dequanter, D., Shahla, M., Paulus, P. & Lothaire, P. (2013) Long term results of sentinel lymph node  
15 biopsy in early oral squamous cell carcinoma. *OncoTargets and therapy*, 6: 799-802.  
16 Not in PICO
- 17 Descamps, G., Duray, A., Rodriguez, A., Chantrain, G., Depuydt, C. E., Delvenne, P. & Saussez, S.  
18 (2012) Detection and quantification of human papillomavirus in benign and malignant parotid  
19 lesions. *Anticancer Research*, 32: 3929-3932.  
20 Not in PICO
- 21 Dhanalakshmi, M., Lakshmana, R. L., Krishnaswamy, M. U., Gopalakrishnan, K. R. & Aruna, P. (2009)  
22 Fine needle aspiration cytology and histopathology of salivary gland lesions: A correlative study in  
23 a rural teaching hospital. *Journal of Chinese Clinical Medicine*, 4: 674-680.  
24 Not in PICO
- 25 Divani, S., Exarhou, M., Theodorou, L.-N., Georgantzis, D. & Skoulakis, H. (2009) Advantages and  
26 difficulties of brush cytology in the identification of early oral cancer. *Archive of Oncology*, 17: 11-  
27 12.  
28 Not in PICO
- 29 Driemel, O., Murzik, U., Escher, N., Melle, C., Bleul, A., Dahse, R., Reichert, T. E., Ernst, G. & von, E. F.  
30 (2007) Protein profiling of oral brush biopsies: S100A8 and S100A9 can differentiate between  
31 normal, premalignant, and tumor cells. *Proteomics Clinical Applications*, 1: 486-493.  
32 Not in PICO
- 33 Elwood, J. M. & Gallagher, R. P. (1985) Factors influencing early diagnosis of cancer of the oral cavity.  
34 *CMAJ Canadian Medical Association Journal*, 133: 651-656.  
35 Not in PICO
- 36 Epstein, J. B., Scully, C. & Spinelli, J. (1992) Toluidine blue and Lugol's iodine application in the  
37 assessment of oral malignant disease and lesions at risk of malignancy. *Journal of Oral Pathology*  
38 *and Medicine*, 21: 160-163.  
39 Not in PICO
- 40 Epstein, J. B., Guneri, P., Boyacioglu, H. & Abt, E. (2012) The limitations of the clinical oral  
41 examination in detecting dysplastic oral lesions and oral squamous cell carcinoma. *Journal of the*  
42 *American Dental Association*, 143: 1332-1342.  
43 Not in PICO
- 44 Ergun, S., Ozel, S., Koray, M., Kurklu, E., Ak, G. & Tanyeri, H. (2009) Dentists' knowledge and opinions  
45 about oral mucosal lesions. *International Journal of Oral & Maxillofacial Surgery*, 38: 1283-1288.  
46 Not in PICO
- 47 Ethunandan, M., Davies, B., Pratt, C. A., Puxeddu, R. & Brennan, P. A. (2009) Primary epithelial  
48 submandibular salivary gland tumours--review of management in a district general hospital  
49 setting. *Oral Oncology*, 45: 173-176.  
50 Not in PICO

- 1 Florentine, B. D., Staymates, B., Rabadi, M., Barstis, J., Black, A. & Cancer Committee of the Henry  
2 Mayo Newhall Memorial Hospital (2006) The reliability of fine-needle aspiration biopsy as the  
3 initial diagnostic procedure for palpable masses: a 4-year experience of 730 patients from a  
4 community hospital-based outpatient aspiration biopsy clinic. *Cancer*, 107: 406-416.  
5 Not in PICO (40% referrals from primary care practitioners; results not split by referral type)
- 6 Folia, M., Kany, M., Fillola, G., Serrano, E. & Pessey, J. J. (2002) [Value of of fine-needle aspiration  
7 cytology and MRI in parotid gland masses]. [French]. *Revue de Laryngologie Otologie Rhinologie*,  
8 123: 153-157.  
9 Not in PICO
- 10 Foroughi, R., Seyedmajidi, M., Bijani, A. & Omid, D. M. (2013) Comparison of clinical diagnosis and  
11 histopathological report of referred biopsies to oral and maxillofacial pathology department of  
12 dental school of Babol, Iran (2003-2010). *Journal of Babol University of Medical Sciences*, 15: 71-  
13 77.  
14 Not in PICO
- 15 Francisco, A. L. N., Correr, W. R., Kurachi, C., Pinto, C. A. L. & Kowalski, L. P. (2010) Fluorescence  
16 spectroscopy for early detection of oral cancer. *Histopathology*, 57: 133.  
17 Not in PICO
- 18 Francisco, A. L. N., Correr, W. R., Azevedo, L. H., Kern, V. G., Pinto, C. A. L., Kowalski, L. P. & Kurachi,  
19 C. (2014) Fluorescence spectroscopy for the detection of potentially malignant disorders and  
20 squamous cell carcinoma of the oral cavity. *Photodiagnosis and Photodynamic Therapy*, 11: 82-  
21 90.  
22 Not in PICO
- 23 Franklin, C. D. & Jones, A. V. (2006) A survey of oral and maxillofacial pathology specimens submitted  
24 by general dental practitioners over a 30-year period. *British Dental Journal*, 200: 447-450.  
25 Not in PICO
- 26 Freitas, V. S., dos Santos, J. N., Oliveira, M. C., Santos, P. P., Freitas, R. A. & de Souza, L. B. (2012)  
27 Intraoral granular cell tumors: clinicopathologic and immunohistochemical study. *Quintessence*  
28 *International*, 43: 135-142.  
29 Not in PICO
- 30 Frydrych, A. M., Parsons, R., Threlfall, T., Austin, N., Davies, G. R., Booth, D. & Slack-Smith, L. M.  
31 (2010) Oral cavity squamous cell carcinoma survival by biopsy type: a cancer registry study.  
32 *Australian Dental Journal*, 55: 378-384.  
33 Not in PICO
- 34 Gandolfo, S., Carbone, M., Carrozzo, M. & Scamuzzi, S. (1993) [Biopsy technics in oral oncology:  
35 excisional or incisional biopsy? A critical review of the literature and the authors' personal  
36 contribution]. [Review] [38 refs] [Italian]. *Minerva Stomatologica*, 42: 69-75.  
37 Narrative review
- 38 Gillenwater, A., Papadimitrakopoulou, V. & Richards-Kortum, R. (2006) Oral premalignancy: New  
39 methods of detection and treatment. *Current Oncology Reports*, 8: 146-154.  
40 Narrative review
- 41 Gillenwater, A. M. & Chambers, M. S. (2006) Diagnosis of premalignant lesions and early cancers of  
42 the oral cavity. *Texas Dental Journal*, 123: 512-520.  
43 Narrative review
- 44 Gilliam, K. (1986) Saving lives in the dental office. *Dentistry Today*, 23: 84.  
45 Narrative review
- 46 Giroux-Slavas, J. (2000) Missing the diagnosis of oral cancer: recognition & liability. *Pennsylvania*  
47 *Dental Journal*, 67: 34-35.  
48 Narrative review
- 49 Godballe, C., Schultz, J. H., Krogdahl, A., Moller-Grontved, A. & Johansen, J. (2003) Parotid  
50 carcinoma: impact of clinical factors on prognosis in a histologically revised series. *Laryngoscope*,

- 1 113: 1411-1417.  
2 Not in PICO
- 3 Goerres, G. W., Schmid, D. T., Schuknecht, B. & Eyrich, G. K. (2005) Bone invasion in patients with  
4 oral cavity cancer: comparison of conventional CT with PET/CT and SPECT/CT.[Erratum appears in  
5 Radiology. 2006 Apr;239(1):303]. *Radiology*, 237: 281-287.  
6 Not in PICO
- 7 Gonsalves, W. C., Chi, A. C. & Neville, B. W. (2007) Common oral lesions: Part II. Masses and  
8 neoplasia. *American Family Physician*, 75: 509-512.  
9 Narrative review
- 10 Gray, M., Gold, L., Burls, A. & Elley, K. (2000) The effectiveness of toluidine blue dye as an adjunct to  
11 oral cancer screening in general dental practice (DARE structured abstract). *Database of Abstracts*  
12 *of Reviews of Effects.*, 40.  
13 Not in PICO
- 14 Gupta, S., Shah, J. S., Parikh, S., Limbdiwala, P. & Goel, S. (2014) - Clinical correlative study on early  
15 detection of oral cancer and precancerous lesions by modified oral brush biopsy and cytology  
16 followed by histopathology. - *Journal of Cancer Research & Therapeutics*, 10: 232-238.  
17 Not in PICO
- 18 Gynther, G. W., Rozell, B. & Heimdahl, A. (2000) Direct oral microscopy and its value in diagnosing  
19 mucosal lesions: a pilot study. *Oral Surgery Oral Medicine Oral Pathology Oral Radiology &*  
20 *Endodontics*, 90: 164-170.  
21 Not in PICO
- 22 Habermann, C. R., Gossrau, P., Graessner, J., Arndt, C., Cramer, M. C., Reitmeier, F., Jaehne, M. &  
23 Adam, G. (2005) Diffusion-weighted echo-planar MRI: a valuable tool for differentiating primary  
24 parotid gland tumors?.[Erratum appears in Rofo. 2005 Sep;177(9):1312]. *Rofo: Fortschritte auf*  
25 *dem Gebiete der Rontgenstrahlen und der Nuklearmedizin*, 177: 940-945.  
26 Not in PICO
- 27 Hamad, L. O., Vervoorts, A., Hennig, T. & Bayer, R. (2010) Ex vivo photodynamic diagnosis to detect  
28 malignant cells in oral brush biopsies. *Lasers in medical science*, 25: 293-301.  
29 Not in PICO
- 30 Hanken, H., Kraatz, J., Smeets, R., Heiland, M., Assaf, A. T., Blessmann, M., Eichhorn, W., Clauditz, T.  
31 S., Grobe, A., Kolk, A. & Rana, M. (2013) The detection of oral pre- malignant lesions with an  
32 autofluorescence based imaging system (VELscope) - a single blinded clinical evaluation.[Erratum  
33 appears in Head Face Med. 2013;9:26 Note: Assaf, Alexandre Thomas [added]]. *Head & Face*  
34 *Medicine*, 9: 23.  
35 Not in PICO
- 36 Haris, P. S., Balan, A., Jayasree, R. S. & Gupta, A. K. (2009) Autofluorescence spectroscopy for the in  
37 vivo evaluation of oral submucous fibrosis. *Photomedicine and Laser Surgery*, 27: 757-761.  
38 Not in PICO
- 39 Hartig, G., Zhang, J., Voytovich, G. M., Newton, M., Chen, A., Collins, S. P. & Wu, S. Q. (2000)  
40 Fluorescent in situ hybridization evaluation of p53 gene deletions at a tumor interface of lingual  
41 carcinoma. *Laryngoscope*, 110: 1474-1478.  
42 Not in PICO
- 43 Hasegawa, Y., Terada, A., Yatabe, Y., Hanai, N., Ozawa, T. & Hirakawa, H. (2011) Sentinel lymph node  
44 biopsy in early tongue cancer patients. *Oral Oncology*, 47: S16.  
45 Not in PICO
- 46 Heller, K. S., Dubner, S., Chess, Q. & Attie, J. N. (1992) Value of fine needle aspiration biopsy of  
47 salivary gland masses in clinical decision-making. *American Journal of Surgery*, 164: 667-670.  
48 Not in PICO
- 49 Hsieh, R., Yen, M.-F., Chen, H.-H. & Zavras, A. (2013) Metabolic syndrome and development of oral  
50 neoplasms. *American Journal of Epidemiology*, 177: S60.  
51 Not in PICO



- 1 Hueston, W. J. & Kaur, D. (2013) Upper respiratory conditions: oral cancers. *Fp Essentials*, 415: 22-  
2 26.  
3 Narrative review
- 4 Ikeda, M., Motoori, K., Hanazawa, T., Nagai, Y., Yamamoto, S., Ueda, T., Funatsu, H. & Ito, H. (2004)  
5 Warthin tumor of the parotid gland: diagnostic value of MR imaging with histopathologic  
6 correlation. *Ajnr: American Journal of Neuroradiology*, 25: 1256-1262.  
7 Not in PICO
- 8 Isaac, U., Isaac, J. S. & Memon, F. (2009) Presentation of histological types and common sites of oral  
9 cancers in lower Sindh. *Journal of the Liaquat University of Medical and Health Sciences*, 8: 210-  
10 213.  
11 Not in PICO
- 12 Iseli, T. A., Lin, M. J., Tsui, A., Guiney, A., Wiesenfeld, D. & Iseli, C. E. (2012) Are wider surgical  
13 margins needed for early oral tongue cancer? *Journal of Laryngology & Otology*, 126: 289-294.  
14 Not in PICO
- 15 Jankittivong, A., Swadison, S., Thangpitsityotin, M. & Langlais, R. P. (2009) Oral squamous cell  
16 carcinoma: a clinicopathological study of 342 Thai cases. *The journal of contemporary dental  
17 practice*, 10: E033-E040.  
18 Not in PICO
- 19 James, K., Toner, M. & Stassen, L. F. (2011) Performing mucosal tissue biopsies in general dental  
20 practice. *Journal of the Irish Dental Association*, 57: 203-208.  
21 Narrative review
- 22 Jayanthi, J. L., Nisha, G. U., Manju, S., Philip, E. K., Jeemon, P., Baiju, K. V., Beena, V. T. & Subhash, N.  
23 (2011) Diffuse reflectance spectroscopy: diagnostic accuracy of a non-invasive screening  
24 technique for early detection of malignant changes in the oral cavity. *BMJ Open*, 1: e000071.  
25 Not in PICO
- 26 Jeong, W. J., Paik, J. H., Cho, S. W., Sung, M. W., Kim, K. H. & Ahn, S. H. (2012) Excisional biopsy for  
27 management of lateral tongue leukoplakia. *Journal of Oral Pathology & Medicine*, 41: 384-388.  
28 Not in PICO
- 29 Jiang, C. F., Wang, C. Y. & Chiang, C. P. (2004) Oral cancer detection in fluorescent image by color  
30 image fusion. *Conference Proceedings: ...Annual International Conference of the IEEE Engineering  
31 in Medicine & Biology Society*, 2: 1260-1262.  
32 Narrative review
- 33 Jones, D. L. & Rankin, K. V. (2013) Oral cancer: FAQ.[Reprint of *Tex Dent J*. 2013 May;130(5):438-43;  
34 PMID: 23923466]. *Journal of Michigan Dental Association*, 95: 32-35.  
35 Narrative review
- 36 Kahn, M. A., Lynch, D. P., Turner, J. E. & Mincer, H. H. (1998) The dos and don'ts of an oral mucosal  
37 biopsy performed by the general dentist. *The Journal of the Tennessee Dental Association*, 78: 28-  
38 31.  
39 Narrative review
- 40 Kammerer, P. W., Koch, F. P., Santoro, M., Babaryka, G., Biesterfeld, S., Brieger, J. & Kunkel, M.  
41 (2013) Prospective, blinded comparison of cytology and DNA-image cytometry of brush biopsies  
42 for early detection of oral malignancy. *Oral Oncology*, 49: 420-426.  
43 Not in PICO
- 44 Kannan, S., Thakkar, P. & Dcruz, A. K. (2011) Tuberculosis masquerading as oral malignancy. *Indian  
45 journal of medical and paediatric oncology : official journal of Indian Society of Medical &  
46 Paediatric Oncology*, 32: 180-182.  
47 Not in PICO
- 48 Kantola, S., Parikka, M., Jokinen, K., Hyrynkans, K., Soini, Y., Alho, O. P. & Salo, T. (2000) Prognostic  
49 factors in tongue cancer - relative importance of demographic, clinical and histopathological  
50 factors. *British Journal of Cancer*, 83: 614-619.  
51 Not in PICO

- 1 Kaugars, G. E., Silverman, J., Ray, A. K., Page, D. G., Abbey, L. M., Burns, J. C. & Svirsky, J. A. (1998)  
2 The use of exfoliative cytology for the early diagnosis of oral cancers: Is there a role for it in  
3 education and private practice? *Journal of Cancer Education*, 13: 85-89.  
4 Not in PICO
- 5 Kawaratani, H., Tsujimoto, T., Yoshikawa, M., Kawanami, F., Shirai, Y., Yoshiji, H., Morita, K. & Fukui,  
6 H. (2013) Large cell neuroendocrine carcinoma presenting with neck swelling in the  
7 submandibular gland: a case report. *Journal of Medical Case Reports [Electronic Resource]*, 7: 81.  
8 Not in PICO
- 9 Kerr, A. R. & Cruz, G. D. (2002) Oral cancer. Practical prevention and early detection for the dental  
10 team. *New York State Dental Journal*, 68: 44-54.  
11 Narrative review
- 12 Kljanienco, J. & Vielh, P. (1997) Fine-needle sampling of salivary gland lesions. IV. Review of 50 cases  
13 of mucoepidermoid carcinoma with histologic correlation. [Review] [41 refs]. *Diagnostic*  
14 *Cytopathology*, 17: 92-98.  
15 Not in PICO
- 16 Kljanienco, J., el-Naggar, A. K. & Vielh, P. (1999) Comparative cytologic and histologic study of  
17 fifteen salivary basal-cell tumors: differential diagnostic considerations. *Diagnostic*  
18 *Cytopathology*, 21: 30-34.  
19 Not in PICO
- 20 Koerner, K. R. (2006) Evaluation and treatment by general dentists of oral soft-tissue lesions.  
21 *Dentistry Today*, 25: 90-95.  
22 Narrative review
- 23 Kokalj, V. N., Cizmarevic, B., Zagorac, A., Zagradisnik, B. & Lanisnik, B. (2014) - An evaluation of SOX2  
24 and hTERT gene amplifications as screening markers in oral and oropharyngeal squamous cell  
25 carcinomas. - *Molecular Cytogenetics*, 7: 5.  
26 Not in PICO
- 27 Kokalj, V. N., Cizmarevic, B., Zagorac, A., Zagradisnik, B. & Lanisnik, B. (2014) An evaluation of SOX2  
28 and hTERT gene amplifications as screening markers in oral and oropharyngeal squamous cell  
29 carcinomas. *Molecular Cytogenetics*, 7: 5.  
30 Not in PICO
- 31 Kominek, P., Vitek, P., Urban, O., Zelenik, K., Halamka, M., Feltl, D., Cvek, J. & Matousek, P. (2013)  
32 Chromoendoscopy to detect early synchronous second primary esophageal carcinoma in patients  
33 with squamous cell carcinomas of the head and neck? *Gastroenterology research & practice*,  
34 2013: 236264.  
35 Not in PICO
- 36 Kondori, I., Mottin, R. W. & Laskin, D. M. (2011) Accuracy of dentists in the clinical diagnosis of oral  
37 lesions. *Quintessence International*, 42: 575-577.  
38 Not in PICO
- 39 Kotecha, S., Bhatia, P. & Rout, P. G. (533) Diagnostic ultrasound in the head and neck region. *Dental*  
40 *Update*, 35: 529-530.  
41 Narrative review
- 42 Krahl, D., Altenburg, A. & Zouboulis, C. C. (2008) Reactive hyperplasias, precancerous and malignant  
43 lesions of the oral mucosa. [Review] [19 refs]. *Journal der Deutschen Dermatologischen*  
44 *Gesellschaft*, 6: 217-232.  
45 Narrative review
- 46 Kress, E., Schulz, H. G. & Neumann, T. (1993) [Diagnosis of diseases of the large salivary glands of the  
47 head by ultrasound, sialography and CT-sialography. A comparison of methods]. [German]. *HNO*,  
48 41: 345-351.  
49 Not in PICO

- 1 Kusakawa, J., Kameyama, T. & Nakamura, Y. (1998) Evaluation of excisional biopsy for stage I and II  
2 squamous cell carcinoma of the oral cavity. *International Journal of Clinical Oncology*, 3: 317-322.  
3 Not in PICO
- 4 Laronde, D. M., Williams, P. M., Hislop, T. G., Poh, C., Ng, S., Zhang, L. & Rosin, M. P. (2014) - Decision  
5 making on detection and triage of oral mucosa lesions in community dental practices: screening  
6 decisions and referral. - *Community Dentistry & Oral Epidemiology*, 42: 375-384.  
7 Not in PICO
- 8 Laudenbach, J. M. (2013) Oral medicine update: oral cancer--screening, lesions and related  
9 infections. *Journal of the California Dental Association*, 41: 326-328.  
10 Narrative review
- 11 Lee, Y. Y., Wong, K. T., King, A. D. & Ahuja, A. T. (2008) Imaging of salivary gland tumours. [Review]  
12 [44 refs]. *European Journal of Radiology*, 66: 419-436.  
13 Narrative review
- 14 Leunig, A., Betz, C. S., Mehlmann, M., Stepp, H., Arbogast, S., Grevers, G. & Baumgartner, R. (2000)  
15 Detection of squamous cell carcinoma of the oral cavity by imaging 5-aminolevulinic acid-induced  
16 protoporphyrin IX fluorescence. *Laryngoscope*, 110: 78-83.  
17 Not in PICO
- 18 Litonjua, L. S. (1997) Algorithm for the management of oral pathologic lesions. *Journal of the*  
19 *Philippine Dental Association*, 49: 60-63.  
20 Narrative review
- 21 Liu Joseph, L. Y., Walsh, T., Kerr, A. R., Lingen, M., Brocklehurst, P., Ogden, G., Warnakulasuriya, S. &  
22 Scully, C. (2012) Diagnostic tests for oral cancer and potentially malignant disorders in patients  
23 presenting with clinically evident lesions. *Cochrane Database of Systematic Reviews*.  
24 Protocol
- 25 Liu, W., Shi, L. J., Wu, L., Feng, J. Q., Yang, X., Li, J., Zhou, Z. T. & Zhang, C. P. (2012) Oral cancer  
26 development in patients with leukoplakia--clinicopathological factors affecting outcome. *PLoS*  
27 *ONE [Electronic Resource]*, 7: e34773.  
28 Not in PICO
- 29 Liu, X., Bai, X. F. & Huang, S. H. (2012) [A diagnostic meta-analysis: sentinel lymph node biopsy for  
30 neck metastasis in patients with early oral squamous cell carcinoma]. [Chinese]. *Chung-Hua Kou*  
31 *Chiang i Hsueh Tsa Chih Chinese Journal of Stomatology*, 47: 350-353.  
32 Not in PICO
- 33 Logan, R. M. & Goss, A. N. (2010) Biopsy of the oral mucosa and use of histopathology services.  
34 *Australian Dental Journal*, 55: Suppl-13.  
35 Narrative review
- 36 Lopez, J. P., Velandrino, N. A., Martinez, B. Y. & Fernandez, S. M. (2007) Attitude towards oral biopsy  
37 among general dentists in Murcia. *Medicina Oral, Patologia Oral y Cirugia Bucal*, 12: E116-E121.  
38 Not in PICO
- 39 Lydiatt, D. D. (2002) Cancer of the oral cavity and medical malpractice. *Laryngoscope*, 112: 816-819.  
40 Not in PICO
- 41 M S, Shetty, P., Decruz, A. M. & Pai, P. (2013) The Self-Reported Knowledge, Attitude and the  
42 Practices Regarding the Early Detection of Oral Cancer and Precancerous Lesions among the  
43 Practising Dentists of Dakshina Kannada-A Pilot Study. *Journal of Clinical and Diagnostic Research*  
44 *JCDR*, 7: 1491-1494.  
45 Not in PICO
- 46 MacCarthy, D., Flint, S. R., Healy, C. & Stassen, L. F. (2011) Oral and neck examination for early  
47 detection of oral cancer--a practical guide. *Journal of the Irish Dental Association*, 57: 195-199.  
48 Narrative review
- 49 MacCarthy, D., Nunn, J., Healy, C. M., Stassen, L. F., Gorman, T., Martin, B., Toner, M., Clarke, M.,  
50 Dougall, A., McLoughlin, J., Kelly, A., Waldron, C., O'Sullivan, M., Doyle, C. & Flint, S. (2012)  
51 Outcomes from the first mouth cancer awareness and clinical check-up day in the Dublin Dental

- 1 University Hospital. *Journal of the Irish Dental Association*, 58: 101-108.  
2 Not in PICO
- 3 Mao, L. (2010) Identifying the premalignant lesion at high risk for progression to cancer. *Cancer*  
4 *Prevention Research*, 3.  
5 Narrative review
- 6 Maraki, D., Becker, J. & Boecking, A. (2004) Cytologic and DNA-cytometric very early diagnosis of oral  
7 cancer. *Journal of Oral Pathology & Medicine*, 33: 398-404.  
8 Not in PICO
- 9 Martinez-Conde, R., Aguirre, J. M., Burgos, J. J. & Rivera, J. M. (2001) Clinicopathological factors in  
10 early squamous cell carcinoma of the tongue and floor of the mouth, in Biscay (the Basque  
11 Country, Spain). [Spanish, English]. *Medicina Oral*, 6: 87-94.  
12 Not in PICO
- 13 Masthan, K. M. K., Aravindha, B. N., Dash, K. C. & Elumalai, M. (2012) Advanced diagnostic aids in  
14 oral cancer. *Asian Pacific Journal of Cancer Prevention*, 13: 3573-3576.  
15 Narrative review
- 16 Matsuzuka, T., Miura, T., Suzuki, M., Yokoyama, S., Matsui, T., Nomoto, Y., Kunii, M., Saijoh, S. &  
17 Omori, K. (2011) Sentinel node biopsy for deciding neck dissection for early-stage tongue cancer.  
18 *Japanese Journal of Head and Neck Cancer*, 37: 355-358.  
19 Not in PICO
- 20 Matthias, C., Mack, B., Berghaus, A. & Gires, O. (2008) Keratin 8 expression in head and neck  
21 epithelia. *BMC Cancer*, 8: 267.  
22 Not in PICO
- 23 Maurer, K., Eschrich, K., Schellenberger, W., Bertolini, J., Rupf, S. & Remmerbach, T. W. (2013) Oral  
24 brush biopsy analysis by MALDI-ToF Mass Spectrometry for early cancer diagnosis. *Oral Oncology*,  
25 49: 152-156.  
26 Not in PICO
- 27 McIntosh, L., McCullough, M. J. & Farah, C. S. (2009) The assessment of diffused light illumination  
28 and acetic acid rinse (Microlux/DL) in the visualisation of oral mucosal lesions. *Oral Oncology*, 45:  
29 e227-e231.  
30 Not in PICO
- 31 Mehrotra, R., Gupta, A., Singh, M. & Ibrahim, R. (2006) Application of cytology and molecular biology  
32 in diagnosing premalignant or malignant oral lesions. *Molecular Cancer*, 5.  
33 Narrative review
- 34 Mehrotra, R., Mishra, S., Singh, M. & Singh, M. (2011) The efficacy of oral brush biopsy with  
35 computer-assisted analysis in identifying precancerous and cancerous lesions. *Head & neck*  
36 *oncology*, 3: 39.  
37 Same as Mehrotra 2011
- 38 Mehrotra, R. & Gupta, D. K. (2011) Exciting new advances in oral cancer diagnosis: avenues to early  
39 detection. [Review]. *Head & neck oncology*, 3: 33.  
40 Narrative review
- 41 Mehrotra, R., Mishra, S. & Singh, M. (2011) The efficacy of oral brush biopsy with computer-assisted  
42 analysis in identifying precancerous and cancerous lesions. *Head and Neck Oncology*, 3.  
43 Not in PICO
- 44 Mehrotra, R. & Gupta, D. K. (2011) Exciting new advances in oral cancer diagnosis: Avenues to early  
45 detection. *Head and Neck Oncology*, 3.  
46 Narrative review
- 47 Mercadante, V., Paderni, C. & Campisi, G. (2012) Novel non-invasive adjunctive techniques for early  
48 oral cancer diagnosis and oral lesions examination. [Review]. *Current Pharmaceutical Design*, 18:  
49 5442-5451.  
50 Narrative review

- 1 Messadi, D. V. (2013) Diagnostic aids for detection of oral precancerous conditions. [Review].  
2 *International Journal of Oral Science*, 5: 59-65.  
3 Narrative review
- 4 Mittal, N., Palaskar, S. & Shankari, M. (2012) Rose Bengal staining - diagnostic aid for potentially  
5 malignant and malignant disorders: a pilot study. *Indian Journal of Dental Research*, 23: 561-564.  
6 Not in PICO
- 7 Monroe, M. M. & Gross, N. D. (2012) Evidence-based practice: management of the clinical node-  
8 negative neck in early-stage oral cavity squamous cell carcinoma. [Review]. *Otolaryngologic*  
9 *Clinics of North America*, 45: 1181-1193.  
10 Narrative review
- 11 Monroe, M. M. & Lai, S. Y. (2014) - Sentinel lymph node biopsy for oral cancer: supporting evidence  
12 and recent novel developments. - *Current Oncology Reports*, 16: 385.  
13 Not in PICO
- 14 Mordas, A., Blozelyte-Plesniene, L., Cepulis, V., Venius, J., Liutkeviciute-Navickiene, J. &  
15 Rutkovskiene, L. (2011) Intra-arterial fluorescence diagnostics of oral cancer. *European Journal of*  
16 *Cancer*, 47: S573.  
17 Not in PICO
- 18 Morelatto, R. A., Herrera, M. C., Fernandez, E. N., Corball, A. G. & Lopez de Blanc, S. A. (2007)  
19 Diagnostic delay of oral squamous cell carcinoma in two diagnosis centers in Cordoba Argentina.  
20 *Journal of Oral Pathology & Medicine*, 36: 405-408.  
21 Not in PICO
- 22 Mota-Ramirez, A., Silvestre, F. J. & Simo, J. M. (2007) Oral biopsy in dental practice. [Review] [24  
23 refs]. *Medicina Oral, Patologia Oral y Cirugia Bucal*, 12: E504-E510.  
24 Narrative review
- 25 Munde, A. D., Karle, R. R., Wankhede, P. K., Shaikh, S. S. & Kulkurni, M. (2013) Demographic and  
26 clinical profile of oral lichen planus: A retrospective study. *Contemporary Clinical Dentistry*, 4:  
27 181-185.  
28 Not in PICO
- 29 Murata, Y., Yamada, I., Umehara, I., Okada, N. & Shibuya, H. (1998) Diagnostic accuracy of  
30 technetium-99m-pertechnetate scintigraphy with lemon juice stimulation to evaluate Warthin's  
31 tumor. *Journal of Nuclear Medicine*, 39: 43-46.  
32 Not in PICO
- 33 Murti, P. R., Warnakulasuriya, K. A., Johnson, N. W., Bhonsle, R. B., Gupta, P. C., Daftary, D. K. &  
34 Mehta, F. S. (1998) p53 expression in oral precancer as a marker for malignant potential. *Journal*  
35 *of Oral Pathology & Medicine*, 27: 191-196.  
36 Not in PICO
- 37 Nagaraju, K., Prasad, S. & Ashok, L. (2010) Diagnostic efficiency of toluidine blue with Lugol's iodine  
38 in oral premalignant and malignant lesions. *Indian Journal of Dental Research*, 21: 218-223.  
39 Not in PICO
- 40 Naugler, C. (2008) Practice tips. Brush biopsy sampling of oral lesions. *Canadian Family Physician*, 54:  
41 194.  
42 Narrative review
- 43 Nayyar, A. S. (2012) Novel biochemical markers: early detection and prevention of malignant  
44 transformation a pilot study. *Acta Medica Iranica*, 50: 597-602.  
45 Not in PICO
- 46 Ng, S.-H., Chan, S.-C., Liao, C.-T., Chang, J. T. C., Ko, S.-F., Wang, H.-M., Chin, S.-C., Lin, C.-Y., Huang,  
47 S.-F. & Yen, T.-C. (2008) Distant metastases and synchronous second primary tumors in patients  
48 with newly diagnosed oropharyngeal and hypopharyngeal carcinomas: Evaluation of 18F-FDG PET  
49 and extended-field multi-detector row CT. *Neuroradiology*, 50: 969-979.  
50 Not in PICO

- 1 Nicotera, G., Di Stasio, S. M. & Angelillo, I. F. (2004) Knowledge and behaviors of primary care  
2 physicians on oral cancer in Italy. *Oral Oncology*, 40: 490-495.  
3 Not in PICO
- 4 Noorman van der Dussen MF (1994) [Oral cancer. The importance of early diagnosis and role of the  
5 dentist]. [French]. *Revue Belge de Medecine Dentaire*, 49: 35-49.  
6 Narrative review
- 7 Ogden, G., Lewthwaite, R. & Shepherd, S. D. (2013) Early detection of oral cancer: how do I ensure I  
8 don't miss a tumour? *Dental Update*, 40: 462-465.  
9 Narrative review
- 10 Oka, K., Chikamatsu, K., Eura, M., Katsura, F., Yumoto, E. & Tokunaga, H. (2002) [Clinical significance  
11 of fine-needle aspiration biopsy in major salivary gland tumors]. [Japanese]. *Nippon Jibiinkoka  
12 Gakkai Kaiho [Journal of the Oto-Rhino-Laryngological Society of Japan]*, 105: 1109-1115.  
13 Not in PICO
- 14 Omitola, O. G., Ajayi, O. F., Banjo, A. A., Anunobi, C. C. & Arotiba, G. T. (2010) The sensitivity,  
15 specificity and accuracy of fine needle aspirational cytology in the diagnosis of oro-facial  
16 neoplasms at Lagos University Teaching Hospital, Nigeria. *Odonto-Stomatologie Tropicale*, 33: 21-  
17 25.  
18 Not in PICO
- 19 Paderni, C., Compilato, D., Lo, M. L. & Campisi, G. (2010) Direct visualization of oral-cavity tissue  
20 fluorescence and toluidine blue staining: New adjunctive aids for oral medicine practitioners in  
21 early oral cancer diagnosis and potentially malignant disorders follow-up? *Oral Diseases*, 16: 535-  
22 536.  
23 Not in PICO (tests)
- 24 Pallagatti, S., Sheikh, S., Puri, N., Gupta, D. & Singh, B. (2011) Colposcopy: a new ray in the diagnosis  
25 of oral lesions. [Review]. *Indian Journal of Dental Research*, 22: 810-815.  
26 Narrative review
- 27 Patton, L. L., Epstein, J. B. & Kerr, A. R. (1993) Adjunctive techniques for oral cancer examination and  
28 lesion diagnosis: a systematic review of the literature. [Review] [34 refs]. *Journal of the American  
29 Dental Association*, 139: 896-905.  
30 Duplicate
- 31 Patton, L. L., Elter, J. R., Southerland, J. H. & Strauss, R. P. (2005) Knowledge of oral cancer risk  
32 factors and diagnostic concepts among North Carolina dentists: Implications for diagnosis and  
33 referral. *Journal of the American Dental Association*, 136: 602-610.  
34 Not in PICO
- 35 Patton, L. L., Epstein, J. B. & Kerr, A. R. (2008) Adjunctive techniques for oral cancer examination and  
36 lesion diagnosis a systematic review of the literature. *Journal of the American Dental Association*,  
37 139: 896-905.  
38 Not in PICO, but included cytopathology papers checked for relevance
- 39 Pektas, Z. O., Keskin, A., Gunhan, O. & Karslioglu, Y. (2006) Evaluation of nuclear morphometry and  
40 DNA ploidy status for detection of malignant and premalignant oral lesions: quantitative cytologic  
41 assessment and review of methods for cytomorphometric measurements. *Journal of Oral &  
42 Maxillofacial Surgery*, 64: 628-635.  
43 Not in PICO
- 44 Pentenero, M., Carrozzo, M., Pagano, M., Galliano, D., Broccoletti, R., Scully, C. & Gandolfo, S. (2003)  
45 Oral mucosal dysplastic lesions and early squamous cell carcinomas: underdiagnosis from  
46 incisional biopsy. *Oral Diseases*, 9: 68-72.  
47 Not in PICO
- 48 Pentenero, M., Marino, R., Valenta, G. T., Navone, R. & Gandolfo, S. (2014) Microbiopsy a novel  
49 sampling technique to early detect dysplastic/malignant alterations in oral mucosal lesions:  
50 practicability by general dentists. *Journal of Oral Pathology & Medicine*, 43: 435-440.  
51 Not in PICO

- 1 Pentenero, M., Marino, R., Tempia, V. G., Navone, R. & Gandolfo, S. (2014) - Microbiopsy a novel  
2 sampling technique to early detect dysplastic/malignant alterations in oral mucosal lesions:  
3 practicability by general dentists. - *Journal of Oral Pathology & Medicine*, 43: 435-440.  
4 Duplicate
- 5 Pentenero, M., Marino, R., Tempia, V. G., Navone, R. & Gandolfo, S. (2014) Microbiopsy a novel  
6 sampling technique to early detect dysplastic/malignant alterations in oral mucosal lesions:  
7 Practicability by general dentists. *Journal of Oral Pathology and Medicine*, 43: 435-440.  
8 Duplicate
- 9 Pillay, M., Vasudevan, D. M., Rao, C. P. & Vidya, M. (2003) p53 expression in oral cancer:  
10 observations of a South Indian study. *Journal of Experimental & Clinical Cancer Research*, 22: 447-  
11 451.  
12 Not in PICO
- 13 Poate, T. W., Buchanan, J. A., Hodgson, T. A. & et.al. (2004) An audit of the efficacy of the oral brush  
14 biopsy technique in a specialist oral medicine unit. *Oral Oncology*, 40: 829-834.  
15 Not in PICO
- 16 Poh, C. F., Ng, S., Berean, K. W., Williams, P. M., Rosin, M. P. & Zhang, L. (2008) Biopsy and  
17 histopathologic diagnosis of oral premalignant and malignant lesions. *Journal (Canadian Dental  
18 Association)*, 74: 283-288.  
19 Narrative review
- 20 Poulias, E., Melakopoulos, I. & Tosios, K. (2011) Metastatic breast carcinoma in the mandible  
21 presenting as a periodontal abscess: a case report. *Journal of Medical Case Reports [Electronic  
22 Resource]*, 5: 265.  
23 Not in PICO
- 24 Rajput, D. V. & Tupkari, J. V. (2010) Early detection of oral cancer: PAP and AgNOR staining in brush  
25 biopsies. *Journal of Oral & Maxillofacial Pathology*, 14: 52-58.  
26 Not in PICO
- 27 Regezi, J. A., Zarbo, R. J., Regev, E., Pisanty, S., Silverman, S. & Gazit, D. (1995) p53 protein  
28 expression in sequential biopsies of oral dysplasias and in situ carcinomas. *Journal of Oral  
29 Pathology & Medicine*, 24: 18-22.  
30 Not in PICO
- 31 Remmerbach, T. W., Meyer-Ebrecht, D., Aach, T., Wurflinger, T., Bell, A. A., Schneider, T. E., Nietzke,  
32 N., Frerich, B. & Bocking, A. (2009) Toward a multimodal cell analysis of brush biopsies for the  
33 early detection of oral cancer. *Cancer*, 117: 228-235.  
34 Not in PICO
- 35 Richards, D. (2010) Does toluidine blue detect more oral cancer? *Evidence-Based Dentistry*, 11: 104-  
36 105.  
37 Not in PICO
- 38 Robinson, P. N. & Mickelson, A. R. (2006) Early Diagnosis of Oral Cavity Cancers. *Otolaryngologic  
39 Clinics of North America*, 39: 295-306.  
40 Narrative review
- 41 Rogers, S. N., Pabla, R., McSorley, A., Lowe, D., Brown, J. S. & Vaughan, E. D. (2007) An assessment of  
42 deprivation as a factor in the delays in presentation, diagnosis and treatment in patients with oral  
43 and oropharyngeal squamous cell carcinoma. *Oral Oncology*, 43: 648-655.  
44 Not in PICO
- 45 Sardella, A., Demarosi, F., Lodi, G., Canegallo, L., Rimondini, L. & Carrassi, A. (2007) Accuracy of  
46 referrals to a specialist oral medicine unit by general medical and dental practitioners and the  
47 educational implications. *Journal of Dental Education*, 71: 487-491.  
48 Not in PICO
- 49 Scala, M., Moresco, L., Comandini, D., Monteghirfo, S. & Tomei, D. (1997) [The role of the general  
50 practitioner and dentist in the early diagnosis of preneoplastic and neoplastic lesions of the oral

- 1 cavity]. [Italian]. *Minerva Stomatologica*, 46: 133-137.
- 2 Narrative review
- 3 Scheifele, C., Schmidt-Westhausen, A.-M., Dietrich, T. & Reichart, P. A. (2004) The sensitivity and  
4 specificity of the OralCDx technique: Evaluation of 103 cases. *Oral Oncology*, 40: 824-828.
- 5 Not in PICO
- 6 Schmid-Meier, E. (1984) [Diagnostic possibilities in suspected tumor]. [German]. *Schweizerische*  
7 *Monatsschrift fur Zahnmedizin*, 94: Spec-7.
- 8 Not in PICO
- 9 Schoengen, A., Binder, T., Krause, H. R., Stussak, G. & Zeelen, U. (1995) [The value of fine needle  
10 aspiration cytology in suspected neoplastic salivary gland enlargement]. [German]. *HNO*, 43: 239-  
11 243.
- 12 Not in PICO
- 13 Sciubba, J. J. (1999) Improving detection of precancerous and cancerous oral lesions. Computer-  
14 assisted analysis of the oral brush biopsy. U.S. Collaborative OralCDx Study Group. *Journal of the*  
15 *American Dental Association*, 130: 1445-1457.
- 16 Primary care, but result not reported for index test negative patients (618/945)
- 17 Scully, C. (1993) Clinical diagnostic methods for the detection of premalignant and early malignant  
18 oral lesions. [Review] [51 refs]. *Community Dental Health*, 10: Suppl-52.
- 19 Narrative review
- 20 Scully, C. & Ward-Booth, R. P. (1995) Detection and treatment of early cancers of the oral cavity.  
21 [Review] [111 refs]. *Critical Reviews in Oncology-Hematology*, 21: 63-75.
- 22 Narrative review
- 23 Scully, C. & Kirby, J. (2014) Statement on mouth cancer diagnosis and prevention. *British Dental*  
24 *Journal*, 216: 37-38.
- 25 Narrative review
- 26 Sen, E., Basut, O., Ozturk, I., Demir, U. L., Ozmen, O. A., Kasapoglu, F. & Durgut, O. (2012) [The role of  
27 sentinel lymph node biopsy in oral cavity cancer]. [Turkish]. *Kulak Burun Bogaz Ihtisas*  
28 *Dergisi/Journal of Ear, Nose & Throat: Kbb*, 22: 81-86.
- 29 Not in PICO
- 30 Seoane, J., Varela-Centelles, P. I., Ramirez, J. R., Cameselle-Teijeiro, J. & Romero, M. A. (2004)  
31 Artefacts in oral incisional biopsies in general dental practice: a pathology audit. *Oral Diseases*,  
32 10: 113-117.
- 33 Not in PICO
- 34 Shah, S. K., Le, M. C. & Carpenter, W. M. (2009) Retrospective review of pediatric oral lesions from a  
35 dental school biopsy service. *Pediatric Dentistry*, 31: 14-19.
- 36 Not in PICO
- 37 Silverman S Jr (2000) Diagnosing oral lesions. Interview by Phillip Bonner. *Dentistry Today*, 19: 80-87.  
38 Interview
- 39 Silverman, J., Migliorati, C. & Barbosa, J. (1984) Toluidine blue staining in the detection of oral  
40 precancerous and malignant lesions. *Oral Surgery Oral Medicine and Oral Pathology*, 57: 379-382.
- 41 Not in PICO
- 42 Silverman, J. (2000) Diagnosing oral lesions. Interview by Phillip Bonner. *Dentistry Today*, 19: 80-87.  
43 Interview
- 44 Silverman, S. (1994) Oral cancer. *Seminars in Dermatology*, 13: 132-137.
- 45 Narrative review
- 46 Singh, T. & Schenberg, M. (2013) Delayed diagnosis of oral squamous cell carcinoma following dental  
47 treatment. *Annals of the Royal College of Surgeons of England*, 95: 369-373.
- 48 Not in PICO
- 49 Sousa, F. B., - de Freitas e Silva MR, Fernandes, C. P., Silva, P. G. & Alves, A. P. (2014) - Oral cancer  
50 from a health promotion perspective: experience of a diagnosis network in Ceara. - *Pesquisa*



- 1 *Odontologica Brasileira = Brazilian Oral Research*, 28 Spec, 2014..
- 2 Not in PICO
- 3 Stanley, R. E. (1991) Parapharyngeal space tumours. *Annals of the Academy of Medicine, Singapore*,
- 4 20: 589-596.
- 5 Not in PICO
- 6 Stell, P. M., Wood, G. D. & Scott, M. H. (1982) Early oral cancer: treatment by biopsy excision. *British*
- 7 *Journal of Oral Surgery*, 20: 234-238.
- 8 Not in PICO
- 9 Subhash, N., Mallia, J. R., Thomas, S. S., Mathews, A., Sebastian, P. & Madhavan, J. (2006) Oral
- 10 cancer detection using diffuse reflectance spectral ratio R540/R575 of oxygenated hemoglobin
- 11 bands. *Journal of Biomedical Optics*, 11: 014018-014Feb.
- 12 Narrative review
- 13 Sudbo, J., Bryne, M., Johannessen, A. C., Kildal, W., Danielsen, H. E. & Reith, A. (2001) Comparison of
- 14 histological grading and large-scale genomic status (DNA ploidy) as prognostic tools in oral
- 15 dysplasia.[Retraction in *J Pathol*. 2007 Jan;211(1):109; PMID: 17136756]. *Journal of Pathology*,
- 16 194: 303-310.
- 17 Not in PICO
- 18 Sugerma, P. B. & Savage, N. W. (2002) Oral lichen planus: causes, diagnosis and management.
- 19 [Review] [40 refs]. *Australian Dental Journal*, 47: 290-297.
- 20 Narrative review
- 21 Svistun, E., Alizadeh-Naderi, R., El-Naggar, A., Jacob, R., Gillenwater, A. & Richards-Kortum, R. (2004)
- 22 Vision enhancement system for detection of oral cavity neoplasia based on autofluorescence.
- 23 *Head & Neck*, 26: 205-215.
- 24 Not in PICO
- 25 Terada, T. (2011) Hepatocellular carcinoma metastatic to the gingiva as a first manifestation of
- 26 hepatocellular carcinoma. *Journal of Maxillofacial & Oral Surgery*, 10: 271-274.
- 27 Not in PICO
- 28 Thapasum, F. A., Faraz, M. & Shamaz, M. (2011) Primary care clinicians' knowledge of oral cancer: A
- 29 Study of oral and general physicians in Kuala Muda & Kota Setar Districts, Malaysia. *Oral*
- 30 *Oncology*, 47: S108.
- 31 Not in PICO
- 32 To, E. W., Tsang, W. M., Cheng, J., Lai, E., Pang, P., Ahuja, A. T. & Ying, M. (2003) Is neck ultrasound
- 33 necessary for early stage oral tongue carcinoma with clinically NO neck? *Dento-Maxillo-Facial*
- 34 *Radiology*, 32: 156-159.
- 35 Not in PICO
- 36 Uppal, N. & Baliga, M. (2014) - Necrotizing sialometaplasia: A rare lesion that mimics oral cancer
- 37 clinically and histopathologically. - *Otolaryngologia Polska*, 68: 154-156.
- 38 Not in PICO
- 39 Urquhart, A., Hutchins, L. G. & Berg, R. L. (2001) Preoperative computed tomography scans for
- 40 parotid tumor evaluation. *Laryngoscope*, 111: t-8.
- 41 Not in PICO
- 42 van Heerden, W. F. & Butow, K. W. (2002) The role of the dentist in the prevention and early
- 43 diagnosis of oral cancer. *SADJ*, 57: 22-24.
- 44 Narrative review
- 45 van, d. W., I (2005) [Research methods in dentistry 7. Diagnostic tests in oral diseases]. [Review] [6
- 46 refs] [Dutch]. *Nederlands Tijdschrift Voor Tandheelkunde*, 112: 3-6.
- 47 Narrative review
- 48 Vashisht, N., Ravikiran, A., Samatha, Y., Rao, P. C., Naik, R. & Vashisht, D. (2014) -
- 49 Chemiluminescence and Toluidine Blue as Diagnostic Tools for Detecting Early Stages of Oral
- 50 Cancer: An invivo Study. - *Journal of Clinical and Diagnostic Research JCDR*, 8: ZC35-ZC38.
- 51 Not in PICO

- 1 Vercellino, V., Gandolfo, S., Camoletto, D., Griffa, B. & Mori, C. (1985) Toluidine blue (tolonium  
2 chloride) in the early diagnosis of dysplasias and carcinomas of the oral mucosa. [Italian]. *Minerva*  
3 *Stomatologica*, 34: 257-261.  
4 Narrative review
- 5 Vigneswaran, N. & Williams, M. D. (2014) - Epidemiologic trends in head and neck cancer and aids in  
6 diagnosis. - *Oral & Maxillofacial Surgery Clinics of North America*, 26: 123-141.  
7 Narrative review
- 8 Vora, H. H., Trivedi, T. I., Shukla, S. N., Shah, N. G., Goswami, J. V. & Shah, P. M. (2006) p53  
9 expression in leukoplakia and carcinoma of the tongue. *International Journal of Biological*  
10 *Markers*, 21: 74-80.  
11 Not in PICO
- 12 Wakui, T., Hakata, Y., Doi, Y., Asano, K., Kawamata, H. & Imai, Y. (2014) Investigation of sentinel  
13 lymph node biopsy using genetic analysis in squamous cell carcinoma of the tongue. *Dokkyo*  
14 *Journal of Medical Sciences*, 41: 129-136.  
15 Not in PICO
- 16 Wan, A. & Savage, N. W. (2010) Biopsy and diagnostic histopathology in dental practice in Brisbane:  
17 usage patterns and perceptions of usefulness. *Australian Dental Journal*, 55: 162-169.  
18 Not in PICO
- 19 Wang, H.-C., Zuo, C.-T., Hua, F.-C., Huang, Z.-M., Tan, H.-B., Zhao, J. & Guan, Y.-H. (2010) Efficacy of  
20 conventional whole-body 18F-FDG PET/CT in the incidental findings of parotid masses. *Annals of*  
21 *Nuclear Medicine*, 24: 571-577.  
22 Not in PICO
- 23 Wang, Y. C., Fang, K. H., Jung, S. M., Zheng, J. & Hao, S. P. (2010) Excisional biopsy with margin  
24 control for oral cancers. *Head & Neck*, 32: 1528-1533.  
25 Not in PICO
- 26 Warnakulasuriya, K. A. A. S. & Nanayakkara, B. G. (1991) Reproducibility of An Oral-Cancer and  
27 Precancer Detection Program Using A Primary Health-Care Model in Sri-Lanka. *Cancer Detection*  
28 *and Prevention*, 15: 331-334.  
29 Not in PICO
- 30 Warnakulasuriya, S., Gould, A., Leuci, S., Mignogna, M., Seoane-Leston, J. M., Diz-Dios, P., McAlister,  
31 C., McEvoy, P., Thermidou, I. & Rapidis, A. D. (2013) Leonardo da Vinci Partnership - A lifelong  
32 learning programme to raise awareness of dental and medical professionals within Europe for the  
33 early detection of oral cancer - Phase 2. *Oral Oncology*, 49: S59.  
34 Not in PICO
- 35 White, M. W., Rajadhyaksha, M., Gonzalez, S., Fabian, R. L. & Anderson, R. R. (1999) Noninvasive  
36 imaging of human oral mucosa in vivo by confocal reflectance microscopy. *Laryngoscope*, 109:  
37 1709-1717.  
38 Not in PICO
- 39 Whitesides, L. M., Ferreira, L. R. & Ord, R. A. (1995) Audit of clinical information and diagnoses  
40 supplied to the pathologist following biopsy of oral squamous cell carcinomas. *MSDA Journal*, 38:  
41 63-65.  
42 Not in PICO
- 43 Williams, H. K., Hey, A. A. & Browne, R. M. (1997) The use by general dental practitioners of an oral  
44 pathology diagnostic service over a 20-year period: the Birmingham Dental Hospital experience.  
45 *British Dental Journal*, 182: 424-429.  
46 Not in PICO
- 47 Williams, P. M., Poh, C. F., Hovan, A. J., Ng, S. & Rosin, M. P. (2008) Evaluation of a suspicious oral  
48 mucosal lesion. *Journal (Canadian Dental Association)*, 74: 275-280.  
49 Narrative review

- 1 Wong, D. S. & Li, G. K. (2000) The role of fine-needle aspiration cytology in the management of  
2 parotid tumors: a critical clinical appraisal. *Head & Neck*, 22: 469-473.  
3 Not in PICO
- 4 Wyss, E., Mueller-Garamvolgyi, E., Ghadjar, P., Rauch, D., Zbaren, P. & Arnold, A. (2013) Diagnosis  
5 and treatment outcomes for patients with lymphoma of the parotid gland. *Laryngoscope*, 123:  
6 662-669.  
7 Not in PICO
- 8 Yamauchi, M., Shinozaki, K., Doi, M., Nitta, T. & Nishisaka, T. (2014) - A Case of Gingival Metastasis  
9 from Rectal Cancer in Which Immunohistochemistry and PET-CT Were Useful for the Diagnostic  
10 Procedure. - *Case Reports Oncology*, 7: 246-251.  
11 Not in PICO
- 12 Yang, Y., Li, Y. X., Yang, X., Jiang, L., Zhou, Z. J. & Zhu, Y. Q. (2013) Progress risk assessment of oral  
13 premalignant lesions with saliva miRNA analysis. *BMC Cancer*, 13: 129.  
14 Not in PICO
- 15 Yesilova, E., Akgunlu, F., Dolanmaz, D., Yasar, F. & Sener, S. (2007) Osteosarcoma: a case report.  
16 *European journal of dentistry*, 1: 60-63.  
17 Not in PICO
- 18 Yoshihara, T. (2002) Bilateral enlargement of the submandibular glands - Clinical and pathological  
19 appearance. [Japanese]. *Practica Oto-Rhino-Laryngologica*, 95: 555-561.  
20 Narrative review
- 21 Zenk, W., Dietel, W., Schleier, P. & Gunzel, S. (1999) [Visualizing carcinomas of the mouth cavity by  
22 stimulating synthesis of fluorescent protoporphyrin IX]. [German]. *Mund-, Kiefer- und*  
23 *Gesichtschirurgie*, 3: 205-209.  
24 Not in PICO
- 25 Zhang, S., Bao, R., Bagby, J. & Abreo, F. (2009) Fine needle aspiration of salivary glands: 5-Year  
26 experience from a single academic center. *Acta Cytologica*, 53: 375-382.  
27 Not in PICO
- 28 Zheng, W., Soo, K. C., Sivanandan, R. & Olivo, M. (2002) Detection of squamous cell carcinomas and  
29 pre-cancerous lesions in the oral cavity by quantification of 5-aminolevulinic acid induced  
30 fluorescence endoscopic images. *Lasers in Surgery & Medicine*, 31: 151-157.  
31 Not in PICO
- 32 Zheng, W., Olivo, M. & Soo, K. C. (2004) The use of digitized endoscopic imaging of 5-ALA-induced  
33 PPIX fluorescence to detect and diagnose oral premalignant and malignant lesions in vivo.  
34 *International Journal of Cancer*, 110: 295-300.  
35 Not in PICO
- 36 Zini, A., Czerninski, R. & Sgan-Cohen, H. D. (2010) Oral cancer over four decades: epidemiology,  
37 trends, histology, and survival by anatomical sites. *Journal of Oral Pathology & Medicine*, 39: 299-  
38 305.  
39 Narrative review
- 40 Zunt, S. L. (2001) Transepithelial Brush Biopsy: an adjunctive diagnostic procedure. *Journal of the*  
41 *Indiana Dental Association*, 80: 6-8.  
42 Narrative review  
43  
44  
45

**THYROID CANCER****Review question:**

What is the risk of thyroid cancer in patients presenting in primary care with symptom(s)?

**Results****Literature search**


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	All-2012	1325	162	03/10/2012
<i>Premedline</i>	All-2012	44	0	03/10/2012
<i>Embase</i>	All-2012	1696	137	04/10/2012
<i>Cochrane Library</i>	All-2012	147	1	01/10/2012
<i>Psychinfo</i>	All-2012	5	1	03/10/2012
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	All-2012	196	32	01/10/2012
<i>Biomed Central</i>	All-2012	460	4	01/10/2012

Total References retrieved (after de-duplication): 274

**Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	10/2012-27/08/2014	65	4	27/08/2014
<i>Premedline</i>	10/2012-27/08/2014	105	3	27/08/2014
<i>Embase</i>	10/2012-27/08/2014	126	2	27/08/2014
<i>Cochrane Library</i>	10/2012-27/08/2014	89	0	27/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	10/2012-27/08/2014	45	0	27/08/2014

Total References retrieved (after de-duplication): 6



1

2 **Study results**

3 No evidence was identified.

4 **References**

5 **Included studies**

6 None

7

8 **Excluded studies (with excl reason)**

9 (2003) Information from your family doctor. Thyroid nodules. *American Family Physician*, 67: 573-  
10 574.

11 Patient information leaflet

12 (2006) [Assess the patients' necks!]. [German]. *MMW Fortschritte der Medizin*, 148: 62-63.

13 Put down as Narrative review, but not seen. Not available unless we try using a world wide  
14 search, which I have decided not to as highly unlikely it will be relevant.

15 Ageev, I. S., Chizhikov, N. V., Paniushov, S. P., Tiumin, V. B., Grishaev, A. A. & Meniasheva, E. A.

16 (2005) [Thyroid cancer in male patients]. [Russian]. *Voprosy Onkologii*, 51: 717-718.

17 Not in PICO

18 Ainahi, A., Kebbou, M., Timinouni, M., Benabdeljalil, N. & Oufara, S. (2006) Treatment evaluation,  
19 follow-up and familial screening of medullary thyroid carcinoma by highly specific calcitonin  
20 measurements. *Indian Journal of Cancer*, 43: 75-79.

21 Not in PICO

22 Alexander, C. L., Izquierdo, R. E., Figge, J. & Horton, J. (1995) Diagnosis and management of thyroid  
23 cancer. *Cancer Control*, 2: 128-135.

24 Narrative review

25 Alfonso, E., Sanabria, A. & Castillo, M. (2011) Surgeons overestimate the risk of malignancy in thyroid  
26 nodules, evaluation of subjective estimates using a bayesian analysis. *Biomedica*, 31: 590-598.

27 Not in PICO

28 Allen, M., Sapinho, I., Raposo, L. & Torrinha, J. (2008) [Cyto-histological correlation of malignant  
29 thyroid nodules: clinical factors as predictors of malignancy]. [Portuguese]. *Acta Medica*

- 1 *Portuguesa*, 21: 135-140.
- 2 Not in PICO
- 3 Amirova, N. M., Rodnikovskii, V. B. & Soldatov, I. P. (1989) The diagnosis of cancer and nodular  
4 formations of the thyroid by using a mathematical table. [Russian]. *Problemy Endokrinologii*, 35:  
5 28-29.
- 6 Not in PICO
- 7 Andry, G., Willemse, E., Digonnet, A., De, K. C., Vandeveld, L., Plat, L., Larsimont, D., Muylle, K. &  
8 Lemort, M. (2009) [Thyroid cancers]. [French][Erratum appears in Rev Med Brux. 2009 Sep-  
9 Oct;30(5):482]. *Revue Medicale de Bruxelles*, 30: 279-286.
- 10 Narrative review
- 11 Arbelle, J. E., Shalom, S. I., Benbassat, C., Dickstein, G., Glasser, B. & Liel, Y. (836) [Summary of the  
12 Israeli Endocrine Society's consensus statement on the diagnosis, treatment and follow-up of  
13 well-differentiated thyroid cancer]. [27 refs] [Hebrew]. *Harefuah*, 147: 825-832.
- 14 Narrative review
- 15 Arif, S., Blanes, A. & Diaz-Cano, S. J. (2002) Hashimoto's thyroiditis shares features with early  
16 papillary thyroid carcinoma. [Review] [32 refs]. *Histopathology*, 41: 357-362.
- 17 Narrative review
- 18 Arora, N., Scognamiglio, T., Zhu, B. & Fahey, T. J., III (2008) Do benign thyroid nodules have  
19 malignant potential? An evidence-based review. [Review] [93 refs]. *World Journal of Surgery*, 32:  
20 1237-1246.
- 21 Not in PICO
- 22 Arslan, M. S., Topaloglu, O., Tural, E., Karbek, B., Ucan, B., Unsal, I. O., Gungunes, A., Ozkaya, E. C.,  
23 Bozkurt, N. C., Ozbek, M., Cakal, E., Sahin, M. & Delibasi, T. (2012) Hyperprolactinemia: A risk  
24 factor of thyroid disease in patients with prolactinoma. *Endocrine Reviews*, 33.
- 25 Not in PICO
- 26 Babcock, D. S. (372) Thyroid disease in the pediatric patient: emphasizing imaging with sonography.  
27 [Review] [26 refs]. *Pediatric Radiology*, 36: 299-308.
- 28 Narrative review
- 29 Bae, J. S., Chae, B. J., Park, W. C., Kim, J. S., Kim, S. H., Jung, S. S. & Song, B. J. (2009) Incidental  
30 thyroid lesions detected by FDG-PET/CT: prevalence and risk of thyroid cancer. *World Journal of*  
31 *Surgical Oncology*, 7: 63.
- 32 Not in PICO
- 33 Bartos, M., Pomorski, L. & Narebski, J. (2000) [The diagnosis and operative treatment of solitary  
34 thyroid nodule: a prospective study]. [Polish]. *Wiadomosci Lekarskie*, 53: 134-141.
- 35 Not in PICO
- 36 Bennedbaek, F. N., Perrild, H. & Hegedus, L. (1999) Diagnosis and treatment of the solitary thyroid  
37 nodule. Results of a European survey. *Clinical Endocrinology*, 50: 357-363.
- 38 Not in PICO
- 39 Berchtold, R., Studer, H. & Teuscher, J. (1982) Which diseases of the thyroid should be operated  
40 upon?. [German]. *Therapeutische Umschau*, 39: 768-775.
- 41 Not in PICO
- 42 Bergholm, U., Adami, H. O., Bergstrom, R., Johansson, H., Lundell, G., Telenius-Berg, M. & Akerstrom,  
43 G. (1989) Clinical characteristics in sporadic and familial medullary thyroid carcinoma. A  
44 nationwide study of 249 patients in Sweden from 1959 through 1981. *Cancer*, 63: 1196-1204.
- 45 Not in PICO
- 46 Beristain Hernandez, J. L., Servin, T. E., Sosa, C. A., Velazquez Garcia, J. A., Pozzo, B. R., Delgadillo, T.  
47 G., Serrano, G., I, Marquez, H. A., Bevia, P. F., Piscil Salazar, M. A., Ortiz De La Pena Salazar  
48 Ilarregui, Sanchez Gonzalez, F. J. & Espinoza, A. A. (2010) [Determination of the diagnostic  
49 accuracy of 99mTc sestamibi scanning in patients with thyroid nodule and a definitive  
50 histopathological report]. [Spanish]. *Endocrinologia y Nutricion*, 57: 460-466.
- 51 Not in PICO

- 1 Besic, N., Sesek, M., Peric, B., Zgajnar, J. & Hocevar, M. (2008) Predictive factors of carcinoma in 327  
2 patients with follicular neoplasm of the thyroid. *Medical Science Monitor*, 14: CR459-CR467.  
3 Not in PICO
- 4 Bleyer, A. (2009) CAUTION! Consider Cancer: Common Symptoms and Signs for Early Detection of  
5 Cancer in Young Adults. *Seminars in Oncology*, 36: 207-212.  
6 Narrative review
- 7 Bomeli, S. R., LeBeau, S. O. & Ferris, R. L. (2010) Evaluation of a thyroid nodule. [Review] [44 refs].  
8 *Otolaryngologic Clinics of North America*, 43: 229-238.  
9 Narrative review
- 10 Brennan, M. & French, J. (2007) Thyroid lumps and bumps. *Australian Family Physician*, 36: 531-536.  
11 Narrative review
- 12 Brenner, W., Bohuslavizki, K. H., Klutmann, S. & Henze, E. (1997) Diagnostic value of currently  
13 available tumor markers in thyroid cancers. *Radiology and Oncology*, 31: 18-20.  
14 Narrative review
- 15 Brownlie, B., Mercer, P., Turner, J. & Allison, R. (2008) Thyroid malignancies: a New Zealand South  
16 Island thyroid clinic experience 1995-2006. *New Zealand Medical Journal*, 121: 36-45.  
17 Not in PICO
- 18 Brunese, L., Romeo, A., Iorio, S., Napolitano, G., Fucili, S., Zeppa, P., Vallone, G., Lombardi, G.,  
19 Bellastella, A., Biondi, B. & Sodano, A. (2008) Thyroid B-flow twinkling sign: a new feature of  
20 papillary cancer. *European Journal of Endocrinology*, 159: 447-451.  
21 Not in PICO
- 22 Brunt, L. M. & Wells, S. A., Jr. (1983) The Multiple Endocrine Neoplasia syndromes. *Annales*  
23 *Chirurgiae et Gynaecologiae*, 72: 153-159.  
24 Narrative review
- 25 Bukhari, U., Sadiq, S., Memon, J. & Baig, F. (2009) Thyroid carcinoma in Pakistan: a retrospective  
26 review of 998 cases from an academic referral center. *Hematology/oncology & stem cell therapy*,  
27 2: 345-348.  
28 Not in PICO
- 29 Cairncross, L. & Panieri, E. (2013) Pre-operative diagnosis of thyroid cancer: Clinical, radiological and  
30 pathological correlation. *South African Journal of Surgery*, 51: 46-49.  
31 Not in PICO
- 32 Cakir, M., Celik, E., Tuncer, F. B. & Tekin, A. (2013) A rare coexistence of thyroid lymphoma with  
33 papillary thyroid carcinoma. *Annals of African Medicine*, 12: 188-190.  
34 Not in PICO
- 35 Caplan, R. H., Wester, S. M., Lambert, P. J. & Rooney, B. L. (2000) Efficient evaluation of thyroid  
36 nodules by primary care providers and thyroid specialists. *American Journal of Managed Care*, 6:  
37 1134-1140.  
38 Not in PICO
- 39 Caplan, R. H. (2001) Evaluation of palpable thyroid nodules: Are endocrinologists assessing patients  
40 efficiently? *Endocrinologist*, 11: 321-326.  
41 Narrative review
- 42 Carter, W. B., Tourtelot, J. B., Savell, J. G. & Lilienfeld, H. (2011) New treatments and shifting  
43 paradigms in differentiated thyroid cancer management. [Review]. *Cancer Control*, 18: 96-103.  
44 Narrative review
- 45 Caruso, D. R., O'Dorisio, T. M. & Mazzaferri, E. L. (1991) Multiple endocrine neoplasia. [Review] [26  
46 refs]. *Current Opinion in Oncology*, 3: 103-108.  
47 Narrative review
- 48 Castro, M. R. & Gharib, H. (2000) Thyroid nodules and cancer. *Postgraduate Medicine*, 107: 113-124.  
49 Narrative review

- 1 Castro, M. R. & Gharib, H. (2005) Continuing controversies in the management of thyroid nodules.  
2 [Review] [79 refs]. *Annals of Internal Medicine*, 142: 926-931.  
3 Narrative review
- 4 Cattaneo, F., Burgi, U. & Mueller, B. (1999) [Goiter and nodular thyroid disease: clinical guidelines for  
5 diagnosis and treatment. (Waiting? Hormone therapy? Surgery? radioiodine?). [Review] [42 refs]  
6 [German]. *Therapeutische Umschau*, 56: 356-363.  
7 Narrative review
- 8 Chabon, S. L. (505) Identification and evaluation of thyroid nodules. [Review] [8 refs]. *Lippincott's*  
9 *Primary Care Practice*, 1: 499-504.  
10 Narrative review
- 11 Chadha, N. K. & Forte, V. (2009) Pediatric head and neck malignancies. [Review] [41 refs]. *Current*  
12 *Opinion in Otolaryngology & Head & Neck Surgery*, 17: 471-476.  
13 Narrative review
- 14 Chang, Y. J., Mittal, V., Remine, S., Manyam, H., Sabir, M., Richardson, T. & Young, S. (2006)  
15 Correlation between clinical and histological findings in parathyroid tumors suspicious for  
16 carcinoma. *American Surgeon*, 72: 419-426.  
17 Not in PICO
- 18 Chen, H., Roberts, J. R., Ball, D. W., Eisele, D. W., Baylin, S. B., Udelsman, R. & Bulkley, G. B. (1998)  
19 Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by  
20 operative resection. *Annals of Surgery*, 227: 887-895.  
21 Not in PICO
- 22 Cheung, K., Roman, S. A., Wang, T. S., Walker, H. D. & Sosa, J. A. (2008) Calcitonin measurement in  
23 the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis.  
24 *Journal of Clinical Endocrinology & Metabolism*, 93: 2173-2180.  
25 Not in PICO
- 26 Choi, Y. J., Park, Y. L. & Koh, J. H. (2008) Prevalence of thyroid cancer at a medical screening center:  
27 pathological features of screen-detected thyroid carcinomas. *Yonsei Medical Journal*, 49: 748-  
28 756.  
29 Not in PICO
- 30 Chow, S. M., Law, S. C. K., Au, S. K., Leung, T. W., Chan, P. T. M., Mendenhall, W. M. & Lau, W. H.  
31 (2002) Differentiated thyroid carcinoma: Comparison between papillary and follicular carcinoma  
32 in a single institute. *Head and Neck-Journal for the Sciences and Specialties of the Head and Neck*,  
33 24: 670-677.  
34 Not in PICO
- 35 Chung, W. Y., Chang, H. S., Kim, E. K. & Park, C. S. (2001) Ultrasonographic mass screening for thyroid  
36 carcinoma: a study in women scheduled to undergo a breast examination. *Surgery Today*, 31:  
37 763-767.  
38 Not in PICO
- 39 Clero, E., Doyon, F., Chungue, V., Rachedi, F., Boissin, J. L., Sebbag, J., Shan, L., Bost-Bezeaud, F.,  
40 Petitdidier, P., Dewailly, E., Rubino, C. & de, V. F. (2012) Dietary iodine and thyroid cancer risk in  
41 French Polynesia: a case-control study. *Thyroid*, 22: 422-429.  
42 Not in PICO
- 43 Conzo, G., Troncone, G., Docimo, G., Pizza, A., Sciascia, V., Bellevicine, C., Napolitano, S., Della, P. C.,  
44 Palazzo, A., Signoriello, G. & Santini, L. (2013) Cytologically undetermined thyroid's follicular  
45 lesions: surgical procedures and histological outcome in 472 cases. *Annali Italiani di Chirurgia*, 84:  
46 251-256.  
47 Not in PICO
- 48 Corrias, A., Mussa, A., Baronio, F., Arrigo, T., Salerno, M., Segni, M., Vigone, M. C., Gastaldi, R., Zirilli,  
49 G., Tuli, G., Beccaria, L., Iughetti, L., Einaudi, S., Weber, G., De, L. F., Cassio, A. & Study Group for  
50 Thyroid Diseases of Italian Society for Pediatric Endocrinology and Diabetology (SIEDP/ISPED)  
51 (2010) Diagnostic features of thyroid nodules in pediatrics. *Archives of Pediatrics & Adolescent*



- 1 *Medicine*, 164: 714-719.  
2 Not in PICO
- 3 Costante, G. & Filetti, S. (2011) Early diagnosis of medullary thyroid carcinoma: is systematic  
4 calcitonin screening appropriate in patients with nodular thyroid disease? *The Oncologist*, 16: 49-  
5 52.  
6 Narrative review
- 7 D'Ugo, D., Persiani, R., Pende, V., D'Andrilli, A., De, C. E., Rausei, S. & Picciocchi, A. (2001) [Clinical  
8 role of the cytologic study of thyroid nodules]. [Italian]. *Annali Italiani di Chirurgia*, 72: 287-291.  
9 Not in PICO
- 10 Damante, G., Scaloni, A. & Tell, G. (2009) Thyroid tumors: novel insights from proteomic studies.  
11 [Review] [130 refs]. *Expert Review of Proteomics*, 6: 363-376.  
12 Narrative review
- 13 Damion, J. & Hybels, R. L. (106) The neck mass. 2. Inflammatory and neoplastic causes. *Postgraduate*  
14 *Medicine*, 81: 97-103.  
15 Narrative review
- 16 Danese, D., Centanni, M., Farsetti, A. & Andreoli, M. (1997) Diagnosis of thyroid carcinoma. [Review]  
17 [85 refs]. *Journal of Experimental & Clinical Cancer Research*, 16: 337-347.  
18 Narrative review
- 19 Dardas, M., Abboud, M., Salti, I., Sabri, A., Shoucair, M., Saleh, M., Azar, S., Rodriguez-Galindo, C. &  
20 Muwakkit, S. (2009) Thyroid Cancer in Lebanese Children and Adolescents: A 15-Year Experience  
21 at A Single Institution. *Pediatric Hematology and Oncology*, 26: 439-447.  
22 Not in PICO
- 23 Davies, L., Ouellette, M., Hunter, M. & Welch, H. G. (2010) The increasing incidence of small thyroid  
24 cancers: where are the cases coming from? *Laryngoscope*, 120: 2446-2451.  
25 Not in PICO
- 26 Deandrea, M., Ragazzoni, F., Motta, M., Torchio, B., Mormile, A., Garino, F., Magliona, G., Gamarra,  
27 E., Ramunni, M. J., Garberoglio, R. & Limone, P. P. (2010) Diagnostic value of a cytomorphological  
28 subclassification of follicular patterned thyroid lesions: a study of 927 consecutive cases with  
29 histological correlation. *Thyroid*, 20: 1077-1083.  
30 Not in PICO
- 31 Delisle, M.-J., Schwartz, C., Theobald, S., Maes, B., Vaudrey, C. & Pochart, J.-M. (1996) The thyroid  
32 carcinomas. Interest of a regional registry of 627 patients diagnosed, treated and followed by a  
33 multidisciplinary group. [French]. *Annales d'Endocrinologie*, 57: 41-49.  
34 Not in PICO
- 35 Delisle, M. J., Hannequin, P., Liehn, J. C., Gibold, C., Maes, B., Vaudrey, C., Pochart, J. M. & Morel, M.  
36 (1986) [Thyroid cancer in Champagne-Ardenne: 1967-1984. Epidemiologic findings in a regional  
37 register]. [French]. *Bulletin du Cancer*, 73: 165-170.  
38 Not in PICO
- 39 Delisle, M. J., Schwartz, C., Theobald, S., Maes, B., Vaudrey, C. & Pochart, J. M. (1996) Cancers of the  
40 thyroid. Value of a regional registry on 627 patients diagnosed, treated and followed by a  
41 multidisciplinary team. [French]. *Annales d'Endocrinologie*, 57: 41-49.  
42 Not in PICO
- 43 Demeter, J. G., De Jong, S. A., Lawrence, A. M. & Paloyan, E. (1991) Anaplastic thyroid carcinoma:  
44 Risk factors and outcome. *Surgery*, 110: 956-963.  
45 Not in PICO
- 46 Demidov, V. P., Voronetskii, I. B., Sergeev, S. A. & Babakulyeva, D. (1982) [Current diagnostic and  
47 treatment problems in thyroid cancer]. [Russian]. *Voprosy Onkologii*, 28: 70-77.  
48 Not in PICO
- 49 Desai, M. P. (1997) Disorders of thyroid gland in India. *Indian Journal of Pediatrics*, 64: 11-20.  
50 Not in PICO

- 1 Dietlein, M., Wegscheider, K., Vaupel, R., Schmidt, M. & Schicha, H. (2007) Management of  
2 multinodular goiter in Germany (Papillon 2005): do the approaches of thyroid specialists and  
3 primary care practitioners differ? *Nuclear-Medizin*, 46: 65-75.  
4 Not in PICO
- 5 Dietlein, M., Wegscheider, K., Vaupel, R., Schmidt, M. & Schicha, H. (2008) Survey of management of  
6 solitary thyroid nodules in Germany. *Nuclear-Medizin*, 47: 87-96.  
7 Not in PICO
- 8 Dionigi, G., Tanda, M. L., Piantanida, E., Boni, L., Rovera, F., Dionigi, R. & Bartalena, L. (2009) Time  
9 interval in diagnosis and treatment of papillary thyroid cancer: a descriptive, retrospective study.  
10 *American Journal of Surgery*, 197: 434-438.  
11 Not in PICO
- 12 Domanski, M. C., Ashktorab, S. & Bielamowicz, S. A. (2010) Primary care perceptions of  
13 otolaryngology. *Otolaryngology-Head and Neck Surgery*, 143: 337-340.  
14 Not in PICO
- 15 Dong, S., Lu, G. Z., Gao, Y. M., Zhang, H., Guo, X. H. & Gao, Y. (2008) [A clinical pathological study of  
16 thyroid nodules detected by physical examinations]. [Chinese]. *Chung-Hua Nei Ko Tsa Chih*  
17 *Chinese Journal of Internal Medicine*, 47: 189-192.  
18 Not in PICO
- 19 Dotzenrath, C., Goretzki, P. E., Cupisti, K., Simon, D., Witte, J., Yang, Q., Ohmann, C. & Roher, H. D.  
20 (2001) Is there any consensus in diagnostic and operative strategy with respect to medullary  
21 thyroid cancer? A questionnaire answered by 73 endocrine surgical units. *Langenbecks Archives*  
22 *of Surgery*, 386: 47-52.  
23 Not in PICO
- 24 Elahi, S., Manzoor-ul-Hassan, A., Syed, Z., Nazeer, L., Nagra, S. A. & Hyder, S. W. (2005) A study of  
25 goiter among female adolescents referred to Centre for Nuclear Medicine, Lahore. *Pakistan*  
26 *Journal of Medical Sciences*, 21: 56-62.  
27 Not in PICO
- 28 Elsaesser, H. (2005) 14 Years of thyroid disorders in general practice - What is left?. [German].  
29 *Zeitschrift fur Allgemeinmedizin*, 81: 97-102.  
30 Narrative review
- 31 Ershova, G. I. (2004) Methods of improvement of diagnosis of thyroid cancer. [Russian]. *Khirurgiia*,  
32 47-49.  
33 Narrative review
- 34 Esik, O., Szavcsur, P., Szakall S Jr, Bajzik, G., Repa, I., Dabasi, G., Fuzy, M., Szentirmay, Z., Perner, F.,  
35 Kasler, M., Lengyel, Z. & Tron, L. (2001) Angiography effectively supports the diagnosis of hepatic  
36 metastases in medullary thyroid carcinoma. *Cancer*, 91: 2084-2095.  
37 Not in PICO
- 38 Esik, O., Tusnady, G., Tron, L., Boer, A., Szentirmay, Z., Szabolcs, I., Racz, K., Lengyel, E., Szekely, J. &  
39 Kasler, M. (2002) Markov model-based estimation of individual survival probability for medullary  
40 thyroid cancer patients. *Pathology and Oncology Research*, 8: 93-104.  
41 Not in PICO
- 42 Evans, T. C. (2003) Thyroid disease. *Primary Care - Clinics in Office Practice*, 30: 625-640.  
43 Narrative review
- 44 Faggiano, A., Del Prete, M., Marciello, F., Marotta, V., Ramundo, V. & Colao, A. (2011) Thyroid  
45 diseases in elderly. *Minerva Endocrinologica*, 36: 211-231.  
46 Narrative review
- 47 Feldmann, M. (1980) Thyroid investigations in general practice. [German]. *Zeitschrift fur*  
48 *Allgemeinmedizin*, 56: 1893-1896.  
49 Not in PICO
- 50 Filicori, F., Keutgen, X. M., Buitrago, D., AlDailami, H., Crowley, M., Fahey, T. J., III & Zarnegar, R.  
51 (2011) Risk stratification of indeterminate thyroid fine-needle aspiration biopsy specimens based

- 1 on mutation analysis. *Surgery*, 150: 1085-1091.  
 2 Not in PICO
- 3 Fromigue, J., De, B. T., Baudin, E., Dromain, C., Leboulleux, S. & Schlumberger, M. (2006) Review:  
 4 Chemoembolization for liver metastases from medullary thyroid carcinoma. *Journal of Clinical*  
 5 *Endocrinology and Metabolism*, 91: 2496-2499.  
 6 Not in PICO
- 7 Fruth, K. & Mann, W. J. (2009) [Malignant thyroid neoplasms: a diagnostic challenge for ENT  
 8 specialists]. [German]. *HNO*, 57: 257-261.  
 9 Not in PICO
- 10 Fuhrer, D., Bockisch, A. & Schmid, K. W. (516) Euthyroid goiter with and without nodules--diagnosis  
 11 and treatment. [Review]. *Deutsches Arzteblatt International*, 109: 506-515.  
 12 Narrative review
- 13 Gallego, C., Gonzalez-Diaz, S., Del Carmen, Z. M., Arias-Cruz, A., Garcia-Calderin, D., Salas, K. Y. M.,  
 14 Calva, M. & Sansores, L. A. D. (2012) CVID: A common but still underdiagnosed disease. *World*  
 15 *Allergy Organization Journal*, 5: S207-S208.  
 16 Not in PICO
- 17 Gamboa-Dominguez, A., Lino-Silva, S., Candanedo-Gonzalez, F., Medina-Lopez, E., Acuna-Gonzalez,  
 18 D., Jacinto-Cortes, I. & Gonzalez-Trevino, O. (2011) [Trends of thyroid pathology in a referral  
 19 center: steady prevalence of papillary thyroid carcinoma but goiter increase in thyroidectomies].  
 20 [Spanish]. *Revista de Investigacion Clinica*, 63: 148-154.  
 21 Not in PICO
- 22 Gavrioloia, G. V., Gavrioloia, M. R. & Novac, M. L. (2011) Bioacoustics response of small benign or  
 23 malignant nodules. *Conference Proceedings: ...Annual International Conference of the IEEE*  
 24 *Engineering in Medicine & Biology Society*, 2011: 7695-7698.  
 25 Not in PICO
- 26 Gharib, H., McConahey, W. M., Tieg, R. D., Bergstralh, E. J., Goellner, J. R., Grant, C. S., van Heerden,  
 27 J. A., Sizemore, G. W. & Hay, I. D. (1992) Medullary thyroid carcinoma: clinicopathologic features  
 28 and long-term follow-up of 65 patients treated during 1946 through 1970. *Mayo Clinic*  
 29 *Proceedings*, 67: 934-940.  
 30 Not in PICO
- 31 Giammarile, F., Houzard, C., Bournaud, C., Hafdi, Z., Sassolas, G. & Borson-Chazot, F. (2004)  
 32 Diagnostic management of suspected metastatic thyroid carcinoma: clinical value of octreotide  
 33 scintigraphy in patients with negative high-dose radioiodine scans. *European Journal of*  
 34 *Endocrinology*, 150: 277-283.  
 35 Not in PICO
- 36 Gibbons, V., Conaglen, J. V., Lillis, S., Naras, V. & Lawrenson, R. (2008) Epidemiology of thyroid  
 37 disease in Hamilton (New Zealand) general practice. *Australian and New Zealand Journal of Public*  
 38 *Health*, 32: 421-423.  
 39 Not in PICO
- 40 Giuffrida, D. & Gharib, H. (1995) Controversies in the Management of Cold, Hot, and Occult Thyroid-  
 41 Nodules. *American Journal of Medicine*, 99: 642-650.  
 42 Narrative review
- 43 Glastonbury, C. M., Davidson, H. C., Haller, J. R. & Harnsberger, H. R. (2000) The CT and MR imaging  
 44 features of carcinoma arising in thyroglossal duct remnants. *American Journal of Neuroradiology*,  
 45 21: 770-774.  
 46 Not in PICO
- 47 Glinioer, D. (2010) Consensus guidelines for the management of thyroid disorders associated with  
 48 the pregnancy: An overview. *Endocrine Abstracts*, 20: S26.  
 49 Guideline/Not in PICO
- 50 Goldstein, R. E., Nettekville, J. L., Burkey, B. & Johnson, J. E. (2002) Implications of follicular  
 51 neoplasms, atypia, and lesions suspicious for malignancy diagnosed by fine-needle aspiration of

- 1 thyroid nodules. *Annals of Surgery*, 235: 656-662.
- 2 Not in PICO
- 3 Gomes, E. M. D., Vaisman, F., Vidal, A. P., Corbo, R., da Cruz, M. D. G., Teixeira, P. D. D., Buescu, A. &  
4 Vaisman, M. (2011) Frequency of thyroid carcinoma and thyroid autoimmunity in first-degree  
5 relatives of patients with papillary thyroid carcinoma - A single center experience. *Arquivos*  
6 *Brasileiros de Endocrinologia e Metabologia*, 55: 326-330.
- 7 Not in PICO
- 8 Gomez Saez, J. M. & en nombre del grupo de Cancer de Tiroides de la Sociedad Espanola de  
9 Endocrinologia (2010) [Is our approach to thyroid nodules and differentiated thyroid carcinoma in  
10 agreement with the American guideline and European consensus?]. [Spanish]. *Endocrinologia y*  
11 *Nutricion*, 57: 357-363.
- 12 Not in PICO
- 13 Gossain, V. V., Charnas, J., Carella, M. J., Rovner, D. R. & Calaca, W. M. (1998) Evaluation of "solitary"  
14 thyroid nodules in a community practice: a managed care approach. *American Journal of*  
15 *Managed Care*, 4: 679-684.
- 16 Not in PICO
- 17 Guerrier, B., Berthet, J. P., Cartier, C., Dehesdin, D., Edet-Sanson, A., Le, C. G., Garrel, R., Kania, R.,  
18 Makeieff, M., Page, C., Poiree, S., Potard, G., Prades, J. M., Righini, C., Roussel, F. & Toubert, M. E.  
19 (2012) French ENT Society (SFORL) practice guidelines for lymph-node management in adult  
20 differentiated thyroid carcinoma. *European Annals of Otorhinolaryngology, Head and Neck*  
21 *Diseases*, 129: 197-206.
- 22 Guideline
- 23 Guliana, J. M., Modigliani, E., Guillausseau, P. J., Aubert, P., Milhaud, G., Moukhtar, M. S. &  
24 Calmettes, C. (1989) Detection and prognosis of medullary cancer of the thyroid gland. Influence  
25 of national multidisciplinary cooperation. [French]. *Presse medicale (Paris, France : 1983)*, 18:  
26 521-524.
- 27 Not in PICO
- 28 Haid, A., Zimmermann, G., Fritzsche, H., Kargl, M., De, M. R. & Gruber, U. (1989) Simultaneous  
29 occurrence of thyroid cancer and hyperthyroid goiter nodules in an endemic area. [German].  
30 *Chirurg*, 60: 39-43.
- 31 Narrative review
- 32 Hakala, T., Kholova, I., Sand, J., Saaristo, R. & Kellokumpu-Lehtinen, P. (2013) A core needle biopsy  
33 provides more malignancy-specific results than fine-needle aspiration biopsy in thyroid nodules  
34 suspicious for malignancy. *Journal of Clinical Pathology*, 66: 1046-1050.
- 35 Not in PICO
- 36 Hamburger, J. I., Miller, J. M. & Kini, S. R. (1983) Lymphoma of the thyroid. *Annals of Internal*  
37 *Medicine*, 99: 685-693.
- 38 Not in PICO
- 39 Hammond, I., Lentle, B. C. & Odell, P. F. (2010) The pursuit of impalpable thyroid nodules: are we  
40 using scarce resources wisely? *Canadian Association of Radiologists Journal*, 61: 98-101.
- 41 Narrative review
- 42 Hands, K. E., Cervera, A. & Fowler, L. J. (2010) Enlarged benign-appearing cervical lymph nodes by  
43 ultrasonography are associated with increased likelihood of cancer somewhere within the thyroid  
44 in patients undergoing thyroid nodule evaluation. *Thyroid*, 20: 857-862.
- 45 Not in PICO
- 46 Haq, M. & Harmer, C. (2004) Thyroid cancer: an overview. [Review] [28 refs]. *Nuclear Medicine*  
47 *Communications*, 25: 861-867.
- 48 Narrative review
- 49 Harach, H. R. & Ceballos, G. A. (2008) Thyroid cancer, thyroiditis and dietary iodine: A review based  
50 on the salta, argentina model. *Endocrine Pathology*, 19: 209-220.
- 51 Narrative review

- 1 Harris, P. E. (2002) The management of thyroid cancer in adults: a review of new guidelines. *Clinical*  
2 *Medicine*, 2: 144-146.  
3 Guideline
- 4 HAYES & -Inc (2013) BRAF p.Val600Glu testing in papillary thyroid carcinoma (Structured abstract).  
5 *Health Technology Assessment.Database..*  
6 Not in PICO
- 7 Hemminki, K., Sundquist, J. & Bermejo, J. L. (2008) Familial risks for cancer as the basis for evidence-  
8 based clinical referral and counseling. *The Oncologist*, 13: 239-247.  
9 Not in PICO
- 10 Hennemann, G. & Van Der Snoek, J. A. (1985) Consensus meeting on the diagnostic procedure in  
11 single thyroid nodule. [Dutch]. *Nederlands Tijdschrift Voor Geneeskunde*, 129: 1878-1882.  
12 Guideline/consensus statement
- 13 Henry, J. F., Denizot, A., Puccini, M., Niccoli, P., Conte-Devolx, B. & de, M. C. (1996) Early diagnosis of  
14 sporadic medullary cancers of the thyroid: value of systematic assay of calcitonin. [French].  
15 *Presse medicale (Paris, France : 1983)*, 25: 1583-1588.  
16 Not in PICO
- 17 Herraiz, M., Barbesino, G., Faquin, W., Chan-Smutko, G., Patel, D., Shannon, K. M., Daniels, G. H. &  
18 Chung, D. C. (2007) Prevalence of thyroid cancer in familial adenomatous polyposis syndrome  
19 and the role of screening ultrasound examinations. *Clinical Gastroenterology & Hepatology*, 5:  
20 367-373.  
21 Not in PICO
- 22 Herrmann, B. L., Schmid, K. W., Goerges, R., Kemen, M. & Mann, K. (2010) Calcitonin screening and  
23 pentagastrin testing: Predictive value for the diagnosis of medullary carcinoma in nodular thyroid  
24 disease. *European Journal of Endocrinology*, 162: 1141-1145.  
25 Not in PICO
- 26 Hobbs, C. & Bova, R. (2010) Neck lumps: A guide to assessment and management. *Medicine Today*,  
27 11: 26-34.  
28 Narrative review
- 29 Holzer, S., Reiners, C., Mann, K., Bamberg, M., Rothmund, M., Dudeck, J., Stewart, A. K. & Hundahl,  
30 S. A. (2000) Patterns of care for patients with primary differentiated carcinoma of the thyroid  
31 gland treated in Germany during 1996. *Cancer*, 89: 192-201.  
32 Not in PICO
- 33 Huang, T. W., Lai, J. H., Wu, M. Y., Chen, S. L., Wu, C. H. & Tam, K. W. (2013) Systematic review of  
34 clinical practice guidelines in the diagnosis and management of thyroid nodules and cancer. *BMC*  
35 *Medicine*, 11: 191.  
36 Not in PICO
- 37 Huong, J., Menezes, J. & Naqvi, S. (2012) Respiratory failure leading to an unexpected diagnosis of  
38 men syndrome. *Journal of Hospital Medicine*, 7: S216.  
39 Not in PICO
- 40 Huszno, B. (1987) Early diagnosis of cancer of the thyroid based on current clinical data. [Polish].  
41 *Endokrynologia Polska*, 38: 49-107.  
42 Not in PICO
- 43 Ilyes, I. (2011) [Current questions of thyroid diseases in childhood]. [Review] [Hungarian]. *Orvosi*  
44 *Hetilap*, 152: 617-627.  
45 Narrative review
- 46 Irani, S., Rashidian, A., Yousefi-Nooraie, R. & Soltani, A. (2011) Evaluating clinical practice guidelines  
47 developed for the management of thyroid nodules and thyroid cancers and assessing the  
48 reliability and validity of the AGREE instrument. *Journal of Evaluation in Clinical Practice*, 17: 729-  
49 736.  
50 Not in PICO

- 1 Isaacs, J. D., Lundgren, C. I., Sidhu, S. B., Sywak, M. S., Edhouse, P. J. & Delbridge, L. W. (2008) The  
2 Delphian lymph node in thyroid cancer. *Annals of Surgery*, 247: 477-482.  
3 Not in PICO
- 4 Ito, K. (1989) [Definition, diagnosis and treatment of thyroid carcinoma at an early stage].  
5 [Japanese]. *Nippon Rinsho - Japanese Journal of Clinical Medicine*, 47: 1147-1151.  
6 Not in PICO/narrative review
- 7 Izikson, L., English III, J. C. & Zirwas, M. J. (2006) The flushing patient: Differential diagnosis, workup,  
8 and treatment. *Journal of the American Academy of Dermatology*, 55: 193-208.  
9 Narrative review
- 10 Jett, J. R. (2010) Mediastinal tumors. *Respirology*, 15: 18.  
11 Narrative review
- 12 Joung, K. H., Park, J. Y., Kim, K. S. & Koo, B. S. (2014) Primary amyloid goiter mimicking rapid growing  
13 thyroid malignancy. *European Archives of Oto-Rhino-Laryngology*, 271: 417-420.  
14 Not in PICO
- 15 Kahn, C., Simonella, L., Sywak, M., Boyages, S., Ung, O. & O'Connell, D. (2012) Pathways to the  
16 diagnosis of thyroid cancer in New South Wales: a population-based cross-sectional study. *Cancer  
17 Causes & Control*, 23: 35-44.  
18 Not in PICO
- 19 Kalvachova, B. (2011) The thyroid gland in primary pediatric care. [Czech]. *Pediatric pro Praxi*, 12: 91-  
20 93.  
21 Narrative review
- 22 Kanakatti Shankar, R., Rutter, M., Chernausek, S., Samuels, P., Mo, J. & Rutter, M. (2012) Medullary  
23 thyroid cancer in a 9-week-old infant with familial MEN 2B: Implications for timing of prophylactic  
24 thyroidectomy. *International Journal of Pediatric Endocrinology*, 2012: 25.  
25 Not in PICO
- 26 Karges, W., Dralle, H., Raue, F., Mann, K., Reiners, C., Grussendorf, M., Hufner, M., Niederle, B. &  
27 Brabant, G. (2004) Calcitonin Measurement to Detect Medullary Thyroid Carcinoma in Nodular  
28 Goiter: German Evidence-Based Consensus Recommendation. *Experimental and Clinical  
29 Endocrinology and Diabetes*, 112: 52-58.  
30 Consensus statement/guideline
- 31 Karges, W. (2010) [Calcitonin determination for early diagnosis of medullary thyroid cancer].  
32 [Review] [German]. *Chirurg*, 81: 620-626.  
33 Narrative review
- 34 Kassum, T. A., Goldstein, D. P., Rafferty, M. A., Rotstein, L. E. & Irish, J. C. (2007) Thyroid scintigraphy  
35 in the assessment of the solitary thyroid nodule: Differences in practice patterns between family  
36 physicians and specialists. *Journal of Otolaryngology*, 36: 49-53.  
37 Not in PICO
- 38 Khachatryan, A. S. (2011) [Problems of early clinical diagnosis of thyroid cancer]. [Russian]. *Georgian  
39 medical news*, 19-23.  
40 Not in PICO
- 41 Khachatryan, A. S. (2012) [Problem of early intra- and preoperative pathomorphologic diagnosis of  
42 thyroid cancer]. [Russian]. *Georgian Medical News*.(202):11-6, 2012 Jan., 11-16.  
43 Not in PICO
- 44 Khachatryan, A. (2012) [Background diseases in thyroid cancer]. [Russian]. *Georgian Medical  
45 News*.(203):7-11, 2012 Feb., 7-11.  
46 Not in PICO
- 47 Khairy, G. A. & Guraya, S. Y. (2004) Primary care evaluation of thyroid disease: Which clinical group  
48 needs urgent surgical referral? *Bahrain Medical Bulletin*, 26: 143-146.  
49 Not in PICO
- 50 Knox, M. A. (2013) Thyroid nodules. *American Family Physician*, 88: 193-196.  
51 Narrative review

- 1 Komminoth, P. (2010) Medullary carcinoma and familial non-medullary thyroid carcinoma: When do  
2 you suspect the thyroid tumor is familiar? *Virchows Archiv*, 457: 129.  
3 Not in PICO
- 4 Koulouri, O., Auldin, M. A., Agarwal, R., Kieffer, V., Robertson, C., Smith, J. F., Levy, M. J. & Howlett,  
5 T. A. (2011) Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary  
6 thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine. *Clinical  
7 Endocrinology*, 74: 744-749.  
8 Not in PICO
- 9 Koutras, D. A. (2001) Thyroid nodules in children and adolescents: consequences in adult life.  
10 [Review] [29 refs]. *Journal of Pediatric Endocrinology*, 14: Suppl-7.  
11 Not in PICO
- 12 Kwak, J. Y., Kim, E. K., Kim, M. J. & Son, E. J. (2009) Significance of sonographic characterization for  
13 managing subcentimeter thyroid nodules. *Acta Radiologica*, 50: 917-923.  
14 Not in PICO
- 15 Kwak, J. Y. & Kim, E. K. (2013) Cancer: Indeterminate thyroid nodules--added testing, added value?  
16 *Nature Reviews Endocrinology*, 9: 321-323.  
17 Not in PICO
- 18 La, G. L., O'Malley, M., Milas, M., Burke, C., Kalady, M., Church, J. & Weiss, S. R. (2011) Uncovering  
19 the hidden risk of thyroid cancer in MYH-associated polyposis. *Familial Cancer*, 10: 719.  
20 Not in PICO
- 21 Lacey, N. A., Jones, A. & Clarke, S. E. (2001) Role of radionuclide imaging in hyperthyroid patients  
22 with no clinical suspicion of nodules. *British Journal of Radiology*, 74: 486-489.  
23 Not in PICO
- 24 Ladenson, P. W. (1996) Optimal laboratory testing for diagnosis and monitoring of thyroid nodules,  
25 goiter, and thyroid cancer. *Clinical Chemistry*, 42: 183-187.  
26 Narrative review
- 27 Langer, M., Maddeddu, G. & Dettori, G. (1980) The problem of cancer diagnosis in thyroid nodules.  
28 [German]. *Schweizerische Medizinische Wochenschrift*, 110: 1411-1414.  
29 Not in PICO
- 30 Leclere, J., Beckers, C., Cussac, J. F., Renan, C. A. & Vielh, P. (1993) Thyroid nodule. [French].  
31 *Medecine Nucleaire*, 17: 191-201.  
32 Narrative review
- 33 Lee, J., Kee, H. N., Woung, Y. C., Soh, E.-Y. & Cheong, S. P. (2008) Clinicopathologic features and  
34 treatment outcomes in differentiated thyroid carcinoma patients with concurrent Graves'  
35 disease. *Journal of Korean Medical Science*, 23: 796-801.  
36 Not in PICO
- 37 Lee, N. C. & Norton, J. A. (2000) Multiple endocrine neoplasia type 2B--genetic basis and clinical  
38 expression. [Review] [59 refs]. *Surgical Oncology*, 9: 111-118.  
39 Narrative review
- 40 Lee, S. M. & Kwak, K. H. (2010) Risk Factors and a Predictive Model for Thyroid Cancer in Korean  
41 Women. *Cancer Nursing*, 33: 310-319.  
42 Narrative review
- 43 Leux, C. & Guenel, P. (2010) Risk factors of thyroid tumors: Role of environmental and occupational  
44 exposures to chemical pollutants. [French]. *Revue d'Epidemiologie et de Sante Publique*, 58: 359-  
45 367.  
46 Narrative review
- 47 Liang, H., Zhong, Y., Luo, Z., Huang, Y., Lin, H., Luo, M., Zhan, S., Xie, K., Ma, Y. & Li, Q. Q. (2010)  
48 Assessment of biomarkers for clinical diagnosis of papillary thyroid carcinoma with distant  
49 metastasis. *International Journal of Biological Markers*, 25: 38-45.  
50 Narrative review

- 1 Liang, H., Zhong, Y., Luo, Z., Huang, Y., Lin, H., Zhan, S., Xie, K. & Li, Q. Q. (2011) Diagnostic value of  
2 16 cellular tumor markers for metastatic thyroid cancer: an immunohistochemical study.  
3 *Anticancer Research*, 31: 3433-3440.  
4 Not in PICO
- 5 Liel, Y. & Fraenkel, N. (2005) Brief report: Use and misuse of thyroid ultrasound in the initial workup  
6 of patients with suspected thyroid problems referred by primary care physicians to an endocrine  
7 clinic. *Journal of General Internal Medicine*, 20: 766-768.  
8 Not in PICO
- 9 Lin, J. D., Chao, T. C., Huang, B. Y., Chen, S. T., Chang, H. Y. & Hsueh, C. (2005) Thyroid cancer in the  
10 thyroid nodules evaluated by ultrasonography and fine-needle aspiration cytology. *Thyroid*, 15:  
11 708-717.  
12 Not in PICO
- 13 Lin, K.-D., Lin, J.-D., Huang, M.-J., Huang, H.-S., Jeng, L.-B. & Ho, Y.-S. (1998) Acute suppurative  
14 thyroiditis and aggressive malignant thyroid tumors: Differences in clinical presentation. *Journal*  
15 *of Surgical Oncology*, 67: 28-32.  
16 Not in PICO
- 17 Lind, P., Igerc, I. & Kohlfurst, S. (2005) [Diagnosis, treatment and follow-up in the case of  
18 differentiated thyroid cancer]. [German]. *Wiener Medizinische Wochenschrift*, 155: 429-435.  
19 Narrative review
- 20 Listewnik, M. H., Birkenfeld, B., Chosia, M., Elbl, B., Niedzialkowska, K. & Sawrymowicz, M. (2010)  
21 The occurrence of malignant thyroid lesions in patients after radioiodine treatment due to benign  
22 thyroid diseases. *Endokrynologia Polska*, 61: 454-457.  
23 Not in PICO
- 24 Listewnik, M. H., Birkenfeld, B., Piwowarska-Bilska, H., Cichon-Bankowska, K., Iglinska-Wagner, L.,  
25 Watrak, W., Smolira, W., Zorga, P., Niedzialkowska, K., Elbl, B. & Sawrymowicz, M. (2010) The  
26 application of SPECT/CT scintigraphy with MIBI-Tc99(m) in the diagnosis of thyroid nodules - a  
27 preliminary report. *Endokrynologia Polska*, 61: 422-426.  
28 Not in PICO
- 29 Listewnik, M. H., Birkenfeld, B., Chosia, M., Elbl, B., Piwowarska-Bilska, H., Zorga, P. &  
30 Niedzialkowska, K. (2011) Thyroid fine-needle aspiration biopsy: which lesions should be biopsied  
31 before 131I therapy? *Annales Academiae Medicae Stetinensis*, 57: 54-58.  
32 Not in PICO
- 33 Little, J. W. (2006) Thyroid disorders. Part III: neoplastic thyroid disease. *Oral Surgery Oral Medicine*  
34 *Oral Pathology Oral Radiology & Endodontics*, 102: 275-280.  
35 Narrative review
- 36 Liu, W., Yang, J., Zhang, Y., Shao, K.-W. & Zhu, C.-S. (2010) The value of calcification in CT  
37 differentiating benign and malignant thyroid lesions. [Chinese]. *Chinese Journal of Radiology*, 44:  
38 147-151.  
39 Not in PICO
- 40 Lowenstein, E. B. & Lowenstein, E. J. (2010) Cutaneous manifestations of endocrine neoplasia.  
41 *Giornale Italiano di Dermatologia e Venereologia*, 145: 229-244.  
42 Narrative review
- 43 Luger, A. (2005) [Schilddrüse und polyendokrinopathien]. [Review] [24 refs] [German]. *Wiener*  
44 *Medizinische Wochenschrift*, 155: 454-457.  
45 Narrative review
- 46 Lyshchik, A., Higashi, T., Asato, R., Tanaka, S., Ito, J., Hiraoka, M., Insana, M. F., Brill, A. B., Saga, T. &  
47 Togashi, K. (2007) Cervical lymph node metastases: Diagnosis at sonoelastography - Initial  
48 experience. *Radiology*, 243: 258-267.  
49 Not in PICO



- 1 Machens, A., Holzhausen, H. J. & Dralle, H. (2005) The prognostic value of primary tumor size in  
2 papillary and follicular thyroid carcinoma - A comparative analysis. *Cancer*, 103: 2269-2273.  
3 Not in PICO
- 4 Machens, A., Hauptmann, S. & Dralle, H. (2008) Referral bias in thyroid cancer surgery: direction and  
5 magnitude. *European Journal of Surgical Oncology*, 34: 556-562.  
6 Not in PICO
- 7 Machens, A. & Dralle, H. (2009) Age disparities in referrals to specialist surgical care for papillary  
8 thyroid cancer. *European Journal of Surgical Oncology*, 35: 1312-1317.  
9 Not in PICO
- 10 Malesevic, M., Mihailovic, J., Vojcic, J. & Popadic, S. (2003) [Early diagnosis, therapy, follow-up and  
11 survival in patients with thyroid malignancies]. [Serbian]. *Acta Chirurgica Iugoslavica*, 50: 177-  
12 183.  
13 Not in PICO/narrative review
- 14 Mallick, U. K., Ball, S., Fenwick, J. D., James, R. A., Johnson, S. J., Kendall-Taylor, P., Lennard, T. W. J.,  
15 Lucraft, H. H., Proud, G., Perros, P., Weightman, D. R. & Douglas, F. (2000) Northern cancer  
16 network guidelines for management of thyroid cancer. *Clinical Oncology*, 12: 373-391.  
17 Guideline
- 18 Mallick, U. K. & Charalambous, H. (2004) Current issues in the management of differentiated thyroid  
19 cancer. [Review] [74 refs]. *Nuclear Medicine Communications*, 25: 873-881.  
20 Not in PICO
- 21 Mallory, S. B. (1995) Cowden syndrome (multiple hamartoma syndrome). [Review] [30 refs].  
22 *Dermatologic Clinics*, 13: 27-31.  
23 Narrative review
- 24 Marcy, P. Y., Thariat, J., Bozec, A., Poissonnet, G., Benisvy, D. & Dassonville, O. (2009) Venous  
25 obstruction of thyroid malignancy origin: the Antoine Lacassagne Institute experience. *World*  
26 *Journal of Surgical Oncology*, 7: 40.  
27 Not in PICO
- 28 Marqusee, E., Benson, C. B., Frates, M. C., Doubilet, P. M., Larsen, P. R., Cibas, E. S. & Mandel, S. J.  
29 (2000) Usefulness of ultrasonography in the management of nodular thyroid disease. *Annals of*  
30 *Internal Medicine*, 133: 696-700.  
31 Not in PICO
- 32 Martinez, I., V, Perez, M. A., Roset, S. L., Sanchez de, T. J., Regas Bech de, C. J. & Marques, G. A.  
33 (1993) [Thyroid cancer in childhood: review of 7 cases]. [Spanish]. *Anales Espanoles de Pediatria*,  
34 38: 229-231.  
35 Not in PICO
- 36 Massol, J., Pazart, L., Aho, S., Strauch, G., Leclere, J. & Durieux, P. (1993) [Management of the thyroid  
37 nodule. Preliminary results of a practice survey of 685 general practitioners and specialists].  
38 [French]. *Annales d'Endocrinologie*, 54: 220-225.  
39 Not in PICO
- 40 Mauny, F., Grandmottet, M., Marquet, G., Floret, N., Crenn, D., Olivier-Koehret, M. & Viel, J.-F.  
41 (2002) Childhood thyroid cancer in the French region of Franche-Comte: Chernobyl impact not  
42 proven. [French]. *Environnement, Risques et Sante*, 1: 283-288.  
43 Not in PICO
- 44 Mazzaferri, E. L. (1999) An overview of the management of papillary and follicular thyroid  
45 carcinoma. [Review] [38 refs]. *Thyroid*, 9: 421-427.  
46 Narrative review
- 47 McTiernan, A., Weiss, N. S. & Daling, J. R. (1987) Incidence of thyroid cancer in women in relation to  
48 known or suspected risk factors for breast cancer. *Cancer Research*, 47: 292-295.  
49 Not in PICO

- 1 Mehanna, H. M., Jain, A., Morton, R. P., Watkinson, J. & Shaha, A. (2009) Investigating the thyroid  
2 nodule. [Review] [25 refs]. *BMJ*, 338: b733.  
3 Narrative review
- 4 Mehrotra, P. K., Mishra, A., Mishra, S. K., Agarwal, G., Agarwal, A. & Verma, A. K. (2011) Medullary  
5 thyroid cancer: clinico-pathological profile and outcome in a tertiary care center in North India.  
6 *World Journal of Surgery*, 35: 1273-1280.  
7 Not in PICO
- 8 Michikawa, T., Inoue, M., Shimazu, T., Sawada, N., Iwasaki, M., Sasazuki, S., Yamaji, T., Tsugane, S. &  
9 Japan Public Health Center-based Prospective Study Group (2012) Seaweed consumption and the  
10 risk of thyroid cancer in women: the Japan Public Health Center-based Prospective Study.  
11 *European Journal of Cancer Prevention*, 21: 254-260.  
12 Not in PICO
- 13 Moonim, M. T. (2012) Thyroid microcarcinoma - Definitions and significance. *Journal of Pathology*,  
14 228: S4.  
15 Narrative review
- 16 Moser, E. (2005) Thyroid diseases in general practice - Impact of nuclear medicine diagnostics and  
17 therapy. [German]. *Zeitschrift fur Allgemeinmedizin*, 81: 109-114.  
18 Narrative review
- 19 Mukasa, K., Noh, J. Y., Kunii, Y., Matsumoto, M., Sato, S., Yasuda, S., Suzuki, M., Ito, K. & Ito, K. (2011)  
20 Prevalence of malignant tumors and adenomatous lesions detected by ultrasonographic  
21 screening in patients with autoimmune thyroid diseases. *Thyroid*, 21: 37-41.  
22 Not in PICO
- 23 Mulla, Z. D. & Margo, C. E. (2000) Primary malignancies of the thyroid: Epidemiologic analysis of the  
24 Florida Cancer Data System registry. *Annals of Epidemiology*, 10: 24-30.  
25 Not in PICO
- 26 Naidoo, J., O'Briain, S., Sheehy, N., Vandenberghe, E., Gilham, C. & O'Mahony, D. (2011) Thyroid  
27 lymphoma presenting as a rapidly expanding neck mass. *Journal of Clinical Oncology*, 29.  
28 Not in PICO
- 29 Natale, F., Tedesco, M. A., Mocerino, R., Rinaldi, G., Tassinario, G., De, S., V, Gregorio, G. & Calabro,  
30 R. (2007) Feasibility, accuracy, and clinical relevance of a rapid thyroid evaluation during carotid  
31 duplex ultrasonography in hypertensive patients. *Journal of Clinical Hypertension*, 9: 518-521.  
32 Not in PICO
- 33 Nguyen, G.-K., Ginsberg, J., Crockford, P. M. & Villanueva, R. R. (1997) Hashimoto's thyroiditis:  
34 Cytodiagnostic accuracy and pitfalls. *Diagnostic Cytopathology*, 16: 531-536.  
35 Not in PICO
- 36 Nicolosi, A., Addis, E., Calo, P. G. & Tarquini, A. (1994) [Hyperthyroidism and cancer of the thyroid].  
37 [Italian]. *Minerva Chirurgica*, 49: 491-495.  
38 Not in PICO
- 39 Nieder, C., Andratschke, N. H., Geinitz, H. & Grosu, A. L. (2012) Use of the Graded Prognostic  
40 Assessment (GPA) score in patients with brain metastases from primary tumours not represented  
41 in the diagnosis-specific GPA studies. *Strahlentherapie und Onkologie*, 188: 692-695.  
42 Not in PICO
- 43 Nys, P., Cordray, J.-P. & Merceron, R.-E. (2009) Etiologic discussion and clinical relevance of thyroid  
44 ultrasonography in subclinical hypothyroidism. A retrospective study in 1845 patients. *Annales  
45 d'Endocrinologie*, 70: 59-63.  
46 Not in PICO (referred)
- 47 Oberwittler, H., Nawroth, P. P., Ziegler, R. & Seibel, M. J. (1998) Clinical presentation of thyroid  
48 carcinomas. [German]. *Tumor Diagnostik und Therapie*, 19: 52-55.  
49 Narrative review
- 50 Oi, N. & Ohi, K. (2013) Comparison of the symptoms of menopause and symptoms of thyroid disease  
51 in Japanese women aged 35-59 years. *Climacteric*, 16: 555-560.

- 1 Not in PICO (population/outcome [e.g., no distinction between benign & malignant thyroid  
2 tumours])
- 3 OlaOlorun, D. A., Meier, D. E. & Tarpley, J. L. (2000) Operative management of thyroid abnormalities  
4 in a general medical practice hospital in sub-Saharan Africa. *Tropical Doctor*, 30: 221-223.  
5 Not in PICO
- 6 Omori, K. (2011) Diagnosis of voice disorders. *Japan Medical Association Journal*, 54: 248-253.  
7 Narrative review
- 8 Orlandi, F., Caraci, P., Mussa, A., Saggiorato, E., Pancani, G. & Angeli, A. (2001) Treatment of  
9 medullary thyroid carcinoma: an update. [Review] [143 refs]. *Endocrine-Related Cancer*, 8: 135-  
10 147.  
11 Narrative review
- 12 Ortiz, R., Hupart, K. H., Defesi, C. R. & Surks, M. I. (1998) Effect of early referral to an endocrinologist  
13 on efficiency and cost of evaluation and development of treatment plan in patients with thyroid  
14 nodules. *The Journal of clinical endocrinology and metabolism*, 83: 3803-7.  
15 Not in PICO
- 16 Ott, J. J., Ullrich, A. & Miller, A. B. (2009) The importance of early symptom recognition in the  
17 context of early detection and cancer survival. *European Journal of Cancer*, 45: 2743-2748.  
18 Narrative review
- 19 Pacini, F., Burrioni, L., Ciuoli, C., Di, C. G. & Guarino, E. (2004) Management of thyroid nodules: a  
20 clinicopathological, evidence-based approach. [Review] [32 refs]. *European Journal of Nuclear  
21 Medicine & Molecular Imaging*, 31: 1443-1449.  
22 Narrative review
- 23 Panigrahi, B., Roman, S. A. & Sosa, J. A. (2010) Medullary thyroid cancer: are practice patterns in the  
24 United States discordant from American Thyroid Association guidelines? *Annals of Surgical  
25 Oncology*, 17: 1490-1498.  
26 Not in PICO
- 27 Parham, M., Aminorroaya, A. & Amini, M. (2009) Prevalence of palpable thyroid nodule in Isfahan,  
28 Iran, 2006: a population based study. *Experimental & Clinical Endocrinology & Diabetes*, 117: 209-  
29 213.  
30 Not in PICO
- 31 Park, K. W., Shin, J. H., Han, B. K., Ko, E. Y. & Chung, J. H. (2011) Inoperable symptomatic recurrent  
32 thyroid cancers: preliminary result of radiofrequency ablation. *Annals of Surgical Oncology*, 18:  
33 2564-2568.  
34 Not in PICO
- 35 Paschke, R., Schmid, K. W., Gartner, R., Mann, K., Dralle, H. & Reiners, C. (2010) [Epidemiology,  
36 pathophysiology, guideline-adjusted diagnostics, and treatment of thyroid nodules]. [German].  
37 *Medizinische Klinik*, 105: 80-87.  
38 Narrative review
- 39 Patel, N. & Vanderpump, M. (2005) Goitres and thyroid carcinoma. *Practitioner*, 249: 574-577.  
40 Narrative review
- 41 Petrone, L. R. (1996) A primary care approach to the adult patient with nodular thyroid disease.  
42 *Archives of Family Medicine*, 5: 92-100.  
43 Narrative review
- 44 Petronella, P., Scorzelli, M., Luise, R., Iannaci, G., Sapere, P., Ferretti, M., Costanzo, R. M. A., Freda,  
45 F., Canonico, S. & Rossiello, R. (2012) Primary thyroid angiosarcoma: an unusual localization.  
46 *World Journal of Surgical Oncology*, 10: 73.  
47 Not in PICO
- 48 Pichon, M. F., Basuyau, J. P., Gory-Delabaere, G., Eche, N., Daver, A., Blanc-Vincent, M. P., Riedinger,  
49 J. M., Deneux, L. & Bidart, J. M. (2001) Standards, Options and Recommendations for tumor  
50 markers in thyroid cancers. *Bulletin du Cancer*, 88: 775-792.  
51 Guideline

- 1 Polyzos, S. A., Kita, M. & Avramidis, A. (2007) Thyroid nodules - stepwise diagnosis and management.  
2 [Review] [227 refs]. *Hormones*, 6: 101-119.  
3 Narrative review
- 4 Popovtzer, A., Shpitzer, T., Bahar, G., Feinmesser, R. & Segal, K. (2006) Thyroid cancer in children:  
5 management and outcome experience of a referral center. *Otolaryngology - Head & Neck*  
6 *Surgery*, 135: 581-584.  
7 Not in PICO
- 8 Puigdevall, V., Serrano, L. & Lapuerta, L. (1997) Acute thyroidal situations in primary care. [Spanish].  
9 *Atencion Primaria*, 20: 148-152.  
10 Narrative review
- 11 Puthenparambil, J., Lechner, K. & Kornek, G. (2010) Autoimmune hemolytic anemia as a  
12 paraneoplastic phenomenon in solid tumors: A critical analysis of 52 cases reported in the  
13 literature. *Wiener Klinische Wochenschrift*, 122: 229-236.  
14 Not in PICO
- 15 Quadbeck, B. & Mann, K. (1998) Malignant struma - Diagnostics of thyroid cancer. [German]. *Tumor*  
16 *Diagnostik und Therapie*, 19: 56-59.  
17 Narrative review
- 18 Quadbeck, B., Pruellage, J., Roggenbuck, U., Hirche, H., Janssen, O. E., Mann, K. & Hoermann, R.  
19 (2002) Long-term follow-up of thyroid nodule growth. *Experimental & Clinical Endocrinology &*  
20 *Diabetes*, 110: 348-354.  
21 Not in PICO
- 22 Rahimi, M., Farshchian, N., Rezaee, E., Shahebrahimi, K. & Madani, H. (2013) To differentiate benign  
23 from malignant thyroid nodule comparison of sonography with FNAC findings. *Pakistan Journal of*  
24 *Medical Sciences*, 29: 77-80.  
25 Not in PICO
- 26 Raijmakers, P. G., Paul, M. A. & Lips, P. (2008) Sentinel node detection in patients with thyroid  
27 carcinoma: a meta-analysis. *World Journal of Surgery*, 32: 1961-1967.  
28 Not in PICO
- 29 Rakover, Y., Dharan, M. & Luboshitsky, R. (1994) Hirschsprung's disease associated with isolated  
30 familial medullary carcinoma of the thyroid. *Journal of Pediatric Endocrinology*, 7: 373-377.  
31 Not in PICO
- 32 Ramschak-Schwarzer, S., Langsteger, W., Wolf, G., Dimai, H. P. & Leb, G. (1997) Management of  
33 suspected malignant nodular goiter in pregnancy. [German]. *Acta Medica Austriaca*, 24: 146-147.  
34 Narrative review
- 35 Ranganathan, B., Thriyayi, S., Yap, B., Loughran, S. & Homer, J. J. (2012) Regional audit on thyroid  
36 cytology reporting. *Clinical Otolaryngology*, 37: 115.  
37 Abstract only, not enough information available to ascertain relevance, but I don't think it is in  
38 PICO
- 39 Re, M., Pepe, M., Orlando, G., Sorcini, G., Clemenzia, G., Canova, R., Falcone, M., Cancrini, A., Gallo,  
40 G. & Russo, G. (1989) Tumour markers in the early diagnosis of thyroid tumours. [Italian].  
41 *Minerva Medica*, 80: 341-343.  
42 Not in PICO
- 43 Redlich, A., Boxberger, N., Kurt, W. S., Fruhwald, M., Rohrer, T. & Vorwerk, P. (2012) Sensitivity of  
44 fine-needle biopsy in detecting pediatric differentiated thyroid carcinoma. *Pediatric Blood &*  
45 *Cancer*, 59: 233-237.  
46 Not in PICO
- 47 Regional Thyroid Cancer Group (2000) Northern Cancer Network guidelines for management of  
48 thyroid cancer. [Review] [155 refs]. *Clinical Oncology (Royal College of Radiologists)*, 12: 373-391.  
49 Guideline
- 50 Reynolds, R. M., Weir, J., Stockton, D. L., Brewster, D. H., Sandeep, T. C. & Strachan, M. W. J. (2005)  
51 Changing trends in incidence and mortality of thyroid cancer in Scotland. *Clinical Endocrinology*,

- 1 62: 156-162.  
2 Not in PICO
- 3 Richards, M. L. (2009) Thyroid cancer genetics: multiple endocrine neoplasia type 2, non-medullary  
4 familial thyroid cancer, and familial syndromes associated with thyroid cancer. [Review] [58 refs].  
5 *Surgical Oncology Clinics of North America*, 18: 39-52.  
6 Narrative review
- 7 Rifat, S. F. & Ruffin, M. T. (1994) Management of thyroid nodules. [Review] [36 refs]. *American*  
8 *Family Physician*, 50: 785-790.  
9 Narrative review
- 10 Rivkees, S. A., Mazzaferri, E. L., Verburg, F. A., Reiners, C., Luster, M., Breuer, C. K., Dinauer, C. A. &  
11 Udelsman, R. (2011) The Treatment of Differentiated Thyroid Cancer in Children: Emphasis on  
12 Surgical Approach and Radioactive Iodine Therapy. *Endocrine Reviews*, 32: 798-826.  
13 Narrative review
- 14 Ron, E., Lubin, E. & Modan, B. (1984) Screening for early detection of radiation-associated thyroid  
15 cancer: a pilot study. *Israel Journal of Medical Sciences*, 20: 1164-1168.  
16 Not in PICO
- 17 Ron, E., Curtis, R., Hoffman, D. A. & Flannery, J. T. (1984) Multiple primary breast and thyroid cancer.  
18 *British Journal of Cancer*, 49: 87-92.  
19 Not in PICO
- 20 Rosen, J. E. & Stone, M. D. (2006) Contemporary diagnostic approach to the thyroid nodule. *Journal*  
21 *of Surgical Oncology*, 94: 649-661.  
22 Narrative review
- 23 Rosenberg, H. K. (2009) Sonography of pediatric neck masses. *Ultrasound Quarterly*, 25: 111-127.  
24 Narrative review
- 25 Rousset, B., Ziercher, L. & Borson-Chazot, F. (2011) Molecular analyses of thyroid tumors for  
26 diagnosis of malignancy on fine-needle aspiration biopsies and for prognosis of invasiveness on  
27 surgical specimens. *Annales d'Endocrinologie*, 72: 125-128.  
28 Not in PICO
- 29 Rubinstein, W. S. (2010) Endocrine cancer predisposition syndromes: hereditary paraganglioma,  
30 multiple endocrine neoplasia type 1, multiple endocrine neoplasia type 2, and hereditary thyroid  
31 cancer. [Review]. *Hematology - Oncology Clinics of North America*, 24: 907-937.  
32 Narrative review
- 33 Rukhman, N. & Silverberg, A. (2011) Thyroid cancer in older men. [Review]. *Aging Male*, 14: 91-98.  
34 Narrative review
- 35 Sadetzki, S., Calderon-Margalit, R., Peretz, C., Novikov, I., Barchana, M. & Papa, M. Z. (2003) Second  
36 primary breast and thyroid cancers (Israel). *Cancer Causes and Control*, 14: 367-375.  
37 Not in PICO
- 38 Sahin, T. T., Yuksel, O., Girgin, G., Sipahi, H., Dikmen, K., Azili, C., Taneri, F. & Baydar, T. (2009) Is  
39 neopterin level a predictive and differential biomarker in patients with thyroid disorders? *Journal*  
40 *of Endocrinological Investigation*, 32: 147-149.  
41 Not in PICO
- 42 Saller, B., Moeller, L., Gorges, R., Janssen, O. E. & Mann, K. (2002) Role of conventional ultrasound  
43 and color Doppler sonography in the diagnosis of medullary thyroid carcinoma. *Experimental and*  
44 *Clinical Endocrinology and Diabetes*, 110: 403-407.  
45 Not in PICO
- 46 Sarac, F., Savas, S., Yalcin, M. A. & Akcicek, F. (2011) Thyroid nodules in patients with adrenal  
47 incidentaloma. *European Geriatric Medicine*, 2: S102.  
48 Not in PICO
- 49 Schmid, K. W. & Reiners, C. (2011) [When is thyroid fine-needle biopsy most effective?]. [German].  
50 *Pathologe*, 32: 169-172.  
51 Narrative review

- 1 Schmidt, M. & Schicha, H. (2011) [Thyroid disorders]. [German]. *Versicherungsmedizin /*  
2 *herausgegeben von Verband der Lebensversicherungs-Unternehmen e, und: 176-179.*  
3 Narrative review
- 4 Schroder, S. & Bocker, W. (1983) [Early cancer of the thyroid. Subclassification of 268 differentiated  
5 thyroid cancers]. [German]. *Pathologe, 4: 225-234.*  
6 Not in PICO
- 7 Sebastian-Ochoa, N., Fernandez-Garcia, J. C., Mancha, D., I, Sebastian-Ochoa, A., Fernandez, G. D.,  
8 Ortega Jimenez, M. V., Gallego, D. E. & Tinahones, M. F. (2011) [Clinical experience in a high-  
9 resolution thyroid nodule clinic]. [Spanish]. *Endocrinologia y Nutricion, 58: 409-415.*  
10 Not in PICO
- 11 Serra, M., Mendez, M. A., Davins, J., Borrell, M., Baxarias, J. & Rios, L. (1995) Thyroid pathology in a  
12 health center. [Spanish]. *Atencion primaria / Sociedad Espanola de Medicina de Familia y*  
13 *Comunitaria, 15: 457-460.*  
14 Not in PICO
- 15 Sherman, S. I. (2003) Thyroid carcinoma. *Lancet, 361: 501-511.*  
16 Narrative review
- 17 Shinozaki, N., Sakamoto, A., Kasai, N., Uchida, M. & Sakurai, K. (1983) [Multiple primary malignancies  
18 associated with thyroid cancer]. [Japanese]. *Gan No Rinsho - Japanese Journal of Cancer Clinics,*  
19 *29: 1385-1391.*  
20 Not in PICO
- 21 Siegmund, T., Scholz, I. & Schumm-Draeger, P. M. (2004) [How to treat benign thyroid gland  
22 nodules]. [German]. *MMW Fortschritte der Medizin, 146: 24-27.*  
23 Narrative review
- 24 Silver, C. E., Brauer, R. J. & Schreiber, K. (1984) Cytologic evaluation of thyroid nodules: New criteria  
25 for surgery. *New York State Journal of Medicine, 84: 109-112.*  
26 Narrative review
- 27 Singer, P. A., Cooper, D. S., Daniels, G. H., Ladenson, P. W., Greenspan, F. S., Levy, E. G., Braverman,  
28 L. E., Clark, O. H., McDougall, I. R., Ain, K. V. & Dorfman, S. G. (1996) Treatment guidelines for  
29 patients with thyroid nodules and well-differentiated thyroid cancer. *Archives of Internal*  
30 *Medicine, 156: 2165-2172.*  
31 Guideline
- 32 Sipos, J. A. & Mazzaferri, E. L. (2008) The therapeutic management of differentiated thyroid cancer.  
33 *Expert Opinion on Pharmacotherapy, 9: 2627-2637.*  
34 Narrative review
- 35 Sippel, R. S., Kunnimalaiyaan, M. & Chen, H. (2008) Current management of medullary thyroid  
36 cancer. *The Oncologist, 13: 539-547.*  
37 Narrative review
- 38 Smellie, W. S. A., Vanderpump, M. P. J., Fraser, W. D., Bowley, R. & Shaw, N. (2008) Best practice in  
39 primary care pathology: Review 11. *Journal of Clinical Pathology, 61: 410-418.*  
40 Narrative review
- 41 Smith, L. H. & Oi, R. H. (1984) Detection of malignant ovarian neoplasms: a review of the literature. I.  
42 Detection of the patient at risk; clinical, radiological and cytological detection. [Review] [205  
43 refs]. *Obstetrical & Gynecological Survey, 39: 313-328.*  
44 Not in PICO
- 45 Sogol, P. B., Sugawara, M., Gordon, H. E., Shellow, W. V., Hernandez, F. & Hershman, J. M. (1983)  
46 Cowden's disease: familial goiter and skin hamartomas. A report of three cases. *Western Journal*  
47 *of Medicine, 139: 324-328.*  
48 Not in PICO
- 49 Soh, E. Y. & Park, C. S. (1993) Diagnostic approach to thyroid carcinoma in Graves' disease. *Yonsei*  
50 *Medical Journal, 34: 191-194.*  
51 Not in PICO

- 1 Stevenson, J. C., Hillyard, C. J., Spanos, E., MacIntyre, I., Ackroyd, N., Lynn, J., Brown, M. J. &  
2 Stevenson, B. M. (1981) Sipple syndrome: marked variability of the disease within a family and  
3 implications for management. *Postgraduate Medical Journal*, 57: 104-108.  
4 Not in PICO
- 5 Stiefelhagen, P. (2001) [Thyroid gland diseases. The etiology of many symptoms]. [German]. *MMW*  
6 *Fortschritte der Medizin*, 143: Suppl-86.  
7 Narrative review
- 8 Stojadinovic, A., Peoples, G., Libutti, S., Henry, L., Eberhardt, J., Howard, R., Gur, D., Elster, E. &  
9 Nissan, A. (2009) Development of a clinical decision model for thyroid nodules. *BMC Surgery*, 9:  
10 12.  
11 Not in PICO
- 12 Suehiro, F. (2006) Thyroid cancer detected by mass screening over a period of 16 years at a health  
13 care center in Japan. *Surgery Today*, 36: 947-953.  
14 Not in PICO
- 15 Sultana, N., March, Z. & Trousdale, R. (2012) Prevalence of thyroid cancer in minority patients with  
16 thyroid nodules at an urban inner city hospital. *Endocrine Reviews*, 33.  
17 Not in PICO
- 18 Svinaryov, M. & Aranovich, V. (2003) Iodine deficiency disorders in the Saratov province in Russia.  
19 *Journal of Endocrinological Investigation*, 26: Suppl-9.  
20 Not in PICO
- 21 Szybinski, P. & Nowak, W. (2001) [Thyroid carcinoma--contemporary diagnostic principles and  
22 treatment]. [Review] [22 refs] [Polish]. *Przegląd Lekarski*, 58: 809-813.  
23 Narrative review
- 24 Tamiolakis, D., Tsamis, I., Thomaidis, V., Lambropoulou, M., Alexiadis, G., Venizelos, I., Jivanakis, T. &  
25 Papadopoulou, N. (2007) Oral complaints caused from metastases to the mandible and maxilla.  
26 *Chirurgia (Bucharest, Romania : 1990)*, 102: 439-442.  
27 Not in PICO
- 28 Telander, R. L., Zimmerman, D., Sizemore, G. W., van Heerden, J. A. & Grant, C. S. (1989) Medullary  
29 carcinoma in children. Results of early detection and surgery. *Archives of Surgery*, 124: 841-843.  
30 Not in PICO
- 31 Terris, D. J., Anderson, S. K., Seybt, M. W. & Gourin, C. G. (2008) Findings from a public thyroid  
32 screening protocol: ultrasound and disease characteristics. *Orl; Journal of Oto-Rhino-Laryngology*  
33 *& its Related Specialties*, 70: 335-337.  
34 Not in PICO
- 35 Todd, C. H. (2009) Management of thyroid disorders in primary care: Challenges and controversies.  
36 *Postgraduate Medical Journal*, 85: 655-659.  
37 Narrative review
- 38 Tonjes, A. & Paschke, R. (573) [Diagnosis and therapy of thyroid nodules]. [Review] [22 refs]  
39 [German]. *Internist*, 46: 565-572.  
40 Narrative review
- 41 Tranquart, F., Bleuzen, A., Pierre-Renault, P., Chabrolle, C., Sam, G. M. & Lecomte, P. (2008)  
42 [Elastosonography of thyroid lesions]. [French]. *Journal de Radiologie*, 89: t-9.  
43 Not in PICO
- 44 Tuttle, R. M. & Fagin, J. A. (100) Can risk-adapted treatment recommendations replace the 'one size  
45 fits all' approach for early-stage thyroid cancer patients? *Oncology (Williston Park)*, 23: 592.  
46 Not in PICO
- 47 Tuttle, R. M., Vaisman, F. & Tronko, M. D. (2011) Clinical presentation and clinical outcomes in  
48 Chernobyl-related paediatric thyroid cancers: what do we know now? What can we expect in the  
49 future?. [Review]. *Clinical Oncology (Royal College of Radiologists)*, 23: 268-275.  
50 Narrative review

- 1 Upile, T., Jerjes, W., Mahil, J., Tailor, H., Balakumar, R., Rao, A., Qureshi, Y., Bowman, I. &  
2 Mukhopadhyay, S. (2011) How to do it: the difficult thyroid. *Head & Neck Oncology*, 3: 54.  
3 Narrative review
- 4 Vaisman, F., Bulzico, D. A., Pessoa, C. H. C. N., Bordallo, M. A. N., de Mendonca, U. B. T., Dias, F. L.,  
5 Coeli, C. M., Corbo, R. & Vaisman, M. (2011) Prognostic factors of a good response to initial  
6 therapy in children and adolescents with differentiated thyroid cancer. *Clinics*, 66: 281-286.  
7 Not in PICO
- 8 Valeri, R., Chatzis, O., Mygdakos, N., Sioutopoulou, D., Makrantonakis, P., Angel, I., Pazaitou, K. &  
9 Destouni, C. (2011) Occurrence of second primary malignancies in patients with thyroid cancer.  
10 *Cytopathology*, 22: 108.  
11 Not in PICO
- 12 Van den Brink, J. L., De Herder, W. W., Bonjer, H. J. & Poulblon, R. M. L. (2000) Palpable thyroid  
13 nodules; a diagnostic protocol for otolaryngologists. [Dutch]. *Nederlands Tijdschrift voor Keel-  
14 Neus- Oorheelkunde*, 6: 101-106.  
15 Not in PICO
- 16 Van den Bruel, A., Moreno-Reyes, R., Bex, M., Daumerie, C. & Glinoyer, D. (2008) Is the management  
17 of thyroid nodules and differentiated thyroid cancer in accordance with recent consensus  
18 guidelines? - Results of a national survey. *Clinical Endocrinology*, 68: 599-604.  
19 Not in PICO
- 20 van, L. J., Wessels, P., van, R. E., Boer, A. M., Wiersma, A., Goudswaard, A. N. & Nederlands, H. G.  
21 (2007) [Summary of the practice guideline 'Thyroid disorders' (first revision) from the Dutch  
22 College of General Practitioners]. [Dutch]. *Nederlands Tijdschrift Voor Geneeskunde*, 151: 2829-  
23 2832.  
24 Guideline
- 25 Vidal-Trecan, G. M., Pazart, L. H. & Massol, J. A. (1999) A method for guideline development:  
26 assessing practical feasibility and adaptation of thyroid nodule guidelines. *Journal of Evaluation in  
27 Clinical Practice*, 5: 189-198.  
28 Not in PICO
- 29 Vitale, G., Tagliaferri, P., Caraglia, M., Rampone, E., Ciccarelli, A., Bianco, A. R., Abbruzzese, A. &  
30 Lupoli, G. (2000) Slow release lanreotide in combination with interferon-alpha2b in the treatment  
31 of symptomatic advanced medullary thyroid carcinoma. *Journal of Clinical Endocrinology and  
32 Metabolism*, 85: 983-988.  
33 Not in PICO
- 34 von der Weid, N. X. (2008) Adult life after surviving lymphoma in childhood. [Review] [41 refs].  
35 *Supportive Care in Cancer*, 16: 339-345.  
36 Narrative review
- 37 Voronetskii, I. B. & Varshavskii, I. (1989) [Standardization of diagnostic studies in thyroid diseases].  
38 [Russian]. *Meditssinskaia Radiologija*, 34: 16-20.  
39 Narrative review
- 40 Wade, H. (1980) The treatment and preoperative diagnosis of differentiated thyroid carcinoma  
41 presenting as a clinically solitary nodule. *British Journal of Surgery*, 67: 728-731.  
42 Narrative review
- 43 Wakasugi-Sato, N., Wakasugi, T., Oda, M., Yamashita, Y., Yoshioka, I., Yamamoto, N., Habu, M.,  
44 Kodama, M., Kokuryo, S., Ichimiya, H., Miyamoto, I., Tanaka, T., Kito, S., Matsumoto-Takeda, S.,  
45 Ishikawa, A., Seta, Y., Matsuo, K., Takahashi, T., Tominaga, K. & Morimoto, Y. (2010) Clinical  
46 significance of ultrasonographic examination including detection of thyroid gland diseases when  
47 surveying cervical lymph nodes in subjects with oral squamous cell carcinoma. *Oral Surgery Oral  
48 Medicine Oral Pathology Oral Radiology & Endodontics*, 109: e78-e85.  
49 Not in PICO



1 Wanis, K., Oucharek, J. & Groot, G. (2013) Quality of thyroid referrals in Saskatchewan. *Quality in*  
 2 *Primary Care*, 21: 247-252.  
 3 Not in PICO

4 Wasko, R., Michalek, K., Pacholska, J., Obrepalska-Stepiowska, A., Gozdicka-Jozefiak, A. & Sowinski,  
 5 J. (2005) Clinical significance of the insulin-like growth factor I gene promoter (P1) polymorphism  
 6 in thyroid nodular disease. *Neuroendocrinology Letters*, 26: 699-703.  
 7 Not in PICO

8 Watkinson, J. C. & British Thyroid Association (2004) The British Thyroid Association guidelines for  
 9 the management of thyroid cancer in adults. *Nuclear Medicine Communications*, 25: 897-900.  
 10 Guideline

11 Watkinson, J. C., Franklyn, J. A. & Olliff, J. F. (2006) Detection and surgical treatment of cervical  
 12 lymph nodes in differentiated thyroid cancer. *Thyroid*, 16: 187-194.  
 13 Narrative review

14 Weinrib, S. L., Lane, W. S. & Rappaport, J. M. (2012) Successful Management of Differentiated  
 15 Thyroid Cancer in A Community-Based Endocrine Practice. *Endocrine Practice*, 18: 170-178.  
 16 Not in PICO

17 Weiss, R. E. & Lado-Abeal, J. (2002) Thyroid nodules: diagnosis and therapy. *Current Opinion in*  
 18 *Oncology*, 14: 46-52.  
 19 Narrative review

20 Welkenhuysen, M. & Evers-Kiebooms, G. (2002) General practitioners and predictive genetic testing  
 21 for late-onset diseases in Flanders: what are their opinions and do they want to be involved?  
 22 *Community Genetics*, 5: 128-137.  
 23 Not in PICO

24 Wellhoner, P. (2011) Endocrine disorders and the gastrointestinal tract : What consequences are  
 25 possible?. [German]. *Gastroenterologe*, 6: 285-291.  
 26 Narrative review

27 Wemeau, J. L. & Do, C. C. (2002) [Thyroid nodule, cancer and pregnancy]. [Review] [32 refs] [French].  
 28 *Annales d Endocrinologie*, 63: 438-442.  
 29 Narrative review

30 Wojciechowski, B. & Kusmann, J. (2013) Thyroid nodules as secondary finding. *Langenbeck's Archives*  
 31 *of Surgery*, 398: 1019.  
 32 Not in PICO

33 Wu, S. Y. & Weiss, R. E. (2006) Radioiodine imaging in the primary care of thyroid disease.  
 34 *Postgraduate Medicine*, 119: 70-77.  
 35 Narrative review

36 Wygoda, A., Wygoda, Z., Jarzab, B. & Skladowski, K. (2004) Parathyroid cancer - Differential diagnosis  
 37 difficulties and therapeutic problems. [Polish]. *Nowotwory*, 54: 377-383.  
 38 Narrative review

39 Zhang, L., Wei, W. J., Ji, Q. H., Zhu, Y. X., Wang, Z. Y., Wang, Y., Huang, C. P., Shen, Q., Li, D. S. & Wu,  
 40 Y. (2012) Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Microcarcinoma: A Study of  
 41 1066 Patients. *Journal of Clinical Endocrinology & Metabolism*, 97: 1250-1257.  
 42 Not in PICO

44 **Review question:**  
 45 Which investigations of symptoms of suspected thyroid cancer should be done with clinical  
 46 responsibility retained by primary care?

47  
 48 **Results**

49 **Literature search**

Database name	Dates Covered	No of references	No of references	Finish date of
---------------	---------------	------------------	------------------	----------------


		found	retrieved	search
<i>Medline</i>	1980-2013	545	118	16/05/2013
<i>Premedline</i>	1980-2013	53	9	16/05/2013
<i>Embase</i>	1980-2013	770	150	17/05/2013
<i>Cochrane Library</i>	1980-2013	70	13	20/05/2013
<i>Psychinfo</i>	1980-2013	2	1	16/05/2013
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	1980-2013	65	12	20/05/2013

1 Total References retrieved (after de-duplication): 205

2  
3 **Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	5/2013-27/08/2014	16	5	27/08/2014
<i>Premedline</i>	5/2013-27/08/2014	48	10	27/08/2014
<i>Embase</i>	5/2013-27/08/2014	47	8	27/08/2014
<i>Cochrane Library</i>	5/2013-27/08/2014	3	1	27/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	5/2013-27/08/2014	13	1	27/08/2014

4 Total References retrieved (after de-duplication): 22



5  
6  
7 **Study results**

8 No evidence was identified pertaining to the diagnostic accuracy of ultrasound, thyroid function  
9 tests, or fine needle aspiration in patients with suspected thyroid cancer where the clinical  
10 responsibility was retained by primary care.

**References****Included studies**

None

**Excluded studies (with excl reason)**

Acharya, U. R., Faust, O., Sree, S. V., Molinari, F., Garberoglio, R. & Suri, J. S. (2011) Cost-effective and non-invasive automated benign & malignant thyroid lesion classification in 3D contrast-enhanced ultrasound using combination of wavelets and textures: A class of thyroscan algorithms. *Technology in Cancer Research and Treatment*, 10: 371-380.

Reference test not in PICO

Acharya, U. R., Faust, O., Sree, S. V., Molinari, F. & Suri, J. S. (2012) ThyroScreen system: high resolution ultrasound thyroid image characterization into benign and malignant classes using novel combination of texture and discrete wavelet transform. *Computer Methods & Programs in Biomedicine*, 107: 233-241.

Population not in PICO

Aksu, O., Koroglu, B. K., Ersoy, I. H., Koroglu, M., Ciris, M., Ersoy, S. & Tamer, M. N. (2014) Thyroid fine needle aspiration biopsy: Which method should be preferred in an endemic goiter region? *Acta Medica Mediterranea*, 30: 297-301.

Not in PICO (secondary care)

Al-Qasabi, Q. O. (1999) The role of fine needle aspiration biopsy and frozen section in the management of nodular thyroid lesions. *Saudi Medical Journal*, 20: 258-262.

Population not in PICO

Allen, M., Sapinho, I., Raposo, L. & Torrinha, J. (2008) [Cyto-histological correlation of malignant thyroid nodules: clinical factors as predictors of malignancy]. [Portuguese]. *Acta Medica Portuguesa*, 21: 135-140.

Population not in PICO

Alonso, N., Lucas, A., Salinas, I., Castella, E. & Sanmarti, A. (2003) Frozen section in a cytological diagnosis of thyroid follicular neoplasm. *Laryngoscope*, 113: 563-566.

Population not in PICO

Altavilla, G., Pascale, M. & Nenci, I. (1990) Fine needle aspiration cytology of thyroid gland diseases. *Acta Cytologica*, 34: 251-256.

Population not in PICO

Alter, C. A. & Moshang, T., Jr. (1991) Diagnostic dilemma. The goiter. [Review] [31 refs]. *Pediatric Clinics of North America*, 38: 567-578.

Narrative review

Anne, S., Teot, L. A. & Mandell, D. L. (2008) Fine needle aspiration biopsy: role in diagnosis of pediatric head and neck masses. *International Journal of Pediatric Otorhinolaryngology*, 72: 1547-1553.

Population not in PICO

Appetecchia, M., Bacaro, D., Brigida, R., Milardi, D., Bianchi, A. & Solivetti, F. (2006) Second generation ultrasonographic contrast agents in the diagnosis of neoplastic thyroid nodules. *Journal of Experimental & Clinical Cancer Research*, 25: 325-330.

Population not in PICO

Aron, M., Kapila, K. & Verma, K. (2006) Role of fine-needle aspiration cytology in the diagnosis of secondary tumors of the thyroid - twenty years' experience. *Diagnostic Cytopathology*, 34: 240-245.

Population not in PICO

Aversa, S., Pivano, G., Vergano, R., Mussa, A., Gonzatto, I., Ondolo, C. & Orlandi, F. (1999) [The accuracy of the fine needle aspiration biopsy in 1250 thyroid nodules]. [Italian]. *Acta*

- 1 *Otorhinolaryngologica Italica*, 19: 260-264.  
 2 Population not in PICO
- 3 Aversa, S., Pivano, G., Vergano, R., Mussa, A., Gonzatto, I., Ondolo, C. & Orlandi, F. (1999) The  
 4 accuracy of the fine needle aspiration biopsy in 1250 thyroid nodules. [Italian]. *Acta*  
 5 *otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e*  
 6 *chirurgia cervico-facciale*, 19: 260-264.  
 7 Duplicate
- 8 Avetis'ian, I. L., Iarovoi, A. O. & Gul'chii, N. V. (1999) Guided fine-needle biopsy of thyroid nodular  
 9 formations in the early diagnosis of thyroid carcinoma. [Russian]. *Likars'ka sprava / Ministerstvo*  
 10 *okhorony zdorov'ia Ukrainy*, 106-110.  
 11 Paper in Russian with English abstract. Unable to translate the whole paper, but from abstract  
 12 appear to be in secondary care
- 13 Babcock, D. S. (372) Thyroid disease in the pediatric patient: emphasizing imaging with sonography.  
 14 [Review] [26 refs]. *Pediatric Radiology*, 36: 299-308.  
 15 Narrative review
- 16 Bajaj, J., Morgenstern, N., Sugrue, C., Wasserman, J. & Wasserman, P. (2012) Clinical impact of  
 17 second opinion in thyroid fine needle aspiration cytology (FNAC): A study of 922 interinstitutional  
 18 consultations. *Diagnostic Cytopathology*, 40: 422-429.  
 19 Reference test not in PICO
- 20 Bal'ter, S. A., Paches, A. I., Anokhin, B. M., Mironova, G. T. & Chubarova, N. V. (1989) [Ultrasonic  
 21 tomography in the diagnosis of diseases of the thyroid gland]. [Russian]. *Voprosy Onkologii*, 35:  
 22 920-924.  
 23 Narrative review
- 24 Bannas, P., Derlin, T., Groth, M., Apostolova, I., Adam, G., Mester, J. & Klutmann, S. (2012) Can (18)F-  
 25 FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and  
 26 elevated thyroglobulin levels but negative I-131 whole body scan? *Annals of Nuclear Medicine*,  
 27 26: 77-85.  
 28 Population not in PICO
- 29 Bartolazzi, A., Bellotti, C. & Sciacchitano, S. (2012) Methodology and technical requirements of the  
 30 galectin-3 test for the preoperative characterization of thyroid nodules. *Applied*  
 31 *Immunohistochemistry and Molecular Morphology*, 20: 2-7.  
 32 Narrative review
- 33 Bartos, M., Pomorski, L. & Narebski, J. (2000) The diagnosis and operative treatment of solitary  
 34 thyroid nodule: a prospective study. [Polish]. *Wiadomosci lekarskie (Warsaw, Poland : 1960)*, 53:  
 35 134-141.  
 36 Population not in PICO
- 37 Basharat, R., Bukhari, M. H., Saeed, S. & Hamid, T. (2011) Comparison of fine needle aspiration  
 38 cytology and thyroid scan in solitary thyroid nodule. *Pathology Research International*, 2011:  
 39 754041.  
 40 Population not in PICO
- 41 Baskin, H. J. (2004) New applications of thyroid and parathyroid ultrasound. [Review] [50 refs].  
 42 *Minerva Endocrinologica*, 29: 195-206.  
 43 Narrative review
- 44 Behnia, M. & Gharib, H. (1996) Primary care diagnosis of thyroid disease. *Hospital Practice*, 31: 121-  
 45 134.  
 46 Narrative review
- 47 Block, M. A. (1987) Diagnosis and management of carcinoma of the thyroid. *Comprehensive Therapy*,  
 48 13: 48-56.  
 49 Narrative review
- 50 Boi, F., Lai, M. L., Deias, C., Piga, M., Serra, A., Uccheddu, A., Faa, G. & Mariotti, S. (2003) The  
 51 usefulness of 99mTc-SestaMIBI scan in the diagnostic evaluation of thyroid nodules with

- 1 oncocytic cytology. *European Journal of Endocrinology*, 149: 493-498.  
 2 Population not in PICO
- 3 Boigon, M. & Moyer, D. (1977) Solitary thyroid nodules. Separating benign from malignant  
 4 conditions. [Review] [14 refs]. *Postgraduate Medicine*, 98: 73-74.  
 5 Narrative review
- 6 Brake, M. K., Bartlett, C., Hart, R. D., Trites, J. R. B. & Taylor, S. M. (2011) Complementary and  
 7 alternative medicine use in the thyroid patients of a head and neck practice. *Otolaryngology -  
 8 Head and Neck Surgery*, 145: 208-212.  
 9 Test not in PICO
- 10 Bravis, V., Lingam, R., Haroon, M. & Devendra, D. (2009) Access to thyroid ultrasound: Audit of  
 11 clinical efficiency & governance of the rapid access one-stop thyroid ultrasound FNA clinic.  
 12 *Endocrine Abstracts*, 19: 395.  
 13 Reference test not in PICO
- 14 Brennan, M. & French, J. (2007) Thyroid lumps and bumps. *Australian Family Physician*, 36: 531-536.  
 15 Narrative review
- 16 Breslin, M., Lawrance, J. A., Desai, M., Ryder, W. D. & Allan, E. (2004) The role of ultrasound-guided  
 17 fine-needle aspiration biopsy in the previously treated patient with thyroid cancer. *Clinical  
 18 Otolaryngology & Allied Sciences*, 29: 146-148.  
 19 Population not in PICO
- 20 Briggs, J. C., A'amar, O., Bigio, I., Rosen, J. E., Lee, S. L., Sharon, A. & Sauer-Budge, A. F. (2014)  
 21 Integrated Device for in Vivo Fine Needle Aspiration Biopsy and Elastic Scattering Spectroscopy in  
 22 Preoperative Thyroid Nodules. *Journal of Medical Devices-Transactions of the Asme*, 8.  
 23 Not in PICO
- 24 Brougham, K., Nixon, F., Maurice, Y., Clark, A. H. & Srinivasan, V. (2011) A correlation review of  
 25 diagnostic modalities for assessing thyroid nodules. *Journal of Pathology*, 224: S32.  
 26 Case series
- 27 Brown, R. L., de Souza, J. A. & Cohen, E. E. W. (2011) Thyroid cancer: Burden of illness and  
 28 management of disease. *Journal of Cancer*, 2: 193-199.  
 29 Narrative review
- 30 Brunese, L., Romeo, A., Iorio, S., Napolitano, G., Fucili, S., Zeppa, P., Vallone, G., Lombardi, G.,  
 31 Bellastella, A., Biondi, B. & Sodano, A. (2008) Thyroid B-flow twinkling sign: a new feature of  
 32 papillary cancer. *European Journal of Endocrinology / European Federation of Endocrine Societies*,  
 33 159: 447-451.  
 34 Population not in PICO
- 35 Brychta, I., Dropco, I., Stencl, J. & Danis, D. (2002) Diagnostic reliability of aspiration biopsy and  
 36 peroperative histology in thyroid gland carcinoma. [Slovak]. *Lekarsky Obzor*, 51: 173-175.  
 37 Population not in PICO
- 38 Buitrago, R. F., Saenz de Santamaria, M. J. & Moreno, C. J. (1989) [Cytological diagnosis of thyroid  
 39 nodules by fine needle aspiration. A study of 385 cases from primary care]. [Spanish]. *Atencion  
 40 Primaria*, 6: 714-718.  
 41 Reference test not in PICO
- 42 Cairncross, L. & Panieri, E. (2013) Pre-operative diagnosis of thyroid cancer: Clinical, radiological and  
 43 pathological correlation. *South African Journal of Surgery*, 51: 46-49.  
 44 Not in PICO
- 45 Cakir, M., Celik, E., Tuncer, F. B. & Tekin, A. (2013) A rare coexistence of thyroid lymphoma with  
 46 papillary thyroid carcinoma. *Annals of African Medicine*, 12: 188-190.  
 47 Not in PICO
- 48 Can, A. S. & Peker, K. (2008) Comparison of palpation-versus ultrasound-guided fine-needle  
 49 aspiration biopsies in the evaluation of thyroid nodules. *BMC Research Notes*, 1: 12.  
 50 Population not in PICO

- 1 Caplan, R. H., Wester, S. M., Lambert, P. J. & Rooney, B. L. (2000) Efficient evaluation of thyroid  
2 nodules by primary care providers and thyroid specialists. *American Journal of Managed Care*, 6:  
3 1134-1140.  
4 Reference test not in PICO
- 5 Caplan, R. H. (2001) Evaluation of palpable thyroid nodules: Are endocrinologists assessing patients  
6 efficiently? *Endocrinologist*, 11: 321-326.  
7 Test not in PICO
- 8 Cappelli, C., Tironi, A., Mattanza, C., Cumetti, D., Agosti, B., Gandossi, E., Pirola, I., Martino, E.,  
9 Cherubini, L., Micheletti, L., Castellano, M. & Agabiti, R. E. (2005) Cost-effectiveness of fine-  
10 needle-aspiration cytology of thyroid nodules with intranodular vascular pattern using two  
11 different needle types (Structured abstract). *Endocrine Pathology*, 16: 349-354.  
12 Population not in PICO
- 13 Cappelli, C., Castellano, M., Pirola, I., Gandossi, E., De, M. E., Cumetti, D., Agosti, B. & Rosei, E. A.  
14 (2006) Thyroid nodule shape suggests malignancy. *European Journal of Endocrinology*, 155: 27-  
15 31.  
16 Population not in PICO
- 17 Carpi, A., Ferrari, E., De, G. C., Sagripanti, A., Nicolini, A. & Di, C. G. (1994) The value of aspiration  
18 needle biopsy in evaluating thyroid nodules. *Thyroidology*, 6: 5-9.  
19 Population not in PICO
- 20 Carpi, A., Nicolini, A., Sagripanti, A., Righi, C., Menchini, F. F. & Di, C. G. (2000) Large-needle  
21 aspiration biopsy for the preoperative selection of palpable thyroid nodules diagnosed by fine-  
22 needle aspiration as a microfollicular nodule or suspected cancer. *American Journal of Clinical  
23 Pathology*, 113: 872-877.  
24 Population not in PICO
- 25 Carpi, A., Nicolini, A., Sagripanti, A., Menchini, F. F., Righi, C., Romani, R. & Di, C. G. (2002) Large-  
26 needle aspiration biopsy for the preoperative selection of follicular adenoma diagnosed by fine-  
27 needle aspiration as a microfollicular nodule or suspected cancer. *American Journal of Clinical  
28 Oncology: Cancer Clinical Trials*, 25: 209-212.  
29 Population not in PICO
- 30 Carpi, A., Rossi, G., Mechanick, J. I., Nicolini, A., Camici, M., Russo, M. A. & Di, C. G. (2011) Large  
31 needle aspiration biopsy histology for preoperative selection of Hurthle cell thyroid nodules.  
32 *Histopathology*, 59: 892-896.  
33 Population not in PICO
- 34 Castells, I., Pardo, N., Videla, S., Gimenez, G., Llargues, E., Simo, O., Recasens, M. A., Guirao, X., Mira,  
35 X., Serrano, A. & Sanmarti, A. (2013) [Healthcare impact of introduction of thyroid ultrasound in a  
36 thyroid nodule pathology unit]. [Spanish]. *Endocrinologia y Nutricion*, 60: 53-59.  
37 Reference test not in PICO
- 38 Castro, M. R. & Gharib, H. (2000) Thyroid nodules and cancer. *Postgraduate Medicine*, 107: 113-124.  
39 Narrative review
- 40 Castro, M. R. & Gharib, H. (2005) Continuing controversies in the management of thyroid nodules.  
41 [Review] [79 refs]. *Annals of Internal Medicine*, 142: 926-931.  
42 Narrative review
- 43 Cattaneo, F., Burgi, U. & Mueller, B. (1999) [Goiter and nodular thyroid disease: clinical guidelines for  
44 diagnosis and treatment. (Waiting? Hormone therapy? Surgery? radioiodine?)]. [Review] [42 refs]  
45 [German]. *Therapeutische Umschau*, 56: 356-363.  
46 Narrative review
- 47 Cavaliere, A., Colella, R., Puxeddu, E., Gambelunghe, G., Avenia, N., d'Ajello, M., Cartaginese, F.,  
48 Vitali, R., Bellezza, G., Giansanti, M., Sidoni, A. & De, F. P. (2008) Fine needle aspiration cytology  
49 of thyroid nodules: conventional vs thin layer technique. *Journal of Endocrinological  
50 Investigation*, 31: 303-308.  
51 Reference test not in PICO

- 1 Cerutti, J. M. (2011) Employing genetic markers to improve diagnosis of thyroid tumor fine needle  
2 biopsy. *Current Genomics*, 12: 589-596.  
3 Narrative review
- 4 Chabon, S. L. (505) Identification and evaluation of thyroid nodules. [Review] [8 refs]. *Lippincott's*  
5 *Primary Care Practice*, 1: 499-504.  
6 Narrative review
- 7 Chammas, M. C., de Araujo Filho, V. J., Moyses, R. A., Brescia, M. D., Mulatti, G. C., Brandao, L. G.,  
8 Cerri, G. G. & Ferraz, A. R. (2008) Predictive value for malignancy in the finding of  
9 microcalcifications on ultrasonography of thyroid nodules. *Head & Neck*, 30: 1206-1210.  
10 Reference test not in PICO
- 11 Chang, D. L. F., Leung, A. M., Braverman, L. E. & Pearce, E. N. (2011) Thyroid testing during  
12 pregnancy at an Academic Boston Area Medical Center. *Journal of Clinical Endocrinology and*  
13 *Metabolism*, 96: E1452-E1456.  
14 Population not in PICO
- 15 Chang, Y.-J., Mittal, V., Remine, S., Manyam, H., Sabir, M., Richardson, T. & Young, S. (2006)  
16 Correlation between clinical and histological findings in parathyroid tumors suspicious for  
17 carcinoma. *American Surgeon*, 72: 419-426.  
18 Population not in PICO
- 19 Choi, J. W., Lee, J. H., Baek, J. H., Choi, B. S., Jeong, K. S., Ryu, J. S., Kim, T. Y., Kim, W. B. & Shong, Y.  
20 K. (2010) Diagnostic accuracy of ultrasound and 18-F-FDG PET or PET/CT for patients with  
21 suspected recurrent papillary thyroid carcinoma. *Ultrasound in Medicine & Biology*, 36: 1608-  
22 1615.  
23 Population not in PICO
- 24 Cibas, E. S. (2010) Fine-needle aspiration in the work-up of thyroid nodules. [Review] [78 refs].  
25 *Otolaryngologic Clinics of North America*, 43: 257-271.  
26 Narrative review
- 27 Cochand-Priollet, B., Vielh, P., Royer, B., Belleannee, G., Collet, J. F., Goubin-Versini, I., Leteurtre, E. &  
28 sous l'egide de la Societe francaise de cytologie clinique (2012) [Thyroid cytopathology: Bethesda  
29 System 2010]. [French]. *Annales de Pathologie*, 32: 177-183.  
30 Narrative review
- 31 Conti, P. S., Durski, J. M., Bacqai, F., Grafton, S. T. & Singer, P. A. (1999) Imaging of locally recurrent  
32 and metastatic thyroid cancer with positron emission tomography. *Thyroid*, 9: 797-804.  
33 Population not in PICO
- 34 Conzo, G., Troncone, G., Docimo, G., Pizza, A., Sciascia, V., Bellevicine, C., Napolitano, S., Della, P. C.,  
35 Palazzo, A., Signoriello, G. & Santini, L. (2013) Cytologically undetermined thyroid's follicular  
36 lesions: surgical procedures and histological outcome in 472 cases. *Annali Italiani di Chirurgia*, 84:  
37 251-256.  
38 Not in PICO
- 39 Corrias, A., Mussa, A., Baronio, F., Arrigo, T., Salerno, M., Segni, M., Vigone, M. C., Gastaldi, R., Zirilli,  
40 G., Tuli, G., Beccaria, L., Iughetti, L., Einaudi, S., Weber, G., De, L. F., Cassio, A. & Study Group for  
41 Thyroid Diseases of Italian Society for Pediatric Endocrinology and Diabetology (SIEDP/ISPED)  
42 (2010) Diagnostic features of thyroid nodules in pediatrics. *Archives of Pediatrics & Adolescent*  
43 *Medicine*, 164: 714-719.  
44 Population not in PICO
- 45 D'Ugo, D., Persiani, R., Pende, V., De, C. E., Rausei, S. & Picciocchi, A. (2000) The impact of the fine  
46 needle aspiration in the management of thyroid nodules. [Italian]. *Minerva Endocrinologica*, 25:  
47 5-10.  
48 Population not in PICO
- 49 D'Ugo, D., Persiani, R., Pende, V., D'Andrilli, A., De, C. E., Rausei, S. & Picciocchi, A. (2001) [Clinical  
50 role of the cytologic study of thyroid nodules]. [Italian]. *Annali Italiani di Chirurgia*, 72: 287-291.  
51 Population not in PICO

- 1 Dan, H.-J., Wang, Y., Dan, H.-Y., Lu, B.-J., Li, T. & Hu, B. (2010) Diagnosis of small single solid thyroid  
2 nodule with real-time ultrasound elastography. [Chinese]. *Chinese Journal of Medical Imaging  
3 Technology*, 26: 63-65.  
4 Population not in PICO
- 5 Daneman, D. & Daneman, A. (2005) Diagnostic imaging of the thyroid and adrenal glands in  
6 childhood. *Endocrinology and Metabolism Clinics of North America*, 34: 745-768.  
7 Narrative review
- 8 Deandrea, M., Mormile, A., Veglio, M., Motta, M., Pellerito, R., Gallone, G., Grassi, A., Torchio, B.,  
9 Bradac, R., Garberoglio, R. & Fonzo, D. (2002) Fine-needle aspiration biopsy of the thyroid:  
10 Comparison between thyroid palpation and ultrasonography. *Endocrine Practice*, 8: 282-286.  
11 Population not in PICO
- 12 Demirci, H., Erdamar, H., Karakoc, A. & Arslan, M. (2010) Thyroid fine needle aspiration biopsy: is  
13 topical local anaesthesia beneficial? *International journal of clinical practice.*, 64: 25-28.  
14 Reference test not in PICO
- 15 Deshpande, H. A., Morgensztern, D. & Sosa, J. A. (2011) Medullary thyroid cancer in the past,  
16 present and future: From bench to bedside. *Expert Review of Endocrinology and Metabolism*, 6:  
17 585-597.  
18 Narrative review
- 19 Dong, M. J., Liu, Z. F., Zhao, K., Ruan, L. X., Wang, G. L., Yang, S. Y., Sun, F. & Luo, X. G. (2009) Value of  
20 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body  
21 scan: a meta-analysis (DARE structured abstract). *Nuclear Medicine Communications.*, 30: 639-  
22 650.  
23 Test not in PICO
- 24 Dong, S., Lu, G. Z., Gao, Y. M., Zhang, H., Guo, X. H. & Gao, Y. (2008) [A clinical pathological study of  
25 thyroid nodules detected by physical examinations]. [Chinese]. *Chung-Hua Nei Ko Tsa Chih  
26 Chinese Journal of Internal Medicine*, 47: 189-192.  
27 Paper in Chinese with English abstract. Unable to translate the whole paper, but from abstract  
28 appear to be in secondary care
- 29 Drozd, V., Polyanskaya, O., Ostapenko, V., Demidchik, Y., Biko, I. & Reiners, C. (2002) Systematic  
30 ultrasound screening as a significant tool for early detection of thyroid carcinoma in Belarus.  
31 *Journal of pediatric endocrinology & metabolism : JPEM*, 15: 979-984.  
32 Population not in PICO
- 33 Dumitriu, L., Mogos, I. & Calin, E. (1984) Fine-needle aspiration biopsy of the thyroid correlated with  
34 clinical scintigraphic, echographic and pathologic data in nodular and diffuse goiter.  
35 *Endocrinologie*, 22: 261-268.  
36 Population not in PICO
- 37 Ershova, G. I. (2004) [Methods of improvement of diagnosis of thyroid cancer]. [Russian].  
38 *Khirurgiia.(12):47-9, 2004.*, 47-49.  
39 Reference test not in PICO
- 40 Faquin, W. C., Bongiovanni, M. & Sadow, P. M. (2011) Update in thyroid fine needle aspiration.  
41 *Endocrine Pathology*, 22: 178-183.  
42 Narrative review
- 43 Filatov, A. A., Svjatov, A. V. & Scerbakova, N. G. (1989) [The clinical value of ultrasonic study of the  
44 thyroid gland]. [German]. *Radiologia Diagnostica*, 30: 633-638.  
45 Population not in PICO
- 46 Fitz-Patrick, D., Navin, J. J. & Fukunaga, B. N. (1968) Fine-needle aspiration biopsy of thyroid nodules.  
47 A diagnostic method that minimizes the need for surgery. *Postgraduate Medicine*, 80: 62-65.  
48 Narrative review
- 49 Fleischer, B. & Borm, D. (1984) Early diagnosis and treatment of thyroid carcinoma. [German].  
50 *Therapiewoche*, 34: 4568-4571.  
51 Narrative review



- 1 Florentine, B. D., Staymates, B., Rabadi, M., Barstis, J., Black, A. & Cancer Committee of the Henry  
2 Mayo Newhall Memorial Hospital (2006) The reliability of fine-needle aspiration biopsy as the  
3 initial diagnostic procedure for palpable masses: a 4-year experience of 730 patients from a  
4 community hospital-based outpatient aspiration biopsy clinic. *Cancer*, 107: 406-416.  
5 Population not in PICO
- 6 Flynn, K. (1996) Positron emission tomography: systematic review. PET as a diagnostic test in head  
7 and neck cancer (DARE structured abstract). *Database of Abstracts of Reviews of Effects.*, 18.  
8 Test not in PICO
- 9 Freeman, L. M. & Blafox, M. D. (2011) Letter from the editors: Controversies and changing concepts  
10 in thyroid cancer management. *Seminars in Nuclear Medicine*, 41: 81-82.  
11 Letter from Editor
- 12 Fruth, K. & Mann, W. J. (2009) [Malignant thyroid neoplasms: a diagnostic challenge for ENT  
13 specialists]. [German]. *HNO*, 57: 257-261.  
14 Population not in PICO
- 15 Fuhrer, D., Bockisch, A. & Schmid, K. W. (516) Euthyroid goiter with and without nodules--diagnosis  
16 and treatment. [Review]. *Deutsches Arzteblatt International*, 109: 506-515.  
17 Narrative review
- 18 Fukunari, N., Nagahama, M., Sugino, K., Mimura, T., Ito, K. & Ito, K. (2004) Clinical evaluation of color  
19 Doppler imaging for the differential diagnosis of thyroid follicular lesions. *World Journal of*  
20 *Surgery*, 28: 1261-1265.  
21 Population not in PICO
- 22 Furlan, J. C., Bedard, Y. C. & Rosen, I. B. (2005) Single versus sequential fine-needle aspiration biopsy  
23 in the management of thyroid nodular disease (Structured abstract). *Canadian Journal of Surgery*,  
24 48: 12-18.  
25 Reference test not in PICO
- 26 Goldstein, R. E., Netterville, J. L., Burkey, B. & Johnson, J. E. (2002) Implications of follicular  
27 neoplasms, atypia, and lesions suspicious for malignancy diagnosed by fine-needle aspiration of  
28 thyroid nodules. *Annals of Surgery*, 235: 656-662.  
29 Population not in PICO
- 30 Gossain, V. V., Charnas, J., Carella, M. J., Rovner, D. R. & Calaca, W. M. (1998) Evaluation of "solitary"  
31 thyroid nodules in a community practice: a managed care approach. *American Journal of*  
32 *Managed Care*, 4: 679-684.  
33 Reference test not in PICO
- 34 Grob, F., Carrillo, D., Martinez-Aguayo, A., Zoroquain, P., Solar, A., Nicolaidis, I. & Gonzalez, H.  
35 (2014) - [Diagnostic yield of fine-needle aspiration cytology for the detection of thyroid cancer in  
36 pediatric patients]. [Spanish]. - *Revista Medica de Chile*, 142: 330-335.  
37 Not in PICO
- 38 Grunwald, F., Kalicke, T., Feine, U., Lietzenmayer, R., Scheidhauer, K., Dietlein, M., Schober, O.,  
39 Lerch, H., Brandt-Mainz, K., Burchert, W., Hiltermann, G., Cremerius, U. & Biersack, H. J. (1999)  
40 Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a  
41 multicentre study. *European Journal of Nuclear Medicine*, 26: 1547-1552.  
42 Population not in PICO
- 43 Grussendorf, M. (2001) Laboratory diagnostic of thyroid diseases in daily clinical practice.  
44 *Medizinische Welt*, 52: 24-27.  
45 Narrative review
- 46 Gu, M. (2014) The role of interventional cytopathologist in the cytologic diagnosis of thyroid  
47 nodules-an experience of a community FNA clinic of 1,424 nodules in 958 patients. *Laboratory*  
48 *Investigation*, 94: 104A.  
49 Published as abstract only. Not enough information available to ascertain relevance.
- 50 Gul, K., Ersoy, R., Dirikoc, A., Korukluoglu, B., Ersoy, P. E., Aydin, R., Ugras, S. N., Belenli, O. K. & Cakir,  
51 B. (2009) Ultrasonographic evaluation of thyroid nodules: Comparison of ultrasonographic,

- 1 cytological, and histopathological findings. *Endocrine*, 36: 464-472.  
 2 Population not in PICO
- 3 Gul, K., Aydin, C., Balkan, F., Erkan, A., Ersoy, R. & Cakir, B. (2010) Nondiagnostic fine needle  
 4 aspiration biopsy results. *Endocrine Abstracts*, 20: 146.  
 5 Population not in PICO
- 6 Gursoy, A., Anil, C. & Erismis, B. (2010) Fine needle aspiration biopsy of a thyroid nodule: A  
 7 comparison of diagnostic performance of experienced and inexperienced physicians. *Endocrine*  
 8 *Abstracts*, 22: 845.  
 9 Population not in PICO
- 10 Hakala, T., Kholova, I., Sand, J., Saaristo, R. & Kellokumpu-Lehtinen, P. (2013) A core needle biopsy  
 11 provides more malignancy-specific results than fine-needle aspiration biopsy in thyroid nodules  
 12 suspicious for malignancy. *Journal of Clinical Pathology*, 66: 1046-1050.  
 13 Not in PICO
- 14 Hamburger, J. I. (1988) Needle aspiration for thyroid nodules. Skip ultrasound--do initial assessment  
 15 in the office. *Postgraduate Medicine*, 84: 61-66.  
 16 Population not in PICO
- 17 Hamburger, J. I. & Husain, M. (1988) Semiquantitative criteria for fine-needle biopsy diagnosis:  
 18 reduced false-negative diagnoses. *Diagnostic Cytopathology*, 4: 14-17.  
 19 Population not in PICO
- 20 Hammond, I., Lentle, B. C. & Odell, P. F. (2010) The pursuit of impalpable thyroid nodules: are we  
 21 using scarce resources wisely? *Canadian Association of Radiologists Journal*, 61: 98-101.  
 22 Narrative review
- 23 Hammond, I. & Schweitzer, M. E. (2011) A resource allocation metric for thyroid biopsies. *JACR*  
 24 *Journal of the American College of Radiology*, 8: 49-52.  
 25 Population not in PICO
- 26 Harolds, J. A. (2011) New scrutiny of outpatient therapy with I-131. *Clinical Nuclear Medicine*, 36:  
 27 206-208.  
 28 Narrative review
- 29 HAYES & -Inc (2013) BRAF p.Val600Glu testing in papillary thyroid carcinoma (Structured abstract).  
 30 *Health Technology Assessment.Database..*  
 31 Not in PICO
- 32 Higashi, T., Ito, K., Nishikawa, Y., Everhart, F. R., Jr., Ozaki, O., Manabe, Y., Suzuki, A., Yashiro, T.,  
 33 Hasegawa, M. & Mimura, T. (1988) Gallium-67 imaging in the evaluation of thyroid malignancy.  
 34 *Clinical Nuclear Medicine*, 13: 792-799.  
 35 Test not in PICO
- 36 Higashi, T., Kudo, T. & Kinuya, S. (2012) Radioactive iodine (131I) therapy for differentiated thyroid  
 37 cancer in Japan: Current issues with historical review and future perspective. *Annals of Nuclear*  
 38 *Medicine*, 26: 99-112.  
 39 Narrative review
- 40 Ho, S., I, Depczynski, B., Lin, M., Clark, J. R., Wong, V., Lin, P. & Campbell, P. (2011) Positron emission  
 41 tomography in non-medullary thyroid cancer. *ANZ Journal of Surgery*, 81: 116-124.  
 42 Narrative review
- 43 Hoang, J. K., Raduazo, P., Yousem, D. M. & Eastwood, J. D. (2012) What to Do With Incidental  
 44 Thyroid Nodules on Imaging? An Approach for the Radiologist. *Seminars in Ultrasound, CT and*  
 45 *MRI*, 33: 150-157.  
 46 Narrative review
- 47 Holan, J., Plank, J. & Uhrin, P. (1982) Results of thin-needle aspiration cytology combined with  
 48 scintigraphy in nodular goiter. [Slovak]. *Bratislavske Lekarske Listy*, 77: 670-677.  
 49 Population not in PICO
- 50 Hooft, L., Hoekstra, O. S., Deville, W., Lips, P., Teule, G. J., Boers, M. & Tulder, M. W. (2001)  
 51 Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of

- 1 papillary or follicular thyroid cancer (DARE structured abstract). *Journal of Clinical Endocrinology*  
2 *and Metabolism*, 86: 3779-3786.
- 3 Test not in PICO
- 4 Huang, I.-C., Chou, F.-F., Liu, R.-T., Tung, S.-C., Chen, J.-F., Kuo, M.-C., Hsieh, C.-J. & Wang, P.-W.  
5 (2012) Long-term outcomes of distant metastasis from differentiated thyroid carcinoma. *Clinical*  
6 *Endocrinology*, 76: 439-447.
- 7 Population not in PICO
- 8 Huang, T. W., Lai, J. H., Wu, M. Y., Chen, S. L., Wu, C. H. & Tam, K. W. (2013) Systematic review of  
9 clinical practice guidelines in the diagnosis and management of thyroid nodules and cancer. *BMC*  
10 *Medicine*, 11: 191.
- 11 Not in PICO
- 12 Iared, W., Shigueoka, D. C., Cristofoli, J. C., Andriolo, R., Atallah, A. N., Ajzen, S. A. & Valente, O.  
13 (2010) Use of color Doppler ultrasonography for the prediction of malignancy in follicular thyroid  
14 neoplasms: systematic review and meta-analysis (DARE structured abstract). *Journal of*  
15 *Ultrasound in Medicine*, 29: 419-425.
- 16 Population not in PICO
- 17 Ito, K. (1989) [Definition, diagnosis and treatment of thyroid carcinoma at an early stage].  
18 [Japanese]. *Nippon Rinsho - Japanese Journal of Clinical Medicine*, 47: 1147-1151.
- 19 Narrative review
- 20 Jargin, S. V. (2011) Validity of thyroid cancer incidence data following the chernobyl accident. *Health*  
21 *Physics*, 101: 754-757.
- 22 Narrative review
- 23 Jaume, J. C. & Chen, H. (2011) Inadequate cytology of thyroid nodules. Repeat it or live with it.  
24 *Annals of Surgical Oncology*, 18: 1222-1223.
- 25 Narrative review
- 26 Jiskra, J., Kubinyi, J. & Telicka, Z. (2012) Radioiodine 131I therapy of hyperthyroidism on an  
27 outpatient basis - Safe, effective and economic option. [Czech]. *Vnitřní Lekarství*, 58: 94-98.
- 28 Test not in PICO
- 29 Joung, K. H., Park, J. Y., Kim, K. S. & Koo, B. S. (2014) Primary amyloid goiter mimicking rapid growing  
30 thyroid malignancy. *European Archives of Oto-Rhino-Laryngology*, 271: 417-420.
- 31 Not in PICO
- 32 Kaczka, K., Celnik, A., Luks, B., Jasion, J. & Pomorski, L. (2012) Sentinel lymph node biopsy techniques  
33 in thyroid pathologies--a meta-analysis. *Endokrynologia Polska*, 63: 222-231.
- 34 Test not in PICO
- 35 Karger, S., Engelhardt, C., Eszlinger, M., Tonjes, A., Herrmann, F., Muller, P., Schmidt, T., Weiss, C. L.,  
36 Dralle, H., Lippitzsch, F., Tannapfel, A. & Fuhrer, D. (2006) Cytology and mRNA expression analysis  
37 of fine needle aspirates of thyroid nodules in an East German region with borderline iodine  
38 deficiency. *Hormone & Metabolic Research*, 38: 662-667.
- 39 Population not in PICO
- 40 Kashiwagi, S., Onoda, N., Asano, Y., Watanabe, M., Morisaki, T., Aomatsu, N., Nakamura, M.,  
41 Kawajiri, H., Takashima, T., Ohsawa, M., Ishikawa, T., Wakasa, K. & Hirakawa, K. (2012) [Needle  
42 biopsy using a Monopty Biopsy Instrument for the accurate diagnosis of thyroid cancer].  
43 [Japanese]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*, 39: 2407-2409.
- 44 Population not in PICO
- 45 Kassum, T. A., Goldstein, D. P., Rafferty, M. A., Rotstein, L. E. & Irish, J. C. (2007) Thyroid scintigraphy  
46 in the assessment of the solitary thyroid nodule: Differences in practice patterns between family  
47 physicians and specialists. *Journal of Otolaryngology*, 36: 49-53.
- 48 Population not in PICO
- 49 Khairy, G. A. & Guraya, S. Y. (2004) Primary care evaluation of thyroid disease: Which clinical group  
50 needs urgent surgical referral? *Bahrain Medical Bulletin*, 26: 143-146.
- 51 Population not in PICO

- 1 Khalid, A. N., Hollenbeak, C. S., Quraishi, S. A., Fan, C. Y. & Stack, B. C. (2006) The cost-effectiveness  
2 of iodine 131 scintigraphy, ultrasonography, and fine-needle aspiration biopsy in the initial  
3 diagnosis of solitary thyroid nodules (Structured abstract). *Archives of Otolaryngology, Head and*  
4 *Neck Surgery*, 132: 244-250.  
5 Population not in PICO
- 6 Khalid, A. N., Quraishi, S. A., Hollenbeak, C. S. & Stack, B. C. (2008) Fine-needle aspiration biopsy  
7 versus ultrasound-guided fine-needle aspiration biopsy: cost-effectiveness as a frontline  
8 diagnostic modality for solitary thyroid nodules (Structured abstract). *Head and Neck*, 30: 1035-  
9 1039.  
10 Reference test not in PICO
- 11 Kim, D.-L., Song, K.-H. & Kim, S. K. (2008) High prevalence of carcinoma in ultrasonography-guided  
12 fine needle aspiration cytology of thyroid nodules. *Endocrine Journal*, 55: 135-142.  
13 Population not in PICO
- 14 Klopper, J. P. & McDermott, M. T. (2007) Palpable pediatric thyroid abnormalities - diagnostic pitfalls  
15 necessitate a high index of clinical suspicion: a case report. *Journal of Medical Case Reports*  
16 *[Electronic Resource]*, 1: 29.  
17 Case series
- 18 Knox, M. A. (2013) Thyroid nodules. *American Family Physician*, 88: 193-196.  
19 Narrative review
- 20 Ko, S. Y., Kim, E. K., Sung, J. M., Moon, H. J. & Kwak, J. Y. (2014) - Diagnostic performance of  
21 ultrasound and ultrasound elastography with respect to physician experience. - *Ultrasound in*  
22 *Medicine & Biology*, 40: 854-863.  
23 Not in PICO
- 24 Koutras, D. A. (2001) Thyroid nodules in children and adolescents: consequences in adult life.  
25 [Review] [29 refs]. *Journal of Pediatric Endocrinology*, 14: Suppl-7.  
26 Narrative review
- 27 Kovatcheva, R., Ivanova, R. S., Ivanova, R. B., Kanev, N., Sarafova, A. & Borissova, A.-M. (2004)  
28 Diagnostic value of echography, ultrasound-guided fine-needle biopsy and cytology in the early  
29 diagnosis of papillary thyroid cancer. [Bulgarian]. *Endokrinologiya*, 9: 42-48.  
30 Population not in PICO
- 31 Krawiecka-Jaworska, E. & Bujnowska-Fedak, M. M. (2009) The usefulness of ultrasound of the neck  
32 region, in particular the thyroid gland and lymph nodes, in general practice. [Polish]. *Family*  
33 *Medicine and Primary Care Review*, 11: 37-41.  
34 Reference test not in PICO
- 35 Kuz'michev, A. S. (1981) Thermography in the diagnosis of thyroid neoplasms. [Russian]. *Voprosy*  
36 *Onkologii*, 27: 33-37.  
37 Population not in PICO
- 38 Kwak, J. Y., Kim, E. K., Kim, M. J. & Son, E. J. (2009) Significance of sonographic characterization for  
39 managing subcentimeter thyroid nodules. *Acta Radiologica*, 50: 917-923.  
40 Population not in PICO
- 41 Kwak, J. Y. & Kim, E. K. (2013) Cancer: Indeterminate thyroid nodules--added testing, added value?  
42 *Nature Reviews Endocrinology*, 9: 321-323.  
43 Not in PICO
- 44 Labat-Moleur, F., Seigneurin, D., Breyton, M., Bachelot, I. & Sarrazin, R. (1995) Role and limitation of  
45 fine needle cytology of the thyroid. [French]. *Lyon Chirurgical*, 91: 117-119.  
46 Narrative review
- 47 Langer, M., Madeddu, G., Dettori, G., Tanda, F. & Solinas, A. M. (1980) [The problem of cancer  
48 diagnosis in thyroid nodules: a study in an endemic area for goiter in North Sardinia]. [German].  
49 *Schweizerische Medizinische Wochenschrift. Journal Suisse de Medecine*, 110: 1411-1414.  
50 Population not in PICO

- 1 Leclere, J., Beckers, C., Cussac, J. F., Renan, C. A. & Vielh, P. (1993) Thyroid nodule. [French].  
2 *Medecine Nucleaire*, 17: 191-201.  
3 Narrative review
- 4 Lee, J. K., Liu, R. S., Wu, S. Y., Huang, W. S. & Chou, M. C. (2006) Thallium-201 scan in evaluating  
5 thyroid nodules following equivocal fine-needle aspiration cytology. *Nuklearmedizin*, 45: 201-205.  
6 Test not in PICO
- 7 Leung, B. C. H. (2003) Management of thyroid nodules. *Hong Kong Practitioner*, 25: 611-615.  
8 Narrative review
- 9 Levy, M. J., Clain, J. E., Clayton, A., Halling, K. C., Kipp, B. R., Rajan, E., Roberts, L. R., Root, R. M.,  
10 Sebo, T. J., Topazian, M. D., Wang, K. K., Wiersema, M. J. & Gores, G. J. (2007) Preliminary  
11 experience comparing routine cytology results with the composite results of digital image  
12 analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA.  
13 *Gastrointestinal Endoscopy*, 66: 483-490.  
14 Population not in PICO
- 15 Li, H., Robinson, K. A., Anton, B., Saldanha, I. J. & Ladenson, P. W. (2011) Cost-effectiveness of a  
16 novel molecular test for cytologically indeterminate thyroid nodules. *Endocrine Reviews*, 32.  
17 Population not in PICO
- 18 Liang, H., Zhong, Y., Luo, Z., Huang, Y., Lin, H., Zhan, S., Xie, K. & Li, Q. Q. (2011) Diagnostic value of  
19 16 cellular tumor markers for metastatic thyroid cancer: an immunohistochemical study.  
20 *Anticancer Research*, 31: 3433-3440.  
21 Population not in PICO
- 22 Liel, Y. & Fraenkel, N. (2005) Brief report: Use and misuse of thyroid ultrasound in the initial workup  
23 of patients with suspected thyroid problems referred by primary care physicians to an endocrine  
24 clinic. *Journal of General Internal Medicine*, 20: 766-768.  
25 Population not in PICO
- 26 Lin, J. D., Chao, T. C., Huang, B. Y., Chen, S. T., Chang, H. Y. & Hsueh, C. (2005) Thyroid cancer in the  
27 thyroid nodules evaluated by ultrasonography and fine-needle aspiration cytology. *Thyroid*, 15:  
28 708-717.  
29 Population not in PICO
- 30 Lind, P. & Kohlfurst, S. (2006) Respective roles of thyroglobulin, radioiodine imaging, and positron  
31 emission tomography in the assessment of thyroid cancer. [Review] [82 refs]. *Seminars in Nuclear  
32 Medicine*, 36: 194-205.  
33 Narrative review
- 34 Listewnik, M. H., Birkenfeld, B., Piwowarska-Bilska, H., Cichon-Bankowska, K., Iglinska-Wagner, L.,  
35 Watrak, W., Smolira, W., Zorga, P., Niedzialkowska, K., Elbl, B. & Sawrymowicz, M. (2010) The  
36 application of SPECT/CT scintigraphy with MIBI-Tc99(m) in the diagnosis of thyroid nodules - a  
37 preliminary report. *Endokrynologia Polska*, 61: 422-426.  
38 Population not in PICO
- 39 Listewnik, M. H., Birkenfeld, B., Chosia, M., Elbl, B., Piwowarska-Bilska, H., Zorga, P. &  
40 Niedzialkowska, K. (2011) Thyroid fine-needle aspiration biopsy: which lesions should be biopsied  
41 before 131I therapy? *Annales Academiae Medicae Stetinensis*, 57: 54-58.  
42 Reference test not in PICO
- 43 Little, J. W. (2006) Thyroid disorders. Part III: neoplastic thyroid disease. *Oral Surgery, Oral Medicine,  
44 Oral Pathology, Oral Radiology, and Endodontics*, 102: 275-280.  
45 Narrative review
- 46 Liu, F. H., Liou, M. J., Hsueh, C., Chao, T. C. & Lin, J. D. (2010) Thyroid follicular neoplasm: analysis by  
47 fine needle aspiration cytology, frozen section, and histopathology. *Diagnostic Cytopathology*, 38:  
48 801-805.  
49 Population not in PICO
- 50 Maia, F. F., Matos, P. S., Pavin, E. J., Vassallo, J. & Zantut-Wittmann, D. E. (2011) Value of repeat  
51 ultrasound-guided fine-needle aspiration in thyroid nodule with a first benign cytologic result:

- 1 impact of ultrasound to predict malignancy. *Endocrine*, 40: 290-296.  
 2 Population not in PICO
- 3 Malesevic, M., Mihailovic, J., Vojcic, J. & Popadic, S. (2003) [Early diagnosis, therapy, follow-up and  
 4 survival in patients with thyroid malignancies]. [Serbian]. *Acta Chirurgica Iugoslavica*, 50: 177-  
 5 183.  
 6 Population not in PICO
- 7 Marqusee, E., Benson, C. B., Frates, M. C., Doubilet, P. M., Larsen, P. R., Cibas, E. S. & Mandel, S. J.  
 8 (2000) Usefulness of ultrasonography in the management of nodular thyroid disease. *Annals of*  
 9 *Internal Medicine*, 133: 696-700.  
 10 Population not in PICO
- 11 McShane, D. P., Freeman, J. L., Noyek, A. M. & Steinhardt, M. I. (1987) A review of conventional and  
 12 CT imaging in the evaluation of thyroid malignancies.[Erratum appears in J Otolaryngol 1987  
 13 Jun;16(3):192]. *Journal of Otolaryngology*, 16: 4-9.  
 14 Narrative review
- 15 Mehanna, H. M., Jain, A., Morton, R. P., Watkinson, J. & Shaha, A. (2009) Investigating the thyroid  
 16 nodule. [Review] [25 refs]. *BMJ*, 338: b733.  
 17 Narrative review
- 18 Meier, J. D. & Grimmer, J. F. (2014) - Evaluation and management of neck masses in children.  
 19 [Review]. - *American Family Physician*, 89: 353-358.  
 20 Narrative review
- 21 Meller, J. & Becker, W. (2002) The continuing importance of thyroid scintigraphy in the era of high-  
 22 resolution ultrasound. [Review] [98 refs]. *European Journal of Nuclear Medicine & Molecular*  
 23 *Imaging*, 29: Suppl-38.  
 24 Narrative review
- 25 Mikosch, P., Gallowitsch, H. J., Kresnik, E., Jester, J., Wurtz, F. G., Kerschbaumer, K., Unterweger, O.,  
 26 Dinges, H. P. & Lind, P. (2000) Value of ultrasound-guided fine-needle aspiration biopsy of thyroid  
 27 nodules in an endemic goitre area. *European Journal of Nuclear Medicine*, 27: 62-69.  
 28 Population not in PICO
- 29 Miller, J. M., Kini, S. R. & Hamburger, J. I. (1985) The diagnosis of malignant follicular neoplasms of  
 30 the thyroid by needle biopsy. *Cancer*, 55: 2812-2817.  
 31 Population not in PICO
- 32 Mosci, C. & Iagaru, A. (2011) PET/CT imaging of thyroid cancer. [Review]. *Clinical Nuclear Medicine*,  
 33 36: e180-e185.  
 34 Narrative review
- 35 Muddegowda, P. H., Lingegowda, J., Natesan, R. & Kurpad, R. (2011) Divide and rule: Cytodiagnosis  
 36 of thyroid lesions using pattern analysis: A study of 233 cases. *Diagnostic Cytopathology*, 39: 888-  
 37 895.  
 38 Population not in PICO
- 39 Nabriski, D., Ness-Abramof, R., Brosh, T., Konen, O., Shapiro, M. S. & Shenkman, L. (2003) Clinical  
 40 relevance of non-palpable thyroid nodules as assessed by ultrasound-guided fine needle  
 41 aspiration biopsy. *Journal of Endocrinological Investigation*, 26: 61-64.  
 42 Reference test not in PICO
- 43 Nacamulli, D., Nico, L., Barollo, S., Zambonin, L., Pennelli, G., Girelli, M. E., Casal, I. E., Pelizzo, M. R.,  
 44 Vianello, F., Negro, I., Watutantrige-Fernando, S., Mantero, F., Rugge, M. & Mian, C. (2012)  
 45 Comparison of the diagnostic accuracy of combined elastosonography and BRAF analysis vs  
 46 cytology and ultrasonography for thyroid nodule suspected of malignancy. *Clinical Endocrinology*,  
 47 77: 608-614.  
 48 Population not in PICO
- 49 Oberwittler, H., Nawroth, P. P., Ziegler, R. & Seibel, M. J. (1998) Clinical presentation of thyroid  
 50 carcinomas. [German]. *Tumor Diagnostik und Therapie*, 19: 52-55.  
 51 Narrative review

- 1 Oj, N. & Ohi, K. (2013) Comparison of the symptoms of menopause and symptoms of thyroid disease  
2 in Japanese women aged 35-59 years. *Climacteric*, 16: 555-560.  
3 Not in PICO (population/outcome [e.g., no distinction between benign & malignant thyroid  
4 tumours])
- 5 Ongphiphadhanakul, B., Rajatanavin, R., Chiemchanya, S., Chailurkit, L., Kongsuksai, A. & Isarangkul  
6 Na Ayuthya, W. I. (1992) Systematic inclusion of clinical and laboratory data improves diagnostic  
7 accuracy of fine-needle aspiration biopsy in solitary thyroid nodules. *Acta Endocrinologica*, 126:  
8 233-237.  
9 Population not in PICO
- 10 Ortiz, R., Hupart, K. H., DeFesi, C. R. & Surks, M. I. (1998) Effect of early referral to an endocrinologist  
11 on efficiency and cost of evaluation and development of treatment plan in patients with thyroid  
12 nodules. *Journal of Clinical Endocrinology & Metabolism*, 83: 3803-3807.  
13 Population not in PICO
- 14 Ota, H., Ito, Y., Matsuzuka, F., Kuma, S., Fukata, S., Morita, S., Kobayashi, K., Nakamura, Y., Kakudo,  
15 K., Amino, N. & Miyauchi, A. (2006) Usefulness of ultrasonography for diagnosis of malignant  
16 lymphoma of the thyroid. *Thyroid*, 16: 983-987.  
17 Population not in PICO
- 18 Paschke, R., Schmid, K. W., Gartner, R., Mann, K., Dralle, H. & Reiners, C. (2010) [Epidemiology,  
19 pathophysiology, guideline-adjusted diagnostics, and treatment of thyroid nodules]. [German].  
20 *Medizinische Klinik*, 105: 80-87.  
21 Narrative review
- 22 Pelizzo, M. R., Merante, B., I, Toniato, A., Piotto, A., Bernante, P., Paggetta, C., De Salvo, G. L., Carpi,  
23 A., Rubello, D. & Casara, D. (2006) Sentinel node mapping and biopsy in thyroid cancer: a surgical  
24 perspective. *Biomedicine & Pharmacotherapy*, 60: 405-408.  
25 Population not in PICO
- 26 Perez, J. A., Pisano, R., Kinast, C., Valencia, V., Araneda, M. & Mera, M. E. (1991) [Needle aspiration  
27 cytology in euthyroid uninodular goiter]. [Spanish]. *Revista Medica de Chile*, 119: 158-163.  
28 Population not in PICO
- 29 Petrone, L. R. (1996) A primary care approach to the adult patient with nodular thyroid disease.  
30 [Review] [98 refs]. *Archives of Family Medicine*, 5: 92-100.  
31 Narrative review
- 32 Punthakee, X., Palme, C. E., Franklin, J. H., Zhang, I., Freeman, J. L. & Bedard, Y. C. (2005) Fine-needle  
33 aspiration biopsy findings suspicious for papillary thyroid carcinoma: a review of cytopathological  
34 criteria. *Laryngoscope*, 115: 433-436.  
35 Population not in PICO
- 36 Quon, A., Fischbein, N. J., McDougall, I. R., Le, Q. T., Loo, B. W., Jr., Pinto, H. & Kaplan, M. J. (2007)  
37 Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and  
38 neck and thyroid carcinoma. [Review] [62 refs]. *Journal of Nuclear Medicine*, 48: Suppl-67S.  
39 Narrative review
- 40 Raber, W., Kmen, E., Kaserer, K., Waldhausl, W. & Vierhapper, H. (1997) [The "cold" nodule of the  
41 thyroid gland: 20 years experience with 2,071 patients and diagnostic limits of fine needle  
42 biopsy]. [German]. *Wiener Klinische Wochenschrift*, 109: 116-122.  
43 Population not in PICO
- 44 Raggiunti, B., Capone, F., Franchi, A., Fiore, G., Filipponi, S., Colagrande, V., Di, N. M., Mangifesta, R.  
45 & Ballone, E. (2011) Ultrasound elastography: Can it provide valid information for differentiation  
46 of benign and malignant thyroid nodules? *Journal of Ultrasound*, 14: 136-141.  
47 Population not in PICO
- 48 Rahimi, M., Farshchian, N., Rezaee, E., Shahebrahimi, K. & Madani, H. (2013) To differentiate benign  
49 from malignant thyroid nodule comparison of sonography with FNAC findings. *Pakistan Journal of*  
50 *Medical Sciences*, 29: 77-80.  
51 Not in PICO

- 1 Rajmakers, P. G., Paul, M. A. & Lips, P. (2008) Sentinel node detection in patients with thyroid  
2 carcinoma: a meta-analysis. *World Journal of Surgery*, 32: 1961-1967.  
3 Test not in PICO
- 4 Ranganathan, B., Thriyayi, S., Yap, B., Loughran, S. & Homer, J. J. (2012) Regional audit on thyroid  
5 cytology reporting. *Clinical Otolaryngology*, 37: 115.  
6 Abstract only, not enough information available to ascertain relevance, but I don't think it is in  
7 PICO
- 8 Ravula, S., ZopfiConklin, A., Fung, P. C., Hirschowitz, S. L. & Sullivan, P. S. (2012) The benefits of a  
9 repeat FNA in follicular lesion of undetermined significance (FLUS) cases. *Laboratory*  
10 *Investigation*, 92: 103A.  
11 Reference test not in PICO
- 12 Redlich, A., Boxberger, N., Kurt, W. S., Fruhwald, M., Rohrer, T. & Vorwerk, P. (2012) Sensitivity of  
13 fine-needle biopsy in detecting pediatric differentiated thyroid carcinoma. *Pediatric Blood &*  
14 *Cancer*, 59: 233-237.  
15 Population not in PICO
- 16 Rifat, S. F. & Ruffin IV, M. T. (1994) Management of thyroid nodules. *American Family Physician*, 50:  
17 785-790.  
18 Narrative review
- 19 Rizzo, M., Sindoni, A., Talamo, R. R., Bonaffini, O., Panetta, S., Scisca, C., Altavilla, G., Denaro, L.,  
20 Rosano, A., Saraceno, G., Trimarchi, F. & Benvenga, S. (2013) Annual increase in the frequency of  
21 papillary thyroid carcinoma as diagnosed by fine-needle aspiration at a cytology unit in Sicily.  
22 *Hormones*, 12: 46-57.  
23 Population not in PICO
- 24 Rodriguez-Gil, Y., Perez-Barrios, A., Alberti-Masgrau, N., Garzon, A. & De, A. P. (2012) Fine-needle  
25 aspiration cytology diagnosis of metastatic nonhaematological neoplasms of the breast: A series  
26 of seven cases. *Diagnostic Cytopathology*, 40: 297-304.  
27 Case series
- 28 Rosario, P. W., Penna, G. C. & Calsolari, M. R. (2014) - Predictive factors of malignancy in thyroid  
29 nodules with repeatedly nondiagnostic cytology (Bethesda category I): value of ultrasonography.  
30 - *Hormone & Metabolic Research*, 46: 294-298.  
31 Not in PICO
- 32 Rosen, J. E. & Stone, M. D. (2006) Contemporary diagnostic approach to the thyroid nodule. *Journal*  
33 *of Surgical Oncology*, 94: 649-661.  
34 Narrative review
- 35 Rosenberg, H. K. (2009) Sonography of pediatric neck masses. *Ultrasound Quarterly*, 25: 111-127.  
36 Narrative review
- 37 Rossi, E. D., Morassi, F., Santeusano, G., Zannoni, G. F. & Fadda, G. (2010) Thyroid fine needle  
38 aspiration cytology processed by ThinPrep: an additional slide decreased the number of  
39 inadequate results. *Cytopathology*, 21: 97-102.  
40 Reference test not in PICO
- 41 Rousset, B., Ziercher, L. & Borson-Chazot, F. (2011) Molecular analyses of thyroid tumors for  
42 diagnosis of malignancy on fine-needle aspiration biopsies and for prognosis of invasiveness on  
43 surgical specimens. *Annales d'Endocrinologie*, 72: 125-128.  
44 Population not in PICO
- 45 Ruchala, M. & Szczepanek, E. (2008) Thyroid nodular disease. [Polish]. *Family Medicine and Primary*  
46 *Care Review*, 10: 1383-1392.  
47 Narrative review
- 48 Saller, B., Moeller, L., Gorges, R., Janssen, O. E. & Mann, K. (2002) Role of conventional ultrasound  
49 and color Doppler sonography in the diagnosis of medullary thyroid carcinoma. *Experimental and*  
50 *Clinical Endocrinology and Diabetes*, 110: 403-407.  
51 Population not in PICO



- 1 Scacchi, M., Andrioli, M., Carzaniga, C., Vitale, G., Moro, M., Poggi, L., Pecori, G. F., Fatti, L. M. &  
2 Cavagnini, F. (2009) Elastasonographic evaluation of thyroid nodules in acromegaly. *European*  
3 *Journal of Endocrinology*, 161: 607-613.  
4 Reference test not in PICO
- 5 Scheffler, P., Forest, V. I., Leboeuf, R., Florea, A. V., Tamilia, M., Sands, N. B., Hier, M. P., Mlynarek, A.  
6 M. & Payne, R. J. (2014) - Serum thyroglobulin improves the sensitivity of the McGill thyroid  
7 nodule score for well-differentiated thyroid cancer. - *Thyroid*, 24: 852-857.  
8 Not in PICO
- 9 Schmid, K. W., Lucciarini, P., Ladurner, D., Zechmann, W. & Hofstadter, F. (1987) Papillary carcinoma  
10 of the thyroid gland. Analysis of 94 cases with preoperative fine needle aspiration cytologic  
11 examination. *Acta Cytologica*, 31: 591-594.  
12 Population not in PICO
- 13 Schmid, K. W. & Reiners, C. (2011) [When is thyroid fine-needle biopsy most effective?]. [German].  
14 *Pathologe*, 32: 169-172.  
15 Narrative review
- 16 Schueller-Weidekamm, C., Schueller, G., Kaserer, K., Scheuba, C., Ringl, H., Weber, M., Czerny, C. &  
17 Herneth, A. M. (2010) Diagnostic value of sonography, ultrasound-guided fine-needle aspiration  
18 cytology, and diffusion-weighted MRI in the characterization of cold thyroid nodules. *European*  
19 *Journal of Radiology*, 73: 538-544.  
20 Population not in PICO
- 21 Schwarzrock, R., Muller, S., Schober, O. & Hundeshagen, H. (1983) Ultrasonography in malignant  
22 thyroid disease. [German]. *Aktuelle Endokrinologie und Stoffwechsel*, 4: 107-120.  
23 Reference test not in PICO
- 24 Sebastian-Ochoa, N., Fernandez-Garcia, J. C., Mancha, D., I, Sebastian-Ochoa, A., Fernandez, G. D.,  
25 Ortega Jimenez, M. V., Gallego, D. E. & Tinahones, M. F. (2011) [Clinical experience in a high-  
26 resolution thyroid nodule clinic]. [Spanish]. *Endocrinologia y Nutricion*, 58: 409-415.  
27 Population not in PICO
- 28 Seiberling, K. A., Dutra, J. C. & Gunn, J. (2008) Ultrasound-guided fine needle aspiration biopsy of  
29 thyroid nodules performed in the office. *The Laryngoscope*, 118: 228-231.  
30 Population not in PICO
- 31 Sellami, M., Tababi, S., Mamy, J., Zainine, R., Charfi, A., Beltaief, N., Sahtout, S. & Besbes, G. (2011)  
32 Interest of fine-needle aspiration cytology in thyroid nodule. [Review]. *European annals of*  
33 *otorhinolaryngology, head & neck diseases*, 128: 159-164.  
34 Population not in PICO
- 35 Shammam, A., Degirmenci, B., Mountz, J. M., McCook, B. M., Branstetter, B., Bencherif, B., Joyce, J.  
36 M., Carty, S. E., Kuffner, H. A. & Avril, N. (2007) 18F-FDG PET/CT in patients with suspected  
37 recurrent or metastatic well-differentiated thyroid cancer.[Erratum appears in J Nucl Med. 2007  
38 Mar;48(3):412 Note: Bencherif, Badreddine B [corrected to Bencherif, Badreddine]]. *Journal of*  
39 *Nuclear Medicine*, 48: 221-226.  
40 Population not in PICO
- 41 Shrestha, M., Crothers, B. A. & Burch, H. B. (2012) The impact of thyroid nodule size on the risk of  
42 malignancy and accuracy of fine-needle aspiration: a 10-year study from a single institution.  
43 *Thyroid*, 22: 1251-1256.  
44 Population not in PICO
- 45 Shulutko, A. M., Semikov, V. I., Ivanova, N. A., Seredin, V. P., Mironova, M. V., Patalova, A. R.,  
46 Gorbacheva, A. V. & Kulikov, I. O. (2002) [Ultrasonic method of study and puncture biopsy in  
47 diagnosing thyroid nodules]. [Russian]. *Khirurgiia.(5):7-12, 2002., 7-12.*  
48 Population not in PICO
- 49 Song, J., Wang, D., Yuan, H. & Zong, S.-Y. (2008) Analysis of contrast-enhanced ultrasonography in  
50 detection of solitary thyroid nodules. [Chinese]. *Chinese Journal of Medical Imaging Technology*,

- 1 24: 44-47.
- 2 Population not in PICO
- 3 Southwick, H. W. (1981) Head and neck cancer: Early detection. *Cancer*, 47: 1188-1192.
- 4 Narrative review
- 5 Stavric, G. D., Karanfilski, B. T., Kalamaras, A. K., Serafimov, N. Z., Georgievska, B. S. & Korubin, V. H.
- 6 (1980) Early diagnosis and detection of clinically non-suspected thyroid neoplasia by the cytologic
- 7 method: a critical review of 1536 aspiration biopsies. *Cancer*, 45: 340-344.
- 8 Population not in PICO
- 9 Stevens, C., Lee, J. K., Sadatsafavi, M. & Blair, G. K. (2009) Pediatric thyroid fine-needle aspiration
- 10 cytology: a meta-analysis (DARE structured abstract). *Journal of Pediatric Surgery*, 44: 2184-2191.
- 11 Population not in PICO
- 12 Suen, K. C. (2002) Fine-needle aspiration biopsy of the thyroid. *CMAJ*, 167: 491-495.
- 13 Narrative review
- 14 Szybinski, Z., Szot, W., Bobrowski, A., Huszno, B., Nowak, K., Popiela, T. & Chlap, Z. (1988) [Fine-
- 15 needle biopsy in the early diagnosis of thyroid neoplasms]. [Polish]. *Endokrynologia Polska*, 39:
- 16 291-299.
- 17 Population not in PICO
- 18 Tagaya, N. & Kubota, K. (2012) Reevaluation of needlescopic surgery. *Surgical Endoscopy and Other*
- 19 *Interventional Techniques*, 26: 137-143.
- 20 Population not in PICO
- 21 Takeyama, H., Tabei, I., Uchida, K. & Morikawa, T. (2009) Sentinel node biopsy for follicular tumours
- 22 of the thyroid gland. *British Journal of Surgery*, 96: 490-495.
- 23 Population not in PICO
- 24 Todd, C. H. (2009) Management of thyroid disorders in primary care: Challenges and controversies.
- 25 *Postgraduate Medical Journal*, 85: 655-659.
- 26 Narrative review
- 27 Tonjes, A. & Paschke, R. (573) [Diagnosis and therapy of thyroid nodules]. [Review] [22 refs]
- 28 [German]. *Internist*, 46: 565-572.
- 29 Narrative review
- 30 Tranquart, F., Bleuzen, A., Pierre-Renoult, P., Chabrolle, C., Sam, G. M. & Lecomte, P. (2008)
- 31 Elastasonography of thyroid lesions. [French]. *Journal de Radiologie*, 89: 35-39.
- 32 Population not in PICO
- 33 Treglia, G., Castaldi, P., Villani, M. F., Perotti, G., de, W. C., Filice, A., Ambrosini, V., Cremonini, N.,
- 34 Santimaria, M., Versari, A., Fanti, S., Giordano, A. & Rufini, V. (2012) Comparison of 18F-DOPA,
- 35 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid
- 36 carcinoma. *European Journal of Nuclear Medicine & Molecular Imaging*, 39: 569-580.
- 37 Population not in PICO
- 38 Varhaug, J. E., Segadal, E. & Heimann, P. (1981) The utility of fine needle aspiration biopsy cytology
- 39 in the management of thyroid tumors. *World Journal of Surgery*, 5: 573-577.
- 40 Population not in PICO
- 41 Vassilatou, E., Proikas, K., Margari, N., Papadimitriou, N., Hadjidakis, D. & Dimitriadis, G. (2014) - An
- 42 adolescent with a rare midline neck tumor: thyroid carcinoma in a thyroglossal duct cyst. -
- 43 *Journal of Pediatric Hematology/Oncology*, 36: 407-409.
- 44 Not in PICO
- 45 Vera, M. I., Merono, T., Urrutia, M. A., Parisi, C., Morosan, Y., Rosmarin, M., Schnitman, M., Brites, F.,
- 46 Grisendi, S., Serrano, M. S., Luciani, W., Serrano, L., Zuk, C., De, B. G., Cejas, C., Faingold, M. C. &
- 47 Brenta, G. (2014) - Differential profile of ultrasound findings associated with malignancy in mixed
- 48 and solid thyroid nodules in an elderly female population. - *Journal of Thyroid Research*, 2014:
- 49 761653.
- 50 Not in PICO (secondary care)

- 1 Verbeek Hans, H. G., de Groot Jan, W. B., Sluiter, W. J., Muller Kobold, A. C., Plukker John, T. M. &  
 2 Links, T. P. (2012) Calcitonin testing for detection of medullary thyroid cancer in patients with  
 3 thyroid nodules. *Cochrane Database of Systematic Reviews*.  
 4 Population not in PICO
- 5 Verbeek, H. H., Plukker, J. T., Koopmans, K. P., de Groot, J. W., Hofstra, R. M., Muller Kobold, A. C.,  
 6 van der Horst-Schrivers AN, Brouwers, A. H. & Links, T. P. (2012) Clinical relevance of 18F-FDG PET  
 7 and 18F-DOPA PET in recurrent medullary thyroid carcinoma. *Journal of Nuclear Medicine*, 53:  
 8 1863-1871.  
 9 Population not in PICO
- 10 Vetshev, P. S., Chilingaridi, K. E., Loshchenov, V. B., Gabaidze, D. I., Vetshev, S. P., Baranova, O. V. &  
 11 Ozerov, S. K. (2001) Comparative assessment of diagnostic methods in adenomas of the thyroid  
 12 gland. [Russian]. *Khirurgiia*, 4-10.  
 13 Population not in PICO
- 14 Vette, J. K. (1985) Computed tomography of the thyroid gland. *Acta Endocrinologica*,  
 15 Supplementum.: 1-82.  
 16 Narrative review
- 17 Vidal-Casariago, A., Lopez-Gonzalez, L., Jimenez-Perez, A., Ballesteros-Pomar, M. D., Kyriakos, G.,  
 18 Urioste-Fondo, A., Alvarez-San, M. R., Cano-Rodriguez, I. & Jimenez-Garcia de la Marina JM  
 19 (2012) Accuracy of ultrasound elastography in the diagnosis of thyroid cancer in a low-risk  
 20 population. *Experimental & Clinical Endocrinology & Diabetes*, 120: 635-638.  
 21 Reference test not in PICO
- 22 Voronetskii, I. B. & Varshavskii, I. (1989) [Standardization of diagnostic studies in thyroid diseases].  
 23 [Russian]. *Meditinskaiia Radiologiia*, 34: 16-20.  
 24 Narrative review
- 25 Wale, A., Miles, K., Young, B., Zammit, C., Williams, A., Quin, J. & Dizdarevic, S. (2011) Accuracy and  
 26 potential cost-effectiveness of 99mTc-Methoxyisobutylisonitrile (MIBI) scintigraphy for the  
 27 assessment of thyroid nodules in the context of the British Thyroid Association (BTA) guidelines.  
 28 *Nuclear Medicine Communications*, 32: 435-436.  
 29 Population not in PICO
- 30 Wang, Q. C., Cheng, W., Wen, X., Li, J. B., Jing, H. & Nie, C. L. (2014) - Shorter distance between the  
 31 nodule and capsule has greater risk of cervical lymph node metastasis in papillary thyroid  
 32 carcinoma. - *Asian Pacific Journal of Cancer Prevention: Apjcp*, 15: 855-860.  
 33 Not in PICO
- 34 Wang, Z., Zhang, H., Zhang, P., He, L. & Dong, W. (2014) - Diagnostic Value of Ultrasound-detected  
 35 Calcification in Thyroid Nodules. - *Annals of the Academy of Medicine, Singapore*, 43: 102-106.  
 36 Not in PICO
- 37 Wanis, K., Oucharek, J. & Groot, G. (2013) Quality of thyroid referrals in Saskatchewan. *Quality in*  
 38 *Primary Care*, 21: 247-252.  
 39 Not in PICO
- 40 Weiss, R. E. & Lado-Abeal, J. (2002) Thyroid nodules: diagnosis and therapy. *Current Opinion in*  
 41 *Oncology*, 14: 46-52.  
 42 Narrative review
- 43 Wojciechowski, B. & Kusmann, J. (2013) Thyroid nodules as secondary finding. *Langenbeck's Archives*  
 44 *of Surgery*, 398: 1019.  
 45 Not in PICO
- 46 Wolf, G., Aigner, R. M., Schaffler, G., Schwarz, T. & Krippel, P. (2003) Pathology results in  
 47 [18F]fluorodeoxyglucose positron emission tomography of the thyroid gland. *Nuclear Medicine*  
 48 *Communications*, 24: 1225-1230.  
 49 Population not in PICO
- 50 Wolinski, K., Szkudlarek, M., Szczepanek-Parulska, E. & Ruchala, M. (2014) - Usefulness of different  
 51 ultrasound features of malignancy in predicting the type of thyroid lesions: a meta-analysis of

- 1 prospective studies. - *Polskie Archiwum Medycyny Wewnętrznej*, 124: 97-104.
- 2 Not in PICO
- 3 Wu, S. Y. & Weiss, R. E. (2006) Radioiodine imaging in the primary care of thyroid disease.
- 4 *Postgraduate Medicine*, 119.
- 5 Narrative review
- 6 Yip, L., Farris, C., Kabaker, A. S., Hodak, S. P., Nikiforova, M. N., McCoy, K. L., Stang, M. T., Smith, K. J.,
- 7 Nikiforov, Y. E. & Carty, S. E. (2011) Cost impact of routine molecular testing for indeterminate
- 8 thyroid nodule fine needle aspiration biopsies. *Thyroid*, 21: A42-A43.
- 9 Reference test not in PICO
- 10 Yokozawa, T., Fukata, S., Kuma, K., Matsuzuka, F., Kobayashi, A., Hirai, K., Miyauchi, A. & Sugawara,
- 11 M. (1996) Thyroid cancer detected by ultrasound-guided fine-needle aspiration biopsy. *World*
- 12 *Journal of Surgery*, 20: 848-853.
- 13 Population not in PICO
- 14
- 15

**BRAIN AND CENTRAL NERVOUS SYSTEM CANCERS****Review question:**


What is the risk of brain and CNS cancer in patients presenting in primary care with symptom(s)?

**Results****Literature search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1980-2012	1668	138	20/02/2013
<i>Premedline</i>	1980-2012	24	1	20/02/2013
<i>Embase</i>	1980-2012	3631	174	25/02/2013
<i>Cochrane Library</i>	1980-2012	489	1	26/02/2013
<i>Psychinfo</i>	1980-2012	43	6	20/02/2013
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	1980-2012	974	33	26/02/2013

**Total References retrieved (after de-duplication): 277****Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	2013-12/08/2014	53	5	12/08/2014
<i>Premedline</i>	2013-12/08/2014	58	6	12/08/2014
<i>Embase</i>	2013-12/08/2014	304	6	12/08/2014
<i>Cochrane Library</i>	2013-12/08/2014	224	0	12/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	2013-12/08/2014	87	2	12/08/2014

**Total References retrieved (after de-duplication): 19**

**Risk of bias in the included studies**

The risk of bias and applicability concerns are summarised for the included study in the figure below. The main issue to note is that a number of the studies employed case-control (or other non-consecutive, non-randomised) designs which have been shown to inflate the test accuracy characteristics. However, the statistical analyses employed by the authors may have gone some way in counteracting this influence. Other issues of concern include that some of the studies were conducted abroad and their direct relevance to UK-based primary care may therefore be limited, that the symptoms were underspecified in one study and therefore of limited use for the present purposes, and that some of the reference standards employed were of questionable quality and applicability.

	Risk of Bias				Applicability Concerns		
	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard
Ansell (2009)	+	+	+	+	+	+	+
Dommett (2012, 2013)	+	+	+	+	+	+	+
Hamilton (2007)	+	+	+	+	?	+	+
Herr (1989)	+	+	?	+	+	+	?
Kernick (2008)	+	+	+	+	+	+	+
Kernick (2009)	+	+	+	+	+	+	+
Skiendziekowski (1980)	?	+	+	+	+	?	?

+	?	+
High	Unclear	Low

**Study results**

Table 1: Brain & CNS cancer: Study results for adult populations.

Study	Symptom(s)	Patient group	Positive predictive value % (95% CI) Frequency
Hamilton (2007)	Headache	All included patients	0.09 (0.08-0.1)
Hamilton (2007)	Headache*	Patients 60-69 years	0.12 (NR)
Kernick (2008)	Undifferentiated headache	All included patients	0.15 (0.12-0.19) 97/63921
Kernick (2008)	Undifferentiated headache	Patients < 50 years	0.08 (0.05-0.11) 32/40866
Kernick (2008)	Undifferentiated headache	Patients ≥ 50 years	0.28 (0.22-0.36) 65/23055
Kernick (2008)	Primary headache	All included patients	0.045 (0.023-0.088) 10/21758
Kernick (2008)	Primary headache	Patients < 50 years	0.03 (0.01-0.08)

			5/16282
Kernick (2008)	Primary headache	Patients $\geq$ 50 years	0.09 (0.03-0.23) 5/5476
Hamilton (2007)	Motor loss	All included patients	0.026 (0.024-0.03)
Hamilton (2007)	New-onset seizure	All included patients	1.2 (1-1.4)
Hamilton (2007)	New-onset seizure*	Patients 60-69 years	2.3 (NR)
Hamilton (2007)	Confusion	All included patients	0.2 (0.16-0.24)
Hamilton (2007)	Memory loss	All included patients	0.036 (0.026-0.052)
Hamilton (2007)	Visual disorder	All included patients	0.035 (0.025-0.051)
Hamilton (2007)	Headache + any of the other symptoms reported by Hamilton (2007)	All included patients	0.39 (0.31-0.48)
Herr (1989)	Dizziness	All included patients	0 (0-3.7) 0/125
Skienziekowski (1980)	Weakness and/or dizziness	All included patients	0 (0-4.4) 0/106
Hamilton (2007)	Weakness	All included patients	0.14 (0.11-0.18)

\* Peak PPVs for these symptoms are in this age group.

Table 2: Brain & CNS cancer: Positive predictive values for any childhood cancer: Patients aged 0-14 years

Study	Symptom(s)	Patient group	Positive predictive value % (95% CI) Frequency
Dommett (2012)	Any NICE alert symptom 0-3 months before diagnosis	All included patients	0.055 (0.047-0.065) Cases: 342/1267 Control: 211/15318
Dommett (2012)	Any NICE alert symptom 0-12 months before diagnosis	All included patients	0.07 (0.064-0.078) Cases: 427/1267 Control: 829/15318
Dommett (2012)	Neurological symptoms 0-12 months before diagnosis	All included patients	0.083 (0.067-0.105) Cases: 108/1267 Control: 207/15318
Dommett (2012)	Headache 0-12 months before diagnosis	All included patients	0.064 (0.051-0.082) Cases: 90/1267 Control: 224/15318
Dommett (2013a)	Headache 0-3 months before diagnosis	All included patients	0.06 (0.04-0.08) Cases: 73/1267 Control: 55/15318
Dommett (2013a)	Headache 0-3 months before diagnosis and $\geq$ 3 consultations	All included patients	0.13 (0.08-0.22)
Dommett (2012)	Lymphadenopathy 0-12 months before diagnosis	All included patients	0.096 (0.074-0.126) Cases: 82/1267 Control: 136/15318
Dommett (2013a)	Lymphadenopathy 0-3 months before diagnosis	All included patients	0.09 (0.06-0.13) Cases: 69/1267 Control: 33/15318
Dommett (2013a)	Lymphadenopathy 0-3 months before diagnosis	All included patients	0.2 (0.1-0.39)

	and $\leq 3$ consultations		
Dommett (2012)	Lump/mass/swelling 0-12 months before diagnosis	All included patients	0.172 (0.119-0.25) Cases: 56/1267 Control: 52/15318
Dommett (2013a)	Lump/mass/swelling below neck excluding abdomen 0-3 months before diagnosis	All included patients	0.11 (0.06-0.2) Cases: 42/1267 Control: 16/15318
Dommett (2013a)	Lump/mass/swelling below neck excluding abdomen 0-3 months before diagnosis and $\geq 3$ consultations	All included patients	0.3 (0.09-0.99)
Dommett (2012)	Fatigue 0-12 months before diagnosis	All included patients	0.085 (0.06-0.121) Cases: 47/1267 Control: 88/15318
Dommett (2013a)	Fatigue 0-12 months before diagnosis	All included patients	0.07 (0.04-0.12) Cases: 42/1267 Control: 24/15318
Dommett (2013a)	Fatigue 0-12 months before diagnosis and $\geq 3$ consultations	All included patients	0.12 (0.06-0.23)
Dommett (2012)	Back pain 0-12 months before diagnosis	All included patients	0.088 (0.06-0.128) Cases: 40/1267 Control: 73/15318
Dommett (2012)	Bruising 0-12 months before diagnosis	All included patients	0.08 (0.054-0.118) Cases: 38/1267 Control: 76/15318
Dommett (2013a)	Bruising 0-3 months before diagnosis	All included patients	0.08 (0.05-0.13) Cases: 33/1267 Control: 18/15318
Dommett (2013a)	Bruising 0-3 months before diagnosis and $\geq 3$ consultations	All included patients	0.38 (0.09-1.64)
Dommett (2013a)	Pallor 0-3 months before diagnosis	All included patients	0.41 (0.12-1.34) Cases: 33/1267 Control: 18/15318
Dommett (2013a)	Pallor 0-3 months before diagnosis and $\geq 3$ consultations	All included patients	0.76 (0.1-5.7)
Dommett (2013a)	Lump mass swelling head and neck 0-3 months before diagnosis	All included patients	0.3 (0.1-0.84) Cases: 28/1267 Control: 4/15318
Dommett (2013a)	Lump mass swelling head and neck 0-3 months before diagnosis and $\leq 3$ consultations	All included patients	0.76 (0.1-5.7)
Dommett (2013a)	Abnormal movement 0-3 months before diagnosis	All included patients	0.08 (0.04-0.14) Cases: 49/1267 Control: 26/15318
Dommett (2013a)	Abnormal movement 0-	All included patients	0.15 (0.07-0.32)



	3 months before diagnosis and $\geq 3$ consultations		
Dommett (2013a)	Bleeding 0-3 months before diagnosis	All included patients	0.06 (0.03-0.1) Cases: 28/1267 Control: 21/15318
Dommett (2013a)	Bleeding 0-3 months before diagnosis and $\geq 3$ consultations	All included patients	0.11 (0.04-0.31)
Dommett (2013a)	Visual symptoms 0-3 months before diagnosis	All included patients	0.06 (0.03-0.1) Cases: 28/1267 Control: 21/15318
Dommett (2013a)	Visual symptoms 0-3 months before diagnosis and $\leq 3$ consultations	All included patients	0.23 (0.07-0.77)
Dommett (2013a)	Pain 0-3 months before diagnosis	All included patients	0.04 (0.03-0.06) Cases: 42/1267 Control: 41/15318
Dommett (2013a)	Pain 0-3 months before diagnosis and $\geq 3$ consultations	All included patients	0.14 (0.07-0.31)
Dommett (2013a)	Musculoskeletal symptoms 0-3 months before diagnosis	All included patients	0.04 (0.03-0.07) Cases: 107/1267 Control: 102/15318
Dommett (2013a)	Musculoskeletal symptoms 0-3 months before diagnosis and $\geq 3$ consultations	All included patients	0.13 (0.08-0.19)
Dommett (2012)	Urinary symptoms 0-12 months before diagnosis	All included patients	0.266 (0.117-0.609) Cases: 15/1267 Control: 9/15318
Dommett (2013a)	$\geq 3$ consultations	All included patients	0.02
Dommett (2013a)	Childhood infection 0-3 months before diagnosis	All included patients	Cases: 54/1267 Control: 236/15318
Dommett (2013a)	Upper respiratory tract infection 0-3 months before diagnosis	All included patients	Cases: 143/1267 Control: 942/15318
Dommett (2013a)	Vomiting 0-3 months before diagnosis	All included patients	Cases: 86/1267 Control: 105/15318
Dommett (2013a)	Cough 0-3 months before diagnosis	All included patients	Cases: 77/1267 Control: 654/15318
Dommett (2013a)	Rash 0-3 months before diagnosis	All included patients	Cases: 63/1267 Control: 555/15318
Dommett (2013a)	Abdominal pain 0-3 months before diagnosis	All included patients	Cases: 60/1267 Control: 137/15318
Dommett (2013a)	Abdominal mass 0-3 months before diagnosis	All included patients	Cases: 48/1267 Control: 0/15318
Dommett (2013a)	Fever 0-3 months before diagnosis	All included patients	Cases: 49/1267 Control: 166/15318
Dommett (2013a)	Eye swelling 0-3 months before diagnosis	All included patients	Cases: 39/1267 Control: 238/15318

Dommett (2013a)	Shortness of breath 0-3 months before diagnosis	All included patients	Cases: 35/1267 Control: 221/15318
Dommett (2013a)	Constipation 0-3 months before diagnosis	All included patients	Cases: 26/1267 Control: 61/15318
Dommett (2012)	Hepatosplenomegaly 0-12 months before diagnosis	All included patients	2.19 (0.295-17.034) Cases: 14/1267 Control: 1/15318

1 The positive predictive values are calculated using Bayesian statistics.

2

3 Table 3: Brain & CNS cancer: Positive predictive values for central nervous system (CNS) child- or  
4 young adulthood cancer tumour

Study	Symptom(s)	Patient group	Positive predictive value % (95% CI) Frequency
Dommett (2013a)	Abnormal movement 0-3 months before diagnosis	All included CNS childhood cancer tumour patients and controls aged 0-14 years	0.11 (0.03-0.35)
Dommett (2013a)	Visual symptoms 0-3 months before diagnosis	All included CNS childhood cancer tumour patients and controls aged 0-14 years	0.07 (0.02-0.24)
Dommett (2013a)	Vomiting 0-3 months before diagnosis	All included CNS childhood cancer tumour patients and controls aged 0-14 years	0.04 (0.02-0.07)
Ansell (2009)	Vomiting and unsteadiness	All included CNS childhood cancer tumour patients and controls aged 0-14 years	0.15 (0.01-0.1) 1/654
Ansell (2009)	Vomiting and visual difficulties	All included CNS childhood cancer tumour patients and controls aged 0-14 years	0.088 (0.005-0.6) 1/1142
Ansell (2009)	Headache and unsteadiness	All included CNS childhood cancer tumour patients and controls aged 0-14 years	0.085 (0.005-0.6) 1/1172
Ansell (2009)	"All other symptom combinations (except vomiting or headache with anorexia) had a predictive probability [of a child having a brain tumour given a visit to a GP with both symptoms] of between 1 in 1500 and 1 in 8000 children". <i>The predictive probabilities of vomiting or headache with anorexia appeared to be even lower.</i>		
Dommett (2013a)	Headache 0-3 months before diagnosis	All included CNS childhood cancer	0.03 (0.02-0.06)

		tumour patients and controls aged 0-14 years	
Kernick (2009)	Headache (any type)	All included patients aged 5-17 years	0.03 (0.01-0.05) 13/48575
Kernick (2009)	Primary headache	All included patients aged 5-17 years	0 (0-0.05) 0/9321
Kernick (2009)	Undifferentiated headache	All included patients aged 5-17 years	0.03 (0.02-0.06) 13/38705
Dommett (2013a)	Pain 0-3 months before diagnosis	All included CNS childhood cancer tumour patients and controls aged 0-14 years	0.03 (0.01-0.08)
Dommett (2013a)	Seizure 0-3 months before diagnosis	All included CNS childhood cancer tumour patients and controls aged 0-14 years	0.02 (0.01-0.06)
Dommett (2013a)	≥ 3 consultations	All included CNS childhood cancer tumour patients and controls aged 0-14 years	0.01 (0-0.01)
Dommett (2013b)	Seizure	All included CNS patients and controls aged 15-24 years	0.0238 (0.0082-0.0695) Cases: 18/154 Controls: 4/1906
Dommett (2013b)	Headache	All included CNS patients and controls aged 15-24 years	0.0145 (0.0077-0.0276) Cases: 33/154 Controls: 12/1906
Dommett (2013b)	Vomiting	All included CNS patients and controls aged 15-24 years	0.0116 (0.0041-0.031) Cases: 11/154 Controls: 5/1906
Dommett (2013b)	Pain	All included CNS patients and controls aged 15-24 years	0.0029 (0.0014-0.006) Cases: 11/154 Controls: 20/1906
Dommett (2013b)	Visual symptoms	All included CNS patients and controls aged 15-24 years	Cases: 8.4% Controls: 0%
Dommett (2013b)	≥ 3 consultations	All included CNS patients and controls aged 15-24 years	0.0023 (0.0019-0.0029) Cases: 73/154 Controls: 165/1906

1 The positive predictive values are calculated using Bayesian statistics.

2

3 **Evidence statement(s):**

1 The positive predictive values of having a brain tumour in adulthood ranged from 0% (for dizziness  
2 and/or weakness) to 2.3% (for new-onset seizure in 60-69 year old patients) for symptomatic  
3 patients presenting to primary care (4 studies, N = 106588). The included studies were associated  
4 with 0-4 bias/applicability concerns each (see also Table 1).

6 The positive predictive values of having any childhood cancer ranged from 0.04% (for pain or  
7 musculoskeletal symptoms) to 2.19% (for hepatosplenomegaly) for symptomatic patients aged 0-14  
8 years old presenting to primary care (1 study, N = 30855). The evidence quality is somewhat  
9 compromised by the case-control design of the study (see also Table 2).

11 The positive predictive values of having central nervous system childhood or young adulthood  
12 cancer tumours ranged from < 0.013% (for vomiting or headache with anorexia) to 0.15 (for  
13 vomiting in combination with unsteadiness) for patients aged 0-14 years old, from 0% (for primary  
14 headache) to 0.03% (for undifferentiated headache) for patients aged 5-17 years, and from 0.0029%  
15 (for pain) to 0.0238% (for seizure) for patients aged 15-24 years (3 studies, N = 79910). The evidence  
16 quality is somewhat compromised by the case-control design of two of the studies (see also Table 3).

18 **Evidence tables**

19 **Ansell (2009)**

<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	National population-based case-control study (United Kingdom Childhood Cancer Study; UKCCS)
Was a consecutive or random sample of patients enrolled?	<b>No</b>
Was a case-control design avoided?	<b>No</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>High risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p><u>Cases:</u> 195 children; mean (SE) age = 7.31 (0.27) years; 93 males/102 females; astrocytoma: N = 78; medulloblastoma: N = 46; other: N = 71.</p> <p><u>Controls:</u> 285 children; mean (SE) age = 7.25 (0.22) years; 142 males/143 females;</p> <p><u>Inclusion criteria:</u> Cases: Children aged 0–14 years newly diagnosed with cancer between 1992-1996 in Great Britain were eligible to take part. Children with brain tumours were recruited from 1992-1994. These data were systematically collected from primary care records by 4 of the 10 UKCCS regions: “GP records were abstracted for 195 of 221 (88%) children with brain tumours and for 286 controls.” Controls: (1-?)2 gender-, month and year of birth-, and region of residence-matched controls were randomly recruited from primary care population</p>

	registers. Exclusion criteria: None listed Clinical setting: Primary care, UK.	
<b>Are there concerns that the included patients and setting do not match the review question?</b>		<b>Low concern</b>
<b>INDEX TEST</b>		
<b>A. Risk of bias</b>		
<b>Index test</b>	Relevant signs and symptoms were defined as those that might be suggestive of a brain tumour: Anorexia, abnormal movements, back problems, cognitive impairment, congenital anomalies, drowsiness, emotional problems, focal weakness, growth problems, head tilt, headache, hearing problems, hydrocephalus, incontinence, papilloedema, problem behaviour, seizures, unsteady on feet, visual problems, vomiting, other neurological signs and symptoms not already included.	
Were the index test results interpreted without knowledge of the results of the reference standard?		<b>Yes</b>
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?		<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>		<b>Low concern</b>
<b>REFERENCE STANDARD</b>		
<b>A. risk of bias</b>		
Reference standard(s)	Cancer diagnosis or not in their General Practice record.	
Is the reference standard likely to correctly classify the target condition?		<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?		<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		<b>Low concern</b>
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	All patients appear to be accounted for.	
Was there an appropriate interval between index test and reference standard?		<b>Yes</b>
Did all patients receive the same reference standard?		<b>Yes</b>
Were all patients included in the analysis?		<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>		<b>Low risk</b>
<b>NOTES</b>		

1

<b>Dommett (2012; 2013a,b)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Population-based nested case-control study using data from the General Practice Research Database (GPRD)
Was a consecutive or random sample of patients enrolled?	<b>No</b>
Was a case-control design avoided?	<b>No</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>High risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p><u>Cases:</u> 1267 children; aged 0-4 years: N = 436; aged 5-14 years: N = 831; 703 males/564 females. Cancer type: Leukemia: N = 368; brain: N = 270; lymphoma: N = 142; bone: N = 107; soft tissue sarcoma: N = 91; renal: N = 82; neuroblastoma: N = 75; other ICD codes: N = 132. 1064 teenagers and young adults (TYA): 15-24 years: Gender not reported. Cancer type: Leukemia: N = 143; brain: N = 154; lymphoma: N = 270; bone: N = 96; soft tissue sarcoma: N = 100; other ICD codes: N = 301 (including testis: N = 60; skin: N = 49; ovary: N = 20 and thyroid: N = 17).</p> <p><u>Controls:</u> 15318 children; aged 0-4 years: N = 4802; aged 5-14 years: N = 10516; 8461 males/6857 females. 13206 TYA. Gender not reported</p> <p><u>Inclusion criteria:</u> The sample comprised all children and TYU aged 0–24 years, inclusive, drawn from all general practices contributing research-standard data to the GPRD between 1 January 1988 and 31 December 2010. To be included, the practices had to have been contributing research-standard data for a minimum of 1 year before each child’s date of cancer diagnosis or the index date (see below) for matched controls. Cases: Patients diagnosed with the following cancers: leukaemia, lymphoma, neuroblastoma, soft tissue sarcoma, hepatic, renal, bone and central nervous system tumours, using pre-defined medical codes used in the GPRD. The date of diagnosis for cases was defined as the date of pathological diagnosis, but if this was unavailable, the date of the first cancer code entered in the GPRD was used. Controls: Up to 13 controls (children with no diagnosis of cancer at any time) were selected per case, using a computer-generated random sequence, matched on age (within 1 year), sex and practice, and had to be currently registered on the date of diagnosis of their matched case (the index date).</p> <p><u>Exclusion criteria:</u> None listed <u>Clinical setting:</u> Primary care, UK.</p>

<b>Are there concerns that the included patients and setting do not match the review question?</b>		<b>Low concern</b>
<b>INDEX TEST</b>		
<b>A. Risk of bias</b>		
<b>Index test</b>	The GPRD uses just over 100 000 medical codes to encompass all primary care events, including both symptoms and diagnoses. From this list, libraries of codes were assembled representing individual alert symptoms derived from the NICE referral guidelines for suspected cancer in children. <i>No more information reported.</i>	
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>	
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?	<b>Yes</b>	
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>	
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>	
<b>REFERENCE STANDARD</b>		
<b>A. risk of bias</b>		
Reference standard(s)	Cancer diagnosis in the UK's General Practice Research Database.	
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>	
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>	
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>	
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>	
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	All patients appear to be accounted for.	
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>	
Did all patients receive the same reference standard?	<b>Yes</b>	
Were all patients included in the analysis?	<b>Yes</b>	
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>	
<b>NOTES</b>	This study is published in three papers. There is almost complete overlap between the patients used in Kernick (2009) with the patients aged 5-17 years in this study.	
1		
2	<b>Hamilton (2007)</b>	
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		

Patient sampling	Population-based nested case-control study using data from the General Practice Research Database (GPRD)	
Was a consecutive or random sample of patients enrolled?	No	
Was a case-control design avoided?	No	
Did the study avoid inappropriate exclusions?	Yes	
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?	Yes	
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?	Yes	
<b>Could the selection of patients have introduced bias?</b>	<b>High risk</b>	
<b><u>B. Concerns regarding applicability</u></b>		
Patient characteristics and setting	<p><u>Cases:</u> 3505 patients with 2397 <i>malignant tumours (incl 948 gliomas and 280 astrocytomas, and other rare tumours; the rest were benign)</i>; aged 18-29 years: N = 159 (malignant tumours N = 134); aged 30-39 years: N = 276 (malignant tumours N = 206); aged 40-49 years: N = 432 (malignant tumours N = 280); aged 50-59 years: N = 675 (malignant tumours N = 471); aged 60-69 years: N = 822 (malignant tumours N = 584); aged 70-79 years: N = 767 (malignant tumours N = 511); aged 80-89 years: N = 339 (malignant tumours N = 191); aged &gt;90 years: N = 35 (malignant tumours N = 20); 1661 males/1844 females.</p> <p><u>Controls:</u> N = 17173 or 24824</p> <p><u>Inclusion criteria:</u> Cases: Patients aged 18 years or over with a brain tumour diagnosed between May 1988 and March 2006, and with at least 2 years of data before the first tumour code (the index date), who had consulted at least once within the 6 months before the index date Controls: 7 randomly selected, practice-, sex- and age (within 1 year)-matched controls were selected per case, who had consulted at least once within the 6 months before the index date.</p> <p><u>Exclusion criteria:</u> Controls: Prior brain tumour. <u>Clinical setting:</u> Primary care, UK.</p>	
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>	
<b>INDEX TEST</b>		
<b><u>A. Risk of bias</u></b>		
<b>Index test</b>	<p>“Libraries of codes for clinical variables previously described with brain tumours were assembled... Occurrences of these variables in the 6 months before the index date in cases and controls were identified. Variables were retained only if they occurred in at least 1% of cases or controls..... Re-consultations with the same symptom were also retained if the subsequent symptom was also present in 1% or more cases or controls. No restriction was placed on reporting of the variable before the 6 month period of study, except for seizures which were only used if the patient had no previous seizure or anticonvulsant therapy code in their records.”</p>	
Were the index test results interpreted without knowledge	Yes	



of the results of the reference standard?		
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?		Yes
<b>Could the conduct or interpretation of the index test have introduced bias?</b>		Low risk
<b>B. Concerns regarding applicability</b>		
Are there concerns that the index test, its conduct, or interpretation differ from the review question?		Low concern
<b>REFERENCE STANDARD</b>		
<b>A. risk of bias</b>		
Reference standard(s)	Brain tumour diagnosis in the UK's General Practice Research Database.	
Is the reference standard likely to correctly classify the target condition?		Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?		Unclear
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>		Low risk
<b>B. Concerns regarding applicability</b>		
Are there concerns that the target condition as defined by the reference standard does not match the question?		Low concern
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	All patients appear to be accounted for.	
Was there an appropriate interval between index test and reference standard?		Yes
Did all patients receive the same reference standard?		Yes
Were all patients included in the analysis?		Yes
<b>Could the patient flow have introduced bias?</b>		Low risk
<b>NOTES</b>	This study includes a significant minority with benign tumours (see "Patient characteristics and setting" above).	
1		
2	<b>Herr (1989)</b>	
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Prospective patient series from a North American hospital emergency department	
Was a consecutive or random sample of patients enrolled?		Unclear
Was a case-control design avoided?		Yes
Did the study avoid inappropriate exclusions?		Unclear
<b>Could the selection of patients have introduced bias?</b>		High risk
<b>B. Concerns regarding applicability</b>		
Patient characteristics and setting	137 patients "representing 46% of the logbook entries for dizziness over this period"; 12 patients were excluded due to missing data leaving 125 patients; 51 males/73 females; mean age (range) = 46.9 (18-82) years.	

	<p><u>Inclusion criteria:</u>  “From March 1, 1986, to August 1, 1987, we sought consecutive patients presenting to the Northwestern Memorial Hospital ED with a chief complaint of “dizzy,” “lightheaded,” “faint,” or synonymous phrase. Each was required to have one or more attributes of dizziness as described by Drachman and Hart [ref given] (Figure 1*). Syncope, medical problems, or previous dizziness were not exclusions provided dizziness was among the presenting chief complaints.” *A definite rotational sensation; a sensation of impending faint or loss of consciousness; disequilibrium or loss of balance without head sensation; ill-defined “lightheadedness” other than vertigo, syncope, or disequilibrium.</p> <p><u>Exclusion criteria:</u> None listed</p> <p><u>Clinical setting:</u> Hospital emergency department, USA.</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>High concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	Chief complaint of “dizzy,” “lightheaded,” “faint,” or synonymous phrase, with one or more of the following attributes of dizziness: A definite rotational sensation; a sensation of impending faint or loss of consciousness; disequilibrium or loss of balance without head sensation; ill-defined “lightheadedness” other than vertigo, syncope, or disequilibrium.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Emergency physicians’ diagnosis and minimum 1-4 weeks follow up.
Is the reference standard likely to correctly classify the target condition?	<b>Unclear</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Unclear concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients appear to be accounted for.
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>

Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	Yes
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	
1	
2	<b>Kernick (2008)</b>
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Cases [patients with a code of headache in their records] from a case-control study using data from the General Practice Research Database (GPRD)
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	85679 patients with a primary or undifferentiated headache: Primary headache: N = 21758, with migraine (N = 15891), tension-type headache (N = 4987), and cluster headache (N = 880); 5795 males/15963 females; median (IQR) age = 38 (29-50) years. Undifferentiated headache: N = 63921; 23200 males/40721 females; median (IQR) age = 41 (30-58) years.  <u>Inclusion criteria:</u> Patients were aged 18 years or over, with a description of headache in their records and no other headache classification code in the previous year. Patients were accepted from the inception of the database in January 1987 to June 2005 who had at least 1 year of full data in their records after the index headache consultation. <u>Exclusion criteria:</u> Patients with a secondary headache that had a further descriptor. <u>Clinical setting:</u> Primary care, UK.
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	Index headache codes were categorised into primary headache (migraine, tension-type headache, or cluster headache). Secondary headaches that had a further descriptor were discarded. All other codes were classified as undifferentiated headache.
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?	Yes
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or</b>	<b>Low concern</b>

<b>interpretation differ from the review question?</b>		
<b>REFERENCE STANDARD</b>		
<b>A. risk of bias</b>		
Reference standard(s)	Headache-related outcome/diagnosis in the UK's General Practice Research Database in the year after the index consultation.	
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>	
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>	
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>	
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>	
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	All patients appear to be accounted for.	
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>	
Did all patients receive the same reference standard?	<b>Yes</b>	
Were all patients included in the analysis?	<b>Yes</b>	
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>	
<b>NOTES</b>		
1		
2 <b>Kernick (2009)</b>		
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Cases [patients with a code of headache in their records] from a case-control study using data from the General Practice Research Database (GPRD)	
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>	
Was a case-control design avoided?	<b>Yes</b>	
Did the study avoid inappropriate exclusions?	<b>Yes</b>	
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>	
<b>B. Concerns regarding applicability</b>		
Patient characteristics and setting	<p>48575 patients with a primary, secondary or undifferentiated headache (21180 males/27395 females; age bands: 5-8 years: N = 3623; 9-12 years: N = 13804; 13-17 years: N = 31148):</p> <p>Primary headache: N = 9321, with migraine (N = 7468), tension-type headache (N = 1565), and cluster headache (N = 288);</p> <p>Secondary headache: N = 549</p> <p>Undifferentiated headache: N = 38705.</p> <p><u>Inclusion criteria:</u> Patients were aged 5-17 years, with a description of headache in their records and no other headache classification code in the previous year. Patients were accepted from the inception of the database in January 1987 to June 2005 who had at least 1 year of full data in their</p>	

	records after the index headache consultation. <u>Exclusion criteria:</u> None listed. <u>Clinical setting:</u> Primary care, UK.	
<b>Are there concerns that the included patients and setting do not match the review question?</b>		<b>Low concern</b>
<b>INDEX TEST</b>		
<b><u>A. Risk of bias</u></b>		
<b>Index test</b>	Index headache codes were categorised into primary headache (migraine, tension-type headache, or cluster headache) or secondary headaches if they had a further descriptor. All other codes were classified as undifferentiated headache.	
Were the index test results interpreted without knowledge of the results of the reference standard?		<b>Yes</b>
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?		<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>		<b>Low risk</b>
<b><u>B. Concerns regarding applicability</u></b>		
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>		<b>Low concern</b>
<b>REFERENCE STANDARD</b>		
<b><u>A. risk of bias</u></b>		
Reference standard(s)	Headache-related outcome/diagnosis in the UK's General Practice Research Database in the year after the index consultation.	
Is the reference standard likely to correctly classify the target condition?		<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?		<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>		<b>Low risk</b>
<b><u>B. Concerns regarding applicability</u></b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		<b>Low concern</b>
<b>FLOW AND TIMING</b>		
<b><u>A. risk of bias</u></b>		
Flow and timing	All patients appear to be accounted for.	
Was there an appropriate interval between index test and reference standard?		<b>Yes</b>
Did all patients receive the same reference standard?		<b>Yes</b>
Were all patients included in the analysis?		<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>		<b>Low risk</b>
<b>NOTES</b>	There is almost complete overlap between the patients used in this study and the patients aged 5-17 years in Dommett (2012, 2013a,b).	
1		
2	<b>Skiendzielewski (1980)</b>	
<b>PATIENT SELECTION</b>		

<b>A. risk of bias</b>	
Patient sampling	Retrospective patient series from a North American hospital emergency department
Was a consecutive or random sample of patients enrolled?	<b>Unclear</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Unclear</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	106 patients; ca 35% were aged < 30 years; age range = 7-88 years; 38 males/68 females; N = 10 with weakness only, N = 85 with dizziness, and N = 15 with a combination of weakness and dizziness.  <u>Inclusion criteria:</u> "We retrospectively studied the cases of 106 patients who presented to the Geisinger Medical Center Emergency Department with the chief complaints of weakness and/or dizziness during a six-month period. The patients were examined by a number of physicians whose experience varied from that of a first-year resident to a staff emergency physician". <u>Exclusion criteria:</u> Cases with specific muscle weakness, e.g., paralysis of a limb. <u>Clinical setting:</u> Hospital emergency department, USA.
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>High concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	Weakness and/or dizziness. Special attention was given to the presence of true vertigo, current medications, physical findings, abnormal laboratory data, and diagnosis on discharge.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Unclear concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	"Follow-up was obtained either from records of subsequent outpatient visits or, more frequently, from personal telephone conversations." 1-7 months.
Is the reference standard likely to correctly classify the target condition?	<b>Unclear</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>High risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined</b>	<b>Unclear concern</b>

<b>by the reference standard does not match the question?</b>	
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients appear to be accounted for.
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	

1

2 **References**3 **Included studies**

- 4 Ansell, P., Johnston, T., Simpson, J., Crouch, S., Roman, E., Picton, S., Ansell, P., Johnston, T.,  
5 Simpson, J., Crouch, S., Roman, E. & Picton, S. (2010) Brain tumor signs and symptoms: analysis of  
6 primary health care records from the UKCCS. *Pediatrics*, 125: 112-119.
- 7 Dommert, R. M., Redaniel, M. T., Stevens, M. C. G., Hamilton, W., and Martin, R. M. Features of  
8 childhood cancer in primary care: A population-based nested case-control study. *British Journal*  
9 *of Cancer* 106[5], 982-987. 2012.
- 10 Dommert, R. M., Redaniel, T., Stevens, M. C. G., Martin, R. M., and Hamilton, W. Risk of childhood  
11 cancer with symptoms in primary care: A population-based case-control study. *British Journal of*  
12 *General Practice*; DOI:10.3399/bjgp13X660742. 2013a.
- 13 Dommert, R. M., Redaniel, M. T., Stevens, M. C. G., Hamilton, W., and Martin, R. M. Features of  
14 cancer in teenagers and young adults in primary care: A population-based nested case-control  
15 study. *British Journal of Cancer* 2329-2333. 2013b.
- 16 Hamilton, W., Kernick, D., Hamilton, W. & Kernick, D. (2007) Clinical features of primary brain  
17 tumours: a case-control study using electronic primary care records. *British Journal of General*  
18 *Practice*, 57: 695-699.
- 19 Herr, R. D., Zun, L. & Mathews, J. J. (1989) A directed approach to the dizzy patient. *Ann Emerg Med*,  
20 18: 664-672.
- 21 Kernick, D., Stapley, S., Goadsby, P. J., Hamilton, W., Kernick, D., Stapley, S., Goadsby, P. J. &  
22 Hamilton, W. (2008) What happens to new-onset headache presented to primary care? A case-  
23 cohort study using electronic primary care records. *Cephalalgia*, 28: 1188-1195.
- 24 Kernick, D., Stapley, S., Campbell, J., Hamilton, W., Kernick, D., Stapley, S., Campbell, J. & Hamilton,  
25 W. (2009) What happens to new-onset headache in children that present to primary care? A  
26 case-cohort study using electronic primary care records. *Cephalalgia*, 29: 1311-1316.
- 27 Skindzielewski, J. J. & Martyak, G. (1980) The weak and dizzy patient. *Ann Emerg Med*, 9: 353-356.

28

29 **Excluded studies (with excl reason)**

- 30 (1999) Communication gaps in paediatric care. *International Journal for Quality in Health Care*, 11:  
31 533-534.  
32 Not in PICO
- 33 Abbas, A. & Abbas, A. (1989) Headache. *Practitioner*, 233: 1081-1084.  
34 Narrative review
- 35 Abernethy Holland, A. J. L. (2008) Central Nervous System/Brain Tumour 2-week Referral Guidelines:  
36 Prospective 3-year Audit. *Clinical Oncology*, 20: 201-202.  
37 Not in PICO
- 38 Abramson, D. H., Beaverson, K., Sangani, P., Vora, R. A., Lee, T. C., Hochberg, H. M., Kirsztot, J.,  
39 Ranjithan, M., Abramson, D. H., Beaverson, K., Sangani, P., Vora, R. A., Lee, T. C., Hochberg, H. M.,

- 1 Kirsztrot, J. & Ranjithan, M. (2003) Screening for retinoblastoma: presenting signs as  
2 prognosticators of patient and ocular survival. *Pediatrics*, 112: 1248-1255.  
3 Not in PICO
- 4 Aggarwal, A. (2011) CNS neoplasm: A missed diagnosis. *Indian Journal of Pediatrics*, 78: 116-117.  
5 Narrative review
- 6 Ahrensberg, J. M., Schroder, H., Hansen, R. P., Olesen, F. & Vedsted, P. (2012) The initial cancer  
7 pathway for children - one-fourth wait more than 3 months. *Acta Paediatrica*, 101: 655-662.  
8 Not in PICO
- 9 Ahrensberg, J. M., Hansen, R. P., Olesen, F., Schröder, H. & Vedsted, P. (2012) Presenting  
10 symptoms of children with cancer: A primary-care population-based study. *British Journal of  
11 General Practice*, 62: e458-s465.  
12 Not in PICO
- 13 Ahrensberg, J. M., Olesen, F., Hansen, R. P., Schroder, H. & Vedsted, P. (2013) Childhood cancer and  
14 factors related to prolonged diagnostic intervals: a Danish population-based study. *British Journal  
15 of Cancer*, 108: 1280-1287.  
16 Not in PICO
- 17 Allcutt, D. A. M. (1992) Presentation and diagnosis of brain tumours. *British Journal of Hospital  
18 Medicine*, 47: 745-752.  
19 Narrative review
- 20 Almeida, C. & Machado, I. (2009) Early diagnosis in childhood cancer: The shortest way for the cure.  
21 *Pediatric Blood and Cancer*, Conference: 846.  
22 Not in PICO
- 23 Alvord, L. S. & Herr, R. D. (1994) ENG in the emergency room: Subtest results in acutely dizzy patients.  
24 *J AM Acad Audiol*, 5: 384-389.  
25 Not in PICO: 21.5% (20/91) patients had unknown diagnosis, final 4-week diagnosis was based on  
26 4-week follow up, and no consistent reference standard.
- 27 Ang, S. H., Chan, Y. C., Mahadevan, M., Ang, S. H., Chan, Y. C. & Mahadevan, M. (2009) Emergency  
28 department headache admissions in an acute care hospital: why do they occur and what can we  
29 do about it? *Annals of the Academy of Medicine, Singapore*, 38: 1007-1010.  
30 Not in PICO
- 31 Antoneli, C. B. S. (2004) The Pediatrician's ability to recognize the presenting signs and symptoms of  
32 retinoblastoma. *Revista da Associação Médica Brasileira (1992)*, 50: 400-402.  
33 Not in PICO
- 34 Arce, D., Sass, P., Abul-Khoudoud, H., Arce, D., Sass, P. & Abul-Khoudoud, H. (2001) Recognizing  
35 spinal cord emergencies. [Review] [18 refs][Erratum appears in Am Fam Physician 2002 May  
36 1;65(9):1751]. *American Family Physician*, 64: 631-638.  
37 Narrative review
- 38 Avery, J. K. (1996) Headache--an important symptom. *The Journal of the Arkansas Medical Society*,  
39 92: 449-450.  
40 Not in PICO
- 41 Badr, H. (2009) Latency of pediatric brain tumors diagnosis in province of Delta, a team experience.  
42 *Egyptian Journal of Neurology, Psychiatry and Neurosurgery*, 46: 323-328.  
43 Not in PICO
- 44 Baggesen, K. (1999) Leukocoria (white pupil) among children--mother is always right. *Tidsskrift for  
45 Den Norske Lægeforening*, 119: 794-795.  
46 Not in PICO
- 47 Bai S. (2011) Delay in the diagnosis of retinoblastoma in China. *Acta Ophthalmologica*, 89: e72-e74.  
48 Not in PICO
- 49 Balestrini, M. R., Micheli, R., Giordano, L., Lasio, G., Giombini, S., Balestrini, M. R., Micheli, R.,  
50 Giordano, L., Lasio, G. & Giombini, S. (1994) Brain tumors with symptomatic onset in the first two



- 1 years of life. *Childs Nervous System*, 10: 104-110.
- 2 Not in PICO
- 3 Balmer, A. (2006) Diagnosis and current management of retinoblastoma. *Oncogene*, 25: 5341-5349.
- 4 Narrative review
- 5 Balmer, A., Munier, F., Balmer, A. & Munier, F. (2007) Differential diagnosis of leukocoria and
- 6 strabismus, first presenting signs of retinoblastoma. *Clinical Ophthalmology*, 1: 431-439.
- 7 Narrative review
- 8 Bartleson, J. D. (2006) When and how to investigate the patient with headache. *Seminars in*
- 9 *Neurology*, 26: 163-170.
- 10 Narrative review
- 11 Bassi, A. (2010) A note-based study of how patients first present with primary brain tumors. *Neuro-*
- 12 *Oncology*, Conference: September.
- 13 Not in PICO
- 14 Becker, L. A., Green, L. A., Beaufait, D., Kirk, J., Froom, J., Freeman, W. L., Becker, L. A., Green, L. A.,
- 15 Beaufait, D., Kirk, J., Froom, J. & Freeman, W. L. (1993) Detection of intracranial tumors,
- 16 subarachnoid hemorrhages, and subdural hematomas in primary care patients: a report from
- 17 ASPN, Part 2. *Journal of Family Practice*, 37: 135-141.
- 18 Not in PICO
- 19 Bird, S. (2010) Failure to diagnose: Brain tumour. *Australian Family Physician*, 39: 335-337.
- 20 Narrative review
- 21 Blanco-Lago, R., M+ílaga-Di+®guez, I., Pardo-Vega, R., Escribano-Garc+ja, C., Bernardo-Fern+índez, B.
- 22 & Fern+índez-Castro, A. (2012) Incidence and characteristics of tumours of the central nervous
- 23 system among the paediatric population of asturias. new data about an incidence on the rise.
- 24 *Revista de Neurologia*, 54: 530-536.
- 25 Not in PICO
- 26 Boesert, P., Gruttner, C., van, E. R. & Haxel, B. (2014) - [Changes in taste ability in patients with
- 27 vestibular schwannoma]. [German]. - *Laryngo- Rhino- Otologie*, 93: 450-454.
- 28 Not in PICO
- 29 Boiardi, A., Salmaggi, A., Eoli, M., Lamperti, E., Silvani, A., Boiardi, A., Salmaggi, A., Eoli, M., Lamperti,
- 30 E. & Silvani, A. (2004) Headache in brain tumours: a symptom to reappraise critically. [Review]
- 31 [15 refs]. *Neurological Sciences*, 25 Suppl 3: S143-S147.
- 32 Narrative review
- 33 Boranic, M. (2003) Solid malignant tumors in children. *Paediatrica Croatica, Supplement*, 47: 19-24.
- 34 Narrative review
- 35 Borgheresi, A. (1985) Epilepsy as the first symptom of a cerebral tumour. Retrospective study of
- 36 seventy cases. *Bollettino - Lega Italiana contro l'Epilessia*, 51-52: 119-121.
- 37 Not in PICO
- 38 Bos, R. F., Ramaker, C., van Ouwkerk, W. J., Linszen, W. H. & Wolf, B. H. (2002) [Vomiting as a first
- 39 neurological sign of brain tumors in children] [Dutch]. *Nederlands Tijdschrift Voor Geneeskunde*,
- 40 146: 1393-1398.
- 41 Not in PICO
- 42 Bracho, M. F. B. (2004) Clinical presentation and delay in the diagnosis of CNS tumours in children.
- 43 *Revista Chilena de Pediatría*, 75: 327-332.
- 44 Not in PICO
- 45 Brasme, J.-F. C. (2012) Interval between onset of symptoms and diagnosis of medulloblastoma in
- 46 children: Distribution and determinants in a population-based study. *European Journal of*
- 47 *Pediatrics*, 171: 25-32.
- 48 Not in PICO
- 49 Brasme, J. F., Morfouace, M., Grill, J., Martinot, A., Amalberti, R., Bons-Letouzey, C., Chalumeau, M.,
- 50 Brasme, J. F., Morfouace, M., Grill, J., Martinot, A., Amalberti, R., Bons-Letouzey, C. & Chalumeau,
- 51 M. (2012) Delays in diagnosis of paediatric cancers: a systematic review and comparison with

- 1 expert testimony in lawsuits. [Review]. *Lancet Oncology*, 13: e445-e459.
- 2 Not in PICO
- 3 Brasme, J. F., Grill, J., Doz, F., Lacour, B., Valteau-Couanet, D., Gaillard, S., Delalande, O., Aghakhani,  
4 N., Puget, S. & Chalumeau, M. (2012) Long time to diagnosis of medulloblastoma in children is  
5 not associated with decreased survival or with worse neurological outcome. *PLoS ONE*, 7.
- 6 Not in PICO
- 7 Brasme, J. F., Chalumeau, M., Doz, F., Lacour, B., Valteau-Couanet, D., Gaillard, S., Delalande, O.,  
8 Aghakhani, N., Sainte-Rose, C., Puget, S., Grill, J., Brasme, J. F., Chalumeau, M., Doz, F., Lacour, B.,  
9 Valteau-Couanet, D., Gaillard, S., Delalande, O., Aghakhani, N., Sainte-Rose, C., Puget, S. & Grill, J.  
10 (2012) Interval between onset of symptoms and diagnosis of medulloblastoma in children:  
11 distribution and determinants in a population-based study. *European Journal of Pediatrics*, 171:  
12 25-32.
- 13 Not in PICO
- 14 Brenner, M., Oakley, C., Lewis, D., Brenner, M., Oakley, C. & Lewis, D. (2008) The evaluation of  
15 children and adolescents with headache. [Review] [20 refs]. *Current Pain & Headache Reports*,  
16 12: 361-366.
- 17 Narrative review
- 18 Butros, L. J., Abramson, D. H., Dunkel, I. J., Butros, L. J., Abramson, D. H. & Dunkel, I. J. (2002)  
19 Delayed diagnosis of retinoblastoma: analysis of degree, cause, and potential consequences.  
20 *Pediatrics*, 109: E45.
- 21 Not in PICO
- 22 Cabral, D. A. T. (1999) Malignancies in children who initially present with rheumatic complaints.  
23 *Journal of Pediatrics*, 134: 53-57.
- 24 Not in PICO
- 25 Calderon-Garciduenas, A. L., Pacheco-Calleros, J., Castelan-Maldonado, E., Necedal-Rustrian, F. C.,  
26 Calderon-Garciduenas, A. L., Pacheco-Calleros, J., Castelan-Maldonado, E. & Necedal-Rustrian, F.  
27 C. (2008) [Primary lymphoma of the central nervous system: 20 years' experience in a referral  
28 hospital]. [Spanish]. *Revista de Neurologia*, 46: 84-88.
- 29 Not in PICO
- 30 Canty, C. A. & Canty, C. A. (2009) Retinoblastoma: an overview for advanced practice nurses.  
31 [Review] [23 refs]. *Journal of the American Academy of Nurse Practitioners*, 21: 149-155.
- 32 Narrative review
- 33 Canzano, J. C. H. (1999) Utility of pupillary dilation for detecting leukocoria in patients with  
34 retinoblastoma. *Pediatrics*, 104: e44.
- 35 Not in PICO
- 36 Cao, M.-H. (2003) Unusual cases of hearing loss in children. *Medecine et Hygiene*, 61: 1957-1961.
- 37 Not in PICO
- 38 Carville, S. (2012) Diagnosis and management of headaches in young people and adults: Summary of  
39 NICE guidance. *BMJ (Online)*, 345.
- 40 Guideline
- 41 Cea-Soriano, L., Wallander, M. A., Garcia Rodriguez, L. A., Cea-Soriano, L., Wallander, M. A. & Garcia  
42 Rodriguez, L. A. (2012) Epidemiology of meningioma in the United Kingdom. *Neuroepidemiology*,  
43 39: 27-34.
- 44 Not in PICO
- 45 Chacowry, P. K., Platon, A. & Delemont, C. (1724) [Imaging in the evaluation of headaches]. [French].  
46 *Revue Medicale Suisse*, 9: 1720-1722.
- 47 Narrative review
- 48 Chen, H. Y., Wu, D. L., Tsai, R. K., Chen, H. Y., Wu, D. L. & Tsai, R. K. (1998) Acute esotropia may be a  
49 presenting sign of intracranial neoplasm. *Kaohsiung Journal of Medical Sciences*, 14: 710-716.
- 50 Not in PICO

- 1 Cheng, K.-S. (2009) Short Stature Without Neurological Manifestations in a Child with a Suprasellar  
2 Tumor. *Tzu Chi Medical Journal*, 21: 161-164.  
3 Not in PICO
- 4 Cho, J. C., Miller, A., Kettner, N. W., Cho, J. C. S., Miller, A. & Kettner, N. W. (2009) Cervical  
5 ependymoma in a male adolescent with neck and back pain. *Journal of Manipulative &  
6 Physiological Therapeutics*, 32: 695-700.  
7 Not in PICO
- 8 Ciobanu, A., Miron, I., Tansanu, I., Ciobanu, A., Miron, I. & Tansanu, I. (2012) [Features of brain stem  
9 tumors in children]. [Romanian]. *Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti  
10 Din Iasi*, 116: 56-61.  
11 Not in PICO
- 12 Comi, A. M., Backstrom, J. W., Burger, P. C., Duffner, P. K., Comi, A. M., Backstrom, J. W., Burger, P.  
13 C. & Duffner, P. K. (1998) Clinical and neuroradiologic findings in infants with intracranial  
14 ependymomas. Pediatric Oncology Group. *Pediatric Neurology*, 18: 23-29.  
15 Not in PICO
- 16 Crawford, J. R., Santi, M. R., Vezina, G., Myseros, J. S., Keating, R. F., LaFond, D. A., Rood, B. R.,  
17 MacDonald, T. J. & Packer, R. J. (2007) CNS germ cell tumor (CNSGCT) of childhood: presentation  
18 and delayed diagnosis. *Neurology*, 68: 1668-1673.  
19 Not in PICO
- 20 Creutzig, U. G. (1995) Early diagnosis of neoplastic diseases in childhood. *Onkologie*, 18: 24-27.  
21 Narrative review
- 22 Crummer, R. W., Hassan, G. A., Crummer, R. W. & Hassan, G. A. (2004) Diagnostic approach to  
23 tinnitus. [Review] [21 refs]. *American Family Physician*, 69: 120-126.  
24 Narrative review
- 25 Dai, A. I., Backstrom, J. W., Burger, P. C., Duffner, P. K., Dai, A. I., Backstrom, J. W., Burger, P. C. &  
26 Duffner, P. K. (2003) Supratentorial primitive neuroectodermal tumors of infancy: clinical and  
27 radiologic findings. *Pediatric Neurology*, 29: 430-434.  
28 Not in PICO
- 29 Damek, D. M. (2009) Cerebral Edema, Altered Mental Status, Seizures, Acute Stroke, Leptomeningeal  
30 Metastases, and Paraneoplastic Syndrome. *Emergency Medicine Clinics of North America*, 27:  
31 209-229.  
32 Narrative review
- 33 Dang-Tan, T., Trottier, H., Mery, L. S., Morrison, H. I., Barr, R. D., Greenberg, M. L. & Franco, E. L.  
34 (2008) Delays in diagnosis and treatment among children and adolescents with cancer in Canada.  
35 *Pediatric Blood & Cancer*, 51: 468-474.  
36 Not in PICO
- 37 Davies E. Clarke (2004) Early symptoms of brain tumours. *Journal of Neurology, Neurosurgery and  
38 Psychiatry*, 75: 1205-1206.  
39 Not in PICO
- 40 de Aguirre, J. C., Antoneli, C. B. G., Ribeiro, K. B., Simoes, M., Novaes, P. E. R. S., Chojniak, M. M. M. &  
41 Arias, V. (2007) Retinoblastoma in children older than 5 years of age. *Pediatric Blood & Cancer*,  
42 48: 292-295.  
43 Not in PICO
- 44 De Donato, G. (1995) Incidence of normal hearing in acoustic neuroma. *Acta otorhinolaryngologica  
45 Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale*,  
46 15: 73-79.  
47 Not in PICO
- 48 De Vile, C. J., Sufraz, R., Lask, B. D., Stanhope, R., De Vile, C. J., Sufraz, R., Lask, B. D. & Stanhope, R.  
49 (1995) Occult intracranial tumours masquerading as early onset anorexia nervosa. *BMJ*, 311:  
50 1359-1360.  
51 Not in PICO

- 1 De, R., Moffat, D. A., De, R. & Moffat, D. A. (506) The GP's role in acoustic neuroma. *Practitioner*,  
2 248: 501-506.  
3 Narrative review
- 4 Del Zoppo, P. (2009) Unforgettable cases in pediatric general practice: "Vomit of students and  
5 others". *Medico e Bambino*, 28: 187.  
6 Not in PICO
- 7 DeVile, C. J. S. (1995) Occult intracranial tumours masquerading as early onset anorexia nervosa.  
8 *British Medical Journal*, 311: 1359-1360.  
9 Not in PICO
- 10 Dixon-Woods, M., Findlay, M., Young, B., Cox, H., Heney, D., Dixon-Woods, M., Findlay, M., Young,  
11 B., Cox, H. & Heney, D. (2001) Parents' accounts of obtaining a diagnosis of childhood cancer.  
12 *Lancet*, 357: 670-674.  
13 Not in PICO
- 14 Dobes, M., Shadbolt, B., Khurana, V. G., Jain, S., Smith, S. F., Smee, R., Dexter, M., Cook, R., Dobes,  
15 M., Shadbolt, B., Khurana, V. G., Jain, S., Smith, S. F., Smee, R., Dexter, M. & Cook, R. (2011) A  
16 multicenter study of primary brain tumor incidence in Australia (2000-2008). *Neuro-Oncology*, 13:  
17 783-790.  
18 Not in PICO
- 19 Dobrovoljac, M., Hengartner, H., Boltshauser, E. & Grotzer, M. A. (2002) Delay in the diagnosis of  
20 paediatric brain tumours. *European Journal of Pediatrics*, 161: 663-667.  
21 Not in PICO
- 22 Dorner, L. (2007) Posterior fossa tumors in children: How long does it take to establish the  
23 diagnosis? *Child's Nervous System*, 23: 887-890.  
24 Not in PICO
- 25 Dorronsoro, M., I (2004) Malignant disease presenting as rheumatic manifestations. *Anales de*  
26 *Pediatría*, 61: 393-397.  
27 Not in PICO
- 28 Dorsch, J. N. (2014) Neurologic syndromes of the head and neck. *Primary Care - Clinics in Office*  
29 *Practice*, 41: 133-149.  
30 Narrative review
- 31 Dorsch, J. N. (2014) Neurologic syndromes of the head and neck. *Primary Care - Clinics in Office*  
32 *Practice*, 41: 133-149.  
33 Narrative review
- 34 Drexler, E. D. & Drexler, E. D. (173) Severe headaches. When to worry, what to do. *Postgraduate*  
35 *Medicine*, 87: 164-173.  
36 Narrative review
- 37 Edgeworth, J., Bullock, P., Bailey, A., Gallagher, A., Crouchman, M., Edgeworth, J., Bullock, P., Bailey,  
38 A., Gallagher, A. & Crouchman, M. (1996) Why are brain tumours still being missed? *Archives of*  
39 *Disease in Childhood*, 74: 148-151.  
40 Not in PICO
- 41 Eitel, B. & Eitel, B. (1987) [Ambulatory diagnosis and outpatient management of patients with  
42 hypophyseal adenomas]. [German]. *Zeitschrift für Die Gesamte Innere Medizin und Ihre*  
43 *Grenzgebiete*, 42: 321-324.  
44 Not in PICO
- 45 El Shakankiry, H. (2012) Migraine in the paediatric age group: A diagnostic challenge. *Developmental*  
46 *Medicine and Child Neurology*, Conference: June.  
47 Not in PICO
- 48 Epelman, S. & Epelman, S. (2012) Preserving vision in retinoblastoma through early detection and  
49 intervention. *Current Oncology Reports*, 14: 213-219.  
50 Narrative review

- 1 Fattal-Valevski, A., Nissan, N., Kramer, U. & Constantini, S. (2013) Seizures as the clinical presenting  
2 symptom in children with brain tumors. *Journal of Child Neurology*, 28: 292-296.  
3 Not in PICO
- 4 Fazzini, F. (2006) Epilepsy secondary to early onset brain tumors (< 3 yrs). *Bollettino - Lega Italiana*  
5 *contro l'Epilessia*, 165-166.  
6 Not in PICO
- 7 Fern, L. A. C. (2011) How frequently do young people with potential cancer symptoms present in  
8 primary care? *British Journal of General Practice*, 61: e223-e230.  
9 Not in PICO
- 10 Fernandez, A. (2010) Prevalence of pituitary adenomas: A community-based, cross-sectional study in  
11 Banbury (Oxfordshire, UK). *Clinical Endocrinology*, 72: 377-382.  
12 Not in PICO
- 13 Fernandez, C. P. A. (2007) Clinical practice guideline for the diagnosis and treatment of  
14 craniopharyngioma and other parasellar lesions. *Endocrinologia y Nutricion*, 54: 13-22.  
15 Narrative review
- 16 Field, M., Shanley, S. & Kirk, J. (2007) Inherited cancer susceptibility syndromes in paediatric  
17 practice. *Journal of Paediatrics and Child Health*, 43: 219-229.  
18 Narrative review
- 19 Fleming, A. J., Chi, S. N., Fleming, A. J. & Chi, S. N. (2012) Brain tumors in children. [Review]. *Current*  
20 *Problems in Pediatric & Adolescent Health Care*, 42: 80-103.  
21 Not in PICO
- 22 Flores, L. E., Williams, D. L., Bell, B. A., O'Brien, M., Ragab, A. H., Flores, L. E., Williams, D. L., Bell, B.  
23 A., O'Brien, M. & Ragab, A. H. (1986) Delay in the diagnosis of pediatric brain tumors. *American*  
24 *Journal of Diseases of Children*, 140: 684-686.  
25 Not in PICO
- 26 Forgie, S. E. & Robinson, J. L. (2007) Pediatric malignancies presenting as a possible infectious  
27 disease. *BMC Infectious Diseases*, 7.  
28 Not in PICO
- 29 Forsyth, P. A., Posner, J. B., Forsyth, P. A. & Posner, J. B. (1993) Headaches in patients with brain  
30 tumors: a study of 111 patients. *Neurology*, 43: 1678-1683.  
31 Not in PICO
- 32 Fruhwald, M. C., Rutkowski, S., Fruhwald, M. C. & Rutkowski, S. (2011) Tumors of the central nervous  
33 system in children and adolescents. [Review]. *Deutsches Arzteblatt International*, 108: 390-397.  
34 Narrative review
- 35 Fu, X. (1996) Ocular symptoms of tumors at sella turcica region. *Yan ke xue bao = Eye science / "Yan*  
36 *ke xue bao" bian ji bu*, 12: 166-168.  
37 Not in PICO
- 38 Furuta, T., Tabuchi, A., Adachi, Y., Mizumatsu, S., Tamesa, N., Ichikawa, T., Tamiya, T., Matsumoto,  
39 K., Ohmoto, T., Furuta, T., Tabuchi, A., Adachi, Y., Mizumatsu, S., Tamesa, N., Ichikawa, T., Tamiya,  
40 T., Matsumoto, K. & Ohmoto, T. (1998) Primary brain tumors in children under age 3 years. *Brain*  
41 *Tumor Pathology*, 15: 7-12.  
42 Not in PICO
- 43 Galassi, E., Godano, U., Cavallo, M., Donati, R., Nasi, M. T., Galassi, E., Godano, U., Cavallo, M.,  
44 Donati, R. & Nasi, M. T. (1989) Intracranial tumors during the 1st year of life.[Erratum appears in  
45 Childs Nerv Syst 1990 May;6(3):184]. *Childs Nervous System*, 5: 288-298.  
46 Not in PICO
- 47 Garcia, H. B. (2008) Suspicion of cancer in pediatrics. *Pediatrica Integral*, 12: 537-544.  
48 Narrative review
- 49 Gardner, M., Hess, C. & Josephson, S. (2013) Utilization and outcomes of cranial computed  
50 tomography in a pediatric population. *Neurology*, 80.  
51 Not in PICO

- 1 Garnett, M. R., Puget, S., Grill, J. & Sainte-Rose, C. (2007) Craniopharyngioma. *Orphanet Journal of*  
 2 *Rare Diseases*, 2: 18.  
 3 Narrative review
- 4 George, J. L., Marchal, J. C., George, J. L. & Marchal, J. C. (2010) [Orbital tumors in children: clinical  
 5 examination, imaging, specific progression]. [French]. *Neuro-Chirurgie*, 56: 244-248.  
 6 Narrative review
- 7 Gerber, N. U., Von Hoff, K., Von Bueren, A. O., Treulieb, W., Deinlein, F., Benesch, M., Zwiener, I.,  
 8 Soerensen, N., Warmuth-Metz, M., Pietsch, T., Mittler, U., Kuehl, J., Kortmann, R. D., Grotzer, M.  
 9 A. & Rutkowski, S. (2012) A long duration of the prediagnostic symptomatic interval is not  
 10 associated with an unfavourable prognosis in childhood medulloblastoma. *European Journal of*  
 11 *Cancer*, 48: 2028-2036.  
 12 Not in PICO
- 13 Giercke, K., Schutt, H., Giercke, K. & Schutt, H. (1983) [Early recognition of tumors of the CNS].  
 14 [German]. *Psychiatrie, Neurologie und Medizinische Psychologie*, 35: 541-546.  
 15 Not in PICO
- 16 Goadsby, P. J. (2004) To scan or not to scan in headache. *British Medical Journal*, 329: 469-470.  
 17 Narrative review
- 18 Goddard, A. G. K. (1999) Delay in diagnosis of retinoblastoma: Risk factors and treatment outcome.  
 19 *British Journal of Ophthalmology*, 83: 1320-1323.  
 20 Not in PICO
- 21 Goldman, A. (2006) Symptoms in children/young people with progressive malignant disease: United  
 22 Kingdom Children's Cancer Study Group/Paediatric Oncology Nurses Forum Survey. *Pediatrics*,  
 23 117: e1179-e1186.  
 24 Not in PICO
- 25 Gordon, G. S., Wallace, S. J., Neal, J. W., Gordon, G. S., Wallace, S. J. & Neal, J. W. (1995) Intracranial  
 26 tumours during the first two years of life: presenting features. *Archives of Disease in Childhood*,  
 27 73: 345-347.  
 28 Not in PICO
- 29 Grant, R. (2004) Overview: Brain tumour diagnosis and management/Royal College of Physicians  
 30 guidelines. *Neurology in Practice*, 75: ii18-ii23.  
 31 Guideline
- 32 Grattan-Smith, P. J., Ryan, M. M. & Procopis, P. G. (2000) Persistent or severe back pain and stiffness  
 33 are ominous symptoms requiring prompt attention. *Journal of Paediatrics and Child Health*, 36:  
 34 208-212.  
 35 Not in PICO
- 36 Grondin, R. T. S. (2009) Pediatric Brain Tumors. *Advances in Pediatrics*, 56: 249-269.  
 37 Narrative review
- 38 Gurney, J. G., Mueller, B. A., Preston-Martin, S., McDaniel, A. M., Holly, E. A., Pogoda, J. M., Davis, R.  
 39 L., Gurney, J. G., Mueller, B. A., Preston-Martin, S., McDaniel, A. M., Holly, E. A., Pogoda, J. M. &  
 40 Davis, R. L. (1997) A study of pediatric brain tumors and their association with epilepsy and  
 41 anticonvulsant use. *Neuroepidemiology*, 16: 248-255.  
 42 Not in PICO
- 43 Haider S. (2008) Leukocoria in children. *Journal of Pediatric Ophthalmology and Strabismus*, 45: 179-  
 44 180.  
 45 Not in PICO
- 46 Haimi, M., Nahum, M. P. & Ben Arush, M. W. (2004) Delay in diagnosis of children with cancer: A  
 47 retrospective study of 315 children. *Pediatric Hematology and Oncology*, 21: 37-48.  
 48 Not in PICO
- 49 Haldorsen, I. S., Espeland, A., Larsen, J. L., Mella, O., Haldorsen, I. S., Espeland, A., Larsen, J. L. &  
 50 Mella, O. (2005) Diagnostic delay in primary central nervous system lymphoma. *Acta Oncologica*,

- 1 44: 728-734.  
2 Not in PICO  
3 Halperin, E. C., Watson, D. M. & George, S. L. (2001) Duration of symptoms prior to diagnosis is  
4 related inversely to presenting disease stage in children with medulloblastoma. *Cancer*, 91: 1444-  
5 1450.  
6 Not in PICO  
7 Hamdan, A. & Mitchell, P. (2012) The Two-Week Wait Rule for Suspected Cns/Brain Tumours in the  
8 Uk: A Decade Analysis of Referral Patterns, Guideline Compliance and Diagnostic Efficacy. *Neuro-  
9 Oncology*, 14: 20.  
10 Not in PICO  
11 Hamdan, A. & Mitchell, P. (2013) The two-week wait guideline for suspected CNS tumours: A decade  
12 analysis. *British Journal of Neurosurgery*, 27: 642-645.  
13 Not in PICO  
14 Hamilton, W. (2008) The price of diagnosis. *British Journal of General Practice*, 58: 837-838.  
15 Not in PICO  
16 Hamilton, W. (2009) The CAPER studies: Five case-control studies aimed at identifying and  
17 quantifying the risk of cancer in symptomatic primary care patients. *British Journal of Cancer*,  
18 101: S80-S86.  
19 Narrative review  
20 Harcourt, J. P., Vijaya-Sekaran, S., Loney, E., Lennox, P., Harcourt, J. P., Vijaya-Sekaran, S., Loney, E. &  
21 Lennox, P. (1999) The incidence of symptoms consistent with cerebellopontine angle lesions in a  
22 general ENT out-patient clinic. *Journal of Laryngology & Otology*, 113: 518-522.  
23 Not in PICO  
24 Hartley, P. (2001) Curing cancer in children - Early recognition and appropriate treatment are the  
25 key. *South African Medical Journal*, 91: 40-42.  
26 Narrative review  
27 Hayashi, N., Kidokoro, H., Miyajima, Y., Fukazawa, T., Natsume, J., Kubota, T. & Kojima, S. (2010)  
28 How do the clinical features of brain tumours in childhood progress before diagnosis? *Brain and  
29 Development*, 32: 636-641.  
30 Not in PICO  
31 Heathcote, A. C., Wormald, J. C. R. & Stocks, R. (2012) An unusual suspect causing behavioural  
32 problems and pituitary failure in a child. *BMJ Case Reports*.  
33 Not in PICO  
34 Hered, R. W. (2011) Effective vision screening of young children in the pediatric office. *Pediatric  
35 Annals*, 40: 76-82.  
36 Narrative review  
37 Higelin, F. G. (1997) Emergency medicine for the practitioner: headaches. *Revue Medicale de la  
38 Suisse Romande*, 117: 295-298.  
39 Not in PICO  
40 Hoffman, R. M., Einstadter, D., Kroenke, K., Hoffman, R. M., Einstadter, D. & Kroenke, K. (1999)  
41 Evaluating dizziness. *American Journal of Medicine*, 107: 468-478.  
42 Semi-systematic review, have checked included studies for relevance  
43 Hortedahl, K. (2012) Clinical competence and childhood cancer - A view from primary care. *Acta  
44 Paediatrica, International Journal of Paediatrics*, 101: 559-561.  
45 Narrative review  
46 Huang, X., X (2012) Clinical features of intracranial vestibular schwannomas. *Oncology Letters*, 5: 57-  
47 62.  
48 Not in PICO  
49 Idowu, O. (2007) Symptomatic primary intracranial neoplasms in Nigeria, West Africa. *Journal of  
50 Neurological Sciences*, 24: 212-218.  
51 Not in PICO

- 1 Inci, M. F. O. (2012) A rare presentation of craniopharyngioma: Delayed puberty. *BMJ Case Reports*, ,  
2 2012. Date of Publication: 2012.  
3 Narrative review
- 4 Ivey, J. B., Brown, R. D., Ivey, J. B. & Brown, R. D. (2007) She passed out again. Astrocytomas.  
5 *Pediatric Nursing*, 33: 430-431.  
6 Not in PICO
- 7 Jackson, C., Glasson, W., Jackson, C. & Glasson, W. (1998) Prevention of visual loss. Screening in  
8 general practice. *Australian Family Physician*, 27: 150-153.  
9 Narrative review
- 10 Jahn, K. & Jahn, K. (2009) [Vertigo in children. Clinical presentation, course and treatment]. [Review]  
11 [37 refs] [German]. *Nervenarzt*, 80: 900-908.  
12 Narrative review
- 13 Jaklewicz, H. & Dilling-Ostrowska, E. (1980) Psychiatric symptomatology in cerebral tumour in  
14 children. [Polish]. *Psychiatria Polska*, 4: 229-233.  
15 Not in PICO
- 16 Jellema, K., Overbeeke, J. J., Teepen, H. L., Visser, L. H., Jellema, K., Overbeeke, J. J., Teepen, H. L. J.  
17 M. & Visser, L. H. (2005) Time to diagnosis of intraspinal tumors. *European Journal of Neurology*,  
18 12: 621-624.  
19 Not in PICO
- 20 Johnson, A. H., Jordan, C., Mazewski, C. M., Johnson, A. H., Jordan, C. & Mazewski, C. M. (2009) Off-  
21 therapy headaches in pediatric brain tumor patients: a retrospective review. *Journal of Pediatric*  
22 *Oncology Nursing*, 26: 354-361.  
23 Not in PICO
- 24 Jooma, R., Hayward, R. D., Grant, D. N., Jooma, R., Hayward, R. D. & Grant, D. N. (1984) Intracranial  
25 neoplasms during the first year of life: analysis of one hundred consecutive cases. *Neurosurgery*,  
26 14: 31-41.  
27 Not in PICO
- 28 Joseph, E. & Joseph, E. (1983) Vertigo in children: two cases of 'scarlet face'. Authentic case histories  
29 from Australian general practice illustrating pitfalls in diagnosis and management. *Australian*  
30 *Family Physician*, 12: 516.  
31 Not in PICO
- 32 Kabbouche, M. A., Cleves, C., Kabbouche, M. A. & Cleves, C. (2010) Evaluation and management of  
33 children and adolescents presenting with an acute setting. *Seminars in Pediatric Neurology*, 17:  
34 105-108.  
35 Narrative review
- 36 Kaimbo, W. K. M. (2002) Presenting signs of retinoblastoma in Congolese patients. *Bulletin de la*  
37 *Societe belge d'ophtalmologie*, 37-41.  
38 Not in PICO
- 39 Kaiserova, E. (2004) Early diagnostics of central nervous system tumours in children. *Lekarsky Obzor*,  
40 53: 133-139.  
41 Narrative review
- 42 Kallio, M., Ilveskoski, I., Kallio, M. & Ilveskoski, I. (1995) [When should you suspect a brain tumor?].  
43 [Review] [5 refs] [Finnish]. *Duodecim*, 111: 2009-2012.  
44 Narrative review
- 45 Kameda-Smith, M. M., White, M. A., George, E. J. & Brown, J. I. (2012) Time to diagnosis of  
46 paediatric posterior fossa tumours: an 11-year West of Scotland experience 2000-2011. *British*  
47 *Journal of Neurosurgery*.  
48 Not in PICO
- 49 Kameda-Smith, M. M., White, M. A., St George, E. J. & Brown, J. I. (2013) Time to diagnosis of  
50 paediatric posterior fossa tumours: an 11-year West of Scotland experience 2000-2011. *British*



- 1 *Journal of Neurosurgery*, 27: 364-369.
- 2 Not in PICO
- 3 Kantar, M., Ertan, Y., Turhan, T., Kitis, O., Anacak, Y., Akalin, T., Ersahin, Y., Cetingul, N., Kantar, M.,  
4 Ertan, Y., Turhan, T., Kitis, O., Anacak, Y., Akalin, T., Ersahin, Y. & Cetingul, N. (2009) Anaplastic  
5 astroblastoma of childhood: aggressive behavior. *Childs Nervous System*, 25: 1125-1129.
- 6 Not in PICO
- 7 Karatas, M. (2008) Central vertigo and dizziness: Epidemiology, differential diagnosis, and common  
8 causes. *Neurologist*, 14: 355-364.
- 9 Narrative review
- 10 Kato, M., Nakamura, H., Terai, H., Konishi, S., Nagayama, R., Takaoka, K., Kato, M., Nakamura, H.,  
11 Terai, H., Konishi, S., Nagayama, R. & Takaoka, K. (2008) Why does delay exist in the diagnosis of  
12 intradural spinal cord tumor despite the availability of MRI? *Journal of Clinical Neuroscience*, 15:  
13 880-885.
- 14 Not in PICO
- 15 Keeble, S., Abel, G. A., Saunders, C. L., McPhail, S., Walter, F. M., Neal, R. D., Rubin, G. P. &  
16 Lyratzopoulos, G. (2014) Variation in promptness of presentation among 10,297 patients  
17 subsequently diagnosed with one of 18 cancers: Evidence from a National Audit of Cancer  
18 Diagnosis in Primary Care. *International Journal of Cancer*, 135: 1220-1228.
- 19 Not in PICO
- 20 Kerber, K. A., Meurer, W. J., West, B. T., Fendrick, A. M., Kerber, K. A., Meurer, W. J., West, B. T. &  
21 Fendrick, A. M. (2008) Dizziness presentations in U.S. emergency departments, 1995-2004.  
22 *Academic Emergency Medicine*, 15: 744-750.
- 23 Not in PICO (no reference standard)
- 24 Kernick, D., Williams, S., Kernick, D. & Williams, S. (2011) Should GPs have direct access to  
25 neuroradiological investigation when adults present with headache? *British Journal of General  
26 Practice*, 61: 409-411.
- 27 Narrative review
- 28 Kernick, D. P. A. (2008) Imaging patients with suspected brain tumour: Guidance for primary care.  
29 *British Journal of General Practice*, 58: 880-885.
- 30 Narrative review
- 31 Kesser, B. W. & Kesser, B. W. (2010) Clinical thresholds for when to test for retrocochlear lesions:  
32 con. [Review] [15 refs]. *Archives of Otolaryngology -- Head & Neck Surgery*, 136: 727-729.
- 33 Narrative review
- 34 Kieran, M. W., Walker, D., Frappaz, D., Prados, M., Kieran, M. W., Walker, D., Frappaz, D. & Prados,  
35 M. (2010) Brain tumors: from childhood through adolescence into adulthood. [Review]. *Journal of  
36 Clinical Oncology*, 28: 4783-4789.
- 37 Narrative review
- 38 Klitbo, D. M., Nielsen, R., Illum, N. O., Wehner, P. S., Carlsen, N., Klitbo, D. M., Nielsen, R., Illum, N.  
39 O., Wehner, P. S. & Carlsen, N. (2011) Symptoms and time to diagnosis in children with brain  
40 tumours. *Danish Medical Bulletin*, 58: A4285.
- 41 Not in PICO
- 42 Kochanova, I. S. (2004) Adenoma of the pituitary gland in the ophthalmologist's out-patient practice.  
43 *Ceska a Slovenska Oftalmologie*, 60: 348-355.
- 44 Not in PICO
- 45 Kroenke, K., Hoffman, R. M., Einstadter, D., Kroenke, K., Hoffman, R. M. & Einstadter, D. (2000) How  
46 common are various causes of dizziness? A critical review. [Review] [40 refs]. *Southern Medical  
47 Journal*, 93: 160-167.
- 48 Semi-systematic review, have checked included studies for relevance
- 49 Kroenke, K. L. (1992) Causes of persistent dizziness. A prospective study of 100 patients in  
50 ambulatory care. *Annals of Internal Medicine*, 117: 898-904.
- 51 Not in PICO (reference standard)

- 1 Kukal, K., Dobrovoljac, M., Boltshauser, E., Ammann, R. A., Grotzer, M. A., Kukal, K., Dobrovoljac, M.,  
2 Boltshauser, E., Ammann, R. A. & Grotzer, M. A. (2009) Does diagnostic delay result in decreased  
3 survival in paediatric brain tumours? *European Journal of Pediatrics*, 168: 303-310.  
4 Not in PICO
- 5 Kyprianou, I. & Nassab, R. (2005) A comparative study of referral patterns and management of  
6 patients with malignant brain tumours in Birmingham, UK, and Toronto, Canada. *British Journal  
7 of Neurosurgery*, 19: 229-234.  
8 Not in PICO
- 9 Larner, A. J. (2006) Referral guidelines for suspected central nervous system or brain tumours.  
10 *Journal of Neurology Neurosurgery and Psychiatry*, 77: 1305-1306.  
11 Guideline
- 12 Lateef, T. M., Grewal, M., McClintock, W., Chamberlain, J., Kaulas, H. & Nelson, K. B. (2009)  
13 Headache in Young Children in the Emergency Department: Use of Computed Tomography.  
14 *Pediatrics*, 124: E12-E17.  
15 Not in PICO
- 16 Lefavre, J. F., Cohen, S. R., Riski, J. E., Burstein, F. D., Lefavre, J. F., Cohen, S. R., Riski, J. E. &  
17 Burstein, F. D. (1997) Velopharyngeal incompetence as the presenting symptom of malignant  
18 brainstem tumor. *Cleft Palate-Craniofacial Journal*, 34: 154-158.  
19 Not in PICO
- 20 Leone, M. A., Ivashynka, A. V., Tonini, M. C., Bogliun, G., Montano, V., Ravetti, C., Gambaro, P.,  
21 Paladin, F., Beghi, E., ARES (Alcohol Related Seizures) study group., Leone, M. A., Ivashynka, A. V.,  
22 Tonini, M. C., Bogliun, G., Montano, V., Ravetti, C., Gambaro, P., Paladin, F., Beghi, E. & ARES  
23 (Alcohol Related Seizures) study group. (2011) Risk factors for a first epileptic seizure  
24 symptomatic of brain tumour or brain vascular malformation. A case control study. *Swiss Medical  
25 Weekly*, 141: w13155.  
26 Not in PICO
- 27 Lewis, D. W. (1996) Pediatric headaches: What do the children want? *Headache: The Journal of Head  
28 and Face Pain*, 36.  
29 Not in PICO
- 30 Listernick, R. (2003) A 9-year-old boy with bizarre behavior and growth delay. *Pediatric Annals*, 32:  
31 292-295.  
32 Not in PICO
- 33 Lobo-Antunes, N. & Lobo-Antunes, N. (1999) [Urgent neurological consultation in children with  
34 systemic cancer]. [Review] [140 refs] [Spanish]. *Revista de Neurologia*, 29: 349-359.  
35 Not in PICO
- 36 Loh, A. H. P., Aung, L., Ha, C., Tan, A. M., Quah, T. C. & Chui, C. H. (2012) Diagnostic delay in pediatric  
37 solid tumors: A population based study on determinants and impact on outcomes. *Pediatric  
38 Blood and Cancer*, 58: 561-565.  
39 Not in PICO
- 40 Lovrencic-Huzjan, A., Jadrijevic-Tomas, A., Samovojska, D., Cindric, I., Bencina, B., Bedekovic, M. R. &  
41 Kes, V. B. (2013) One year study of vertigo in the neurological emergency room. *Acta Clinica  
42 Croatica, Supplement*, 52: 73.  
43 Not in PICO
- 44 Lueder, G. T. (2005) The effect of initial recognition of abnormalities by physicians on outcome of  
45 retinoblastoma. *Journal of AAPOS*, 9: 383-385.  
46 Not in PICO
- 47 Lyratzopoulos, G., Abel, G. A., McPhail, S., Neal, R. D. & Rubin, P. (2013) Measures of promptness of  
48 cancer diagnosis in primary care: secondary analysis of national audit data on patients with 18  
49 common and rarer cancers. *British Journal of Cancer*, 108: 686-690.  
50 Not in PICO

- 1 Madlon-Kay, D. J. (1985) Evaluation and outcome of the dizzy patient. *Journal of Family Practice*, 21:  
2 109-113.  
3 Not in PICO (some patients already had cancer, mean follow up (i.e., index test) = 6 months,  
4 45/121 had unknown diagnosis
- 5 Mann, S. D. D. (1998) Intractable vomiting due to a brainstem lesion in the absence of neurological  
6 signs or raised intracranial pressure. *Gut*, 42: 875-877.  
7 Not in PICO
- 8 Matuja, W. B. & Matuja, W. B. (1991) Headache: pattern and features as experienced in a neurology  
9 clinic in Tanzania. *East African Medical Journal*, 68: 935-943.  
10 Not in PICO
- 11 McDonald, W. I. & McDonald, W. I. (1982) The symptomatology of tumours of the anterior visual  
12 pathways. *Canadian Journal of Neurological Sciences*, 9: 381-390.  
13 Narrative review
- 14 McGee, S., Burkett, K. W., McGee, S. & Burkett, K. W. (2000) Identifying common pediatric  
15 neurosurgical conditions in the primary care setting. [Review] [46 refs]. *Nursing Clinics of North  
16 America*, 35: 61-85.  
17 Narrative review
- 18 McIntosh, D. (2010) Delays in diagnosing cancer in children presenting via emergency departments  
19 in the West of Scotland: A retrospective case note review. *Pediatric Blood and Cancer*,  
20 Conference: 975-976.  
21 Not in PICO
- 22 McIntyre, F. L. & McIntyre, F. L. (1993) One in a million: when extraordinary cases occur in an  
23 ordinary practice. *Journal of Family Practice*, 36: 17-18.  
24 Not in PICO
- 25 Medina, L. S., Kuntz, K. M., Pomeroy, S., Medina, L. S., Kuntz, K. M. & Pomeroy, S. (2001) Children  
26 with headache suspected of having a brain tumor: a cost-effectiveness analysis of diagnostic  
27 strategies. *Pediatrics*, 108: 255-263.  
28 Not in PICO
- 29 Melamud, A. (2006) Retinoblastoma. *American Family Physician*, 73: 1039-1044.  
30 Narrative review
- 31 Melen, O. & Melen, O. (1987) Neuro-ophthalmologic features of pituitary tumors. [Review] [29 refs].  
32 *Endocrinology & Metabolism Clinics of North America*, 16: 585-608.  
33 Narrative review
- 34 Mezue, W. C. O. (2012) Management of giant pituitary tumors affecting vision in Nigeria. *World  
35 Neurosurgery*, 77: 606-609.  
36 Not in PICO
- 37 Mi, S.-J. L. (2009) The first consultation in the eye of the 45 cases of sellar tumors. *International  
38 Journal of Ophthalmology*, 9: 798-799.  
39 Not in PICO
- 40 Moffat, D. A., Jones, S. E., Mahendran, S., Humphriss, R., Baguley, D. M., Moffat, D. A., Jones, S. E.  
41 M., Mahendran, S., Humphriss, R. & Baguley, D. M. (2004) Referral patterns in vestibular  
42 schwannomas --10 years on. *Clinical Otolaryngology & Allied Sciences*, 29: 515-517.  
43 Not in PICO
- 44 Molassiotis, A., Wilson, B., Brunton, L., Chandler, C., Molassiotis, A., Wilson, B., Brunton, L. &  
45 Chandler, C. (2010) Mapping patients' experiences from initial change in health to cancer  
46 diagnosis: a qualitative exploration of patient and system factors mediating this process.  
47 *European Journal of Cancer Care*, 19: 98-109.  
48 Not in PICO
- 49 Molassiotis, A., Wilson, B., Brunton, L., Chaudhary, H., Gattamaneni, R., McBain, C., Molassiotis, A.,  
50 Wilson, B., Brunton, L., Chaudhary, H., Gattamaneni, R. & McBain, C. (2010) Symptom experience  
51 in patients with primary brain tumours: a longitudinal exploratory study. *European Journal of*

- 1     *Oncology Nursing*, 14: 410-416.  
2     Not in PICO
- 3     Moll, G. W., Bock, H. G., Moll, G. W. & Bock, H. G. (2001) Two tumors detected by thyroid  
4     assessment in two children. *Endocrine Practice*, 7: 467-473.  
5     Not in PICO
- 6     Momota, H., Iwami, K., Fujii, M., Motomura, K., Natsume, A., Ogino, J., Hasegawa, T., Wakabayashi,  
7     T., Momota, H., Iwami, K., Fujii, M., Motomura, K., Natsume, A., Ogino, J., Hasegawa, T. &  
8     Wakabayashi, T. (2011) Rhabdoid glioblastoma in a child: case report and literature review.  
9     [Review]. *Brain Tumor Pathology*, 28: 65-70.  
10    Not in PICO
- 11    Morfouace, M., Chalumeau, M., Grill, J. & Brasme, J. F. (2011) Diagnostic delays of brain tumors in  
12    children: Determinants and consequences. *Archives de Pediatrie*, 18: H77-H78.  
13    Not in PICO
- 14    Morgan, M., Jenkins, L., Ridsdale, L., Morgan, M., Jenkins, L. & Ridsdale, L. (2007) Patient pressure  
15    for referral for headache: a qualitative study of GPs' referral behaviour. *British Journal of General  
16    Practice*, 57: 29-35.  
17    Not in PICO
- 18    Mrugala, M., Giglio, P., Keene, C. & Ferreira, M. (2014) Drop attacks secondary to an extra-axial  
19    tumor compressing the midbrain. *Neuro-Oncology*, 16: i135.  
20    Not in PICO
- 21    Mullaney, P. B. K. (1996) Retinoblastoma referral patterns in Saudi Arabia. *Ophthalmic Epidemiology*,  
22    3: 35-46.  
23    Not in PICO
- 24    Munot, P. (2009) Paediatric brain tumours in a district general hospital in the UK: A 7-year  
25    experience. *Developmental Medicine and Child Neurology*, Conference: January.  
26    Not in PICO
- 27    Murtagh, J. (1488) Dizziness (vertigo). *Australian Family Physician*, 20: 1483-1485.  
28    Narrative review
- 29    Nagahiro, S., Matsukado, Y., Kaku, M., Wada, S., Urasaki, E., Nagahiro, S., Matsukado, Y., Kaku, M.,  
30    Wada, S. & Urasaki, E. (1983) [Evaluation of blink reflexes in cerebellopontine angle tumors].  
31    [Japanese]. *No to Shinkei - Brain & Nerve*, 35: 1117-1124.  
32    Not in PICO
- 33    Natalwala, A., Bharkhada, V., Noel, G., Cruickshank, G., Natalwala, A., Bharkhada, V., Noel, G. &  
34    Cruickshank, G. (2011) Comparison of time taken from initial presentation to histological  
35    diagnosis of Glioblastoma Multiforme (GBM) in Birmingham, United Kingdom and Strasbourg,  
36    France. *Clinical Neurology & Neurosurgery*, 113: 358-361.  
37    Not in PICO
- 38    Nucci, P. (2009) Abnormal head posture due to ocular problems: A review. *Current Pediatric  
39    Reviews*, 5: 105-111.  
40    Narrative review
- 41    O'Brien, A., Hugo, P., Stapleton, S., Lask, B. E.-M. A. & O'Brien, A. b. ac. u. (2001) "Anorexia saved my  
42    life": Coincidental anorexia nervosa and cerebral meningioma. [References]. *International Journal  
43    of Eating Disorders*, .30.  
44    Not in PICO
- 45    O'Brien, M., Curtis, C., D'Hemecourt, P., Proctor, M., O'Brien, M., Curtis, C., D'Hemecourt, P. &  
46    Proctor, M. (2009) Case report: a case of persistent back pain and constipation in a 5-year-old  
47    boy. *Physician & Sportsmedicine*, 37: 133-137.  
48    Not in PICO
- 49    O'Sullivan, E. (2002) Precocious puberty: A parent's perspective. *Archives of Disease in Childhood*, 86:  
50    320-321.  
51    Not in PICO

- 1 Orlopp, K., Schmidt-Wolf, I. G., Urbach, H., Schlegel, U., Orlopp, K., Schmidt-Wolf, I. G. H., Urbach, H.  
2 & Schlegel, U. (2005) [Acute central nervous symptoms in oncologic patients]. [Review] [28 refs]  
3 [German]. *Internist*, 46: 19-29.  
4 Narrative review
- 5 Ozcan S.Evran (2008) Glioblastoma multiforme presenting with psychiatric symptoms in a primary  
6 care setting: review of isolated psychiatric symptoms with brain tumors. *Neurosurgery Quarterly*,  
7 18: 148-150.  
8 Not in PICO
- 9 Pane, A. (2009) Diplopia - A symptom to take seriously. *Medicine Today*, 10: 74-76.  
10 Narrative review
- 11 Park, S. H., Chi, J. G., Cho, B. K., Wang, K. C., Park, S. H., Chi, J. G., Cho, B. K. & Wang, K. C. (1993)  
12 Spinal cord ganglioglioma in childhood. [Review] [22 refs]. *Pathology, Research & Practice*, 189:  
13 189-196.  
14 Not in PICO
- 15 Parker, A. (1996) Difficulties in diagnosing intrinsic spinal cord tumours. *Archives of Disease in*  
16 *Childhood*, 75: 204-207.  
17 Not in PICO
- 18 Patel, H., Garg, B. P., Salanova, V., Boaz, J. C., Luerssen, T. G., Kalsbeck, J. E., Patel, H., Garg, B. P.,  
19 Salanova, V., Boaz, J. C., Luerssen, T. G. & Kalsbeck, J. E. (2001) Tumor-related epilepsy in  
20 children. *Journal of Child Neurology*, 16: 141-145.  
21 Not in PICO
- 22 Paul, S. P., Debono, R. & Walker, D. (2013) Clinical update: Recognising brain tumours early in  
23 children. *Community Practitioner*, 86: 42-45.  
24 Narrative review
- 25 Pengiran Tengah, D. S., Byrne, P. O., Wills, A. J., Pengiran Tengah, D. S. N. A., Byrne, P. O. & Wills, A.  
26 J. (2003) Urgent 2-week referrals for CNS/brain tumours: a retrospective audit. *Clinical Oncology*  
27 *(Royal College of Radiologists)*, 15: 7-9.  
28 Not in PICO
- 29 Perek, D. & Perek-Polnik, M. (2003) [Brain tumors in children][Polish]. *Przegląd Lekarski*, 60: 27-34.  
30 Narrative review
- 31 Perek, D. (2005) Wrong interpretation of symptoms of posterior fossa tumors causing delay of  
32 diagnosis. *Pediatrics Polska*, 80: 80-84.  
33 Not in PICO
- 34 Perkins, P. D. & Perkins, P. D. (1986) Once in a lifetime: a case of a pineal tumour. *Journal of the*  
35 *Royal College of General Practitioners*, 36: 416-417.  
36 Not in PICO
- 37 Perry, J. J., Stiell, I. G., Wells, G. A., Mortensen, M., Lesiuk, H., Sivilotti, M., Kapur, A., Perry, J. J.,  
38 Stiell, I. G., Wells, G. A., Mortensen, M., Lesiuk, H., Sivilotti, M. & Kapur, A. (2005) Attitudes and  
39 judgment of emergency physicians in the management of patients with acute headache.  
40 *Academic Emergency Medicine*, 12: 33-37.  
41 Not in PICO
- 42 Peters, K. S. (2004) Secondary headache and head pain emergencies. *Primary Care - Clinics in Office*  
43 *Practice*, 31: 381-393.  
44 Narrative review
- 45 Phi, J. H., Kim, S. K., Kang, T. H., Wang, K. C., Phi, J. H., Kim, S. K., Kang, T. H. & Wang, K. C. (2012)  
46 Hydrocephalic fits: forgotten but not gone. *Childs Nervous System*, 28: 1863-1868.  
47 Not in PICO
- 48 Pittner, M. (2010) Blindness due to unrecognized bilateral optic nerve sheath meningioma in a 14-  
49 year-old girl (case report). *Neuropediatrics*, Conference.  
50 Not in PICO

- 1 Pollock, B. H., Krischer, J. P., Vietti, T. J., Pollock, B. H., Krischer, J. P. & Vietti, T. J. (1991) Interval  
2 between symptom onset and diagnosis of pediatric solid tumors. *Journal of Pediatrics*, 119: 725-  
3 732.  
4 Not in PICO
- 5 Powell, H. R., Choa, D. I., Powell, H. R. F. & Choa, D. I. (2010) Should all patients referred for  
6 magnetic resonance imaging scans of their internal auditory meatus be followed up in ENT  
7 clinics? *European Archives of Oto-Rhino-Laryngology*, 267: 1361-1366.  
8 Not in PICO
- 9 Prasad, J., Cousins, V. C., Prasad, J. & Cousins, V. C. (319) Asymmetrical hearing loss. *Australian*  
10 *Family Physician*, 37: 312-319.  
11 Narrative review
- 12 Prashad, P. S., Marcus, C. L., Brown, L. W., Dlugos, D. J., Feygin, T., Harding, B. N., Heuer, G. G. &  
13 Mason, T. B. (2013) Brain tumor presenting as somnambulism in an adolescent. *Pediatric*  
14 *Neurology*, 49: 209-212.  
15 Not in PICO
- 16 Provenzale, J. M. & Provenzale, J. M. (2010) Imaging findings of structural causes of epilepsy in  
17 children: a guide for the radiologist in the emergency room. *Emergency Radiology*, 17: 479-486.  
18 Not in PICO
- 19 Puchner, M. J. F. (1998) Suprasellar meningioma. A disease still frequently diagnosed too late.  
20 *Deutsche medizinische Wochenschrift (1946)*, 123: 991-996.  
21 Not in PICO
- 22 Purcell, C. (2011) Can we diagnose Brain Tumours in Children Earlier? An Irish Audit. *British Journal*  
23 *of Neurosurgery*, Conference: 565-566.  
24 Not in PICO
- 25 Qaddoumi, I. (2010) Characterization of intracranial neoplasms in the first 120 days of life. *Neuro-*  
26 *Oncology*, Conference: ii84.  
27 Not in PICO
- 28 Raab, C. P., Gartner, J. C., Jr., Raab, C. P. & Gartner, J. C. J. (2009) Diagnosis of childhood cancer.  
29 [Review] [33 refs]. *Primary Care; Clinics in Office Practice*, 36: 671-684.  
30 Narrative review
- 31 Rajan, B., Ashley, S., Thomas, D. G., Marsh, H., Britton, J., Brada, M., Rajan, B., Ashley, S., Thomas, D.  
32 G., Marsh, H., Britton, J. & Brada, M. (1997) Craniopharyngioma: improving outcome by early  
33 recognition and treatment of acute complications. *International Journal of Radiation Oncology,*  
34 *Biology, Physics*, 37: 517-521.  
35 Not in PICO
- 36 Ramcharan, R., Midha, R., Ramcharan, R. & Midha, R. (2004) Clinical presentation and physical  
37 examination. [Review] [16 refs]. *Neurosurgery Clinics of North America*, 15: 125-132.  
38 Narrative review
- 39 Ramelli, G. P., von der, W. N., Stanga, Z., Mullis, P. E., Buergi, U., Ramelli, G. P., von der Weid, N.,  
40 Stanga, Z., Mullis, P. E. & Buergi, U. (1998) Suprasellar germinomas in childhood and adolescence:  
41 diagnostic pitfalls. *Journal of Pediatric Endocrinology*, 11: 693-697.  
42 Not in PICO
- 43 Reulecke, B. C., Erker, C. G., Fiedler, B. J., Niederstadt, T. U., Kurlemann, G., Reulecke, B. C., Erker, C.  
44 G., Fiedler, B. J., Niederstadt, T. U. & Kurlemann, G. (2008) Brain tumors in children: initial  
45 symptoms and their influence on the time span between symptom onset and diagnosis. *Journal*  
46 *of Child Neurology*, 23: 178-183.  
47 Not in PICO
- 48 Rho, Y. I., Chung, H. J., Suh, E. S., Lee, K. H., Eun, B. L., Nam, S. O., Kim, W. S., Eun, S. H., Kim, Y. O.,  
49 Rho, Y. I., Chung, H. J., Suh, E. S., Lee, K. H., Eun, B. L., Nam, S. O., Kim, W. S., Eun, S. H. & Kim, Y.  
50 O. (2011) The role of neuroimaging in children and adolescents with recurrent headaches--

- 1 multicenter study. *Headache*, 51: 403-408.  
2 Not in PICO
- 3 Rittman, T., Corns, R., Kumar, A., Bhangoo, R., Ashkan, K., Rittman, T., Corns, R., Kumar, A., Bhangoo,  
4 R. & Ashkan, K. (2012) Is referral to the neuro-oncology MDT safe? *British Journal of*  
5 *Neurosurgery*, 26: 321-324.  
6 Not in PICO
- 7 Ruggieri, M., Iannetti, P., Polizzi, A., La, M., I, Spalice, A., Giliberto, O., Platania, N., Gabriele, A. L.,  
8 Albanese, V., Pavone, L., Ruggieri, M., Iannetti, P., Polizzi, A., La Mantia, I., Spalice, A., Giliberto,  
9 O., Platania, N., Gabriele, A. L., Albanese, V. & Pavone, L. (2005) Earliest clinical manifestations  
10 and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients.  
11 *Neuropediatrics*, 36: 21-34.  
12 Not in PICO
- 13 Ruis, C., van den Berg, E., van Stralen, H. E., Huenges Wajer, I. M., Biessels, G. J., Kappelle, L. J.,  
14 Postma, A. & van Zandvoort, M. J. (2014) - Symptom Checklist 90-Revised in neurological  
15 outpatients. - *Journal of Clinical & Experimental Neuropsychology: Official Journal of the*  
16 *International Neuropsychological Society*, 36: 170-177.  
17 Not in PICO
- 18 Rutkowski S. (2005) Brain tumors in children. Diagnostics and interdisciplinary therapeutic strategies.  
19 *Onkologe*, 11: 1090-1100.  
20 Narrative review
- 21 Rutkowski, S. & Rutkowski, S. (2007) Timely identification of suspected paediatric CNS tumours.  
22 *Lancet Oncology*, 8: 664.  
23 Narrative review
- 24 Rutkowski, S. (2008) Childhood brain tumors. Clinical symptoms and diagnostic standards.  
25 *Monatsschrift fur Kinderheilkunde*, 156: 1165-1172.  
26 Narrative review
- 27 Saffra, N. K. (2011) Isolated sixth cranial nerve palsy as the presenting symptom of a rapidly  
28 expanding ACTH positive pituitary adenoma: a case report. *BMC ophthalmology*, 11: 2011.  
29 Not in PICO
- 30 Saito, N. (1996) Pineal tumor and alternating skew deviation. *Neuro-Ophthalmology Japan*, 13: 304-  
31 308.  
32 Not in PICO
- 33 Sakata, H. (2012) Vertigo and disequilibrium during early childhood. *Equilibrium Research*, 71: 253-  
34 263.  
35 Narrative review
- 36 Sakuma, T. (2002) A case of acoustic neurinoma occurring in a 5-year-old child. *Practica Oto-Rhino-*  
37 *Laryngologica*, 95: 585-590.  
38 Not in PICO
- 39 Salander, P., Bergenheim, A. T., Hamberg, K., Henriksson, R., Salander, P., Bergenheim, A. T.,  
40 Hamberg, K. & Henriksson, R. (1999) Pathways from symptoms to medical care: a descriptive  
41 study of symptom development and obstacles to early diagnosis in brain tumour patients. *Family*  
42 *Practice*, 16: 143-148.  
43 Not in PICO
- 44 Sam, M. C., So, E. L., Sam, M. C. & So, E. L. (2001) Significance of epileptiform discharges in patients  
45 without epilepsy in the community. *Epilepsia*, 42: 1273-1278.  
46 Not in PICO
- 47 Samuelsson, K. (1997) Clinical assessment without direct contact with the patient. Very delayed  
48 diagnosis of brain tumor. *Lakartidningen*, 94: 3075-3076.  
49 Not in PICO

- 1 Sanchez Echaniz, J. (1991) Migraine in a pediatric emergency service. *Anales Espanoles de Pediatria*,  
2 34: 267-271.  
3 Setting not in PICO
- 4 Saxena, A. (2009) Growing pains - Diagnose with care! *European Journal of Paediatric Neurology*,  
5 Conference: September.  
6 Not in PICO
- 7 Scalzone, M. (2009) Diencephalic syndrome and brain tumours: A rare cause of growth failure.  
8 *European Journal of Oncology*, 14: 53-56.  
9 Narrative review
- 10 Segal, D. L. (2012) Delay in diagnosis of primary intradural spinal cord tumors. *Surgical Neurology*  
11 *International*, 3.  
12 Not in PICO
- 13 Seregard, S. (1996) A study of children with retinoblastoma. Diagnosis is often delayed.  
14 *Lakartidningen*, 93: 1133-1135.  
15 Not in PICO
- 16 Sethi, R. V., Marino, R., Niemierko, A., Tarbell, N. J., Yock, T. I. & MacDonald, S. M. (2013) Delayed  
17 diagnosis in children with intracranial germ cell tumors. *Journal of Pediatrics*, 163: 1448-1453.  
18 Not in PICO
- 19 Shay, V., Fattal-Valevski, A., Beni-Adani, L., Constantini, S., Shay, V., Fattal-Valevski, A., Beni-Adani, L.  
20 & Constantini, S. (2012) Diagnostic delay of pediatric brain tumors in Israel: a retrospective risk  
21 factor analysis. *Childs Nervous System*, 28: 93-100.  
22 Not in PICO
- 23 Shedid, D. B. (2004) Clinical presentation of spinal tumors. *Neurosurgery Quarterly*, 14: 224-228.  
24 Narrative review
- 25 Silvani, A., Gaviani, P., Lamperti, E., Botturi, A., Ferrari, D., Simonetti, G., Salmaggi, A., Silvani, A.,  
26 Gaviani, P., Lamperti, E., Botturi, A., Ferrari, D., Simonetti, G. & Salmaggi, A. (2011) Malignant  
27 gliomas: early diagnosis and clinical aspects. *Neurological Sciences*, 32 Suppl 2: S207-S208.  
28 Narrative review
- 29 Simon, J. W., Kaw, P., Simon, J. W. & Kaw, P. (2001) Commonly missed diagnoses in the childhood  
30 eye examination. [Review] [16 refs]. *American Family Physician*, 64: 623-628.  
31 Narrative review
- 32 Skinner, S. A. (1988) Early diagnosis of brain tumor. *Postgraduate Medicine*, 83: 117-124.  
33 Narrative review
- 34 Sloane, P. D., Dallara, J., Roach, C., Bailey, K. E., Mitchell, M., McNutt, R., Sloane, P. D., Dallara, J.,  
35 Roach, C., Bailey, K. E., Mitchell, M. & McNutt, R. (1994) Management of dizziness in primary  
36 care. *Journal of the American Board of Family Practice*, 7: 1-8.  
37 Not in PICO
- 38 Snyder, H., Robinson, K., Shah, D., Brennan, R. & Handrigan, M. (1993) Signs and symptoms of  
39 patients with brain tumors presenting to the emergency department. *Journal of Emergency*  
40 *Medicine*, 11: 253-258.  
41 Not in PICO
- 42 Snyder, M. C. T. (2011) A bitter pill to swallow. *Journal of Investigative Medicine*, Conference: 380.  
43 Not in PICO
- 44 Soucy, E. A., Gao, F., Gutmann, D. H., Dunn, C. M., Soucy, E. A., Gao, F., Gutmann, D. H. & Dunn, C.  
45 (2012) Developmental delays in children with neurofibromatosis type 1. *Journal of Child*  
46 *Neurology*, 27: 641-644.  
47 Not in PICO
- 48 Spira, P. J. & Spira, P. J. (1984) Headaches. A specialist's view. *Australian Family Physician*, 13: 8-12.  
49 Narrative review



- 1 Strain, J. D. (2007) ACR Appropriateness Criteria on Headache-Child. *JACR Journal of the American*  
2 *College of Radiology*, 4: 18-23.  
3 Narrative review
- 4 Stricker, S. J. (2006) Evaluation and treatment of the child with tiptoe gait. *International Pediatrics*,  
5 21: 91-96.  
6 Narrative review
- 7 Subaciute, J. & Subaciute, J. (2002) [Early diagnosis of spinal cord schwannoma: the significance of  
8 the pain syndrome]. [Lithuanian]. *Medicina (Kaunas)*, 38: 1086-1088.  
9 Not in PICO
- 10 Taieb, C. R. (2011) Prevalence and procedure for vertigo follow-up in France. *Value in Health*,  
11 Conference: A318.  
12 Not in PICO
- 13 Tan, A. (1991) Non-neurological manifestations of intracranial tumours: a report of four cases. *The*  
14 *Journal of the Singapore Paediatric Society*, 33: 173-177.  
15 Not in PICO
- 16 Tarng, D.-C. (1995) Diabetes insipidus as an early sign of pineal tumor. *American Journal of*  
17 *Nephrology*, 15: 161-164.  
18 Not in PICO
- 19 Taylor, M., Couto-Silva, A. C., Adan, L., Trivin, C., Sainte-Rose, C., Zerah, M., Valteau-Couanet, D.,  
20 Doz, F., Chalumeau, M. & Brauner, R. (2012) Hypothalamic-pituitary lesions in pediatric patients:  
21 Endocrine symptoms often precede neuro-ophthalmic presenting symptoms. *Journal of*  
22 *Pediatrics*, 161: 855-863.  
23 Not in PICO
- 24 Tengah, D. S. N. A., Byrne, P. O. & Wills, A. J. (2003) Urgent 2-week referrals for CNS/brain tumours:  
25 A retrospective audit. *Clinical Oncology*, 15: 7-9.  
26 Not in PICO
- 27 Teo, W. Y. & Myseros, J. S. (2014) - The gut or the brain?-gastrointestinal misdiagnoses of infantile  
28 brain tumors. - *Childs Nervous System*, 30: 1449-1453.  
29 Not in PICO
- 30 Teppo, H., Heikkinen, J., Laitakari, K., Alho, O. P., Teppo, H., Heikkinen, J., Laitakari, K. & Alho, O. P.  
31 (2009) Diagnostic delays in vestibular schwannoma. *Journal of Laryngology & Otology*, 123: 289-  
32 293.  
33 Not in PICO
- 34 Thimm, A. (2010) Optic pathway gliomas in children with neurofibromatosis type 1: A long term  
35 study in 38 patients. *Neuropediatrics*, Conference.  
36 Not in PICO
- 37 Thomas, V. (2011) Review of presenting symptoms and time to diagnosis of children with primary  
38 brain tumours. *Archives of Disease in Childhood*, Conference: April.  
39 Not in PICO
- 40 Thulesius, H., Pola, J., Hakansson, A., Thulesius, H., Pola, J. & Hakansson, A. (2000) Diagnostic delay  
41 in pediatric malignancies--a population-based study. *Acta Oncologica*, 39: 873-876.  
42 Not in PICO
- 43 Traccis S.Zoroddu (2004) Evaluating patients with vertigo: Bedside examination. *Neurological*  
44 *Sciences*, 25: S16-S19.  
45 Narrative review
- 46 Trojanowski, T., Kaminski, S., Golabek, W., Pawlik, Z., Siwiec, H., Trojanowski, T., Kaminski, S.,  
47 Golabek, W., Pawlik, Z. & Siwiec, H. (1990) [Diagnosis of cerebello-pontine angle tumors]. [Polish].  
48 *Polski Tygodnik Lekarski*, 45: 561-563.  
49 Not in PICO
- 50 Vazquez Roman, S., Martinez, A. A., Llorente, O. L., Rojo, C. P., Hinojosa, B. J., Vazquez Roman, S.,  
51 Martinez Anton, A., Llorente Otones, L., Rojo Conejo, P. & Hinojosa Bernal, J. (2008) [Initial signs

- 1 and symptoms of brain tumors in children]. [Spanish]. *Neurologia*, 23: 215-219.
- 2 Not in PICO
- 3 Visudhiphan, P. (1982) Torticollis as the presenting sign in cervical spine infection and tumor. *Clinical*  
4 *Pediatrics*, 21: 71-76.
- 5 Not in PICO
- 6 Wadud, S. A., Ahmed, S., Choudhury, N. & Chowdhury, D. (2014) - Evaluation of ophthalmic  
7 manifestations in patients with intracranial tumours. - *Mymensingh Medical Journal: MMJ*, 23:  
8 268-271.
- 9 Not in PICO
- 10 Wagner, U., Granditsch, G., Wagner, U. & Granditsch, G. (1986) [Failure to thrive as a main symptom  
11 of intracranial tumors in early childhood]. [German]. *Padiatrie und Padologie*, 21: 147-153.
- 12 Not in PICO
- 13 Walker, D., Chu, T., Shah, A., Wilne, S. & Coleman, M. (2014) A new clinical guideline (2007) and  
14 national awareness campaign (2011) accelerated brain tumour diagnosis in uk children  
15 (headsmart-be brain tumour aware). *Neuro-Oncology*, 16: i26.
- 16 Not in PICO
- 17 Wallach, M. (2006) Shorter time to diagnosis and improved stage at presentation in Swiss patients  
18 with retinoblastoma treated from 1963 to 2004. *Pediatrics*, 118: e1493-e1498.
- 19 Not in PICO
- 20 White, J. (2012) Delay in the diagnosis of retinoblastoma: An update. *Clinical and Experimental*  
21 *Ophthalmology*, Conference: December.
- 22 Not in PICO
- 23 White, J. R., Carlson, M. L., Van Gompel, J. J., Neff, B. A., Driscoll, C. L., Lane, J. I. & Link, M. J. (2013)  
24 Lipomas of the cerebellopontine angle and internal auditory canal: Primum Non Nocere.  
25 *Laryngoscope*, 123: 1531-1536.
- 26 Not in PICO
- 27 White, M. A. J. (2009) Posterior fossa tumours in children: Time to diagnosis. *British Journal of*  
28 *Neurosurgery*, Conference: 472-473.
- 29 Not in PICO
- 30 Wiet, R. J., Monsell, E. M., Hotaling, A. J., Wiet, R. J., Monsell, E. M. & Hotaling, A. J. (130) Hearing  
31 and balance disorders. How to recognize, when to refer. *Postgraduate Medicine*, 77: 119-130.
- 32 Narrative review
- 33 Williams, L. (2012) A web-based electronic neurology referral system: A solution for an  
34 overburdened healthcare system? *Irish Medical Journal*, 105.
- 35 Not in PICO
- 36 Wilne, S., Collier, J., Kennedy, C., Koller, K., Grundy, R., Walker, D., Wilne, S., Collier, J., Kennedy, C.,  
37 Koller, K., Grundy, R. & Walker, D. (2007) Presentation of childhood CNS tumours: a systematic  
38 review and meta-analysis. *Lancet Oncology*, 8: 685-695.
- 39 Not in PICO
- 40 Wilne, S., Koller, K., Collier, J., Kennedy, C., Grundy, R., Walker, D., Wilne, S., Koller, K., Collier, J.,  
41 Kennedy, C., Grundy, R. & Walker, D. (2010) The diagnosis of brain tumours in children: a  
42 guideline to assist healthcare professionals in the assessment of children who may have a brain  
43 tumour. [Review] [32 refs]. *Archives of Disease in Childhood*, 95: 534-539.
- 44 Guideline
- 45 Wilne, S., Walker, D., Wilne, S. & Walker, D. (2010) Spine and spinal cord tumours in children: a  
46 diagnostic and therapeutic challenge to healthcare systems. [Review] [32 refs]. *Archives of*  
47 *Disease in Childhood Education & Practice*, 95: 47-54.
- 48 Narrative review
- 49 Wilne, S., Collier, J., Kennedy, C., Jenkins, A., Grout, J., Mackie, S., Koller, K., Grundy, R., Walker, D.,  
50 Wilne, S., Collier, J., Kennedy, C., Jenkins, A., Grout, J., Mackie, S., Koller, K., Grundy, R. & Walker,  
51 D. (2012) Progression from first symptom to diagnosis in childhood brain tumours. *European*

- 1 *Journal of Pediatrics*, 171: 87-93.  
2 Not in PICO
- 3 Wilne, S. H., Ferris, R. C., Nathwani, A., Kennedy, C. R., Wilne, S. H., Ferris, R. C., Nathwani, A. &  
4 Kennedy, C. R. (2006) The presenting features of brain tumours: a review of 200 cases. *Archives*  
5 *of Disease in Childhood*, 91: 502-506.  
6 Not in PICO
- 7 Wilson, M., Cummins, C. L., Macpherson, L., Sun, Y., Natarajan, K., Grundy, R. G., Arvanitis, T. N.,  
8 Kauppinen, R. A. & Peet, A. C. (2013) Magnetic resonance spectroscopy metabolite profiles  
9 predict survival in paediatric brain tumours. *European Journal of Cancer*, 49: 457-464.  
10 Not in PICO
- 11 Wilson, P. E., Oleszek, J. L. & Clayton, G. H. (2007) Pediatric spinal cord tumors and masses. *Journal*  
12 *of Spinal Cord Medicine*, 30: S15-S20.  
13 Not in PICO
- 14 Wirix, M. (2000) Delayed diagnosis of retinoblastoma. *Bulletin de la Societe belge d'ophtalmologie*,  
15 37-41.  
16 Not in PICO
- 17 Wolf, G. (1980) Early symptoms of brain tumors. *Fortschritte der Medizin*, 98: 1215-1218.  
18 Not in PICO
- 19 Wong, B. Y., Capper, R., Wong, B. Y. W. & Capper, R. (2012) Incidence of vestibular schwannoma and  
20 incidental findings on the magnetic resonance imaging and computed tomography scans of  
21 patients from a direct referral audiology clinic. *Journal of Laryngology & Otology*, 126: 658-662.  
22 Not in PICO
- 23 Xie, C., Ahmed, A. & Banerjee, A. (2013) A comparison of primary care access to non-trauma  
24 computed tomography (CT) and magnetic resonance imaging (MRI) of the brain with hospital  
25 clinician referrals. *Clinical Radiology*, 68: S8-S9.  
26 Not in PICO
- 27 Young, G., Toretsky, J. A., Campbell, A. B., Eskenazi, A. E., Young, G., Toretsky, J. A., Campbell, A. B. &  
28 Eskenazi, A. E. (2000) Recognition of common childhood malignancies. [Review] [18 refs].  
29 *American Family Physician*, 61: 2144-2154.  
30 Narrative review
- 31 Yule, S. M., Hide, T. A., Cranney, M., Simpson, E., Barrett, A., Yule, S. M., Hide, T. A., Cranney, M.,  
32 Simpson, E. & Barrett, A. (2001) Low grade astrocytomas in the West of Scotland 1987-96:  
33 treatment, outcome, and cognitive functioning. *Archives of Disease in Childhood*, 84: 61-64.  
34 Not in PICO
- 35 Zajac, A., Gergont, A., Krocza, S., Wesolowska, E., Zajac, A., Gergont, A., Krocza, S. & Wesolowska,  
36 E. (2008) [Clinical manifestation of neoplasm cerebri in children hospitalized in pediatric  
37 neurology department]. [Polish]. *Przegląd Lekarski*, 65: 813-818.  
38 Not in PICO
- 39 Zalewska-Szewczyk, B., Zielinska, E., Zakrzewski, K., Bulas, M., Andrzejewski, W., Bodalski, J.,  
40 Zalewska-Szewczyk, B., Zielinska, E., Zakrzewski, K., Bulas, M., Andrzejewski, W. & Bodalski, J.  
41 (2005) [Prognosis of clinical course of primary brain tumours in children in relationship to the  
42 duration and characteristic features of initial clinical symptoms]. [Polish]. *Medycyna Wieku*  
43 *Rozwojowego*, 9: 567-578.  
44 Not in PICO
- 45 Zapala, D. A. & Zapala, D. A. (2008) The importance of sudiologic red flags in patient management  
46 decisions. [References]. *Journal of the American Academy of Audiology*, .19.  
47 Not in PICO
- 48 Zelwianska, B., Gucwa-Piotrowska, G., Lis-Hille, A., Krocza, S., Zelwianska, B., Gucwa-Piotrowska, G.,  
49 Lis-Hille, A. & Krocza, S. (2008) [Types of diagnosis in the outpatient practice during the years  
50 2006-2007]. [Polish]. *Przegląd Lekarski*, 65: 769-772.  
51 Not in PICO

Zhang, C. H., Zhang, T. C., Zhong, J. S., Li, Y. W., Zhang, C. M., Zhang, C. h., Zhang, T. c., Zhong, J. s., Li, Y. w. & Zhang, C. m. (2004) [Early diagnosis of the tumors in orbital apex and optic nerve]. [Chinese]. *Chung-Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]*, 40: 34-36.

Not in PICO

Zhang, R. (2007) [Misdiagnosis of facial never tumor]. *Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery*, 42: 817-820.

Not in PICO

### Review question:

Which investigations of symptoms of suspected brain and CNS cancer should be done with clinical responsibility retained by primary care?

## Results

### Literature search


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1980-6/2013	1173	101	17/06/2013
<i>Premedline</i>	1980-6/2013	112	6	19/06/2013
<i>Embase</i>	1980-6/2013	2171	90	19/06/2013
<i>Cochrane Library</i>	1980-6/2013	209	2	19/06/2013
<i>Psychinfo</i>	1980-6/2013	62	2	17/02/2013
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	1980-6/2013	57	1	19/06/2013

Total References retrieved (after de-duplication): 162

### Update Search

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	6/2013-12/08/2014	40	2	12/08/2014
<i>Premedline</i>	6/2013-12/08/2014	22	1	12/08/2014
<i>Embase</i>	6/2013-12/08/2014	62	6	12/08/2014
<i>Cochrane Library</i>	6/2013-12/08/2014	96	0	12/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	6/2013-12/08/2014	22	0	12/08/2014

Total References retrieved (after de-duplication): 5



1

2 **Study results**

3 No evidence was identified pertaining to the diagnostic accuracy of CT or MRI scans in patients with  
 4 suspected brain or CNS cancer where the clinical responsibility was retained by primary care.  
 5

6 **References**

7 **Included studies**

8 None

9

10 **Excluded studies (with excl reason)**

11 (2001) Promoting self-referral for advanced imaging. *Effective Clinical Practice*, 4: 93-94.

12 Not in PICO

13 Abramovich, S. J. (1987) Auditory brain stem response and computed tomography in acoustic  
 14 tumour investigations. *Journal of Laryngology and Otology*, 101: 334-345.

15 Narrative review

16 Abul-Kasem, K., Thurnher, M., Puchner, S., Overgaard, A. & Sundgren, P. (2009) Multimodal  
 17 magnetic resonance imaging increases the overall diagnostic accuracy in brain tumors.  
 18 *Neuroradiology*, 51: S146.

19 Abstract only. Not in PICO.

20 Ahrensberg, J. M., Olesen, F., Hansen, R. P., Schroder, H. & Vedsted, P. (2013) Childhood cancer and  
 21 factors related to prolonged diagnostic intervals: a Danish population-based study. *British Journal  
 22 of Cancer*, 108: 1280-1287.

23 Not in PICO

24 Allcutt, D. A. & Mendelow, A. D. (1992) Presentation and diagnosis of brain tumours. [Review] [11  
 25 refs]. *British Journal of Hospital Medicine*, 47: 745-752.

26 Narrative review

27 Aprile, I., Bencivenga, S., Loreti, F. & Torni, C. (2011) Intracranial tumour characterization: Whole  
 28 brain evaluation with MR perfusion images and SPECT-CT. *Neuroradiology Journal*, 24: 838-845.

29 Not in PICO

- 1 Baba, K., Akhter, S., Jan, G. M. & Shah, A. (2002) Cerebrospinal fluid cytology in "brain tumours" - A  
 2 study over a period of 10 years (1991-2000). *JK Practitioner*, 9: 101-102.  
 3 Not in PICO
- 4 Badiane, M., Afidja, A., Ba-Diop, S., Badiane, S. B., Niang, E. H. & Ba-Ly, A. (1998) [Diagnostic x-ray  
 5 computed tomography of craniocerebral tumors. Apropos of 108 cases collected at the Soweto  
 6 Center of Dakar]. [Review] [8 refs] [French]. *Dakar Medical*, 43: 34-36.  
 7 Not in PICO
- 8 Baehring, J. M., Bi, W. L., Bannykh, S., Piepmeier, J. M. & Fulbright, R. K. (2007) Diffusion MRI in the  
 9 early diagnosis of malignant glioma. *Journal of Neuro-Oncology*, 82: 221-225.  
 10 Not in PICO
- 11 Barrett, J. A. Development of an evidence based referral protocol for early diagnosis of vestibular  
 12 schwannomas. Dissertation Abstracts International: Section B: The Sciences and Engineering  
 13 69[8-B], 4639. 2009.  
 14 Not in PICO
- 15 Batista, D. L., Riar, J., Keil, M. & Stratakis, C. A. (2007) Diagnostic tests for children who are referred  
 16 for the investigation of Cushing syndrome. *Pediatrics*, 120: e575-e586.  
 17 Not in PICO
- 18 Bauherz, G. (1996) [Usefulness of headache classification in the planning of radiological studies].  
 19 [Review] [15 refs] [French]. *Revue Medicale de Bruxelles*, 17: 293-299.  
 20 Narrative review
- 21 Becker, L. A., Green, L. A., Beaufait, D., Kirk, J., From, J. & Freeman, W. L. (1993) Detection of  
 22 intracranial tumors, subarachnoid hemorrhages, and subdural hematomas in primary care  
 23 patients: a report from ASPN, Part 2. *Journal of Family Practice*, 37: 135-141.  
 24 Not in PICO
- 25 Becker, L. A., Green, L. A., Beaufait, D., Kirk, J., From, J. & Freeman, W. L. (1993) Use of CT scans for  
 26 the investigation of headache: a report from ASPN, Part 1. *Journal of Family Practice*, 37: 129-  
 27 134.  
 28 Not in PICO (no reference standard for the CT-negative patients)
- 29 Benamore, R. E., Wright, D. & Britton, I. (2005) Is primary care access to CT brain examinations  
 30 effective? *Clinical Radiology*, 60: 1083-1089.  
 31 Not in PICO
- 32 Berns, S. & Pearl, G. (2006) Middle ear adenoma. [Review] [11 refs]. *Archives of Pathology &  
 33 Laboratory Medicine*, 130: 1067-1069.  
 34 Narrative review
- 35 Beuthien-Baumann, B., Bredow, J., Burchert, W., Fuchtnner, F., Bergmann, R., Alheit, H. D., Reiss, G.,  
 36 Hliscs, R., Steinmeier, R., Franke, W. G., Johannsen, B. & Kotzerke, J. (2003) 3-O-methyl-6-  
 37 [18F]fluoro-L-DOPA and its evaluation in brain tumour imaging. *European Journal of Nuclear  
 38 Medicine & Molecular Imaging*, 30: 1004-1008.  
 39 Not in PICO
- 40 Bhat, S., Yadav, S. P., Suri, V., Patir, R., Kurkure, P., Kellie, S. & Sachdeva, A. (2011) Management of  
 41 childhood brain tumors: Consensus report by the pediatric hematology oncology (PHO) chapter  
 42 of Indian Academy of Pediatrics (IAP). *Indian Journal of Pediatrics*, 78: 1510-1519.  
 43 Guideline
- 44 Blagoveshchenskaia, N. S., Egorova, V. K. & Tumanova, A. A. (1989) The early diagnosis of acoustic  
 45 neurinomas. [Russian]. *Zhurnal voprosy neirokhirurgii imeni N. N.*: 52-54.  
 46 Not in PICO
- 47 Blews, D. E., Wang, H., Kumar, A. J., Robb, P. A., Phillips, P. C. & Bryan, R. N. (1990) Intradural spinal  
 48 metastases in pediatric patients with primary intracranial neoplasms: Gd-DTPA enhanced MR vs  
 49 CT myelography. *Journal of Computer Assisted Tomography*, 14: 730-735.  
 50 Not in PICO

- 1 Bonneville, J. F., Cattin, F., Racle, A., Bouchareb, M., Boulard, D., Potelon, P. & Tang, Y. S. (1989)  
2 Dynamic CT of the laterosellar extradural venous spaces. *Ajnr: American Journal of*  
3 *Neuroradiology*, 10: 535-542.  
4 Not in PICO
- 5 Bonneville, J. F. (2000) Pituitary adenomas: value of MR imaging. [French]. *Journal de Radiologie*, 81:  
6 939-942.  
7 Narrative review
- 8 Brasme, J. F., Morfouace, M., Grill, J., Martinot, A., Amalberti, R., Bons-Letouzey, C. & Chalumeau, M.  
9 (2012) Delays in diagnosis of paediatric cancers: a systematic review and comparison with expert  
10 testimony in lawsuits. [Review]. *Lancet Oncology*, 13: e445-e459.  
11 Not in PICO
- 12 Brasme, J. F., Chalumeau, M., Doz, F., Lacour, B., Valteau-Couanet, D., Gaillard, S., Delalande, O.,  
13 Aghakhani, N., Sainte-Rose, C., Puget, S. & Grill, J. (2012) Interval between onset of symptoms  
14 and diagnosis of medulloblastoma in children: distribution and determinants in a population-  
15 based study. *European Journal of Pediatrics*, 171: 25-32.  
16 Not in PICO
- 17 Chacowry, P. K., Platon, A. & Delemont, C. (1724) [Imaging in the evaluation of headaches]. [French].  
18 *Revue Medicale Suisse*, 9: 1720-1722.  
19 Narrative review
- 20 Chandana, S. R., Movva, S., Arora, M. & Singh, T. (2008) Primary brain tumors in adults. *American*  
21 *Family Physician*, 77: 1423-1430.  
22 Narrative review
- 23 Cheng, G., Smith, R. & Tan, A. K. (2003) Cost comparison of auditory brainstem response versus  
24 magnetic resonance imaging screening of acoustic neuroma. *Journal of Otolaryngology*, 32: 394-  
25 399.  
26 Not in PICO
- 27 Chu, C. M., Rasalkar, D. D., Hu, Y. J., Cheng, F. W. T., Li, C. K. & Chu, W. C. W. (2011) Clinical  
28 presentations and imaging findings of neuroblastoma beyond abdominal mass and a review of  
29 imaging algorithm. *British Journal of Radiology*, 84: 81-91.  
30 Not in PICO
- 31 Chuang, S. & Harwood-Nash, D. (1986) Tumors and cysts. *Neuroradiology*, 28: 463-475.  
32 Narrative review
- 33 Clarke, C. E., Edwards, J., Nicholl, D. J. & Sivaguru, A. (2010) Imaging results in a consecutive series of  
34 530 new patients in the Birmingham Headache Service. *Journal of Neurology*, 257: 1274-1278.  
35 Not in PICO
- 36 Cordeiro, J. G., Pinsker, M., Trippel, M., Nikkhah, G. & Reithmeier, T. (2011) Value of F-FET PET in  
37 comparison to stereotactic serial biopsy in the diagnosis of brain lesions. *Acta Neurochirurgica*,  
38 153: 735.  
39 Not in PICO
- 40 Costantini, D. L., Vali, R., Chan, J., McQuattie, S. & Charron, M. (2013) Dual-time-point FDG PET/CT  
41 for the evaluation of pediatric tumors. *American Journal of Roentgenology*, 200: 408-413.  
42 Not in PICO
- 43 Damgaard-Pedersen, K. (1980) CT and IVU in the diagnosis of Wilms' tumour. A comparative study.  
44 *Pediatric Radiology*, 9: 207-211.  
45 Not in PICO
- 46 Davatzikos, C., Zacharaki, E. I., Gooya, A. & Clark, V. (2011) Multi-parametric analysis and registration  
47 of brain tumors: constructing statistical atlases and diagnostic tools of predictive value.  
48 *Conference Proceedings: ...Annual International Conference of the IEEE Engineering in Medicine &*  
49 *Biology Society*, 2011: 6979-6981.  
50 Not in PICO

- 1 Dawes, P. J. D. & Basiouny, H. E. (1999) Outcome of using magnetic resonance imaging as an initial  
2 screen to exclude vestibular schwannoma in patients presenting with unilateral tinnitus. *Journal*  
3 *of Laryngology and Otology*, 113: 818-822.  
4 Not in PICO
- 5 De, R. & Moffat, D. A. (506) The GP's role in acoustic neuroma. *Practitioner*, 248: 501-504.  
6 Narrative review
- 7 Djupesland, P., Sauer, T. & Freng, A. (1993) Puncture cytology in tumors of the head and neck region.  
8 [Norwegian]. *Tidsskrift for Den Norske Laegeforening*, 113: 1985-1987.  
9 Not in PICO
- 10 Dorsch, J. N. (2014) Neurologic syndromes of the head and neck. *Primary Care - Clinics in Office*  
11 *Practice*, 41: 133-149.  
12 Narrative review
- 13 Dort, J. C., Cook, E. F., Watson, C., Shaw, G., Brown, D. K. & Eggermont, J. J. (2009) Power spectrum  
14 auditory brainstem response: novel approach to the evaluation of patients with unilateral  
15 auditory symptoms. *Journal of Otolaryngology: Head and Neck Surgery*, 38: 59-66.  
16 Not in PICO
- 17 Dubrulle, F., Delomez, J., Kiaei, A., Berger, P., Vincent, C., Vaneecloo, F. M. & Lemaitre, L. (2002)  
18 Mass screening for retrocochlear disorders: low-field-strength (0.2-T) versus high-field-strength  
19 (1.5-T) MR imaging. *Ajnr: American Journal of Neuroradiology*, 23: 918-923.  
20 Not in PICO
- 21 Duncan, G. & Caird, F. I. (1991) Review of 18 years' experience of a diagnostic geriatric neurology  
22 referral service. *Scottish Medical Journal*, 36: 139-142.  
23 Not in PICO
- 24 Fayed, N. & Modrego, P. J. (2005) The contribution of magnetic resonance spectroscopy and  
25 echoplanar perfusion-weighted MRI in the initial assessment of brain tumours. *Journal of Neuro-*  
26 *Oncology*, 72: 261-265.  
27 Not in PICO
- 28 Ferda, J., Ferdova, E., Marik, K., Mracek, J. & Hes, O. (2013) Pre-bioptical imaging of gliomas using  
29 PET/CT with application of 18F-fluorothymidine. [Czech]. *Ceska Radiologie*, 67: 19-24.  
30 Not in PICO
- 31 Fink, K. & Fink, J. (2013) Imaging of brain metastases. *Surgical neurology international*, 4: S209-S219.  
32 Narrative review
- 33 Floeth, F. W., Pauleit, D., Wittsack, H. J., Langen, K. J., Reifenberger, G., Hamacher, K., Messing-  
34 Junger, M., Zilles, K., Weber, F., Stummer, W., Steiger, H. J., Woebker, G., Muller, H. W., Coenen,  
35 H. & Sabel, M. (2005) Multimodal metabolic imaging of cerebral gliomas: positron emission  
36 tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. *Journal of*  
37 *Neurosurgery*, 102: 318-327.  
38 Not in PICO
- 39 Forsyth, P. A. & Posner, J. B. (1993) Headaches in patients with brain tumors: a study of 111 patients.  
40 *Neurology*, 43: 1678-1683.  
41 Not in PICO
- 42 Franko, A., Holjar-Erlic, I., Miletic, D., Eskinja, N., Krstulja, M., Petranovic, D., Mendrila, I. & Kucic-  
43 Brusic, S. (2006) Importance of computed tomography and magnetic resonance in the diagnosis  
44 of brain tumors. [Croatian]. *Medicina*, 42: 98-102.  
45 Not in PICO
- 46 Galasko, D., Kwo-On-Yuen PF & Thal, L. (1988) Intracranial mass lesions associated with late-onset  
47 psychosis and depression. [Review] [95 refs]. *Psychiatric Clinics of North America*, 11: 151-166.  
48 Narrative review
- 49 Gardner, M., Hess, C. & Josephson, S. (2013) Utilization and outcomes of cranial computed  
50 tomography in a pediatric population. *Neurology*, 80.  
51 Not in PICO



- 1 Garon, B. R., Sierzant, T. & Ormiston, C. (186) Silent aspiration: results of 2,000 video fluoroscopic  
2 evaluations. *Journal of Neuroscience Nursing*, 41: 178-185.  
3 Not in PICO
- 4 George, J. L. & Marchal, J. C. (2010) [Orbital tumors in children: clinical examination, imaging,  
5 specific progression]. [French]. *Neuro-Chirurgie*, 56: 244-248.  
6 Narrative review
- 7 Giussani, C., Poliakov, A., Ferri, R. T., Plawner, L. L., Browd, S. R., Shaw, D. W. W., Filardi, T. Z.,  
8 Hoepfner, C., Geyer, J. R., Olson, J. M., Douglas, J. G., Villavicencio, E. H., Ellenbogen, R. G. &  
9 Ojemann, J. G. (2010) DTI fiber tracking to differentiate demyelinating diseases from diffuse brain  
10 stem glioma. *Neuroimage*, 52: 217-223.  
11 Not in PICO
- 12 Goodman, J. (1988) Neck pain. *Primary Care - Clinics in Office Practice*, 15: 689-708.  
13 Narrative review
- 14 Grant, R. (2004) Overview: Brain tumour diagnosis and management/Royal College of Physicians  
15 guidelines. *Neurology in Practice*, 75: ii18-ii23.  
16 Guideline
- 17 Hadjivassiliou, M., Alder, S. J., Van Beek, E. J., Hanney, M. B., Lorenz, E., Rao, D. G., Sharrack, B. &  
18 Tindale, W. B. (2009) PET scan in clinically suspected paraneoplastic neurological syndromes: a 6-  
19 year prospective study in a regional neuroscience unit. *Acta Neurologica Scandinavica*, 119: 186-  
20 193.  
21 Not in PICO
- 22 Hamdan, A. & Mitchell, P. (2013) The two-week wait guideline for suspected CNS tumours: A decade  
23 analysis. *British Journal of Neurosurgery*, 27: 642-645.  
24 Not in PICO
- 25 Hamlin, J. A. & Hasso, A. N. (1994) Magnetic resonance imaging of the skull base. *Topics in Magnetic  
26 Resonance Imaging*, 6: 183-201.  
27 Narrative review
- 28 Hankey, G. J. & Stewart-Wynne, E. G. (1987) An analysis of cranial computerized tomography  
29 scanning in private neurological practice. *Clinical & Experimental Neurology*, 23: 187-190.  
30 Not in PICO
- 31 Harcourt, J. P., Vijaya-Sekaran, S., Loney, E. & Lennox, P. (1999) The incidence of symptoms  
32 consistent with cerebellopontine angle lesions in a general ENT out-patient clinic. *Journal of  
33 Laryngology & Otology*, 113: 518-522.  
34 Not in PICO
- 35 Harder, H. (1988) Audiovestibular tests in the diagnosis of cerebellopontine angle tumours. *Acta  
36 Oto-Laryngologica Supplement*, 452: 5-11.  
37 Not in PICO
- 38 Havlik, R., Kollar, A. & Lejska, M. (2000) Recommendation of a diagnostic algorithm in suspected  
39 tumours of the VIIIth cranial nerve. [Czech]. *Otorinolaryngologie a Foniatrie*, 49: 101-104.  
40 Narrative review
- 41 Heller, M., Wohrle, M., Jend, H. H., Hormann, K. & Helmke, K. (1983) [The value of CT in the  
42 diagnosis of tumours of the cerebello-pontine angle. Comparison of various radiological, clinical  
43 and otological examination]. [German]. *Rofo: Fortschritte auf dem Gebiete der Rontgenstrahlen  
44 und der Nuklearmedizin*, 139: 48-55.  
45 Not in PICO (very specific brain tumours)
- 46 Hill, T. W., Nielsen, M. K. & Nepper-Rasmussen, J. (2013) Admission criteria to the Danish Brain  
47 Cancer Program are moderately associated with magnetic resonance imaging findings. *Danish  
48 Medical Journal*, 60: A4580.  
49 Not in PICO
- 50 Holveck, A., Grand, S., Boini, S., Kirchin, M., Le Bas, J. F., Dietemann, J. L., Bracard, S. & Kremer, S.  
51 (2010) Dynamic susceptibility contrast-enhanced MRI evaluation of cerebral intraventricular

- 1 tumors: preliminary results. *Journal of Neuroradiology. Journal de Neuroradiologie*, 37: 269-275.  
2 Not in PICO
- 3 Hutter, A., Schwetye, K. E., Bierhals, A. J. & McKinstry, R. C. (2003) Brain neoplasms: epidemiology,  
4 diagnosis, and prospects for cost-effective imaging. [Review] [87 refs]. *Neuroimaging Clinics of*  
5 *North America*, 13: 237-250.  
6 Narrative review
- 7 Jadvar, H., Connolly, L. P., Fahey, F. H. & Shulkin, B. L. (2007) PET and PET/CT in pediatric oncology.  
8 [Review] [190 refs]. *Seminars in Nuclear Medicine*, 37: 316-331.  
9 Not in PICO
- 10 Jellema, K., Overbeeke, J. J., Teepe, H. L. & Visser, L. H. (2005) Time to diagnosis of intraspinal  
11 tumors. *European Journal of Neurology*, 12: 621-624.  
12 Not in PICO
- 13 Jeong, H. J., Chung, J. K., Kim, Y. K., Kim, C. Y., Kim, D. G., Jeong, J. M., Lee, D. S., Jung, H. W. & Lee,  
14 M. C. (2002) Usefulness of whole-body (18)F-FDG PET in patients with suspected metastatic brain  
15 tumors. *Journal of Nuclear Medicine*, 43: 1432-1437.  
16 Not in PICO
- 17 Kameda-Smith, M. M., White, M. A., St George, E. J. & Brown, J. I. (2013) Time to diagnosis of  
18 paediatric posterior fossa tumours: an 11-year West of Scotland experience 2000-2011. *British*  
19 *Journal of Neurosurgery*, 27: 364-369.  
20 Not in PICO
- 21 Kan, S. (2014) - [Imaging diagnosis of central nervous system malignant lymphoma]. [Japanese]. -  
22 *Brain & Nerve / Shinkei Kenkyu no Shinpo*, 66: 917-926.  
23 Narrative review
- 24 Kanou, Y., Arita, K., Kurisu, K., Tomohide, A. & Iida, K. (2002) Clinical implications of dynamic MRI for  
25 pituitary adenomas: Clinical and histologic analysis. *Journal of Clinical Neuroscience*, 9: 659-663.  
26 Not in PICO
- 27 Kellie, S. J. (1995) Brain tumours in children: Clinical features and management. *Modern Medicine of*  
28 *Australia*, 38: 42-53.  
29 Narrative review
- 30 Kernick, D. & Williams, S. (2011) Should GPs have direct access to neuroradiological investigation  
31 when adults present with headache? *British Journal of General Practice*, 61: 409-411.  
32 Narrative review
- 33 Kernick, D. P., Ahmed, F., Bahra, A., Dowson, A., Elrington, G., Fontebasso, M., Giffin, N. J.,  
34 Lipscombe, S., MacGregor, A., Peatfield, R., Weatherby, S., Whitmarsh, T. & Goadsby, P. J. (2008)  
35 Imaging patients with suspected brain tumour: guidance for primary care. *British Journal of*  
36 *General Practice*, 58: 880-885.  
37 Narrative review
- 38 Kesser, B. W. (2010) Clinical thresholds for when to test for retrocochlear lesions: con. [Review] [15  
39 refs]. *Archives of Otolaryngology -- Head & Neck Surgery*, 136: 727-729.  
40 Narrative review
- 41 Kim, D. W., Jung, S. A., Kim, C. G. & Park, S. A. (2010) The efficacy of dual time point F-18 FDG PET  
42 imaging for grading of brain tumors. *Clinical Nuclear Medicine*, 35: 400-403.  
43 Not in PICO
- 44 Kim, S. H., Chang, W. S., Kim, J. P., Minn, Y. K., Choi, J., Chang, J. W., Kim, T. S., Park, Y. G. & Chang, J.  
45 H. (2011) Peripheral compressing artifacts in brain tissue from stereotactic biopsy with  
46 sidecutting biopsy needle: A pitfall for adequate glioma grading. *Clinical Neuropathology*, 30: 328-  
47 332.  
48 Not in PICO
- 49 Knox, J., Chuni, C., Naqvi, Z., Crawford, P. & Waring, W. S. (2012) Presentations to an acute medical  
50 unit due to headache: A review of 306 consecutive cases. *Acute Medicine*, 11: 144-149.  
51 Not in PICO

- 1 Ko, M. W., Turkeltaub, P. E., Lee, E. B., Gonatas, N. K., Volpe, N. J., Moster, M. L. & Galetta, S. L.  
2 (2009) Primary diffuse leptomeningeal gliomatosis mimicking a chronic inflammatory meningitis.  
3 *Journal of the Neurological Sciences*, 278: 127-131.  
4 Narrative review
- 5 Kovanlikaya, A., Karabay, N., Cakmakci, H., Uysal, K., Olgun, N. & Ergor, G. (2003) Surveillance  
6 imaging and cost effectivity in pediatric brain tumors. *European Journal of Radiology*, 47: 188-  
7 192.  
8 Not in PICO
- 9 Kwan, T. L., Tang, K. W., Pak, K. K. & Cheung, J. Y. (2004) Screening for vestibular schwannoma by  
10 magnetic resonance imaging: analysis of 1821 patients. *Hong Kong Medical Journal*, 10: 38-43.  
11 Not in PICO
- 12 Lafosse, P. (1983) [Use of computer tomography in the diagnosis of syndromes of the  
13 cerebellopontine angle]. [French]. *Annales d'Oto-Laryngologie et de Chirurgie Cervico-Faciale*, 100:  
14 217-221.  
15 Not in PICO
- 16 Lafosse, P. (1983) Diagnostic value of computed tomography imaging in cerebellopontine angle  
17 syndrome. [French]. *Annales d'Oto-Laryngologie et de Chirurgie Cervico-Faciale*, 100: 217-221.  
18 Not in PICO
- 19 Lambrinides, K. & Reichert, M. (111) MR imaging of pineoblastomas. *Radiologic Technology*, 66: 106-  
20 110.  
21 Narrative review
- 22 Lee, J.-S., Park, Y.-S., Kwon, J.-T., Nam, T.-K., Lee, T.-J. & Kim, J.-K. (2011) Radiological apoplexy and  
23 its correlation with acute clinical presentation, angiogenesis and tumor microvascular density in  
24 pituitary adenomas. *Journal of Korean Neurosurgical Society*, 50: 281-287.  
25 Not in PICO
- 26 Li, H.-H., Sun, W.-G., Liu, H. & Fan, G.-G. (2012) Value of half-dose contrast-enhanced three  
27 dimensional fluid-attenuated inversion recovery sequence in diagnosis of brain metastasis  
28 tumors. [Chinese]. *Chinese Journal of Interventional Imaging and Therapy*, 9: 593-596.  
29 Not in PICO
- 30 Lis, E., Bilsky, M. H., Pisinski, L., Boland, P., Healey, J. H., O'malley, B. & Krol, G. (2004) Percutaneous  
31 CT-guided biopsy of osseous lesion of the spine in patients with known or suspected malignancy.  
32 *AJNR*, American: 1583-1588.  
33 Not in PICO
- 34 Lovrencic-Huzjan, A., Jadrijevic-Tomas, A., Samovojska, D., Cindric, I., Bencina, B., Bedekovic, M. R. &  
35 Kes, V. B. (2013) One year study of vertigo in the neurological emergency room. *Acta Clinica  
36 Croatica, Supplement*, 52: 73.  
37 Not in PICO
- 38 Maki, J. L., Marr, B. P. & Abramson, D. H. (2009) Diagnosis of retinoblastoma: how good are referring  
39 physicians? *Ophthalmic Genetics*, 30: 199-205.  
40 Not in PICO
- 41 Manaka, S. (1988) [Diagnosis of early stage of brain tumors]. [Japanese]. *Gan No Rinsho - Japanese  
42 Journal of Cancer Clinics*, 34: 1285-1294.  
43 Narrative review
- 44 Martin-Berra, J. C., Alvaro, L. C., Aranzabal, I., Freijo, M. M., Huete, B. & Cortina, C. (2002) [Non  
45 tumoural cerebral biopsies: an analysis of 50 cases]. [Spanish]. *Revista de Neurologia*, 34: 306-  
46 309.  
47 Not in PICO
- 48 Matsuhisa, A., Toriihara, A., Kubota, K., Makino, T., Mizusawa, H. & Shibuya, H. (2012) Utility of F-18  
49 FDG PET/CT in screening for paraneoplastic neurological syndromes. *Clinical Nuclear Medicine*,  
50 37: 39-43.  
51 Not in PICO

- 1 Mayr, N. A., Yuh, W. T., Muhonen, M. G., Fisher, D. J., Nguyen, H. D., Ehrhardt, J. C., Wen, B. C.,  
2 Doornbos, J. F. & Hussey, D. H. (1994) Cost-effectiveness of high-dose MR contrast studies in the  
3 evaluation of brain metastases (Structured abstract). *American Journal of Neuroradiology*, 15:  
4 1053-1061.  
5 Not in PICO
- 6 McFadyen, M. B. (2004) First seizures, the epilepsies and other paroxysmal disorders prospective  
7 audit of a first seizure clinic. *Scottish Medical Journal*, 49: 126-130.  
8 Not in PICO
- 9 McGann, G. M. & Platts, A. (1991) Computed tomography of cranial metastatic malignant  
10 melanoma: features, early detection and unusual cases. *British Journal of Radiology*, 64: 310-313.  
11 Not in PICO
- 12 Medina, L. S., Kuntz, K. M. & Pomeroy, S. (2001) Children with headache suspected of having a brain  
13 tumor: a cost-effectiveness analysis of diagnostic strategies. *Pediatrics*, 108: 255-263.  
14 Not in PICO
- 15 Melzer, H. I., Coppenrath, E., Schmid, I., Albert, M. H., von, S. D., Tudball, C., Bartenstein, P. &  
16 Pfluger, T. (2011) 123I-MIBG scintigraphy/SPECT versus 18F-FDG PET in paediatric  
17 neuroblastoma. *European Journal of Nuclear Medicine & Molecular Imaging*, 38: 1648-1658.  
18 Not in PICO
- 19 Mentzel, H. J., Kentouche, K., Sauner, D., Fleischmann, C., Vogt, S., Gottschild, D., Zintl, F. & Kaiser,  
20 W. A. (2004) Comparison of whole-body STIR-MRI and 99mTc-methylene-diphosphonate  
21 scintigraphy in children with suspected multifocal bone lesions. *European Radiology*, 14: 2297-  
22 2302.  
23 Not in PICO
- 24 Mertens, K., Bolcaen, J., Ham, H., Deblaere, K., Van den Broecke, C., Boterberg, T., De, V. F. &  
25 Goethals, I. (2012) The optimal timing for imaging brain tumours and other brain lesions with  
26 18F-labelled fluoromethylcholine: a dynamic positron emission tomography study. *Nuclear  
27 Medicine Communications*, 33: 954-959.  
28 Not in PICO
- 29 Meyer, J. S., Harty, M. P. & Khademian, Z. (2002) Imaging of neuroblastoma and Wilms' tumor.  
30 *Magnetic Resonance Imaging Clinics of North America*, 10: 275-302.  
31 Narrative review
- 32 Miabi, Z. (2011) Metastatic brain tumors: a retrospective review in East Azarbyjan (Tabriz). *Acta  
33 Medica Iranica*, 49: 115-117.  
34 Not in PICO
- 35 Milstein, J. M., Cohen, M. E. & Sinks, L. F. (1985) The influence and reliability of neurologic  
36 assessment and Karnofsky performance score on prognosis. *Cancer*, 56: Suppl-6.  
37 Narrative review
- 38 Mizuno, M., Yoshioka, K., Ito, K., Takegoshi, H. & Sasaki, T. (1995) The changing profile of acoustic  
39 neuromas in recent years. [Japanese]. *Equilibrium Research*, 54: 450-457.  
40 Not in PICO
- 41 Moffat, D. A., Jones, S. E., Mahendran, S., Humphriss, R. & Baguley, D. M. (2004) Referral patterns in  
42 vestibular schwannomas --10 years on. *Clinical Otolaryngology & Allied Sciences*, 29: 515-517.  
43 Not in PICO
- 44 Molassiotis, A., Wilson, B., Brunton, L. & Chandler, C. Mapping patients' experiences from initial  
45 change in health to cancer diagnosis: A qualitative exploration of patient and system factors  
46 mediating this process. [References]. *European Journal of Cancer Care* 19[1], 98-109. 2010.  
47 Not in PICO
- 48 Muroff, L. R. & Runge, V. M. (1995) The use of MR contrast in neoplastic disease of the brain.  
49 [Review] [70 refs]. *Topics in Magnetic Resonance Imaging*, 7: 137-157.  
50 Narrative review

- 1 Natalwala, A., Bharkhada, V., Noel, G. & Cruickshank, G. (2011) Comparison of time taken from initial  
2 presentation to histological diagnosis of Glioblastoma Multiforme (GBM) in Birmingham, United  
3 Kingdom and Strasbourg, France. *Clinical Neurology & Neurosurgery*, 113: 358-361.  
4 Not in PICO
- 5 Nilsson, J. & Bjorkengren, U. (1996) [A study of referrals: what is the outcome of cranial computer  
6 tomography? Medical and economic benefits!]. [Swedish]. *Lakartidningen*, 93: 3365-3368.  
7 Not in PICO
- 8 Nishimoto, A. & Furuta, T. (1988) [Early diagnosis of metastatic brain tumor]. [Japanese]. *Gan No*  
9 *Rinsho - Japanese Journal of Cancer Clinics*, 34: 1484-1490.  
10 Narrative review
- 11 Nishiyama, Y., Yamamoto, Y., Fukunaga, K., Satoh, K., Kunishio, K. & Ohkawa, M. (2001) Comparison  
12 of 99Tcm-MIBI with 201Tl chloride SPET in patients with malignant brain tumours. *Nuclear*  
13 *Medicine Communications*, 22: 631-639.  
14 Not in PICO
- 15 Papanikolaou, V., Khan, M. H. & Keogh, I. J. (2010) Incidental findings on MRI scans of patients  
16 presenting with audiovestibular symptoms. *BMC Ear, Nose and Throat Disorders*, 10.  
17 Not in PICO
- 18 Parker, A., Robinson, R. O. & Bullock, P. (1996) Difficulties in diagnosing intrinsic spinal cord tumours.  
19 *Archives of Disease in Childhood*, 75: 204-207.  
20 Not in PICO
- 21 Pascual-Castroviejo, I., Villarejo, F., Perez-Higueras, A., Morales, C. & Pascual-Pascual, S. I. (1983)  
22 Childhood choroid plexus neoplasms. A study of 14 cases less than 2 years old. *European Journal*  
23 *of Pediatrics*, 140: 51-56.  
24 Not in PICO
- 25 Patel, R. R., Subramaniam, R. M., Mandrekar, J. N., Hammack, J. E., Lowe, V. J. & Jett, J. R. (2008)  
26 Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of  
27 positron emission tomography in diagnosis. *Mayo Clinic Proceedings*, 83: 917-922.  
28 Not in PICO
- 29 Paul, S. P., Debono, R. & Walker, D. (2013) Clinical update: Recognising brain tumours early in  
30 children. *Community Practitioner*, 86: 42-45.  
31 Narrative review
- 32 Pauleit, D., Floeth, F., Tellmann, L., Hamacher, K., Hautzel, H., Muller, H. W., Coenen, H. H. & Langen,  
33 K. J. (2004) Comparison of O-(2-18F-fluoroethyl)-L-tyrosine PET and 3-123I-iodo-alpha-methyl-L-  
34 tyrosine SPECT in brain tumors. *Journal of Nuclear Medicine*, 45: 374-381.  
35 Not in PICO
- 36 Pech, A., Cannoni, M., Sarrat, P., Bernard, P., Thomassin, J. M., Zanaret, M., Triglia, J. M. & Giovanni,  
37 A. (1988) Contribution of nuclear magnetic resonance in the neuro-otologic diagnosis of acoustic  
38 neuroma. Screening and evaluation of its extension. [French]. *Annales d'oto-laryngologie et de*  
39 *chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris*, 105: 39-  
40 45.  
41 Not in PICO
- 42 Peponis, N. T. (1986) Diagnosis of acoustic neuroma. *Journal of the American Osteopathic*  
43 *Association*, 86: 369-378.  
44 Narrative review
- 45 Petiot, P., Herbin, P., Vighetto, A. & Aimard, G. (1995) False negative results by X scanners in  
46 intracranial tumors in adults. [French]. *Revue Neurologique*, 151: 734-738.  
47 Not in PICO
- 48 Pettet, G., Renowden, S. & Mortimer, A. (2012) Use of MRI in the investigation of suspected acoustic  
49 neuroma. A retrospective review of 1000 scans. *Clinical Radiology*, 67: S25.  
50 Not in PICO

- 1 Plotkin, M., Blechschmidt, C., Auf, G., Nyuyki, F., Geworski, L., Denecke, T., Brenner, W. &  
2 Stockhammer, F. (2010) Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of  
3 non-contrast-enhancing gliomas. *European Radiology*, 20: 2496-2502.  
4 Not in PICO
- 5 Porto, L., Kieslich, M., Bartels, M., Schwabe, D., Zanella, F. E. & Du, M. R. (2010) Leptomeningeal  
6 metastases in pediatrics: magnetic resonance image manifestations and correlation with cerebral  
7 spinal fluid cytology. *Pediatrics International*, 52: 541-546.  
8 Not in PICO
- 9 Powell, H. R. & Choa, D. I. (2010) Should all patients referred for magnetic resonance imaging scans  
10 of their internal auditory meatus be followed up in ENT clinics? *European Archives of Oto-Rhino-  
11 Laryngology*, 267: 1361-1366.  
12 Not in PICO
- 13 Prashad, P. S., Marcus, C. L., Brown, L. W., Dlugos, D. J., Feygin, T., Harding, B. N., Heuer, G. G. &  
14 Mason, T. B. (2013) Brain tumor presenting as somnambulism in an adolescent. *Pediatric  
15 Neurology*, 49: 209-212.  
16 Not in PICO
- 17 Purcell, C., Qassim, A., Alcutt, D., Sattar, T., Crimmins, D., Nicholson, A. J. & Caird, J. (2011) Can we  
18 diagnose Brain Tumours in Children Earlier? An Irish Audit. *British Journal of Neurosurgery*, 25:  
19 565-566.  
20 Not in PICO
- 21 Raber, E., Dort, J. C., Sevic, R. & Winkelaar, R. (1997) Asymmetric hearing loss: toward cost-effective  
22 diagnosis. *Journal of Otolaryngology*, 26: 88-91.  
23 Not in PICO
- 24 Ramelli, G. P., von der, W. N., Stanga, Z., Mullis, P. E. & Buergi, U. (1998) Suprasellar germinomas in  
25 childhood and adolescence: diagnostic pitfalls. *Journal of Pediatric Endocrinology*, 11: 693-697.  
26 Not in PICO
- 27 Rao, P. (2008) Role of MRI in paediatric neurooncology. [Review] [30 refs]. *European Journal of  
28 Radiology*, 68: 259-270.  
29 Narrative review
- 30 Reulecke, B. C., Erker, C. G., Fiedler, B. J., Niederstadt, T. U. & Kurlemann, G. (2008) Brain tumors in  
31 children: initial symptoms and their influence on the time span between symptom onset and  
32 diagnosis. *Journal of Child Neurology*, 23: 178-183.  
33 Not in PICO
- 34 Rizzo, D., Freneaux, P., Brisse, H., Louvrier, C., Lequin, D., Nicolas, A., Ranchere, D., Verkarre, V.,  
35 Jouvret, A., Dufour, C., Edan, C., Stephan, J. L., Orbach, D., Sarnacki, S., Pierron, G., Parfait, B.,  
36 Peuchmaur, M., Delattre, O. & Bourdeaut, F. (2012) SMARCB1 deficiency in tumors from the  
37 peripheral nervous system: a link between schwannomas and rhabdoid tumors? *American  
38 Journal of Surgical Pathology*, 36: 964-972.  
39 Not in PICO
- 40 Ruckenstein, M. J. (1995) A practical approach to dizziness questions to bring vertigo and other  
41 causes into focus. *Postgraduate Medicine*, 97: 70-78+81.  
42 Narrative review
- 43 Saga, T., Kawashima, H., Araki, N., Takahashi, J. A., Nakashima, Y., Higashi, T., Oya, N., Mukai, T.,  
44 Hojo, M., Hashimoto, N., Manabe, T., Hiraoka, M. & Togashi, K. (2006) Evaluation of primary brain  
45 tumors with FLT-PET: usefulness and limitations. *Clinical Nuclear Medicine*, 31: 774-780.  
46 Not in PICO
- 47 Sato, Y. (1992) Pediatric primary brain tumors. [Review] [37 refs]. *Topics in Magnetic Resonance  
48 Imaging*, 4: 64-77.  
49 Narrative review

- 1 Savitz, M. H. (1992) Free-hand CT-guided needle for biopsy and drainage of intracerebral lesions. Ten  
2 years experience. *International Surgery*, 77: 211-215.  
3 Not in PICO
- 4 Scarabino, T., Giannatempo, G. M., Nemore, F., Popolizio, T. & Stranieri, A. (2005) Supratentorial  
5 low-grade gliomas. *Neuroradiology*. [Review] [14 refs]. *Journal of Neurosurgical Sciences*, 49: 73-  
6 76.  
7 Narrative review
- 8 Schuknecht, B., Huber, P., Buller, B. & Nadjmi, M. (1992) Spinal leptomeningeal neoplastic disease.  
9 Evaluation by MR, myelography and CT myelography. *European Neurology*, 32: 11-16.  
10 Not in PICO
- 11 Seidl, Z., Vymazal, J., Mechl, M., Goyal, M., Herman, M., Colosimo, C., Pasowicz, M., Yeung, R.,  
12 Paraniak-Gieszczyk, B., Yemen, B., Anzalone, N., Citterio, A., Schneider, G., Bastianello, S. &  
13 Ruscalleda, J. (2012) Does higher gadolinium concentration play a role in the morphologic  
14 assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of  
15 gadobutrol versus gadobenate dimeglumine (the MERIT Study). *Ajnr: American Journal of*  
16 *Neuroradiology*, 33: 1050-1058.  
17 Not in PICO
- 18 Sethi, R. V., Marino, R., Niemierko, A., Tarbell, N. J., Yock, T. I. & MacDonald, S. M. (2013) Delayed  
19 diagnosis in children with intracranial germ cell tumors. *Journal of Pediatrics*, 163: 1448-1453.  
20 Not in PICO
- 21 Shaffer, K. A., Houghton, V. M. & Wilson, C. R. (1980) High resolution computed tomography of the  
22 temporal bone. *Radiology*, 134: 409-414.  
23 Not in PICO
- 24 Shay, V., Fattal-Valevski, A., Beni-Adani, L. & Constantini, S. (2012) Diagnostic delay of pediatric brain  
25 tumors in Israel: A retrospective risk factor analysis. *Child's Nervous System*, 28: 93-100.  
26 Not in PICO
- 27 Sheen, V., Tucker, M. A., Abramson, D. H., Seddon, J. M. & Kleinerman, R. A. (2008) Cancer screening  
28 practices of adult survivors of retinoblastoma at risk of second cancers. *Cancer*, 113: 434-441.  
29 Not in PICO
- 30 Sighvatsson, V., Ericson, K. & Tomasson, H. (1998) Optimising contrast-enhanced cranial CT for  
31 detection of brain metastases. *Acta Radiologica*, 39: 718-722.  
32 Not in PICO
- 33 Skinner, S. A. (1988) Early diagnosis of brain tumor. *Postgraduate Medicine*, 83: 117-124.  
34 Narrative review
- 35 Snelling, J. D., Krywawych, M., Majithia, A. & Harcourt, J. P. (2008) The compliance, true positive and  
36 false negative rates of the Charing Cross protocol for magnetic resonance imaging screening for  
37 cerebellopontine angle lesions. *Journal of Laryngology & Otology*, 122: 255-258.  
38 Not in PICO
- 39 Sotaniemi, K. A., Rantala, M., Pyhtinen, J. & Myllyla, V. V. (1991) Clinical and CT correlates in the  
40 diagnosis of intracranial tumours. *Journal of Neurology Neurosurgery and Psychiatry*, 54: 645-647.  
41 Not in PICO
- 42 Steiger, J. R. (2005) Audiologic referral criteria: Sample clinic guidelines. *Hearing Journal*, 58: 38-42.  
43 Not in PICO
- 44 Straathof, C. S., de Bruin, H. G., Dippel, D. W. & Vecht, C. J. (1999) The diagnostic accuracy of  
45 magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis.  
46 *Journal of Neurology*, 246: 810-814.  
47 Not in PICO
- 48 Struffert, T., Grunwald, I., Roth, C. & Reith, W. (1228) [Spinal intradural tumors]. [Review] [6 refs]  
49 [German]. *Radiologe*, 44: 1211-1227.  
50 Narrative review

- 1 Tadmor, R., Harwood-Nash, D. C. F. & Savoiaro, M. (1980) Brain tumors in the first two years of life:  
2 CT diagnosis. *American Journal of Neuroradiology*, 1: 411-417.  
3 Not in PICO
- 4 Thakkar, S. D., Feigen, U. & Mautner, V. F. (1999) Spinal tumours in neurofibromatosis type 1: an  
5 MRI study of frequency, multiplicity and variety. *Neuroradiology*, 41: 625-629.  
6 Not in PICO
- 7 Thomas, L. & Honnorat, J. (2014) [Brain metastases: epidemiology, diagnosis and imaging]. [French].  
8 *La Revue du praticien*, 64: 668-673.  
9 Narrative review
- 10 Thorsteinsson, R., Sorensen, M., Jensen, T. L., Bernhardtson, T. M., Gjerris, F., Carstensen, H.,  
11 Schmiegelow, K. & Raaschou-Nielsen, O. (2005) [Central nervous system tumours in children. An  
12 evaluation of the completeness and validity of the Cancer Registry]. [Danish]. *Ugeskrift for*  
13 *Laeger*, 167: 3782-3785.  
14 Not in PICO
- 15 Thorsteinsson, R., Sorensen, M., Jensen, T. L., Bernhardtson, T. M., Gjerris, F., Carstensen, H.,  
16 Schmiegelow, K. & Raaschou-Nielsen, O. (2005) Completeness and validity of registration of  
17 childhood CNS tumours in the Danish Cancer Registry. [Danish]. *Ugeskrift for Laeger*, 167: 3782-  
18 3785.  
19 Not in PICO
- 20 Tyutin, L. A., Zeidlits, V. N., Pozdnyakova, O. F. & Rokhlin, G. D. (1993) Brain tumors in MR imaging.  
21 [Russian]. *Vestnik Rentgenologii i Radiologii*, 68: 10-13.  
22 Not in PICO
- 23 van der Sande, J. J., Kroger, R. & Boogerd, W. (1990) Multiple spinal epidural metastases; an  
24 unexpectedly frequent finding. *Journal of Neurology, Neurosurgery & Psychiatry*, 53: 1001-1003.  
25 Not in PICO
- 26 Vander, B. T., Asenbaum, S., Bartenstein, P., Halldin, C., Kapucu, O., Van, L. K., Varrone, A., Tatsch, K.  
27 & European Association of Nuclear Medicine (EANM) (2006) EANM procedure guidelines for brain  
28 tumour imaging using labelled amino acid analogues. *European Journal of Nuclear Medicine &*  
29 *Molecular Imaging*, 33: 1374-1380.  
30 Not in PICO; guideline
- 31 Vandervelde, C. & Connor, S. E. (2009) Diagnostic yield of MRI for audiovestibular dysfunction using  
32 contemporary referral criteria: correlation with presenting symptoms and impact on clinical  
33 management. *Clinical Radiology*, 64: 156-163.  
34 Not in PICO
- 35 Warbey, V. S., Ferner, R. E., Dunn, J. T., Calonje, E. & O'Doherty, M. J. (2009) [18F]FDG PET/CT in the  
36 diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. *European*  
37 *journal of nuclear medicine and molecular imaging*, 36: 751-757.  
38 Not in PICO
- 39 Weckesser, M., Langen, K. J., Rickert, C. H., Kloska, S., Straeter, R., Hamacher, K., Kurlemann, G.,  
40 Wassmann, H., Coenen, H. H. & Schober, O. (2005) O-(2-[18F]fluoroethyl)-L-tyrosine PET in the  
41 clinical evaluation of primary brain tumours. *European Journal of Nuclear Medicine & Molecular*  
42 *Imaging*, 32: 422-429.  
43 Not in PICO
- 44 Weissman, D. E., Gilbert, M., Wang, H. & Grossman, S. A. (1985) The use of computed tomography of  
45 the spine to identify patients at high risk for epidural metastases. *Journal of Clinical Oncology*, 3:  
46 1541-1544.  
47 Not in PICO
- 48 White, J. R., Carlson, M. L., Van Gompel, J. J., Neff, B. A., Driscoll, C. L., Lane, J. I. & Link, M. J. (2013)  
49 Lipomas of the cerebellopontine angle and internal auditory canal: Primum Non Nocere.  
50 *Laryngoscope*, 123: 1531-1536.  
51 Not in PICO



- 1 Wills, A. (2011) Direct access to brain mr imaging for headache in primary care; Better than an  
2 aspirin? *Journal of Neurology, Neurosurgery and Psychiatry*, 82: 1-2.  
3 Not in PICO
- 4 Wilne, S., Koller, K., Collier, J., Kennedy, C., Grundy, R. & Walker, D. (2010) The diagnosis of brain  
5 tumours in children: a guideline to assist healthcare professionals in the assessment of children  
6 who may have a brain tumour. [Review] [32 refs]. *Archives of Disease in Childhood*, 95: 534-539.  
7 Guideline
- 8 Wilson, M., Cummins, C. L., Macpherson, L., Sun, Y., Natarajan, K., Grundy, R. G., Arvanitis, T. N.,  
9 Kauppinen, R. A. & Peet, A. C. (2013) Magnetic resonance spectroscopy metabolite profiles  
10 predict survival in paediatric brain tumours. *European Journal of Cancer*, 49: 457-464.  
11 Not in PICO
- 12 Wirix, M., Parys-Vanginderdeuren, R., Casteels, I. & Uyttebrouck, A. (2000) Delayed diagnosis of  
13 retinoblastoma. *Bulletin de la Societe Belge d Ophtalmologie*.(278):37-41, 2000., 37-41.  
14 Not in PICO
- 15 Wong, B. Y. & Capper, R. (2012) Incidence of vestibular schwannoma and incidental findings on the  
16 magnetic resonance imaging and computed tomography scans of patients from a direct referral  
17 audiology clinic. *Journal of Laryngology & Otology*, 126: 658-662.  
18 Not in PICO
- 19 Wong, J. J., Huda, S. & Wieshmann, U. C. (2012) An unusual presentation of an epidermoid brain  
20 tumour: a tale of two specialties. *BMJ Case Reports*, 2012, 2012.  
21 Not in PICO
- 22 Wong, M. L. & Brackmann, D. E. (1981) Computed cranial tomography in acoustic tumor diagnosis.  
23 *JAMA*, 245: 2497-2500.  
24 Not in PICO
- 25 Xiangsong, Z., Xinjian, W., Yong, Z. & Weian, C. (2008) 13N-NH3: a selective contrast-enhancing  
26 tracer for brain tumor. *Nuclear Medicine Communications*, 29: 1052-1058.  
27 Not in PICO
- 28 Xie, C., Ahmed, A. & Banerjee, A. (2013) A comparison of primary care access to non-trauma  
29 computed tomography (CT) and magnetic resonance imaging (MRI) of the brain with hospital  
30 clinician referrals. *Clinical Radiology*, 68: S8-S9.  
31 Not in PICO
- 32 Yagishita, A., Kanzaki, J. & Shiga, H. (1983) Diagnosis of small acoustic tumors by air CT  
33 cisternography. [Japanese]. *Neurologia Medico-Chirurgica*, 23: 441-446.  
34 Not in PICO
- 35 Yamamoto, Y., Nishiyama, Y., Kimura, N., Kameyama, R., Kawai, N., Hatakeyama, T., Kaji, M. &  
36 Ohkawa, M. (2008) 11C-Acetate PET in the evaluation of brain glioma: Comparison with 11C-  
37 Methionine and 18F-FDG-PET. *Molecular Imaging and Biology*, 10: 281-287.  
38 Not in PICO
- 39 You, J. J., Gladstone, J., Symons, S., Rotstein, D., Laupacis, A. & Bell, C. M. (2011) Patterns of care and  
40 outcomes after computed tomography scans for headache. *American Journal of Medicine*, 124:  
41 58-63.  
42 Not in PICO
- 43 Zhou, C. W., Zhang, H. M. & Ouyang, H. (2004) [Intracranial metastasis of malignant tumors: clinical  
44 characteristics and MR imaging features]. [Chinese]. *Chung-Hua Chung Liu Tsa Chih [Chinese  
45 Journal of Oncology]*, 26: 554-557.  
46 Not in PICO
- 47 Zhou, H., Chen, M. & Zhao, D. (2013) Longitudinal MRI evaluation of intracranial development and  
48 vascular characteristics of breast cancer brain metastases in a mouse model. *PLoS ONE [Electronic  
49 Resource]*, 8: e62238.  
50 Not in PICO

1 Zielinska-Bliniewska, H., Michalska, J., Pietkiewicz, P., Milonski, J., Kusmierczyk, K. & Olszewski, J.  
2 (2011) Posterior cranial fossa tumours as a cause of sudden hearing deterioration and/or vertigo.  
3 [Polish]. *Otolaryngologia Polska*, 65: 98-101.  
4 Not in PICO

5 Zyss, T. & Goscinski, I. (1996) [Can psychiatric examination be useful in early diagnosis of intracranial  
6 expansion processes?]. [Polish]. *Psychiatria Polska*, 30: 151-158.  
7 Not in PICO  
8  
9

**HAEMATOLOGICAL CANCERS****LEUKEMIA****Review question:**

What is the risk of leukaemia in adults and children presenting in primary care with symptom(s)?

**Results****Literature search**


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	All-2012	1689	42	11/03/2013
<i>Premedline</i>	All-2012	33	1	11/03/2013
<i>Embase</i>	All-2012	3598	57	13/03/2013
<i>Cochrane Library</i>	All-2012	427	0	13/03/2013
<i>Psychinfo</i>	All-2012	12	0	11/03/2013
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	All-2012	648	10	18/03/2013
Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search

Total References retrieved (after de-duplication): 98

**Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	3/2013-18/08/2014	30	3	18/08/2014
<i>Premedline</i>	3/2013-18/08/2014	85	7	18/08/2014
<i>Embase</i>	3/2013-18/08/2014	195	4	18/08/2014
<i>Cochrane Library</i>	3/2013-18/08/2014	88	0	18/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	3/2013-18/08/2014	135	3	18/08/2014

Total References retrieved (after de-duplication): 9



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11

**Risk of bias in the included studies**

The risk of bias and applicability concerns are summarised for the included studies in the figure below. One main issue to note is that one study employed a case-control design which has been shown to inflate the test accuracy characteristics. However, the statistical analyses employed by the authors may have gone some way in counteracting this influence. Another potential threat to the applicability of the findings concerns the fact that the second study employed a patient sample which may not be directly applicable to the current question.

	Risk of Bias				Applicability Concerns		
	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard
Dommett (2013a,b)	⊖	+	+	+	+	+	+
Hallissey (1990)	+	+	+	+	?	+	+

⊖ High      ? Unclear      + Low

12  
13  
14  
15  
16

**Study results**

Table 1: Leukaemia: Positive predictive values for leukaemia/lymphoma childhood cancer

Study	Symptom(s)	Patient group	Positive predictive value (95% CI)
Dommett (2013a)	Bruising 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.53 (0.07-3.91)
Dommett (2013a)	Pallor 0-3 months before	All included	0.43 (0.06-3.15)

	diagnosis	leukemia/lymphoma patients and controls aged 0-14 years	
Dommett (2013a)	Lump mass swelling head and neck 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.35 (0.05-2.65)
Dommett (2013a)	Fatigue 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.07 (0.03-0.15)
Dommett (2013a)	Lymphadenopathy 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.06 (0.04-0.11)
Dommett (2013a)	Lump mass swelling below neck excluding abdomen 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.05 (0.02-0.13)
Dommett (2013a)	Bleeding 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.03 (0.01-0.08)
Dommett (2013a)	Pain 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.03 (0.01-0.06)
Dommett (2013a)	Musculoskeletal symptoms 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.02 (0.01-0.03)
Dommett (2013a)	Fever 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.01 (0.01-0.01)
Dommett (2013a)	Abdominal pain 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.01 (0-0.01)
Dommett (2013a)	≥ 3 consultations	All included leukemia/lymphoma patients and controls aged 0-14 years	0.01 (0.01-0.01)

1 The positive predictive values are calculated using Bayesian statistics.

2

3 Table 2: Leukaemia: Positive predictive values for teenage and young adult, and adult leukaemia

Study	Symptom(s)	Patient group	Positive predictive value (95% CI)
Dommett (2013b)	Bruising	All included leukaemia patients and controls aged 15-24 years	0.0117 (0.004-0.0343) Cases: 9/143

			Controls: 5/1799
Dommett (2013b)	Fatigue	All included leukaemia patients and controls aged 15-24 years	0.0121 (0.0052-0.0282) Cases: 15/143 Controls: 8/1799
Dommett (2013b)	Lymphadenopathy	All included leukaemia patients and controls aged 15-24 years	0.0151 (0.004-0.0578) Cases: 7/143 Controls: 3/1799
Dommett (2013b)	≥ 3 consultations	All included leukaemia patients and controls aged 15-24 years	0.0038 (0.003-0.0048) Cases: 74/143 Controls: 125/1799
Hallissey (1990)	Dyspepsia	All patients	0.04 (0.002-0.3) 1/2585

1 The positive predictive values are calculated using Bayesian statistics for Dommett (2013b).

## 2 Evidence statement(s):

3 The positive predictive values of having leukaemia/lymphoma childhood cancer ranged from 0.01%  
4 (for fever and abdominal pain) to 0.53% (for bruising) for patients aged 0-14 years old, the positive  
5 predictive values of having young adulthood leukaemia ranged from 0.0117% (for bruising) to  
6 0.0151% (for lymphadenopathy) for patients aged 15-24 years (1 study, N = 30855), and the positive  
7 predictive value of having adulthood leukaemia was 0.04% (for dyspepsia) for patients aged > 40  
8 years (1 study, N = 2585) . Both studies were associated with 1 bias/applicability concern (see also  
9 Tables 1-2).

10

## 11 Evidence tables

### 12 Dommett (2013a,b)

<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Population-based nested case-control study using data from the General Practice Research Database (GPRD)
Was a consecutive or random sample of patients enrolled?	<b>No</b>
Was a case-control design avoided?	<b>No</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>High risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	Cases: 1267 children; aged 0-4 years: N = 436; aged 5-14 years: N = 831; 703 males/564 females. Cancer type: Leukemia: N = 368; brain: N = 270; lymphoma: N = 142; bone: N = 107; soft tissue sarcoma: N = 91; renal: N = 82; neuroblastoma: N = 75;

	<p>other ICD codes: N = 132.</p> <p>1064 teenagers and young adults (TYA): 15-24 years: Gender not reported. Cancer type: Leukemia: N = 143; brain: N = 154; lymphoma: N = 270; bone: N = 96; soft tissue sarcoma: N = 100; other ICD codes: N = 301 (including testis: N = 60; skin: N = 49; ovary: N = 20 and thyroid: N = 17).</p> <p><u>Controls:</u> 15318 children; aged 0-4 years: N = 4802; aged 5-14 years: N = 10516; 8461 males/6857 females. 13206 TYA. Gender not reported</p> <p><u>Inclusion criteria:</u> The sample comprised all children and TYU aged 0–24 years, inclusive, drawn from all general practices contributing research-standard data to the GPRD between 1 January 1988 and 31 December 2010. To be included, the practices had to have been contributing research-standard data for a minimum of 1 year before each child's date of cancer diagnosis or the index date (see below) for matched controls. Cases: Patients diagnosed with the following cancers: leukaemia, lymphoma, neuroblastoma, soft tissue sarcoma, hepatic, renal, bone and central nervous system tumours, using pre-defined medical codes used in the GPRD. The date of diagnosis for cases was defined as the date of pathological diagnosis, but if this was unavailable, the date of the first cancer code entered in the GPRD was used. Controls: Up to 13 controls (children with no diagnosis of cancer at any time) were selected per case, using a computer-generated random sequence, matched on age (within 1 year), sex and practice, and had to be currently registered on the date of diagnosis of their matched case (the index date). <u>Exclusion criteria:</u> None listed <u>Clinical setting:</u> Primary care, UK.</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b><u>A. Risk of bias</u></b>	
<b>Index test</b>	The GPRD uses just over 100 000 medical codes to encompass all primary care events, including both symptoms and diagnoses. From this list, libraries of codes were assembled representing individual alert symptoms derived from the NICE referral guidelines for suspected cancer in children. <i>No more information reported.</i>
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b><u>B. Concerns regarding applicability</u></b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b><u>A. risk of bias</u></b>	

Reference standard(s)	Cancer diagnosis in the UK's General Practice Research Database.	
Is the reference standard likely to correctly classify the target condition?	Yes	
Were the reference standard results interpreted without knowledge of the results of the index tests?	Unclear	
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	Low risk	
<b><u>B. Concerns regarding applicability</u></b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	Low concern	
<b>FLOW AND TIMING</b>		
<b><u>A. risk of bias</u></b>		
Flow and timing	All patients appear to be accounted for.	
Was there an appropriate interval between index test and reference standard?	Yes	
Did all patients receive the same reference standard?	Yes	
Were all patients included in the analysis?	Yes	
<b>Could the patient flow have introduced bias?</b>	Low risk	
<b>NOTES</b>	This study is published in three papers.	
1		
2	<b>Hallissey (1990)</b>	
<b>PATIENT SELECTION</b>		
<b><u>A. risk of bias</u></b>		
Patient sampling	Propective consecutive patient series from a group of 10 general practices in England.	
Was a consecutive or random sample of patients enrolled?	Yes	
Was a case-control design avoided?	Yes	
Did the study avoid inappropriate exclusions?	Yes	
<b>Could the selection of patients have introduced bias?</b>	Low risk	
<b><u>B. Concerns regarding applicability</u></b>		
Patient characteristics and setting	N = 2585 aged > 40 years. No other information reported. The patient group was equally divided between new patients with dyspepsia, old patients with uninvestigated dyspepsia, and old patients with investigated dyspepsia.  <u>Inclusion criteria:</u> All patients over 40 years making their first attendance during the study period (4 years and 9 months) with any degree of dyspepsia <u>Exclusion criteria:</u> None listed. <u>Clinical setting:</u> Primary care, England.	
<b>Are there concerns that the included patients and setting do not match the review question?</b>	Unclear concern	
<b>INDEX TEST</b>		
<b><u>A. Risk of bias</u></b>		
Index test	Dyspepsia of any degree	
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes	



<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Upper gastrointestinal endoscopy within 4 weeks and follow up.
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	2659 patients were seen and 2585 attended for investigation
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	Malignancy was detected in 115 patients: Gastric adenocarcinoma (57), gastric lymphoma (1; added to the gastric adenocarcinoma data in the PPV), oesophageal cancer (15), colorectal (14), pancreatic (6), bronchial (8), prostatic (2), duodenal (1, also added to the gastric carcinoma data in the PPV), liver (1), gall bladder (1), carcinoid (1), uterine (1), leukaemia (1), cirrinomatosis of unknown primary (7).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13

## References

### Included studies

Dommett, R. M., Redaniel, T., Stevens, M. C. G., Martin, R. M., and Hamilton, W. Risk of childhood cancer with symptoms in primary care: A population-based case-control study. *British Journal of General Practice*; DOI:10.3399/bjgp13X660742. 2013a.

Dommett, R. M., Redaniel, M. T., Stevens, M. C. G., Hamilton, W., and Martin, R. M. Features of cancer in teenagers and young adults in primary care: A population-based nested case-control study. *British Journal of Cancer* 2329-2333. 2013b.

Hallissey, M.T., Allum, W.H., Jewkes, A.J., Ellis, A.J., Fielding, J.W.L. Early detection of gastric cancer. *British Medical Journal* 301, 513-515. 1990.

### Excluded studies (with excl reason)

- 1 (1967) Role of the dentist in detection and prevention of systemic diseases. *Journal of the American*  
 2 *Dental Association (1939)*, 75: 1291-1292.  
 3 Not in PICO
- 4 Abel, G. A., Friese, C. R., Magazu, L. S., Richardson, L. C., Fernandez, M. E., De Zengotita, J. J. & Earle,  
 5 C. C. (2008) Delays in referral and diagnosis for chronic hematologic malignancies: A literature  
 6 review. *Leukemia & Lymphoma*, 49: 1352-1359.  
 7 Not in PICO
- 8 Abel, G. A., Friese, C. R., Neville, B. A., Wilson, K. M., Hastings, B. T., Earle, C. C., Keating, N. L.,  
 9 Richardson, L. C., Abel, G. A., Friese, C. R., Neville, B. A., Wilson, K. M., Hastings, B. T., Earle, C. C.,  
 10 Keating, N. L. & Richardson, L. C. (2012) Referrals for suspected hematologic malignancy: a survey  
 11 of primary care physicians. *American Journal of Hematology*, 87: 634-636.  
 12 Not in PICO
- 13 Adlekha, S. & Chadha, T. (2013) Bernard Soulier Syndrome associated with acute myeloid leukemia.  
 14 *Indian Journal of Medical Sciences*, 67: 145-147.  
 15 Not in PICO
- 16 Ahrensberg, J. M., Olesen, F., Hansen, R. P., Schroder, H. & Vedsted, P. (2013) Childhood cancer and  
 17 factors related to prolonged diagnostic intervals: a Danish population-based study. *British Journal*  
 18 *of Cancer*, epub ahead of print.  
 19 Not in PICO
- 20 AUDO-GIANOTTI, G. B. (1963) EARLY DIAGNOSIS OF MALIGNANT BLOOD DISEASES. *Il Cancro*, 16:  
 21 1963.  
 22 Not in PICO
- 23 Ayremlou, P. (2012) Demographic and prognostic factors of 455 patients with acute leukemia  
 24 admitted to two referral hospitals in Tehran-Iran during ten years (2001-2011). *Iranian Journal of*  
 25 *Cancer Prevention*, 5: 157-163.  
 26 Not in PICO
- 27 Bansal, D. & Totadri, S. (2014) - Common hematological disorders in children.[Erratum appears in  
 28 *Indian J Pediatr*. 2014 Jun;81(6):635]. - *Indian Journal of Pediatrics*, 81: 42-50.  
 29 Narrative review
- 30 Bansal, D. & Totadri, S. (2014) Common hematological disorders in children. *Indian Journal of*  
 31 *Pediatrics*, 81: 42-50.  
 32 Narrative review
- 33 Baughan, P., Keatings, J. & O'Neill, B. (2011) Urgent suspected cancer referrals from general practice:  
 34 audit of compliance with guidelines and referral outcomes. *British Journal of General Practice*, 61:  
 35 e700-e706.  
 36 Not in PICO
- 37 Bedu-Addo, G., Ampem, A. Y. & Bates, I. (2013) The role of bone marrow aspirate and trephine  
 38 samples in haematological diagnoses in patients referred to a teaching hospital in Ghana. *Ghana*  
 39 *Medical Journal*, 47: 74-78.  
 40 Not in PICO
- 41 Bernbeck, B., Wuller, D., Janssen, G., Wessalowski, R., Gobel, U. & Schneider, D. T. (2009) Symptoms  
 42 of childhood acute lymphoblastic leukemia: red flags to recognize leukemia in daily practice.  
 43 *Klinische Padiatrie*, 221: 369-373.  
 44 Not in PICO
- 45 Bhaskar, M. E. (2011) Nail changes in a patient with leukaemia. *BMJ*, 342: 177.  
 46 Not in PICO
- 47 Bleyer, A. (2009) CAUTION! Consider Cancer: Common Symptoms and Signs for Early Detection of  
 48 Cancer in Young Adults. *Seminars in Oncology*, 36: 207-212.  
 49 Narrative review

- 1 Cabral, D. A. T. (1999) Malignancies in children who initially present with rheumatic complaints.  
2 *Journal of Pediatrics*, 134: 53-57.  
3 Not in PICO
- 4 Campbell, E. W., Jr., Smith, M. R., Campbell, E. W. J. & Smith, M. R. (1996) Hematology for primary  
5 care physicians. *Disease-a-Month*, 42: 131-194.  
6 Narrative review
- 7 Canfield, K. N., Spector, L. G., Robison, L. L., Lazovich, D., Roesler, M., Olshan, A. F., Smith, F. O.,  
8 Heerema, N. A., Barnard, D. R., Blair, C. K., Ross, J. A., Canfield, K. N., Spector, L. G., Robison, L. L.,  
9 Lazovich, D., Roesler, M., Olshan, A. F., Smith, F. O., Heerema, N. A., Barnard, D. R., Blair, C. K. &  
10 Ross, J. A. (2004) Childhood and maternal infections and risk of acute leukaemia in children with  
11 Down syndrome: a report from the Children's Oncology Group. *British Journal of Cancer*, 91:  
12 1866-1872.  
13 Not in PICO
- 14 Cardwell, C. R., McKinney, P. A., Patterson, C. C., Murray, L. J., Cardwell, C. R., McKinney, P. A.,  
15 Patterson, C. C. & Murray, L. J. (2008) Infections in early life and childhood leukaemia risk: a UK  
16 case-control study of general practitioner records. *British Journal of Cancer*, 99: 1529-1533.  
17 Not in PICO
- 18 Carriere, B. (2001) Vertebral fractures as initial signs for acute lymphoblastic leukemia. *Pediatric*  
19 *Emergency Care*, 17: 258-261.  
20 Not in PICO
- 21 Casado, P. R., Barrios, L. M., de Inocencio, A. J., Baro, F. M., Vivanco Martinez, J. L., Casado Picon, R.,  
22 Barrios Lopez, M., de Inocencio Arocena, J., Baro Fernandez, M. & Vivanco Martinez, J. L. (2010)  
23 [Musculoskeletal pain: a common initial sign of acute lymphoblastic leukaemia]. [Spanish]. *Anales*  
24 *de Pediatria*, 72: 428-431.  
25 Not in PICO
- 26 Cavkaytar, O. (2010) Limping as an initial symptom of acute leukemia. *Cocuk Sagligi ve Hastaliklari*  
27 *Dergisi*, 53: 295-297.  
28 Narrative review
- 29 Clarke, R. T., Jones, C. H. D., Mitchell, C. D. & Thompson, M. J. (2014) 'Shouting from the roof tops': A  
30 qualitative study of how children with leukaemia are diagnosed in primary care. *BMJ Open*, 4.  
31 Not in PICO
- 32 Clarke, R. T., Jones, C. H., Mitchell, C. D. & Thompson, M. J. (2014) - 'Shouting from the roof tops': a  
33 qualitative study of how children with leukaemia are diagnosed in primary care. - *BMJ Open*, 4:  
34 e004640.  
35 Duplicate
- 36 Clarke, R. T., Jones, C. H. D., Mitchell, C. D. & Thompson, M. J. (2014) 'Shouting from the roof tops': a  
37 qualitative study of how children with leukaemia are diagnosed in primary care. *BMJ Open*, 4.  
38 Duplicate
- 39 Creutzig, U., van den Heuvel-Eibrink MM, Gibson, B., Dworzak, M. N., Adachi, S., de, B. E., Harbott, J.,  
40 Hasle, H., Johnston, D., Kinoshita, A., Lehrnbecher, T., Leverger, G., Mejstrikova, E., Meshinchi, S.,  
41 Pession, A., Raimondi, S. C., Sung, L., Stary, J., Zwaan, C. M., Kaspers, G. J. & Reinhardt, D. (2012)  
42 Diagnosis and management of acute myeloid leukemia in children and adolescents:  
43 recommendations from an international expert panel. *Blood*, 120: 3187-3205.  
44 Narrative review/guideline
- 45 Cwiklinska, M., Balwierz, W., Cwiklinska, M. & Balwierz, W. (2009) [Osteoarticular pains as early  
46 manifestation of malignancies in children]. [Polish]. *Przegląd Lekarski*, 66: 39-44.  
47 Not in PICO
- 48 da Fonseca, M. A. & da Fonseca, M. A. (2007) Head and neck extramedullary disease as the initial  
49 presentation of acute myelogenous leukemia in a child. *Journal of Dentistry for Children (Chicago,*  
50 *Ill, ).* 74: 241-244.  
51 Not in PICO

- 1 Davis, A. S., Viera, A. J. & Mead, M. D. (2014) Leukemia: An overview for primary care. *American*  
 2 *Family Physician*, 89: 731-738.  
 3 Narrative review
- 4 Davis, A. S., Viera, A. J. & Mead, M. D. (2014) - Leukemia: an overview for primary care. [Review]. -  
 5 *American Family Physician*, 89: 731-738.  
 6 Duplicate
- 7 Davis, A. S., Viera, A. J. & Mead, M. D. (2014) Leukemia: An Overview for Primary Care. *American*  
 8 *Family Physician*, 89: 731-738.  
 9 Duplicate
- 10 Delaney, M., Schellhase, K. G., Young, S., Geiger, S., Fink, A., Mast, A. E., Delaney, M., Schellhase, K.  
 11 G., Young, S., Geiger, S., Fink, A. & Mast, A. E. (2011) Blood center practice and education for  
 12 blood donors with anemia. *Transfusion*, 51: 929-936.  
 13 Not in PICO
- 14 Dorronsor Martin, I., Merino Munoz, R., Sastre-Urguelles, A., Garcia-Miguel Garcia-Rosado, P. &  
 15 Garcia-Consuegra, M. J. (2004) [Malignant disease presenting as rheumatic manifestations].  
 16 [Spanish]. *Anales de Pediatría*, 61: 393-397.  
 17 Not in PICO
- 18 Dutschke, K., Siebenburger, H. & Schrader, W. (1998) [Acute lymphatic leukemia of the T-cell line.  
 19 Visual impairment as the initial symptom] [German]. *Ophthalmologe*, 95: 831-834.  
 20 Not in PICO
- 21 Edgren, G., Bagnardi, V., Bellocco, R., Hjalgrim, H., Rostgaard, K., Melbye, M., Reilly, M., Adami, H. O.,  
 22 Hall, P., Nyren, O., Edgren, G., Bagnardi, V., Bellocco, R., Hjalgrim, H., Rostgaard, K., Melbye, M.,  
 23 Reilly, M., Adami, H. O., Hall, P. & Nyren, O. (2010) Pattern of declining hemoglobin concentration  
 24 before cancer diagnosis. *International Journal of Cancer*, 127: 1429-1436.  
 25 Not in PICO
- 26 Entin, E. & Entin, E. (1993) Family medicine: a small vignette. *Rhode Island Medicine*, 76: 275.  
 27 Not in PICO
- 28 Ferguson, R. H. (1978) Connective tissue disease: when to suspect malignancies. *Geriatrics*, 33: 26-  
 29 31.  
 30 Not in PICO
- 31 Fodor, A. (1978) Early symptoms and signs of malignant hemopathies. *Viata Medicală; Revista de*  
 32 *Informare Profesională Științifică a Cadrelor Medii Sanitare*, 26: 97-99.  
 33 Not in PICO
- 34 Follows, G. A. C. (2001) Fast-track referral system for patients with haematological malignancy.  
 35 *Clinical and Laboratory Haematology*, 23: 333-334.  
 36 Not in PICO
- 37 Foran, J. M., Shammo, J. M., Foran, J. M. & Shammo, J. M. (2012) Clinical presentation, diagnosis,  
 38 and prognosis of myelodysplastic syndromes. [Review]. *American Journal of Medicine*, 125: S6-13.  
 39 Narrative review
- 40 Forlenza, C. J. & Levy, A. S. (2013) Pathology turnaround time in pediatric oncology: a tool to prepare  
 41 patients and families for the diagnostic waiting period. *Journal of Pediatric*  
 42 *Hematology/Oncology*, 35: 534-536.  
 43 Not in PICO
- 44 Gans, R. O. B. (1999) Clinical thinking and decision-making in practice. A man with deep venous  
 45 thrombosis. *Nederlands Tijdschrift Voor Geneeskunde*, 143: 2307-2312.  
 46 Not in PICO
- 47 Garcia Hernandez, B. (2008) Suspicion of cancer in pediatrics. *Pediatrica Integral*, 12: 537-544.  
 48 Narrative review
- 49 Goss, J. F. (2003) Blood disorders: sickle cell disease & leukemia--more similar than you may think.  
 50 *JEMS : a journal of emergency medical services*, 28: 72-84.  
 51 Not in PICO

- 1 Green, A. E. (1978) Haematology in general practice - some moral tales. *Update*, 17: 973-981.  
2 Not in PICO
- 3 Gunawan, S., Sepang, F. & Mantik, M. (2013) Health Knowledge and Belief of Primary Health Care  
4 Provider About Childhood Leukemia in Manado. *Pediatric Blood & Cancer*, 60: 181.  
5 Not in PICO
- 6 Hamilton, W. (2012) Emergency admissions of cancer as a marker of diagnostic delay. *British Journal  
7 of Cancer*, 107: 1205-1206.  
8 Not in PICO
- 9 Heckner, F. (1969) Early diagnosis of malignant blood diseases. *Zeitschrift fur Allgemeinmedizin*, 45:  
10 1423-1426.  
11 Not in PICO
- 12 Hippisley-Cox, J. (2013) Symptoms and risk factors to identify men with suspected cancer in primary  
13 care: Derivation and validation of an algorithm. *British Journal of General Practice*, 63: e1-e10.  
14 Not in PICO (reports cancer risk overall, not limited to blood cancers)
- 15 Hippisley-Cox, J. & Coupland, C. (2013) Symptoms and risk factors to identify women with suspected  
16 cancer in primary care: Derivation and validation of an algorithm. *British Journal of General  
17 Practice*, 63: e11-e21.  
18 Not in PICO (reports cancer risk overall, not limited to blood cancers)
- 19 Hooker, W. P. (2003) Lessons for us all. One doctor's experience with a fatal illness [4]. *Canadian  
20 Family Physician*, 49: 147-148.  
21 Not in PICO
- 22 Howell, D. A., Smith, A. G., Jack, A., Patmore, R., Macleod, U., Mironska, E. & Roman, E. (2013) Time-  
23 to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the  
24 Haematological Malignancy Research Network. *BMC Hematology*, 13: 9.  
25 Not in PICO
- 26 HUTCHISON, J. H. & HUTCHISON, J. H. (1965) CHILD CARE IN GENERAL PRACTICE. ANAEMIA IN  
27 INFANCY AND CHILDHOOD. *British Medical Journal*, 1: 701-703.  
28 Not in PICO
- 29 Huttenlocher, A. (1997) Evaluation of the erythrocyte sedimentation rate in children presenting with  
30 limp, fever, or abdominal pain. *Clinical Pediatrics*, 36: 339-344.  
31 Not in PICO (secondary care)
- 32 Hutter, J. J. (2010) Childhood leukemia. *Pediatrics in Review*, 31: 234-241.  
33 Narrative review
- 34 Jaffe, D., Fleisher, G., Grosflam, J., Jaffe, D., Fleisher, G. & Grosflam, J. (1985) Detection of cancer in  
35 the pediatric emergency department. *Pediatric Emergency Care*, 1: 11-15.  
36 Not in PICO
- 37 Jandial S. (2008) Examination of the musculoskeletal system in children - a simple approach.  
38 *Paediatrics and Child Health*, 18: 47-55.  
39 Narrative review
- 40 Jayachandran, N. V. T. (2009) Cutaneous vasculitis as a presenting manifestation of acute myeloid  
41 leukemia. *International Journal of Rheumatic Diseases*, 12: 70-73.  
42 Not in PICO
- 43 Jonsson, O. G., Sartain, P., Ducore, J. M. & Buchanan, G. R. (1990) Bone pain as an initial symptom of  
44 childhood acute lymphoblastic leukemia: association with nearly normal hematologic indexes.  
45 *Journal of Pediatrics*, 117: 233-237.  
46 Not in PICO
- 47 Kecmanovic, Z., V (1961) Ophthalmologic symptoms as first signs in leukaemia (serbian). *Medicinski  
48 Pregled*, 14: 355-357.  
49 Not in PICO

- 1 Khan, A. M. K. (2010) Myelodysplastic syndromes: What a primary care physician needs to know.  
2 *Disease-a-Month*, 56: 468-478.  
3 Narrative review
- 4 Khan, A. M. K. (2012) Why are myelosplastic syndromes unrecognized and underdiagnosed?: a  
5 primary care perspective. *American Journal of Medicine*, 125: S15-S17.  
6 Not in PICO
- 7 Kubba, H. (2006) Childhood epistaxis. *Clinical Otolaryngology*, 31: 212-213.  
8 Narrative review
- 9 Kuroda, H., Ishikawa, K., Jomen, W., Yoshida, M., Yamada, M., Abe, T., Sakurai, T., Fujii, S., Maeda,  
10 M., Matsuno, T., Sato, M., Fujita, M., Nagashima, K., Ieko, M. & Kato, J. (2013) Primary  
11 myelofibrosis complicated by acquired hemophilia A and subsequent development of acute  
12 myeloid leukemia. *Rinsho Ketsueki - Japanese Journal of Clinical Hematology*, 54: 2192-2198.  
13 Not in PICO
- 14 Kvezereli-Kopadze, A., Mtvarelidze, Z., Kvezereli-Kopadze, M., Kvezereli-Kopadze, A., Mtvarelidze, Z.  
15 & Kvezereli-Kopadze, M. (2008) [Autoimmune haemolytic anaemia - as a mask of acute  
16 erythroleukaemia]. [Russian]. *Georgian Medical News*, News.: 43-47.  
17 Not in PICO
- 18 Lee, S. M., Kim, D. G., Bang, D., Lee, S. M., Kim, D. G. & Bang, D. (1994) Persistent erythema  
19 infectiosum-like rash as a prodrome of acute lymphocytic leukemia. *Pediatric Dermatology*, 11:  
20 156-159.  
21 Not in PICO
- 22 Lefevre, Y., Ceroni, D., Laedermann, A., de, R., V, de, C. G., Ayse, H. O., Kaelin, A., Lefevre, Y., Ceroni,  
23 D., Laedermann, A., de Rosa, V., de Coulon, G., Ayse, H. O. & Kaelin, A. (2009) Pediatric leukemia  
24 revealed by a limping episode: a report of four cases. *Orthopaedics & traumatology, surgery &  
25 research*, 95: 77-81.  
26 Not in PICO
- 27 Lins, M. M., Amorim, M., Vilela, P., Viana, M., Ribeiro, R. C., Pedrosa, A., Lucena-Silva, N., Howard, S.  
28 C. & Pedrosa, F. (2012) Delayed diagnosis of leukemia and association with morbid-mortality in  
29 children in Pernambuco, Brazil. *Journal of Pediatric Hematology/Oncology*, 34: e271-e276.  
30 Not in PICO
- 31 Listerick, R. (2011) A 16-year-old girl with leg pain and swelling. *Pediatric Annals*, 40: 536-537.  
32 Not in PICO
- 33 Lewis, S. (2000) Malignant disease and the adolescent. *Journal of the Royal College of Physicians of  
34 London*, 34: 27-31.  
35 Narrative review
- 36 Ma, S. K., Chan, G. C., Ha, S. Y., Chiu, D. C., Lau, Y. L. & Chan, L. C. (1997) Clinical presentation,  
37 hematologic features and treatment outcome of childhood acute lymphoblastic leukemia: a  
38 review of 73 cases in Hong Kong. *Hematological Oncology*, 15: 141-149.  
39 Not in PICO
- 40 Mahmoudi, S., Mehrazmay, A., Salesi, M. & Mamishi, S. (2014) Fever of unknown origin: A  
41 retrospective study of 95 children in an Iranian referral hospital. *British Journal of Biomedical  
42 Science*, 71: 40-42.  
43 Not in PICO
- 44 Mansour, K. M., Kuypers, F. A., Wang, T. N., Miller, A. M., Larkin, S. K., Morris, C. R., Mansour, K. M.,  
45 Kuypers, F. A., Wang, T. N., Miller, A. M., Larkin, S. K. & Morris, C. R. (2011) Secretory  
46 phospholipase A2: a marker of infection in febrile children presenting to a pediatric ED. *American  
47 Journal of Emergency Medicine*, 29: 1163-1168.  
48 Not in PICO (secondary care)
- 49 Maurer, C. & Hallek, M. (2013) [Chronic lymphocytic leukemia]. [Review] [German]. *Deutsche  
50 Medizinische Wochenschrift*, 138: 2153-2166.  
51 Narrative review

- 1 Murray, M. J. N. (2008) Unresponsive asthma: Don't forget mediastinal masses. *BMJ (Clinical*  
2 *research ed, )*. 336: 521-522.  
3 Letter
- 4 Musiej-Nowakowska, E., Rostropowicz-Denisiewicz, K., Musiej-Nowakowska, E. & Rostropowicz-  
5 Denisiewicz, K. (1986) Differential diagnosis of neoplastic and rheumatic diseases in children.  
6 *Scandinavian Journal of Rheumatology*, 15: 124-128.  
7 Not in PICO
- 8 Nagarajarao, H. S. A. (2009) Unusual presentation of chronic myelogenous leukemia as multiple skin  
9 chloromas. *Acta Cytologica*, 53: 235-238.  
10 Not in PICO
- 11 Nguyen, H. S., Haider, K. M. & Ackerman, L. L. (2013) Unusual causes of papilledema: Two illustrative  
12 cases. *Surgical neurology international*, 4: 60.  
13 Not in PICO
- 14 Nortje, C. J. (2003) General practitioner's radiology case 16. Acute leukemia. *SADJ : journal of the*  
15 *South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging*,  
16 58: 393.  
17 Not in PICO
- 18 Oscier, D. (2004) Guidelines on the diagnosis and management of chronic lymphocytic leukaemia.  
19 *British Journal of Haematology*, 125: 294-317.  
20 Guideline
- 21 Peter, S. A., Cervantes, J. F., Peter, S. A. & Cervantes, J. F. (1995) Hypercalcemia associated with adult  
22 T-cell leukemia/lymphoma (ATL). [Review] [15 refs]. *Journal of the National Medical Association*,  
23 87: 746-748.  
24 Not in PICO
- 25 Picon, R. C. L. (2010) Musculoskeletal pain: A common initial sign of acute lymphoblastic leukaemia.  
26 *Anales de Pediatria*, 72: 428-431.  
27 Not in PICO
- 28 Pieczyrak, R. (2010) Fever as a symptom in the internal disease daily practice. *Internal Medicine*  
29 *Journal*, Conference: March.  
30 Not in PICO
- 31 Plezbert, J. A., Bose, M., Carlisle, G., Plezbert, J. A., Bose, M. & Carlisle, G. (1994) Chronic  
32 myelogenous leukemia in a 16-yr-old. *Journal of Manipulative & Physiological Therapeutics*, 17:  
33 610-613.  
34 Not in PICO
- 35 Raab, C. P. & Gartner, J. C. (2009) Diagnosis of Childhood Cancer. *Primary Care*, 36: 671-+.  
36 Narrative review
- 37 Racil, Z., Buresova, L., Brejcha, M., Prochazkova, J., Zounar, R., Timilsina, S., Razga, F., Toskova, M.,  
38 Cetkovsky, P., Mayer, J., Racil, Z., Buresova, L., Brejcha, M., Prochazkova, J., Zounar, R., Timilsina,  
39 S., Razga, F., Toskova, M., Cetkovsky, P. & Mayer, J. (2011) Clinical and laboratory features of  
40 leukemias at the time of diagnosis: an analysis of 1,004 consecutive patients. *American Journal of*  
41 *Hematology*, 86: 800-803.  
42 Not in PICO
- 43 Ramesh, P. M., Marwaha, R. K., Anish, T. S., Ramesh, P. M., Marwaha, R. K. & Anish, T. S. (2011)  
44 Childhood cancer in developing society: A roadmap of health care. *Indian journal of medical and*  
45 *paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology*, 32: 30-  
46 33.  
47 Not in PICO
- 48 Reddy, S. C. J. (1998) Retinal changes in chronic leukemia. *Biomedical Research*, 9: 125-129.  
49 Not in PICO

- 1 Reuss-Borst, M. A. (2005) The association of rheumatic diseases with hemato-/oncological disorders.  
2 *Zeitschrift fur Rheumatologie*, 64: 3-11.  
3 Narrative review
- 4 Robazzi, T. C. M. V. (2007) Osteoarticular manifestations as initial presentation of acute leukemias in  
5 children and adolescents in Bahia, Brazil. *Journal of Pediatric Hematology/Oncology*, 29: 622-626.  
6 Not in PICO
- 7 Roman, E., Simpson, J., Ansell, P., Kinsey, S., Mitchell, C. D., McKinney, P. A., Birch, J. M., Greaves, M.  
8 & Eden, T. (2007) Childhood acute lymphoblastic leukemia and infections in the first year of life: a  
9 report from the United Kingdom Childhood Cancer Study. *American Journal of Epidemiology*, 165:  
10 496-504.  
11 Not in PICO
- 12 Roushan, N. (2007) Acute leukemia presenting with ascites and confusion [7]. *Leukemia and*  
13 *Lymphoma*, 48: 1234-1236.  
14 Not in PICO
- 15 Saraswatula, A., McShane, D., Tideswell, D., Burke, G. A. A., Williams, D. M., Nicholson, J. C. &  
16 Murray, M. J. (2009) Mediastinal masses masquerading as common respiratory conditions of  
17 childhood: a case series. *European Journal of Pediatrics*, 168: 1395-1399.  
18 Narrative review
- 19 Sauter, D., Spiekermann, K., Feuring-Buske, M., Braess, J., Sauter, D., Spiekermann, K., Feuring-  
20 Buske, M. & Braess, J. (2007) [Nonsymptomatic leukocytosis]. [German]. *MMW Fortschritte der*  
21 *Medizin*, 149: 29-32.  
22 Narrative review
- 23 Savage, D. G., Szydlo, R. M. & Goldman, J. M. (1997) Clinical features at diagnosis in 430 patients  
24 with chronic myeloid leukaemia seen at a referral centre over a 16-year period. *British Journal of*  
25 *Haematology*, 96: 111-116.  
26 Not in PICO
- 27 Schaller, J. (1972) Arthritis as a presenting manifestation of malignancy in children. *Journal of*  
28 *Pediatrics*, 81: 793-797.  
29 Not in PICO
- 30 Scott, R. B. (1993) Common blood disorders: A primary care approach. *Geriatrics*, 48: 72-80.  
31 Narrative review
- 32 Serwint, J. R., Dias, M. M., Chang, H., Sharkey, M., Walker, A. R., Serwint, J. R., Dias, M. M., Chang, H.,  
33 Sharkey, M. & Walker, A. R. (2005) Outcomes of febrile children presumed to be  
34 immunocompetent who present with leukopenia or neutropenia to an ambulatory setting.  
35 *Clinical Pediatrics*, 44: 593-600.  
36 Not in PICO
- 37 Silverstein, M. N. K. (1963) Leukemia with osteoarticular symptoms and signs. *Annals of Internal*  
38 *Medicine*, 59: 637-645.  
39 Not in PICO
- 40 Singer, J. & Henry, S. (2008) Upper airway obstruction as the presenting manifestation of leukemia.  
41 *Pediatric Emergency Care*, 24: 310-312.  
42 Not in PICO
- 43 Smith, L. B., Valdes, Y., Check, W. E., Britt, P. M., Frankel, L. S., Smith, L. B., Valdes, Y., Check, W. E.,  
44 Britt, P. M. & Frankel, L. S. (2007) Juvenile myelomonocytic leukemia presenting with facial nerve  
45 paresis: a unique presentation. [Review] [7 refs]. *Journal of Pediatric Hematology/Oncology*, 29:  
46 770-773.  
47 Not in PICO
- 48 Stobbe, H. & Stobbe, H. (1979) [Contents and methodological aspects in the early diagnosis of  
49 leukemia and malignant lymphomas]. [German]. *Zeitschrift fur Arztliche Fortbildung (Jena)*, 73:  
50 667-668.  
51 Input as "Not in PICO (1979)", but is actually also "Narrative review"



- 1 Sweet, J. M. & Sweet, J. M. (2004) The numb chin syndrome: a critical sign for primary care  
2 physicians. *Archives of Internal Medicine*, 164: 1347-1348.  
3 Not in PICO
- 4 Tazi, L. (2009) Priapism as the first manifestation of chronic myeloid leukemia. *Annals of Saudi  
5 Medicine*, 29: 412-October.  
6 Not in PICO
- 7 Teo, W. Y., Chan, M. Y., Ng, K. C. & Tan, A. M. (2012) Bony presentations of childhood  
8 haematological malignancy to the emergency room. *Journal of Paediatrics and Child Health*, 48:  
9 311-316.  
10 Not in PICO
- 11 Thomas, W. (2013) Co-incidental finding of pancytopenia. *British Journal of Medical Practitioners*, 5.  
12 Not in PICO
- 13 Thulesius, H., Pola, J. & Hakansson, A. (2000) Diagnostic delay in pediatric malignancies - A  
14 population-based study. *Acta Oncologica*, 39: 873-876.  
15 Not in PICO
- 16 Torgerson, S. R., Haddad, R. Y., Atallah, E., Torgerson, S. R., Haddad, R. Y. & Atallah, E. (2012) Chronic  
17 myelogenous leukemia for primary care physicians. [Review]. *Disease-a-Month*, 58: 168-176.  
18 Narrative review
- 19 Tsai, M. J., Yan, D. C., Chiang, B. L., Chou, C. C., Hsieh, K. H., Lin, K. H., Tsai, M. J., Yan, D. C., Chiang, B.  
20 L., Chou, C. C., Hsieh, K. H. & Lin, K. H. (1995) Childhood leukemia mimicking juvenile rheumatoid  
21 arthritis. *Chung-Hua Min Kuo Hsiao Erh Ko i Hsueh Hui Tsa Chih*, 36: 274-278.  
22 Not in PICO
- 23 Usul, A. C., Paydas, S., Gunaldi, M., Bozkurt, D. B., Ercolak, V., Zorludemir, S. & Acikalin, A. (2013)  
24 Sweet syndrome in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma:  
25 curious lymphocyte/neutrophil fluctuations. *Turkish Journal of Haematology*, 30: 413-415.  
26 Not in PICO
- 27 van der Haring, I. S., Witjes, M. J., van der Haring, I. S. & Witjes, M. J. H. (2006) [Diagnostic  
28 considerations concerning a case of an unusual gingivitis]. [Dutch]. *Nederlands Tijdschrift Voor  
29 Tandheelkunde*, 113: 284-287.  
30 Not in PICO
- 31 Welles, S. L., Levine, P. H., Joseph, E. M., Goberdhan, L. J., Lee, S., Miotti, A., Cervantes, J., Bertoni,  
32 M., Jaffe, E., Dosik, H., Welles, S. L., Levine, P. H., Joseph, E. M., Goberdhan, L. J., Lee, S., Miotti,  
33 A., Cervantes, J., Bertoni, M., Jaffe, E. & Dosik, H. (1994) An enhanced surveillance program for  
34 adult T-cell leukemia in central Brooklyn. *Leukemia*, 8 Suppl 1: S111-S115.  
35 Not in PICO
- 36 Werner, A. H., Scarfone, R., Mostoufi-Moab, S., Werner, A. H., Scarfone, R. & Mostoufi-Moab, S.  
37 (2010) A febrile young infant with splenomegaly and ecchymoses. *Pediatric Emergency Care*, 26:  
38 442-444.  
39 Not in PICO
- 40 Williams, P. D., Williams, A. R., Kelly, K. P., Dobos, C., Gieseking, A., Connor, R., Ridder, L., Potter, N.  
41 & Del, F. D. (2012) A symptom checklist for children with cancer: the Therapy-Related Symptom  
42 Checklist-Children. *Cancer Nursing*, 35: 89-98.  
43 Not in PICO
- 44 Young, G., Toretsky, J. A., Campbell, A. B., Eskenazi, A. E., Young, G., Toretsky, J. A., Campbell, A. B. &  
45 Eskenazi, A. E. (2000) Recognition of common childhood malignancies. [Review] [18 refs].  
46 *American Family Physician*, 61: 2144-2154.  
47 Narrative review
- 48 Zombori, L., Kovacs, G., Csoka, M. & Derfalvi, B. (2013) Rheumatic symptoms in childhood leukaemia  
49 and lymphoma-a ten-year retrospective study. *Pediatric Rheumatology*, 11.  
50 Not in PICO

Zwimpfer, J. & Zwimpfer, J. (2000) [Case from general practice. Splenomegaly. Hairy-cell leukemia].  
 [German]. *Praxis*, 89: 1160-1161.  
 Not in PICO

### Review question:

Which investigations of symptoms of suspected leukemia should be done with clinical responsibility retained by primary care?

### Results

#### Literature search


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1980-2013	239	34	18/04/2013
<i>Premedline</i>	1980-2013	28	8	18/04/2013
<i>Embase</i>	1980-2013	261	21	18/04/2013
<i>Cochrane Library</i>	1980-2013	7	0	18/04/2013
<i>Psychinfo</i>	1980-2013	2	0	18/04/2013
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	1980-2013	57	5	18/04/2013

Total References retrieved (after de-duplication): 57

#### Update Search

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	4/2013-18/08/2014	10	2	18/08/2014
<i>Premedline</i>	4/2013-18/08/2014	30	2	18/08/2014
<i>Embase</i>	4/2013-18/08/2014	51	3	18/08/2014
<i>Cochrane Library</i>	4/2013-18/08/2014	11	0	18/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	4/2013-18/08/2014	11	1	18/08/2014

Total References retrieved (after de-duplication): 6



1

2 **Study results**

3 No evidence was identified pertaining to the diagnostic accuracy of white blood cell count in  
 4 patients with suspected leukaemia where the clinical responsibility was retained by primary care.  
 5

6 **References**

7 **Included studies**

8 None

9

10 **Excluded studies (with excl reason)**

11 Adekha, S. & Chadha, T. (2013) Bernard Soulier Syndrome associated with acute myeloid leukemia.  
 12 *Indian Journal of Medical Sciences*, 67: 145-147.

13 Not in PICO

14 Avery, P. R. & Avery, A. C. (2004) Molecular methods to distinguish reactive and neoplastic  
 15 lymphocyte expansions and their importance in transitional neoplastic states. [Review] [83 refs].  
 16 *Veterinary Clinical Pathology*, 33: 196-207.

17 Narrative review

18 Bansal, D. & Totadri, S. (2014) Common hematological disorders in children. *Indian Journal of*  
 19 *Pediatrics*, 81: 42-50.

20 Narrative review

21 Bansal, D. & Totadri, S. (2014) Common hematological disorders in children. *Indian Journal of*  
 22 *Pediatrics*, 81: 42-50.

23 Narrative review

24 Bedu-Addo, G., Ampem, A. Y. & Bates, I. (2013) The role of bone marrow aspirate and trephine  
 25 samples in haematological diagnoses in patients referred to a teaching hospital in Ghana. *Ghana*  
 26 *Medical Journal*, 47: 74-78.

27 Not in PICO

- 1 Bennett, M., Higgins, E., Curran, S. & Marren, P. (2010) Leukaemia cutis mimicking florid  
2 rhinophymatous rosacea. *British Journal of Dermatology*, 163: 443.  
3 Not in PICO
- 4 Bernbeck, B., Wuller, D., Janssen, G., Wessalowski, R., Gobel, U. & Schneider, D. T. (2009) Symptoms  
5 of Childhood Acute Lymphoblastic Leukemia: Red Flags to Recognize Leukemia in Daily Practice.  
6 *Klinische Padiatrie*, 221: 369-373.  
7 Not in PICO
- 8 Bindels, L. B., Porporato, P., Dewulf, E. M., Verrax, J., Neyrinck, A. M., Martin, J. C., Scott, K. P., Buc,  
9 C. P., Feron, O., Muccioli, G. G., Sonveaux, P., Cani, P. D. & Delzenne, N. M. (2012) Gut  
10 microbiota-derived propionate reduces cancer cell proliferation in the liver. *British Journal of*  
11 *Cancer*, 107: 1337-1344.  
12 Not in PICO
- 13 Bode, B. & Tinguely, M. (2012) [Role of cytology in hematopathological diagnostics]. [Review]  
14 [German]. *Pathologe*, 33: 316-323.  
15 Narrative review
- 16 Brasme, J. F., Morfouace, M., Grill, J., Martinot, A., Amalberti, R., Bons-Letouzey, C. & Chalumeau, M.  
17 (2012) Delays in diagnosis of paediatric cancers: a systematic review and comparison with expert  
18 testimony in lawsuits. [Review]. *Lancet Oncology*, 13: e445-e459.  
19 Not in PICO
- 20 Buddula, A. & Assad, D. (2011) Peripheral T-Cell lymphoma manifested as gingival enlargement in a  
21 patient with chronic lymphocytic leukemia. *Journal of Indian Society of Periodontology*, 15: 67-69.  
22 Not in PICO
- 23 Calpin, C., Dick, P., Poon, A. & Feldman, W. (1998) Is bone marrow aspiration needed in acute  
24 childhood idiopathic thrombocytopenic purpura to rule out leukemia? *Archives of Pediatrics &*  
25 *Adolescent Medicine*, 152: 345-347.  
26 Not in PICO
- 27 Campbell, E. W., Jr. & Smith, M. R. (1996) Hematology for primary care physicians. *Disease-a-Month*,  
28 42: 131-194.  
29 Narrative review
- 30 Cronin, C. G., Cashell, T., Mhuirheartaigh, J. N., Swords, R., Murray, M., O'Sullivan, G. J. & O'Keefe,  
31 D. (2009) Bone biopsy of new suspicious bone lesions in patients with primary carcinoma:  
32 prevalence and probability of an alternative diagnosis. *AJR.American Journal of Roentgenology*,  
33 193: W407-W410.  
34 Not in PICO
- 35 Davis, A. S., Viera, A. J. & Mead, M. D. (2014) - Leukemia: an overview for primary care. [Review]. -  
36 *American Family Physician*, 89: 731-738.  
37 Narrative review
- 38 Davis, A. S., Viera, A. J. & Mead, M. D. (2014) Leukemia: An Overview for Primary Care. *American*  
39 *Family Physician*, 89: 731-738.  
40 Duplicate
- 41 Derman, O., Okstuz-Kanbur, N., Yenicesu, I. & Klink, E. (2005) Iron deficiency anemia in a group of  
42 Turkish adolescents: frequency and contributing factors. *International Journal of Adolescent*  
43 *Medicine & Health*, 17: 179-186.  
44 Not in PICO
- 45 Dommett, R. M., Redaniel, M. T., Stevens, M. C., Hamilton, W. & Martin, R. M. (2013) Features of  
46 cancer in teenagers and young adults in primary care: a population-based nested case-control  
47 study. *British Journal of Cancer*, 108: 2329-2333.  
48 Already included
- 49 Dorransoro, M., I, Merino, M. R., Sastre-Urguelles, A., Garcia-Miguel Garcia-Rosado, P. & Garcia-  
50 Consuegra, M. J. (2004) [Malignant disease presenting as rheumatic manifestations]. [Spanish].

- 1 *Anales de Pediatria*, 61: 393-397.  
2 Not in PICO
- 3 Forgie, S. E. & Robinson, J. L. (2007) Pediatric malignancies presenting as a possible infectious  
4 disease. *BMC Infectious Diseases*, 7.  
5 Not in PICO
- 6 Forlenza, C. J. & Levy, A. S. (2013) Pathology turnaround time in pediatric oncology: a tool to prepare  
7 patients and families for the diagnostic waiting period. *Journal of Pediatric*  
8 *Hematology/Oncology*, 35: 534-536.  
9 Not in PICO
- 10 Franco, A., Lewis, K. N., Blackmon, J. M. & Manaloor, E. J. (2010) Hyperostosis - an unusual  
11 radiographic presentation of Myelodysplastic Syndrome transformed to Acute Myeloid Leukemia.  
12 *Journal of Radiology Case Reports*, 4: 18-25.  
13 Not in PICO
- 14 Gandhi, J. (2009) Natural killer cell leukaemia. *BMJ Case Reports*, 2009, 2009.  
15 Not in PICO
- 16 Garrett Kevin, M. K. M., Hoffer, F. A., Behm, F. G., Gow, K. W., Hudson, M. M. & Sandlund, J. T.  
17 (2002) Interventional radiology techniques for the diagnosis of lymphoma or leukemia. *Pediatric*  
18 *Radiology*, 32: 653-662.  
19 Not in PICO
- 20 Goldschmidt, N., Libson, E., Bloom, A., Amir, G. & Paltiel, O. (2003) Clinical utility of computed  
21 tomography-guided core needle biopsy in the diagnostic re-evaluation of patients with  
22 lymphoproliferative disorders and suspected disease progression. *Annals of Oncology*, 14: 1438-  
23 1441.  
24 Not in PICO
- 25 Haase, R., Merkel, N., Diwan, O., Elsner, K. & Kramm, C. M. (2009) Leukapheresis and exchange  
26 transfusion in children with acute leukemia and hyperleukocytosis. A single center experience.  
27 *Klinische Padiatrie*, 221: 374-378.  
28 Not in PICO
- 29 Hager, H. B. (2012) Basophilia-is microscopic examination worth the effort? *International Journal of*  
30 *Laboratory Hematology*, 34: 115-116.  
31 Not in PICO
- 32 Hajda, M., Koranyi, K., Salomvary, B. & Bajcsay, A. (2005) [Clinical presentation, differential diagnosis  
33 and treatment of lacrimal gland tumours]. [Hungarian]. *Magyar Onkologia*, 49: 65-70.  
34 Not in PICO
- 35 Howell, D. A., Smith, A. G., Jack, A., Patmore, R., Macleod, U., Mironska, E. & Roman, E. (2013) Time-  
36 to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the  
37 Haematological Malignancy Research Network. *BMC Hematology*, 13: 9.  
38 Not in PICO
- 39 Itoh, M., Oki, M., Yanagi, H., Oka, A., Tajiri, S., Fukuda, R., Ozawa, H. & Takagi, A. (2012)  
40 Disseminated mucormycosis infection after the first course of dose-modified R-EPOCH for  
41 advanced-stage lymphoma. *Journal of Infection & Chemotherapy*, 18: 395-398.  
42 Not in PICO
- 43 Khan, A. M., Komrokji, R. S. & Haddad, R. Y. (2010) Myelodysplastic syndromes: What a primary care  
44 physician needs to know. *Disease-a-Month*, 56: 468-478.  
45 Narrative review
- 46 Kuroda, H., Ishikawa, K., Jomen, W., Yoshida, M., Yamada, M., Abe, T., Sakurai, T., Fujii, S., Maeda,  
47 M., Matsuno, T., Sato, M., Fujita, M., Nagashima, K., Ieko, M. & Kato, J. (2013) Primary  
48 myelofibrosis complicated by acquired hemophilia A and subsequent development of acute  
49 myeloid leukemia. *Rinsho Ketsueki - Japanese Journal of Clinical Hematology*, 54: 2192-2198.  
50 Not in PICO

- 1 Lamki, Z. A., Wali, Y. A., Shah, W. M. & Zachariah, M. (2004) Relapsed acute leukemia in children:  
2 Oman Experience. *Pediatric Hematology and Oncology*, 21: 167-173.  
3 Not in PICO
- 4 Lehmitz, R. & Pahnke, J. (2009) Involvement of CNS in leukaemia and lymphomas--CSF meningeosis  
5 and immunocytochemical phenotyping. [German]. *Fortschritte der Neurologie-Psychiatrie*, 77:  
6 S37-S38.  
7 Narrative review
- 8 Linden, A., Zankovich, R., Theissen, P., Diehl, V. & Schicha, H. (1989) Malignant lymphoma: bone  
9 marrow imaging versus biopsy. *Radiology*, 173: 335-339.  
10 Not in PICO
- 11 Mackie, K. E., Zhou, Z., Robbins, P., Bulsara, M. & Zheng, M. H. (2011) Histopathology of femoral  
12 head donations: a retrospective review of 6161 cases. *Journal of Bone & Joint Surgery - American*  
13 *Volume*, 93: 1500-1509.  
14 Not in PICO
- 15 Mahmoudi, S., Mehrazmay, A., Salesi, M. & Mamishi, S. (2014) Fever of unknown origin: A  
16 retrospective study of 95 children in an Iranian referral hospital. *British Journal of Biomedical*  
17 *Science*, 71: 40-42.  
18 Not in PICO
- 19 Mates, M., Heyd, J., Souroujon, M., Ben, S. A., Manny, N. & Hershko, C. (1995) The haematologist as  
20 watchdog of community health by full blood count. *QJM*, 88: 333-339.  
21 Not in PICO
- 22 Matos, D. M. & Falcao, R. P. (2011) Monoclonal B-cell lymphocytosis: a brief review for general  
23 clinicians. *Sao Paulo Medical Journal*, 129: 171-175.  
24 Narrative review
- 25 Maurer, C. & Hallek, M. (2013) [Chronic lymphocytic leukemia]. [Review] [German]. *Deutsche*  
26 *Medizinische Wochenschrift*, 138: 2153-2166.  
27 Narrative review
- 28 McDermott, M. K. & Bell, E. M. (1999) A review of Waldenstrom's macroglobulinemia. [Review] [17  
29 refs]. *Clinical Journal of Oncology Nursing*, 3: 107-111.  
30 Narrative review
- 31 Menezes, L. & Rao, J. R. (2012) Acute myelomonocytic leukemia presenting with gingival  
32 enlargement as the only clinical manifestation. *Journal of Indian Society of Periodontology*, 16:  
33 597-601.  
34 Not in PICO
- 35 Mohsenin, A., Sinard, J. & Huang, J. J. (2012) Necrobiotic xanthogranuloma and chronic lymphocytic  
36 leukemia of the conjunctiva masquerading as scleritis and uveitis. *Clinical Ophthalmology*, 6:  
37 2045-2047.  
38 Not in PICO
- 39 Morse, E. E., Yamase, H. T., Greenberg, B. R., Sporn, J., Harshaw, S. A., Kiraly, T. R., Ziemba, R. A. &  
40 Fallon, M. A. (1994) The role of flow cytometry in the diagnosis of lymphoma: a critical analysis.  
41 *Annals of Clinical & Laboratory Science*, 24: 6-11.  
42 Not in PICO
- 43 Nagarajarao, H. S., Akhtar, I., Heard, K. & Baliga, M. (2009) Unusual Presentation of Chronic  
44 Myelogenous Leukemia as Multiple Skin Chloromas Report of a Case with Clinical and Cytologic  
45 Correlation. *Acta Cytologica*, 53: 235-238.  
46 Not in PICO
- 47 Nguyen, H. S., Haider, K. M. & Ackerman, L. L. (2013) Unusual causes of papilledema: Two illustrative  
48 cases. *Surgical neurology international*, 4: 60.  
49 Not in PICO
- 50 Oscier, D., Fegan, C., Hillmen, P., Illidge, T., Johnson, S., Maguire, P., Matutes, E. & Milligan, D. (2004)  
51 Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. *British Journal of*

- 1 *Haematology*, 125: 294-317.  
 2 Guideline
- 3 Petrasch, S. (1998) [Management of hematologic systemic diseases and rare tumor entities with  
 4 manifestations in the oromaxillofacial area]. [Review] [74 refs] [German]. *Mund-, Kiefer- und*  
 5 *Gesichtschirurgie*, 2: 172-180.  
 6 Narrative review
- 7 Price, E. A., Mehra, R. & Schrier, S. L. (2009) Iron deficiency is a common cause of anemia in elderly  
 8 outpatients, however iron repletion frequently does not fully correct the anemia. *Blood*, 114.  
 9 Not in PICO
- 10 Raab, C. P. & Gartner, J. C., Jr. (2009) Diagnosis of childhood cancer. [Review] [33 refs]. *Primary Care;*  
 11 *Clinics in Office Practice*, 36: 671-684.  
 12 Narrative review
- 13 Ravoet, C., Demartin, S., Gerard, R., Dehon, M., Peny, M. O., Petit, B., Delannoy, A. & Husson, B.  
 14 (2004) Contribution of flow cytometry to the diagnosis of malignant and non malignant  
 15 conditions in lymph node biopsies. *Leukemia & Lymphoma*, 45: 1587-1593.  
 16 Not in PICO
- 17 Rawstron, A. C., Green, M. J., Kuzmicki, A., Kennedy, B., Fenton, J. A., Evans, P. A., O'Connor, S. J.,  
 18 Richards, S. J., Morgan, G. J., Jack, A. S. & Hillmen, P. (2002) Monoclonal B lymphocytes with the  
 19 characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with  
 20 normal blood counts. *Blood*, 100: 635-639.  
 21 Not in PICO
- 22 Rosati, P., Jenkner, A., De, V. R., Boldrini, R., Chiodi, P., Celesti, L. & Giampaolo, R. (2011) 'Tell me  
 23 about your pain': abdominal pain and a history of bullying. *BMJ Case Reports*, 2011, 2011.  
 24 Not in PICO
- 25 Rossbach, H.-C. (2009) Diagnostic pitfalls in acute leukemia. *Fetal and Pediatric Pathology*, 28: 69-77.  
 26 Narrative review
- 27 Sauter, D., Spiekermann, K., Feuring-Buske, M. & Braess, J. (1933) [Nonsymptomatic leukocytosis].  
 28 [German]. *MMW Fortschritte der Medizin*, 149: 29-32.  
 29 Narrative review
- 30 Schindhelm, R. K., van Marwijk Kooy, M. R., Coenen, J. L., Huijgens, P. C. & Kuiper-Kramer, P. A.  
 31 (2010) [Monoclonal B-cell lymphocytosis: physiological entity or preliminary stage of chronic  
 32 lymphocytic leukaemia?]. [Review] [17 refs] [Dutch]. *Nederlands Tijdschrift Voor Geneeskunde*,  
 33 154: A1520.  
 34 Narrative review
- 35 Schleiffenbaum, B. E., Ruegg, R., Zimmermann, D. & Fehr, J. (1996) Early diagnosis of low grade  
 36 malignant lymphoma and chronic lymphocytic leukaemia. Verification of morphologically  
 37 suspected malignancy in blood lymphocytes by flow cytometry. *European Journal of*  
 38 *Haematology*, 57: 341-348.  
 39 Not in PICO
- 40 Schroeder, M. A. & Blum, W. (2010) Evidence-based mini-review: Should patients over the age of 60  
 41 with INT-2 or high-risk myelodysplastic syndrome undergo allogeneic stem cell transplantation  
 42 prior to progression to acute myelogenous leukemia?. [Review]. *Hematology*, 2010: 322-324.  
 43 Not in PICO
- 44 Serwint, J. R., Dias, M. M., Chang, H., Sharkey, M. & Walker, A. R. (2005) Outcomes of febrile children  
 45 presumed to be immunocompetent who present with leukopenia or neutropenia to an  
 46 ambulatory setting. *Clinical Pediatrics*, 44: 593-600.  
 47 Not in PICO
- 48 Shakoor, K. A. (1989) Fine needle aspiration cytology in advanced pediatric tumors. *Pediatric*  
 49 *Pathology*, 9: 713-718.  
 50 Not in PICO

- 1 Shields, J. A., Shields, C. L., Ehya, H., Eagle, R. C., Jr. & De, P. P. (1993) Fine-needle aspiration biopsy  
2 of suspected intraocular tumors. The 1992 Urwick Lecture. *Ophthalmology*, 100: 1677-1684.  
3 Not in PICO
- 4 Smellie, W. S. A., Forth, J., Smart, S. R. S., Galloway, M. J., Irving, W., Bareford, D., Collinson, P. O.,  
5 Kerr, K. G., Summerfield, G., Carey, P. J. & Minhas, R. (2007) Best practice in primary care  
6 pathology: review 7. *Journal of Clinical Pathology*, 60: 458-465.  
7 Narrative review
- 8 Sykakis, E. & Patwary, S. N. (2011) Acute myeloid leukaemia presenting as gaze palsy. *Case Reports in*  
9 *Ophthalmology*, 2: 343-346.  
10 Not in PICO
- 11 Taamallah-Malek, I., Chebbi, A., Bouladi, M., Nacef, L., Bouguila, H. & Ayed, S. (2013) [Massive  
12 bilateral subconjunctival hemorrhage revealing acute lymphoblastic leukemia]. [French]. *Journal*  
13 *Francais d Ophthalmologie*, 36: e45-e48.  
14 Not in PICO
- 15 Tani, E., Costa, I., Svedmyr, E. & Skoog, L. (1995) Diagnosis of lymphoma, leukemia, and metastatic  
16 tumor involvement of the cerebrospinal fluid by cytology and immunocytochemistry. *Diagnostic*  
17 *Cytopathology*, 12: 14-22.  
18 Not in PICO
- 19 Teo, W.-Y., Chan, M.-Y., Ng, K.-C. & Tan, A.-M. (2012) Bony presentations of childhood  
20 haematological malignancy to the emergency room. *Journal of Paediatrics and Child Health*, 48:  
21 311-316.  
22 Not in PICO
- 23 Torgerson, S. R., Haddad, R. Y. & Atallah, E. (2012) Chronic Myelogenous Leukemia for Primary Care  
24 Physicians. *Disease-a-Month*, 58: 168-176.  
25 Narrative review
- 26 Urabe, A. (1988) [Diagnosis of leukemia and lymphoma]. [Japanese]. *Gan No Rinsho - Japanese*  
27 *Journal of Cancer Clinics*, 34: 1445-1448.  
28 Narrative review
- 29 Usul, A. C., Paydas, S., Gunaldi, M., Bozkurt, D. B., Ercolak, V., Zorludemir, S. & Acikalin, A. (2013)  
30 Sweet syndrome in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma:  
31 curious lymphocyte/neutrophil fluctuations. *Turkish Journal of Haematology*, 30: 413-415.  
32 Not in PICO
- 33 Varshney, R., Deka, M., Bhattacharya, J. & Gogoi, P. K. (2012) Clinico-haematological analysis of  
34 haematological malignancy, a hospital based study. *Indian Journal of Hematology and Blood*  
35 *Transfusion*, 28: 245.  
36 Not in PICO
- 37 Wakely, P. E., Jr. & Kornstein, M. J. (1996) Aspiration cytopathology of lymphoblastic lymphoma and  
38 leukemia: the MCV experience. *Pediatric Pathology & Laboratory Medicine*, 16: 243-252.  
39 Not in PICO
- 40 Zombori, L., Kovacs, G., Csoka, M. & Derfalvi, B. (2013) Rheumatic symptoms in childhood leukaemia  
41 and lymphoma-a ten-year retrospective study. *Pediatric Rheumatology*, 11.  
42 Not in PICO  
43  
44  
45



**MYELOMA****Review question:**

What is the risk of myeloma in patients presenting in primary care with symptom(s)?

**Results****Literature search results**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1980-2013	565	16	09/04/2013
<i>Premedline</i>	1980--2013	74	9	10/04/2013
<i>Embase</i>	1980--2013	773	35	11/04/2013
<i>Cochrane Library</i>	1980--2013	684	0	10/04/2013
<i>Psychinfo</i>	1980--2013	21	3	11/04/2013
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	1980--2013	545	7	12/04/2013


Total references retrieved (after de-duplication): 60

**Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	4/2013-19/08/2014	20	0	19/08/2014
<i>Premedline</i>	4/2013-19/08/2014	40	3	19/08/2014
<i>Embase</i>	4/2013-19/08/2014	38	3	19/08/2014
<i>Cochrane Library</i>	4/2013-19/08/2014	349	0	19/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	4/2013-19/08/2014	44	2	19/08/2014

Total References retrieved (after de-duplication): 6


**Study flow diagram**



**Risk of bias in the included studies**

The risk of bias and applicability concerns are summarised per study in the figure below. The main issues to note are (1) that two of the studies employed samples of patients that are not directly representative of an unselected symptomatic population of patients presenting to the UK-based GP, and (2) that two of the studies employed patient selection methods that were not clearly consecutive or random in nature, which, in turn, may result in inflated estimates of the positive predictive values. However, the statistics employed by Shephard (2014) may have gone some way in counteracting this influence.

**Risk of bias summary**



**Study results**

Table 1: Myeloma: Positive predictive values of individual symptoms for myeloma in patients aged > 14-15 years

Study	Symptom(s)	Patient group	PPV % (95% CI) for myeloma; prevalence of myeloma
Deyo (1988)	Back pain	All included patients	0.05 (0.003-0.3); 1/1975
Suarez-Almazor (1997)	Acute low back pain	All included patients	0 (0-0.5) or 0.21 (0.04-0.83) 0-2/963 Unclear if diagnosis was prior to symptom
Shephard (2014)	Joint pain	Patients ≥ 60 years	0.05 (0.04-0.06)
Shephard (2014)	Shortness of breath	Patients ≥ 60 years	0.06 (0.05-0.06)
Shephard (2014)	Chest infection	Patients ≥ 60 years	0.06 (0.05-0.06)
Shephard (2014)	Chest pain	Patients ≥ 60 years	0.1 (0.09-0.11)
Shephard (2014)	Fracture	Patients ≥ 60 years	0.1 (0.08-0.12)
Shephard (2014)	Nausea	Patients ≥ 60 years	0.1 (0.08-0.12)

Shephard (2014)	Combined bone pain	Patients ≥ 60 years	0.1 (0.1-0.2)
Shephard (2014)	Nosebleeds	Patients ≥ 60 years	0.1 (0.1-0.2)
Shephard (2014)	Back pain	Patients ≥ 60 years	0.1 (0.1-0.2)
Shephard (2014)	Weight loss	Patients ≥ 60 years	0.2 (0.1-0.2)
Shephard (2014)	Rib pain	Patients ≥ 60 years	0.2 (0.1-0.3)
Shephard (2014)	Low haemoglobin	Patients ≥ 60 years	0.17 (0.16-0.19)
Shephard (2014)	Leucopenia	Patients ≥ 60 years	0.3 (0.2-0.3)
Shephard (2014)	Low platelets	Patients ≥ 60 years	0.2 (0.1-0.2)
Shephard (2014)	Raised inflammatory markers	Patients ≥ 60 years	0.2 (0.18-0.22)
Shephard (2014)	Raised creatinine	Patients ≥ 60 years	0.08 (0.08-0.09)
Shephard (2014)	Raised MVC	Patients ≥ 60 years	0.18 (0.16-0.22)
Shephard (2014)	Hypercalcaemia	Patients ≥ 60 years	0.7 (0.5-1)

**Abbreviations:** CI, confidence interval; FP, False positives; PPV, positive predictive value; TP, True positives; NR, Not reported.

Table 2: Myeloma: Positive predictive value of symptom combinations for myeloma in patients aged > 14-15 years

Study	Symptom(s)	Patient group	PPV % (95% CI) for myeloma; prevalence of myeloma
Shephard (2014)	Joint pain and shortness of breath	Patients ≥ 60 years	0.1 (0.1-0.2)
Shephard (2014)	Joint pain and chest infection	Patients ≥ 60 years	0.3 (NR)
Shephard (2014)	Joint pain and chest pain	Patients ≥ 60 years	0.1 (NR)
Shephard (2014)	Joint pain and fracture	Patients ≥ 60 years	0.1 (NR)
Shephard (2014)	Joint pain and nausea	Patients ≥ 60 years	0.1 (NR)
Shephard (2014)	Joint pain and combined bone pain	Patients ≥ 60 years	0.1 (NR)
Shephard (2014)	Joint pain and nosebleeds	Patients ≥ 60 years	Non-calculable
Shephard (2014)	Joint pain and back pain	Patients ≥ 60 years	0.1 (0.1-0.2)
Shephard (2014)	Joint pain and	Patients ≥ 60	Non-calculable

	weight loss	years	
Shephard (2014)	Joint pain and rib pain	Patients ≥ 60 years	0.7 (NR)
Shephard (2014)	Shortness of breath and chest infection	Patients ≥ 60 years	0.1 (NR)
Shephard (2014)	Shortness of breath and chest pain	Patients ≥ 60 years	0.1 (0.05-0.1)
Shephard (2014)	Shortness of breath and fracture	Patients ≥ 60 years	0.1 (0.1-0.3)
Shephard (2014)	Shortness of breath and nausea	Patients ≥ 60 years	0.1 (0.1-0.2)
Shephard (2014)	Shortness of breath and combined bone pain	Patients ≥ 60 years	0.2 (0.1-0.3)
Shephard (2014)	Shortness of breath and nosebleeds	Patients ≥ 60 years	0.1 (NR)
Shephard (2014)	Shortness of breath and back pain	Patients ≥ 60 years	0.1 (0.1-0.2)
Shephard (2014)	Shortness of breath and weight loss	Patients ≥ 60 years	0.1 (0.1-0.3)
Shephard (2014)	Shortness of breath and rib pain	Patients ≥ 60 years	0.2 (NR)
Shephard (2014)	Chest infection and chest pain	Patients ≥ 60 years	0.2 (0.1-0.3)
Shephard (2014)	Chest infection and fracture	Patients ≥ 60 years	0.2 (0.1-0.3)
Shephard (2014)	Chest infection and nausea	Patients ≥ 60 years	0.1 (0.1-0.2)
Shephard (2014)	Chest infection and combined bone pain	Patients ≥ 60 years	0.3 (NR)
Shephard (2014)	Chest infection and nosebleeds	Patients ≥ 60 years	0.1 (NR)
Shephard (2014)	Chest infection and back pain	Patients ≥ 60 years	0.2 (0.1-0.2)
Shephard (2014)	Chest infection and weight loss	Patients ≥ 60 years	0.3 (NR)
Shephard (2014)	Chest infection and rib pain	Patients ≥ 60 years	0.2 (NR)
Shephard (2014)	Chest pain and fracture	Patients ≥ 60 years	0.3 (0.2-0.6)

Shephard (2014)	Chest pain and nausea	Patients ≥ 60 years	0.3 (0.2-0.4)
Shephard (2014)	Chest pain and combined bone pain	Patients ≥ 60 years	0.2 (0.1-0.4)
Shephard (2014)	Chest pain and nosebleeds	Patients ≥ 60 years	0.3 (NR)
Shephard (2014)	Chest pain and back pain	Patients ≥ 60 years	0.3 (0.2-0.4)
Shephard (2014)	Chest pain and weight loss	Patients ≥ 60 years	0.1 (NR)
Shephard (2014)	Chest pain and rib pain	Patients ≥ 60 years	0.9 (NR)
Shephard (2014)	Fracture and nausea	Patients ≥ 60 years	0.2 (0.1-0.4)
Shephard (2014)	Fracture and combined bone pain	Patients ≥ 60 years	0.8 (NR)
Shephard (2014)	Fracture and nosebleeds	Patients ≥ 60 years	Non-calculable
Shephard (2014)	Fracture and back pain	Patients ≥ 60 years	0.5 (0.3-0.9)
Shephard (2014)	Fracture and weight loss	Patients ≥ 60 years	0.3 (NR)
Shephard (2014)	Fracture and rib pain	Patients ≥ 60 years	0.7 (NR)
Shephard (2014)	Nausea and combined bone pain	Patients ≥ 60 years	0.6 (NR)
Shephard (2014)	Nausea and nosebleeds	Patients ≥ 60 years	Non-calculable
Shephard (2014)	Nausea and back pain	Patients ≥ 60 years	0.4 (0.2-0.6)
Shephard (2014)	Nausea and weight loss	Patients ≥ 60 years	0.3 (NR)
Shephard (2014)	Nausea and rib pain	Patients ≥ 60 years	0.3 (NR)
Shephard (2014)	Combined bone pain and nosebleeds	Patients ≥ 60 years	Non-calculable
Shephard (2014)	Combined bone pain and back pain	Patients ≥ 60 years	0.5 (0.3-0.8)
Shephard (2014)	Combined bone pain and weight loss	Patients ≥ 60 years	Non-calculable
Shephard (2014)	Combined bone pain and rib pain	Patients ≥ 60 years	0.5 (NR)
Shephard (2014)	Nosebleeds and back pain	Patients ≥ 60 years	1.5 (NR)

Shephard (2014)	Nosebleeds and weight loss	Patients ≥ 60 years	0.3 (NR)
Shephard (2014)	Nosebleeds and rib pain	Patients ≥ 60 years	Non-calculable
Shephard (2014)	Back pain and weight loss	Patients ≥ 60 years	0.5 (NR)
Shephard (2014)	Back pain and rib pain	Patients ≥ 60 years	1.1 (NR)
Shephard (2014)	Weight loss and rib pain	Patients ≥ 60 years	Non-calculable
Shephard (2014)	Back pain first episode and low haemoglobin	Patients ≥ 60 years	0.5 (0.4-0.7)
Shephard (2014)	Back pain first episode and leucopenia	Patients ≥ 60 years	0.6 (0.4-1.2)
Shephard (2014)	Back pain first episode and low platelets	Patients ≥ 60 years	0.7 (0.4-1.3)
Shephard (2014)	Back pain first episode and raised inflammatory markers	Patients ≥ 60 years	0.6 (0.4-0.7)
Shephard (2014)	Back pain first episode and raised creatinine	Patients ≥ 60 years	0.3 (0.2-0.4)
Shephard (2014)	Back pain first episode and raised MCV	Patients ≥ 60 years	0.4 (0.3-0.6)
Shephard (2014)	Back pain first episode and hypercalcaemia	Patients ≥ 60 years	4 (NR)
Shephard (2014)	Back pain second episode and low haemoglobin	Patients ≥ 60 years	0.9 (0.6-1.3)
Shephard (2014)	Back pain second episode and leucopenia	Patients ≥ 60 years	2 (NR)
Shephard (2014)	Back pain second episode and low platelets	Patients ≥ 60 years	0.7 (NR)
Shephard (2014)	Back pain second episode and raised inflammatory markers	Patients ≥ 60 years	1.1 (0.7-1.6)
Shephard (2014)	Back pain	Patients ≥ 60	0.5 (0.3-0.7)

	second episode and raised creatinine	years	
Shephard (2014)	Back pain second episode and raised MCV	Patients ≥ 60 years	0.8 (0.4-1.6)
Shephard (2014)	Back pain second episode and hypercalcaemia	Patients ≥ 60 years	>10 (NR)
Shephard (2014)	Shortness of breath and low haemoglobin	Patients ≥ 60 years	0.2 (0.1-0.2)
Shephard (2014)	Shortness of breath and leucopenia	Patients ≥ 60 years	0.3 (0.2-0.6)
Shephard (2014)	Shortness of breath and low platelets	Patients ≥ 60 years	0.3 (0.1-0.5)
Shephard (2014)	Shortness of breath and raised inflammatory markers	Patients ≥ 60 years	0.2 (0.1-0.2)
Shephard (2014)	Shortness of breath and raised creatinine	Patients ≥ 60 years	0.1 (0.07-0.11)
Shephard (2014)	Shortness of breath and raised MCV	Patients ≥ 60 years	0.2 (0.1-0.3)
Shephard (2014)	Shortness of breath and hypercalcaemia	Patients ≥ 60 years	1.5 (NR)
Shephard (2014)	Chest pain and low haemoglobin	Patients ≥ 60 years	0.3 (0.2-0.4)
Shephard (2014)	Chest pain and leucopenia	Patients ≥ 60 years	0.3 (0.1-0.6)
Shephard (2014)	Chest pain and low platelets	Patients ≥ 60 years	0.3 (0.2-0.6)
Shephard (2014)	Chest pain and raised inflammatory markers	Patients ≥ 60 years	0.5 (0.3-0.6)
Shephard (2014)	Chest pain and raised creatinine	Patients ≥ 60 years	0.2 (0.1-0.2)
Shephard (2014)	Chest pain and raised MCV	Patients ≥ 60 years	0.3 (0.2-0.6)
Shephard (2014)	Chest pain and	Patients ≥ 60	1.9 (NR)



	hypercalcaemia	years	
Shephard (2014)	Chest infection and low haemoglobin	Patients ≥ 60 years	0.2 (0.2-0.3)
Shephard (2014)	Chest infection and leucopenia	Patients ≥ 60 years	0.3 (0.1-0.5)
Shephard (2014)	Chest infection and low platelets	Patients ≥ 60 years	0.2 (0.1-0.4)
Shephard (2014)	Chest infection and raised inflammatory markers	Patients ≥ 60 years	0.3 (0.2-0.4)
Shephard (2014)	Chest infection and raised creatinine	Patients ≥ 60 years	0.1 (0.1-0.2)
Shephard (2014)	Chest infection and raised MCV	Patients ≥ 60 years	0.3 (0.2-0.4)
Shephard (2014)	Chest infection and hypercalcaemia	Patients ≥ 60 years	2 (NR)
Shephard (2014)	Nosebleeds and low haemoglobin	Patients ≥ 60 years	0.4 (0.2-0.8)
Shephard (2014)	Nosebleeds and leucopenia	Patients ≥ 60 years	> 10 (NR)
Shephard (2014)	Nosebleeds and low platelets	Patients ≥ 60 years	1.2 (NR)
Shephard (2014)	Nosebleeds and raised inflammatory markers	Patients ≥ 60 years	0.9 (NR)
Shephard (2014)	Nosebleeds and raised creatinine	Patients ≥ 60 years	0.2 (0.1-0.4)
Shephard (2014)	Nosebleeds and raised MCV	Patients ≥ 60 years	0.3 (NR)
Shephard (2014)	Nosebleeds and hypercalcaemia	Patients ≥ 60 years	NR
Shephard (2014)	Fracture and low haemoglobin	Patients ≥ 60 years	0.3 (0.2-0.4)
Shephard (2014)	Fracture and leucopenia	Patients ≥ 60 years	> 10 (NR)
Shephard (2014)	Fracture and low platelets	Patients ≥ 60 years	0.1 (NR)
Shephard (2014)	Fracture and raised inflammatory markers	Patients ≥ 60 years	0.4 (0.2-0.6)
Shephard (2014)	Fracture and	Patients ≥ 60	0.2 (0.1-0.4)

	raised creatinine	years	
Shephard (2014)	Fracture and raised MCV	Patients ≥ 60 years	0.3 (NR)
Shephard (2014)	Fracture and hypercalcaemia	Patients ≥ 60 years	> 10 (NR)
Shephard (2014)	Nausea and low haemoglobin	Patients ≥ 60 years	0.2 (0.1-0.3)
Shephard (2014)	Nausea and leucopenia	Patients ≥ 60 years	0.4 (NR)
Shephard (2014)	Nausea and low platelets	Patients ≥ 60 years	0.3 (NR)
Shephard (2014)	Nausea and raised inflammatory markers	Patients ≥ 60 years	0.3 (0.2-0.5)
Shephard (2014)	Nausea and raised creatinine	Patients ≥ 60 years	0.2 (0.1-0.3)
Shephard (2014)	Nausea and raised MCV	Patients ≥ 60 years	0.3 (0.2-0.7)
Shephard (2014)	Nausea and hypercalcaemia	Patients ≥ 60 years	1 (NR)
Shephard (2014)	Combined bone pain and low haemoglobin	Patients ≥ 60 years	0.5 (0.3-1)
Shephard (2014)	Combined bone pain and leucopenia	Patients ≥ 60 years	> 5 (NR)
Shephard (2014)	Combined bone pain and low platelets	Patients ≥ 60 years	0.1 (NR)
Shephard (2014)	Combined bone pain and raised inflammatory markers	Patients ≥ 60 years	0.5 (0.3-0.9)
Shephard (2014)	Combined bone pain and raised creatinine	Patients ≥ 60 years	0.2 (0.1-0.4)
Shephard (2014)	Combined bone pain and raised MCV	Patients ≥ 60 years	0.5 (NR)
Shephard (2014)	Combined bone pain and hypercalcaemia	Patients ≥ 60 years	1.4 (NR)
Shephard (2014)	Joint pain and low haemoglobin	Patients ≥ 60 years	0.2 (0.1-0.3)
Shephard (2014)	Joint pain and leucopenia	Patients ≥ 60 years	0.3 (NR)
Shephard (2014)	Joint pain and	Patients ≥ 60	0.2 (NR)

	low platelets	years	
Shephard (2014)	Joint pain and raised inflammatory markers	Patients ≥ 60 years	0.1 (0.1-0.2)
Shephard (2014)	Joint pain and raised creatinine	Patients ≥ 60 years	0.1 (0.05-0.13)
Shephard (2014)	Joint pain and raised MCV	Patients ≥ 60 years	0.2 (NR)
Shephard (2014)	Joint pain and hypercalcaemia	Patients ≥ 60 years	> 10 (NR)
Shephard (2014)	Rib pain and low haemoglobin	Patients ≥ 60 years	0.9 (NR)
Shephard (2014)	Rib pain and leucopenia	Patients ≥ 60 years	0.5 (NR)
Shephard (2014)	Rib pain and low platelets	Patients ≥ 60 years	NR
Shephard (2014)	Rib pain and raised inflammatory markers	Patients ≥ 60 years	0.4 (0.2-0.8)
Shephard (2014)	Rib pain and raised creatinine	Patients ≥ 60 years	0.8 (NR)
Shephard (2014)	Rib pain and raised MCV	Patients ≥ 60 years	1.1 (NR)
Shephard (2014)	Rib pain and hypercalcaemia	Patients ≥ 60 years	> 10 (NR)
Shephard (2014)	Weight loss and low haemoglobin	Patients ≥ 60 years	0.4 (0.?-0.7)
Shephard (2014)	Weight loss and leucopenia	Patients ≥ 60 years	0.5 (NR)
Shephard (2014)	Weight loss and low platelets	Patients ≥ 60 years	0.5 (NR)
Shephard (2014)	Weight loss and raised inflammatory markers	Patients ≥ 60 years	0.6 (0.3-1.1)
Shephard (2014)	Weight loss and raised creatinine	Patients ≥ 60 years	0.5 (NR)
Shephard (2014)	Weight loss and raised MCV	Patients ≥ 60 years	0.6 (NR)
Shephard (2014)	Weight loss and hypercalcaemia	Patients ≥ 60 years	0.5 (NR)

1 **Abbreviations:** CI, confidence interval; FP, False positives; PPV, positive predictive value; TP, True  
2 positives, NR, Not reported. Shepard (2014) reports that PPVs were not calculated if < 5 cases had  
3 the feature(s) and CIs were omitted where < 10 cases or controls had the combined features.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

**Evidence statements:**

The positive predictive values for myeloma of single symptoms presenting in a primary care setting ranged from 0% (for 'acute low back pain') to 0.7% (for hypercalcaemia in patients aged  $\geq 60$  years; 3 studies, N = 17798). The studies were subject to 1-3 bias or applicability concerns (See also Table 1).

The positive predictive values for myeloma of symptom pairs presenting in a primary care setting ranged from 0.1% (for raised creatinine with 'shortness of breath'/ chest infection / joint pain, and for joint pain with 'raised inflammatory markers'/back pain/ 'combined bone pain'/ nausea/fracture/chest pain/ 'shortness of breath', and for 'shortness of breath' with chest infection / chest pain/ fracture/ nausea/ nosebleeds/ back pain/ weight loss, and for chest infection with nosebleeds/nausea, and for chest pain with weight loss; all in patients aged  $\geq 60$  years) to  $> 10\%$  (for hypercalcaemia with 'back pain second episode'/ fracture / joint pain/rib pain, and for leucopenia with nosebleeds/fracture; all in patients aged  $\geq 60$  years; 1 study, N = 14860). The study was subject to 1 bias concern (see also Table 2).

**Evidence tables****Deyo (1988)**

<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective consecutive? patient series
Was a consecutive or random sample of patients enrolled?	<b>Unclear</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Yes (probably)</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>N = 1975, mean (SD; range) age = 39.5 (15.4; 15-86) years, 62% females. 54% of the patients were seeking medical care for back pain for the first time and 76% of the patients had had back pain for <math>&lt; 3</math> months. 3% had a history of back pain surgery. Maximal back pain in the low back (84%) or in the upper back (16%).</p> <p><u>Inclusion criteria:</u> Patients who sought treatment between March 1982 and September 1984 in the walk-in clinic of a public hospital where virtually all patients are self-referred. In each case back pain was part of the chief complaint.</p> <p><u>Exclusion criteria:</u> Neck pain.</p> <p><u>Clinical setting:</u> Walk-in clinic of a public hospital; this clinic is a source of primary care for indigent persons in a county in the USA with a population of approximately 1 million.</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>High concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	Back pain; not further specified.

Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	The reference standard consisted of a search on each patient name in the institutional tumour registry $\geq 6$ months after the index visit. The registry included every patient with a histological diagnosis of cancer made in the authors' hospital system regardless of site of care. The authors point out that "while this method might fail to identify cancer patients who sought care elsewhere, it is likely that most patients sought follow-up for a particular illness at the same facility.
Is the reference standard likely to correctly classify the target condition?	<b>Unclear</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No (but all patients had a positive index test)</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All the patients are accounted for in the results.
Was there an appropriate interval between index test and reference standard?	<b>Yes (probably)</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	It is a concern that some patients with cancer might have been missed due to the choice of reference standard because this would result in an underestimation of the positive predictive value. 38/1975 patients were found in the tumour registry. Of those 38, 13 patients had tumours that were probable causes of back pain, and 4 of these 13 patients already had a diagnosis of cancer at presentation. The 9/1975 patients who had undiagnosed cancer that the back pain could be attributed to had: Lymphoma (NOS; 2), cancer of unknown primary (1), prostate cancer (1), retroperitoneal liposarcoma (1), lung cancer (1), renal cell (1), multiple myeloma (1), mucinous adenocarcinoma (of gallbladder?; 1)
1	
2	<b>Shephard (2014)</b>
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	

Patient sampling	Matched case-control study using patients in the UK's Clinical Practice Research Database (CPRD).	
Was a consecutive or random sample of patients enrolled?	No	
Was a case-control design avoided?	No	
Did the study avoid inappropriate exclusions?	Yes	
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?	Yes	
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?	Yes	
<b>Could the selection of patients have introduced bias?</b>	<b>High risk</b>	
<b><u>B. Concerns regarding applicability</u></b>		
Patient characteristics and setting	<p><u>Cases:</u> N = 2703, 1449 males/ 1254 females, median age at diagnosis = 73 (IQR = 64-80) years; median number of consultations in the year before diagnosis = 16 (IQR = 10-25); UK.</p> <p><u>Controls:</u> N = 12157; 6359 males/ 5798 females; median age at matched-case diagnosis = 73 (IQR = 65-80) years median number of consultations in the year before diagnosis = 8 (IQR = 4-14); UK.</p> <p><u>Inclusion criteria:</u> Cases: Patients aged <math>\geq 40</math> years with one of 23 myeloma diagnostic codes in the CPRD between January 2000 and December 2009, with min. 1 year of data before diagnosis. The first instance of a myeloma cancer code was assigned the data of diagnosis/index date. Controls: Up to 5 controls per case, matched on sex, general practice, and to 1 year of age of the case. The index date was the index date of the matched case.</p> <p><u>Exclusion criteria:</u> Any case or control with less than 1 year of data before the index date; cases without controls; controls with myeloma; controls with only one line consisting of incomplete data (suggestion they had not sought medical care after registration).</p> <p><u>Clinical setting:</u> UK primary care</p>	
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>	
<b>INDEX TEST</b>		
<b><u>A. Risk of bias</u></b>		
<b>Index test</b>	<p>"Symptoms, diseases and abnormal investigations reported in the myeloma literature and from patient online support groups were studied". "The GPRD contains over 100,000 medical codes; several codes can potentially be associated with each feature. A symptom library of codes was compiled for each feature. Occurrences of features were identified in the year before the index date. Only those features present in <math>\geq 2\%</math> of cases or controls were retained (this was invariably cases)." "Abnormal investigation results were defined as the patient having a test value falling outside their local laboratory's normal range. Patients with a normal laboratory result were grouped with those who had not been tested." "Some tests were grouped together. The raised inflammatory markers variable was a composite of any</p>	

	of abnormal erythrocyte sedimentation rate, plasma viscosity, or C-reactive protein, as different local laboratories had local preferences for the inflammatory marker of choice; similarly abnormal liver function tests reflected a raised value of any of the hepatic enzymes reported by each laboratory. In clinical practice, haemoglobin, white cell count and platelets are normally requested together ('the full blood count'). We used these slightly differently in our analyses; for the multivariable analyses, a composite variable 'cytopenia' was deemed to be positive if any of the haemoglobin, white cell count or platelets was abnormally low; for positive predictive values (see below) the three different cell types were analysed separately. Bone pain codes often had an anatomical descriptor as well as the words 'bone pain'. We retained 'rib pain', 'back pain' and 'joint pain' as separate entities; remaining bone pain codes, such as 'tibial pain' were merged with the generic 'bone pain' code, making a group we called 'combined bone pain'.
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?	Yes
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	Low risk
<b><u>B. Concerns regarding applicability</u></b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	Low concern
<b>REFERENCE STANDARD</b>	
<b><u>A. risk of bias</u></b>	
Reference standard(s)	One of 23 myeloma diagnostic codes in the CPRD.
Is the reference standard likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	Unclear
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	Low risk
<b><u>B. Concerns regarding applicability</u></b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	Low concern
<b>FLOW AND TIMING</b>	
<b><u>A. risk of bias</u></b>	
Flow and timing	A total of 16233 patients were identified, 13503 controls and 2730 cases. After the exclusion criteria were applied there were 12157 controls and 2703 cases.
Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	Yes
<b>Could the patient flow have introduced bias?</b>	Low risk

1  
2

<b>NOTES</b>	62 symptoms and 22 abnormal test results were considered initially.	
<b>Suarez-Almazor (1997)</b>		
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Retrospective consecutive patient series	
Was a consecutive or random sample of patients enrolled?	Yes	
Was a case-control design avoided?	Yes	
Did the study avoid inappropriate exclusions?	Yes	
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>	
<b>B. Concerns regarding applicability</b>		
Patient characteristics and setting	<p>N = 1550, of whom N = 331 had chronic (&gt; 3 months?) back pain, N = 963 had acute (&lt; 3 months) low back pain, and N = 256 had back pain of unspecified duration. Of the patients with acute low back pain, 442 were males, and it appears that the mean (SD) age = 42.2 (15.6) years for the patients with acute low back pain, 14/963 had a history of cancer</p> <p><u>Inclusion criteria:</u> All patients aged ≥ 18 years presenting to four family clinics in Edmonton (Alberta, Canada) between January 1 1992 and December 31 1993 with low back pain or leg pain compatible with sciatic pain for which no visit had been made within the past 12 months.</p> <p><u>Exclusion criteria:</u> Low back pain attributable to visceral pain (e.g., urinary infection, inflammatory pelvic disease), previous diagnosis of ankylosing spondylitis, pregnancy.</p> <p><u>Clinical setting:</u> Four family clinics in Edmonton (Alberta, Canada), two of which are university-affiliated and hospital-based, with the other two based in the community.</p>	
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>	
<b>INDEX TEST</b>		
<b>A. Risk of bias</b>		
Index test	Acute (< 3 months) low back pain; not further specified.	
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes	
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>	
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>	
<b>REFERENCE STANDARD</b>		
<b>A. risk of bias</b>		
Reference standard(s)	Follow up consisting of chart review after a minimum of 2 years. Patients were considered to have cancer if recorded in the physician notes or in reports from laboratory or diagnostic tests.	
Is the reference standard likely to correctly classify the target condition?	Yes	
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No (but all patients had a positive index test)</b>	



<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>		<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		<b>Low concern</b>
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	The results are only presented for the patients with acute low back pain.	
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>	
Did all patients receive the same reference standard?	<b>Yes</b>	
Were all patients included in the analysis?	<b>Yes</b>	
<b>Could the patient flow have introduced bias?</b>		<b>Low risk</b>
<b>NOTES</b>	13/963 patients with acute low back pain had active cancer. 3 of those 13 patients had the cancer diagnosis prior to the index visit; 3/13 patients had tumours that were probable causes of the acute low back pain (spinal infiltrates from multiple myeloma [2] and metastatic bone disease with compression fractures [1]), and 10/13 patients had cancer that was not considered to have caused the acute low back pain (bladder cancer [3], colon [1], breast [1], thyroid [1], lung [1], prostate [1], endometrium [1], oesophagus [1]). However, as it is not reported which of these patients already had a diagnosis of cancer pre-index visit, it is not possible to present the data accurately for the individual cancers.	

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

**References**

**Included studies**

Deyo, R. A. and Diehl, A. K. Cancer as a cause of back pain: Frequency, clinical presentation, and diagnostic strategies. *Journal of General Internal Medicine* 3, 230-238. 1-11-1988.

Shephard, E.A., Neal, R.D., Rose, P., Walter, F.M., Litt, E.J., Hamilton, W.T. Quantifying the risk of myeloma from symptoms reported in primary care patients: A large case-control study using electronic records. In press. *British Journal of General Practice*.

Suarez-Almazor, M. E., Belseck, E., Russell, A. S., and Mackel, J. V. Use of lumbar radiographs for the early diagnosis of low back pain. Proposed guidelines would increase utilization. *JAMA* 277[22], 1782-1786. 11-6-1997.

**Excluded studies (with exclusion reason)**

Abel, G. A., Friese, C. R., Magazu, L. S., Richardson, L. C., Fernandez, M. E., De Zengotita, J. J. & Earle, C. C. (2008) Delays in referral and diagnosis for chronic hematologic malignancies: A literature review. *Leukemia & Lymphoma*, 49: 1352-1359.

Exclusion reason : expert review

Abel, G. A., Friese, C. R., Neville, B. A., Wilson, K. M., Hastings, B. T., Earle, C. C., Keating, N. L. & Richardson, L. C. (2012) Referrals for suspected hematologic malignancy: A survey of primary care physicians. *American Journal of Hematology*, 87: 634-636.

Exclusion reason : expert review

Adam, Z., Bednarik, J., Neunauer, J., Chaloupka, R., Vorlicek, J., Vanicek, J., Pour, L., Cermakova, Z., Weinreb, M., Scudla, V., Maisnar, V., Straub, J., Schutzova, M. & Gregora, E. (1999) Recommended diagnostic steps for general practitioners attending patients with difficulties that could indicate multiple myeloma. [Czech]. *Prakticky Lekar*, 86: 25.

- 1 Exclusion reason : expert review
- 2 Adam, Z., Bednarik, J., Neubauer, J., Chaloupka, R., Fojtik, Z., Vanicek, J., Pour, L., Cermakova, Z.,  
3 Scudla, V., Maisnar, V., Straub, J., Schutzova, M., Gregora, E., Weinreb, M., Stuchlikova, K.,  
4 Stanicek, J., Hajek, R., Krejci, M., Vorlicek, J. & Czech Myeloma Society (2006) [Recommendations  
5 for early identification of damage to the skeleton by malignant processes, and for early diagnosis  
6 of multiple myeloma]. [Czech]. *Vnitřní Lekarství*, 52: Suppl-31.
- 7 Exclusion reason : expert review
- 8 Alvarez-Cordoves, M. M., Mirpuri-Mirpuri, P. G. & Perez-Monje, A. (2013) [Diagnosis of multiple  
9 myeloma in primary care. Suspicion with an appropriate clinical history]. [Spanish]. *Semergen*  
10 *Sociedad Espanola de Medicina Rural y Generalista*, 39: e21-e24.
- 11 Exclusion reason : Narrative review
- 12 American Academy of Family Physicians (2008) Information from your family doctor. Multiple  
13 myeloma: what you should know. *American Family Physician*, 78: 860.
- 14 Exclusion reason : expert review
- 15 Antunes, N. L. (2001) The spectrum of neurologic disease in children with systemic cancer. *Pediatric*  
16 *Neurology*, 25: 227-235.
- 17 Exclusion reason : population not in PICO
- 18 Artz, A. S. & Thirman, M. J. (2011) Unexplained anemia predominates despite an intensive evaluation  
19 in a racially diverse cohort of older adults from a referral anemia clinic. *Journals of Gerontology*  
20 *Series A-Biological Sciences & Medical Sciences*, 66: 925-932.
- 21 Exclusion reason : population not in PICO
- 22 Behdad, A., Ross, C. W., Jacques, J., Kota, U., Brown, N. A., Keren, D. & Stoolman, L. (2013) Utility of  
23 9-color, 11-parameter flow cytometry for detection of plasma cell neoplasms: A comparison with  
24 bone marrow morphologic findings and concurrent M-protein studies in serum and urine. *Blood*,  
25 122.
- 26 Exclusion reason : Not in PICO
- 27 Berrady, R., Baybay, H., Khammar, Z., Lahlou, M., Lamchacti, L., Gallouj, S., El, H. A., Mernissi, F.-Z.  
28 & Bono, W. (2012) Acquired ichthyosis and haematological malignancies: Five cases. [French].  
29 *Annales de Dermatologie et de Venereologie*, 139: January.
- 30 Exclusion reason : population not in PICO
- 31 Bianchi, G., Richardson, P. G. & Anderson, K. C. (2014) Best Treatment Strategies in High-Risk  
32 Multiple Myeloma: Navigating a Gray Area. *Journal of Clinical Oncology*, 32: 2125-2132.
- 33 Exclusion reason : Not in PICO
- 34 Buchner-Daley, L., Brady-West, D. & McGrowder, D. (2012) Clinical and Biochemical Profile of  
35 Monoclonal Gammopathies in Caribbean Patients in a Resource-limited Setting. *Asian Pacific*  
36 *Journal of Cancer Prevention: Apjcp*, 13: 6501-6504.
- 37 Exclusion reason : population not in PICO
- 38 Burnand, J., Waeber, G. & Duchosal, M. A. (2150) [Hematological malignancy: management of  
39 anemia and leukopenia by primary care physicians]. [French]. *Revue Medicale Suisse*, 5: 2147-  
40 2148.
- 41 Exclusion reason : expert review
- 42 Chan, D. T., Craig, K., Donovan, K. & Phillips, A. (2006) Myeloma renal disease: presentation and  
43 outcome. *Nephron*, 104: c126-c131.
- 44 Exclusion reason : population not in PICO
- 45 Charakidis, M. & Russell, D. J. (2010) Spontaneous splenic rupture in Waldenström's  
46 macroglobulinemia: a case report. *Journal of Medical Case Reports [Electronic Resource]*, 4: 300.
- 47 Exclusion reason : case report
- 48 Chua, T. & Hyder, A. (2010) Gastrointestinal histoplasmosis and the role of narrow band imaging.  
49 *American Journal of Gastroenterology.Conference: 75th Annual Scientific Meeting of the*  
50 *American College of Gastroenterology San Antonio, TX United States.Conference Start: 20101015*  
51 *Conference End: 20101020.Conference Publication: (var.pagings), 105: October.*

- 1 Exclusion reason : case report
- 2 Clark, P. & Wroblewski, T. (2011) Unexpected MRI findings in a 24 year-old male with newly  
3 diagnosed acute lymphoblastic leukemia with hip pain. *Journal of General Internal  
4 Medicine*. Conference: 34th Annual Meeting of the Society of General Internal Medicine Phoenix,  
5 AZ United States. Conference Start: 20110504 Conference End: 20110507. Conference Publication:  
6 (var.pagings), 26: May.
- 7 Exclusion reason : case report
- 8 Cohen, Y., Gutwein, O., Garach-Jehoshua, O., Bar-Haim, A. & Kornberg, A. (2013) GPRC5D is a  
9 promising marker for monitoring the tumor load and to target multiple myeloma cells.  
10 *Hematology*, 18: 348-351.
- 11 Exclusion reason : Not in PICO
- 12 Dharmarajan, T. S. & Thadisina, S. (2011) Anemia in the old: Possible indicator of serious underlying  
13 disease, warrants evaluation. S. Thadisina MD, RO Russell MD, TS Dharmarajan MD, AGSF  
14 Montefiore Medical Center (North), Bronx, NY. *Journal of the American Geriatrics  
15 Society*. Conference: 2011 Annual Scientific Meeting of the American Geriatrics Society National  
16 Harbor, MD United States. Conference Start: 20110511 Conference End: 20110514. Conference  
17 Publication: (var.pagings), 59: April.
- 18 Exclusion reason : case report
- 19 dos Santos, V. M., Brito, E. F. O., Paz, B. C. S. & Leal, C. T. (2012) Rib Plasmacytoma and IgA Multiple  
20 Myeloma with Hyperviscosity Syndrome. *Archives of Iranian Medicine*, 15: 517-519.
- 21 Exclusion reason : case report
- 22 Dvorak, C. (2006) Common complaints, difficult diagnosis: Multiple myeloma. [References]. *Journal  
23 of the American Academy of Nurse Practitioners*, 18: 190-194.
- 24 Exclusion reason : case report
- 25 Edgren, G., Bagnardi, V., Bellocco, R., Hjalgrim, H., Rostgaard, K., Melbye, M., Reilly, M., Adami, H. O.,  
26 Hall, P. & Nyren, O. (2010) Pattern of declining hemoglobin concentration before cancer  
27 diagnosis. *International Journal of Cancer*, 127: 1429-1436.
- 28 Exclusion reason : population not in PICO
- 29 El, S. U., Hassan, T., Besheer, M., El, B. R., El, G. K. & Morad, M. H. (2009) Skeletal manifestations in  
30 children with different hematological diseases and hematological malignancies at Zagazig  
31 university hospital [retrospective study from 1998 to 2008]. *Haematologica*. Conference: 14th  
32 Congress of the European Hematology Association Berlin Germany. Conference Start: 20090604  
33 Conference End: 20090607. Conference Publication: (var.pagings), 94: June.
- 34 Exclusion reason : population not in PICO
- 35 Engelhardt, M., Terpos, E., Kleber, M., Gay, F., Wasch, R., Morgan, G., Cavo, M., van de Donk, N.,  
36 Beilhack, A., Bruno, B., Johnsen, H. E., Hajek, R., Driessen, C., Ludwig, H., Beksac, M., Boccadoro,  
37 M., Straka, C., Brighen, S., Gramatzki, M., Larocca, A., Lokhorst, H., Magarotto, V., Morabito, F.,  
38 Dimopoulos, M. A., Einsele, H., Sonneveld, P. & Palumbo, A. (2014) European Myeloma Network  
39 recommendations on the evaluation and treatment of newly diagnosed patients with multiple  
40 myeloma. *Haematologica*, 99: 232-242.
- 41 Exclusion reason : Not in PICO
- 42 Eslick, R. & Talaulikar, D. (2013) Multiple myeloma: from diagnosis to treatment. *Australian Family  
43 Physician*, 42: 684-688.
- 44 Exclusion reason : Narrative review
- 45 Fadul, N. A., El Osta, B., Dalal, S., Poulter, V. A. & Bruera, E. (2008) Comparison of symptom burden  
46 among patients referred to palliative care with hematologic malignancies versus those with solid  
47 tumors. [References]. *Journal of Palliative Medicine*, 11: 422-427.
- 48 Exclusion reason : population not in PICO
- 49 Faiman, B. (2007) Clinical updates and nursing considerations for patients with multiple myeloma.  
50 [Review] [52 refs]. *Clinical Journal of Oncology Nursing*, 11: 831-840.
- 51 Exclusion reason : expert review

- 1 Foran, J. M. & Shammo, J. M. (2012) Clinical presentation, diagnosis, and prognosis of  
2 myelodysplastic syndromes. [Review]. *American Journal of Medicine*, 125: Suppl-13.
- 3 Exclusion reason : expert review
- 4 Friese, C. R., Abel, G. A., Magazu, L. S., Neville, B. A., Richardson, L. C. & Earle, C. C. (2009) Diagnostic  
5 delay and complications for older adults with multiple myeloma. *Leukemia & Lymphoma*, 50:  
6 392-400.
- 7 Exclusion reason : cases only
- 8 Fujimi, A., Hashimoto, A., Kanisawa, Y., Okuda, T., Minami, S., Doi, T., Matsuno, T., Ishikawa, K. &  
9 Uemura, N. (2013) Loss of CD23 expression after bortezomib plus dexamethasone therapy in  
10 CCND1/IGH-positive multiple myeloma. *Rinsho Ketsueki - Japanese Journal of Clinical  
11 Hematology*, 54: 224-228.
- 12 Exclusion reason : case report
- 13 Galhotra, R., Saggarr, K., Gupta, K. & Singh, P. (2012) Primary isolated extramedullary plasmacytoma  
14 of mesentery: A rare case report. *The gulf journal of oncology*, 1: 81-84.
- 15 Exclusion reason : case report
- 16 George, E. D. & Sadovsky, R. (1999) Multiple myeloma: recognition and management. [Review] [31  
17 refs]. *American Family Physician*, 59: 1885-1894.
- 18 Exclusion reason : expert review
- 19 Guven, G. S., Uzun, O., Cakir, B., Akova, M. & Unal, S. (2006) Infectious complications in patients with  
20 hematological malignancies consulted by the Infectious Diseases team: a retrospective cohort  
21 study (1997-2001). *Supportive Care in Cancer*, 14: 52-55.
- 22 Exclusion reason : population not in PICO
- 23 Hegguler, S. (2011) Differential diagnosis of low back pain. *Turkiye Fiziksel Tip ve Rehabilitasyon  
24 Dergisi*.Conference: 23rd National Physical Medicine and Rehabilitation Congress Antalya  
25 Turkey.Conference Start: 20110511 Conference End: 20110515.Conference Publication:  
26 (var.pagings), 57: 2011.
- 27 Exclusion reason : expert review
- 28 Heringer, L. & Crevensten, H. (2010) Recurrent paralysis due to hyperthyroidism causing  
29 hypokalemia. *Journal of General Internal Medicine*.Conference: 33rd Annual Meeting of the  
30 Society of General Internal Medicine Minneapolis, MN United States.Conference Start: 20100428  
31 Conference End: 20100501.Conference Publication: (var.pagings), 25: June.
- 32 Exclusion reason : case report
- 33 Howell, D. A., Smith, A. G., Jack, A., Patmore, R., Macleod, U., Mironska, E. & Roman, E. (2013) Time-  
34 to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the  
35 Haematological Malignancy Research Network. *BMC Hematology*, 13: 9.
- 36 Exclusion reason : Not in PICO
- 37 Jahanmir, J. (2012) First report of hemialgia as a presenting symptom in multiple myeloma. *Journal  
38 of Hospital Medicine*.Conference: 2012 Annual Meeting of the Society of Hospital Medicine, SHM  
39 2012 San Diego, CA United States.Conference Start: 20120401 Conference End:  
40 20120404.Conference Publication: (var.pagings), 7: March.
- 41 Exclusion reason : case report
- 42 Kapoor, J., Trinidad, A., Mochloulis, G. & Mohamid, W. (2012) Plasmacytoma of the atlas presenting  
43 as hoarseness: a rare cause of unilateral vocal fold palsy. *Journal of Laryngology & Otology*, 126:  
44 870-872.
- 45 Exclusion reason : case report
- 46 Kariyawasan, C. C., Hughes, D. A., Jayatillake, M. M. & Mehta, A. B. (2007) Multiple myeloma: causes  
47 and consequences of delay in diagnosis. *QJM*, 100: 635-640.
- 48 Exclusion reason : cases only
- 49 Karwicki, L., Kmiecik, M. & Kopka, M. (2003) Surgical treatment of metastatic tumors to long bones  
50 in the material of the Unit. *Ortopedia Traumatologia Rehabilitacja*, 5: 358-363.
- 51 Exclusion reason : population not in PICO

- 1 Kelly, M. B., Meenaghan, T. & Dowling, M. (2010) Myeloma: making sense of a complex blood  
2 cancer. *British Journal of Nursing*, 19: 1415-1421.
- 3 Exclusion reason : expert review
- 4 Krych, M. (2005) [Acute renal failure]. [Review] [33 refs] [German]. *Internist*, 46: 30-38.
- 5 Exclusion reason : expert review
- 6 Li, N., Lv, Y., Zeng, H., He, F., Yao, Y. & He, X. (2012) Renal impairment in multiple myeloma:  
7 presenting features in different departments. *Journal of Huazhong University of Science and*  
8 *Technology.Medical Sciences*, 32: 65-68.
- 9 Exclusion reason : population not in PICO
- 10 Magee, C., Vella, J. P., Tormey, W. P. & Walshe, J. J. (1998) Multiple myeloma and renal failure: one  
11 center's experience. *Renal Failure*, 20: 597-606.
- 12 Exclusion reason : population not in PICO
- 13 Mistry, P. K., Sadan, S., Yang, R., Yee, J. & Yang, M. (2007) Consequences of diagnostic delays in type  
14 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an  
15 opportunity for early diagnosis and intervention. *American Journal of Hematology*, 82: 697-701.
- 16 Exclusion reason : population not in PICO
- 17 Mutevelizade, G., Reyhan, M. & Yapar, A. F. (2012) Evaluation skin metastasis with 18FFDG PET/CT.  
18 *European Journal of Nuclear Medicine and Molecular Imaging*.Conference: 25th Annual Congress  
19 of the European Association of Nuclear Medicine, EANM 2012 Milan Italy.Conference Start:  
20 20121027 Conference End: 20121031.Conference Publication: (var.pagings), 39: October.
- 21 Exclusion reason : population not in PICO
- 22 Nathrath, M. & Teichert, V. L., I (2009) Oncologic causes of bone pain. [German]. *Monatsschrift fur*  
23 *Kinderheilkunde*, 157: July.
- 24 Exclusion reason : expert review
- 25 Nau, K. C. & Lewis, W. D. (2008) Multiple myeloma: diagnosis and treatment. [Review] [29 refs].  
26 *American Family Physician*, 78: 853-859.
- 27 Exclusion reason : expert review
- 28 Ozer, A. O., Unalacak, M. & Unluoglu, I. (2014) A case of multiple myeloma at a family medicine  
29 outpatient clinic. [Turkish]. *Konuralp Tip Dergisi*, 6: 64-66.
- 30 Exclusion reason : Not in PICO
- 31 Patriarca, F., Fanin, R., Silvestri, F., Russo, D. & Baccarani, M. (1998) Multiple myeloma: presenting  
32 features and survival according to hospital referral. *Eastern Cooperative Study Group on*  
33 *Monoclonal Gammopathies. Leukemia & Lymphoma*, 30: 551-562.
- 34 Exclusion reason : population not in PICO
- 35 Phongtankuel, V. & Ward, L. (2011) Oh my aching back! A classic diagnosis of multiple myeloma.  
36 *Journal of General Internal Medicine*.Conference: 34th Annual Meeting of the Society of General  
37 Internal Medicine Phoenix, AZ United States.Conference Start: 20110504 Conference End:  
38 20110507.Conference Publication: (var.pagings), 26: May.
- 39 Exclusion reason : case report
- 40 Prideaux, S. M., Conway, O. E. & Chevassut, T. J. (2014) - The genetic architecture of multiple  
41 myeloma. [Review]. - *Advances in Hematology*, 2014: 864058.
- 42 Exclusion reason : Narrative review
- 43 Rajer, M. & Kovac, V. (2008) Malignant spinal cord compression. *Radiology and Oncology*, 42: 01.
- 44 Exclusion reason : expert review
- 45 Ramon Rodriguez, L. G., Rivera-Keeling, C., Arencibia-Nunez, A., Avila-Cabrera, O. M., Izquierdo-  
46 Cano, L., Espinosa-Estrada, E., Gonzalez-Pinedo, L., Quintero-Sierra, Y., Gutierrez-Diaz, A. &  
47 Hernandez-Padron, C. (2013) Clinical and laboratory characterization of multiple myeloma at the  
48 Institute of Hematology and Immunology. *Revista Cubana de Hematologia, Inmunologia y*  
49 *Hemoterapia*, 29: 382-397.
- 50 Exclusion reason : Not in PICO

- 1 Reisfield, G. M., Paulian, G. D. & Wilson, G. R. (2005) "Johnny can't read": Another cause of failed  
2 analgesia. [References]. American Journal of Hospice & Palliative Medicine, 22: 433-436.  
3 Exclusion reason : case report
- 4 Rentschler, J., Herrmann, R., Fischer, N., Potthast, S. & Vetter, M. (2011) Lenalidomide in heavily  
5 pretreated angioimmunoblastic T-cell lymphoma (AITL). Journal of Clinical Oncology.Conference:  
6 ASCO Annual Meeting 2011 Chicago, IL United States.Conference Start: 20110603 Conference  
7 End: 20110607.Conference Publication: (var.pagings), 29: 20.  
8 Exclusion reason : case report
- 9 Roberts, C. C., Daffner, R. H., Weissman, B. N., Bancroft, L., Bennett, D. L., Blebea, J. S., Bruno, M. A.,  
10 Fries, I. B., Germano, I. M., Holly, L., Jacobson, J. A., Luchs, J. S., Morrison, W. B., Olson, J. J.,  
11 Payne, W. K., Resnik, C. S., Schweitzer, M. E., Seeger, L. L., Taljanovic, M., Wise, J. N. & Lutz, S. T.  
12 (2010) ACR Appropriateness Criteria on Metastatic Bone Disease. JACR Journal of the American  
13 College of Radiology, 7: June.  
14 Exclusion reason : expert review
- 15 Romera, M., Heras, I., Castilla, C., Nieto, J. B., Manchado, J. J., Perez-Ceballos, E., Amigo, M. L.,  
16 Lozano, M. & Vicente, V. (2011) Clinical features and outcome of respiratory syncytial virus  
17 infection in 26 haematologic disorders patients. Bone Marrow Transplantation.Conference:  
18 European Group for Blood and Marrow Transplantation, EBMT 2011 Paris France.Conference  
19 Start: 20110403 Conference End: 20110406.Conference Publication: (var.pagings), 46: April.  
20 Exclusion reason : population not in PICO
- 21 Samson, D. (2001) Diagnosis and management of multiple myeloma. British Journal of Haematology,  
22 115.  
23 Exclusion reason : expert review
- 24 Scherber, R., Dueck, A. C., Johansson, P., Barbui, T., Barosi, G., Vannucchi, A. M., Passamonti, F.,  
25 Andreasson, B., Ferarri, M. L., Rambaldi, A., Samuelsson, J., Birgegard, G., Tefferi, A., Harrison, C.  
26 N., Radia, D. & Mesa, R. A. (2011) The Myeloproliferative Neoplasm Symptom Assessment Form  
27 (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood, 118:  
28 401-408.  
29 Exclusion reason : population not in PICO
- 30 Sethi, B., Butola, K. S. & Kumar, Y. (2012) A Diagnostic Dilemma: Waldenstrom's  
31 Macroglobulinemia/Plasma Cell Leukemia. Case Reports in Pathology Print, 2012: 271407.  
32 Exclusion reason : case report
- 33 Shebl, F. M., Warren, J. L., Eggers, P. W. & Engels, E. A. (2012) Cancer risk among elderly persons  
34 with end-stage renal disease: A population-based case-control study. BMC Nephrology, 13: 65.  
35 Exclusion reason : population not in PICO
- 36 Siddiqui, I., Bhally, H. S., Niaz, Q. & Burney, I. A. (2002) Tumor-induced hypercalcemia: predictors of  
37 early mortality. JPMA.The Journal of the Pakistan Medical Association, 52: Aug.  
38 Exclusion reason : population not in PICO
- 39 Silvestris, F., Cafforio, P., Tucci, M. & Dammacco, F. (2002) Negative regulation of erythroblast  
40 maturation by Fas-L+/TRAIL+ highly malignant plasma cells: A major pathogenetic mechanism of  
41 anemia in multiple myeloma. Blood, 99: 15.  
42 Exclusion reason : population not in PICO
- 43 Tandon, N. & Gupta, S. (2014) - Cryptosporidiosis causing severe persistent diarrhea in a patient with  
44 multiple myeloma: A Case report and brief review of literature. - *Indian journal of medical and  
45 paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology*, 35: 93-  
46 95.  
47 Exclusion reason : Not in PICO
- 48 Teo, W. Y., Chan, M. Y., Ng, K. C. & Tan, A. M. (2012) Bony presentations of childhood  
49 haematological malignancy to the emergency room. Journal of Paediatrics & Child Health, 48:  
50 311-316.  
51 Exclusion reason : cases only

1 Tucci, M., Grinello, D., Cafforio, P., Silvestris, F. & Dammacco, F. (2002) Anemia in multiple myeloma:  
2 role of deregulated plasma cell apoptosis. [Review] [44 refs]. *Leukemia & Lymphoma*, 43: 1527-  
3 1533.

4 Exclusion reason : population not in PICO

5 Udiawar, M., Bejnariu, C. & Davies, S. (2012) Metastatic haematological malignancy presenting as a  
6 sellar mass. *BMJ Case Reports*, 2012, 2012.

7 Exclusion reason : case report

8 Varma, S., Varma, N., Reddy, V., Naseem, S., Bose, P. & Malhotra, P. (2012) Detection of paroxysmal  
9 nocturnal hemoglobinuria-phenotype in patients with chronic lymphocytic leukemia and multiple  
10 myeloma. *Indian Journal of Pathology and Microbiology*, 55: April-June.

11 Exclusion reason : population not in PICO

12 Waldmann, A., Barragan, B., Cursaru, V., Heberlein, C., Hrianka, M., Richter, F. & Sadzuga, R. (2010)  
13 Detecting myeloma-ways to shortening an often painful and tedious patient odyssey: Results  
14 from an international survey conducted by myeloma euronet, The European network of myeloma  
15 patient groups. *Haematologica*.Conference: 15th Congress of the European Hematology  
16 Association, EHA 2010 Barcelona Spain.Conference Start: 20100610 Conference End:  
17 20100613.Conference Publication: (var.pagings), 95: June.

18 Exclusion reason : cases only

19 Weckmann, M. (2012) Delirium incidence and cause in younger hospitalized patients with advanced  
20 cancer. *Journal of Pain and Symptom Management*.Conference: Annual Assembly of the  
21 American Academy of Hospice and Palliative Medicine and the Hospice and Palliative Nurses  
22 Association 2012 Denver, CO United States.Conference Start: 20120307 Conference End: 2012,  
23 43: February.

24 Exclusion reason : population not in PICO

25 Zagroda, M., Prystupa, A. & Mosiewicz, J. (2013) Diverse clinical presentation in the course of  
26 multiple myeloma. *Family Medicine and Primary Care Review*, 15: 423-425.

27 Exclusion reason : Not in PICO

## 29 Review question:

30 Which investigations of symptoms of suspected myeloma should be done with clinical responsibility  
31 retained by primary care?  
32

## 33 Results

### 34 Literature search

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1980-2013	618	49	08/04/2013
<i>Premedline</i>	1980-2013	39	11	08/04/2013
<i>Embase</i>	1980-2013	636	54	08/04/2013
<i>Cochrane Library</i>	1980-2013	646	3	09/04/2013
<i>Psychinfo</i>	1980-2013	2	0	08/04/2013
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	1980-2013	66	11	09/04/2013


35 Total References retrieved (after de-duplication): 109

### 36 Update Search

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	4/2013-19/08/2014	15	0	19/08/2014

<b>Premedline</b>	4/2013-19/08/2014	49	5	19/08/2014
<b>Embase</b>	4/2013-19/08/2014	52	4	19/08/2014
<b>Cochrane Library</b>	4/2013-19/08/2014	345	0	19/08/2014
<b>Web of Science (SCI &amp; SSCI) and ISI Proceedings</b>	4/2013-19/08/2014	5	1	19/08/2014

1 Total References retrieved (after de-duplication): 8



4

5

6 **Study results**

7 No evidence was identified pertaining to the diagnostic accuracy of paraprotein/serum  
 8 electrophoresis/Bence-Jones protein tests, ESR, X-ray, viscosity or calcium tests in patients with  
 9 suspected myeloma cancer where the clinical responsibility was retained by primary care.

10

11 **References**

12 **Included studies**

13 None

14

15 **Excluded studies (with excl reason)**

16 (2002) Can blood tests detect cancer early? Health News, 8: 4.

17 Exclusion reason : expert review

18 Abadie, J. M. & Bankson, D. D. (2006) Assessment of serum free light chain assays for plasma cell  
 19 disorder screening in a Veterans Affairs population. Annals of Clinical & Laboratory Science, 36:  
 20 157-162.



- 1 Exclusion reason : screening study
- 2 Abi-Fadel, F., Desai, N. R., Vatandoust, G., Said, R., Gottesman, A. & Terjanian, T. (2010) Monoclonal  
3 gammopathy of undetermined significance with amyloid deposition in the lung and non-amyloid  
4 eosinophilic deposition in the brain: a case report. *Case Reports in Medicine*, 2010: 406102.
- 5 Exclusion reason : case report
- 6 Adam, Z., Bednarik, J., Neubauer, J., Chaloupka, R., Fojtik, Z., Vanicek, J., Pour, L., Cermakova, Z.,  
7 Scudla, V., Maisnar, V., Straub, J., Schutzova, M., Gregora, E., Weinreb, M., Stuchlikova, K.,  
8 Stanicek, J., Hajek, R., Krejci, M., Vorlicek, J. & Czech Myeloma Society (2006) [Recommendations  
9 for early identification of damage to the skeleton by malignant processes, and for early diagnosis  
10 of multiple myeloma]. [Czech]. *Vnitřní Lekarství*, 52: Suppl-31.
- 11 Exclusion reason : expert review
- 12 Adam, Z., Bednarik, J., Neunauer, J., Chaloupka, R., Vorlicek, J., Vanicek, J., Pour, L., Cermakova, Z.,  
13 Weinreb, M., Scudla, V., Maisnar, V., Straub, J., Schutzova, M. & Gregora, E. (2006)  
14 Recommended diagnostic steps for general practitioners attending patients with difficulties that  
15 could indicate multiple myeloma. [Czech]. *Praktický Lekar*, 86: 396-410.
- 16 Exclusion reason : repeat publication
- 17 Adam, Z., Bolcak, K., Stanicek, J., Buchler, T., Pour, L., Krejci, M., Prasek, J., Neubauer, J., Vorlicek, J. &  
18 Hajek, R. (2007) Fluorodeoxyglucose positron emission tomography in multiple myeloma, solitary  
19 plasmocytoma and monoclonal gammopathy of unknown significance. *Neoplasma*, 54: 536-540.
- 20 Exclusion reason : population not in PICO
- 21 Ahmad, M. (2007) Continuous ambulatory peritoneal dialysis in patients with renal failure due to  
22 multiple myeloma. *International Urology & Nephrology*, 39: 629-633.
- 23 Exclusion reason : population not in PICO
- 24 Albain, K. S., Unger, J. M., Crowley, J. J., Coltman, C. A., Jr. & Hershman, D. L. (2009) Racial disparities  
25 in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.  
26 *Journal of the National Cancer Institute*, 101: 984-992.
- 27 Exclusion reason : population not in PICO
- 28 Almeshhedani, M., Salamat, A. & Al-Ismail, S. (2009) Evaluating the potential use of risk  
29 categorisation in the management of MGUS. *Haematologica*, 94: 389-390.
- 30 Exclusion reason : population not in PICO
- 31 Alvarez-Cordoves, M. M., Mirpuri-Mirpuri, P. G. & Perez-Monje, A. (2013) [Diagnosis of multiple  
32 myeloma in primary care. Suspicion with an appropriate clinical history]. [Spanish]. *Semergen  
33 Sociedad Espanola de Medicina Rural y Generalista*, 39: e21-e24.
- 34 Exclusion reason : Narrative review
- 35 Artz, A. S. & Thirman, M. J. (2011) Unexplained anemia predominates despite an intensive evaluation  
36 in a racially diverse cohort of older adults from a referral anemia clinic. *Journals of Gerontology  
37 Series A-Biological Sciences & Medical Sciences*, 66: 925-932.
- 38 Exclusion reason : population not in PICO
- 39 Barlogie, B., Epstein, J., Selvanayagam, P. & Alexanian, R. (1989) Plasma cell myeloma--new  
40 biological insights and advances in therapy. [Review] [172 refs]. *Blood*, 73: 865-879.
- 41 Exclusion reason : expert review
- 42 Bassani-Sternberg, M., Barnea, E., Beer, I., Avivi, I., Katz, T. & Admon, A. (2009) Cancer diagnostics  
43 based analysis of the serum soluble hla class I peptidome. *European Journal of Immunology*, 39:  
44 S609-S610.
- 45 Exclusion reason : population not in PICO
- 46 Behdad, A., Ross, C. W., Jacques, J., Kota, U., Brown, N. A., Keren, D. & Stoolman, L. (2013) Utility of  
47 9-color, 11-parameter flow cytometry for detection of plasma cell neoplasms: A comparison with  
48 bone marrow morphologic findings and concurrent M-protein studies in serum and urine. *Blood*,  
49 122.
- 50 Exclusion reason : Not in PICO

- 1 Bergesio, F., Ciciani, A. M., Santostefano, M., Brugnano, R., Manganaro, M., Palladini, G., Palma, A.  
2 M. D., Gallo, M., Tosi, P. L. & Salvadori, M. (2007) Renal involvement in systemic amyloidosis - An  
3 Italian retrospective study on epidemiological and clinical data at diagnosis. *Nephrology Dialysis*  
4 *Transplantation*, 22: 1608-1618.  
5 Exclusion reason : population not in PICO
- 6 Bhatnagar, N., Rabin, N., West, P. & Luckit, J. (2010) Detection and referral of serum paraproteins  
7 identified by discretionary testing. *British Journal of Haematology*, 149: 79-80.  
8 Exclusion reason : cases only
- 9 Bianchi, G., Richardson, P. G. & Anderson, K. C. (2014) Best Treatment Strategies in High-Risk  
10 Multiple Myeloma: Navigating a Gray Area. *Journal of Clinical Oncology*, 32: 2125-2132.  
11 Exclusion reason : Not in PICO
- 12 Bowden, M., Crawford, J., Cohen, H. J. & Noyama, O. (1993) A comparative study of monoclonal  
13 gammopathies and immunoglobulin levels in Japanese and United States elderly.[Erratum  
14 appears in *J Am Geriatr Soc* 1993 Jun;41(6):622]. *Journal of the American Geriatrics Society*, 41:  
15 11-14.  
16 Exclusion reason : screening study
- 17 Buchner-Daley, L., Brady-West, D. & McGrowder, D. (2012) n, cases only Clinical and Biochemical  
18 Profile of Monoclonal Gammopathies in Caribbean Patients in a Resource-limited Setting. *Asian*  
19 *Pacific Journal of Cancer Prevention: Apjcp*, 13: 6501-6504.  
20 Exclusion reason : cases only
- 21 Burkhardt, R., Frisch, B. & Kettner, G. (1980) The clinical study of micro-metastatic cancer by bone  
22 biopsy. *Bulletin du Cancer*, 67: 291-305.  
23 Exclusion reason : population not in PICO
- 24 Chan, D. T., Craig, K., Donovan, K. & Phillips, A. (2006) Myeloma renal disease: presentation and  
25 outcome. *Nephron*, 104: c126-c131.  
26 Exclusion reason : population not in PICO
- 27 Chang, H., Stewart, A. K., Qi, X. Y., Li, Z. H., Yi, Q. L. & Trudel, S. (2005) Immunohistochemistry  
28 accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. *Blood*, 106: 353-  
29 355.  
30 Exclusion reason : test not in PICO
- 31 Chennuru, S., Koduri, J. & Baumann, M. A. (2008) Risk factors for symptomatic hypocalcaemia  
32 complicating treatment with zoledronic acid. *Internal Medicine Journal*, 38: 635-637.  
33 Exclusion reason : population not in PICO
- 34 Chew, S. T., Fitzwilliam, J., Indridason, O. S. & Kovalik, E. C. (1999) Role of urine and serum protein  
35 electrophoresis in evaluation of nephrotic-range proteinuria. *American Journal of Kidney*  
36 *Diseases*, 34: 135-139.  
37 Exclusion reason : population not in PICO
- 38 He, Y., Wheatley, K., Glasmacher, A., Ross, H., Djulbegovic, B. (2003). Early versus deferred treatment  
39 for early stage multiple myeloma. *Cochrane Database of Systematic Reviews*, issue 1.  
40 Exclusion reason : test not in PICO
- 41 Cohen, H. J., Crawford, J., Rao, M. K., Pieper, C. F. & Currie, M. S. (1998) Racial differences in the  
42 prevalence of monoclonal gammopathy in a community-based sample of the elderly.[Erratum  
43 appears in *Am J Med* 1998 Oct;105(4):362]. *American Journal of Medicine*, 104: 439-444.  
44 Exclusion reason : screening study
- 45 Cohen, Y., Gutwein, O., Garach-Jehoshua, O., Bar-Haim, A. & Kornberg, A. (2013) GPRC5D is a  
46 promising marker for monitoring the tumor load and to target multiple myeloma cells.  
47 *Hematology*, 18: 348-351.  
48 Exclusion reason : Not in PICO
- 49 Colon-Emeric, C., Yballe, L., Sloane, R., Pieper, C. F. & Lyles, K. W. (2000) Expert physician  
50 recommendations and current practice patterns for evaluating and treating men with  
51 osteoporotic hip fracture. *Journal of the American Geriatrics Society*, 48: 1261-1263.

- 1 Exclusion reason : population not in PICO  
2 Comenzo, R. L. (2009) How I treat amyloidosis. *Blood*, 114: 3147-3157.
- 3 Exclusion reason : expert review  
4 Coyne, M. R. E., Wellik, L., Braggio, E., O'Dwyer, M. E., Santocanale, C., Valdez, R., Bergsagel, P. L. &  
5 Chesi, M. (2011) Examining measures of proliferation for use in risk stratification of myeloma.  
6 *Blood*, 118.
- 7 Exclusion reason : expert review  
8 Cronin, C. G., Cashell, T., Mhuirheartaigh, J. N., Swords, R., Murray, M., O'Sullivan, G. J. & O'Keeffe,  
9 D. (2009) Bone biopsy of new suspicious bone lesions in patients with primary carcinoma:  
10 prevalence and probability of an alternative diagnosis. *AJR.American Journal of Roentgenology*,  
11 193: W407-W410.
- 12 Exclusion reason : population not in PICO  
13 Decaux, O., Cuggia, M., Ruelland, A., Cazalets, C., Cador, B., Jego, P. & Grosbois, B. (2006)  
14 [Monoclonal gammopathies of undetermined significance and their progression over time.  
15 Retrospective study of 190 patients]. [French]. *Presse Medicale*, 35: 1143-1150.
- 16 Exclusion reason : population not in PICO  
17 Desport, E., Bridoux, F., Sirac, C., Delbes, S., Bender, S., Fernandez, B., Quellard, N., Lacombe, C.,  
18 Goujon, J. M., Lavergne, D., Abraham, J., Touchard, G., Femand, J. P. & Jaccard, A. (2012) AL  
19 Amyloidosis. *Orphanet Journal of Rare Diseases*, 7.
- 20 Exclusion reason : expert review  
21 Dharmarajan, T. S. & Thadisina, S. (2011) Anemia in the old: Possible indicator of serious underlying  
22 disease,warrants evaluation. S. Thadisina MD, RO Russell MD, TS Dharmarajan MD, AGSF  
23 Montefiore Medical Center (North), Bronx, NY. *Journal of the American Geriatrics Society*, 59:  
24 S120.
- 25 Exclusion reason : case report  
26 Djunic, I. S., Elezovic, I., Milosevic-Jovcic, N., Ilic, V., Antic, D., Vidovic, A. & Tomin, D. (2009) Acquired  
27 von Willebrand syndrome in patients with multiple myeloma. *Journal of Thrombosis and*  
28 *Haemostasis*, 7: 841.
- 29 Exclusion reason : population not in PICO  
30 Doyle, A., Soutar, R. & Geddes, C. C. (2009) Multiple myeloma in chronic kidney disease. Utility of  
31 discretionary screening using serum electrophoresis. *Nephron*, 111: c7-11.
- 32 Exclusion reason : screening study  
33 Doyle, L. M., Gundrum, J. D., Farnen, J. P., Wright, L. J., Kranig, J. A. I. & Go, R. S. (2009) Determining  
34 why and which clinicians order serum protein electrophoresis (SPEP), subsequent diagnoses  
35 based on indications, and clinical significance of routine follow-up: A study of patients with  
36 monoclonal gammopathy of undetermined significance (MGUS). *Blood*, 114.
- 37 Exclusion reason : population not in PICO  
38 Dunfack, G., V, Bertaud, G., V, Duvaufferrier, R., Bourde, A., Morelli, J. & Lasbleiz, J. (2012) Ontology  
39 driven decision support systems for medical diagnosis - an interactive form for consultation in  
40 patients with plasma cell disease. *Studies in Health Technology & Informatics*, 180: 108-112.
- 41 Exclusion reason : test not in PICO  
42 Durham, B. H., Afify, A., Jess, H., Song, J. Y., Dwyre, D. M. & Chen, M. (2013) Pragmatic algorithm for  
43 improving the diagnostic quality of fine needle aspiration cytopathology in the classification of  
44 hematolymphoid proliferations. *Laboratory Investigation*, 93: 474A.
- 45 Exclusion reason : population not in PICO  
46 Elis, A., Radnay, J., Shapiro, H., Itzhaky, D., Manor, Y. & Lishner, M. (2006) Should bone marrow  
47 examination be routinely performed for the diagnosis of monoclonal gammopathy of  
48 undetermined significance? *Israel Medical Association Journal: Imaj*, 8: 840-842.
- 49 Exclusion reason : population not in PICO  
50 Ferrero, S., Capello, D., Svaldi, M., Boi, M., Gatti, D., Drandi, D., Rossi, D., Barbiero, S., Mantoan, B.,  
51 Mantella, E., Zanni, M., Ghione, P., Larocca, A., Passera, R., Bertoni, F., Gattei, V., Forconi, F.,

- 1 Laurenti, L., Del, P. G., Marasca, R., Cortelazzo, S., Gaidano, G., Palumbo, A., Boccadoro, M. &  
2 Ladetto, M. (2012) Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy  
3 chain genes. *Haematologica*, 97: 849-853.  
4 Exclusion reason : test not in PICO
- 5 Eslick, R. & Talaulikar, D. (2013) Multiple myeloma: from diagnosis to treatment. *Australian Family  
6 Physician*, 42: 684-688.  
7 Exclusion reason : Narrative review
- 8 Fonseca, R. & Stewart, A. K. (2007) Targeted therapeutics for multiple myeloma: the arrival of a risk-  
9 stratified approach. [Review] [98 refs]. *Molecular Cancer Therapeutics*, 6: 802-810.  
10 Exclusion reason : expert review
- 11 Fuchida, S., Okano, A., Hatsuse, M., Murakami, S., Haruyama, H. & Shimazaki, C. (2012) [Successful  
12 treatment with lenalidomide plus dexamethasone for multiple myeloma complicated with  
13 systemic amyloidosis]. [Japanese]. *Rinsho Ketsueki - Japanese Journal of Clinical Hematology*, 53:  
14 1937-1939.  
15 Exclusion reason : case report
- 16 Fujimi, A., Hashimoto, A., Kanisawa, Y., Okuda, T., Minami, S., Doi, T., Matsuno, T., Ishikawa, K. &  
17 Uemura, N. (2013) Loss of CD23 expression after bortezomib plus dexamethasone therapy in  
18 CCND1/IGH-positive multiple myeloma. *Rinsho Ketsueki - Japanese Journal of Clinical  
19 Hematology*, 54: 224-228.  
20 Exclusion reason : case report
- 21 Gala, J. L., McLachlan, J. M., Bell, D. R., Michaux, J. L. & Ma, D. D. (1994) Specificity and sensitivity of  
22 immunocytochemistry for detecting P-glycoprotein in haematological malignancies. *Journal of  
23 Clinical Pathology*, 47: 619-624.  
24 Exclusion reason : population not in PICO
- 25 Galhotra, R., Saggar, K., Gupta, K. & Singh, P. (2012) Primary isolated extramedullary plasmacytoma  
26 of mesentery: A rare case report. *The gulf journal of oncology*, 1: 81-84.  
27 Exclusion reason : case report
- 28 Garrett, K. M., Hoffer, F. A., Behm, F. G., Gow, K. W., Hudson, M. M. & Sandlund, J. T. (2002)  
29 Interventional radiology techniques for the diagnosis of lymphoma or leukemia. *Pediatric  
30 Radiology*, 32: 653-662.  
31 Exclusion reason : population not in PICO
- 32 Gkotzamanidou, M., Terpos, E., Papatheodorou, A., Eleutherakis-Papaiakovou, E., Dimopoulos, M. A.  
33 & Kastiris, E. (2011) Circulating angiogenic cytokines are elevated in patients with smoldering  
34 myeloma; Implications into disease biology. *Blood*, 118.  
35 Exclusion reason : population not in PICO
- 36 Gleeson, T. G., Moriarty, J., Shortt, C. P., Gleeson, J. P., Fitzpatrick, P., Byrne, B., McHugh, J.,  
37 O'Connell, M., O'Gorman, P. & Eustace, S. J. (2009) Accuracy of whole-body low-dose  
38 multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and  
39 correlation of disease distribution with whole-body MRI (WBMRI). *Skeletal Radiology*, 38: 225-  
40 236.  
41 Exclusion reason : test not in PICO
- 42 Grey, M. R. & Kelsey, P. (1998) Delayed diagnosis and unnecessary percutaneous biopsies in cases of  
43 myeloma presenting as chest wall tumours. *Clinical and Laboratory Haematology*, 20: 259-262.  
44 Exclusion reason : not primary care
- 45 Grosbois, B., Decaux, O., Guenet, L., Goasguen, J. & Jegou, P. (1085) [Nosology and management of  
46 monoclonal gammopathy]. [French]. *Bulletin de l'Academie Nationale de Medecine*, 193: 1069-  
47 1085.  
48 Exclusion reason : expert review
- 49 Hallek, M., Neumann, C., Schaffer, M., Danhauser-Riedl, S., von, B. N., de, V. G., Druker, B. J.,  
50 Yasukawa, K., Griffin, J. D. & Emmerich, B. (1997) Signal transduction of interleukin-6 involves

- 1 tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn,  
2 Hck, and Lyn in multiple myeloma cell lines. *Experimental Hematology*, 25: 1367-1377.
- 3 Exclusion reason : population not in PICO
- 4 Heringer, L. & Crevensten, H. (2010) Recurrent paralysis due to hyperthyroidism causing  
5 hypokalemia. *Journal of General Internal Medicine*, 25: S544-S545.
- 6 Exclusion reason : case report
- 7 Hofmeister, C. C., Yang, X., Pichiorri, F., Chen, P., Rozewski, D. M., Johnson, A. J., Lee, S., Liu, Z., Garr,  
8 C. L., Hade, E. M., Ji, J., Schaaf, L. J., Benson, D. M., Jr., Kraut, E. H., Hicks, W. J., Chan, K. K., Chen,  
9 C. S., Farag, S. S., Grever, M. R., Byrd, J. C. & Phelps, M. A. (2011) Phase I trial of lenalidomide and  
10 CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779  
11 interaction via P-glycoprotein. *Journal of Clinical Oncology*, 29: 3427-3434.
- 12 Exclusion reason : population not in PICO
- 13 Howell, D. A., Smith, A. G., Jack, A., Patmore, R., Macleod, U., Mironska, E. & Roman, E. (2013) Time-  
14 to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the  
15 Haematological Malignancy Research Network. *BMC Hematology*, 13: 9.
- 16 Exclusion reason : Not in PICO
- 17 Hu, H., Wang, L., Xu, H., Peng, J. & Jia, Y. (2014) - Clinical analysis of six cases of multiple myeloma  
18 first presenting with coagulopathy. - *Blood Coagulation & Fibrinolysis*, 25: 553-556.
- 19 Exclusion reason : Not in PICO
- 20 Ichikawa, T. & Kumazaki, T. (2000) Clinical usefulness of computed tomography arteriography and  
21 computed tomography during arterial portography for the diagnosis of early and early advanced  
22 hepatocellular carcinoma. *Journal of Nippon Medical School = Nihon Ika Daigaku Zasshi*, 67: 105-  
23 109.
- 24 Exclusion reason : population not in PICO
- 25 Jakubowska-Pietkiewicz, E., Szczepaniak-Kubat, A., Zalewska-Szewczyk, B. & Chlebna-Sokol, D. (2010)  
26 Skeletal status at diagnosis in children with hematologic malignancy - Pilot study. *Advances in  
27 Clinical and Experimental Medicine*, 19: 531-535.
- 28 Exclusion reason : population not in PICO
- 29 Jauch, A., Neben, K., Hielscher, T., Hillengass, J., Lehnert, N., Raab, S. R., Hose, D., Granzow, M., Ho,  
30 A. D., Goldschmidt, H. & Bartram, C. R. (2013) The chromosomal abnormalities deletion 17p13,  
31 t(4;14), and gain 1q21 predict progression from smoldering to symptomatic multiple myeloma.  
32 *Medizinische Genetik*, 25: 105-106.
- 33 Exclusion reason : population not in PICO
- 34 Jin, X., Chen, Y., Yu, N., Zuo, X., Song, S., Yin, X., Huang, Y., Zhang, W. & Chen, J. (2013) Detection of  
35 galactomannan and (1-3)-beta-D-glucan for early diagnosis of invasive Aspergillosis in  
36 hematological cancer patients. *International Journal of Pharmacology*, 9: 86-91.
- 37 Exclusion reason : population not in PICO
- 38 Kitamura, M., Yamaguchi, H., Murakawa, K., Murao, T. & Iizuka, Y. (1982) Screening for multiple  
39 myeloma using routine laboratory test results. *Clinical Biochemistry*, 15: 17-21.
- 40 Exclusion reason : population not in PICO
- 41 Kleber, M., Hieke, S., Koch, B., Ihorst, G., Wasch, R., Schumacher, M. & Engelhardt, M. (2012)  
42 Conditional survival analysis in a large cohort of multiple myeloma patients provides detailed  
43 information about long-term survival and constitutes a different way to identify patients with  
44 extended life expectancy. *Blood*, 120.
- 45 Exclusion reason : not primary care
- 46 Klincova, M., Mikulasova, A., Kovarova, L., Sandecka, V., Radocha, J., Maisnar, V., Adam, Z., Krejci,  
47 M., Pour, L., Zahradova, L., Krivanova, A., Szturz, P. & Hajek, R. (2011) Prognosis of high-risk group  
48 of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple  
49 myeloma (SMM). [Czech]. *Onkologie*, 5: 146-150.
- 50 Exclusion reason : expert review

- 1 Krishnarmannam, V., Gilbert, W., Green, T., Santos, M., Goodin, J., Lewis, R. E. & Cruse, J. M. (2012)  
2 HLA-A\*7401 and HLA-c\*0401 allelic disease association with plasma cell neoplasia. *FASEB*  
3 *Journal*, 26.  
4 Exclusion reason : test not in PICO
- 5 Kyle, R. A. & Rajkumar, S. V. (2007) Monoclonal Gammopathy of Undetermined Significance and  
6 Smoldering Multiple Myeloma. *Hematology/Oncology Clinics of North America*, 21: 1093-1113.  
7 Exclusion reason : expert review
- 8 Kyrtonis, M.-C., Dedoussis, G., Zervas, C., Perifanis, V., Baxevanis, C., Stamatelou, M. & Maniatis, A.  
9 (1996) Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma.  
10 *British Journal of Haematology*, 93: 398-400.  
11 Exclusion reason : test not in PICO
- 12 Lammeren-Venema, D., Regelink, J. C., Riphagen, I. I., Zweegman, S., Hoekstra, O. S. & Zijlstra, J. M.  
13 (2012) 18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-  
14 related bone disease: a systematic review (DARE structured abstract). *Cancer*, 118: 1971-1981.  
15 Exclusion reason : test not in PICO
- 16 Li, N., Lv, Y., Zeng, H., He, F., Yao, Y. & He, X. (2012) Renal impairment in multiple myeloma:  
17 presenting features in different departments. *Journal of Huazhong University of Science and*  
18 *Technology.Medical Sciences*, 32: 65-68.  
19 Exclusion reason : population not in PICO
- 20 Magee, C., Vella, J. P., Tormey, W. P. & Walshe, J. J. (1998) Multiple myeloma and renal failure: one  
21 center's experience. *Renal Failure*, 20: 597-606.  
22 Exclusion reason : not primary care
- 23 Magony, S., Valkusz, Z., Csajbok, E., Sepp, K., Gardi, J., Szecsi, M., Julesz, J. & Wittmann, T. (2013) [In  
24 the labyrinth of calcium metabolism]. [Hungarian]. *Orvosi Hetilap*, 154: 351-355.  
25 Exclusion reason : case report
- 26 Malik, D. B. & Aggarwal, S. (2014) Normolipemic xanthomas; A rare cutaneous finding leading to  
27 diagnosis of multiple myeloma. *Journal of General Internal Medicine*, 29: S396-S397.  
28 Exclusion reason : Not in PICO
- 29 Martinez, A., Aymerich, M., Castillo, M., Colomer, D., Bellosillo, B., Campo, E. & Villamor, N. (2003)  
30 Routine use of immunophenotype by flow cytometry in tissues with suspected hematological  
31 malignancies. *Cytometry Part B, Clinical Cytometry*, 56: 8-15.  
32 Exclusion reason : test not in PICO
- 33 Mbagaya, W. & Barth, J. H. (2011) Hyperlipidaemia as initial presentation of myeloma.  
34 *Atherosclerosis*, 218: e6-e7.  
35 Exclusion reason : case report
- 36 Mohr, R. & Gross, R. (1980) Plasmocytoma. [German]. *Deutsches Arzteblatt*, 77: 2721-2727.  
37 Exclusion reason : expert review
- 38 Mylin, A. K., Rasmussen, T., Johansen, J. S., Knudsen, L. M., Norgaard, P. H., Lenhoff, S., Dahl, I. M.,  
39 Johnsen, H. E. & Nordic Myeloma Study Group (2006) Serum YKL-40 concentrations in newly  
40 diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells. *European*  
41 *Journal of Haematology*, 77: 416-424.  
42 Exclusion reason : test not in PICO
- 43 Nageshwaran, S., Majumdar, K. & Russell, S. (2012) Hypergammaglobulinemia, normal serum  
44 albumin and hypercalcaemia: a case of systemic sarcoidosis with initial diagnostic confusion. *BMJ*  
45 *Case Reports*, 2012, 2012.  
46 Exclusion reason : case report
- 47 Nau, K. C. & Lewis, W. D. (2008) Multiple myeloma: Diagnosis and treatment. *American Family*  
48 *Physician*, 78: 853-859.  
49 Exclusion reason : expert review
- 50 Ninomiya, S., Fukuno, K., Kanemura, N., Goto, N., Kasahara, S., Yamada, T., Tsurumi, H. & Moriwaki,  
51 H. (2010) IgG type multiple myeloma and concurrent IgA type monoclonal gammopathy of

- 1 undetermined significance complicated by necrotizing skin ulcers due to type I cryoglobulinemia.  
2 Journal of Clinical & Experimental Hematopathology, 50: 71-74.
- 3 Exclusion reason : case report
- 4 O'Connell, T. X., Horita, T. J. & Kasravi, B. (2005) Understanding and interpreting serum protein  
5 electrophoresis. American Family Physician, 71: 105-112.
- 6 Exclusion reason : not primary care
- 7 Ong, F., Hermans, J., Noordijk, E. M., Wijermans, P. W., Seelen, P. J., de Kieviet, W., Gerrits, W. B. J.,  
8 Kluin, P. M. & Kluin-Nelemans, J. C. (1997) A population-based registry on paraproteinaemia in  
9 the Netherlands. British Journal of Haematology, 99: 914-920.
- 10 Exclusion reason : population not in PICO
- 11 Palladini, G., Russo, P., Bosoni, T., Verga, L., Sarais, G., Lavatelli, F., Nuvolone, M., Obici, L., Casarini,  
12 S., Donadei, S., Albertini, R., Righetti, G., Marini, M., Graziani, M. S., D'Eril, G. V. M., Moratti, R. &  
13 Merlini, G. (2009) Identification of Amyloidogenic Light Chains Requires the Combination of  
14 Serum-Free Light Chain Assay with Immunofixation of Serum and Urine. Clinical Chemistry, 55:  
15 499-504.
- 16 Exclusion reason : test not in PICO
- 17 Papageorgiou, A., Ziakas, P. D., Tzioufas, A. G. & Voulgarelis, M. (2013) Indications for bone marrow  
18 examination in autoimmune disorders with concurrent haematologic alterations. Clinical &  
19 Experimental Rheumatology, 31: 76-83.
- 20 Exclusion reason : population not in PICO
- 21 Peruzzi, B., Carretti, F., Rondelli, T., Caporale, R., Fanelli, A. & Grazia Gelli, A. M. (2012) Seven-color  
22 flow cytometry for evaluation of bone marrow plasma cells disorders: Different aberrant  
23 phenotype with different aggressiveness. Cytometry Part B - Clinical Cytometry, 82B: 401-402.
- 24 Exclusion reason : test not in PICO
- 25 Pettersson, D., Mellstedt, H. & Holm, G. (1980) Immunoglobulin isotypes on monoclonal blood  
26 lymphocytes in human plasma cell myeloma. Journal of Clinical & Laboratory Immunology, 3: 93-  
27 98.
- 28 Exclusion reason : test not in PICO
- 29 Portier, M., Lees, D., Caron, E., Jourdan, M., Boiron, J. M., Bataille, R. & Klein, B. (1992) Up-regulation  
30 of interleukin (IL)-6 receptor gene expression in vitro and in vivo in IL-6 deprived myeloma cells.  
31 FEBS Letters, 302: 35-38.
- 32 Exclusion reason : population not in PICO
- 33 Rajeswaran, C., Spencer, J., Barth, J. H. & Orme, S. M. (2007) Utility of biochemical screening in the  
34 context of evaluating patients with a presumptive diagnosis of osteoporosis. Clinical  
35 Rheumatology, 26: 362-365.
- 36 Exclusion reason : population not in PICO
- 37 Ramon Rodriguez, L. G., Rivera-Keeling, C., Arencibia-Nunez, A., Avila-Cabrera, O. M., Izquierdo-  
38 Cano, L., Espinosa-Estrada, E., Gonzalez-Pinedo, L., Quintero-Sierra, Y., Gutierrez-Diaz, A. &  
39 Hernandez-Padron, C. (2013) Clinical and laboratory characterization of multiple myeloma at the  
40 Institute of Hematology and Immunology. *Revista Cubana de Hematologia, Inmunologia y*  
41 *Hemoterapia*, 29: 382-397.
- 42 Exclusion reason : Not in PICO
- 43 Raza, S., TaherNazerHussain, F., Patnaik, M., Knudson, R., Van, D. D. & Tefferi, A. (2011) Autosomal  
44 monosomies among 24,262 consecutive cytogenetic studies: prevalence, chromosomal  
45 distribution and clinicopathologic correlates of sole abnormalities. American Journal of  
46 Hematology, 86: 353-356.
- 47 Exclusion reason : test not in PICO
- 48 Renuga, G., Babu, A. & Arumugam, K. R. (2008) Molecular characterization of plasma proteins to  
49 confirm the risk factor for regression to multiple myeloma. Asian Journal of Microbiology,  
50 Biotechnology and Environmental Sciences, 10: 229-234.
- 51 Exclusion reason : test not in PICO

- 1 Rimsza, L. M., Campbell, K., Dalton, W. S., Salmon, S., Willcox, G. & Grogan, T. M. (1999) The major  
2 vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in  
3 multiple myeloma. *Leukemia & Lymphoma*, 34: 315-324.
- 4 Exclusion reason : test not in PICO
- 5 Ross, J. R., Saunders, Y., Edmonds, P. M., Patel, S., Wonderling, D., Normand, C. & Broadley, K. (2004)  
6 A systematic review of the role of bisphosphonates in metastatic disease. [Review] [335 refs].  
7 *Health Technology Assessment (Winchester, England)*, 8: 1-176.
- 8 Exclusion reason : treatment study
- 9 Savini, P., Lanzi, A., Castagnari, B., Gollini, C., Re, G., Musardo, G. & Stefanini, G. F. (2009) Proposal  
10 for the management of the MGUS. *Haematologica*, 94: 244-245.
- 11 Exclusion reason : expert review
- 12 Schmidt, G. P., Schoenberg, S. O., Reiser, M. F. & Baur-Melnyk, A. (2005) Whole-body MR imaging of  
13 bone marrow. [Review] [40 refs]. *European Journal of Radiology*, 55: 33-40.
- 14 Exclusion reason : test not in PICO
- 15 Schmidt, G. P., Baur, A., Stäbler, A., Schoenberg, S. O., Steinborn, M., Baltin, V. & Reiser, M. F. (2005)  
16 [Estimation of diffuse bone marrow infiltration of the spine in multiple myeloma: correlation of  
17 MRT with histological results]. *RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der*  
18 *Nuklearmedizin*, 177: 745-750.
- 19 Exclusion reason : test not in PICO
- 20 Sethi, B., Butola, K. S. & Kumar, Y. (2012) A Diagnostic Dilemma: Waldenström's  
21 Macroglobulinemia/Plasma Cell Leukemia. *Case Reports in Pathology Print*, 2012: 271407.
- 22 Exclusion reason : case report
- 23 Shaheen, S. P. & Levinson, S. S. (2009) Serum free light chain analysis may miss monoclonal light  
24 chains that urine immunofixation electrophoreses would detect. *Clinica Chimica Acta*, 406: 162-  
25 166.
- 26 Exclusion reason : population not in PICO
- 27 Sharma, A., Tripathi, M., Satyam, A. & Kumar, L. (2009) Study of antioxidant levels in patients with  
28 multiple myeloma. *Leukemia & Lymphoma*, 50: 809-815.
- 29 Exclusion reason : test not in PICO
- 30 Smellie, W. S. A. & Spickett, G. P. (2006) Cases in primary care laboratory medicine - Paraprotein  
31 management. *British Medical Journal*, 333: 185-187.
- 32 Exclusion reason : editorial
- 33 Smith, D. B., Harris, M., Gowland, E., Chang, J. & Scarffe, J. H. (1986) Non-secretory multiple  
34 myeloma: a report of 13 cases with a review of the literature. *Hematological Oncology*, 4: 307-  
35 313.
- 36 Exclusion reason : cases only
- 37 Suzuki, S., Ikusaka, M., Miyahara, M. & Shikino, K. (2014) - Positron emission tomography findings in  
38 a patient with multiple myeloma of polymyalgia rheumatica-like symptoms caused by  
39 paraneoplastic syndrome. - *BMJ Case Reports*, 2014, 2014..
- 40 Exclusion reason : Not in PICO
- 41 Takemura, Y., Hayashi, K., Miyoshi, K., Mori, S., Kugai, N. & Sekiguchi, S. (1992) [Laboratory tests in  
42 primary care medicine: "essential laboratory tests" (2). Usefulness of hematological, biochemical  
43 and serological tests in diagnosis of new outpatients]. [Japanese]. *Rinsho Byori - Japanese Journal*  
44 *of Clinical Pathology*, 40: 403-409.
- 45 Exclusion reason : population not in PICO
- 46 Talbot, R. W., Bannister, J. J. & Hills, N. H. (1984) A haematuria diagnostic service in a district general  
47 hospital. *Annals of the Royal College of Surgeons of England*, 66: 348-350.
- 48 Exclusion reason : population not in PICO
- 49 Tate, J., Caldwell, G., Daly, J., Gillis, D., Jenkins, M., Jovanovich, S., Martin, H., Steele, R., Wienholt, L.  
50 & Mollee, P. (2012) Recommendations for standardized reporting of protein electrophoresis in  
51 Australia and New Zealand. *Annals of Clinical Biochemistry*, 49: 242-256.



- 1 Exclusion reason : expert review
- 2 Thakkinstian, A., Tran, H., Reeves, G., Murch, S. & Attia, J. (2008) A clinical decision rule to aid  
3 ordering of serum and urine protein electrophoresis for case-finding of paraproteins in  
4 hospitalized inpatients. *Journal of General Internal Medicine*, 23: 1688-1692.
- 5 Exclusion reason : not primary care
- 6 Van Zaanen, H. C., Lokhorst, H. M., Aarden, L. A., Rensink, H. J., Warnaar, S. O. & Van Oers, M. H.  
7 (1998) Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple  
8 myeloma: effects on soluble IL6 receptor and soluble gp130. *Leukemia & Lymphoma*, 31: 551-  
9 558.
- 10 Exclusion reason : test not in PICO
- 11 Vardiman, J. (2011) Classification of hematologic neoplasms: Current and future approaches for the  
12 myeloid neoplasms. *International Journal of Laboratory Hematology*, 33: 1-2.
- 13 Exclusion reason : expert review
- 14 Varshney, R., Deka, M., Bhattacharya, J. & Gogoi, P. K. (2012) Clinico-haematological analysis of  
15 haematological malignancy, a hospital based study. *Indian Journal of Hematology and Blood  
16 Transfusion*, 28: 245.
- 17 Exclusion reason : not primary care
- 18 Vieillard, M. H., Boutry, N., Chastanet, P., Duquesnoy, B., Cotten, A. & Cortet, B. (2005) Contribution  
19 of percutaneous biopsy to the definite diagnosis in patients with suspected bone tumor. *Joint,  
20 Bone, Spine: Revue du Rhumatisme*, 72: 53-60.
- 21 Exclusion reason : test not in PICO
- 22 Vladutiu, A. O. (1987) Prevalence of M-proteins in serum of hospitalized patients. Physicians'  
23 response to finding M-proteins in serum protein electrophoresis. *Annals of Clinical & Laboratory  
24 Science*, 17: 157-161.
- 25 Exclusion reason : test not in PICO
- 26 Wahane, R. N., Lele, V. R. & Bobhate, S. K. (2007) Fine needle aspiration cytology of bone tumors.  
27 *Acta Cytologica*, 51: 711-720.
- 28 Exclusion reason : test not in PICO
- 29 Waldmann, A., Barragan, B., Cursaru, V., Heberlein, C., Hrianka, M., Richter, F. & Sadzuga, R. (2010)  
30 Detecting myeloma-ways to shortening an often painful and tedious patient odyssey: Results  
31 from an international survey conducted by myeloma euronet, The European network of myeloma  
32 patient groups. *Haematologica*, 95: 389.
- 33 Exclusion reason : cases only
- 34 Watanaboonyongcharoen, P., Nakorn, T. N., Rojnuckarin, P., Lawasut, P. & Intragumtornchai, T.  
35 (2012) Prevalence of monoclonal gammopathy of undetermined significance in Thailand.  
36 *International Journal of Hematology*, 95: 176-181.
- 37 Exclusion reason : screening study
- 38 Wei, A. & Juneja, S. (2003) Bone marrow immunohistology of plasma cell neoplasms. *Journal of  
39 Clinical Pathology*, 56: 406-411.
- 40 Exclusion reason : test not in PICO
- 41 Wilson, A. B., Prout, M. N., Neogi, T. & Jick, S. (2012) The role of surveillance bias in the incidence of  
42 the myelodysplastic syndromes and chronic myeloproliferative disorders. *Pharmacoepidemiology  
43 and Drug Safety*, 21: 336.
- 44 Exclusion reason : test not in PICO
- 45 Zagroda, M., Prystupa, A. & Mosiewicz, J. (2013) Diverse clinical presentation in the course of  
46 multiple myeloma. *Family Medicine and Primary Care Review*, 15: 423-425.
- 47 Exclusion reason : Not in PICO
- 48 Zhang, H., Zhang, L., Wang, J., Ma, Y., Zhang, J., Mo, F., Zhang, W., Yan, S., Yang, G. & Lin, B. (2009)  
49 Proteomic analysis of bone tissues of patients with osteonecrosis of the femoral head. *Omics a  
50 Journal of Integrative Biology*, 13: 453-466.
- 51 Exclusion reason : test not in PICO

1 Zhang, L., Li, J., Yang, H., Luo, Z. & Zou, J. (2012) Histological evaluation of bone biopsy results during  
2 PVP or PKP of vertebral compression fractures. *Oncology Letters*, 5: 135-138.  
3 Exclusion reason : test not in PICO  
4 Zhang, S., Suvannasankha, A., Crean, C. D., White, V. L., Chen, C. S. & Farag, S. S. (2011) The novel  
5 histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and  
6 cell cycle arrest in multiple myeloma cells. *International Journal of Cancer*, 129: 204-213.  
7 Exclusion reason : test not in PICO  
8 Zima, T., Spicka, I., Stipek, S., Crkovska, J., Platenik, J., Merta, M. & Tesar, V. (1996) Antioxidant  
9 enzymes and lipid peroxidation in patients with multiple myeloma. *Neoplasma*, 43: 69-73.  
10 Exclusion reason : population not in PICO  
11  
12

**NON-HODGKIN'S LYMPHOMA****Review question:**

What is the risk of Non-Hodgkin's lymphoma in patients presenting in primary care with symptom(s)?

**Results****Literature search**


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	All-2012	1184	141	16/10/12
<i>Premedline</i>	All-2012	18	5	16/10/12
<i>Embase</i>	All-2012	856	102	18/10/12
<i>Cochrane Library</i>	All-2012	89	0	18/10/12
<i>Psychinfo</i>	All-2012	4	1	16/10/12
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	All-2012	71	26	18/10/12
<i>Biomed Central</i>	All-2012	244	9	18/10/12

Total References retrieved (after de-duplication): 256

**Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	10/2012-20/08/2014	48	2	20/08/2014
<i>Premedline</i>	10/2012-20/08/2014	44	7	20/08/2014
<i>Embase</i>	10/2012-20/08/2014	93	3	20/08/2014
<i>Cochrane Library</i>	10/2012-20/08/2014	78	0	20/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	10/2012-20/08/2014	12	0	20/08/2014

Total References retrieved (after de-duplication): 12



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12

**Risk of bias in the included studies**

The risk of bias and applicability concerns are summarised per study in the figure below. The main issue to note is that 2/3 studies employed samples of patients that are not directly representative of an unselected symptomatic population of patients presenting to the UK-based GP, and that there was some uncertainty about the verification of the outcome for some of the patients. Dommett (2012; 2013a,b) employed a case-control design which has been shown to inflate the test accuracy characteristics. However, the statistical analyses employed by the authors may have gone some way in counteracting this influence.

	<u>Risk of Bias</u>				<u>Applicability Concerns</u>		
	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard
Deyo (1988)	?	+	?	+	-	+	+
Dommett (2012, 2013)	-	+	+	+	+	+	+
Williamson (1985)	+	+	+	?	+	+	+

<span style="color: red;">-</span> High	<span style="color: yellow;">?</span> Unclear	<span style="color: green;">+</span> Low
---	---	--

13  
14  
15  
16  
17  
18

**Study results**

1 Table 1: Non-Hodgkin's lymphoma: Adult and mixed age populations

Study	Symptom(s)	Patient group	Result
Deyo (1988)	Back pain	All included patients	0.1 (0.02-0.41) 2/1975 7 had other types of cancer: lymphoma (NOS): N = 2, unknown primary: N = 1, Prostate: N = 1, retroperitoneal liposarcoma: N = 1, lung cancer: N = 1, renal cell: N = 1, multiple myeloma: N = 1, mucinous adenocarcinoma (of gallbladder?): N = 1
Williamson (1985)	Lymphadenopathy	All included patients	0.8 (0.1-3.2) TP = 2, FP = 247 Cancer: Hodgkin's: N = 1 Adenocarcinoma: N = 1

2 TP = True positives, FP = False positives.

3

4 Table 2: Non-Hodgkin's lymphoma: Positive predictive values for leukaemia/lymphoma childhood cancer

Study	Symptom(s)	Patient group	Positive predictive value (95% CI)
Domett (2013a)	Bruising 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.53 (0.07-3.91)
Domett (2013a)	Pallor 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.43 (0.06-3.15)
Domett (2013a)	Lump mass swelling head and neck 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.35 (0.05-2.65)
Domett (2013a)	Fatigue 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.07 (0.03-0.15)
Domett (2013a)	Lymphadenopathy 0-3 months before diagnosis	All included leukemia/lymphoma	0.06 (0.04-0.11)

		patients and controls aged 0-14 years	
Dommett (2013a)	Lump mass swelling below neck excluding abdomen 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.05 (0.02-0.13)
Dommett (2013a)	Bleeding 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.03 (0.01-0.08)
Dommett (2013a)	Pain 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.03 (0.01-0.06)
Dommett (2013a)	Musculoskeletal symptoms 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.02 (0.01-0.03)
Dommett (2013a)	Fever 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.01 (0.01-0.01)
Dommett (2013a)	Abdominal pain 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.01(0-0.01)
Dommett (2013a)	≥ 3 consultations	All included leukemia/lymphoma patients and controls aged 0-14 years	0.01(0.01-0.01)

1 The positive predictive values are calculated using Bayesian statistics.

2

3 Table 3: Non-Hodgkin's lymphoma: Positive predictive values for teenage and young adult lymphoma

4

Study	Symptom(s)	Patient group	Positive predictive value (95% CI) Frequency
Dommett (2013b)	Lump mass swelling head and neck	All included lymphoma patients and controls aged 15-24 years	0.5034 (0.0696-3.68) Cases: 35/270 Controls: 1/3350
Dommett (2013b)	Lump mass swelling below neck excluding abdomen	All included lymphoma patients and controls aged 15-24 years	0.0279 (0.0152-0.0515) Cases: 29/270 Controls: 15/3350
Dommett (2013b)	Lymphadenopathy	All included lymphoma patients and controls aged 15-24 years	0.278 (0.1-0.75) Cases: 77/270 Controls: 4/3350
Dommett (2013b)	'Lump mass swelling head and neck', 'lymphadenopathy' and 'lump mass swelling	All included lymphoma patients and controls aged 15-24 years	0.0903 (0.057-0.1425)

	below neck excluding abdomen' combined as a single symptom		
Dommett (2013b)	≥ 3 consultations	All included lymphoma patients and controls aged 15-24 years	0.0086 (0.0075-0.0099) Cases: 175/270 Controls: 294/3350

1 The positive predictive values are calculated using Bayesian statistics.

2 **Evidence statement(s):**

3 Adult and mixed age populations

4 Back pain (1 study, N = 1975) and lymphadenopathy (1 study, N = 249) presenting in a primary care  
5 setting do not appear to confer a markedly increased risk of Hodgkin's/Non-Hodgkin's lymphoma,  
6 although the study populations are probably not directly representative of the typical unselected  
7 symptomatic UK GP population (see also Table 1).

8  
9 Children and teenagers and young adults

10 The positive predictive values of having leukaemia/lymphoma childhood cancer ranged from 0.01%  
11 (for fever and abdominal pain) to 0.53% (for bruising) for patients aged 0-14 years old, and the  
12 positive predictive values of having young adulthood lymphoma ranged from 0.0279% (for 'lump  
13 mass swelling below the neck excluding the abdomen') to 0.5034% (for 'lump mass swelling head  
14 and neck') for patients aged 15-24 years (1 study, N = 30855). The evidence quality is somewhat  
15 compromised by the case-control design of the study (see also Tables 2-3).

16  
17 **Evidence tables**

18 **Deyo (1988)**

<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective consecutive? patient series
Was a consecutive or random sample of patients enrolled?	<b>Unclear</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Yes (probably)</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	N = 1975, mean (SD; range) age = 39.5 (15.4; 15-86) years, 62% females. 54% of the patients were seeking medical care for back pain for the first time and 76% of the patients had had back pain for < 3 months. 3% had a history of back pain surgery. Maximal back pain in the low back (84%) or in the upper back (16%).  <u>Inclusion criteria:</u> Patients who sought treatment between March 1982 and September 1984 in the walk-in clinic of a public hospital where virtually all patients are self-referred. In each case back pain was part of the chief complaint. <u>Exclusion criteria:</u> Neck pain. <u>Clinical setting:</u> Walk-in clinic of a public hospital; this clinic is a source of primary care for indigent persons in a county in the USA with a population of

	approximately 1 million.	
<b>Are there concerns that the included patients and setting do not match the review question?</b>		<b>High concern</b>
<b>INDEX TEST</b>		
<b>A. Risk of bias</b>		
<b>Index test</b>	Back pain; not further specified.	
Were the index test results interpreted without knowledge of the results of the reference standard?		<b>Yes</b>
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?		<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>		<b>Low concern</b>
<b>REFERENCE STANDARD</b>		
<b>A. risk of bias</b>		
Reference standard(s)	The reference standard consisted of a search on each patient name in the institutional tumour registry $\geq 6$ months after the index visit. The registry included every patient with a histological diagnosis of cancer made in the authors' hospital system regardless of site of care. The authors point out that "while this method might fail to identify cancer patients who sought care elsewhere, it is likely that most patients sought follow-up for a particular illness at the same facility.	
Is the reference standard likely to correctly classify the target condition?		<b>Unclear</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?		<b>No (but all patients had a positive index test)</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>		<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		<b>Low concern</b>
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	All the patients are accounted for in the results.	
Was there an appropriate interval between index test and reference standard?		<b>Yes (probably)</b>
Did all patients receive the same reference standard?		<b>Yes</b>
Were all patients included in the analysis?		<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>		<b>Low risk</b>
<b>NOTES</b>	It is a concern that some patients with cancer might have been missed due to the choice of reference standard because this would result in an underestimation of the positive predictive value. 38/1975 patients were found in the tumour registry. Of those 38, 13 patients had tumours that were probable causes of back pain, and 4 of these 13	



	patients already had a diagnosis of cancer at presentation. The 9/1975 patients who had undiagnosed cancer that the back pain could be attributed to had: Lymphoma (NOS; 2), cancer of unknown primary (1), prostate cancer (1), retroperitoneal liposarcoma (1), lung cancer (1), renal cell (1), multiple myeloma (1), mucinous adenocarcinoma (of gallbladder?; 1)
1	
2	<b>Dommett (2012; 2013a,b)</b>
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Population-based nested case-control study using data from the General Practice Research Database (GPRD)
Was a consecutive or random sample of patients enrolled?	<b>No</b>
Was a case-control design avoided?	<b>No</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>High risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p><u>Cases:</u> 1267 children; aged 0-4 years: N = 436; aged 5-14 years: N = 831; 703 males/564 females. Cancer type: Leukemia: N = 368; brain: N = 270; lymphoma: N = 142; bone: N = 107; soft tissue sarcoma: N = 91; renal: N = 82; neuroblastoma: N = 75; other ICD codes: N = 132. 1064 teenagers and young adults (TYA): 15-24 years: Gender not reported. Cancer type: Leukemia: N = 143; brain: N = 154; lymphoma: N = 270; bone: N = 96; soft tissue sarcoma: N = 100; other ICD codes: N = 301 (including testis: N = 60; skin: N = 49; ovary: N = 20 and thyroid: N = 17).</p> <p><u>Controls:</u> 15318 children; aged 0-4 years: N = 4802; aged 5-14 years: N = 10516; 8461 males/6857 females. 13206 TYA. Gender not reported</p> <p><u>Inclusion criteria:</u> The sample comprised all children and TYU aged 0–24 years, inclusive, drawn from all general practices contributing research-standard data to the GPRD between 1 January 1988 and 31 December 2010. To be included, the practices had to have been contributing research-standard data for a minimum of 1 year before each child’s date of cancer diagnosis or the index date (see below) for matched controls. Cases: Patients diagnosed with the following cancers: leukaemia, lymphoma, neuroblastoma, soft tissue sarcoma, hepatic, renal, bone and central nervous system tumours, using pre-defined medical codes used in the GPRD. The date of diagnosis for cases was defined as the date of pathological diagnosis, but if this was unavailable, the date of the first cancer code entered in the GPRD was used.</p>

	Controls: Up to 13 controls (children with no diagnosis of cancer at any time) were selected per case, using a computer-generated random sequence, matched on age (within 1 year), sex and practice, and had to be currently registered on the date of diagnosis of their matched case (the index date). Exclusion criteria: None listed Clinical setting: Primary care, UK.
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	The GPRD uses just over 100 000 medical codes to encompass all primary care events, including both symptoms and diagnoses. From this list, libraries of codes were assembled representing individual alert symptoms derived from the NICE referral guidelines for suspected cancer in children. <i>No more information reported.</i>
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Cancer diagnosis in the UK's General Practice Research Database.
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients appear to be accounted for.
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	This study is published in three papers.

1  
2

<b>Williamson (1985)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Retrospective consecutive patient series
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes (probably)
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	N = 249, mean age = 24 years, 26% were < 15 years; 58% females.  <u>Inclusion criteria:</u> Patients seen at the Family Medical Care Centre of the University of Missouri-Columbia, between July 1 19978 and June 30 1983 whose diagnoses were coded as “enlarged lymph nodes, not infected” (ICHPPC 266) and “lymphadenitis, acute” (ICHPPC 209). <u>Exclusion criteria:</u> None listed <u>Clinical setting:</u> Family Medical Care Centre of the University of Missouri-Columbia.
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	Diagnoses coded as “enlarged lymph nodes, not infected” (ICHPPC 266) and “lymphadenitis, acute” (ICHPPC 209).
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Diagnoses were accepted if verified by history, physical examination or laboratory tests. Outcomes were determined, where possible, from the medical record. Follow up was considered adequate to determine an adverse outcome if one of four criteria were met: 1) A definite diagnosis was made, 2) The nodes were documented to be resolving, 3) There was at least one chart entry for any condition at least 6 months after the index visit for lymphadenopathy, or 4) The patient was reached by telephone and determined to have a favourable outcome.
Is the reference standard likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No (but all patients had a positive index test)</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>

<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	11/249 patients did not fit the criteria for adequate follow up: 3/11 had return visits showing no increase in the size of the nodes, 6/11 had nodes < 1 cm in size and were told to come back if the nodes did not resolve, 2/11 presented with cervical lymph nodes described as 1 cm in size and follow up examination was not recommended. None of these 11 patients could be reached by phone.
Was there an appropriate interval between index test and reference standard?	<b>Yes (probably)</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Unclear</b>
<b>Could the patient flow have introduced bias?</b>	<b>Unclear risk</b>
<b>NOTES</b>	The author note that the study would not have included all the patients presenting with enlarged lymph nodes during the study period because not all such patients would have the diagnosis noted as required for study entry, e.g., a diagnosis of infectious mononucleosis made on the first visit would probably have been coded as such and not as enlarged lymph nodes.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

**References**

**Included studies**

Deyo, R. A. and Diehl, A. K. Cancer as a cause of back pain: Frequency, clinical presentation, and diagnostic strategies. *Journal of General Internal Medicine* 3, 230-238. 1-11-1988.

Dommett, R. M., Redaniel, M. T., Stevens, M. C. G., Hamilton, W., and Martin, R. M. Features of childhood cancer in primary care: A population-based nested case-control study. *British Journal of Cancer* 106[5], 982-987. 2012.

Dommett, R. M., Redaniel, T., Stevens, M. C. G., Martin, R. M., and Hamilton, W. Risk of childhood cancer with symptoms in primary care: A population-based case-control study. *British Journal of General Practice*; DOI:10.3399/bjgp13X660742. 2013a.

Dommett, R. M., Redaniel, M. T., Stevens, M. C. G., Hamilton, W., and Martin, R. M. Features of cancer in teenagers and young adults in primary care: A population-based nested case-control study. *British Journal of Cancer* 2329-2333. 2013b.

Williamson, H. A., Jr. Lymphadenopathy in a family practice: a descriptive study of 249 cases. *Journal of Family Practice* 20[5], 449-452. 1985.

**Excluded studies (with excl reason)**

Abrams, D. I., Lewis, B. J., and Volberding, P. A. Lymphadenopathy: endpoint or prodrome? Update of a 24-month prospective study. *Annals of the New York Academy of Sciences* 437, 207-215. 1984.

Excl reason: Discussion paper/not in PICO

Adegboye, V. O., Ogunseyinde, A. O., Obajimi, M. O., Ogunbiyi, O., Brimmo, A. I., and Adebo, O. A. Presentation of primary mediastinal masses in Ibadan. *East African Medical Journal* 80[9], 484-487. 2003.

Excl reason: Not in PICO

- 1 Ahmed, S., Kussick, S. J., Siddiqui, A. K., Bhuiya, T. A., Khan, A., Sarewitz, S., Steinberg, H., Sison, C. P.,  
2 and Rai, K. R. Bronchial-associated lymphoid tissue lymphoma: a clinical study of a rare disease.  
3 *European Journal of Cancer* 40[9], 1320-1326. 2004.  
4 Excl reason: Not in PICO
- 5 Ahmed, S., Shahid, R. K., Sison, C. P., Fuchs, A., and Mehrotra, B. Orbital lymphomas: A  
6 clinicopathologic study of a rare disease. *American Journal of the Medical Sciences* 331[2], 79-  
7 83. 2006.  
8 Excl reason: Not in PICO
- 9 Aizenberg, D. and Berlin, C. An unusual cause of the piriformis syndrome. *Journal of General Internal*  
10 *Medicine* 25, S491. 2010. Springer New York.  
11 Excl reason: Not in PICO
- 12 Akpata, O. Orofacial surgical emergencies. *West African Journal of Medicine* 30[5], 313-318. 2011.  
13 Excl reason: Narrative review/Not in PICO
- 14 Al Diab, A. R., Aleem, A., Qayum, A., Al Askar, A. S., and Ajarim, D. S. Clinico-Pathological Pattern of  
15 Extranodal Non-Hodgkin's Lymphoma in Saudi Arabia. *Asian Pacific Journal of Cancer Prevention*  
16 12[12], 3277-3282. 2011.  
17 Excl reason: Not in PICO
- 18 Allam, Wafa, Ismaili, Nabil, Elmajjaoui, Sanaa, Elgueddari, Bel, Ismaili, Mohammed, and Errihani,  
19 Hassan. Primary Nasopharyngeal non-Hodgkin lymphomas: a retrospective review of 26  
20 Moroccan patients. *BMC Ear, Nose and Throat Disorders* 9[1], 11. 2009.  
21 Excl reason: Not in PICO
- 22 Allgar, V. L. and Neal, R. D. General practitioners' management of cancer in England: secondary  
23 analysis of data from the National Survey of NHS Patients - Cancer. *European Journal of Cancer*  
24 *Care* 14[5], 409-416. 2005.  
25 Excl reason: Not in PICO
- 26 Allgar, V. L. and Neal, R. D. Delays in the diagnosis of six cancers: analysis of data from the National  
27 Survey of NHS Patients: Cancer. *British Journal of Cancer* 92[11], 1959-1970. 2005.  
28 Excl reason: Not in PICO
- 29 Allhiser, J. N., McKnight, T. A., and Shank, J. C. Lymphadenopathy in a family practice. *Journal of*  
30 *Family Practice* 12[1], 27-32. 1981.  
31 Excl reason: Retrospective case series of 80 patients based on case notes. Authors looked for  
32 cases of lymphadenopathy or acute lymphadenitis in the records. 19% of the cases were  
33 discovered by the physician (i.e., not patients consulting for this symptom). No aetiology  
34 recorded for 29% (N = 23) of the cases, and no cancers recorded as aetiology for the other 71%,  
35 but no clear verification of cause and final diagnoses not reported.
- 36 Arce-Salinas, C. A., Morales-Velazquez, J. L., Villasenor-Ovies, P., and Muro-Cruz, D. Classical fever of  
37 unknown origin (FUO): current causes in Mexico. *Revista de Investigacion Clinica* 57[6], 762-769.  
38 2005.  
39 Excl reason: Not in PICO
- 40 Ashraf, F. Primary pancreatic lymphoma mimicking adenocarcinoma of pancreas. *American Journal*  
41 *of Gastroenterology* 105, S214. 2010. Nature Publishing Group.  
42 Excl reason: Not in PICO
- 43 Back, H., Gustavsson, B., Ridell, B., Rodjer, S., and Westin, J. Primary gastrointestinal lymphoma  
44 incidence, clinical presentation, and surgical approach. *Journal of Surgical Oncology* 33[4], 234-  
45 238. 1986.  
46 Excl reason: Not in PICO
- 47 Bailey, A. A., Debinski, H. S., Appleyard, M. N., Remedios, M. L., Hooper, J. E., Walsh, A. J., and Selby,  
48 W. S. Diagnosis and outcome of small bowel tumors found by capsule endoscopy: A three-center  
49 Australian experience. *American Journal of Gastroenterology* 101[10], 2237-2243. 2006.  
50 Excl reason: Not in PICO

- 1 Bakshi, N. and Maghfoor, I. The current lymphoma classification: New concepts and practical  
2 applications-triumphs and woes. *Annals of Saudi Medicine* 32[3], 296-305. 2012.  
3 Excl reason: Narrative review
- 4 Baldini, Chiara, Giusti, Laura, Ciregia, Federica, Da Valle, Ylenia, Giacomelli, Camillo, Donadio, Elena,  
5 Ferro, Francesco, Galimberti, Sara, Donati, Valentina, Bazzichi, Laura, Bombardieri, Stefano, and  
6 Lucacchini, Antonio. Correspondence between salivary proteomic pattern and clinical course in  
7 primary Sjogren syndrome and non-Hodgkin's lymphoma: a case report. *Journal of Translational  
8 Medicine* 9[1], 188. 2011.  
9 Excl reason: Not in PICO
- 10 Barr, L. C., Glees, J. P., and Gazet, J. C. Diagnostic laparotomy in suspected malignant lymphoma.  
11 *Annals of the Royal College of Surgeons of England* 66[6], 402-404. 1984.  
12 Excl reason: Not in PICO
- 13 Barroca, H. & Bom-Successo, M. (2014) Fine needle biopsy with cytology in paediatrics: The  
14 importance of a multidisciplinary approach and the role of ancillary techniques. *Cytopathology*,  
15 25: 6-20.  
16 Excl reason: Narrative review
- 17 Basavaraj, K. F., Ramalingam, K., Sarkar, A. & Muddaiah, S. (2012) Primary non-Hodgkin's lymphoma  
18 of gingiva in a 28-year-old HIV-positive patient. *Journal of Natural Science Biology & Medicine*, 3:  
19 189-191.  
20 Excl reason: Not in PICO
- 21 Baumgartner, J. E., Rachlin, J. R., Beckstead, J. H., Meeker, T. C., Levy, R. M., Wara, W. M., and  
22 Rosenblum, M. L. Primary central nervous system lymphomas: natural history and response to  
23 radiation therapy in 55 patients with acquired immunodeficiency syndrome. *Journal of  
24 Neurosurgery* 73[2], 206-211. 1990.  
25 Excl reason: Not in PICO
- 26 Bazemore, A. W. and Smucker, D. R. Lymphadenopathy and malignancy. [Review] [32 refs].  
27 *American Family Physician* 66[11], 2103-2110. 1-12-2002.  
28 Excl reason: Narrative review
- 29 Beck, P. L., Gill, M. J., and Sutherland, L. R. HIV-associated non-Hodgkin's lymphoma of the  
30 gastrointestinal tract. *American Journal of Gastroenterology* 91[11], 2377-2381. 1996.  
31 Excl reason: Not in PICO
- 32 Beelte, S., Haas, R., Germing, U., and Jansing, P. J. [Paradigm change in the assessment of myeloid  
33 and lymphoid neoplasms associated with occupational benzene exposure]. [Review] [45 refs]  
34 [German]. *Medizinische Klinik* 104[3], 197-203. 15-3-2009.  
35 Excl reason: Narrative review
- 36 Ben, Rejeb A., Kchir, N., Bouali, M. R., Ebdelli, N., Fsili, R., Khediri, F., Ben, Ayedo F., Zitouna, M. M.,  
37 Ben, Mami N., Kacem, M., Filali, A., and Ben, Ammar A. Gastric MALT lymphoma. A clinico-  
38 pathological study of 65 cases. Relationship to *Helicobacter pylori*. *Tunisie Medicale* 78[8-9],  
39 484-493. 2000.  
40 Excl reason: Not in PICO
- 41 Benson, M. K. and Hasley, P. A rash decision: Not simply another atopic dermatitis! *Journal of  
42 General Internal Medicine* 26, S436-S437. 2011. Springer New York.  
43 Excl reason: Not in PICO
- 44 Bosch, X., Foix, A., Jordan, A., Coca, A., and Lopez-Soto, A. Outpatient Quick Diagnosis Units for the  
45 evaluation of suspected severe diseases: an observational, descriptive study. *Clinics (Sao Paulo,  
46 Brazil)* 66[5], 737-741. 2011.  
47 Excl reason: Not in PICO
- 48 Brant, J. M., Beck, S., Dudley, W. N., Cobb, P., Pepper, G., and Miaskowski, C. Symptom trajectories  
49 in posttreatment cancer survivors. *Cancer Nursing* 34[1], 67-77. 2011.  
50 Excl reason: Not in PICO

- 1 Brockmeyer, N. and Barthel, B. Clinical manifestations and therapies of AIDS associated tumors.  
2 [Review] [244 refs]. *European Journal of Medical Research* 3[3], 127-147. 23-3-1998.  
3 Excl reason: Narrative review
- 4 Buis, J. and de Jongh, T. O. [Examining the lymph nodes]. [Review] [Dutch]. *Nederlands Tijdschrift*  
5 *Voor Geneeskunde* 155, A2652. 2011.  
6 Excl reason: Narrative review
- 7 Burg, G., Kempf, W., Cozzio, A., Dobbeling, U., Feit, J., Golling, P., Michaelis, S., Scharer, L., Nestle, F.,  
8 and Dummer, R. Cutaneous malignant lymphomas: update 2006. [Review] [97 refs]. *Journal der*  
9 *Deutschen Dermatologischen Gesellschaft* 4[11], 914-933. 2006.  
10 Excl reason: Narrative review
- 11 Calderon-Garciduenas, A. L., Pacheco-Calleros, J., Castelan-Maldonado, E., and Necedal-Rustrian, F.  
12 C. [Primary lymphoma of the central nervous system: 20 years' experience in a referral hospital].  
13 [Spanish]. *Revista de Neurologia* 46[2], 84-88. 16-1-2008.  
14 Excl reason: Not in PICO
- 15 Campbell, E. W., Jr. and Smith, M. R. Hematology for primary care physicians. *Disease-a-Month*  
16 42[3], 131-194. 1996.  
17 Excl reason: Narrative review
- 18 Carroccio, A., Iannitto, E., Di, Prima L., Cirrincione, S., Troncone, R., Paparo, F., Trapani, L. G.,  
19 Gucciardi, A., Aversa, M. R., Montalto, G., and Notarbartolo, A. Screening for celiac disease in  
20 non-Hodgkin's lymphoma patients: A serum anti-transglutaminase-based approach. *Digestive*  
21 *Diseases and Sciences* 48[8], 1530-1536. 1-8-2003.  
22 Excl reason: Not in PICO
- 23 Caruso, M. L. and Rizzi, E. Gastric Malt lymphoma: a clinicopathological study. *Anticancer Research*  
24 18[5B], 3781-3783. 1998.  
25 Excl reason: Not in PICO
- 26 Caturelli, E., Bartolucci, F., Biasini, E., Vigliotti, M. L., Andriulli, A., Siena, D. A., Attino, V., and  
27 Bisceglia, M. Diagnosis of liver nodules observed in chronic liver disease patients during  
28 ultrasound screening for early detection of hepatocellular carcinoma. *American Journal of*  
29 *Gastroenterology* 97[2], 397-405. 2002.  
30 Excl reason: Not in PICO
- 31 Cekic, S., Risimic, D., Stankovic-Babic, G., Babic, R., Jaksic, V., Jovanovic, I., and Dordevic-Jocic, J.  
32 Papilledema as a diagnostic challenge - Report of three cases. *Central European Journal of*  
33 *Medicine* 7[1], 100-107. 2012.  
34 Excl reason: Not in PICO
- 35 Chau, I., Kelleher, M. T., Cunningham, D., Norman, A. R., Wotherspoon, A., Trott, P., Rhys-Evans, P.,  
36 Querci Della, Rovere G., Brown, G., Allen, M., Waters, J. S., Haque, S., Murray, T., and Bishop, L.  
37 Rapid access multidisciplinary lymph node diagnostic clinic: analysis of 550 patients. *British*  
38 *Journal of Cancer* 88[3], 354-361. 10-2-2003.  
39 Excl reason: Not in PICO
- 40 Cheng, A. L., Su, I. J., Chen, Y. C., Uen, W. C., and Wang, C. H. Characteristic clinicopathologic features  
41 of Epstein-Barr virus-associated peripheral T-cell lymphoma. *Cancer* 72[3], 909-916. 1-8-1993.  
42 Excl reason: Not in PICO
- 43 Cherian, S., Das, S., Mauzo, S., Koya, H. H., Varghese, D. & Hussain, R. (2013) Primary pulmonary  
44 lymphoma: An extremely rare disease. *Chest*, 144.  
45 Excl reason: Not in PICO
- 46 Chiang, I. P., Wang, H. H., Cheng, A. L., Lin, J. T., and Su, I. J. Low-grade gastric B-cell lymphoma of  
47 mucosa-associated lymphoid tissue: clinicopathologic analysis of 19 cases. *Journal of the*  
48 *Formosan Medical Association* 95[11], 857-865. 1996.  
49 Excl reason: Not in PICO
- 50 Choi, Y. R., An, J. Y., Kim, M. K., Han, H.-S., Lee, K. H., Kim, S.-W., Lee, K. M. & Choe, K. H. (2013) The  
51 diagnostic efficacy and safety of endobronchial ultrasound-guided transbronchial needle

- 1 aspiration as an initial diagnostic tool. *Korean Journal of Internal Medicine*, 28: 660-667.
- 2 Excl reason: Not in PICO
- 3 Cholongitas, Evangelos, Papadakis, Emanouil, Kaklamanis, Loukas, and Dasenaki, Maria. Peripheral
- 4 facial palsy in elderly: Not always a benign condition. [References]. *Geriatrics & Gerontology*
- 5 *International* 9[1], 100-101. 2009.
- 6 Excl reason: Not in PICO
- 7 Cisleanu, D., Vladareanu, A. M., Bumbea, H., Radesi, S., Voican, I., Ciufu, C., Marinescu, C., Onisai, M.,
- 8 Nicolescu, A., Dervesteanu, M., Dobrea, C., Popov, V., Colita, D., and Mut-Popescu, D. Outcome
- 9 of aggressive ATL-HTLV1 patients after CHOP21 as first line treatment - Bucharest experience.
- 10 *Haematologica* 94, 404-405. 2009. *Haematologica Journal Office*.
- 11 Excl reason: Not in PICO
- 12 Coe, A., Conway, J., Evans, J., Goebel, M. & Mishra, G. (2013) The yield of EUS-FNA in undiagnosed
- 13 upper abdominal adenopathy is very high. *Journal of Clinical Ultrasound*, 41: 210-213.
- 14 Excl reason: Not in PICO
- 15 Connolly, A. A. and MacKenzie, K. Paediatric neck masses--a diagnostic dilemma. *Journal of*
- 16 *Laryngology & Otology* 111[6], 541-545. 1997.
- 17 Excl reason: Not in PICO
- 18 Cornalba, G. P., Dore, R., and Colombo, E. [Abdominal manifestations in immunocompromised
- 19 patients]. [Review] [30 refs] [Italian]. *Radiologia Medica* 87[5:Suppl 2], Suppl-61. 1994.
- 20 Excl reason: Not in PICO
- 21 Cuschieri, A. Malignant tumours of the stomach. [Review] [53 refs]. *Recenti Progressi in Medicina*
- 22 81[6], 374-386. 1990.
- 23 Excl reason: Narrative review
- 24 Das, S. K., Saha, S. K., Das, A., Halder, A. K., Banerjee, S. N., and Chakraborty, M. A study of
- 25 comparison of efficacy and safety of talc and povidone iodine for pleurodesis of malignant
- 26 pleural effusions. *Journal of the Indian Medical Association* 106[9], 589-590. 20-11-0592.
- 27 Excl reason: Not in PICO
- 28 Davis, R. D., Jr., Oldham, H. N., Jr., and Sabiston, D. C., Jr. Primary cysts and neoplasms of the
- 29 mediastinum: recent changes in clinical presentation, methods of diagnosis, management, and
- 30 results. *Annals of Thoracic Surgery* 44[3], 229-237. 1987.
- 31 Excl reason: Not in PICO
- 32 de-The, G. Epstein-Barr virus and Burkitt's lymphoma worldwide: the causal relationship revisited.
- 33 *IARC Scientific Publications* [60], 165-176. 1985.
- 34 Excl reason: Not in PICO
- 35 Doberneck, R. C. The diagnostic yield of lymph node biopsy. *Archives of Surgery* 118[10], 1203-1205.
- 36 1983.
- 37 Excl reason: Not in PICO
- 38 Dodd III, G. D., Greenler, D. P., and Confer, S. R. Thoracic and abdominal manifestations of
- 39 lymphoma occurring in the immunocompromised patient. *Radiologic Clinics of North America*
- 40 30[3], 597-610. 1992.
- 41 Excl reason: Not in PICO
- 42 Doolabh, N., Anthony, T., Simmang, C., Bieligm, S., Lee, E., Huber, P., Hughes, R., and Turnage, R.
- 43 Primary colonic lymphoma. *Journal of Surgical Oncology* 74[4], 257-262. 2000.
- 44 Excl reason: Not in PICO
- 45 Dowd, T. R. Primary care approach to lymphadenopathy. *Nurse Practitioner* 19[12], 36-4. 1994.
- 46 Excl reason: Narrative summary
- 47 Du, M. Q. and Isaccson, P. G. Gastric MALT lymphoma: from aetiology to treatment. [Review] [74
- 48 refs]. *Lancet Oncology* 3[2], 97-104. 2002.
- 49 Excl reason: Narrative review
- 50 Dughayli, Mohamad, Baidoun, Fadi, and Lupovitch, Aaron. Synchronous perforation of non-
- 51 Hodgkin's lymphoma of the small intestine and colon: a case report. *Journal of Medical Case*



- 1 Reports 5[1], 57. 2011.  
2 Excl reason: Not in PICO
- 3 Duncavage, J. A., Campbell, B. H., Hanson, G. A., Kun, L. E., Hansen, R. M., Toohill, R. J., and Malin, T.  
4 C. Diagnosis of malignant lymphomas of the nasal cavity, paranasal sinuses and nasopharynx.  
5 Laryngoscope 93[10], 1276-1280. 1983.  
6 Excl reason: Not in PICO
- 7 Edgren, G., Bagnardi, V., Bellocco, R., Hjalgrim, H., Rostgaard, K., Melbye, M., Reilly, M., Adami, H. O.,  
8 Hall, P., and Nyren, O. Pattern of declining hemoglobin concentration before cancer diagnosis.  
9 International Journal of Cancer 127[6], 1429-1436. 1-9-2010.  
10 Excl reason: Not in PICO
- 11 Elgendy, I. Y. & Lo, M. C. (2014) - Unilateral lower extremity swelling as a rare presentation of non-  
12 Hodgkin's lymphoma. - *BMJ Case Reports*, 2014, 2014..  
13 Excl reason: Not in PICO
- 14 Ellis, D., Jaffe, R., Green, M., Janosky, J. J., Lombardo-Lane, S., Shapiro, R., Scantlebury, V., Vivas,  
15 C., and Jordan, M. L. Epstein-Barr virus-related disorders in children undergoing renal  
16 transplantation with tacrolimus-based immunosuppression. *Transplantation* 68[7], 997-1003.  
17 15-10-1999.  
18 Excl reason: Not in PICO
- 19 Evron, E., Goland, S., Klepfish, A., Malnick, S. D. H., Sokolowski, N., and Stoegeer, Z. M. Primary  
20 multifocal lymphoma of bone presenting as hypercalcemic crisis: Report of a rare manifestation  
21 of extranodal lymphoma. *Leukemia & Lymphoma* 34[1-2], 197-200. 1999.  
22 Excl reason: Not in PICO
- 23 Ezzie, M. E., Janssen, W. J., O'Brien, J. M., Fox, C. C., and Schwarz, M. I. Clinical problem-solving.  
24 Failure to respond--a 52-year-old man presented to his primary care physician with dyspnea and  
25 cough. *New England Journal of Medicine* 358[1], 70-74. 3-1-2008.  
26 Excl reason: Not in PICO
- 27 Farrer, F. Cancer screening in primary care. *SA Pharmaceutical Journal* 77[9], 41-45. 2010.  
28 Excl reason: Narrative review/Not in PICO
- 29 Ferrario, A., Aghemo, A., Goldaniga, M. C., Merli, M., Vincenti, D., Rossi, F. G., De, Gasperi E., Olivero,  
30 B., Cro, L., Rattotti, S., Arcaini, L., Onida, F., and Baldini, L. Indolent B-Cell lymphomas treated  
31 upfront with antiviral therapy: A series of 13 patients. *Blood* 116[21]. 19-11-2010. American  
32 Society of Hematology.  
33 Excl reason: Not in PICO
- 34 Ferrer, R. Lymphadenopathy: differential diagnosis and evaluation. [Review] [12 refs]. *American*  
35 *Family Physician* 58[6], 1313-1320. 15-10-1998.  
36 Excl reason: Narrative review
- 37 Fijten, G. H. and Blijham, G. H. Unexplained lymphadenopathy in family practice. An evaluation of  
38 the probability of malignant causes and the effectiveness of physicians' workup. *Journal of*  
39 *Family Practice* 27[4], 373-376. 1988.  
40 Excl reason: Not in PICO
- 41 Foster, T., Miller, J. D., Boye, M. E., and Russell, M. W. Economic Burden of Follicular Non-Hodgkin's  
42 Lymphoma. *Pharmacoeconomics* 27[8], 657-679. 2009.  
43 Excl reason: Narrative review
- 44 Frederiksen, B. L., Brown, P. D., Dalton, S. O., Steding-Jessen, M., and Osler, M. Socioeconomic  
45 inequalities in prognostic markers of non-Hodgkin lymphoma: Analysis of a national clinical  
46 database. *European Journal of Cancer* 47[6], 910-917. 2011.  
47 Excl reason: Not in PICO
- 48 Friedman, D. R., Coan, A. D., Smith, S. K., Herndon II, J. E., and Abernethy, A. P. Informational needs  
49 assessment of non-Hodgkin lymphoma survivors and their physicians. *American Journal of*  
50 *Hematology* 85[7], 528-532. 2010.  
51 Excl reason: Not in PICO

- 1 Friedmann, A. M. Evaluation and management of lymphadenopathy in children. [Review] [7 refs].  
2 Pediatrics in Review 29[2], 53-60. 2008.  
3 Excl reason: Narrative review
- 4 Frikha, Zied, Abid, Leila, Abid, Dorra, Mallek, Souad, Frikha, Imed, Abdennadher, Mohamed, Rekik,  
5 Noomen, and Kammoun, Samir. Cardiac tamponade and paroxysmal third-degree  
6 atrioventricular block revealing a primary cardiac non-Hodgkin large B-cell lymphoma of the  
7 right ventricle: a case report. Journal of Medical Case Reports 5[1], 433. 2011.  
8 Excl reason: Not in PICO
- 9 Front, D., Bar-Shalom, R., Epelbaum, R., Haim, N., Ben-Arush, M. W., Ben-Shahar, M., Gorenberg, M.,  
10 Kleinhaus, U., Parmett, S., Kolodny, G. M., and Israel, O. Early detection of lymphoma recurrence  
11 with gallium-67 scintigraphy. Journal of Nuclear Medicine 34[12], 2101-2104. 1993.  
12 Excl reason: Not in PICO
- 13 Gallego, C., Gonzalez-Diaz, S., Del Carmen, Zarate M., Arias-Cruz, A., Garcia-Calderin, D., Salas, K. Y.  
14 M., Calva, M., and Sansores, L. A. D. CVID: A common but still underdiagnosed disease. World  
15 Allergy Organization Journal 5, S207-S208. 2012. Lippincott Williams and Wilkins.  
16 Excl reason: Not in PICO
- 17 Galvao, Neto A., Shaft, N., Protiva, P., Oroszi, G., and Sahakian, A. Colonic mantle cell lymphoma in  
18 situ: A report of a unique case. Virchows Archiv 457[2], 255-256. 2010. Springer Verlag.  
19 Excl reason: Not in PICO
- 20 Garment, A., Demopoulos, B., and Caesar, E. P. Neck swelling and night sweating. Journal of General  
21 Internal Medicine 25, S533-S534. 2010. Springer New York.  
22 Excl reason: Not in PICO
- 23 Geh, J. I. and Spittle, M. F. Oncological problems in AIDS--a review of the clinical features and  
24 management. [Review] [74 refs]. Annals of the Academy of Medicine, Singapore 25[3], 380-391.  
25 1996.  
26 Excl reason: Narrative review
- 27 Genta, R. M. The gastritis connection: prevention and early detection of gastric neoplasms. [Review]  
28 [55 refs]. Journal of Clinical Gastroenterology 36[5:Suppl], Suppl-9. 2003.  
29 Excl reason: Narrative review
- 30 Genvresse, I., Luftner, D., Spath-Schwalbe, E., and Buttgereit, F. Prevalence and clinical significance  
31 of anticardiolipin and anti-beta2-glycoprotein-I antibodies in patients with non-Hodgkin's  
32 lymphoma. European Journal of Haematology 68[2], 84-90. 2002.  
33 Excl reason: Not in PICO
- 34 Ghai, S., Pattison, J., Ghai, S., O'Malley, M. E., Khalili, K., and Stephens, M. Primary gastrointestinal  
35 lymphoma: spectrum of imaging findings with pathologic correlation. [Review] [39 refs].  
36 Radiographics 27[5], 1371-1388. 2007.  
37 Excl reason: Narrative review
- 38 Gonzalez, Q. H., Heslin, M. J., Davila-Cervantes, A., Alvarez-Tostado, J., De Los Monteros, A. E., Shore,  
39 G., and Vickers, S. M. Primary colonic lymphoma. American Surgeon 74[3], 214-216. 2008.  
40 Excl reason: Not in PICO
- 41 Gosche, J. R. and Vick, L. Acute, subacute, and chronic cervical lymphadenitis in children. [Review]  
42 [21 refs]. Seminars in Pediatric Surgery 15[2], 99-106. 2006.  
43 Excl reason: Narrative review
- 44 Graili, P., Bakhshayeshkaram, M., and Zahirifard, S. Lymphoma diagnosis on computed tomography  
45 guided needle biopsy. Journal of Thoracic Imaging 24[3], w1-w2. 2009. Lippincott Williams and  
46 Wilkins.  
47 Excl reason: Not in PICO
- 48 Gregory, R. K., Cunningham, D., Fisher, T. A., Rhys-Evans, P., Middleton, G. W., Bishop, L.,  
49 Wotherspoon, A., Trott, P. A., and Nash, A. G. Investigating lymphadenopathy--report on the first  
50 12 months of the lymph node diagnostic clinic at the Royal Marsden Hospital. Postgraduate

- 1 Medical Journal 76[899], 566-568. 2000.  
2 Excl reason: Not in PICO (referred patients)
- 3 Groothoff, J. W. Long-term outcomes of children with end-stage renal disease. [Review] [30 refs].  
4 Pediatric Nephrology 20[7], 849-853. 2005.  
5 Excl reason: Not in PICO
- 6 Grosfeld, J. L., Skinner, M. A., Rescorla, F. J., West, K. W., and Scherer, L. R., III. Mediastinal tumors in  
7 children: experience with 196 cases. *Annals of Surgical Oncology* 1[2], 121-127. 1994.  
8 Excl reason: Not in PICO
- 9 Guccion, J. G., Gibert, C. L., Ortega, L. G., and Hadfield, T. L. Cat scratch disease and acquired  
10 immunodeficiency disease: diagnosis by transmission electron microscopy. *Ultrastructural*  
11 *Pathology* 20[3], 195-202. 1996.  
12 Excl reason: Not in PICO
- 13 Guiliani, P., Gicquel, N., Lepain, C., and Peziere, N. AIDS and lymphoma. Some problems for the  
14 patient care team. [French]. *Soins; la revue de reference infirmiere* [538-539], 10-13. 1990.  
15 Excl reason: Not in PICO
- 16 Guindi, M. Role of *Helicobacter pylori* in the pathogenesis of gastric carcinoma and progression of  
17 lymphoid nodules to lymphoma. [Review] [39 refs]. *Canadian Journal of Gastroenterology* 13[3],  
18 224-227. 1999.  
19 Excl reason: Narrative review
- 20 Gumustas, O. G., Gumustas, A., Yalcin, R., Savci, G., and Soylu, R. A. Unusual causes of small bowel  
21 obstruction and contemporary diagnostic algorithm. [Review] [30 refs]. *Journal of Medical*  
22 *Imaging & Radiation Oncology* 52[3], 208-215. 2008.  
23 Excl reason: Not in PICO
- 24 Gunatilake, S. S. & Wimalaratna, H. (2014) - Angioedema as the first presentation of B-cell non-  
25 Hodgkin lymphoma - an unusual case with normal C1 esterase inhibitor level: a case report. -  
26 *BMC Research Notes*, 7: 495.  
27 Excl reason: Not in PICO
- 28 Gupta, R. and Bhardwaj, S. Bilateral primary non Hodgkin's lymphoma of the breast: A rare case  
29 report. *JK Science* 14[1], 43-44. 2011.  
30 Excl reason: Not in PICO
- 31 Guven, G. S., Uzun, O., Cakir, B., Akova, M., and Unal, S. Infectious complications in patients with  
32 hematological malignancies consulted by the Infectious Diseases team: a retrospective cohort  
33 study (1997-2001). *Supportive Care in Cancer* 14[1], 52-55. 2006.  
34 Excl reason: Not in PICO
- 35 Hakkou, J., Rostom, S., Bahiri, R., and Hajjaj-Hassouni, N. Paraneoplastic rheumatic syndromes:  
36 Report of eight cases and review of literature. *Rheumatology International* 32[6], 1485-1489.  
37 2012.  
38 Excl reason: Not in PICO
- 39 Haldorsen, I. S., Espeland, A., Larsen, J. L., and Mella, O. Diagnostic delay in primary central nervous  
40 system lymphoma. *Acta Oncologica* 44[7], 728-734. 2005.  
41 Excl reason: Not in PICO
- 42 Hamburger, J. Sjogren's syndrome - Managing oral and systemic symptoms via a multi-disciplinary  
43 approach. *Oral Diseases* 10[5], 306-309. 2004.  
44 Excl reason: Not in PICO
- 45 Han, S. H., Maeng, Y. H., Kim, Y. S., Jo, J. M., Kwon, J. M., Kim, W. K. & Kim, M. O. (2014) Primary  
46 anaplastic large cell lymphoma of the lung presenting with acute atelectasis. *Thoracic Cancer*, 5:  
47 78-81.  
48 Excl reason: Not in PICO
- 49 Hanaoka, M., Tsukimori, K., Hojo, S., Abe, Y., Mutou, T., Muta, K., Iwasa, A., Yao, T., and Nakano, H.  
50 B-cell lymphoma during pregnancy associated with hemophagocytic syndrome and placental

- 1 involvement. *Clinical Lymphoma & Myeloma* 7[7], 486-490. 2007.
- 2 Excl reason: Not in PICO
- 3 Harrington, K. J., Michalaki, V. J., Vini, L., Nutting, C. M., Syrigos, K. N., A'Hern, R., and Harmer, C. L.
- 4 Management of non-Hodgkin's lymphoma of the thyroid: the Royal Marsden Hospital
- 5 experience. *British Journal of Radiology* 78[929], 405-410. 2005.
- 6 Excl reason: Not in PICO
- 7 Hart, S., Horsman, J. M., Radstone, C. R., Hancock, H., Goepel, J. R., and Hancock, B. W. Localised
- 8 extranodal lymphoma of the head and neck: The Sheffield Lymphoma Group experience (1971-
- 9 2000). *Clinical Oncology* 16[3], 186-192. 2004.
- 10 Excl reason: Not in PICO
- 11 Hartmann, M. and Sartor, K. [Primary malignant lymphoma of the brain]. [Review] [26 refs]
- 12 [German]. *Radiologe* 37[1], 42-50. 1997.
- 13 Excl reason: Narrative review
- 14 Hashimoto, S., Kitahara, T., Arimoto, T., Kamada, T., Shirato, H., Nishioka, T., and Nojima, T. [A
- 15 clinical and pathological study of non-Hodgkin's lymphoma of the nasal cavity and paranasal
- 16 sinuses]. [Japanese]. *Nippon Igaku Hoshasen Gakkai Zasshi - Nippon Acta Radiologica* 53[6], 679-
- 17 687. 25-6-1993.
- 18 Excl reason: Not in PICO
- 19 Heitman, B. and Irizarry, A. Infectious disease causes of lymphadenopathy: localized versus diffuse.
- 20 [Review] [50 refs]. *Lippincott's Primary Care Practice* 3[1], 19-38. 1999.
- 21 Excl reason: Narrative review
- 22 Hiller, E. [Malignant Hodgkin's and non-Hodgkin's lymphomas]. [German]. *MMW Fortschritte der*
- 23 *Medizin* 147[9], 31-34. 3-3-2005.
- 24 Excl reason: Narrative review
- 25 Hojo, A., Nakayama, H., Aramaki, O., Higaki, T., Moriguchi, M., Sugitani, M., Miura, K., Takeuchi, J.,
- 26 Nishiyama, R., Moriyama, M. & Takayama, T. (2013) Diagnostic value of open biopsy for
- 27 malignant T-cell lymphoma of the liver. *International Surgery*, 98: 13-18.
- 28 Excl reason: Not in PICO
- 29 Hojsak, I., Misak, Z., and Kolacek, S. Coeliac disease today: The search for complications and
- 30 associated disorders. [Croatian]. *Paediatrica Croatica* 49[2], 79-84. 2005.
- 31 Excl reason: Narrative review
- 32 Holstein, K., Janning, M., Marx, G., Lentz, B., Bokemeyer, C., and Langer, F. Another case of acquired
- 33 haemophilia (AH) associated with a myeloproliferative neoplasm (MPN): Implications for the
- 34 differential diagnosis of underlying malignancies. *Hamostaseologie* 32[1], A86. 2012. Schattauer
- 35 GmbH.
- 36 Excl reason: Not in PICO
- 37 Hong, J., Kim, J. H., Park, J. & Lee, J. H. (2013) Clinical symptom or sign-directed surveillance can be
- 38 more useful in detecting relapse compared to routine imaging in patients with diffuse large b-
- 39 cell lymphoma in remission. *Blood*, 122.
- 40 Excl reason: Not in PICO
- 41 Horton, K. M. and Fishman, E. K. Multidetector-row computed tomography and 3-dimensional
- 42 computed tomography imaging of small bowel neoplasms: current concept in diagnosis.
- 43 [Review] [29 refs]. *Journal of Computer Assisted Tomography* 28[1], 106-116. 2004.
- 44 Excl reason: Narrative review
- 45 Huang, JiaJia, Jiang, WenQi, Xu, RuiHua, Huang, HuiQiang, Lv, Yue, Xia, ZhongJun, Sun, XiaoFei, Guan,
- 46 ZhongZhen, Lin, TongYu, and Li, ZhiMing. Primary gastric non-Hodgkin's lymphoma in Chinese
- 47 patients: clinical characteristics and prognostic factors. *BMC Cancer* 10[1], 358. 2010.
- 48 Excl reason: Not in PICO
- 49 Huda, S., Tyne, H., and Iniesta, I. B-cell non-hodgkin lymphoma presenting with diplopia, ataxia, and
- 50 subacute polyneuropathy: Neoplastic vs paraneoplastic? *Journal of Neurology, Neurosurgery*

- 1 and Psychiatry 81[11], e41. 2010. BMJ Publishing Group.  
2 Excl reason: Not in PICO
- 3 Huhn, D. Clinical aspects and therapy of malignant lymphomas in AIDS--symptomatology of AIDS  
4 encephalopathy. [German]. *Verhandlungen der Deutschen Gesellschaft für Innere Medizin* 92,  
5 330-336. 1986.  
6 Excl reason: Not in PICO
- 7 Ichimaru, M., Kamiyama, S., Moriuchi, Y., Kuraishi, Y., Usui, N., Toki, H., Okabe, K., Niho, Y., Shibuya, T.,  
8 and Umei, T. [Clinical study on the effect of natural alpha-interferon (HLBI) in the treatment of  
9 adult T-cell leukemia]. [Japanese]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer &  
10 Chemotherapy]* 15[10], 2975-2981. 1988.  
11 Excl reason: Not in PICO
- 12 Imteyaz, H. & Stern, M. (2013) N-type calcium channel binding antibodies in a patient with  
13 paraneoplastic cerebellar degeneration in association with non-hodgkins lymphoma: A case  
14 report. *PM and R*, 5: S183.  
15 Excl reason: Not in PICO
- 16 Jakubowska-Pietkiewicz, E., Szczepaniak-Kubat, A., Zalewska-Szewczyk, B., and Chlebna-Sokol, D.  
17 Skeletal status at diagnosis in children with hematologic malignancy - Pilot study. *Advances in  
18 Clinical and Experimental Medicine* 19[4], 531-535. 2010.  
19 Excl reason: Not in PICO
- 20 Jett, J. R. Mediastinal tumors. *Respirology* 15, 18. 2010. Blackwell Publishing.  
21 Excl reason: Narrative review
- 22 Johnson, P. T., Nazarian, L. N., Feld, R. I., Needleman, L., Lev-Toaff, A. S., Segal, S. R., and Halpern, E.  
23 J. Sonographically guided renal mass biopsy: indications and efficacy. *Journal of Ultrasound in  
24 Medicine* 20[7], 749-753. 20-11-0755.  
25 Excl reason: Not in PICO
- 26 Jordan, R., Diss, T. C., Lench, N. J., Isaacson, P. G., and Speight, P. M. Immunoglobulin gene  
27 rearrangements in lymphoplasmacytic infiltrates of labial salivary glands in Sjogren's syndrome.  
28 A possible predictor of lymphoma development. *Oral surgery, oral medicine, oral pathology, oral  
29 radiology, and endodontics* 79[6], 723-729. 1995.  
30 Excl reason: Not in PICO
- 31 Joshi, P. V., Lele, V. R. & Shaikh, I. (2013) Mortui vivos docent--the dead teach the living: 18-  
32 flurodeoxyglucose positron emission tomography-computed tomography findings in a case of  
33 intravascular B cell lymphoma. *Journal of Cancer Research & Therapeutics*, 9: 141-144.  
34 Excl reason: Not in PICO
- 35 Jovanovic, J., Brkic, S., Klasnja, B., and Fabri, M. [Epstein-Barr, hepatitis B and hepatitis C virus  
36 infections and their oncogenic potentials]. [Croatian]. *Medicinski Pregled* 50[11-12], 499-504.  
37 1997.  
38 Excl reason: Narrative review
- 39 Jovic, R., Vlaski, L., Komazec, Z., and Canji, K. [Results of treatment of deep neck abscesses and  
40 phlegmons]. [Croatian]. *Medicinski Pregled* 52[9-10], 402-408. 1999.  
41 Excl reason: Not in PICO
- 42 Kalauch, A., Benter, T., Kroschinsky, F., Stroszczyński, C., Kellermann, S., Ehninger, G., and Schuler, M.  
43 Sezary Syndrome: Infiltration of the gastric wall - Does it matter? *Onkologie* 34, 135. 2011. S.  
44 Karger AG.  
45 Excl reason: Not in PICO
- 46 Kapoor, A. Pulmonary lymphomatoid granulomatosis : An uncommon cause of multiple pulmonary  
47 nodules. *Chest* 140[4 MEETING ABSTRACT]. 2011. American College of Chest Physicians.  
48 Excl reason: Not in PICO
- 49 Karakayli, G., Beckham, G., Orengo, I., and Rosen, T. Exfoliative dermatitis. *American Family  
50 Physician* 59[3], 625-630. 1-2-1999.  
51 Excl reason: Narrative review

- 1 Karolina, O.-H., Osmola-Mankowska, A., Silny, W., Danczak-Pazdrowska, A. & Polanska, A. (2013) The  
2 possibility of monitoring using the highfrequency ultrasound in patients with the primary  
3 cutaneous t-cell lymphoma. *Skin Research and Technology*, 19: e586.  
4 Excl reason: Not in PICO
- 5 Kassis, J., Maeda, A., Teramoto, N., Takada, K., Wu, C., Klein, G., and Wells, A. EBV-expressing AGS  
6 gastric carcinoma cell sublines present increased motility and invasiveness. *International Journal*  
7 *of Cancer* 99[5], 644-651. 10-6-2002.  
8 Excl reason: Not in PICO
- 9 Kawaguchi, S., Nakazawa, S., Yoshino, J., and Ichikawa, T. Clinical diagnosis of benign lymphoma of  
10 the stomach. [Japanese]. *Stomach and Intestine* 16[2], 137-144. 1981.  
11 Excl reason: Not in PICO
- 12 Khadzhiev, E., Popova, L., and Raikov, Kh. [Autoimmune hemolytic anemia in malignant lymphomas].  
13 [Bulgarian]. *Vutreshni Bolesti* 28[6], 56-60. 1989.  
14 Excl reason: Not in PICO
- 15 Khojasteh, A., Reynolds, R. D., and Khojasteh, C. A. Malignant lymphoreticular lesions in patients  
16 with immune disorders resembling acquired immunodeficiency syndrome (AIDS): review of 80  
17 cases. [Review] [39 refs]. *Southern Medical Journal* 79[9], 1070-1075. 1986.  
18 Excl reason: Narrative review
- 19 Khorana, A., Bunn, P., McLaughlin, P., Vose, J., Stewart, C., and Czuczman, M. S. A phase II  
20 multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-  
21 Hodgkin's lymphoma. *Leukemia & Lymphoma* 41[1-2], 77-87. 2001.  
22 Excl reason: Not in PICO
- 23 Kinlen, L. J. Childhood leukaemia and non-Hodgkins lymphoma in young people living close to  
24 nuclear reprocessing sites. *Biomedicine & Pharmacotherapy* 47[10], 429-434. 1993.  
25 Excl reason: Narrative review
- 26 Kojima, M., Motoori, T., and Nakamura, S. Benign, atypical and malignant lymphoproliferative  
27 disorders in rheumatoid arthritis patients. [Review] [44 refs]. *Biomedicine & Pharmacotherapy*  
28 60[10], 663-672. 2006.  
29 Excl reason: Narrative review
- 30 Kortsik, C. S., Heine, M., Staedt, U., Kirschstein, W., and Gladisch, R. [Malignant tumor-like  
31 abdominal lymphoma in Whipple's disease]. [German]. *Deutsche Medizinische Wochenschrift*  
32 114[28-29], 1107-1109. 14-7-1989.  
33 Excl reason: Not in PICO
- 34 Kose, D., Paksoy, Y., Koksal, Y. & Unal, E. (2014) - Neurological complication of non Hodgkin  
35 lymphoma in childhood: experience from a single center in Turkey. - *Childs Nervous System*, 30:  
36 639-645.  
37 Excl reason: Not in PICO
- 38 Krejsgaard, T., Odum, N., Geisler, C., Wasik, M. A., and Woetmann, A. Regulatory T cells and  
39 immunodeficiency in mycosis fungoides and Sezary syndrome. [Review]. *Leukemia* 26[3], 424-  
40 432. 2012.  
41 Excl reason: Narrative review
- 42 Krishnan, A., Shirkhoda, A., Tehranzadeh, J., Armin, A. R., Irwin, R., and Les, K. Primary bone  
43 lymphoma: radiographic-MR imaging correlation. [Review] [27 refs]. *Radiographics* 23[6], 1371-  
44 1383. 1384.  
45 Excl reason: Narrative review
- 46 Kutikova, L., Bowman, L., Chang, S., Long, S. R., Arning, M., and Crown, W. H. Medical costs  
47 associated with non-Hodgkin's lymphoma in the United States during the first two years of  
48 treatment. *Leukemia & Lymphoma* 47[8], 1535-1544. 2006.  
49 Excl reason: Not in PICO
- 50 Labenz, J. and Malfertheiner, P. European guidelines on the diagnosis and therapy of *Helicobacter*  
51 *pylori* infections (Maastricht consensus report). [German]. *Munchener Medizinische*

- 1 Wochenschrift 139[24], 30-32. 1997.  
2 Excl reason: Guideline
- 3 Lai, Y., Zhang, M., Wang, L., Yang, A., Li, J., Zhang, X., Zhou, X., Hong, T., Qian, J. & Zhong, D. (2014)  
4 Uveitis and T cell lymphoma: A rare but notable relationship. *Medical Oncology*, 31.  
5 Excl reason: Not in PICO
- 6 Lee, S. C., Hong, S. W., Lee, Y. S., Jeong, J. J., Nam, K. H., Chung, W. Y., Chang, H. S., and Park, C. S.  
7 Primary thyroid mucosa-associated lymphoid tissue lymphoma; a clinicopathological study of  
8 seven cases. *Journal of The Korean Surgical Society* 81[6], 374-379. 2011.  
9 Excl reason: Not in PICO
- 10 Leslie, L. A., Lebowitz, B., Neugut, A. I., Gregory, Mears J., Bhagat, G., and Green, P. H. Incidence of  
11 lymphoproliferative disorders in patients with celiac disease. *American Journal of Hematology*  
12 87[8], 754-759. 2012.  
13 Excl reason: Not in PICO
- 14 Lukic, S., Marjanovic, G., and Zivanovic, J. Palpable lymphadenopathy in primary care. *Acta Facultatis*  
15 *Medicae Naissensis* 28[1], 17-23. 2011.  
16 Excl reason: Narrative review
- 17 Madan, A., Sethi, P. & Tripathi, K. (2013) Upper extremity venous thrombosis--calm before the storm.  
18 *Journal of General Internal Medicine*, 28: S415.  
19 Excl reason: Not in PICO
- 20 Mady, S. M. Managing lumps in the neck. [Review] [4 refs]. *Practitioner* 242[1587], 472-475. 1998.  
21 Excl reason: Narrative review
- 22 Maher, N., O'Brien, Y., Milner, M., and Gleeson, N. Lymphoma--the great masquerader. *Irish Journal*  
23 *of Medical Science* 180, S134-S135. 2011. Springer.  
24 Excl reason: Not in PICO
- 25 Maksimovic, Z., Cvetkovic, S., Markovic, M., Perisic, M., Colic, M., and Putnik, S. [Differential  
26 diagnosis of deep vein thrombosis]. [Serbian]. *Srpski Arhiv Za Celokupno Lekarstvo* 129[1-2], 13-  
27 17. 2001.  
28 Excl reason: Not in PICO
- 29 Malfertheiner, P. Current European concepts in the management of *Helicobacter pylori* infection.  
30 The Maastricht consensus report. *Gut* 41[1], 8-13. 1997.  
31 Excl reason: Narrative review/guideline
- 32 Mann, G., Attarbaschi, A., Steiner, M., Simonitsch, I., Strobl, H., Urban, C., Meister, B., Haas, O.,  
33 Dworzak, M., and Gadner, H. Early and reliable diagnosis of non-Hodgkin lymphoma in childhood  
34 and adolescence: Contribution of cytomorphology and flow cytometric immunophenotyping.  
35 *Pediatric Hematology and Oncology* 23[3], 167-176. 2006.  
36 Excl reason: Not in PICO
- 37 Marshall, N. A., Culligan, D. J., Johnston, P. W., Millar, C., Barker, R. N., and Vickers, M. A. CD4+ T-cell  
38 responses to Epstein-Barr virus (EBV) latent membrane protein 1 in infectious mononucleosis  
39 and EBV-associated non-Hodgkin lymphoma: Th1 in active disease but Tr1 in remission. *British*  
40 *Journal of Haematology* 139[1], 81-89. 2007.  
41 Excl reason: Not in PICO
- 42 Matsukura, N. [*Helicobacter pylori* infection and gastric diseases--pathogenesis and effects of  
43 eradication]. [Review] [59 refs] [Japanese]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer &*  
44 *Chemotherapy]* 29[8], 1341-1349. 2002.  
45 Excl reason: Narrative review
- 46 Matsuo, T., Fujiwara, N., and Nakata, Y. First presenting signs or symptoms of sarcoidosis in a  
47 Japanese population. *Japanese Journal of Ophthalmology* 49[2], 149-152. 2005.  
48 Excl reason: Not in PICO
- 49 McQueen, A., Martin, S. A., and Lio, P. A. Derm emergencies: detecting early signs of trouble. *Journal*  
50 *of Family Practice* 61[2], 71-78. 2012.  
51 Excl reason: Narrative/educational review

- 1 Megraud, F. Helicobacter pylori infection: Review and practice. [French]. Presse Medicale 39[7-8],  
2 815-822. 2010.  
3 Excl reason: Narrative review
- 4 Meier, J. D. & Grimmer, J. F. (2014) - Evaluation and management of neck masses in children.  
5 [Review]. - *American Family Physician*, 89: 353-358.  
6 Excl reason: Narrative review
- 7 Melbye, M., Smedby, K. E., Lehtinen, T., Rostgaard, K., Glimelius, B., Munksgaard, L., Schollkopf, C.,  
8 Sundstrom, C., Chang, E. T., Koskela, P., Adami, H. O., and Hjalgrim, H. Atopy and risk of non-  
9 Hodgkin lymphoma. *Journal of the National Cancer Institute* 99[2], 158-166. 17-1-2007.  
10 Excl reason: Not in PICO
- 11 Miller, K. C., Musial, L., Whitworth, A., and Chanan-Khan, A. Management of patients with chronic  
12 lymphocytic leukemia treated with lenalidomide. [Review]. *Clinical Journal of Oncology Nursing*  
13 14[4], 491-499. 2010.  
14 Excl reason: Narrative review
- 15 Misawa, S., Tsuda, S., Taniwaki, M., Horiike, S., Ariyama, Y., Hirakawa, K., Ueda, Y., Kaneko, H.,  
16 Nakao, M., and Kashima, K. [A combined consecutive therapy with fosfomycin and  
17 sulbactam/cefoperazone for bacterial infections associated with hematological diseases].  
18 [Japanese]. *Japanese Journal of Antibiotics* 48[4], 514-521. 1995.  
19 Excl reason: Not in PICO
- 20 Montes Teves, P. A., Soria Medina, J. I., Gamarra Espinoza, Z. I., and Monge, Salgado E. [The  
21 physician's attitude towards infection by Helicobacter pylori in clinical practice]. [Spanish].  
22 *Revista de Gastroenterologia del Peru* 22[3], 221-227. 2002.  
23 Excl reason: Not in PICO
- 24 Morita, R., Yoshii, M., Nakajima, K., Kohsaka, T., Miki, M., and Torizuka, K. Clinical evaluation of  
25 serum ferritin to iron ratio in malignant diseases. *European Journal of Nuclear Medicine* 6[7],  
26 331-336. 1981.  
27 Excl reason: Not in PICO
- 28 Morrow, T. J., Volpe, S., Gupta, S., Tannous, R. E., and Fridman, M. Anemia of cancer in intermediate-  
29 grade non-Hodgkin's lymphoma. *Southern Medical Journal* 95[8], 889-896. 2002.  
30 Excl reason: Not in PICO
- 31 Morse, E. E., Yamase, H. T., Greenberg, B. R., Sporn, J., Harshaw, S. A., Kiraly, T. R., Ziemba, R. A., and  
32 Fallon, M. A. The role of flow cytometry in the diagnosis of lymphoma: a critical analysis. *Annals*  
33 *of Clinical & Laboratory Science* 24[1], 6-11. 1994.  
34 Excl reason: Not in PICO
- 35 Mueller, N. Overview: viral agents and cancer. [Review] [18 refs]. *Environmental Health Perspectives*  
36 103, Suppl-61. 1995.  
37 Excl reason: Narrative review
- 38 Munir, N. and Bradley, P. J. Diagnosis and management of neoplastic lesions of the submandibular  
39 triangle. *Oral Oncology* 44[3], 251-260. 2008.  
40 Excl reason: Not in PICO
- 41 Musiej-Nowakowska, E. and Rostropowicz-Denisiewicz, K. Differential diagnosis of neoplastic and  
42 rheumatic diseases in children. *Scandinavian Journal of Rheumatology* 15[2], 124-128. 1986.  
43 Excl reason: Not in PICO
- 44 Naito, Y., Okabe, Y., Kawahara, A., Taira, T., Yamagushi, T., Abe, H., Arikawa, S., Nakayama, M.,  
45 Yasumoto, M., Eriguchi, N., Naito, H., Kage, M., and Yano, H. Guide to diagnosing primary  
46 pancreatic lymphoma, B-cell type: immunocytochemistry improves the diagnostic accuracy of  
47 endoscopic ultrasonography-guided fine needle aspiration cytology. *Diagnostic Cytopathology*  
48 40[8], 732-736. 2012.  
49 Excl reason: Not in PICO
- 50 Nakamura, S., Aoyagi, K., Iwanaga, S., Yao, T., Tsuneyoshi, M., and Fujishima, M. Synchronous and  
51 metachronous primary gastric lymphoma and adenocarcinoma: a clinicopathological study of 12



- 1 patients. *Cancer* 79[6], 1077-1085. 15-3-1997.  
2 Excl reason: Not in PICO
- 3 Naranji, I., Zakri, R. H. & Liston, T. (2013) Mantle cell lymphoma presenting as a pelvi-ureteric  
4 junction obstruction: a case report. *Journal of Medical Case Reports [Electronic Resource]*, 7:  
5 105.  
6 Excl reason: Not in PICO
- 7 Narsana, N., Xie, J., Singhvi, G., and Aron, J. A case of non-hodgkins lymphoma mimicking metastatic  
8 colorectal cancer. *American Journal of Gastroenterology* 105, S320. 2010. Nature Publishing  
9 Group.  
10 Excl reason: Not in PICO
- 11 Naserallah, Z. and Al, Maher M. Clinical picture and outcome of poor risk non-Hodgkin's lymphoma  
12 in Saudi children. *International Pediatrics* 9[4], 247-250. 1994.  
13 Excl reason: Not in PICO
- 14 Nau, K. C. and Lewis, W. D. Multiple myeloma: diagnosis and treatment. [Review] [29 refs]. *American*  
15 *Family Physician* 78[7], 853-859. 1-10-2008.  
16 Excl reason: Narrative review
- 17 Navani, N., Nankivell, M., Woolhouse, I., Harrison, R. N., Munavvar, M., Oltmanns, U., Falzon, M.,  
18 Kocjan, G., Rintoul, R. C., and Janes, S. M. Endobronchial ultrasound-guided transbronchial  
19 needle aspiration for the diagnosis of intrathoracic lymphadenopathy in patients with  
20 extrathoracic malignancy: a multicenter study. *Journal of Thoracic Oncology: Official Publication*  
21 *of the International Association for the Study of Lung Cancer* 6[9], 1505-1509. 2011.  
22 Excl reason: Not in PICO
- 23 Neal, R. D. and Allgar, V. L. Sociodemographic factors and delays in the diagnosis of six cancers:  
24 analysis of data from the 'National Survey of NHS Patients: Cancer'. *British Journal of Cancer*  
25 92[11], 1971-1975. 2005.  
26 Excl reason: Not in PICO
- 27 Niscola, P., Cartoni, C., Romani, C., Brunetti, G. A., D'Elia, G. M., Cupelli, L., Tendas, A., de, Fabritiis P.,  
28 Mandelli, F., and Foa, R. Epidemiology, features and outcome of pain in patients with advanced  
29 hematological malignancies followed in a home care program: an Italian survey. *Annals of*  
30 *Hematology* 86[9], 671-676. 2007.  
31 Excl reason: Not in PICO
- 32 Nishimura, H. [Diagnosis of soft tissue tumors: 10 checkpoints]. [Review] [32 refs] [Japanese].  
33 *Nippon Igaku Hoshasen Gakkai Zasshi - Nippon Acta Radiologica* 61[6], 275-291. 2001.  
34 Excl reason: Narrative review
- 35 Nishimura, H. Diagnosis of soft tissue tumors: 10 checkpoints. [Japanese]. *Nihon Igaku Hoshasen*  
36 *Gakkai zasshi Nippon*[6], 275-291. 2001.  
37 Excl reason: Narrative review
- 38 Niv, Y. and Abuksis, G. Survey of the opinions, knowledge and practices of surgeons and internists  
39 regarding *Helicobacter pylori* test-and-treat policy. *Journal of Clinical Gastroenterology* 36[2],  
40 139-143. 2003.  
41 Excl reason: Not in PICO
- 42 Nuernberg, D., Ignee, A., and Dietrich, C. F. [Ultrasound in gastroenterology--liver and spleen].  
43 [Review] [92 refs] [German]. *Zeitschrift fur Gastroenterologie* 44[9], 991-1000. 2006.  
44 Excl reason: Narrative review
- 45 Nurnberg, D. [Ultrasound of adrenal gland tumours and indications for fine needle biopsy (uFNB)].  
46 [Review] [116 refs] [German]. *Ultraschall in der Medizin* 26[6], 458-469. 2005.  
47 Excl reason: Narrative summary
- 48 Ogwang, M. D., Zhao, W., Ayers, L. W., and Mbulaiteye, S. M. Accuracy of Burkitt lymphoma  
49 diagnosis in constrained pathology settings: importance to epidemiology. *Archives of Pathology*  
50 *& Laboratory Medicine* 135[4], 445-450. 2011.  
51 Excl reason: Not in PICO

- 1 Ol'khova, E. B., Shumeiko, N. K., and Fomichev, M. I. [Mesadenitis in children with acute abdominal  
2 pain syndrome: clinical and echographic parallels]. [Review] [Russian]. Vestnik Rentgenologii i  
3 Radiologii.(3):45-8, 2011 Jul-Aug. [3], 45-48. 2011.  
4 Excl reason: Narrative review
- 5 Otrock, Z. K., Hatoum, H. A., Uthman, I. W., Taher, A. T., Saab, S., and Shamseddine, A. I. Non-  
6 Hodgkin's lymphoma in a woman with adult-onset Still's disease: a case report. Journal of  
7 Medical Case Reports [Electronic Resource] 2, 73. 2008.  
8 Excl reason: Not in PICO
- 9 Paauw, D. S., Wenrich, M. D., Curtis, J. R., Carline, J. D., and Ramsey, P. G. Ability of primary care  
10 physicians to recognize physical findings associated with HIV infection. JAMA 274[17], 1380-  
11 1382. 1-11-1995.  
12 Excl reason: Not in PICO
- 13 Pagano, J. S. Epstein-Barr virus: the first human tumor virus and its role in cancer. [Review] [24 refs].  
14 Proceedings of the Association of American Physicians 111[6], 573-580. 1999.  
15 Excl reason: Narrative review
- 16 Pasic, S., Minic, A., Djuric, P., Micic, D., Kuzmanovic, M., Sarjanovic, L., and Markovic, M. Fever of  
17 unknown origin in 185 paediatric patients: a single-centre experience. Acta Paediatrica 95[4],  
18 463-466. 2006.  
19 Excl reason: Not in PICO
- 20 Patel, H. and Sisson, S. Wegeners granulomatosis in a patient with fever of unknown origin. Journal  
21 of General Internal Medicine 25, S564. 2010. Springer New York.  
22 Excl reason: Not in PICO
- 23 Paulaviciene, R., Asoklis, R., Malysko, K., Petroska, D., Kryzauskaite, L., and Rutkauskaite, D.  
24 Diagnostic aspects and immunologic identification potentials of ocular adnexal lymphoma:  
25 Report of selected cases. Acta Ophthalmologica 90, 80. 2012. Blackwell Publishing Ltd.  
26 Excl reason: Not in PICO
- 27 Perkins, S. L., Segal, G. H., and Kjeldsberg, C. R. Work-up of lymphadenopathy in children. [Review]  
28 [18 refs]. Seminars in Diagnostic Pathology 12[4], 284-287. 1995.  
29 Excl reason: Narrative review
- 30 Pietinalho, A., Ohmichi, M., Hiraga, Y., Lofroos, A. B., and Selroos, O. The mode of presentation of  
31 sarcoidosis in Finland and Hokkaido, Japan. A comparative analysis of 571 Finnish and 686  
32 Japanese patients. Sarcoidosis Vasculitis & Diffuse Lung Diseases 13[2], 159-166. 1996.  
33 Excl reason: Not in PICO
- 34 Pittman, M. E., Chen, L., Frater, J. L., Hassan, A., Nguyen, T. T., and Kreisel, F. Utility of cerebrospinal  
35 fluid in the diagnosis of non-hodgkin lymphoma. Laboratory Investigation 92, 103A. 2012.  
36 Nature Publishing Group.  
37 Excl reason: Not in PICO
- 38 Pongas, G., Hamilos, G., Rolston, K. V., and Kontoyiannis, D. P. Formal adult infectious disease  
39 specialist consultations in the outpatient setting at a comprehensive cancer center (1998-2008):  
40 diverse and impactful. Supportive Care in Cancer 20[2], 261-265. 2012.  
41 Excl reason: Not in PICO
- 42 Purysko, A. S., Coppa, C. P., Kalady, M. F., Pai, R. K., Leao Filho, H. M., Thupili, C. R. & Remer, E. M.  
43 (2014) - Benign and malignant tumors of the rectum and perirectal region. - *Abdominal Imaging*,  
44 39: 824-852.  
45 Excl reason: Narrative review
- 46 Pylpchuk, R. D., Schouten, L. J., Goldbohm, R. A., Schouten, H. C., and van den Brandt, P. A. Body  
47 mass index, height, and risk of lymphatic malignancies: a prospective cohort study. American  
48 Journal of Epidemiology 170[3], 297-307. 1-8-2009.  
49 Excl reason: Not in PICO
- 50 Raderer, M., Puspok, A., Stummvoll, G., Langle, F., and Chott, A. Early cancer of the stomach arising  
51 after successful treatment of gastric MALT lymphoma in patients with autoimmune disease.

- 1 Scandinavian Journal of Gastroenterology 38[3], 294-297. 2003.  
2 Excl reason: Not in PICO
- 3 Ragupathy, K. & Bappa, L. (2013) Primary vaginal Non-Hodgkin lymphoma: Gynecologic diagnosis of  
4 a hematologic malignancy. *Journal of Lower Genital Tract Disease*, 17: 326-329.  
5 Excl reason: Not in PICO
- 6 Raza, K. and Dunitz, J. 19 Year old patient with "Recurrent asthma". American Journal of Respiratory  
7 and Critical Care Medicine 181[1 MeetingAbstracts]. 1-5-2010. American Thoracic Society.  
8 Excl reason: Not in PICO
- 9 Reamy, B. V., Bunt, C. W., and Fletcher, S. A diagnostic approach to pruritus. American Family  
10 Physician 84[2], 195-202. 15-7-2011.  
11 Excl reason: Narrative review
- 12 Reddy, U., Bewick, J., Good, C., Chevassut, T., and Das-Purkayastha, P. K. Diffuse large B-cell  
13 lymphoma: An unusual cause of severe otalgia and facial palsy. *BMJ Case Reports* . 2012.  
14 Excl reason: Not in PICO
- 15 Ridolfo, A. L., Santambrogio, S., Mainini, F., Vago, L., Gervasoni, C., Gori, A., Parravicini, C., Monforte,  
16 A. A., and Galli, M. High frequency of non-Hodgkin's lymphoma in patients with HIV-associated  
17 Kaposi's sarcoma. *AIDS* 10[2], 181-185. 1996.  
18 Excl reason: Not in PICO
- 19 Riederer, A., Zietz, C., Ihrler, S., and Vogl, T. [Cystic lymphoepithelial lesions in the head and neck  
20 area in HIV-infected patients]. [German]. *Laryngo- Rhino- Otologie* 73[4], 209-214. 1994.  
21 Excl reason: Not in PICO
- 22 Robotin, M. C., Law, M. G., Milliken, S., Goldstein, D., Garsia, R. J., Dolan, G. M., Kaldor, J. M., and  
23 Grulich, A. E. Clinical features and predictors of survival of AIDS-related non-Hodgkin's  
24 lymphoma in a population-based case series in Sydney, Australia. *Hiv Medicine* 5[5], 377-384.  
25 2004.  
26 Excl reason: Not in PICO
- 27 Romera, M., Heras, I., Castilla, C., Nieto, J. B., Manchado, J. J., Perez-Ceballos, E., Amigo, M. L.,  
28 Lozano, M., and Vicente, V. Clinical features and outcome of respiratory syncytial virus infection  
29 in 26 haematologic disorders patients. *Bone Marrow Transplantation* 46, S224. 2011. Nature  
30 Publishing Group.  
31 Excl reason: Not in PICO
- 32 Rubio-Rivas, M., Vidaller, A., Pujol, I. Farriols, and Mast, R. [Rapid diagnosis unit in a third level  
33 hospital. Descriptive study of the first year and a half]. [Spanish]. *Revista Clinica Espanola*  
34 208[11], 561-563. 2008.  
35 Excl reason: Not in PICO
- 36 Ruffer, J. U., Flechtner, H., Heim, M., Schwarz, R., and Weis, J. [Cancer fatigue syndrome]. [German].  
37 *Versicherungsmedizin* 55[1], 3-7. 1-3-2003.  
38 Excl reason: Not in PICO
- 39 Rustagi, T., DeVries, K., and Diez, L. Screening colonoscopy in chronic hepatitis C patients. *American*  
40 *Journal of Gastroenterology* 105, S562-S563. 2010. Nature Publishing Group.  
41 Excl reason: Not in PICO
- 42 Saber, M. M., Zeeneldin, A. A., Samra, M. A. & Farag, S. A. (2013) Primary gastrointestinal lymphoma  
43 in an Egyptian district: a study using a population-based cancer registry. *Journal of Egyptian*  
44 *National Cancer Institute*, 25: 95-101.  
45 Excl reason: Not in PICO
- 46 Saito, R., Ishizuka, E., Iwasaki, A., Chiba, K., Ambo, T., and Kobayashi, K. Malignant lymphoma of the  
47 testis: A case report. [Japanese]. *Nishinohon Journal of Urology* 57[9], 1016-1018. 1995.  
48 Excl reason: Not in PICO
- 49 Sakakihara, Y. [Primary care in pediatrics: Immediate diagnosis in first visit]. [Review] [0 refs]  
50 [Japanese]. *Nippon Rinsho - Japanese Journal of Clinical Medicine* 64[11], 2164. 2006.  
51 Excl reason: Narrative review? (Japanese one page article)

- 1 Sauter, E. R., Arensman, R. M., and Falterman, K. W. Thymic enlargement in children. *American*  
2 *Surgeon* 57[1], 21-23. 1991.  
3 Excl reason: Not in PICO
- 4 Savage, S. A., Wotherspoon, H. A., Fitzsimons, E. J., and MacKenzie, K. Cervical lymphadenopathy  
5 resulting in a diagnosis of lymphoma. *Scottish Medical Journal* 53[3], 13-16. 2008.  
6 Excl reason: Not in PICO
- 7 Schechter, M. T., Boyko, W. J., Jeffries, E., Willoughby, B., Nitz, R., and Constance, P. The Vancouver  
8 Lymphadenopathy-AIDS Study: 1. Persistent generalized lymphadenopathy. *Canadian Medical*  
9 *Association Journal* 132[11], 1273-1279. 1-6-1985.  
10 Excl reason: Not in PICO
- 11 Schleiffenbaum, B. and Fehr, J. Value of the blood picture and flow cytometry immunotyping in the  
12 early diagnosis of low-grade lymphoma. [German]. *Therapeutische Umschau Revue*[2], 117-122.  
13 1996.  
14 Excl reason: Narrative review
- 15 Schleiffenbaum, B. and Fehr, J. [Value of the blood picture and flow cytometry immunotyping in the  
16 early diagnosis of low-grade lymphoma]. [Review] [15 refs] [German]. *Therapeutische Umschau*  
17 *53*[2], 117-122. 1996.  
18 Excl reason: Narrative review
- 19 Schmidt, N., Kostev, K., Ziller, V., Kowall, B. & Rathmann, W. (2014) Association of diabetes and  
20 cancer-diagnoses in primary care practices in Germany. *Journal of Clinical Oncology*, 32.  
21 Excl reason: Published as abstract only. Not enough information available to ascertain relevance.
- 22 Schroder, J. [Enlarged lymph nodes as an incidental finding. How can carcinoma be excluded?].  
23 [German]. *MMW Fortschritte der Medizin* 143[7], 30-32. 15-2-2001.  
24 Excl reason: Narrative review
- 25 Schusterbauer, C., Cairoli, A., and Ketterer, N. [Management of lymphoma and pregnancy]. [French].  
26 *Revue Medicale Suisse* 5[204], 1104-1106. 1108.  
27 Excl reason: Narrative review
- 28 Scully, C. and Felix, D. H. Oral medicine--update for the dental practitioner lumps and swellings.  
29 *British Dental Journal* 199[12], 763-770. 24-12-2005.  
30 Excl reason: Narrative review
- 31 Sengupta, S. and Pal, R. Clinicopathological correlates of pediatric head and neck cancer. *Journal of*  
32 *Cancer Research and Therapeutics* 5[3], 181-185. 2009.  
33 Excl reason: Not in PICO
- 34 Sharma, A., Bajpai, J., Raina, V., and Mohanti, B. K. HIV-associated non-Hodgkins lymphoma:  
35 Experience from a regional cancer center. *Indian Journal of Cancer* 47[1], 35-39. 2010.  
36 Excl reason: Not in PICO
- 37 Sheth, S., Ali, S., and Fishman, E. Imaging of renal lymphoma: patterns of disease with pathologic  
38 correlation. [Review] [49 refs]. *Radiographics* 26[4], 1151-1168. 2006.  
39 Excl reason: Narrative review
- 40 Shibuya, T., Osada, T., Mori, H., Matsumoto, K., Beppu, K., Sakamoto, N., Nagahara, A., Otaka, M.,  
41 Ogihara, T., and Watanabe, S. Use of double balloon endoscopy for the early diagnosis of small  
42 intestinal malignant neoplasms. *Gastrointestinal Endoscopy* 69[5], AB200. 2009. Mosby Inc.  
43 Excl reason: Not in PICO
- 44 Small, M., Vidyarthi, G., Boyd, W., and Haley, J. A. Amyloidosis in a patient with maltoma of stomach.  
45 *American Journal of Gastroenterology* 105, S41. 2010. Nature Publishing Group.  
46 Excl reason: Not in PICO
- 47 Snarski, E., Drozd, J., Ejno, T., Brzezinski, R., Szarewicz, H., and Wiktor-Jedrzejczak, W. [Time to  
48 diagnosis as an index of efficiency of the health care system--lymphoma study]. [Polish].  
49 *Wiadomosci Lekarskie* 59[1-2], 58-60. 2006.  
50 Excl reason: Not in PICO

- 1 Soderholm, A. L., Lindqvist, C., Heikinheimo, K., Forssell, K., and Happonen, R. P. Non-Hodgkin's  
2 lymphomas presenting through oral symptoms. *International Journal of Oral & Maxillofacial*  
3 *Surgery* 19[3], 131-134. 1990.  
4 Excl reason: Not in PICO
- 5 Spillane, J. A., Kendall, B. E., and Moseley, I. F. Cerebral lymphoma: Clinical radiological correlation.  
6 *Journal of Neurology Neurosurgery and Psychiatry* 45[3], 199-208. 1982.  
7 Excl reason: Not in PICO
- 8 Sposto, R., Meadows, A. T., Chilcote, R. R., Steinherz, P. G., Kjeldsberg, C., Kadin, M. E., Krailo, M. D.,  
9 Termuhlen, A. M., Morse, M., and Siegel, S. E. Comparison of long-term outcome of children and  
10 adolescents with disseminated non-lymphoblastic non-hodgkin lymphoma treated with COMP or  
11 daunomycin-comp: A report from the children's cancer group. *Medical and Pediatric Oncology*  
12 37[5], 432-441. 2001.  
13 Excl reason: Not in PICO
- 14 Srinivasan, R. E., Turner, A. G., and Panda, M. Lymphomas can "cry wolf" too. *Journal of General*  
15 *Internal Medicine* 26, S408. 2011. Springer New York.  
16 Excl reason: Not in PICO
- 17 Srinivasan, S., Takeshita, K., Holkova, B., Czuczman, M. S., Miller, K., Bernstein, Z. P., Driscoll, D., and  
18 Chanan-Khan, A. Clinical characteristics of gastrointestinal lymphomas associated with AIDS (GI-  
19 ARL) and the impact of HAART. *Hiv Clinical Trials* 5[3], 140-145. 2004.  
20 Excl reason: Not in PICO
- 21 Stenstad, T. [Adult-onset Still's disease. An underdiagnosed condition?]. [Norwegian]. *Tidsskrift for*  
22 *Den Norske Laegeforening* 115[29], 3616-3618. 30-11-1995.  
23 Excl reason: Not in PICO
- 24 Stiefelhagen, P. [Enlarged lymph nodes. Routine general practice finding]. [German]. *MMW*  
25 *Fortschritte der Medizin* 143, Suppl-42. 2001.  
26 Excl reason: Narrative review
- 27 Stohlner, V., Chatzizacharias, N. A., Parthasarathy, M. & Groot-Wassink, T. (2013) Jejunojejunal  
28 Intussusception as the Initial Presentation of Non-Hodgkin's B-Cell Lymphoma in an Adult  
29 Patient: A Case Report and Review of the Literature. *Case Reports in Surgery*, 2013: 619031.  
30 Excl reason: Not in PICO
- 31 Subortseva, I., Lepkov, S., Poddybnaya, I., Storogakov, G., Kovrigina, A., Kolomyicev, O., Kosura, S.,  
32 and Malihova, O. Simultaneous development of hepatocellular carcinoma and non-hodgkin  
33 lymphoma in a patient with chronic hepatitis C. *Hepatology International* 5[1], 382-383. 2011.  
34 Springer New York.  
35 Excl reason: Not in PICO
- 36 Subortseva, I. N., Poddubnaya, I., Kovrigina, A. M., Kokosadze, N. V., and Osmanov, D. S. Difficulties  
37 in differential diagnosis of primary pulmonary lymphoma. *Journal of Thoracic Oncology* 5[5  
38 SUPPL. 1], S115. 2010. International Association for the Study of Lung Cancer.  
39 Excl reason: Not in PICO
- 40 Suresh, S., Saifuddin, A., and O'Donnell, P. Lymphoma presenting as a musculoskeletal soft tissue  
41 mass: MRI findings in 24 cases. *European Radiology* 18[11], 2628-2634. 2008.  
42 Excl reason: Not in PICO
- 43 Tao, J., Shelat, S. G., Jaffe, E. S., and Bagg, A. Aggressive Epstein-Barr virus-associated, CD8+, CD30+,  
44 CD56+, surface CD3-, natural killer (NK)-like cytotoxic T-cell lymphoma. *American Journal of*  
45 *Surgical Pathology* 26[1], 111-118. 2002.  
46 Excl reason: Not in PICO
- 47 te Raa, G. D., van Oers, M. H., and Kater, A. P. Monoclonal B-cell lymphocytosis: Recommendations  
48 from the Dutch Working Group on CLL for daily practice. *Netherlands Journal of Medicine* 70[5],  
49 236-241. 2012.  
50 Excl reason: Narrative review

- 1 Teo, W.-Y., Chan, M.-Y., Ng, K.-C., and Tan, A.-M. Bony presentations of childhood haematological  
2 malignancy to the emergency room. *Journal of Paediatrics and Child Health* 48[4], 311-316.  
3 2012.  
4 Excl reason: Not in PICO
- 5 Thalhammer-Scherrer, R., Veitl, M., Exner, M., Schneider, B., Geissler, K., Simonitsch, I., and  
6 Schwarzingler, I. Role of immunological lymphocyte subset typing as a screening method for  
7 lymphoid malignancies in daily routine practice. *Cytometry* 42[1], 5-10. 15-2-2000.  
8 Excl reason: Not in PICO
- 9 Tobinai, K. Current management of adult T-cell leukemia/lymphoma. *Oncology (Williston Park)*  
10 23[14], 1250-1256. 2009.  
11 Excl reason: Narrative review
- 12 Tomiak, C. Prognosis of Primary Sjogren's Syndrome with Special Regard to the Risk of Lymphoma.  
13 *Aktuelle Rheumatologie* 33[6], 325-336. 2008.  
14 Excl reason: Narrative review
- 15 Tsachouridou, O., Christoforidou, A., Metallidis, S., Papaioannou, M., Kollaras, P., Kolokotronis, A.,  
16 Chrysanthis, T., Pilalas, D., and Markou, K. Plasmablastic lymphoma of the oral cavity, a B cell-  
17 derived lymphoma associated with HIV infection: A case series. *European Archives of Oto-Rhino-  
18 Laryngology* 269[6], 1713-1719. 2012.  
19 Excl reason: Not in PICO
- 20 Tsai, M. S., Kuo, C. Y., Wang, M. C., Wu, H. C., Chien, C. C., and Liu, J. W. Clinical features and risk  
21 factors for mortality in *Aeromonas* bacteremic adults with hematologic malignancies. *Journal of  
22 Microbiology, Immunology & Infection* 39[2], 150-154. 2006.  
23 Excl reason: Not in PICO
- 24 Urushizaki, I. [Palliative therapy in cancer. 4. Palliation of the symptoms from a malignant tumor.  
25 (2)]. [Review] [32 refs] [Japanese]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer &  
26 Chemotherapy]* 17[8:Pt 1], t-35. 1990.  
27 Excl reason: Narrative review
- 28 Vanis, N., Mesihovic, R., Ibricevic, L. & Dobrila-Dintinjana, R. (2013) Predictive value of endoscopic  
29 ultrasound in diagnosis and staging of primary gastric lymphoma. *Collegium Antropologicum*, 37:  
30 Suppl-7.  
31 Excl reason: Not in PICO
- 32 Varoczy, L., Danko, A., Simon, Z., Gergely, L., Rész, Z., and Illes, A. Malignant lymphomas in the  
33 elderly: A single institute experience highlights future directions. *Archives of Gerontology and  
34 Geriatrics* 45[1], 43-53. 2007.  
35 Excl reason: Not in PICO
- 36 Vasil'ev, V. I., Probatova, N. A., Tupitsin, N. N., Varlamova, E. I., Logvinenko, O. A., Rodionova, E. B.,  
37 Kovrigina, A. M., Kokosadze, N. V., Panin, M. G., Gaiduk, I. V., Gorbunova, T. V., Kondrat'eva, T.  
38 T., Sholokhova, E. N., Simonova, M. V., Safonova, T. N., and Radenska-Lopovok, S. G. [MALT-  
39 lymphomas in Sjogren's disease]. [Russian]. *Terapevticheskii Arkhiv* 78[1], 45-52. 2006.  
40 Excl reason: Not in PICO
- 41 Vaughn, C. P., Crockett, D. K., Lin, Z., Lim, M. S., and Elenitoba-Johnson, K. S. Identification of  
42 proteins released by follicular lymphoma-derived cells using a mass spectrometry-based  
43 approach. *Proteomics* 6[10], 3223-3230. 2006.  
44 Excl reason: Not in PICO
- 45 Verghese, G., Refaat, S. & Karar, A. (2013) Unusual presentation of diffuse large B-cell lymphoma  
46 (DLBCL) as acute osteomyelitis of the femur. *Journal of the Bahrain Medical Society*, 24: 140-144.  
47 Excl reason: Not in PICO
- 48 Voulgarelis, M., Dafni, U. G., Isenberg, K. A., and Moutsopoulos, H. M. Malignant lymphoma in  
49 primary Sjogren's syndrome - A multicenter, retrospective, clinical study by the European  
50 concerted action on Sjogren's syndrome. *Arthritis and Rheumatism* 42[8], 1765-1772. 1999.  
51 Excl reason: Not in PICO

- 1 Vowles, R. H., Ghiacy, S., and Jefferis, A. F. A clinic for the rapid processing of patients with neck  
2 masses. *Journal of Laryngology & Otology* 112[11], 1061-1064. 1998.  
3 Excl reason: Not in PICO
- 4 Wagner, H. J. and Knyrim, K. Relief of malignant obstructive jaundice by endoscopic or percutaneous  
5 insertion of metal stents. *Bildgebung/Imaging* 60[2], 76-82. 1993.  
6 Excl reason: Not in PICO
- 7 Wakely, P. E., Jr. and Kornstein, M. J. Aspiration cytopathology of lymphoblastic lymphoma and  
8 leukemia: the MCV experience. *Pediatric Pathology & Laboratory Medicine* 16[2], 243-252. 1996.  
9 Excl reason: Not in PICO
- 10 Walker, T. L. and Lopez, G. E. A case of an abdominal mass: follicular lymphoma. *Permanente Journal*  
11 15[4], 61-64. 2011.  
12 Excl reason: Not in PICO
- 13 Watanabe, H. Malignant lymphoma of the stomach. Collected eighty-seven cases. [Japanese].  
14 *Stomach and Intestine* 15[9], 909-910. 1980.  
15 Excl reason: Not in PICO
- 16 Webb, T. H., Lillemoe, K. D., Pitt, H. A., Jones, R. J., and Cameron, J. L. Pancreatic lymphoma. Is  
17 surgery mandatory for diagnosis or treatment? *Annals of Surgery* 209[1], 25-30. 1989.  
18 Excl reason: Not in PICO
- 19 Welles, S. L., Levine, P. H., Joseph, E. M., Goberdhan, L. J., Lee, S., Miotti, A., Cervantes, J., Bertoni,  
20 M., Jaffe, E., and Dosik, H. An enhanced surveillance program for adult T-cell leukemia in central  
21 Brooklyn. *Leukemia* 8, Suppl-5. 1994.  
22 Excl reason: Not in PICO
- 23 Wennekes, L., Ottevanger, P. B., Raemaekers, J. M., Schouten, H. C., De Kok, M. W. E., Punt, C. J. A.,  
24 Grol, R. P., Wollersheim, H. C., and Hermens, R. P. Development and Measurement of Guideline-  
25 Based Indicators for Patients With Non-Hodgkin's Lymphoma. *Journal of Clinical Oncology*  
26 29[11], 1436-1444. 2011.  
27 Excl reason: Not in PICO
- 28 Wesnes, K. A., Brooker, H., and Edgar, C. The disruptions to cognition, everyday function, and quality  
29 of life in oncology patients: A therapeutic opportunity? *Neurotherapeutics* 7[3], 331-332. 2010.  
30 Elsevier Inc.  
31 Excl reason: Not in PICO
- 32 Wierecky, J. and Bokemeyer, C. [Compression syndromes]. [Review] [28 refs] [German]. *Internist*  
33 46[1], 9-18. 2005.  
34 Excl reason: Narrative review
- 35 Williams, N. P., Shirley, S. E., Williams, E., Wharfe, G., and Hanchard, B. Malignant lymphoma of  
36 gastric mucosa-associated lymphoid tissue in Jamaica. *West Indian Medical Journal* 48[3], 150-  
37 154. 1999.  
38 Excl reason: Narrative review
- 39 Wood, L. A., Coupland, R. W., North, S. A., and Palmer, M. C. Outcome of advanced stage low grade  
40 follicular lymphomas in a population-based retrospective cohort. *Cancer* 85[6], 1361-1368. 15-3-  
41 1999.  
42 Excl reason: Not in PICO
- 43 Woods, W. G. The use and significance of biologic markers in the evaluation and staging of a child  
44 with cancer. *Cancer* 58[2:Suppl], Suppl-8. 15-7-1986.  
45 Excl reason: Narrative review
- 46 Wutzler, P., Farber, I., and Sauerbrei, A. Demonstration of Epstein-Barr virus in malignant non-  
47 Hodgkin's lymphomas. *Oncology* 43[4], 224-229. 1986.  
48 Excl reason: Not in PICO
- 49 Yamada, Y., Kamihira, S., Murata, K., Yamamura, M., Maeda, T., Tsukasaki, K., Jubash, T., Atogami, S.,  
50 Sohda, H., Taguchi, T., and Tomonaga, M. Frequent hepatic involvement in adult T cell leukemia:

- 1 comparison with non-Hodgkin's lymphoma. *Leukemia & Lymphoma* 26[3-4], 327-335. 1997.  
 2 Excl reason: Not in PICO
- 3 Yamashita, H., Takahashi, Y., Kano, T., Kaneko, H., and Mimori, A. [Malignant lymphoma presenting  
 4 as inflammation of unknown origin]. [Japanese]. *Nihon Rinsho Meneki Gakkai Kaishi* 35[2], 136-  
 5 143. 2012.  
 6 Excl reason: Not in PICO
- 7 Yang, J. and Yuan, G. [Primary intracranial malignant lymphoma: report of 40 cases]. [Chinese].  
 8 *Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery]* 34[2], 102-103. 1996.  
 9 Excl reason: Not in PICO
- 10 Yano, M., Yamakawa, Y., Niwa, H., Fukai, I., Kiriya, M., Saito, Y., Kani, H., Sasaki, H., and Masaoka,  
 11 A. [Clinical considerations from sixteen cases with mediastinal malignant lymphoma]. [Japanese].  
 12 *Nippon Kyobu Geka Gakkai Zasshi - Journal of the Japanese Association for Thoracic Surgery*  
 13 44[8], 1114-1118. 1996.  
 14 Excl reason: Not in PICO
- 15 Yao, M., Cheng, A. L., Su, I. J., Lin, M. T., Uen, W. C., Tien, H. F., Wang, C. H., and Chen, Y. C.  
 16 Clinicopathological spectrum of haemophagocytic syndrome in Epstein-Barr virus-associated  
 17 peripheral T-cell lymphoma. *British Journal of Haematology* 87[3], 535-543. 1994.  
 18 Excl reason: Not in PICO
- 19 Yokota, T., Meguro, K., Yamada, Y., Kikuchi, S., Yamauchi, H., and Hatori, M. Diffuse peritonitis  
 20 caused by perforation of ileal lymphoma: Two case reports and clinicopathological features of 81  
 21 cases in Japan. *Leukemia and Lymphoma* 47[6], 1157-1159. 2006.  
 22 Excl reason: Not in PICO
- 23 Yoshihara, T. Bilateral enlargement of the submandibular glands - Clinical and pathological  
 24 appearance. [Japanese]. *Practica Oto-Rhino-Laryngologica* 95[6], 555-561. 2002.  
 25 Excl reason: Not in PICO/narrative review
- 26 Young, G., Toretsky, J. A., Campbell, A. B., and Eskenazi, A. E. Recognition of common childhood  
 27 malignancies. [Review] [18 refs]. *American Family Physician* 61[7], 2144-2154. 1-4-2000.  
 28 Excl reason: Narrative review
- 29 Yu, Xue, Chen, Wendy, and O'Connell, Dianne. Improved survival for non-Hodgkin lymphoma  
 30 patients in New South Wales, Australia. *BMC Cancer* 10[1], 231. 2010.  
 31 Excl reason: Not in PICO
- 32 Zafrani, E. S., Leclercq, B., Vernant, J. P., Pinaudeau, Y., Chomette, G., and Dhumeaux, D. Massive  
 33 blastic infiltration of the liver: a cause of fulminant hepatic failure. *Hepatology* 3[3], 428-432.  
 34 1983.  
 35 Excl reason: Not in PICO
- 36 Zajkowska, J. M., Garkowski, A., Zajkowska, A., Pancewicz, S. A., and Letmanowski, M. Cases of  
 37 cancer diagnosed at the Department of Infectious Diseases and Neuroinfections at the Medical  
 38 University of Bialystok. [Polish]. *Nowotwory* 62[3], 163-167. 2012.  
 39 Excl reason: Not in PICO
- 40 Zawitkowska-Klaczynska, J., Katski, K., Nurzynska-Flak, J., and Kowalczyk, J. Primary chest tumours in  
 41 children. *Annales Universitatis Mariae Curie-Sklodowska - Sectio d - Medicina* 58[2], 106-110.  
 42 2003.  
 43 Excl reason: Not in PICO
- 44 Zenone, T. Parotid gland non-Hodgkin lymphoma in primary Sjogren syndrome. *Rheumatology*  
 45 *International* 32[5], 1387-1390. 2012.  
 46 Excl reason: Not in PICO
- 47 Zhang, J., Grubor, V., Love, C. L., Banerjee, A., Richards, K. L., Mieczowski, P., Dunphy, C. H., Choi, W.  
 48 W. L., Auv, W.-Y., Srivastava, G., Lugar, P. L., Rizzieri, D. A., Lagoo, A. S., Bernal-Mizrachi, L.,  
 49 Mann, K. P., Flowers, C. R., Naresh, K. N., Evens, A. M., Gordon, L. I., Czader, M. B., Gill, J. I., Hsi,  
 50 E. D., Liu, Q., Fan, A., Walsh, K., Jima, D. D., Luftig, M., Ni, T., Zhu, J., Chadburn, A., Levy, S.,  
 51 Dunson, D. B., and Dave, S. S. The genetic landscape of immune-competent and HIV lymphoma.



1 Infectious Agents and Cancer 7. 19-4-2012. BioMed Central Ltd.

2 Excl reason: Not in PICO

3 Zhou, Q. T., Zhu, H., and He, B. [Clinical analysis of lymphoma with chest involvement: report of 25  
4 cases]. [Chinese]. *Chung-Hua Nei Ko Tsa Chih Chinese Journal of Internal Medicine* 48[10], 846-  
5 849. 2009.

6 Excl reason: Not in PICO

7 Ziaei, M., Elgohary, M. A. & Bremner, F. D. (2013) Palinopsia as the initial manifestation of non-  
8 hodgkin's lymphoma. *International Ophthalmology*, 33: 553-556.

9 Excl reason: Not in PICO

10 Zlotnick, D. M., Merrens, E. J., Fingar, E. L., and Levy, N. B. A 69-year-old male presenting with  
11 hypotension and anasarca. *American Journal of Hematology* 83[4], 311-314. 2008.

12 Excl reason: Not in PICO

13 Zullo, A., Hassan, C., Cristofari, F., Iegri, C., Villiva, N., Andriani, A., and Morini, S. Can we eradicate  
14 gastric MALT-lymphoma?. [Italian]. *Italian Journal of Medicine* 4[3], 154-158. 2010.

15 Excl reason: Narrative review

### 17 Review question:

18 Which investigations of symptoms of suspected Non-Hodgkin's lymphoma cancer should be done  
19 with clinical responsibility retained by primary care?  
20

### 21 Results

#### 22 Literature search

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1980-2012	320	102	20/12/2012
<i>Premedline</i>	1980-2012	3	1	07/01/2013
<i>Embase</i>	1980-2012	331	64	20/12/2012
<i>Cochrane Library</i>	1980-2012	31	0	07/01/2013
<i>Psychinfo</i>	1980-2012	0	0	07/01/2013
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	1980-2012	31	2	07/01/2013
<i>Biomed Central</i>	1980-2012	312	1	07/01/2013


23 Total References retrieved (after de-duplication): 140

#### 25 Update Search

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	2013- 20/08/2014	19	5	20/08/2014
<i>Premedline</i>	2013- 20/08/2014	5	4	20/08/2014
<i>Embase</i>	2013- 20/08/2014	87	16	20/08/2014
<i>Cochrane Library</i>	2013- 20/08/2014	19	0	20/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	2013- 20/08/2014	3	0	20/08/2014

26 Total References retrieved (after de-duplication): 22  
27

1



2

3

4

5

## Study results

6

7

No evidence was identified pertaining to the diagnostic accuracy of CT scan, ultrasound, chest X-ray or LDH in patients with suspected non-hodgkin's lymphoma cell cancer where the clinical responsibility was retained by primary care.

9

10

11

## References

12

### Included studies

13

None

14

15

### Excluded studies

16

Abel, G. A., Vanderplas, A., Rodriguez, M. A., Crosby, A. L., Czuczman, M. S., Niland, J. C., Gordon, L. I., Millenson, M., Zelenetz, A. D., Friedberg, J. W., and LaCasce, A. S. High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. *Leukemia & Lymphoma* 53[6], 1113-1116. 2012.

20

Excl reason: Not relevant to PICO

21

Alzubi, A., Zollei, I., Krenacs, L., Intzedy, K., and Hudak, J. [Primary T-cell lymphoma of the small bowel]. [Hungarian]. *Magyar Sebeszet* 61[2], 79-83. 2008.

23

Excl reason: Single Case/Foreign Language

24

Ambrosini, V., Rubello, D., Castellucci, P., Nanni, C., Farsad, M., Zinzani, P., Alavi, A., Tehranipour, N., Al-Nahhas, A., and Fanti, S. Diagnostic role of 18F-FDG-PET in gastric MALT lymphoma. *Nuclear Medicine Review* 9[1], 37-40. 2006.

27

Excl reason: Population not relevant to PICO

28

Amezyane, T., Lecoules, S., Bordier, L., Blade, J. S., Desrame, J., Bechade, D., Coutant, G., and Algayres, J. P. [Humoral hypercalcemia revealing a malignant non hodgkin lymphoma]. [French]. *Annales d Endocrinologie* 69[1], 58-62. 2008.

31

Excl reason: Single Case/Foreign Language

32

Antunes, A. A., Nesrallah, L. J., and Srougi, M. Non-Hodgkin lymphoma of the bladder. *International Braz J Urol* 30[6], 499-501. 2004.

34

Excl reason: Single Case

- 1 Aroor, A. R., Rama, P. S., Seshadri, S., Teerthanath, S. & Raghuraj, U. (2014) A study of clinical  
2 characteristics of mediastinal mass. *Journal of Clinical and Diagnostic Research*, 8: 77-80.  
3 Excl reason: Not in PICO
- 4 Asai, S., Miyachi, H., Oshima, S., Kawakami, C., Kubota, M., and Ando, Y. A scoring system for  
5 ultrasonographic differentiation between cervical malignant lymphoma and benign  
6 lymphadenitis. *Rinsho Byori - Japanese Journal of Clinical Pathology* 49[6], 613-619. 2001.  
7 Excl reason: Not relevant to PICO
- 8 Ashraf, F. Primary pancreatic lymphoma mimicking adenocarcinoma of pancreas. *American Journal of  
9 Gastroenterology* 105, S214. 2010. Nature Publishing Group.  
10 Excl reason: Single Case
- 11 Baba, H. A., Tietze, L., Merkelbach, S., and Fuzesi, L. Diagnosis of non-Hodgkin lymphoma of the  
12 maxilla with support of polymerase chain reaction. *General & Diagnostic Pathology* 142[1], 53-57.  
13 1996.  
14 Excl reason: Single Case
- 15 Banno, S., Nitta, M., Takada, K., Hasegawa, R., Niimi, T., and Yamamoto, T. [Non-Hodgkin's  
16 lymphoma with pulmonary involvement and various immunological abnormalities in an elderly  
17 patient]. [Japanese]. *Nippon Ronen Igakkai Zasshi - Japanese Journal of Geriatrics* 30[6], 506-510.  
18 1993.  
19 Excl reason: Single Case/Foreign Language
- 20 Barroca, H. & Bom-Successo, M. (2014) Fine needle biopsy with cytology in paediatrics: The  
21 importance of a multidisciplinary approach and the role of ancillary techniques. *Cytopathology*,  
22 25: 6-20.  
23 Excl reason: Narrative review
- 24 Basavaraj, K. F., Ramalingam, K., Sarkar, A. & Muddaiah, S. (2012) Primary non-Hodgkin's lymphoma  
25 of gingiva in a 28-year-old HIV-positive patient. *Journal of Natural Science Biology & Medicine*, 3:  
26 189-191.  
27 Excl reason: Not in PICO
- 28 Beissert, M., Jenett, M., Wetzler, T., Hinterseher, I., Kessler, C., and Hahn, D. Enlarged lymph nodes  
29 of the neck: evaluation with parallel extended field-of-view sonographic sequences. *Journal of  
30 Ultrasound in Medicine* 19[3], 195-200. 2000.  
31 Excl reason: Not relevant to PICO
- 32 Benchekroun, A., Qarro, A., Kasmaoui, H., Iken, A., Marzouk, M., and Faik, M. [Primary and bilateral  
33 non-Hodgkin's lymphoma of the adrenal gland (a case report and literature review)]. [French].  
34 *Annales de Chirurgie* 128[8], 557-560. 2003.  
35 Excl reason: Single Case/Foreign Language
- 36 Benson, M. K. and Hasley, P. A rash decision: Not simply another atopic dermatitis! *Journal of  
37 General Internal Medicine* 26, S436-S437. 2011. Springer New York.  
38 Excl reason: Single Case/Expert Review
- 39 Berberoglu, K., Unal, S. N., Kebudi, R., Turkmen, C., and Cantez, S. Role of <sup>99m</sup>Tc-hexakis-2-  
40 methoxyisobutylisonitrile for detecting marrow metastases in childhood solid tumours. *Nuclear  
41 Medicine Communications* 26[12], 1075-1080. 2005.  
42 Excl reason: Not relevant to PICO
- 43 Bianchi, C., Scamuzzi, C., and Mattioli, F. P. [Non-Hodgkin's lymphoma with perianal localization in  
44 patients with acquired immunodeficiency syndrome: a case report]. [Italian]. *Annali Italiani di  
45 Chirurgia* 67[2], 277-280. 1996.  
46 Excl reason: Expert Review/Foreign Language
- 47 Bisdas, S., Fetscher, S., Feller, A. C., Baghi, M., Knecht, R., Gstoettner, W., Vogl, T. J., and Balzer, J. O.  
48 Primary B cell lymphoma of the sphenoid sinus: CT and MRI characteristics with correlation to  
49 perfusion and spectroscopic imaging features. *European Archives of Oto-Rhino-Laryngology*  
50 264[10], 1207-1213. 2007.  
51 Excl reason: Outcomes not relevant to PICO

- 1 Braun, B. and Dormeyer, H. H. Ultrasonically guided fine needle aspiration biopsy of hepatic and  
2 pancreatic space-occupying lesions and percutaneous abscess drainage. *Klinische Wochenschrift*  
3 59[12], 707-712. 15-6-1981.  
4 Excl reason: Not relevant to PICO
- 5 Brocker, K. A., Alt, C. D., Eichbaum, M., Sohn, C., Kauczor, H. U., and Hallscheidt, P. Imaging of female  
6 pelvic malignancies regarding MRI, CT, and PET/CT : part 1. [Review]. *Strahlentherapie und*  
7 *Onkologie* 187[10], 611-618. 2011.  
8 Excl reason: Expert Review
- 9 Browder, D. A. and Erhard, R. E. Decision making for a painful hip: A case requiring referral. *Journal*  
10 *of Orthopaedic & Sports Physical Therapy* 35[11], 738-744. 2005.  
11 Excl reason: Single Case/Not relevant to PICO
- 12 Buess, M., Steuerwald, M., Wegmann, W., and Rothen, M. Obstructive jaundice caused by  
13 enteropathy-associated T-cell lymphoma in a patient with celiac sprue. *Journal of*  
14 *Gastroenterology* 39[11], 1110-1113. 2004.  
15 Excl reason: Single Case
- 16 Cavanna, L., Vallisa, D., Lazzaro, A., Civardi, G., Berte, R., Moroni, C. F., Bernuzzi, P., Arcari, A., and  
17 Anselmi, E. On the Need of Biopsy Confirmation at Suspected First Recurrence of Cancer [4].  
18 *American Journal of Clinical Oncology: Cancer Clinical Trials* 27[2], 212-213. 2004.  
19 Excl reason: Expert Review
- 20 Chan-Kai, B. T. and Yen, M. T. Combined positron emission tomography/computed tomography  
21 imaging of orbital lymphoma. *American Journal of Ophthalmology* 140[3], 531-533. 2005.  
22 Excl reason: Single Case
- 23 Cherian, S., Das, S., Mauzo, S., Koya, H. H., Varghese, D. & Hussain, R. (2013) Primary pulmonary  
24 lymphoma: An extremely rare disease. *Chest*, 144.  
25 Excl reason: Not in PICO
- 26 Choi, Y. R., An, J. Y., Kim, M. K., Han, H.-S., Lee, K. H., Kim, S.-W., Lee, K. M. & Choe, K. H. (2013) The  
27 diagnostic efficacy and safety of endobronchial ultrasound-guided transbronchial needle  
28 aspiration as an initial diagnostic tool. *Korean Journal of Internal Medicine*, 28: 660-667.  
29 Excl reason: Not in PICO
- 30 Coe, A., Conway, J., Evans, J., Goebel, M. & Mishra, G. (2013) The yield of EUS-FNA in undiagnosed  
31 upper abdominal adenopathy is very high. *Journal of Clinical Ultrasound*, 41: 210-213.  
32 Excl reason: Not in PICO
- 33 Cwiklinska, M., Czogala, M., Balwierz, W., Hnatko-Kolacz, M., Moryl-Bujakowska, A., Malinowska, I.,  
34 Sladek, M., Wieczorek, M., Fyderek, K., Matysiak, M., Rygielska, M., and Sierhej, I.  
35 [Hemophagocytic syndrome in children with different underlying conditions]. [Polish]. *Przegląd*  
36 *Lekarski* 67[6], 430-435. 2010.  
37 Excl reason: Not relevant to PICO
- 38 Davidson, P., De, W. K. & Kulasegaram, R. (2014) A retrospective analysis of chest and abdomen CT  
39 scanning in an unselected HIV-positive population. *HIV Medicine*, 15: 130.  
40 Excl reason: Not in PICO
- 41 Davis, R. D., Jr., Oldham, H. N., Jr., and Sabiston, D. C., Jr. Primary cysts and neoplasms of the  
42 mediastinum: recent changes in clinical presentation, methods of diagnosis, management, and  
43 results. *Annals of Thoracic Surgery* 44[3], 229-237. 1987.  
44 Excl reason: Expert Review
- 45 dos Santos, Lucas. Is there a role for consolidative radiotherapy in the treatment of aggressive and  
46 localized Non-Hodgkin Lymphoma? A systematic review with meta-analysis. *BMC Cancer* 12[288].  
47 2012.  
48 Excl reason: Not relevant to PICO
- 49 Duncavage, J. A., Campbell, B. H., Hanson, G. A., Kun, L. E., Hansen, R. M., Toohill, R. J., and Malin, T.  
50 C. Diagnosis of malignant lymphomas of the nasal cavity, paranasal sinuses and nasopharynx.

- 1 Laryngoscope 93[10], 1276-1280. 1983.  
2 Excl reason: Not relevant to PICO
- 3 Ellenrieder, V., Beckh, K., Muller, D., Klatt, S., and Adler, G. Intrahepatic high-grade malignant non-  
4 Hodgkin lymphoma in a patient with chronic hepatitis C infection. *Zeitschrift fur*  
5 *Gastroenterologie* 34[5], 283-285. 1996.  
6 Excl reason: Single Case
- 7 Fass, L. Imaging and cancer: A review. *Molecular Oncology* 2[2], 115-152. 2008.  
8 Excl reason: Expert Review
- 9 Ferone, D., Semino, C., Boschetti, M., Cascini, G. L., Minuto, F., and Lastoria, S. Initial staging of  
10 lymphoma with octreotide and other receptor imaging agents. [Review] [92 refs]. *Seminars in*  
11 *Nuclear Medicine* 35[3], 176-185. 2005.  
12 Excl reason: Expert Review
- 13 Fey, M. F. [Salient clinical features of lymphoma and related lymphoproliferative disorders].  
14 [German]. *Therapeutische Umschau* 67[10], 491-495. 2010.  
15 Excl reason: Expert Review/Foreign Language
- 16 Flox, Camacho A., Hernandez, Hernandez F., Salguero, Bodes R., Sanchez, Perez, I, Carbonell, Porras  
17 A., and Tascon, Perez J. [Primary cardiac lymphoma: diagnosis by transjugular biopsy]. [Spanish].  
18 *Revista Espanola de Cardiologia* 56[11], 1141-1144. 2003.  
19 Excl reason: Single Case/Foreign Language
- 20 Ford, C., Patel, P., Burney, K., Fernandez, C., Fisher, R. & Youd, P. (2014) Should we investigate  
21 mesenteric panniculitis?: UK experience of 58 patients. *Gut*, 63: A101.  
22 Excl reason: Not in PICO
- 23 Fornari, F., Civardi, G., Cavanna, L., Rossi, S., Buscarini, E., Di, Stasi M., Sbolli, G., and Buscarini, L.  
24 Ultrasonically guided fine-needle aspiration biopsy: A highly diagnostic procedure for hepatic  
25 tumors. *American Journal of Gastroenterology* 85[8], 1009-1013. 1990.  
26 Excl reason: Not relevant to PICO
- 27 Front, D., Bar-Shalom, R., Epelbaum, R., Haim, N., Ben-Arush, M. W., Ben-Shahar, M., Gorenberg, M.,  
28 Kleinhaus, U., Parmett, S., and Kolodny, G. M. Early detection of lymphoma recurrence with  
29 gallium-67 scintigraphy. *Journal of Nuclear Medicine* 34[12], 2101-2104. 1993.  
30 Excl reason: Intervention not relevant to PICO
- 31 Funauchi, M., Ikoma, S., Kishimoto, K., Shimazu, H., Nozaki, Y., Sugiyama, M., and Kinoshita, K. A case  
32 of adult onset Still's disease showing marked accumulation in the liver and spleen, on positron  
33 emission tomography-CT images. *Rheumatology International* 28[10], 1061-1064. 2008.  
34 Excl reason: Single case
- 35 Garrett, K. M., Hoffer, F. A., Behm, F. G., Gow, K. W., Hudson, M. M., and Sandlund, J. T.  
36 Interventional radiology techniques for the diagnosis of lymphoma or leukemia. *Pediatric*  
37 *Radiology* 32[9], 653-662. 2002.  
38 Excl reason: Interventions not relevant to PICO
- 39 Gentile, M., Cutrona, G., Fabris, S., Pesce, E., Di, Raimondo F., Di, Renzo N., Mauro, F. R., Cantaffa, R.,  
40 Brugiattelli, M., Merli, F., Baldini, L., Quintana, G., Iannitto, E., Di, Tonno P., Fragasso, A., Molica,  
41 S., Callea, V., Sacchi, S., Federico, M., Neri, A., Ferrarini, M., and Morabito, F. Inclusion of total  
42 body CT scan in the initial work-up of CLL patients with early-stage on clinical grounds:  
43 preliminary Results of a prospective, multicenter o-cll1-GISL study. *Haematologica* 94, 375. 2009.  
44 *Haematologica Journal Office*.  
45 Excl reason: Not in PICO
- 46 Ghai, S., Pattison, J., Ghai, S., O'Malley, M. E., Khalili, K., and Stephens, M. Primary gastrointestinal  
47 lymphoma: spectrum of imaging findings with pathologic correlation. [Review] [39 refs].  
48 *Radiographics* 27[5], 1371-1388. 2007.  
49 Excl reason: Expert Review
- 50 Goldschmidt, N., Libson, E., Bloom, A., Amir, G., and Paltiel, O. Clinical utility of computed  
51 tomography-guided core needle biopsy in the diagnostic re-evaluation of patients with

- 1 lymphoproliferative disorders and suspected disease progression. *Annals of Oncology* 14[9],  
2 1438-1441. 2003.  
3 Excl reason: Not relevant to PICO
- 4 Gomez-Leon, N., Pinilla, I., Rodriguez-Vigil, B., Hernandez, D., Reza, M., and Madero, R. Integrated  
5 PET/CT scanner in oncology applications: A radiologic perspective. [Spanish]. *Radiologia* 49[1], 29-  
6 36. 2007.  
7 Excl reason: Not relevant to PICO
- 8 Gould, P. V. and Saikali, S. A comparison of digitized frozen section and smear preparations for  
9 intraoperative neurotelepathology. *Analytical Cellular Pathology* 35[2], 85-91. 2012.  
10 Excl reason: Comparisons not relevant to PICO
- 11 Graziosi, L., Bugiantella, W., Cavazzoni, E., Cantarella, F., Porcari, M., Baffa, N., and Donini, A. Role of  
12 FDG-PET/CT in follow-up of patients treated with resective gastric surgery for tumour. *Annali*  
13 *Italiani di Chirurgia* 82[2], 125-129. 2011.  
14 Excl reason: Not relevant to PICO
- 15 Grubstein, A., Shitrit, D., Sapir, E. E., Cohen, M., and Kramer, M. R. Pulmonary amyloidosis: Detection  
16 with PET-CT. *Clinical Nuclear Medicine* 30[6], 420-421. 2005.  
17 Excl reason: Not relevant to PICO
- 18 Gutte, H., Hojgaard, L., and Kjaer, A. Early clinical experience and impact of 18F-FDG PET. *Nuclear*  
19 *Medicine Communications* 26[11], 989-994. 2005.  
20 Excl reason: Not relevant to PICO
- 21 Hachisuka, Y. and Uomoto, M. A case of pulmonary mucosa-associated lymphoid tissue type  
22 lymphoma with low-grade accumulation of 18-fluorodeoxyglucose on positron emission  
23 tomography. [Japanese]. *Japanese Journal of Lung Cancer* 48[1], 56-61. 2008.  
24 Excl reason: Single Case
- 25 Hahm, M. H., Kim, H. J., Shin, K. M., Cho, S. H., Park, J. Y., Jung, J. H., Jeong, J. Y. & Bae, J. H. (2014) -  
26 Concurrent invasive ductal carcinoma of the breast and malignant follicular lymphoma, initially  
27 suspected to be metastatic breast cancer: a case report. - *Journal of Breast Cancer*, 17: 91-97.  
28 Excl reason: Not in PICO
- 29 Haldorsen, I. S., Espeland, A., Larsen, J. L., and Mella, O. Diagnostic delay in primary central nervous  
30 system lymphoma. *Acta Oncologica* 44[7], 728-734. 2005.  
31 Excl reason: Not relevant to PICO
- 32 Han, S. H., Maeng, Y. H., Kim, Y. S., Jo, J. M., Kwon, J. M., Kim, W. K. & Kim, M. O. (2014) Primary  
33 anaplastic large cell lymphoma of the lung presenting with acute atelectasis. *Thoracic Cancer*, 5:  
34 78-81.  
35 Excl reason: Not in PICO
- 36 Hartmann, M. and Sartor, K. [Primary malignant lymphoma of the brain]. [Review] [26 refs]  
37 [German]. *Radiologe* 37[1], 42-50. 1997.  
38 Excl reason: Expert Review/Foreign Language
- 39 Hausdorf, G., Erttmann, R., Hubner, C., and Winkler, K. [Sonographic findings in malignant  
40 lymphoblastic T-cell lymphomas in childhood]. [German]. *Onkologie* 5[6], 284-288. 1982.  
41 Excl reason: Not relevant to PICO/Foreign Language
- 42 Heisner, K., Jordan, K., Paul, S., Rosenwald, A., and Voigt, W. Granulocytic sarcoma with primary  
43 compression of spinal court as precursor of a acute myeloid leukemia: A case report. *Onkologie*  
44 33[6], 142. 2010. S. Karger AG.  
45 Excl reason: Single Case
- 46 Hesselmann, V., Zahringer, M., Krug, B., Wesselmann, C., Haferkamp, K., Wickenhauser, C., and  
47 Lackner, K. Computed-tomography-guided percutaneous core needle biopsies of suspected  
48 malignant lymphomas: impact of biopsy, lesion, and patient parameters on diagnostic yield. *Acta*  
49 *Radiologica* 45[6], 641-645. 2004.  
50 Excl reason: Not relevant to PICO

- 1 Ho, C. L. Clinical PET imaging--an Asian perspective. [Review] [53 refs]. *Annals of the Academy of*  
2 *Medicine, Singapore* 33[2], 155-165. 2004.  
3 Excl reason: Expert Review
- 4 Hojo, A., Nakayama, H., Aramaki, O., Higaki, T., Moriguchi, M., Sugitani, M., Miura, K., Takeuchi, J.,  
5 Nishiyama, R., Moriyama, M. & Takayama, T. (2013) Diagnostic value of open biopsy for  
6 malignant T-cell lymphoma of the liver. *International Surgery*, 98: 13-18.  
7 Excl reason: Not in PICO
- 8 Hong, J., Kim, J. H., Park, J. & Lee, J. H. (2013) Clinical symptom or sign-directed surveillance can be  
9 more useful in detecting relapse compared to routine imaging in patients with diffuse large b-cell  
10 lymphoma in remission. *Blood*, 122.  
11 Excl reason: Not in PICO
- 12 Horton, K. M. and Fishman, E. K. Multidetector-row computed tomography and 3-dimensional  
13 computed tomography imaging of small bowel neoplasms: current concept in diagnosis. [Review]  
14 [29 refs]. *Journal of Computer Assisted Tomography* 28[1], 106-116. 2004.  
15 Excl reason: Expert Review
- 16 Huang, W. C., Tsai, C. C., Chan, C. C., Lai, H. Y., and Huang, S. H. Imprint cytology in diagnosing-  
17 primary non-Hodgkin's lymphoma of the breast during intraoperative frozen consultation: a case  
18 report. *Acta Cytologica* 54[5:Suppl], Suppl-70. 2010.  
19 Excl reason: Single Case
- 20 Hubner, K. F., Buonocore, E., Singh, S. K., Gould, H. R., and Cotten, D. W. Characterization of chest  
21 masses by FDG positron emission tomography. *Clinical Nuclear Medicine* 20[4], 293-298. 1995.  
22 Excl reason: Comparison not relevant to PICO
- 23 Imai, A., Kawabata, I., and Tamaya, T. Primary brain malignant lymphoma newly diagnosed during  
24 pregnancy. *Journal of Medicine* 26[5-6], 333-336. 1995.  
25 Excl reason: Not relevant to PICO
- 26 Imteyaz, H. & Stern, M. (2013) N-type calcium channel binding antibodies in a patient with  
27 paraneoplastic cerebellar degeneration in association with non-hodgkins lymphoma: A case  
28 report. *PM and R*, 5: S183.  
29 Excl reason: Not in PICO
- 30 Iwanami, T., Kuwata, T., Iwata, T., and Kawaguchi, M. Pulmonary malignant lymphoma presenting as  
31 a cavity containing nodule. [Japanese]. *Japanese Journal of Lung Cancer* 52[3], 296-299. 2012.  
32 Excl reason: Single Case
- 33 Jawa, A., Mehta, S., Grupp, S., Kramer, S. S., Carpentieri, D. F., and Dormans, J. P. Face and thigh  
34 swelling in a 6-year-old girl. *Clinical Orthopaedics & Related Research*.(415):309-18, 2003 Oct.  
35 [415], 309-318. 2003.  
36 Excl reason: Not relevant to PICO
- 37 Johnson, C. D., Kent, D. M., Varjabedian, G. C., and Lepoudre, C. Malignant lymphoma of the  
38 maxillary sinus. [Review] [15 refs]. *Journal of the American Osteopathic Association* 93[2], 252-  
39 258. 1993.  
40 Excl reason: Expert Review
- 41 Joshi, P. V., Lele, V. R. & Shaikh, I. (2013) Mortui vivos docent--the dead teach the living: 18-  
42 flurodeoxyglucose positron emission tomography-computed tomography findings in a case of  
43 intravascular B cell lymphoma. *Journal of Cancer Research & Therapeutics*, 9: 141-144.  
44 Excl reason: Not in PICO
- 45 Kalkner, M., Rehn, S., Andersson, T., Elvin, A., Hagberg, H., Lindgren, P. G., Sundstrom, C., and  
46 Glimelius, B. Diagnostics of malignant lymphomas with ultrasound guided 1.2 mm biopsy-gun.  
47 *Acta Oncologica* 33[1], 33-37. 1994.  
48 Excl reason: Intervention not relevant to PICO
- 49 Karolina, O.-H., Osmola-Mankowska, A., Silny, W., Danczak-Pazdrowska, A. & Polanska, A. (2013) The  
50 possibility of monitoring using the highfrequency ultrasound in patients with the primary

- 1 cutaneous t-cell lymphoma. *Skin Research and Technology*, 19: e586.
- 2 Excl reason: Not in PICO
- 3 Kashiwagi, S., Onoda, N., Asano, Y., Morisaki, T., Aomatsu, N., Yoshii, M., Nakamura, M., Kawajiri, H.,  
4 Takashima, T., Osawa, M., Ishikawa, T., Wakasa, K., and Hirakawa, K. [Ultrasound guided vacuum-  
5 assisted biopsy for diagnosis of malignant lymphoma]. [Japanese]. *Gan to Kagaku Ryoho*  
6 [Japanese Journal of Cancer & Chemotherapy] 38[12], 2526-2528. 2011.
- 7 Excl reason: Intervention not relevant to PICO/Foreign Language
- 8 Kato, H., Naganuma, T., Iizawa, Y., Kitagawa, M., Tanaka, M., and Isaji, S. Primary non-Hodgkin's  
9 lymphoma of the gallbladder diagnosed by laparoscopic cholecystectomy. *Journal of Hepato-*  
10 *Biliary-Pancreatic Surgery* 15[6], 659-663. 2008.
- 11 Excl reason: Single Case
- 12 Kato, K. (2014) - [Malignant lymphoma and adult T-cell leukemia-lymphoma]. [Review] [Japanese]. -  
13 *Rinsho Ketsueki - Japanese Journal of Clinical Hematology*, 55: 191-200.
- 14 Excl reason: Not in PICO
- 15 Kawakami, K., Nomura, H., Watanabe, Y., and Momma, F. [Primary pancreatic lymphoma with  
16 elevated serum CA19-9 level]. [Japanese]. *Rinsho Ketsueki - Japanese Journal of Clinical*  
17 *Hematology* 43[4], 292-297. 2002.
- 18 Excl reason: Single Case/Foreign Language
- 19 Kawashima, S., Okita, K., Yamawaki, T., Matsukawa, N., and Ojika, K. [Case of paraneoplastic limbic  
20 encephalitis associated with malignant B cell lymphoma]. [Review] [10 refs] [Japanese]. *Brain &*  
21 *Nerve / Shinkei Kenkyu no Shinpo* 61[2], 208-212. 2009.
- 22 Excl reason: Single Case/Foreign Language
- 23 Kirby, A. M. and Mikhaeel, N. G. The role of FDG PET in the management of lymphoma: what is the  
24 evidence base?. [Review] [123 refs]. *Nuclear Medicine Communications* 28[5], 335-354. 2007.
- 25 Excl reason: Expert Review
- 26 Komatsuda, T., Ishida, H., Konno, K., Sato, M., Hosino, T., Naganuma, H., Hirata, M., Watanabe, S.,  
27 and Miyashita, M. Primary malignant lymphoma of the liver not associated with AIDS: US and  
28 Doppler findings. *Ultrasound International* 9[1], 1-7. 2003.
- 29 Excl reason: Not relevant to PICO
- 30 Krishnan, A., Shirkhoda, A., Tehranzadeh, J., Armin, A. R., Irwin, R., and Les, K. Primary bone  
31 lymphoma: radiographic-MR imaging correlation. [Review] [27 refs]. *Radiographics* 23[6], 1371-  
32 1383. 1384.
- 33 Excl reason: Expert Review
- 34 Lane, K. A. and Bilyk, J. R. Preliminary study of positron emission tomography in the detection and  
35 management of orbital malignancy. *Ophthalmic Plastic & Reconstructive Surgery* 22[5], 361-365.  
36 2006.
- 37 Excl reason: Not relevant to PICO
- 38 Leitha, T., Glaser, C., Pruckmayer, M., Rasse, M., Millesi, W., Lang, S., Nasel, C., Backfrieder, W., and  
39 Kainberger, F. Technetium-99m-MIBI in primary and recurrent head and neck tumors:  
40 contribution of bone SPECT image fusion. *Journal of Nuclear Medicine* 39[7], 1166-1171. 1998.
- 41 Excl reason: Intervention/Population not relevant to PICO
- 42 Li, L., Wu, Q. L., Liu, L. Z., Mo, Y. X., Xie, C. M., Zheng, L., Chen, L., and Wu, P. H. Value of CT-guided  
43 core-needle biopsy in diagnosis and classification of malignant lymphomas using automated  
44 biopsy gun. *World Journal of Gastroenterology* 11[31], 4843-4847. 21-8-2005.
- 45 Excl reason: Intervention not relevant to PICO
- 46 Linden, A., Zankovich, R., Theissen, P., Diehl, V., and Schicha, H. Malignant lymphoma: bone marrow  
47 imaging versus biopsy. *Radiology* 173[2], 335-339. 1989.
- 48 Excl reason: Check relevance
- 49 Madan, A., Sethi, P. & Tripathi, K. (2013) Upper extremity venous thrombosis-calm before the storm.  
50 *Journal of General Internal Medicine*, 28: S415.
- 51 Excl reason: Not in PICO



- 1 Maher, N., O'Brien, Y., Milner, M., and Gleeson, N. Lymphoma-the great masquerader. *Irish Journal*  
2 *of Medical Science* 180, S134-S135. 2011. Springer.
- 3 Excl reason: Single Case
- 4 Marquez Moreno, A. J., Manas, Uxo J., Amores, Ramirez F., Aguilar, Cuevas R., Ortega Jimenez, M. V.,  
5 Leiva, Vera C., and Perez, Rodriguez D. [Synchronous chromophobe renal carcinoma and  
6 centrocytic lymphoma]. [Spanish]. *Archivos Espanoles de Urologia* 56[4], 415-417. 2003.
- 7 Excl reason: Single Case/Foreign Language
- 8 Mathews, M. S., Bota, D. A., Kim, R. C., Hasso, A. N., and Linskey, M. E. Primary leptomenigeal  
9 plasmablastic lymphoma. *Journal of Neuro-Oncology* 104[3], 835-838. 2011.
- 10 Excl reason: Single Case
- 11 McCormick, Z. and Casey, E. B cell lymphoma initially presenting as cervical radiculitis: A case report.  
12 *PM and R* 4[10 SUPPL. 1], S277. 2012. Elsevier Inc.
- 13 Excl reason: Single Case
- 14 Meier, J. D. & Grimmer, J. F. (2014) - Evaluation and management of neck masses in children.  
15 [Review]. - *American Family Physician*, 89: 353-358.
- 16 Excl reason: Narrative review
- 17 Michallet, A. S., Trotman, J., and Tychyj-Pinel, C. Role of early PET in the management of diffuse large  
18 B-cell lymphoma. [Review]. *Current Opinion in Oncology* 22[5], 414-418. 2010.
- 19 Excl reason: Expert Review
- 20 Minamimoto, R., Senda, M., Terauchi, T., Jinnouchi, S., Inoue, T., Iinuma, T., Inoue, T., Ito, K., Iwata,  
21 H., Uno, K., Oku, S., Oguchi, K., Tsukamoto, E., Nakashima, R., Nishizawa, S., Fukuda, H., Murano,  
22 T., and Yoshida, T. Analysis of various malignant neoplasms detected by FDG-PET cancer  
23 screening program: based on a Japanese Nationwide Survey. *Annals of Nuclear Medicine* 25[1],  
24 45-54. 2011.
- 25 Excl reason: Not relevant to PICO
- 26 Mitsufoji, T., Fujimitsu, R., Ida, M., Urakawa, H., Kora, S., Takeshita, M., Miyajima, S., and Yoshimitsu,  
27 K. Papillary renal cell carcinoma with extensive paraaortic nodal metastasis mimicking malignant  
28 lymphoma. *Magnetic Resonance in Medical Sciences* 10[3], 201-204. 2011.
- 29 Excl reason: Single Case
- 30 Mizusawa, H., Okaneya, T., Yoneyama, T., and Taguchi, I. [Primary malignant lymphoma of the  
31 adrenal gland: a case report]. [Japanese]. *Hinyokika Kiyo - Acta Urologica Japonica* 41[12], 991-  
32 994. 1995.
- 33 Excl reason: Single Case/Foreign Language
- 34 Mohler, M., Gutzler, F., Kallinowski, B., Goeser, T., and Stremmel, W. Primary hepatic high-grade  
35 non-Hodgkin's lymphoma and chronic hepatitis C infection. *Digestive Diseases and Sciences*  
36 42[11], 2241-2245. 1997.
- 37 Excl reason: Not relevant to PICO
- 38 Morimoto, Y., Kuriyama, S., Yoshiji, H., Matsumoto, M., Masui, K., Sakamoto, T., Kojima, H.,  
39 Yoshikawa, M., Fukui, H., and Nakae, D. A case of early gastric malignant lymphoma diagnosed  
40 and completely resected by strip biopsy. *Journal of Gastroenterology* 30[2], 248-253. 1995.
- 41 Excl reason: Single Case
- 42 Mukasa, K., Noh, J. Y., Kunii, Y., Matsumoto, M., Sato, S., Yasuda, S., Suzuki, M., Ito, K., and Ito, K.  
43 Prevalence of malignant tumors and adenomatous lesions detected by ultrasonographic  
44 screening in patients with autoimmune thyroid diseases. *Thyroid* 21[1], 37-41. 2011.
- 45 Excl reason: Not relevant to PICO
- 46 Naito, Y., Okabe, Y., Kawahara, A., Taira, T., Yamagushi, T., Abe, H., Arikawa, S., Nakayama, M.,  
47 Yasumoto, M., Eriguchi, N., Naito, H., Kage, M., and Yano, H. Guide to diagnosing primary  
48 pancreatic lymphoma, B-cell type: immunocytochemistry improves the diagnostic accuracy of  
49 endoscopic ultrasonography-guided fine needle aspiration cytology. *Diagnostic Cytopathology*  
50 40[8], 732-736. 2012.
- 51 Excl reason: Single Case

- 1 Nakamura, K., Sasaki, M., Kunitake, N., Kimura, M., Watanabe, T., Sasaki, T., Terashima, H.,  
2 Kuwabara, Y., Sakai, S., and Masuda, K. Relapse patterns of localized non-Hodgkin's lymphoma of  
3 the head and neck after clinical remission: results of a strict follow-up procedure. *International*  
4 *Journal of Clinical Oncology* 6[6], 302-305. 2001.  
5 Excl reason: Not relevant to PICO
- 6 Nakao, K., Waga, S., Sakaida, H., Sakakura, M., Tocho, H., Ohno, H., and Miyazaki, M. [Primary spinal  
7 intramedullary malignant lymphoma: case report]. [Review] [19 refs] [Japanese]. *No Shinkei Geka*  
8 *- Neurological Surgery* 22[6], 583-587. 1994.  
9 Excl reason: Single Case/Foreign Language
- 10 Nakazato, T., Suzuki, K., Mihara, A., Sanada, Y., Yoshida, S., and Kakimoto, T. [Intravascular large B-  
11 cell lymphoma with pontine involvement successfully treated with R-hyper-CVAD/R-MTX-Ara-C  
12 regimen]. [Japanese]. *Rinsho Ketsueki - Japanese Journal of Clinical Hematology* 51[2], 148-152.  
13 2010.  
14 Excl reason: Single Case/Foreign Language
- 15 Naranji, I., Zakri, R. H. & Liston, T. (2013) Mantle cell lymphoma presenting as a pelvi-ureteric  
16 junction obstruction: a case report. *Journal of Medical Case Reports [Electronic Resource]*, 7: 105.  
17 Excl reason: Not in PICO
- 18 Narsana, N., Xie, J., Singhvi, G., and Aron, J. A case of non-hodgkins lymphoma mimicking metastatic  
19 colorectal cancer. *American Journal of Gastroenterology* 105, S320. 2010. Nature Publishing  
20 Group.  
21 Excl reason: Single Case
- 22 Nattermann, C. and Dancygier, H. [Endosonography of stomach tumors]. [Review] [51 refs]  
23 [German]. *Leber, Magen, Darm* 22[6], 211-219. 1992.  
24 Excl reason: Expert Review/Foreign Language
- 25 Neef, B., Kunzig, B., Sinn, I., Kieninger, G., and von, Gaisberg U. [Primary pancreatic lymphoma. A  
26 rare cause of pain-free icterus]. [German]. *Deutsche Medizinische Wochenschrift* 122[1-2], 12-17.  
27 3-1-1997.  
28 Excl reason: Single Case/Foreign Language
- 29 Neef, B., Kunzig, B., Sinn, I., Kieninger, C., and Gaisberg, U. V. Primary malignant non-Hodgkin  
30 pancreatic lymphoma, a rare cause of of pain-free jaundice. [German]. *Deutsche Medizinische*  
31 *Wochenschrift* 122[1-2], 12-17. 1997.  
32 Excl reason: Expert Review
- 33 Ng, E. and Ilsen, P. F. Orbital metastases. *Optometry (St.Louis, Mo.)* 81[12], 647-657. 2010.  
34 Excl reason: Not relevant to PICO
- 35 Nortje, C. J. General practitioner's radiology case 63. Burkitt's lymphoma. *SADJ* 63[4], 248. 2008.  
36 vNot relevant to PICO
- 37 Nozawa, A., Mizuno, S., Hoshi, H., Kuroda, E., Isaji, M., and Yasuda, K. A case of bilateral adrenal  
38 malignant lymphoma with high accumulation of 67Ga-citrate. [Japanese]. *Japanese Journal of*  
39 *Clinical Radiology* 44[6], 729-732. 1999.  
40 Excl reason: Single Case
- 41 O'Donnell, K. R. and Kane, P. D. You're the flight surgeon. Non-Hodgkins lymphoma. [Review] [5  
42 refs]. *Aviation Space & Environmental Medicine* 74[7], 785-787. 2003.  
43 Excl reason: Expert Review
- 44 Odemis, B., Parlak, E., Basar, O., Yuksel, O., and Sahin, B. Biliary tract obstruction secondary to  
45 malignant lymphoma: experience at a referral center. *Digestive Diseases & Sciences* 52[9], 2323-  
46 2332. 2007.  
47 Excl reason: Not relevant to PICO
- 48 Ohtaki, Y., Ishii, G., Hasegawa, T., and Nagai, K. Adult neuroblastoma arising in the superior  
49 mediastinum. *Interactive Cardiovascular & Thoracic Surgery* 13[2], 220-222. 2011.  
50 Excl reason: Single Case

- 1 Okazaki, A., Katoh, S., Noda, M., Katsumata, Y., Shirouzu, I., and Maehara, T. [Clinical usefulness of  
2 <sup>67</sup>Ga-citrate scintigraphy combined early image in malignant lymphoma--detection of abdominal  
3 lesions]. [Japanese]. *Nippon Igaku Hoshasen Gakkai Zasshi - Nippon Acta Radiologica* 50[8], 1007-  
4 1015. 25-8-1990.  
5 Excl reason: Foreign Language/Not relevant to PICO
- 6 Omori, K., Tetsuhara, K., Hiramoto, H., Shoda, H., Sanefuji, H., and Okamoto, N. [A case of primary  
7 small intestinal malignant lymphoma found based on multiple pulmonary nodules with  
8 cavitation]. [Japanese]. *Nihon Kokyuki Gakkai Zasshi* 48[7], 497-501. 2010.  
9 Excl reason: Single Case/Foreign Language
- 10 Orita, Y., Sato, Y., Kondo, E., Ishihara, H., Hirai, H., Hanakawa, H., Onoda, T., Igawa, T., Saito, R.,  
11 Nishizaki, K., and Yoshino, T. Minimally invasive procedure for accurate diagnosis of mucosa-  
12 associated lymphoid tissue lymphoma of the head and neck. *Japanese Journal of Clinical*  
13 *Oncology* 42[4], 325-330. 2012.  
14 Excl reason: Single Case
- 15 Ota, H., Ito, Y., Matsuzuka, F., Kuma, S., Fukata, S., Morita, S., Kobayashi, K., Nakamura, Y., Kakudo,  
16 K., Amino, N., and Miyauchi, A. Usefulness of ultrasonography for diagnosis of malignant  
17 lymphoma of the thyroid. *Thyroid* 16[10], 983-987. 2006.  
18 Excl reason: Not relevant to PICO
- 19 Pedote, P., Gaudio, F., Moschetta, M., Cimmino, A., Specchia, G., and Angelelli, G. CT-guided needle  
20 biopsy performed with modified coaxial technique in the diagnosis of malignant lymphomas.  
21 *Radiologia Medica* 115[8], 1292-1303. 2010.  
22 Excl reason: Intervention not relevant to PICO
- 23 Picardi, M., Gennarelli, N., Ciancia, R., De, Renzo A., Gargiulo, G., Ciancia, G., Sparano, L., Zeppa, P.,  
24 Martinelli, V., Pettinato, G., Lobello, R., Pane, F., and Rotoli, B. Randomized comparison of power  
25 Doppler ultrasound-directed excisional biopsy with standard excisional biopsy for the  
26 characterization of lymphadenopathies in patients with suspected lymphoma. *Journal of Clinical*  
27 *Oncology* 22[18], 3733-3740. 15-9-2004.  
28 Excl reason: Comparison not relevant to PICO
- 29 Pickhardt, P. J., Kim, D. H., Meiners, R. J., Wyatt, K. S., Hanson, M. E., Barlow, D. S., Cullen, P. A.,  
30 Remtulla, R. A., and Cash, B. D. Colorectal and extracolonic cancers detected at screening CT  
31 colonography in 10,286 asymptomatic adults. *Radiology* 255[1], 83-88. 2010.  
32 Excl reason: Not relevant to PICO
- 33 Qiao, W. L., Zhao, J. H., Wang, C., He, Z. Y., Wang, T. S., and Xing, Y. [Comparison of <sup>18</sup>F-FDG  
34 coincidence SPECT imaging and computed tomography in the initial staging and therapeutic  
35 evaluation of lymphomas]. [Chinese]. *Chung-Hua Chung Liu Tsa Chih [Chinese Journal of*  
36 *Oncology]* 29[7], 536-539. 2007.  
37 Excl reason: Foreign Language/Population not relevant
- 38 Ragupathy, K. & Bappa, L. (2013) Primary vaginal Non-Hodgkin lymphoma: Gynecologic diagnosis of  
39 a hematologic malignancy. *Journal of Lower Genital Tract Disease*, 17: 326-329.  
40 Excl reason: Not in PICO
- 41 Rahman, S., Rahman, W., and Rahman, F. A case of facial swelling and proptosis. *Dental Update*  
42 31[9], 553-554. 2004.  
43 Excl reason: Single Case
- 44 Reamy, B. V., Bunt, C. W., and Fletcher, S. A diagnostic approach to pruritus.[Summary for patients in  
45 *Am Fam Physician*. 2011 Jul 15;84(2):203; PMID: 21766770]. *American Family Physician* 84[2],  
46 195-202. 15-7-2011.  
47 Excl reason: Not relevant to PICO
- 48 Romer, W., Hanauske, A. R., Ziegler, S., Thodtmann, R., Weber, W., Fuchs, C., Enne, W., Herz, M.,  
49 Nerl, C., Garbrecht, M., and Schwaiger, M. Positron emission tomography in non-Hodgkin's  
50 lymphoma: assessment of chemotherapy with fluorodeoxyglucose. *Blood* 91[12], 4464-4471. 15-

- 1 6-1998.  
2 Excl reason: Not relevant to PICO  
3 Saber, M. M., Zeeneldin, A. A., Samra, M. A. & Farag, S. A. (2013) Primary gastrointestinal lymphoma  
4 in an Egyptian district: a study using a population-based cancer registry. *Journal of Egyptian*  
5 *National Cancer Institute*, 25: 95-101.  
6 Excl reason: Not in PICO  
7 Sakata, R., Makiyama, K., Noguchi, G., Sano, F., Nakaigawa, N., Yao, M., Nakayama, T., Yamanaka, S.,  
8 and Kubota, Y. [A case of retroperitoneal angioleiomyoma resected by laparoscopy]. [Japanese].  
9 *Hinyokika Kyo - Acta Urologica Japonica* 58[2], 75-78. 2012.  
10 Excl reason: Single Case/Foreign Language  
11 Saraswatula, A., McShane, D., Tideswell, D., Burke, G. A. A., Williams, D. M., Nicholson, J. C., and  
12 Murray, M. J. Mediastinal masses masquerading as common respiratory conditions of childhood:  
13 A case series. *European Journal of Pediatrics* 168[11], 1395-1399. 2009.  
14 Excl reason: Not relevant to PICO  
15 Sasaki, Y., Yamagishi, F., Suzuki, K., Miyazawa, H., Sugimoto, N., and Abe, Y. [Primary pulmonary  
16 malignant lymphoma of the T-cell type]. [Japanese]. *Nihon Kyobu Shikkan Gakkai Zasshi*. Japanese  
17 *Journal of Thoracic Diseases* 33[12], 1454-1458. 1995.  
18 Excl reason: Single Case/Foreign Language  
19 Sato, K., Ozaki, K., Fujiwara, S., Oh, I., Matsuyama, T., Ohmine, K., Suzuki, T., Mori, M., Nagai, T.,  
20 Muroi, K., and Ozawa, K. Incidental carcinomas detected by PET/CT scans in patients with  
21 malignant lymphoma. *International Journal of Hematology* 92[4], 647-650. 2010.  
22 Excl reason: Outcomes not relevant to PICO  
23 Scholmerich, J., Volk, B. A., and Gerok, W. Value and limitations of abdominal ultrasound in tumour  
24 staging--liver metastasis and lymphoma. *European Journal of Radiology* 7[4], 243-245. 1987.  
25 Excl reason: Not relevant to PICO  
26 Schwartz, A., Gospodarowicz, M. K., Khalili, K., Pintilie, M., Goddard, S., Keller, A., and Tsang, R. W.  
27 An audit of imaging test utilization for the management of lymphoma in an oncology hospital:  
28 implications for resource planning? *British Journal of Radiology* 79[938], 116-122. 2006.  
29 Excl reason: Not relevant to PICO  
30 Shinoda, M., Nagura, E., Uchida, K., Kimura, M., Mukoyama, M., and Yamada, H. A case of malignant  
31 lymphoma, highly suspected to be of pancreatic origin, with multiple nodular hepatic invasions.  
32 [Japanese]. *Japanese Journal of Cancer and Chemotherapy* 21[14], 2517-2520. 1994.  
33 Excl reason: Single Case  
34 Sklair-Levy, M., Polliack, A., Shaham, D., Applbaum, Y. H., Gillis, S., Ben-Yehuda, D., Sherman, Y., and  
35 Libson, E. CT-guided core-needle biopsy in the diagnosis of mediastinal lymphoma. *European*  
36 *Radiology* 10[5], 714-718. 2000.  
37 Excl reason: Intervention not relevant to PICO  
38 Soldani, S., Roni, P., Filidei, M., Castiglioni, M., and Riccioni, N. Diagnostic value of ultrasound-guided  
39 FNAB in the evaluation of osteolytic bone lesions suspected for metastases. [Italian]. *Giornale*  
40 *Italiano di Ultrasonologia* 8[1], 31-35. 1997.  
41 Excl reason: Not relevant to PICO  
42 Stohlner, V., Chatzizacharias, N. A., Parthasarathy, M. & Groot-Wassink, T. (2013) Jejunojejunal  
43 Intussusception as the Initial Presentation of Non-Hodgkin's B-Cell Lymphoma in an Adult Patient:  
44 A Case Report and Review of the Literature. *Case Reports in Surgery*, 2013: 619031.  
45 Excl reason: Not in PICO  
46 Subortseva, I. N., Poddubnaya, I., Kovrigina, A. M., Kokosadze, N. V., and Osmanov, D. S. Difficulties  
47 in differential diagnosis of primary pulmonary lymphoma. *Journal of Thoracic Oncology* 5[5  
48 SUPPL. 1], S115. 2010. International Association for the Study of Lung Cancer.  
49 Excl reason: Not relevant to PICO  
50 Sudhoff, T., Hollerbach, S., Wilhelms, I., Willert, J., Reiser, M., Topalidis, T., Schmiegel, W., and  
51 Graeven, U. [Clinical utility of EUS-FNA in upper gastrointestinal and mediastinal disease].

- 1 [German]. Deutsche Medizinische Wochenschrift 129[42], 2227-2232. 15-10-2004.  
2 Excl reason: Not relevant to PICO
- 3 Suresh, S., Saifuddin, A., and O'Donnell, P. Lymphoma presenting as a musculoskeletal soft tissue  
4 mass: MRI findings in 24 cases. European Radiology 18[11], 2628-2634. 2008.  
5 Excl reason: Not relevant to PICO
- 6 Takahashi, M., Matsumoto, H., Fujita, Y., Sato, K., Takeda, A., Yamazaki, Y., and Tobise, K. [A case of  
7 malignant lymphoma showing a stratum of lymphoma cells]. [Japanese]. Nihon Kokyuki Gakkai  
8 Zasshi 38[10], 792-796. 2000.  
9 Excl reason: Single Case/Foreign Language
- 10 Takahashi, R., Nishikawa, M., Nomi, F., Kusano, N., Kakemizu, N., and Ishigatsubo, Y. [Case of  
11 intravascular lymphoma diagnosed by transbronchial lung biopsy, with transient spontaneous  
12 remission]. [Japanese]. Nihon Kokyuki Gakkai Zasshi 48[11], 825-830. 2010.  
13 Excl reason: Single Case/Foreign Language
- 14 Takahashi, Y., Yamashita, S., Kiyosawa, M., Mochizuki, M., Kumagai, J., and Tokumaru, A. Malignant  
15 lymphoma presenting as orbital apex syndrome. [Japanese]. Folia Ophthalmologica Japonica  
16 52[6], 523-527. 2001.  
17 Excl reason: Single Case
- 18 Tamai, Y., Murakami, E., Nakamori, Y., Mizutani, M., and Sekine, T. [A case of gastric stenosis due to  
19 primary gastric malignant lymphoma during administration of R-CHOP]. [Japanese]. Gan to  
20 Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy] 38[8], 1371-1373. 2011.  
21 Excl reason: Single Case/Foreign Language
- 22 Tambo, M., Fujimoto, K., Miyake, M., Hoshiyama, F., Matsushita, C., and Hirao, Y. Clinicopathological  
23 review of 46 primary retroperitoneal tumors. International Journal of Urology 14[9], 785-788.  
24 2007.  
25 Excl reason: Not relevant to PICO
- 26 Tao, H., Nakata, M., Saeki, H., Kurita, A., and Takashima, S. Unsuspected Primary Pulmonary  
27 Malignant Lymphoma. Japanese Journal of Thoracic and Cardiovascular Surgery 50[12], 533-536.  
28 2002.  
29 Excl reason: Single Case
- 30 Terada, T. Primary signet-ring cell carcinoma of the lung: a case report with an immunohistochemical  
31 study. International Journal of Clinical & Experimental Pathology 5[2], 171-174. 2012.  
32 Excl reason: Single Case
- 33 Terauchi, T., Murano, T., Daisaki, H., Kanou, D., Shoda, H., Kakinuma, R., Hamashima, C., Moriyama,  
34 N., and Kakizoe, T. Evaluation of whole-body cancer screening using 18F-2-deoxy-2-fluoro-D-  
35 glucose positron emission tomography: a preliminary report. Annals of Nuclear Medicine 22[5],  
36 379-385. 2008.  
37 Excl reason: Population not relevant to PICO
- 38 Thompson, D. R., Faust, T. W., Stone, M. J., and Polter, D. E. Hepatic failure as the presenting  
39 manifestation of malignant lymphoma. Clinical Lymphoma 2[2], 123-128. 2001.  
40 Excl reason: Not relevant to PICO
- 41 Toma, P., Granata, C., Rossi, A., and Garaventa, A. Multimodality imaging of Hodgkin disease and  
42 non-Hodgkin lymphomas in children. [Review] [55 refs]. Radiographics 27[5], 1335-1354. 2007.  
43 Excl reason: Expert Review
- 44 Utsunomiya, D., Awai, K., Urata, J., Hirayama, T., and Yamashita, Y. Primary cardiac lymphoma:  
45 Computed tomography and magnetic resonance imaging features. Japanese Journal of Radiology  
46 27[6], 243-246. 2009.  
47 Excl reason: Single case
- 48 Vanis, N., Mesihovic, R., Ibricevic, L. & Dobrila-Dintinjana, R. (2013) Predictive value of endoscopic  
49 ultrasound in diagnosis and staging of primary gastric lymphoma. *Collegium Antropologicum*, 37:  
50 Suppl-7.  
51 Excl reason: Not in PICO

- 1 Verghese, G., Refaat, S. & Karar, A. (2013) Unusual presentation of diffuse large B-cell lymphoma  
2 (DLBCL) as acute osteomyelitis of the femur. *Journal of the Bahrain Medical Society*, 24: 140-144.  
3 Excl reason: Not in PICO
- 4 Wachter, D., Tschischka, S., Huegens-Penzel, M., Kuchelmeister, K., Bohle, R. M., Boker, D. K., and  
5 Nestler, U. T-cell lymphoma mimicking schwannoma of a cervical nerve root. *Neurosurgical*  
6 *Review* 32[1], 117-121. 20-1-0021.  
7 Excl reason: Not relevant to PICO
- 8 Wahab, M. F., El-Gindy, I. M., and Fathy, G. M. Screening tests for diagnosis of cervical  
9 lymphadenopathy presenting as prolonged fever. *Journal of the Egyptian Public Health*  
10 *Association* 73[5-6], 538-562. 1998.  
11 Excl reason: Not relevant to PICO
- 12 Wang, J., Sun, N. C., Renslo, R., Chuang, C. C., Tabbarah, H. J., Barajas, L., and French, S. W. Clinically  
13 silent primary adrenal lymphoma: a case report and review of the literature. [Review] [49 refs].  
14 *American Journal of Hematology* 58[2], 130-136. 1998.  
15 Excl reason: Expert review
- 16 Webb, T. H., Lillemoe, K. D., Pitt, H. A., Jones, R. J., and Cameron, J. L. Pancreatic lymphoma. Is  
17 surgery mandatory for diagnosis or treatment? *Annals of Surgery* 209[1], 25-30. 1989.  
18 Excl reason: Not relevant to PICO
- 19 Weber, W. A., Avril, N., and Schwaiger, M. Relevance of positron emission tomography (PET) in  
20 oncology. [Review] [168 refs]. *Strahlentherapie und Onkologie* 175[8], 356-373. 1999.  
21 Excl reason: Expert Review
- 22 Weber, W. A. 18F-FDG PET in non-Hodgkin's lymphoma: qualitative or quantitative? *Journal of*  
23 *Nuclear Medicine* 48[10], 1580-1582. 2007.  
24 Excl reason: No data
- 25 Wennekes, L., Ottevanger, P. B., Raemaekers, J. M., Schouten, H. C., De Kok, M. W. E., Punt, C. J. A.,  
26 Grol, R. P., Wollersheim, H. C., and Hermens, R. P. Development and Measurement of Guideline-  
27 Based Indicators for Patients With Non-Hodgkin's Lymphoma. *Journal of Clinical Oncology* 29[11],  
28 1436-1444. 2011.  
29 Excl reason: Not relevant to PICO
- 30 Willson, T., Sambo, T., Fontaine, J.-P., Connolly, M. & Podbielski, F. (2014) Primary pulmonary T-cell  
31 lymphoma presenting as bilateral interstitial infiltrates. *Chest*, 145.  
32 Excl reason: Not in PICO
- 33 Winde, G., Hecker, A., Schmid, U., and Keller, R. The prognosis of primary malignancies of the small  
34 intestine. [German]. *Chirurgische Praxis* 62[3], 399-413. 2004.  
35 Excl reason: Expert Review/Foreign Language
- 36 Yang, J. and Yuan, G. [Primary intracranial malignant lymphoma: report of 40 cases]. [Chinese].  
37 *Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery]* 34[2], 102-103. 1996.  
38 Excl reason: Excl reason: Not relevant to PICO/Foreign Language
- 39 Yucel, C., Ozdemir, H., and Isik, S. Role of endosonography in the evaluation of gastric malignancies.  
40 *Journal of Ultrasound in Medicine* 18[4], 283-288. 1999.  
41 Excl reason: Expert Review
- 42 Zepeda-Gomez, S., Camacho, J., Oviedo-Cardenas, E., and Lome-Maldonado, C. Gastric infiltration of  
43 diffuse large B-cell lymphoma: Endoscopic diagnosis and improvement of lesions after  
44 chemotherapy. *World Journal of Gastroenterology* 14[27], 4407-4409. 21-7-2008.  
45 Excl reason: Single Case
- 46 Zhou, Q. T., Zhu, H., and He, B. [Clinical analysis of lymphoma with chest involvement: report of 25  
47 cases]. [Chinese]. *Chung-Hua Nei Ko Tsa Chih Chinese Journal of Internal Medicine* 48[10], 846-  
48 849. 2009.  
49 Excl reason: Foreign Language

1 Ziaei, M., Elgohary, M. A. & Bremner, F. D. (2013) Palinopsia as the initial manifestation of non-  
2 hodgkin's lymphoma. *International Ophthalmology*, 33: 553-556.  
3 Excl reason: Not in PICO  
4 Ztot, S., Cherradi, R., Haddour, L., Belhaj, S., Kettani, F., Benmimoun, E. G., and Arharbi, M. [Primary  
5 cardiac lymphoma. Report of a case]. [French]. *Archives des Maladies du Coeur et des Vaisseaux*  
6 95[1], 61-64. 2002.  
7 Excl reason: Expert Review/Foreign Language  
8  
9  
10

## HODGKIN'S LYMPHOMA

**Review question:**

What is the risk of Hodgkin's lymphoma in patients presenting in primary care with symptom(s)?

**Results****Literature search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	All-2012	356	35	25/10/2012
<i>Premedline</i>	All-2012	8	0	25/10/2012
<i>Embase</i>	All-2012	587	49	25/10/2012
<i>Cochrane Library</i>	All-2012	124	0	25/10/2012
<i>Psychinfo</i>	All-2012	8	0	25/10/2012
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	All-2012	184	6	25/10/2012
<i>Biomed Central</i>	All-2012	279	2	25/10/2012


Total References retrieved (after de-duplication): 83

**Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	10/2012-26/08/2014	12	0	26/08/2014
<i>Premedline</i>	10/2012-26/08/2014	27	0	26/08/2014
<i>Embase</i>	10/2012-26/08/2014	224	0	26/08/2014
<i>Cochrane Library</i>	10/2012-26/08/2014	37	0	26/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	10/2012-26/08/2014	42	0	26/08/2014

Total References retrieved (after de-duplication): 0





1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12

**Risk of bias in the included studies**

The risk of bias and applicability concerns are summarised per study in the figure below. The main issue to note is that 2/3 studies employed samples of patients that are not directly representative of an unselected symptomatic population of patients presenting to the UK-based GP, and that there was some uncertainty about the verification of the outcome for some of the patients. Dommett (2012; 2013a,b) employed a case-control design which has been shown to inflate the test accuracy characteristics. However, the statistical analyses employed by the authors may have gone some way in counteracting this influence.

	Risk of Bias				Applicability Concerns		
	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard
Deyo (1988)	?	+	?	+	-	+	+
Dommett (2012, 2013)	-	+	+	+	+	+	+
Williamson (1985)	+	+	+	?	+	+	+

<span style="color: red;">-</span> High	<span style="color: yellow;">?</span> Unclear	<span style="color: green;">+</span> Low
---	---	--

13  
14  
15  
16  
17  
18

**Study results**

Table 1: Hodgkin’s lymphoma: Adult and mixed age populations

Study	Symptom(s)	Patient group	PPVs (95% CI)
Deyo (1988)	Back pain	All included patients	0.1 (0.02-0.41) 2/1975 7 had other types of cancer: lymphoma (NOS): N = 2, unknown primary: N = 1, Prostate: N = 1, retroperitoneal liposarcoma: N = 1, lung cancer: N = 1, renal cell: N = 1, multiple myeloma: N = 1, mucinous adenocarcinoma (of gallbladder?): N = 1
Williamson (1985)	Lymphadenopathy	All included patients	0.8 (0.1-3.2) TP = 2, FP = 247 Cancer: Hodgkin's: N = 1 Adenocarcinoma: N = 1

1 TP = True positives, FP = False positives.

2

3 Table 2: Hodgkin's lymphoma: Positive predictive values for leukaemia/lymphoma childhood cancer

Study	Symptom(s)	Patient group	Positive predictive value (95% CI)
Dommett (2013a)	Bruising 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.53 (0.07-3.91)
Dommett (2013a)	Pallor 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.43 (0.06-3.15)
Dommett (2013a)	Lump mass swelling head and neck 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.35 (0.05-2.65)
Dommett (2013a)	Fatigue 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.07 (0.03-0.15)
Dommett (2013a)	Lymphadenopathy 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.06 (0.04-0.11)

Dommett (2013a)	Lump mass swelling below neck excluding abdomen 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.05 (0.02-0.13)
Dommett (2013a)	Bleeding 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.03 (0.01-0.08)
Dommett (2013a)	Pain 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.03 (0.01-0.06)
Dommett (2013a)	Musculoskeletal symptoms 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.02 (0.01-0.03)
Dommett (2013a)	Fever 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.01 (0.01-0.01)
Dommett (2013a)	Abdominal pain 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.01(0-0.01)
Dommett (2013a)	≥ 3 consultations	All included leukemia/lymphoma patients and controls aged 0-14 years	0.01(0.01-0.01)

1 The positive predictive values are calculated using Bayesian statistics.

2

3 Table 3: Hodgkin's lymphoma: Positive predictive values for teenage and young adult lymphoma

Study	Symptom(s)	Patient group	Positive predictive value (95% CI) Frequency
Dommett (2013b)	Lump mass swelling head and neck	All included lymphoma patients and controls aged 15-24 years	0.5034 (0.0696-3.68) Cases: 35/270 Controls: 1/3350
Dommett (2013b)	Lump mass swelling below neck excluding abdomen	All included lymphoma patients and controls aged 15-24 years	0.0279 (0.0152-0.0515) Cases: 29/270 Controls: 15/3350
Dommett (2013b)	Lymphadenopathy	All included lymphoma patients and controls aged 15-24 years	0.278 (0.1-0.75) Cases: 77/270 Controls: 4/3350
Dommett (2013b)	'Lump mass swelling head and neck', 'lymphadenopathy' and 'lump mass swelling below neck excluding abdomen' combined as a single symptom	All included lymphoma patients and controls aged 15-24 years	0.0903 (0.057-0.1425)

Dommett (2013b)	≥ 3 consultations	All included lymphoma patients and controls aged 15-24 years	0.0086 (0.0075-0.0099) Cases: 175/270 Controls: 294/3350
-----------------	-------------------	--	--

1 The positive predictive values are calculated using Bayesian statistics.

2 **Evidence statement(s):**

3 Adult and mixed age populations

4 Back pain (1 study, N = 1975) and lymphadenopathy (1 study, N = 249) presenting in a primary care  
5 setting do not appear to confer a markedly increased risk of Hodgkin's/Non-Hodgkin's lymphoma,  
6 although the study populations are probably not directly representative of the typical unselected  
7 symptomatic UK GP population (see also Table 1).

8  
9 Children and teenagers and young adults

10 The positive predictive values of having leukaemia/lymphoma childhood cancer ranged from 0.01%  
11 (for fever and abdominal pain) to 0.53% (for bruising) for patients aged 0-14 years old, and the  
12 positive predictive values of having young adulthood lymphoma ranged from 0.0279% (for 'lump  
13 mass swelling below the neck excluding the abdomen') to 0.5034% (for 'lump mass swelling head  
14 and neck') for patients aged 15-24 years (1 study, N = 30855). The evidence quality is somewhat  
15 compromised by the case-control design of the study (see also Tables 2-3).

16  
17 **Evidence tables**

18 **Deyo (1988)**

<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective consecutive? patient series
Was a consecutive or random sample of patients enrolled?	<b>Unclear</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Yes (probably)</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	N = 1975, mean (SD; range) age = 39.5 (15.4; 15-86) years, 62% females. 54% of the patients were seeking medical care for back pain for the first time and 76% of the patients had had back pain for < 3 months. 3% had a history of back pain surgery. Maximal back pain in the low back (84%) or in the upper back (16%).  <u>Inclusion criteria:</u> Patients who sought treatment between March 1982 and September 1984 in the walk-in clinic of a public hospital where virtually all patients are self-referred. In each case back pain was part of the chief complaint. <u>Exclusion criteria:</u> Neck pain. <u>Clinical setting:</u> Walk-in clinic of a public hospital; this clinic is a source of primary care for indigent persons in a county in the USA with a population of approximately 1 million.
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>High concern</b>

<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	Back pain; not further specified.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	The reference standard consisted of a search on each patient name in the institutional tumour registry $\geq 6$ months after the index visit. The registry included every patient with a histological diagnosis of cancer made in the authors' hospital system regardless of site of care. The authors point out that "while this method might fail to identify cancer patients who sought care elsewhere, it is likely that most patients sought follow-up for a particular illness at the same facility.
Is the reference standard likely to correctly classify the target condition?	<b>Unclear</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No (but all patients had a positive index test)</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
<b>Flow and timing</b>	All the patients are accounted for in the results.
Was there an appropriate interval between index test and reference standard?	<b>Yes (probably)</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	It is a concern that some patients with cancer might have been missed due to the choice of reference standard because this would result in an underestimation of the positive predictive value. 38/1975 patients were found in the tumour registry. Of those 38, 13 patients had tumours that were probable causes of back pain, and 4 of these 13 patients already had a diagnosis of cancer at presentation. The 9/1975 patients who had undiagnosed cancer that the back pain could be attributed to had: Lymphoma (NOS; 2), cancer of unknown primary (1), prostate cancer

1  
2

	(1), retroperitoneal liposarcoma (1), lung cancer (1), renal cell (1), multiple myeloma (1), mucinous adenocarcinoma (of gallbladder?; 1)
<b>Dommett (2012; 2013a,b)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Population-based nested case-control study using data from the General Practice Research Database (GPRD)
Was a consecutive or random sample of patients enrolled?	<b>No</b>
Was a case-control design avoided?	<b>No</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>High risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p><u>Cases:</u> 1267 children; aged 0-4 years: N = 436; aged 5-14 years: N = 831; 703 males/564 females. Cancer type: Leukemia: N = 368; brain: N = 270; lymphoma: N = 142; bone: N = 107; soft tissue sarcoma: N = 91; renal: N = 82; neuroblastoma: N = 75; other ICD codes: N = 132. 1064 teenagers and young adults (TYA): 15-24 years: Gender not reported. Cancer type: Leukemia: N = 143; brain: N = 154; lymphoma: N = 270; bone: N = 96; soft tissue sarcoma: N = 100; other ICD codes: N = 301 (including testis: N = 60; skin: N = 49; ovary: N = 20 and thyroid: N = 17).</p> <p><u>Controls:</u> 15318 children; aged 0-4 years: N = 4802; aged 5-14 years: N = 10516; 8461 males/6857 females. 13206 TYA. Gender not reported</p> <p><u>Inclusion criteria:</u> The sample comprised all children and TYU aged 0–24 years, inclusive, drawn from all general practices contributing research-standard data to the GPRD between 1 January 1988 and 31 December 2010. To be included, the practices had to have been contributing research-standard data for a minimum of 1 year before each child’s date of cancer diagnosis or the index date (see below) for matched controls. Cases: Patients diagnosed with the following cancers: leukaemia, lymphoma, neuroblastoma, soft tissue sarcoma, hepatic, renal, bone and central nervous system tumours, using pre-defined medical codes used in the GPRD. The date of diagnosis for cases was defined as the date of pathological diagnosis, but if this was unavailable, the date of the first cancer code entered in the GPRD was used. Controls: Up to 13 controls (children with no diagnosis of cancer at any time) were selected per case, using a computer-generated random sequence, matched on age (within 1 year), sex and practice, and had to be currently</p>

	registered on the date of diagnosis of their matched case (the index date). <u>Exclusion criteria:</u> None listed <u>Clinical setting:</u> Primary care, UK.
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	The GPRD uses just over 100 000 medical codes to encompass all primary care events, including both symptoms and diagnoses. From this list, libraries of codes were assembled representing individual alert symptoms derived from the NICE referral guidelines for suspected cancer in children. <i>No more information reported.</i>
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Cancer diagnosis in the UK's General Practice Research Database.
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients appear to be accounted for.
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	This study is published in three papers.
1	
2	<b>Williamson (1985)</b>
<b>PATIENT SELECTION</b>	

<b>A. risk of bias</b>	
Patient sampling	Retrospective consecutive patient series
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes (probably)
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	N = 249, mean age = 24 years, 26% were < 15 years; 58% females.  Inclusion criteria: Patients seen at the Family Medical Care Centre of the University of Missouri-Columbia, between July 1 19978 and June 30 1983 whose diagnoses were coded as “enlarged lymph nodes, not infected” (ICHPPC 266) and “lymphadenitis, acute” (ICHPPC 209). Exclusion criteria: None listed Clinical setting: Family Medical Care Centre of the University of Missouri-Columbia.
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	Diagnoses coded as “enlarged lymph nodes, not infected” (ICHPPC 266) and “lymphadenitis, acute” (ICHPPC 209).
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Diagnoses were accepted if verified by history, physical examination or laboratory tests. Outcomes were determined, where possible, from the medical record. Follow up was considered adequate to determine an adverse outcome if one of four criteria were met: 1) A definite diagnosis was made, 2) The nodes were documented to be resolving, 3) There was at least one chart entry for any condition at least 6 months after the index visit for lymphadenopathy, or 4) The patient was reached by telephone and determined to have a favourable outcome.
Is the reference standard likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	No (but all patients had a positive index test)
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined</b>	<b>Low concern</b>



<b>by the reference standard does not match the question?</b>		
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	11/249 patients did not fit the criteria for adequate follow up: 3/11 had return visits showing no increase in the size of the nodes, 6/11 had nodes < 1 cm in size and were told to come back if the nodes did not resolve, 2/11 presented with cervical lymph nodes described as 1 cm in size and follow up examination was not recommended. None of these 11 patients could be reached by phone.	
Was there an appropriate interval between index test and reference standard?	<b>Yes (probably)</b>	
Did all patients receive the same reference standard?	<b>Yes</b>	
Were all patients included in the analysis?	<b>Unclear</b>	
<b>Could the patient flow have introduced bias?</b>	<b>Unclear risk</b>	
<b>NOTES</b>	The author note that the study would not have included all the patients presenting with enlarged lymph nodes during the study period because not all such patients would have the diagnosis noted as required for study entry, e.g., a diagnosis of infectious mononucleosis made on the first visit would probably have been coded as such and not as enlarged lymph nodes.	

1

2 **References**3 **Included studies**

- 4 Deyo, R. A. and Diehl, A. K. Cancer as a cause of back pain: Frequency, clinical presentation, and  
5 diagnostic strategies. *Journal of General Internal Medicine* 3, 230-238. 1-11-1988.
- 6 Dommett, R. M., Redaniel, M. T., Stevens, M. C. G., Hamilton, W., and Martin, R. M. Features of  
7 childhood cancer in primary care: A population-based nested case-control study. *British Journal*  
8 *of Cancer* 106[5], 982-987. 2012.
- 9 Dommett, R. M., Redaniel, T., Stevens, M. C. G., Martin, R. M., and Hamilton, W. Risk of childhood  
10 cancer with symptoms in primary care: A population-based case-control study. *British Journal of*  
11 *General Practice*; DOI:10.3399/bjgp13X660742. 2013a.
- 12 Dommett, R. M., Redaniel, M. T., Stevens, M. C. G., Hamilton, W., and Martin, R. M. Features of  
13 cancer in teenagers and young adults in primary care: A population-based nested case-control  
14 study. *British Journal of Cancer* 2329-2333. 2013b.
- 15 Williamson, H. A., Jr. Lymphadenopathy in a family practice: a descriptive study of 249 cases. *Journal*  
16 *of Family Practice* 20[5], 449-452. 1985.

17

18 **Excluded studies (with excl reason)**

- 19 Certificated training: Enlarged lymph nodes - Finding in general practice. [German]. *MMW-*  
20 *Fortschritte der Medizin* 142[17], I-XII. 27-4-2000.  
21 Excl reason: Narrative review
- 22 Acikel, C. H., Kir, T., Komurcu, S., Kilic, S., Ozett, A., Rzayev, M., Arpaci, F., Ozturk, B., Ogur, R.,  
23 Ataergin, S., Kuzhan, O., and Hasde, M. Some sociodemographic and diagnostic characteristics of  
24 military patients treated in the Department of Medical Oncology, Gulhane Military Medical  
25 Academy. *Military Medicine* 171[5], 420-424. 2006.  
26 Excl reason: Not in PICO
- 27 Ahmed, S., Shahid, R. K., Sison, C. P., Fuchs, A., and Mehrotra, B. Orbital lymphomas: A  
28 clinicopathologic study of a rare disease. *American Journal of the Medical Sciences* 331[2], 79-  
29 83. 2006.  
30 Excl reason: Not in PICO

- 1 Au, W. Y., Gascoyne, R. D., Gallagher, R. E., Le, N., Klasa, R. D., Liang, R. H. S., Choy, C., Foo, W., and  
2 Connors, J. M. Hodgkin's lymphoma in Chinese migrants to British Columbia: A 25-year survey.  
3 *Annals of Oncology* 15[4], 626-630. 2004.  
4 Excl reason: Not in PICO
- 5 Bennett, M., Higgins, E., Curran, S., and Marren, P. Leukaemia cutis mimicking florid rhinophymatous  
6 rosacea. *British Journal of Dermatology* 163[2], 443. 2010. Blackwell Publishing Ltd.  
7 Excl reason: Not in PICO
- 8 Bien, E., Stachowicz-Stencel, T., Zawitkowska-Klaczynska, J., Adamkiewicz-Drozynska, E., Odoj, T.,  
9 Polczynska, K., Mitura-Lesiuk, M., Stefanowicz, J., Sierota, D., Szolkiewicz, A., Birkholz, D.,  
10 Hennig, M., Kowalczyk, J. R., and Balcerska, A. [Clinical characteristics and therapy outcome in  
11 children with stage IV Hodgkin's lymphoma--the experience of two oncological centres]. [Polish].  
12 *Medycyna Wieku Rozwojowego* 10[3:Pt 1], t-8. 2006.  
13 Excl reason: Not in PICO
- 14 Bleyer, A. CAUTION! Consider Cancer: Common Symptoms and Signs for Early Detection of Cancer in  
15 Young Adults. *Seminars in Oncology* 36[3], 207-212. 2009.  
16 Excl reason: Narrative review
- 17 Brabant, G., Toogood, A. A., Shalet, S. M., Frobisher, C., Lancashire, E. R., Reulen, R. C., Winter, D. L.,  
18 and Hawkins, M. M. Hypothyroidism following childhood cancer therapy-an under diagnosed  
19 complication. *International Journal of Cancer* 130[5], 1145-1150. 1-3-2012.  
20 Excl reason: Not in PICO
- 21 Broccia, G., Gabbas, A., and Longinotti, M. Newly diagnosed cases of hematologic malignancies in  
22 Sardinia in the early 2000s: An estimation of their number, age and geographic distribution on  
23 the basis of a previous epidemiologic survey. *Haematologica* 90[3], 429-430. 2005.  
24 Excl reason: Not in PICO
- 25 Cainelli, F., Tanko, M. N., and Vento, S. The challenge of lymphomas in sub-Saharan Africa. *The*  
26 *Lancet Oncology* 11[7], 610-611. 2010.  
27 Excl reason: Not in PICO
- 28 Calza, L., Manfredi, R., Colangeli, V., Dentale, N., and Chiodo, F. Hodgkin's disease in the setting of  
29 human immunodeficiency virus infection. *Scandinavian Journal of Infectious Diseases* 35[2], 136-  
30 141. 2003.  
31 Excl reason: Not in PICO
- 32 Carbone, A. and Gloghini, A. "Intrafollicular neoplasia" of nodular lymphocyte predominant Hodgkin  
33 lymphoma: description of a hypothetic early step of the disease. [Review]. *Human Pathology*  
34 43[5], 619-628. 2012.  
35 Excl reason: Narrative review
- 36 Carvalho, P. C., Carvalho, Mda G., Degraive, W., Lilla, S., De, Nucci G., Fonseca, R., Spector, N.,  
37 Musacchio, J., and Domont, G. B. Differential protein expression patterns obtained by mass  
38 spectrometry can aid in the diagnosis of Hodgkin's disease. *Journal of Experimental Therapeutics*  
39 *& Oncology* 6[2], 137-145. 2007.  
40 Excl reason: Narrative review
- 41 Cohen, A. J., Thompson, L., Edwards, F. H., and Bellamy, R. F. Primary cysts and tumors of the  
42 mediastinum. *Annals of Thoracic Surgery* 51[3], 378-386. 1991.  
43 Excl reason: Not in PICO
- 44 Crouch, S., Simpson, J., Ansell, P., Kane, E., Howell, D., Smith, A., Newton, R., Jack, A., and Roman, E.  
45 Illness patterns prior to diagnosis of lymphoma: Analysis of UK medical records. *Cancer*  
46 *Epidemiology* 35[2], 145-150. 2011.  
47 Excl reason: Case-control comparison of number of visits to GP for infectious & non-infectious  
48 diagnoses in 15 years prior to diagnosis, but omitted data in the year prior to diagnosis in order  
49 not to swamp earlier effects. Same data as Newton 2007

- 1 Damion, J. and Hybels, R. L. The neck mass. 2. Inflammatory and neoplastic causes. Postgraduate  
2 Medicine 81[6], 97-103. 106.  
3 Excl reason: Narrative review
- 4 Danilenko, A. A. and Shakhtarina, S. V. [Hodgkin's disease and second malignancies]. [Review] [70  
5 refs] [Russian]. Voprosy Onkologii 55[6], 692-702. 2009.  
6 Excl reason: Not in PICO
- 7 Edgren, G., Bagnardi, V., Bellocco, R., Hjalgrim, H., Rostgaard, K., Melbye, M., Reilly, M., Adami, H.-  
8 O., Hall, P., and Nyren, O. Pattern of declining hemoglobin concentration before cancer  
9 diagnosis. International Journal of Cancer 127[6], 1429-1436. 1-9-2010.  
10 Excl reason: Not in PICO
- 11 El, Safy U., Rifky, E. H., Badr, M., Hassan, T., Beshier, M., El, Garbey K., and Hussein, O. Retrospective  
12 analytical study of musculoskeletal manifestations of pediatric oncology in the last two decade at  
13 east delta of Egypt. Pediatric Blood and Cancer 53[5], 853-854. 2009. Wiley-Liss Inc.  
14 Excl reason: Not in PICO
- 15 Forsyth, C. and Joshua, D. Hodgkin's disease: A GP's guide to diagnosis and management. Modern  
16 Medicine of Australia 39[6], 127-135. 1996.  
17 Excl reason: Narrative review
- 18 Friedmann, A. M. Evaluation and management of lymphadenopathy in children. Pediatrics in Review  
19 29[2], 53-60. 2008.  
20 Excl reason: Narrative review
- 21 Ganesan, P., Kumar, L., Raina, V., Sharma, A., Bakhshi, S., Sreenivas, V., Vijayaraghavan, M., and  
22 Thulkar, S. Hodgkin's lymphoma--long-term outcome: an experience from a tertiary care cancer  
23 center in North India. Annals of Hematology 90[10], 1153-1160. 2011.  
24 Excl reason: Not in PICO
- 25 Ganz, P. A., Moinpour, C. M., Pauler, D. K., Kornblith, A. B., Gaynor, E. R., Balcerzak, S. P., Gatti, G. S.,  
26 Erba, H. P., McCoy, S., Press, O. W., and Fisher, R. I. Health status and quality of life in patients  
27 with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133. Journal of  
28 Clinical Oncology 21[18], 3512-3519. 15-9-2003.  
29 Excl reason: Not in PICO
- 30 Garcia, Hernandez B. Suspicion of cancer in pediatrics. [Spanish]. Pediatria Integral 12[6], 537-544.  
31 2008.  
32 Excl reason: Narrative review
- 33 Gelfand, J. M., Shin, D. B., Neimann, A. L., Wang, X., Margolis, D. J., and Troxel, A. B. The risk of  
34 lymphoma in patients with psoriasis. Journal of Investigative Dermatology 126[10], 2194-2201.  
35 30-10-2006.  
36 Excl reason: Not in PICO
- 37 Glass, C. Role of the primary care physician in Hodgkin lymphoma. American Family Physician 78[5],  
38 615-622. 1-9-2008.  
39 Excl reason: Narrative review
- 40 Glass, C. Information from your family doctor. Hodgkin lymphoma: a cancer of the lymph nodes.  
41 American Family Physician 78[5], 625-626. 1-9-2008.  
42 Excl reason: Patient education material
- 43 Glass, C. Information from your family doctor. Hodgkin lymphoma: a cancer of the lymph nodes.  
44 American Family Physician 78[5], 625-626. 1-9-2008.  
45 Excl reason: Patient education material
- 46 Gobbi, P. G., Parrinello, G. A., and Di, Prisco U. New clinical criteria for the assessment of liver  
47 involvement in Hodgkin's disease. European Journal of Cancer and Clinical Oncology 18[12],  
48 1243-1249. 1982.  
49 Excl reason: Not in PICO
- 50 Gordon, L. M., Johnson, R. H., Au, M. A., and Albritton, K. H. Primary care referral patterns for  
51 adolescent and young adult (AYA) cancer patients: A multistate study. Journal of Clinical

- 1 Oncology 29[15 SUPPL. 1]. 20-5-2011. American Society of Clinical Oncology.  
2 Excl reason: Not in PICO
- 3 Guccion, J. G., Gibert, C. L., Ortega, L. G., and Hadfield, T. L. Cat scratch disease and acquired  
4 immunodeficiency disease: diagnosis by transmission electron microscopy. *Ultrastructural*  
5 *Pathology* 20[3], 195-202. 1996.  
6 Excl reason: Not in PICO
- 7 Guven, M., Ozturk, B., Sayal, A., and Ozet, A. Lipid peroxidation and antioxidant system in the blood  
8 of patients with Hodgkin's disease. *Clinical Biochemistry* 33[3], 209-212. 2000.  
9 Excl reason: Not in PICO
- 10 Hajda, M., Koranyi, K., Salomvary, B., and Bajcsay, A. [Clinical presentation, differential diagnosis and  
11 treatment of lacrimal gland tumours]. [Hungarian]. *Magyar Onkologia* 49[1], 65-70. 2005.  
12 Excl reason: Not in PICO
- 13 Hiller, E. [Malignant Hodgkin's and non-Hodgkin's lymphomas]. [German]. *MMW Fortschritte der*  
14 *Medizin* 147[9], 31-34. 3-3-2005.  
15 Excl reason: Narrative review
- 16 Howell, D. A., Shellens, R., Roman, E., Garry, A. C., Patmore, R., and Howard, M. R. Haematological  
17 malignancy: Are patients appropriately referred for specialist palliative and hospice care? A  
18 systematic review and meta-analysis of published data. *Palliative Medicine* 25[6], 630-641. 2011.  
19 Excl reason: Not in PICO
- 20 Huhn, D. [Clinical aspects and therapy of malignant lymphomas in AIDS--symptomatology of AIDS  
21 encephalopathy]. [German]. *Verhandlungen der Deutschen Gesellschaft fur Innere Medizin* 92,  
22 330-336. 1986.  
23 Excl reason: Not in PICO
- 24 Isaacson, P. G. Haematopathology practice: the commonest problems encountered in a consultation  
25 practice. [Review] [18 refs]. *Histopathology* 50[7], 821-834. 2007.  
26 Excl reason: Narrative review
- 27 James, B. O., Ajayi, S. O., Ogun, O. A., and Oladokun, R. E. Factors influencing time to diagnosis of  
28 childhood cancer in Ibadan, Nigeria. *African Health Sciences* 9[4], 247-253. 2009.  
29 Excl reason: Not in PICO
- 30 Kasper, Ekkehard, Lam, Fred, Luedi, Markus, Zinn, Pascal, and Pihan, German. Primary epidural  
31 lymphocyte-depleted Hodgkin's lymphoma of the thoracic spine - presentation of a rare disease  
32 variant. *BMC Neurology* 12[1], 64. 2012.  
33 Excl reason: Not in PICO
- 34 Khojasteh, A., Reynolds, R. D., and Khojasteh, C. A. Malignant lymphoreticular lesions in patients  
35 with immune disorders resembling acquired immunodeficiency syndrome (AIDS): review of 80  
36 cases. [Review] [39 refs]. *Southern Medical Journal* 79[9], 1070-1075. 1986.  
37 Excl reason: Narrative review
- 38 Killeen, M. R. Approaches to the measurement of depressive symptomatology in children with  
39 cancer: attempting to circumvent the effects of defensiveness. *Journal of Child & Family Nursing*  
40 3[2], 139-141. 2000.  
41 Excl reason: Not in PICO
- 42 Kouroukis, C. T., Chia, S., Verma, S., Robson, D., Desbiens, C., Cripps, C., and Mikhael, J. Canadian  
43 supportive care recommendations for the management of neutropenia in patients with cancer.  
44 *Current Oncology* 15[1], 9-23. 2008.  
45 Excl reason: Not in PICO
- 46 Kristensen, P., Hilt, B., Svendsen, K., and Grimsrud, T. K. Incidence of lymphohaematopoietic cancer  
47 at a university laboratory: a cluster investigation. *European Journal of Epidemiology* 23[1], 11-  
48 15. 2008.  
49 Excl reason: Not in PICO
- 50 Laskar, S., Gupta, T., Vimal, S., Muckaden, M. A., Saikia, T. K., Pai, S. K., Naresh, K. N., and Dinshaw, K.  
51 A. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of

- 1 doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need? *Journal of*  
2 *Clinical Oncology* 22[1], 62-68. 2004.
- 3 Excl reason: Not in PICO
- 4 Lukic, S., Marjanovic, G., and Zivanovic, J. Palpable lymphadenopathy in primary care. *Acta Facultatis*  
5 *Medicae Naissensis* 28[1], 17-23. 2011.
- 6 Excl reason: Narrative review
- 7 Meekes, I., Van Der Staak, F., and Van, Oostrom C. Results of splenectomy performed on a group of  
8 91 children. *European Journal of Pediatric Surgery* 5[1], 19-22. 1995.
- 9 Excl reason: Not in PICO
- 10 Miettinen, M., Franssila, K. O., and Saxen, E. Hodgkin's disease, lymphocytic predominance nodular.  
11 Increased risk for subsequent non-Hodgkin's lymphomas. *Cancer* 51[12], 2293-2300. 1983.
- 12 Excl reason: Not in PICO
- 13 Milliken, S. T., Clezy, K. R., Cooper, S. G., and Romeril, K. HIV-related lymphoma and other  
14 malignancies. *Medical Journal of Australia* 164[8], 489-491. 15-4-1996.
- 15 Excl reason: Not in PICO
- 16 Milliken, S. T., Clezy, K. R., Cooper, S. G., and Romeril, K. R. Managing HIV. Part 5: Treating secondary  
17 outcomes. 5.13 HIV-related lymphoma and other malignancies. *The Medical journal of Australia*  
18 164[8], 489-491. 15-4-1996.
- 19 Excl reason: Not in PICO
- 20 Morrison, C., Gordon, S., and Yeo, T. P. Hodgkin's disease in primary care. [Review] [21 refs]. *Nurse*  
21 *Practitioner* 25[7], 44-50. 1956.
- 22 Excl reason: Narrative review
- 23 Morse, E. E., Yamase, H. T., Greenberg, B. R., Sporn, J., Harshaw, S. A., Kiraly, T. R., Ziemba, R. A., and  
24 Fallon, M. A. The role of flow cytometry in the diagnosis of lymphoma: A critical analysis. *Annals*  
25 *of Clinical and Laboratory Science* 24[1], 6-11. 1994.
- 26 Excl reason: Not in PICO
- 27 Moses, S. Pruritus. *American Family Physician* 68[6], 1135-1146. 15-9-2003.
- 28 Excl reason: Narrative review
- 29 Nakamura, S. [Overview of 2008 WHO Classification of Malignant Lymphoma]. [Japanese]. *Rinsho*  
30 *byori The*[11], 1105-1111. 2010.
- 31 Excl reason: Narrative review
- 32 Nay, C., Luthi, F., Ketterer, N., Bauer, J., and Leyvraz, S. Overview on cancer in young adults. [French].  
33 *Revue Medicale Suisse* 3[112], 1305-1310. 23-5-2007.
- 34 Excl reason: Narrative review
- 35 Newton, R., Crouch, S., Ansell, P., Simpson, J., Willett, E. V., Smith, A., Burton, C., Jack, A., and  
36 Roman, E. Hodgkin's lymphoma and infection: findings from a UK case-control study. *British*  
37 *Journal of Cancer* 97[9], 1310-1314. 5-11-2007.
- 38 Excl reason: Case-control comparison of number of visits to GP for infectious & non-infectious  
39 diagnoses in 15 years prior to diagnosis, but omitted data in the year prior to diagnosis in order  
40 not to swamp earlier effects. Same data as Crouch 2011. Only data included for the year prior to  
41 diagnosis was no of cases & controls visiting their GP at least once split by infectious/non-  
42 infectious diagnosis (including tiredness & malaise). No further split into individual symptoms.
- 43 Ng, A. K., Li, S., Neuberg, D., Silver, B., Weeks, J., and Mauch, P. Factors influencing treatment  
44 recommendations in early-stage Hodgkin's disease: a survey of physicians. *Annals of Oncology*  
45 15[2], 261-269. 2004.
- 46 Excl reason: Not in PICO
- 47 Odemis, B., Parlak, E., Basar, O., Yuksel, O., and Sahin, B. Biliary tract obstruction secondary to  
48 malignant lymphoma: experience at a referral center. *Digestive Diseases & Sciences* 52[9], 2323-  
49 2332. 2007.
- 50 Excl reason: Not in PICO

- 1 Pagano, J. S. Epstein-Barr virus: The first human tumor virus and its role in cancer. Proceedings of the  
2 Association of American Physicians 111[6], 573-580. 1999.  
3 Excl reason: Narrative review
- 4 Pollock, B. H., Krischer, J. P., and Vietti, T. J. Interval between symptom onset and diagnosis of  
5 pediatric solid tumors. Journal of Pediatrics 119[5], 725-732. 1991.  
6 Excl reason: Not in PICO
- 7 Pongas, G., Hamilos, G., Rolston, K. V., and Kontoyiannis, D. P. Formal adult infectious disease  
8 specialist consultations in the outpatient setting at a comprehensive cancer center (1998-2008):  
9 diverse and impactful. Supportive Care in Cancer 20[2], 261-265. 2012.  
10 Excl reason: Not in PICO
- 11 Proctor, S. J. and Wilkinson, J. A web-based study concept designed to progress clinical research for  
12 'orphan' disease areas in haematological oncology in the elderly: the SHIELD programme. Critical  
13 Reviews in Oncology-Hematology 61[1], 79-83. 2007.  
14 Excl reason: Not in PICO
- 15 Razavi, D., Delvaux, N., Bredart, A., Paesmans, M., Debusscher, L., Bron, D., and Stryckmans, P.  
16 Screening for psychiatric disorders in a lymphoma out-patient population. European Journal of  
17 Cancer 28A[11], 1869-1872. 1992.  
18 Excl reason: Not in PICO
- 19 Reamy, B. V., Bunt, C. W., and Fletcher, S. A diagnostic approach to pruritus. American Family  
20 Physician 84[2], 195-202. 15-7-2011.  
21 Excl reason: Narrative review
- 22 Rose, C., Stovall, E., Ganz, P. A., Desch, C., and Hewitt, M. Cancer Quality Alliance: Blueprint for a  
23 better cancer care system. CA: A Cancer Journal for Clinicians 58[5], 266-292. 2008.  
24 Excl reason: Not in PICO
- 25 Ruffer, J. U., Flechtner, H., Heim, M., Schwarz, R., and Weis, J. [Cancer fatigue syndrome]. [German].  
26 Versicherungsmedizin 55[1], 3-7. 1-3-2003.  
27 Excl reason: Not in PICO
- 28 Schleiffenbaum, B. and Fehr, J. Value of the blood picture and flow cytometry immunotyping in the  
29 early diagnosis of low-grade lymphoma. [German]. Therapeutische Umschau Revue[2], 117-122.  
30 1996.  
31 Excl reason: Narrative review
- 32 Schott, A. F. Leukemia and lymphoma. Primary Care Update for Ob/Gyns 4[1], 6-14. 1997.  
33 Excl reason: Narrative review
- 34 Siddiqi, T. and Joyce, R. M. A case of HIV-negative primary effusion lymphoma treated with  
35 bortezomib, pegylated liposomal doxorubicin, and rituximab. Clinical Lymphoma & Myeloma  
36 8[5], 300-304. 2008.  
37 Excl reason: Not in PICO
- 38 Smith, S. Unravelling diagnostic delay of hodgkin lymphoma in the teenage and young adult  
39 population - A substantive investigation. European Journal of Cancer 47, S310. 2011. Elsevier  
40 Ltd.  
41 Excl reason: Published as abstract only, so not possible to check in more detail. May be  
42 published in full when update search done
- 43 Spencer, A., Reed, K., and Arthur, C. Pilot study of an outpatient-based approach for advanced  
44 lymphoma using vinorelbine, gemcitabine and filgrastim. Internal Medicine Journal 37[11], 760-  
45 766. 2007.  
46 Excl reason: Not in PICO
- 47 Thompson, C. A., Mauck, K., Havyer, R., Bhagra, A., Kalsi, H., and Hayes, S. N. Care of the adult  
48 Hodgkin lymphoma survivor. [Review]. American Journal of Medicine 124[12], 1106-1112. 2011.  
49 Excl reason: Not in PICO
- 50 Timms, J. M., Bell, A., Flavell, J. R., Murray, P. G., Rickinson, A. B., Traverse-Glehen, A., Berger, F., and  
51 Delecluse, H.-J. Target cells of Epstein-Barr-virus (EBV)-positive post-transplant

- 1 lymphoproliferative disease: Similarities to EBV-positive Hodgkin's lymphoma. *Lancet* 361[9353],  
2 217-223. 18-1-2003.  
3 Excl reason: Not in PICO
- 4 van den Akker, Machiel, Zudekov, Vadiem, Moser, Asher, and Kapelushnik, Joseph. An osseous lesion  
5 in a 10-year-old boy with Hodgkin's lymphoma: a case report. *Journal of Medical Case Reports*  
6 5[1], 511. 2011.  
7 Excl reason: Not in PICO
- 8 Varnum, S. M., Webb-Robertson, B. J., Hessol, N. A., Smith, R. D., and Zangar, R. C. Plasma  
9 biomarkers for detecting Hodgkin's lymphoma in HIV patients. *PLoS ONE [Electronic Resource]*  
10 6[12], e29263. 2011.  
11 Excl reason: Not in PICO
- 12 Waller, H. D. [Hodgkin's disease--current problems in etiology and clinical picture]. [Review] [23 refs]  
13 [German]. *Strahlentherapie* 161[4], 191-196. 1985.  
14 Excl reason: Narrative review
- 15 Wesnes, K. A., Brooker, H., and Edgar, C. The disruptions to cognition, everyday function, and quality  
16 of life in oncology patients: A therapeutic opportunity? *Neurotherapeutics* 7[3], 331-332. 2010.  
17 Elsevier Inc.  
18 Excl reason: Not in PICO
- 19 White, L. N. Cancer prevention and detection: from twenty to sixty-five years of age. *Oncology*  
20 *Nursing Forum* 13[2], 59-64. 1986.  
21 Excl reason: Narrative review
- 22 Wilkinson, A. R., Mahore, S. D., and Maimoon, S. A. FNAC in the diagnosis of lymph node  
23 malignancies: A simple and sensitive tool. *Indian Journal of Medical and Paediatric Oncology*  
24 33[1], 21-24. 2012.  
25 Excl reason: Not in PICO
- 26 Yamashita, H., Takahashi, Y., Kano, T., Kaneko, H., and Mimori, A. Malignant lymphoma presenting as  
27 inflammation of unknown origin. *Japanese Journal of Clinical Immunology* 35[2], 136-143. 2012.  
28 Excl reason: Not in PICO
- 29 Yano, M., Yamakawa, Y., Niwa, H., Fukai, I., Kiriya, M., Saito, Y., Kani, H., Sasaki, H., and Masaoka,  
30 A. [Clinical considerations from sixteen cases with mediastinal malignant lymphoma]. [Japanese].  
31 *Nippon Kyobu Geka Gakkai Zasshi - Journal of the Japanese Association for Thoracic Surgery*  
32 44[8], 1114-1118. 1996.  
33 Excl reason: Not in PICO
- 34 Yeole, B. B. and Jussawalla, D. J. Descriptive epidemiology of lymphatic malignancies in Greater  
35 Bombay. *Oncology Reports* 5[3], 771-777. 1998.  
36 Excl reason: Not in PICO
- 37 Ying, J., Li, H., Murray, P., Gao, Z., Chen, Y.-W., Wang, Y., Lee, K. Y., Chan, A. T. C., Ambinder, R. F.,  
38 Srivastava, G., and Tao, Q. Tumor-specific methylation of the 8p22 tumor suppressor gene *DLC1*  
39 is an epigenetic biomaker for Hodgkin, nasal NK/T-cell and other types of lymphomas.  
40 *Epigenetics* 2[1], 15-21. 2007.  
41 Excl reason: Not in PICO

**Review question:**

44 Which investigations of symptoms of suspected Hodgkin's lymphoma should be done with clinical  
45 responsibility retained by primary care?

**Results****Literature search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1980-2013	89	20	14/05/2013

<b>Premedline</b>	1980-2013	5	2	14/05/2013
<b>Embase</b>	1980-2013	71	19	14/05/2013
<b>Cochrane Library</b>	1980-2013	31	1	14/05/2013
<b>Psychinfo</b>	1980-2013	2	0	14/05/2013
<b>Web of Science (SCI &amp; SSCI) and ISI Proceedings</b>	1980-2013	8	3	14/05/2013


1 Total References retrieved (after de-duplication): 38

2

3 **Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<b>Medline</b>	5/2013-26/08/2014	6	0	26/08/2014
<b>Premedline</b>	5/2013-26/08/2014	7	2	26/08/2014
<b>Embase</b>	5/2013-26/08/2014	17	1	26/08/2014
<b>Cochrane Library</b>	5/2013-26/08/2014	4	0	26/08/2014
<b>Web of Science (SCI &amp; SSCI) and ISI Proceedings</b>	5/2013-26/08/2014	2	0	26/08/2014

4 Total References retrieved (after de-duplication): 3



5

6 **Study results**

7 No evidence was identified pertaining to the diagnostic accuracy of chest x-ray, CT scan, ultrasound  
 8 or LDH in patients with suspected Hodgkin’s lymphoma where the clinical responsibility was retained  
 9 by primary care.

10

11 **References**

12 **Included studies**



- 1 None  
2
- 3 **Excluded studies (with excl reason)**
- 4 Bares, R., Galonska, P., Dempke, W., Handt, S., Bull, U. & Osieka, R. (1993) Somatostatin receptor  
5 scintigraphy in malignant lymphoma: first results and comparison with glucose metabolism  
6 measured by positron-emission tomography. *Hormone & Metabolic Research - Supplement*, 27:  
7 56-58.  
8 Not in PICO
- 9 Coleman, M. & Kostakoglu, L. (2006) Early 18F-labeled fluoro-2-deoxy-D-glucose positron emission  
10 tomography scanning in the lymphomas: changing the paradigms of treatments? *Cancer*, 107:  
11 1425-1428.  
12 Narrative review
- 13 Eich, H. T., Staar, S., Gossmann, A., Hansemann, K., Skripnitchenko, R., Kocher, M., Semrau, R.,  
14 Engert, A., Josting, A., Franklin, J., Krug, B., Diehl, V. & Muller, R.-P. (2004) Centralized radiation  
15 oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in  
16 required involved field - Results of a quality assurance program of the German Hodgkin Study  
17 Group. *International Journal of Radiation Oncology Biology Physics*, 58: 1121-1127.  
18 Not in PICO
- 19 El-Galaly, T. C., Mylam, K. J., Brown, P., Specht, L., Christiansen, I., Munksgaard, L., Johnsen, H. E.,  
20 Loft, A., Bukh, A., Iyer, V., Nielsen, A. L. & Hutchings, M. (2012) Positron emission  
21 tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first  
22 remission has a low positive predictive value and high costs. *Haematologica-the Hematology  
23 Journal*, 97: 931-936.  
24 Not in PICO
- 25 Friedmann, A. M. (2008) Evaluation and management of lymphadenopathy in children. *Pediatrics in  
26 Review*, 29: 53-60.  
27 Narrative review
- 28 Gallamini, A.; Borra, A. (2014). Role of PET in lymphoma. *Current Treatment Options in Oncology*, 15,  
29 248-61.  
30 Not in PICO
- 31 Garrett Kevin, M. K. M., Hoffer, F. A., Behm, F. G., Gow, K. W., Hudson, M. M. & Sandlund, J. T.  
32 (2002) Interventional radiology techniques for the diagnosis of lymphoma or leukemia. *Pediatric  
33 Radiology*, 32: 653-662.  
34 Not in PICO
- 35 Gerrits, C. J., Overhagen, H., Lom, K., Adriaansen, H. J. & Löwenberg, B. (1994) Ultrasound  
36 examination of pathological cervical lymph nodes in patients with non-Hodgkin's lymphoma and  
37 Hodgkin's disease. *British journal of haematology.*, 88: 626-628.  
38 Not in PICO
- 39 Glass, C. (2008) Role of the primary care physician in Hodgkin lymphoma. *American Family Physician*,  
40 78: 615-626.  
41 Narrative review
- 42 Goldschmidt, N., Libson, E., Bloom, A., Amir, G. & Paltiel, O. (2003) Clinical utility of computed  
43 tomography-guided core needle biopsy in the diagnostic re-evaluation of patients with  
44 lymphoproliferative disorders and suspected disease progression. *Annals of Oncology*, 14: 1438-  
45 1441.  
46 Not in PICO
- 47 Hesselmann, V., Zahringer, M., Krug, B., Wesselmann, C., Haferkamp, K., Wickenhauser, C. &  
48 Lackner, K. (2004) Computed-tomography-guided percutaneous core needle biopsies of  
49 suspected malignant lymphomas: impact of biopsy, lesion, and patient parameters on  
50 diagnostic yield. *Acta Radiologica*, 45: 641-645.  
51 Not in PICO

- 1 Hodgson, D. C., Grunfeld, E., Gunraj, N. & Del, G. L. (2010) A population-based study of follow-up  
2 care for Hodgkin lymphoma survivors: Opportunities to improve surveillance for relapse and  
3 late effects. *Cancer*, 116: 3417-3425.  
4 Not in PICO
- 5 Hutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Berthelsen, A. K., Keiding, S., D'Amore, F.,  
6 Boesen, A. M., Roemer, L. & Specht, L. (2006) Position emission tomography with or without  
7 computed tomography in the primary staging of Hodgkin's lymphoma. *Haematologica-the*  
8 *Hematology Journal*, 91: 482-489.  
9 Not in PICO
- 10 Jabshetty, S., Malakkla, N., Khatri, V. & Friedman, H. (2011) Primary Hodgkin's lymphoma: A rare  
11 cause of solitary pulmonary nodule. *Journal of General Internal Medicine*, 26: S524.  
12 Not in PICO
- 13 Kalkner, M., Rehn, S., Andersson, T., Elvin, A., Hagberg, H., Lindgren, P. G., Sundstrom, C. &  
14 Glimelius, B. (1994) Diagnostics of malignant lymphomas with ultrasound guided 1.2 MM  
15 biopsy- gun. *Acta Oncologica*, 33: 33-37.  
16 Not in PICO
- 17 Kirby, A. M. & Mikhaeel, N. G. (2007) The role of FDG PET in the management of lymphoma: what is  
18 the evidence base?. [Review] [123 refs]. *Nuclear Medicine Communications*, 28: 335-354.  
19 Narrative review
- 20 Li, L., Wu, Q.-L., Liu, L.-Z., Mo, Y.-X., Xie, C.-M., Zheng, L., Chen, L. & Wu, P.-H. (2005) Value of CT-  
21 guided core-needle biopsy in diagnosis and classification of malignant lymphomas using  
22 automated biopsy gun. *World Journal of Gastroenterology*, 11: 4843-4847.  
23 Not in PICO
- 24 Linden, A., Zankovich, R., Theissen, P., Diehl, V. & Schicha, H. (1989) Malignant lymphoma: bone  
25 marrow imaging versus biopsy. *Radiology*, 173: 335-339.  
26 Not in PICO
- 27 Liu, Y. (2012) Concurrent FDG Avid Nasopharyngeal Lesion and Generalized Lymphadenopathy on  
28 PET-CT Imaging Is Indicative of Lymphoma in Patients with HIV Infection. *AIDS Research &*  
29 *Treatment*, 2012: 764291.  
30 Not in PICO
- 31 Morrison, C., Gordon, S. & Yeo, T. P. (1956) Hodgkin's disease in primary care. *The Nurse*  
32 *practitioner*, 25: 44, 47-50, 56.  
33 Narrative review
- 34 Moses, S. (2003) Pruritus. *American Family Physician*, 68: 1135-1146.  
35 Narrative review
- 36 Munker, R., Glass, J., Griffeth, L. K., Sattar, T., Zamani, R., Heldmann, M., Shi, R. & Lilien, D. L. (2004)  
37 Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's  
38 disease. *Annals of Oncology*, 15: 1699-1704.  
39 Not in PICO
- 40 Neufang, K. F. & Beyer, D. (1983) [Conventional diagnosis of lymphadenopathies--value of  
41 conventional roentgen examination and supplementation of other imaging technics]. [German].  
42 *Rontgen-Blatter*, 36: 30-44.  
43 Narrative review
- 44 Odemis, B., Parlak, E., Basar, O., Yuksel, O. & Sahin, B. (2007) Biliary tract obstruction secondary to  
45 malignant lymphoma: experience at a referral center. *Digestive Diseases & Sciences*, 52: 2323-  
46 2332.  
47 Not in PICO
- 48 Omur, O.; Baran, Y.; Oral, A.; Ceylan, Y. (2014). Fluorine-18 fluorodeoxyglucose PET-CT for extranodal  
49 staging of non-Hodgkin and Hodgkin lymphoma. *Diagnostic & Interventional Radiology*, 20, 185-  
50 92.  
51 Not in PICO

- 1 Pan, Z. G., Hunter, W. J. & Deng, C. S. (2010) Postmortem diagnosis of Hodgkin lymphoma: An issue  
2 regarding to fine needle aspiration biopsy. *Laboratory Investigation*, 90: 11A.  
3 Not in PICO
- 4 Raab, C. P. & Gartner, J. C., Jr. (2009) Diagnosis of childhood cancer. [Review] [33 refs]. *Primary Care;  
5 Clinics in Office Practice*, 36: 671-684.  
6 Narrative review
- 7 Reamy, B. V., Bunt, C. W. & Fletcher, S. (2011) A diagnostic approach to pruritus.[Summary for  
8 patients in Am Fam Physician. 2011 Jul 15;84(2):203; PMID: 21766770]. *American Family  
9 Physician*, 84: 195-202.  
10 Narrative review
- 11 Richardson, S. E., Sudak, J., Warbey, V., Ramsay, A. & McNamara, C. J. (2012) Routine bone marrow  
12 biopsy is not necessary in the staging of patients with classical Hodgkin lymphoma in the 18F-  
13 fluoro-2-deoxyglucose positron emission tomography era. *Leukemia & Lymphoma*, 53: 381-385.  
14 Not in PICO
- 15 Sato, K., Ozaki, K., Fujiwara, S.-I., Oh, I., Matsuyama, T., Ohmine, K., Suzuki, T., Mori, M., Nagai, T.,  
16 Muroi, K. & Ozawa, K. (2010) Incidental carcinomas detected by PET/CT scans in patients with  
17 malignant lymphoma. *International Journal of Hematology*, 92: 647-650.  
18 Not in PICO
- 19 Savage, S. A. H., Wotherspoon, H. A., Fitzsimons, E. J. & MacKenzie, K. (2008) Cervical  
20 lymphadenopathy resulting in a diagnosis of lymphoma. *Scottish Medical Journal*, 53: 13-16.  
21 Not in PICO
- 22 Sklair-Levy, M., Polliack, A., Shaham, D., Applbaum, Y. H., Gillis, S., Ben-Yehuda, D., Sherman, Y. &  
23 Libson, E. (2000) CT-guided core-needle biopsy in the diagnosis of mediastinal lymphoma.  
24 *European Radiology*, 10: 714-718.  
25 Not in PICO
- 26 Tappauf, M., Lackner, H., Sovinz, P., Schwinger, W., Benesch, M., Strenger, V., Schmidt, S. & Urban,  
27 C. (2011) Multifocal osseous involvement in a patient with Hodgkin lymphoma. *Monatsschrift  
28 fur Kinderheilkunde*, 159: 326.  
29 Not in PICO
- 30 Toma, P., Granata, C., Rossi, A. & Garaventa, A. (2007) Multimodality imaging of Hodgkin disease and  
31 non-Hodgkin lymphomas in children. [Review] [55 refs]. *Radiographics*, 27: 1335-1354.  
32 Narrative review
- 33 Treglia, G., Lococo, F., Petrone, G., Stefanelli, A., Carnassale, G., Calcagni, M. L., Granone, P. &  
34 Giordano, A. (2013) A Rare Case of Primary Thymic Hodgkin Lymphoma in an Elderly Patient  
35 Detected by 18F-FDG PET/CT. *Clinical Nuclear Medicine*, 38: e236-e238.  
36 Not in PICO
- 37 Vanis,N.; Mesihovic,R.; Ibricevic,L.; Dobrila-Dintinjana,R. (2013). Predictive value of endoscopic  
38 ultrasound in diagnosis and staging of primary gastric lymphoma. *Collegium Antropologicum*,  
39 37, 291-7.  
40 Not in PICO
- 41 Wickmann, L., Luders, H. & Dorffel, W. (2003) 18-FDG-PET-findings in children and adolescents with  
42 Hodgkin's disease: Retrospective evaluation of the correlation to other imaging procedures in  
43 initial staging and to the predictive value of follow up examinations. [German]. *Klinische  
44 Padiatrie*, 215: 146-150.  
45 Not in PICO
- 46 Williams, E. & Ledingham, J. (2010) Biopsy proven Hodgkin'S Lymphoma (HL) and sarcoid in a patient  
47 with Rheumatoid Arthritis (RA). *Rheumatology*, 49: i40-i41.  
48 Not in PICO
- 49 Yasuda, I., Tsurumi, H., Omar, S., Iwashita, T., Kojima, Y., Yamada, T., Sawada, M., Takami, T.,  
50 Moriwaki, H. & Soehendra, N. (2006) Endoscopic ultrasound-guided fine-needle aspiration

1 biopsy for lymphadenopathy of unknown origin. *Endoscopy*, 38: 919-924.  
2 Not in PICO  
3 You, J. J., Inculet, R. I., Sukhbinder, K. D. T., Chan, A. M., Freeman, M., Cline, K. J., Pritchard, K. I.,  
4 Dayes, I. S., Gu, C.-S., Julian, J. A., Gulenchyn, K. Y., Evans, W. K. & Levine, M. N. (2012) Positron  
5 emission tomography/computed tomography (PET/CT) for the diagnosis of recurrent cancer  
6 (PETREC): A multicenter, prospective cohort study. *Journal of Clinical Oncology*, 30.  
7 Not in PICO  
8 Zhou, Q. T., Zhu, H. & He, B. (2009) [Clinical analysis of lymphoma with chest involvement: report of  
9 25 cases]. [Chinese]. *Chung-Hua Nei Ko Tsa Chih Chinese Journal of Internal Medicine*, 48: 846-  
10 849.  
11 Not in PICO  
12  
13

**SARCOMAS****BONE SARCOMA****Review question:**

What is the risk of bone sarcoma in patients presenting in primary care with symptom(s)?

**Results****Literature search**


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	All-2012	2069	78	11/10/12
<i>Premedline</i>	All-2012	57	8	11/10/12
<i>Embase</i>	All-2012	2009	76	11/10/12
<i>Cochrane Library</i>	All-2012	407	2	15/10/12
<i>Psychinfo</i>	All-2012	10	1	11/10/12
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	All-2012	706	14	15/10/12
<i>Biomed Central</i>	All-2012	138	5	15/10/12

Total References retrieved (after de-duplication): 155

**Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	10/2012-26/08/2014	85	1	26/08/2014
<i>Premedline</i>	10/2012-26/08/2014	60	4	26/08/2014
<i>Embase</i>	10/2012-26/08/2014	258	6	26/08/2014
<i>Cochrane Library</i>	10/2012-26/08/2014	262	0	26/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	10/2012-26/08/2014	134	0	26/08/2014

Total References retrieved (after de-duplication): 9






1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

**Risk of bias in the included studies**

The risk of bias and applicability concerns are summarised per study in the figure below. The main issue to note is that 4/5 studies employed samples of patients that are not directly representative of an unselected symptomatic population of patients presenting to the UK-based GP. In the case of Pharisa (2009) whose sample consisted of patients presenting as emergencies, the symptom spectrum is likely to be of the more severe kind than those typically seen by a GP in the UK, but in the other cases (e.g., presentations to physiotherapists, chiropractors and hospital-based walk-in and family clinics) it is unclear how the patients differ from those of primary current interest. Dommett (2012, 2013a,b) only presented results for bone and soft tissue sarcoma in combination and also employed a case-control design which has been shown to inflate the test accuracy characteristics. However, the statistical analyses employed by the authors may have gone some way in counteracting this influence. Finally, two studies employed reference standards that are at some (unknown level of) risk of failing to identify all patients with cancer, which means that the relevant PPVs may be underestimated (to the extent that the reference standards have failed to identify patients with cancer).

	Risk of Bias				Applicability Concerns		
	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard
Deyo (1988)	?	+	?	+	-	+	+
Dommett (2012, 2013)	-	+	+	+	+	+	+
Henschke (2009)	+	+	+	+	-	+	+
Pharisa (2009)	+	+	+	+	-	+	+
Suarez-Almazor (1997)	+	+	?	+	?	+	+

 <b>High</b>	 <b>Unclear</b>	 <b>Low</b>
---	--	--

1  
2  
3  
4  
5  
6

**Study results**

Table 1: Bone sarcoma: Patients aged > 14-15 years

Study	Symptom(s)	Patient group	PPVs (95% CI); prevalence
Deyo (1988)	Back pain	All included patients	0 (0-0.2) 0/1975 None had bone sarcoma, but N = 9 had other types of cancer
Suarez-Almazor (1997)	Acute low back pain	All included patients	TP = 0-1, FP = 962-963 Unclear if diagnosis prior to symptom
Henschke (2009)	Acute low back pain	All included patients	0 (0-0.4) 0/1172 None had cancer
Henschke (2009)	Acute low back pain + age at onset < 20 years or > 55 years	Subgroup with both symptoms	0 (0-1.7) 0/281 None had cancer
Henschke (2009)	Acute low back pain + previous history of cancer	Subgroup with both symptoms	0 (0-9.6) 0/46 None had cancer
Henschke (2009)	Acute low back pain + tried bed rest, but no relief	Subgroup with both symptoms	0 (0-2.4) 0/192 None had cancer
Henschke (2009)	Acute low back pain + unexplained weight loss	Subgroup with both symptoms	0 (0-69) 0/3

			None had cancer
Henschke (2009)	Acute low back pain + insidious onset	Subgroup with both symptoms	0 (0-2.3) 0/202 None had cancer
Henschke (2009)	Acute low back pain + systemically unwell	Subgroup with both symptoms	0 (0-15.5) 0/27 None had cancer
Henschke (2009)	Acute low back pain + constant progressive non-mechanical pain	Subgroup with both symptoms	0 (0-13) 0/33 None had cancer
Henschke (2009)	Acute low back pain + sensory level altered from trunk down	Subgroup with both symptoms	0 (0-20.9) 0/19 None had cancer

1 TP = True positives, FP = False positives.

2

3 Table 2: Bone sarcoma: Positive predictive values for child- or young adulthood bone tumour/soft  
4 tissue sarcoma

Study	Symptom(s)	Patient group	Positive predictive value (95% CI) Frequency
Dommett (2013a)	Lump mass swelling below neck excluding abdomen 0-3 months before diagnosis	All included bone tumour/soft tissue sarcoma patients and controls aged 0-14 years	0.03 (0.01-0.14)
Dommett (2013a)	Musculoskeletal symptoms 0-3 months before diagnosis	All included bone tumour/soft tissue sarcoma patients and controls aged 0-14 years	0.01 (0-0.01)
Dommett (2013a)	Trauma 0-3 months before diagnosis	All included bone tumour/soft tissue sarcoma patients and controls aged 0-14 years	0 (0-0)
Dommett (2013a)	≥ 3 consultations	All included bone tumour/soft tissue sarcoma patients and controls aged 0-14 years	0 (0-0)
Dommett (2013b)	Lump mass swelling	All included bone tumour/soft tissue sarcoma patients and controls aged 15-24 years	0.0415 (0.0124-0.1392) Cases: 19/196 Controls: 3/2438
Dommett (2013b)	Musculoskeletal symptoms	All included bone tumour/soft tissue sarcoma patients and controls aged 15	0.0093 (0.0058-0.0151) Cases: 37/196 Controls: 26/2438
Dommett (2013b)	Chest pain	All included bone tumour/soft tissue	0.0027 (0.001-0.0077)



		sarcoma patients and controls aged 15	Cases: 5/196 Controls: 12/2438
Dommett (2013b)	≥ 3 consultations	All included bone tumour/soft tissue sarcoma patients and controls aged 15	0.003 (0.0024-0.0037) Cases: 86/196 Controls: 189/2438
Pharisa (2009)	Neck pain	Children ≤ 16 years	TP = 0, FP = 170 None had cancer

1 The positive predictive values are calculated using Bayesian statistics. TP = true positives, FP = false  
2 positives

### 3 Evidence statement(s):

#### 4 Adult patients

5 Acute low back pain alone (2 studies, N = 2135) or in combination with other single risk  
6 factors/symptoms (1 study, N = 19-281), and back pain (1 study, N = 1975) presenting in a primary  
7 care setting do not appear to confer an increased risk of bone sarcoma, although the study  
8 populations are probably not directly representative of the typical unselected symptomatic UK GP  
9 population (see also Table 1).

#### 11 Children, teenage and young adult patients

12 The positive predictive values of having childhood or young adulthood bone sarcoma tumour/soft  
13 tissue sarcoma ranged from 0% (for trauma) to 0.03% (for 'lump mass swelling below neck excluding  
14 abdomen') for patients aged 0-14 years old, and from 0.0027% (for chest pain) to 0.0415% (for 'lump  
15 mass swelling') for patients aged 15-24 years (1 study, N = 30855). The evidence quality is somewhat  
16 compromised by the case-control design of the study (see also Table 2).

17  
18 Neck pain (1 study, N = 170) presenting in a primary care setting does not appear to confer an  
19 increased risk of bone sarcoma, although the study population is not directly representative of the  
20 typical unselected symptomatic UK GP population (see also Table 2).

### 22 Evidence tables

#### 23 Deyo (1988)

<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective consecutive? patient series
Was a consecutive or random sample of patients enrolled?	<b>Unclear</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Yes (probably)</b>
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
Patient	N = 1975, mean (SD; range) age = 39.5 (15.4; 15-86) years, 62% females. 54%

characteristics and setting	<p>of the patients were seeking medical care for back pain for the first time and 76% of the patients had had back pain for &lt; 3 months. 3% had a history of back pain surgery. Maximal back pain in the low back (84%) or in the upper back (16%).</p> <p><u>Inclusion criteria:</u> Patients who sought treatment between March 1982 and September 1984 in the walk-in clinic of a public hospital where virtually all patients are self-referred. In each case back pain was part of the chief complaint.</p> <p><u>Exclusion criteria:</u> Neck pain.</p> <p><u>Clinical setting:</u> Walk-in clinic of a public hospital; this clinic is a source of primary care for indigent persons in a county in the USA with a population of approximately 1 million.</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>High concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	Back pain; not further specified.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
<b>Reference standard(s)</b>	The reference standard consisted of a search on each patient name in the institutional tumour registry $\geq 6$ months after the index visit. The registry included every patient with a histological diagnosis of cancer made in the authors' hospital system regardless of site of care. The authors point out that "while this method might fail to identify cancer patients who sought care elsewhere, it is likely that most patients sought follow-up for a particular illness at the same facility.
Is the reference standard likely to correctly classify the target condition?	<b>Unclear</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No (but all patients had a positive index test)</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	

Flow and timing	All the patients are accounted for in the results.
Was there an appropriate interval between index test and reference standard?	<b>Yes (probably)</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	It is a concern that some patients with cancer might have been missed due to the choice of reference standard because this would result in an underestimation of the positive predictive value. 38/1975 patients were found in the tumour registry. Of those 38, 13 patients had tumours that were probable causes of back pain, and 4 of these 13 patients already had a diagnosis of cancer at presentation. The 9/1975 patients who had undiagnosed cancer that the back pain could be attributed to had: Lymphoma (NOS; 2), cancer of unknown primary (1), prostate cancer (1), retroperitoneal liposarcoma (1), lung cancer (1), renal cell (1), multiple myeloma (1), mucinous adenocarcinoma (of gallbladder?; 1)
1	
2	<b>Dommett (2012; 2013a,b)</b>
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Population-based nested case-control study using data from the General Practice Research Database (GPRD)
Was a consecutive or random sample of patients enrolled?	<b>No</b>
Was a case-control design avoided?	<b>No</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>High risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<u>Cases:</u> 1267 children; aged 0-4 years: N = 436; aged 5-14 years: N = 831; 703 males/564 females. Cancer type: Leukemia: N = 368; brain: N = 270; lymphoma: N = 142; bone: N = 107; soft tissue sarcoma: N = 91; renal: N = 82; neuroblastoma: N = 75; other ICD codes: N = 132. 1064 teenagers and young adults (TYA): 15-24 years: Gender not reported. Cancer type: Leukemia: N = 143; brain: N = 154; lymphoma: N = 270; bone: N = 96; soft tissue sarcoma: N = 100; other ICD codes: N = 301 (including testis: N = 60; skin: N = 49; ovary: N = 20 and thyroid: N = 17). <u>Controls:</u> 15318 children; aged 0-4 years: N = 4802; aged 5-14 years: N = 10516; 8461 males/6857 females. 13206 TYA. Gender not reported  <u>Inclusion criteria:</u>

	<p>The sample comprised all children and TYU aged 0–24 years, inclusive, drawn from all general practices contributing research-standard data to the GPRD between 1 January 1988 and 31 December 2010. To be included, the practices had to have been contributing research-standard data for a minimum of 1 year before each child's date of cancer diagnosis or the index date (see below) for matched controls.</p> <p>Cases: Patients diagnosed with the following cancers: leukaemia, lymphoma, neuroblastoma, soft tissue sarcoma, hepatic, renal, bone and central nervous system tumours, using pre-defined medical codes used in the GPRD. The date of diagnosis for cases was defined as the date of pathological diagnosis, but if this was unavailable, the date of the first cancer code entered in the GPRD was used.</p> <p>Controls: Up to 13 controls (children with no diagnosis of cancer at any time) were selected per case, using a computer-generated random sequence, matched on age (within 1 year), sex and practice, and had to be currently registered on the date of diagnosis of their matched case (the index date).</p> <p><u>Exclusion criteria</u>: None listed</p> <p><u>Clinical setting</u>: Primary care, UK.</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	The GPRD uses just over 100 000 medical codes to encompass all primary care events, including both symptoms and diagnoses. From this list, libraries of codes were assembled representing individual alert symptoms derived from the NICE referral guidelines for suspected cancer in children. <i>No more information reported.</i>
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Cancer diagnosis in the UK's General Practice Research Database.
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	

<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		<b>Low concern</b>
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	All patients appear to be accounted for.	
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>	
Did all patients receive the same reference standard?	<b>Yes</b>	
Were all patients included in the analysis?	<b>Yes</b>	
<b>Could the patient flow have introduced bias?</b>		<b>Low risk</b>
<b>NOTES</b>	This study is published in three papers.	
1		
2	<b>Henschke (2009)</b>	
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Prospective consecutive patient series	
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>	
Was a case-control design avoided?	<b>Yes</b>	
Did the study avoid inappropriate exclusions?	<b>Yes</b>	
<b>Could the selection of patients have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
Patient characteristics and setting	<p>N = 1172, mean (SD) age = 43.97 (15.1) years, 626 males/546 females; Primary care physician consulted: Medical practitioner (N = 267), physiotherapist (N = 851), chiropractor (N = 54); Previous episode of low back pain (N = 888); Duration of low back pain: &lt; 1 week (N = 696), 1-2 weeks (N = 145), 2-3 weeks (N = 174), 3-4 weeks (N = 73), 4-5 weeks (N = 30), 5-6 weeks (N = 54).</p> <p><u>Inclusion criteria</u>: Consecutive English-speaking (and writing) patients aged ≥ 14 years with acute low back pain who presented for a first consultation to participating primary care providers in the Sydney region of Australia. <i>Please note that in Australia, the majority of primary care management for low back pain is provided by general medical practitioners, physiotherapists and chiropractors.</i></p> <p><u>Exclusion criteria</u>: Diagnosis of serious pathology prior to the consultation, which was considered to be the cause of the current episode of low back pain.</p> <p><u>Clinical setting</u>: Primary care (including physiotherapy and chiropractice)</p>	
<b>Are there concerns that the included patients and setting do not match the review question?</b>		<b>High concern</b>
<b>INDEX TEST</b>		
<b>A. Risk of bias</b>		
Index test	An episode of acute low back pain was defined as pain in the area bounded superiorly by T12 and inferiorly by the buttock crease, lasting for more than 24 hours but less than 6 weeks, and preceded by a period of at least 1 month without back pain. Patients remained eligible if they also had pain that referred beyond this region.	
Were the index test results interpreted without knowledge		<b>Yes</b>

of the results of the reference standard?	
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	The reference standard consisted of close follow up for 12 months. Participants were contacted by telephone 6 weeks, 3 months, and 12 months after the initial consultation. At each follow up contact, participants were asked the following question: "Low back pain is occasionally the result of a fracture, infection, arthritis, or cancer. Has a health care provider said that your back pain is caused by one of these rare diseases?" Participants were also prompted to provide any further details of a diagnosis or explanation for their low back pain that had been provided to them. All patients with potentially serious pathology were subsequently examined by a study rheumatologist. At each follow up contact, participants were also questioned to establish whether they had recovered from the episode of low back pain. Recovery was defined as 1 month with no pain, no interference with function due to pain, and return to previous work status for 1 month. Patients suspected by their primary care clinician of having a serious spinal pathology and those who reported having a serious spinal pathology during the follow up period were referred immediately to 1 of 2 study rheumatologists for a clinical assessment. Within 2 weeks from the time of referral, the rheumatologists examined each patient in their clinics and were additionally provided with the complete medical histories and all test results.
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No (but all patients had a positive index test)</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients appear to be accounted for in the results
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	Please note that the primary care physician consulted were: Medical practitioner: N = 267, physiotherapist: N = 851, chiropractor: N = 54

1  
2

<b>Pharisa (2009)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Retrospective consecutive patient series
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>N = 170 (61 females/109 males), mean age = 9.05 years, median age = 9 years (range = 7 weeks to 16 years). A history of trauma was clearly reported in 106 of the children and clinical examination revealed restricted neck movements in 48 of these patients and painful movements without restriction in 28 of these patients. None of the patients had a neurological deficit on initial physical examination.</p> <p><u>Inclusion criteria:</u> All children aged ≤ 16 years presenting with neck pain and/or restricted neck movements from October 2004 to September 2005. Although any child with a complaint of neck pain was considered for inclusion in the study, only those whose neck pain was confirmed during medical examination were included.</p> <p><u>Exclusion criteria:</u> Toxic-appearing children with obvious signs of meningitis</p> <p><u>Clinical setting:</u> Emergency department of the Children's Hospital of Lausanne, Switzerland</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>High concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	"Neck pain confirmed during medical examination"
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Chart review and follow-up, including telephone calls to paediatricians to confirm final diagnosis
Is the reference standard likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No (but all patients had a positive index test)</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>

<b>B. Concerns regarding applicability</b>		
Are there concerns that the target condition as defined by the reference standard does not match the question?		Low concern
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	Follow up data were obtained by telephone in 134/170 patients, but final diagnoses are presented for all 170 patients.	
Was there an appropriate interval between index test and reference standard?		Yes
Did all patients receive the same reference standard?		Yes
Were all patients included in the analysis?		Yes
<b>Could the patient flow have introduced bias?</b>		<b>Low risk</b>
<b>NOTES</b>		
1		
2 <b>Suarez-Almazor (1997)</b>		
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Retrospective consecutive patient series	
Was a consecutive or random sample of patients enrolled?		Yes
Was a case-control design avoided?		Yes
Did the study avoid inappropriate exclusions?		Yes
<b>Could the selection of patients have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
Patient characteristics and setting	<p>N = 1550, of whom N = 331 had chronic (&gt; 3 months?) back pain, N = 963 had acute (&lt; 3 months) low back pain, and N = 256 had back pain of unspecified duration. Of the patients with acute low back pain, 442 were males, and it appears that the mean (SD) age = 42.2 (15.6) years for the patients with acute low back pain, 14/963 had a history of cancer</p> <p><u>Inclusion criteria:</u> All patients aged ≥ 18 years presenting to four family clinics in Edmonton (Alberta, Canada) between January 1 1992 and December 31 1993 with low back pain or leg pain compatible with sciatic pain for which no visit had been made within the past 12 months.</p> <p><u>Exclusion criteria:</u> Low back pain attributable to visceral pain (e.g., urinary infection, inflammatory pelvic disease), previous diagnosis of ankylosing spondylitis, pregnancy.</p> <p><u>Clinical setting:</u> Four family clinics in Edmonton (Alberta, Canada), two of which are university-affiliated and hospital-based, with the other two based in the community.</p>	
Are there concerns that the included patients and setting do not match the review question?		Unclear concern
<b>INDEX TEST</b>		
<b>A. Risk of bias</b>		
Index test	Acute (< 3 months) low back pain; not further specified.	
Were the index test results interpreted without knowledge of the results of the reference standard?		Yes
<b>Could the conduct or interpretation of the index test</b>		<b>Low risk</b>



<b>have introduced bias?</b>		
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>		<b>Low concern</b>
<b>REFERENCE STANDARD</b>		
<b>A. risk of bias</b>		
Reference standard(s)	Follow up consisting of chart review after a minimum of 2 years. Patients were considered to have cancer if recorded in the physician notes or in reports from laboratory or diagnostic tests.	
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>	
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No (but all patients had a positive index test)</b>	
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Unclear risk</b>	
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		<b>Low concern</b>
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	The results are only presented for the patients with acute low back pain.	
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>	
Did all patients receive the same reference standard?	<b>Yes</b>	
Were all patients included in the analysis?	<b>Yes</b>	
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>	
<b>NOTES</b>	13/963 patients with acute low back pain had active cancer. 3 of those 13 patients had the cancer diagnosis prior to the index visit; 3/13 patients had tumours that were probable causes of the acute low back pain (spinal infiltrates from multiple myeloma [2] and metastatic bone disease with compression fractures [1]), and 10/13 patients had cancer that was not considered to have caused the acute low back pain (bladder cancer [3], colon [1], breast [1], thyroid [1], lung [1], prostate [1], endometrium [1], oesophagus [1]). However, as it is not reported which of these patients already had a diagnosis of cancer pre-index visit, it is not possible to present the data accurately for the individual cancers.	

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11

**References**

**Included studies**

Deyo, R. A. and Diehl, A. K. Cancer as a cause of back pain: Frequency, clinical presentation, and diagnostic strategies. *Journal of General Internal Medicine* 3, 230-238. 1-11-1988.

Dommett, R. M., Redaniel, M. T., Stevens, M. C. G., Hamilton, W., and Martin, R. M. Features of childhood cancer in primary care: A population-based nested case-control study. *British Journal of Cancer* 106[5], 982-987. 2012.

Dommett, R. M., Redaniel, T., Stevens, M. C. G., Martin, R. M., and Hamilton, W. Risk of childhood cancer with symptoms in primary care: A population-based case-control study. *British Journal of General Practice*; DOI:10.3399/bjgp13X660742. 2013a.

- 1 Dommett, R. M., Redaniel, M. T., Stevens, M. C. G., Hamilton, W., and Martin, R. M. Features of  
2 cancer in teenagers and young adults in primary care: A population-based nested case-control  
3 study. *British Journal of Cancer* 2329-2333. 2013b.
- 4 Henschke, N., Maher, C. G., Refshauge, K. M., Herbert, R. D., Cumming, R. G., Bleasel, J., York, J.,  
5 Das, A., and McAuley, J. H. Prevalence of and screening for serious spinal pathology in  
6 patients presenting to primary care settings with acute low back pain. *Arthritis &  
7 Rheumatism* 60[10], 3072-3080. 2009.
- 8 Pharisa, C., Lutz, N., Roback, M. G., and Gehri, M. Neck complaints in the pediatric emergency  
9 department: A consecutive case series of 170 children. *Pediatric Emergency Care* 25[12],  
10 823-826. 2009.
- 11 Suarez-Almazor, M. E., Belseck, E., Russell, A. S., and Mackel, J. V. Use of lumbar radiographs for  
12 the early diagnosis of low back pain. Proposed guidelines would increase utilization. *JAMA*  
13 277[22], 1782-1786. 11-6-1997.
- 14
- 15 **Excluded studies (with excl reason)**
- 16 (1998) Practice guidelines: uterine corpus--sarcomas. Society of Gynecologic Oncologists Clinical  
17 Practice Guidelines. *Oncology (Williston Park)*, 12: 284-286.  
18 Guideline
- 19 (2002) Information from your family doctor. Osteosarcoma. *American Family Physician*, 65: 1135-  
20 1136.  
21 Patient information material
- 22 Abughazaleh, K. & Kwar, N. (2011) Osteonecrosis of the jaws: What the physician needs to know:  
23 Practical considerations. *Disease-a-Month*, 57: 231-241.  
24 Narrative review
- 25 Ahrensberg, J. M., Schroder, H., Hansen, R. P., Olesen, F. & Vedsted, P. (2012) The initial cancer  
26 pathway for children - one-fourth wait more than 3 months. *Acta Paediatrica*, 101: 655-662.  
27 Not in PICO
- 28 Albrechts, A. E. & Rapini, R. P. (1995) Malignancy in Maffucci's syndrome. [Review] [31 refs].  
29 *Dermatologic Clinics*, 13: 73-78.  
30 Narrative review
- 31 Araujo, F. I., Monteiro, A. & Kalil, R. K. (2010) Giant cell-rich osteosarcoma - Two cases report and  
32 literature review. *Histopathology*, 57: 14-15.  
33 Not in PICO
- 34 Arndt, C. A. S., Rose, P. S., Folpe, A. L. & Laack, N. N. (2012) Common Musculoskeletal Tumors of  
35 Childhood and Adolescence. *Mayo Clinic Proceedings*, 87: 475-487.  
36 Not in PICO
- 37 Ashwood, N., Witt, J. D., Hallam, P. J. & Cobb, J. P. (2003) Analysis of the referral pattern to a  
38 supraregional bone and soft tissue tumour service. *Annals of the Royal College of Surgeons of  
39 England*, 85: 272-276.  
40 Not in PICO
- 41 Babic, M., Milenkovic, Z. & Basic, H. (2002) Manual percutaneous method for diagnosis of spinal  
42 tumors. *Zentralblatt fur Neurochirurgie*, 63: 120-123.  
43 Not in PICO
- 44 Baker, A. D. L. & Burke, J. G. (2008) Back Pain: background, aetiology, diagnosis and treatment.  
45 *Foundation Years*, 4: 302-308.  
46 Narrative review
- 47 Barbera, C. & Lewis, M. M. (1988) Office evaluation of bone tumors. [Review] [33 refs]. *Orthopedic  
48 Clinics of North America*, 19: 821-838.  
49 Narrative review

- 1 Barsa, P. & Hackel, M. (2003) Red Flags in the diagnosis and treatment of the low back pain. [Czech].  
2 *Bolest*, 6: 171-175.  
3 Narrative review
- 4 Bates, D. W. & Reuler, J. B. (1988) Back pain and epidural spinal cord compression. [Review] [52  
5 refs]. *Journal of General Internal Medicine*, 3: 191-197.  
6 Narrative review
- 7 Baumgartner, E. & Vischer, T. L. (1997) Back pain: Current approaches. [French]. *Schweizerische  
8 Medizinische Wochenschrift*, 127: 1901-1910.  
9 Narrative review
- 10 Bell, W. C., Klein, M. J., Pitt, M. J. & Siegal, G. P. (2006) Molecular pathology of chondroid neoplasms:  
11 part 1, benign lesions. [Review] [41 refs]. *Skeletal Radiology*, 35: 805-813.  
12 Narrative review
- 13 Bethapudi, S., Ritchie, D. A., MacDuff, E. & Straiton, J. (2014) Imaging in osteofibrous dysplasia,  
14 osteofibrous dysplasia-like adamantinoma, and classic adamantinoma. *Clinical Radiology*, 69:  
15 200-208.  
16 Not in PICO
- 17 Biau, D. J., Weiss, K. R., Bhumbra, R. S., Davidson, D., Brown, C., Wunder, J. S. & Ferguson, P. C.  
18 (2013) Using the CUSUM test to control the proportion of inadequate open biopsies of  
19 musculoskeletal tumors. *Clinical Orthopaedics & Related Research*, 471: 905-914.  
20 Not in PICO
- 21 Biedermann, H. & Koch, L. (1996) Differential diagnosis of KISS syndrome. [German]. *Manuelle  
22 Medizin*, 34: 73-81.  
23 Narrative review
- 24 Bielack, S. S., Carrle, D., Harges, J., Schuck, A. & Paulussen, M. (2008) Bone Tumors in Adolescents  
25 and Young Adults. *Current Treatment Options in Oncology*, 9: 67-80.  
26 Narrative review
- 27 Biswas, D., Saha, S. & Bera, S. P. (2007) Relative distribution of the tumours of ear, nose and throat  
28 in the paediatric patients. *International Journal of Pediatric Otorhinolaryngology*, 71: 801-805.  
29 Not in PICO
- 30 Bleyer, A., Morgan, S. & Barr, R. (2006) Proceedings of a workshop: bridging the gap in care and  
31 addressing participation in clinical trials. *Cancer*, 107: Suppl-8.  
32 Not in PICO
- 33 Bovee, J. V. (2008) Multiple osteochondromas. *Orphanet journal of rare diseases*, 3: 3.  
34 Narrative review
- 35 Cabral, D. A. & Tucker, L. B. (1999) Malignancies in children who initially present with rheumatic  
36 complaints. *Journal of Pediatrics*, 134: 53-57.  
37 Not in PICO
- 38 Chadha, N. K. & Forte, V. (2009) Pediatric head and neck malignancies. [Review] [41 refs]. *Current  
39 Opinion in Otolaryngology & Head & Neck Surgery*, 17: 471-476.  
40 Narrative review
- 41 Costelloe, C. M., Chuang, H. H., Chasen, B. A., Pan, T., Fox, P. S., Bassett, R. L. & Madewell, J. E.  
42 (2013) Bone Windows for Distinguishing Malignant from Benign Primary Bone Tumors on FDG  
43 PET/CT. *Journal of Cancer*, 4: 524-530.  
44 Not in PICO
- 45 Craft, A. (1988) What can we do for the child with malignant disease? *Practitioner*, 232: 584-589.  
46 Narrative review
- 47 Cuffy, M., Abir, F. & Longo, W. E. (2006) Management of less common tumors of the colon, rectum,  
48 and anus. [Review] [164 refs]. *Clinical Colorectal Cancer*, 5: 327-337.  
49 Narrative review
- 50 Desandes, E., Lacour, B., Sommelet, D., White-Koning, M., Velten, M., Tretarre, B., Marr, A.,  
51 Maarouf, N., Guizard, A. V., Delafosse, P., Danzon, A., Cotte, C. & Brugieres, L. (2007) Cancer

- 1 adolescent pathway in France between 1988 and 1997. *European Journal of Oncology Nursing*,  
2 11: 74-81.
- 3 Not in PICO
- 4 Dhillon, M. S., Singh, B., Singh, D. P., Prabhu, V. & Nagi, O. N. (1994) Primary bone tumors of the  
5 talus. *Journal of the American Podiatric Medical Association*, 84: 379-384.
- 6 Not in PICO
- 7 Didolkar, M. M., Anderson, M. E., Hochman, M. G., Rissmiller, J. G., Goldsmith, J. D., Gebhardt, M. G.  
8 & Wu, J. S. (2013) Image guided core needle biopsy of musculoskeletal lesions: Are nondiagnostic  
9 results clinically useful? *Clinical Orthopaedics and Related Research*, 471: 3601-3609.
- 10 Not in PICO
- 11 Donthineni, R. & Ofluoglu, O. (2010) Solitary enchondromas of long bones: pattern of referral and  
12 outcome. *Acta Orthopaedica et Traumatologica Turcica*, 44: 397-402.
- 13 Not in PICO
- 14 Downie, A., Williams, C. M., Henschke, N., Hancock, M. J., Ostelo, R. W. J. G., De Vet, H. C. W.,  
15 Macaskill, P., Irwig, L., Van Tulder, M. W., Koes, B. W. & Maher, C. G. (2013) Red flags to screen  
16 for malignancy and fracture in patients with low back pain: Systematic review. *BMJ (Online)*, 347.  
17 Systematic review, checked for relevant studies.
- 18 Drudge-Coates, L. & Rajbabu, K. (2008) Diagnosis and management of malignant spinal cord  
19 compression: part 1. [Review] [30 refs]. *International Journal of Palliative Nursing*, 14: 110-116.
- 20 Narrative review
- 21 Dyrop, H. B., Safwat, A., Vedsted, P., Maretty-Nielsen, K., Hansen, B. H., Jorgensen, P. H., Baad-  
22 Hansen, T., Bungler, C. & Keller, J. (2013) Cancer patient pathways shortens waiting times and  
23 accelerates the diagnostic process of suspected sarcoma patients in Denmark. *Health Policy*, 113:  
24 110-117.
- 25 Not in PICO
- 26 Earl, H. & Souhami, R. L. (1990) Adolescent bone tumours. [Review] [3 refs]. *Practitioner*, 234: 816-  
27 818.
- 28 Narrative review
- 29 Eaton, K. D. & Frieze, D. A. (2008) Cancer pain: Perspectives of a medical oncologist. *Current Pain and*  
30 *Headache Reports*, 12: 270-276.
- 31 Not in PICO
- 32 Eggesbo, H. B. (2012) Imaging of sinonasal tumours. [Review]. *Cancer Imaging*, 12: 136-152.
- 33 Narrative review
- 34 El, S. U., Hassan, T., Besheer, M., El, B. R., El, G. K. & Morad, M. H. (2009) Skeletal manifestations in  
35 children with different hematological diseases and hematological malignancies at Zagazig  
36 university hospital [retrospective study from 1998 to 2008]. *Haematologica*, 94: 690.
- 37 Not in PICO
- 38 Erol, B., Bezer, M. & Guven, O. (2004) Evaluation of pediatric musculoskeletal tumors. *Marmara*  
39 *Medical Journal*, 17: 140-145.
- 40 Narrative review
- 41 Eyre, R., Feltbower, R., James, P., Blakey, K., Mubwandarikwa, E., Forman, D., McKinney, P., Pearce,  
42 M. & McNally, R. (2010) The epidemiology of bone cancer in 0 - 39 year olds in northern England,  
43 1981 - 2002. *BMC Cancer*, 10: 357.
- 44 Not in PICO
- 45 Ferreira, N. & Marais, L. C. (2012) Osteosarcoma presentation stages at a tumour unit in South  
46 Africa. *South African Medical Journal.Suid-Afrikaanse Tydskrif Vir Geneeskunde*, 102: 673-676.
- 47 Not in PICO
- 48 Fletcher, C. D. (2008) Undifferentiated sarcomas: what to do? And does it matter? A surgical  
49 pathology perspective. *Ultrastructural Pathology*, 32: 31-36.
- 50 Not in PICO

- 1 Frincu, D. L., Francu, L. L., Chirana, A., Calin, D., Nitescu, A. & Crisan-Dabija, R. (2002) Quantitative  
2 histopathological criteria in predicting the giant bone cell tumors's grading. [Romanian]. *Revista*  
3 *Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi*, 106: 147-153.  
4 Not in PICO
- 5 Frink, S. J., Snearly, W. & Parsons, T. W., III (1998) Malignant tumors about the knee. [Review] [33  
6 refs]. *American Journal of Knee Surgery*, 11: 257-266.  
7 Narrative review
- 8 George, A. & Grimer, R. (2012) Early symptoms of bone and soft tissue sarcomas: could they be  
9 diagnosed earlier? *Annals of the Royal College of Surgeons of England*, 94: 261-266.  
10 Not in PICO
- 11 Gereige, R. & Kumar, M. (2010) Bone lesions: Benign and malignant. *Pediatrics in Review*, 31: 355-  
12 363.  
13 Narrative review
- 14 Ghandhi, D., Ayoub, A. F., Pogrel, M. A., MacDonald, G., Brocklebank, L. M. & Moos, K. F. (2006)  
15 Ameloblastoma: a surgeon's dilemma. *Journal of Oral & Maxillofacial Surgery*, 64: 1010-1014.  
16 Not in PICO
- 17 Gordon, L. M., Johnson, R. H., Au, M. A. & Albritton, K. H. (2011) Primary care referral patterns for  
18 adolescent and young adult (AYA) cancer patients: A multistate study. *Journal of Clinical*  
19 *Oncology*, 29.  
20 Not in PICO
- 21 Gosling, T., Probst, C., Langer, F., Rosenthal, H., Brunnemer, U. & Krettek, C. (679) [Diagnostics and  
22 treatment of primary bone tumors]. [Review] [German]. *Chirurg*, 81: 657-678.  
23 Narrative review
- 24 Goyal, S., Roscoe, J., Ryder, W. D., Gattamaneni, H. R. & Eden, T. O. (2004) Symptom interval in  
25 young people with bone cancer. *European Journal of Cancer*, 40: 2280-2286.  
26 Not in PICO
- 27 Gray, A. J. (2005) Back pain in children and adolescents. *Medicine Today*, 6: 27-33.  
28 Narrative review
- 29 Grobler, L. J. (1998) Back and leg pain in older adults: Presentation, diagnosis, and treatment. *Clinics*  
30 *in Geriatric Medicine*, 14: 543-576.  
31 Narrative review
- 32 Grossi, M. (1998) Management and longterm complications of pediatric cancer. *Pediatric Clinics of*  
33 *North America*, 45: 1637-+.  
34 Narrative review
- 35 Gundlach, K. K. (1981) [Indications for suspected tumor in syndromes involving the mouth, jaw and  
36 face]. [German]. *Deutsche Zahnarztliche Zeitschrift*, 36: 712-716.  
37 Narrative review
- 38 Harms, D. (1995) New entities, concepts, and questions in childhood tumor pathology. *General &*  
39 *diagnostic pathology*, 141: 1-14.  
40 Narrative review
- 41 Hashimoto, N., Rabo, C. S., Okita, Y., Kinoshita, M., Kagawa, N., Fujimoto, Y., Morii, E. I., Kishima, H.,  
42 Maruno, M., Kato, A. & Yoshimine, T. (2012) Slower growth of skull base meningiomas compared  
43 with non-skull base meningiomas based on volumetric and biological studies: Clinical article.  
44 *Journal of Neurosurgery*, 116: 574-580.  
45 Not in PICO
- 46 Heare, T., Hensley, M. A. & Dell'Orfano, S. (2009) Bone tumors: osteosarcoma and Ewing's sarcoma.  
47 *Current Opinion in Pediatrics*, 21: 365-372.  
48 Narrative review
- 49 Heick, J. D., Bustillo, K. L. & Farris, J. W. (2014) Recognition of signs and symptoms of a Type 1  
50 chondrosarcoma: a case report. *Physiotherapy Theory & Practice*, 30: 49-55.  
51 Not in PICO

- 1 Helwig, H. (1980) Early diagnosis of malignant bone tumors in childhood. [German]. *Padiatrische*  
2 *Praxis*, 23: 79-85.  
3 Narrative review
- 4 Henschke, N., Maher, C. G., Ostelo, R. W., de Vet, H. C., Macaskill, P. & Irwig, L. (2013) Red flags to  
5 screen for malignancy in patients with low-back pain. [Review]. *Cochrane Database of Systematic*  
6 *Reviews*, 2: CD008686.  
7 Systematic review, included studies checked for relevance.
- 8 Hill, C. E., Boyce, L. & van der Ploeg, I. D. (2014) Spontaneous resolution of a solitary  
9 osteochondroma of the distal femur: a case report and review of the literature. *Journal of*  
10 *Pediatric Orthopaedics, Part B*, 23: 73-75.  
11 Not in PICO
- 12 Hobusch, G. & Holzer, G. (2011) Osteoporosis and fractures in primary malign bone tumours.  
13 [German]. *Journal fur Mineralstoffwechsel*, 18: 64-68.  
14 Narrative review
- 15 Jackson, C. G., Cueva, R. A., Thedinger, B. A. & Glasscock III, M. E. (1990) Conservation surgery for  
16 glomus jugulare tumors: The value of early diagnosis. *Laryngoscope*, 100: 1031-1036.  
17 Not in PICO
- 18 Jellema, K., Overbeeke, J. J., Teepen, H. L. & Visser, L. H. (2005) Time to diagnosis of intraspinal  
19 tumors. *European Journal of Neurology*, 12: 621-624.  
20 Not in PICO
- 21 Joines, J. D., McNutt, R. A., Carey, T. S., Deyo, R. A. & Rouhani, R. (2001) Finding cancer in primary  
22 care outpatients with low back pain: a comparison of diagnostic strategies. *Journal of General*  
23 *Internal Medicine*, 16: 14-23.  
24 Not in PICO
- 25 Joshi, A., Magar, S. R., Chand, P., Panth, R. & Khatri Chhetri, B. R. (2013) Tru-cut biopsy as the initial  
26 method of tissue diagnosis in bone tumors with soft tissue extension. *Indian Journal of*  
27 *Orthopaedics*, 47: 195-199.  
28 Not in PICO
- 29 Jurgens, H. (1990) Ewing's sarcoma in children and adolescents: Update of the German GPO-CESS  
30 studies. *British Journal of Cancer*, 62: 327-328.  
31 Not in PICO
- 32 Kato, M., Nakamura, H., Terai, H., Konishi, S., Nagayama, R. & Takaoka, K. (2008) Why does delay  
33 exist in the diagnosis of intradural spinal cord tumor despite the availability of MRI? *Journal of*  
34 *Clinical Neuroscience*, 15: 880-885.  
35 Not in PICO
- 36 Khoo, M. M. Y. & Saifuddin, A. (2013) The role of MRI in image-guided needle biopsy of focal bone  
37 and soft tissue neoplasms. *Skeletal Radiology*, 42: 905-915.  
38 Narrative review
- 39 Khysh, I. T. & Tolstopiatov, B. A. (1980) Errors in the early diagnosis of primary tumors of the pelvic  
40 bones. [Russian]. *Khirurgiia*, 74-78.  
41 Russian. Narrative review?
- 42 Kidane, B., Gandhi, R., Sarro, A., Valiante, T. A., Harvey, B. J. & Rampersaud, Y. R. (2011) Is referral to  
43 a spine surgeon a double-edged sword? Patient concerns before consultation. *Canadian Family*  
44 *Physician*, 57: 803-810.  
45 Not in PICO
- 46 Kim, H. J. & Green, D. W. (2008) Adolescent back pain. *Current Opinion in Pediatrics*, 20: 37-45.  
47 Narrative review
- 48 Kirchner, J., Schmidt, H., Esther, A. H. & Schilling, M. (1999) Rothmund Thomson syndrome and  
49 osteosarcoma. [German]. *Rontgenpraxis*, 52: 71-73.  
50 Narrative review

- 1 Kotru, M. & Singh, N. (2007) The value of recognizing suspect diagnoses in the triple diagnosis of  
2 giant cell tumor of bone. *Indian Journal of Orthopaedics*, 41: 97-100.  
3 Narrative review
- 4 Kozlowski, K., Azouz, E. M., Campbell, J., Marton, D., Morris, L., Padovani, J., Sprague, P., Beluffi, G.,  
5 Berzero, G. F. & Cherubino, P. (1988) Primary bone tumours of the hand. Report of 21 cases.  
6 *Pediatric Radiology*, 18: 140-148.  
7 Not in PICO
- 8 Kuchuk, M., Addison, C. L., Clemons, M., Kuchuk, I. & Wheatley-Price, P. (2013) Incidence and  
9 consequences of bone metastases in lung cancer patients. *Journal of Bone Oncology*, 2: 22-29.  
10 Not in PICO
- 11 Kwong, D. L. W., Ha, S. Y., Chau, K. Y., Choi, P. H. K., Chan, G. C. F., Kwong, P. W. K. & Lau, Y. L. (1998)  
12 Multidisciplinary management of osteosarcoma: Experience in Hong Kong. *Pediatric Hematology  
13 and Oncology*, 15: 229-236.  
14 Not in PICO
- 15 Lahl, M., Fisher, V. L. & Laschinger, K. (2008) Ewing's sarcoma family of tumors: An overview from  
16 diagnosis to survivorship. *Clinical Journal of Oncology Nursing*, 12: 89-97.  
17 Narrative review
- 18 Leithner, A. & Windhager, R. (2007) [Bone and soft tissue tumors: diagnostic principles]. [German].  
19 *Wiener Medizinische Wochenschrift*, 157: 21-26.  
20 Narrative review
- 21 Li, X. & Hemminki, K. (2002) Parental cancer as a risk factor for bone cancer: a nation-wide study  
22 from Sweden. *Journal of Clinical Epidemiology*, 55: 111-114.  
23 Not in PICO
- 24 Li, Y., Dang, T. A. & Man, T. K. (2012) Plasma proteomic profiling of pediatric osteosarcoma. *Methods  
25 in Molecular Biology*, 818: 81-96.  
26 Narrative review
- 27 Mackey, J. R., Wood, L., Nabholtz, J.-M., Jensen, J. & Venner, P. (2000) A Phase II trial of  
28 triamcinolone hexacetonide for symptomatic recurrent malignant ascites. *Journal of Pain and  
29 Symptom Management*, 19: 193-199.  
30 Not in PICO
- 31 Marec-Berard, P., Delafosse, C. & Foussat, C. (2005) [Cancer-related bone pain in children]. [Review]  
32 [40 refs] [French]. *Archives de Pediatrie*, 12: 191-198.  
33 Narrative review
- 34 Mastrangelo, G., Fadda, E., Cegolon, L., Montesco, M. C., Ray-Coquard, I., Buja, A., Fedeli, U.,  
35 Frasson, A., Spolaore, P. & Rossi, C. R. (2010) A European project on incidence, treatment, and  
36 outcome of sarcoma. *BMC Public Health*, 10: 188.  
37 Not in PICO
- 38 Mattiassich, G., Ensaf, F., Hager, M. & Wechselberger, G. (2012) A suspected malignancy in osteolytic  
39 bone tumour of the thumb. *BMJ Case Reports*, 2012, 2012.  
40 Not in PICO
- 41 Mazur, J. M. & Stauffer, E. S. (1981) Evaluation and treatment of bone tumors. *The Journal of family  
42 practice*, 12: 333-341.  
43 Narrative review
- 44 Merchant, S., Cheifetz, R., Knowling, M., Khurshed, F. & McGahan, C. (2012) Practice referral  
45 patterns and outcomes in patients with primary retroperitoneal sarcoma in British Columbia.  
46 *American Journal of Surgery*, 203: 632-638.  
47 Not in PICO
- 48 Muscolo, D. L., Ayerza, M. A., Makino, A., Costa-Paz, M. & Aponte-Tinao, L. A. (2003) Tumors about  
49 the knee misdiagnosed as athletic injuries. *Journal of Bone & Joint Surgery - American Volume*,  
50 85-A: 1209-1214.  
51 Not in PICO

- 1 Myriokefalitaki, E., D'Costa, D., Smith, M. & Ahmed, A. S. (2013) Primary bone metastasis as initial  
 2 presentation of endometrial cancer (stage IVb). *Archives of Gynecology & Obstetrics*, 288: 739-  
 3 746.  
 4 Not in PICO
- 5 Ngwenya, S. (2006) General practitioner's pathology case 8. *SADJ*, 61: 360.  
 6 Not in PICO
- 7 Ngwenya, S. (2006) General practitioner's pathology. Case 2. Diagnosis: Oral Kaposi's sarcoma with  
 8 secondary ulceration. *SADJ*, 61: 079.  
 9 Not in PICO
- 10 Niemeyer, P., Delling, G., Werner, M., Simank, H. G. & Bernd, L. (2003) [Telecommunication and  
 11 telepathology in orthopedic oncology. Possibilities in diagnosis and therapy of primary malignant  
 12 bone tumors]. [German]. *Orthopade*, 32: 949-954.  
 13 Not in PICO
- 14 Ochsner, P. E. (1986) [Tumors of the child's foot]. [German]. *Orthopade*, 15: 227-232.  
 15 Narrative review
- 16 Ottaviani, D., Ferracini, R., Ferrero, G., Ciuffreda, L. & Bertetto, O. (2004) 'Osteo-Oncology  
 17 Multidisciplinary Care Group': A Novel Approach to the Metastatic and Primary Bone Tumor  
 18 Patient. the Molinette Experience. *Annals of Oncology*, 15: 52.  
 19 Not in PICO
- 20 Pallini, R., Maira, G., Pierconti, F., Falchetti, M. L., Alvino, E., Cimino-Reale, G., Fernandez, E.,  
 21 D'Ambrosio, E. & Larocca, L. M. (2003) Chordoma of the skull base: Predictors of tumor  
 22 recurrence. *Journal of Neurosurgery*, 98: 812-822.  
 23 Not in PICO
- 24 Pan, K. L., Zolqarnain, A. & Chia, Y. Y. (2006) Delay in treatment of primary malignant and aggressive  
 25 musculoskeletal tumours. *Medical Journal of Malaysia*, 61: Suppl-6.  
 26 Not in PICO
- 27 Patel, D. R., Moore, M. D. & Greydanus, D. E. (2007) Musculoskeletal diagnosis in adolescents.  
 28 [Review] [12 refs]. *Adolescent Medicine*, 18: 1-10.  
 29 Narrative review
- 30 Pecherstorfer, M., Brenner, K. & Zojer, N. (2003) Current management strategies for hypercalcemia.  
 31 *Treatments in Endocrinology*, 2: 273-292.  
 32 Narrative review
- 33 Perrier, L., Buja, A., Mastrangelo, G., Vecchiato, A., Sandona, P., Ducimetiere, F., Blay, J. Y., Gilly, F.  
 34 N., Siani, C., Biron, P., Ranchere-Vince, D., Decouvelaere, A. V., Thiesse, P., Bergeron, C., Dei Tos,  
 35 A. P., Coindre, J. M., Rossi, C. R. & Ray-Coquard, I. (2012) Clinicians' adherence versus non  
 36 adherence to practice guidelines in the management of patients with sarcoma: a cost-  
 37 effectiveness assessment in two European regions. *BMC Health Services Research*, 12: 82.  
 38 Not in PICO
- 39 Philip, T., Blay, J. Y., Brunat-Mentigny, M., Carrie, C., Chauvot, P., Farsi, F., Fervers, B., Gentet, J. C.,  
 40 Giammarile, F., Kohler, R., Mathoulin, S., Patricot, L. M. & Thiesse, P. (1999) Standards, Options  
 41 and Recommendations (SOR) for diagnosis, treatment and follow-up of osteosarcoma. *Bulletin du*  
 42 *Cancer*, 86: 159-176.  
 43 Guideline
- 44 Piccirillo, E., Agarwal, M., Rohit, Khrais, T. & Sanna, M. (2004) Management of temporal bone  
 45 hemangiomas. *Annals of Otology, Rhinology & Laryngology*, 113: 431-437.  
 46 Not in PICO
- 47 Pohlig, F., Lenze, U., Lenze, F. W., Muhlhofer, H., Schauwecker, J., Rechl, H. & von Eisenhart-Rothe, R.  
 48 (2013) [Biopsies from bone and soft tissue sarcoma : a nationwide survey in Germany]. [German].  
 49 *Orthopade*, 42: 934-940.  
 50 Not in PICO



- 1 Pollack, E. S. (1993) Emergency department presentation of childhood malignancies. *Emergency*  
2 *Medicine Clinics of North America*, 11: 517-529.  
3 Narrative review
- 4 Porta, S. J., Garzon, R. C., Fernandez, O. A. & Gomez-Batiste, X. (2008) Cancer pain epidemiology: A  
5 review. [Spanish]. *Medicina Paliativa*, 15: 307-314.  
6 Not in PICO
- 7 Potratz, J., Dirksen, U., Jurgens, H. & Craft, A. (2012) Ewing Sarcoma: Clinical State-of-the-Art.  
8 *Pediatric Hematology and Oncology*, 29: 1-11.  
9 Narrative review
- 10 Prado, F. O., Nishimoto, I. N., Perez, D. E., Kowalski, L. P. & Lopes, M. A. (2009) Head and neck  
11 chondrosarcoma: Analysis of 16 cases. *British Journal of Oral and Maxillofacial Surgery*, 47: 555-  
12 557.  
13 Not in PICO
- 14 Przewozny, T., Stodulski, D. & Stankiewicz, C. (2011) [Major salivary gland disorders in children and  
15 adolescents]. [Polish]. *Otolaryngologia Polska*, 65: 350-356.  
16 Not in PICO
- 17 Quinn, R. H., Randall, R. L., Benevenia, J., Berven, S. H. & Raskin, K. A. (2013) Contemporary  
18 management of metastatic bone disease: tips and tools of the trade for general practitioners. *The*  
19 *Journal of bone and joint surgery*, American: 1887-1895.  
20 Narrative review
- 21 Raab, C. P. & Gartner, J. C., Jr. (2009) Diagnosis of childhood cancer. [Review] [33 refs]. *Primary Care;*  
22 *Clinics in Office Practice*, 36: 671-684.  
23 Narrative review
- 24 Ralston, S. H., Boyce, B. F., Cowan, R. A., Gardner, M. D., Fraser, W. D. & Boyle, I. T. (1989)  
25 Contrasting mechanisms of hypercalcemia in patients with early and advanced humoral  
26 hypercalcemia of malignancy. *Journal of Bone and Mineral Research*, 4: 103-111.  
27 Not in PICO
- 28 Rawal, Y. B., Angiero, F., Allen, C. M., Kalmar, J. R., Sedghizadeh, P. P. & Steinhilber, A. M. (2006)  
29 Gnathic osteoblastoma: clinicopathologic review of seven cases with long-term follow-up. *Oral*  
30 *Oncology*, 42: 123-130.  
31 Not in PICO
- 32 Reichelt, A. (1982) Clinical manifestations of primary malignant bone tumors. [German].  
33 *Therapiewoche*, 32: 321-324.  
34 Narrative review
- 35 Reid, R. (2007) Update on sarcomas of bone and soft tissue. [Review] [9 refs]. *Scottish Medical*  
36 *Journal*, 52: 31-35.  
37 Narrative review
- 38 Riedel, R. F., Larrier, N., Dodd, L., Kirsch, D., Martinez, S. & Brigman, B. E. (2009) The Clinical  
39 Management of Chondrosarcoma. *Current Treatment Options in Oncology*, 10: 94-106.  
40 Narrative review
- 41 Riley, R. D., Burchill, S. A., Abrams, K. R., Heney, D., Sutton, A. J., Jones, D. R., Lambert, P. C., Young,  
42 B., Wailoo, A. J. & Lewis, I. J. (2003) A systematic review of molecular and biological markers in  
43 tumours of the Ewing's sarcoma family. [Review] [84 refs]. *European Journal of Cancer*, 39: 19-30.  
44 Not in PICO
- 45 Ritter, J. & Bielack, S. S. (2010) Osteosarcoma. *Annals of Oncology*, 21: 320-325.  
46 Narrative review
- 47 Robben, B. J. & Jutte, P. C. (2012) [A boy with a painful knee: bone tumour or stress fracture?].  
48 [Dutch]. *Nederlands Tijdschrift Voor Geneeskunde*, 156: A4465.  
49 Not in PICO

- 1 Rodrigues, K. E. & de, C. B. (2003) [Early diagnosis of childhood cancer: a team responsibility].  
2 [Review] [33 refs] [Portuguese]. *Revista da Associacao Medica Brasileira*, 49: 29-34.  
3 Narrative review
- 4 Ruff, R. L. & Lanska, D. J. (1989) Epidural metastases in prospectively evaluated veterans with  
5 canceled and back pain. *Cancer*, 63: 2234-2241.  
6 Not in PICO; found in the van Hoogen review
- 7 Russell, E. C., Dunn, N. L. & Massey, G. V. (1999) Lymphomas and bone tumors: clinical presentation,  
8 management, and potential late effects of current treatment strategies. [Review] [37 refs].  
9 *Adolescent Medicine State of the Art Reviews*, 10: 419-435.  
10 Narrative review
- 11 Saber, B., Nawal, A., Mohamed, F. & Hassan, E. (2008) Primary osteosarcoma of the breast: case  
12 report. *Cases Journal*, 1: 80.  
13 Not in PICO
- 14 Sampson, V. B., Gorlick, R., Kamara, D. & Anders, K. E. (2013) A review of targeted therapies  
15 evaluated by the pediatric preclinical testing program for osteosarcoma. *Frontiers in Oncology*, 3:  
16 132.  
17 Narrative review
- 18 Schaser, K. D., Bail, H. J., Haas, N. P. & Melcher, I. (2002) [Treatment concepts of benign bone tumors  
19 and tumor-like bone lesions]. [Review] [61 refs] [German]. *Chirurg*, 73: 1181-1190.  
20 Narrative review
- 21 Schatz, J., Soper, J., McCormack, S., Healy, M., Deady, L. & Brown, W. (2010) Imaging of tumors in  
22 the ankle and foot. *Topics in Magnetic Resonance Imaging*, 21: 37-50.  
23 Narrative review
- 24 Schnurr, C., Pippin, M., Stuetzer, H., Delank, K. S., Michael, J. W. & Eysel, P. (2008) Treatment delay  
25 of bone tumours, compilation of a sociodemographic risk profile: a retrospective study. *BMC*  
26 *Cancer*, 8: 22.  
27 Not in PICO
- 28 Schubiner, J. M. & Simon, M. A. (1987) Primary bone tumors in children. *Orthopedic Clinics of North*  
29 *America*, 18: 577-595.  
30 Narrative review
- 31 Senac, M. O., Jr., Isaacs, H. & Gwinn, J. L. (1986) Primary lesions of bone in the 1st decade of life:  
32 retrospective survey of biopsy results. *Radiology*, 160: 491-495.  
33 Not in PICO
- 34 Shanahan, E. M. & Buchbinder, R. (2010) The painful shoulder. *Medicine Today*, 11: 73-79.  
35 Narrative review
- 36 Shaw, P. H. S., Adams, R., Jordan, C. & Crosby, T. D. L. (2007) A clinical review of the investigation  
37 and management of carcinoma of unknown primary in a single cancer network. *Clinical Oncology*,  
38 19: 87-95.  
39 Not in PICO
- 40 Shedid, D. & Benzel, E. C. (2004) Clinical presentation of spinal tumors. *Neurosurgery Quarterly*, 14:  
41 224-228.  
42 Narrative review
- 43 Shimose, S., Sugita, T., Kubo, T., Matsuo, T., Nobuto, H. & Ochi, M. (2008) Differential diagnosis  
44 between osteomyelitis and bone tumors. *Acta Radiologica*, 49: 928-933.  
45 Not in PICO
- 46 Singer, F. R. & Fernandez, M. (1987) Therapy of hypercalcemia of malignancy. *American Journal of*  
47 *Medicine*, 82: 34-41.  
48 Narrative review
- 49 Skotakova, J., Mach, V., Bajciová, V., Mudry, P. & Ondrus, S. (2006) [Malignant tumors of long bones  
50 in children: differential diagnosis and the role of imaging methods]. [Czech]. *Acta Chirurgiae*

- 1 *Orthopaedicae et Traumatologiae Cechoslovaca*, 73: 183-189.  
2 Not in PICO
- 3 Soldatos, T., McCarthy, E. F., Attar, S., Carrino, J. A. & Fayad, L. M. (2011) Imaging features of  
4 chondrosarcoma. [Review]. *Journal of Computer Assisted Tomography*, 35: 504-511.  
5 Narrative review
- 6 Sroczyk, L., Cader, J. & Wieckiewicz, W. (2009) Gardner's syndrome - Literature review. [Polish].  
7 *Gastroenterologia Polska*, 16: 248-250.  
8 Narrative review
- 9 Stella, G., De, S. N., Boero, S. & Rondinella, F. (1998) Benign tumors of the pediatric spine: statistical  
10 notes. *La Chirurgia degli organi di movimento*, 83: 15-21.  
11 Not in PICO
- 12 Stephen, J. P. (1983) Back pain in childhood and adolescence. *Australian Family Physician*, 12: 335-  
13 340.  
14 Narrative review
- 15 Strangio, L. & Brudner, C. (1995) When pain cuts to the bone. *RN*, 58: 28-29.  
16 Not in PICO
- 17 Streitbueger, A., Harges, J., Gebert, C., Ahrens, H., Winkelmann, W. & Gosheger, G. (882) [Cartilage  
18 tumours of the bone. Diagnosis and therapy]. [Review] [26 refs] [German]. *Orthopade*, 35: 871-  
19 881.  
20 Narrative review
- 21 Subbiah, V., Anderson, P., Lazar, A. J., Burdett, E., Raymond, K. & Ludwig, J. A. (2009) Ewing's  
22 Sarcoma: Standard and Experimental Treatment Options. *Current Treatment Options in Oncology*,  
23 10: 126-140.  
24 Narrative review
- 25 Sulko, J., Olipra, W. & Oberc, A. (2011) [Ischial tuberosity fractures in children]. [Polish]. *Chirurgia*  
26 *Narzadow Ruchu i Ortopedia Polska*, 76: 134-137.  
27 Not in PICO
- 28 Sundaresan, N. (1986) Chordomas. *Clinical Orthopaedics and Related Research*, NO.: 135-142.  
29 Narrative review
- 30 Teo, H. E. & Peh, W. C. (2004) Primary bone tumors of adulthood. *Cancer Imaging*, 4: 74-83.  
31 Narrative review
- 32 Thun, M. J. & Sinks, T. (2004) Understanding cancer clusters. *Ca-A Cancer Journal for Clinicians*, 54:  
33 273-280.  
34 Narrative review
- 35 Toepfer, A., Lenze, U., Holzapfel, B. M., Rechl, H., von Eisenhart-Rothe, R. & Gollwitzer, H. (581)  
36 [Tumors of the foot: diagnostics and therapy]. [German]. *Orthopade*, 41: 563-580.  
37 Narrative review
- 38 Tucker, W. S. & Nasser-Sharif, F. J. (1997) Benign skull lesions. *Canadian Journal of Surgery*, 40: 449-  
39 455.  
40 Not in PICO
- 41 Ulaner, G., Hwang, S., Lefkowitz, R. A., Landa, J. & Panicek, D. M. (2013) Musculoskeletal tumors and  
42 tumor-like conditions: Common and avoidable pitfalls at imaging in patients with known or  
43 suspected cancer: Part A: Benign conditions that may mimic malignancy. *International*  
44 *Orthopaedics*, 37: 871-876.  
45 Narrative review
- 46 Ulaner, G., Hwang, S., Landa, J., Lefkowitz, R. A. & Panicek, D. M. (2013) Musculoskeletal tumours  
47 and tumour-like conditions: Common and avoidable pitfalls at imaging in patients with known or  
48 suspected cancer: Part B: Malignant mimics of benign tumours. *International Orthopaedics*, 37:  
49 877-882.  
50 Narrative review

- 1 van den Hoogen, H. M., Koes, B. W., van Eijk, J. T. & Bouter, L. M. (1995) On the accuracy of history,  
2 physical examination, and erythrocyte sedimentation rate in diagnosing low back pain in general  
3 practice. A criteria-based review of the literature. *Spine*, 20: 318-327.  
4 Review, not systematic, but checked references and ordered an additional 2.
- 5 van Staa, T. P., Selby, P., Leufkens, H. G., Lyles, K., Sprafka, J. M. & Cooper, C. (2002) Incidence and  
6 natural history of Paget's disease of bone in England and Wales. *Journal of Bone & Mineral  
7 Research*, 17: 465-471.  
8 Not in PICO
- 9 van, D. B. & Freyschmidt, J. (2002) [Standardized procedure for suspected bone tumor]. [German].  
10 *Chirurg*, 73: 1153-1161.  
11 Narrative review
- 12 Vera, L., Dolcino, M., Mora, M., Oddo, S., Gualco, M., Minuto, F. & Giusti, M. (2011) Primary  
13 hyperparathyroidism diagnosed after surgical ablation of a costal mass mistaken for giant-cell  
14 bone tumor: a case report. *Journal of Medical Case Reports [Electronic Resource]*, 5: 596.  
15 Not in PICO
- 16 Verdegaal, S. H., Bovee, J. V., Pansuriya, T. C., Grimer, R. J., Ozger, H., Jutte, P. C., San, J. M., Biau, D.  
17 J., van der Geest, I. C., Leithner, A., Streitburger, A., Klenke, F. M., Gouin, F. G., Campanacci, D. A.,  
18 Marec-Berard, P., Hogendoorn, P. C., Brand, R. & Taminiau, A. H. (2011) Incidence, predictive  
19 factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome:  
20 an international multicenter study of 161 patients. *The Oncologist*, 16: 1771-1779.  
21 Not in PICO
- 22 Vijay, H., Navil, V., Vaibhav, J., Chopra, A., Goel, A. & Sood, R. (2009) Body aches, tender bones and  
23 rapid loss of weight: a case report. *Cases Journal*, 2: 37.  
24 Not in PICO
- 25 Vitzthum, E. H., Krumbholz, S. & Willenberg, E. (1982) Problems of an early recognition of spinal  
26 tumours. [German]. *Zentralblatt fur Neurochirurgie*, 43: 151-158.  
27 Not in PICO
- 28 Von Hochstetter, A. R. (1987) Suspected neoplastic lesion of bone: Biopsy planning by the  
29 pathologist. [German]. *Schweizerische Medizinische Wochenschrift*, 117: 1302-1306.  
30 Narrative review
- 31 von Salis-Soglio, G. & Prietzel, T. (606) [Diagnostic methods in suspected malignant bone and soft  
32 tissue tumors]. [German]. *Orthopade*, 31: 595-605.  
33 Not in PICO
- 34 von Salis-Soglio, G. & Prietzel, T. (2002) Diagnostic procedures for suspected malignant tumors of  
35 bone and soft tissues. [German]. *Orthopade*, 31: 595-607.  
36 Not in PICO
- 37 Wakiaga, J. M., Onyango, J. F. & Awange, D. O. (1997) Clinico-pathological analysis of jaw tumours  
38 and tumour-like conditions at the Kenyatta national hospital. *East African Medical Journal*, 74:  
39 65-68.  
40 Not in PICO
- 41 Waller, D. A. & Newman, R. J. (1990) Primary bone tumours of the thoracic skeleton: an audit of the  
42 Leeds regional bone tumour registry. *Thorax*, 45: 850-855.  
43 Not in PICO
- 44 Ward, S. (1999) Orthopaedic oncology for the nononcologist orthopaedist: introduction and  
45 common errors to avoid. *Instructional Course Lectures*, 48: 577-586.  
46 Narrative review
- 47 Wayte, N., Da, S. L., Chenevix-Trench, G. & Lakhani, S. R. (2008) What's in a cancer syndrome?  
48 Genes, phenotype and pathology. *Pathology*, 40: 247-259.  
49 Narrative review

1 Weber, K., Damron, T. A., Frassica, F. J. & Sim, F. H. (2008) Malignant bone tumors. *Instructional*  
 2 *Course Lectures*, 57: 673-688.  
 3 Narrative review

4 Widhe, B. & Widhe, T. (2000) Initial symptoms and clinical features in osteosarcoma and Ewing  
 5 sarcoma. *Journal of Bone and Joint Surgery - Series A*, 82: 667-674.  
 6 Not in PICO

7 Widhe, B., Widhe, T. & Bauer, H. C. (2007) Ewing sarcoma of the rib--initial symptoms and clinical  
 8 features: tumor missed at the first visit in 21 of 26 patients. *Acta Orthopaedica*, 78: 840-844.  
 9 Not in PICO

10 Widhe, B. & Bauer, H. C. (2011) Diagnostic difficulties and delays with chest wall chondrosarcoma: a  
 11 Swedish population based Scandinavian Sarcoma Group study of 106 patients. *Acta Oncologica*,  
 12 50: 435-440.  
 13 Not in PICO

14 Winters, M. E., Klutz, P. & Zilberstein, J. (2006) Back pain emergencies. [Review] [82 refs]. *Medical*  
 15 *Clinics of North America*, 90: 505-523.  
 16 Narrative review

17 Yanagisawa, Y., Furue, H., Kawamata, T., Uta, D., Yamamoto, J., Furuse, S., Katafuchi, T., Imoto, K.,  
 18 Iwamoto, Y. & Yoshimura, M. (2010) Bone cancer induces a unique central sensitization through  
 19 synaptic changes in a wide area of the spinal cord. *Molecular Pain*, 6: 38.  
 20 Not in PICO

21 Yang, R.-S. (2001) The application of expandable endoprosthetic reconstruction for limb salvage  
 22 surgery in the skeletally immature patients. *Biomedical Engineering - Applications, Basis and*  
 23 *Communications*, 13: 141-147.  
 24 Narrative review

25 Yesilova, E., Akgunlu, F., Dolanmaz, D., Yasar, F. & Sener, S. (2007) Osteosarcoma: a case report.  
 26 *European journal of dentistry*, 1: 60-63.  
 27 Not in PICO

28 Yiannakopoulos, C. K., Foufa, K., Theocharakis, S., Stamoulis, E. & Maniatis, V. (2012) Osteoid  
 29 osteoma of the radial styloid mimicking wrist arthritis: a case study. *Hand Surgery*, 17: 225-228.  
 30 Not in PICO

31 Young, P. S., Bell, S. W., MacDuff, E. M. & Mahendra, A. (2013) Primary osseous tumors of the  
 32 hindfoot: why the delay in diagnosis and should we be concerned? *Clinical Orthopaedics &*  
 33 *Related Research*, 471: 871-877.  
 34 Not in PICO

35 Zawitkowska-Klaczynska, J., Katski, K., Nurzynska-Flak, J. & Kowalczyk, J. (2003) Primary chest  
 36 tumours in children. *Annales Universitatis Mariae Curie-Skłodowska - Sectio d - Medicina*, 58: 106-  
 37 110.  
 38 Not in PICO

39 Zhang, D., Chen, L., Ni, C.-F., Liu, Y.-Z., Jin, Y.-H., Zhu, X.-L. & Zou, J.-W. (2013) Percutaneous coaxial  
 40 biopsy in diagnosis of musculoskeletal tumors. [Chinese]. *Chinese Journal of Medical Imaging*  
 41 *Technology*, 29: 1493-1496.  
 42 Not in PICO

44 **Review question:**

45 Which investigations of symptoms of suspected bone sarcoma should be done with clinical  
 46 responsibility retained by primary care?

48 **Results**

49 **Literature search**

Database name	Dates	No of references	No of references	Finish date of
---------------	-------	------------------	------------------	----------------


	Covered	found	retrieved	search
<b>Medline</b>	1980-2013	1289	104	25/03/2013
<b>Premedline</b>	1980-2013	100	16	25/03/2013
<b>Embase</b>	1980-2013	1277	125	27/03/2013
<b>Cochrane Library</b>	1980-2013	158	6	27/03/2013
<b>Psychinfo</b>	1980-2013	10	0	27/03/2013
<b>Web of Science (SCI &amp; SSCI) and ISI Proceedings</b>	1980-2013	166	9	27/03/2013

1 Total References retrieved (after de-duplication): 219

2  
3 **Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<b>Medline</b>	3/2013-26/08/2014	60	7	26/08/2014
<b>Premedline</b>	3/2013-26/08/2014	98	11	26/08/2014
<b>Embase</b>	3/2013-26/08/2014	104	9	26/08/2014
<b>Cochrane Library</b>	3/2013-26/08/2014	116	0	26/08/2014
<b>Web of Science (SCI &amp; SSCI) and ISI Proceedings</b>	3/2013-26/08/2014	26	0	26/08/2014

4 Total References retrieved (after de-duplication): 19



7 **Study results**

8 No evidence was identified pertaining to the diagnostic accuracy of x-ray, calcium or alkaline  
9 phosphatase in patients with suspected bone sarcoma where the clinical responsibility was retained  
10 by primary care.

11

1 **References**

2 **Included studies**

3 None

4  
5 **Excluded studies (with excl reason)**

6 Aboulafia, A. J., Levin, A. M. & Blum, J. (2002) Prereferral evaluation of patients with suspected bone  
7 and soft tissue tumors. *Clinical Orthopaedics and Related Research*, 83-88.

8 Not in PICO

9 Adams, S. C., Potter, B. K., Pitcher, D. J. & Temple, H. T. (2010) Office-based core needle biopsy of  
10 bone and soft tissue malignancies: an accurate alternative to open biopsy with infrequent  
11 complications. *Clinical Orthopaedics and Related Research*, 468: 2774-2780.

12 Not in PICO

13 Ahrensberg, J. M., Schroder, H., Hansen, R. P., Olesen, F. & Vedsted, P. (2012) The initial cancer  
14 pathway for children - one-fourth wait more than 3 months. *Acta Paediatrica*, 101: 655-662.

15 Not in PICO

16 Aitchison, F. A., Poon, F. W., Hadley, M. D., Gray, H. W. & Forrester, A. W. (1992) Vertebral  
17 metastases and an equivocal bone scan: value of magnetic resonance imaging. *Nuclear Medicine  
18 Communications*, 13: 429-431.

19 Not in PICO

20 Ak, I., Sivrikoz, M. C., Entok, E. & Vardareli, E. (2010) Discordant findings in patients with non-small-  
21 cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-  
22 emission tomography/computed tomography. *European Journal of Cardio-Thoracic Surgery*, 37:  
23 792-796.

24 Not in PICO

25 Altay, M., Bayrakci, K., Yildiz, Y., Erekul, S. & Saglik, Y. (2007) Secondary chondrosarcoma in cartilage  
26 bone tumors: Report of 32 patients. *Journal of Orthopaedic Science*, 12: 415-423.

27 Not in PICO

28 Alyas, F. & Saifuddin, A. (2008) Fluid-fluid levels in bone neoplasms: variation of T1-weighted signal  
29 intensity of the superior to inferior layers--diagnostic significance on magnetic resonance  
30 imaging. *European Radiology*, 18: 2642-2651.

31 Not in PICO

32 Araujo, F. I., Monteiro, A. & Kalil, R. K. (2010) Giant cell-rich osteosarcoma - Two cases report and  
33 literature review. *Histopathology*, 57: 14-15.

34 Not in PICO

35 Ashwood, N., Witt, J. D., Hallam, P. J. & Cobb, J. P. (2003) Analysis of the referral pattern to a  
36 supraregional bone and soft tissue tumour service. *Annals of the Royal College of Surgeons of  
37 England*, 85: 272-276.

38 Not in PICO

39 Badiane, M., Afidja, A., Ba-Diop, S., Badiane, S. B., Niang, E. H. & Ba-Ly, A. (1998) Diagnostic x-ray  
40 computed tomography of craniocerebral tumors. Apropos of 108 cases collected at the Soweto  
41 Center of Dakar. [French]. *Dakar Medical*, 43: 34-36.

42 Not in PICO

43 Bahgat, M., Bahgat, Y., Bahgat, A. & Elwany, Y. (2012) Chondrosarcoma of the nasal septum. *BMJ  
44 Case Reports*, 2012, 2012.

45 Not in PICO

46 Balogh, L., Postenyi, Z., Haasz, V., Polyak, A., Marian, T., Garai, I., Galuska, L., Balkay, L., Trencsenyi,  
47 G., Nagy, T., Trencsenyi, J., Janoki, G., Janoki, G., Torok, R. & Thuroczy, J. (2011) PET/CT imaging in  
48 dogs and cats - Tumor target scale and unusual uptake. *Nuclear Medicine Review*, 14: A10.

49 Not in PICO

- 1 Bastiaannet, E., Groen, H., Jager, P. L., Cobben, D. C., Graaf, W. T., Vaalburg, W. & Hoekstra, H. J.  
2 (2004) The value of FDG-PET in the detection, grading and response to therapy of soft tissue and  
3 bone sarcomas: a systematic review and meta-analysis (DARE structured abstract). *Cancer*  
4 *Treatment Reviews*, 30: 83-101.  
5 Not in PICO
- 6 Begic, A., Kucukalic-Selimovic, E., Obralic, N., Duric, O., Lacevic, N. & Skopljak, A. (2006) Correlation  
7 between bone scintigraphy and tumor markers in patients with breast carcinoma. *Bosnian*  
8 *Journal of Basic Medical Sciences*, 6: 75-77.  
9 Not in PICO
- 10 Beheshti, M., Vali, R., Waldenberger, P., Fitz, F., Nader, M., Loidl, W., Broinger, G., Stoiber, F.,  
11 Foglman, I. & Langsteger, W. (2008) Detection of bone metastases in patients with prostate  
12 cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. *European Journal of*  
13 *Nuclear Medicine and Molecular Imaging*, 35: 1766-1774.  
14 Not in PICO
- 15 Bell, S. W., Young, P. S. & Mahendra, A. (2012) Primary bone tumours of the talus: the Scottish Bone  
16 Tumour Registry experience. *Journal of Foot & Ankle Surgery*, 18: 277-282.  
17 Not in PICO
- 18 Benchakroun, M., El, B. A., Kharmaz, M., Zaddoug, O., Chiboub, H., El, Y. M., Hermas, M., Wahbi, S.,  
19 Ouazzani, N. & El, M. M. (2004) Osteoid osteoma in the foot (10 cases report). [French]. *Medecine*  
20 *et Chirurgie du Pied*, 20: 23-38.  
21 Not in PICO
- 22 Berrey, B. H., Jr. (1989) The treacherous biopsy. *Military Medicine*, 154: 171-174.  
23 Not in PICO
- 24 Bethapudi, S., Ritchie, D. A., MacDuff, E. & Straiton, J. (2014) Imaging in osteofibrous dysplasia,  
25 osteofibrous dysplasia-like adamantinoma, and classic adamantinoma. *Clinical Radiology*, 69:  
26 200-208.  
27 Not in PICO
- 28 Bethapudi, S., Ritchie, D. A., MacDuff, E. & Straiton, J. (2014) - Imaging in osteofibrous dysplasia,  
29 osteofibrous dysplasia-like adamantinoma, and classic adamantinoma. [Review]. - *Clinical*  
30 *Radiology*, 69: 200-208.  
31 Narrative review
- 32 Biau, D. J., Weiss, K. R., Bhumbra, R. S., Davidson, D., Brown, C., Wunder, J. S. & Ferguson, P. C.  
33 (2013) Using the CUSUM test to control the proportion of inadequate open biopsies of  
34 musculoskeletal tumors. *Clinical Orthopaedics & Related Research*, 471: 905-914.  
35 Not in PICO
- 36 Bikle, D. D. (1997) Biochemical markers in the assessment of bone disease. *American Journal of*  
37 *Medicine*, 103: 427-436.  
38 Narrative review
- 39 Blay, J. Y., Sleijfer, S., Schoffski, P., Kawai, A., Brodowicz, T., Demetri, G. D. & Maki, R. G. (2014) -  
40 International expert opinion on patient-tailored management of soft tissue sarcomas. [Review]. -  
41 *European Journal of Cancer*, 50: 679-689.  
42 Not in PICO
- 43 Bombardieri, E., Martinetti, A., Miceli, R., Mariani, L., Castellani, M. R. & Seregini, E. (1997) Can bone  
44 metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone  
45 metastases from breast cancer? *European Journal of Nuclear Medicine*, 24: 1349-1355.  
46 Not in PICO
- 47 Bombardieri, E., Aktolun, C., Baum, R. P., Bishof-Delaloye, A., Buscombe, J., Chatal, J. F., Maffioli, L.,  
48 Moncayo, R., Morteimans, L. & Reske, S. N. (2003) Bone scintigraphy: procedure guidelines for  
49 tumour imaging. *European Journal of Nuclear Medicine & Molecular Imaging*, 30: BP99-106.  
50 Not in PICO



- 1 Bommer, K. K., Ramzy, I. & Mody, D. (1997) Fine-needle aspiration biopsy in the diagnosis and  
2 management of bone lesions - A study of 450 cases. *Cancer Cytopathology*, 81: 148-156.  
3 Not in PICO
- 4 Bovee, J. V. (2008) Multiple osteochondromas. [Review] [86 refs]. *Orphanet Journal Of Rare*  
5 *Diseases*, 3: 3.  
6 Narrative review
- 7 Brechot, J. M., Roche, N., Marichy, C., Lebeau, B., Debieuvre, D., Darneau, G., Coste, E., Grivaux, M.,  
8 Falchero, L., Vlastos, F., Souquet, P. J. & Groupe d'Oncologie de la Societe de Pneumologie de  
9 Langue Francaise (2005) [Treatment of anemia and bone metastasis in metastatic non-small-cell  
10 lung cancer. A French survey]. [French]. *Revue de Pneumologie Clinique*, 61: t-9.  
11 Not in PICO
- 12 Bruns, J., Yazigee, O., Werner, M., Delling, G. & Hossfeld, D. K. (2006) Use of biopsy for confirming  
13 musculoskeletal tumors. [German]. *Onkologe*, 12: 119-127.  
14 Narrative review
- 15 Bruns, J., Delling, G., Henne-Bruns, D. & Hossfeld, D. K. (2008) Biopsy of tumors of the  
16 musculoskeletal system. *Deutsches Arzteblatt International*, 105: 492-497.  
17 Narrative review
- 18 Burkhardt, R., Frisch, B. & Kettner, G. (1980) The clinical study of micro-metastatic cancer by bone  
19 biopsy. *Bulletin du Cancer*, 67: 291-305.  
20 Not in PICO
- 21 Bussieres, A. E., Taylor, J. A. M. & Peterson, C. (2008) Diagnostic Imaging Practice Guidelines for  
22 Musculoskeletal Complaints in Adults-An Evidence-Based Approach-Part 3: Spinal Disorders.  
23 *Journal of Manipulative and Physiological Therapeutics*, 31: 33-88.  
24 Guideline
- 25 Caglar, M., Velipasaoglu, Z. & Tuncel, M. (2010) SPECT-CT offers high diagnostic accuracy when  
26 findings on planar bone scintigraphy are inconclusive. *European Journal of Nuclear Medicine and*  
27 *Molecular Imaging*, 37: S211-S212.  
28 Not in PICO
- 29 Casadei, R., Ferraro, A., Ferruzzi, A., Biagini, R. & Ruggieri, P. (1991) Bone tumors of the foot:  
30 epidemiology and diagnosis. *Chirurgia Degli Organi di Movimento*, 76: 47-62.  
31 Not in PICO
- 32 Casazza, B. A. (2012) Diagnosis and treatment of acute low back pain. [Review]. *American Family*  
33 *Physician*, 85: 343-350.  
34 Not in PICO
- 35 Chao, T. Y., Ho, C. L., Lee, S. H., Chen, M. M., Janckila, A. & Yam, L. T. (2004) Tartrate-resistant acid  
36 phosphatase 5b as a serum marker of bone metastasis in breast cancer patients. *Journal of*  
37 *Biomedical Science*, 11: 511-516.  
38 Not in PICO
- 39 Chen, G., Zhang, M., Hu, J., Jiang, X., Wang, C. & Li, B. (2010) Clinical application of 18F-FDG PET/CT  
40 in detection of primary tumors of multiple bone metastatic tumors. [Chinese]. *Journal of*  
41 *Shanghai Jiaotong University (Medical Science)*, 30: 1039-1042.  
42 Not in PICO
- 43 Costelloe, C. M., Chuang, H. H., Chasen, B. A., Pan, T., Fox, P. S., Bassett, R. L. & Madewell, J. E.  
44 (2013) Bone Windows for Distinguishing Malignant from Benign Primary Bone Tumors on FDG  
45 PET/CT. *Journal of Cancer*, 4: 524-530.  
46 Not in PICO
- 47 Cronin, C. G., Cashell, T., Mhuircheartaigh, J. N., Swords, R., Murray, M., O'Sullivan, G. J. & O'Keefe,  
48 D. (2009) Bone biopsy of new suspicious bone lesions in patients with primary carcinoma:  
49 prevalence and probability of an alternative diagnosis. *AJR.American Journal of Roentgenology*,  
50 193: W407-W410.  
51 Not in PICO

- 1 Daffner, R. H., Lupetin, A. R., Dash, N., Deeb, Z. L., Sefczek, R. J. & Schapiro, R. L. (1986) MRI in the  
2 detection of malignant infiltration of bone marrow. *AJR.American Journal of Roentgenology*, 146:  
3 353-358.  
4 Not in PICO
- 5 Dane, F., Turk, H. M., Sevinc, A., Buyukberber, S., Camci, C. & Tarakcioglu, M. (2008) Markers of bone  
6 turnover in patients with lung cancer. *Journal of the National Medical Association*, 100: 425-428.  
7 Not in PICO
- 8 Daniel, J., Ullah, E., Wahab, S. & Kumar, J. (2009) Relevance of MRI in prediction of malignancy of  
9 musculoskeletal system--a prospective evaluation. *BMC musculoskeletal disorders*, 10: 125.  
10 Not in PICO
- 11 De Ioris, M. A., Prete, A., Cozza, R., Podda, M., Manzitti, C., Pession, A., Schiavello, E., Contoli, B.,  
12 Balter, R., Fagioli, F., Bisogno, G., Amoroso, L., Locatelli, F. & Luksch, R. (2013) Ewing Sarcoma of  
13 the Bone in Children under 6 Years of Age. *PLoS ONE*, 8.  
14 Not in PICO
- 15 Delling, G., Jobke, B., Burisch, S. & Werner, M. (1281) [Cartilage tumors. Classification, conditions for  
16 biopsy and histologic characteristics]. [Review] [30 refs] [German]. *Orthopade*, 34: 1267-1281.  
17 Narrative review
- 18 Dhanoa, A., Singh, V. A., Mansor, A., Yusof, M. Y., Lim, K. T. & Thong, K. L. (2012) Acute  
19 haematogenous community-acquired methicillin-resistant *Staphylococcus aureus* osteomyelitis in  
20 an adult: case report and review of literature. *BMC Infectious Diseases*, 12: 270.  
21 Not in PICO
- 22 Didolkar, M. M., Anderson, M. E., Hochman, M. G., Rissmiller, J. G., Goldsmith, J. D., Gebhardt, M. G.  
23 & Wu, J. S. (2013) Image guided core needle biopsy of musculoskeletal lesions: Are nondiagnostic  
24 results clinically useful? *Clinical Orthopaedics and Related Research*, 471: 3601-3609.  
25 Not in PICO
- 26 Dollahite, H. A., Tatum, L., Moinuddin, S. M. & Carnesale, P. G. (1989) Aspiration biopsy of primary  
27 neoplasms of bone. *Journal of Bone & Joint Surgery - American Volume*, 71: 1166-1169.  
28 Not in PICO
- 29 Dommett, R., Stevens, M., Redaniel, T., Hamilton, W. & Martin, R. (2013) Features of cancer in  
30 teenagers and young adults (TYA) presenting to primary care in the uk: A population-based  
31 nested case-control study. *Pediatric Blood and Cancer*, 60: 3.  
32 Already included
- 33 Donthineni, R. & Ofluoglu, O. (2010) Solitary enchondromas of long bones: Pattern of referral and  
34 outcome. *Acta Orthopaedica et Traumatologica Turcica*, 44: 397-402.  
35 Not in PICO
- 36 Dotan, Z. A. (2008) Bone imaging in prostate cancer. [Review] [73 refs]. *Nature Clinical Practice*  
37 *Urology*, 5: 434-444.  
38 Not in PICO
- 39 Downie, A., Williams, C. M., Henschke, N., Hancock, M. J., Ostelo, R. W. J. G., De Vet, H. C. W.,  
40 Macaskill, P., Irwig, L., Van Tulder, M. W., Koes, B. W. & Maher, C. G. (2013) Red flags to screen  
41 for malignancy and fracture in patients with low back pain: Systematic review. *BMJ (Online)*, 347.  
42 Systematic review, checked for relevant studies.
- 43 Duda, S. H., Johst, U., Krahmer, K., Pereira, P., Konig, C., Schafer, J., Huppert, P., Schott, U., Bohm, P.  
44 & Claussen, C. D. (2001) [Technique and results of CT-guided percutaneous bone biopsy].  
45 [German]. *Orthopade*, 30: 545-550.  
46 Not in PICO
- 47 Dyrop, H. B., Safwat, A., Vedsted, P., Margety-Nielsen, K., Hansen, B. H., Jorgensen, P. H., Baad-  
48 Hansen, T., Bunger, C. & Keller, J. (2013) Cancer patient pathways shortens waiting times and  
49 accelerates the diagnostic process of suspected sarcoma patients in Denmark. *Health Policy*, 113:  
50 110-117.  
51 Not in PICO

- 1 Edeiken, B. & deSantos, L. A. (1983) Percutaneous needle biopsy of the irradiated skeleton.  
2 *Radiology*, 146: 653-655.  
3 Not in PICO
- 4 Etchebehere, M., De Camargo, O. P., Croci, A. T., De Oliveira, C. R. C. M. & Baptista, A. M. (1999) The  
5 role of percutaneous biopsy in the definitive histological diagnosis of suspected cartilaginous  
6 bone lesions prior to surgery. [Portuguese]. *Revista Brasileira de Ortopedia*, 34: 77-80.  
7 Not in PICO
- 8 Fayad, L. M., Bluemke, D. A., Weber, K. L. & Fishman, E. K. (2006) Characterization of pediatric  
9 skeletal tumors and tumor-like conditions: specific cross-sectional imaging signs. [Review] [9  
10 refs]. *Skeletal Radiology*, 35: 259-268.  
11 Not in PICO
- 12 Fogelman, I., Cook, G., Israel, O. & Van der Wall, H. (2005) Positron emission tomography and bone  
13 metastases. [Review] [36 refs]. *Seminars in Nuclear Medicine*, 35: 135-142.  
14 Not in PICO
- 15 Fottner, A., Baur-Melnyk, A., Birkenmaier, C., Jansson, V. & Durr, H.-R. (2009) Stress fractures  
16 presenting as tumours: A retrospective analysis of 22 cases. *International Orthopaedics*, 33: 489-  
17 492.  
18 Not in PICO
- 19 Frank, J. A., Ling, A., Patronas, N. J., Carrasquillo, J. A., Horvath, K., Hickey, A. M. & Dwyer, A. J. (1990)  
20 Detection of malignant bone tumors: MR imaging vs scintigraphy. *American Journal of*  
21 *Roentgenology*, 155: 1043-1048.  
22 Not in PICO
- 23 Freeman, S. J., Sonoda, L. I., Seshadri, N., Howard, W., Set, P. A. & Balan, K. K. (2010) What is the  
24 significance of solitary bony abnormalities on bone scintigrams of children with malignancy?  
25 *Pediatric Hematology & Oncology*, 27: 380-386.  
26 Not in PICO
- 27 Friedrich, P., Ortiz, R., Strait, K., Fuentes, S., Gamboa, Y., Arambu, I., Ah-Chu-Sanchez, M., London,  
28 W., Rodriguez-Galindo, C., Antillon-Klussmann, F., Baez, F. & Central American Association of  
29 Pediatric Hematologists Oncologists AHOPCA (2013) Pediatric sarcoma in Central America:  
30 outcomes, challenges, and plans for improvement. *Cancer*, 119: 871-879.  
31 Not in PICO
- 32 Fukutomi, M., Yokota, M., Chuman, H., Harada, H., Zaitzu, Y., Funakoshi, A., Wakasugi, H. & Iguchi, H.  
33 (2001) Increased incidence of bone metastases in hepatocellular carcinoma. *European Journal of*  
34 *Gastroenterology & Hepatology*, 13: 1083-1088.  
35 Not in PICO
- 36 George, A. & Grimer, R. (2012) Early symptoms of bone and soft tissue sarcomas: Could they be  
37 diagnosed earlier? *Annals of the Royal College of Surgeons of England*, 94: e261-e266.  
38 Not in PICO
- 39 George, J. L. & Marchal, J. C. (2010) [Orbital tumors in children: clinical examination, imaging,  
40 specific progression]. [French]. *Neuro-Chirurgie*, 56: 244-248.  
41 Narrative review
- 42 Gnanasegaran, G., Cook, G., Adamson, K. & Fogelman, I. (2009) Patterns, variants, artifacts, and  
43 pitfalls in conventional radionuclide bone imaging and SPECT/CT. [Review] [106 refs]. *Seminars in*  
44 *Nuclear Medicine*, 39: 380-395.  
45 Narrative review
- 46 Griffiths, H. J., Galloway, H. R., Thompson, J., Suh, J.-S., Nelson, T. E., Everson, L., Edlin, J. P., Lynn, B.  
47 J. & Lang, D. (1993) The use of MRI in the diagnosis of benign and malignant bone and soft tissue  
48 tumours. *Australasian Radiology*, 37: 35-39.  
49 Not in PICO
- 50 Gussetis, E. S., Schwabe, D., Gerein, V. & Kornhuber, B. (1997) Differential diagnosis based on  
51 immunological-phenotyping in suspected malignant bone marrow involvement in childhood.

- 1 *Pediatric Hematology & Oncology*, 14: 29-41.  
 2 Not in PICO
- 3 Hajdarbegovic, E. & Nijsten, T. (2014) - [A man with a painful and swollen ankle]. [Dutch]. -  
 4 *Nederlands Tijdschrift voor Geneeskunde*, 158: A6894.  
 5 Not in PICO
- 6 Heck, R. K., O'Malley, A. M., Kellum, E. L., Donovan, T. B., Ellzey, A. & Witte, D. A. (2007) Errors in the  
 7 MRI evaluation of musculoskeletal tumors and tumorlike lesions. *Clinical Orthopaedics and*  
 8 *Related Research*, 28-33.  
 9 Not in PICO
- 10 Hefti, F. (1993) [Malignant bone tumors--is amputation still necessary today?]. [Review] [55 refs]  
 11 [German]. *Schweizerische Rundschau fur Medizin Praxis*, 82: 307-315.  
 12 Narrative review
- 13 Heick, J. D., Bustillo, K. L. & Farris, J. W. (2014) Recognition of signs and symptoms of a Type 1  
 14 chondrosarcoma: a case report. *Physiotherapy Theory & Practice*, 30: 49-55.  
 15 Not in PICO
- 16 Helwig, H. (1980) Early diagnosis of malignant bone tumors in childhood. [German]. *Padiatrische*  
 17 *Praxis*, 23: 79-85.  
 18 Narrative review
- 19 Henschke, N., Maher, C. G., Ostelo, R. W., de Vet, H. C., Macaskill, P. & Irwig, L. (2013) Red flags to  
 20 screen for malignancy in patients with low-back pain. [Review]. *Cochrane Database of Systematic*  
 21 *Reviews*, 2: CD008686.  
 22 Systematic review, included studies checked for relevance.
- 23 Hill, C. E., Boyce, L. & van der Ploeg, I. D. (2014) Spontaneous resolution of a solitary  
 24 osteochondroma of the distal femur: a case report and review of the literature. *Journal of*  
 25 *Pediatric Orthopaedics, Part B*, 23: 73-75.  
 26 Not in PICO
- 27 Hoffer, F. A. (2002) Primary skeletal neoplasms: osteosarcoma and ewing sarcoma. [Review] [20  
 28 refs]. *Topics in Magnetic Resonance Imaging*, 13: 231-239.  
 29 Narrative review
- 30 Holzapfel, B. M., Ludemann, M., Holzapfel, D. E., Rechl, H. & Rudert, M. (2012) Open biopsy of bone  
 31 and soft tissue tumors. Guidelines for precise surgical procedures. [German]. *Operative*  
 32 *Orthopadie und Traumatologie*, 24: 403-417.  
 33 Not in PICO
- 34 Horikoshi, H., Kikuchi, A., Onoguchi, M., Sjostrand, K. & Edenbrandt, L. (2012) Computer-aided  
 35 diagnosis system for bone scintigrams from Japanese patients: Importance of training database.  
 36 *Annals of Nuclear Medicine*, 26: 622-626.  
 37 Not in PICO
- 38 Hsu, P.-K., Hsu, H.-S., Lee, H.-C., Hsieh, C.-C., Wu, Y.-C., Wang, L.-S., Huang, B.-S., Hsu, W.-H. &  
 39 Huang, M.-H. (2006) Management of primary chest wall tumors: 14 years' clinical experience.  
 40 *Journal of the Chinese Medical Association*, 69: 377-382.  
 41 Not in PICO
- 42 Hu, Y. G. (251) Arteriographic findings in bone tumors: experience with 170 cases. [Chinese].  
 43 *Zhonghua wai ke za zhi [Chinese journal of surgery]*, 28: 195-197, 251.  
 44 Not in PICO
- 45 Huang, H., Chen, Y. P., Cao, G. H. & Lin, Z. C. (2005) [Magnetic resonance imaging and radiography  
 46 for diagnosis of lower limb osteosarcoma: a comparative study]. [Chinese]. *Di Yi Junyi Daxue*  
 47 *Xuebao*, 25: 1552-1554.  
 48 Not in PICO
- 49 Jia, Z. Y. & Deng, H. F. (2007) [Preliminary application of 99Tc(m)-MIBI scintigraphy for judgment of  
 50 bone malignant and benign lesions]. [Chinese]. *Sichuan da Xue Xue Bao.Yi Xue Ban/Journal of*

- 1 *Sichuan University. Medical Science Edition*, 38: 689-692.  
2 Not in PICO
- 3 Joerger, M. & Huober, J. (2012) Diagnostic and prognostic use of bone turnover markers. [Review].  
4 *Recent Results in Cancer Research*, 192: 197-223.  
5 Narrative review
- 6 Joines, J. D., McNutt, R. A., Carey, T. S., Deyo, R. A. & Rouhani, R. (2001) Finding cancer in primary  
7 care outpatients with low back pain: a comparison of diagnostic strategies. *Journal of General*  
8 *Internal Medicine*, 16: 14-23.  
9 Not in PICO
- 10 Joshi, A., Magar, S. R., Chand, P., Panth, R. & Khatri Chhetri, B. R. (2013) Tru-cut biopsy as the initial  
11 method of tissue diagnosis in bone tumors with soft tissue extension. *Indian Journal of*  
12 *Orthopaedics*, 47: 195-199.  
13 Not in PICO
- 14 Jung, K., Lein, M., Stephan, C., Von, H. K., Semjonow, A., Sinha, P., Loening, S. A. & Schnorr, D. (2004)  
15 Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone  
16 metastatic spread: diagnostic and prognostic implications. *International Journal of Cancer*, 111:  
17 783-791.  
18 Not in PICO
- 19 Kabukcuoglu, F., Kabukcuoglu, Y., Kuzgun, U. & Evren, I. (1998) Fine needle aspiration of malignant  
20 bone lesions. *Acta Cytologica*, 42: 875-882.  
21 Not in PICO
- 22 Kafchitsas, K., Habermann, B., Tonak, M. & Kurth, A. A. (2010) Bone tumours of the vertebral  
23 column. [German]. *Osteologie*, 19: 332-339.  
24 Narrative review
- 25 Kao, C. H., Hsieh, J. F., Tsai, S. C., Ho, Y. J. & Yen, R. F. (2000) Comparison and discrepancy of 18F-2-  
26 deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone  
27 metastases. *Anticancer Research*, 20: 2189-2192.  
28 Not in PICO
- 29 Katabi, M., Anract, P., Forest, M. & Tomeno, B. (1996) Low grade intramedullary osteosarcoma. A  
30 study of eight cases. [French]. *Revue de Chirurgie Orthopedique et Reparatrice de l'Appareil*  
31 *Moteur*, 82: 208-215.  
32 Not in PICO
- 33 Khoo, M. M. Y. & Saifuddin, A. (2013) The role of MRI in image-guided needle biopsy of focal bone  
34 and soft tissue neoplasms. *Skeletal Radiology*, 42: 905-915.  
35 Narrative review
- 36 Kobayashi, M., Okabayashi, T., Sano, T. & Araki, K. (2005) Metastatic bone cancer as a recurrence of  
37 early gastric cancer -- characteristics and possible mechanisms. [Review] [27 refs]. *World Journal*  
38 *of Gastroenterology*, 11: 5587-5591.  
39 Not in PICO
- 40 Konig, R., van, K. G. & Braun, A. (1983) [Contribution of computer tomography to the evaluation of  
41 space-occupying processes and abnormalities of the skeletal system]. [German].  
42 *Computertomographie*, 3: 25-31.  
43 Not in PICO
- 44 Korholz, D., Verheyen, J., Kemperdick, H. F. & Gobel, U. (1998) Evaluation of follow-up investigations  
45 in osteosarcoma patients: suggestions for an effective follow-up program. *Medical & Pediatric*  
46 *Oncology*, 30: 52-58.  
47 Not in PICO
- 48 Korholz, D., Verheyen, J., Engelbrecht, V., Guillaume, T., Vosberg, H. & Gobel, U. (2000) [Follow-up of  
49 patients with osteosarcoma and Ewing's sarcoma: a retrospective cost-benefit analysis].  
50 [German]. *Klinische Padiatrie*, 212: 220-223.  
51 Not in PICO

- 1 Kornaat, P. R., Camerlinck, M., Vanhoenacker, F. M., De, P. G. & Kroon, H. M. (2010) Brodie's abscess  
 2 revisited. [Review] [12 refs]. *Jbr-Btr: Organe de la Societe Royale Belge de Radiologie*, 93: 81-86.  
 3 Narrative review
- 4 Kotru, M. & Singh, N. (2007) The value of recognizing suspect diagnoses in the triple diagnosis of  
 5 giant cell tumor of bone. *Indian Journal of Orthopaedics*, 41: 97-100.  
 6 Narrative review
- 7 Kozlowski, K., Azouz, E. M., Campbell, J., Marton, D., Morris, L., Padovani, J., Sprague, P., Beluffi, G.,  
 8 Berzero, G. F. & Cherubino, P. (1988) Primary bone tumours of the hand. Report of 21 cases.  
 9 *Pediatric Radiology*, 18: 140-148.  
 10 Not in PICO
- 11 Krakorova, D. A. (2012) Aspects of ortopedical oncology. [Czech]. *Onkologie*, 6: 190-194.  
 12 Narrative review
- 13 Krasnow, A. Z., Hellman, R. S., Timins, M. E., Collier, B. D., Anderson, T. & Isitman, A. T. (1997)  
 14 Diagnostic bone scanning in oncology. *Seminars in Nuclear Medicine*, 27: 107-141.  
 15 Narrative review
- 16 Krishnan, A., Shirkhoda, A., Tehranzadeh, J., Armin, A. R., Irwin, R. & Les, K. (2003) Primary Bone  
 17 Lymphoma: Radiographic-MR Imaging Correlation. *Radiographics*, 23: 1371-1383.  
 18 Narrative review
- 19 Kuchuk, M., Addison, C. L., Clemons, M., Kuchuk, I. & Wheatley-Price, P. (2013) Incidence and  
 20 consequences of bone metastases in lung cancer patients. *Journal of Bone Oncology*, 2: 22-29.  
 21 Not in PICO
- 22 Kuleta-Bosak, E., Kluczevska, E., Machnik-Broncel, J., Madziara, W., Ciupinska-Kajor, M., Sojka, D.,  
 23 Rogala, W., Juszczyk, J. & Wilk, R. (2010) Suitability of imaging methods (X-ray, CT, MRI) in the  
 24 diagnostics of Ewing's sarcoma in children - analysis of own material. *Polish Journal of Radiology*,  
 25 75: 18-28.  
 26 Not in PICO
- 27 Lammeren-Venema, D., Regelink, J. C., Riphagen, I. I., Zweegman, S., Hoekstra, O. S. & Zijlstra, J. M.  
 28 (2012) 18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-  
 29 related bone disease: a systematic review (DARE structured abstract). *Cancer*, 118: 1971-1981.  
 30 Not in PICO
- 31 Langer, S. W., Kamby, C., Thomsen, H. S., Sorensen, T., Hvid-Jacobsen, K., Dombernowsky, P. &  
 32 Nielsen, S. L. (1993) [The value of bone marrow scintigraphy in patients with recurrent breast  
 33 cancer]. [Danish]. *Ugeskrift for Laeger*, 155: 778-782.  
 34 Not in PICO
- 35 Leithner, A. & Windhager, R. (2007) Guidelines for the biopsy of bone and soft tissue tumours.  
 36 [German]. *Orthopade*, 36: 167-175.  
 37 Not in PICO
- 38 Leithner, A., Maurer-Ertl, W. & Windhager, R. (2009) Biopsy of bone and soft tissue tumours: hints  
 39 and hazards. *Recent Results in Cancer Research*, Fortschritte: 3-10.  
 40 Not in PICO
- 41 Levecq, L., De, P. P. & Guagnini, A. P. (2005) [Epidemiology of ocular and orbital lesions referred to  
 42 an ocular oncology center]. [French]. *Journal Francais d Ophthalmologie*, 28: 840-844.  
 43 Not in PICO
- 44 Lewis, V. O., Morris, C. D. & Parsons, T. W. (2013) Malignant and benign bone tumors that you are  
 45 likely to see. *Instructional Course Lectures*, 62: 535-549.  
 46 Narrative review
- 47 Li, S., Xue, H. D., Sun, F. & Jin, Z. Y. (2009) [Feasibility and clinical value of whole body diffusion  
 48 weighted magnetic resonance imaging in detection of bone metastases]. [Chinese]. *Chung-Kuo i*  
 49 *Hsueh Ko Hsueh Yuan Hsueh Pao Acta Academiae Medicinae Sinicae*, 31: 192-199.  
 50 Not in PICO

- 1 Li, X. & Hemminki, K. (2002) Parental cancer as a risk factor for bone cancer: a nation-wide study  
2 from Sweden. *Journal of Clinical Epidemiology*, 55: 111-114.  
3 Not in PICO
- 4 Lis, E., Bilsky, M. H., Pisinski, L., Boland, P., Healey, J. H., O'malley, B. & Krol, G. (2004) Percutaneous  
5 CT-guided biopsy of osseous lesion of the spine in patients with known or suspected malignancy.  
6 *Ajnr: American Journal of Neuroradiology*, 25: 1583-1588.  
7 Not in PICO
- 8 Malhas, A. M., Grimer, R. J., Abudu, A., Carter, S. R., Tillman, R. M. & Jeys, L. (2011) The final  
9 diagnosis in patients with a suspected primary malignancy of bone. *Journal of Bone & Joint*  
10 *Surgery - British Volume*, 93: 980-983.  
11 Not in PICO
- 12 Malhas, A. M., Sumathi, V. P., James, S. L., Menna, C., Carter, S. R., Tillman, R. M., Jeys, L. & Grimer,  
13 R. J. (2012) Low-grade central osteosarcoma: a difficult condition to diagnose. *Sarcoma*, 2012:  
14 764796.  
15 Not in PICO
- 16 Malik, A., Wigney, L., Murray, S. & Gerrand, C. H. (2007) The effectiveness of "two-week" referrals  
17 for suspected bone and soft tissue sarcoma. *Sarcoma*, 2007.  
18 Not in PICO
- 19 Mankin, H. J., Mankin, C. J. & Simon, M. A. (1996) The hazards of the biopsy, revisited - For the  
20 members of the Musculoskeletal Tumor Society. *Journal of Bone and Joint Surgery-American*  
21 *Volume*, 78A: 656-663.  
22 Not in PICO
- 23 Martin, C. T., Morcuende, J., Buckwalter, J. A. & Miller, B. J. (2012) Prereferral MRI Use in Patients  
24 with Musculoskeletal Tumors Is Not Excessive. *Clinical Orthopaedics and Related Research*, 470:  
25 3240-3245.  
26 Not in PICO
- 27 Matsui, R. (1999) Quantitative assessment of 201TI-SPECT in tumors of bone and soft tissue.  
28 [Japanese]. *Kakuigaku*, 36: 219-228.  
29 Not in PICO
- 30 Mattiassich, G., Ensaf, F., Hager, M. & Wechselberger, G. (2012) A suspected malignancy in osteolytic  
31 bone tumour of the thumb. *BMJ Case Reports*, 2012, 2012.  
32 Not in PICO
- 33 Mattiassich, G., Ensaf, F., Hager, M. & Wechselberger, G. (2012) A suspected malignancy in osteolytic  
34 bone tumour of the thumb. *BMJ Case Reports*, 2012, 2012.  
35 Not in PICO
- 36 Mazur, J. M. & Stauffer, E. S. (1981) Evaluation and treatment of bone tumors. *The Journal of family*  
37 *practice*, 12: 333-341.  
38 Narrative review
- 39 Meijer, W. G., van, d., V, Jager, P. L., van der Jagt, E. J., Piers, B. A., Kema, I. P., de Vries, E. G. &  
40 Willemse, P. H. (2003) Bone metastases in carcinoid tumors: clinical features, imaging  
41 characteristics, and markers of bone metabolism. *Journal of Nuclear Medicine*, 44: 184-191.  
42 Not in PICO
- 43 Mende, U., Ewerbeck, V., Krempien, B., Ludwig, R., Peichardt, P., Troger, J., Zoller, J. & Braun, A.  
44 (1992) Sonography in the therapy-related diagnosis and follow-up of primary bone and soft tissue  
45 tumors. [German]. *Bildgebung/Imaging*, 59: 4-14.  
46 Not in PICO
- 47 Mentzel, H.-J., Kentouche, K., Sauner, D., Fleischmann, C., Vogt, S., Gottschild, D., Zintl, F. & Kaiser,  
48 W. A. (2004) Comparison of whole-body STIR-MRI and 99mTc-methylene-diphosphonate  
49 scintigraphy in children with suspected multifocal bone lesions. *European Radiology*, 14: 2297-  
50 2302.  
51 Not in PICO

- 1 Merrill, R. M., Baker, R. K., Lyon, J. L. & Gren, L. H. (2009) Healthcare claims for identifying the level  
2 of diagnostic investigation and treatment of cancer. *Medical Science Monitor*, 15: H25-H31.  
3 Not in PICO
- 4 Mespreuve, M., De, B. F. & Van, D. R. (1989) [Osteoid osteoma of the spine]. [Dutch]. *Journal Belge  
5 de Radiologie*, 72: 73-78.  
6 Narrative review
- 7 Milo, Y., Robenpor, M., Tamir, G., Ekstein, J. & Hauben, D. J. (1994) Reliability of plain X-ray and  
8 computed tomography in diagnosis of invasive tumors of the scalp. *European Journal of Plastic  
9 Surgery*, 17: 184-188.  
10 Not in PICO
- 11 Min, R., Zun, Z., Lizheng, W., Minjun, D., Shengwen, L., Wenjun, Y. & Chenping, Z. (2011) Oral and  
12 maxillofacial desmoid-type fibromatoses in an eastern Chinese population: a report of 20 cases.  
13 *Oral Surgery Oral Medicine Oral Pathology Oral Radiology & Endodontics*, 111: 340-345.  
14 Not in PICO
- 15 Moores, D. W. O., Line, B., Dziuban, J. & McKneally, M. F. (1990) Nuclear scan-guided rib biopsy.  
16 *Journal of Thoracic and Cardiovascular Surgery*, 99: 620-621.  
17 Not in PICO
- 18 Myriokefalitaki, E., D'Costa, D., Smith, M. & Ahmed, A. S. (2013) Primary bone metastasis as initial  
19 presentation of endometrial cancer (stage IVb). *Archives of Gynecology & Obstetrics*, 288: 739-  
20 746.  
21 Not in PICO
- 22 Nagata, Y., Shiraishi, K. & Matsuyama, H. (2012) [A case of primary chondrosarcoma difficult to  
23 differentiate from retroperitoneal tumor]. [Japanese]. *Hinyokika Kiyo - Acta Urologica Japonica*,  
24 58: 605-608.  
25 Not in PICO
- 26 Neubauer, H., Evangelista, L., Hassold, N., Winkler, B., Schlegel, P. G., Kostler, H., Hahn, D. & Beer, M.  
27 (2012) Diffusion-weighted MRI for detection and differentiation of musculoskeletal tumorous and  
28 tumor-like lesions in pediatric patients. *World Journal of Pediatrics*, 8: 342-349.  
29 Not in PICO
- 30 Ng, E. S., Saw, A., Sengupta, S., Nazarina, A. R. & Path, M. (2002) Giant cell tumour of bone with late  
31 presentation: Review of treatment and outcome. *Journal of Orthopaedic Surgery*, 10: 120-128.  
32 Not in PICO
- 33 Ngwenya, S. (2006) General practitioner's pathology. Case 2. Diagnosis: Oral Kaposi's sarcoma with  
34 secondary ulceration. *SADJ*, 61: 079.  
35 Not in PICO
- 36 Niemeyer, P., Delling, G., Werner, M., Simank, H. G. & Bernd, L. (2003) [Telecommunication and  
37 telepathology in orthopedic oncology. Possibilities in diagnosis and therapy of primary malignant  
38 bone tumors]. [German]. *Orthopade*, 32: 949-954.  
39 Not in PICO
- 40 Nishiyama, Y., Yamamoto, Y., Toyama, Y., Satoh, K., Ohkawa, M. & Tanabe, M. (2000) Diagnostic  
41 value of Tl-201 and three-phase bone scintigraphy for bone and soft-tissue tumors. *Clinical  
42 Nuclear Medicine*, 25: 200-205.  
43 Not in PICO
- 44 Nthumba, P. M. (2012) Osteosarcoma of the jaws: a review of literature and a case report on  
45 synchronous multicentric osteosarcomas. *World Journal of Surgical Oncology*, 10.  
46 Not in PICO
- 47 O'Connor, M. I. (2007) Musculoskeletal imaging: What information is important to the orthopedic  
48 oncologist? *Seminars in Musculoskeletal Radiology*, 11: 273-278.  
49 Narrative review
- 50 Ochsner, P. E. (1986) [Tumors of the child's foot]. [German]. *Orthopade*, 15: 227-232.  
51 Narrative review



- 1 Otsuka, N., Fukunaga, M., Furukawa, Y. & Tanaka, H. (1994) The usefulness of early whole body bone  
2 scintigraphy in the detection of bone metastasis from prostatic cancer. [Japanese]. *Kakuigaku*,  
3 31: 541-550.  
4 Not in PICO
- 5 Palma, O., Canali, N., Scaroni, P. & Torri, A. M. (1989) Fine needle aspiration biopsy: its use in the  
6 management of orbital and intraocular tumors. *Tumori*, 75: 589-593.  
7 Not in PICO
- 8 Palmerini, E., Staals, E. L., Ferrari, S. & Bacci, G. (2009) Diagnosis and prognosis for the Ewing family  
9 of tumors. *Expert Opinion on Medical Diagnostics*, 3: 445-452.  
10 Narrative review
- 11 Panzica, M., Luke, U., Mommsen, P. & Krettek, C. (2014) - [Biopsy and approach routes for bone  
12 tumors. Where and how much is sufficient?]. [German]. - *Unfallchirurg*, 117: 501-509.  
13 Narrative review
- 14 Parkkola, R. K., Mattila, K. T., Heikkila, J. T., Ekfors, T. O., Kallajoki, M. A., Komu, M. E., Vaara, T. J. &  
15 Aro, H. T. (2001) Dynamic contrast-enhanced MR imaging and MR-guided bone biopsy on a 0.23 T  
16 open imager. *Skeletal Radiology*, 30: 620-624.  
17 Not in PICO
- 18 Patel, D. R., Moore, M. D. & Greydanus, D. E. (2007) Musculoskeletal diagnosis in adolescents.  
19 [Review] [12 refs]. *Adolescent Medicine*, 18: 1-10.  
20 Narrative review
- 21 Pecherstorfer, M., Brenner, K. & Zojer, N. (2003) Current management strategies for hypercalcemia.  
22 *Treatments in Endocrinology*, 2: 273-292.  
23 Not in PICO
- 24 Pectasides, D., Farmakis, D., Nikolaou, M., Kanakis, I., Kostopoulou, V., Papaconstantinou, I.,  
25 Karamanos, N. K., Economopoulos, T. & Raptis, S. A. (2005) Diagnostic value of bone remodeling  
26 markers in the diagnosis of bone metastases in patients with breast cancer. *Journal of*  
27 *Pharmaceutical & Biomedical Analysis*, 37: 171-176.  
28 Not in PICO
- 29 Peterson, J. J., Bancroft, L. W. & Kransdorf, M. J. (2005) Principles of tumor imaging. [Review] [28  
30 refs]. *European Journal of Radiology*, 56: 319-330.  
31 Narrative review
- 32 Philip, T., Blay, J. Y., Brunat-Mentigny, M., Carrie, C., Chauvot, P., Farsi, F., Fervers, B., Gentet, J. C.,  
33 Giammarile, F., Kohler, R., Mathoulin, S., Patricot, L. M. & Thiesse, P. (1999) Standards, Options  
34 and Recommendations (SOR) for diagnosis, treatment and follow-up of osteosarcoma. *Bulletin du*  
35 *Cancer*, 86: 159-176.  
36 Guideline
- 37 Piccirillo, E., Agarwal, M., Rohit, Khrais, T. & Sanna, M. (2004) Management of temporal bone  
38 hemangiomas. *Annals of Otolaryngology, Rhinology & Laryngology*, 113: 431-437.  
39 Not in PICO
- 40 Pilkington, G. R. & Pallesen, G. (1989) Phenotypic characterization of non-haemopoietic small cell  
41 tumours of childhood with monoclonal antibodies to leucocytes, epithelial cells and cytoskeletal  
42 proteins. *Histopathology*, 14: 347-357.  
43 Not in PICO
- 44 Plate, A. M., Steiner, G. & Posner, M. A. (2006) Malignant tumors of the hand and wrist. *The Journal*  
45 *of the American Academy of Orthopaedic Surgeons*, 14: 680-692.  
46 Narrative review
- 47 Pohlig, F., Kirchhoff, C., Lenze, U., Schauwecker, J., Burgkart, R., Rechl, H. & von Eisenhart-Rothe, R.  
48 (2012) Percutaneous core needle biopsy versus open biopsy in diagnostics of bone and soft tissue  
49 sarcoma: a retrospective study. *European Journal of Medical Research*, 17: 29.  
50 Not in PICO

- 1 Pohlig, F., Lenze, U., Lenze, F. W., Muhlhofer, H., Schauwecker, J., Rechl, H. & von Eisenhart-Rothe, R.  
2 (2013) [Biopsies from bone and soft tissue sarcoma : a nationwide survey in Germany]. [German].  
3 *Orthopade*, 42: 934-940.  
4 Not in PICO
- 5 Pollahne, W., Pfeifer, M. & Minne, H. W. (2007) [Use of imaging procedures in the diagnostics of  
6 osteoporosis interpretation of x-rays and bone density measurements]. [German]. *Wiener*  
7 *Medizinische Wochenschrift*, 157: 593-605.  
8 Not in PICO
- 9 Porter, A. D., Simpson, A. H., Davis, A. M., Griffin, A. M. & Bell, R. S. (1994) Diagnosis and  
10 Management of Sacral Bone-Tumors. *Canadian Journal of Surgery*, 37: 473-478.  
11 Not in PICO
- 12 Pozmogov, A. I. (1991) [The potentials for the x-ray diagnosis of early forms of malignant neoplasms  
13 in basic locations]. [Russian]. *Vrachebnoe Delo*.(3):6-11, 1991 Mar., 6-11.  
14 In Russian. Not enough information can be extracted to ascertain relevance
- 15 Preteseille, O., Barral, F. G., Court, L., Russias, B., Manet, L., Tanji, P., Mosnier, J. F., Fessy, M. H. &  
16 Thomas, T. (2003) [Value of percutaneous core needle biopsy in the investigation of a suspected  
17 bone tumor]. [French]. *Journal de Radiologie*, 84: 693-697.  
18 Not in PICO
- 19 Puls, F., Niblett, A. J. & Mangham, D. C. (2014) Molecular pathology of bone tumours: Diagnostic  
20 implications. *Histopathology*, 64: 461-476.  
21 Narrative review
- 22 Puls, F., Niblett, A. J. & Mangham, D. C. (2014) - Molecular pathology of bone tumours: diagnostic  
23 implications. - *Histopathology*, 64: 461-476.  
24 Duplicate
- 25 Qu, X., Huang, X., Yan, W., Wu, L. & Dai, K. (2012) A meta-analysis of 18fdg-pet-ct, 18fdg-pet, mri and  
26 bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. [Review].  
27 *European Journal of Radiology*, 81: 1007-1015.  
28 Not in PICO
- 29 Quinn, R. H., Randall, R. L., Benevenia, J., Berven, S. H. & Raskin, K. A. (2013) Contemporary  
30 management of metastatic bone disease: tips and tools of the trade for general practitioners. *The*  
31 *Journal of bone and joint surgery, American*: 1887-1895.  
32 Narrative review
- 33 Raab, C. P. & Gartner, J. C., Jr. (2009) Diagnosis of childhood cancer. [Review] [33 refs]. *Primary Care;*  
34 *Clinics in Office Practice*, 36: 671-684.  
35 Narrative review
- 36 Ralston, S. H., Boyce, B. F., Cowan, R. A., Gardner, M. D., Fraser, W. D. & Boyle, I. T. (1989)  
37 Contrasting mechanisms of hypercalcemia in patients with early and advanced humoral  
38 hypercalcemia of malignancy. *Journal of Bone and Mineral Research*, 4: 103-111.  
39 Not in PICO
- 40 Rapidis, A. D., Archondakis, G., Anteriotis, D. & Skouteris, C. A. (1997) Chondrosarcomas of the skull  
41 base: review of the literature and report of two cases. [Review] [29 refs]. *Journal of Cranio-*  
42 *Maxillo-Facial Surgery*, 25: 322-327.  
43 Not in PICO
- 44 Rattier, C., Rossi, D., Rossi, I., Siles, S., Coulange, C., Rampal, M. & Serment, G. (1995) Bone  
45 scintigraphy and classical prognostic factors in prostatic carcinoma at stage M1b. [French].  
46 *Medecine Nucleaire*, 19: 159-168.  
47 Not in PICO
- 48 Rawal, Y. B., Angiero, F., Allen, C. M., Kalmar, J. R., Sedghizadeh, P. P. & Steinhilber, A. M. (2006)  
49 Gnathic osteoblastoma: clinicopathologic review of seven cases with long-term follow-up. *Oral*  
50 *Oncology*, 42: 123-130.  
51 Not in PICO

- 1 Ray-Coquard, I., Montesco, M. C., Coindre, J. M., Dei Tos, A. P., Lurkin, A., Ranchere-Vince, D.,  
2 Vecchiato, A., Decouvelaere, A. V., Mathoulin-Pelissier, S., Albert, S., Cousin, P., Cellier, D.,  
3 Toffolatti, L., Rossi, C. R., Blay, J. Y. & Conticanet group (2012) Sarcoma: concordance between  
4 initial diagnosis and centralized expert review in a population-based study within three European  
5 regions. *Annals of Oncology*, 23: 2442-2449.  
6 Not in PICO
- 7 Reichelt, A. (1982) Clinical manifestations of primary malignant bone tumors. [German].  
8 *Therapiewoche*, 32: 321-324.  
9 Narrative review
- 10 Riley, R. D., Burchill, S. A., Abrams, K. R., Heney, D., Sutton, A. J., Jones, D. R., Lambert, P. C., Young,  
11 B., Wailoo, A. J. & Lewis, I. J. (2003) A systematic review of molecular and biological markers in  
12 tumours of the Ewing's sarcoma family. [Review] [84 refs]. *European Journal of Cancer*, 39: 19-30.  
13 Not in PICO
- 14 Robinson, L. A. (1997) Radioisotope-guided surgical biopsy of suspected osseous metastases. *Cancer*  
15 *Control*, 4: 517-522.  
16 Not in PICO
- 17 Romero, J., Exner, G. U., Hodler, J. & Von Hochstetter, A. R. (1991) Use of MRI in the differential  
18 diagnosis of fatigue fractures and bone tumors. [German]. *Zeitschrift fur Orthopadie und Ihre*  
19 *Grenzgebiete*, 129: 305-312.  
20 Not in PICO
- 21 Ropper, A. E., Cahill, K. S., Hanna, J. W., McCarthy, E. F., Gokaslan, Z. L. & Chi, J. H. (2011) Primary  
22 Vertebral Tumors: A Review of Epidemiologic, Histological, and Imaging Findings, Part I: Benign  
23 Tumors. *Neurosurgery*, 69: 1171-1180.  
24 Narrative review
- 25 Rowe, R. G., Thomas, D. G., Schuetze, S. M., Hafez, K. S., Lawlor, E. R. & Chugh, R. (2013) Ewing  
26 sarcoma of the kidney: case series and literature review of an often overlooked entity in the  
27 diagnosis of primary renal tumors. *Urology*, 81: 347-353.  
28 Not in PICO
- 29 Ruhs, S. A., el-Khoury, G. Y. & Chrischilles, E. A. (1996) A cost minimization approach to the diagnosis  
30 of skeletal neoplasms. *Skeletal Radiology*, 25: 449-454.  
31 Not in PICO
- 32 Saifuddin, A., Mitchell, R., Burnett, S. J., Sandison, A. & Pringle, J. A. (2000) Ultrasound-guided needle  
33 biopsy of primary bone tumours. *Journal of Bone & Joint Surgery - British Volume*, 82: 50-54.  
34 Not in PICO
- 35 Sampson, V. B., Gorlick, R., Kamara, D. & Anders, K. E. (2013) A review of targeted therapies  
36 evaluated by the pediatric preclinical testing program for osteosarcoma. *Frontiers in Oncology*, 3:  
37 132.  
38 Narrative review
- 39 Sato, N., Hino, M. & Sano, M. (2003) Detection of bone metastases in routine follow-up after  
40 treatment for primary breast cancer. *Breast Cancer*, 10: 335-340.  
41 Not in PICO
- 42 Scharf, S. & Zhao, Q. H. (1999) Radionuclide bone scanning in routine clinical practice. [Review] [10  
43 refs]. *Lippincott's Primary Care Practice*, 3: 521-528.  
44 Narrative review
- 45 Schatz, J., Soper, J., McCormack, S., Healy, M., Deady, L. & Brown, W. (2008) Imaging of tumors in  
46 the ankle and foot. *Techniques in Foot and Ankle Surgery*, 7: 208-223.  
47 Narrative review
- 48 Schmidt, G. P., Schoenberg, S. O., Reiser, M. F. & Baur-Melnyk, A. (2005) Whole-body MR imaging of  
49 bone marrow. [Review] [40 refs]. *European Journal of Radiology*, 55: 33-40.  
50 Narrative review

- 1 Schnurr, C., Pippan, M., Stuetzer, H., Delank, K. S., Michael, J. W. & Eysel, P. (2008) Treatment delay  
2 of bone tumours, compilation of a sociodemographic risk profile: a retrospective study. *BMC*  
3 *cancer*, 8: 22.  
4 Not in PICO
- 5 Schweiberer, L., Baumgart, R. & Zeiler, C. (1997) Instrumental diagnosis for therapy decision making-  
6 -what is possible and desirable, what is essential and what is superfluous?. [German].  
7 *Langenbecks Archiv fur Chirurgie*, Supplement.: 410-414.  
8 Narrative review
- 9 Scutellari, P. N., Addonisio, G., Righi, R. & Giganti, M. (2000) [Diagnostic imaging of bone  
10 metastases]. [Italian]. *Radiologia Medica*, 100: 429-435.  
11 Not in PICO
- 12 Scutellari, P. N., Antinolfi, G., Galeotti, R. & Giganti, M. (2003) [Metastatic bone disease. Strategies  
13 for imaging]. [Review] [46 refs] [Italian]. *Minerva Medica*, 94: 77-90.  
14 Not in PICO
- 15 Senac, M. O., Jr., Isaacs, H. & Gwinn, J. L. (1986) Primary lesions of bone in the 1st decade of life:  
16 retrospective survey of biopsy results. *Radiology*, 160: 491-495.  
17 Not in PICO
- 18 Sergieva, S. B., Alexandrova, E., Baichev, G., Nikolcheva, L., Milev, A. & Dimitrov, B. (2010) Clinical  
19 application of SPECT-CT in cancer patients with suspected bone metastases. *European Journal of*  
20 *Nuclear Medicine and Molecular Imaging*, 37: S440-S441.  
21 Not in PICO
- 22 Shaffer, K. A., Houghton, V. M. & Wilson, C. R. (1980) High resolution computed tomography of the  
23 temporal bone. *Radiology*, 134: 409-414.  
24 Not in PICO
- 25 Shie, P., Cardarelli, R., Brandon, D., Erdman, W. & Rahim, N. A. (2008) Meta-analysis: comparison of  
26 F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of  
27 bone metastases in patients with breast cancer (DARE structured abstract). *Clinical Nuclear*  
28 *Medicine*, 33: 97-101.  
29 Not in PICO
- 30 Siller, C. S. & Lewis, I. J. (2010) Update and review of the management of bone tumours. *Paediatrics*  
31 *and Child Health*, 20: 103-108.  
32 Narrative review
- 33 Skoldenberg, E., Soderberg, M., Wangberg, J. & Ljungman, G. (2011) Cutting needle biopsies in the  
34 management of childhood tumors. *Pediatric Blood and Cancer*, 57: 747.  
35 Not in PICO
- 36 Skotakova, J., Mach, V., Bajciová, V., Mudry, P. & Ondrus, S. (2006) Malignant tumors of long bones  
37 in children: Differential diagnosis and the role of imaging methods. [Czech]. *Acta Chirurgiae*  
38 *Orthopaedicae et Traumatologiae Cechoslovaca*, 73: 183-189.  
39 Not in PICO
- 40 Skrzynski, M. C., Biermann, S., Montag, A. & Simon, M. A. (1996) Diagnostic accuracy and charge-  
41 savings of outpatient core needle biopsy compared with open biopsy of musculoskeletal tumors  
42 (Structured abstract). *Journal of Bone and Joint Surgery.American volume.*, 78A: 644-649.  
43 Not in PICO
- 44 Smolarz, K., Jungehulsing, M., Krug, B., Linden, A., Gohring, U. J. & Schicha, H. (1990) [Magnetic  
45 resonance tomography of the bone marrow in cancer patients with a solitary area of increased  
46 uptake in the bone scintigram]. [German]. *Nuclear-Medizin*, 29: 269-273.  
47 Not in PICO
- 48 Soldani, S., Roni, P., Filidei, M., Castiglioni, M. & Riccioni, N. (1997) Diagnostic value of ultrasound-  
49 guided FNAB in the evaluation of osteolytic bone lesions suspected for metastases. [Italian].  
50 *Giornale Italiano di Ultrasonologia*, 8: 31-35.  
51 Not in PICO

- 1 Song, W. S., Jeon, D. G., Cho, W. H., Kong, C. B., Cho, S. H., Lee, J. W. & Lee, S. Y. (2014) - Plain  
2 radiologic findings and chronological changes of incipient phase osteosarcoma overlooked by  
3 primary physicians. - *Clinics in Orthopedic Surgery*, 6: 230-235.  
4 Not in PICO
- 5 Souza, F. F., de, A. M., O'Regan, K., Jagganathan, J., Krajewski, K. & Ramaiya, N. (2013) Malignant  
6 primary chest wall neoplasms: A pictorial review of imaging findings. *Clinical Imaging*, 37: 8-17.  
7 Not in PICO
- 8 Steinborn, M. M., Heuck, A. F., Tiling, R., Bruegel, M., Gauger, L. & Reiser, M. F. (1999) Whole-body  
9 bone marrow MRI in patients with metastatic disease to the skeletal system. *Journal of Computer  
10 Assisted Tomography*, 23: 123-129.  
11 Not in PICO
- 12 Steve, M., Ernenwein, D., Chaine, A., Bertolus, C., Goudot, P. & Ruhin-Poncet, B. (2011) [Jaw  
13 osteosarcomas]. [French]. *Revue de Stomatologie et de Chirurgie Maxillo-Faciale*, 112: 286-292.  
14 Not in PICO
- 15 Streitbuerger, A., Harges, J., Gebert, C., Ahrens, H., Winkelmann, W. & Gosheger, G. (882) [Cartilage  
16 tumours of the bone. Diagnosis and therapy]. [Review] [26 refs] [German]. *Orthopade*, 35: 871-  
17 881.  
18 Narrative review
- 19 Strobel, K., Exner, U. E., Stumpe, K. D., Hany, T. F., Bode, B., Mende, K., Veit-Haibach, P., von  
20 Schulthess, G. K. & Hodler, J. (2008) The additional value of CT images interpretation in the  
21 differential diagnosis of benign vs. malignant primary bone lesions with 18F-FDG-PET/CT.  
22 *European Journal of Nuclear Medicine & Molecular Imaging*, 35: 2000-2008.  
23 Not in PICO
- 24 Talbot, J.-N., Paycha, F. & Balogova, S. (2011) Diagnosis of bone metastasis: Recent comparative  
25 studies of imaging modalities. *Quarterly Journal of Nuclear Medicine and Molecular Imaging*, 55:  
26 374-410.  
27 Not in PICO
- 28 Tamiolakis, D., Tsamis, I., Thomaidis, V., Lambropoulou, M., Alexiadis, G., Venizelos, I., Jivanakis, T. &  
29 Papadopoulos, N. (2007) Oral complaints caused from metastases to the mandible and maxilla.  
30 *Chirurgia (Bucuresti)*, 102: 439-442.  
31 Not in PICO
- 32 Tan, J. Z., Schlicht, S. M., Powell, G. J., Thomas, D., Slavin, J. L., Smith, P. J. & Choong, P. F. (2006)  
33 Multidisciplinary approach to diagnosis and management of osteosarcoma - a review of the St  
34 Vincent's Hospital experience. *International Seminars in Surgical Oncology*, 3: 38.  
35 Not in PICO
- 36 Tanveer, N. & Mishra, K. (2014) - Chordoma Cutis - A Diagnosis not to be Missed. - *Journal of Clinical  
37 and Diagnostic Research JCDR*, 8: FD17-FD18.  
38 Not in PICO
- 39 Tappauf, M., Lackner, H., Sovinz, P., Schwinger, W., Benesch, M., Strenger, V., Schmidt, S. & Urban,  
40 C. (2011) Multifocal osseous involvement in a patient with Hodgkin lymphoma. *Monatsschrift fur  
41 Kinderheilkunde*, 159: 326.  
42 Not in PICO
- 43 Tateishi, U., Gladish, G. W., Kusumoto, M., Hasegawa, T., Yokoyama, R., Tsuchiya, R. & Moriyama, N.  
44 (2003) Chest Wall Tumors: Radiologic Findings and Pathologic Correlation - Part 2. Malignant  
45 Tumors. *Radiographics*, 23: 1491-1508.  
46 Not in PICO
- 47 Taylor, J. A. M. & Bussieres, A. (2012) Diagnostic imaging for spinal disorders in the elderly: a  
48 narrative review. *Chiropractic and Manual Therapies*, 20.  
49 Narrative review
- 50 Teo, H. E. & Peh, W. C. (2004) Primary bone tumors of adulthood. *Cancer Imaging*, 4: 74-83.  
51 Narrative review

- 1 Thorban, S., Roder, J. D. & Siewert, J. R. (1999) Detection of micrometastasis in bone marrow of  
2 pancreatic cancer patients. *Annals of Oncology*, 10: Suppl-3.  
3 Not in PICO
- 4 Thrall, J. H. & Ellis, B. I. (1987) Skeletal metastases. *Radiologic Clinics of North America*, 25: 1155-  
5 1170.  
6 Narrative review
- 7 Trigg, S. D. (2004) Biopsy of hand, wrist, and forearm tumors. *Hand Clinics*, 20: 131-135.  
8 Narrative review
- 9 Tucker, W. S. & Nasser-Sharif, F. J. (1997) Benign skull lesions. *Canadian Journal of Surgery*, 40: 449-  
10 455.  
11 Not in PICO
- 12 Ulaner, G., Hwang, S., Lefkowitz, R. A., Landa, J. & Panicek, D. M. (2013) Musculoskeletal tumors and  
13 tumor-like conditions: Common and avoidable pitfalls at imaging in patients with known or  
14 suspected cancer: Part A: Benign conditions that may mimic malignancy. *International*  
15 *Orthopaedics*, 37: 871-876.  
16 Narrative review
- 17 Ulaner, G., Hwang, S., Landa, J., Lefkowitz, R. A. & Panicek, D. M. (2013) Musculoskeletal tumours  
18 and tumour-like conditions: Common and avoidable pitfalls at imaging in patients with known or  
19 suspected cancer: Part B: Malignant mimics of benign tumours. *International Orthopaedics*, 37:  
20 877-882.  
21 Narrative review
- 22 Ulaner, G. A., Magnan, H., Healey, J. H., Weber, W. A. & Meyers, P. A. (2014) - Is methylene  
23 diphosphonate bone scan necessary for initial staging of Ewing sarcoma if 18F-FDG PET/CT is  
24 performed? - *AJR*, American Journal of Roentgenology. 202: 859-867.  
25 Not in PICO
- 26 van de Sande, M. A., Bramer, J. A., Jutte, P. C., Schreuder, H. W. & Dijkstra, P. D. (2010) [Diagnosis  
27 and treatment of bone metastasis]. [Review] [Dutch]. *Nederlands Tijdschrift Voor Geneeskunde*,  
28 154: A2125.  
29 Narrative review
- 30 Van Der Woude, H.-J., Verstraete, K. L., Hogendoorn, P. C. W., Taminiau, A. H. M., Hermans, J. &  
31 Bloem, J. L. (1998) Musculoskeletal tumors: Does fast dynamic contrast-enhanced subtraction  
32 MR imaging contribute to the characterization? *Radiology*, 208: 821-828.  
33 Not in PICO
- 34 Van Hoof, V. O., Van Oosterom, A. T., Lepoutre, L. G. & De Broe, M. E. (1992) Alkaline phosphatase  
35 isoenzyme patterns in malignant disease. *Clinical Chemistry*, 38: 2546-2551.  
36 Not in PICO
- 37 van, D. B. & Freyschmidt, J. (2002) [Standardized procedure for suspected bone tumor]. [German].  
38 *Chirurg*, 73: 1153-1161.  
39 Narrative review
- 40 Venkateswaran, L., Rodriguez-Galindo, C., Merchant, T. E., Poquette, C. A., Rao, B. N. & Pappo, A. S.  
41 (2001) Primary Ewing tumor of the vertebrae: Clinical characteristics, prognostic factors, and  
42 outcome. *Medical and Pediatric Oncology*, 37: 30-35.  
43 Not in PICO
- 44 Vieillard, M.-H., Boutry, N., Chastanet, P., Duquesnoy, B., Cotten, A. & Cortet, B. (2005) Contribution  
45 of percutaneous biopsy to the definite diagnosis in patients with suspected bone tumor. *Joint*  
46 *Bone Spine*, 72: 53-60.  
47 Not in PICO
- 48 Von Hochstetter, A. R. (1987) Suspected neoplastic lesion of bone: Biopsy planning by the  
49 pathologist. [German]. *Schweizerische Medizinische Wochenschrift*, 117: 1302-1306.  
50 Narrative review

- 1 Von Salis-Soglio, G. & Prietzel, T. (2002) Diagnostic procedures for suspected malignant tumors of  
2 bone and soft tissues. [German]. *Orthopade*, 31: 595-607.  
3 Narrative review
- 4 Wahane, R. N., Lele, V. R. & Bobhate, S. K. (2007) Fine needle aspiration cytology of bone tumors.  
5 *Acta Cytologica*, 51: 711-720.  
6 Not in PICO
- 7 Waimann, C. A., Lu, H. & Suarez Almazor, M. E. (2011) Rheumatic manifestations of primary and  
8 metastatic bone tumors and paraneoplastic bone disease. [Review]. *Rheumatic Diseases Clinics of*  
9 *North America*, 37: 527-549.  
10 Narrative review
- 11 Walther, C., Domanski, H. A., von Steyern, F. V., Mandahl, N. & Mertens, F. (2011) Chromosome  
12 banding analysis of cells from fine-needle aspiration biopsy samples from soft tissue and bone  
13 tumors: is it clinically meaningful? *Cancer genetics*, 204: 203-206.  
14 Not in PICO
- 15 Wang, K., Allen, L., Fung, E., Chan, C. C., Chan, J. C. & Griffith, J. F. (2005) Bone scintigraphy in  
16 common tumors with osteolytic components. [Review] [0 refs]. *Clinical Nuclear Medicine*, 30:  
17 655-671.  
18 Narrative review
- 19 Weissbach, L. (2006) [Diagnostic work-up of bone metastases of genitourinary tumors and their  
20 treatment with bisphosphonates. Interdisciplinary consensus conference, Frankfurt, 2006].  
21 [Review] [18 refs] [German]. *Urologe (Ausg.A)*, 45: 1527-1531.  
22 Not in PICO
- 23 Widhe, B., Widhe, T. & Bauer, H. C. (2007) Ewing sarcoma of the rib--initial symptoms and clinical  
24 features: tumor missed at the first visit in 21 of 26 patients. *Acta Orthopaedica*, 78: 840-844.  
25 Not in PICO
- 26 Widhe, B. & Bauer, H. C. (2011) Diagnostic difficulties and delays with chest wall chondrosarcoma: a  
27 Swedish population based Scandinavian Sarcoma Group study of 106 patients. *Acta Oncologica*,  
28 50: 435-440.  
29 Not in PICO
- 30 Winderen, M., Stenwig, A. E., Solheim, O. P., Saeter, G. & Aas, M. (1999) Dynamic bone scintigraphy  
31 for evaluation of tumor response after preoperative chemotherapy. A retrospective study of  
32 osteosarcoma and Ewing's sarcoma patients. *Acta Orthopaedica Scandinavica, Supplement*, 70:  
33 11-17.  
34 Not in PICO
- 35 Wisanuyotin, T., Mitchai, J., Sirichativapee, W., Kosuwon, W., Sumnanoont, C. & Jeeravipoolvarn, P.  
36 (2009) Tissue imprint for intra-operative evaluation of musculoskeletal tumors. *Journal of the*  
37 *Medical Association of Thailand*, 92: 654-659.  
38 Not in PICO
- 39 Wong, K. F., Chan, J. K. & Ma, S. K. (1993) Solid tumour with initial presentation in the bone marrow-  
40 -a clinicopathologic study of 25 adult cases. [Review] [15 refs]. *Hematological Oncology*, 11: 35-  
41 42.  
42 Not in PICO
- 43 Xie, J.-B., Chen, J.-T. & Song, X.-H. (2011) Diagnosis value of 18FDG-PET/CT and 99Tcm-MDP bone  
44 scan in bone metastases of tumors: A meta-analysis. *Chinese Journal of Evidence-Based Medicine*,  
45 11.  
46 Not in PICO
- 47 Xu, D. Y. (1988) [An X-ray analysis of 22 cases of malignant giant cell tumor of bone (with emphasis  
48 on reliable signs of early malignant changes). [Chinese]. *Chung-Hua Fang She Hsueh Tsa Chih*  
49 *Chinese Journal of Radiology*, 22: 208-211.  
50 Not in PICO

- 1 Yamamoto, Y., Kawaguchi, Y., Kawase, Y., Maeda, Y. & Nishiyama, Y. (2011) A comparative study of  
2 F-18 FDG PET and 201Tl scintigraphy for detection of primary malignant bone and soft-tissue  
3 tumors. *Clinical Nuclear Medicine*, 36: 290-294.  
4 Not in PICO
- 5 Yang, H. L., Liu, T., Wang, X. M., Xu, Y. & Deng, S. M. (2011) Diagnosis of bone metastases: a meta-  
6 analysis comparing 18FDG PET, CT, MRI and bone scintigraphy (DARE structured abstract).  
7 *European Radiology*, 21: 2604-2617.  
8 Not in PICO
- 9 Yang, Z. M., Shen, C. C., Li, H., Shi, Z. L. & Tao, H. M. (2012) Current treatment of sacral giant cell  
10 tumour of bone: A review. *Journal of International Medical Research*, 40: 415-425.  
11 Narrative review
- 12 Yao, L., Nelson, S. D., Seeger, L. L., Eckardt, J. J. & Eilber, F. R. (1999) Primary musculoskeletal  
13 neoplasms: Effectiveness of core-needle biopsy. *Radiology*, 212: 682-686.  
14 Not in PICO
- 15 Yasui, K., Kanazawa, S., Tanaka, A. & Hiraki, Y. (1996) [Percutaneous CT guided bone biopsy in  
16 patients with suspected bone neoplasm]. [Japanese]. *Nippon Igaku Hoshasen Gakkai Zasshi -*  
17 *Nippon Acta Radiologica*, 56: 178-182.  
18 Not in PICO
- 19 Young, P. S., Bell, S. W., MacDuff, E. M. & Mahendra, A. (2013) Primary osseous tumors of the  
20 hindfoot: why the delay in diagnosis and should we be concerned? *Clinical Orthopaedics &*  
21 *Related Research*, 471: 871-877.  
22 Not in PICO
- 23 Zeng, H., Kang, B., Liu, G. & Tang, X. (245) Ultrasonographic diagnosis of bone tumor of the knee and  
24 its clinical implication. *Journal of Tongji Medical University = Tong ji yi ke da xue xue bao*, 21: 236-  
25 237, 245.  
26 Not in PICO
- 27 Zhang, D., Chen, L., Ni, C.-F., Liu, Y.-Z., Jin, Y.-H., Zhu, X.-L. & Zou, J.-W. (2013) Percutaneous coaxial  
28 biopsy in diagnosis of musculoskeletal tumors. [Chinese]. *Chinese Journal of Medical Imaging*  
29 *Technology*, 29: 1493-1496.  
30 Not in PICO
- 31 Zhang, L., Li, J., Yang, H., Luo, Z. & Zou, J. (2012) Histological evaluation of bone biopsy results during  
32 PVP or PKP of vertebral compression fractures. *Oncology Letters*, 5: 135-138.  
33 Not in PICO
- 34 Zhang, X.-B., Zhang, X.-Z., Huang, Z.-G. & Wang, W. (2009) CT-guided percutaneous biopsy of  
35 malignant musculoskeletal tumors: An analysis of its diagnostic accuracy. [Chinese]. *Journal of*  
36 *Interventional Radiology*, 18: 834-837.  
37 Not in PICO
- 38 Zhao, H. & Wang, L. (2011) Whole body diffusion weighted imaging with background suppression for  
39 diagnosing bone metastases. [Chinese]. *Chinese Journal of Clinical Oncology*, 38: 677-679.  
40 Not in PICO
- 41 Zharkov, P. L. (2000) [Problems in the radiologic diagnosis of osteogenic sarcoma]. [Russian].  
42 *Voprosy Onkologii*, 46: 699-703.  
43 Narrative review
- 44 Zieger, M. (1982) [Diagnosis of occult skeletal metastasis: alkaline phosphatase versus skeletal  
45 scintigraphy]. [German]. *Medizinische Klinik - Praxis-Ausg*, 77: 44-50.  
46 Not in PICO
- 47 Zieger, M. (1982) Detection of occult bony metastasis: Alkaline phosphatase versus bony  
48 scintigraphy. [German]. *Medizinische Klinik*, 77: 360-363.  
49 Not in PICO
- 50 Zissimopoulos, A., Bantis, A., Stellos, K., Petrakis, G. & Matthaios, D. (2008) Association between  
51 bone scintigraphy and serum levels of procollagen (I) and PSA in the detection of bone disease in



1 prostate cancer patients. *Journal of B.U.On.*, 13: 69-74.  
 2 Not in PICO  
 3

#### 4 **SOFT TISSUE SARCOMA**

#### 5 **Review question:**

6 What is the risk of soft tissue sarcoma in patients presenting in primary care with symptom(s)?  
 7  
 8

#### 9 **Results**

#### 10 **Literature search**


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	All-2012	389	66	08/11/2012
<i>Premedline</i>	All-2012	26	6	08/11/2012
<i>Embase</i>	All-2012	287	63	08/11/2012
<i>Cochrane Library</i>	All-2012	82	0	08/11/2012
<i>Psychinfo</i>	All-2012	20	2	08/11/2012
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	All-2012	192	6	08/11/2012
<i>Biomed Central</i>	All-2012	128	4	08/11/2012

11 Total References retrieved (after de-duplication): 118  
 12

#### 13 **Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	11/2012-26/08/2014	61	2	26/08/2014
<i>Premedline</i>	11/2012-26/08/2014	56	4	26/08/2014
<i>Embase</i>	11/2012-26/08/2014	23	2	26/08/2014
<i>Cochrane Library</i>	11/2012-26/08/2014	27	0	26/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	11/2012-26/08/2014	25	0	26/08/2014


14 Total References retrieved (after de-duplication): 7



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11

**Risk of bias in the included studies**

The risk of bias and applicability concerns are summarised for the included study in the figure below. The main issue to note is that the study only presented results for bone and soft tissue sarcoma in combination and also employed a case-control design which has been shown to inflate the test accuracy characteristics. However, the statistical analyses employed by the authors may have gone some way in counteracting the influence of the latter.



12  
13  
14  
15  
16  
17

**Study results**

Table 1: Soft tissue sarcoma: Positive predictive values for child- or young adulthood bone cancer tumour/soft tissue sarcoma

Study	Symptom(s)	Patient group	Positive predictive value (95% CI) Frequency
Dommett (2013a)	Lump mass swelling below neck excluding	All included bone cancer tumour/soft	0.03 (0.01-0.14)

	abdomen 0-3 months before diagnosis	tissue sarcoma patients and controls aged 0-14 years	
Dommett (2013a)	Musculoskeletal symptoms 0-3 months before diagnosis	All included bone cancer tumour/soft tissue sarcoma patients and controls aged 0-14 years	0.01 (0-0.01)
Dommett (2013a)	Trauma 0-3 months before diagnosis	All included bone cancer tumour/soft tissue sarcoma patients and controls aged 0-14 years	0 (0-0)
Dommett (2013a)	≥ 3 consultations	All included bone cancer tumour/soft tissue sarcoma patients and controls aged 0-14 years	0 (0-0)
Dommett (2013b)	Lump mass swelling	All included bone cancer tumour/soft tissue sarcoma patients and controls aged 15-24 years	0.0415 (0.0124-0.1392) Cases: 19/196 Controls: 3/2438
Dommett (2013b)	Musculoskeletal symptoms	All included lymphoma patients and controls aged 15-24 years	0.0093 (0.0058-0.0151) Cases: 37/196 Controls: 26/2438
Dommett (2013b)	Chest pain	All included lymphoma patients and controls aged 15-24 years	0.0027 (0.001-0.0077) Cases: 5/196 Controls: 12/2438
Dommett (2013b)	≥ 3 consultations	All included lymphoma patients and controls aged 15-24 years	0.003 (0.0024-0.0037) Cases: 86/196 Controls: 189/2438

1 The positive predictive values are calculated using Bayesian statistics.

2 **Evidence statement(s):**

3 The positive predictive values of having childhood or young adulthood bone cancer tumour/soft  
4 tissue sarcoma ranged from 0% (for trauma) to 0.03% (for 'lump mass swelling below neck excluding  
5 abdomen') for patients aged 0-14 years old, and from 0.0027% (for chest pain) to 0.0415% (for 'lump  
6 mass swelling') for patients aged 15-24 years (1 study, N = 30855). The evidence quality is somewhat  
7 compromised by the case-control design of the study (see also Table 1).  
8

9 **Evidence tables**

10 **Dommett (2012; 2013a,b)**

**PATIENT SELECTION**

**A. risk of bias**

Patient sampling	Population-based nested case-control study using data from the General Practice Research Database (GPRD)	
Was a consecutive or random sample of patients enrolled?	No	
Was a case-control design avoided?	No	
Did the study avoid inappropriate exclusions?	Yes	
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?	Yes	
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?	Yes	
<b>Could the selection of patients have introduced bias?</b>	<b>High risk</b>	
<b><u>B. Concerns regarding applicability</u></b>		
Patient characteristics and setting	<p><u>Cases:</u> 1267 children; aged 0-4 years: N = 436; aged 5-14 years: N = 831; 703 males/564 females. Cancer type: Leukemia: N = 368; brain: N = 270; lymphoma: N = 142; bone: N = 107; soft tissue sarcoma: N = 91; renal: N = 82; neuroblastoma: N = 75; other ICD codes: N = 132. 1064 teenagers and young adults (TYA): 15-24 years: Gender not reported. Cancer type: Leukemia: N = 143; brain: N = 154; lymphoma: N = 270; bone: N = 96; soft tissue sarcoma: N = 100; other ICD codes: N = 301 (including testis: N = 60; skin: N = 49; ovary: N = 20 and thyroid: N = 17).</p> <p><u>Controls:</u> 15318 children; aged 0-4 years: N = 4802; aged 5-14 years: N = 10516; 8461 males/6857 females. 13206 TYA. Gender not reported</p> <p><u>Inclusion criteria:</u> The sample comprised all children and TYU aged 0–24 years, inclusive, drawn from all general practices contributing research-standard data to the GPRD between 1 January 1988 and 31 December 2010. To be included, the practices had to have been contributing research-standard data for a minimum of 1 year before each child’s date of cancer diagnosis or the index date (see below) for matched controls. Cases: Patients diagnosed with the following cancers: leukaemia, lymphoma, neuroblastoma, soft tissue sarcoma, hepatic, renal, bone and central nervous system tumours, using pre-defined medical codes used in the GPRD. The date of diagnosis for cases was defined as the date of pathological diagnosis, but if this was unavailable, the date of the first cancer code entered in the GPRD was used. Controls: Up to 13 controls (children with no diagnosis of cancer at any time) were selected per case, using a computer-generated random sequence, matched on age (within 1 year), sex and practice, and had to be currently registered on the date of diagnosis of their matched case (the index date).</p> <p><u>Exclusion criteria:</u> None listed <u>Clinical setting:</u> Primary care, UK.</p>	
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>	
<b>INDEX TEST</b>		

<b>A. Risk of bias</b>	
<b>Index test</b>	The GPRD uses just over 100 000 medical codes to encompass all primary care events, including both symptoms and diagnoses. From this list, libraries of codes were assembled representing individual alert symptoms derived from the NICE referral guidelines for suspected cancer in children. <i>No more information reported.</i>
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Cancer diagnosis in the UK's General Practice Research Database.
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients appear to be accounted for.
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	This study is published in three papers.

1

2

**References**

3

**Included studies**

4

Dommett, R. M., Redaniel, M. T., Stevens, M. C. G., Hamilton, W., and Martin, R. M. Features of childhood cancer in primary care: A population-based nested case-control study. *British Journal of Cancer* 106[5], 982-987. 2012.

6

7

Dommett, R. M., Redaniel, T., Stevens, M. C. G., Martin, R. M., and Hamilton, W. Risk of childhood cancer with symptoms in primary care: A population-based case-control study. *British Journal of General Practice*; DOI:10.3399/bjgp13X660742. 2013a.

8

9

- 1 Dommett, R. M., Redaniel, M. T., Stevens, M. C. G., Hamilton, W., and Martin, R. M. Features of  
 2 cancer in teenagers and young adults in primary care: A population-based nested case-control  
 3 study. *British Journal of Cancer* 2329-2333. 2013b.  
 4
- 5 **Excluded studies (with excl reason)**
- 6 (1998) Practice guidelines: uterine corpus--sarcomas. Society of Gynecologic Oncologists Clinical  
 7 Practice Guidelines. *Oncology (Williston Park)*, 12: 284-286.  
 8 Guideline
- 9 (2006) New report on childhood cancer shows early detection can save thousands of children's lives.  
 10 *European Journal of Oncology*, 11: 65-67.  
 11 Narrative review
- 12 Abbas, M., Dammrich, M. E., Braubach, P., Meinardus, A., Kramer, M. W., Merseburger, A. S.,  
 13 Herrmann, T. R., Grunwald, V. & Kreipe, H. H. (2014) - Synovial sarcoma of the kidney in a young  
 14 patient with a review of the literature. - *Rare Tumors*, 6: 5393.  
 15 Not in PICO
- 16 Abellan, J. F., Lamo De Espinosa, J. M., Duart, J., Patino-Garcia, A., Martin-Algarra, S., Martinez-  
 17 Monge, R. & San-Julian, M. (2009) Nonreferral of possible soft tissue sarcomas in adults: A  
 18 dangerous omission in policy. *Sarcoma*, 2009.  
 19 Not in PICO
- 20 Aboulafia, A. J., Levin, A. M. & Blum, J. (2002) Prereferral evaluation of patients with suspected bone  
 21 and soft tissue tumors. *Clinical Orthopaedics and Related Research*, 83-88.  
 22 Not in PICO
- 23 Ajekigbe, L. & Stothard, J. (2006) The effectiveness of sodium tetradecyl sulfate in the treatment of  
 24 wrist ganglia. *Canadian Journal of Plastic Surgery*, 14: 28-30.  
 25 Not in PICO
- 26 Alvegard, T., Sundby, H. K., Bauer, H. & Rydholm, A. (2009) The Scandinavian Sarcoma Group: 30  
 27 years' experience. *Acta Orthopaedica, Supplement*, 80: 1-104.  
 28 Not in PICO
- 29 Amstalden, E. M. I., Alvarenga, M., Goncalves, J. C. B. & Cassone, A. E. (2010) Perivascular epithelioid  
 30 cell tumor (PEComa) of bone and soft tissue - Relate of two cases. *Histopathology*, 57: 21.  
 31 Not in PICO
- 32 Anderson, B. D. & Schoenfeldt, M. (1330) Clinical trials referral resource. Current clinical trials in  
 33 rhabdomyosarcoma. *Oncology (Williston Park)*, 19: 1319-1320.  
 34 Not in PICO
- 35 Arbiser, Z. K., Folpe, A. L. & Weiss, S. W. (2001) Consultative (expert) second opinions in soft tissue  
 36 pathology. Analysis of problem-prone diagnostic situations. *American Journal of Clinical  
 37 Pathology*, 116: 473-476.  
 38 Not in PICO
- 39 Barzi, D. M., Sami, S. H. & Fallah, E. (2014) - Pseudo-aneurysm of anterior tibia artery simulating a  
 40 soft tissue sarcoma: a case report. - *Acta Medica Iranica*, 52: 234-237.  
 41 Not in PICO
- 42 Bennis, M., Dalsing, M., Sawchuck, A. & Wurtz, L. D. (2006) Soft tissue sarcomas may present with  
 43 deep vein thrombosis. *Journal of Vascular Surgery*, 43: 788-793.  
 44 Not in PICO
- 45 Bleyer, A. (2009) CAUTION! Consider Cancer: Common Symptoms and Signs for Early Detection of  
 46 Cancer in Young Adults. *Seminars in Oncology*, 36: 207-212.  
 47 Narrative review
- 48 Browder, D. A. & Erhard, R. E. (2005) Decision making for a painful hip: A case requiring referral.  
 49 *Journal of Orthopaedic & Sports Physical Therapy*, 35: 738-744.  
 50 Not in PICO

- 1 Bruns, J., Delling, G., Henne-Bruns, D. & Hossfeld, D. K. (2008) Biopsy of tumors of the  
2 musculoskeletal system. *Deutsches Arzteblatt International*, 105: 492-497.  
3 Narrative review
- 4 Bui, B. N., Blay, J. Y., Bonichon, F., Bonvalot, S., Chevalier-Place, A., Coindre, J. M., Delannes, M., Le  
5 Cesne, A., Morice, P., Ray-Coquard, I., Pautier, P., Le Pechoux, C., Stoeckle, E., Taieb, S. &  
6 Bosquet, L. (2007) Clinical practice guidelines: 2006. Update of recommendations for the  
7 management of patients with soft tissue sarcoma (sarcoma of the extremity, uterine sarcoma and  
8 retroperitoneal sarcoma). *Oncologie*, 9: 173-177.  
9 Guideline
- 10 Cerdan Carbonero, M. T., Sanz, L. R. & Martinez, R. C. (2005) Improving communication between  
11 levels of health care: Direct referral of patients to a "one-stop" service for major outpatient  
12 surgery. [Spanish]. *Atencion Primaria*, 35: 283-287.  
13 Not in PICO
- 14 Chadha, N. K. & Forte, V. (2009) Pediatric head and neck malignancies. [Review] [41 refs]. *Current*  
15 *Opinion in Otolaryngology & Head & Neck Surgery*, 17: 471-476.  
16 Narrative review
- 17 Chao, C., McMasters, K. M. & Edwards, M. J. (2002) Advances in the treatment of soft-tissue  
18 sarcomas. [Review] [21 refs]. *Journal of the Kentucky Medical Association*, 100: 10-16.  
19 Narrative review
- 20 Chaudrey, K., Naseer, T., Khan, S., Alexis, R., Grosman, I. & Zachary, K. (2010) Glomus tumor a  
21 diagnostic challenge-a report of 2 cases. *American Journal of Gastroenterology*, 105: S170-S171.  
22 Not in PICO
- 23 Chotel, F., Unnithan, A., Chandrasekar, C. R., Parot, R., Jeys, L. & Grimer, R. J. (2008) Variability in the  
24 presentation of synovial sarcoma in children: A plea for greater awareness. *Journal of Bone and*  
25 *Joint Surgery - Series B*, 90: 1090-1096.  
26 Not in PICO
- 27 Chou, L. B., Ho, Y. Y. & Malawer, M. M. (2009) Tumors of the foot and ankle: Experience with 153  
28 cases. *Foot and Ankle International*, 30: 836-841.  
29 Not in PICO
- 30 Clark, M. A. & Thomas, J. M. (2005) Delay in referral to a specialist soft-tissue sarcoma unit.  
31 *European Journal of Surgical Oncology*, 31: 443-448.  
32 Not in PICO
- 33 Coffin, C. M. & Dehner, L. P. (1998) Pathologic evaluation of pediatric soft tissue tumors. *American*  
34 *Journal of Clinical Pathology*, 109: S38-S52.  
35 Narrative review
- 36 Comba, P., Fazzo, L. & Berrino, F. (2004) [Soft tissue sarcomas in Mantua: epidemiological evidence  
37 and perspectives for environmental remediation]. [Italian]. *Epidemiologia e Prevenzione*, 28: 266-  
38 271.  
39 Not in PICO
- 40 Cooper, T. M., Sheehan, M., Collins, D. & O'Connor, T. P. (1996) Soft tissue sarcoma of the extremity.  
41 *Annals of the Royal College of Surgeons of England*, 78: 453-456.  
42 Not in PICO
- 43 Costani, G., Rabitti, P., Mambrini, A., Bai, E. & Berrino, F. (2000) Soft tissue sarcomas in the general  
44 population living near a chemical plant in Northern Italy. *Tumori*, 86: 381-383.  
45 Not in PICO
- 46 Cutts, S., Andrea, F., Piana, R. & Haywood, R. (2012) The management of soft tissue sarcomas.  
47 [Review]. *Surgeon Journal of the Royal Colleges of Surgeons of Edinburgh & Ireland*, 10: 25-32.  
48 Narrative review
- 49 Daigeler, A., Vogt, P. M., Busch, K., Pennekamp, W., Weyhe, D., Lehnhardt, M., Steinstraesser, L.,  
50 Steinau, H. U. & Kuhnen, C. (2007) Elastofibroma dorsi--differential diagnosis in chest wall

- 1 tumours. *World Journal of Surgical Oncology*, 5: 15.  
2 Not in PICO
- 3 Daigeler, A., Kuhnen, C., Hauser, J., Goertz, O., Tilkorn, D., Steintraesser, L., Steinau, H. U. &  
4 Lehnhardt, M. (2008) Alveolar soft part sarcoma: clinicopathological findings in a series of 11  
5 cases. *World Journal of Surgical Oncology*, 6: 71.  
6 Not in PICO
- 7 Damron, T. A. & Heiner, J. (2000) Distant soft tissue metastases: a series of 30 new patients and 91  
8 cases from the literature. [Review] [55 refs]. *Annals of Surgical Oncology*, 7: 526-534.  
9 Not in PICO
- 10 Damron, T. A., Beauchamp, C. P., Rougraff, B. T. & Ward, W. G. (2003) Soft-tissue lumps and bumps.  
11 *Journal of Bone and Joint Surgery - Series A*, 85: 1142-1155.  
12 Narrative review
- 13 Desandes, E., Lacour, B., Sommelet, D., White-Koning, M., Velten, M., Tretarre, B., Marr, A.,  
14 Maarouf, N., Guizard, A. V., Delafosse, P., Danzon, A., Cotte, C. & Brugieres, L. (2007) Cancer  
15 adolescent pathway in France between 1988 and 1997. *European Journal of Oncology Nursing*,  
16 11: 74-81.  
17 Not in PICO
- 18 Desandes, E., Bonnay, S., Berger, C., Brugieres, L., Clavel, J., Isfan, F., Lacour, B., Laurence, V.,  
19 Sommelet, D. & Tron, I. (2010) Quality of management of adolescents with cancer in France.  
20 *Pediatric Blood and Cancer*, 55: 789.  
21 Not in PICO
- 22 Didolkar, M. M., Anderson, M. E., Hochman, M. G., Rissmiller, J. G., Goldsmith, J. D., Gebhardt, M. G.  
23 & Wu, J. S. (2013) Image guided core needle biopsy of musculoskeletal lesions: Are nondiagnostic  
24 results clinically useful? *Clinical Orthopaedics and Related Research*, 471: 3601-3609.  
25 Not in PICO
- 26 Elliott, R. S., Flint, M. & French, G. (2012) Refer prior to biopsy of suspected appendicular soft tissue  
27 sarcoma. *New Zealand Medical Journal*, 125: 12-19.  
28 Not in PICO
- 29 Femiano, F., Cozzolino, S. & Malzone, A. (1990) [Gardner's syndrome]. [Italian]. *Archivio*  
30 *Stomatologico*, 31: 437-439.  
31 Narrative review
- 32 Fleegler, E. J. (1994) An approach to soft tissue sarcomas of the hand and upper limb. *Journal of*  
33 *Hand Surgery*, 19: 411-419.  
34 Narrative review
- 35 Fletcher, C. D. (2008) Undifferentiated sarcomas: what to do? And does it matter? A surgical  
36 pathology perspective. *Ultrastructural Pathology*, 32: 31-36.  
37 Not in PICO
- 38 Fletcher, C. D. (2014) - The evolving classification of soft tissue tumours - an update based on the  
39 new 2013 WHO classification. [Review]. - *Histopathology*, 64: 2-11.  
40 Narrative review
- 41 Fletcher, C. D. M. (2014) The evolving classification of soft tissue tumours - an update based on the  
42 new 2013 WHO classification. *Histopathology*, 64: 2-11.  
43 Narrative review
- 44 Forgie, S. & Robinson, J. (2007) Pediatric malignancies presenting as a possible infectious disease.  
45 *BMC Infectious Diseases*, 7: 44.  
46 Not in PICO
- 47 Frink, S. J., Snearly, W. & Parsons 3rd.T.W. (1998) Malignant tumors about the knee. *The American*  
48 *journal of knee surgery*, 11: 257-266.  
49 Narrative review



- 1 Gartner, L., Pearce, C. J. & Saifuddin, A. (2009) The role of the plain radiograph in the  
2 characterisation of soft tissue tumours. [Review] [43 refs]. *Skeletal Radiology*, 38: 549-558.  
3 Not in PICO
- 4 George, A. & Grimer, R. (2012) Early symptoms of bone and soft tissue sarcomas: Could they be  
5 diagnosed earlier? *Annals of the Royal College of Surgeons of England*, 94: e261-e266.  
6 Not in PICO
- 7 Giudice, G., Cardone, F., Giancaspero, G. & Vollono, E. (1996) Sarcomas of tissues: Risk and  
8 prognostic factors. [Italian]. *Rivista Italiana di Chirurgia Plastica*, 28: 95-100.  
9 Narrative review
- 10 Glencross, J., Balasubramanian, S. P., Bacon, J., Robinson, M. H. & Reed, M. W. (2003) An audit of the  
11 management of soft tissue sarcoma within a health region in the UK. *European Journal of Surgical  
12 Oncology*, 29: 670-675.  
13 Not in PICO
- 14 Gragera, M. B. G., Blanco, F. A. & Garcia, B. F. (1999) Nasopharyngeal cancer presented with cervical  
15 nodes. [Spanish]. *MEDIFAM - Revista de Medicina Familiar y Comunitaria*, 9: 50-54.  
16 Narrative review
- 17 Granowetter, L. Pediatric oncology: A medical overview. 9-34. 1994.  
18 Ref Type: Generic  
19 Ref ID: 114  
20 Reprint: Not in File  
21 Abstract: (from the chapter) present basic medical information about childhood cancer /  
22 [present] an overview of the characteristics, manifestations, and current thought regarding  
23 etiology / [present] information about establishing and explaining the diagnosis and treatment  
24 plans to the family / [discuss] the course and general principles of cancer treatment / [discuss]  
25 the most common pediatric malignancies [e.g., acute lymphoblastic and nonlymphoblastic  
26 leukemia, brain tumors, lymphomas, Wilms' tumor, neuroblastoma, bone tumors and soft tissue  
27 sarcomas, and retinoblastoma] / [summarize the] late effects of treatment (PsycINFO Database  
28 Record (c) 2012 APA, all rights reserved)  
29 Notes: DB - PsycINFO  
30 AN - Book: 1994-98308-001  
31 SO - Bearison, David J [Ed]; Mulhern, Raymond K [Ed]. (1994). Pediatric psychooncology:  
32 Psychological perspectives on children with cancer. (pp. 9-34). xvi, 247 pp. New York, NY, US:  
33 Oxford University Press; US  
34  
35 n
- 36 Grimer, R. J., Taylor, W. S. J., Carter, S. R., Tillman, R. M., Abudu, A. & Jeys, L. (2010) "Two-week  
37 waits" - Are they leading to earlier diagnosis of soft-tissue sarcomas? *Sarcoma*, 2010.  
38 Not in PICO
- 39 Grovas, A., Fremgen, A., Rauck, A., Ruymann, F. B., Hutchinson, C. L., Winchester, D. P. & Menck, H.  
40 R. (1997) The National Cancer Data Base report on patterns of childhood cancers in the United  
41 States. *Cancer*, 80: 2321-2332.  
42 Not in PICO
- 43 Gustafson, P., Dreinhofer, K. E. & Rydholm, A. (1994) Soft tissue sarcoma should be treated at a  
44 tumor center. A comparison of quality of surgery in 375 patients. *Acta Orthopaedica  
45 Scandinavica*, 65: 47-50.  
46 Not in PICO
- 47 Habrand, J. L. & Le, P. C. (2003) Local control of childhood and adult soft tissue sarcomas. *European  
48 Journal of Cancer, Supplement*, 1: 221-236.  
49 Not in PICO

- 1 Harms, D. (1995) New entities, concepts, and questions in childhood tumor pathology. *General &*  
2 *diagnostic pathology*, 141: 1-14.  
3 Narrative review
- 4 Hasegawa, T., Matsuno, Y., Shimoda, T., Umeda, T., Yokoyama, R. & Hirohashi, S. (2001) Proximal-  
5 type epithelioid sarcoma: a clinicopathologic study of 20 cases. *Modern Pathology*, 14: 655-663.  
6 Not in PICO
- 7 Heim-Hall, J. & Yohe, S. L. (2008) Application of immunohistochemistry to soft tissue neoplasms.  
8 [Review] [182 refs]. *Archives of Pathology & Laboratory Medicine*, 132: 476-489.  
9 Narrative review
- 10 Hogh, J., Sneppen, O., Nordentoft, A. M., Jensen, O. M. & Wethelund, J. O. (1988) [Extravisceral soft  
11 tissue sarcoma. Basis for referral and prognoses in 145 cases]. [Danish]. *Ugeskrift for Laeger*, 150:  
12 1408-1411.  
13 Not in PICO
- 14 Hooper, G. (2011) Sarcoma services in New Zealand. *New Zealand Medical Journal*, 124: 5-6.  
15 Not in PICO
- 16 Hussein, R. & Smith, M. A. (2005) Soft tissue sarcomas: are current referral guidelines sufficient?  
17 *Annals of the Royal College of Surgeons of England*, 87: 171-173.  
18 Not in PICO
- 19 Iqbal, C. W., St, P. S. & Ishitani, M. B. (2011) Pediatric dermatofibrosarcoma protuberans: multi-  
20 institutional outcomes. *Journal of Surgical Research*, 170: 69-72.  
21 Not in PICO
- 22 Johnson, G. D., Smith, G., Dramis, A. & Grimer, R. J. (2008) Delays in referral of soft tissue sarcomas.  
23 *Sarcoma*, 2008.  
24 Not in PICO
- 25 Joshi, A., Magar, S. R., Chand, P., Panth, R. & Khatri Chhetri, B. R. (2013) Tru-cut biopsy as the initial  
26 method of tissue diagnosis in bone tumors with soft tissue extension. *Indian Journal of*  
27 *Orthopaedics*, 47: 195-199.  
28 Not in PICO
- 29 Kim, S., Chun, M., Wang, H., Cho, S., Oh, Y. T., Kang, S. H. & Yang, J. (2007) Bone metastasis from  
30 primary hepatocellular carcinoma: characteristics of soft tissue formation. *Cancer Research &*  
31 *Treatment*, 39: 104-108.  
32 Not in PICO
- 33 Kleinerman, R., Schonfeld, S. & Tucker, M. (2012) Sarcomas in Hereditary Retinoblastoma. *Clinical*  
34 *Sarcoma Research*, 2: 15.  
35 Narrative review
- 36 Klosky, J. L. & Spunt, S. L. Sarcoma. [References]. 187-190. 2010.  
37 Ref Type: Generic  
38 Ref ID: 113  
39 Reprint: Not in File  
40 Abstract: (from the chapter) Bone and soft tissue sarcomas are a heterogeneous group of cancers  
41 that arise from primitive mesenchymal cells throughout the body. Population-based data suggest  
42 that these cancers account for approximately 0.9% of cancer cases overall, but 13% of cancers in  
43 pediatric patients. Aggressive multimodality therapy, including various combinations of surgery,  
44 chemotherapy, and radiotherapy, is generally necessary for cure. Currently, the overall 5-year  
45 survival rate of patients with bone and soft tissue sarcomas is about two-thirds of that of the  
46 general population. Thus, sarcomas produce considerable morbidity as well as mortality. This  
47 chapter reviews the major clinical features, treatment, and outcomes of bone and soft tissue  
48 sarcomas, and addresses the major psychological issues facing individuals affected by these rare  
49 tumors. (PsycINFO Database Record (c) 2012 APA, all rights reserved)  
50 Notes: DB - PsycINFO  
51 AN - Book: 2010-06876-025

- 1 SO - Holland, Jimmie C [Ed]; Breitbart, William S [Ed]; Jacobsen, Paul B [Ed]; Lederberg,  
2 Marguerite S [Ed]; Loscalzo, Matthew J [Ed]; McCorkle, Ruth [Ed]. (2010). *Psycho-oncology* (2nd  
3 ed.). (pp. 187-190). xxv, 685 pp. New York, NY, US: Oxford University Press; US  
4  
5 n
- 6 Kransdorf, M. J. (1995) Benign soft-tissue tumors in a large referral population: distribution of  
7 specific diagnoses by age, sex, and location. *AJR.American Journal of Roentgenology*, 164: 395-  
8 402.  
9 Not in PICO
- 10 Kurth, W. & Gillet, P. (2006) [Lumps and bumps. Diagnosis and management of soft-tissue tumors].  
11 [Review] [11 refs] [French]. *Revue Medicale de Liege*, 61: 763-770.  
12 Narrative review
- 13 Leinung, S., Schonfelder, M. & Wurl, P. (2004) [Differential diagnosis of soft tissue sarcomas].  
14 [German]. *Chirurg*, 75: 1159-1164.  
15 Not in PICO
- 16 Leinung, S., Mobius, C., Udelnow, A., Hauss, J. & Wurl, P. (2007) Histopathological outcome of 597  
17 isolated soft tissue tumors suspected of soft tissue sarcoma: a single-center 12-year experience.  
18 *European Journal of Surgical Oncology*, 33: 508-511.  
19 Not in PICO
- 20 Leithner, A. & Windhager, R. (2007) Bone and soft tissue tumors: Diagnostic principles. [German].  
21 *Wiener Medizinische Wochenschrift*, 157: 21-26.  
22 Narrative review
- 23 Lewis, C. & Cutts, S. (2004) Managing soft tissue tumours. *Practitioner*, 248: 828-834.  
24 Narrative review
- 25 Leyvraz, S. & Costa, J. (1988) [Interdisciplinary detection of soft tissue sarcomas. Diagnosis, grading  
26 and staging]. [Review] [44 refs] [German]. *Orthopade*, 17: 121-127.  
27 Narrative review
- 28 Lopez-Terrada, D. (2006) Integrating the diagnosis of childhood malignancies. [Review] [77 refs].  
29 *Advances in Experimental Medicine & Biology*, 587: 121-137.  
30 Narrative review
- 31 Luba, M. C., Bangs, S. A., Mohler, A. M. & Stulberg, D. L. (2003) Common benign skin tumors.  
32 [Review] [36 refs]. *American Family Physician*, 67: 729-738.  
33 Narrative review
- 34 MacIntyre, J. (2007) Pharmacologic application of sunitinib malate in the management of  
35 gastrointestinal stromal tumors. [Review] [23 refs]. *Clinical Journal of Oncology Nursing*, 11: 237-  
36 241.  
37 Narrative review
- 38 Malik, A., Wigney, L., Murray, S. & Gerrand, C. H. (2007) The effectiveness of "two-week" referrals  
39 for suspected bone and soft tissue sarcoma. *Sarcoma*, 2007: 23870.  
40 Not in PICO
- 41 Mastrangelo, G., Fadda, E., Cegolon, L., Montesco, M. C., Ray-Coquard, I., Buja, A., Fedeli, U.,  
42 Frasson, A., Spolaore, P. & Rossi, C. R. (2010) A European project on incidence, treatment, and  
43 outcome of sarcoma. *BMC Public Health*, 10: 188.  
44 Not in PICO
- 45 Mendez, M. C., Muinos, Y., Blanco, G., Saornil, M. A., Garcia-Alvarez, C., Sarasa, J. L. & Valbuena, C.  
46 (2012) Embryonal rhabdomyosarcoma of the caruncle in a 4 year-old boy: case report. *Arquivos*  
47 *Brasileiros de Oftalmologia*, 75: 207-209.  
48 Not in PICO
- 49 Merchant, S., Cheifetz, R., Knowling, M., Khurshed, F. & McGahan, C. (2012) Practice referral  
50 patterns and outcomes in patients with primary retroperitoneal sarcoma in British Columbia.

- 1 *American Journal of Surgery*, 203: 632-638.  
2 Not in PICO
- 3 Miettinen, M. (2006) From morphological to molecular diagnosis of soft tissue tumors. [Review] [70  
4 refs]. *Advances in Experimental Medicine & Biology*, 587: 99-113.  
5 Narrative review
- 6 Miron, I., Miron, L., Dumitras, S., Aprodu, G., Ciobanu, A. & Tansanu, I. (2007) [Statistical study of the  
7 evolution over ten years of the clinical and therapeutic approach in childhood soft tissue  
8 sarcoma]. [Romanian]. *Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi*,  
9 111: 358-362.  
10 Not in PICO
- 11 Myhre-Jensen, O. (1981) A consecutive 7-year series of 1331 benign soft tissue tumours.  
12 Clinicopathologic data. Comparison with sarcomas. *Acta Orthopaedica Scandinavica*, 52: 287-  
13 293.  
14 Not in PICO
- 15 Nijhuis, P. H., Schaapveld, M., Otter, R. & Hoekstra, H. J. (2001) Soft tissue sarcoma--compliance with  
16 guidelines. *Cancer*, 91: 2186-2195.  
17 Not in PICO
- 18 Patel, S. R., Zagars, G. K. & Pisters, P. W. (2003) The follow-up of adult soft-tissue sarcomas. [Review]  
19 [15 refs]. *Seminars in Oncology*, 30: 413-416.  
20 Narrative review
- 21 Pencavel, T. D., Strauss, D. C., Thomas, G. P., Thomas, J. M. & Hayes, A. J. (2010) Does the two-week  
22 rule pathway improve the diagnosis of soft tissue sarcoma? A retrospective review of referral  
23 patterns and outcomes over five years in a regional sarcoma centre. *Annals of the Royal College  
24 of Surgeons of England*, 92: 417-421.  
25 Not in PICO
- 26 Penel, N., Valentin, F., Giscard, S., Vanseymortier, L. & Beuscart, R. (2007) General practitioners  
27 assessment of a structured report on medical decision making by a regional multidisciplinary  
28 cancer committee. *Bulletin du Cancer*, 94: E23-E26.  
29 Not in PICO
- 30 Perrier, L., Buja, A., Mastrangelo, G., Vecchiato, A., Sandona, P., Ducimetiere, F., Blay, J. Y., Gilly, F.  
31 N., Siani, C., Biron, P., Ranchere-Vince, D., Decouvelaere, A. V., Thiesse, P., Bergeron, C., Dei Tos,  
32 A. P., Coindre, J. M., Rossi, C. R. & Ray-Coquard, I. (2012) Clinicians' adherence versus non  
33 adherence to practice guidelines in the management of patients with sarcoma: a cost-  
34 effectiveness assessment in two European regions. *BMC Health Services Research*, 12: 82.  
35 Not in PICO
- 36 Persson, B. M. & Rydholm, A. (1986) Soft-tissue masses of the locomotor system. A guide to the  
37 clinical diagnosis of malignancy. *Acta Orthopaedica Scandinavica*, 57: 216-219.  
38 Not in PICO
- 39 Pignolo, R. J., Shore, E. M. & Kaplan, F. S. (2011) Fibrodysplasia ossificans progressiva: clinical and  
40 genetic aspects. [Review]. *Orphanet Journal Of Rare Diseases*, 6: 80.  
41 Narrative review
- 42 Pinkerton, R., Sommelet, D., Brunat-Mentigny, M., Farsi, F., Martel, I., Philip, T., Ranchere-Vince, D.  
43 & Thiesse, P. (1998) Standards, Options and Recommendations (SOR) for clinical care of  
44 rhabdomyosarcoma (RMS) and other soft tissue sarcoma in children. *Bulletin du Cancer*, 85:  
45 1015-1042.  
46 Guideline
- 47 Pitcher, M. E., Fish, S. & Thomas, J. M. (1994) Management of soft tissue sarcoma. *British Journal of  
48 Surgery*, 81: 1136-1139.  
49 Not in PICO

- 1 Plate, A. M., Steiner, G. & Posner, M. A. (2006) Malignant tumors of the hand and wrist. *The Journal*  
2 *of the American Academy of Orthopaedic Surgeons*, 14: 680-692.  
3 Narrative review
- 4 Prakash, P. K. & Hanna, F. W. (256) Differential diagnosis of neck lumps. [Review] [2 refs].  
5 *Practitioner*, 246: 252-254.  
6 Narrative review
- 7 Qadir, I., Umer, M., Umer, H., Uddin, N., Karsan, F. & Rabbani, S. (2012) Managing soft tissue  
8 sarcomas in a developing country: are prognostic factors similar to those of developed world?  
9 *World Journal of Surgical Oncology*, 10: 188.  
10 Not in PICO
- 11 Raees-Karami, S. R., Jafarieh, H., Ziyayi, V., Foumani, R. S. & Aghighi, Y. (2012) Evaluation of 20 years  
12 experience of fibrodysplasia ossificans progressiva in Iran: Lessons for early diagnosis and  
13 prevention. *Clinical Rheumatology*, 31: 1133-1137.  
14 Not in PICO
- 15 Ramos-Pascua, L. R., Sanchez-Herraez, S., Casas-Ramos, P., Izquierdo-Garcia, F. J. & Maderuelo-  
16 Fernandez, J. A. (2014) - [Health care circuit for patients with soft tissue sarcomas of the  
17 extremities. A tortuous and slow road to referral units]. [Spanish]. - *Revista Espanola de Cirugia*  
18 *Ortopedica y Traumatologia*, 58: 160-170.  
19 Not in PICO
- 20 Randall, R. L., Mann, J. A. & Johnston, J. O. (1996) Orthopedic soft-tissue tumors. Concepts for the  
21 primary care physician. [Review] [51 refs]. *Primary Care; Clinics in Office Practice*, 23: 241-261.  
22 Narrative review
- 23 Randall, R. L., Bruckner, J. D., Papenhausen, M. D., Thurman, T. & Conrad, E. U., III (2004) Errors in  
24 diagnosis and margin determination of soft-tissue sarcomas initially treated at non-tertiary  
25 centers. *Orthopedics*, 27: 209-212.  
26 Not in PICO
- 27 Ray-Coquard, I., Thiesse, P., Ranchere-Vince, D., Chauvin, F., Bobin, J. Y., Sunyach, M. P., Carret, J. P.,  
28 Mongodin, B., Marec-Berard, P., Philip, T. & Blay, J. Y. (2004) Conformity to clinical practice  
29 guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas.  
30 *Annals of Oncology*, 15: 307-315.  
31 Not in PICO
- 32 Rigor, B. M., Sr. (2000) Pelvic cancer pain. [Review] [46 refs]. *Journal of Surgical Oncology*, 75: 280-  
33 300.  
34 Narrative review
- 35 Romanus, B., Lindahl, S. & Stener, B. (1986) Accessory soleus muscle. A clinical and radiographic  
36 presentation of eleven cases. *Journal of Bone & Joint Surgery - American Volume*, 68: 731-734.  
37 Not in PICO
- 38 Rooser, B., Rydholm, A. & Alvegard, T. (1987) Centralization of soft tissue sarcoma. Status in Sweden  
39 in 1982. *Acta Orthopaedica Scandinavica*, 58: 641-644.  
40 Not in PICO
- 41 Rose, C., Stovall, E., Ganz, P. A., Desch, C. & Hewitt, M. (2008) Cancer Quality Alliance: Blueprint for a  
42 better cancer care system. *CA: A Cancer Journal for Clinicians*, 58: 266-292.  
43 Narrative review/not in PICO
- 44 Rougraff, B. T., Lawrence, J. & Davis, K. (2012) Length of symptoms before referral: prognostic  
45 variable for high-grade soft tissue sarcoma? *Clinical Orthopaedics & Related Research*, 470: 706-  
46 711.  
47 Not in PICO
- 48 Rydholm, A. (1992) Soft tissue lesions in adults: biopsy--yes or no? *Annals of Oncology*, 3: Suppl-8.  
49 Not in PICO

- 1 Rydholm, A. (1997) Centralization of soft tissue sarcoma. The southern Sweden experience. *Acta*  
2 *Orthopaedica Scandinavica.Supplementum*, 273: 4-8.  
3 Not in PICO
- 4 Seleye-Fubara, D., Nwosu, S. O. & Yellowe, B. E. (2005) Soft tissue sarcomas in the Niger Delta Region  
5 of Nigeria (a referral hospital's study).[Erratum appears in Niger J Med. 2005 Oct-Dec;14(4):461  
6 Note: Bob-Yellowe, E [corrected to Yellowe, BE]]. *Nigerian Journal of Medicine: Journal of the*  
7 *National Association of Resident Doctors of Nigeria*, 14: 188-194.  
8 Not in PICO
- 9 Shah, H., Bhurgri, Y. & Pervez, S. (2005) Malignant Smooth Muscle Tumours of Soft Tissue - A  
10 demographic and clinicopathological study at a tertiary care hospital. *Journal of the Pakistan*  
11 *Medical Association*, 55: 138-143.  
12 Not in PICO
- 13 Sharif, M. A. & Hamdani, S. N. (2010) Second opinion and discrepancy in the diagnosis of soft tissue  
14 lesions at surgical pathology. *Indian journal of pathology & microbiology*, 53: 460-464.  
15 Not in PICO
- 16 Sinha, S. & Peach, A. H. (2010) Diagnosis and management of soft tissue sarcoma. [Review]. *BMJ*,  
17 341: c7170.  
18 Narrative review
- 19 Stachowicz-Stencel, T. & Bien, E. (2007) Bone pains in malignant disorders in children. *Family*  
20 *Medicine and Primary Care Review*, 9: 859-861.  
21 Narrative review
- 22 Strauss, D. C., Qureshi, Y. A., Hayes, A. J., Thway, K., Fisher, C. & Thomas, J. M. (2010) The role of  
23 core needle biopsy in the diagnosis of suspected soft tissue tumours. *Journal of Surgical*  
24 *Oncology*, 102: 523-529.  
25 Not in PICO
- 26 Styring, E., Billing, V., Hartman, L., Nilbert, M., Seinen, J. M., Veurink, N., Vult von, S. F. & Rydholm, A.  
27 (2012) Simple guidelines for efficient referral of soft-tissue sarcomas: a population-based  
28 evaluation of adherence to guidelines and referral patterns. *Journal of Bone & Joint Surgery -*  
29 *American Volume*, 94: 1291-1296.  
30 Not in PICO
- 31 Thway, K. & Fisher, C. (2009) Histopathological diagnostic discrepancies in soft tissue tumours  
32 referred to a specialist centre. *Sarcoma*, 2009.  
33 Not in PICO
- 34 Trishkin, V. A. & Stoliarov, V. I. (1988) [Difficulties and errors in the ambulatory diagnosis of soft  
35 tissue sarcomas]. [Russian]. *Khirurgiia.(11):100-3, 1988 Nov.*, 100-103.  
36 Russian. Looks like narrative review
- 37 Trishkin, V. A., Vesnin, A. G., Stoliarov, V. I., Semenov, I. I., Novikov, A. I. & Chibisova, M. A. (1994) [A  
38 comparative analysis of the current methods for the outpatient diagnosis of soft tissue tumors].  
39 [Russian]. *Vestnik Khirurgii Imeni i - i - Grekova*, 152: 93-98.  
40 Not in PICO
- 41 Tsel', E. A. (1986) [Complex diagnosis of soft tissue tumors under ambulatory conditions]. [Russian].  
42 *Voprosy Onkologii*, 32: 68-71.  
43 Not in PICO
- 44 Tunn, P.-U. & Schlag, P. M. (1995) Early detection of soft tissue and limbs tumours. [German].  
45 *Onkologie*, 18: 61-63.  
46 Narrative review
- 47 Venkatesan, M., Richards, C. J., McCulloch, T. A., Perks, A. G., Raurell, A., Ashford, R. U. & East  
48 Midlands Sarcoma Service (2012) Inadvertent surgical resection of soft tissue sarcomas. *European*  
49 *Journal of Surgical Oncology*, 38: 346-351.  
50 Not in PICO

1 Vogt, T. (249) [Angiosarcoma]. [Review] [27 refs] [German]. *Hautarzt*, 59: 237-248.

2 Narrative review

3 Warzecha, J., Kamand, A., Daecke, W. & Meurer, A. (2010) [Benign soft tissue tumors in  
4 orthopedics]. [Review] [German]. *Orthopade*, 39: 1171-1180.

5 Narrative review

6 Weber, R., Knaup, P., Knietig, R., Haux, R., Merzweiler, A., Mludek, V., Schilling, F. H. & Wiedemann,  
7 T. (2001) Object-oriented business process analysis of the cooperative soft tissue sarcoma trial of  
8 the german society for paediatric oncology and haematology (GPOH). *Studies in Health  
9 Technology & Informatics*, 84: 1-62.

10 Not in PICO

11 Williams, J. E., Kuo, P. Y., Yen, J. T. C., Parker, G. M., Chapman, S., Kandikattu, S., Sohanpal, I. &  
12 Barbachano, Y. (2011) The prevalence of pain in patients attending sarcoma outpatient clinics.  
13 *Sarcoma*, 2011.

14 Not in PICO

15 Williams, K. J. & Hayes, A. J. (2014) - A guide to oncological management of soft tissue tumours of  
16 the abdominal wall. - *Hernia*, 18: 91-97.

17 Narrative review/Not in PICO

18 Zacherl, M., Kastner, N., Glehr, M., Scheipl, S., Schwantzer, G., Koch, H., Leithner, A. & Windhager, R.  
19 (2012) Influence of prereferral surgery in soft tissue sarcoma: 10 years' experience in a single  
20 institution. *Orthopedics*, 35: e1214-e1220.

21 Not in PICO

## 23 Review question:

24 Which investigations of symptoms of suspected soft tissue sarcoma should be done with clinical  
25 responsibility retained by primary care?

## 27 Results

### 28 Literature search

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1980-2013	164	33	20/06/2013
<i>Premedline</i>	1980-2013	14	3	24/06/2013
<i>Embase</i>	1980-2013	145	51	24/06/2013
<i>Cochrane Library</i>	1980-2013	34	3	24/06/2013
<i>Psychinfo</i>	1980-2013	0	0	24/06/2013
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	1980-2013	47	10	24/06/2013


29 Total References retrieved (after de-duplication): 74

### 31 Update Search

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	6/2013- 26/08/2014	3	0	26/08/2014
<i>Premedline</i>	6/2013- 26/08/2014	17	2	26/08/2014
<i>Embase</i>	6/2013- 26/08/2014	21	3	26/08/2014
<i>Cochrane Library</i>	6/2013- 26/08/2014	10	0	26/08/2014

<b>Web of Science (SCI &amp; SSCI) and ISI Proceedings</b>	6/2013-26/08/2014	11	1	26/08/2014
--	-------------------	----	---	------------

1 Total References retrieved (after de-duplication): 6



2

### 3 Study results

4 No evidence was identified pertaining to the diagnostic accuracy of ultrasound in patients with  
5 suspected soft tissue sarcoma where the clinical responsibility was retained by primary care.

6

### 7 References

#### 8 Included studies

9 None

10

#### 11 Excluded studies (with excl reason)

12 Abellan, J. F., Lamo De Espinosa, J. M., Duart, J., Patino-Garcia, A., Martin-Algarra, S., Martinez-  
13 Monge, R. & San-Julian, M. (2009) Nonreferral of possible soft tissue sarcomas in adults: A  
14 dangerous omission in policy. *Sarcoma*, 2009.

15 Not in PICO

16 Aboulafia, A. J., Levin, A. M. & Blum, J. (2002) Prereferral evaluation of patients with suspected bone  
17 and soft tissue tumors. *Clinical Orthopaedics and Related Research*, 83-88.

18 Not in PICO

19 Adams, S. C., Potter, B. K., Pitcher, D. J. & Temple, H. T. (2010) Office-based core needle biopsy of  
20 bone and soft tissue malignancies: an accurate alternative to open biopsy with infrequent  
21 complications. *Clinical Orthopaedics and Related Research*, 468: 2774-2780.

22 Not in PICO

23 Akerman, M., Idvall, I. & Rydholm, A. (1980) Cytodiagnosis of soft tissue tumors and tumor-like  
24 conditions by means of fine needle aspiration biopsy. *Archives of Orthopaedic and Traumatic  
25 Surgery*, 96: 61-67.

26 Not in PICO

27 Andreou, D. & Tunn, P. U. (2009) Sentinel node biopsy in soft tissue sarcoma. *Recent Results in  
28 Cancer Research*, Fortschritte: 25-36.

29 Narrative review



- 1 Arya, S., Nagarkatti, D. G., Dudhat, S. B., Nadkarni, K. S., Joshi, M. S. & Shinde, S. R. (2000) Soft tissue  
2 sarcomas: Ultrasonographic evaluation of local recurrences. *Clinical Radiology*, 55: 193-197.  
3 Not in PICO
- 4 Bastiaannet, E., Groen, H., Jager, P. L., Cobben, D. C., Graaf, W. T., Vaalburg, W. & Hoekstra, H. J.  
5 (2004) The value of FDG-PET in the detection, grading and response to therapy of soft tissue and  
6 bone sarcomas: a systematic review and meta-analysis (DARE structured abstract). *Cancer*  
7 *Treatment Reviews.*, 30: 83-101.  
8 Not in PICO
- 9 Bennis, M., Dalsing, M., Sawchuck, A. & Wurtz, L. D. (2006) Soft tissue sarcomas may present with  
10 deep vein thrombosis. *Journal of Vascular Surgery*, 43: 788-793.  
11 Not in PICO
- 12 Benson, C. & Judson, I. (2014) Role of expert centres in the management of sarcomas - A UK  
13 perspective. *European Journal of Cancer*, 50: 1951-1956.  
14 Narrative review
- 15 Bredella, M. A., Caputo, G. R. & Steinbach, L. S. (2002) Value of FDG positron emission tomography in  
16 conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal  
17 sarcomas. *American Journal of Roentgenology*, 179: 1145-1150.  
18 Not in PICO
- 19 Bui, B. N., Blay, J. Y., Bonichon, F., Bonvalot, S., Chevalier-Place, A., Coindre, J. M., Delannes, M., Le  
20 Cesne, A., Morice, P., Ray-Coquard, I., Pautier, P., Le Pechoux, C., Stoeckle, E., Taieb, S. &  
21 Bosquet, L. (2007) Clinical practice guidelines: 2006. Update of recommendations for the  
22 management of patients with soft tissue sarcoma (sarcoma of the extremity, uterine sarcoma and  
23 retroperitoneal sarcoma). *Oncologie*, 9: 173-177.  
24 Not in PICO
- 25 Bui, N. B., Stockle, E., Coindre, J. M., Kantor, G., Kind, M. & Thomas, L. (1996) Locally advanced soft  
26 tissue sarcoma of the thoracic wall. *Bulletin du Cancer*, 83: 335-343.  
27 Not in PICO
- 28 Coates, M. (2003) Ultrasound and soft-tissue mass lesions - A note of caution. *New Zealand Medical*  
29 *Journal*, 116.  
30 Narrative review
- 31 Coffin, C. M. & Dehner, L. P. (1998) Pathologic evaluation of pediatric soft tissue tumors. *American*  
32 *Journal of Clinical Pathology*, 109: S38-S52.  
33 Narrative review
- 34 Comandone, A., Berno, E., Boglione, A., Oliva, C., Ingui', M., Linari, A., Giubellino, E., Gino, G., Del  
35 Prever, E. M. B., Faletti, C., Piana, R., Turbiglio, M., Monasterolo, G., Pochettino, P., Dal, C. O.,  
36 Cutin, S. C. & Bergnolo, P. (2012) Delay in diagnosis and treatment of soft tissue sarcomas (STS):  
37 Causes of late intervention and their role in prognosis-A prospective, multidisciplinary group  
38 study. *Journal of Clinical Oncology*, 30.  
39 Not in PICO
- 40 Datir, A., James, S. L. J., Ali, K., Lee, J., Ahmad, M. & Saifuddin, A. (2008) MRI of soft-tissue masses:  
41 the relationship between lesion size, depth, and diagnosis. *Clinical Radiology*, 63: 373-378.  
42 Not in PICO
- 43 Didolkar, M. M., Anderson, M. E., Hochman, M. G., Rissmiller, J. G., Goldsmith, J. D., Gebhardt, M. G.  
44 & Wu, J. S. (2013) Image guided core needle biopsy of musculoskeletal lesions: Are nondiagnostic  
45 results clinically useful? *Clinical Orthopaedics and Related Research*, 471: 3601-3609.  
46 Not in PICO
- 47 Domett, R., Stevens, M., Redaniel, T., Hamilton, W. & Martin, R. (2013) Features of cancer in  
48 teenagers and young adults (TYA) presenting to primary care in the uk: A population-based  
49 nested case-control study. *Pediatric Blood and Cancer*, 60: 3.  
50 Already included

- 1 Elliott, R. S., Flint, M. & French, G. (2012) Refer prior to biopsy of suspected appendicular soft tissue  
2 sarcoma. *New Zealand Medical Journal*, 125: 12-19.  
3 Not in PICO
- 4 Eyesan, S. U., Idowu, O. K. & Mbah, O. (2014) Referral for bone and soft tissue tumors: New pathway  
5 for resource constrained health care systems. *Journal of Clinical Oncology*, 32.  
6 Not in PICO
- 7 Fisher, C. & Thway, K. (2006) Pathology of tumours of soft tissue. *Surgery*, 24: 402-406.  
8 Narrative review
- 9 Fleming, J. B., Cantor, S. B., Varma, D. G. K., Holst, D., Feig, B. W., Hunt, K. K., Patel, S. R., Benjamin,  
10 R. S., Pollock, R. E. & Pisters, P. W. T. (2001) Utility of chest computed tomography for staging in  
11 patients with T1 extremity soft tissue sarcomas. *Cancer*, 92: 863-868.  
12 Not in PICO
- 13 Fletcher, C. D. M. (2014) The evolving classification of soft tissue tumours - an update based on the  
14 new 2013 WHO classification. *Histopathology*, 64: 2-11.  
15 Narrative review
- 16 Hayes, A. J., Alexander, N., Clark, M. A. & Thomas, J. M. (2004) Elastofibroma: A rare soft tissue  
17 tumour with a pathognomonic anatomical location and clinical symptom. *European Journal of  
18 Surgical Oncology*, 30: 450-453.  
19 Not in PICO
- 20 Heim-Hall, J. & Yohe, S. L. (2008) Application of immunohistochemistry to soft tissue neoplasms.  
21 *Archives of Pathology and Laboratory Medicine*, 132: 476-489.  
22 Narrative review
- 23 Høglund, M., Muren, C. & Brattstrom, G. (1997) A statistical model for ultrasound diagnosis of soft-  
24 tissue tumours in the hand and forearm. *Acta radiologica (Stockholm, Sweden : 1987)*, 38: 355-  
25 358.  
26 Not in PICO
- 27 Ioannidis, J. P. & Lau, J. (2002) Positron emission tomography (FDG) for soft tissue sarcoma (STS)  
28 (DARE structured abstract). *Database of Abstracts of Reviews of Effects.*, 57.  
29 Not in PICO
- 30 Jager, P. L., Plaat, B. E., de Vries, E. G., Molenaar, W. M., Vaalburg, W., Piers, D. A. & Hoekstra, H. J.  
31 (2000) Imaging of soft-tissue tumors using L-3-[iodine-123]iodo-alpha-methyl-tyrosine single  
32 photon emission computed tomography: comparison with proliferative and mitotic activity,  
33 cellularity, and vascularity. *Clinical Cancer Research*, 6: 2252-2259.  
34 Not in PICO
- 35 Joshi, A., Magar, S. R., Chand, P., Panth, R. & Khatri Chhetri, B. R. (2013) Tru-cut biopsy as the initial  
36 method of tissue diagnosis in bone tumors with soft tissue extension. *Indian Journal of  
37 Orthopaedics*, 47: 195-199.  
38 Not in PICO
- 39 Karpeh, M. S., Brennan, M. F., Cance, W. G., Woodruff, J. M., Pollack, D., Casper, E. S., Dudas, M. E.,  
40 Latres, E., Drobnjak, M. & Cordon-Cardo, C. (1995) Altered patterns of retinoblastoma gene  
41 product expression in adult soft-tissue sarcomas. *British Journal of Cancer*, 72: 986-991.  
42 Not in PICO
- 43 Kaufman, M., Pinkenson, M., Krigmont, M. & Weissberg, D. (1980) Fine needle aspiration for  
44 cytologic diagnosis. [Hebrew]. *Harefuah*, 98: 105-106+148.  
45 Not in PICO
- 46 Kind, M., Stock, N. & Coindre, J. M. (2009) Histology and imaging of soft tissue sarcomas. *European  
47 Journal of Radiology*, 72: 6-15.  
48 Narrative review
- 49 Lakkaraju, A., Sinha, R., Garikipati, R., Edward, S. & Robinson, P. (2009) Ultrasound for initial  
50 evaluation and triage of clinically suspicious soft-tissue masses. *Clinical Radiology*, 64: 615-621.  
51 Not in PICO

- 1 Le Bleu, P. T. & Steffes, J. (2014) Malignant fibrous histiocytoma: An evaluation of what lies beneath.  
2 *Journal of the American Academy of Dermatology*, 70: AB48.  
3 Not in PICO
- 4 Lewis, C. & Cutts, S. (2004) Managing soft tissue tumours. *Practitioner*, 248: 828-834.  
5 Narrative review
- 6 Leyvraz, S. & Costa, J. (1988) Interdisciplinary detection of soft tissue sarcomas. Diagnosis, grading  
7 and staging. [German]. *Der Orthopade*, 17: 121-127.  
8 Narrative review
- 9 Leyvraz, S. & Costa, J. (1988) Histological diagnosis and grading of soft-tissue sarcomas. *Seminars in*  
10 *Surgical Oncology*, 4: 3-6.  
11 Narrative review
- 12 Liu, J. C., Chiou, H. J., Chen, W. M., Chou, Y. H., Chen, T. H., Chen, W., Yen, C. C., Chiu, S. Y. & Chang,  
13 C. Y. (2004) Sonographically guided core needle biopsy of soft tissue neoplasms. *Journal of*  
14 *Clinical Ultrasound*, 32: 294-298.  
15 Not in PICO
- 16 Lucas, J. D., O'Doherty, M. J., Cronin, B. F., Marsden, P. K., Lodge, M. A., McKeet, P. H. & Smith, M. A.  
17 (1999) Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose  
18 positron emission tomography. *British Journal of Surgery*, 86: 550-556.  
19 Not in PICO
- 20 Marcantonio, D. R., Weatherall, P. T. & Berrey Jr, B. H. (1998) Practical considerations in the imaging  
21 of soft tissue tumors. *Orthopedic Clinics of North America*, 29: 1-17.  
22 Narrative review
- 23 Marzano, L., Failoni, S., Gallazzi, M. & Garbagna, P. (2004) The role of diagnostic imaging in synovial  
24 sarcoma. Our experience. [Italian, English]. *Radiologia Medica*, 107: 533-540.  
25 Not in PICO
- 26 Mastrangelo, G., Fadda, E., Cegolon, L., Montesco, M. C., Ray-Coquard, I., Buja, A., Fedeli, U.,  
27 Frasson, A., Spolaore, P. & Rossi, C. R. (2010) A European project on incidence, treatment, and  
28 outcome of sarcoma. *BMC Public Health*, 10: 188.  
29 Not in PICO
- 30 Mende, U., Ewerbeck, V., Krempien, B., Ludwig, R., Peichardt, P., Troger, J., Zoller, J. & Braun, A.  
31 (1992) Sonography in the therapy-related diagnosis and follow-up of primary bone and soft tissue  
32 tumors. [German]. *Bildgebung/Imaging*, 59: 4-14.  
33 Not in PICO
- 34 Miron, I., Miron, L., Dumitras, S., Aprodu, G., Ciobanu, A. & Tansanu, I. (2007) Statistical study of the  
35 evolution over ten years of the clinical and therapeutic approach in childhood soft tissue  
36 sarcoma. [Romanian]. *Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi*,  
37 111: 358-362.  
38 Not in PICO
- 39 Mohr, Z., Hirche, C., Klein, T., Kneif, S. & Hunerbein, M. (2012) Vacuum-assisted minimally invasive  
40 biopsy of soft-tissue tumors. *Journal of Bone and Joint Surgery - Series A*, 94: 103-109.  
41 Not in PICO
- 42 Myhre-Jensen, O. (1981) A consecutive 7-year series of 1331 benign soft tissue tumours.  
43 Clinicopathologic data. Comparison with sarcomas. *Acta Orthopaedica Scandinavica*, 52: 287-  
44 293.  
45 Not in PICO
- 46 Narvani, A. A., Tsiridis, E., Saifuddin, A., Briggs, T. & Cannon, S. (2009) Does image guidance improve  
47 accuracy of core needle bio in diagnosis of soft tissue tumours? *Acta Orthopaedica Belgica*, 75:  
48 239-244.  
49 Not in PICO

- 1 Neeff, H. & Imdahl, A. (2005) Soft-tissue tumors: primary excision or wait and see?. [German]. *MMW*  
2 *Fortschritte der Medizin*, 147: 41-43.  
3 Narrative review
- 4 Nishimura, H. (2001) Diagnosis of soft tissue tumors: 10 checkpoints. [Japanese]. *Nihon Igaku*  
5 *Hoshasen Gakkai zasshi*, Nippon: 275-291.  
6 Narrative review
- 7 Nobauer-Huhmann, I. M. (2014) - [Soft tissue tumors : Imaging strategy for local primary diagnostics  
8 - manifestation, pearls and pitfalls in MRI]. [German]. - *Radiologe*, 54: 803-818.  
9 Narrative review
- 10 Noebauer-Huhmann, I., Krssak, M., Amann, G., Panotopoulos, J., Funovics, P., Fruehwald-Pallamar,  
11 J., Weber, M., Kainberger, F. & Trattinig, S. (2011) Soft tissue tumours at 3 Tesla MRI: Influence of  
12 a myxoid matrix on diffusion weighted imaging. *Skeletal Radiology*, 40: 811.  
13 Not in PICO
- 14 Papandreou, I., Moschouris, H., Papadopoulos, G., Papadaki, E., Gerle, Z. & Papadaki, M. (2011)  
15 Ultrasound and color doppler imaging in the evaluation of soft tissue lumps in infants and  
16 children. *Acta Paediatrica, International Journal of Paediatrics*, 100: 52.  
17 Not in PICO
- 18 Pedersen, L., Balslev, I., Guldhammer, B. & Rose, C. (1988) Repeated fine needle aspirations in the  
19 diagnosis of soft tissue metastases in breast cancer. *European Journal of Cancer and Clinical*  
20 *Oncology*, 24: 1039-1040.  
21 Not in PICO
- 22 Pencavel, T. D., Strauss, D. C., Thomas, G. P., Thomas, J. M. & Hayes, A. J. (2010) Does the two-week  
23 rule pathway improve the diagnosis of soft tissue sarcoma? A retrospective review of referral  
24 patterns and outcomes over five years in a regional sarcoma centre. *Annals of the Royal College*  
25 *of Surgeons of England*, 92: 417-421.  
26 Not in PICO
- 27 Penel, N., Valentin, F., Giscard, S., Vanseymortier, L. & Beuscart, R. (2007) General practitioners  
28 assessment of a structured report on medical decision making by a regional multidisciplinary  
29 cancer committee. *Bulletin du Cancer*, 94: E23-E26.  
30 Not in PICO
- 31 Perek-Polnik, M., Filipek, I., Dembowska-Baginska, B., Owsik, A., Drogosiewicz, M., Jurkiewicz, E. &  
32 Perek, D. (2006) [Children with neurofibroma type 1 treated in the Children's Memorial Health  
33 Institute]. [Polish]. *Medycyna Wieku Rozwojowego*, 10: 699-709.  
34 Not in PICO
- 35 Pinkerton, R., Sommelet, D., Brunat-Mentigny, M., Farsi, F., Martel, I., Philip, T., Ranchere-Vince, D.  
36 & Thiesse, P. (1998) Standards, Options and Recommendations (SOR) for clinical care of  
37 rhabdomyosarcoma (RMS) and other soft tissue sarcoma in children. *Bulletin du Cancer*, 85:  
38 1015-1042.  
39 Guideline
- 40 Porter, G. A., Cantor, S. B., Ahmad, S. A., Lenert, J. T., Ballo, M. T., Hunt, K. K., Feig, B. W., Patel, S. R.,  
41 Benjamin, R. S., Pollock, R. E. & Pisters, P. W. (2002) Cost-effectiveness of staging computed  
42 tomography of the chest in patients with T2 soft tissue sarcomas (Structured abstract). *Cancer*,  
43 94: 197-204.  
44 Not in PICO
- 45 Qureshi, Y., Strauss, D., Hayes, A. & Thomas, J. (2009) Accuracy of core needle biopsy in the diagnosis  
46 of soft tissue tumours. *European Journal of Surgical Oncology*, 35: 1210-1211.  
47 Not in PICO
- 48 Rahim, R. R., Schenker, M., Barry, R. B. M. & Langtry, J. A. A. (2011) Lack of consensus in the surgical  
49 treatment of cutaneous granular cell tumours. *British Journal of Dermatology*, 165: 102.  
50 Not in PICO

- 1 Randall, R. L., Mann, J. A. & Johnston, J. O. (1996) Orthopedic soft-tissue tumors - Concepts for the  
2 primary care physician. *Primary Care*, 23: 241-&  
3 Narrative review
- 4 Randall, R. L., Bruckner, J. D., Papenhausen, M. D., Thurman, T. & Conrad III, E. U. (2004) Errors in  
5 diagnosis and margin determination of soft-tissue sarcomas initially treated at non-tertiary  
6 centers. *Orthopedics*, 27: 209-212.  
7 Not in PICO
- 8 Ray-Coquard, I., Thiesse, P., Ranchere-Vince, D., Chauvin, F., Bobin, J. Y., Sunyach, M. P., Carret, J. P.,  
9 Mongodin, B., Marec-Berard, P., Philip, T. & Blay, J. Y. (2004) Conformity to clinical practice  
10 guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas.  
11 *Annals of Oncology*, 15: 307-315.  
12 Not in PICO
- 13 Roic, G., Ercegovic, S., Vlahovic, T., Cop, S., Bumci, I. & Visnjic, S. (1999) Sonographic diagnosis of  
14 soft-tissue foreign bodies in children. *Radiology and Oncology*, 33: 189-192.  
15 Not in PICO
- 16 Rosenthal, T. C. & Kraybill, W. (1999) Soft tissue sarcomas: Integrating primary care recognition with  
17 tertiary care center treatment. *American Family Physician*, 60: 567-572.  
18 Narrative review
- 19 Rowbotham, E., Bhuva, S., Gupta, H. & Robinson, P. (2012) Assessment of referrals into the soft  
20 tissue sarcoma service: Evaluation of imaging early in the pathway process. *Sarcoma*, 2012.  
21 Not in PICO
- 22 Rydholm, A., Akerman, M., Idvall, I. & Persson, B. M. (1982) Aspiration cytology of soft tissue  
23 tumours. A prospective study of its influence on choice of surgical procedure. *International*  
24 *Orthopaedics*, 6: 209-214.  
25 Not in PICO
- 26 Rydholm, A. (1983) Management of patients with soft-tissue tumors. Strategy developed at a  
27 regional oncology center. *Acta Orthopaedica Scandinavica*, 54.  
28 Not in PICO
- 29 Sakata, K., Johnson, F. E., Beitler, A. L., Kraybill, W. G. & Virgo, K. S. (2003) Extremity soft tissue  
30 sarcoma patient follow-up: tumor grade and size affect surveillance strategies after potentially  
31 curative surgery. *International Journal of Oncology*, 22: 1335-1343.  
32 Not in PICO
- 33 Schatz, J., Soper, J., McCormack, S., Healy, M., Deady, L. & Brown, W. (2008) Imaging of tumors in  
34 the ankle and foot. *Techniques in Foot and Ankle Surgery*, 7: 208-223.  
35 Narrative review
- 36 Schmitt, R., Warmuth-Metz, M., Lanz, U., Lucas, D., Feyerabend, T. & Schindler, G. (1990) [Computed  
37 tomography of soft tissue tumors of the hand and the forearm]. [German]. *Radiologe*, 30: 185-  
38 192.  
39 Not in PICO
- 40 Schulte, M., Brecht-Krauss, D., Heymer, B., Guhlmann, A., Hartwig, E., Sarkar, M. R., Diederichs, C. G.,  
41 Schultheiss, M., Kotzerke, J. & Reske, S. N. (1999) Fluorodeoxyglucose positron emission  
42 tomography of soft tissue tumours: is a non-invasive determination of biological activity possible?  
43 *European Journal of Nuclear Medicine*, 26: 599-605.  
44 Not in PICO
- 45 Seleye-Fubara, D., Nwosu, S. O. & Yellowe, B. E. (2005) Soft tissue sarcomas in the Niger Delta Region  
46 of Nigeria (a referral hospital's study). *Nigerian journal of medicine : journal of the National*  
47 *Association of Resident Doctors of Nigeria*, 14: 188-194.  
48 Not in PICO
- 49 Silk, A. W. & Schuetze, S. M. (2012) Histology-specific therapy for advanced soft tissue sarcoma and  
50 benign connective tissue tumors. *Current Treatment Options in Oncology*, 13: 285-298.  
51 Not in PICO

- 1 Strauss, D. C., Qureshi, Y. A., Hayes, A. J., Thway, K., Fisher, C. & Thomas, J. M. (2010) The role of  
2 core needle biopsy in the diagnosis of suspected soft tissue tumours. *Journal of Surgical*  
3 *Oncology*, 102: 523-529.  
4 Not in PICO
- 5 Suresh, S., Saifuddin, A. & O'Donnell, P. (2008) Lymphoma presenting as a musculoskeletal soft  
6 tissue mass: MRI findings in 24 cases. *European Radiology*, 18: 2628-2634.  
7 Not in PICO
- 8 Thunnissen, F. B. J. M., Kroese, A. H., Ambergen, A. W., Peterse, J. L., Jansen, J. W., Ladde, B. E.,  
9 vanPel, R., Tiebosch, A. T. M. G. & Schaafsma, W. (1997) Which cytological criteria are the most  
10 discriminative to distinguish carcinoma, lymphoma, and soft-tissue sarcoma? A probabilistic  
11 approach. *Diagnostic Cytopathology*, 17: 333-338.  
12 Not in PICO
- 13 Thway, K. & Fisher, C. (2009) Histopathological diagnostic discrepancies in soft tissue tumours  
14 referred to a specialist centre. *Sarcoma*, 2009.  
15 Not in PICO
- 16 Trishkin, V. A. & Bykov, S. A. (1988) [Direct angioscintigraphy of soft tissue sarcomas in outpatient  
17 diagnosis]. [Russian]. *Voprosy Onkologii*, 34: 1374-1378.  
18 Not in PICO
- 19 Trishkin, V. A., Vesnin, A. G., Stoliarov, V. I., Semenov, I. I., Novikov, A. I. & Chibisova, M. A. (1994) [A  
20 comparative analysis of the current methods for the outpatient diagnosis of soft tissue tumors].  
21 [Russian]. *Vestnik Khirurgii Imeni i - i - Grekova*, 152: 93-98.  
22 Narrative review
- 23 Tsukushi, S., Nishida, Y., Wasa, J., Urakawa, H. & Ishiguro, N. (2011) Clinicopathological assessment  
24 of T1 soft tissue sarcomas. *Archives of Orthopaedic and Trauma Surgery*, 131: 695-699.  
25 Not in PICO
- 26 Wainwright, K. & Wegner, E. (2013) Incidental finding of a soft tissue sarcoma on bone scan. *Internal*  
27 *Medicine Journal*, 43: 26-27.  
28 Not in PICO
- 29 Waldt, S., Rechl, H., Rummeny, E. J. & Woertler, K. (2003) Imaging of benign and malignant soft  
30 tissue masses of the foot. [Review] [34 refs]. *European Radiology*, 13: 1125-1136.  
31 Narrative review  
32  
33

**CHILDHOOD CANCERS****NEUROBLASTOMA, RETINOBLASTOMA, WILM'S TUMOUR****Review question:**

What is the risk of neuroblastoma, retinoblastoma and Wilm's tumour in children presenting in primary care with symptom(s)?

**Results****Literature search****Neuroblastoma:**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	All-2012	384	29	14/11/2012
<i>Premedline</i>	All-2012	19	0	14/11/2012
<i>Embase</i>	All-2012	198	28	14/11/2012
<i>Cochrane Library</i>	All-2012	59	1	14/11/2012
<i>Psychinfo</i>	All-2012	14	0	14/11/2012
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	All-2012	33	5	14/11/2012
<i>Biomed Central</i>	All-2012	166	1	14/11/2012

Total References retrieved (after de-duplication): 45

**Neuroblastoma: Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	11/2012-27/08/2014	8	1	27/08/2014
<i>Premedline</i>	11/2012-27/08/2014	49	1	27/08/2014
<i>Embase</i>	11/2012-27/08/2014	62	2	27/08/2014
<i>Cochrane Library</i>	11/2012-27/08/2014	21	0	27/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	11/2012-27/08/2014	6	1	27/08/2014

Total References retrieved (after de-duplication): 5

**Retinoblastoma:**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	All-2012	576	62	15/11/2012
<i>Premedline</i>	All-2012	13	3	14/11/2012
<i>Embase</i>	All-2012	386	62	15/11/2012
<i>Cochrane Library</i>	All-2012	67	0	15/11/2012
<i>Psychinfo</i>	All-2012	1	0	15/11/2012
<i>Web of Science (SCI</i>	All-2012	30	8	15/11/2012

<b>&amp; SSCI) and ISI Proceedings</b>				
<b>Biomed Central</b>	All-2012	75	0	15/11/2012

1 Total References retrieved (after de-duplication): 83

2

3 **Retinoblastoma: Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<b>Medline</b>	11/2012-27/08/2014	28	4	27/08/2014
<b>Premedline</b>	11/2012-27/08/2014	31	1	27/08/2014
<b>Embase</b>	11/2012-27/08/2014	51	2	27/08/2014
<b>Cochrane Library</b>	11/2012-27/08/2014	64	1	27/08/2014
<b>Web of Science (SCI &amp; SSCI) and ISI Proceedings</b>	11/2012-27/08/2014	10	0	27/08/2014

4 Total References retrieved (after de-duplication): 4

5

6

7 **Wilm's tumour:**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<b>Medline</b>	All-2012	281	53	13/11/2012
<b>Premedline</b>	All-2012	20	3	13/11/2012
<b>Embase</b>	All-2012	311	55	14/11/2012
<b>Cochrane Library</b>	All-2012	34	0	14/11/2012
<b>Psychinfo</b>	All-2012	0	0	13/11/2012
<b>Web of Science (SCI &amp; SSCI) and ISI Proceedings</b>	All-2012	7	3	14/11/2012
<b>Biomed Central</b>	All-2012	4	0	14/11/2012

8 Total References retrieved (after de-duplication): 93


9

10 **Wilm's tumour: Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<b>Medline</b>	11/2012-27/08/2014	20	3	27/08/2014
<b>Premedline</b>	11/2012-27/08/2014	45	2	27/08/2014
<b>Embase</b>	11/2012-27/08/2014	33	0	27/08/2014
<b>Cochrane Library</b>	11/2012-27/08/2014	22	0	27/08/2014
<b>Web of Science (SCI &amp; SSCI) and ISI Proceedings</b>	11/2012-27/08/2014	2	0	27/08/2014

11 Total References retrieved (after de-duplication): 3






1  
2  
3  
4  
5  
6  
7  
8  
9

**Risk of bias in the included studies**

The risk of bias and applicability concerns are summarised for the included study in the figure below. The main issue to note is that the study employed a case-control design which has been shown to inflate the test accuracy characteristics. However, the statistical analyses employed by the authors may have gone some way in counteracting this influence.



10  
11  
12  
13  
14  
15

**Study results**

Table 1: Childhood cancers (neuroblastoma, retinoblastoma, Wilm’s tumour): Positive predictive values for any childhood cancer: Patients aged 0-14 years

Study	Symptom(s)	Patient group	Positive predictive value (95% CI) Frequency
Dommett (2012)	Any NICE alert symptom 0-3 months before diagnosis	All included patients	0.055 (0.047-0.065) Cases: 342/1267 Control: 211/15318
Dommett (2012)	Any NICE alert symptom 0-12 months before	All included patients	0.07 (0.064-0.078) Cases: 427/1267

	diagnosis		Control: 829/15318
Dommett (2012)	Neurological symptoms 0-12 months before diagnosis	All included patients	0.083 (0.067-0.105) Cases: 108/1267 Control: 207/15318
Dommett (2012)	Headache 0-12 months before diagnosis	All included patients	0.064 (0.051-0.082) Cases: 90/1267 Control: 224/15318
Dommett (2013a)	Headache 0-3 months before diagnosis	All included patients	0.06 (0.04-0.08) Cases: 73/1267 Control: 55/15318
Dommett (2013a)	Headache 0-3 months before diagnosis and $\geq 3$ consultations	All included patients	0.13 (0.08-0.22)
Dommett (2012)	Lymphadenopathy 0-12 months before diagnosis	All included patients	0.096 (0.074-0.126) Cases: 82/1267 Control: 136/15318
Dommett (2013a)	Lymphadenopathy 0-3 months before diagnosis	All included patients	0.09 (0.06-0.13) Cases: 69/1267 Control: 33/15318
Dommett (2013a)	Lymphadenopathy 0-3 months before diagnosis and $\leq 3$ consultations	All included patients	0.2 (0.1-0.39)
Dommett (2012)	Lump/mass/swelling 0-12 months before diagnosis	All included patients	0.172 (0.119-0.25) Cases: 56/1267 Control: 52/15318
Dommett (2013a)	Lump/mass/swelling below neck excluding abdomen 0-3 months before diagnosis	All included patients	0.11 (0.06-0.2) Cases: 42/1267 Control: 16/15318
Dommett (2013a)	Lump/mass/swelling below neck excluding abdomen 0-3 months before diagnosis and $\geq 3$ consultations	All included patients	0.3 (0.09-0.99)
Dommett (2012)	Fatigue 0-12 months before diagnosis	All included patients	0.085 (0.06-0.121) Cases: 47/1267 Control: 88/15318
Dommett (2013a)	Fatigue 0-12 months before diagnosis	All included patients	0.07 (0.04-0.12) Cases: 42/1267 Control: 24/15318
Dommett (2013a)	Fatigue 0-12 months before diagnosis and $\geq 3$ consultations	All included patients	0.12 (0.06-0.23)
Dommett (2012)	Back pain 0-12 months before diagnosis	All included patients	0.088 (0.06-0.128) Cases: 40/1267 Control: 73/15318
Dommett (2012)	Bruising 0-12 months before diagnosis	All included patients	0.08 (0.054-0.118) Cases: 38/1267 Control: 76/15318
Dommett (2013a)	Bruising 0-3 months before diagnosis	All included patients	0.08 (0.05-0.13) Cases: 33/1267

			Control: 18/15318
Dommett (2013a)	Bruising 0-3 months before diagnosis and $\geq 3$ consultations	All included patients	0.38 (0.09-1.64)
Dommett (2013a)	Pallor 0-3 months before diagnosis	All included patients	0.41 (0.12-1.34) Cases: 33/1267 Control: 18/15318
Dommett (2013a)	Pallor 0-3 months before diagnosis and $\geq 3$ consultations	All included patients	0.76 (0.1-5.7)
Dommett (2013a)	Lump mass swelling head and neck 0-3 months before diagnosis	All included patients	0.3 (0.1-0.84) Cases: 28/1267 Control: 4/15318
Dommett (2013a)	Lump mass swelling head and neck 0-3 months before diagnosis and $\leq 3$ consultations	All included patients	0.76 (0.1-5.7)
Dommett (2013a)	Abnormal movement 0-3 months before diagnosis	All included patients	0.08 (0.04-0.14) Cases: 49/1267 Control: 26/15318
Dommett (2013a)	Abnormal movement 0-3 months before diagnosis and $\geq 3$ consultations	All included patients	0.15 (0.07-0.32)
Dommett (2013a)	Bleeding 0-3 months before diagnosis	All included patients	0.06 (0.03-0.1) Cases: 28/1267 Control: 21/15318
Dommett (2013a)	Bleeding 0-3 months before diagnosis and $\geq 3$ consultations	All included patients	0.11 (0.04-0.31)
Dommett (2013a)	Visual symptoms 0-3 months before diagnosis	All included patients	0.06 (0.03-0.1) Cases: 28/1267 Control: 21/15318
Dommett (2013a)	Visual symptoms 0-3 months before diagnosis and $\leq 3$ consultations	All included patients	0.23 (0.07-0.77)
Dommett (2013a)	Pain 0-3 months before diagnosis	All included patients	0.04 (0.03-0.06) Cases: 42/1267 Control: 41/15318
Dommett (2013a)	Pain 0-3 months before diagnosis and $\geq 3$ consultations	All included patients	0.14 (0.07-0.31)
Dommett (2013a)	Musculoskeletal symptoms 0-3 months before diagnosis	All included patients	0.04 (0.03-0.07) Cases: 107/1267 Control: 102/15318
Dommett (2013a)	Musculoskeletal symptoms 0-3 months before diagnosis and $\geq 3$ consultations	All included patients	0.13 (0.08-0.19)
Dommett (2012)	Urinary symptoms 0-12 months before diagnosis	All included patients	0.266 (0.117-0.609) Cases: 15/1267

			Control: 9/15318
Dommett (2013a)	≥ 3 consultations	All included patients	0.02
Dommett (2013a)	Childhood infection 0-3 months before diagnosis	All included patients	Cases: 54/1267 Control: 236/15318
Dommett (2013a)	Upper respiratory tract infection 0-3 months before diagnosis	All included patients	Cases: 143/1267 Control: 942/15318
Dommett (2013a)	Vomiting 0-3 months before diagnosis	All included patients	Cases: 86/1267 Control: 105/15318
Dommett (2013a)	Cough 0-3 months before diagnosis	All included patients	Cases: 77/1267 Control: 654/15318
Dommett (2013a)	Rash 0-3 months before diagnosis	All included patients	Cases: 63/1267 Control: 555/15318
Dommett (2013a)	Abdominal pain 0-3 months before diagnosis	All included patients	Cases: 60/1267 Control: 137/15318
Dommett (2013a)	Abdominal mass 0-3 months before diagnosis	All included patients	Cases: 48/1267 Control: 0/15318
Dommett (2013a)	Fever 0-3 months before diagnosis	All included patients	Cases: 49/1267 Control: 166/15318
Dommett (2013a)	Eye swelling 0-3 months before diagnosis	All included patients	Cases: 39/1267 Control: 238/15318
Dommett (2013a)	Shortness of breath 0-3 months before diagnosis	All included patients	Cases: 35/1267 Control: 221/15318
Dommett (2013a)	Constipation 0-3 months before diagnosis	All included patients	Cases: 26/1267 Control: 61/15318
Dommett (2012)	Hepatosplenomegaly 0-12 months before diagnosis	All included patients	2.19 (0.295-17.034) Cases: 14/1267 Control: 1/15318

1 The positive predictive values are calculated using Bayesian statistics.

2

3 Table 2: Childhood cancers (neuroblastoma, retinoblastoma, Wilm's tumour): Positive predictive  
4 values for any childhood cancer: Patients aged 0-4 years

Study	Symptom(s)	Patient group	Positive predictive value (95% CI) Frequency
Dommett (2012)	Any NICE alert symptom 0-3 months before diagnosis	Patients aged 0-4 years	0.081 (0.059-0.112) Cases: 96/436 Control: 55/4802
Dommett (2012)	Any NICE alert symptom 0-12 months before diagnosis	Patients aged 0-4 years	0.093 (0.077-0.113) Cases: 124/436 Control: 248/4802
Dommett (2012)	Neurological symptoms 0-12 months before diagnosis	Patients aged 0-4 years	0.076 (0.054-0.107) Cases: 43/436 Control: 105/4802
Dommett (2012)	Headache 0-12 months before diagnosis	Patients aged 0-4 years	0.135 (0.055-0.335) Cases: 8/436 Control: 11/4802
Dommett (2012)	Lymphadenopathy 0-12 months before diagnosis	Patients aged 0-4 years	0.061 (0.037-0.1) Cases: 20/436 Control: 61/4802
Dommett (2012)	Lump/mass/swelling 0-	Patients aged 0-4 years	0.198 (0.099-0.399)

	12 months before diagnosis		Cases: 16/436 Control: 15/4802
Dommett (2012)	Fatigue 0-12 months before diagnosis	Patients aged 0-4 years	0.087 (0.048-0.16) Cases: 15/436 Control: 32/4802
Dommett (2012)	Back pain 0-12 months before diagnosis	Patients aged 0-4 years	0.186 (0.047-0.742) Cases: 4/436 Control: 4/4802
Dommett (2012)	Bruising 0-12 months before diagnosis	Patients aged 0-4 years	0.155 (0.086-0.279) Cases: 20/436 Control: 24/4802
Dommett (2012)	Urinary symptoms 0-12 months before diagnosis	Patients aged 0-4 years	0.739 (0.159-3.496) Cases: 8/436 Control: 2/4802
Dommett (2012)	Hepatosplenomegaly 0-12 months before diagnosis	Patients aged 0-4 years	1.286 (0.161-10.569) Cases: 7/436 Control: 1/4802

1 The positive predictive values are calculated using Bayesian statistics.

2

3 Table 3: Childhood cancers (neuroblastoma, retinoblastoma, Wilm's tumour): Positive predictive  
4 values for any childhood cancer: Patients aged 5-14 years

Study	Symptom(s)	Patient group	Positive predictive value (95% CI) Frequency
Dommett (2012)	Any NICE alert symptom 0-3 months before diagnosis	Patients aged 5-14 years	0.056 (0.047-0.068) Cases: 246/831 Control: 156/10516
Dommett (2012)	Any NICE alert symptom 0-12 months before diagnosis	Patients aged 5-14 years	0.075 (0.066-0.084) Cases: 303/831 Control: 581/10561
Dommett (2012)	Neurological symptoms 0-12 months before diagnosis	Patients aged 5-14 years	0.091 (0.067-0.123) Cases: 65/831 Control: 102/10516
Dommett (2012)	Headache 0-12 months before diagnosis	Patients aged 5-14 years	0.055 (0.043-0.07) Cases: 82/831 Control: 213/10516
Dommett (2012)	Lymphadenopathy 0-12 months before diagnosis	Patients aged 5-14 years	0.118 (0.085-0.164) Cases: 62/831 Control: 75/10516
Dommett (2012)	Lump/mass/swelling 0-12 months before diagnosis	Patients aged 5-14 years	0.154 (0.099-0.24) Cases: 40/831 Control: 37/10516
Dommett (2012)	Fatigue 0-12 months before diagnosis	Patients aged 5-14 years	0.082 (0.053-0.125) Cases: 32/831 Control: 56/10516
Dommett (2012)	Back pain 0-12 months before diagnosis	Patients aged 5-14 years	0.075 (0.05-0.111) Cases: 36/831 Control: 69/10516
Dommett (2012)	Bruising 0-12 months before diagnosis	Patients aged 5-14 years	0.049 (0.029-0.084) Cases: 18/831 Control: 52/10516

Dommett (2012)	Urinary symptoms 0-12 months before diagnosis	Patients aged 5-14 years	0.143 (0.05-0.407) Cases: 7/831 Control: 7/10516
Dommett (2012)	Hepatosplenomegaly 0-12 months before diagnosis	Patients aged 5-14 years	Cases: 7/831 Control: 0/10516

1 The positive predictive values are calculated using Bayesian statistics.

2

3 Table 4: Childhood cancers (neuroblastoma, retinoblastoma, Wilm's tumour): Positive predictive  
4 values for leukaemia/lymphoma childhood cancer

Study	Symptom(s)	Patient group	Positive predictive value (95% CI)
Dommett (2013a)	Bruising 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.53 (0.07-3.91)
Dommett (2013a)	Pallor 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.43 (0.06-3.15)
Dommett (2013a)	Lump mass swelling head and neck 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.35 (0.05-2.65)
Dommett (2013a)	Fatigue 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.07 (0.03-0.15)
Dommett (2013a)	Lymphadenopathy 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.06 (0.04-0.11)
Dommett (2013a)	Lump mass swelling below neck excluding abdomen 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.05 (0.02-0.13)
Dommett (2013a)	Bleeding 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.03 (0.01-0.08)
Dommett (2013a)	Pain 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.03 (0.01-0.06)
Dommett (2013a)	Musculoskeletal symptoms 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.02 (0.01-0.03)
Dommett (2013a)	Fever 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls	0.01 (0.01-0.01)

		aged 0-14 years	
Dommett (2013a)	Abdominal pain 0-3 months before diagnosis	All included leukemia/lymphoma patients and controls aged 0-14 years	0.01 (0-0.01)
Dommett (2013a)	≥ 3 consultations	All included leukemia/lymphoma patients and controls aged 0-14 years	0.01 (0.01-0.01)

1 The positive predictive values are calculated using Bayesian statistics.

2

3 Table 5: Childhood cancers (neuroblastoma, retinoblastoma, Wilm's tumour): Positive predictive  
4 values for teenage and young adult leukaemia

Study	Symptom(s)	Patient group	Positive predictive value (95% CI)
Dommett (2013b)	Bruising	All included leukaemia patients and controls aged 15-24 years	0.0117 (0.004-0.0343) Cases: 9/143 Controls: 5/1799
Dommett (2013b)	Fatigue	All included leukaemia patients and controls aged 15-24 years	0.0121 (0.0052-0.0282) Cases: 15/143 Controls: 8/1799
Dommett (2013b)	Lymphadenopathy	All included leukaemia patients and controls aged 15-24 years	0.0151 (0.004-0.0578) Cases: 7/143 Controls: 3/1799
Dommett (2013b)	≥ 3 consultations	All included leukaemia patients and controls aged 15-24 years	0.0038 (0.003-0.0048) Cases: 74/143 Controls: 125/1799

5 The positive predictive values are calculated using Bayesian statistics.

6 Table 6: Childhood cancers (neuroblastoma, retinoblastoma, Wilm's tumour): Positive predictive  
7 values for teenage and young adult lymphoma

Study	Symptom(s)	Patient group	Positive predictive value (95% CI) Frequency
Dommett (2013b)	Lump mass swelling head and neck	All included lymphoma patients and controls aged 15-24 years	0.5034 (0.0696-3.68) Cases: 35/270 Controls: 1/3350
Dommett (2013b)	Lump mass swelling below neck excluding abdomen	All included lymphoma patients and controls aged 15-24 years	0.0279 (0.0152-0.0515) Cases: 29/270 Controls: 15/3350
Dommett (2013b)	Lymphadenopathy	All included lymphoma patients and controls aged 15-24 years	0.278 (0.1-0.75) Cases: 77/270 Controls: 4/3350
Dommett (2013b)	'Lump mass swelling head and neck', 'lymphadenopathy' and	All included lymphoma patients and controls aged 15-24 years	0.0903 (0.057-0.1425)

	'lump mass swelling below neck excluding abdomen' combined as a single symptom		
Dommett (2013b)	≥ 3 consultations	All included lymphoma patients and controls aged 15-24 years	0.0086 (0.0075-0.0099) Cases: 175/270 Controls: 294/3350

1 The positive predictive values are calculated using Bayesian statistics.

2 Table 7: Childhood cancers (neuroblastoma, retinoblastoma, Wilm's tumour): Positive predictive values for central nervous system (CNS) child- or young adulthood cancer tumour

Study	Symptom(s)	Patient group	Positive predictive value (95% CI) Frequency
Dommett (2013a)	Abnormal movement 0-3 months before diagnosis	All included CNS childhood cancer tumour patients and controls aged 0-14 years	0.11 (0.03-0.35)
Dommett (2013a)	Visual symptoms 0-3 months before diagnosis	All included CNS childhood cancer tumour patients and controls aged 0-14 years	0.07 (0.02-0.24)
Dommett (2013a)	Vomiting 0-3 months before diagnosis	All included CNS childhood cancer tumour patients and controls aged 0-14 years	0.04 (0.02-0.07)
Dommett (2013a)	Headache 0-3 months before diagnosis	All included CNS childhood cancer tumour patients and controls aged 0-14 years	0.03 (0.02-0.06)
Dommett (2013a)	Pain 0-3 months before diagnosis	All included CNS childhood cancer tumour patients and controls aged 0-14 years	0.03 (0.01-0.08)
Dommett (2013a)	Seizure 0-3 months before diagnosis	All included CNS childhood cancer tumour patients and controls aged 0-14 years	0.02 (0.01-0.06)
Dommett (2013a)	≥ 3 consultations	All included CNS childhood cancer tumour patients and controls aged 0-14 years	0.01 (0-0.01)
Dommett (2013b)	Seizure	All included CNS	0.0238 (0.0082-



		patients and controls aged 15-24 years	0.0695) Cases: 18/154 Controls: 4/1906
Dommett (2013b)	Headache	All included CNS patients and controls aged 15-24 years	0.0145 (0.0077-0.0276) Cases: 33/154 Controls: 12/1906
Dommett (2013b)	Vomiting	All included CNS patients and controls aged 15-24 years	0.0116 (0.0041-0.031) Cases: 11/154 Controls: 5/1906
Dommett (2013b)	Pain	All included CNS patients and controls aged 15-24 years	0.0029 (0.0014-0.006) Cases: 11/154 Controls: 20/1906
Dommett (2013b)	Visual symptoms	All included CNS patients and controls aged 15-24 years	Cases: 8.4% Controls: 0%
Dommett (2013b)	≥ 3 consultations	All included CNS patients and controls aged 15-24 years	0.0023 (0.0019-0.0029) Cases: 73/154 Controls: 165/1906

1 The positive predictive values are calculated using Bayesian statistics.

2

3 Table 8: Childhood cancers (neuroblastoma, retinoblastoma, Wilm's tumour): Positive predictive  
4 values for child- or young adulthood bone cancer tumour/soft tissue sarcoma

Study	Symptom(s)	Patient group	Positive predictive value (95% CI) Frequency
Dommett (2013a)	Lump mass swelling below neck excluding abdomen 0-3 months before diagnosis	All included bone cancer tumour/soft tissue sarcoma patients and controls aged 0-14 years	0.03 (0.01-0.14)
Dommett (2013a)	Musculoskeletal symptoms 0-3 months before diagnosis	All included bone cancer tumour/soft tissue sarcoma patients and controls aged 0-14 years	0.01 (0-0.01)
Dommett (2013a)	Trauma 0-3 months before diagnosis	All included bone cancer tumour/soft tissue sarcoma patients and controls aged 0-14 years	0 (0-0)
Dommett (2013a)	≥ 3 consultations	All included bone cancer tumour/soft tissue sarcoma patients and controls aged 0-14 years	0 (0-0)
Dommett (2013b)	Lump mass swelling	All included bone	0.0415 (0.0124-

		cancer tumour/soft tissue sarcoma patients and controls aged 15-24 years	0.1392) Cases: 19/196 Controls: 3/2438
Dommett (2013b)	Musculoskeletal symptoms	All included lymphoma patients and controls aged 15-24 years	0.0093 (0.0058-0.0151) Cases: 37/196 Controls: 26/2438
Dommett (2013b)	Chest pain	All included lymphoma patients and controls aged 15-24 years	0.0027 (0.001-0.0077) Cases: 5/196 Controls: 12/2438
Dommett (2013b)	≥ 3 consultations	All included lymphoma patients and controls aged 15-24 years	0.003 (0.0024-0.0037) Cases: 86/196 Controls: 189/2438

1 The positive predictive values are calculated using Bayesian statistics.

2 Table 9: Childhood cancers (neuroblastoma, retinoblastoma, Wilm's tumour): Positive predictive  
3 values for childhood abdominal cancer tumour

Study	Symptom(s)	Patient group	Positive predictive value (95% CI)
Dommett (2013a)	Bleeding 0-3 months before diagnosis	All included abdominal cancer patients and controls aged 0-14 years	0.03 (0.01-0.12)
Dommett (2013a)	Lump mass swelling below neck excluding abdomen 0-3 months before diagnosis	All included abdominal cancer patients and controls aged 0-14 years	0.03 (0.00-0.23)
Dommett (2013a)	Weight loss 0-3 months before diagnosis	All included abdominal cancer patients and controls aged 0-14 years	0.02 (0.00-0.1)
Dommett (2013a)	Abdominal pain 0-3 months before diagnosis	All included abdominal cancer patients and controls aged 0-14 years	0.01 (0.01-0.02)
Dommett (2013a)	Musculoskeletal symptoms 0-3 months before diagnosis	All included abdominal cancer patients and controls aged 0-14 years	0.01 (0.00-0.01)
Dommett (2013a)	Childhood infection 0-3 months before diagnosis	All included abdominal cancer patients and controls aged 0-14 years	0 (0-0)
Dommett (2013a)	≥ 3 consultations	All included abdominal cancer patients and controls aged 0-14 years	0 (0-0)

4

**Evidence statement(s):**

The positive predictive values of having any childhood cancer ranged from 0.04% (for pain and musculoskeletal symptoms) to 2.19% (for hepatosplenomegaly) in all included patients aged 0-14 years, and from 0.061% (for lymphadenopathy) to 1.286% (for hepatosplenomegaly) for patients aged 0-4 years old, and from 0.049% (for bruising) to 0.154% (for 'lump/mass/swelling' [the PPV for hepatosplenomegaly could not be calculated as none of the controls experienced this symptom]) for patients aged 5-14 years old (all from 1 study, N = 16585). The evidence quality is somewhat compromised by the case-control design of the study (see also Tables 1-3).

The positive predictive values of having leukaemia/lymphoma childhood cancer ranged from 0.01% (for fever and abdominal pain) to 0.53% (for bruising) for patients aged 0-14 years old; the positive predictive values of having young adulthood leukaemia ranged from 0.0117% (for bruising) to 0.0151% (for lymphadenopathy) for patients aged 15-24 years; and the positive predictive values of having young adulthood lymphoma ranged from 0.0279% (for 'lump mass swelling below the neck excluding the abdomen') to 0.5034% (for 'lump mass swelling head and neck') for patients aged 15-24 years (1 study, N = 30855). The evidence quality is somewhat compromised by the case-control design of the study (see also Tables 4-6).

The positive predictive values of having central nervous system childhood or young adulthood cancer tumours ranged from 0.02% (for seizure) to 0.11 (for abnormal movement) for patients aged 0-14 years old, and from 0.0029% (for pain) to 0.0238% (for seizure) for patients aged 15-24 years (1 study, N = 30855). The evidence quality is somewhat compromised by the case-control design of the study (see also Table 7).

The positive predictive values of having childhood or young adulthood bone cancer tumour/soft tissue sarcoma ranged from 0% (for trauma) to 0.03% (for 'lump mass swelling below neck excluding abdomen') for patients aged 0-14 years old, and from 0.0027% (for chest pain) to 0.0415% (for 'lump mass swelling') for patients aged 15-24 years (1 study, N = 30855). The evidence quality is somewhat compromised by the case-control design of the study (see also Table 8).

The positive predictive values of having childhood abdominal cancer tumours ranged from 0% (for childhood infection) to 0.03% (for bleeding and 'lump mass swelling below neck excluding abdomen') for patients aged 0-15 years old (1 study, N = 16585). The evidence quality is somewhat compromised by the case-control design of the study (see also Table 9).

**Evidence tables****Dommett (2012; 2013a,b)**

<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Population-based nested case-control study using data from the General Practice Research Database (GPRD)
Was a consecutive or random sample of patients enrolled?	<b>No</b>
Was a case-control design avoided?	<b>No</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to	<b>Yes</b>

balance the comparison groups for potential confounders?		
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?		<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>		<b>High risk</b>
<b>B. Concerns regarding applicability</b>		
Patient characteristics and setting	<p><u>Cases:</u> 1267 children; aged 0-4 years: N = 436; aged 5-14 years: N = 831; 703 males/564 females. Cancer type: Leukemia: N = 368; brain: N = 270; lymphoma: N = 142; bone: N = 107; soft tissue sarcoma: N = 91; renal: N = 82; neuroblastoma: N = 75; other ICD codes: N = 132. 1064 teenagers and young adults (TYA): 15-24 years: Gender not reported. Cancer type: Leukemia: N = 143; brain: N = 154; lymphoma: N = 270; bone: N = 96; soft tissue sarcoma: N = 100; other ICD codes: N = 301 (including testis: N = 60; skin: N = 49; ovary: N = 20 and thyroid: N = 17).</p> <p><u>Controls:</u> 15318 children; aged 0-4 years: N = 4802; aged 5-14 years: N = 10516; 8461 males/6857 females. 13206 TYA. Gender not reported</p> <p><u>Inclusion criteria:</u> The sample comprised all children and TYU aged 0–24 years, inclusive, drawn from all general practices contributing research-standard data to the GPRD between 1 January 1988 and 31 December 2010. To be included, the practices had to have been contributing research-standard data for a minimum of 1 year before each child’s date of cancer diagnosis or the index date (see below) for matched controls. Cases: Patients diagnosed with the following cancers: leukaemia, lymphoma, neuroblastoma, soft tissue sarcoma, hepatic, renal, bone and central nervous system tumours, using pre-defined medical codes used in the GPRD. The date of diagnosis for cases was defined as the date of pathological diagnosis, but if this was unavailable, the date of the first cancer code entered in the GPRD was used. Controls: Up to 13 controls (children with no diagnosis of cancer at any time) were selected per case, using a computer-generated random sequence, matched on age (within 1 year), sex and practice, and had to be currently registered on the date of diagnosis of their matched case (the index date). <u>Exclusion criteria:</u> None listed <u>Clinical setting:</u> Primary care, UK.</p>	
<b>Are there concerns that the included patients and setting do not match the review question?</b>		<b>Low concern</b>
<b>INDEX TEST</b>		
<b>A. Risk of bias</b>		
Index test	The GPRD uses just over 100 000 medical codes to encompass all primary care events, including both symptoms and diagnoses. From this list, libraries of codes were assembled representing individual alert symptoms derived from the NICE referral guidelines for suspected cancer in children. <i>No more information reported.</i>	
Were the index test results interpreted without knowledge		<b>Yes</b>

of the results of the reference standard?	
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b><u>B. Concerns regarding applicability</u></b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b><u>A. risk of bias</u></b>	
Reference standard(s)	Cancer diagnosis in the UK's General Practice Research Database.
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b><u>B. Concerns regarding applicability</u></b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b><u>A. risk of bias</u></b>	
Flow and timing	All patients appear to be accounted for.
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	This study is published in three papers.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14

## References

### Included studies

- Dommett, R. M., Redaniel, M. T., Stevens, M. C. G., Hamilton, W., and Martin, R. M. Features of childhood cancer in primary care: A population-based nested case-control study. *British Journal of Cancer* 106[5], 982-987. 2012.
- Dommett, R. M., Redaniel, T., Stevens, M. C. G., Martin, R. M., and Hamilton, W. Risk of childhood cancer with symptoms in primary care: A population-based case-control study. *British Journal of General Practice*; DOI:10.3399/bjgp13X660742. 2013a.
- Dommett, R. M., Redaniel, M. T., Stevens, M. C. G., Hamilton, W., and Martin, R. M. Features of cancer in teenagers and young adults in primary care: A population-based nested case-control study. *British Journal of Cancer* 2329-2333. 2013b.

### Excluded studies (with excl reason)

- 1 (1999) Doctor-patient relationships in primary care. Doctor, help! My child has cancer. [Review] [0  
2 refs]. *BMJ*, 319: 554-556.  
3 Not in PICO
- 4 (2006) New report on childhood cancer shows early detection can save thousands of children's lives.  
5 *European Journal of Oncology*, 11: 65-67.  
6 Narrative review
- 7 (2007) Erratum: Retinoblastoma (American Family Physician (2006) (1039-1041)). *American Family*  
8 *Physician*, 75: 980.  
9 Erratum
- 10 Abdu, L. & Malami, S. (2011) Clinicopathological pattern and management of retinoblastoma in  
11 Kano, Nigeria. *Annals of African Medicine*, 10: 214-219.  
12 Not in PICO
- 13 Abramson, D. H., Notterman, R. B., Ellsworth, R. M. & Kitchin, F. D. (1983) Retinoblastoma treated in  
14 infants in the first six months of life. *Archives of Ophthalmology*, 101: 1362-1366.  
15 Not in PICO
- 16 Abramson, D. H., Beaverson, K., Sangani, P., Vora, R. A., Lee, T. C., Hochberg, H. M., Kirsztrot, J. &  
17 Ranjithan, M. (2003) Screening for retinoblastoma: presenting signs as prognosticators of patient  
18 and ocular survival. *Pediatrics*, 112: t-55.  
19 Not in PICO
- 20 Adegboye, V. O., Ogunseyinde, A. O., Obajimi, M. O., Ogunbiyi, O., Brimmo, A. I. & Adebo, O. A.  
21 (2003) Presentation of primary mediastinal masses in Ibadan. *East African Medical Journal*, 80:  
22 484-487.  
23 Not in PICO
- 24 Agrons, G. A., Kingsman, K. D., Wagner, B. J. & Sotelo-Avila, C. (1997) Rhabdoid tumor of the kidney  
25 in children: a comparative study of 21 cases. *AJR.American Journal of Roentgenology*, 168: 447-  
26 451.  
27 Not in PICO
- 28 Ahmed, S., Goel, S., Khandwala, M., Agrawal, A., Chang, B. & Simmons, I. G. (2006) Neuroblastoma  
29 with orbital metastasis: ophthalmic presentation and role of ophthalmologists. *Eye*, 20: 466-470.  
30 Not in PICO
- 31 Ahrensberg, J. M., Fenger-Gron, M. & Vedsted, P. (2013) Use of primary care during the year before  
32 childhood cancer diagnosis: a nationwide population-based matched comparative study. *PLoS*  
33 *ONE [Electronic Resource]*, 8: e59098.  
34 Not in PICO
- 35 Alkatan, H., Al-Amry, M., Al-Hussain, H., Al-Dhibi, H. & al-Mesfer, S. (2011) Medulloepithelioma of  
36 the ciliary body: The delay in diagnosis and frequent initial mismanagement. *Canadian Journal of*  
37 *Ophthalmology*, 46: 431-438.  
38 Not in PICO
- 39 Almeida, C., Machado, I., Aguiar, L. & Almeida, F. (2009) Early diagnosis in childhood cancer: The  
40 shortest way for the cure. *Pediatric Blood and Cancer*, 53: 846.  
41 Not in PICO
- 42 Anastassiou, G., Bornfeld, N., Schueler, A. O., Schilling, H., Weber, S., Fluehs, D., Jurklies, B., Vij, O. &  
43 Sauerwein, W. (2006) Ruthenium-106 plaque brachytherapy for symptomatic vasoproliferative  
44 tumours of the retina. *British Journal of Ophthalmology*, 90: 447-450.  
45 Not in PICO
- 46 Anderson, B. D., Mason, S. & Cheson, B. D. (1986) Clinical trials referral resource. Current clinical  
47 trials in neuroblastoma. *Oncology (Williston Park)*, 16: 82-84.  
48 Not in PICO
- 49 Anderson, P. (2000) Taking care to the child. *Nursing Times*, 96: 51-53.  
50 Not in PICO

- 1 Angelini, P., Plantaz, D., De, B. B., Passagia, J. G., Rubie, H. & Pastore, G. (2011) Late sequelae of  
 2 symptomatic epidural compression in children with localized neuroblastoma. *Pediatric blood &*  
 3 *cancer*, 57: 473-480.  
 4 Not in PICO
- 5 Antoneli, C. B., Steinhorst, F., Ribeiro, K. C., Chojniak, M. M., Novaes, P. E., Arias, V. & Bianchi, A.  
 6 (2004) The Pediatrician's ability to recognize the presenting signs and symptoms of  
 7 retinoblastoma. [Portuguese]. *Revista da Associacao Medica Brasileira (1992)*, 50: 400-402.  
 8 Not in PICO
- 9 Antunes, N. L. & De Angelis, L. M. (1999) Neurologic consultations in children with systemic cancer.  
 10 *Pediatric Neurology*, 20: 121-124.  
 11 Not in PICO
- 12 Aston, J. W., Jr. (1990) Pediatric update #16. The orthopaedic presentation of neuroblastoma.  
 13 *Orthopaedic Review*, 19: 929-932.  
 14 Not in PICO
- 15 Atkins, L. A., Forbes, L. J. L., Austoker, J., Bankhead, C., Martin, F., Robb, K., Wardle, J. & Ramirez, A.  
 16 J. (2010) Interventions to increase cancer awareness and promote early presentation: A  
 17 systematic review. *Psycho-Oncology*, 19: S12.  
 18 Not in PICO
- 19 Auber, F., Jeanpierre, C., Denamur, E., Jaubert, F., Schleiermacher, G., Patte, C., Cabrol, S., Leverger,  
 20 G., Nihoul-Fekete, C. & Sarnacki, S. (2009) Management of Wilms tumors in Drash and Frasier  
 21 syndromes. *Pediatric blood & cancer*, 52: 55-59.  
 22 Not in PICO
- 23 Augsburger, J. J. (1983) Ocular tumors in children. *Pediatric Clinics of North America*, 30: 1071-1086.  
 24 Narrative review
- 25 Aung, L., Chan, Y. H., Sabai, S. M., Khaing, T., Yeoh, E. J. & Quah, T. C. (2009) Retinoblastoma: A  
 26 recent experience at the national university hospital, Singapore. *Pediatric Blood and Cancer*, 53:  
 27 811-812.  
 28 Not in PICO
- 29 Austoker, J., Bankhead, C., Forbes, L. J., Atkins, L., Martin, F., Robb, K., Wardle, J. & Ramirez, A. J.  
 30 (2009) Interventions to promote cancer awareness and early presentation: systematic review.  
 31 [Review] [38 refs]. *British Journal of Cancer*, 101: Suppl-9.  
 32 Not in PICO
- 33 Badalian, G. K., Kurbanmuradov, B. K., Nurgaliev, Z. B., Sharoev, T. A. & Khobbi, N. N. (1990) [The  
 34 diagnostic and prognostic characteristics of nephroblastoma recurrences in children]. [Russian].  
 35 *Urologiia i Nefrologiia.(2):23-6, 1990 Mar-Apr., 23-26.*  
 36 Not in PICO
- 37 Badhu, B., Sah, S. P., Thakur, S. K. D., Dulal, S., Kumar, S., Sood, A., Das, H. & Sah, R. P. (2005) Clinical  
 38 presentation of retinoblastoma in Eastern Nepal. *Clinical and Experimental Ophthalmology*, 33:  
 39 386-389.  
 40 Not in PICO
- 41 Baggesen, K., Flage, T. & Arnljot, H. M. (1999) [Leukocoria (white pupil) among children--mother is  
 42 always right]. [Norwegian]. *Tidsskrift for Den Norske Laegeforening*, 119: 794-795.  
 43 Narrative review
- 44 Bahakim, H. M. & el-Idrissy, I. M. (1989) Epidemiological observations of consanguinity and  
 45 retinoblastoma in Arabia. A retrospective study. *Tropical & Geographical Medicine*, 41: 361-364.  
 46 Not in PICO
- 47 Bai, S., Ren, R., Li, B., Xu, X., Zhao, B., Gao, F., Li, L. & Jonas, J. B. (2011) Delay in the diagnosis of  
 48 retinoblastoma in China. *Acta Ophthalmologica*, 89: e72-e74.  
 49 Not in PICO
- 50 Ballock, R. T., Wiesner, G. L., Myers, M. T. & Thompson, G. H. (1997) Hemihypertrophy. Concepts and  
 51 controversies. [Review] [67 refs]. *Journal of Bone & Joint Surgery - American Volume*, 79: 1731-

- 1 1738.  
2 Narrative review
- 3 Balmer, A., Zografos, L. & Munier, F. (2006) Diagnosis and current management of retinoblastoma.  
4 [Review] [60 refs]. *Oncogene*, 25: 5341-5349.  
5 Narrative review
- 6 Balmer, A. & Munier, F. (2007) Differential diagnosis of leukocoria and strabismus, first presenting  
7 signs of retinoblastoma. *Clinical Ophthalmology*, 1: 431-439.  
8 Narrative review
- 9 Barroca, H. & Bom-Successo, M. (2014) Fine needle biopsy with cytology in paediatrics: The  
10 importance of a multidisciplinary approach and the role of ancillary techniques. *Cytopathology*,  
11 25: 6-20.  
12 Narrative review
- 13 Bernard, J. L., Gentet, J. C. & Raybaud, C. (1984) Detection and early diagnosis of solid tumors in  
14 children. [French]. *Medecine Infantile*, 91: 599-608.  
15 Narrative review
- 16 Bliznakova, D. (2003) Differential diagnosis of some kidney diseases in childhood. [Bulgarian].  
17 *Bulgarian Medicine*, 11: 7-10.  
18 Narrative review
- 19 Boles, C. B., Vitale, B. F. & Porro, G. (1995) [The pediatric physician and consultation in  
20 ophthalmology]. [Review] [46 refs] [Italian]. *Minerva Pediatrica*, 47: 493-504.  
21 Not in PICO
- 22 Boranic, M. (2003) Solid malignant tumors in children. [Croatian]. *Paediatrica Croatica, Supplement*,  
23 47: 19-24.  
24 Narrative review
- 25 Borer, J. G., Kaefer, M., Barnewolt, C. E., Elias, E. R., Hobbs, N., Retik, A. B. & Peters, C. A. (1999)  
26 Renal findings on radiological followup of patients with Beckwith- Wiedemann syndrome. *Journal*  
27 *of Urology*, 161: 235-239.  
28 Not in PICO
- 29 Boricean, I. D. & Barar, A. (2011) Understanding ocular torticollis in children. *Oftalmologia*  
30 *(Bucharest, Romania : 1990)*, 55: 10-26.  
31 Narrative review
- 32 Bornfeld, N., Schuler, A., Boloni, R., Jurklies, C., Wieland, R., Sauerwein, W. & Lohmann, D. (1977)  
33 [Retinoblastoma]. [Review] [39 refs] [German]. *Ophthalmologe*, 103: 59-76.  
34 Narrative review
- 35 Bove, K. E. (1999) Wilms' tumor and related abnormalities in the fetus and newborn. [Review] [59  
36 refs]. *Seminars in Perinatology*, 23: 310-318.  
37 Narrative review
- 38 Brady, G. (2003) Retinoblastoma: Care and support of the pediatric patient and family. *Insight -*  
39 *Journal of the American Society of Ophthalmic Registered Nurses*, 28: 67-69.  
40 Narrative review
- 41 Brasme, J.-F., Morfouace, M., Grill, J., Martinot, A., Amalberti, R., Bons-Letouzey, C. & Chalumeau,  
42 M. (2012) Delays in diagnosis of paediatric cancers: A systematic review and comparison with  
43 expert testimony in lawsuits. *The Lancet Oncology*, 13: e445-e459.  
44 Not in PICO
- 45 Brasme, J.-F., Chalumeau, M., Doz, F., Lacour, B., Valteau-Couanet, D., Gaillard, S., Delalande, O.,  
46 Aghakhani, N., Sainte-Rose, C., Puget, S. & Grill, J. (2012) Interval between onset of symptoms  
47 and diagnosis of medulloblastoma in children: Distribution and determinants in a population-  
48 based study. *European Journal of Pediatrics*, 171: 25-32.  
49 Not in PICO
- 50 Brown, B. J., Ajayi, S. O., Ogun, O. A. & Oladokun, R. E. (2009) Factors influencing time to diagnosis of  
51 childhood cancer in Ibadan, Nigeria.[Erratum appears in Afr Health Sci. 2010 Jun;10(2):137 Note:



- 1 James, B O [corrected to Brown, B J]. *African Health Sciences*, 9: 247-253.  
2 Not in PICO
- 3 Bursztyn, J. (2005) [New developments in 2005 for the management of visual deficit in the infant].  
4 [French]. *Archives de Pediatrie*, 12: 357-360.  
5 Not in PICO
- 6 Butros, L. J., Abramson, D. H. & Dunkel, I. J. (2002) Delayed diagnosis of retinoblastoma: analysis of  
7 degree, cause, and potential consequences. *Pediatrics*, 109: E45.  
8 Not in PICO
- 9 Cabral, D. A. & Tucker, L. B. (1999) Malignancies in children who initially present with rheumatic  
10 complaints. *Journal of Pediatrics*, 134: 53-57.  
11 Not in PICO
- 12 Caiulo, V. A., Caiulo, S., Gargasole, C., Chiriaco, G., Latini, G., Cataldi, L. & Mele, G. (2012) Ultrasound  
13 mass screening for congenital anomalies of the kidney and urinary tract. *Pediatric Nephrology*,  
14 27: 949-953.  
15 Not in PICO
- 16 Canadian Retinoblastoma Society (2009) National Retinoblastoma Strategy Canadian Guidelines for  
17 Care: Strategie therapeutique du retinoblastome guide clinique canadien. *Canadian Journal of*  
18 *Ophthalmology*, 44: Suppl-88.  
19 Guideline
- 20 Canty, C. A. (2009) Retinoblastoma: an overview for advanced practice nurses. [Review] [23 refs].  
21 *Journal of the American Academy of Nurse Practitioners*, 21: 149-155.  
22 Narrative review
- 23 Canzano, J. C. & Handa, J. T. (1999) Utility of pupillary dilation for detecting leukocoria in patients  
24 with retinoblastoma. *Pediatrics*, 104: e44.  
25 Not in PICO
- 26 Castillo, B. V., Jr. & Kaufman, L. (2003) Pediatric tumors of the eye and orbit. [Review] [67 refs].  
27 *Pediatric Clinics of North America*, 50: 149-172.  
28 Narrative review
- 29 Cepulic, M., Cizmic, A., Petkovic, I., Fattorini, I., Nakic, M. & Stepan, G. J. (2003) Nephroblastomas -  
30 Wilms' tumor (WT). [Croatian]. *Paediatrica Croatica, Supplement*, 47: 75-80.  
31 Not in PICO
- 32 Cerecedo, D. F., Lopez, A. E., Rivera, M. H., Arias, G. J., Ramirez, S. F. & Rodriguez, C. M. (2003)  
33 [Survival and clinical features of retinoblastoma]. [Spanish]. *Anales de Pediatria*, 58: 3-9.  
34 Not in PICO
- 35 Chantada, G., Fandino, A., Manzitti, J., Urrutia, L. & Schwartzman, E. (1999) Late diagnosis of  
36 retinoblastoma in a developing country. *Archives of Disease in Childhood*, 80: 171-174.  
37 Not in PICO
- 38 Chen, D. Y. & Uzzo, R. G. (2011) Evaluation and management of the renal mass. [Review]. *Medical*  
39 *Clinics of North America*, 95: 179-189.  
40 Narrative review
- 41 Chen, Y. F., Li, Y. W., Sheih, C. P. & Hsu, C. Y. (1999) Renal cell carcinoma: unusual pediatric renal  
42 tumors. *Journal of the Formosan Medical Association*, 98: 118-121.  
43 Not in PICO
- 44 Cheng, G. Y., Li, B., Li, L. Q., Gao, F., Ren, R. J., Xu, X. L. & Jonas, J. B. (2008) Review of 1375  
45 enucleations in the TongRen Eye Centre, Beijing. *Eye*, 22: 1404-1409.  
46 Not in PICO
- 47 Choyke, P. L., Siegel, M. J., Craft, A. W., Green, D. M. & DeBaun, M. R. (1999) Screening for Wilms  
48 tumor in children with Beckwith-Wiedemann syndrome or idiopathic hemihypertrophy. *Medical*  
49 *& Pediatric Oncology*, 32: 196-200.  
50 Not in PICO

- 1 Chung, E. M., Specht, C. S. & Schroeder, J. W. (2007) From the archives of the AFIP: Pediatric orbit  
2 tumors and tumorlike lesions: neuroepithelial lesions of the ocular globe and optic nerve.  
3 [Review] [114 refs]. *Radiographics*, 27: 1159-1186.  
4 Narrative review
- 5 Claviez, A., Hero, B., Schneppenheim, R. & Berthold, F. (1996) [Hepatopathy in patients with stage 4S  
6 neuroblastoma]. [German]. *Klinische Padiatrie*, 208: 221-228.  
7 Not in PICO
- 8 Clericuzio, C. L. & Martin, R. A. (2009) Diagnostic criteria and tumor screening for individuals with  
9 isolated hemihyperplasia. *Genetics in Medicine*, 11: 220-222.  
10 Narrative review
- 11 Cook, A., Farhat, W. & Khoury, A. (2005) Update on Wilms' tumor in children. *Journal Medical  
12 Libanais*, 53: 85-90.  
13 Narrative review
- 14 Craft, A. W., Parker, L., Stiller, C. & Cole, M. (1995) Screening for Wilms' tumour in patients with  
15 Aniridia, Beckwith syndrome, or hemihypertrophy. *Medical and Pediatric Oncology*, 24: 231-234.  
16 Narrative review
- 17 Creutzig, U. & Graf, N. (1995) Early diagnosis of neoplastic diseases in childhood. [German].  
18 *Onkologie*, 18: 24-27.  
19 Narrative review
- 20 Croft, D. & Dickerson, M. (1994) Ultrasound differentiation of two pediatric abdominal masses.  
21 *Journal of Diagnostic Medical Sonography*, 10: 12-17.  
22 Narrative review
- 23 D'Angio, G. J., Beckwith, J. B. & Breslow, N. E. (1980) Wilms' tumor: An update. *Cancer*, 45: 1791-  
24 1798.  
25 Narrative review
- 26 Davidson, A., Hartley, P., Desai, F., Daubenton, J., Rode, H. & Millar, A. (2006) Wilms tumour  
27 experience in a South African centre. *Pediatric blood & cancer*, 46: 465-471.  
28 Not in PICO
- 29 de la Briere, A. (2010) [The mission of nurses of patients with ocular cancers]. [French]. *Soins; La  
30 Revue de Reference Infirmiere.(744):46, 2010 Apr., 46.*  
31 Not in PICO
- 32 De, B. B., Conte, M., Nigro, M., Milanaccio, C. & Garaventa, A. (1994) [Neuroblastoma: update on  
33 clinical aspects and therapy]. [Review] [28 refs] [Italian]. *Pediatria Medica e Chirurgica*, 16: 7-14.  
34 Narrative review
- 35 DeBaun, M. R. & Tucker, M. A. (1998) Risk of cancer during the first four years of life in children from  
36 The Beckwith-Wiedemann Syndrome Registry. *Journal of Pediatrics*, 132: t-400.  
37 Not in PICO
- 38 Defachelles, A.-S., Rocourt, N., Branchereau, S. & Peuchmaur, M. (2012) Pancreatoblastoma in  
39 children: Diagnosis and therapeutic management. [French]. *Bulletin du Cancer*, 99: 793-799.  
40 Narrative review
- 41 Dehner, L. P. (1994) Pleuropulmonary blastoma is the pulmonary blastoma of childhood. *Seminars in  
42 Diagnostic Pathology*, 11: 144-151.  
43 Narrative review
- 44 Dhamija, R., Pittock, S., McKeon, A., Lachance, D., Mack, K., Patterson, M. & Lennon, V. (2010) Anti-  
45 neuronal nuclear antibody-type 1 in children. *Annals of Neurology*, 68: S98.  
46 Not in PICO
- 47 Diaconescu, S., Olaru, C., Mihaila, D., Aprodu, S. G. & Miron, I. (2013) Risk stratification and  
48 consecutive prognosis progresses in childhood Wilms tumors. Two cases report. *Chirurgia  
49 (Bucuresti)*, 108: 106-111.  
50 Not in PICO

- 1 Dimaras, H., Kimani, K., Dimba, E. A., Gronsdahl, P., White, A., Chan, H. S. & Gallie, B. L. (2012)  
 2 Retinoblastoma. [Review]. *Lancet*, 379: 1436-1446.  
 3 Narrative review
- 4 Dorronsoro, M., I, Merino, M. R., Sastre-Urguelles, A., Garcia-Miguel Garcia-Rosado, P. & Garcia-  
 5 Consuegra, M. J. (2004) [Malignant disease presenting as rheumatic manifestations]. [Spanish].  
 6 *Anales de Pediatría*, 61: 393-397.  
 7 Not in PICO
- 8 Ell, C. & Schott, G. (1994) [Suspected kidney tumor--diagnostic-therapeutic procedure]. [German].  
 9 *Fortschritte der Medizin*, 112: 123-124.  
 10 Narrative review
- 11 Epelman, S. (2012) Preserving vision in retinoblastoma through early detection and intervention.  
 12 *Current Oncology Reports*, 14: 213-219.  
 13 Narrative review
- 14 Erwenne, C. M. & Franco, E. L. (1989) Age and lateness of referral as determinants of extra-ocular  
 15 retinoblastoma. *Ophthalmic Paediatrics & Genetics*, 10: 179-184.  
 16 Not in PICO
- 17 Esquembre Menor, C. T. & Castel, S., V (1988) [Early diagnosis of cancer in children]. [Review] [0 refs]  
 18 [Spanish]. *Anales Espanoles de Pediatría*, 29: Suppl-7.  
 19 Narrative review
- 20 Essuman, V., Ntim-Amponsah, C. T., Akafo, S., Renner, L. & Edusei, L. (2010) Presentation of  
 21 retinoblastoma at a paediatric eye clinic in Ghana. *Ghana Medical Journal*, 44: 10-15.  
 22 Not in PICO
- 23 Exelby, P. R. (1981) Retroperitoneal malignant tumors: Wilms' tumor and neuroblastoma. *Surgical*  
 24 *Clinics of North America*, 61: 1219-1237.  
 25 Narrative review
- 26 Exelby, P. R. (1991) Wilms' tumor 1991. Clinical evaluation and treatment. *Urologic Clinics of North*  
 27 *America*, 18: 589-597.  
 28 Narrative review
- 29 Fallat, M. E. & Donahoe, P. K. (2006) Intersex genetic anomalies with malignant potential. *Current*  
 30 *Opinion in Pediatrics*, 18: 305-311.  
 31 Narrative review
- 32 Ferris, I. T., Berbel, T. O., Ortega Garcia, J. A., Lopez Andreu, J. A., Garcia, I. C., Balaguer, G. J. &  
 33 Aliaga, V. J. (2003) Risk factors for pediatric malignant renal tumors. [Spanish]. *Revista Espanola*  
 34 *de Pediatría*, 59: 527-536.  
 35 Not in PICO
- 36 Forgie, S. E. & Robinson, J. L. (2007) Pediatric malignancies presenting as a possible infectious  
 37 disease. *BMC Infectious Diseases*, 7.  
 38 Not in PICO
- 39 Fragkandrea, I., Nixon, J. A. & Panagopoulou, P. (2013) Signs and symptoms of childhood cancer: a  
 40 guide for early recognition. *American Family Physician*, 88: 185-192.  
 41 Narrative review
- 42 Fragkandrea, I., Nixon, J. A. & Panagopoulou, P. (2013) Signs and central nervous system (CNS): Early  
 43 endocrine manifestations: A guide for early recognition. *American Family Physician*, 88: 185-192.  
 44 Narrative review
- 45 Friedman, L. S. & Kaufman, L. M. (2003) Guidelines for pediatrician referrals to the ophthalmologist.  
 46 *Pediatric Clinics of North America*, 50: 41-53.  
 47 Guideline
- 48 Furtwangler, R., Schenk, J.-P., Reinhard, H., Leuschner, I., Rube, C., Von, S. D. & Graf, N. (2005)  
 49 Nephroblastoma - Wilms' tumor. Genetics, radiological diagnostics and therapy concept - An  
 50 overview. [German]. *Onkologie*, 11: 1077-1089.  
 51 Narrative review

- 1 Furtwangler, R., Nourkami, N., Alkassar, M., Von, S. D., Stehr, M. & Graf, N. (2010) Syndromes and  
2 syndrome-like features in bilateral wilms tumor are associated with inferior outcome. *Pediatric*  
3 *Blood and Cancer*, 55: 885.  
4 Not in PICO
- 5 Garcia, H. B. (2008) Suspicion of cancer in pediatrics. [Spanish]. *Pediatría Integral*, 12: 537-544.  
6 Narrative review
- 7 Ghalayini, I. F. & Bani-Hani, I. H. (2003) Detection, staging and clinical implications of renal cell  
8 carcinoma. *Saudi Medical Journal*, 24: 79-83.  
9 Not in PICO
- 10 Gillan, T. L., Hughes, R., Godbout, R. & Grundy, P. E. (2003) The Simpson-Golabi-Behmel gene, GPC3,  
11 is not involved in sporadic Wilms tumorigenesis. *American Journal of Medical Genetics*, 122: 30-  
12 36.  
13 Not in PICO
- 14 Glick, R. D., Hicks, M. J., Nuchtern, J. G., Wesson, D. E., Olutoye, O. O. & Cass, D. L. (2004) Renal  
15 tumors in infants less than 6 months of age. [Review] [21 refs]. *Journal of Pediatric Surgery*, 39:  
16 522-525.  
17 Not in PICO
- 18 Goddard, A. G., Kingston, J. E. & Hungerford, J. L. (1999) Delay in diagnosis of retinoblastoma: risk  
19 factors and treatment outcome. *British Journal of Ophthalmology*, 83: 1320-1323.  
20 Not in PICO
- 21 Goddard, K., Brown, T., Hukin, J., DeZorzi, P., Johnston, D., Punnett, A., Rassekh, S., Shaikh, F. &  
22 Olson, R. (2010) Case-based interactive e-learning programs for pediatric oncology: Rationale,  
23 development and user evaluation results. *Pediatric Blood and Cancer*, 55: 974.  
24 Not in PICO
- 25 Gogate, P., Gilbert, C. & Zin, A. (2011) Severe visual Impairment and blindness in infants: Causes and  
26 opportunities for control. *Middle East African Journal of Ophthalmology*, 18: 109-114.  
27 Narrative review
- 28 Gombos, D. S. & Diba, R. (2005) Estimating the incidence of retinoblastoma in Texas. *Texas Medicine*,  
29 101: 70-72.  
30 Not in PICO
- 31 Gomez-Martinez, R., Silva-Padilla, N., Torres-Sauza, B. & Huerta-Rosas, J. (2005) [Solid malignant  
32 neoplasms in the first year of life]. [Spanish]. *Anales de Pediatría*, 62: 529-534.  
33 Not in PICO
- 34 Graf, N. (1996) Diagnosis and therapy of Wilms' tumor. [German]. *Praxis*, 85: 753-761.  
35 Narrative review
- 36 Graf, N. (1996) [Wilms' tumor]. [Review] [48 refs] [German]. *Praxis*, 85: 753-761.  
37 Narrative review
- 38 Gunes, D. (2010) Childhood cancers and bone pain: Review. [Turkish]. *Turkiye Klinikleri Pediatri*, 19:  
39 216-222.  
40 Narrative review
- 41 Gutjahr, P. (1991) Congenital Wilms' tumors are mostly (benign) mesoblastic nephromas--  
42 significance of prenatally detected solid kidney tumors. [German]. *Geburtshilfe und*  
43 *Frauenheilkunde*, 51: 124-126.  
44 Not in PICO
- 45 Hadley, G. P., Govender, D. & Landers, G. (2002) Malignant solid tumours in neonates: An African  
46 perspective. *Pediatric Surgery International*, 18: 653-657.  
47 Not in PICO
- 48 Haider, S., Qureshi, W. & Ali, A. (2008) Leukocoria in children. *Journal of Pediatric Ophthalmology*  
49 *and Strabismus*, 45: 179-180.  
50 Not in PICO

- 1 Hammond, D. (1988) Opportunities for cancer prevention and early detection among children.  
2 *Cancer*, 62: 1829-1832.  
3 Narrative review
- 4 Hecht, F. (2007) Familial cancer syndromes: Catalog with comments. *Cytogenetic and Genome*  
5 *Research*, 118: 222-228.  
6 Narrative review
- 7 Hered, R. W. (2011) Effective vision screening of young children in the pediatric office. *Pediatric*  
8 *Annals*, 40: 76-82.  
9 Narrative review
- 10 Heuch, J. M., Heuch, I. & Kvale, G. (1996) Birth characteristics and risk of Wilms' tumour: A  
11 nationwide prospective study in Norway. *British Journal of Cancer*, 74: 1148-1151.  
12 Not in PICO
- 13 Hillbrand, M., Georg, D., Gadner, H., Potter, R. & Dieckmann, K. (2008) Abdominal cancer during  
14 early childhood: A dosimetric comparison of proton beams to standard and advanced photon  
15 radiotherapy. *Radiotherapy and Oncology*, 89: 141-149.  
16 Narrative review
- 17 Hormann, M. (2008) [Neuroblastoma in children]. [German]. *Radiologe*, 48: 940-945.  
18 Narrative review
- 19 Hu, V. H., Starling, A., Baynham, S. N., Wager, H. & Shun-Shin, G. A. (2012) Accuracy of referrals from  
20 an orthoptic vision screening program for 3- to 4-year-old preschool children. *Journal of AAPOS*,  
21 16: 49-52.  
22 Not in PICO
- 23 Huang, S., Crawford, J. B., Porco, T. & Rutar, T. (2010) Clinicopathologic review of pediatric  
24 enucleations during the last 50 years. *Journal of AAPOS*, 14: 328-333.  
25 Not in PICO
- 26 Huh, J., Noh, C. I., Kim, Y. W., Choi, J. Y., Yun, Y. S., Shin, H. Y., Ahn, H. S. & Kim, Y. J. (1999) Secondary  
27 cardiac tumor in children. *Pediatric Cardiology*, 20: 400-403.  
28 Not in PICO
- 29 Hwang, S.-K., Paek, S.-H., Gyu, K. D., Jeon, Y.-K., Chi, J. G. & Jung, H.-W. (2002) Olfactory  
30 neuroblastomas: Survival rate and prognostic factor. *Journal of Neuro-Oncology*, 59: 217-226.  
31 Not in PICO
- 32 Ikpeme, E. E. & Dixon-Umo, O. T. (2013) Paediatric renal diseases in uyo, Nigeria : A 10 year review.  
33 *Pediatric Nephrology*, 28: 1411.  
34 Not in PICO
- 35 Israels, T., Ribeiro, R. C. & Molyneux, E. M. (2010) Strategies to improve care for children with cancer  
36 in Sub-Saharan Africa. [Review]. *European Journal of Cancer*, 46: 1960-1966.  
37 Narrative review
- 38 Jackson, C. & Glasson, W. (1998) Prevention of visual loss. Screening in general practice. *Australian*  
39 *Family Physician*, 27: 150-153.  
40 Narrative review
- 41 Jadresic, L., Leake, J., Gordon, I., Dillon, M. J., Grant, D. B., Pritchard, J., Risdon, R. A. & Barratt, T. M.  
42 (1990) Clinicopathologic review of twelve children with nephropathy, Wilms tumor, and genital  
43 abnormalities (Drash syndrome). *Journal of Pediatrics*, 117: 717-725.  
44 Not in PICO
- 45 James, B. O., Ajayi, S. O., Ogun, O. A. & Oladokun, R. E. (2009) Factors influencing time to diagnosis  
46 of childhood cancer in Ibadan, Nigeria. *African Health Sciences*, 9: 247-253.  
47 Not in PICO
- 48 Januszkiewicz, D., Lastowska, M. & Zielinski, W. (1990) Neuroblastoma in children. Results of the  
49 treatment and analysis of selected prognostic factors. [Polish]. *Nowotwory*, 40: 143-148.  
50 Not in PICO

- 1 Jett, J. R. (2010) Mediastinal tumors. *Respirology*, 15: 18.  
2 Narrative review
- 3 Joseph, B., Madhavan, J., Mamatha, G., Ramprasad, V. L., Gopal, L. & Kumaramanickavel, G. (2006)  
4 Retinoblastoma: a diagnostic model for India. *Asian Pacific Journal of Cancer Prevention: Apjcp*, 7:  
5 485-488.  
6 Not in PICO
- 7 Junuzovic, D., Kerleta, A. & Masic, I. (2013) The frequency of renal cell carcinoma in population of  
8 patients with kidney tumors. *Medicinski Arhiv*, 67: 27-30.  
9 Not in PICO
- 10 Kaimbo, W. K., Mvitu, M. M. & Missotten, L. (2002) Presenting signs of retinoblastoma in Congolese  
11 patients. *Bulletin de la Societe Belge d Ophthalmologie*.(283):37-41, 2002., 37-41.  
12 Not in PICO
- 13 Kamath, V. B., Sowmya, V., Ballal, C. K. & Mendonca, N. (2013) Esthesioneuroblastoma as an unusual  
14 cause for dystopia. *Orbit*, 32: 392-394.  
15 Not in PICO
- 16 Kehrer-Sawatzki, H. & Cooper, D. N. (2008) Mosaicism in sporadic neurofibromatosis type 1:  
17 variations on a theme common to other hereditary cancer syndromes?. [Review] [136 refs].  
18 *Journal of Medical Genetics*, 45: 622-631.  
19 Narrative review
- 20 Khalifa, N. M., Maximous, D. W. & Abd-Elsayed, A. A. (2008) Fetus in fetu: a case report. *Journal of*  
21 *Medical Case Reports [Electronic Resource]*, 2: 2.  
22 Not in PICO
- 23 Kim, H. J., McLawhorn, A. S., Goldstein, M. J. & Boland, P. J. (2012) Malignant Osseous Tumors of the  
24 Pediatric Spine. *Journal of the American Academy of Orthopaedic Surgeons*, 20: 646-656.  
25 Narrative review
- 26 Kumar, H. R., Sandoval, J. A., Lovell, M. A., Fenton, L. Z. & Bealer, J. F. (2010) Primary pancreatic  
27 neuroblastoma: an unusual tumor in infancy. *Journal of Pediatric Surgery*, 45: 642-646.  
28 Not in PICO
- 29 Kushner, B. H. & Cheung, N. K. (2005) Neuroblastoma--from genetic profiles to clinical challenge.  
30 *New England Journal of Medicine*, 353: 2215-2217.  
31 Comment
- 32 Lai, H., Ma, F. & Lai, S. (2003) Identification of the novel role of pRB in eye cancer. [Review] [38 refs].  
33 *Journal of Cellular Biochemistry*, 88: 121-127.  
34 Narrative review
- 35 Leal, C. A., Rivera-Luna, R., Martinez, A., Cardenas, R. S., Salazar, A., Lanche, M. T. & Ridaura, S. C.  
36 (1995) Retinoblastoma in initial stages. Clinical experience at the Instituto Nacional de Pediatria.  
37 [Spanish]. *Revista del Instituto Nacional de Cancerologia*, 41: 192-195.  
38 Not in PICO
- 39 Lebedev, V. I., Pashkov, I. V., Boichenko, E. I., Sharov, T. A., Zaeva, G. E., Sokolova, I. N., Glekov, I. V.,  
40 Mentkevich, G. L. & Ordukhian, Z. S. (1996) [Experience in treating Nephroblastomas]. [Review]  
41 [10 refs] [Russian]. *Vestnik Rossiiskoi Akademii Meditsinskikh Nauk*.(10):13-7, 1996., 13-17.  
42 Narrative review
- 43 Levecq, L., De, P. P. & Guagnini, A. P. (2005) [Epidemiology of ocular and orbital lesions referred to  
44 an ocular oncology center]. [French]. *Journal Francais d Ophthalmologie*, 28: 840-844.  
45 Not in PICO
- 46 Levitt, G. (2012) Renal tumours: Long-term outcome. *Pediatric Nephrology*, 27: 911-916.  
47 Narrative review
- 48 Levy, D., Aerts, I., Michon, J., Lumbroso-Le, R. L., Cellier, C. & Orbach, D. (2014) Childhood cancer:  
49 Progress but prognosis still very unequal. Example of Retinoblastoma and high-risk  
50 Neuroblastoma. [French]. *Bulletin du Cancer*, 101: 250-257.  
51 Narrative review

- 1 Lewis, G. & Maxwell, A. P. (2002) Early diagnosis improves survival in kidney cancer. *Practitioner*,  
2 256: 13-16.  
3 Narrative review
- 4 Licata, B. & Turazzi, S. (210) Bleeding cerebral neoplasms with symptomatic hematoma. *Journal of*  
5 *Neurosurgical Sciences*, 47: 201-210.  
6 Not in PICO
- 7 Lin, Y. C. (2003) Early recognition of infant malignancy: the five most common infant cancers.  
8 *Neonatal network : NN*, 22: 11-19.  
9 Narrative review
- 10 Ling, R. E., Capsomidis, A. & Patel, S. R. (2014) Identifying childhood cancer: How is the urgent  
11 suspected cancer referral pathway performing? *Archives of Disease in Childhood*, 99: A108.  
12 Not in PICO
- 13 Long, J. A., Descotes, J. L. & Rambeaud, J. J. (2007) [Kidney cancer diagnosis]. [Review] [10 refs]  
14 [French]. *Revue du Praticien*, 57: 603-612.  
15 Narrative review
- 16 Ludick, A. (2013) Taking the early warning signs of childhood cancer to the rural areas of gauteng in  
17 south africa: Training health professionals. *Pediatric Blood and Cancer*, 60: 228.  
18 Not in PICO
- 19 Lueder, G. T. (2005) The effect of initial recognition of abnormalities by physicians on outcome of  
20 retinoblastoma. *Journal of Aapos: American Association for Pediatric Ophthalmology &*  
21 *Strabismus*, 9: 383-385.  
22 Not in PICO
- 23 Lyons, C. J. & Hungerford, J. (1990) Detection of ocular malignancies. *Journal of the Royal Society of*  
24 *Medicine*, 83: 165-167.  
25 Not in PICO
- 26 Makdoui, K. & Crafoord, S. (2011) Vasoproliferative retinal tumours in a Swedish population. *Acta*  
27 *Ophthalmologica*, 89: 91-94.  
28 Not in PICO
- 29 Maki, J. L., Marr, B. P. & Abramson, D. H. (2009) Diagnosis of retinoblastoma: how good are referring  
30 physicians? *Ophthalmic Genetics*, 30: 199-205.  
31 Not in PICO
- 32 Malkani, I., Warriar, R. P., Yu, L. C. & Ode, D. L. (1993) Retinoblastoma: a review. [Review] [31 refs].  
33 *Indian Journal of Pediatrics*, 60: 227-236.  
34 Narrative review
- 35 Marsh-Tootle, W. L., McGwin, G., Kohler, C. L., Kristofco, R. E., Datla, R. V. & Wall, T. C. (2011)  
36 Efficacy of a web-based intervention to improve and sustain knowledge and screening for  
37 amblyopia in primary care settings. *Investigative Ophthalmology and Visual Science*, 52: 7160-  
38 7167.  
39 Not in PICO
- 40 Matejovsky, Z. & Povysil, C. (1986) Ewing's sarcoma. New clinico-pathological aspects. [German].  
41 *Zentralblatt fur Allgemeine Pathologie und Pathologische Anatomie*, 132: 11-24.  
42 Narrative review
- 43 Maxwell, P. (2013) Identifying signs of retinoblastoma. *Nursing Times*, 109: 17-23.  
44 Narrative review
- 45 Mazur, K. A. (2010) Neuroblastoma: What the nurse practitioner should know. *Journal of the*  
46 *American Academy of Nurse Practitioners*, 22: 236-245.  
47 Narrative review
- 48 McHugh, K. (2007) Renal and adrenal tumours in children. [Review] [19 refs]. *Cancer Imaging*, 7: 41-  
49 51.  
50 Narrative review

- 1 McNeil, D. E., Brown, M., Ching, A. & DeBaun, M. R. (2001) Screening for Wilms tumor and  
2 hepatoblastoma in children with Beckwith-Wiedemann syndromes: a cost-effective model.  
3 *Medical & Pediatric Oncology*, 37: 349-356.  
4 Not in PICO
- 5 Meel, R., Radhakrishnan, V. & Bakhshi, S. (2012) Current therapy and recent advances in the  
6 management of retinoblastoma. *Indian journal of medical and paediatric oncology : official  
7 journal of Indian Society of Medical & Paediatric Oncology*, 33: 80-88.  
8 Narrative review
- 9 Melamud, A., Palekar, R. & Singh, A. (2006) Retinoblastoma. [Review] [21 refs][Erratum appears in  
10 Am Fam Physician. 2007 Apr 1;75(7):980]. *American Family Physician*, 73: 1039-1044.  
11 Narrative review
- 12 Memon, F., Rathi, S. L. & Memon, M. H. (2007) Pattern of solid paediatric malignant neoplasm at  
13 Lumhs, Jamshoro, Pakistan. *Journal of Ayub Medical College, Abbottabad: JAMC*, 19: 55-57.  
14 Not in PICO
- 15 Mierzwa, D. M. & Romanowska, D. B. (2012) Assessment of the influence of one's education on early  
16 diagnosis of multiple primary cancer in patients with uveal melanoma. *Klinika.oczna*, 114: 111-  
17 114.  
18 Not in PICO
- 19 Millar, A. J., Davidson, A., Rode, H., Numanoglu, A., Hartley, P. S., Daubenton, J. D. & Desai, F. (2005)  
20 Bilateral Wilms' tumors: a single-center experience with 19 cases. *Journal of Pediatric Surgery*, 40:  
21 1289-1294.  
22 Not in PICO
- 23 Miron, I., Miron, L., Dumitras, S., Aprodu, G., Ciobanu, A. & Tansanu, I. (2007) Statistical study of the  
24 evolution over ten years of the clinical and therapeutic approach in childhood soft tissue  
25 sarcoma. [Romanian]. *Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi*,  
26 111: 358-362.  
27 Not in PICO
- 28 Mitchell, W. G., Davalos-Gonzalez, Y., Brumm, V. L., Aller, S. K., Burger, E., Turkel, S. B., Borchert, M.  
29 S., Hollar, S. & Padilla, S. (2002) Opsoclonus-ataxia caused by childhood neuroblastoma:  
30 developmental and neurologic sequelae.[Erratum appears in Pediatrics 2002 Oct;110(4):853-4].  
31 *Pediatrics*, 109: 86-98.  
32 Not in PICO
- 33 Mohanna, M. A. & Sallam, A. K. (2014) - Idiopathic hemihypertrophy. - *Saudi Medical Journal*, 35:  
34 403-405.  
35 Not in PICO
- 36 Mott, M. G. (1995) Neoplasia in Childhood - 25 Years of Progress. *Annals of Oncology*, 6: 3-9.  
37 Narrative review
- 38 Motzer, R. J., Bolger, G. B., Boston, B., Carducci, M. A., Fishman, M., Hancock, S. L., Hauke, R. J.,  
39 Hudes, G. R., Jonasch, E., Kantoff, P., Kuzel, T. M., Lange, P. H., Levine, E. G., Logothetis, C.,  
40 Margolin, K. A., Pohar, K., Redman, B. G., Robertson, C. N., Samlowski, W. E., Sheinfeld, J. &  
41 National Comprehensive, C. N. (2006) Kidney cancer. Clinical practice guidelines in oncology.  
42 *Journal of the National Comprehensive Cancer Network*, 4: 1072-1081.  
43 Guideline
- 44 Moukheiber, A. K., Nicollas, R., Roman, S., Coze, C. & Triglia, J. M. (2001) Primary pediatric  
45 neuroblastic tumors of the neck. *International Journal of Pediatric Otorhinolaryngology*, 60: 155-  
46 161.  
47 Not in PICO
- 48 Mouratova, T. (2005) Trilateral retinoblastoma: a literature review, 1971-2004. [Review] [92 refs].  
49 *Bulletin de la Societe Belge d Ophtalmologie.(297):25-35, 2005., 25-35.*  
50 Narrative review



- 1 Mullaney, P. B., Karcioglu, Z. A., al-Mesfer, S. & Dowaidi, M. (1996) Retinoblastoma referral patterns  
2 in Saudi Arabia. *Ophthalmic Epidemiology*, 3: 35-46.  
3 Not in PICO
- 4 Musarella, M. A., Chan, H. S., DeBoer, G. & Gallie, B. L. (1984) Ocular involvement in neuroblastoma:  
5 prognostic implications. *Ophthalmology*, 91: 936-940.  
6 Not in PICO
- 7 Nabie, R., Taheri, N., Fard, A. M. & Fouladi, R. F. (2012) Characteristics and clinical presentations of  
8 pediatric retinoblastoma in North-western Iran. *International Journal of Ophthalmology*, 5: 510-  
9 512.  
10 Not in PICO
- 11 Nakamura, L. & Ritchey, M. (2010) Current management of wilms' tumor. [Review] [58 refs]. *Current*  
12 *Urology Reports*, 11: 58-65.  
13 Narrative review
- 14 Narukawa, T., Naitoh, Y., Taniguchi, H., Ueno, A., Nakagawa, H., Suzuki, K., Fujihara, A., Okihara, K. &  
15 Miki, T. (2014) - [A pediatric wilms' tumor presenting with a right renal injury]. [Japanese]. -  
16 *Hinyokika Kyo - Acta Urologica Japonica*, 60: 329-331.  
17 Not in PICO
- 18 Naseripour, M., Nazari, H., Bakhtiari, P., Modarres-Zadeh, M., Vosough, P. & Ausari, M. (2009)  
19 Retinoblastoma in Iran: Outcomes in terms of patients' survival and globe survival. *British Journal*  
20 *of Ophthalmology*, 93: 28-32.  
21 Not in PICO
- 22 Nathan, N. R. & Donahue, S. P. (2011) Modification of Plusoptix referral criteria to enhance  
23 sensitivity and specificity during pediatric vision screening. *Journal of AAPOS*, 15: 551-555.  
24 Not in PICO
- 25 Nathrath, M. & Teichert, V. L., I (2009) Oncologic causes of bone pain. [German]. *Monatsschrift fur*  
26 *Kinderheilkunde*, 157: 655-660.  
27 Narrative review
- 28 Nishimura, O. & Ohata, M. (1994) [Neuroblastoma]. [Review] [10 refs] [Japanese]. *Ryoikibetsu*  
29 *Shokogun Shirizu.(4):440-1, 1994., 440-441.*  
30 Narrative review?
- 31 Nucci, P. & Curiel, B. (2009) Abnormal head posture due to ocular problems: A review. *Current*  
32 *Pediatric Reviews*, 5: 105-111.  
33 Narrative review
- 34 O'Doherty, M., Lanigan, B., Breathnach, F., O'Meara, A., Gallie, B., Chan, H. & O'Keefe, M. (2005) A  
35 retrospective review of visual outcome and complications in the treatment of retinoblastoma.  
36 *Irish Medical Journal*, 98: 17-20.  
37 Not in PICO
- 38 Osman, Y., Haraz, A., El-Mekresh, M., Gomha, A. M., El-Ghar, M. A. & Eraky, I. (2011) Adrenal tumors  
39 with venous thrombosis: a single-institution experience. *Urologia Internationalis*, 87: 182-185.  
40 Not in PICO
- 41 Ott, J. J., Ullrich, A. & Miller, A. B. (2009) The importance of early symptom recognition in the  
42 context of early detection and cancer survival. *European Journal of Cancer*, 45: 2743-2748.  
43 Narrative review
- 44 Ozdemir, H., Tacyildiz, N., Unal, E., Yavuz, G., Ugur, H. & Gunduz, K. (2007) Clinical and  
45 epidemiological characteristics of retinoblastoma: Correlation with prognosis in a Turkish  
46 Pediatric Oncology Center. *Pediatric Hematology and Oncology*, 24: 221-231.  
47 Not in PICO
- 48 Pakakasama, S. & Tomlinson, G. E. (2002) Genetic predisposition and screening in pediatric cancer.  
49 *Pediatric Clinics of North America*, 49: 1393-1413.  
50 Narrative review

- 1 Palazzi, M. A., Stephan, C., Brandalise, S. R. & Aguiar, S. D. S. (2013) Retinoblastoma diagnosis: A  
2 proposal based on the experience of Centro Infantil Boldrini, Brazil. *Pediatric Hematology and*  
3 *Oncology*, 30: 379-385.  
4 Not in PICO
- 5 Paltiel, H. J. (2007) Sonography of Pediatric Renal Tumors. *Ultrasound Clinics*, 2: 89-104.  
6 Narrative review
- 7 Paradies, G., Zullino, F., Orofino, A. & Leggio, S. (2013) Mediastinal teratomas in children. Case  
8 reports and review of the literature. *Annali Italiani di Chirurgia*, 84(4):395-403, -403, 2013.  
9 Not in PICO
- 10 Park, C. S., Ha, H. G., Lee, S. D. & Chung, M. K. (2009) Clinical characteristics of Wilms' tumor  
11 according to age. [Korean]. *Korean Journal of Urology*, 50: 1188-1192.  
12 Not in PICO
- 13 Paulino, A. C. (1999) Trilateral retinoblastoma: is the location of the intracranial tumor important?.  
14 [Review] [45 refs]. *Cancer*, 86: 135-141.  
15 Not in PICO
- 16 Peng, X., Wang, G., Zhang, F., Meng, S. & Lu, N. (2002) [Clinical features of 48 cases with retinal  
17 angioma]. [Chinese]. *Chung-Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]*, 38: 550-  
18 552.  
19 Not in PICO
- 20 Petrus, L. V., Hall, T. R., Boechat, M. I., Westra, S. J., Curran, J. G., Steckel, R. J. & Kangaroo, H. (1992)  
21 The pediatric patient with suspected adrenal neoplasm: which radiological test to use? *Medical &*  
22 *Pediatric Oncology*, 20: 53-57.  
23 Not in PICO
- 24 Pollock, B. H., Krischer, J. P. & Vietti, T. J. (1991) Interval between symptom onset and diagnosis of  
25 pediatric solid tumors. *Journal of Pediatrics*, 119: 725-732.  
26 Not in PICO
- 27 Priest, J. R., McDermott, M. B., Bhatia, S., Watterson, J., Manivel, J. C. & Dehner, L. P. (1997)  
28 Pleuropulmonary blastoma: A clinicopathologic study of 50 cases. *Cancer*, 80: 147-161.  
29 Not in PICO
- 30 Provenzi, M., Saettini, F., Conter, V., Chinaglia, D., Vai, P., Bruno, A., Cavalleri, L., Foglia, C., Gibaldi, E.,  
31 Collini, P. & Spreafico, F. (2013) Is there a role for FDG-PET for the assessment of treatment  
32 efficacy in Wilms' tumor? A case report and literature review. *Pediatric Hematology & Oncology*,  
33 30(7):633-9, -9, 2013.  
34 Not in PICO
- 35 Pujol, J. F., Perel, Y., Fayon, M., Dossantos, P., Cazauran, J. M., Bucco, P. & Guillard, J. M. (1992)  
36 Malignant Systemic Hypertension-Related Cardiac-Failure in A Child with Nephroblastoma.  
37 *Pediatric*, 47: 441-444.  
38 Not in PICO
- 39 Raab, C. P. & Gartner, J. C., Jr. (2009) Diagnosis of childhood cancer. [Review] [33 refs]. *Primary Care;*  
40 *Clinics in Office Practice*, 36: 671-684.  
41 Narrative review
- 42 Rahi, J. S. & Lynn, R. (1998) A survey of paediatricians' practice and training in routine infant eye  
43 examination. *Archives of Disease in Childhood*, 78: 364-366.  
44 Not in PICO
- 45 Reinhard, H., Aliani, S., Ruebe, C., Stockle, M., Leuschner, I. & Graf, N. (2004) Wilms' tumor in adults:  
46 Results of the Society of Pediatric Oncology (SIOP) 93-01/Society for Pediatric Oncology and  
47 Hematology (GPOH) Study. *Journal of Clinical Oncology*, 22: 4500-4506.  
48 Not in PICO
- 49 Rezaimehr, Y. & Bhargava, R. (2013) Neuroblastoma presenting as persistent postprandial emesis in  
50 a neonate. *Pediatric Emergency Care*, 29(12):1273-5, -5, 2013.  
51 Not in PICO

- 1 Riley, R. D., Burchill, S. A., Abrams, K. R., Heney, D., Lambert, P. C., Jones, D. R., Sutton, A. J., Young,  
2 B., Wailoo, A. J. & Lewis, I. J. (2003) A systematic review and evaluation of the use of tumour  
3 markers in paediatric oncology: Ewing's sarcoma and neuroblastoma (Structured abstract).  
4 *Health Technology Assessment Database*, 1.  
5 Not in PICO
- 6 Ritchey, M., Daley, S., Shamberger, R. C., Ehrlich, P., Hamilton, T., Haase, G. & Sawin, R. (2008)  
7 Ureteral extension in Wilms' tumor: a report from the National Wilms' Tumor Study Group  
8 (NWTSG). *Journal of Pediatric Surgery*, 43: 1625-1629.  
9 Not in PICO
- 10 Rodrigues, K. E. & de, C. B. (2003) Early diagnosis of childhood cancer: a team responsibility.  
11 [Portuguese]. *Revista da Associacao Medica Brasileira (1992)*, 49: 29-34.  
12 Narrative review
- 13 Roganovic, J. (2006) Hepatic tumours. [Croatian]. *Paediatrica Croatica, Supplement*, 50: 260-264.  
14 Narrative review
- 15 Ross, G., Lipper, E. G., Abramson, D. & Preiser, L. (2001) The development of young children with  
16 retinoblastoma. *Archives of Pediatrics & Adolescent Medicine*, 155: 80-83.  
17 Not in PICO
- 18 Roth, A. (1981) The role of the general practitioner and the family in the initial diagnosis and  
19 treatment of the squinting child. [French]. *Therapeutische Umschau*, 38: 228-234.  
20 Narrative review
- 21 Royer-Pokora, B., Beier, M., Henzler, M., Alam, R., Schumacher, V., Weirich, A. & Huff, V. (2004)  
22 Twenty-four new cases of WT1 germline mutations and review of the literature:  
23 genotype/phenotype correlations for Wilms tumor development. *American Journal of Medical  
24 Genetics.Part A*, 127A: 249-257.  
25 Not in PICO
- 26 Royer-Pokora, B. (2007) Genetic predisposition to Wilms tumor. [German]. *Medizinische Genetik*, 19:  
27 234-238.  
28 Narrative review
- 29 Ruccione, K. S. (1992) Wilms' tumor: a paradigm, a parallel, and a puzzle. [Review] [67 refs].  
30 *Seminars in Oncology Nursing*, 8: 241-251.  
31 Narrative review
- 32 Sampson, V. B., Gorlick, R., Kamara, D. & Anders, K. E. (2013) A review of targeted therapies  
33 evaluated by the pediatric preclinical testing program for osteosarcoma. *Frontiers in Oncology*,  
34 3:132.  
35 Narrative review
- 36 Sasaki, H., Sato, Y., Kondo, S., Fukai, I., Kiriya, M., Yamakawa, Y. & Fuji, Y. (2002) Expression of the  
37 periostin mRNA level in neuroblastoma. *Journal of Pediatric Surgery*, 37: 1293-1297.  
38 Not in PICO
- 39 Schenk, J.-P., Engelmann, D., Rohrschneider, W., Zieger, B., Semler, O., Graf, N. & Troger, J. (2004)  
40 Rhabdoid tumors of the kidney in childhood - A retrospective radiomorphologic analysis of 22  
41 patients as part of the nephroblastoma study SIOP 93/01-GPOH registered cases. [German]. *RoFo  
42 Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren*, 176: 965-971.  
43 Not in PICO
- 44 Schilling, F. H. (2002) [Neuroblastoma Early Detection Model Project. Background and results].  
45 [German]. *Kinderkrankenschwester*, 21: 295-296.  
46 Narrative review
- 47 Schmidt, D. (2005) [Retinal angiomas]. [Review] [176 refs] [German]. *Klinische Monatsblätter für  
48 Augenheilkunde*, 222: 90-109.  
49 Narrative review
- 50 Schmidt, D., Anderson, L., Bingen, K., Hoag, J., Kupst, M. J. & Warwick, A. B. (2010) Late effects in  
51 adult survivors of childhood cancer: Considerations for the general practitioner. *Wisconsin*

- 1 *Medical Journal*, 109: 98-108.  
 2 Narrative review
- 3 See, W. A. & Williams, R. D. (1992) Tumors of the kidney, ureter, and bladder. *Western Journal of*  
 4 *Medicine*, 156: 523-534.  
 5 Narrative review
- 6 Seregard, S., Ek, U., Preisler, G., af, T. E., Jacobson, L., Oskar, K., Illerstahl, I. & Kock, E. (1996) [A study  
 7 of children with retinoblastoma. Diagnosis is often delayed]. [Swedish]. *Lakartidningen*, 93: 1133-  
 8 1135.  
 9 Not in PICO
- 10 Servodidio, C. A., Abramson, D. H. & Romanella, A. (1991) Retinoblastoma. [Review] [19 refs]. *Cancer*  
 11 *Nursing*, 14: 117-123.  
 12 Narrative review
- 13 Shamberger, R. C., Haase, G. M., Argani, P., Perlman, E. J., Cotton, C. A., Takashima, J., Green, D. M.  
 14 & Ritchey, M. L. (652) Bilateral Wilms' tumors with progressive or nonresponsive disease. *Journal*  
 15 *of Pediatric Surgery*, 41: 652-657.  
 16 Not in PICO
- 17 Shi, G. H., Chen, Y., Yao, X. D., Zhang, S. L., Dai, B., Feng, L. Q., Zhang, H. L., Shen, Y. J., Zhu, Y., Zhu, Y.  
 18 P., Xiao, W. J., Ma, C. G., Wen, L. G., Qin, X. J., Yang, L. F. & Ye, D. W. (2013) Individualized renal  
 19 mass biopsy strategy for Chinese patients with different subtypes and necrosis area. *Urologic*  
 20 *Oncology*, 31(6):920-3, -3, 2013.  
 21 Not in PICO
- 22 Shields, J. A., Shields, C. L., Gunduz, K. & Eagle, R. C., Jr. (1999) Neoplasms of the retinal pigment  
 23 epithelium: the 1998 Albert Ruedemann, Sr, memorial lecture, Part 2. *Archives of Ophthalmology*,  
 24 117: 601-608.  
 25 Not in PICO
- 26 Simon, J. W. & Kaw, P. (2001) Commonly missed diagnoses in the childhood eye examination.  
 27 [Review] [16 refs]. *American Family Physician*, 64: 623-628.  
 28 Narrative review
- 29 Simon, T. (555) [Neuroblastoma]. [Review] [7 refs] [German]. *Urologe (Ausg.A)*, 44: 543-554.  
 30 Narrative review
- 31 Somashekhar, M., Kadamba, P. S. & Wakodkar, M. (2008) Chronic disseminated intravascular  
 32 coagulation presenting as renal mass. *Journal of Indian Association of Pediatric Surgeons*, 13: 144-  
 33 146.  
 34 Not in PICO
- 35 Sovinz, P., Urban, C., Lackner, H., Benesch, M. & Langmann, G. (2006) Retinoblastoma: a proposal for  
 36 a multimodal treatment concept for intraocular retinoblastoma in Austria. *Wiener Klinische*  
 37 *Wochenschrift*, 118: 22-30.  
 38 Not in PICO
- 39 Stepan, J., Cepulic, M., Petkovic, I., Cizmic, A. & Nakic, M. (2007) Nephroblastomas - Wilm's tumor  
 40 (WT). [Croatian]. *Paediatrica Croatica, Supplement*, 51: 92-97.  
 41 Narrative review
- 42 Stricker, S. J. & Hunt, T. (2004) Evaluation of leg length discrepancy in children. *International*  
 43 *Pediatrics*, 19: 134-142+144.  
 44 Narrative review
- 45 Suita, S. (2002) Stephen L. Gans overseas lecture. Mass screening for neuroblastoma in Japan:  
 46 lessons learned and future directions. *Journal of Pediatric Surgery*, 37: 949-954.  
 47 Not in PICO
- 48 Teplick, A., Kowalski, M., Biegel, J. A. & Nichols, K. E. (2011) Educational paper : Screening in cancer  
 49 predisposition syndromes: Guidelines for the general pediatrician. *European Journal of Pediatrics*,  
 50 170: 285-294.  
 51 Narrative review

- 1 Van Den Heuvel-Eibrink, M. M., Grundy, P., Graf, N., Pritchard-Jones, K., Bergeron, C., Patte, C., Van,  
2 T. H., Rey, A., Langford, C., Anderson, J. R. & De, K. J. (2008) Characteristics and survival of 750  
3 children diagnosed with a renal tumor in the first seven months of life: A collaborative study by  
4 the SIOP/GPOH/SFOP, NWTSG, and UKCCSG Wilms tumor study groups. *Pediatric Blood and  
5 Cancer*, 50: 1130-1134.  
6 Not in PICO
- 7 Varan, A. (2008) Wilms' tumor in children: An overview. *Nephron - Clinical Practice*, 108: c83-c90.  
8 Narrative review
- 9 Vemuganti, G. K., Jalali, S., Honavar, S. G. & Shekar, G. C. (2001) Enucleation in a tertiary eye care  
10 centre in India: prevalence, current indications and clinicopathological correlation. *Eye*, 15: 6-5.  
11 Not in PICO
- 12 Verma, N., Fromberg, G., Ghose, S. & Chandershekhar, G. (1987) Ultrasonography in orbital  
13 retinoblastoma. *Orbit*, 6: 37-41.  
14 Not in PICO (referred population)
- 15 Vingtain, P., Negrel, A. D., Ginoux, J., Cozette, P., Rivaud, C., Queguiner, P., Feuillerat, J. & Chovet, M.  
16 (1986) [Orbital and ocular tumors in the Republic of Mali]. [French]. *Medecine Tropicale*, 46: 147-  
17 153.  
18 Not in PICO
- 19 Vujanic, G. M. (2006) Renal tumours in early life. *Current Diagnostic Pathology*, 12: 210-219.  
20 Narrative review
- 21 Wakamb, G. K., Nkashama, G. M., Mbuli, R. L., Borasisi, G. C. & Nikulu, J. I. (2013) [Problematic of the  
22 management of childhood cancer: experience of retinoblastoma in Lubumbashi (DR Congo) and  
23 the importance of early diagnosis]. [French]. *The Pan African medical journal*, 14: 64.  
24 Not in PICO
- 25 Wallach, M., Balmer, A., Munier, F., Houghton, S., Pampallona, S., von der, W. N., Beck-Popovic, M.,  
26 Swiss Pediatric Oncology Group & Swiss Childhood, C. R. (2006) Shorter time to diagnosis and  
27 improved stage at presentation in Swiss patients with retinoblastoma treated from 1963 to 2004.  
28 *Pediatrics*, 118: e1493-e1498.  
29 Not in PICO
- 30 Wayte, N., Da, S. L., Chenevix-Trench, G. & Lakhani, S. R. (2008) What's in a cancer syndrome?  
31 Genes, phenotype and pathology. *Pathology*, 40: 247-259.  
32 Narrative review
- 33 Weng, E. Y., Mortier, G. R. & Graham, J. (1995) Beckwith-Wiedemann syndrome: An update and  
34 review for the primary pediatrician. *Clinical Pediatrics*, 34: 317-326.  
35 Narrative review
- 36 White, J. & Gole, G. (2012) Delay in the diagnosis of retinoblastoma: An update. *Clinical and  
37 Experimental Ophthalmology*, 40: 37.  
38 Not in PICO
- 39 Wiesbauer, P. (2008) [Nephrogenic tumors]. [German]. *Radiologe*, 48: 932-939.  
40 Narrative review
- 41 Wirix, M., Parys-Vanginderdeuren, R., Casteels, I. & Uyttebrouck, A. (2000) Delayed diagnosis of  
42 retinoblastoma. *Bulletin de la Societe Belge d Ophtalmologie*.(278):37-41, 2000., 37-41.  
43 Not in PICO
- 44 Wolf, W. J. & Bancroft, B. (1980) Early detection of childhood malignancies. *Pediatric Nursing*, 6: 43-  
45 46.  
46 Narrative review
- 47 Young, G., Toretsky, J. A., Campbell, A. B. & Eskenazi, A. E. (2000) Recognition of common childhood  
48 malignancies. *American Family Physician*, 61: 2144-2154.  
49 Narrative review
- 50 Zawitkowska-Klaczynska, J., Katski, K., Nurzynska-Flak, J. & Kowalczyk, J. (2003) Primary chest  
51 tumours in children. *Annales Universitatis Mariae Curie-Sklodowska - Sectio d - Medicina*, 58: 106-

110.

Not in PICO

Zeller, G. X. & De, S. E. (1991) [A numerical overview of various forms of retinoblastoma]. [Review] [14 refs] [German]. *Klinische Monatsblätter für Augenheilkunde*, 198: 81-82.

Narrative review

Zintl, E. & Deufrains, A. (1989) [Contribution of the pediatrician in the early diagnosis of eye diseases. 2]. [Review] [10 refs] [German]. *Kinderärztliche Praxis*, 57: 263-270.

Narrative review

Zoller, G., Lakomek, M. & Ringert, R. H. (1992) [Wilm's tumor 1992. State of research and results of current therapeutic concepts]. [Review] [20 refs] [German]. *Urologe (Auszg.A)*, 31: 360-367.

Narrative review

**Review question:**

Which investigations of symptoms of suspected retinoblastoma, neuroblastoma and Wilm's tumour in children should be done with clinical responsibility retained by primary care?

**Results****Literature search****Retinoblastoma:**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1980-2013	341	42	26/06/2013
<i>Premedline</i>	1980-2013	15	2	26/06/2013
<i>Embase</i>	1980-2013	240	21	26/06/2013
<i>Cochrane Library</i>	1980-2013	19	0	26/06/2013
<i>Psychinfo</i>	1980-2013	1	0	26/06/2013
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	1980-2013	34	9	26/06/2013

Total References retrieved (after de-duplication): 66

**Retinoblastoma: Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	6/2013-27/08/2014	8	1	27/08/2014
<i>Premedline</i>	6/2013-27/08/2014	11	1	27/08/2014
<i>Embase</i>	6/2013-27/08/2014	11	2	27/08/2014
<i>Cochrane Library</i>	6/2013-27/08/2014	7	0	27/08/2014
<i>Web of Science (SCI &amp; SSCI) and ISI Proceedings</i>	6/2013-27/08/2014	8	0	27/08/2014

Total References retrieved (after de-duplication): 2

**Neuroblastoma:**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search

<b>Medline</b>	1980-2013	220	16	25/06/2013
<b>Premedline</b>	1980-2013	21	5	25/06/2013
<b>Embase</b>	1980-2013	135	14	25/06/2013
<b>Cochrane Library</b>	1980-2013	4	1	25/06/2013
<b>Psychinfo</b>	1980-2013	4	0	25/06/2013
<b>Web of Science (SCI &amp; SSCI) and ISI Proceedings</b>	1980-2013	26	2	25/06/2013

1 Total References retrieved (after de-duplication): 33

2

3 **Neuroblastoma: Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<b>Medline</b>	6/2013-27/08/2014	6	0	27/08/2014
<b>Premedline</b>	6/2013-27/08/2014	26	4	27/08/2014
<b>Embase</b>	6/2013-27/08/2014	18	2	27/08/2014
<b>Cochrane Library</b>	6/2013-27/08/2014	17	0	27/08/2014
<b>Web of Science (SCI &amp; SSCI) and ISI Proceedings</b>	6/2013-27/08/2014	5	0	27/08/2014

4 Total References retrieved (after de-duplication): 6

5

6 **Wilm's tumour:**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<b>Medline</b>	1980-2013	266	23	26/06/2013
<b>Premedline</b>	1980-2013	22	2	26/06/2013
<b>Embase</b>	1980-2013	219	11	26/06/2013
<b>Cochrane Library</b>	1980-2013	40	0	26/06/2013
<b>Psychinfo</b>	1980-2013	1	0	26/06/2013
<b>Web of Science (SCI &amp; SSCI) and ISI Proceedings</b>	1980-2013	5	1	26/06/2013

7 Total References retrieved (after de-duplication): 28


8

9 **Wilm's tumour: Update Search**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<b>Medline</b>	6/2013-27/08/2014	9	1	27/08/2014
<b>Premedline</b>	6/2013-27/08/2014	28	2	27/08/2014
<b>Embase</b>	6/2013-27/08/2014	29	3	27/08/2014
<b>Cochrane Library</b>	6/2013-27/08/2014	13	0	27/08/2014
<b>Web of Science (SCI &amp; SSCI) and ISI Proceedings</b>	6/2013-27/08/2014	1	0	27/08/2014

<b>SSCI) and ISI Proceedings</b>	27/08/2014			
----------------------------------	------------	--	--	--

1 Total References retrieved (after de-duplication): 4



2

3

4

5

## Study results

6 No evidence was identified pertaining to the diagnostic accuracy of tests in children with suspected  
7 retinoblastoma, neuroblastoma and Wilm's tumour where the clinical responsibility was retained by  
8 primary care.

9

## 10 References

### 11 Included studies

12 None

13

### 14 Excluded studies (with excl reason)

15 Ahmed, S., Goel, S., Khandwala, M., Agrawal, A., Chang, B. & Simmons, I. G. (2006) Neuroblastoma  
16 with orbital metastasis: ophthalmic presentation and role of ophthalmologists. *Eye*, 20: 466-470.  
17 Not in PICO

18 Ahrensberg, J. M., Fenger-Gron, M. & Vedsted, P. (2013) Use of primary care during the year before  
19 childhood cancer diagnosis: a nationwide population-based matched comparative study. *PLoS*  
20 *ONE [Electronic Resource]*, 8: e59098.

21 Not in PICO

22 Alkatan, H., Al-Amry, M., Al-Hussain, H., Al-Dhibi, H. & al-Mesfer, S. (2011) Medulloepithelioma of  
23 the ciliary body: The delay in diagnosis and frequent initial mismanagement. *Canadian Journal of*  
24 *Ophthalmology*, 46: 431-438.

25 Not in PICO

26 Aston, J. W., Jr. (1990) Pediatric update #16. The orthopaedic presentation of neuroblastoma.  
27 *Orthopaedic Review*, 19: 929-932.

28 Not in PICO

29 Augsburger, J. J. & Shields, J. A. (1984) Fine needle aspiration biopsy of solid intraocular tumors:  
30 indications, instrumentation and techniques. *Ophthalmic Surgery*, 15: 34-40.

31 Not in PICO



- 1 Augsburger, J. J., Shields, J. A., Folberg, R., Lang, W., O'Hara, B. J. & Claricci, J. D. (1985) Fine needle  
2 aspiration biopsy in the diagnosis of intraocular cancer. Cytologic-histologic correlations.  
3 *Ophthalmology*, 92: 39-49.  
4 Not in PICO
- 5 Augsburger, J. J. (1988) Fine needle aspiration biopsy of suspected metastatic cancers to the  
6 posterior uvea. *Transactions of the American Ophthalmological Society*, 86: 499-560.  
7 Not in PICO
- 8 Badhu, B., Sah, S. P., Thakur, S. K. D., Dulal, S., Kumar, S., Sood, A., Das, H. & Sah, R. P. (2005) Clinical  
9 presentation of retinoblastoma in Eastern Nepal. *Clinical and Experimental Ophthalmology*, 33:  
10 386-389.  
11 Not in PICO
- 12 Bai, S., Ren, R., Li, B., Xu, X., Zhao, B., Gao, F., Li, L. & Jonas, J. B. (2011) Delay in the diagnosis of  
13 retinoblastoma in China. *Acta Ophthalmologica*, 89: e72-e74.  
14 Not in PICO
- 15 Balmer, A., Zografos, L. & Munier, F. (2006) Diagnosis and current management of retinoblastoma.  
16 [Review] [60 refs]. *Oncogene*, 25: 5341-5349.  
17 Narrative review
- 18 Balmer, A. & Munier, F. (2007) Differential diagnosis of leukocoria and strabismus, first presenting  
19 signs of retinoblastoma. *Clinical Ophthalmology*, 1: 431-439.  
20 Narrative review
- 21 Barroca, H. & Bom-Successo, M. (2014) Fine needle biopsy with cytology in paediatrics: The  
22 importance of a multidisciplinary approach and the role of ancillary techniques. *Cytopathology*,  
23 25: 6-20.  
24 Narrative review
- 25 Bilal, M. M. & Brown, J. J. (1997) MR imaging of renal and adrenal masses in children. *Magnetic  
26 Resonance Imaging Clinics of North America*, 5: 179-197.  
27 Narrative review
- 28 Bliznakova, D. (2003) Differential diagnosis of some kidney diseases in childhood. [Bulgarian].  
29 *Bulgarian Medicine*, 11: 7-10.  
30 Narrative review
- 31 Boubaker, A. & Bischof, D. A. (2003) Nuclear medicine procedures and neuroblastoma in childhood.  
32 Their value in the diagnosis, staging and assessment of response to therapy. [Review] [55 refs].  
33 *Quarterly Journal of Nuclear Medicine*, 47: 31-40.  
34 Narrative review
- 35 Brasme, J. F., Morfouace, M., Grill, J., Martinot, A., Amalberti, R., Bons-Letouzey, C. & Chalumeau, M.  
36 (2012) Delays in diagnosis of paediatric cancers: a systematic review and comparison with expert  
37 testimony in lawsuits. [Review]. *Lancet Oncology*, 13: e445-e459.  
38 Not in PICO
- 39 Brink, H. M., Pinckers, A. J. & Verbeek, A. M. (1990) The electro-oculogram in uveal melanoma. A  
40 prospective study. *Documenta Ophthalmologica*, 75: 329-334.  
41 Not in PICO
- 42 Butros, L. J., Abramson, D. H. & Dunkel, I. J. (2002) Delayed diagnosis of retinoblastoma: analysis of  
43 degree, cause, and potential consequences. *Pediatrics*, 109: E45.  
44 Not in PICO
- 45 Cabral, D. A. & Tucker, L. B. (1999) Malignancies in children who initially present with rheumatic  
46 complaints. *Journal of Pediatrics*, 134: 53-57.  
47 Not in PICO
- 48 Canty, C. A. (2009) Retinoblastoma: an overview for advanced practice nurses. [Review] [23 refs].  
49 *Journal of the American Academy of Nurse Practitioners*, 21: 149-155.  
50 Narrative review

- 1 Canzano, J. C. & Handa, J. T. (1999) Utility of pupillary dilation for detecting leukocoria in patients  
2 with retinoblastoma. *Pediatrics*, 104: e44.  
3 Not in PICO
- 4 Chen, K. S., Lai, M. K., Huang, C. C., Chu, S. H. & Leu, M. L. (1995) Urologic cancers in uremic patients.  
5 *American Journal of Kidney Diseases*, 25: 694-700.  
6 Not in PICO
- 7 Ciocalteu, A. M., Ardeleanu, S. & Checherita, I. A. (2011) [The role of ultrasonography exam in  
8 orbital-ocular tumors]. [Romanian]. *Revista Medico-Chirurgicala a Societatii de Medici Si*  
9 *Naturalisti Din Iasi*, 115: 1113-1118.  
10 Narrative review
- 11 Clericuzio, C. L. & Martin, R. A. (2009) Diagnostic criteria and tumor screening for individuals with  
12 isolated hemihyperplasia. *Genetics in Medicine*, 11: 220-222.  
13 Narrative review
- 14 Cozzi, D. A., Mele, E., Ceccanti, S., Natale, F., Clerico, A., Schiavetti, A. & Dominici, C. (2013) Long-  
15 term follow-up of the "wait and see" approach to localized perinatal adrenal neuroblastoma.  
16 *World Journal of Surgery*, 37: 459-465.  
17 Not in PICO
- 18 Croft, D. & Dickerson, M. (1994) Ultrasound differentiation of two pediatric abdominal masses.  
19 *Journal of Diagnostic Medical Sonography*, 10: 12-17.  
20 Narrative review
- 21 Damato, B. (2001) Time to treatment of uveal melanoma in the United Kingdom. *Eye*, 15: 2-8.  
22 Not in PICO
- 23 Damato, E. M. & Damato, B. E. (2012) Detection and time to treatment of uveal melanoma in the  
24 United Kingdom: an evaluation of 2,384 patients. *Ophthalmology*, 119: 1582-1589.  
25 Not in PICO
- 26 Damgaard-Pedersen, K. (1980) CT and IVU in the diagnosis of Wilms' tumour. A comparative study.  
27 *Pediatric Radiology*, 9: 207-211.  
28 Not in PICO
- 29 DE, F. G. (1956) [Early diagnosis and treatment of Wilms' tumor in infancy]. [Portuguese]. *Revista*  
30 *Brasileira de Cirurgia*, 31: 375-383.  
31 Outside of agreed date range (pre 1980)
- 32 Diaconescu, S., Olaru, C., Mihaila, D., Aprodu, S. G. & Miron, I. (2013) Risk stratification and  
33 consecutive prognosis progresses in childhood Wilms Tumors. Two cases report. *Chirurgia*  
34 *(Bucuresti)*, 108: 106-111.  
35 Not in PICO
- 36 Diaconescu, S., Olaru, C., Mihaila, D., Aprodu, S. G. & Miron, I. (2013) Risk stratification and  
37 consecutive prognosis progresses in childhood Wilms tumors. Two cases report. *Chirurgia*  
38 *(Bucuresti)*, 108: 106-111.  
39 Not in PICO
- 40 Dieckhues, B. (1986) [Value of serologic tumor tests in malignant melanoma of the choroid].  
41 [German]. *Klinische Monatsblätter für Augenheilkunde*, 188: 114-117.  
42 Not in PICO
- 43 Diniz, G., Aktas, S., Turedi, A., Ortac, R. & Vergin, C. (2010) Telomerase activity in wilms tumor.  
44 *Pediatric Blood and Cancer*, 55: 884-885.  
45 Not in PICO
- 46 Dommett, R. M., Redaniel, M. T., Stevens, M. C. G., Hamilton, W. & Martin, R. M. (2012) Features of  
47 childhood cancer in primary care: A population-based nested case-control study. *British Journal*  
48 *of Cancer*, 106: 982-987.  
49 Not in PICO

- 1 Drlicek, G., Hayder, W. & Kratochwil, A. (1987) [Use of sonography at the peripheral hospital in the  
2 diagnosis of kidney tumors]. [German]. *Wiener Klinische Wochenschrift*, 99: 835-838.  
3 Not in PICO
- 4 Dubashi, B., Cyriac, S. & Tenali, S. G. (2009) Clinicopathological analysis and outcome of primary  
5 mediastinal malignancies - A report of 91 cases from a single institute. *Annals of Thoracic  
6 Medicine*, 4: 140-142.  
7 Not in PICO
- 8 Edeling, C.-J., Frederiksen, P. B., Kamper, J. & Jeppesen, P. (1987) Diagnosis and treatment of  
9 neuroblastoma using metaiodobenzylguanidine. *Clinical Nuclear Medicine*, 12: 632-637.  
10 Not in PICO
- 11 Edeling, C. J. (1983) Ga-67 imaging in pediatric oncology. *Clinical Nuclear Medicine*, 8: 205-209.  
12 Not in PICO
- 13 Edeling, C. J., Buchler, F. P., Kamper, J. & Jeppesen, P. (1986) Diagnosis and treatment of  
14 neuroblastoma using <sup>131</sup>I-meta-iodobenzylguanidine. *Nuclear-Medizin*, 25: 172-175.  
15 Not in PICO
- 16 Ell, C. & Schott, G. (1994) [Suspected kidney tumor--diagnostic-therapeutic procedure]. [German].  
17 *Fortschritte der Medizin*, 112: 123-124.  
18 Narrative review
- 19 Esquembre Menor, C. T. & Castel, S., V (1988) [Early diagnosis of cancer in children]. [Review] [0 refs]  
20 [Spanish]. *Anales Espanoles de Pediatria*, 29: Suppl-7.  
21 Narrative review
- 22 Faulkner-Jones, B. E., Foster, W. J., Harbour, J. W., Smith, M. E. & Davila, R. M. (2005) Fine needle  
23 aspiration biopsy with adjunct immunohistochemistry in intraocular tumor management. *Acta  
24 Cytologica*, 49: 297-308.  
25 Not in PICO
- 26 Fitz, C. R., Chuang, S. H. & Harwood-Nash, D. C. (1985) Computed tomography diagnoses of eye  
27 tumors and anomalies in early childhood and infancy. *Annales de Radiologie*, 28: 235-240.  
28 Not in PICO
- 29 Fragkandrea, I., Nixon, J. A. & Panagopoulou, P. (2013) Signs and central nervous system (CNS): Early  
30 endocrine manifestations: A guide for early recognition. *American Family Physician*, 88: 185-192.  
31 Narrative review
- 32 Gallagher, R. P., Elwood, J. M., Rootman, J., Threlfall, W. J. & Davis, J. (1988) Symptoms and time to  
33 presentation and treatment in ocular melanoma: the Western Canada Melanoma Study.  
34 *Canadian Journal of Ophthalmology*, 23: 11-13.  
35 Not in PICO
- 36 Gao, L., Lin, W. H., Gong, Z. J., Liu, Y., Liu, Y. M. & Zhu, M. H. (2004) [Fine needle aspiration cytology  
37 of eyelid sebaceous gland carcinoma and its differential diagnosis]. [Chinese]. *Chung-Hua Ping Li  
38 Hsueh Tsa Chih - Chinese Journal of Pathology*, 33: 36-39.  
39 Not in PICO
- 40 Garcia, H. B. (2008) Suspicion of cancer in pediatrics. [Spanish]. *Pediatria Integral*, 12: 537-544.  
41 Narrative review
- 42 George, J. L. & Marchal, J. C. (2010) Orbital tumors in children: Clinical examination, imaging, specific  
43 progression. [French]. *Neurochirurgie*, 56: 244-248.  
44 Narrative review
- 45 Gillmore, R., Xue, S.-A., Holler, A., Kaeda, J., Hadjiminas, D., Healy, V., Dina, R., Parry, S. C.,  
46 Bellantuono, I., Ghani, Y., Coombes, R. C., Waxman, J. & Stauss, H. J. (2006) Detection of Wilms'  
47 tumor antigen-specific CTL in tumor-draining lymph nodes of patients with early breast cancer.  
48 *Clinical Cancer Research*, 12: 34-42.  
49 Not in PICO

- 1 Gombos, D. S. & Diba, R. (2005) Estimating the incidence of retinoblastoma in Texas. *Texas Medicine*,  
2 101: 70-72.  
3 Not in PICO
- 4 Griffiths, D. F. R. & Vujanic, G. M. (2002) Cystic lesions of the kidney - Selected topics. *Current*  
5 *Diagnostic Pathology*, 8: 94-101.  
6 Narrative review
- 7 Gutjahr, P. (1991) [Congenital Wilms' tumors are mostly (benign) mesoblastic nephromas--  
8 significance of prenatally detected solid kidney tumors]. [German]. *Geburtshilfe und*  
9 *Frauenheilkunde*, 51: 124-126.  
10 Not in PICO
- 11 Holden, R. & Damato, B. E. (1996) Preventable delays in the treatment of intraocular melanoma in  
12 the UK. *Eye*, 10: 127-129.  
13 Not in PICO
- 14 Hsu, W. M., Lee, H., Juan, H. F., Shih, Y. Y., Wang, B. J., Pan, C. Y., Jeng, Y. M., Chang, H. H., Lu, M. Y.,  
15 Lin, K. H., Lai, H. S., Chen, W. J., Tsay, Y. G., Liao, Y. F. & Hsieh, F. J. (2008) Identification of GRP75  
16 as an independent favorable prognostic marker of neuroblastoma by a proteomics analysis.  
17 *Clinical Cancer Research*, 14: 6237-6245.  
18 Not in PICO
- 19 Ikpeme, E. E. & Dixon-Umo, O. T. (2013) Paediatric renal diseases in uyo, Nigeria : A 10 year review.  
20 *Pediatric Nephrology*, 28: 1411.  
21 Not in PICO
- 22 Israels, T., Ribeiro, R. C. & Molyneux, E. M. (2010) Strategies to improve care for children with cancer  
23 in Sub-Saharan Africa. [Review]. *European Journal of Cancer*, 46: 1960-1966.  
24 Narrative review
- 25 Jakobiec, F. A., Yeo, J. H., Trokel, S. L., Abbott, G. F., Anderson, R., Citrin, C. M. & Alper, M. G. (1982)  
26 Combined clinical and computed tomographic diagnosis of primary lacrimal fossa lesions.  
27 *American Journal of Ophthalmology*, 94: 785-807.  
28 Not in PICO
- 29 Januszkiewicz, D., Lastowska, M. & Zielinski, W. (1990) [Neuroblastoma in children. Results of the  
30 treatment and analysis of selected prognostic factors]. [Polish]. *Nowotwory*, 40: 143-148.  
31 Not in PICO
- 32 Junuzovic, D., Kerleta, A. & Masic, I. (2013) The frequency of renal cell carcinoma in population of  
33 patients with kidney tumors. *Medicinski Arhiv*, 67: 27-30.  
34 Not in PICO
- 35 Kamaleshwaran, K. K., Shibu, D. K., Mohanan, V. & Shinto, A. S. (2014) - Rare case of trilateral  
36 retinoblastoma with spinal canal drop metastasis detected with fluorine-18 fluorodeoxyglucose  
37 positronemission tomography/computed tomography imaging. - *Indian Journal of Nuclear*  
38 *Medicine*, 29: 115-116.  
39 Not in PICO
- 40 Kamath, V. B., Sowmya, V., Ballal, C. K. & Mendonca, N. (2013) Esthesioneuroblastoma as an unusual  
41 cause for dystopia. *Orbit*, 32: 392-394.  
42 Not in PICO
- 43 Kato, K., Kubota, T., Ikeda, M., Tadokoro, M., Abe, S., Nakano, S., Nishino, M., Kobayashi, H. &  
44 Ishigaki, T. (2006) Low efficacy of 18F-FDG PET for detection of uveal malignant melanoma  
45 compared with 123I-IMP SPECT. *Journal of Nuclear Medicine*, 47: 404-409.  
46 Not in PICO
- 47 Kersten, R. C., Ewing-Chow, D., Kulwin, D. R. & Gallon, M. (1997) Accuracy of clinical diagnosis of  
48 cutaneous eyelid lesions. *Ophthalmology*, 104: 479-484.  
49 Not in PICO

- 1 Kostopoulou, O., Delaney, B. C. & Munro, C. W. (2008) Diagnostic difficulty and error in primary care  
2 - A systematic review. *Family Practice*, 25: 400-413.  
3 Not in PICO
- 4 Kreft, B., Flacke, S., Conrad, R., Pauleit, D., Bachmann, R., Wardelmann, E., Albers, P. & Schild, H.  
5 (1999) [The pathological/MR tomographic correlation and differential diagnosis of malignant  
6 kidney tumors]. [German]. *Rofo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der  
7 Nuklearmedizin*, 171: 106-112.  
8 Not in PICO
- 9 Kumar, H. R., Sandoval, J. A., Lovell, M. A., Fenton, L. Z. & Bealer, J. F. (2010) Primary pancreatic  
10 neuroblastoma: an unusual tumor in infancy. *Journal of Pediatric Surgery*, 45: 642-646.  
11 Not in PICO
- 12 Lau, D. T., Norris, M. D., Marshall, G. M., Haber, M. & Ashton, L. J. (2011) HLA-G polymorphisms,  
13 genetic susceptibility, and clinical outcome in childhood neuroblastoma. *Tissue Antigens*, 78: 421-  
14 427.  
15 Not in PICO
- 16 Law, C., Krema, H. & Simpson, E. R. (2012) Referral patterns of intraocular tumour patients to a  
17 dedicated Canadian ocular oncology department. *Canadian Journal of Ophthalmology*, 47: 254-  
18 261.  
19 Not in PICO
- 20 Lewis, G. & Maxwell, A. P. (2002) Early diagnosis improves survival in kidney cancer. *Practitioner*,  
21 256: 13-16.  
22 Narrative review
- 23 Ling, R. E., Capsomidis, A. & Patel, S. R. (2014) Identifying childhood cancer: How is the urgent  
24 suspected cancer referral pathway performing? *Archives of Disease in Childhood*, 99: A108.  
25 Not in PICO
- 26 Long, J. A., Descotes, J. L. & Rambeaud, J. J. (2007) [Kidney cancer diagnosis]. [Review] [10 refs]  
27 [French]. *Revue du Praticien*, 57: 603-612.  
28 Narrative review
- 29 Ludick, A. (2013) Taking the early warning signs of childhood cancer to the rural areas of gauteng in  
30 south africa: Training health professionals. *Pediatric Blood and Cancer*, 60: 228.  
31 Not in PICO
- 32 Lueder, G. T. (2005) The effect of initial recognition of abnormalities by physicians on outcome of  
33 retinoblastoma. *Journal of Aapos: American Association for Pediatric Ophthalmology &  
34 Strabismus*, 9: 383-385.  
35 Not in PICO
- 36 Lyons, C. J. & Hungerford, J. (1990) Detection of ocular malignancies. *Journal of the Royal Society of  
37 Medicine*, 83: 165-167.  
38 Not in PICO
- 39 Maaita, J. F., Sunna, L. F., Al-Madani, M. V. & Horrani, S. M. (2003) Eye diseases in children in  
40 Southern Jordan. *Saudi Medical Journal*, 24: 154-156.  
41 Not in PICO
- 42 Machehkin, V. A. (1980) [Reliability of ultrasonic diagnosis in suspected intraocular tumor]. [Russian].  
43 *Vestnik Oftalmologii*.(2):58-61, 1980 Mar-Apr., 58-61.  
44 Not in PICO
- 45 Maki, J. L., Marr, B. P. & Abramson, D. H. (2009) Diagnosis of retinoblastoma: how good are referring  
46 physicians? *Ophthalmic Genetics*, 30: 199-205.  
47 Not in PICO
- 48 Margolis, R., Brasil, O. F., Lowder, C. Y., Singh, R. P., Kaiser, P. K., Smith, S. D., Perez, V. L., Sonnie, C.  
49 & Sears, J. E. (2007) Vitrectomy for the diagnosis and management of uveitis of unknown cause.  
50 *Ophthalmology*, 114: 1893-1897.  
51 Not in PICO

- 1 Martin, K., Rossi, V., Ferrucci, S. & Pian, D. (2010) Retinal astrocytic hamartoma. *Optometry-Journal*  
2 *of the American Optometric Association*, 81: 221-233.  
3 Not in PICO
- 4 Maxwell, P. (2013) Identifying signs of retinoblastoma. *Nursing Times*, 109: 17-23.  
5 Narrative review
- 6 Mazur, K. A. (2010) Neuroblastoma: What the nurse practitioner should know. *Journal of the*  
7 *American Academy of Nurse Practitioners*, 22: 236-245.  
8 Narrative review
- 9 McBride, D. (2010) Identification of proteins may lead to urinary test for kidney cancer. *ONS*  
10 *Connect*, 25: 17.  
11 Narrative review
- 12 Melamud, A., Palekar, R. & Singh, A. (2006) Retinoblastoma. *American Family Physician*, 73: 1039-  
13 1044.  
14 Narrative review
- 15 Melzer, H. I., Coppenrath, E., Schmid, I., Albert, M. H., Von, S. D., Tudball, C., Bartenstein, P. &  
16 Pflugger, T. (2011) 123I-MIBG scintigraphy/SPECT versus 18F-FDG PET in paediatric  
17 neuroblastoma. *European Journal of Nuclear Medicine and Molecular Imaging*, 38: 1648-1658.  
18 Not in PICO
- 19 Messmer, E. M., Mackert, M. J., Zapp, D. M. & Kampik, A. (2006) In vivo confocal microscopy of  
20 pigmented conjunctival tumors. *Graefes Archive for Clinical & Experimental Ophthalmology*, 244:  
21 1437-1445.  
22 Not in PICO
- 23 Midea, E. & Parrozzani, R. (2012) Biopsies in Uveal Melanoma. *Current Concepts in Uveal*  
24 *Melanoma*, 49: 81-95.  
25 Narrative review
- 26 Mierzwa, D. M. & Romanowska, D. B. (2012) Assessment of the influence of one's education on early  
27 diagnosis of multiple primary cancer in patients with uveal melanoma. *Klinika. oczna*, 114: 111-  
28 114.  
29 Not in PICO
- 30 Morgan-Followell, B. & Reyes, E. L. (2013) Child Neurology: Diagnosis of Lambert-Eaton myasthenic  
31 syndrome in children. *Neurology*, 80: e220-e222.  
32 Not in PICO
- 33 Morrissey, J. J., London, A. N., Luo, J. & Kharasch, E. D. (2010) Urinary biomarkers for the early  
34 diagnosis of kidney cancer. *Mayo Clinic Proceedings*, 85: 413-421.  
35 Not in PICO
- 36 Mullaney, P. B., Karcioğlu, Z. A., al-Mesfer, S. & Dowaidi, M. (1996) Retinoblastoma referral patterns  
37 in Saudi Arabia. *Ophthalmic Epidemiology*, 3: 35-46.  
38 Not in PICO
- 39 Musumeci, R. & Botturi, M. (1978) [The radiological symptomatology of primary malignant neoplasia  
40 of the kidney (author's transl)]. [Italian]. *Radiologia Medica*, 64: 753-768.  
41 Narrative review
- 42 Nabie, R., Taheri, N., Fard, A. M. & Fouladi, R. F. (2012) Characteristics and clinical presentations of  
43 pediatric retinoblastoma in North-western Iran. *International Journal of Ophthalmology*, 5: 510-  
44 512.  
45 Not in PICO
- 46 Nadel, H. R. (2014) - SPECT/CT in pediatric patient management. - *European Journal of Nuclear*  
47 *Medicine & Molecular Imaging*, 41 Suppl 1: S104-S114.  
48 Narrative review
- 49 Nathrath, M. & Teichert, V. L., I (2009) Oncologic causes of bone pain. [German]. *Monatsschrift für*  
50 *Kinderheilkunde*, 157: 655-660.  
51 Narrative review

- 1 Nozaki, C., Horibe, K., Iwata, H., Ishiguro, Y., Hamaguchi, M. & Takahashi, M. (2000) Prognostic  
2 impact of telomerase activity in patients with neuroblastoma. *International Journal of Oncology*,  
3 17: 341-345.  
4 Not in PICO
- 5 Palazzi, M. A., Stephan, C., Brandalise, S. R. & Aguiar, S. D. S. (2013) Retinoblastoma diagnosis: A  
6 proposal based on the experience of Centro Infantil Boldrini, Brazil. *Pediatric Hematology and*  
7 *Oncology*, 30: 379-385.  
8 Not in PICO
- 9 Palko, A., Kun, E., Greksa, E. & Khertelendi, A. (1991) [The role of computerized tomography in the  
10 diagnosis and evaluation of the dissemination of malignant kidney tumors]. [Russian]. *Vestnik*  
11 *Rentgenologii i Radiologii*.(2):37-40, 1991 Mar-Apr., 37-40.  
12 Not in PICO
- 13 Paradies, G., Zullino, F., Orofino, A. & Leggio, S. (2013) Mediastinal teratomas in children. Case  
14 reports and review of the literature. *Annali Italiani di Chirurgia*, 84(4):395-403, -403, 2013.  
15 Not in PICO
- 16 Parmar, R., Wadia, F., Yassa, R. & Zenios, M. (2013) Neuroblastoma: a rare cause of a limping child.  
17 How to avoid a delayed diagnosis? *Journal of Pediatric Orthopedics*, 33: e45-e51.  
18 Not in PICO
- 19 Patel, N., Salchow, D. J. & Materin, M. (2013) Differentials and approach to leukocoria. *Connecticut*  
20 *Medicine*, 77: 133-140.  
21 Narrative review
- 22 Petrus, L. V., Hall, T. R., Boechat, M. I., Westra, S. J., Curran, J. G., Steckel, R. J. & Kangarloo, H. (1992)  
23 The pediatric patient with suspected adrenal neoplasm: which radiological test to use? *Medical &*  
24 *Pediatric Oncology*, 20: 53-57.  
25 Not in PICO
- 26 Pickuth, D., Heywang-Kobrunner, S. H. & Spielmann, R. P. (1999) Computed tomography and  
27 magnetic resonance imaging features of olfactory neuroblastoma: An analysis of 22 cases. *Clinical*  
28 *Otolaryngology and Allied Sciences*, 24: 457-461.  
29 Not in PICO
- 30 Pollock, B. H., Krischer, J. P. & Vietti, T. J. (1991) Interval between symptom onset and diagnosis of  
31 pediatric solid tumors. *Journal of Pediatrics*, 119: 725-732.  
32 Not in PICO
- 33 Provenzi, M., Saettini, F., Conter, V., Chinaglia, D., Vai, P., Bruno, A., Cavalleri, L., Foglia, C., Girdali, E.,  
34 Collini, P. & Spreafico, F. (2013) Is there a role for FDG-PET for the assessment of treatment  
35 efficacy in Wilms' tumor? A case report and literature review. *Pediatric Hematology & Oncology*,  
36 30(7):633-9, -9, 2013.  
37 Not in PICO
- 38 Psooy, K. (2007) Long-term urological follow-up of multicystic dysplastic kidneys: Is it still indicate in  
39 2007? *Cuaj-Canadian Urological Association Journal*, 1: 113-116.  
40 Not in PICO
- 41 Qian, Y. (1994) Visual acuity test of children in the strabismus clinic. [Chinese]. *Zhonghua hu li za zhi*  
42 = *Chinese journal of nursing*, 29: 92-93.  
43 Not in PICO
- 44 Raab, C. P. & Gartner, J. C., Jr. (2009) Diagnosis of childhood cancer. [Review] [33 refs]. *Primary Care;*  
45 *Clinics in Office Practice*, 36: 671-684.  
46 Narrative review
- 47 Reiman, T. A., Siegel, M. J. & Shackelford, G. D. (1986) Wilms tumor in children: abdominal CT and US  
48 evaluation. *Radiology*, 160: 501-505.  
49 Not in PICO

- 1 Reither, M., Schumacher, R. & Klingmuller, V. (1983) [Sonographic diagnosis of abdominal tumors in  
2 childhood]. [German]. *Ultraschall in der Medizin*, 4: 139-146.  
3 Not in PICO
- 4 Rezaimehr, Y. & Bhargava, R. (2013) Neuroblastoma presenting as persistent postprandial emesis in  
5 a neonate. *Pediatric Emergency Care*, 29%(12):1273-5, -5, 2013.  
6 Not in PICO
- 7 Rice, M. L., Leske, D. A., Smestad, C. E. & Holmes, J. M. (2008) Results of ocular dominance testing  
8 depend on assessment method. *Journal of AAPOS*, 12: 365-369.  
9 Not in PICO
- 10 Riley, R. D., Burchill, S. A., Abrams, K. R., Heney, D., Lambert, P. C., Jones, D. R., Sutton, A. J., Young,  
11 B., Wailoo, A. J. & Lewis, I. J. (2003) A systematic review and evaluation of the use of tumour  
12 markers in paediatric oncology: Ewing's sarcoma and neuroblastoma (Structured abstract).  
13 *Health Technology Assessment.Database.*, 1.  
14 Not in PICO
- 15 Ritchey, M., Daley, S., Shamberger, R. C., Ehrlich, P., Hamilton, T., Haase, G., Sawin, R. & National  
16 Wilms' Tumor Study Group (2008) Ureteral extension in Wilms' tumor: a report from the National  
17 Wilms' Tumor Study Group (NWTSG). *Journal of Pediatric Surgery*, 43: 1625-1629.  
18 Not in PICO
- 19 Rosati, P., Jenkner, A., De, V. R., Boldrini, R., Chiodi, P., Celesti, L. & Giampaolo, R. (2011) 'Tell me  
20 about your pain': abdominal pain and a history of bullying. *BMJ Case Reports*, 2011, 2011.  
21 Not in PICO
- 22 Rossi, E., Imbach, P., Kaser, H. & Wagner, H. P. (1978) [The malignant neoplasm in pediatrics].  
23 [German]. *Schweizerische Medizinische Wochenschrift.Journal Suisse de Medecine*, 108: 513-517.  
24 Narrative review
- 25 Roth, A. (1981) The role of the general practitioner and the family in the initial diagnosis and  
26 treatment of the squinting child. [French]. *Therapeutische Umschau*, 38: 228-234.  
27 Narrative review
- 28 Saeed, P., van Furth, W. R., Tanck, M., Kooremans, F., Freling, N., Streekstra, G. I., Regensburg, N. I.,  
29 van der Sprenkel, J. W., Peerdeman, S. M., van Overbeeke, J. J. & Mourits, M. P. (2011) Natural  
30 history of sphenoidal meningiomas. *Acta Neurochirurgica*, 153: 395-402.  
31 Not in PICO
- 32 Sampson, V. B., Gorlick, R., Kamara, D. & Anders, K. E. (2013) A review of targeted therapies  
33 evaluated by the pediatric preclinical testing program for osteosarcoma. *Frontiers in Oncology*,  
34 3:132.  
35 Narrative review
- 36 Schmechel, C. & Raatzsch, H. (1965) [Prognosis and early diagnosis of primary kidney tumors].  
37 [German]. *Landarzt*, 41: 139-142.  
38 Outside of agreed date range (pre 1980)
- 39 Schmidt, D., Anderson, L., Bingen, K., Hoag, J., Kupst, M. J. & Warwick, A. B. (2010) Late effects in  
40 adult survivors of childhood cancer: Considerations for the general practitioner. *Wisconsin  
41 Medical Journal*, 109: 98-108.  
42 Narrative review
- 43 Seregard, S., Ek, U., Preisler, G., af, T. E., Jacobson, L., Oskar, K., Illerstahl, I. & Kock, E. (1996) [A study  
44 of children with retinoblastoma. Diagnosis is often delayed]. [Swedish]. *Lakartidningen*, 93: 1133-  
45 1135.  
46 Not in PICO
- 47 Servodidio, C. A., Abramson, D. H. & Romanella, A. (1991) Retinoblastoma. *Cancer Nursing*, 14: 117-  
48 123.  
49 Narrative review



- 1 Shakoor, K. A. & Phil, M. (1989) Fine needle aspiration cytology in advanced pediatric tumors.  
2 *Pediatric Pathology*, 9: 713-718.  
3 Not in PICO
- 4 Shi, G. H., Chen, Y., Yao, X. D., Zhang, S. L., Dai, B., Feng, L. Q., Zhang, H. L., Shen, Y. J., Zhu, Y., Zhu, Y.  
5 P., Xiao, W. J., Ma, C. G., Wen, L. G., Qin, X. J., Yang, L. F. & Ye, D. W. (2013) Individualized renal  
6 mass biopsy strategy for Chinese patients with different subtypes and necrosis area. *Urologic*  
7 *Oncology*, 31(6):920-3, -3, 2013.  
8 Not in PICO
- 9 Shields, J. A., Shields, C. L., Ehya, H., Eagle, R. C., Jr. & De, P. P. (1993) Fine-needle aspiration biopsy  
10 of suspected intraocular tumors. The 1992 Urwick Lecture. *Ophthalmology*, 100: 1677-1684.  
11 Not in PICO
- 12 Skoldenberg, E., Soderberg, M., Wangberg, J. & Ljungman, G. (2011) Cutting needle biopsies in the  
13 management of childhood tumors. *Pediatric Blood and Cancer*, 57: 747.  
14 Not in PICO
- 15 Sumarac, Z. & Petronic, V. (1973) [Varieties in the symptomatology and diagnosis of malignant  
16 kidney tumors]. [Serbian]. *Srpski Arhiv Za Celokupno Lekarstvo*, 100: 627-637.  
17 Outside of agreed date range (pre 1980)
- 18 Taupitz, A. (1969) [Early diagnosis of urologic tumors]. [German]. *Zeitschrift fur Allgemeinmedizin*,  
19 45: 1417-1423.  
20 Outside of agreed date range (pre 1980)
- 21 Temming, P., Lohmann, D., Bornfeld, N., Sauerwein, W., Goericke, S. L. & Eggert, A. (2012) Current  
22 Concepts for Diagnosis and Treatment of Retinoblastoma in Germany: Aiming for Safe Tumor  
23 Control and Vision Preservation. *Klinische Padiatrie*, 224: 339-347.  
24 Narrative review
- 25 Valverde, A. S., Martin, R. J., Alvarez, V. H. & Encinas Martin, J. L. (2000) [Posterior uveal  
26 pseudomelanoma. Clinical differential diagnosis at the referral hospital]. [Spanish]. *Archivos de la*  
27 *Sociedad Espanola de Oftalmologia*, 75: 529-534.  
28 Not in PICO
- 29 Van Den Heuvel-Eibrink, M. M., Grundy, P., Graf, N., Pritchard-Jones, K., Bergeron, C., Patte, C., Van,  
30 T. H., Rey, A., Langford, C., Anderson, J. R. & De, K. J. (2008) Characteristics and survival of 750  
31 children diagnosed with a renal tumor in the first seven months of life: A collaborative study by  
32 the SIOP/GPOH/SFOP, NWTSG, and UKCCSG Wilms tumor study groups. *Pediatric Blood and*  
33 *Cancer*, 50: 1130-1134.  
34 Not in PICO
- 35 Vogel, M. & Meyer-Schwickerath, G. (1982) [Diagnostic considerations and measures in suspected  
36 malignant melanoma of the choroid]. [German]. *Bucherei des Augenarztes*.(89):98-105, 1982., 98-  
37 105.  
38 Not in PICO
- 39 Wakamb, G. K., Nkashama, G. M., Mbuli, R. L., Borasisi, G. C. & Nikulu, J. I. (2013) [Problematic of the  
40 management of childhood cancer: experience of retinoblastoma in Lubumbashi (DR Congo) and  
41 the importance of early diagnosis]. [French]. *The Pan African medical journal*, 14: 64.  
42 Not in PICO
- 43 Wallach, M., Balmer, A., Munier, F., Houghton, S., Pampallona, S., von der, W. N., Beck-Popovic, M.,  
44 Swiss Pediatric Oncology Group & Swiss Childhood, C. R. (2006) Shorter time to diagnosis and  
45 improved stage at presentation in Swiss patients with retinoblastoma treated from 1963 to 2004.  
46 *Pediatrics*, 118: e1493-e1498.  
47 Not in PICO
- 48 Warnecke, M. U. & Bartels, H. (1986) [The significance of nephrosonography for the early  
49 recognition of kidney tumors]. [German]. *Ultraschall in der Medizin*, 7: 3-6.  
50 Not in PICO

- 1 Wende, S., Kazner, E. & Grumme, T. (1980) The diagnostic value of computed tomography in orbital  
2 diseases. A cooperative study of 520 cases. *Neurosurgical Review*, 3: 43-49.  
3 Not in PICO
- 4 White, J. & Gole, G. (2012) Delay in the diagnosis of retinoblastoma: An update. *Clinical and*  
5 *Experimental Ophthalmology*, 40: 37.  
6 Not in PICO
- 7 White, J. & Gole, G. (2012) Delay in the diagnosis of retinoblastoma: An update. *Clinical and*  
8 *Experimental Ophthalmology*, 40: 37.  
9 Not in PICO
- 10 Wirix, M., Parys-Vanginderdeuren, R., Casteels, I. & Uyttebrouck, A. (2000) Delayed diagnosis of  
11 retinoblastoma. *Bulletin de la Societe Belge d Ophtalmologie*.(278):37-41, 2000., 37-41.  
12 Not in PICO
- 13 Xu, G., Hu, J., Wu, Y., Xiao, Y. & Xu, M. (2013) Botryoid Wilms' tumor: a case report and review of the  
14 literature. *World Journal of Surgical Oncology*, 11: 102.  
15 Not in PICO
- 16 Zagorski, Z., Lang, G. & Naumann, G. (1991) [Eye tumors in children. Histopathological aspects of  
17 differential diagnosis]. [Polish]. *Klinika Oczna*, 93: 59-62.  
18 Narrative review
- 19 Zhang, C. H., Zhang, T. C., Zhong, J. S., Li, Y. W. & Zhang, C. M. (2004) [Early diagnosis of the tumors  
20 in orbital apex and optic nerve]. [Chinese]. *Chung-Hua Yen Ko Tsa Chih [Chinese Journal of*  
21 *Ophthalmology]*, 40: 34-36.  
22 Not in PICO  
23  
24

## NON-SITE SPECIFIC SYMPTOMS

### ABDOMINAL PAIN

#### Risk of bias in the included studies

The risk of bias and applicability concerns are summarised per study in the figure below. The main validity issues to note is that patient sampling was not clearly consecutive or random in some of the studies, with some studies also conducted in populations that are not clearly directly relevant to the current question and the quality of others suffering from missing data. Studies employing non-consecutive/random sampling are at risk of bias because, for example, case-control studies have been shown to be associated with inflated test accuracy parameters compared to designs that incorporate random or consecutive patient selection. Studies conducted in other settings than UK-based primary care are only applicable to the extent that the study populations and settings are comparable to a UK GP population as defined for the current purposes. Other issues to note concern missing data, the influence of which on the results is difficult to determine.

	Risk of Bias				Applicability Concerns		
	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard
Bellentani (1990)	+	+	+	+	?	?	+
Collins (2012)	+	+	+	+	+	+	+
Collins (2012a)	+	+	+	+	+	+	+
Collins (2013)	+	+	+	+	+	+	+
Collins (2013a)	+	+	+	+	+	+	+
Hamilton (2005)	-	+	+	+	+	+	+
Hippisley-Cox (2011)	+	+	+	?	+	+	+
Hippisley-Cox (2012)	+	+	+	-	+	+	+
Hippisley-Cox (2012a)	+	+	+	+	+	+	+
Hippisley-Cox (2012b)	+	+	+	-	+	+	+
Moellmann (1981)	+	+	?	-	?	+	+
Panzuto (2003)	-	+	+	?	?	+	+
Stapley (2012)	-	+	+	+	+	+	+

- High     
 ? Unclear     
 + Low

**Table 1: Non-site specific symptoms of concern: Calculation of overall positive predictive value of abdominal pain for cancer**

Cancer site	Study	Lower age limit	Upper age limit	PPV (95% CI), prevalence
Bladder/renal	Hippisley-Cox (2012)	30	84	0.2 (0.2-0.2)
Colorectal	Various*	30	84	1.524
Oesophagus/stomach	Meta-analysis	varied	varied	0.34 (0.16-0.71)
Pancreatic	Hippisley-Cox (2012)	30	84	0.3 (0.3-0.4)
Sum				2.364

1 \* Not sure which one to pick, so used average.

2 **Table 2: Non-site specific symptoms of concern: Positive predictive values for abdominal pain**

Cancer site	Comment/relevant recs	Study	Symptom	Patient group	Positive predictive value% (95% CI), prevalence	Sex	Age inclusion, lower limit	Age inclusion, upper limit
Bladder/renal		Collins (2013)	Abdominal pain	All patients	0.11 (0.1-0.13)	both	30	84
Bladder/renal		Collins (2013)	Abdominal pain	Men	0.2 (0.2-0.21)	men	30	84
Bladder/renal		Collins (2013)	Abdominal pain	Women	0.1 (0.1-0.1)	women	30	84
Bladder/renal		Hippisley-Cox (2012)	Abdominal pain	All patients	0.2 (0.2-0.2)	both	30	84
Colorectal		Hamilton (2005)	Abdominal pain (reported once)	All patients	1.1 (0.9-1.3) Cases: 148/349 Controls: 163/1744	both	40	no upper limit
Colorectal		Hamilton (2005)	Abdominal pain	Patients 40-69 years	0.65 (NR)	both	40	69
Colorectal		Hamilton (2005)	Abdominal pain	Patients ≥ 70 years	2 (NR)	both	70	no upper limit
Colorectal		Hamilton (2005)	Abdominal pain (reported)	All patients	3 (1.8-5.2)	both	40	no upper limit

			d twice)					
Colorectal		Hamilton (2005)	Abdominal pain and abdominal tenderness	All patients	1.4 (0.3-2.2)	both	40	no upper limit
Colorectal		Hamilton (2005)	Abdominal tenderness (reported once)	All patients	1.1 (0.8-1.5) Cases: 62/349 Controls: 67/1744	both	40	no upper limit
Pancreatic		Collins (2013a)	Abdominal pain	All patients	0.14 (0.12-0.15)	both	30	84
Pancreatic		Collins (2013a)	Abdominal pain	Women	0.1 (0.09-0.12)	women	30	84
Pancreatic		Collins (2013a)	Abdominal pain	Men	0.19 (0.16-0.22)	men	30	84
Pancreatic		Hippisley-Cox (2012b)	Abdominal pain	All patients	0.3 (0.3-0.4)	both	30	84
Pancreatic		Stapley (2012)	Abdominal pain	All patients	0.2 (0.19-0.22)	both	40	no upper limit
Pancreatic		Stapley (2012)	Abdominal pain	Patients ≥ 60 years	0.3 (0.3-0.4)	both	60	no upper limit
Pancreatic		Stapley (2012)	Abdominal pain (attended ≥ twice)	Patients ≥ 60 years	1 (0.8-1.2)	both	60	no upper limit
<b>META-ANALYSES (1) Colorectal</b>								
Colorectal		Meta-analyses	Abdominal pain	N = 371703 patients/4 studies	2.04 (0.53-7.55)	both	2 studies 30-84, 1 study 18-87, 1 study NR  Individual study details provided below	
Colorectal		Meta-analyses	Abdominal pain	N = 371480; w/o Panzuto	1.02 (0.38-2.69)	both	2 studies 30-84, 1 study NR Individual study details provided below	

				(2003)				
<b>The 4 studies below are those included in the meta-analysis reported in the cells above:</b>								
Colorectal		Bellentani (1990)	Abdominal pain	All patients (N = 254)	3.9 (2-7.3)	both	NR	NR
Colorectal		Collins (2012)	Abdominal pain	All patients (N = 245989)	0.5 (0.5-0.5)	both	30	84
Colorectal		Hippisley-Cox (2012a)	Abdominal pain	All patients (N = 125237)	0.7 (0.6-0.7)	both	30	84
Colorectal		Panzuto (2003)	Abdominal pain	All patients (N = 223)	13.5 (9.4-18.8)	both	18	87
<b>The following results are any extra analyses reported by the studies included in the above meta-analysis:</b>								
Colorectal		Collins (2012)	Abdominal pain	Men 30-84 years	0.6 (0.6-0.7)	men	30	84
Colorectal		Collins (2012)	Abdominal pain	Women 30-84 years	0.4 (0.4-0.5)	women	30	84
<b>META-ANALYSES (2) Oesophageal</b>								
Oesophagus/stomach	2 combining gastro-oesophageal and 1 reporting on oesophageal cancer separately	Meta-analyses	Abdominal pain	N = 3389979/3 studies	0.23 (0.14-0.36)	both	2 studies 30-84, 1 study 40- >90 Individual study details provided below.	
<b>The 3 studies below are those included in the meta-analysis reported in the cell above (Please note the same data from Collins (2012a) and Hippisley-Cox (2011) appear both here and under stomach, avoid double counting it):</b>								
Oesophageal/stomach		Collins (2012a)	Abdominal pain	All patients	0.2 (0.2-0.2) 437/2469	both	30	84

ach					98			
Oesophageal/stomach		Hippisley-Cox (2011)	Abdominal pain	All patients	0.3 (0.3-0.4) 309/91627	both	30	84
Oesophageal		Møllmann (1981)	Upper abdominal pain > 2 weeks	All patients	0 (0-0.8) 0/577	both	40	>90
<b>The following results are any extra analyses reported by the studies included in the above meta-analysis:</b>								
Oesophageal/stomach		Collins (2012a)	Abdominal pain	Women	0.1 (0.1-0.1) 139/144266	women	30	84
Oesophageal/stomach		Collins (2012a)	Abdominal pain	Men	0.3 (0.3-0.3) 298/102732	men	30	84
<b>META-ANALYSES (3) Stomach</b>								
Oesophagus/stomach	2 combining gastro-oesophageal and 1 reporting on stomach cancer separately	Meta-analyses	Abdominal pain	N = 3389979/3 studies	0.34 (0.16-0.71)	both	2 studies 30-84, 1 study 40- >90	
<b>The 3 studies below are those included in the meta-analysis reported in the cell above (Please note the same data from Collins (2012a) and Hippisley-Cox (2011) appear both here and under oesophageal, avoid double counting it):</b>								
Oesophageal/stomach		Collins (2012)	Abdominal pain	All patients	0.2 (0.2-0.2) 437/246998	both	30	84
Oesophageal/stomach		Hippisley-Cox (2011)	Abdominal pain	All patients	0.3 (0.3-0.4) 309/91627	both	30	84
Stomach		Møllmann (1981)	Upper abdominal pain > 2 weeks	All patients	1 (0.4-2.4) 6/577	both	40	>90

1 **Evidence statement(s):**  
 2 Abdominal pain (9 studies, N = 6248014) presenting in a primary care setting is associated with an  
 3 overall positive predictive value of 2.364% for cancer. The studies were associated with 0-3  
 4 bias/applicability concerns (see also Table 1).

6 **Evidence tables**

7 **Bellentani (1990)**

<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective consecutive patient series
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>N = 254 (103 males/151 females); mean (SD) age of patients = Not reported; N = 140 were studied in primary care, N = 114 were referred to the gastroenterology services. It is unclear from the publication whether the patients who were referred to secondary care were a subset of "254 consecutive patients who presented to their GP during the study period for chronic abdominal pain" or whether they are recruited directly from secondary care (see Inclusion criteria).</p> <p><u>Inclusion criteria:</u> All consecutive patients consulting 14 GPs of the local health district, taking care of 14000 citizens, or referred to the outpatient clinic of the Gastroenterology Unit, either complaining of recurrent abdominal pain or having intestinal problems (as judged by the GP), between January 1987 and March 1988.</p> <p><u>Exclusion criteria:</u> Patients with acute abdomen, acute gastroenteritis or a clear cut diagnosis of upper gastrointestinal tract disease (gastritis, oesophagitis, peptic ulcer, or dyspepsia).</p> <p><u>Clinical setting:</u> Primary/secondary care, Italy.</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	Recurrent abdominal pain or intestinal problems (as judged by the GP; not further specified)
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Unclear concern</b>
<b>REFERENCE STANDARD</b>	



<b>A. risk of bias</b>	
Reference standard(s)	Double-contrast barium enema or colonoscopy no more than 2 months after the enrolment in the study.
Is the reference standard likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	Unclear (but all patients had a positive index test)
Could the reference standard, its conduct, or its interpretation have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Are there concerns that the target condition as defined by the reference standard does not match the question?	Low concern
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients are accounted for in the results but the number of true negatives and false negatives could not be ascertained from the reported results.
Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	Yes
Could the patient flow have introduced bias?	Low risk
<b>NOTES</b>	
1	
2	
<b>Collins (2012)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Retrospective patient series using the THIN database.
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
Could the selection of patients have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	A total of 2135540 patients were identified from 364 practices. <u>Symptoms:</u> Rectal bleeding (N = 56234; 28423 men, 27811 women), abdominal pain (N = 245989; 102192 men, 143797 women), appetite loss (N = 5776; 2481 men, 3295 women), weight loss (N = 28289; 12891 men, 15398 women), anaemia (N = 18125; 4466 men, 13659 women), change in bowel habit (men only, N = 1670). <u>Incident cases of colorectal cancer during the 2-year follow up period:</u> N = 3712 (2036 men, 1676 women). <u>Inclusion criteria:</u> Patients aged 30–84 years and registered with practices between 1 January 2000 and 30 June 2008. Entry to the cohort was defined as the latest of the study start date; the date the patient registered with the practice; and for those patients with red flag symptoms (see below), the date of the first

	recorded onset within the study period. <u>Exclusion criteria:</u> Patients without a postcode-related Townsend score, patients with a history of colorectal cancer at baseline, and patients with a recorded 'red-flag' symptom in the 12 months prior to the study entry date. <u>Clinical setting:</u> Primary care, UK
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	'Red-flag' symptoms: Rectal bleeding, loss of appetite, weight loss, abdominal pain, change in bowel habit (men only), and anaemia.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	2-year follow up
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients seem to be accounted for
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	The is <b><i>very large, if not complete, overlap</i></b> of the data used in this study with those used in Hamilton (2008 [for anaemia], 2009)
1	
2	<b>Collins (2012a)</b>
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Retrospective patient series using the THIN database.

Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
Could the selection of patients have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>A total of 2135540 patients were identified from 364 practices.</p> <p><u>Symptoms:</u> Dysphagia (N = 19237; 8846 men, 10391 women), abdominal pain (N = 246998; 102732 men, 144266 women), appetite loss (N = 5838; 2521 men, 3317 women), weight loss (N = 28403; 12938 men, 15465 women), haematemesis (N = 10792; 6162 men, 4630 women), anaemia (N = 18355; 4563 men, 13792 women).</p> <p><u>Incident cases of gastro-oesophageal cancer during the 2-year follow up period:</u> N = 1766 (1184 men, 582 women; 32% gastric cancer, 68% oesophageal cancer).</p> <p><u>Inclusion criteria:</u> Patients aged 30–84 years and registered with practices between 1 January 2000 and 30 June 2008. Entry to the cohort was defined as the latest of the study start date; the date the patient registered with the practice; and for those patients with red flag symptoms (see below), the date of the first recorded onset within the study period.</p> <p><u>Exclusion criteria:</u> Patients with a prior diagnosis of gastro-oesophageal cancer, registration with the general practice &lt; 12 months, or with invalid dates.</p> <p><u>Clinical setting:</u> Primary care, UK</p>
Are there concerns that the included patients and setting do not match the review question?	Low concern
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	'Red-flag' symptoms: Haematemesis, dysphagia, loss of appetite, weight loss, anaemia, and abdominal pain.
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
Could the conduct or interpretation of the index test have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Low concern
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	2-year follow up
Is the reference standard likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias?	Low risk

<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients seem to be accounted for
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	The study did not distinguish between gastric and oesophageal cancer
1	
2	
<b>Collins (2013)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Retrospective patient series using the THIN database.
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>A total of 2145133 patients (1063355 men, 1081778 women) were identified from 364 practices.</p> <p><u>Symptoms:</u>  Haemoglobin &lt; 11 g/dl recorded in the last year (N = 16961; 3969 men, 12992 women), abdominal pain (N = 253344; 105247 men, 148097 women), appetite loss (N = 6097; 2616 men, 3481 women), weight loss (N = 29369; 13332 men, 16037 women), haematuria (N = 37810; 22810 men, 15000 women), previous diagnosis of cancer apart from renal tract cancer at study entry (N = 49303; 18130 men, 31173 women).</p> <p><u>Incident cases of renal tract cancer during the 2-year follow up period:</u>  N = 2283 (1685 men, 598 women).</p> <p><u>Inclusion criteria:</u>  Patients aged 30–84 years and registered with practices between 1 January 2000 and 30 June 2008. Entry to the cohort was defined as the latest of the study start date; the date the patient registered with the practice; and for those patients with red flag symptoms (e.g., haematuria, abdominal pain, weight loss, appetite loss, and anaemia), the date of the first recorded onset within the study period.</p> <p><u>Exclusion criteria:</u> Patients with a prior diagnosis of renal tract cancer, registered less than 12 months with the general practice, had invalid dates, &lt; 30 years old or ≥ 85 years old.</p> <p><u>Clinical setting:</u> Primary care, UK</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	

<b>A. Risk of bias</b>	
<b>Index test</b>	'Red-flag' symptoms were defined as symptoms that might alarm the patient and also indicate the presence of renal tract cancer; that is, symptoms of haematuria, loss of appetite, weight loss, or abdominal pain.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
<b>Reference standard(s)</b>	Renal tract cancer, which was defined as incident diagnosis of cancer of the bladder, kidney, ureter, or urethra during the 2 years after study entry, recorded either on the patient's GP record using the relevant UK diagnostic Read Codes. Patients without the outcome were censored at the earliest of the date of death, date of leaving the practice study of 2 years of follow up.
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
<b>Flow and timing</b>	All patients seem to be accounted for
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	It is unclear why no data has been presented for men for the symptoms of appetite loss and weight loss.
<b>Collins (2013a)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
<b>Patient sampling</b>	Retrospective patient series using the THIN database.
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>

1  
2

<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>A total of 2150322 patients were identified from 364 practices.</p> <p><u>Symptoms:</u> Dysphagia (men only: N = 9326), abdominal pain (N = 255058; 106768 men, 148290 women), appetite loss (N = 6102; 2658 men, 3444 women), weight loss (N = 29464; 13484 men, 15980 women), abdominal distension (women only: N = 4457), constipation (men only, N = 5326).</p> <p><u>Incident cases of pancreatic cancer during the 2-year follow up period:</u> N = 287 (331 men, 287 women).</p> <p><u>Inclusion criteria:</u> Patients aged 30–84 years and registered with practices between 1 January 2000 and 30 June 2008. Entry to the cohort was defined as the latest of the study start date; the date the patient registered with the practice; and for those patients with red flag symptoms (see below), the date of the first recorded onset within the study period.</p> <p><u>Exclusion criteria:</u> Patients with a prior diagnosis of pancreatic cancer, registration &lt; 12 months with the general practice, or invalid dates.</p> <p><u>Clinical setting:</u> Primary care, UK</p>
Are there concerns that the included patients and setting do not match the review question?	Low concern
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	'Red-flag' symptoms: Dysphagia (men only), loss of appetite, weight loss, abdominal pain, abdominal distension (women only), and constipation (men only).
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
Could the conduct or interpretation of the index test have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Low concern
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	2-year follow up
Is the reference standard likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Are there concerns that the target condition as defined by the reference standard does not match the question?	Low concern
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients seem to be accounted for

Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	Yes
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	
1	
2	<b>Hamilton (2005)</b>
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Population-based matched case-control study involving all 21 general practices in Exeter, Devon, UK.
Was a consecutive or random sample of patients enrolled?	No
Was a case-control design avoided?	No
Did the study avoid inappropriate exclusions?	Yes
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?	Yes
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?	Yes
<b>Could the selection of patients have introduced bias?</b>	<b>High risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p><b>Cases:</b> N = 349 (177 males/172 females), age at diagnosis: &lt; 60 years: N = 45, 60-69 years: N = 97, 70-79 years: N = 113, 80+ years: N = 94. 210/349 had tumours at or distal to the splenic flexure, and 126/349 had tumours proximal to the splenic flexure, the remaining 13/349 has tumours in multiple or unknown sites. Duke's staging was known for 305/349: 170/305 were Duke's A or B, and 135/305 were Duke's C or D.</p> <p><b>Controls:</b> N = 1744 (885 males/859 females), age at diagnosis: &lt; 60 years: N = 225, 60-69 years: N = 487, 70-79 years: N = 555, 80+ years: N = 477.</p> <p><b>Inclusion criteria:</b> Cases: All patients aged ≥ 40 years with a primary colorectal cancer, diagnosed from 1998 to 2002, were identified from the cancer registry at the Royal Devon and Exeter Hospital combined with computerised searches at every practice in Devon to identify any cases missing from the cancer register. Controls: Five controls were matched to each case on sex, general practice, and age (to 1-year bands if possible, increased in 1-year multiples to a maximum of 5 years). Controls were eligible if they were alive at the time of diagnosis of their case.</p> <p><b>Exclusion criteria:</b> Cases and controls: Unobtainable records; no consultations in the 2 years before diagnosis; previous colorectal cancer; or residence outside Exeter at the time of diagnosis.</p>

	Clinical setting: Primary care, UK.	
<b>Are there concerns that the included patients and setting do not match the review question?</b>		<b>Low concern</b>
<b>INDEX TEST</b>		
<b>A. Risk of bias</b>		
<b>Index test</b>	Anonymised photocopies of the full primary care records for 2 years before diagnosis were coded (blinded to case/control status) for all entries using the International Classification of Primary Care-2. Additional codes were created to incorporate all possible clinical features. Only variables occurring in $\geq 2.5\%$ of cases or controls were analysed.	
Were the index test results interpreted without knowledge of the results of the reference standard?		<b>Yes</b>
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?		<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>		<b>Low concern</b>
<b>REFERENCE STANDARD</b>		
<b>A. risk of bias</b>		
<b>Reference standard(s)</b>	Colorectal cancer diagnosis in the cancer registry at the Royal Devon and Exeter Hospital or practice notes.	
Is the reference standard likely to correctly classify the target condition?		<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?		<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		<b>Low concern</b>
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
<b>Flow and timing</b>	All the patients are accounted for.	
Was there an appropriate interval between index test and reference standard?		<b>Yes</b>
Did all patients receive the same reference standard?		<b>Yes</b>
Were all patients included in the analysis?		<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>		<b>Low risk</b>
<b>NOTES</b>		
1		
2	<b>Hippisley-Cox (2011)</b>	
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		



Patient sampling	Prospective patient series using patients in the QResearch database (version 30).
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>A total of 1238971 patients were identified from 189 practices (621478 males, 617493 females), mean (SD) age = 50.1 (15) years, mean (SD) Townsend score = -0.2 (3.6).</p> <p><u>Symptoms:</u> Current dysphagia (N = 8165), current haematemesis (N = 7119), current abdominal pain (N = 126161), current appetite loss (N = 6133), current weight loss (N = 5377), tiredness in the last year (N = 14119), haemoglobin recorded in the last year (N = 12638, haemoglobin &lt; 11 g/dl in the last year (N = 218862).</p> <p><u>Incident cases of gastro-oesophageal cancer during the 2-year follow up period:</u> N = 1343 (776 oesophageal and 567 gastric).</p> <p><u>Inclusion criteria:</u> All practices in England and Wales that had been using their Egton Medical Information Systems (EMIS) computer system for ≥ a year were included. Two-thirds of practices were randomly allocated to the derivation dataset and the remaining practices were allocated to the validation dataset. An open cohort of patients aged 30–84 years was identified, drawn from patients registered with practices between 1 January 2000 and 30 September 2010. Entry to the cohort was defined as the latest of the study start date (1 January 2000); 12 months after the patient registered with the practice; and for those patients with red flag symptoms (see below), the date of the first recorded onset within the study period. <i>The relevant data for the present purposes is only available for the validation cohort, therefore only information pertaining to these patients will be reported.</i></p> <p><u>Exclusion criteria:</u> Patients without a postcode-related Townsend score, patients with a history of gastro-oesophageal cancer at baseline, and patients with a recorded 'red-flag' symptom in the 12 months prior to the study entry date.</p> <p><u>Clinical setting:</u> Primary care, UK</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	'Red-flag' symptoms: Incident dysphagia, haematemesis, loss of appetite, weight loss, anaemia, and abdominal pain.
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>

<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	2-year follow up
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	A total of 1342329 patients were initially identified of whom 103358 patients were excluded for the following reasons: No recorded Townsend score (N = 70847), history of gastro-oesophageal cancer (N = 538), and $\geq$ one 'red flag' symptom recorded in the 12 months prior to study entry (N = 31973), leaving 1238971 patients. However, data is presented for 963040/1238971 patients for all symptoms. The missing data does not appear to include any of the cancer cases, but it is unclear whether some of the missing data includes symptomatic patients, i.e., false positives.
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>No</b>
<b>Could the patient flow have introduced bias?</b>	<b>Unclear risk</b>
<b>NOTES</b>	Results not presented separately for gastric and oesophageal cancer
<b>Hippisley-Cox (2012)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective patient series using patients in the QResearch database (version 30).
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	A total of 1240722 patients were identified from 189 practices (622166 males, 618556 females), mean (SD) age = 50.1 (14.9) years, mean (SD) Townsend score = -0.2 (3.6). <u>Current symptoms and symptoms in the preceding year:</u> Current haematuria (N = 25553), current abdominal pain (N = 128721), current appetite loss (N = 5531), current weight loss (N = 14464), constipation in the last year (N = 8472), diarrhoea in the last year (N =

1  
2

	<p>12171), tiredness in the last year (N = 12669), haemoglobin recoded in the last year (N = 216201), haemoglobin &lt; 11 g/dl in the last year (N = 16169).  <u>Incident cases of renal tract cancer during the 2-year follow up period:</u>  N = 1622; mean age at diagnosis = 70 years, 1187 males/ 435 females; <b>Type of cancer: Bladder: N = 1292; Kidney: N = 307; Ureter: N = 21; Urethra: N = 2.</b></p> <p><u>Inclusion criteria:</u>  All practices in England and Wales that had been using their Egton Medical Information Systems (EMIS) computer system for ≥ a year were included. Two-thirds of practices were randomly allocated to the derivation dataset and the remaining practices were allocated to the validation dataset. An open cohort of patients aged 30–84 years was identified, drawn from patients registered with practices between 1 January 2000 and 30 September 2010. Entry to the cohort was defined as the latest of the study start date (1 January 2000) and 12 months after the patient registered with the practice, ensuring that all patients had ≥ 12 months' registration prior to study entry. For patients with incident haematuria, appetite loss, weight loss, or abdominal pain, the entry date was the date of the first consultation with the symptom within the study period. <i>The relevant data for the present purposes is only available for the validation cohort, therefore only information pertaining to these patients will be reported.</i></p> <p><u>Exclusion criteria:</u> Patients without a postcode-related Townsend score, patients with a history of renal tract cancer at baseline, and patients with a recorded 'red-flag' (see "Definition of symptom" below) symptom in the 12 months prior to the study entry date.</p> <p><u>Clinical setting:</u> Primary care</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	'Red-flag' symptoms were defined as symptoms that might alarm the patient and also indicate the presence of renal tract cancer; that is, symptoms of haematuria, loss of appetite, weight loss, or abdominal pain.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
<b>Reference standard(s)</b>	Renal tract cancer, which was defined as incident diagnosis of cancer of the bladder, kidney, ureter, or urethra during the 2 years after study entry, recorded either on the patient's GP record using the relevant UK diagnostic Read Codes, or their linked Office for National Statistics cause-of-death record, using the relevant ICD-9 codes (188 or 189) or ICD-10 diagnostic codes (C64–67).
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>

Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	A total of 1342329 patients were initially identified of whom 101607 patients were excluded for the following reasons: No recorded Townsend score (N = 70847), history of renal tract cancer (N = 1506), and $\geq$ one 'red flag' symptom recorded in the 12 months prior to study entry (N = 29254), leaving 1240722 patients. However, data is presented for 967681 / 1240722 patients. The missing data does not appear to include any of the cancer cases, but it is unclear whether some of the missing data includes symptomatic patients, i.e., false positives.
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>No</b>
<b>Could the patient flow have introduced bias?</b>	<b>High risk</b>
<b>NOTES</b>	
1	
2 <b>Hippisley-Cox (2012a)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective patient series using patients in the QResearch database (version 30).
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	A total of 1236601 patients were identified from 189 practices (620240 males, 616361 females), mean (SD) age = 50.1 (14.9) years, mean (SD) Townsend score = -0.2 (3.6). <u>Symptoms:</u> Current rectal bleeding (N = 29118), current abdominal pain (N = 125816), current appetite loss (N = 5358), current weight loss (N = 14065), recent change in bowel habit (N = 1821). <u>Incident cases of colorectal cancer during the 2-year follow up period:</u> N = 2603 (1562 colon and 1041 rectum). <u>Inclusion criteria:</u> All practices in England and Wales that had been using their Egton Medical Information Systems (EMIS) computer system for $\geq$ a year were included. Two-thirds of practices were randomly allocated to the derivation dataset

	<p>and the remaining practices were allocated to the validation dataset. An open cohort of patients aged 30–84 years was identified, drawn from patients registered with practices between 1 January 2000 and 30 September 2010. Entry to the cohort was defined as the latest of the study start date (1 January 2000); 12 months after the patient registered with the practice; and for those patients with red flag symptoms (see below), the date of the first recorded onset within the study period. <i>The relevant data for the present purposes is only available for the validation cohort, therefore only information pertaining to these patients will be reported.</i></p> <p><u>Exclusion criteria:</u> Patients without a postcode-related Townsend score, patients with a history of colorectal cancer at baseline, and patients with a recorded 'red-flag' symptom in the 12 months prior to the study entry date.</p> <p><u>Clinical setting:</u> Primary care, UK</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	'Red-flag' symptoms: First onset rectal bleeding, first onset loss of appetite, first onset weight loss, first onset abdominal pain, first onset change in bowel habit (in the past 12 months), and anaemia (recorded haemoglobin < 11 g/dl in the past 12 months).
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	2-year follow up
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	A total of 1342329 patients were initially identified of whom 105728 patients were excluded for the following reasons: No recorded Townsend score (N = 70847), history of colorectal cancer (N = 2908), and ≥ one 'red flag' symptom recorded in the 12 months prior to study entry (N = 31973), leaving 1236601 patients. However, data is presented for 1235547/1236601 patients for all

	symptoms apart from change in bowel habit, which is only presented for 619651/620240 of the male patients. The missing data does not appear to include any of the cancer cases (although this cannot be ascertained for change in bowel habit), but it is unclear whether some of the missing data includes symptomatic patients, i.e., false positives.
Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	No
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	Please note there is some overlap between this patient sample and that of Parker (2007)
1	
2	<b>Hippisley-Cox (2012b)</b>
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective patient series using patients in the QResearch database (version 30).
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>A total of 1243740 patients were identified from 189 practices (624352 males, 619388 females), mean (SD) age = 50.1 (14.9) years, mean (SD) Townsend score = -0.2 (3.6).</p> <p><u>Current symptoms and symptoms in the preceding year:</u>  Current dysphagia (N = 8507), current abdominal pain (N = 129924), current abdominal distension (N = 4929), current appetite loss (N = 5567), current weight loss (N = 14686), constipation in the last year (N = 8476), diarrhoea in the last year (N = 12233), tiredness in the last year (N = 12688), itching in the last year (N = 1454), haemoglobin recoded in the last year (N = 214497), haemoglobin &lt; 11 g/dl in the last year (N = 16172).</p> <p><u>Incident cases of pancreatic cancer during the 2-year follow up period:</u> N = 781.</p> <p><u>Inclusion criteria:</u>  All practices in England and Wales that had been using their Egton Medical Information Systems (EMIS) computer system for ≥ a year were included. Two-thirds of practices were randomly allocated to the derivation dataset and the remaining practices were allocated to the validation dataset. An open cohort of patients aged 30–84 years was identified, drawn from patients registered with practices between 1 January 2000 and 30 September 2010. Entry to the cohort was defined as the latest of the study start date (1 January 2000) and 12 months after the patient registered with the practice, ensuring that all patients had ≥ 12 months' registration prior to study entry. For patients with incident haematuria, appetite loss, weight loss, or abdominal pain, the entry date was the date of the first consultation with the symptom within the study period. <i>The relevant data for the present purposes</i></p>

	<p><i>is only available for the validation cohort, therefore only information pertaining to these patients will be reported.</i></p> <p><u>Exclusion criteria:</u> Patients without a postcode-related Townsend score, patients with a history of pancreatic cancer at baseline, and patients with a recorded 'red-flag' (see "Definition of symptom" below) symptom in the 12 months prior to the study entry date.</p> <p><u>Clinical setting:</u> Primary care</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	'Red-flag' symptoms were defined as symptoms that might alarm the patient and also indicate the presence of pancreatic cancer; that is, symptoms of dysphagia, loss of appetite, weight loss, abdominal distension or abdominal pain.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
<b>Reference standard(s)</b>	Pancreatic cancer, which was defined as incident diagnosis of pancreatic cancer during the 2 years after study entry, recorded either on the patient's GP record using the relevant UK diagnostic Read Codes, or their linked Office for National Statistics cause-of-death record, using the relevant ICD-9 code (157) or ICD-10 diagnostic codes (C25).
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
<b>Flow and timing</b>	A total of 1342329 patients were initially identified of whom 98589 patients were excluded for the following reasons: No recorded Townsend score (N = 70847), history of pancreatic cancer (N = 96), and $\geq$ one 'red flag' symptom recorded in the 12 months prior to study entry (N = 27646), leaving 1243740 patients. However, data is presented for 971706 / 1243740 patients. The missing data does not appear to include any of the cancer cases, but it is unclear whether some of the missing data includes symptomatic patients, i.e., false positives.

Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	No
<b>Could the patient flow have introduced bias?</b>	<b>High risk</b>
<b>NOTES</b>	
1	
2	<b>Møllmann (1981)</b>
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective patient series from an open-access gastroscopy clinic in Denmark.
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	N = 1480; gender not reported; 40-44 years: N = 144; 45-49 years: N = 186; 50-69 years: N = 882; 70-74 years: N = 130; 75-79 years: N = 83; 80-89 years N = 47; 90- years: N = 8.  <u>Inclusion criteria:</u> All patients who, for a 2-year period, presented to their GP with (any of) the following symptoms were referred to the open access gastroscopy clinic: Upper abdominal pain > 2 weeks, nausea and/or vomiting > 2 weeks, weight loss and/or anorexia, gastrointestinal bleeding, and anaemia (i.e., Hb < 80%). <u>Exclusion criteria:</u> Patients who had been examined for any of the above symptoms within the last 6 months. <u>Clinical setting:</u> GPs in Denmark
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	Upper abdominal pain > 2 weeks, nausea and/or vomiting > 2 weeks, weight loss and/or anorexia, gastrointestinal bleeding, and anaemia (i.e., Hb < 80%).
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	2-stage process: Gastroscopy with photography, using a gastroscope, performed with only local anaesthesia of the pharynx. If this investigation disclosed abnormal conditions, the next stage was gastroscopy, possibly with biopsy, using diazepam sedation.



Is the reference standard likely to correctly classify the target condition?	<b>Unclear</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	177/1480 patients declined endoscopy, 2/1480 did not show up for endoscopy, and it was unsuccessful in a further 24 patients, leaving 1277 patients. However, the paper reports that only 1273 had primary endoscopy, and then reports the results for between 1181 and 1297 patients.
Was there an appropriate interval between index test and reference standard?	<b>Yes probably</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>No</b>
<b>Could the patient flow have introduced bias?</b>	<b>High risk</b>
<b>NOTES</b>	There were a total of 18 gastric cancers confirmed in the study. No oesophageal cancers were reported. This research was published in 2 papers.
<b>1</b>	
<b>2</b>	
<b>Panzuto (2003)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective 8-week study of patients presenting to 159 primary care physicians (approximately 63600 patient visits during the study period in total) in Italy.
Was a consecutive or random sample of patients enrolled?	<b>No</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Unclear</b>
<b>Could the selection of patients have introduced bias?</b>	<b>High risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	N = 280; 120 males, 160 females; median age (range) = 61 (18-87) years.  Inclusion criteria: Consecutive patients who consulted their GP “with symptoms considered suspicious for the presence of a colon disease to rule out the presence of colorectal cancer” and who were investigated with a colonoscopy or double-contrast barium enema [The decision of how (colonoscopy or double-contrast barium enema) and when to investigate the colon was made only by the physicians on the basis of the clinical evaluation during the visit].  Exclusion criteria: Patients with previous diagnoses of colorectal disorders or a recent large bowel examination.  Clinical setting: Primary care, Italy.

<b>Are there concerns that the included patients and setting do not match the review question?</b>		<b>Unclear concern</b>
<b>INDEX TEST</b>		
<b>A. Risk of bias</b>		
<b>Index test</b>	Abdominal pain, bloating, constipation, rectal bleeding, diarrhoea, iron-deficiency anaemia (haemoglobin levels < 14 g/dl for males and < 12 g/dl for females, in the presence of ferritin < 30 µg/l and a median corpuscular value < 80 fl), change in bowel habits (onset of diarrhoea or constipation or altered stool in the previous 3 months) and weight loss (decrease of ≥ 3 kg in the 3 months prior to the visit).	
Were the index test results interpreted without knowledge of the results of the reference standard?		<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>		<b>Low concern</b>
<b>REFERENCE STANDARD</b>		
<b>A. risk of bias</b>		
Reference standard(s)	Histology	
Is the reference standard likely to correctly classify the target condition?		<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?		<b>No</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		<b>Low concern</b>
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	56/332 patients were excluded due to lack of mandatory fields (age, sex, clinical history, presenting symptoms and procedure results) in the database (N = 35) or violation of exclusion criteria (N = 18)	
Was there an appropriate interval between index test and reference standard?		<b>Yes</b>
Did all patients receive the same reference standard?		<b>Yes</b>
Were all patients included in the analysis?		<b>No</b>
<b>Could the patient flow have introduced bias?</b>		<b>Unclear risk</b>
<b>NOTES</b>		
1		
2 <b>Stapley (2012)</b>		
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Matched case-control study using patients in the UK's General Practice Research Database (GPRD).	

Was a consecutive or random sample of patients enrolled?	No
Was a case-control design avoided?	No
Did the study avoid inappropriate exclusions?	Yes
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?	Yes
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?	Yes
<b>Could the selection of patients have introduced bias?</b>	<b>High risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p><u>Cases:</u> N = 3635, 1743 males / 1892 females; median number of consultations = 18 (IQR = 11-27); aged 40-49 years: N = 107; 50-59 years: N = 529; 60-69 years: N = 829; 70-79 years: N = 1212; ≥ 80 years: N = 958; UK.</p> <p><u>Controls:</u> N = 16459, gender not reported; median number of consultations = 9 (IQR = 4-15); aged 40-49 years: N = 422; 50-59 years: N = 2239; 60-69 years: N = 3755; 70-79 years: N = 5702; ≥ 80 years: N = 4341; UK.</p> <p><u>Inclusion criteria:</u> Cases: Patients with a record of one of 25 GPRD pancreatic cancer codes between January 2000 and December 2009 inclusive, aged ≥ 40 years, with min. 1 year of data before diagnosis. The first instance of a pancreatic cancer code was assigned the data of diagnosis/index date. Controls: Up to 5 controls were matched to cases on sex, general practice, and to 1 year of age of the case. The index date was the index date of the matched case.</p> <p><u>Exclusion criteria:</u> Pancreatic cancer (controls), no consultations in the year before diagnosis.</p> <p><u>Clinical setting:</u> Primary care</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	All symptoms, physical signs or abnormal investigations compiled from the pancreatic cancer literature were studied, and supplemented by discussion with two pancreatic cancer charities. Libraries of codes relating to these were collated. All codes for fractures were also identified, as a test for any recording bias between cases and controls (making the assumption that the fracture rate would be approximately equal). Occurrences of these features in the year before the index date were identified. Features were only retained for further study if they occurred in ≥5% of cases or controls. Repeat attendances with the same symptom were also retained if the subsequent consultation also occurred in ≥5% of cases or controls. New-onset diabetes was defined as a code for diabetes, or a random blood glucose above the local laboratory's normal range, without similar codes more than 1 year before the index date. For laboratory tests, patients without a test were considered to be the same status as those with a normal result, making our binary variable abnormal result/ no abnormal result. Abnormal liver function

	was defined as any liver enzyme above the normal range, and raised inflammatory markers as either abnormal erythrocyte sedimentation rate or C-reactive protein, as there were too few plasma viscosity results.	
Were the index test results interpreted without knowledge of the results of the reference standard?		Yes
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?		Yes
<b>Could the conduct or interpretation of the index test have introduced bias?</b>		Low risk
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>		Low concern
<b>REFERENCE STANDARD</b>		
<b>A. risk of bias</b>		
Reference standard(s)	Pancreatic cancer code in the UK's General Practice Research Database.	
Is the reference standard likely to correctly classify the target condition?		Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?		Unclear
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>		Low risk
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		Low concern
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	A total of 21624 patients were identified, 17977 controls and 3647 cases. Of the controls the following exclusions were applied: pancreatic cancer (N = 64), case excluded (N = 40), and no data in year pre-index date (N = 1414). Of the cases the following exclusions were applied: No controls (N = 2), and cancer not of pancreatic origin (N = 10).	
Was there an appropriate interval between index test and reference standard?		Yes
Did all patients receive the same reference standard?		Yes
Were all patients included in the analysis?		Yes
<b>Could the patient flow have introduced bias?</b>		Low risk
<b>NOTES</b>		

1  
2  
3  
4  
5  
6  
7

## References

### Included studies

Bellentani, S., Baldoni, P., Petrella, S., Tata, C., Armocida, C., Marchegiano, P., Saccoccio, G., and Manenti, F. A simple score for the identification of patients at high risk of organic diseases of the colon in the family doctor consulting room. The Local IBS Study Group. Family Practice 7[4], 307-312. 1990.

- 1 Collins, G.S., Altman, D.G. Identifying patients with undetected colorectal cancer: An independent  
2 validation of QCancer (Colorectal). *British Journal of Cancer* 107, 260-265. 2012.
- 3 Collins, G.S., Altman, D.G. Identifying patients with undetected gastro-oesophageal cancer in primary  
4 care: External validation of QCancer (Gastro-Oesophageal). *European Journal of Cancer*,  
5 <http://dx.doi.org/10.1016/j.ejca.2012.10.023>. 2012a.
- 6 Collins, G.S., and Altman, D.G. Identifying patients with undetected renal tract cancer in primary  
7 care: An independent and external validation of QCancer (renal) prediction model. *Cancer*  
8 *Epidemiology*, 37, 115-120. 2013.
- 9 Collins, G.S.; Altman, D.G. (2013a). Identifying patients with undetected pancreatic cancer in primary  
10 care: an independent and external validation of QCancer(®) (Pancreas). *British Journal of*  
11 *General Practice*, 63: 636-642.
- 12 Hamilton, W., Round, A., Sharp, D., and Peters, T. J. Clinical features of colorectal cancer before  
13 diagnosis: a population-based case-control study. *British Journal of Cancer* 93[4], 399-405.  
14 22-8-2005.
- 15 Hippisley-Cox, J. and Coupland, C. Identifying patients with suspected gastro-oesophageal cancer in  
16 primary care: Derivation and validation of an algorithm. *British Journal of General Practice*; DOI:  
17 10.3399/bjgp11X606609. 2011.
- 18 Hippisley-Cox, J. and Coupland, C. Identifying patients with suspected renal tract cancer in primary  
19 care: derivation and validation of an algorithm. *British Journal of General Practice* 62[597], e251-  
20 e260. 2012.
- 21 Hippisley-Cox, J. and Coupland, C. Identifying patients with suspected colorectal cancer in primary  
22 care: Derivation and validation of an algorithm. *British Journal of General Practice* 62[594], e29-  
23 e37. 2012a.
- 24 Hippisley-Cox, J. & Coupland, C. (2012b) Identifying patients with suspected pancreatic cancer in  
25 primary care: derivation and validation of an algorithm. *British Journal of General Practice*, 62:  
26 e38-e45.
- 27 Møllmann, K.-M. Early diagnosis of gastric cancer: The possibility of delimiting high risk groups.  
28 *Danish Medical Bulletin* 28, 89-92. 1981.
- 29 Panzuto, F., Chiriatti, A., Bevilacqua, S., Giovannetti, P., Russo, G., Impinna, S., Pistilli, F., Capurso, G.,  
30 Annibale, B., Delle, Fave G., and Digestive and Liver Disease and Primary Care Medicine Lazio  
31 Group. Symptom-based approach to colorectal cancer: survey of primary care physicians in Italy.  
32 *Digestive & Liver Disease* 35[12], 869-875. 2003.
- 33 Stapley, S., Peters, T. J., Neal, R. D., Rose, P. W., Walter, F. M. & Hamilton, W. (2012) The risk of  
34 pancreatic cancer in symptomatic patients in primary care: a large case-control study using  
35 electronic records. *British Journal of Cancer*, 106: 1940-1944.
- 36

37

## APPETITE LOSS

### Risk of bias in the included studies

The risk of bias and applicability concerns are summarised per study in the figure below. The body of evidence was generally of high quality. The main validity issues to note is that patient sampling was not clearly consecutive or random in one of the studies, and that some of studies suffered from missing data. Studies employing non-consecutive/random sampling are at risk of bias because, for example, case-control studies have been shown to be associated with inflated test accuracy parameters compared to designs that incorporate random or consecutive patient selection. The statistical analyses employed by this study are however likely to have gone some way in addressing this issue.

	Risk of Bias				Applicability Concerns		
	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard
Collins (2012)	+	+	+	+	+	+	+
Collins (2012a)	+	+	+	+	+	+	+
Collins (2013)	+	+	+	+	+	+	+
Collins (2013a)	+	+	+	+	+	+	+
Hamilton (2005)	-	+	+	+	+	+	+
Hippisley-Cox (2011)	+	+	+	?	+	+	+
Hippisley-Cox (2012)	+	+	+	-	+	+	+
Hippisley-Cox (2012a)	+	+	+	+	+	+	+
Hippisley-Cox (2012b)	+	+	+	-	+	+	+

- High     
 ? Unclear     
 + Low

**Table 1: Non-site specific symptoms of concern: Calculation of overall positive predictive value of appetite loss for cancer**

Cancer site	Study	Lower age limit	Upper age limit	PPV (95% CI), prevalence
Bladder/renal	Hippisley-Cox (2012)	30	84	0.18 (0.07-0.4)
Colorectal	Hippisley-Cox (2012)	30	84	0.9 (0.6-1.2)
Lung	Hamilton* (2005)	40	no upper limit	1.285
Oesophagus/stomach	Hippisley-Cox (2011)	30	84	1.1 (0.8-1.5) 35/3391

Pancreatic	Hippisley-Cox (2012)	30	84	0.8 (0.5-1.2)
<b>Sum</b>				<b>4.65</b>

1 \* Not sure which one to pick, so used average.

2 **Table 2: Non-site specific symptoms of concern: Positive predictive values for appetite loss**

Cancer site	Comment/relevant recs	Study	Symptom	Patient group	Positive predictive value% (95% CI), prevalence	Sex	Age inclusion, lower limit	Age inclusion, upper limit
Bladder/renal		Collins (2013)	Appetite loss	Women	0.1 (0.04-0.3)	Women	30	84
Bladder/renal		Hippisley-Cox (2012)	Appetite loss	All patients	0.18 (0.07-0.4)	both	30	84
Colorectal		Hippisley-Cox (2012a)	Loss of appetite	All patients	0.9 (0.6-1.2)	both	30	84
Colorectal		Collins (2012)	Loss of appetite	All patients	0.8 (0.6-1.1)	both	30	84
Colorectal		Collins (2012)	Loss of appetite	Men 30-84 years	1 (0.6-1.5)	men	30	84
Colorectal		Collins (2012)	Loss of appetite	Women 30-84 years	0.6 (0.4-1)	women	30	84
Lung		Hamilton (2005)	Appetite loss	All included patients	0.87 (0.6-1.3)	both	40	No upper limit
Lung		Hamilton (2005)	Appetite loss (reported twice)	All included patients	1.7 (NR)	both	40	No upper limit
Lung		Hamilton (2005)	Appetite loss	Patients 40-69 years	1.1 (NR)	both	40	69
Lung		Hamilton (2005)	Appetite loss	All smokers	1.8 (NR)	both	40	No upper limit

Lung		Hamilton (2005)	Appetite loss (reported twice)	All smokers	2.7 (NR)	both	40	No upper limit
Oesophagus/stomach		Collins (2012a)	Appetite loss	All patients	0.6 (0.5-0.9) 37/5838	both	30	84
Oesophagus/stomach		Collins (2012a)	Appetite loss	Women	0.4 (0.2-0.7) 12/3317	women	30	84
Oesophagus/stomach		Collins (2012a)	Appetite loss	Men	1 (0.7-1.5) 25/2521	men	30	84
Oesophagus/stomach		Hippisley-Cox (2011)	Appetite loss	All patients	1.1 (0.8-1.5) 35/3391	both	30	84
Pancreatic		Collins (2013a)	Appetite loss	All patients	0.39 (0.26-0.59)	both	30	84
Pancreatic		Collins (2013a)	Appetite loss	Women	0.32 (0.17-0.59)	women	30	84
Pancreatic		Collins (2013a)	Appetite loss	Men	0.49 (0.27-0.86)	women	30	84
Pancreatic		Hippisley-Cox (2012b)	Appetite loss	All patients	0.8 (0.5-1.2)	both	30	84

1  
2  
3  
4  
5  
6  
7  
8

**Evidence statement(s):**

Appetite loss (5 studies, N = 4961516) presenting in a primary care setting is associated with an overall positive predictive value of 4.65% for cancer. The studies were associated with 0-1 bias/applicability concern (see also Table 1).

**Evidence tables**

**Collins (2012)**

<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Retrospective patient series using the THIN database.
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>



<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>A total of 2135540 patients were identified from 364 practices.</p> <p><u>Symptoms:</u> Rectal bleeding (N = 56234; 28423 men, 27811 women), abdominal pain (N = 245989; 102192 men, 143797 women), appetite loss (N = 5776; 2481 men, 3295 women), weight loss (N = 28289; 12891 men, 15398 women), anaemia (N = 18125; 4466 men, 13659 women), change in bowel habit (men only, N = 1670).</p> <p><u>Incident cases of colorectal cancer during the 2-year follow up period:</u> N = 3712 (2036 men, 1676 women).</p> <p><u>Inclusion criteria:</u> Patients aged 30–84 years and registered with practices between 1 January 2000 and 30 June 2008. Entry to the cohort was defined as the latest of the study start date; the date the patient registered with the practice; and for those patients with red flag symptoms (see below), the date of the first recorded onset within the study period.</p> <p><u>Exclusion criteria:</u> Patients without a postcode-related Townsend score, patients with a history of colorectal cancer at baseline, and patients with a recorded 'red-flag' symptom in the 12 months prior to the study entry date.</p> <p><u>Clinical setting:</u> Primary care, UK</p>
Are there concerns that the included patients and setting do not match the review question?	Low concern
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	'Red-flag' symptoms: Rectal bleeding, loss of appetite, weight loss, abdominal pain, change in bowel habit (men only), and anaemia.
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
Could the conduct or interpretation of the index test have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Low concern
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	2-year follow up
Is the reference standard likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Are there concerns that the target condition as defined by the reference standard does not match the question?	Low concern
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	

Flow and timing	All patients seem to be accounted for
Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	Yes
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	The is <b><i>very large, if not complete, overlap</i></b> of the data used in this study with those used in Hamilton (2008 [for anaemia], 2009)
1	
2	<b>Collins (2012a)</b>
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Retrospective patient series using the THIN database.
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>A total of 2135540 patients were identified from 364 practices.</p> <p><u>Symptoms:</u> Dysphagia (N = 19237; 8846 men, 10391 women), abdominal pain (N = 246998; 102732 men, 144266 women), appetite loss (N = 5838; 2521 men, 3317 women), weight loss (N = 28403; 12938 men, 15465 women), haematemesis (N = 10792; 6162 men, 4630 women), anaemia (N = 18355; 4563 men, 13792 women).</p> <p><u>Incident cases of gastro-oesophageal cancer during the 2-year follow up period:</u> N = 1766 (1184 men, 582 women; 32% gastric cancer, 68% oesophageal cancer).</p> <p><u>Inclusion criteria:</u> Patients aged 30–84 years and registered with practices between 1 January 2000 and 30 June 2008. Entry to the cohort was defined as the latest of the study start date; the date the patient registered with the practice; and for those patients with red flag symptoms (see below), the date of the first recorded onset within the study period.</p> <p><u>Exclusion criteria:</u> Patients with a prior diagnosis of gastro-oesophageal cancer, registration with the general practice &lt; 12 months, or with invalid dates.</p> <p><u>Clinical setting:</u> Primary care, UK</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	'Red-flag' symptoms: Haematemesis, dysphagia, loss of appetite, weight loss, anaemia, and abdominal pain.
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
<b>Could the conduct or interpretation of the index test</b>	<b>Low risk</b>

<b>have introduced bias?</b>		
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>		<b>Low concern</b>
<b>REFERENCE STANDARD</b>		
<b>A. risk of bias</b>		
Reference standard(s)	2-year follow up	
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>	
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>	
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>	
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		<b>Low concern</b>
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	All patients seem to be accounted for	
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>	
Did all patients receive the same reference standard?	<b>Yes</b>	
Were all patients included in the analysis?	<b>Yes</b>	
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>	
<b>NOTES</b>	The study did not distinguish between gastric and oesophageal cancer	
1		
2	<b>Collins (2013)</b>	
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Retrospective patient series using the THIN database.	
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>	
Was a case-control design avoided?	<b>Yes</b>	
Did the study avoid inappropriate exclusions?	<b>Yes</b>	
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>	
<b>B. Concerns regarding applicability</b>		
Patient characteristics and setting	<p>A total of 2145133 patients (1063355 men, 1081778 women) were identified from 364 practices.</p> <p>Symptoms:  Haemoglobin &lt; 11 g/dl recorded in the last year (N = 16961; 3969 men, 12992 women), abdominal pain (N = 253344; 105247 men, 148097 women), appetite loss (N = 6097; 2616 men, 3481 women), weight loss (N = 29369; 13332 men, 16037 women), haematuria (N = 37810; 22810 men, 15000 women), previous diagnosis of cancer apart from renal tract cancer at study entry (N = 49303; 18130 men, 31173 women).</p> <p><u>Incident cases of renal tract cancer during the 2-year follow up period:</u></p>	

	<p>N = 2283 (1685 men, 598 women).</p> <p><u>Inclusion criteria:</u> Patients aged 30–84 years and registered with practices between 1 January 2000 and 30 June 2008. Entry to the cohort was defined as the latest of the study start date; the date the patient registered with the practice; and for those patients with red flag symptoms (e.g., haematuria, abdominal pain, weight loss, appetite loss, and anaemia), the date of the first recorded onset within the study period.</p> <p><u>Exclusion criteria:</u> Patients with a prior diagnosis of renal tract cancer, registered less than 12 months with the general practice, had invalid dates, &lt; 30 years old or ≥ 85 years old.</p> <p><u>Clinical setting:</u> Primary care, UK</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	'Red-flag' symptoms were defined as symptoms that might alarm the patient and also indicate the presence of renal tract cancer; that is, symptoms of haematuria, loss of appetite, weight loss, or abdominal pain.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
<b>Reference standard(s)</b>	Renal tract cancer, which was defined as incident diagnosis of cancer of the bladder, kidney, ureter, or urethra during the 2 years after study entry, recorded either on the patient's GP record using the relevant UK diagnostic Read Codes. Patients without the outcome were censored at the earliest of the date of death, date of leaving the practice study of 2 years of follow up.
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
<b>Flow and timing</b>	All patients seem to be accounted for
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>

Were all patients included in the analysis?	Yes
Could the patient flow have introduced bias?	Low risk
<b>NOTES</b>	It is unclear why no data has been presented for men for the symptoms of appetite loss and weight loss.
1	
2	
<b>Collins (2013a)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Retrospective patient series using the THIN database.
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
Could the selection of patients have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>A total of 2150322 patients were identified from 364 practices.</p> <p><u>Symptoms:</u> Dysphagia (men only: N = 9326), abdominal pain (N = 255058; 106768 men, 148290 women), appetite loss (N = 6102; 2658 men, 3444 women), weight loss (N = 29464; 13484 men, 15980 women), abdominal distension (women only: N = 4457), constipation (men only, N = 5326).</p> <p><u>Incident cases of pancreatic cancer during the 2-year follow up period:</u> N = 287 (331 men, 287 women).</p> <p><u>Inclusion criteria:</u> Patients aged 30–84 years and registered with practices between 1 January 2000 and 30 June 2008. Entry to the cohort was defined as the latest of the study start date; the date the patient registered with the practice; and for those patients with red flag symptoms (see below), the date of the first recorded onset within the study period.</p> <p><u>Exclusion criteria:</u> Patients with a prior diagnosis of pancreatic cancer, registration &lt; 12 months with the general practice, or invalid dates.</p> <p><u>Clinical setting:</u> Primary care, UK</p>
Are there concerns that the included patients and setting do not match the review question?	Low concern
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	'Red-flag' symptoms: Dysphagia (men only), loss of appetite, weight loss, abdominal pain, abdominal distension (women only), and constipation (men only).
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
Could the conduct or interpretation of the index test have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Low concern
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference	2-year follow up

standard(s)	
Is the reference standard likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	Unclear
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	Low risk
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	Low concern
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients seem to be accounted for
Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	Yes
<b>Could the patient flow have introduced bias?</b>	Low risk
<b>NOTES</b>	
1	
2 <b>Hamilton (2005)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Population-based matched case-control study involving all 21 general practices in Exeter, Devon, UK.
Was a consecutive or random sample of patients enrolled?	No
Was a case-control design avoided?	No
Did the study avoid inappropriate exclusions?	Yes
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?	Yes
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?	Yes
<b>Could the selection of patients have introduced bias?</b>	High risk
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p><u>Cases:</u> N = 247 (170 males/77 females), age at diagnosis: &lt; 60 years: N = 35, 60-69 years: N = 60, 70-79 years: N = 118, 80+ years: N = 34.</p> <p><u>Controls:</u> N = 1235 (850 males/385 females), age at diagnosis: &lt; 60 years: N = 178, 60-69 years: N = 310, 70-79 years: N = 575, 80+ years: N = 174.</p> <p><u>Inclusion criteria:</u> Cases: All patients aged ≥ 40 years with a primary lung cancer, diagnosed from 1998 to 2002, were identified from the cancer registry at the Royal Devon and Exeter Hospital combined with computerised searches at every</p>

	<p>practice in Devon to identify any cases missing from the cancer register. Controls: Five controls were matched to each case on sex, general practice, and age. Controls were eligible if they were alive at the time of diagnosis of their case.</p> <p><u>Exclusion criteria:</u> Cases and controls: Unobtainable records; no consultations in the 2 years before diagnosis; previous lung cancer; or residence outside Exeter at the time of diagnosis.</p> <p><u>Clinical setting:</u> Primary care, UK.</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	Anonymised photocopies of the full primary care records for 2 years before diagnosis were coded (blinded to case/control status) for all entries using the International Classification of Primary Care-2. Additional codes were created to incorporate all possible clinical features. Only variables occurring in $\geq 2.5\%$ of cases or controls were analysed.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Lung cancer diagnosis in the cancer registry at the Royal Devon and Exeter Hospital or practice notes.
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All the patients are accounted for.
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>

<b>Could the patient flow have introduced bias?</b>		<b>Low risk</b>
<b>NOTES</b>		
1		
2	<b>Hippisley-Cox (2011)</b>	
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Prospective patient series using patients in the QResearch database (version 30).	
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>	
Was a case-control design avoided?	<b>Yes</b>	
Did the study avoid inappropriate exclusions?	<b>Yes</b>	
<b>Could the selection of patients have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
Patient characteristics and setting	<p>A total of 1238971 patients were identified from 189 practices (621478 males, 617493 females), mean (SD) age = 50.1 (15) years, mean (SD) Townsend score = -0.2 (3.6).</p> <p><u>Symptoms:</u> Current dysphagia (N = 8165), current haematemesis (N = 7119), current abdominal pain (N = 126161), current appetite loss (N = 6133), current weight loss (N = 5377), tiredness in the last year (N = 14119), haemoglobin recorded in the last year (N = 12638, haemoglobin &lt; 11 g/dl in the last year (N = 218862).</p> <p><u>Incident cases of gastro-oesophageal cancer during the 2-year follow up period:</u> N = 1343 (776 oesophageal and 567 gastric).</p> <p><u>Inclusion criteria:</u> All practices in England and Wales that had been using their Egton Medical Information Systems (EMIS) computer system for ≥ a year were included. Two-thirds of practices were randomly allocated to the derivation dataset and the remaining practices were allocated to the validation dataset. An open cohort of patients aged 30–84 years was identified, drawn from patients registered with practices between 1 January 2000 and 30 September 2010. Entry to the cohort was defined as the latest of the study start date (1 January 2000); 12 months after the patient registered with the practice; and for those patients with red flag symptoms (see below), the date of the first recorded onset within the study period. <i>The relevant data for the present purposes is only available for the validation cohort, therefore only information pertaining to these patients will be reported.</i></p> <p><u>Exclusion criteria:</u> Patients without a postcode-related Townsend score, patients with a history of gastro-oesophageal cancer at baseline, and patients with a recorded 'red-flag' symptom in the 12 months prior to the study entry date.</p> <p><u>Clinical setting:</u> Primary care, UK</p>	
<b>Are there concerns that the included patients and setting do not match the review question?</b>		<b>Low concern</b>
<b>INDEX TEST</b>		
<b>A. Risk of bias</b>		
Index test	'Red-flag' symptoms: Incident dysphagia, haematemesis, loss of appetite, weight loss, anaemia, and abdominal pain.	



Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
Could the conduct or interpretation of the index test have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Low concern
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	2-year follow up
Is the reference standard likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Are there concerns that the target condition as defined by the reference standard does not match the question?	Low concern
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	A total of 1342329 patients were initially identified of whom 103358 patients were excluded for the following reasons: No recorded Townsend score (N = 70847), history of gastro-oesophageal cancer (N = 538), and $\geq$ one 'red flag' symptom recorded in the 12 months prior to study entry (N = 31973), leaving 1238971 patients. However, data is presented for 963040/1238971 patients for all symptoms. The missing data does not appear to include any of the cancer cases, but it is unclear whether some of the missing data includes symptomatic patients, i.e., false positives.
Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	No
Could the patient flow have introduced bias?	Unclear risk
<b>NOTES</b>	Results not presented separately for gastric and oesophageal cancer
1	
2 <b>Hippisley-Cox (2012)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective patient series using patients in the QResearch database (version 30).
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
Could the selection of patients have introduced bias?	Low risk

<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>A total of 1240722 patients were identified from 189 practices (622166 males, 618556 females), mean (SD) age = 50.1 (14.9) years, mean (SD) Townsend score = -0.2 (3.6).</p> <p><u>Current symptoms and symptoms in the preceding year:</u>            Current haematuria (N = 25553), current abdominal pain (N = 128721), current appetite loss (N = 5531), current weight loss (N = 14464), constipation in the last year (N = 8472), diarrhoea in the last year (N = 12171), tiredness in the last year (N = 12669), haemoglobin recoded in the last year (N = 216201), haemoglobin &lt; 11 g/dl in the last year (N = 16169).</p> <p><u>Incident cases of renal tract cancer during the 2-year follow up period:</u>            N = 1622; mean age at diagnosis = 70 years, 1187 males/ 435 females; <b>Type of cancer: Bladder: N = 1292; Kidney: N = 307; Ureter: N = 21; Urethra: N = 2.</b></p> <p><u>Inclusion criteria:</u>            All practices in England and Wales that had been using their Egton Medical Information Systems (EMIS) computer system for ≥ a year were included. Two-thirds of practices were randomly allocated to the derivation dataset and the remaining practices were allocated to the validation dataset. An open cohort of patients aged 30–84 years was identified, drawn from patients registered with practices between 1 January 2000 and 30 September 2010. Entry to the cohort was defined as the latest of the study start date (1 January 2000) and 12 months after the patient registered with the practice, ensuring that all patients had ≥ 12 months' registration prior to study entry. For patients with incident haematuria, appetite loss, weight loss, or abdominal pain, the entry date was the date of the first consultation with the symptom within the study period. <i>The relevant data for the present purposes is only available for the validation cohort, therefore only information pertaining to these patients will be reported.</i></p> <p><u>Exclusion criteria:</u> Patients without a postcode-related Townsend score, patients with a history of renal tract cancer at baseline, and patients with a recorded 'red-flag' (see "Definition of symptom" below) symptom in the 12 months prior to the study entry date.</p> <p><u>Clinical setting:</u> Primary care</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	'Red-flag' symptoms were defined as symptoms that might alarm the patient and also indicate the presence of renal tract cancer; that is, symptoms of haematuria, loss of appetite, weight loss, or abdominal pain.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	

Reference standard(s)	Renal tract cancer, which was defined as incident diagnosis of cancer of the bladder, kidney, ureter, or urethra during the 2 years after study entry, recorded either on the patient's GP record using the relevant UK diagnostic Read Codes, or their linked Office for National Statistics cause-of-death record, using the relevant ICD-9 codes (188 or 189) or ICD-10 diagnostic codes (C64–67).
Is the reference standard likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Are there concerns that the target condition as defined by the reference standard does not match the question?	Low concern
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	A total of 1342329 patients were initially identified of whom 101607 patients were excluded for the following reasons: No recorded Townsend score (N = 70847), history of renal tract cancer (N = 1506), and $\geq$ one 'red flag' symptom recorded in the 12 months prior to study entry (N = 29254), leaving 1240722 patients. However, data is presented for 967681 / 1240722 patients. The missing data does not appear to include any of the cancer cases, but it is unclear whether some of the missing data includes symptomatic patients, i.e., false positives.
Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	No
Could the patient flow have introduced bias?	High risk
<b>NOTES</b>	
1	
2 <b>Hippisley-Cox (2012a)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective patient series using patients in the QResearch database (version 30).
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
Could the selection of patients have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	A total of 1236601 patients were identified from 189 practices (620240 males, 616361 females), mean (SD) age = 50.1 (14.9) years, mean (SD) Townsend score = -0.2 (3.6). <u>Symptoms:</u> Current rectal bleeding (N = 29118), current abdominal pain (N = 125816),

	<p>current appetite loss (N = 5358), current weight loss (N = 14065), recent change in bowel habit (N = 1821).</p> <p><u>Incident cases of colorectal cancer during the 2-year follow up period:</u> N = 2603 (1562 colon and 1041 rectum).</p> <p><u>Inclusion criteria:</u> All practices in England and Wales that had been using their Egton Medical Information Systems (EMIS) computer system for <math>\geq</math> a year were included. Two-thirds of practices were randomly allocated to the derivation dataset and the remaining practices were allocated to the validation dataset. An open cohort of patients aged 30–84 years was identified, drawn from patients registered with practices between 1 January 2000 and 30 September 2010. Entry to the cohort was defined as the latest of the study start date (1 January 2000); 12 months after the patient registered with the practice; and for those patients with red flag symptoms (see below), the date of the first recorded onset within the study period. <i>The relevant data for the present purposes is only available for the validation cohort, therefore only information pertaining to these patients will be reported.</i></p> <p><u>Exclusion criteria:</u> Patients without a postcode-related Townsend score, patients with a history of colorectal cancer at baseline, and patients with a recorded 'red-flag' symptom in the 12 months prior to the study entry date.</p> <p><u>Clinical setting:</u> Primary care, UK</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	'Red-flag' symptoms: First onset rectal bleeding, first onset loss of appetite, first onset weight loss, first onset abdominal pain, first onset change in bowel habit (in the past 12 months), and anaemia (recorded haemoglobin < 11 g/dl in the past 12 months).
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	2-year follow up
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>

<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	A total of 1342329 patients were initially identified of whom 105728 patients were excluded for the following reasons: No recorded Townsend score (N = 70847), history of colorectal cancer (N = 2908), and $\geq$ one 'red flag' symptom recorded in the 12 months prior to study entry (N = 31973), leaving 1236601 patients. However, data is presented for 1235547/1236601 patients for all symptoms apart from change in bowel habit, which is only presented for 619651/620240 of the male patients. The missing data does not appear to include any of the cancer cases (although this cannot be ascertained for change in bowel habit), but it is unclear whether some of the missing data includes symptomatic patients, i.e., false positives.
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>No</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	Please note there is some overlap between this patient sample and that of Parker (2007)
1	
2 <b>Hippisley-Cox (2012b)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective patient series using patients in the QResearch database (version 30).
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>A total of 1243740 patients were identified from 189 practices (624352 males, 619388 females), mean (SD) age = 50.1 (14.9) years, mean (SD) Townsend score = -0.2 (3.6).</p> <p><u>Current symptoms and symptoms in the preceding year:</u>  Current dysphagia (N = 8507), current abdominal pain (N = 129924), current abdominal distension (N = 4929), current appetite loss (N = 5567), current weight loss (N = 14686), constipation in the last year (N = 8476), diarrhoea in the last year (N = 12233), tiredness in the last year (N = 12688), itching in the last year (N = 1454), haemoglobin recoded in the last year (N = 214497), haemoglobin &lt; 11 g/dl in the last year (N = 16172).</p> <p><u>Incident cases of pancreatic cancer during the 2-year follow up period:</u> N = 781.</p> <p><u>Inclusion criteria:</u>  All practices in England and Wales that had been using their Egton Medical Information Systems (EMIS) computer system for <math>\geq</math> a year were included. Two-thirds of practices were randomly allocated to the derivation dataset and the remaining practices were allocated to the validation dataset. An open cohort of patients aged 30–84 years was identified, drawn from</p>

	<p>patients registered with practices between 1 January 2000 and 30 September 2010. Entry to the cohort was defined as the latest of the study start date (1 January 2000) and 12 months after the patient registered with the practice, ensuring that all patients had <math>\geq 12</math> months' registration prior to study entry. For patients with incident haematuria, appetite loss, weight loss, or abdominal pain, the entry date was the date of the first consultation with the symptom within the study period. <i>The relevant data for the present purposes is only available for the validation cohort, therefore only information pertaining to these patients will be reported.</i></p> <p><u>Exclusion criteria:</u> Patients without a postcode-related Townsend score, patients with a history of pancreatic cancer at baseline, and patients with a recorded 'red-flag' (see "Definition of symptom" below) symptom in the 12 months prior to the study entry date.</p> <p><u>Clinical setting:</u> Primary care</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	'Red-flag' symptoms were defined as symptoms that might alarm the patient and also indicate the presence of pancreatic cancer; that is, symptoms of dysphagia, loss of appetite, weight loss, abdominal distension or abdominal pain.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
<b>Reference standard(s)</b>	Pancreatic cancer, which was defined as incident diagnosis of pancreatic cancer during the 2 years after study entry, recorded either on the patient's GP record using the relevant UK diagnostic Read Codes, or their linked Office for National Statistics cause-of-death record, using the relevant ICD-9 code (157) or ICD-10 diagnostic codes (C25).
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
<b>Flow and timing</b>	A total of 1342329 patients were initially identified of whom 98589 patients

	were excluded for the following reasons: No recorded Townsend score (N = 70847), history of pancreatic cancer (N = 96), and $\geq$ one 'red flag' symptom recorded in the 12 months prior to study entry (N = 27646), leaving 1243740 patients. However, data is presented for 971706 / 1243740 patients. The missing data does not appear to include any of the cancer cases, but it is unclear whether some of the missing data includes symptomatic patients, i.e., false positives.
Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	No
<b>Could the patient flow have introduced bias?</b>	<b>High risk</b>
<b>NOTES</b>	

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

## References

### Included studies

- Collins, G.S., Altman, D.G. Identifying patients with undetected colorectal cancer: An independent validation of QCancer (Colorectal). *British Journal of Cancer* 107, 260-265. 2012.
- Collins, G.S., Altman, D.G. Identifying patients with undetected gastro-oesophageal cancer in primary care: External validation of QCancer (Gastro-Oesophageal). *European Journal of Cancer*, <http://dx.doi.org/10.1016/j.ejca.2012.10.023>. 2012a.
- Collins, G.S., and Altman, D.G. Identifying patients with undetected renal tract cancer in primary care: An independent and external validation of QCancer (renal) prediction model. *Cancer Epidemiology*, 37, 115-120. 2013.
- Collins, G.S.; Altman, D.G. (2013a). Identifying patients with undetected pancreatic cancer in primary care: an independent and external validation of QCancer<sup>®</sup> (Pancreas). *British Journal of General Practice*, 63: 636-642.
- Hamilton, W., Peters, T. J., Round, A. & Sharp, D. (2005) What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study. *Thorax*, 60: 1059-1065. The data split by smoking status is available from: <http://webarchive.nationalarchives.gov.uk/20130513211237/http://www.ncat.nhs.uk/sites/default/files/work-docs/ncl%20lung%20guide.pdf>
- Hippisley-Cox, J. and Coupland, C. Identifying patients with suspected gastro-oesophageal cancer in primary care: Derivation and validation of an algorithm. *British Journal of General Practice*; DOI: 10.3399/bjgp11X606609. 2011.
- Hippisley-Cox, J. and Coupland, C. Identifying patients with suspected renal tract cancer in primary care: derivation and validation of an algorithm. *British Journal of General Practice* 62[597], e251-e260. 2012.
- Hippisley-Cox, J. and Coupland, C. Identifying patients with suspected colorectal cancer in primary care: Derivation and validation of an algorithm. *British Journal of General Practice* 62[594], e29-e37. 2012a.
- Hippisley-Cox, J. & Coupland, C. (2012b) Identifying patients with suspected pancreatic cancer in primary care: derivation and validation of an algorithm. *British Journal of General Practice*, 62: e38-e45.

## WEIGHT LOSS AND APPETITE LOSS

### Risk of bias in the included studies

The risk of bias and applicability concerns are summarised per study in the figure below. The main validity issues to note is that patient sampling was not based on a consecutive or random series of patients in one of the studies, while the other study was conducted in a population that is not necessarily directly relevant to the current question. Studies employing non-consecutive/random sampling are at high risk of bias because, for example, case-control studies have been shown to be associated with inflated test accuracy parameters compared to designs that incorporate random or consecutive patient selection. Studies conducted in other settings than UK-based primary care are only applicable to the extent that the study populations and settings are comparable to a UK GP population as defined for the current purposes. Other bias and applicability threats to the results concern missing data and a potentially suboptimal reference standard.

	Risk of Bias				Applicability Concerns		
	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard
Hamilton (2005)	+	+	+	+	+	+	+
Moellmann (1981)	+	+	?	-	?	+	+

+ High      ? Unclear      + Low

**Table 1: Non-site specific symptoms of concern: Calculation of overall positive predictive value of appetite loss with weight loss for cancer**

Cancer site	Study	Lower age limit	Upper age limit	PPV (95% CI), prevalence
Lung	Hamilton (2005)	40	no upper limit	2.3 (1.2-4.4)
Oesophagus	Møllmann (1981)	40	>90	0 (0-8.9) 0/50
Stomach	Møllmann (1981)	40	>90	2 (0.1-12) 1/50
<b>Sum</b>				<b>4.3</b>

**Table 2: Non-site specific symptoms of concern: Positive predictive values for weight loss + appetite loss**

Cancer site	Comment/relevant recs	Study	Symptom	Patient group	Positive predictive value% (95% CI), prevalence	Sex	Age inclusion, lower limit	Age inclusion, upper limit
Lung	Rec: Offered FBC and	Hamilton (2005)	Weight loss + appetite	All included	2.3 (1.2-4.4)	both	40	no upper limit



	xray		loss	patients				
Lung	Rec: Offered FBC and xray	Hamilton (2005)	Weight loss + appetite loss	All smokers	5 (NR)	both	40	no upper limit
Oesophagus		Møllmann (1981)	Weight loss and/or anorexia	All patients	0 (0-8.9) 0/50	both	40	>90
Stomach	Rec: UGI endoscopy	Møllmann (1981)	Weight loss and/or anorexia	All patients	2 (0.1-12) 1/50	both	40	>90

1  
2  
3  
4  
5  
6  
7  
8

### Evidence statement(s):

Appetite loss with weight loss (2 studies, N = 2962) presenting in a primary care setting is associated with an overall positive predictive value of 4.3% for cancer. The studies were associated with 1-3 bias/applicability concerns (see also Table 1).

### Evidence tables

#### Hamilton (2005)

<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Population-based matched case-control study involving all 21 general practices in Exeter, Devon, UK.
Was a consecutive or random sample of patients enrolled?	<b>No</b>
Was a case-control design avoided?	<b>No</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>High risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p><u>Cases:</u> N = 247 (170 males/77 females), age at diagnosis: &lt; 60 years: N = 35, 60-69 years: N = 60, 70-79 years: N = 118, 80+ years: N = 34.</p> <p><u>Controls:</u> N = 1235 (850 males/385 females), age at diagnosis: &lt; 60 years: N = 178, 60-69 years: N = 310, 70-79 years: N = 575, 80+ years: N = 174.</p> <p><u>Inclusion criteria:</u> Cases: All patients aged ≥ 40 years with a primary lung cancer, diagnosed from 1998 to 2002, were identified from the cancer registry at the Royal</p>

	Devon and Exeter Hospital combined with computerised searches at every practice in Devon to identify any cases missing from the cancer register. Controls: Five controls were matched to each case on sex, general practice, and age. Controls were eligible if they were alive at the time of diagnosis of their case. <u>Exclusion criteria:</u> Cases and controls: Unobtainable records; no consultations in the 2 years before diagnosis; previous lung cancer; or residence outside Exeter at the time of diagnosis. <u>Clinical setting:</u> Primary care, UK.
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	Anonymised photocopies of the full primary care records for 2 years before diagnosis were coded (blinded to case/control status) for all entries using the International Classification of Primary Care-2. Additional codes were created to incorporate all possible clinical features. Only variables occurring in $\geq 2.5\%$ of cases or controls were analysed.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
<b>Reference standard(s)</b>	Lung cancer diagnosis in the cancer registry at the Royal Devon and Exeter Hospital or practice notes.
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
<b>Flow and timing</b>	All the patients are accounted for.
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>

Were all patients included in the analysis?	Yes
Could the patient flow have introduced bias?	Low risk
<b>NOTES</b>	
1	
2 <b>Møllmann (1981)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective patient series from an open-access gastroscopy clinic in Denmark.
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
Could the selection of patients have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	N = 1480; gender not reported; 40-44 years: N = 144; 45-49 years: N = 186; 50-69 years: N = 882; 70-74 years: N = 130; 75-79 years: N = 83; 80-89 years: N = 47; 90+ years: N = 8.  <u>Inclusion criteria:</u> All patients who, for a 2-year period, presented to their GP with (any of) the following symptoms were referred to the open access gastroscopy clinic: Upper abdominal pain > 2 weeks, nausea and/or vomiting > 2 weeks, weight loss and/or anorexia, gastrointestinal bleeding, and anaemia (i.e., Hb < 80%). <u>Exclusion criteria:</u> Patients who had been examined for any of the above symptoms within the last 6 months. <u>Clinical setting:</u> GPs in Denmark
Are there concerns that the included patients and setting do not match the review question?	Unclear concern
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	Upper abdominal pain > 2 weeks, nausea and/or vomiting > 2 weeks, weight loss and/or anorexia, gastrointestinal bleeding, and anaemia (i.e., Hb < 80%).
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
Could the conduct or interpretation of the index test have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Low concern
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	2-stage process: Gastroscopy with photography, using a gastroscope, performed with only local anaesthesia of the pharynx. If this investigation disclosed abnormal conditions, the next stage was gastroscopy, possibly with biopsy, using diazepam sedation.
Is the reference standard likely to correctly classify the target condition?	Unclear
Were the reference standard results interpreted without	No

knowledge of the results of the index tests?	
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	177/1480 patients declined endoscopy, 2/1480 did not show up for endoscopy, and it was unsuccessful in a further 24 patients, leaving 1277 patients. However, the paper reports that only 1273 had primary endoscopy, and then reports the results for between 1181 and 1297 patients.
Was there an appropriate interval between index test and reference standard?	<b>Yes probably</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>No</b>
<b>Could the patient flow have introduced bias?</b>	<b>High risk</b>
<b>NOTES</b>	There were a total of 18 gastric cancers confirmed in the study. No oesophageal cancers were reported. This research was published in 2 papers.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14

## References


### Included studies

- Hamilton, W., Peters, T. J., Round, A. & Sharp, D. (2005) What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study. *Thorax*, 60: 1059-1065.  
The data split by smoking status is available from:  
<http://webarchive.nationalarchives.gov.uk/20130513211237/http://www.ncat.nhs.uk/sites/default/files/work-docs/ncl%20lung%20guide.pdf>
- Møllmann, K.-M. Early diagnosis of gastric cancer: The possibility of delimiting high risk groups. *Danish Medical Bulletin* 28, 89-92. 1981.
- Møllmann, K.-M. Endoscopic service for general practice. *Danish Medical Bulletin* 28, 96-99. 1981.

## DEEP VEIN THROMBOSIS

### Risk of bias in the included studies

The risk of bias and applicability concerns are summarised in the figure below. The main validity issue to note is that the study was conducted in the Netherlands and the findings are only applicable to the extent that the study population and setting are comparable to a UK GP population as defined for the current purposes.



**Table 1: Non-site specific symptoms of concern: Calculation of overall positive predictive value of deep vein thrombosis for cancer**

Cancer site	Study	Lower age limit	Upper age limit	PPV (95% CI), prevalence
Colorectal	Oudega (2006)	No age incl/excl given, sample mean (SD) age = 60.7 (18.2) years		0.7 (0.2-2.2) 3/430
Urogenital	Oudega (2006)	No age incl/excl given, sample mean (SD) age = 60.7 (18.2) years		1.16 (0.4-2.9) 5/430
Breast	Oudega (2006)	No age incl/excl given, sample mean (SD) age = 60.7 (18.2) years		0.93 (0.3-2.53) 4/430
Lung	Oudega (2006)	No age incl/excl given, sample mean (SD) age = 60.7 (18.2) years		0.7 (0.2-2.2) 3/430
Sum				<u>3.49</u>

**Table 2: Non-site specific symptoms of concern: Positive predictive values for deep vein thrombosis**

Cancer site	Comment/relevant recs	Study	Symptom	Patient group	Positive predictive value% (95% CI), prevalence	Sex	Age inclusion, lower limit	Age inclusion, upper limit

Colorectal		Oudega (2006)	Deep vein thrombosis	All included patients	0.7 (0.2-2.2) 3/430	both	No age incl/excl given, sample mean (SD) age = 60.7 (18.2) years
Urogenital		Oudega (2006)	Deep vein thrombosis	All included patients	1.16 (0.4-2.9) 5/430	both	No age incl/excl given, sample mean (SD) age = 60.7 (18.2) years
Breast		Oudega (2006)	Deep vein thrombosis	All included patients	0.93 (0.3-2.53) 4/430	women	No age incl/excl given, sample mean (SD) age = 60.7 (18.2) years
Lung		Oudega (2006)	Deep vein thrombosis	All included patients	0.7 (0.2-2.2) 3/430	both	No age incl/excl given, sample mean (SD) age = 60.7 (18.2) years
Other		Oudega (2006)	Deep vein thrombosis	All included patients	0.93 (0.3-2.53) 4/430	both	No age incl/excl given, sample mean (SD) age = 60.7 (18.2) years

1

2 **Evidence statement(s):**

3 Deep vein thrombosis (1 study, N = 430) presenting in a primary care setting is associated with an  
4 overall positive predictive value of 3.49% for cancer. The study was associated with 1 applicability  
5 concern (see also Table 1).

6

7 **Evidence tables**8 **Oudega (2006)**

<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective study of all primary care physicians (N = 50) within a catchment area (ca 130000 inhabitants) of a non-teaching hospital in The Netherlands.
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	N = 430; 162 males, 268 females; mean age (SD) = 60.7 (18.2) years. <u>Inclusion criteria:</u> Consecutive patients who consulted their GP between January 1996 and July 2002 and who, after investigation (not referral) was

	confirmed to have deep vein thrombosis. <u>Exclusion criteria:</u> Patients with a known malignancy or a malignancy detected within 2 weeks of deep vein thrombosis diagnosis. <u>Clinical setting:</u> Primary care, The Netherlands.
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	Deep vein thrombosis (suspicion based on painful swollen leg $\leq$ 30 days). Patients were classified as having secondary deep vein thrombosis if $\geq$ 1 of the following risk factors for deep vein thrombosis were present: Recent surgery, prolonged immobilisation, use of oral contraceptives or hormonal replacement therapy. If no risk factors were present patients were classified as having idiopathic deep vein thrombosis.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	2 years follow up.
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients appear to be accounted for
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	In total N = 19 had cancer: 3 colorectal, 5 urogenital (not further subgrouped), 4 breast, 3 lung and 4 other. The urogenital data is added to the renal cancer evidence review.

1

2

**References**

1  
2  
3  
4  
5  
6

**Included studies**  
Oudega, R. (2006) Deep vein thrombosis in primary care: Possible malignancy? *British Journal of General Practice*, 56: 693-696.



## DYSPEPSIA

### Risk of bias in the included studies

The risk of bias and applicability concerns are summarised per study in the figure below. The main validity issues to note is that patient sampling was not clearly consecutive or random in a number of the studies, and the vast majority of the studies were conducted in populations that are not clearly directly relevant to the current question. Studies employing non-consecutive/random sampling are at risk of bias because, for example, case-control studies have been shown to be associated with inflated test accuracy parameters compared to designs that incorporate random or consecutive patient selection. Studies conducted in other settings than UK-based primary care are only applicable to the extent that the study populations and settings are comparable to a UK GP population as defined for the current purposes. Other bias and applicability threats to the results concern missing data and a potentially suboptimal reference standard.

	Risk of Bias				Applicability Concerns		
	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard
Brignoli (1997)	?	+	-	+	?	+	+
Duggan (2008)	?	+	+	+	+	+	+
Edenholm (1985)	?	+	+	-	?	+	+
Hallissey (1990)	+	+	+	+	?	+	+
Hansen (1998)	+	+	+	?	?	+	+
Heikkinen (1995)	+	+	+	+	?	+	+
Jaskiewicz (1991)	?	+	+	+	?	?	+
Kagevi (1989)	+	+	+	+	?	+	+
Meineche-Schmidt (2002)	+	+	+	+	?	+	+
Thomson (2003)	?	+	+	+	?	+	+
Vakil (2009)	?	+	+	+	+	+	+

	High		Unclear		Low
--	------	--	---------	--	-----

**Table 1: Non-site specific symptoms of concern: Calculation of overall positive predictive value of dyspepsia for cancer**

Cancer site	Study	Lower age limit	Upper age limit	PPV (95% CI), prevalence
Liver	Hallissey (1990)	40	no upper limit	0.04 (0.002-0.25) 1/2585
Pancreatic	Hallissey (1990)	40	no upper limit	0.23 (0.09-0.53)

				6/2585
Uterine	Hallissey (1990)	40	no upper limit	0.04 (0.002-0.25) 1/2585
Leukaemia	Hallissey (1990)	40	no upper limit	0.04 (0.002-0.3) 1/2585
Gall bladder	Hallissey (1990)	40	no upper limit	0.04 (0.002-0.3) 1/2585
Prostate	Hallissey (1990)	40	no upper limit	0.08 (0.01-0.3) 2/2585
Bronchial	Hallissey (1990)	40	no upper limit	0.3 (0.1-0.6) 8/2585
Oesophagus/stomach	Meta-analysis	varied	varied	0.65 (0.33-1.3)
Colorectal	Meta-analysis	varied	varied	0.6 (0.27-1.35)
Sum				<u>2.02</u>

1  
2**Table 2: Non-site specific symptoms of concern: Positive predictive values for dyspepsia**

Cancer site	Comment/relevant recs	Study	Symptom	Patient group	Positive predictive value% (95% CI), prevalence	Sex	Age inclusion, lower limit	Age inclusion, upper limit
Liver		Hallissey (1990)	Dyspepsia	All patients	0.04 (0.002-0.25) 1/2585	both	40	no upper limit
Pancreatic		Hallissey (1990)	Dyspepsia	All patients	0.23 (0.09-0.53) 6/2585	both	40	no upper limit
Uterine		Hallissey (1990)	Dyspepsia	All patients	0.04 (0.002-0.25) 1/2585	both	40	no upper limit
Leukaemia		Hallissey (1990)	Dyspepsia	All patients	0.04 (0.002-0.3) 1/2585	both	40	no upper limit
Gall bladder		Hallissey (1990)	Dyspepsia	All patients	0.04 (0.002-0.3) 1/2585	both	40	no upper limit
Prostate		Hallissey (1990)	Dyspepsia	All patients	0.08 (0.01-0.3) 2/2585	both	40	no upper limit
Bronchial		Hallissey (1990)	Dyspepsia	All patients	0.3 (0.1-0.6) 8/2585	both	40	no upper limit

Other		Hallisey (1990)	Dyspepsia	All patients	0.3 (0.1-0.6) 8/2585	both	40	no upper limit
Other		Meineche-Schmidt (2002)	Dyspepsia	All patients	0.4 (0.16-0.92) 6/1491	both	18	65+
<b>META-ANALYSES (1) Oesophageal</b>								
Oesophagus/stomach	2 combining gastro-oesophageal and 9 reporting on oesophageal cancer separately	Meta-analysis	Dyspepsia	N = 11403 /11 studies	0.25 (0.13-0.5)	both	2 studies > 15, 2 studies > 18, 1 study > 40, 1 study 17-80, 2 studies 18-70, 1 study 19-87, 1 study 18- >65, 1 study NR but mean (SD) = 41-42 (15-16)  Individual study details provided below	
<b>The 11 studies below are those included in the meta-analysis reported in the cell above (Please note the same data from Hansen (1998) and Meineche-Schmidt (2002) appear both here and under stomach, avoid double counting it):</b>								
Oesophageal		Brignoli (1997)	Dyspepsia	All patients	0 (0-0.58) 0/828	both	Mean (SD) age = 41-42 (15-16) years	
Oesophageal		Duggan (2008)	Dyspepsia	All patients	0.27 (0.05-1.1) 2/753	both	18	70
Oesophageal		Edenholm (1985)	Persistent epigastric pain/ulcer-like dyspepsia	All patients who received an UGI endoscopy	0.61 (0.03-3.8) 1/165	both	17	80
Oesophageal		Hallisey (1990)	Dyspepsia	All patients	0.58 (0.33-0.98) 15/2585	both	40	No upper limit
Oesophageal/stomach		Hansen (1998)	Dyspepsia	All patients	1 (0.4-2.2) 6/612	both	Mean age (SD) = 47 (16.8)	
Oesophageal		Heikkinen (1995)	Dyspepsia	All patients	0.5 (0.09-2) 2/400	both	77% were > 44 years.	

Oesophageal		Jaskiewicz (1991)	Dyspepsia	All included patients	0 (0-0.8) 0/585	both	19	87
Oesophageal		Kagevi (1989)	Dyspepsia	All included patients	0 (0-2.7) 0/172	both	16	No upper limit
Oesophageal/stomach		Meinche-Schmidt (2002)	Dyspepsia	All patients	0.54 (0.25-1.1) 8/1491	both	18	65+
Oesophageal		Thomson (2003)	Dyspepsia	All patients	0.1 (0.01-0.6) 1/1040	both	18	84
Oesophageal		Vakil (2009)	Dyspepsia without alarm symptoms	All included patients	0.1 (0.03-0.35) 3/2741	both	18	70
<b>The following results are any extra analyses reported by the studies included in the above meta-analysis:</b>								
Oesophageal		Vakil (2009)	Dyspepsia without alarm symptoms	Patients ≥ 45 years old	0.18 (0.03-0.71) 2/1127	both	45	70
Oesophageal		Vakil (2009)	Dyspepsia without alarm symptoms	Patients ≥ 50 years old	0.24 (0.04-1) 2/829	both	50	70
Oesophageal		Vakil (2009)	Dyspepsia without alarm symptoms	Patients ≥ 55 years old	0.18 (0.01-1.16) 1/554	both	55	70
Oesophageal		Vakil (2009)	Dyspepsia without alarm symptoms	Patients ≥ 60 years old	0.3 (0.02-2) 1/323	both	60	70
Oesop		Hanse	Ulcer-	All	0.6 (0.03-	both	Mean age (SD) = 47 (16.8)	

hageal /stomach		n (1998)	like dyspepsia	patients	3.9 1/161			
Oesophageal /stomach		Hansen (1998)	Dysmotility-like dyspepsia	All patients	0 (0-2.9) 0/163	both	Mean age (SD) = 47 (16.8)	
Oesophageal /stomach		Hansen (1998)	Reflux-like dyspepsia	All patients	1.16 (0.2-4.6) 2/173	both	Mean age (SD) = 47 (16.8)	
Oesophageal /stomach		Hansen (1998)	Unclassifiable dyspepsia	All patients	0.9 (0.05-5.8) 1/107	both	Mean age (SD) = 47 (16.8)	
<b>META-ANALYSES (2) Stomach</b>								
Oesophagus /stomach	2 combining gastro-oesophageal and 9 reporting on stomach cancer separately	Meta-analyses	Dyspepsia	N = 11403 /11 studies	0.65 (0.33-1.3)	both	2 studies > 15, 2 studies > 18, 1 study > 40, 1 study 17-80, 2 studies 18-70, 1 study 19-87, 1 study 18- >65, 1 study NR but mean (SD) = 41-42 (15-16)  Individual study details provided below.	
<b>The 11 studies below are those included in the meta-analysis reported in the cell above (Please note the same data from Hansen (1998) and Meineche-Schmidt (2002) appear both here and under oesophageal, avoid double counting it):</b>								
Stomach		Brignoli (1997)	Dyspepsia	All patients	0.4 (0.09-1.14) 3/828	both	Mean (SD) age = 41-42 (15-16) years	
Stomach		Duggan (2008)	Dyspepsia	All patients	0.27 (0.05-1.1) 2/753	both	18	70
Stomach		Edenhalm (1985)	Persistent epigastric pain/ulcer-like dyspepsia	All patients who received an UGI endoscopy	1.2 (0.21-4.77) 2/165	both	17	80
Stomach		Hallisey (1990)	Dyspepsia	All patients	2.28 (1.76-3) 59/2585	both	40	No upper limit
Oesophageal		Hansen	Dyspepsia	All patients	1 (0.4-2.2)	both	Mean age (SD) = 47 (16.8)	

/stomach		(1998)		ts	6/612			
Stomach		Heikkinen (1995)	Dyspepsia	All patients	1.75 (0.8-3.7) 7/400	both	77% were > 44 years.	
Stomach		Jaskiewicz (1991)	Dyspepsia	All included patients	2.7 (1.6-4.5) 16/585	both	19	87
Stomach		Kagevi (1989)	Dyspepsia	All included patients	1.16 (0.2-4.6) 2/172	both	16	No upper limit
Oesophageal/stomach		Meineche-Schmidt (2002)	Dyspepsia	All patients	0.54 (0.25-1.1) 8/1491	both	18	65+
Stomach		Thomson (2003)	Dyspepsia	All patients	0.1 (0.01-0.6) 1/1040	both	18	84
Stomach		Vakil (2009)	Dyspepsia without alarm symptoms	All included patients	0.1 (0.03-0.35) 3/2741	both	18	70
<b>The following results are any extra analyses reported by the studies included in the above meta-analysis:</b>								
Stomach		Jaskiewicz (1991)	Dyspepsia	Males	3.4 (1.8-6) 12/355	Males	19	87
Stomach		Jaskiewicz (1991)	Dyspepsia	Females	1.7 (0.6-4.7) 4/230	Females	19	87
Oesophageal/stomach		Hansen (1998)	Ulcer-like dyspepsia	All patients	0.6 (0.03-3.9) 1/161	Both	Mean age (SD) = 47 (16.8)	
Oesophageal/stomach		Hansen (1998)	Dysmotility-like dyspepsia	All patients	0 (0-2.9) 0/163	Both	Mean age (SD) = 47 (16.8)	
Oesophageal/stomach		Hansen (1998)	Reflux-like dyspepsia	All patients	1.16 (0.2-4.6) 2/173	Both	Mean age (SD) = 47 (16.8)	
Oesophageal		Hansen	Unclassifiable	All patients	0.9 (0.05-5.8)	Both	Mean age (SD) = 47 (16.8)	

/stomach		(1998)	dyspepsia	ts	1/107			
Stomach		Vakil (2009)	Dyspepsia without alarm symptoms	Patients ≥ 45 years old	0.27 (0.07-0.84) 3/1127	both	45	70
Stomach		Vakil (2009)	Dyspepsia without alarm symptoms	Patients ≥ 50 years old	0.36 (0.09-1.15) 3/829	both	50	70
Stomach		Vakil (2009)	Dyspepsia without alarm symptoms	Patients ≥ 55 years old	0 (0-0.86) 0/554	both	55	70
Stomach		Vakil (2009)	Dyspepsia without alarm symptoms	Patients ≥ 60 years old	0 (0-1.47) 0/323	both	60	70
<b>META-ANALYSES (3) Colorectal</b>								
Colorectal	1 study from 15, 1 study from 18-65+ and 1 study from 40.	Meta-analyses	Dyspepsia	3 studies, N = 4476	0.6 (0.27-1.35)	both	15-18	65+
<b>The 3 studies below are those included in the meta-analysis reported in the cell above:</b>								
Colorectal		Hallisey (1990)	Dyspepsia	All patients	0.5 (0.3-0.9) 14/2585	both	40	No upper limit
Colorectal		Heikkinen (1995)	Dyspepsia	All patients	0/400	both	77% were > 44 years.	
Colorectal		Meinche-Schmidt (2002)	Dyspepsia	All patients	1.14 (0.7-1.9)	both	18	65+

1  
2  
3  
4  
5  
6  
7  
8**Evidence statement(s):**

Dyspepsia (11 studies, N = 18464) presenting in a primary care setting is associated with an overall positive predictive value of 2.02% for cancer. The study was associated with 1-3 bias/applicability concerns (see also Table 1).

**Evidence tables****Brignoli (1997)**

<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective patient series from Switzerland.
Was a consecutive or random sample of patients enrolled?	<b>Unclear</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Unclear</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	N = 828; 329 men, 499 women; mean (SD) age = 41-42 (15-16) years.  <u>Inclusion criteria:</u> "Adult patients with epigastric complaints were admitted to the multicentre [omega]-project if their symptoms persisted for over 1 month and their clinical history and appearance did not suggest an organic disorder (i.e. absence of alarm features, such as gastrointestinal blood loss, palpable tumour mass, massive weight loss, etc.). The studies were conducted by general practitioners acting as primary care physicians." <u>Exclusion criteria:</u> None listed <u>Clinical setting:</u> Primary care, Switzerland
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	Epigastric complaints (dyspepsia)
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Endoscopy and 84-day follow up.
Is the reference standard likely to correctly classify the target condition?	<b>No</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No</b>



<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>		<b>High risk</b>
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		<b>Low concern</b>
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	All patients are accounted for	
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>	
Did all patients receive the same reference standard?	<b>Yes</b>	
Were all patients included in the analysis?	<b>Yes</b>	
<b>Could the patient flow have introduced bias?</b>		<b>Low risk</b>
<b>NOTES</b>	3 patients had gastric cancer, 0 patients had oesophageal cancer, and 2 patients had cancer outside the digestive tract.	
1		
2	<b>Duggan (2008)</b>	
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Prospective patient series from 43 GP practices in the UK.	
Was a consecutive or random sample of patients enrolled?	<b>No</b>	
Was a case-control design avoided?	<b>Yes</b>	
Did the study avoid inappropriate exclusions?	<b>Yes</b>	
<b>Could the selection of patients have introduced bias?</b>		<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>		
Patient characteristics and setting	<p>N = 762; 411 men, 351 women; mean (range) age = 42 (18-73) years.</p> <p><u>Inclusion criteria:</u> Patients aged 18-70 with dyspepsia thought by the GP to arise from the upper GI tract and of sufficient severity to justify empirical treatment with an H<sub>2</sub> antagonist or PPI.</p> <p><u>Exclusion criteria:</u> Patients thought to be unfit for investigation, with alarm symptoms suggestive of malignancy (dysphagia, weight loss &gt; 5 g, anaemia, haematemesis, melaena or jaundice), previous radiological or endoscopic diagnosis of peptic ulcer disease or reflux oesophagitis, investigation for dyspepsia in the previous 5 years with either procedure or symptom onset within 6 months of commencement of NSAID therapy, previous H. pylori eradication therapy or more than 3 prescriptions for acid suppression therapy in the previous 6 months.</p> <p><u>Clinical setting:</u> Primary care, UK</p>	
<b>Are there concerns that the included patients and setting do not match the review question?</b>		<b>Low concern</b>
<b>INDEX TEST</b>		
<b>A. Risk of bias</b>		
Index test	Dyspepsia	
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>	

<b>Could the conduct or interpretation of the index test have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>		<b>Low concern</b>
<b>REFERENCE STANDARD</b>		
<b>A. risk of bias</b>		
Reference standard(s)	Endoscopy and 1-2-year follow up.	
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>	
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No</b>	
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		<b>Low concern</b>
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	At 12-month follow up GP data were available for 753/762.	
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>	
Did all patients receive the same reference standard?	<b>Yes</b>	
Were all patients included in the analysis?	<b>Yes</b>	
<b>Could the patient flow have introduced bias?</b>		<b>Low risk</b>
<b>NOTES</b>	2 patients had gastric cancer, 2 patients had oesophageal cancer (the authors report that these patients should not have been included as they had a history of dysphagia).	
1		
2	<b>Edenholm (1985)</b>	
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Prospective patient series from the Distric General Clinic in Huskvarna, Sweden.	
Was a consecutive or random sample of patients enrolled?	<b>Unclear</b>	
Was a case-control design avoided?	<b>Yes</b>	
Did the study avoid inappropriate exclusions?	<b>Unclear</b>	
<b>Could the selection of patients have introduced bias?</b>		<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>		
Patient characteristics and setting	N = 187; 96 men, 91 women; mean/median (range) age = 44 (17-80) years.  <u>Inclusion criteria</u> : Patients who between November 1982 and June 1984 called on the clinic because of abdominal pain and who were diagnosed by the general practitioner as having ulcer-like dyspepsia. The criterion used was persistent epigastric pain. Most patients also had additional symptoms such as acid regurgitation, nausea, belching or vomiting.	

	Exclusion criteria: None listed Clinical setting: GPs in Sweden
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	Ulcer-like dyspepsia. The criterion used was persistent epigastric pain.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	UGI endoscopy
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	20/187 patients declined endoscopy and it was unsuccessful in a further 2 patients. Thus the PPV is likely to be an over-estimate, calculated as 2/165.
Was there an appropriate interval between index test and reference standard?	<b>Yes probably</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>No</b>
<b>Could the patient flow have introduced bias?</b>	<b>High risk</b>
<b>NOTES</b>	There were a total of 3 cancers confirmed in the 165 patients who received UGI endoscopy: 1 oesophageal cancer, 1 stomach cancer, and 1 cancer of the duodenum, the latter of which was included with the stomach cancer
1	
2	<b>Hallissey (1990)</b>
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Propective consecutive patient series from a group of 10 general practices in England.
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>

Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b><u>B. Concerns regarding applicability</u></b>	
Patient characteristics and setting	N = 2585 aged > 40 years. No other information reported. The patient group was equally divided between new patients with dyspepsia, old patients with uninvestigated dyspepsia, and old patients with investigated dyspepsia.  <u>Inclusion criteria:</u> All patients over 40 years making their first attendance during the study period (4 years and 9 months) with any degree of dyspepsia <u>Exclusion criteria:</u> None listed. <u>Clinical setting:</u> Primary care, England.
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b><u>A. Risk of bias</u></b>	
Index test	Dyspepsia of any degree
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b><u>B. Concerns regarding applicability</u></b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b><u>A. risk of bias</u></b>	
Reference standard(s)	Upper gastrointestinal endoscopy within 4 weeks and follow up.
Is the reference standard likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	No
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b><u>B. Concerns regarding applicability</u></b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b><u>A. risk of bias</u></b>	
Flow and timing	2659 patients were seen and 2585 attended for investigation
Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	Yes
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	Malignancy was detected in 115 patients: Gastric adenocarcinoma (57), gastric lymphoma (1; added to the gastric adenocarcinoma data in the PPV),

1  
2

	oesophageal cancer (15), colorectal (14), pancreatic (6), bronchial (8), prostatic (2), duodenal (1, also added to the gastric carcinoma data in the PPV), liver (1), gall bladder (1), carcinoid (1), uterine (1), leukaemia (1), carcinomatosis of unknown primary (7).
<b>Hansen (1998)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective patient series from general an open-access endoscopy clinic in Denmark.
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	N = 612 from 66 GPs; 288 males / 324 females; mean age (SD) = 47 (16.8) years.  <u>Inclusion criteria:</u> "All general practitioners (n = 108) in the city of Odense (population, 170,000) were invited to participate in the study. GPs were asked to refer all patients who consulted them with dyspepsia, regardless of the severity of the symptoms. To obtain compliance with this request the participating GPs were sent numerous reminders. Because of a limited endoscopy capacity not all GPs took part in the study at the same time." Study period was 11 March 1991-27 March 1992. <u>Exclusion criteria:</u> Aged < 18 years, signs of UGI bleeding, abdominal emergency, jaundice, previous surgery in the UGI tract except for closure of an ulcer, supposed acute bacterial or viral infection, pregnancy, or endoscopy contraindicated. <u>Clinical setting:</u> GPs in Denmark
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	Epigastric or retrosternal pain or discomfort, with or without heartburn, nausea, vomiting, and any other symptom considered to be referable to the proximal alimentary tract.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Endoscopy within 1 week of referral and follow up

Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	56 eligible patients declined participation. These patients were older than the study group (mean age = 52 years versus 47 years) and they were characterised by a shorter dyspepsia history (median duration = 1 month, range = 4 days to 35 years versus 2 months, range = 4 days to 14 years). Fewer of the non-participating patients had had a previous endoscopy or UGI radiography (22% versus 43%, but identical proportions of the patients had an ulcer history (11% versus 14%).
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>No</b>
<b>Could the patient flow have introduced bias?</b>	<b>Unclear risk</b>
<b>NOTES</b>	There were a total of 4 cancers histologically confirmed in the study. No subclassification of the cancers reported. Follow up of the 364 patients with normal endoscopy revealed missing date in 5% of the cases and 1 lymphoma and 1 rectal carcinoma. These 6 cancers (NOS) are included in the overall PPV for dyspepsia.

1

2

**Heikkinen (1995)**

<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Consecutive patient series from 11 GPs (from 3 rural health centres) and from the catchment area of 6 physicians in the health centre of an urban area (population [individuals > 14 years old] of study area = 24600) in Finland.
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	N = 400; 152 males, 248 females; 77% were > 44 years.  <u>Inclusion criteria:</u> Consecutive patients who consulted their GP from January 11th 1993 to January 12 <sup>th</sup> 1994 for dyspepsia (defined as upper abdominal or retrosternal pain, discomfort, heartburn, nausea, vomiting, or other symptoms considered to be referable to the proximal alimentary tract).

	<u>Exclusion criteria:</u> Patients with symptoms of an acute condition within the abdomen or who had had an upper intestinal endoscopy performed within the last 3 months or aged < 15 years <u>Clinical setting:</u> Primary care, Finland.
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	Dyspepsia (defined as upper abdominal or retrosternal pain, discomfort, heartburn, nausea, vomiting, or other symptoms considered to be referable to the proximal alimentary tract).
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
<b>Reference standard(s)</b>	Upper gastrointestinal endoscopy, upper abdominal ultrasound, more detailed interview, blood count, serum screening (creatinine, alkaline phosphatase, alanine aminotransferase, amylase, and C-reactive protein), lactose intolerance test, and follow up of $\geq 1$ month.
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
<b>Flow and timing</b>	All patients appear to be accounted for
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	In total N = 9 had cancer: 0 colorectal, 2 oesophageal and 7 stomach (of which 3 were lymphomas of the MALT type (Mucosa-associated lymphoid tissue)).
1	
2	<b>Jaskiewicz (1991)</b>
<b>PATIENT SELECTION</b>	

<b>A. risk of bias</b>	
Patient sampling	Patient series from a program aimed at screening patients with chronic gastric complaints for gastric carcinoma in the South and North-Western Cape Province of South Africa.
Was a consecutive or random sample of patients enrolled?	<b>Unclear</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Unclear</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	N = 585, 355 males, 230 females; mean (range) age males = 45.1 (19-87) years, mean (range) age females = 47.2 (19-87) years.  <u>Inclusion criteria</u> : "participants who were treated for dyspeptic complaints such as epigastric pain, heartburn, post-prandial pain and bloating, vomiting or nausea with a duration of at least 3 months. Patients represented various areas in the south-and north-western Cape province including Namaqualand, and formed part of a programme aimed at screening patients with chronic gastric complaints for gastric carcinoma." <u>Exclusion criteria</u> : None listed <u>Clinical setting</u> : Unclear, South Africa.
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	Unspecified dyspepsia (dyspeptic complaints such as epigastric pain, heartburn, post-prandial pain and bloating, vomiting or nausea with a duration of at least 3 months).
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Unclear concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Endoscopy
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>



<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	All patients appear to be accounted for	
Was there an appropriate interval between index test and reference standard?	Yes	
Did all patients receive the same reference standard?	Yes	
Were all patients included in the analysis?	Yes	
<b>Could the patient flow have introduced bias?</b>		<b>Low risk</b>
<b>NOTES</b>	In total N = 16 had gastric cancer. No oesophageal cancers reported	
1		
2	<b>Kagevi (1989)</b>	
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Propective consecutive patient series from a primary care centre in Sweden.	
Was a consecutive or random sample of patients enrolled?	Yes	
Was a case-control design avoided?	Yes	
Did the study avoid inappropriate exclusions?	Yes	
<b>Could the selection of patients have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
Patient characteristics and setting	<p>N = 172; 88 men, 84 women; mean (SD) age = 43 (16) years.</p> <p><u>Inclusion criteria</u>: "All patients visiting the medical center with complaints referable to the digestive tract were considered for inclusion. Even when the patient consulted the primary care center because of another complaint and coincidentally mentioned gastrointestinal problem, the patient was considered for inclusion. The patient's gastrointestinal problem could have been reported in connection with an earlier visit at the primary care center."</p> <p><u>Exclusion criteria</u>: Patients with jaundice, gastrointestinal bleeding or acute abdominal pain were excluded and so were patients judged to have a non-gastro-enterologic cause of their symptoms (gynaecologic problems, spondylosis deformans, etc), patients aged &lt; 16 years and patients unwilling to participate.</p> <p><u>Clinical setting</u>: Primary care Center, Sweden.</p>	
<b>Are there concerns that the included patients and setting do not match the review question?</b>		<b>Unclear concern</b>
<b>INDEX TEST</b>		
<b>A. Risk of bias</b>		
Index test	Dyspepsia defined as any pain, discomfort, or other symptoms referable to the digestive tract ≥ 2 weeks. Symptoms could be intermittent or continuous.	
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes	
<b>Could the conduct or interpretation of the index test have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>		<b>Low concern</b>

REFERENCE STANDARD	
<b>A. risk of bias</b>	
Reference standard(s)	Esophagogastroduodenoscopy within 1 week and 6 month follow up.
Is the reference standard likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	No
Could the reference standard, its conduct, or its interpretation have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Are there concerns that the target condition as defined by the reference standard does not match the question?	Low concern
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	13/185 patients were excluded as they did not want to have an endoscopy
Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	Yes
Could the patient flow have introduced bias?	Low risk
NOTES	2 patients had gastric cancer, 0 patients had oesophageal cancer.
1	
2 <b>Meineche-Schmidt (2002)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Consecutive patient series from 82 GPs in Denmark.
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
Could the selection of patients have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	N = 1491; 688 males, 803 females; age groups: 18-37 years: N = 377; 38-50 years: N = 369; 51-64 years: N = 338; 65- years: N = 402.  Inclusion criteria: Consecutive patients who consulted their GP between June 1991 and May 1993 for dyspepsia (defined as pain or discomfort in the abdomen judged by the GP to be related to the gastrointestinal tract). Exclusion criteria: None listed. Clinical setting: Primary care, Denmark.
Are there concerns that the included patients and setting do not match the review question?	Unclear concern
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	Dyspepsia (defined as pain or discomfort in the abdomen judged by the GP to be related to the gastrointestinal tract).

Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	18 months-3 years and 10 months follow up.
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients appear to be accounted for
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	In total N = 31 had cancer: 17 colorectal, 8 gastro-oesophageal (no subgroup analyses presented for these patients) and 6 other.
<b>Thomson (2003)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Propective patient series from a group of 49 family physician practices in Canada.
Was a consecutive or random sample of patients enrolled?	<b>Unclear</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Unclear</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	N = 1040, 520 males / 520 females; mean (range) age =45.6 (18-84) years.  <u>Inclusion criteria:</u> Patients ≥ 18 years with a primary complaint of ≥ 3 months intermittent or continuous dyspepsia. Patients could not have used proton pump inhibitors within 30 days or prokinetics or prescription H <sub>2</sub> -receptor

1  
2

	antagonists (H <sub>2</sub> RAS) within 14 days of enrolment. <u>Exclusion criteria:</u> Heartburn or acid regurgitation as their sole symptom; documented history of upper GI pathology/surgery; clinical investigation of dyspepsia by endoscopy or radiology in the previous 6 months or more than twice in the past 10 years; H. pylori eradication treatment in the previous 6 months; irritable bowel syndrome as assessed by the presence of $\geq$ manning criteria; or severe concurrent disease. <u>Clinical setting:</u> Family physician practice, Canada.
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Unclear concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	Dyspepsia defined as symptom complex of epigastric pain/discomfort in association with other upper GI symptoms, including heartburn and acid regurgitation.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Upper gastrointestinal endoscopy within 10 days and 6-months follow up.
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>No</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients are accounted for. 1100/1171 enrolled patients consented to endoscopy, but 60/1100 did not received endoscopy (eligibility criteria not fulfilled [27], lost to follow up [3], withdrew consent [9], non-compliant with the protocol [1], endoscopy-intolerable [2], other [18]).
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	Malignancy was detected in 2 patients: Gastric (MALToma; 1), oesophageal cancer (1).

1  
2

<b>Vakil (2009)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective patient series
Was a consecutive or random sample of patients enrolled?	<b>Unclear</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Yes (probably)</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Unclear risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>N = 2741, mean (range) age = not reported (not reported) years, numbers of females/males: Not reported.</p> <p><u>Inclusion criteria:</u> Patients aged 18-70 years who met Rome II criteria for dyspepsia (intermittent or continuous pain or burning centered in the upper abdomen for <math>\geq 3</math> months).</p> <p><u>Exclusion criteria:</u> Past diagnosis of gastro-oesophageal reflux disease, predominant symptom of heartburn or regurgitation, history of heartburn or regurgitation &gt; 2 days/week, treatment &gt; 2 days/week with non-steroidal anti-inflammatory drugs or cyclooxygenase-2 selective inhibitors or aspirin (except for cardiovascular prophylaxis at doses <math>\leq 325</math> mg/day), concurrent alarm features (e.g., dysphagia, recurrent vomiting, unexplained anaemia, gastro-intestinal bleeding), H pylori eradication treatment within 12 months, maintenance therapy with either a proton pump or an H2-receptor antagonist within 6 months.</p> <p><u>Clinical setting:</u> The study was conducted in 190 primary care health centers in 17 countries (Argentina, Belgium, Brazil, Canada, Denmark, France, Germany, Greece, Iceland, Italy, Norway, Romania, Singapore, South Africa, Spain, Sweden, Switzerland). Patients were recruited from primary care clinics where flyers publicising the study were placed and the primary care physicians recruited patients presenting to their offices with dyspepsia [random or consecutive sampling unlikely].</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	Dyspepsia/ intermittent or continuous pain or burning centered in the upper abdomen for $\geq 3$ months. Symptoms were evaluated using a scale validated in a number of languages
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	

Reference standard(s)	All patients received outpatient endoscopy
Is the reference standard likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	No (but all patients had a positive index test)
Could the reference standard, its conduct, or its interpretation have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Are there concerns that the target condition as defined by the reference standard does not match the question?	Low concern
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All the patients are accounted for in the results.
Was there an appropriate interval between index test and reference standard?	Yes (probably)
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	Yes
Could the patient flow have introduced bias?	Low risk
<b>NOTES</b>	Supported by AstraZeneca R&D Sweden. The authors state that "The sponsor did not play any role in the calculations or in the writing of the manuscript". Six patients had cancer: 3 oesophagus and 3 stomach.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

## References

### Included studies

- Brignoli, R., Watkins, P., Halter, F. The Omega-Project – a comparison of two diagnostic strategies for risk- and cost-oriented management of dyspepsia. *European Journal of Gastroenterology and Hepatology* 9, 337-343. 1997.
- Duggan, A.F., Elliott, C.A., Miller, P., Hawkey, C.J., Logan, R.F.A. Clinical trial: A randomized trial or early endoscopy, *Helicobacter pylori* testing and empirical therapy for the management of dyspepsia in primary care. *Alimentary Pharmacology and Therapeutics* 29, 55-68. 2008.
- Edenholm, M., Gustavsson, R., Jansson, O., et al. Endoscopic findings in patients with ulcer-like dyspepsia. *Scandinavian Journal of Gastroenterology* 20(suppl 109), 163-167. 1985.
- Hallissey, M.T., Allum, W.H., Jewkes, A.J., Ellis, A.J., Fielding, J.W.L. Early detection of gastric cancer. *British Medical Journal* 301, 513-515. 1990.
- Hansen, J.M., Bytzer, P., Schaffalitzky de Muckadell, O.B. Management of dyspeptic patients in primary care: Value of the unaided clinical diagnosis and of dyspepsia subgrouping. *Scandinavian Journal of Gastroenterology* 33, 799-805. 1998.
- Heikkinen, M., Pikkarainen, P., Takala, J., and Rasanen, H. Julkunen R. Etiology of dyspepsia: Four hundred unselected consecutive patients in general practice. *Scandinavian Journal of Gastroenterology* 30[6], 519-523. 1995.
- Jaskiewicz, K., Louwrens, H.D. Chronic atrophic gastritis in a population at risk for gastric carcinoma. *Anmticancer Research* 11, 835-840. 1991.
- Kagevi, I., Löfstedt, S., Persson, L.-G. Endoscopic findings and diagnoses in unselected dyspeptic patients at a primary health care center. *Scandinavian Journal of Gastroenterology* 24, 145-150. 1989.

1 Meineche-Schmidt, V. and Jorgensen, T. 'Alarm symptoms' in patients with dyspepsia: a three-year  
2 prospective study from general practice. *Scandinavian Journal of Gastroenterology* 37[9], 999-  
3 1007. 2002.

4 Thomson, A.B.R., Barkun, A.N., Armstrong, D., Chiba, N., White, R.J., Daniels, S., Escobedos, S.,  
5 Chakraborty, B., Sinclair, S. The prevalence of clinically significant endoscopic findings in primary  
6 care patients with uninvestigated dyspepsia: The Canadian Adult Dyspepsia Empiric Treatment-  
7 Prompt Endoscopy (CADET-PE) study. *Alimentary Pharmacology and Therapeutics* 17, 1481-  
8 1491. 2003.

9 Vakil, N., Talley, N., van Zanten, S. V., Flook, N., Persson, T., Bjorck, E., Lind, T., and Bolling-  
10 Sternevald, E. Cost of Detecting Malignant Lesions by Endoscopy in 2741 Primary Care Dyspeptic  
11 Patients Without Alarm Symptoms. *Clinical Gastroenterology and Hepatology* 7[7], 756-761.  
12 2009.

13

14

15




## WEIGHT LOSS

### Risk of bias in the included studies

The risk of bias and applicability concerns are summarised per study in the figure below. The body of evidence was generally of high quality. The main validity issues to note is that patient sampling was not clearly consecutive or random in a number of the studies, and that some of studies suffered from missing data. Studies employing non-consecutive/random sampling are at risk of bias because, for example, case-control studies have been shown to be associated with inflated test accuracy parameters compared to designs that incorporate random or consecutive patient selection. The statistical analyses employed by these studies are however likely to have gone some way in addressing this issue. One study was conducted in a setting that is unlikely to be directly applicable to UK-based primary care and, as a consequence, also seems to present inflated PPVs that may be more reflective of secondary care. Finally, some of the studies were compromised by missing data, the influence of which on the results is difficult to determine.

	Risk of Bias				Applicability Concerns		
	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard
Collins (2012)	+	+	+	+	+	+	+
Collins (2012a)	+	+	+	+	+	+	+
Collins (2013)	+	+	+	+	+	+	+
Collins (2013a)	+	+	+	+	+	+	+
Hamilton (2005)	-	+	+	+	+	+	+
Hamilton (2005a)	-	+	+	+	+	+	+
Hamilton (2006)	-	+	+	+	+	+	+
Hippisley-Cox (2011)	+	+	+	?	+	+	+
Hippisley-Cox (2012)	+	+	+	+	+	+	+
Hippisley-Cox (2012a)	+	+	+	-	+	+	+
Hippisley-Cox (2012b)	+	+	+	-	+	+	+
Iyen-Omofoman (2013)	+	+	+	+	+	+	+
Panzuto (2003)	-	+	+	?	?	+	+
Stapley (2012)	-	+	+	+	+	+	+

 High	 Unclear	 Low
--	---	---

**Table 1: Non-site specific symptoms of concern: Calculation of overall positive predictive value of weight loss for cancer**



Cancer site	Study	Lower age limit	Upper age limit	PPV (95% CI), prevalence
Bladder/renal	Hippisley-Cox (2012)	30	84	0.41 (0.3-0.6)
Colorectal	Meta-analysis	18	87	3 (0.32-22.89)
Lung	Hamilton (2005)	40	No upper limit	1.1 (0.8-1.6)
Oesophagus/stomach	Hippisley-Cox (2011)	30	84	1.2 (1-1.4) 107/9170
Pancreatic	Hippisley-Cox (2012)	30	84	0.6 (0.5-0.8)
Prostate	Hamilton (2006)	40	No upper limit	0.75 (0.38-1.4)
<b>Sum</b>				<b>7.06</b>

1

2

**Table 2: Non-site specific symptoms of concern: Positive predictive values for weight loss**

Cancer site	Comment/relevant recs	Study	Symptom	Patient group	Positive predictive value% (95% CI), prevalence	Sex	Age inclusion, lower limit	Age inclusion, upper limit
Bladder/renal		Collins (2013a)	Weight loss	Women	0.1 (0.1-0.2)	Women	30	84
Bladder/renal		Hippisley-Cox (2012b)	Weight loss	All patients	0.41 (0.3-0.6)	both	30	84
Lung		Hamilton (2005a)	Weight loss	All included patients	1.1 (0.8-1.6)	both	40	no upper limit
Lung		Hamilton (2005a)	Weight loss (reported twice)	All included patients	1.2 (0.7-2.3)	both	40	no upper limit
Lung		Hamilton (2005a)	Weight loss	All smokers	2.1 (NR)	both	40	no upper limit
Lung		Hamilton (2005a)	Weight loss (reported twice)	All smokers	1.7 (NR)	both	40	no upper limit
Lung		Iyen-Omofoman (2013)	Weight loss	Validation cohort	0.34 (0.23-0.5)	both	40	no upper limit

Oesophagus/stomach		Collins (2012a)	Weight loss	All patients	0.8 (0.7-0.9) 218/28403	both	30	84
Oesophagus/stomach		Collins (2012a)	Weight loss	Women	0.6 (0.4-0.7) 86/15465	Women	30	84
Oesophagus/stomach		Collins (2012a)	Weight loss	Men	1 (0.9-1.2) 132/12938	Men	30	84
Oesophagus/stomach		Hippisley-Cox (2011)	Weight loss	All patients	1.2 (1-1.4) 107/9170	both	30	84
Pancreatic		Collins (2013)	Weight loss	All patients	0.28 (0.22-0.35)	both	30	84
Pancreatic		Collins (2013)	Weight loss	Women	0.16 (0.11-0.24)	women	30	84
Pancreatic		Collins (2013)	Weight loss	Men	0.42 (0.32-0.54)	men	30	84
Pancreatic		Hippisley-Cox (2012a)	Weight loss	All patients	0.6 (0.5-0.8)	both	30	84
Pancreatic		Stapley (2012)	Weight loss	All patients	0.44 (0.36-0.55)	both	40	no upper limit
Pancreatic		Stapley (2012)	Weight loss	Patients ≥ 60 years	0.8 (0.7-1)	both	60	no upper limit
Prostate		Hamilton (2006)	Loss of weight	All included patients	0.75 (0.38-1.4)	men	40	no upper limit
Prostate		Hamilton (2006)	Loss of weight (reported twice)	All included patients	2.1 (NR)	men	40	no upper limit
Colorectal		Hamilton (2005)	Loss of weight (reported once)	All patients	1.2 (0.9-1.6) Cases: 94/349 Controls: 92/1744	both	40	no upper limit

Colorectal		Hamilton (2005)	Loss of weight (reported twice)	All patients	1.4 (0.8-2.6)	both	40	no upper limit
Colorectal		Hamilton (2005)	Loss of weight	Patients 40-69 years	0.74 (NR)	both	40	69
Colorectal		Hamilton (2005)	Loss of weight	Patients $\geq$ 70 years	2.5 (NR)	both	70	no upper limit
Colorectal		Hamilton (2005)	Weight loss 5-10% (read off graph)	Men aged < 60 years	0.1 (0.05-0.2)	Males	40	59
Colorectal		Hamilton (2005)	Weight loss 5-10% (read off graph)	Men aged 60-69 years	0.3 (0.2-0.4)	Males	60	69
Colorectal		Hamilton (2005)	Weight loss 5-10% (read off graph)	Men aged 70-79 years	0.7 (0.5-0.8)	Males	70	79
Colorectal		Hamilton (2005)	Weight loss 5-10% (read off graph)	Men aged $\geq$ 80 years	0.5 (0.3-0.8)	Males	80	no upper limit
Colorectal		Hamilton (2005)	Weight loss $\geq$ 10% (read off graph)	Men < 60 years	0.2 (0.1-0.3)	Males	40	59
Colorectal		Hamilton (2005)	Weight loss $\geq$ 10% (read off graph)	Men 60-69 years	0.7 (0.4-0.9)	Males	60	69
Colorectal		Hamilton (2005)	Weight loss $\geq$ 10% (read off graph)	Men 70-79 years	1.5 (1.2-1.8)	Males	70	79
Colorectal		Hamilton (2005)	Weight loss $\geq$ 10% (read off graph)	Men $\geq$ 80 years	0.8 (0.6-1.4)	Males	80	no upper limit

Colorectal		Hamilton (2005)	Weight loss 5-10% (read off graph)	Women < 60 years	0.05 (0.05-0.05)	Females	40	59
Colorectal		Hamilton (2005)	Weight loss 5-10% (read off graph)	Women 60-69 years	0.2 (0.1-0.3)	Females	60	69
Colorectal		Hamilton (2005)	Weight loss 5-10% (read off graph)	Women 70-79 years	0.4 (0.3-0.6)	Females	70	79
Colorectal		Hamilton (2005)	Weight loss 5-10% (read off graph)	Women ≥ 80 years	0.4 (0.3-0.6)	Females	80	no upper limit
Colorectal		Hamilton (2005)	Weight loss ≥ 10% (read off graph)	Women < 60 years	0.06 (0.06-0.08)	Females	40	59
Colorectal		Hamilton (2005)	Weight loss ≥ 10% (read off graph)	Women 60-69 years	0.5 (0.3-0.7)	Females	60	69
Colorectal		Hamilton (2005)	Weight loss ≥ 10% (read off graph)	Women 70-79 years	0.8 (0.6-1.1)	Females	70	79
Colorectal		Hamilton (2005)	Weight loss ≥ 10% (read off graph)	Women ≥ 80 years	0.8 (0.6-1.1)	Females	80	no upper limit
<b>META-ANALYSES (1) Colorectal</b>								
Colorectal		Meta-analysis	Weight loss	N = 42338 patients/3 studies	3 (0.32-22.89)	both	2 studies 30-84, 1 study 18-87 Individual study details below	
<b>The 3 studies below are those included in the meta-analysis reported in the cell above:</b>								
Colorectal		Collins (2012)	Weight loss	All patients (N =	0.8 (0.7-0.9)	both	30	84

				28289)				
Colorectal		Hippisley-Cox (2012)	Weight loss	All patients (N = 14007)	0.8 (0.7-0.9)	both	30	84
Colorectal		Panzuto (2003)	Weight loss	All patients (N = 42)	35.7 (22-52)	both	18	87
<b>The following results are any extra analyses reported by the studies included in the above meta-analysis:</b>								
Colorectal		Collins (2012)	Weight loss	Males	1 (0.8-1.1)	Males	30	84
Colorectal		Collins (2012)	Weight loss	Females	0.6 (0.5-0.7)	Females	30	84

1

2

**Evidence statement(s):**

3

Weight loss (8 studies, N = 3768550) presenting in a primary care setting is associated with an overall positive predictive value of 7.06% for cancer. The studies were associated with 0-3 bias/applicability concerns (see also Table 1).

4

5

6

7

**Evidence tables**

8

**Collins (2012)****PATIENT SELECTION****A. risk of bias**

Patient sampling	Retrospective patient series using the THIN database.
------------------	---

Was a consecutive or random sample of patients enrolled?	<b>Yes</b>
--	------------

Was a case-control design avoided?	<b>Yes</b>
------------------------------------	------------

Did the study avoid inappropriate exclusions?	<b>Yes</b>
---	------------

<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
--	-----------------

**B. Concerns regarding applicability**

Patient characteristics and setting	<p>A total of 2135540 patients were identified from 364 practices.</p> <p><u>Symptoms:</u> Rectal bleeding (N = 56234; 28423 men, 27811 women), abdominal pain (N = 245989; 102192 men, 143797 women), appetite loss (N = 5776; 2481 men, 3295 women), weight loss (N = 28289; 12891 men, 15398 women), anaemia (N = 18125; 4466 men, 13659 women), change in bowel habit (men only, N = 1670).</p> <p><u>Incident cases of colorectal cancer during the 2-year follow up period:</u> N = 3712 (2036 men, 1676 women).</p> <p><u>Inclusion criteria:</u> Patients aged 30–84 years and registered with practices between 1 January 2000 and 30 June 2008. Entry to the cohort was defined as the latest of the study start date; the date the patient registered with the practice; and for those patients with red flag symptoms (see below), the date of the first recorded onset within the study period.</p> <p><u>Exclusion criteria:</u> Patients without a postcode-related Townsend score,</p>
-------------------------------------	--

	patients with a history of colorectal cancer at baseline, and patients with a recorded 'red-flag' symptom in the 12 months prior to the study entry date. Clinical setting: Primary care, UK
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	'Red-flag' symptoms: Rectal bleeding, loss of appetite, weight loss, abdominal pain, change in bowel habit (men only), and anaemia.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	2-year follow up
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All patients seem to be accounted for
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	The is <b><i>very large, if not complete, overlap</i></b> of the data used in this study with those used in Hamilton (2008 [for anaemia], 2009)
1	
2	<b>Collins (2012a)</b>
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Retrospective patient series using the THIN database.
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>
Was a case-control design avoided?	<b>Yes</b>

Did the study avoid inappropriate exclusions?	Yes
Could the selection of patients have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>A total of 2135540 patients were identified from 364 practices.</p> <p><u>Symptoms:</u> Dysphagia (N = 19237; 8846 men, 10391 women), abdominal pain (N = 246998; 102732 men, 144266 women), appetite loss (N = 5838; 2521 men, 3317 women), weight loss (N = 28403; 12938 men, 15465 women), haematemesis (N = 10792; 6162 men, 4630 women), anaemia (N = 18355; 4563 men, 13792 women).</p> <p><u>Incident cases of gastro-oesophageal cancer during the 2-year follow up period:</u> N = 1766 (1184 men, 582 women; 32% gastric cancer, 68% oesophageal cancer).</p> <p><u>Inclusion criteria:</u> Patients aged 30–84 years and registered with practices between 1 January 2000 and 30 June 2008. Entry to the cohort was defined as the latest of the study start date; the date the patient registered with the practice; and for those patients with red flag symptoms (see below), the date of the first recorded onset within the study period.</p> <p><u>Exclusion criteria:</u> Patients with a prior diagnosis of gastro-oesophageal cancer, registration with the general practice &lt; 12 months, or with invalid dates.</p> <p><u>Clinical setting:</u> Primary care, UK</p>
Are there concerns that the included patients and setting do not match the review question?	Low concern
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	'Red-flag' symptoms: Haematemesis, dysphagia, loss of appetite, weight loss, anaemia, and abdominal pain.
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
Could the conduct or interpretation of the index test have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	
Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Low concern
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	2-year follow up
Is the reference standard likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias?	Low risk
<b>B. Concerns regarding applicability</b>	

<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		<b>Low concern</b>
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	All patients seem to be accounted for	
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>	
Did all patients receive the same reference standard?	<b>Yes</b>	
Were all patients included in the analysis?	<b>Yes</b>	
<b>Could the patient flow have introduced bias?</b>		<b>Low risk</b>
<b>NOTES</b>	The study did not distinguish between gastric and oesophageal cancer	
1		
2	<b>Collins (2013)</b>	
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Retrospective patient series using the THIN database.	
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>	
Was a case-control design avoided?	<b>Yes</b>	
Did the study avoid inappropriate exclusions?	<b>Yes</b>	
<b>Could the selection of patients have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
Patient characteristics and setting	<p>A total of 2150322 patients were identified from 364 practices.</p> <p><u>Symptoms:</u> Dysphagia (men only: N = 9326), abdominal pain (N = 255058; 106768 men, 148290 women), appetite loss (N = 6102; 2658 men, 3444 women), weight loss (N = 29464; 13484 men, 15980 women), abdominal distension (women only: N = 4457), constipation (men only, N = 5326).</p> <p><u>Incident cases of pancreatic cancer during the 2-year follow up period:</u> N = 287 (331 men, 287 women).</p> <p><u>Inclusion criteria:</u> Patients aged 30–84 years and registered with practices between 1 January 2000 and 30 June 2008. Entry to the cohort was defined as the latest of the study start date; the date the patient registered with the practice; and for those patients with red flag symptoms (see below), the date of the first recorded onset within the study period.</p> <p><u>Exclusion criteria:</u> Patients with a prior diagnosis of pancreatic cancer, registration &lt; 12 months with the general practice, or invalid dates.</p> <p><u>Clinical setting:</u> Primary care, UK</p>	
<b>Are there concerns that the included patients and setting do not match the review question?</b>		<b>Low concern</b>
<b>INDEX TEST</b>		
<b>A. Risk of bias</b>		
Index test	'Red-flag' symptoms: Dysphagia (men only), loss of appetite, weight loss, abdominal pain, abdominal distension (women only), and constipation (men only).	
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>	
<b>Could the conduct or interpretation of the index test</b>		<b>Low risk</b>



<b>have introduced bias?</b>		
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>		<b>Low concern</b>
<b>REFERENCE STANDARD</b>		
<b>A. risk of bias</b>		
Reference standard(s)	2-year follow up	
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>	
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>	
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>	
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		<b>Low concern</b>
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	All patients seem to be accounted for	
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>	
Did all patients receive the same reference standard?	<b>Yes</b>	
Were all patients included in the analysis?	<b>Yes</b>	
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>	
<b>NOTES</b>		
1		
2 <b>Collins (2013a)</b>		
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Retrospective patient series using the THIN database.	
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>	
Was a case-control design avoided?	<b>Yes</b>	
Did the study avoid inappropriate exclusions?	<b>Yes</b>	
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>	
<b>B. Concerns regarding applicability</b>		
Patient characteristics and setting	<p>A total of 2145133 patients (1063355 men, 1081778 women) were identified from 364 practices.</p> <p>Symptoms:  Haemoglobin &lt; 11 g/dl recorded in the last year (N = 16961; 3969 men, 12992 women), abdominal pain (N = 253344; 105247 men, 148097 women), appetite loss (N = 6097; 2616 men, 3481 women), weight loss (N = 29369; 13332 men, 16037 women), haematuria (N = 37810; 22810 men, 15000 women), previous diagnosis of cancer apart from renal tract cancer at study entry (N = 49303; 18130 men, 31173 women).</p> <p><u>Incident cases of renal tract cancer during the 2-year follow up period:</u></p>	

	<p>N = 2283 (1685 men, 598 women).</p> <p><u>Inclusion criteria:</u> Patients aged 30–84 years and registered with practices between 1 January 2000 and 30 June 2008. Entry to the cohort was defined as the latest of the study start date; the date the patient registered with the practice; and for those patients with red flag symptoms (e.g., haematuria, abdominal pain, weight loss, appetite loss, and anaemia), the date of the first recorded onset within the study period.</p> <p><u>Exclusion criteria:</u> Patients with a prior diagnosis of renal tract cancer, registered less than 12 months with the general practice, had invalid dates, &lt; 30 years old or ≥ 85 years old.</p> <p><u>Clinical setting:</u> Primary care, UK</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	'Red-flag' symptoms were defined as symptoms that might alarm the patient and also indicate the presence of renal tract cancer; that is, symptoms of haematuria, loss of appetite, weight loss, or abdominal pain.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
<b>Reference standard(s)</b>	Renal tract cancer, which was defined as incident diagnosis of cancer of the bladder, kidney, ureter, or urethra during the 2 years after study entry, recorded either on the patient's GP record using the relevant UK diagnostic Read Codes. Patients without the outcome were censored at the earliest of the date of death, date of leaving the practice study of 2 years of follow up.
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
<b>Flow and timing</b>	All patients seem to be accounted for
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>

Were all patients included in the analysis?	Yes
Could the patient flow have introduced bias?	Low risk
<b>NOTES</b>	It is unclear why no data has been presented for men for the symptoms of appetite loss and weight loss.
1	
2	<b>Hamilton (2005)</b>
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Population-based matched case-control study involving all 21 general practices in Exeter, Devon, UK.
Was a consecutive or random sample of patients enrolled?	No
Was a case-control design avoided?	No
Did the study avoid inappropriate exclusions?	Yes
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?	Yes
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?	Yes
Could the selection of patients have introduced bias?	High risk
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p><u>Cases:</u> N = 349 (177 males/172 females), age at diagnosis: &lt; 60 years: N = 45, 60-69 years: N = 97, 70-79 years: N = 113, 80+ years: N = 94. 210/349 had tumours at or distal to the splenic flexure, and 126/349 had tumours proximal to the splenic flexure, the remaining 13/349 has tumours in multiple or unknown sites. Duke's staging was known for 305/349: 170/305 were Duke's A or B, and 135/305 were Duke's C or D.</p> <p><u>Controls:</u> N = 1744 (885 males/859 females), age at diagnosis: &lt; 60 years: N = 225, 60-69 years: N = 487, 70-79 years: N = 555, 80+ years: N = 477.</p> <p><u>Inclusion criteria:</u> Cases: All patients aged ≥ 40 years with a primary colorectal cancer, diagnosed from 1998 to 2002, were identified from the cancer registry at the Royal Devon and Exeter Hospital combined with computerised searches at every practice in Devon to identify any cases missing from the cancer register. Controls: Five controls were matched to each case on sex, general practice, and age (to 1-year bands if possible, increased in 1-year multiples to a maximum of 5 years). Controls were eligible if they were alive at the time of diagnosis of their case.</p> <p><u>Exclusion criteria:</u> Cases and controls: Unobtainable records; no consultations in the 2 years before diagnosis; previous colorectal cancer; or residence outside Exeter at the time of diagnosis.</p> <p><u>Clinical setting:</u> Primary care, UK.</p>
Are there concerns that the included patients and setting do not match the review question?	Low concern

<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	Anonymised photocopies of the full primary care records for 2 years before diagnosis were coded (blinded to case/control status) for all entries using the International Classification of Primary Care-2. Additional codes were created to incorporate all possible clinical features. Only variables occurring in $\geq 2.5\%$ of cases or controls were analysed.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
<b>Reference standard(s)</b>	Colorectal cancer diagnosis in the cancer registry at the Royal Devon and Exeter Hospital or practice notes.
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
<b>Flow and timing</b>	All the patients are accounted for.
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	
1	
2 <b>Hamilton (2005a)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
<b>Patient sampling</b>	Population-based matched case-control study involving all 21 general practices in Exeter, Devon, UK.
Was a consecutive or random sample of patients enrolled?	<b>No</b>

Was a case-control design avoided?	No
Did the study avoid inappropriate exclusions?	Yes
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?	Yes
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?	Yes
<b>Could the selection of patients have introduced bias?</b>	High risk
<b><u>B. Concerns regarding applicability</u></b>	
Patient characteristics and setting	<p><u>Cases:</u> N = 247 (170 males/77 females), age at diagnosis: &lt; 60 years: N = 35, 60-69 years: N = 60, 70-79 years: N = 118, 80+ years: N = 34.</p> <p><u>Controls:</u> N = 1235 (850 males/385 females), age at diagnosis: &lt; 60 years: N = 178, 60-69 years: N = 310, 70-79 years: N = 575, 80+ years: N = 174.</p> <p><u>Inclusion criteria:</u> Cases: All patients aged ≥ 40 years with a primary lung cancer, diagnosed from 1998 to 2002, were identified from the cancer registry at the Royal Devon and Exeter Hospital combined with computerised searches at every practice in Devon to identify any cases missing from the cancer register. Controls: Five controls were matched to each case on sex, general practice, and age. Controls were eligible if they were alive at the time of diagnosis of their case.</p> <p><u>Exclusion criteria:</u> Cases and controls: Unobtainable records; no consultations in the 2 years before diagnosis; previous lung cancer; or residence outside Exeter at the time of diagnosis.</p> <p><u>Clinical setting:</u> Primary care, UK.</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	Low concern
<b>INDEX TEST</b>	
<b><u>A. Risk of bias</u></b>	
Index test	Anonymised photocopies of the full primary care records for 2 years before diagnosis were coded (blinded to case/control status) for all entries using the International Classification of Primary Care-2. Additional codes were created to incorporate all possible clinical features. Only variables occurring in ≥ 2.5% of cases or controls were analysed.
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?	Yes
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	Low risk
<b><u>B. Concerns regarding applicability</u></b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	Low concern

REFERENCE STANDARD	
<b>A. risk of bias</b>	
Reference standard(s)	Lung cancer diagnosis in the cancer registry at the Royal Devon and Exeter Hospital or practice notes.
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	All the patients are accounted for.
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>Yes</b>
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>
<b>NOTES</b>	
1	
2 <b>Hamilton (2006)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Population-based case-control study, involving all 21 general practices in Exeter, Devon, UK.
Was a consecutive or random sample of patients enrolled?	<b>No</b>
Was a case-control design avoided?	<b>No</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>High risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<u>Cases:</u> 217 male patients; age at diagnosis: < 60 years: N = 15 (7%); 60-69 years: N = 51 (24%); 70-79 years: N = 100 (46%); ≥ 80 years: N = 51 (24%); median number of consultations in the 2 years preceding diagnosis = 14 (IQR = 10-21). <u>Controls:</u> 1080 male patients; age at diagnosis: < 60 years: N = 79 (7%); 60-69 years: N = 253 (23%); 70-79 years: N = 494 (46%); ≥ 80 years: N = 254 (24%); median

	<p>number of consultations in the 2 years preceding diagnosis = 14 (IQR = 10-21).</p> <p><u>Inclusion criteria:</u> Cases: All patients aged 40 years or over with prostate cancer, diagnosed from 1998 to 2002 inclusive, were identified from the cancer registry at the Royal Devon and Exeter Hospital (the only hospital offering urological services to Exeter patients). Computerised searches at every practice identified any cases missing from the register. Cases without positive histology were included if the records contained a consultant urologist diagnosis of cancer based on strong clinical evidence.</p> <p>Controls: Five male controls were matched to each case on general practice and on age (to 1-year bands if possible, increased in 1-year multiples to a maximum of 5 years). Controls were eligible if they were alive at the time of diagnosis of their case.</p> <p><u>Exclusion criteria:</u> Unobtainable records; no consultations in the 2 years before diagnosis; previous prostate cancer; or residence outside Exeter at the time of diagnosis.</p> <p><u>Clinical setting:</u> Primary care, UK</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	All entries into the primary care records for 2 years before diagnosis were coded, blinded to case/control status, using the International Classification of Primary Care-2. Only variables occurring in >2.5% of cases or controls were analysed.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
<b>Reference standard(s)</b>	Prostate cancer code, from 1998 to 2002 inclusive, in the cancer registry at the Royal Devon and Exeter Hospital or the general practice records
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	

<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		<b>Low concern</b>
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	All patients appears to be accounted for	
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>	
Did all patients receive the same reference standard?	<b>Yes</b>	
Were all patients included in the analysis?	<b>Yes</b>	
<b>Could the patient flow have introduced bias?</b>		<b>Low risk</b>
<b>NOTES</b>		
1		
2 <b>Hippisley-Cox (2011)</b>		
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Prospective patient series using patients in the QResearch database (version 30).	
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>	
Was a case-control design avoided?	<b>Yes</b>	
Did the study avoid inappropriate exclusions?	<b>Yes</b>	
<b>Could the selection of patients have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
Patient characteristics and setting	<p>A total of 1238971 patients were identified from 189 practices (621478 males, 617493 females), mean (SD) age = 50.1 (15) years, mean (SD) Townsend score = -0.2 (3.6).</p> <p><u>Symptoms:</u> Current dysphagia (N = 8165), current haematemesis (N = 7119), current abdominal pain (N = 126161), current appetite loss (N = 6133), current weight loss (N = 5377), tiredness in the last year (N = 14119), haemoglobin recorded in the last year (N = 12638, haemoglobin &lt; 11 g/dl in the last year (N = 218862).</p> <p><u>Incident cases of gastro-oesophageal cancer during the 2-year follow up period:</u> N = 1343 (776 oesophageal and 567 gastric).</p> <p><u>Inclusion criteria:</u> All practices in England and Wales that had been using their Egton Medical Information Systems (EMIS) computer system for ≥ a year were included. Two-thirds of practices were randomly allocated to the derivation dataset and the remaining practices were allocated to the validation dataset. An open cohort of patients aged 30–84 years was identified, drawn from patients registered with practices between 1 January 2000 and 30 September 2010. Entry to the cohort was defined as the latest of the study start date (1 January 2000); 12 months after the patient registered with the practice; and for those patients with red flag symptoms (see below), the date of the first recorded onset within the study period. <i>The relevant data for the present purposes is only available for the validation cohort, therefore only information pertaining to these patients will be reported.</i></p> <p><u>Exclusion criteria:</u> Patients without a postcode-related Townsend score,</p>	



	patients with a history of gastro-oesophageal cancer at baseline, and patients with a recorded 'red-flag' symptom in the 12 months prior to the study entry date. <u>Clinical setting</u> : Primary care, UK
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	'Red-flag' symptoms: Incident dysphagia, haematemesis, loss of appetite, weight loss, anaemia, and abdominal pain.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	2-year follow up
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>
<b>FLOW AND TIMING</b>	
<b>A. risk of bias</b>	
Flow and timing	A total of 1342329 patients were initially identified of whom 103358 patients were excluded for the following reasons: No recorded Townsend score (N = 70847), history of gastro-oesophageal cancer (N = 538), and $\geq$ one 'red flag' symptom recorded in the 12 months prior to study entry (N = 31973), leaving 1238971 patients. However, data is presented for 963040/1238971 patients for all symptoms. The missing data does not appear to include any of the cancer cases, but it is unclear whether some of the missing data includes symptomatic patients, i.e., false positives.
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>
Did all patients receive the same reference standard?	<b>Yes</b>
Were all patients included in the analysis?	<b>No</b>
<b>Could the patient flow have introduced bias?</b>	<b>Unclear risk</b>
<b>NOTES</b>	Results not presented separately for gastric and oesophageal cancer

1

<b>Hippisley-Cox (2012)</b>	
<b>PATIENT SELECTION</b>	
<b>A. risk of bias</b>	
Patient sampling	Prospective patient series using patients in the QResearch database (version 30).
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>
Was a case-control design avoided?	<b>Yes</b>
Did the study avoid inappropriate exclusions?	<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
Patient characteristics and setting	<p>A total of 1236601 patients were identified from 189 practices (620240 males, 616361 females), mean (SD) age = 50.1 (14.9) years, mean (SD) Townsend score = -0.2 (3.6).</p> <p><u>Symptoms:</u> Current rectal bleeding (N = 29118), current abdominal pain (N = 125816), current appetite loss (N = 5358), current weight loss (N = 14065), recent change in bowel habit (N = 1821).</p> <p><u>Incident cases of colorectal cancer during the 2-year follow up period:</u> N = 2603 (1562 colon and 1041 rectum).</p> <p><u>Inclusion criteria:</u> All practices in England and Wales that had been using their Egton Medical Information Systems (EMIS) computer system for ≥ a year were included. Two-thirds of practices were randomly allocated to the derivation dataset and the remaining practices were allocated to the validation dataset. An open cohort of patients aged 30–84 years was identified, drawn from patients registered with practices between 1 January 2000 and 30 September 2010. Entry to the cohort was defined as the latest of the study start date (1 January 2000); 12 months after the patient registered with the practice; and for those patients with red flag symptoms (see below), the date of the first recorded onset within the study period. <i>The relevant data for the present purposes is only available for the validation cohort, therefore only information pertaining to these patients will be reported.</i></p> <p><u>Exclusion criteria:</u> Patients without a postcode-related Townsend score, patients with a history of colorectal cancer at baseline, and patients with a recorded 'red-flag' symptom in the 12 months prior to the study entry date.</p> <p><u>Clinical setting:</u> Primary care, UK</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
Index test	'Red-flag' symptoms: First onset rectal bleeding, first onset loss of appetite, first onset weight loss, first onset abdominal pain, first onset change in bowel habit (in the past 12 months), and anaemia (recorded haemoglobin < 11 g/dl in the past 12 months).
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	

<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>		<b>Low concern</b>
<b>REFERENCE STANDARD</b>		
<b>A. risk of bias</b>		
Reference standard(s)	2-year follow up	
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>	
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>	
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>	
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>	
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	A total of 1342329 patients were initially identified of whom 105728 patients were excluded for the following reasons: No recorded Townsend score (N = 70847), history of colorectal cancer (N = 2908), and $\geq$ one 'red flag' symptom recorded in the 12 months prior to study entry (N = 31973), leaving 1236601 patients. However, data is presented for 1235547/1236601 patients for all symptoms apart from change in bowel habit, which is only presented for 619651/620240 of the male patients. The missing data does not appear to include any of the cancer cases (although this cannot be ascertained for change in bowel habit), but it is unclear whether some of the missing data includes symptomatic patients, i.e., false positives.	
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>	
Did all patients receive the same reference standard?	<b>Yes</b>	
Were all patients included in the analysis?	<b>No</b>	
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>	
<b>NOTES</b>	Please note there is some overlap between this patient sample and that of Parker (2007)	
<b>Hippisley-Cox (2012a)</b>		
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Prospective patient series using patients in the QResearch database (version 30).	
Was a consecutive or random sample of patients enrolled?	<b>Yes</b>	
Was a case-control design avoided?	<b>Yes</b>	
Did the study avoid inappropriate exclusions?	<b>Yes</b>	
<b>Could the selection of patients have introduced bias?</b>	<b>Low risk</b>	
<b>B. Concerns regarding applicability</b>		
Patient characteristics and	A total of 1243740 patients were identified from 189 practices (624352 males, 619388 females), mean (SD) age = 50.1 (14.9) years, mean (SD)	

1

2

setting	<p>Townsend score = -0.2 (3.6).</p> <p><u>Current symptoms and symptoms in the preceding year:</u>  Current dysphagia (N = 8507), current abdominal pain (N = 129924), current abdominal distension (N = 4929), current appetite loss (N = 5567), current weight loss (N = 14686), constipation in the last year (N = 8476), diarrhoea in the last year (N = 12233), tiredness in the last year (N = 12688), itching in the last year (N = 1454), haemoglobin recoded in the last year (N = 214497), haemoglobin &lt; 11 g/dl in the last year (N = 16172).</p> <p><u>Incident cases of pancreatic cancer during the 2-year follow up period:</u> N = 781.</p> <p><u>Inclusion criteria:</u>  All practices in England and Wales that had been using their Egton Medical Information Systems (EMIS) computer system for ≥ a year were included. Two-thirds of practices were randomly allocated to the derivation dataset and the remaining practices were allocated to the validation dataset. An open cohort of patients aged 30–84 years was identified, drawn from patients registered with practices between 1 January 2000 and 30 September 2010. Entry to the cohort was defined as the latest of the study start date (1 January 2000) and 12 months after the patient registered with the practice, ensuring that all patients had ≥ 12 months' registration prior to study entry. For patients with incident haematuria, appetite loss, weight loss, or abdominal pain, the entry date was the date of the first consultation with the symptom within the study period. <i>The relevant data for the present purposes is only available for the validation cohort, therefore only information pertaining to these patients will be reported.</i></p> <p><u>Exclusion criteria:</u> Patients without a postcode-related Townsend score, patients with a history of pancreatic cancer at baseline, and patients with a recorded 'red-flag' (see "Definition of symptom" below) symptom in the 12 months prior to the study entry date.</p> <p><u>Clinical setting:</u> Primary care</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	'Red-flag' symptoms were defined as symptoms that might alarm the patient and also indicate the presence of pancreatic cancer; that is, symptoms of dysphagia, loss of appetite, weight loss, abdominal distension or abdominal pain.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
Reference standard(s)	Pancreatic cancer, which was defined as incident diagnosis of pancreatic cancer during the 2 years after study entry, recorded either on the patient's

	GP record using the relevant UK diagnostic Read Codes, or their linked Office for National Statistics cause-of-death record, using the relevant ICD-9 code (157) or ICD-10 diagnostic codes (C25).
Is the reference standard likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	Unclear
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	Low risk
<b><u>B. Concerns regarding applicability</u></b>	
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	Low concern
<b>FLOW AND TIMING</b>	
<b><u>A. risk of bias</u></b>	
Flow and timing	A total of 1342329 patients were initially identified of whom 98589 patients were excluded for the following reasons: No recorded Townsend score (N = 70847), history of pancreatic cancer (N = 96), and $\geq$ one 'red flag' symptom recorded in the 12 months prior to study entry (N = 27646), leaving 1243740 patients. However, data is presented for 971706 / 1243740 patients. The missing data does not appear to include any of the cancer cases, but it is unclear whether some of the missing data includes symptomatic patients, i.e., false positives.
Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	No
<b>Could the patient flow have introduced bias?</b>	High risk
<b>NOTES</b>	
1	
2 <b>Hippisley-Cox (2012b)</b>	
<b>PATIENT SELECTION</b>	
<b><u>A. risk of bias</u></b>	
Patient sampling	Prospective patient series using patients in the QResearch database (version 30).
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
<b>Could the selection of patients have introduced bias?</b>	Low risk
<b><u>B. Concerns regarding applicability</u></b>	
Patient characteristics and setting	A total of 1240722 patients were identified from 189 practices (622166 males, 618556 females), mean (SD) age = 50.1 (14.9) years, mean (SD) Townsend score = -0.2 (3.6). <u>Current symptoms and symptoms in the preceding year:</u> Current haematuria (N = 25553), current abdominal pain (N = 128721), current appetite loss (N = 5531), current weight loss (N = 14464), constipation in the last year (N = 8472), diarrhoea in the last year (N = 12171), tiredness in the last year (N = 12669), haemoglobin recoded in the

	<p>last year (N = 216201), haemoglobin &lt; 11 g/dl in the last year (N = 16169). Incident cases of renal tract cancer during the 2-year follow up period: N = 1622; mean age at diagnosis = 70 years, 1187 males/ 435 females; <b>Type of cancer: Bladder: N = 1292; Kidney: N = 307; Ureter: N = 21; Urethra: N = 2.</b></p> <p><u>Inclusion criteria:</u> All practices in England and Wales that had been using their Egton Medical Information Systems (EMIS) computer system for ≥ a year were included. Two-thirds of practices were randomly allocated to the derivation dataset and the remaining practices were allocated to the validation dataset. An open cohort of patients aged 30–84 years was identified, drawn from patients registered with practices between 1 January 2000 and 30 September 2010. Entry to the cohort was defined as the latest of the study start date (1 January 2000) and 12 months after the patient registered with the practice, ensuring that all patients had ≥ 12 months' registration prior to study entry. For patients with incident haematuria, appetite loss, weight loss, or abdominal pain, the entry date was the date of the first consultation with the symptom within the study period. <i>The relevant data for the present purposes is only available for the validation cohort, therefore only information pertaining to these patients will be reported.</i></p> <p><u>Exclusion criteria:</u> Patients without a postcode-related Townsend score, patients with a history of renal tract cancer at baseline, and patients with a recorded 'red-flag' (see "Definition of symptom" below) symptom in the 12 months prior to the study entry date.</p> <p><u>Clinical setting:</u> Primary care</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b><u>A. Risk of bias</u></b>	
<b>Index test</b>	'Red-flag' symptoms were defined as symptoms that might alarm the patient and also indicate the presence of renal tract cancer; that is, symptoms of haematuria, loss of appetite, weight loss, or abdominal pain.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b><u>B. Concerns regarding applicability</u></b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b><u>A. risk of bias</u></b>	
<b>Reference standard(s)</b>	Renal tract cancer, which was defined as incident diagnosis of cancer of the bladder, kidney, ureter, or urethra during the 2 years after study entry, recorded either on the patient's GP record using the relevant UK diagnostic Read Codes, or their linked Office for National Statistics cause-of-death record, using the relevant ICD-9 codes (188 or 189) or ICD-10 diagnostic codes (C64–67).
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without	<b>Unclear</b>

knowledge of the results of the index tests?		
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		<b>Low concern</b>
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	A total of 1342329 patients were initially identified of whom 101607 patients were excluded for the following reasons: No recorded Townsend score (N = 70847), history of renal tract cancer (N = 1506), and $\geq$ one 'red flag' symptom recorded in the 12 months prior to study entry (N = 29254), leaving 1240722 patients. However, data is presented for 967681 / 1240722 patients. The missing data does not appear to include any of the cancer cases, but it is unclear whether some of the missing data includes symptomatic patients, i.e., false positives.	
Was there an appropriate interval between index test and reference standard?		<b>Yes</b>
Did all patients receive the same reference standard?		<b>Yes</b>
Were all patients included in the analysis?		<b>No</b>
<b>Could the patient flow have introduced bias?</b>		<b>High risk</b>
<b>NOTES</b>		
1 2 <b>Iyen-Omofoman (2013)</b>		
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Case-control study using The Health Improvement Network (THIN) database, which had data from 446 UK general practices with a total of 8.2 million patients.	
Was a consecutive or random sample of patients enrolled?		<b>No</b>
Was a case-control design avoided?		<b>No (for derivation cohort) Yes (for validation cohort)</b>
Did the study avoid inappropriate exclusions?		<b>Yes</b>
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?		<b>Yes</b>
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?		<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>		<b>High risk (for derivation cohort) Low risk (for validation cohort)</b>
<b>B. Concerns regarding applicability</b>		
Patient characteristics and setting	Cases: N = 12074 (7154 males/4920 females), age at diagnosis: 40-45 years: N = 95, 45-50 years: N = 220, 50-55 years: N = 469, 55-60 years: N = 896, 60-65 years: N = 1488, 65-70 years: N = 1750, 70-75 years: N = 2212, 75-80 years: N = 2305, > 80 years: N = 2639.	

	<p><b>Controls:</b> N = 120731 (58034 males/62697 females), age at diagnosis (of cases): 40-45 years: N = 18969, 45-50 years: N = 16756, 50-55 years: N = 15963, 55-60 years: N = 15439, 60-65 years: N = 13475, 65-70 years: N = 11201, 70-75 years: N = 9940, 75-80 years: N = 8191, &gt; 80 years: N = 10797. <b>Validation cohort:</b> N = 1826293 (886994 males/939299 females). Age: Not reported. Incident cases of lung cancer during the 1-year follow up: N = 1728.</p> <p><b>Inclusion criteria:</b> Cases: All incident cases of lung cancer diagnosed between 1 January 2000 and 28 July 2009 in patients aged <math>\geq</math> 40 years. Controls: Ten randomly selected controls aged <math>\geq</math> 40 years with <math>\geq</math> 1 year of active records were matched to each case on general practice. Validation cohort: All THIN patients aged &gt; 39 years, free from lung cancer on 29 July 2009, and <math>\geq</math> 1 year general practice follow up.</p> <p><b>Exclusion criteria:</b> Cases: Patients with &lt; 1 year of active records prior to their first diagnosis of lung cancer. Clinical setting: Primary care, UK.</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	Cough, chest/shoulder pain, dyspnoea, weight loss, hoarseness, upper and lower respiratory tract infections, non-specific chest infections, constipation, depressive disorders, and chronic obstructive pulmonary disease (COPD), recorded over the 2-year period before lung cancer diagnosis.
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>	<b>Low concern</b>
<b>REFERENCE STANDARD</b>	
<b>A. risk of bias</b>	
<b>Reference standard(s)</b>	Lung cancer diagnosis in THIN database
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	



<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		<b>Low concern</b>
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	All the patients are accounted for.	
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>	
Did all patients receive the same reference standard?	<b>Yes</b>	
Were all patients included in the analysis?	<b>Yes</b>	
<b>Could the patient flow have introduced bias?</b>		<b>Low risk</b>
<b>NOTES</b>		
1		
2	<b>Panzuto (2003)</b>	
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Prospective 8-week study of patients presenting to 159 primary care physicians (approximately 63600 patient visits during the study period in total) in Italy.	
Was a consecutive or random sample of patients enrolled?	<b>No</b>	
Was a case-control design avoided?	<b>Yes</b>	
Did the study avoid inappropriate exclusions?	<b>Unclear</b>	
<b>Could the selection of patients have introduced bias?</b>		<b>High risk</b>
<b>B. Concerns regarding applicability</b>		
Patient characteristics and setting	<p>N = 280; 120 males, 160 females; median age (range) = 61 (18-87) years.</p> <p><u>Inclusion criteria:</u> Consecutive patients who consulted their GP "with symptoms considered suspicious for the presence of a colon disease to rule out the presence of colorectal cancer" and who were investigated with a colonoscopy or double-contrast barium enema [The decision of how (colonoscopy or double-contrast barium enema) and when to investigate the colon was made only by the physicians on the basis of the clinical evaluation during the visit].</p> <p><u>Exclusion criteria:</u> Patients with previous diagnoses of colorectal disorders or a recent large bowel examination.</p> <p><u>Clinical setting:</u> Primary care, Italy.</p>	
<b>Are there concerns that the included patients and setting do not match the review question?</b>		<b>Unclear concern</b>
<b>INDEX TEST</b>		
<b>A. Risk of bias</b>		
Index test	Abdominal pain, bloating, constipation, rectal bleeding, diarrhoea, iron-deficiency anaemia (haemoglobin levels < 14 g/dl for males and < 12 g/dl for females, in the presence of ferritin < 30 µg/l and a median corpuscular value < 80 fl), change in bowel habits (onset of diarrhoea or constipation or altered stool in the previous 3 months) and weight loss (decrease of ≥ 3 kg in the 3 months prior to the visit).	
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>	
<b>Could the conduct or interpretation of the index test</b>		<b>Low risk</b>

<b>have introduced bias?</b>		
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</b>		<b>Low concern</b>
<b>REFERENCE STANDARD</b>		
<b>A. risk of bias</b>		
Reference standard(s)	Histology	
Is the reference standard likely to correctly classify the target condition?		<b>Yes</b>
Were the reference standard results interpreted without knowledge of the results of the index tests?		<b>No</b>
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>		<b>Low risk</b>
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>		<b>Low concern</b>
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	56/332 patients were excluded due to lack of mandatory fields (age, sex, clinical history, presenting symptoms and procedure results) in the database (N = 35) or violation of exclusion criteria (N = 18)	
Was there an appropriate interval between index test and reference standard?		<b>Yes</b>
Did all patients receive the same reference standard?		<b>Yes</b>
Were all patients included in the analysis?		<b>No</b>
<b>Could the patient flow have introduced bias?</b>		<b>Unclear risk</b>
<b>NOTES</b>		
1		
2 <b>Stapley (2012)</b>		
<b>PATIENT SELECTION</b>		
<b>A. risk of bias</b>		
Patient sampling	Matched case-control study using patients in the UK's General Practice Research Database (GPRD).	
Was a consecutive or random sample of patients enrolled?		<b>No</b>
Was a case-control design avoided?		<b>No</b>
Did the study avoid inappropriate exclusions?		<b>Yes</b>
<i>For diagnostic case-control studies:</i> Attempts were made within the design or analysis to balance the comparison groups for potential confounders?		<b>Yes</b>
<i>For diagnostic case-control studies:</i> The groups were comparable at baseline, including all major confounding and prognostic factors?		<b>Yes</b>
<b>Could the selection of patients have introduced bias?</b>		<b>High risk</b>
<b>B. Concerns regarding applicability</b>		
Patient	Cases:	

characteristics and setting	<p>N = 3635, 1743 males / 1892 females; median number of consultations = 18 (IQR = 11-27); aged 40-49 years: N = 107; 50-59 years: N = 529; 60-69 years: N = 829; 70-79 years: N = 1212; ≥ 80 years: N = 958; UK.</p> <p><u>Controls:</u> N = 16459, gender not reported; median number of consultations = 9 (IQR = 4-15); aged 40-49 years: N = 422; 50-59 years: N = 2239; 60-69 years: N = 3755; 70-79 years: N = 5702; ≥ 80 years: N = 4341; UK.</p> <p><u>Inclusion criteria:</u> Cases: Patients with a record of one of 25 GPRD pancreatic cancer codes between January 2000 and December 2009 inclusive, aged ≥ 40 years, with min. 1 year of data before diagnosis. The first instance of a pancreatic cancer code was assigned the data of diagnosis/index date. Controls: Up to 5 controls were matched to cases on sex, general practice, and to 1 year of age of the case. The index date was the index date of the matched case.</p> <p><u>Exclusion criteria:</u> Pancreatic cancer (controls), no consultations in the year before diagnosis.</p> <p><u>Clinical setting:</u> Primary care</p>
<b>Are there concerns that the included patients and setting do not match the review question?</b>	<b>Low concern</b>
<b>INDEX TEST</b>	
<b>A. Risk of bias</b>	
<b>Index test</b>	<p>All symptoms, physical signs or abnormal investigations compiled from the pancreatic cancer literature were studied, and supplemented by discussion with two pancreatic cancer charities. Libraries of codes relating to these were collated. All codes for fractures were also identified, as a test for any recording bias between cases and controls (making the assumption that the fracture rate would be approximately equal). Occurrences of these features in the year before the index date were identified. Features were only retained for further study if they occurred in ≥5% of cases or controls. Repeat attendances with the same symptom were also retained if the subsequent consultation also occurred in ≥5% of cases or controls. New-onset diabetes was defined as a code for diabetes, or a random blood glucose above the local laboratory's normal range, without similar codes more than 1 year before the index date. For laboratory tests, patients without a test were considered to be the same status as those with a normal result, making our binary variable abnormal result/ no abnormal result. Abnormal liver function was defined as any liver enzyme above the normal range, and raised inflammatory markers as either abnormal erythrocyte sedimentation rate or C-reactive protein, as there were too few plasma viscosity results.</p>
Were the index test results interpreted without knowledge of the results of the reference standard?	<b>Yes</b>
<i>For diagnostic case-control studies:</i> Investigators were kept 'blind' to other important confounding and prognostic factors?	<b>Yes</b>
<b>Could the conduct or interpretation of the index test have introduced bias?</b>	<b>Low risk</b>
<b>B. Concerns regarding applicability</b>	
<b>Are there concerns that the index test, its conduct, or</b>	<b>Low concern</b>

<b>interpretation differ from the review question?</b>		
<b>REFERENCE STANDARD</b>		
<b>A. risk of bias</b>		
Reference standard(s)	Pancreatic cancer code in the UK's General Practice Research Database.	
Is the reference standard likely to correctly classify the target condition?	<b>Yes</b>	
Were the reference standard results interpreted without knowledge of the results of the index tests?	<b>Unclear</b>	
<b>Could the reference standard, its conduct, or its interpretation have introduced bias?</b>	<b>Low risk</b>	
<b>B. Concerns regarding applicability</b>		
<b>Are there concerns that the target condition as defined by the reference standard does not match the question?</b>	<b>Low concern</b>	
<b>FLOW AND TIMING</b>		
<b>A. risk of bias</b>		
Flow and timing	A total of 21624 patients were identified, 17977 controls and 3647 cases. Of the controls the following exclusions were applied: pancreatic cancer (N = 64), case excluded (N = 40), and no data in year pre-index date (N = 1414). Of the cases the following exclusions were applied: No controls (N = 2), and cancer not of pancreatic origin (N = 10).	
Was there an appropriate interval between index test and reference standard?	<b>Yes</b>	
Did all patients receive the same reference standard?	<b>Yes</b>	
Were all patients included in the analysis?	<b>Yes</b>	
<b>Could the patient flow have introduced bias?</b>	<b>Low risk</b>	
<b>NOTES</b>		

1

2 **References**3 **Included studies**

- 4 Collins, G.S., Altman, D.G. Identifying patients with undetected colorectal cancer: An independent  
5 validation of Qcancer (Colorectal). *British Journal of Cancer* 107, 260-265. 2012.
- 6 Collins, G.S., Altman, D.G. Identifying patients with undetected gastro-oesophageal cancer in primary  
7 care: External validation of Qcancer (Gastro-Oesophageal). *European Journal of Cancer*,  
8 <http://dx.doi.org/10.1016/j.ejca.2012.10.023>. 2012a.
- 9 Collins, G.S.; Altman, D.G. (2013). Identifying patients with undetected pancreatic cancer in primary  
10 care: an independent and external validation of Qcancer® (Pancreas). *British Journal of*  
11 *General Practice*, 63: 636-642.
- 12 Collins, G.S., and Altman, D.G. Identifying patients with undetected renal tract cancer in primary  
13 care: An independent and external validation of Qcancer (renal) prediction model. *Cancer*  
14 *Epidemiology*, 37, 115-120. 2013a.
- 15 Hamilton, W., Round, A., Sharp, D., and Peters, T. J. Clinical features of colorectal cancer before  
16 diagnosis: a population-based case-control study. *British Journal of Cancer* 93[4], 399-405. 22-8-  
17 2005.
- 18 Hamilton, W., Peters, T. J., Round, A. & Sharp, D. (2005a) What are the clinical features of lung  
19 cancer before the diagnosis is made? A population based case-control study. *Thorax*, 60: 1059-  
20 1065.

1 The data split by smoking status is available from:  
2 <http://webarchive.nationalarchives.gov.uk/20130513211237/http://www.ncat.nhs.uk/sites/default/files/work-docs/ncl%20lung%20guide.pdf>  
3  
4 Hamilton, W., Sharp, D. J., Peters, T. J., and Round, A. P. Clinical features of prostate cancer before  
5 diagnosis: a population-based, case-control study. *British Journal of General Practice* 56[531],  
6 756-762. 2006.  
7 Hippisley-Cox, J. and Coupland, C. Identifying patients with suspected gastro-oesophageal cancer in  
8 primary care: Derivation and validation of an algorithm. *British Journal of General Practice*; DOI:  
9 10.3399/bjgp11X606609. 2011.  
10 Hippisley-Cox, J. and Coupland, C. Identifying patients with suspected colorectal cancer in primary  
11 care: Derivation and validation of an algorithm. *British Journal of General Practice* 62[594], e29-  
12 e37. 2012.  
13 Hippisley-Cox, J. & Coupland, C. (2012a) Identifying patients with suspected pancreatic cancer in  
14 primary care: derivation and validation of an algorithm. *British Journal of General Practice*, 62:  
15 e38-e45.  
16 Hippisley-Cox, J. and Coupland, C. Identifying patients with suspected renal tract cancer in primary  
17 care: derivation and validation of an algorithm. *British Journal of General Practice* 62[597], e251-  
18 e260. 2012b.  
19 Iyen-Omofoman, B., Tata, L. J., Baldwin, D. R., Smith, C. J. P. & Hubbard, R. B. (2013) Using socio-  
20 demographic and early clinical features in general practice to identify people with lung cancer  
21 earlier. *Thorax*, 68, 451-9.  
22 Panzuto, F., Chiriatti, A., Bevilacqua, S., Giovannetti, P., Russo, G., Impinna, S., Pistilli, F., Capurso, G.,  
23 Annibale, B., Delle, Fave G., and Digestive and Liver Disease and Primary Care Medicine Lazio  
24 Group. Symptom-based approach to colorectal cancer: survey of primary care physicians in Italy.  
25 *Digestive & Liver Disease* 35[12], 869-875. 2003.  
26 Stapley, S., Peters, T. J., Neal, R. D., Rose, P. W., Walter, F. M. & Hamilton, W. (2012) The risk of  
27 pancreatic cancer in symptomatic patients in primary care: a large case-control study using  
28 electronic records. *British Journal of Cancer*, 106: 1940-1944.  
29  
30  
31